PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Iida, H; Tachibana, S; Kitahara, T; Horiike, S; Ohwada, T; Fujii, K				Iida, H; Tachibana, S; Kitahara, T; Horiike, S; Ohwada, T; Fujii, K			Association of head trauma with cervical spine injury, spinal cord injury, or both	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article								Background: Links between cervical spine and/or spinal cord injuries and head trauma have not been reported in detail. Methods: 188 patients with cervical spine and/or spinal cord injury were divided into two groups, i.e,, with upper cervical and mid-lower cervical injury, and compared for head injury. Results: Associated head trauma was investigated in 188 patients with cervical spine and/or spinal cord injuries; 35% had moderate or severe injuries. Brain damage was more frequently observed in patients with upper cervical injury than in those with mid to lower cervical injury. Those patients with upper cervical injury appeared to have an elevated risk of suffering skull base fractures, traumatic subarachnoid hemorrhage, and contusional hemotoma. Conclusions: Approximately one third of patients with cervical spine and/or spinal card injuries had moderate or severe head injuries, Brain damage was more frequently associated with upper cervical injury. Those patients with upper cervical injury are at greater risk of suffering from skull base fractures and severe intracranial hematomas than those with mid to lower cervical injury.	Kitasato Univ, Sch Med, Dept Neurosurg, Kanagawa, Japan; Kitasato Univ, Sch Med, Dept Crit Care Med, Kanagawa, Japan		Iida, H (corresponding author), 245 0006 Int Goodwill Hosp, 1-28-1 Nishigaoka, Kanagawa, Japan.						BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIS D, 1971, J NEUROSURG, V34, P603, DOI 10.3171/jns.1971.34.5.0603; Harris P., 1967, PARAPLEGIA, V5, P215; MEINECKE FW, 1967, PARAPLEGIA, V5, P196; REISS SJ, 1986, NEUROSURGERY, V18, P327, DOI 10.1227/00006123-198603000-00012; SHRAGO GG, 1973, AM J ROENTGENOL, V118, P670, DOI 10.2214/ajr.118.3.670; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; TEASDALE G, 1974, LANCET, V2, P81; Tricot D A, 1968, Paraplegia, V5, P211	12	65	69	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1999	46	3					450	452		10.1097/00005373-199903000-00018			3	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	175TP	WOS:000079111600020	10088849				2022-02-06	
J	Agrawal, SK; Theriault, E; Fehlings, MG				Agrawal, SK; Theriault, E; Fehlings, MG			Role of group I metabotropic glutamate receptors in traumatic spinal cord white matter injury	JOURNAL OF NEUROTRAUMA			English	Article						axons; glia; group I; immunocytochemistry; mGluR; rat; spinal cord injury	OXYGEN-GLUCOSE DEPRIVATION; DEPENDENT PROTEIN-KINASE; EXCITATORY AMINO-ACIDS; IONOTROPIC GLUTAMATE; CORTICAL CULTURES; ARACHIDONIC-ACID; BRAIN INJURY; GLIAL-CELLS; PHENYLGLYCINE DERIVATIVES; HIPPOCAMPAL-NEURONS	Metabotropic glutamate receptors (mGluRs) participate in glutamate neural transmission, but their role in the pathophysiology of spinal cord injury (SCI) has not been explored. Accordingly, we examined the role of group I mGluRs, which are linked to phospholipase C, in mediating SCI using an in vitro model. A dorsal column segment was isolated from the spinal cord of adult rats, maintained in vitro, and injured by compression for 15 sec with a clip having a 2g closing force. Under control conditions after SCI, the compound action potential (CAP) amplitude was reduced to 69.1 +/- 5.4% of baseline. Blockade of group I mGluR receptors with MCPG, 4CPG, or AIDA resulted in improved recovery of CAP amplitude (82.2 +/- 2.0%, 86.2 +/- 3.9%, and 86.0 +/- 2.5% of baseline, respectively). The group I/II agonist trans-ACPD and selective group I agonist DHPG exacerbated the posttraumatic reduction of CAP amplitude. The phospholipase C inhibitor U-73122 improved recovery of CAP amplitude after traumatic spinal cord axonal injury. Western blotting and immunocytochemistry demonstrated the presence of mGluR1 alpha-immunopositive astrocytes and the absence of mGluR5 in spinal cord white matter. These studies are consistent with the hypothesis that activation of group I mGluR receptors after SCI exacerbates posttraumatic axonal injury through a phospholipase C dependent mechanism, The presence of mGluR1 alpha labeling on astrocytes suggests a role for these cells in the pathophysiology of SCI. Additional studies in vivo, are required to further clarify the role of mGluRs in acute traumatic SCI.	Toronto Hosp, Western Div, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada		Fehlings, MG (corresponding author), Toronto Hosp, Western Div, Playfair Neurosci Unit, Mclaughlin Pavil,Room 12-411,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal S. K., 1997, Society for Neuroscience Abstracts, V23, P2189; Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ANIKSZTEJN L, 1991, EUR J PHARMACOL, V205, P327, DOI 10.1016/0014-2999(91)90921-C; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARRES BA, 1991, J NEUROSCI, V11, P3685; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1988, GLIA, V1, P1; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; Choi S, 1996, J NEUROSCI, V16, P36; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dalby NO, 1996, J PHARMACOL EXP THER, V276, P516; DOLAN EJ, 1979, J NEUROSURG, V51, P229, DOI 10.3171/jns.1979.51.2.0229; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/S0006-8993(96)00667-1; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GALLO V, 1991, GLIA, V4, P245, DOI 10.1002/glia.440040302; GLAUM SR, 1993, J NEUROSCI, V13, P1636; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JENSEN AM, 1993, J NEUROSCI, V13, P1664; KINGSTON AE, 1995, NEUROPHARMACOLOGY, V34, P887, DOI 10.1016/0028-3908(95)00069-I; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; MACVICAR BA, 1988, NEUROSCIENCE, V25, P721, DOI 10.1016/0306-4522(88)90272-2; Maiese K, 1996, J NEUROCHEM, V66, P2419; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MITANI A, 1993, BRAIN RES, V601, P103, DOI 10.1016/0006-8993(93)91700-3; Mukhin A, 1996, J NEUROSCI, V16, P6012; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, EXS, V71, P71; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; OPTIZ T, 1994, NEUROPHARMACOLOGY, V33, P715; OPTIZ T, 1993, NEUROPHARMACOLOGY, V32, P103; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; QUANDT FN, 1986, NEUROSCIENCE, V19, P29, DOI 10.1016/0306-4522(86)90003-5; ROSS SM, 1994, NEUROSCI LETT, V173, P139, DOI 10.1016/0304-3940(94)90168-6; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, NEUROCHEM INT, V24, P439, DOI 10.1016/0197-0186(94)90092-2; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tang E, 1997, EUR J PHARMACOL, V327, P109, DOI 10.1016/S0014-2999(97)89649-5; Teng YD, 1997, J NEUROSCI, V17, P4359; Theriault E, 1997, J COMP NEUROL, V382, P199; Theriault E., 1995, Journal of Neurotrauma, V12, P365; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1994, J NEUROSCI, V14, P6598	74	65	66	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1998	15	11					929	941		10.1089/neu.1998.15.929			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	139RN	WOS:000077043400002	9840766				2022-02-06	
J	Gordon, WA; Sliwinski, M; Echo, J; McLoughlin, M; Sheerer, M; Meili, TE				Gordon, WA; Sliwinski, M; Echo, J; McLoughlin, M; Sheerer, M; Meili, TE			The benefits of exercise in individuals with traumatic brain injury: A retrospective study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							BETA-ENDORPHIN; AEROBIC EXERCISE; DEPRESSION; FITNESS; STATES; MOOD	Objective: This study examined the benefits of exercise. Design: A retrospective study. Setting: A community-based sample. Participants: A sample of 240 individuals with traumatic brain injury (TBI) (64 exercisers and 176 nonexercisers) and 139 individuals without a disability (66 exercisers and 73 nonexercisers). Main Outcome Measures: Scales measuring disability and handicap. Results: It was found that the TBI exercisers were less depressed than nonexercising individuals with TDI, TDI exercisers reported fewer symptoms, and their self-reported health status was better th:ln the nonexercising individuals with TBI. There were no differences between the two groups of individuals with TBI on measures of disability and handicap. Conclusions: The findings suggest that exercise improves mood and aspects of health status but does affect aspects of disability and handicap.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Salomon Brothers, New York, NY USA		Gordon, WA (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.						ANTHONY J, 1991, CLIN SPORT MED, V10, P171; Beck AT, 1987, BECK DEPRESSION INVE; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; BLAIR S, 1989, JAMA-J AM MED ASSOC, V262, P395; Brown R S, 1978, Phys Sportsmed, V6, P34, DOI 10.1080/00913847.1978.11710794; BROWN RS, 1978, PHYSICIAN SPORTSMED, V6, P44; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; CARR DB, 1981, NEW ENGL J MED, V305, P560, DOI 10.1056/NEJM198109033051006; COLT EWD, 1981, LIFE SCI, V28, P1637, DOI 10.1016/0024-3205(81)90319-2; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; GREIST JH, 1979, COMPR PSYCHIAT, V20, P41, DOI 10.1016/0010-440X(79)90058-0; GREIST JH, 1979, PSYCHIAT ANN, V9, P23; HOWARD R, 1988, PHYSIOTHER CAN, V8, P4; JANOWSKI L, 1990, ARCH PHYS MED REHAB, V71, P500; KELEMEN MH, 1990, JAMA-J AM MED ASSOC, V263, P2766, DOI 10.1001/jama.263.20.2766; LAFONTAINE TP, 1992, SPORTS MED, V13, P160, DOI 10.2165/00007256-199213030-00002; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; *MED OUTC TRUST, 1992, SF 36 HLTH SURV; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P533; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SIMON HB, 1992, STAYING WELL YOUR CO; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; TWIST DJ, 1992, AM J PHYS MED REHAB, V71, P156, DOI 10.1097/00002060-199206000-00006; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILDMANN J, 1986, LIFE SCI, V38, P997, DOI 10.1016/0024-3205(86)90233-X; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA	32	65	67	2	20	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					58	67		10.1097/00001199-199808000-00006			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000006	9651240				2022-02-06	
J	Pike, BR; Zhao, XR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL				Pike, BR; Zhao, XR; Newcomb, JK; Wang, KKW; Posmantur, RM; Hayes, RL			Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						alpha-spectrin; fodrin; CPP32; cysteine proteases; brain; rat; trauma	KINASE INHIBITOR STAUROSPORINE; TRAUMATIC BRAIN INJURY; DELAYED NEURONAL DEATH; PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE; GLOBAL-ISCHEMIA; NERVOUS-SYSTEM; ENDONUCLEASE	Caspase 3-like proteases are key executioners in mammalian apoptosis, and the calpain family of cysteine proteases has also been implicated as an effector of the apoptotic cascade, However, the influence of upstream events on calpain/caspase activation and the role of calpain/caspase activation on subsequent downstream events are poorly understood. This investigation examined the temporal profile of apoptosis-related events after staurosporine-induced apoptosis in mixed glial-neuronal septo-hippocampal cell cultures. Following 3 hr exposure to staurosporine (0.5 mu M), calpain and caspase 3-like proteases processed a-spectrin to their signature proteolytic fragments prior to endonuclease-mediated DNA fragmentation (not evident until 6 hr), indicating that endonuclease activation is downstream from calpain/ caspase activation, Cycloheximide, a general protein synthesis inhibitor, completely prevented processing of alpha-spectrin by calpains and caspase 3-like proteases, DNA fragmentation and cell death, indicating that de novo protein synthesis is an upstream event necessary for activation of calpains and caspase 3-like proteases, Calpain inhibitor II and the pan-caspase inhibitor Z-D-DCB each inhibited their respective protease-specific processing of alpha-spectrin and attenuated endonuclease DNA fragmentation and cell death. Thus, activation of calpains and caspase 3-like proteases is an early event in staurosporine-induced apoptosis, and synthesis of, as yet, unknown protein(s) is necessary for their activation. (C) 1998 Wiley-Liss, Inc.	Univ Texas, Dept Neurosurg, Hlth Sci Ctr, Viviam L Smith Ctr Neurol Res, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Ann Arbor, MI USA		Hayes, RL (corresponding author), Univ Texas, Dept Neurosurg, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Med Sch Bldg,Suite 7-154,6431 Fannin St, Houston, TX 77030 USA.	rhayes@heart.med.uth.tmc.edu		Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER		BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Cagnoli CM, 1996, J MOL NEUROSCI, V7, P65, DOI 10.1007/BF02736849; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1984, J IMMUNOL, V132, P38; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CONTI AC, 1996, J NEUROTRAUM, V13, P595; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Linnik MD, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P33; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NEWCOMB JK, 1997, J NEUROTRAUM, V14, P763; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PAPAS S, 1992, EUR J NEUROSCI, V4, P758, DOI 10.1111/j.1460-9568.1992.tb00185.x; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; Sloviter R S, 1996, Neurologia, V11 Suppl 4, P29; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	70	65	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN 1	1998	52	5					505	520		10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZQ760	WOS:000073900300003	9632307				2022-02-06	
J	Selladurai, BM; Vickneswaran, M; Duraisamy, S; Atan, M				Selladurai, BM; Vickneswaran, M; Duraisamy, S; Atan, M			Coagulopathy in acute head injury - a study of its role as a prognostic indicator	BRITISH JOURNAL OF NEUROSURGERY			English	Article						coagulopathy; disseminated intravascular coagulation; head injury; outcome	DISSEMINATED INTRAVASCULAR COAGULATION; ABNORMALITIES; FIBRINOLYSIS; CT	The aim of this investigation was to determine the prognostic value of coagulation abnormalities in a defined subset of patients with acute head injury. Prothrombin time, accelerated partial thromboplastin time (APTT), thrombin clotting time, fibrinogen assay, platelet count, fibrin degradation products (FDP) were assayed in 204 patients with acute closed head injury. Their values were graded on a score 0-3 and the sum score for each patient regarded as the disseminated intravascular coagulation (DIG) score. Moderate to severe DIC scores were evident in 38% of the cohort. At least one parameter was abnormal in 71% of patients. The DIC score correlated inversely with the Glasgow coma score (GCS) (p<0.0001). In the GCS 13-15 subset, FDP scores were significant predictors of poor outcome (p<0.001). In the GCS 6-12 subset, the APTT score (p<0.001), and DIC score (p<0.0001) predicted an adverse outcome. The DIC scores were significantly abnormal in most patients who had a poor outcome, without evidence of adverse predictors on CT. Logistic regression analysis confirmed the independent predictive capacity of APTT, FDP and DIC scores when values for GCS were fixed. Abnormal haemostatic parameters may enhance the predictive ability in subsets of patients with acute head injury defined by clinical or CT predictors.	UNIV KEBANGSAAN MALAYSIA, DIV NEUROSURG, KUALA LUMPUR, MALAYSIA; UNIV KEBANGSAAN MALAYSIA, DEPT RADIOL, KUALA LUMPUR, MALAYSIA; HOSP KUALA LUMPUR, DEPT NEUROSURG, KUALA LUMPUR, MALAYSIA; HOSP KUALA LUMPUR, DEPT HAEMATOL, KUALA LUMPUR, MALAYSIA				Mathaneswaran, Vickneswaran/E-5180-2010; Mathaneswaran, Vickneswaran/A-1228-2011				BICK RL, 1978, AM J HEMATOL, V5, P265, DOI 10.1002/ajh.2830050311; COOPER PR, 1986, NEUROSURGERY, V19, P531; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; SPERO JA, 1980, THROMB HAEMOSTASIS, V43, P28; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718	19	65	75	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	1997	11	5					398	404					7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	YB241	WOS:A1997YB24100005	9474270				2022-02-06	
J	Tavalin, SJ; Ellis, EF; Satin, LS				Tavalin, SJ; Ellis, EF; Satin, LS			Inhibition of the electrogenic Na pump underlies delayed depolarization of cortical neurons after mechanical injury or glutamate	JOURNAL OF NEUROPHYSIOLOGY			English	Article							EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; SODIUM-PUMP; EXTRACELLULAR POTASSIUM; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; CELL-CULTURE; RAT; NEUROTOXICITY; INVITRO	We previously characterized the electrophysiological response of cortical neurons to a brief sublethal stretch-injury using an in vitro model of traumatic brain injury. This model revealed that cortical neurons undergo a stretch-induced delayed depolarization (SIDD) of their resting membrane potential (RMP) which is similar to 10 mV in magnitude. SIDD is dependent on N-methyl-D-aspartate (NIMDA) receptor activation, neuronal firing, and extracellular calcium for its induction but not its maintenance. SIDD was maximal 1 h after the insult and required incubation at 37 degrees C. The present study examined the mechanism mediating SIDD and its relation to glutamate receptor activation. The Na pump inhibitor ouabain was used to assess the contribution of the Na pump to the RMP of control and stretched neurons using whole cell patch-clamp techniques. The nitric oxide(NO) synthase inhibitor N omega-nitro-L-arginine and a polyethylene glycol conjugate of superoxide dismutase were used to assess whether NO or superoxide anion, respectively, were involved in the induction of SIDD. Neurons were exposed to exogenous glutamate in the absence of cell stretch to determine whether glutamate alone can mimic SIDD. We report that SIDD is mediated by Na pump inhibition and is likely to result from reduced energy levels since the RMP of neurons dialyzed with a pipette solution containing 5 mM ATP were identical to controls. NO, but not superoxide anion, also may contribute to SIDD. A 3-min exposure to 10 mu M glutamate produced a SIDD-like depolarization also associated with Na pump inhibition. The results suggest that Na pump inhibition secondary to alterations in cellular energetics underlies SIDD. Na pump inhibition due to glutamate exposure may contribute to traumatic brain injury or neurodegenerative diseases linked to glutamate receptor activation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL, RICHMOND, VA 23298 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07027] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; BRINES ML, 1995, NEUROSCI LETT, V191, P145, DOI 10.1016/0304-3940(95)11577-J; BRINES ML, 1992, BRAIN RES, V591, P94, DOI 10.1016/0006-8993(92)90982-F; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362, DOI 10.1152/jn.1992.68.2.362; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DENHERTOG A, 1969, J PHYSIOL-LONDON, V204, P523, DOI 10.1113/jphysiol.1969.sp008929; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA A, 1992, DEV BRAIN RES, V65, P101, DOI 10.1016/0165-3806(92)90013-M; FUKUDA A, 1992, J NEUROPHYSIOL, V68, P28, DOI 10.1152/jn.1992.68.1.28; GLYNN IM, 1975, ANNU REV PHYSIOL, V37, P13, DOI 10.1146/annurev.ph.37.030175.000305; HAGLUND MM, 1985, BRAIN RES, V343, P198, DOI 10.1016/0006-8993(85)91180-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES SW, 1989, NEURON, V3, P153, DOI 10.1016/0896-6273(89)90028-7; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCCORMICK DA, 1987, J PHYSIOL-LONDON, V393, P743, DOI 10.1113/jphysiol.1987.sp016851; NATHANSON JA, 1995, NEURON, V14, P781, DOI 10.1016/0896-6273(95)90222-8; Nilsson P, 1990, J CEREB BLOOD FLOW M, V10, P331; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; RETZ KC, 1982, J NEUROCHEM, V38, P196, DOI 10.1111/j.1471-4159.1982.tb10872.x; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; THOMPSON SM, 1985, J NEUROSCI, V5, P817; THOMPSON SM, 1986, J NEUROPHYSIOL, V56, P507, DOI 10.1152/jn.1986.56.2.507; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563, DOI 10.1152/jn.1994.72.6.2563; WHITE RJ, 1995, J NEUROSCI, V15, P1318; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zhang L., 1996, FASEB Journal, V10, pA281	46	65	66	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	1997	77	2					632	638		10.1152/jn.1997.77.2.632			7	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	WK036	WOS:A1997WK03600011	9065836				2022-02-06	
J	Wilson, S; Smith, GA; Preisch, J; Casamassimo, PS				Wilson, S; Smith, GA; Preisch, J; Casamassimo, PS			Epidemiology of dental trauma treated in an urban pediatric emergency department	PEDIATRIC EMERGENCY CARE			English	Article							CHILDREN; INJURIES	Study objective: To describe the epidemiology of traumatic dental injuries to children treated in an urban pediatric emergency department (ED). Design: A descriptive study of a consecutive series of patients. Setting: The ED of a large, academic children's hospital. Participants: Children presenting to the ED with dental trauma from December 1992 to November 1993. Results: Of 1459 children treated for dental emergencies, 541 had dental trauma (37%) and were enrolled in this study. Patients ranged in age from five months to 18 years. Fifty-nine percent of patients were less than seven years of age, and 59% of patients were male. Falls caused 63% of injuries, followed by being struck (17%), and motor vehicle crashes (2%). Injuries to the soft tissues included lacerations (32%), swelling (8%), abrasions (7%), and contusions (6%). Injuries to hard dental structures included tooth fractures (33%), luxations (18%), concussions (12%), avulsions (8%), and jaw fractures (1%). Tooth luxation and concussion were more common among children less than seven years of age, and fractures to the tooth crown with dentin exposure (Ellis class II) were seen most often among children with permanent dentition (chi(2) = 41.4, P < 0.005). The central incisors were the teeth most frequently traumatized. Conclusion: Findings of this large consecutive series provide a useful description of the epidemiology of this common type of pediatric trauma for pediatric emergency care providers.	OHIO STATE UNIV,SCH DENT,COLUMBUS,OH 43210		Wilson, S (corresponding author), COLUMBUS CHILDRENS HOSP,DEPT PEDIAT DENT,COLUMBUS,OH 43205, USA.						Andreasen F M, 1991, Curr Opin Dent, V1, P535; Baker SP, 1992, THE INJURY FACT BOOK, VSecond; BATTENHOUSE MR, 1988, J DENT CHILD     JAN, P68; BENAMAR A, 1977, ISRAEL J DENT MED, V26, P35; Berger J L, 1980, J Hosp Dent Pract, V14, P100; BERKOWITZ R, 1980, CLIN PEDIATR, V19, P166, DOI 10.1177/000992288001900302; Carter A P, 1972, J Public Health Dent, V32, P251, DOI 10.1111/j.1752-7325.1972.tb03982.x; FORSBERG CM, 1990, SWED DENT J, V14, P115; HARDWICK JL, 1954, J DENT RES, V33, P730; HARRINGTON MS, 1988, J DENT CHILD     SEP, P334; HAYRINENIMMONEN R, 1990, ENDOD DENT TRAUMATOL, V6, P208; Henry R J, 1991, Pediatr Nurs, V17, P162; Holland T, 1988, J Paediatr Dent, V4, P13; Judd P L, 1985, Ont Dent, V62, P19; JUDD PL, 1985, ONTARIO DENT, V62, P23; Lewis TE, 1959, ANGLE ORTHOD, V29, P128; MAJEWSKI RF, 1988, J DENT CHILD     SEP, P339; MEADOW D, 1984, Pediatric Dentistry, V6, P248; MUELLER W A, 1989, Pediatrician, V16, P147; NELSON L P, 1990, Pediatric Emergency Care, V6, P62, DOI 10.1097/00006565-199003000-00018; Nicholas N K, 1980, N Z Dent J, V76, P8; ONEIL DW, 1989, ORAL SURG ORAL MED O, V68, P691, DOI 10.1016/0030-4220(89)90157-6; PENNYCOOK A, 1993, J ROY SOC MED, V86, P702; PEREZ R, 1991, ENDOD DENT TRAUMATOL, V7, P212; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; SANCHEZ AV, 1990, ENDOD DENT TRAUMATOL, V6, P63; *SPSS, 1992, SPSS PC PLUS TM BAS; TOMS BV, 1976, BRIT DENT J, V140, P415, DOI 10.1038/sj.bdj.4803775; UJI T, 1988, ENDOD DENT TRAUMATOL, V4, P63; Widmer R P, 1992, Aust Fam Physician, V21, P1263; York A H, 1978, N Z Dent J, V74, P218; Zeng Yang, 1994, Pediatric Dentistry, V16, P419	32	65	67	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1997	13	1					12	15		10.1097/00006565-199702000-00004			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	WK328	WOS:A1997WK32800004	9061727				2022-02-06	
J	Ghirnikar, RS; Lee, YL; He, TR; Eng, LF				Ghirnikar, RS; Lee, YL; He, TR; Eng, LF			Chemokine expression in rat stab wound brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						mechanical injury; gliosis; GFAP; astrocyte	FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; LOCALIZATION; ASTROCYTES; CYTOKINES; INCREASE; DISEASE	A traumatic injury to the adult mammalian central nervous system (CNS) results in reactive astrogliosis and the migration of hematogenous cells into the damaged neural tissue. Chemokines, a novel class of chemoattractant cytokines, are now being recognized as mediators of the inflammatory changes that occur following injury. The expression of MCP-1 (macrophage chemotactic peptide-1), a member of the beta family of chemokines, has recently been demonstrated in trauma in the rat brain (Berman et al.: J Immunol 156:3017-3023, 1996). Using a stab wound model for mechanical injury, we studied the expression of two other beta chemokines: RANTES (Regulated on Activation, Normal T cell Expressed and Secreted) and MIP-1 beta (macrophage inflammatory protein-1 beta) in the rat brain. The stab wound injury was characterized by widespread gliosis and infiltration of hematogenous cells. Immunohistochemical staining revealed the presence of RANTES and MIP-1 beta in the injured brain, RANTES and MIP-1 beta were both diffusely expressed in the necrotic tissue and were detected as early as 1 day post-injury (dpi). Double-labeling studies showed that MIP-1 beta, but not RANTES, was expressed by reactive astrocytes near the lesion site. In addition, MIP-1 beta staining was also detected on macrophages at the site of injury. The initial expression of the chemokines closely correlated with the appearance of inflammatory cells in the injured CNS, suggesting that RANTES and MIP-1 beta may play a role in the inflammatory events of traumatic brain injury. This study also demonstrates for the first time MIP-1 beta expression in reactive astrocytes following trauma to the rat CNS. (C) 1996 Wiley-Liss, Inc.	VAPA HLTH CARE SYST, PATHOL RES 113R, DEPT PATHOL, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011632] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-11632] Funding Source: Medline		Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BENVENISTE EN, 1993, ASTROCYTES PHARM FUN, P355; Berman JW, 1996, J IMMUNOL, V156, P3017; BROSNAN CF, 1993, ADV NEUROL, V59, P349; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Hopkins Stephen J., 1995, Trends in Neurosciences, V18, P83, DOI 10.1016/0166-2236(95)93881-W; HULKOWER K, 1993, J IMMUNOL, V150, P2525; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KUNA P, 1993, J IMMUNOL, V150, P1932; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; NEUGARTEN J, 1995, J AM SOC NEPHROL, V5, P1903; NOE KH, 1996, J NEUROCHEM S, V66, pSD71; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHMOUDER RL, 1993, KIDNEY INT, V44, P43, DOI 10.1038/ki.1993.211; SEEBACH J, 1995, J IMMUNOL, V155, P4367; TANI M, 1994, BRAIN PATHOL, V4, P135, DOI 10.1111/j.1750-3639.1994.tb00824.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WILSON SD, 1990, J EXP MED, V171, P1301, DOI 10.1084/jem.171.4.1301; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOODWARD WR, 1992, J NEUROSCI, V12, P142	36	65	65	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	1996	46	6					727	733					7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VY927	WOS:A1996VY92700010	8978507				2022-02-06	
J	Bigler, ED; Johnson, SC; Anderson, CV; Blatter, DD; Gale, SD; Russo, AA; Ryser, DK; Macnamara, SE; Bailey, BJ; Hopkins, RO; Abildskov, TJ				Bigler, ED; Johnson, SC; Anderson, CV; Blatter, DD; Gale, SD; Russo, AA; Ryser, DK; Macnamara, SE; Bailey, BJ; Hopkins, RO; Abildskov, TJ			Traumatic brain injury and memory: The role of hippocampal atrophy	NEUROPSYCHOLOGY			English	Article							RECOGNITION MEMORY; TEMPORAL LOBECTOMY; AMNESIC PATIENTS; HEAD-INJURY; SEGMENTATION; HUMANS; MRI	In traumatically brain-injured (TBI) patients (N = 83), memory performance was examined on the Warrington Recognition Memory Test, Rey-Osterrieth Complex Figure, and the Logical Memory and Visual Reproduction subtests of the Wechsler Memory Scale-Revised in relationship to time postinjury and structural changes based on MRI volumetry, including hippocampus volume. Significant trauma-induced changes were observed, including hippocampal atrophy. Structure-function relationships generally became significant only after 90 days postinjury. Memory tended to relate more to the degree of hippocampal atrophy, particularly left hippocampus, than to nonspecific indicators such as the temporal horns or the ventricle-to-brain ratio. A stronger relationship with left versus right hippocampus was evident for measures of verbal and supposedly nonverbal memory. These results are discussed with regard to the role the hippocampus may play in a neural system of memory.	LDS HOSP,SALT LAKE CITY,UT		Bigler, ED (corresponding author), BRIGHAM YOUNG UNIV,DEPT PSYCHOL,POB 25543,PROVO,UT 84602, USA.			Johnson, Sterling/0000-0002-8501-545X			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BIGLER ED, IN PRESS AM J NEUROR; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BIGLER ED, 1996, M INT NEUR SOC CHIC; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLATTER DD, IN PRESS AM J NEUROR; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; CLARKE LP, 1993, MAGN RESON IMAGING, V11, P95, DOI 10.1016/0730-725X(93)90417-C; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; COMPTON JM, 1992, ARCH CLIN NEUROPSYCH, V7, P165, DOI 10.1016/0887-6177(92)90010-K; FREE SL, 1995, AM J NEURORADIOL, V16, P637; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gean AD, 1994, IMAGING HEAD TRAUMA; GOLDBERG E, 1995, J CLIN EXP NEUROPSYC, V17, P193, DOI 10.1080/01688639508405118; HARTER SB, 1995, AM J NEURORADIOL, V16, P700; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; HUNT WA, 1993, ALCOHOL CLIN EXP RES, V17, P1055, DOI 10.1111/j.1530-0277.1993.tb05664.x; HUPPERT FA, 1976, CORTEX, V12, P3, DOI 10.1016/S0010-9452(76)80024-X; ISAACSON RL, 1986, HIPPOCAMPUS; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KAPUR N, 1987, BRIT J CLIN PSYCHOL, V26, P144, DOI 10.1111/j.2044-8260.1987.tb00741.x; KESNER RP, 1992, NEUROPSYCHOLOGY MEMO, P106; KIM JH, 1995, AM J NEURORADIOL, V16, P627; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LORING DW, 1993, NEUROLOGY, V43, P1789, DOI 10.1212/WNL.43.9.1789; Osborn AG, 1994, DIAGNOSTIC NEURORADI; Osterrieth PA, 1994, ARCH PSYCHOL, V30, P286; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; RAUSCH R, 1993, ARCH NEUROL-CHICAGO, V50, P812, DOI 10.1001/archneur.1993.00540080023008; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROLAND PE, 1991, MEMORY ORG LOCUS CHA, P95; ROSEN DL, 1987, CEREBRAL CORTEX, V6; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1992, NEUROPSYCHOLOGY MEMO; Squire LR., 1987, MEMORY BRAIN; TRENERRY MR, 1993, NEUROLOGY, V43, P1800, DOI 10.1212/WNL.43.9.1800; Warrington EK., 1984, WARRINGTON RECOGNITI; Wechsler D, 1987, MEMORY SCALE REVISED; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	56	65	65	1	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					333	342		10.1037/0894-4105.10.3.333			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200003					2022-02-06	
J	Raskin, SA; Rearick, E				Raskin, SA; Rearick, E			Verbal fluency in individuals with mild traumatic brain injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	International-Neuropsychological-Society Annual Meeting	1994	ANGERS, FRANCE	Int Neuropsychol Soc			MINOR HEAD-INJURY; FRONTAL-LOBE; INTELLIGENCE	Tests of verbal fluency that require either retrieval by semantic category or retrieval by initial letter were presented to 19 participants with mild traumatic brain injury (MTBI) and 24 control (NC) participants. Performance on these tasks was analyzed for total number of words produced, the presence of semantic clusters in the order of words produced, the presence of phonemic clusters in the order of word, produced, and number of errors (i.e., perseverations, words out of category). Individuals with MTBI produced fewer words and made more errors than NCs, but their production contained an equal proportion of semantic and phonemic clusters. These data are discussed in relation to a previous study in patients with Parkinson's disease (PD). FD participants did not make more errors than age-matched NCs despite reduced production. Implications for memory and executive function deficits following MTBI are discussed.	TRINITY COLL,PROGRAM NEUROSCI,HARTFORD,CT 06106; NEUROPSYCHOL SERV,PUYALLUP,WA		Raskin, SA (corresponding author), TRINITY COLL,DEPT PSYCHOL,HARTFORD,CT 06106, USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALVES W, 1992, REHABILITATION POSTC; AUERBACH S, 1989, TRAUMATIC BRAIN INJU, V3, P1; Beck A. T., 1993, BECK DEPRESSION INVE; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; DRACHMAN DA, 1972, J EXP PSYCHOL, V93, P302, DOI 10.1037/h0032489; ESTES WK, 1974, AM PSYCHOL, V29, P740, DOI 10.1037/h0037458; FURRY CA, 1973, J GERONTOL, V28, P73, DOI 10.1093/geronj/28.1.73; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goodglass H., 1972, ASSESSMENT APHASIA R; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hamster K., 1983, MULTILINGUAL APHASIA; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HOLLINGSHEAD AS, 1977, 4 FACTOR INDEX SOCIA; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LAINE M, 1988, J CLIN EXPT NEUROPSY, V10; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; Mateer C.A., 1992, REHABILITATION POSTC; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; MILLER E, 1975, PSYCHOL MED, V5, P255, DOI 10.1017/S0033291700056610; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milner B., 1964, FRONTAL GRANULAR COR; MONTGOMERY K, 1982, THESIS U VICTORIA VI; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RAMIER AM, 1970, REV NEUROL, V123, P17; RASKIN SA, 1992, NEUROPSYCHOLOGIA, V30, P95, DOI 10.1016/0028-3932(92)90018-H; Ruff R. M., 1989, MILD HEAD INJURY; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; WILSON BA, 1992, NEUROPSYCHOLOGY MEMO; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	36	65	65	0	6	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					416	422		10.1037/0894-4105.10.3.416			7	Psychology, Clinical; Neurosciences; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200013					2022-02-06	
J	Posmantur, RM; Kampfl, A; Liu, SJ; Heck, K; Taft, WC; Clifton, GL; Hayes, RL				Posmantur, RM; Kampfl, A; Liu, SJ; Heck, K; Taft, WC; Clifton, GL; Hayes, RL			Cytoskeletal derangements of cortical neuronal processes three hours after traumatic brain injury in rats: An immunofluorescence study	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apical dendrites; axon; calpain; cortex; MAP2; neurofilament; trauma	PROTEINS FOLLOWING OCCLUSION; MIDDLE CEREBRAL-ARTERY; HIPPOCAMPAL SLICES; PROTEOLYSIS; CALCIUM; CALPAIN; DEGRADATION; PHOSPHORYLATION; DEGENERATION; HYPOXIA	Semiquantitative Western blot analyses have shown that traumatic brain injury (TBI) can produce significant loss of cytoskeletal proteins (neurofilament 68 [NF68], neurofilament 200 [NF200] and microtubule associated protein 2 [MAP2]) possibly by calpain-mediated proteolysis. Thus, we employed immunofluorescence (light and confocal microscopy) to study the histopathological correlates of acute neurofilament and MAP2 protein decreases observed 3 hours following unilateral cortical injury in rats. TBI induced dramatic alterations in NF68, NF200, and MAP2 immunolabeling in dendrites within and beyond contusion sites ipsilateral and contralateral to the injury site. Marked changes in immunolabeling were associated with but not exclusively restricted to regions of dark shrunken neurons labeled by hematoxylin and eosin staining, a morphopathological response to injury suggesting impending cell death. Light microscopic studies of NF200 immunofluorescence revealed a prominent fragmented appearance of apical dendrites of pyramidal neurons within layers 3 and 5, as well as a loss of fine dendritic arborization within layer 1. Confocal microscopy detected varying degrees of NF200 disassembly associated with these areas of neurofilament fragmentation. Light microscopic studies of NF68 immunofluorescence detected subtle and less severe structural changes including smaller breaks and focal vacuolization of apical dendrites. Light microscopic immunofluorescence of MAP2 revealed changes similar to those seen for NF200. Acute axonal alterations detected with NF68 were minimal compared to immunofluorescence changes seen in dendritic regions. Therefore, preferential dendritic cytoskeletal derangements may be an early morphological feature of experimental traumatic brain injury in vivo. In addition, these cytoskeletal derangements may not be exclusively restricted to sites of contusion and cell death.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,HOUSTON,TX 77030						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, P01 NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1995, SCIENCE, V268, P2200; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; BRYAN RM, 1995, IN PRESS ANESTH ANAL; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI T, 1989, J NEUROSURG, V67, P244; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harris J.K, 1990, EPILEPSY CURRENT APP, P227; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKKS RR, 1994, SOC NEUR ABS; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; JOHNSON GVW, 1993, J NEUROSCI RES, V34, P642, DOI 10.1002/jnr.490340607; KAKULAS BA, 1992, HDB CLIN NEUROLOGY, P21; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A., 1995, Journal of Neurotrauma, V12, P491; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI Z, 1995, IN PRESS NEUROCHEM I; LUDIN B, 1993, HIPPOCAMPUS, V3, P61; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; North M, 1989, PROTEOLYTIC ENZYMES, P105; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAATMAN KE, 1994, SOC NEUR ABS; SAATMAN KE, 1994, J NEUR ABS, P138; SCHLAEPFER WW, 1973, J CELL BIOL, V59, P456, DOI 10.1083/jcb.59.2.456; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SUGIMOTO A, 1994, CEREBRAL ISCHEMIC BA, P201; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	54	65	73	1	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	1996	55	1					68	80		10.1097/00005072-199601000-00007			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	TP445	WOS:A1996TP44500007	8558173	Bronze			2022-02-06	
J	Memon, ZI; Altura, BT; Benjamin, JL; Cracco, RQ; Altura, BM				Memon, ZI; Altura, BT; Benjamin, JL; Cracco, RQ; Altura, BM			Predictive value of serum ionized but not total magnesium levels in head injuries	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article						brain injury; head injury; ion-selective electrodes; ionized calcium; ionized magnesium	BRAIN INJURY; HYPOMAGNESEMIA; GLUTAMATE; ISCHEMIA	Despite a wealth of recent literature and research on traumatic brain injury, very little has been applicable to diagnosing and treating this syndrome at a tissue level. Part of this problem is the inability to assess rapidly and early in the syndrome the degree or progression of brain injury at a tissue level using simple biochemical analytes. With this in mind, we designed a study in 66 human subjects, who presented with acute blunt head trauma, to determine whether free, ionized serum magnesium (IMg2+) and/or free, ionized serum calcium (ICa2+) levels correlated with the severity of head trauma (HT) and whether any predictive reliable patterns emerge. By using a new ion-selective electrode (ISE) for IMg2+, we have been able to determine IMg2+ and ICa2+ within minutes after sampling in the serum of patients early (1-8 h) after HT. These studies reveal that acute HT is associated with graded deficits (up to 62%, mean=25%) in serum IMg2+, but not in total serum Mg, which are related to severity of injury based on CT scans and other diagnostic parameters. The greater the degree of injury, the greater the ICa2+/IMg2+ ratio. These ionic findings are compatible with the idea that early ischaemia after head trauma may be important in determining neurological outcome. Our findings provide the first evidence for divalent cation changes in blood after traumatic brain injury, which could be of both diagnostic and prognostic value in patients with traumatic brain injury.	SUNY HLTH SCI CTR,DEPT PHYSIOL,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT NEUROL,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY 11203						NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008674] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-08674] Funding Source: Medline		Aikawa J.K., 1981, MAGNESIUM ITS BIOL S, V1st ed.; ALLGROVE J, 1984, CLIN ENDOCRINOL, V21, P435, DOI 10.1111/j.1365-2265.1984.tb03230.x; Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; Altura B T, 1984, Magnesium, V3, P195; Altura B. T., 1992, Magnesium and Trace Elements, V10, P90; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ALTURA BM, 1987, MAGNESIUM CELLULAR P; ALTURA BT, 1992, METHOD FIND EXP CLIN, V14, P297; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P77, DOI 10.3109/00365519409095213; ALTURA BT, 1980, NEUROSCI LETT, V20, P323, DOI 10.1016/0304-3940(80)90168-8; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BECKER DP, 1985, CENTRAL NERVOUS SYST; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Dubey S N, 1975, Neurol India, V23, P17; FAGG GL, 1985, TRENDS NEUROSCI, P207; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; HUANG Q, 1989, FASEB Journal, V3, pA845; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JANE JA, 1991, CENTRAL NERVOUS SYST; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; JUAN D, 1982, SURGERY, V91, P510; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KING LR, 1973, ANN SURG, V177, P126, DOI 10.1097/00000658-197301000-00022; Mangal B D, 1975, J Assoc Physicians India, V23, P339; MARSHALL LF, 1990, CURR OPIN NEUROL NEU, V3, P4; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MCLAURIN RL, 1976, HDB CLIN NEUROLOGY, V23, P109; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUDE RK, 1987, MAGNESIUM CELLULAR P, P183; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6	35	65	67	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5513			SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.	DEC	1995	55	8					671	677		10.3109/00365519509075397			7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	TM055	WOS:A1995TM05500003	8903837				2022-02-06	
J	KARZMARK, P; HALL, K; ENGLANDER, J				KARZMARK, P; HALL, K; ENGLANDER, J			LATE-ONSET POST-CONCUSSION SYMPTOMS AFTER MILD BRAIN INJURY - THE ROLE OF PREMORBID, INJURY-RELATED, ENVIRONMENTAL, AND PERSONALITY FACTORS	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POSTCONCUSSIONAL SYNDROME; SEQUELAE; TRAUMA; IMPACT; TIME	The present study investigated the possible role of a number of pre- peri-, and post-traumatic factors in the experience of post-concussion syndrome (PCS). These factors included: (1) history of premorbid risk factors, (2) severity of injury, and (3) post-morbid functioning and environmental factors. Subjects were 55 persons with mild brain injury. PCS was defined in terms of the severity and impact of 'late-onset' symptoms. Pre- and peri-traumatic factors were not associated with level of PCS symptom impact. Among post-traumatic factors, only level of psychological distress was strongly associated with impact level. The results suggest the importance of psychological factors in prolonged PCS.			KARZMARK, P (corresponding author), SANTA CLARA VALLEY MED CTR,PSYCHOL SERV,751 S BASCOM AVE,SAN JOSE,CA 95128, USA.						ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALFANO PP, 1992, J CLIN EXPT NEUROPSY, V14, P77; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; KAY DWK, 1971, LANCET, V2, P1052; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; Mahon D, 1989, J Neurosci Nurs, V21, P382; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER H, 1961, BRIT MED J, V1, P991; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; Wechsler, 1997, WECHSLER ADULT INTEL; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured]	28	65	65	1	9	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					21	26		10.3109/02699059509004567			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200003	7874092				2022-02-06	
J	FRESTA, M; PUGLISI, G; DIGIACOMO, C; RUSSO, A				FRESTA, M; PUGLISI, G; DIGIACOMO, C; RUSSO, A			LIPOSOMES AS IN-VIVO CARRIERS FOR CITICOLINE - EFFECTS ON RAT CEREBRAL POSTISCHEMIC REPERFUSION	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							REVERSE-PHASE EVAPORATION; PHOSPHOLIPID-VESICLES; ENCAPSULATION EFFICIENCY; CDP-CHOLINE; DELIVERY; RELEASE; BRAIN; DRUG; MICRODIALYSIS; MULTILAMELLAR	Citicoline is a therapeutic agent widely used in the treatment of brain injury, for example in cerebrovascular disease or traumatic accidents. Unfortunately, the strong polar nature of this drug prevents it crossing the blood-brain barrier. In this paper, the possibility of efficiently trapping citicoline in liposomes to improve its therapeutic effects is reported. The citicoline-encapsulation efficiency, drug leakage and size analysis of various liposome systems were studied. The real therapeutic effectiveness of these citicoline liposome formulations was evaluated by biological assay. The effects of free and liposome encapsulated citicoline on survival rate of ischaemic reperfused male Wistar rats (80-100g) were investigated, Of the phospholipid mixtures used in citicoline liposome formulation the best in terms of delivery and therapeutic effects was 1,2-dipalmitoyl-sn-glycero-phosphocholine : dipalmitoyl-DL-alpha-phosphatidyl-L-serine: cholesterol (7:4:7 molar ratio). This phospholipid mixture was also assayed for brain conjugated diene levels in rats, since this parameter is an index of lipid peroxidation in rat cerebral cortex during post-ischaemic reperfusion. A citicoline-loaded phospholipid mixture has produced an increase in rat survival rate of about 24% and a reduction in diene levels of 60%, compared to the free drug.	UNIV CATANIA,IST CHIM FARMACEUT & TOSSICOL,I-95125 CATANIA,ITALY; ETH ZURICH,INST POLYMERE,CH-8092 ZURICH,SWITZERLAND; UNIV CATANIA,IST CHIM BIOL,I-95125 CATANIA,ITALY				Fresta, Massimo/K-8859-2016	Fresta, Massimo/0000-0001-8062-817X; Di Giacomo, Claudia/0000-0002-2665-0007; Russo, Alessandra/0000-0003-2925-6600			AGUT J, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1045; ALLEN TM, 1981, BIOCHIM BIOPHYS ACTA, V640, P385, DOI 10.1016/0005-2736(81)90464-8; ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539; AMSELEM S, 1990, J PHARM SCI, V79, P1045, DOI 10.1002/jps.2600791202; ARIENTI G, 1979, J BIOCH, V28, P39; BAETHMANN A, 1991, ARZNEIMITTEL-FORSCH, V41-1, P310; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENITA S, 1984, J PHARM SCI-US, V73, P1751, DOI 10.1002/jps.2600731223; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berne B. J., 1976, DYNAMIC LIGHT SCATTE; CHU B, 1974, LASER LIGHT SCATTERI; FRESTA M, 1993, DRUG DEV IND PHARM, V19, P559, DOI 10.3109/03639049309062967; FRESTA M, 1993, INT J PHARM, V99, P145, DOI 10.1016/0378-5173(93)90356-K; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GINSBERG MD, 1991, ARZNEIMITTEL-FORSCH, V41-1, P334; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; GREENBERG JH, 1991, ARZNEIMITTEL-FORSCH, V41-1, P324; HENRY RJ, 1964, CLIN CHEM PRINCIPLES, P834; HILLERED L, 1990, J CEREB BLOOD FLOW M, V9, P607; HOGAN M, 1991, ARZNEIMITTEL-FORSCH, V41-1, P332; HOPE MJ, 1986, CHEM PHYS LIPIDS, V40, P89, DOI 10.1016/0009-3084(86)90065-4; Ito U, 1992, MATURATION PHENOMENO, P1; JULIANO RL, 1975, BIOCHEM BIOPH RES CO, V63, P651, DOI 10.1016/S0006-291X(75)80433-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KRIEGLSTEIN J, 1991, ARZNEIMITTEL-FORSCH, V41-1, P303; KUSCHINSKY W, 1991, ARZNEIMITTEL-FORSCH, V41-1, P284; LAROSA C, 1992, THERMOCHIM ACTA, V195, P139, DOI 10.1016/0040-6031(92)80056-3; LAROSA C, 1992, THERMOCHIM ACTA, V198, P181, DOI 10.1016/0040-6031(92)85072-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MARUYAMA K, 1993, BIOCHIM BIOPHYS ACTA, V1149, P209, DOI 10.1016/0005-2736(93)90203-C; MAYHEW E, 1984, LIPOSOME TECHNOLOGY, V2, P19; MCCULLOCH J, 1991, ARZNEIMITTEL-FORSCH, V41-1, P319; NOLL F, 1984, METHOD ENZYMAT AN, V6, P582; PALMER C, 1990, J CEREBR BLOOD F MET, V10, P227, DOI 10.1038/jcbfm.1990.39; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PUGLISI G, 1992, PHARMAZIE, V47, P212; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; SHIMAMOTO K, 1975, TAKEDA KENKYUSHO HO, V34, P189; SIESJO BK, 1991, ARZNEIMITTELFORSCH, V41-1, P288; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TALL AR, 1980, J LIPID RES, V21, P354; VANELLA A, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P311; VANELLA A, 1992, INT J DEV NEUROSCI, V10, P75, DOI 10.1016/0736-5748(92)90008-N; WHEELER KP, 1970, NATURE, V225, P449, DOI 10.1038/225449a0; WIDDER KJ, 1982, J PHARM SCI, V71, P379, DOI 10.1002/jps.2600710403; YASUHARA M, 1974, CURR THER RES CLIN E, V16, P346	48	65	70	0	2	ROYAL PHARMACEUTICAL SOC GREAT BRITAIN	LONDON	1 LAMBETH HIGH ST, LONDON, ENGLAND SE1 7JN	0022-3573			J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	1994	46	12					974	981		10.1111/j.2042-7158.1994.tb03252.x			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	PY734	WOS:A1994PY73400006	7714721				2022-02-06	
J	SEN, S; GOLDMAN, H; MOREHEAD, M; MURPHY, S; PHILLIS, JW				SEN, S; GOLDMAN, H; MOREHEAD, M; MURPHY, S; PHILLIS, JW			ALPHA-PHENYL-TERT-BUTYL-NITRONE INHIBITS FREE-RADICAL RELEASE IN BRAIN CONCUSSION	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						BRAIN CONCUSSION; ESR; POBN; HYDROXYL RADICAL; PBN; FREE RADICALS	CEREBRAL ISCHEMIC-INJURY; PHENYLNITRONE PBN; HEAD-INJURY; REPERFUSION; GENERATION; MICRODIALYSIS; GERBILS	Traumatic brain injury (TBI) is one of the important causes of mortality and morbidity. The pathogenesis of the underlying brain dysfunction is poorly understood. Recent data have suggested that oxygen free radicals play a key role in the primary and secondary processes of acute TBI. We report direct electron spin resonance (ESR) evidence of hydroxyl ((OH)-O-.) radical generation in closed-head injury of rats. Moderate brain concussion was produced by controlled and reproducible mechanical, fixed, closed-head injury. A cortical cup was placed over one cerebral hemisphere within 20 min of the concussion, perfused with artificial cerebrospinal fluid (aCSF) containing the spin trap agent pyridyl-N-oxide-tert-butyl nitrone (POBN, 100 mM), and superfusate samples collected at 10 min intervals for a duration up to 130 min post brain trauma. In addition, POBN was administered systemically (50 mg/kg body wt.) 10 min pretrauma and 20 min posttrauma to improve our ability to detect free radicals. ESR analysis of the superfusate samples revealed six line spectra (alpha(N) = 15.4 G and alpha(H)(beta) = 2.5 G) characteristic of POBN-OH radical adducts, the intensity of which peaked 40 min posttrauma. The signal was undetectable after 120 min. Administration of alpha-phenyl-tert-butyl-nitrone (PBN), a spin adduct forming agent systemically (100 mg/kg body wt. IP 10 min prior to concussion) alone or along with topical PBN (100 mM PBN in aCSF), significantly (p < 0.001) attenuated the ESR signal, suggesting its possible role in the treatment of TBI.	WAYNE STATE UNIV,SCH MED,DEPT PHYSIOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026912] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26912-05] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A20016, G0087C002] Funding Source: Medline		BRITIGAN BE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P213, DOI 10.1016/0304-4165(91)90269-M; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1988, OXYGEN RADICALS TISS, P92; HALLIWELL B, ACTA NEUROL SCAND S, V126; IKEDA Y, 1990, ACT NEUR S, V51, P74; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KIRSCH JR, 1987, FASEB J, V46, P799; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAI EK, 1986, ARCH BIOCHEM BIOPHYS, V244, P156, DOI 10.1016/0003-9861(86)90104-9; LANGE D G, 1990, Free Radical Biology and Medicine, V9, P97; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; ORIOT D, 1990, FASEB J, V4, pA419; OZAWA T, 1990, BIOCH INT, V26, P477; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SAKAMOTO A, 1991, FREE RADICAL BIO MED, V11, P385, DOI 10.1016/0891-5849(91)90155-V; Sano K, 1980, Neurol Res, V2, P253; Sen S., 1993, Society for Neuroscience Abstracts, V19, P636; TORBATI D, 1991, FASEB J, V5, pA891; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; ZINI I, 1992, NEUROSCI LETT, V138, P279, DOI 10.1016/0304-3940(92)90933-X	25	65	65	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN	1994	16	6					685	691		10.1016/0891-5849(94)90183-X			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	NL951	WOS:A1994NL95100002	8070671				2022-02-06	
J	GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D				GENTLEMAN, D; DEARDEN, M; MIDGLEY, S; MACLEAN, D			FORTNIGHTLY REVIEW - GUIDELINES FOR RESUSCITATION AND TRANSFER OF PATIENTS WITH SERIOUS HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN INJURY; CRITICALLY ILL PATIENTS; HEMATOMA		WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; LAW HOSP,CARLUKE ML8 5ER,LANARK,SCOTLAND		GENTLEMAN, D (corresponding author), DUNDEE ROYAL INFIRM,DUNDEE DD1 9ND,SCOTLAND.						ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GENTLEMAN D, 1992, INT SURG, V77, P297; GENTLEMAN D, 1990, LANCET, V335, P327; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LAMBERT SM, 1993, INJURY, V24, P333, DOI 10.1016/0020-1383(93)90058-E; McLaren C A, 1983, J R Coll Surg Edinb, V28, P399; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUNRO HM, 1993, BR J INTENSIVE CARE, V3, P210; REEVE WG, 1990, BRIT MED J, V300, P85, DOI 10.1136/bmj.300.6717.85; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; RUNCIE CJ, 1992, ANAESTHESIA, V47, P327, DOI 10.1111/j.1365-2044.1992.tb02175.x; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; VYVYAN HAL, 1991, ANAESTHESIA, V46, P395; 1988, RECOMMENDATIONS STAN; 1984, BMJ, V288, P983; 1993, ATLS COURSE MANUAL	25	65	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					547	552		10.1136/bmj.307.6903.547			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	WOS:A1993LV18000025	8400978	Bronze, Green Published			2022-02-06	
J	TAHA, JM; CRONE, KR; BERGER, TS; BECKET, WW; PRENGER, EC; SCOTT, RM; WALKER, ML				TAHA, JM; CRONE, KR; BERGER, TS; BECKET, WW; PRENGER, EC; SCOTT, RM; WALKER, ML			SIGMOID SINUS THROMBOSIS AFTER CLOSED HEAD-INJURY IN CHILDREN	NEUROSURGERY			English	Article						HEAD INJURY; SIGMOID SINUS; THROMBOSIS; TRAUMA	MR; SIGN	IN THE LITERATURE, clinical descriptions of sigmoid sinus thrombosis occurring after closed head injury in children are rare. One to 5 days after trauma to the back of the head, five children (aged 1 to 7 yr) presented with gait ataxia, vomiting, and headache. Trauma was mild in four children. Computed tomography of all the children, performed within 5 days after the injury, showed focal hyperdensity in the region of the left sigmoid sinus. Four children had extra-axial hyperdense collections along the left transverse sinus, and three had skull fractures adjacent to the left sigmoid sinus. Magnetic resonance imaging (MRI) of all the children, performed 2 to 6 days after injury, showed left sigmoid-sinus thrombosis and decreased flow or thrombosis within the lateral third of the left transverse sinus. All the children had MRI scans 4 to 6 weeks after their diagnosis and were followed up for 1 to 12 months. In four children whose symptoms subsided completely within 2 to 10 weeks, MRI showed recanalization of the sigmoid sinus within 4 to 6 weeks after injury. In one child whose symptoms resolved after 6 months, sigmoid-sinus thrombosis persisted with the formation of collateral flow. We conclude that traumatic sigmoid-sinus thrombosis should be suspected when a child has persistent or delayed gait ataxia and vomiting after injury to the back of the head. Computed tomography characteristically demonstrated focal hyperdensity within the sigmoid sinus that we term the dense sigmoid-sinus sign. Because the sinus recanalized and the symptoms subsided in most children within 6 weeks, we conclude that prophylactic medical or surgical intervention is not indicated.	UNIV CINCINNATI,COLL MED,DEPT NEUROSURG,231 BETHESDA AVE,CINCINNATI,OH 45267; CHILDRENS HOSP,MED CTR,DIV PEDIATR NEUROSURG,CINCINNATI,OH; CHILDRENS HOSP,MED CTR,DEPT RADIOL,CINCINNATI,OH; MAYFIELD NEUROSURG INST,CINCINNATI,OH								ACHIRON A, 1990, STROKE, V21, P817, DOI 10.1161/01.STR.21.5.817; ANDERSON SC, 1987, J COMPUT ASSIST TOMO, V11, P1059, DOI 10.1097/00004728-198711000-00028; BJORNEBRINK J, 1976, ANGIOLOGY, V27, P688, DOI 10.1177/000331977602701203; BRADLEY WG, 1985, RADIOLOGY, V154, P444; BUOANNO F, 1978, J COMPUT ASSIST TOMO, V2, P281; CONVERS P, 1986, NEUROCHIRURGIE, V32, P495; GHORAYEB BY, 1987, ARCH OTOLARYNGOL, V113, P749; GOLDBERG AL, 1986, J COMPUT ASSIST TOMO, V10, P16, DOI 10.1097/00004728-198601000-00003; GOLDENBERG RA, 1985, ARCH OTOLARYNGOL, V111, P56; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HARRIS TM, 1989, J COMPUT ASSIST TOMO, V13, P682, DOI 10.1097/00004728-198907000-00025; HULCELLE PJ, 1989, NEURORADIOLOGY, V31, P217, DOI 10.1007/BF00344346; IMAIZUMI M, 1980, J NEUROL, V22, P215; KAPP J, 1985, NEUROSURGERY, P1300; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; LENZ R, 1984, LARYNGOSCOPE, V4, P1451; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; MAS JL, 1990, STROKE, V21, P1350, DOI 10.1161/01.STR.21.9.1350; McCormick W.F., 1985, NEUROSURGERY, P1544; MITCHELL D, 1986, J NEUROL NEUROSUR PS, V49, P218, DOI 10.1136/jnnp.49.2.218; NISSEN A J, 1980, American Journal of Otology, V2, P164; RENGACHARY SS, 1985, NEUROSURGERY, P50; RIPPE DJ, 1990, AM J NEURORADIOL, V11, P199; SAMUEL J, 1987, J LARYNGOL OTOL, V101, P1227, DOI 10.1017/S0022215100103561; TOVI F, 1988, J LARYNGOL OTOL, V102, P623, DOI 10.1017/S0022215100105900; TSUDA JS, 1991, AJNR, V12, P481; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494	27	65	69	0	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1993	32	4					541	546		10.1227/00006123-199304000-00008			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	KV759	WOS:A1993KV75900008	8474644				2022-02-06	
J	SHARMA, HS; OLSSON, Y; CERVOSNAVARRO, J				SHARMA, HS; OLSSON, Y; CERVOSNAVARRO, J			EARLY PERIFOCAL CELL CHANGES AND EDEMA IN TRAUMATIC INJURY OF THE SPINAL-CORD ARE REDUCED BY INDOMETHACIN, AN INHIBITOR OF PROSTAGLANDIN SYNTHESIS - EXPERIMENTAL-STUDY IN THE RAT	ACTA NEUROPATHOLOGICA			English	Article						SPINAL CORD TRAUMA; EDEMA; MYELIN BASIC PROTEIN; INDOMETHACIN; PROSTAGLANDINS	ARACHIDONIC-ACID METABOLISM; CENTRAL-NERVOUS-SYSTEM; BRAIN EDEMA; PARA-CHLOROPHENYLALANINE; BLOOD-FLOW; THROMBOXANE; NEUROTRANSMISSION; EICOSANOIDS; MECHANISMS; SEROTONIN	The possibility that prostaglandins participate in the formation of perifocal edema and cell changes following a localized trauma to the spinal cord was investigated in a rat model. A laminectomy was performed in urethane-anesthetized animals at the thoracic T10-11 segment. Using a scalpel blade a unilateral lesion, about 2 mm deep and 5 mm long was made 1 mm to the right of the midline. The deepest part of the injury occupied Rexed's lamina VII of the dorsal horn. Animals were pretreated with the prostaglandin synthesis inhibitor, indomethacin (10 mg/kg, i.p. 30 min prior to trauma). Five hours after the injury the water content was determined and cell changes in and around the primary lesion were examined by light and electron microscopy. Normal and injured rats without indomethacin pretreatment served as controls. Untreated injured rats showed a profound increase of water content in the traumatized T10-11, the rostral (T9) and caudal (T12) segments compared with normal rats. These segments also exhibited marked cell changes in ipsilateral and contralateral dorsal and ventral horns. The gray matter had a spongy appearance and some nerve cells were condensed and distorted. The white matter contained many distorted fibers. Immunostaining for myelin basic protein showed a marked reduction of reaction product in the injured animals compared with normal rats. Ultrastructurally widened extracellular spaces, cytoplasmic vacuolation, swollen and condensed neurons, swollen astrocytes and vesiculation of myelin were frequent findings. Pretreatment of rats with indomethacin significantly reduced the accumulation of water in the traumatized and in the rostral and caudal segments. The structural changes were less pronounced particularly in the cranial and caudal segments. The results indicate that prostaglandins somehow are involved in the pathophysiology of perifocal spinal cord injury and influence both the fluid microenvironment and the early cell changes.	FREE UNIV BERLIN, KLINIKUM STEGLITZ, INST NEUROPATHOL, W-1000 BERLIN 45, GERMANY		SHARMA, HS (corresponding author), UNIV HOSP UPPSALA, INST PATHOL, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.		Sharma, Aruna/D-4430-2011				ABE K, 1989, ANN NY ACAD SCI, V559, P259; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BARKAI AI, 1989, ANN NY ACAD SCI, P559; BHATTACHARYA SK, 1989, INDIAN J EXP BIOL, V27, P393; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DEMEDIUK P, 1989, ANN NY ACAD SCI, V559, P433; DEMEDIUK P, 1989, ANN NY ACAD SCI, V559, P431; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; DEY PK, 1974, J PHYSIOL-LONDON, V241, P629, DOI 10.1113/jphysiol.1974.sp010675; DEY PK, 1983, INDIAN J MED RES, V77, P554; DEY PK, 1974, J PHYSIOL-LONDON, V239, pP102; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1988, BRAIN RES, V463, P63, DOI 10.1016/0006-8993(88)90527-6; FURLOW TW, 1978, STROKE, V9, P591, DOI 10.1161/01.STR.9.6.591; GUSTAFSSON LE, 1989, ANN NY ACAD SCI, V559, P178; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALLENBECK JM, 1983, J NEUROSURG, V58, P749, DOI 10.3171/jns.1983.58.5.0749; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; HSU CY, 1988, J NEUROL SCI, V83, P55, DOI 10.1016/0022-510X(88)90019-6; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; IANNOTTI F, 1981, STROKE, V12, P301, DOI 10.1161/01.STR.12.3.301; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; LANDS WEM, 1968, BIOCHIM BIOPHYS ACTA, V164, P426, DOI 10.1016/0005-2760(68)90168-9; MEANS ED, 1987, HDB SPINAL CORD, V5, P19; MONCADA S, 1978, PHARMACOL REV, V30, P293; Ojeda S. R., 1989, ANN NY ACAD SCI, V559, P192, DOI 10.1111/j.1749- 6632.1989.tb22609.x; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1979, ADV INFLAMMAT RES, V1, P405; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHARMA H S, 1991, Brain Dysfunction, V4, P104; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SIEGAL T, 1990, NEUROSURGERY, V26, P963, DOI 10.1227/00006123-199006000-00007; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Ting P, 1990, Adv Neurol, V52, P119; TSUBOKURA S, 1991, BRAIN RES, V543, P15, DOI 10.1016/0006-8993(91)91043-Z; WHITE RP, 1982, PHARMACOL THERAPEUT, V18, P313, DOI 10.1016/0163-7258(82)90035-3; WIELOCH T, 1990, CURR OPIN NEUROL NEU, V3, P944; WINKLER T, 1992, IN PRESS NEUROSCIENC; WOLFE LS, 1979, ANNU REV PHYSIOL, V41, P669, DOI 10.1146/annurev.ph.41.030179.003321; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; WOLFE LS, 1989, ANN NY ACAD SCI, V559, P74	59	65	66	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JAN	1993	85	2					145	153					9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	KJ618	WOS:A1993KJ61800005	8442406				2022-02-06	
J	LYETH, BG; RAY, M; HAMM, RJ; SCHNABEL, J; SAADY, JJ; POKLIS, A; JENKINS, LW; GUDEMAN, SK; HAYES, RL				LYETH, BG; RAY, M; HAMM, RJ; SCHNABEL, J; SAADY, JJ; POKLIS, A; JENKINS, LW; GUDEMAN, SK; HAYES, RL			POSTINJURY SCOPOLAMINE ADMINISTRATION IN EXPERIMENTAL TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						ACETYLCHOLINE; MUSCARINE; SCOPOLAMINE; TRAUMATIC BRAIN INJURY; BEHAVIOR; RAT; RADIORECEPTOR ASSAY	AMINO-ACIDS; RAT; BEHAVIOR; PLASMA; ASSAY; URINE	A single bolus dose of scopolamine (1.0 mg/kg) or saline (equal volume) was injected (i.p.) at 15-30 or 60 min after fluid percussion traumatic brain injury in the rat. Scopolamine administered at 15 min postinjury significantly reduced beam walking deficits and body weight loss assessed for 5 days after injury. Scopolamine treatment at 30 or 60 min postinjury had no effect on behavioral outcome assessed for 5 days after injury. Plasma concentrations of scopolamine were measured with a radioreceptor assay. The plasma half-life for scopolamine was 21.6 min in injured rats and 17.3 min in normal rats (P < 0.05). These results, along with evidence from previous studies, suggest that a brief period of excessive neuronal excitation can produce relatively long-lasting behavioral deficits. The temporal effectiveness of receptor antagonist intervention in this process appears to be brief.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,POB 693,MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PATHOL,RICHMOND,VA 23298; UNIV NORTH CAROLINA,DEPT SURG,DIV NEUROSURG,CHAPEL HILL,NC 27599; UNIV TEXAS,SCH MED,DEPT SURG,DIV NEUROSURG,HOUSTON,TX 77030					Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS019950, P50NS012587, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19950, NS 12587, NS 21458] Funding Source: Medline		BAYNE WF, 1975, J PHARM SCI, V64, P288, DOI 10.1002/jps.2600640220; CINTRON NM, 1987, J PHARM SCI, V76, P328, DOI 10.1002/jps.2600760413; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V	16	65	65	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 13	1992	569	2					281	286		10.1016/0006-8993(92)90640-U			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HC618	WOS:A1992HC61800012	1540831				2022-02-06	
J	Madsen, T; Erlangsen, A; Orlovska, S; Mofaddy, R; Nordentoft, M; Benros, ME				Madsen, Trine; Erlangsen, Annette; Orlovska, Sonja; Mofaddy, Ramy; Nordentoft, Merete; Benros, Michael E.			Association Between Traumatic Brain Injury and Risk of Suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION-BASED COHORT; MORTALITY; REGISTER; EPILEPSY; DEATH; INDIVIDUALS; PREVALENCE; CHILDREN; HEALTH	IMPORTANCE Traumatic brain injuries (TBIs) can have serious long-term consequences, including psychiatric disorders. However, few studies have assessed the association between TBI and risk of suicide. OBJECTIVE To examine the association between TBI and subsequent suicide. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using nationwide registers covering 7 418 391 individuals (>= 10 years) living in Denmark (1980-2014) with 164 265 624 person-years' follow-up; 567 823 (7.6%) had a medical contact for TBI. Data were analyzed using Poisson regression adjusted for relevant covariates, including fractures not involving the skull, psychiatric diagnoses, and deliberate self-harm. EXPOSURE Medical contacts for TBI recorded in the National Patient Register (1977-2014) as mild TBI (concussion), skull fracture without documented TBI, and severe TBI (head injuries with evidence of structural brain injury). MAIN OUTCOMES AND MEASURES Suicide recorded in the Danish Cause of Death register until December 31, 2014. RESULTS Of 34 529 individuals who died by suicide (mean age, 52 years [SD, 18 years]; 32.7% women; absolute rate 21 per 100 000 person-years [95% CI, 20.8-21.2]), 3536 (10.2%) had medical contact: 2701 with mild TBI, 174 with skull fracture without documented TBI, and 661 with severe TBI. The absolute suicide rate was 41 per 100 000 person-years (95% CI, 39.2-41.9) among those with TBI vs 20 per 100 000 person-years (95% CI, 19.7-20.1) among those with no diagnosis of TBI. The adjusted incidence rate ratio (IRR) was 1.90 (95% CI, 1.83-1.97). Compared with those without TBI, severe TBI (absolute rate, 50.8 per 100 000 person-years; 95% CI, 46.9-54.6) was associated with an IRR of 2.38 (95% CI, 2.20-2.58), whereas mild TBI (absolute rate, 38.6 per 100 000 person-years; 95% CI, 37.1-40.0), and skull fracture without documented TBI (absolute rate, 42.4 per 100 000 person-years; 95% CI, 36.1-48.7) had an IRR of 1.81 (95% CI, 1.74-1.88) and an IRR of 2.01 (95% CI, 1.73-2.34), respectively. Suicide risk was associated with number of medical contacts for TBI compared with those with no TBI contacts: 1 TBI contact, absolute rate, 34.3 per 100 000 person-years (95% CI, 33.0-35.7; IRR, 1.75; 95% CI, 1.68-1.83); 2 TBI contacts, absolute rate, 59.8 per 100 000 person-years (95% CI, 55.1-64.6; IRR, 2.31; 95% CI, 2.13-2.51); and 3 or more TBI contacts, absolute rate, 90.6 per 100 000 person-years (95% CI, 82.3-98.9; IRR, 2.59; 95% CI, 2.35-2.85; all P < .001 for the IRR's). Compared with the general population, temporal proximity since the last medical contact for TBI was associated with risk of suicide (P <. 001), with an IRR of 3.67 (95% CI, 3.33-4.04) within the first 6 months and an incidence IRR of 1.76 (95% CI, 1.67-1.86) after 7 years. CONCLUSIONS AND RELEVANCE In this nationwide registry-based retrospective cohort study individuals with medical contact for TBI, compared with the general population without TBI, had increased suicide risk.	[Madsen, Trine; Erlangsen, Annette; Nordentoft, Merete] Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Kildegardsvej 28, DK-2900 Hellerup, Capital Region, Denmark; [Madsen, Trine; Orlovska, Sonja; Mofaddy, Ramy; Nordentoft, Merete; Benros, Michael E.] Copenhagen Univ Hosp, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark; [Erlangsen, Annette] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Erlangsen, Annette; Nordentoft, Merete] iPSYCH Lundbeck Fdn Initiat Integrated Psychiat R, Aarhus, Denmark; [Erlangsen, Annette] Australian Natl Univ, Ctr Mental Hlth Res, Canberra, ACT, Australia		Madsen, T (corresponding author), Mental Hlth Ctr Copenhagen, Danish Res Inst Suicide Prevent, Kildegardsvej 28, DK-2900 Hellerup, Capital Region, Denmark.	trine.madsen@regionh.dk	Benros, Michael Eriksen/N-5868-2016; Erlangsen, Annette/ABE-1547-2021; Nordentoft, Merete/AAH-3253-2019; Orlovska-Waast, Sonja/K-3057-2019	Benros, Michael Eriksen/0000-0003-4939-9465; Erlangsen, Annette/0000-0003-3475-0558; Nordentoft, Merete/0000-0003-4895-7023	Mental Health Services Capital Region Denmark; Lundbeck FoundationLundbeckfonden	The study was partly funded by the Mental Health Services Capital Region Denmark and an unrestricted grant from the Lundbeck Foundation.	[Anonymous], 1991, INTEGRATED DATABASE; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Benham EC, 2017, AM J SURG, V214, P211, DOI 10.1016/j.amjsurg.2016.11.017; Bragatti JA, 2011, J NEUROL NEUROPHYSIO, pS2, DOI [10.4172/2155-9562, DOI 10.4172/2155-9562]; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Clayton D, 2013, STAT MODELS EPIDEMIO; Erlangsen A, 2015, SCAND J PUBLIC HEALT, V43, P333, DOI 10.1177/1403494815575193; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fralick M, 2016, CAN MED ASSOC J, V188, P497, DOI 10.1503/cmaj.150790; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim SC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111063; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Mors O, 2011, SCAND J PUBLIC HEALT, V39, P54, DOI 10.1177/1403494810395825; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Richard YF, 2015, AM J EPIDEMIOL, V182, P177, DOI 10.1093/aje/kwv014; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson GK, 2007, MED J AUSTRALIA, V187, P229, DOI 10.5694/j.1326-5377.2007.tb01206.x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tollefsen IM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009120; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wirrell EC, 2006, EPILEPSIA, V47, P1674, DOI 10.1111/j.1528-1167.2006.00639.x	34	64	64	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	2018	320	6					580	588		10.1001/jama.2018.10211			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ4KZ	WOS:000441642500012	30120477	Green Published, Bronze			2022-02-06	
J	Alawieh, A; Langley, EF; Weber, S; Adkins, D; Tomlinson, S				Alawieh, Ali; Langley, E. Farris; Weber, Shannon; Adkins, DeAnna; Tomlinson, Stephen			Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						chronic injury; complement; inflammation; therapy	CONTROLLED CORTICAL IMPACT; MEMBRANE ATTACK COMPLEX; ALTERNATIVE PATHWAY; INHIBITION; MOUSE; RECOVERY; SYSTEM; C3; NEUROPATHOLOGY; DYSFUNCTION	The complement system is implicated in promoting acute secondary injury after traumatic brain injury (TBI), but its role in chronic post-traumatic neuropathology remains unclear. Using various injury-site targeted complement inhibitors that block different complement pathways and activation products, we investigated how complement is involved in neurodegeneration and chronic neuroinflammation after TBI in a clinically relevant setting of complement inhibition. The current paradigm is that complement propagates post-TBI neuropathology predominantly through the terminal membrane attack complex (MAC), but the focus has been on acute outcomes. Following controlled cortical impact in adult male mice, we demonstrate that although inhibition of the MAC (with CR2-CD59) reduces acute deficits, inhibition of C3 activation is required to prevent chronic inflammation and ongoing neuronal loss. Activation of C3 triggered a sustained degenerative mechanism of microglial and astrocyte activation, reduced dendritic and synaptic density, and inhibited neuroblast migration several weeks after TBI. Moreover, inhibiting all complement pathways (with CR2-Crry), or only the alternative complement pathway (with CR2-fH), provided similar and significant improvements in chronic histological, cognitive, and functional recovery, indicating a key role for the alternative pathway in propagating chronic post-TBI pathology. Although we confirm a role for the MAC in acute neuronal loss after TBI, this study shows that upstream products of complement activation generated predominantly via the alternative pathway propagate chronic neuroinflammation, thus challenging the current concept that the MAC represents a therapeutic target for treating TBI. A humanized version of CR2fH has been shown to be safe and non-immunogenic in clinical trials.	[Alawieh, Ali; Langley, E. Farris; Weber, Shannon] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA; [Alawieh, Ali; Langley, E. Farris; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Adkins, DeAnna] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Adkins, DeAnna; Tomlinson, Stephen] Ralph Johnson VA Med Ctr, Charleston, SC 29401 USA		Tomlinson, S (corresponding author), Dept Microbiol & Immunol, 173 Ashley Ave,BSB 204,MSC 504, Charleston, SC 29425 USA.	tomlinss@musc.edu	Alawieh, Ali/AAM-1420-2020; Alawieh, Ali/AAM-1898-2020	Alawieh, Ali/0000-0003-2601-8850; Adkins, DeAnna L/0000-0002-3063-5731; tomlinson, stephen/0000-0002-6281-2122	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P20GM109040, U54GM10494, U54GM10491, P30 CA138313, S10 OD018113]; Department of Veterans AffairsUS Department of Veterans Affairs [1I01RX001141, 1I21RX002363]; American Heart Association Predoctoral FellowshipAmerican Heart Association [15PRE25250009]; Center for Oral Health Research (NIGMS Award) [P30GM103331]; Josh Spruill Imaging Facility [NIH-NIGMS P30 GM103342]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA138313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103342, P20GM109040, P30GM103331] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD018113] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001141, I21RX002363] Funding Source: NIH RePORTER	This work was supported by Grants from the NIH (1P20GM109040, U54GM10494, U54GM10491) to D.A. and S.T., the Department of Veterans Affairs (Merit Award 1I01RX001141 and 1I21RX002363) to S.T., and an American Heart Association Predoctoral Fellowship to A. A. (15PRE25250009); and the use of the MUSC Cell and Molecular Imaging Core (supported by awards from the NIH P30 CA138313 and S10 OD018113), the Center for Oral Health Research (NIGMS Award P30GM103331), and the Josh Spruill Imaging Facility (NIH-NIGMS P30 GM103342).	Alawieh A, 2016, IMMUNOL REV, V274, P270, DOI 10.1111/imr.12470; Alawieh A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0464-8; Alawieh A, 2015, ONCOTARGET, V6, P21769, DOI 10.18632/oncotarget.4844; Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Carroll MC, 1998, SEMIN IMMUNOL, V10, P279, DOI 10.1006/smim.1998.0120; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, CURR DIRECT AUTOIMMU, V7, P33; Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068; Janeway C.A., 2001, COMPLEMENT SYSTEM IN, V5th; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Marshall KM, 2014, J EXP MED, V211, P1793, DOI 10.1084/jem.20131902; Metz Gerlinde A, 2009, J Vis Exp, DOI 10.3791/1204; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Patil SS, 2009, BEHAV BRAIN RES, V198, P58, DOI 10.1016/j.bbr.2008.10.029; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Rich MC, 2016, NEUROSCI LETT, V617, P188, DOI 10.1016/j.neulet.2016.02.025; Risitano A.M., 2015, BLOOD, V126, P2137; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	41	64	66	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 7	2018	38	10					2519	2532		10.1523/JNEUROSCI.2197-17.2018			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ6EC	WOS:000427689100012	29437855	Green Published, Bronze			2022-02-06	
J	Zou, P; Liu, XX; Li, G; Wang, YG				Zou, Peng; Liu, Xiaoxiao; Li, Gang; Wang, Yangang			Resveratrol pretreatment attenuates traumatic brain injury in rats by suppressing NLRP3 inflammasome activation via SIRT1	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury; resveratrol; NLR family pyrin domain containing 3; inflammasome; reactive oxygen species; sirtuin 1	ACUTE LUNG INJURY; ENDOTHELIAL-CELLS; STEM-CELLS; NEUROPROTECTION; PATHWAY; STROKE; EXPRESSION; SIRTUINS; DISEASE; MODEL	The inflammatory response in the cerebral cortex serves an important role in the progression of secondary injury following traumatic brain injury (TBI). The NLR family pyrin domain containing 3 (NLRP3) inflammasome is necessary for initiating inflammation and is involved in various central nervous system disorders. The aim of the present study was to investigate the neuroprotective effect of resveratrol and elucidate the underlying mechanisms of resveratrol associated regulation of the NLRP3 inflammasome in TBI. The results demonstrated that the activation of NLRP3, caspase-1 and sirtuin 1 (SIRT1), enhanced the production of inflammatory cytokines and reactive oxygen species (ROS) following TBI. Administration of resveratrol alleviated the degree of TBI, as evidenced by the reduced neuron-specific enolase (NSE) and brain water content (WBC). Resveratrol pretreatment also inhibited the activation of NLRP3 and caspase-1, and reduced the production of inflammatory cytokines and ROS. In addition, resveratrol further promoted SIRT1 activation. Furthermore, the suppressing effect of resveratrol on the NLRP3 inflammasome and ROS was blocked by the SIRT1 inhibitor, sirtinol. The results revealed that the activation of the NLRP3 inflammasome and the subsequent inflammatory responses in the cerebral cortex were involved in the process of TBI. Resveratrol may attenuate the inflammatory response and relieve TBI by reducing ROS production and inhibiting NLRP3 activation. The effect of resveratrol on NLRP3 inflammasome and ROS may also be SIRT1 dependent.	[Zou, Peng; Wang, Yangang] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Liu, Xiaoxiao] Xian Med Univ, Affiliated Northern Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China; [Li, Gang] Jiangxian Peoples Hosp, Dept Neurosurg, Yuncheng 043600, Shanxi, Peoples R China		Wang, YG (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	yg-wang@163.com					Abdel-Aleem GA, 2016, ARCH PHYSIOL BIOCHEM, V122, P200, DOI 10.1080/13813455.2016.1182190; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Czerska M, 2015, MED PR, V66, P393, DOI 10.13075/mp.5893.00137; Dong HJ, 2017, J CRANIOFAC SURG, V28, P1615, DOI 10.1097/SCS.0000000000003563; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Gardner AJ, 2017, PHYS MED REH CLIN N, V28, P413, DOI 10.1016/j.pmr.2016.12.014; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Jardim FR, 2017, MOL NEUROBIOL, DOI [10.1007/s12035-017-0448-z, DOI 10.1007/S12035-017-0448-Z28283884]; Jiang L, 2016, BIOMED PHARMACOTHER, V84, P130, DOI 10.1016/j.biopha.2016.09.020; Jin RL, 2017, MOL CELLS, V40, P222, DOI 10.14348/molcells.2017.2314; Kleszcz R, 2015, PHARMACOL REP, V67, P1068, DOI 10.1016/j.pharep.2015.03.021; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Li L., 2014, AM J CANCER RES, V5, P442; Li YX, 2017, IMMUNOBIOLOGY, V222, P552, DOI 10.1016/j.imbio.2016.11.002; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu Y, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0415-z; Lopez MS, 2015, NEUROCHEM INT, V89, P75, DOI 10.1016/j.neuint.2015.08.009; Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5; Matsushima S, 2015, AM J PHYSIOL-HEART C, V309, pH1375, DOI 10.1152/ajpheart.00053.2015; Minutoli Letteria, 2016, Oxid Med Cell Longev, V2016, P2183026, DOI 10.1155/2016/2183026; Naghibi T, 2017, J CLIN DIAGN RES, V11, pPC6, DOI 10.7860/JCDR/2017/19132.9198; Pennisi M, 2017, J NEUROSCI RES, V95, P1360, DOI 10.1002/jnr.23986; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Shah FA, 2014, J VET MED SCI, V76, P1367, DOI 10.1292/jvms.14-0169; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Su Q, 2016, NEUROL RES, V38, P60, DOI 10.1080/01616412.2015.1133027; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wan D, 2016, BRAIN RES BULL, V121, P255, DOI 10.1016/j.brainresbull.2016.02.011; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; Yang H, 2017, ACTA PHARMACOL SIN, V38, P168, DOI 10.1038/aps.2016.130; Yin N, 2016, AM J TRANSL RES, V8, P2033; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	37	64	74	4	29	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	FEB	2018	17	2					3212	3217		10.3892/mmr.2017.8241			6	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	FT5WP	WOS:000423224300146	29257276	Bronze			2022-02-06	
J	Albayram, O; Kondo, A; Mannix, R; Smith, C; Tsai, CY; Li, CY; Herbert, MK; Qiu, JH; Monuteaux, M; Driver, J; Yan, S; Gormley, W; Puccio, AM; Okonkwo, DO; Lucke-Wold, B; Bailes, J; Meehan, W; Zeidel, M; Lu, KP; Zhou, XZ				Albayram, Onder; Kondo, Asami; Mannix, Rebekah; Smith, Colin; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Qiu, Jianhua; Monuteaux, Michael; Driver, Jane; Yan, Sandra; Gormley, William; Puccio, Ava M.; Okonkwo, David O.; Lucke-Wold, Brandon; Bailes, Julian; Meehan, William; Zeidel, Mark; Lu, Kun Ping; Zhou, Xiao Zhen			Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae	NATURE COMMUNICATIONS			English	Article							PROLYL ISOMERASE PIN1; CLOSED-HEAD INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; COGNITIVE DEFICITS; PHOSPHORYLATED TAU; EXPERIMENTAL-MODEL; UNITED-STATES; MOTOR-SKILLS	Traumatic brain injury (TBI) is characterized by acute neurological dysfunction and associated with the development of chronic traumatic encephalopathy (CTE) and Alzheimer's disease. We previously showed that cis phosphorylated tau (cis P-tau), but not the trans form, contributes to tau pathology and functional impairment in an animal model of severe TBI. Here we found that in human samples obtained post TBI due to a variety of causes, cis P-tau is induced in cortical axons and cerebrospinal fluid and positively correlates with axonal injury and clinical outcome. Using mouse models of severe or repetitive TBI, we showed that cis P-tau elimination with a specific neutralizing antibody administered immediately or at delayed time points after injury, attenuates the development of neuropathology and brain dysfunction during acute and chronic phases including CTE-like pathology and dysfunction after repetitive TBI. Thus, cis P-tau contributes to short-term and long-term sequelae after TBI, but is effectively neutralized by cis antibody treatment.	[Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Driver, Jane; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Translat Therapeut, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA; [Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Zeidel, Mark; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA; [Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA; [Mannix, Rebekah; Qiu, Jianhua; Monuteaux, Michael] Harvard Med Sch, Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA; [Smith, Colin] Univ Edinburgh, Dept Neuropathol, 49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland; [Driver, Jane] Harvard Med Sch, VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, 150S Huntington Ave, Boston, MA 02130 USA; [Yan, Sandra; Gormley, William] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St, Pittsburgh, PA 15213 USA; [Lucke-Wold, Brandon] West Virginia Univ, Dept Neurosurg, Hlth Sci Ctr, Suite 4300,POB 9183, Morgantown, WV 26506 USA; [Bailes, Julian] Univ Chicago, Pritzker Sch Med, NorthShore Univ Hlth Syst, Dept Neurosurg, 3rd Floor Kellogg, Evanston, IL 60637 USA; [Meehan, William] Harvard Med Sch, Childrens Hosp Boston, Div Sports Med, Micheli Ctr Sports Injury Prevent, 319 Longwood Ave, Boston, MA 02115 USA		Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Translat Therapeut, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA.; Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.; Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA.	klu@bidmc.harvard.edu; zhou@bidmc.harvard.edu	Monuteaux, Michael C/O-5032-2018; Herbert, Megan/AAN-8333-2021; Lucke-Wold, Brandon/AAW-1881-2021; Mannix, Rebekah/AAD-8702-2020; Lucke-Wold, Brandon/AAW-3525-2021; Herbert, Megan/E-6348-2015	Lucke-Wold, Brandon/0000-0001-6577-4080; Albayram, Onder/0000-0002-2028-1458; Herbert, Megan/0000-0003-1599-4362	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD40128-11A1]; NIH Alzheimer's Association [R01AG029385, R01AG046319, R01CA167677, DVT-14-322623]; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Research UKAlzheimer's Research UK (ARUK); Weston Brain Institute [MCDN-15-368711]; Thome Memorial Foundation in Alzheimer's Disease Drug Discovery Research; NFLPA pilot; BIDMC pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA167677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS096835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG029385, R01AG046319] Funding Source: NIH RePORTER	We thank Dr Michael Whalen for his expert advice and comments on the manuscript. O.A. is an Alzheimer's Association Research Fellow. The work is supported by grants from NIH (T32 HD40128-11A1) to R.M., NIH (R01AG029385, R01AG046319, R01CA167677) Alzheimer's Association (DVT-14-322623), Alzheimer's Association, Alzheimer's Research UK and Weston Brain Institute (MCDN-15-368711), Thome Memorial Foundation in Alzheimer's Disease Drug Discovery Research to K.P.L, by NFLPA pilot grants to K.P.L., X.Z.Z, and R.M., and BIDMC pilot grant and gift donations from the Owens Family Foundation to X.Z.Z. and K.P.L.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albayram O, 2016, PFLUG ARCH EUR J PHY, V468, P727, DOI 10.1007/s00424-015-1782-5; Albayram O, 2011, P NATL ACAD SCI USA, V108, P11256, DOI 10.1073/pnas.1016442108; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Chen CH, 2015, NEUROBIOL DIS, V76, P13, DOI 10.1016/j.nbd.2014.12.027; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; CORSELLIS JAN, 1959, J MENT SCI, V105, P714, DOI 10.1192/bjp.105.440.714; DEACON RMJ, 2013, JOVE J VIS EXP MAY; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Faul M, 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Giannantoni A, 2011, ARCH PHYS MED REHAB, V92, P1134, DOI 10.1016/j.apmr.2011.02.013; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Iqbal K, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.225; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kallakuri S, 2015, J NEUROSCI RURAL PRA, V6, P481, DOI 10.4103/0976-3147.169767; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Karve Ila P, 2016, Br J Pharmacol, V173, P692, DOI 10.1111/bph.13125; Keller JJ, 2013, NEUROUROL URODYNAM, V32, P354, DOI 10.1002/nau.22309; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P00595; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Lu J, 2015, ARCH PHYS MED REHAB, V96, P702, DOI 10.1016/j.apmr.2014.10.026; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2016, JAMA NEUROL, V73, P1356, DOI 10.1001/jamaneurol.2016.2027; Lu PJ, 1999, NATURE, V399, P784; Mannix R, 2016, NAT REV NEUROL, V12, P486, DOI 10.1038/nrneurol.2016.99; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McEwan WA, 2017, P NATL ACAD SCI USA, V114, P574, DOI 10.1073/pnas.1607215114; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nwachuku EL, 2016, CLIN NEUROL NEUROSUR, V149, P1, DOI 10.1016/j.clineuro.2016.06.009; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pallant J.F., 2007, SPSS SURVIVAL MANUAL; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Pedersen JT, 2015, TRENDS MOL MED, V21, P394, DOI 10.1016/j.molmed.2015.03.003; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rosenmann H, 2006, ARCH NEUROL-CHICAGO, V63, P1459, DOI 10.1001/archneur.63.10.1459; Rosenmann H, 2013, CURR ALZHEIMER RES, V10, P217, DOI 10.2174/1567205011310030001; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Thrane VR, 2013, NAT MED, V19, P1643, DOI 10.1038/nm.3400; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu WQ, 2014, AM J PHYSIOL-RENAL, V306, pF1296, DOI 10.1152/ajprenal.00074.2014; Zare-shahabadi A, 2015, REV NEUROSCIENCE, V26, P385, DOI 10.1515/revneuro-2014-0076; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	84	64	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	OCT 17	2017	8								1000	10.1038/s41467-017-01068-4			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ9RS	WOS:000413118900003	29042562	Green Published, gold			2022-02-06	
J	Dreha-Kulaczewski, S; Joseph, AA; Merboldt, KD; Ludwig, HC; Gartner, J; Frahm, J				Dreha-Kulaczewski, Steffi; Joseph, Arun A.; Merboldt, Klaus-Dietmar; Ludwig, Hans-Christoph; Gaertner, Jutta; Frahm, Jens			Identification of the Upward Movement of Human CSF In Vivo and its Relation to the Brain Venous System	JOURNAL OF NEUROSCIENCE			English	Article						CSF; human; in vivo flow; phase-contrast real-time MRI; respiration	CEREBROSPINAL-FLUID MOVEMENT; FLOW MRI; RESPIRATION; DYNAMICS; RESOLUTION; PULSATION; CLEARANCE; TRANSPORT	CSF flux is involved in the pathophysiology of neurodegenerative diseases and cognitive impairment after traumatic brain injury, all hallmarked by the accumulation of cellular metabolic waste. Its effective disposal via various CSF routes has been demonstrated in animal models. In contrast, the CSF dynamics in humans are still poorly understood. Using novel real-time MRI, forced inspiration has been identified recently as a main driving force of CSF flow in the human brain. Exploiting technical advances toward real-time phase-contrast MRI, the current work analyzed directions, velocities, and volumes of human CSF flow within the brain aqueduct as part of the internal ventricular system and in the spinal canal during respiratory cycles. A consistent upward CSF movement toward the brain in response to forced inspiration was seen in all subjects at the aqueduct, in 11/12 subjects at thoracic level 2, and in 4/12 subjects at thoracic level 5. Concomitant analyses of CSF dynamics and cerebral venous blood flow, that is, in epidural veins at cervical level 3, uniquely demonstrated CSF and venous flow to be closely communicating cerebral fluid systems in which inspiration-induced downward flow of venous blood due to reduced intrathoracic pressure is counterbalanced by an upward movement of CSF. The results extend our understanding of human CSF flux and open important clinical implications, including concepts for drug delivery and new classifications and therapeutic options for various forms of hydrocephalus and idiopathic intracranial hypertension.	[Dreha-Kulaczewski, Steffi; Gaertner, Jutta] Univ Med Ctr Gottingen, Dept Pediat & Adolescent Med, Div Pediat Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Ludwig, Hans-Christoph] Univ Med Ctr Gottingen, Dept Neurosurg, Div Pediat Neurosurg, D-37075 Gottingen, Germany; [Joseph, Arun A.; Merboldt, Klaus-Dietmar; Frahm, Jens] Biomed NMR Forsch GmbH, Max Planck Inst Biophys, D-37077 Gottingen, Germany; [Frahm, Jens] German Ctr Cardiovasc Res, Partner Site, Gottingen, Germany		Dreha-Kulaczewski, S (corresponding author), Univ Med Ctr Gottingen, Dept Pediat & Adolescent Med, Div Pediat Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	sdreha@gwdg.de		Ludwig, Hans/0000-0001-8744-9510; Frahm, Jens/0000-0002-8279-884X	Dorothea Schloezer Program of the Georg-August-University Gottingen, Germany	The work was supported by the Dorothea Schloezer Program of the Georg-August-University Gottingen, Germany (S.D.-K.).	Baledent O, 2004, INVEST RADIOL, V39, P45, DOI 10.1097/01.rli.0000100892.87214.49; Chen LY, 2015, NEUROIMAGE, V122, P281, DOI 10.1016/j.neuroimage.2015.07.073; Chitiboi T, 2014, I S BIOMED IMAGING, P943, DOI 10.1109/ISBI.2014.6868027; Dreha-Kulaczewski S, 2015, J NEUROSCI, V35, P2485, DOI 10.1523/JNEUROSCI.3246-14.2015; DUBOULAY GH, 1966, BRIT J RADIOL, V39, P255, DOI 10.1259/0007-1285-39-460-255; Friese S, 2004, INVEST RADIOL, V39, P120, DOI 10.1097/01.rli.0000112089.66448.bd; Fu X, 2014, TOXICOL SCI, V139, P432, DOI 10.1093/toxsci/kfu048; GIDEON P, 1994, NEURORADIOLOGY, V36, P350, DOI 10.1007/BF00612116; GREITZ D, 1993, ACTA RADIOL, V34, P321; GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Joseph A, 2014, J MAGN RESON IMAGING, V40, P206, DOI 10.1002/jmri.24328; Joseph AA, 2012, NMR BIOMED, V25, P917, DOI 10.1002/nbm.1812; Klose U, 2000, JMRI-J MAGN RESON IM, V11, P438, DOI 10.1002/(SICI)1522-2586(200004)11:4<438::AID-JMRI12>3.0.CO;2-O; Reitan H, 1941, ACTA RADIOL, V22, P762, DOI 10.3109/00016924109136456; Schaetz Sebastian, 2012, Algorithms and Architectures for Parallel Processing. Proceedings of the 12th International Conference, ICA3PP 2012, P114, DOI 10.1007/978-3-642-33078-0_9; Schwartz M, 2012, HUM VACC IMMUNOTHER, V8, P1465, DOI 10.4161/hv.21649; Spector R, 2007, J NEUROCHEM, V103, P425, DOI 10.1111/j.1471-4159.2007.04773.x; Stadlbauer A, 2010, NEUROIMAGE, V51, P42, DOI 10.1016/j.neuroimage.2010.01.110; Stringer MD, 2012, CLIN ANAT, V25, P609, DOI 10.1002/ca.21281; Uecker M, 2010, NMR BIOMED, V23, P986, DOI 10.1002/nbm.1585; Untenberger M, 2016, MAGN RESON MED, V75, P1901, DOI 10.1002/mrm.25696; WILLIAMS B, 1981, ACTA NEUROCHIR, V58, P167, DOI 10.1007/BF01407124; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep31787; Yamada S, 2008, RADIOLOGY, V249, P644, DOI 10.1148/radiol.2492071985; Yamada S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-36; Zenker W, 1996, ANAT EMBRYOL, V193, P1	29	64	65	1	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 1	2017	37	9					2395	2402		10.1523/JNEUROSCI.2754-16.2017			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EP2BX	WOS:000397189100015	28137972	Green Published, Bronze			2022-02-06	
J	Zhang, AL; Sing, DC; Rugg, CM; Feeley, BT; Senter, C				Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin			The Rise of Concussions in the Adolescent Population	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						concussion; traumatic brain injury (TBI); trends; epidemiology; adolescents; youth	TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT VISITS; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; TRENDS; EPIDEMIOLOGY; STATEMENT; DEPRESSION; AWARENESS; DEFICITS	Background: Concussion injuries have been highlighted to the American public through media and research. While recent studies have shown increased traumatic brain injuries (TBIs) diagnosed in emergency departments across the United States, no studies have evaluated trends in concussion diagnoses across the general US population in various age groups. Purpose: To evaluate the current incidence and trends in concussions diagnosed across varying age groups and health care settings in a large cross-sectional population. Study Design: Descriptive epidemiological study. Methods: Administrative health records of 8,828,248 members of a large private-payer insurance group in the United States were queried. Patients diagnosed with concussion from years 2007 through 2014 were stratified by year of diagnosis, age group, sex, classification of concussion, and health care setting of diagnosis (eg, emergency department vs physician's office). Chi-square testing was used for statistical analysis. Results: From a cohort of 8,828,248 patients, 43,884 patients were diagnosed with a concussion. Of these patients, 55% were male and over 32% were in the adolescent age group (10-19 years old). The highest incidence of concussion was seen in patients aged 15 to 19 years (16.5/1000 patients), followed by those aged 10 to 14 years (10.5/1000 patients), 20 to 24 years (5.2/1000 patients), and 5 to 9 years (3.5/1000 patients). Overall, there was a 60% increase in concussion incidence from 2007 to 2014. The largest increases were in the 10- to 14-year (143%) and 15- to 19-year (87%) age groups. Based on International Classification of Disease-9th Revision classification, 29% of concussions were associated with some form of loss of consciousness. Finally, 56% of concussions were diagnosed in the emergency department and 29% in a physician's office, with the remainder in urgent care clinics or inpatient settings. Conclusion: The incidence of concussion diagnosed in the general US population is increasing, driven largely by a substantial rise in the adolescent age group. The youth population should be prioritized for ongoing work in concussion education, diagnosis, treatment, and prevention. Clinical Relevance: The rise of concussions in the adolescent age group across the general population is concerning, and clinical efforts to prevent these injuries are needed.	[Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Zhang, Alan L.; Sing, David C.; Rugg, Caitlin M.; Feeley, Brian T.; Senter, Carlin] Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens St,Box 3004, San Francisco, CA 94158 USA; [Senter, Carlin] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA		Zhang, AL (corresponding author), Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens St,Box 3004, San Francisco, CA 94158 USA.	alan.zhang@ucsf.edu					Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown JA, 2015, BMC SPORTS SCI MED R, V7, DOI 10.1186/s13102-015-0019-4; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Centers for Disease Control and Prevention, 2014, TRAUMATIC BRAIN INJU; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P1775, DOI 10.1001/jama.2010.1487; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Piercy KL, 2015, AM J PUBLIC HEALTH, V105, P421, DOI 10.2105/AJPH.2014.302325; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Sing DC, 2015, ARTHROSCOPY, V31, P2307, DOI 10.1016/j.arthro.2015.06.008; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; U.S. Department of Health and Human Services, 2008, 2008 PHYS ACT GUID A; US Department of Health and Human Services, 2012, PHYS ACT GUID AM MID; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Zhang AL, 2013, ARTHROSCOPY, V29, P623, DOI 10.1016/j.arthro.2012.11.004; Zhang AL, 2012, AM J SPORT MED, V40, P1144, DOI 10.1177/0363546512436944; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696; Zuckerman SL, 2016, AM J SPORT MED, V44, pNP5, DOI 10.1177/0363546515623241; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	45	64	64	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	AUG	2016	4	8							2325967116662458	10.1177/2325967116662458			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DV6II	WOS:000383037100004	27579334	gold, Green Published, Green Submitted			2022-02-06	
J	Veenith, TV; Carter, EL; Geeraerts, T; Grossac, J; Newcombe, VFJ; Outtrim, J; Gee, GS; Lupson, V; Smith, R; Aigbirhio, FI; Fryer, TD; Hong, YT; Menon, DK; Coles, JP				Veenith, Tonny V.; Carter, Eleanor L.; Geeraerts, Thomas; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne; Gee, Gloria S.; Lupson, Victoria; Smith, Rob; Aigbirhio, Franklin I.; Fryer, Tim D.; Hong, Young T.; Menon, David K.; Coles, Jonathan P.			Pathophysiologic Mechanisms of Cerebral Ischemia and Diffusion Hypoxia in Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; NORMOBARIC HYPEROXIA; HEAD-INJURY; TISSUE PO2; PET; METABOLISM; STROKE; MICRODIALYSIS; CONTUSION; PRESSURE	IMPORTANCE Combined oxygen 15-labeled positron emission tomography (O-15 PET) and brain tissue oximetry have demonstrated increased oxygen diffusion gradients in hypoxic regions after traumatic brain injury (TBI). These data are consistent with microvascular ischemia and are supported by pathologic studies showing widespread microvascular collapse, perivascular edema, and microthrombosis associated with selective neuronal loss. Fluorine 18-labeled fluoromisonidazole ([F-18]FMISO), a PET tracer that undergoes irreversible selective bioreduction within hypoxic cells, could confirm these findings. OBJECTIVE To combine [F-18]FMISO and O-15 PET to demonstrate the relative burden, distribution, and physiologic signatures of conventional macrovascular and microvascular ischemia in early TBI. DESIGN, SETTING, AND PARTICIPANTS This case-control study included 10 patients who underwent [F-18]FMISO and O-15 PET within 1 to 8 days of severe or moderate TBI. Two cohorts of 10 healthy volunteers underwent [F-18]FMISO or O-15 PET. The study was performed at the Wolfson Brain Imaging Centre of Addenbrooke's Hospital. Cerebral blood flow, cerebral blood volume, cerebral oxygen metabolism (CMRO2), oxygen extraction fraction, and brain tissue oximetry were measured in patients during [F-18]FMISO and O-15 PET imaging. Similar data were obtained from control cohorts. Data were collected from November 23, 2007, to May 22, 2012, and analyzed from December 3, 2012, to January 6, 2016. MAIN OUTCOMES AND MEASURES Estimated ischemic brain volume (IBV) and hypoxic brain volume (HBV) and a comparison of their spatial distribution and physiologic signatures. RESULTS The 10 patients with TBI (9 men and 1 woman) had a median age of 59 (range, 30-68) years; the 2 control cohorts (8 men and 2 women each) had median ages of 53 (range, 41-76) and 45 (range, 29-59) years. Compared with controls, patients with TBI had a higher median IBV (56 [range, 9-281] vs 1 [range, 0-11] mL; P < .001) and a higher median HBV (29 [range, 0-106] vs 9 [range, 1-24] mL; P = .02). Although both pathophysiologic tissue classes were present within injured and normal appearing brains, their spatial distributions were poorly matched. When compared with tissue within the IBV compartment, the HBV compartment showed similar median cerebral blood flow (17 [range, 11-40] vs 14 [range, 6-22] mL/100 mL/min), cerebral blood volume (2.4 [range, 1.6-4.2] vs 3.9 [range, 3.4-4.8] mL/100 mL), and CMRO2 (44 [range, 27-67] vs 71 [range, 34-88] mu mol/100 mL/min) but a lower oxygen extraction fraction (38%[range, 29%-50%] vs 89%[range, 75%-100%]; P < .001), and more frequently showed CMRO2 values consistent with irreversible injury. Comparison with brain tissue oximetry monitoring suggested that the threshold for increased [F-18]FMISO trapping is probably 15 mm Hg or lower. CONCLUSIONS AND RELEVANCE Tissue hypoxia after TBI is not confined to regions with structural abnormality and can occur in the absence of conventional macrovascular ischemia. This physiologic signature is consistent with microvascular ischemia and is a target for novel neuroprotective strategies.	[Veenith, Tonny V.; Carter, Eleanor L.; Geeraerts, Thomas; Grossac, Julia; Newcombe, Virginia F. J.; Outtrim, Joanne; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,POB 93, Cambridge CB2 0QQ, England; [Veenith, Tonny V.] Univ Hosp Birmingham Natl Hlth Serv Trust, Queen Elizabeth Med Ctr, Dept Crit Care Med, Birmingham, England; [Geeraerts, Thomas; Grossac, Julia] Univ Hosp Toulouse, Dept Anesthesiol & Crit Care, Toulouse, France; [Gee, Gloria S.; Lupson, Victoria; Smith, Rob; Aigbirhio, Franklin I.; Fryer, Tim D.; Hong, Young T.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England		Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,POB 93, Cambridge CB2 0QQ, England.	jpc44@wbic.cam.ac.uk	Veenith, Tonny/AAI-3067-2020; Veenith, Tonny V/A-9948-2010	Veenith, Tonny/0000-0002-4125-8804; Veenith, Tonny V/0000-0002-4125-8804; Newcombe, Virginia/0000-0001-6044-9035; Coles, Jonathan/0000-0003-4013-679X	National Institute of Academic Anaesthesia; Raymond Beverly Sackler studentship; Societe Francaise d'Anesthesie et de Reanimation; Health Foundation/Academy of Medical Sciences; National Institute for Health ResearchNational Institute for Health Research (NIHR); Wellcome TrustWellcome TrustEuropean Commission [WT093267]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI	This study was supported by a clinical research training fellowship from National Institute of Academic Anaesthesia and Raymond Beverly Sackler studentship (Dr Veenith), a clinical research training fellowship from the Societe Francaise d'Anesthesie et de Reanimation (Dr Geeraerts), a Clinician Scientist Fellowship from the Health Foundation/Academy of Medical Sciences (Dr Newcombe), a Senior Investigator Award from the National Institute for Health Research (Dr Menon), grant WT093267 from the Wellcome Trust Project, program grant G9439390 ID 65883 from the Medical Research Council (Acute Brain Injury: Heterogeneity of Mechanisms, Therapeutic Targets and Outcome Effects), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the UK Department of Health (Drs Aigbirhio, Fryer, Menon, and Coles, for the Technology Platform).	Alawneh JA, 2014, EUR J NUCL MED MOL I, V41, P736, DOI 10.1007/s00259-013-2581-x; Alian Aymen A, 2008, J Clin Monit Comput, V22, P169, DOI 10.1007/s10877-008-9118-z; Bartlett RM, 2012, J NUCL MED, V53, P1608, DOI 10.2967/jnumed.112.103523; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; GROSS MW, 1995, INT J CANCER, V61, P567, DOI 10.1002/ijc.2910610422; Hong YT, 2011, J CEREBR BLOOD F MET, V31, P648, DOI 10.1038/jcbfm.2010.141; Hong YT, 2010, NEUROIMAGE, V51, P164, DOI 10.1016/j.neuroimage.2010.02.013; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Markus R, 2004, BRAIN, V127, P1427, DOI 10.1093/brain/awh162; Markus R, 2003, STROKE, V34, P2646, DOI 10.1161/01.STR.0000094422.74023.FF; Markus R, 2002, NEUROIMAGE, V16, P425, DOI 10.1006/nimg.2002.1056; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Moustafa RR, 2007, CRIT CARE, V11, DOI 10.1186/cc5973; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Peeters SGJA, 2015, INT J RADIAT ONCOL, V91, P351, DOI 10.1016/j.ijrobp.2014.09.045; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Ponce LL, 2012, NEUROSURGERY, V70, P1492, DOI 10.1227/NEU.0b013e31824ce933; Read SJ, 1998, NEUROLOGY, V51, P1617, DOI 10.1212/WNL.51.6.1617; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Sarrafzadeh AS, 2010, J CEREBR BLOOD F MET, V30, P36, DOI 10.1038/jcbfm.2009.199; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Takasawa M, 2008, STROKE, V39, P1629, DOI 10.1161/STROKEAHA.107.485938; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	49	64	66	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2016	73	5					542	550		10.1001/jamaneurol.2016.0091			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DL2JW	WOS:000375461900016	27019039	Bronze, Green Submitted			2022-02-06	
J	Wang, XT; Gao, X; Michalski, S; Zhao, S; Chen, JH				Wang, Xiaoting; Gao, Xiang; Michalski, Stephanie; Zhao, Shu; Chen, Jinhui			Traumatic Brain Injury Severity Affects Neurogenesis in Adult Mouse Hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						neural stem cell proliferation; injury severity; traumatic brain injury; neurogenesis	CONTROLLED CORTICAL IMPACT; DENTATE GYRUS; NEURAL STEM; NEURONAL DIFFERENTIATION; ENHANCED NEUROGENESIS; CELL-PROLIFERATION; COGNITIVE RECOVERY; GRANULE CELLS; RATS; MICE	Traumatic brain injury (TBI) has been proven to enhance neural stem cell (NSC) proliferation in the hippocampal dentate gyrus. However, various groups have reported contradictory results on whether TBI increases neurogenesis, partially due to a wide range in the severities of injuries seen with different TBI models. To address whether the severity of TBI affects neurogenesis in the injured brain, we assessed neurogenesis in mouse brains receiving different severities of controlled cortical impact (CCI) with the same injury device. The mice were subjected to mild, moderate, or severe TBI by a CCI device. The effects of TBI severity on neurogenesis were evaluated at three stages: NSC proliferation, immature neurons, and newly-generated mature neurons. The results showed that mild TBI did not affect neurogenesis at any of the three stages. Moderate TBI promoted NSC proliferation without increasing neurogenesis. Severe TBI increased neurogenesis at all three stages. Our data suggest that the severity of injury affects adult neurogenesis in the hippocampus, and thus it may partially explain the inconsistent results of different groups regarding neurogenesis following TBI. Further understanding the mechanism of TBI-induced neurogenesis may provide a potential approach for using endogenous NSCs to protect against neuronal loss after trauma.	[Wang, Xiaoting; Gao, Xiang; Zhao, Shu; Chen, Jinhui] Indiana Univ, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Wang, Xiaoting; Gao, Xiang; Zhao, Shu; Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Wang, Xiaoting; Gao, Xiang; Michalski, Stephanie; Zhao, Shu; Chen, Jinhui] Indiana Univ, Dept Neurol Surg, Indianapolis, IN 46202 USA		Chen, JH (corresponding author), Indiana Univ, 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001108] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761, UL1 RR025761] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R21NS075733-01A1, 1R21NS072631-01A] Funding Source: Medline		Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Belarbi K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00145; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christian KM, 2014, ANNU REV NEUROSCI, V37, P243, DOI 10.1146/annurev-neuro-071013-014134; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faigle R, 2013, BBA-GEN SUBJECTS, V1830, P2435, DOI 10.1016/j.bbagen.2012.09.002; Faul M, 2010, TRAUMATIC BRAIN INJU; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Prigatano GP, 2005, ACT NEUR S, V93, P39; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Thomas R., 2013, REPORT C TRAUMATIC B; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	48	64	65	3	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					721	733		10.1089/neu.2015.4097			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900002	26414411	Green Published			2022-02-06	
J	Kochanek, PM; Bramlett, HM; Dixon, CE; Shear, DA; Dietrich, WD; Schmid, KE; Mondello, S; Wang, KKW; Hayes, RL; Povlishock, JT; Tortella, FC				Kochanek, Patrick M.; Bramlett, Helen M.; Dixon, C. Edward; Shear, Deborah A.; Dietrich, W. Dalton; Schmid, Kara E.; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.			Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						therapy; rat; penetrating ballistic-like brain injury; biomarker; micropig; controlled cortical impact; fluid percussion; neuroprotection	CONTROLLED CORTICAL IMPACT; TIME-DEPENDENT CHANGES; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; RAT MODEL; CEREBROSPINAL-FLUID; DAMAGE; AMANTADINE; CHILDREN; DEFICITS	Traumatic brain injury (TBI) was the signature injury in both the Iraq and Afghan wars and the magnitude of its importance in the civilian setting is finally being recognized. Given the scope of the problem, new therapies are needed across the continuum of care. Few therapies have been shown to be successful. In severe TBI, current guidelines-based acute therapies are focused on the reduction of intracranial hypertension and optimization of cerebral perfusion. One factor considered important to the failure of drug development and translation in TBI relates to the recognition that TBI is extremely heterogeneous and presents with multiple phenotypes even within the category of severe injury. To address this possibility and attempt to bring the most promising therapies to clinical trials, we developed Operation Brain Trauma Therapy (OBTT), a multicenter, pre-clinical drug screening consortium for acute therapies in severe TBI. OBTT was developed to include a spectrum of established TBI models at experienced centers and assess the effect of promising therapies on both conventional outcomes and serum biomarker levels. In this review, we outline the approach to TBI modeling, evaluation of therapies, drug selection, and biomarker assessments for OBTT, and provide a framework for reports in this issue on the first five therapies evaluated by the consortium.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Excellence Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Branch, In Vivo Neuroprotect Labs, Silver Spring, MD USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Schmid, Kara E.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Dept, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Combat Casualty Care Res Program Brain Trauma & N, Silver Spring, MD USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Brockman EC, 2013, J CEREBR BLOOD F MET, V33, P1457, DOI 10.1038/jcbfm.2013.104; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00040; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Langham J., 2000, COCHRANE DATABASE SY, V2; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams A, 2006, J NEUROTRAUM, V23, P1039; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Winn HR, 2007, LANCET NEUROL, V6, P478, DOI 10.1016/S1474-4422(07)70116-3; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	67	64	64	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					513	522		10.1089/neu.2015.4113			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800002	26439468				2022-02-06	
J	Lidster, K; Jefferys, JG; Blumcke, I; Crunelli, V; Flecknell, P; Frenguelli, BG; Gray, WP; Kaminski, R; Pitkanen, A; Ragan, I; Shah, M; Simonato, M; Treyelyan, A; Volk, H; Walker, M; Yates, N; Prescott, MJ				Lidster, Katie; Jefferys, John G.; Bluemcke, Ingmar; Crunelli, Vincenzo; Flecknell, Paul; Frenguelli, Bruno G.; Gray, William P.; Kaminski, Rafal; Pitkanen, Asia; Ragan, Ian; Shah, Mala; Simonato, Michele; Treyelyan, Andrew; Volk, Holger; Walker, Matthew; Yates, Neil; Prescott, Mark J.			Opportunities for improving animal welfare in rodent models of epilepsy and seizures	JOURNAL OF NEUROSCIENCE METHODS			English	Article						3Rs; Animal model; Epilepsy; Mouse; Rat; Refinement; Seizure	TEMPORAL-LOBE EPILEPSY; JOINT-WORKING-GROUP; EARLY-LIFE SEIZURES; GENETIC ABSENCE EPILEPSY; KAINATE-INDUCED EPILEPSY; TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; KAINIC ACID; ENVIRONMENTAL ENRICHMENT; LABORATORY RODENTS	Animal models of epilepsy and seizures, mostly involving mice and rats, are used to understand the pathophysiology of the different forms of epilepsy and their comorbidities, to identify biomarkers, and to discover new antiepileptic drugs and treatments for comorbidities. Such models represent an important area for application of the 3Rs (replacement, reduction and refinement of animal use). This report provides background information and recommendations aimed at minimising pain, suffering and distress in rodent models of epilepsy and seizures in order to improve animal welfare and optimise the quality of studies in this area. The report includes practical guidance on principles of choosing a model, induction procedures, in vivo recordings, perioperative care, welfare assessment, humane endpoints, social housing, environmental enrichment, reporting of studies and data sharing. In addition, some model specific welfare considerations are discussed, and data gaps and areas for further research are identified. The guidance is based upon a systematic review of the scientific literature, survey of the international epilepsy research community, consultation with veterinarians and animal care and welfare officers, and the expert opinion and practical experience of the members of a Working Group convened by the United Kingdom's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Lidster, Katie; Prescott, Mark J.] Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England; [Jefferys, John G.] Univ Oxford, Dept Pharmacol, S Parks Rd, Oxford OX1 3QT, England; [Bluemcke, Ingmar] Univ Erlangen Nurnberg, Inst Neuropathol, D-91054 Erlangen, Germany; [Crunelli, Vincenzo] Cardiff Univ, Neurosci Div, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales; [Flecknell, Paul] Newcastle Univ, Sch Med, Comparat Biol Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Frenguelli, Bruno G.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England; [Gray, William P.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Sch Med, Cardiff CF10 3AX, S Glam, Wales; [Kaminski, Rafal] UCB Pharma, Brussels, Belgium; [Pitkanen, Asia] Univ Eastern Finland, Inst Mol Sci, Dept Neurobiol, Kuopio, Finland; [Ragan, Ian] NC3Rs Board, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England; [Shah, Mala] UCL, UCL Sch Pharm, London, England; [Simonato, Michele] Univ Ferrara, Dept Med Sci, I-44100 Ferrara, Italy; [Treyelyan, Andrew] Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Volk, Holger] Univ London Royal Vet Coll, Dept Clin Sci & Serv, Hatfield, Herts, England; [Walker, Matthew] UCL, Inst Neurol, London, England; [Yates, Neil] Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England		Lidster, K (corresponding author), Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England.	katie.lidster@nc3rs.org.uk	Prescott, Mark/E-4184-2010; Frenguelli, Bruno/C-5007-2015; Blumcke, Ingmar/D-4705-2018; Jefferys, John G R/AAF-1164-2021; Walker, Matthew C/C-1577-2008; Volk, Holger Andreas/B-9965-2011	Frenguelli, Bruno/0000-0001-7214-3172; Blumcke, Ingmar/0000-0001-8676-0788; Jefferys, John G R/0000-0003-0106-4412; Walker, Matthew C/0000-0002-0812-0352; Crunelli, Vincenzo/0000-0001-7154-9752; Flecknell, Paul/0000-0002-1075-1129; Prescott, Mark/0000-0002-8814-0512; Simonato, Michele/0000-0002-3586-2693; Volk, Holger Andreas/0000-0002-7312-638X; Gray, William/0000-0001-7595-8887; Shah, Mala/0000-0002-8323-4739	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802162, G0700369, MR/J013250/1, G0300356, MR/L010305/1] Funding Source: Medline; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L00139X/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0300356, G0700369, MR/J013250/1, G0802162] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L00139X/1] Funding Source: researchfish; Epilepsy Research UK [P1504, P1402] Funding Source: researchfish		Abraham J, 2012, NEUROBIOL DIS, V46, P425, DOI 10.1016/j.nbd.2012.02.006; Akman O, 2015, CNS NEUROSCI THER, V21, P181, DOI 10.1111/cns.12335; Ali A, 2012, EPILEPSIA, V53, P199, DOI 10.1111/j.1528-1167.2011.03314.x; Anna I, 2002, LAB ANIM-UK, V36, P243, DOI 10.1258/002367702320162379; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arcieri S, 2014, EPILEPSIA, V55, P1978, DOI 10.1111/epi.12850; Arndt SS, 2009, PHYSIOL BEHAV, V97, P385, DOI 10.1016/j.physbeh.2009.03.008; Ashall V, 2014, ALTEX-ALTERN ANIM EX, V31, P209, DOI 10.14573/altex.1307261; Auvergne R, 2002, BRAIN RES, V954, P277, DOI 10.1016/S0006-8993(02)03355-3; BAGETTA G, 1990, NEUROPHARMACOLOGY, V29, P765, DOI 10.1016/0028-3908(90)90130-J; Bankstahl M, 2012, BEHAV BRAIN RES, V230, P182, DOI 10.1016/j.bbr.2012.02.004; Baran SW, 2010, ENRICH REC, V3, P4; Barkmeier DT, 2009, CLIN EEG NEUROSCI, V40, P234, DOI 10.1177/155005940904000405; Bartolomucci A, 2001, PHYSIOL BEHAV, V73, P401, DOI 10.1016/S0031-9384(01)00453-X; Bartolomucci A, 2004, PHYSIOL BEHAV, V82, P425, DOI 10.1016/j.physbeh.2004.04.011; Bastlund JF, 2004, J NEUROSCI METH, V138, P65, DOI 10.1016/j.jneumeth.2004.03.004; Bateson P., 2011, REV RES USING NONHUM; Baulac M., 2008, EPILEPSIA, V50, P571, DOI [10.1111/j.1528-1167.2008.01811.x, DOI 10.1111/J.1528-1167.2008.01811.X]; BAUMANS V, 1994, LAB ANIM-UK, V28, P97, DOI 10.1258/002367794780745308; Baumans V, 2005, ILAR J, V46, P162, DOI 10.1093/ilar.46.2.162; Baumans V., 2010, The UFAW handbook on the care and management of laboratory and other research animals, P276, DOI 10.1002/9781444318777.ch21; Belz EE, 2003, PHARMACOL BIOCHEM BE, V76, P481, DOI 10.1016/j.pbb.2003.09.005; Berdoy M, 2003, LAB RAT NATURAL HIST; Berg AT, 2011, EPILEPSIA, V52, P1058, DOI 10.1111/j.1528-1167.2011.03101.x; Berg AT, 2010, LANCET NEUROL, V9, P459, DOI 10.1016/S1474-4422(10)70024-7; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernard PB, 2013, NEUROBIOL DIS, V59, P1, DOI 10.1016/j.nbd.2013.06.013; Blair RE, 2009, NEUROSCI LETT, V453, P233, DOI 10.1016/j.neulet.2009.02.035; Boggiano MM, 2008, PHYSIOL BEHAV, V95, P222, DOI 10.1016/j.physbeh.2008.04.025; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; Bourdi M, 2011, CHEM RES TOXICOL, V24, P794, DOI 10.1021/tx200143x; BRAIN P, 1975, LIFE SCI, V16, P187, DOI 10.1016/0024-3205(75)90017-X; Brooks-Kayal AR, 2013, EPILEPSIA, V54, P44, DOI 10.1111/epi.12298; CALDECOTTHAZARD S, 1982, BRAIN RES, V251, P196, DOI 10.1016/0006-8993(82)91293-8; CALDECOTTHAZARD S, 1982, P W PHARMACOL SOC, V25, P107; Camfield CS, 2009, NEUROLOGY, V73, P1041, DOI 10.1212/WNL.0b013e3181b9c86f; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Chapman K, 2013, REGUL TOXICOL PHARM, V67, P27, DOI 10.1016/j.yrtph.2013.04.003; Chen N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072336; Chung JI, 2013, EXP NEUROL, V249, P95, DOI 10.1016/j.expneurol.2013.08.014; Cilio MR, 2003, EPILEPSIA, V44, P518, DOI 10.1046/j.1528-1157.2003.48802.x; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Coimbra NC, 2001, BRAIN RES, V888, P314, DOI 10.1016/S0006-8993(00)03103-6; COLLIER GH, 1990, J COMP PSYCHOL, V104, P53, DOI 10.1037/0735-7036.104.1.53; Culley DJ, 2004, ANESTH ANALG, V99, P1393, DOI 10.1213/01.ANE.0000135408.14319.CC; Cunliffe VT, 2014, SEIZURE, V24, P44; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Cussler K, 2011, COST MANUAL LAB ANIM, P333; CZUCZWAR SJ, 1986, NEUROPHARMACOLOGY, V25, P465, DOI 10.1016/0028-3908(86)90169-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DESJARDINS D, 1995, PERCEPT MOTOR SKILL, V81, P635, DOI 10.2466/pms.1995.81.2.635; Doheny HC, 2002, BRIT J PHARMACOL, V135, P1425, DOI 10.1038/sj.bjp.0704606; Dugladze T, 2013, P NATL ACAD SCI USA, V110, P15073, DOI 10.1073/pnas.1313505110; Eccles M, 2001, Health Technol Assess, V5, P1; England MJ, 2012, EPILEPSY SPECTRUM; Englot DJ, 2008, J NEUROSCI, V28, P9066, DOI 10.1523/JNEUROSCI.2014-08.2008; Englot DJ, 2010, BRAIN, V133, P3764, DOI 10.1093/brain/awq316; Epps SA, 2013, BIOCHEM PHARMACOL, V85, P135, DOI 10.1016/j.bcp.2012.08.016; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Ewing SG, 2013, J NEUROSCI METH, V219, P324, DOI 10.1016/j.jneumeth.2013.08.003; Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Ferrari PF, 1998, PHYSIOL BEHAV, V63, P821, DOI 10.1016/S0031-9384(97)00544-1; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; FLANDERA V, 1973, PHYSIOL BOHEMOSLOV, V22, P209; Fornari RV, 2012, JOVE-J VIS EXP, DOI 10.3791/3528; Franke H, 2001, PHARMACOL BIOCHEM BE, V70, P291, DOI 10.1016/S0091-3057(01)00612-8; Frankel WN, 2009, TRENDS GENET, V25, P361, DOI 10.1016/j.tig.2009.07.001; Freitas RL, 2005, EXP NEUROL, V191, P225, DOI 10.1016/j.expneurol.2004.10.009; Galanopoulou AS, 2014, NEUROBIOL DIS, V72, P123, DOI 10.1016/j.nbd.2014.09.002; Galanopoulou AS, 2013, EPILEPSIA, V54, P1, DOI 10.1111/epi.12293; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Galanopoulou AS, 2011, BIOMARK MED, V5, P615, DOI [10.2217/BMM.11.71, 10.2217/bmm.11.71]; Giorgi FS, 2014, NEUROBIOL DIS, V72, P144, DOI 10.1016/j.nbd.2014.05.010; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Gouveia K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066401; Grabenstatter HL, 2007, EPILEPSIA, V48, P2287; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Grone BP, 2015, NAT NEUROSCI, V18, P339, DOI 10.1038/nn.3934; Guerrini R, 2014, NEUROTHERAPEUTICS, V11, P269, DOI 10.1007/s13311-014-0267-0; Guo Q, 1993, J Tradit Chin Med, V13, P281; Hannan AJ, 2014, NEUROPATH APPL NEURO, V40, P13, DOI 10.1111/nan.12102; Harhausen D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069529; HASEMAN JK, 1994, FUND APPL TOXICOL, V23, P44, DOI 10.1006/faat.1994.1077; HASHEM A, 1988, ANAESTHESIST, V37, P631; HATCH A, 1963, SCIENCE, V142, P507, DOI 10.1126/science.142.3591.507; HAU J, 1999, HUMANE ENDPOINTS ANI, P71; Hawkins P, 2004, LAB ANIM-UK, V38, P1; Hawkins P, 2011, LAB ANIM-UK, V45, P1, DOI 10.1258/la.2010.010031; Hawkins P, 2014, J NEUROSCI METH, V234, P135, DOI 10.1016/j.jneumeth.2014.02.008; Hayes KE, 2000, CONTEMP TOP LAB ANIM, V39, P18; Heinrichs SC, 2006, EPILEPSY BEHAV, V8, P5, DOI 10.1016/j.yebeh.2005.08.009; Hellier JL, 1998, EPILEPSY RES, V31, P73, DOI 10.1016/S0920-1211(98)00017-5; HELLIER JL, 2005, CURR PROTOC NEUROSCI, V9, P1; Hickman DL, 2010, J AM ASSOC LAB ANIM, V49, P155; Honndorf S, 2011, EPILEPSY RES, V94, P26, DOI 10.1016/j.eplepsyres.2010.12.012; Huang L, 2013, EPILEPSY RES, V106, P326, DOI 10.1016/j.eplepsyres.2013.06.010; Huang X, 2012, NEUROSCIENCE, V215, P90, DOI 10.1016/j.neuroscience.2012.04.011; Hurst JL, 2010, NAT METHODS, V7, P825, DOI [10.1038/NMETH.1500, 10.1038/nmeth.1500]; Hurst JL, 1997, ANIM WELFARE, V6, P329; Inostroza M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038959; Inostroza M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022372; Jedrzejko C, 2001, PSYCHOL REP, V89, P188, DOI 10.2466/PR0.89.5.188-190; Jimenez-Pacheco A, 2013, EPILEPSIA, V54, P1551, DOI 10.1111/epi.12257; Jirkof P, 2015, LAB ANIMAL, V44, P65, DOI 10.1038/laban.662; Jones J., 1999, HUM ENDPOINTS ANIM E, P40; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Kalliokoski O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111065; Kalynchuk LE, 1999, BEHAV NEUROSCI, V113, P766, DOI 10.1037/0735-7044.113.4.766; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; Kirkwood J, 2010, UFAW HDB CARE MANAGE, VEighth; Koh S, 2007, EPILEPSY BEHAV, V10, P26, DOI 10.1016/j.yebeh.2006.11.008; Koppel BS, 2014, NEUROBIOL DIS, V72, P193, DOI 10.1016/j.nbd.2014.08.033; Kotloski RJ, 2015, EXP NEUROL, V264, P121, DOI 10.1016/j.expneurol.2014.11.012; Kulesskaya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024755; Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]; Latham N, 2004, APPL ANIM BEHAV SCI, V86, P261, DOI 10.1016/j.applanim.2004.02.006; Leach MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035656; Leclercq K, 2015, EPILEPSIA, V56, P310, DOI 10.1111/epi.12893; Levesque M, 2013, NEUROSCI BIOBEHAV R, V37, P2887, DOI 10.1016/j.neubiorev.2013.10.011; Lewis MH, 2004, MENT RETARD DEV D R, V10, P91, DOI 10.1002/mrdd.20017; Li Z, 2013, NEUROREPORT, V24, P785, DOI 10.1097/WNR.0b013e328363fed3; LIU Z, 1994, EPILEPSY RES, V19, P191, DOI 10.1016/0920-1211(94)90062-0; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Long JJA, 2009, EXP NEUROL, V219, P308, DOI 10.1016/j.expneurol.2009.05.036; Longo B, 2003, EXP NEUROL, V181, P57, DOI 10.1016/S0014-4886(02)00046-8; Loo P. L. P. van, 2001, Journal of Applied Animal Welfare Science, V4, P91, DOI 10.1207/S15327604JAWS0402_1; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Maheshwari A, 2014, PROG BRAIN RES, V213, P223, DOI 10.1016/B978-0-444-63326-2.00012-0; Manno I, 2011, EPILEPSIA, V52, pE113, DOI 10.1111/j.1528-1167.2011.03166.x; Manser CE, 1998, LAB ANIM, V32, P36, DOI 10.1258/002367798780559473; Manser CE, 1998, LAB ANIM, V32, P23, DOI 10.1258/002367798780559365; Manser CE, 1996, LAB ANIM, V30, P1, DOI 10.1258/002367796780744974; Mantegazza M, 2010, EPILEPSY RES, V92, P1, DOI 10.1016/j.eplepsyres.2010.08.003; Mares J, 2009, PHYSIOL RES, V58, P279, DOI 10.33549/physiolres.931270; Mares P, 2012, PHYSIOL RES, V61, pS103, DOI 10.33549/physiolres.932370; Mares P, 2014, N-S ARCH PHARMACOL, V387, P753, DOI 10.1007/s00210-014-0987-z; Martin BS, 2008, EPILEPSIA, V49, P248, DOI 10.1111/j.1528-1167.2007.01384.x; Martin B, 2010, P NATL ACAD SCI USA, V107, P6127, DOI 10.1073/pnas.0912955107; Mazarati AM, 2009, NEUROBIOL DIS, V34, P457, DOI 10.1016/j.nbd.2009.02.018; McIntyre DC, 2006, MODELS OF SEIZURES AND EPILEPSY, P351, DOI 10.1016/B978-012088554-1/50030-X; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; McLin JP, 2006, EUR J NEUROSCI, V24, P2191, DOI 10.1111/j.1460-9568.2006.05111.x; Meijer MK, 2006, ANIM WELFARE, V15, P31; Mellanby J, 1999, BEHAV BRAIN RES, V100, P113, DOI 10.1016/S0166-4328(98)00118-1; MELLANBY J, 1981, J NEUROL NEUROSUR PS, V44, P1084, DOI 10.1136/jnnp.44.12.1084; MELLANBY J, 1977, J NEUROL NEUROSUR PS, V40, P404, DOI 10.1136/jnnp.40.4.404; Morelli E, 2014, EXP NEUROL, V261, P320, DOI 10.1016/j.expneurol.2014.05.010; Morton, 1999, HUMANE ENDPOINTS ANI, P5; Morton D B, 2000, ILAR J, V41, P80; Morton DB, 2003, LAB ANIM-UK, V37, P261, DOI 10.1258/002367703322389861; Morton DB, 2001, LAB ANIM-UK, V35, P1, DOI 10.1258/0023677011911345; Muller CJ, 2009, GENES BRAIN BEHAV, V8, P481, DOI 10.1111/j.1601-183X.2009.00490.x; National Research Council, 2011, GUIDE CARE USE LAB A; Oliver V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097882; Panayiotopoulos C., 2007, CLIN GUIDE EPILEPTIC; Park DW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6258; Perez-Mendes P, 2011, EPILEPSY RES, V96, P45, DOI 10.1016/j.eplepsyres.2011.04.015; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; Persinger MA, 1996, INT J NEUROSCI, V86, P271, DOI 10.3109/00207459608986718; Perucca E, 2014, NEUROBIOL DIS, V72, P217, DOI 10.1016/j.nbd.2014.05.011; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; PIERSON MG, 1988, HEARING RES, V32, P1, DOI 10.1016/0378-5955(88)90142-6; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P1; Pitkanen A, 2014, NEUROBIOL DIS, V72, P224, DOI 10.1016/j.nbd.2014.05.037; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Poole T, 1997, LAB ANIM-UK, V31, P116, DOI 10.1258/002367797780600198; Prescott M J, 2010, Adv Sci Res, V5, P11, DOI 10.5194/asr-5-11-2010; Prescott MJ, 2010, J NEUROSCI METH, V193, P167, DOI 10.1016/j.jneumeth.2010.09.003; Qiao X, 2013, EPILEPSY RES, V106, P17, DOI 10.1016/j.eplepsyres.2013.06.006; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rice ASC, 2008, PAIN, V139, P243, DOI 10.1016/j.pain.2008.08.017; Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207; Riljak V, 2015, PHYSIOL RES, V64, P263, DOI 10.33549/physiolres.932793; Robinson V, 2004, ATLA-ALTERN LAB ANIM, V32, P373, DOI 10.1177/026119290403201s61; Rutten A, 2002, EUR J NEUROSCI, V16, P501, DOI 10.1046/j.1460-9568.2002.02103.x; Castelhano ASS, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00036; Scharfman HE, 2005, EXP NEUROL, V196, P73, DOI 10.1016/j.expneurol.2005.07.007; Scharfman HE, 2014, NEUROBIOL DIS, V72, P180, DOI 10.1016/j.nbd.2014.07.004; Schauwecker PE, 2011, EPILEPSY RES, V97, P1, DOI 10.1016/j.eplepsyres.2011.09.005; Schridde U, 2004, GENES BRAIN BEHAV, V3, P1, DOI 10.1111/j.1601-1848.2004.00034.x; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shavit Y, 2005, ANESTH ANALG, V101, P1112, DOI 10.1213/01.ane.0000167771.98680.a7; Sherwin CM, 1997, ANIM BEHAV, V53, P67, DOI 10.1006/anbe.1996.0278; Shetty AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043286; Sillanpaa M, 2010, NEW ENGL J MED, V363, P2522, DOI 10.1056/NEJMoa0911610; Simeone KA, 2014, EXP NEUROL, V251, P84, DOI 10.1016/j.expneurol.2013.11.005; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Sperber EF, 1999, DEV BRAIN RES, V116, P59, DOI 10.1016/S0165-3806(99)00075-9; Stables James P., 2003, Epilepsia, V44, P1472, DOI 10.1111/j.0013-9580.2003.32803.x; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Stewart LS, 2012, INT J NEUROSCI, V122, P449, DOI 10.3109/00207454.2012.677881; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; Sunderam S, 2007, J NEUROSCI METH, V163, P373, DOI 10.1016/j.jneumeth.2007.03.007; Szabo CA, 2012, COMPARATIVE MED, V62, P535; Tabb K, 2007, EPILEPSY RES, V74, P140, DOI 10.1016/j.eplepsyres.2007.02.006; THOMPSON JL, 1991, EPILEPSIA, V32, P161, DOI 10.1111/j.1528-1157.1991.tb05239.x; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; TURSKI L, 1989, SYNAPSE, V3, P154, DOI 10.1002/syn.890030207; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Van de Weerd HA, 2001, BEHAV PROCESS, V53, P11, DOI 10.1016/S0376-6357(00)00135-2; Van Loo PLP, 2007, LAB ANIM-UK, V41, P441, DOI 10.1258/002367707782314328; Van Loo PLP, 2004, LAB ANIM-UK, V38, P178, DOI 10.1258/002367704322968867; van Luijtelaar G, 2014, CURR MED CHEM, V21, P704; van Luijtelaar G, 2011, NEUROSCI LETT, V497, P177, DOI 10.1016/j.neulet.2011.02.034; Van Vlissingen JMF, 1999, HUMANE ENDPOINTS ANI, P89; Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612; Viventi J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000738; Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x; Wang DD, 2012, EPILEPSY BEHAV, V24, P314, DOI 10.1016/j.yebeh.2012.03.035; Wasterlain CG, 2013, HAND CLINIC, V111, P427, DOI 10.1016/B978-0-444-52891-9.00046-4; Weiergraber M, 2005, BRAIN RES PROTOC, V14, P154, DOI 10.1016/j.brainresprot.2004.12.006; Williams P, 2006, J NEUROSCI METH, V155, P39, DOI 10.1016/j.jneumeth.2005.12.035; Wolfensohn S, 2013, J PHARMACOL TOX MET, V67, P9, DOI 10.1016/j.vascn.2012.09.001; WOZNIAK DF, 1991, EXP NEUROL, V114, P250, DOI 10.1016/0014-4886(91)90042-B; Wu C, 2008, J NEUROSCI METH, V171, P126, DOI 10.1016/j.jneumeth.2008.03.001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu J, 2013, EPILEPSY RES, V106, P311, DOI 10.1016/j.eplepsyres.2013.07.002; Yang J, 2006, J NEUROSCI, V26, P406, DOI 10.1523/JNEUROSCI.4413-05.2006; Yin P, 2013, EPILEPSY BEHAV, V27, P9, DOI 10.1016/j.yebeh.2012.12.015; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537; Zayachkivsky A, 2013, J NEUROPHYSIOL, V109, P900, DOI 10.1152/jn.00593.2012; Zhao Q, 2006, MODELS OF SEIZURES AND EPILEPSY, P341, DOI 10.1016/B978-012088554-1/50029-3	233	64	65	0	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2016	260				SI		2	25		10.1016/j.jneumeth.2015.09.007			24	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DE7QN	WOS:000370831900002	26376175	hybrid, Green Published, Green Accepted			2022-02-06	
J	Xing, ZH; Xia, Z; Peng, WJ; Li, J; Zhang, CH; Fu, CY; Tang, T; Luo, JK; Zou, Y; Fan, R; Liu, WP; Xiong, XG; Huang, W; Sheng, CX; Gan, PP; Wang, Y				Xing, Zhihua; Xia, Zian; Peng, Weijun; Li, Jun; Zhang, Chunhu; Fu, Chunyan; Tang, Tao; Luo, Jiekun; Zou, Yong; Fan, Rong; Liu, Weiping; Xiong, Xingui; Huang, Wei; Sheng, Chenxia; Gan, Pingping; Wang, Yang			Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway	SCIENTIFIC REPORTS			English	Article							MAMMALIAN TARGET; MACROPHAGE POLARIZATION; INFLAMMATORY RESPONSES; ARACHIDONIC-ACID; TISSUE LOSS; TNF-ALPHA; RAPAMYCIN; MTOR; NEUROINFLAMMATION; DEFICITS	Neuroinflammation is central to the pathology of traumatic brain injury (TBI). Xuefu Zhuyu decoction (XFZY) is an effective traditional Chinese medicine to treat TBI. To elucidate its potential molecular mechanism, this study aimed to demonstrate that XFZY functions as an anti-inflammatory agent by inhibiting the PI3K-AKT-mTOR pathway. Sprague-Dawley rats were exposed to controlled cortical impact to produce a neuroinflammatory response. The treatment groups received XFZY (9 g/kg and 18 g/kg), Vehicle group and Sham group were gavaged with equal volumes of saline. The modified neurologic severity score (mNSS) and the Morris water maze test were used to assess neurological deficits. Arachidonic acid (AA) levels in brain tissue were measured using tandem gas chromatography-mass spectrometry. TNF-alpha and IL-1 beta levels in injured ipsilateral brain tissue were detected by ELISA. AKT and mTOR expression were measured by western blot analysis. The results indicated that XFZY significantly enhanced spatial memory acquisition. XFZY (especially at a dose of 9 g/kg) markedly reduced the mNSS and levels of AA, TNF-alpha and IL-1 beta. Significant downregulation of AKT/mTOR/p70S6K proteins in brain tissues was observed after the administration of XFZY (especially at a dose of 9 g/kg). XFZY may be a promising therapeutic strategy for reducing inflammation in TBI.	[Xing, Zhihua; Xia, Zian; Zhang, Chunhu; Tang, Tao; Luo, Jiekun; Fan, Rong; Liu, Weiping; Xiong, Xingui; Huang, Wei; Wang, Yang] Cent S Univ, Lab Ethnopharmacol, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun; Sheng, Chenxia] Cent S Univ, Dept Tradit Chinese Med, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Li, Jun] Cent S Univ, Thyroid Tumour Internal Med Dept, Canc Hosp, Xiangya Sch Med, Changsha 410011, Hunan, Peoples R China; [Fu, Chunyan] Shaoyang Med Coll Level Specialty Sch, Dept Pharm, Shaoyang 422000, Peoples R China; [Zou, Yong] Cent S Univ, Xiangya Hosp, Dept Gerontol & Resp Dis, Changsha 410008, Hunan, Peoples R China; [Gan, Pingping] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China		Wang, Y (corresponding author), Cent S Univ, Lab Ethnopharmacol, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.	wangyang_xy87@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81202781, 81403259, 81303098]; Science and Technology Plan Projects of Hunan Province, China [2013SK3280]; People's Livelihood Support of Science and Technology Special Funds of Changsha, China [K1205018-31]	This research was supported by the National Natural Science Foundation of China (Grant Nos. 81303074, 81202781, 81403259 and 81303098), Science and Technology Plan Projects of Hunan Province, China (No. 2013SK3280) and People's Livelihood Support of Science and Technology Special Funds of Changsha, China (No. K1205018-31).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Huang X., 2006, ZHONGGUO ZHONG YI JI, V15, P144; Huang X., 2006, ZHONGGUO ZHONG YI JI, V15, P121; Hwang HJ, 2008, J MICROBIOL BIOTECHN, V18, P1641; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lin C, 2015, SCI REP-UK, V5, DOI 10.1038/srep13442; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Luo L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5407; Ma CH, 2015, J ETHNOPHARMACOL, V168, P349, DOI 10.1016/j.jep.2015.03.068; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Paoletti I, 2013, INFLAMMATION, V36, P1316, DOI 10.1007/s10753-013-9670-7; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; PINKEL D, 1958, CANCER RES, V18, P853; Rosi S, 2005, J NEUROSCI, V25, P723, DOI 10.1523/JNEUROSCI.4469-04.2005; Steiner N, 2016, NEUROCHEM INT, V95, P46, DOI 10.1016/j.neuint.2015.10.013; Sucher NJ, 2013, EXPERT OPIN DRUG DIS, V8, P21, DOI 10.1517/17460441.2013.739602; Sun M, 2008, CHIN J INTEGR MED, V14, P137, DOI 10.1007/s11655-008-0137-x; Sun X, 2010, BIOORG MED CHEM LETT, V20, P4120, DOI 10.1016/j.bmcl.2010.05.076; Teng F., 2014, J EVIDENCE BASED COM, V2014; Wang J., 2013, J EVIDENCE BASED COM, V2013; Wang J, 2013, PAIN PHYSICIAN, V16, pE563; Wang N, 2011, NEURAL REGEN RES, V6, P1635, DOI 10.3969/j.issn.1673-5374.2011.21.006; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang Z.W., 2010, SHANXI ZHONG YI, V31, P850; Weichhart T, 2008, ANN RHEUM DIS, V67, P70, DOI 10.1136/ard.2008.098459; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Yue HF, 2007, J PHARMACEUT BIOMED, V43, P1122, DOI 10.1016/j.jpba.2006.10.009; Zhai PP, 2015, NEUROPHARMACOLOGY, V95, P1, DOI 10.1016/j.neuropharm.2015.02.026; Zhu XX, 2014, J CEREBR BLOOD F MET, V34, P1531, DOI 10.1038/jcbfm.2014.113; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	61	64	66	3	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 28	2016	6								20040	10.1038/srep20040			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB8RY	WOS:000368785500001	26818584	Green Published, gold			2022-02-06	
J	Ding, K; Xu, JG; Wang, HD; Zhang, L; Wu, Y; Li, T				Ding, Ke; Xu, Jianguo; Wang, Handong; Zhang, Li; Wu, Yong; Li, Tao			Melatonin protects the brain from apoptosis by enhancement of autophagy after traumatic brain injury in mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						Melatonin; Traumatic brain injury; Autophagy; Apoptosis	SUBARACHNOID HEMORRHAGE; CELL-DEATH; PATHWAY; MECHANISM; RAPAMYCIN; STRESS; MODEL; DEGENERATION; INFLAMMATION; INVOLVEMENT	Melatonin has been proven to possess neuroprotection property against various neurological diseases by decreasing cerebral oxidative stress and inhibiting inflammatory process. However, whether administration of inelatonin influences the autophagy pathway, which has recently been reported playing a pivotal role in traumatic brain injury, is yet not fully understood. We supposed that treatment of melatonin enhances the autophagy pathway after traumatic brain injury (TBI) in mice and subsequently inhibited the mitochondrion apoptotic pathway. Firstly, we investigated the neurological severity score, brain water content and neuronal apoptosis in mice cortex to demonstrate the neuroprotection of melatonin. Then we determined the autophagy markers, namely Beclinl and LC3-II, using western blot and immunofluorescence. Next, we evaluated the mitochondrial apoptotic pathway in the presence or absence of melatonin. More significantly, we employed 3-methyladenine (3-MA) to inhibit the autophagy pathway, to further confirm our hypothesis. The results showed that melatonin significantly ameliorated secondary brain injury induced by TBI. In addition, melatonin enhanced autophagy after TBI, which was accompanied by a decrease in both the translocation of Bax to mitochondria and the release of cytochrome C to cytoplasm. Furthermore, simultaneous treatment of 3-MA reversed the beneficial effects of melatonin on mitochondrial apoptotic pathway. Taken together, we conclude that melatonin enhances autophagy, which inhibits mitochondrial apoptotic pathway, thus protecting mice from secondary brain injury after TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Ding, Ke; Xu, Jianguo; Wang, Handong; Zhang, Li; Wu, Yong; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]; Jiangsu Provincial Science and Technology Department [BL2013027]; Medical Science Youth Breeding Project of PLA [14QNP035]	This work was supported by Grants from the National Natural Science Foundation of China (no. 81371357), Jiangsu Provincial Science and Technology Department (no.BL2013027) and Medical Science Youth Breeding Project of PLA (no.14QNP035).	Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bromme HJ, 2000, J PINEAL RES, V29, P201, DOI 10.1034/j.1600-0633.2002.290402.x; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; Chang CC, 2012, J PINEAL RES, V53, P188, DOI 10.1111/j.1600-079X.2012.00986.x; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gooneratne NS, 2012, J PINEAL RES, V52, P437, DOI 10.1111/j.1600-079X.2011.00958.x; Hamacher-Brady A, 2006, J BIOL CHEM, V281, P29776, DOI 10.1074/jbc.M603783200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kongsuphol P, 2009, J PINEAL RES, V46, P199, DOI 10.1111/j.1600-079X.2008.00648.x; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Radogna F, 2010, BIOCHEM PHARMACOL, V80, P1844, DOI 10.1016/j.bcp.2010.07.041; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Xu JG, 2014, BRAIN RES, V1582, P237, DOI 10.1016/j.brainres.2014.07.042; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	46	64	67	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2015	91						46	54		10.1016/j.neuint.2015.10.008			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CZ0FL	WOS:000366780400005	26527380				2022-02-06	
J	Harvey, LD; Yin, Y; Attarwala, IY; Begum, G; Deng, J; Yan, HQ; Dixon, CE; Sun, DD				Harvey, Lloyd D.; Yin, Yan; Attarwala, Insiya Y.; Begum, Gulnaz; Deng, Julia; Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan			Administration of DHA Reduces Endoplasmic Reticulum Stress-Associated Inflammation and Alters Microglial or Macrophage Activation in Traumatic Brain Injury	ASN NEURO			English	Article						cortical contusion injury; docosahexaenoic acid; microglial polarization; neuroinflammation; nuclear factor kappa-light-chain-enhancer of activated B cells; secondary injury	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; DOCOSAHEXAENOIC ACID; ER STRESS; RESPONSES; IMPACT; EXPRESSION; MODEL	We investigated the effects of the administration of docosahexaenoic acid (DHA) post-traumatic brain injury (TBI) on reducing neuroinflammation. TBI was induced by cortical contusion injury in Sprague Dawley rats. Either DHA (16mg/kg in dimethyl sulfoxide) or vehicle dimethyl sulfoxide (1ml/kg) was administered intraperitonially at 5min after TBI, followed by a daily dose for 3 to 21 days. TBI triggered activation of microglia or macrophages, detected by an increase of Iba1 positively stained microglia or macrophages in peri-lesion cortical tissues at 3, 7, and 21 days post-TBI. The inflammatory response was further characterized by expression of the proinflammatory marker CD16/32 and the anti-inflammatory marker CD206 in Iba1(+) microglia or macrophages. DHA-treated brains showed significantly fewer CD16/32(+) microglia or macrophages, but an increased CD206(+) phagocytic microglial or macrophage population. Additionally, DHA treatment revealed a shift in microglial or macrophage morphology from the activated, amoeboid-like state into the more permissive, surveillant state. Furthermore, activated Iba1(+) microglial or macrophages were associated with neurons expressing the endoplasmic reticulum (ER) stress marker CHOP at 3 days post-TBI, and the administration of DHA post-TBI concurrently reduced ER stress and the associated activation of Iba1(+) microglial or macrophages. There was a decrease in nuclear translocation of activated nuclear factor kappa-light-chain-enhancer of activated B cells protein at 3 days in DHA-treated tissue and reduced neuronal degeneration in DHA-treated brains at 3, 7, and 21 days after TBI. In summary, our study demonstrated that TBI mediated inflammatory responses are associated with increased neuronal ER stress and subsequent activation of microglia or macrophages. DHA administration reduced neuronal ER stress and subsequent association with microglial or macrophage polarization after TBI, demonstrating its therapeutic potential to ameliorate TBI-induced cellular pathology.	[Harvey, Lloyd D.; Attarwala, Insiya Y.; Begum, Gulnaz; Deng, Julia; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Yin, Yan] Dalian Med Univ, Hosp 2, Dept Neurol, Dalian, Peoples R China; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA		Sun, DD (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.	sund@upmc.edu		Harvey, Lloyd/0000-0001-5934-9934; Yin, Yan/0000-0002-5982-7462	University of Pittsburgh Neurology Departmental start-up funds; UPMC Endowed Chair Professorship on Brain Disorder Research; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS089051]; United States Department of Veterans Aairs VA [RRD#B6761R]; Brackenridge Summer and Fall Research Fellowships; Chancellor's Undergraduate Research Fellowship; Honors College-Health Sciences Research Fellowship; James V. Kunkel, M.D. Translational Research Fellowship; Chinese Dalian Municipal Bureau Study Abroad Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089051] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by University of Pittsburgh Neurology Departmental start-up funds, a UPMC Endowed Chair Professorship on Brain Disorder Research, and the National Institutes of Health [R01NS089051] (DS) and the United States Department of Veterans Aairs VA [RR&D#B6761R] (CED). LDH was supported by the Brackenridge Summer and Fall Research Fellowships, the Chancellor's Undergraduate Research Fellowship, the Honors College-Health Sciences Research Fellowship, and the James V. Kunkel, M.D. Translational Research Fellowship. YY was supported by the Chinese Dalian Municipal Bureau Study Abroad Research Award.	Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Ajmone-Cat MA, 2012, J NEUROSCI RES, V90, P575, DOI 10.1002/jnr.22783; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kaur P, 2008, NEUROTOXICOLOGY, V29, P978, DOI 10.1016/j.neuro.2008.06.004; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenz KM, 2015, NEUROSCIENTIST, V21, P306, DOI 10.1177/1073858414536468; Liu Y, 2010, J NEUROSCI, V30, P15210, DOI 10.1523/JNEUROSCI.3950-10.2010; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Shi YJ, 2011, J NEUROCHEM, V119, P124, DOI 10.1111/j.1471-4159.2011.07403.x; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	37	64	64	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	NOV-DEC	2015	7	6								10.1177/1759091415618969			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA2EH	WOS:000367607600003	26685193	Green Published, gold			2022-02-06	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Adolescents Demonstrate Greater Gait Balance Control Deficits After Concussion Than Young Adults	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						cerebral concussion; postural balance; development; adolescence	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; RECOVERY; ATTENTION; STABILITY; AGE; PERFORMANCE; STATEMENT; SYMPTOMS	Background: Age has been described as a factor that affects recovery after concussion. The recommended management protocol is to treat adolescents in a more cautious manner than adults. However, few studies have prospectively and longitudinally assessed the way these age groups perform on motor tasks after concussion. Purpose: To examine dual-task gait balance control deficits after concussion in a group of adolescents and young adults in reference to matched control subjects within 72 hours of injury and throughout 2 months after injury. Study Design: Cohort study; Level of evidence, 2. Methods: Adolescents and young adults who sustained a concussion and individually matched controls completed a whole-body motion gait analysis while simultaneously performing a cognitive task. Subjects with concussion reported to the laboratory within 72 hours after injury and at the following time points: 1 week, 2 weeks, 1 month, and 2 months after injury. Control subjects completed the same protocol at similar time points. Gait balance control measurements included whole-body center-of-mass (COM) medial-lateral displacement/velocity and anterior velocity. Results: A total of 38 subjects with concussion, 19 young adults (mean SD age, 20.3 +/- 2.4 years) and 19 adolescents (mean +/- SD age, 15.1 +/- 1.1 years), and 38 individually matched control subjects were tested. Within 72 hours of injury, adolescents displayed significantly greater COM medial-lateral displacement (P = .001) and peak velocity (P = .001) relative to their control group, and the young adult concussion group displayed significantly less peak COM anterior velocity than their control group (P = .01). Across the 2 months of testing, adolescents with concussion displayed significantly greater total COM medial-lateral displacement than did adolescent controls (P = .001), while young adults with concussion did not significantly differ from their matched controls (P = .07). Conclusion: An examination of gait balance control during dual-task walking revealed that after concussion, in reference to matched controls, adolescents demonstrated greater gait balance control deficits than did young adults initially and throughout the 2-month postinjury period, supporting the recommendation of conservative management for adolescents after concussion.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon and Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by Veterans Administration subcontract awards (A4842C8 and A4843C), the Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (W81XWH-11-1-0717).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	29	64	64	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					625	632		10.1177/0363546514560994			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500015	25540297				2022-02-06	
J	Vargas, G; Rabinowitz, A; Meyer, J; Arnett, PA				Vargas, Gray; Rabinowitz, Amanda; Meyer, Jessica; Arnett, Peter A.			Predictors and Prevalence of Postconcussion Depression Symptoms in Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; depressive symptoms; sports	TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; COGNITIVE RESERVE; MILD; CONCUSSION; ASSOCIATION; IMPAIRMENT; DISORDERS	Context: Depression is common after concussion and is associated with functional outcome and quality of life after injury. However, few baseline predictors of postconcussion depressive symptoms (PCDS) have been found. Objective: To describe the prevalence of depressive symptoms in a collegiate athlete sample at baseline and postconcussion, compare these levels of symptoms and change in symptoms with those of a control group with no reported concussions in the past year, and examine the baseline predictors for PCDS. Design: Case-control study. Setting: Undergraduate institution. Patients or Other Participants: Participants were 84 collegiate athletes (65 men, 19 women) with concussion and 42 individuals (23 men, 21 women) with no history of recent concussion who served as controls. Main Outcome Measure(s): The Beck Depression Inventory-Fast Screen was administered to the concussion group at baseline and postconcussion and to the control group at 2 time points. Results: Seventeen athletes (20%) showed a reliable increase in depression, and more athletes reported clinically important depression postconcussion than at baseline. Only 2 participants (5%) in the control group showed a reliable increase in depression. Concussed athletes were more likely to show a reliable increase in depression symptoms than control participants (chi(2)(1) = 5.2, P = .02). We also found several predictors of PCDS in the athletes, including baseline depression symptoms (r = 0.37, P < .001), baseline postconcussion symptoms (r = 0.25, P = .03), estimated premorbid intelligence (full-scale IQ; r = -0.29, P = .009), and age of first participation in organized sport (r = 0.34, P = .002). For the control group, predictors of depression symptoms at time 2 were number of previous head injuries (r = 0.31, P = .05) and baseline depression symptoms (r = 0.80, P < .001). Conclusions: A large proportion of athletes showed a reliable increase in depression after concussion, and we identified several baseline predictors. Given that depression affects quality of life and recovery from concussion, more research is necessary to better understand why certain athletes show an increase in PCDS and how these can be better predicted and prevented.	[Vargas, Gray] Alfred I DuPont Hosp Children, Dept Behav Hlth, Wilmington, DE 19803 USA; [Rabinowitz, Amanda] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Meyer, Jessica; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA		Vargas, G (corresponding author), Alfred I DuPont Hosp Children, Dept Behav Hlth, 1600 Rockland Rd, Wilmington, DE 19803 USA.	grayvargas@gmail.com					Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Barnett JH, 2006, PSYCHOL MED, V36, P1053, DOI 10.1017/S0033291706007501; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Steer RA, 1999, GEN HOSP PSYCHIAT, V21, P106, DOI 10.1016/S0163-8343(98)00070-X; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271	30	64	65	0	19	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2015	50	3					250	255		10.4085/1062-6050-50.3.02			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	CQ8AM	WOS:000360828300003	25643158	Green Published, Bronze			2022-02-06	
J	Miller, DM; Singh, IN; Wang, JA; Hall, ED				Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Nrf2-ARE activator carnosic acid decreases mitochondrial dysfunction, oxidative damage and neuronal cytoskeletal degradation following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						Lipid peroxidation; Mitochondria; Nrf2; Oxidative damage; Traumatic brain injury; 4-Hydroxy-2-nonenal	IN-VITRO; PROTECTS; SULFORAPHANE; EXPRESSION; CALPAIN; STRESS; KEAP1; VIVO; NEURODEGENERATION; TRANSCRIPTION	The importance of free radical-induced oxidative damage after traumatic brain injury (TBI) has been well documented. Despite multiple clinical trials with radical-scavenging antioxidants that are neuroprotective in TBI models, none is approved for acute TBI patients. As an alternative antioxidant target, Nrf2 is a transcription factor that activates expression of antioxidant and cytoprotective genes by binding to antioxidant response elements (AREs) within DNA. Previous research has shown that neuronal mitochondria are susceptible to oxidative damage post-TBI, and thus the current study investigates whether Nrf2-ARE activation protects mitochondrial function when activated post-TBI. It was hypothesized that administration of carnosic acid (CA) would reduce oxidative damage biomarlcers in the brain tissue and also preserve cortical mitochondrial respiratory function post-TBI. A mouse controlled cortical impact (CCI) model was employed with a 1.0 mm cortical deformation injury. Administration of CA at 15 min post-TBI reduced cortical lipid peroxidation, protein nitration, and cytoskeletal breakdown markers in a dose-dependent manner at 48 h post-injury. Moreover, CA preserved mitochondrial respiratory function compared to vehicle animals. This was accompanied by decreased oxidative damage to mitochondrial proteins, suggesting the mechanistic connection of the two effects. Lastly, delaying the initial administration of CA up to 8 h post-TBI was still capable of reducing cytoskeletal breakdown, thereby demonstrating a clinically relevant therapeutic window for this approach. This study demonstrates that pharmacological Nrf2-ARE induction is capable of neuroprotective efficacy when administered after TBI. (C) 2014 Elsevier Inc All rights reserved.	[Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Miller, Darren M.; Singh, Indrapal N.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 741 S Limestone St,BBSRB Room B477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA022738]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1T32 NS077889, 2P30 NS051220-01]; Kentucky Spinal Cord & Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, T32NS077889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by grants NIH-NIDA 1T32 DA022738, NIH-NINDS 1T32 NS077889, and NIH-NINDS 2P30 NS051220-01, and funds from the Kentucky Spinal Cord & Head Injury Research Trust.	Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Miller DM, 2013, FREE RADICAL BIO MED, V57, P1, DOI 10.1016/j.freeradbiomed.2012.12.011; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	26	64	67	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2015	264						103	110		10.1016/j.expneurol.2014.11.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4IC	WOS:000349590400011	25432068	Green Accepted			2022-02-06	
J	Liu, L; Sun, TY; Liu, ZL; Chen, XR; Zhao, LL; Qu, GQ; Li, QJ				Liu, Liang; Sun, Tingyi; Liu, Zilong; Chen, Xiaorui; Zhao, Lili; Qu, Guoqiang; Li, Qingjie			Traumatic Brain Injury Dysregulates MicroRNAs to Modulate Cell Signaling in Rat Hippocampus	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; POSTTRANSCRIPTIONAL REGULATION; LEWY BODIES; EXPRESSION; GENDER; CASK	Traumatic brain injury (TBI) is a common cause for cognitive and communication problems, but the molecular and cellular mechanisms are not well understood. Epigenetic modifications, such as microRNA (miRNA) dysregulation, may underlie altered gene expression in the brain, especially hippocampus that plays a major role in spatial learning and memory and is vulnerable to TBI. To advance our understanding of miRNA in pathophysiological processes of TBI, we carried out a time-course microarray analysis of microRNA expression profile in rat ipsilateral hippocampus and examined histological changes, apoptosis and synapse ultrastructure of hippocampus post moderate TBI. We found that 10 out of 156 reliably detected miRNAs were significantly and consistently altered from one hour to seven days after injury. Bioinformatic and gene ontology analyses revealed 107 putative target genes, as well as several biological processes that might be initiated by those dysregulated miRNAs. Among those differentially expressed microRNAs, miR-144, miR-153 and miR-340-5p were confirmed to be elevated at all five time points after TBI by quantitative RT-PCR. Western blots showed three of the predicated target proteins, calcium/calmodulin-dependent serine protein kinase (CASK), nuclear factor erythroid 2-related factor 2 (NRF2) and alpha-synuclein (SNCA), were concurrently down-regulated, suggesting that miR-144, miR-153 and miR-340-5p may play important roles collaboratively in the pathogenesis of TBI-induced cognitive and memory impairments. These microRNAs might serve as potential targets for progress assessment and intervention against TBI to mitigate secondary damage to the brain.	[Liu, Liang; Sun, Tingyi; Liu, Zilong; Chen, Xiaorui; Zhao, Lili; Qu, Guoqiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430074, Peoples R China; [Liu, Liang] China Univ Polit Sci & Law, Minist Educ, Key Lab Evidence Sci, Beijing, Peoples R China; [Li, Qingjie] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA		Liu, ZL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430074, Peoples R China.	lzlongfy@gmail.com; quli@utmb.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81102304]; Ministry of Education of ChinaMinistry of Education, China [20090142120054]; Foundation of Huazhong University of Science and Technology [20100573]	This work was supported by grants from the National Natural Science Foundation of China (grant number: 81102304) (http://www.nsfc.gov.cn/), Doctoral Fund of Ministry of Education of China (grant number: 20090142120054) (http://www.cutech.edu.cn/cn/index.htm), and Foundation of Huazhong University of Science and Technology (grant number: 20100573) (http://kfy.hust.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Baba M, 1998, AM J PATHOL, V152, P879; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Cabin DE, 2002, J NEUROSCI, V22, P8797; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Carasatorre Mariana, 2013, Curr Top Behav Neurosci, V15, P73, DOI 10.1007/7854_2012_229; Chao HW, 2008, J CELL BIOL, V182, P141, DOI 10.1083/jcb.200712094; Chen KY, 2011, MOL CELL NEUROSCI, V48, P171, DOI 10.1016/j.mcn.2011.07.009; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cheng C, 2013, J BIOL CHEM, V288, P13748, DOI 10.1074/jbc.M112.381392; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Craig AM, 2007, CURR OPIN NEUROBIOL, V17, P43, DOI 10.1016/j.conb.2007.01.011; Dharap A, 2010, J NEUROCHEM, V113, P1685, DOI 10.1111/j.1471-4159.2010.06735.x; Doxakis E, 2010, J BIOL CHEM, V285, P12726, DOI 10.1074/jbc.M109.086827; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Fairless R, 2008, J NEUROSCI, V28, P12969, DOI 10.1523/JNEUROSCI.5294-07.2008; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Fortin DL, 2005, J NEUROSCI, V25, P10913, DOI 10.1523/JNEUROSCI.2922-05.2005; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jeyifous O, 2009, NAT NEUROSCI, V12, P1011, DOI 10.1038/nn.2362; Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li XH, 2012, NEUROSCI LETT, V514, P46, DOI 10.1016/j.neulet.2012.02.054; Liang CL, 2012, BRAIN RES, V1455, P103, DOI 10.1016/j.brainres.2011.10.051; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Nistico R, 2012, MOL NEUROBIOL, V46, P572, DOI 10.1007/s12035-012-8324-3; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Patuzzo C, 2012, BALK J MED GENET, V15, P51, DOI 10.2478/v10034-012-0019-6; Persengiev S, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.03.014; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rau CS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-181; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Xu JZ, 2011, INT J CANCER, V129, P2527, DOI 10.1002/ijc.25917; Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhang Y, 2011, J CELL BIOCHEM, V112, P2435, DOI 10.1002/jcb.23168	66	64	66	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103948	10.1371/journal.pone.0103948			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM4GX	WOS:000339812700068	25089700	Green Published, gold, Green Submitted			2022-02-06	
J	Chen, X; Duan, XS; Xu, LJ; Zhao, JJ; She, ZF; Chen, WW; Zheng, ZJ; Jiang, GD				Chen, X.; Duan, X. -S.; Xu, L. -J.; Zhao, J. -J.; She, Z. -F.; Chen, W. -W.; Zheng, Z. -J.; Jiang, G. -D.			INTERLEUKIN-10 MEDIATES THE NEUROPROTECTION OF HYPERBARIC OXYGEN THERAPY AGAINST TRAUMATIC BRAIN INJURY IN MICE	NEUROSCIENCE			English	Article						interleukin-10; hyperbaric oxygen; traumatic brain injury; apoptosis; inflammation; edema	SPINAL-CORD-INJURY; NEURONAL APOPTOSIS; BARRIER FUNCTION; EDEMA; EXPRESSION; DAMAGE; MATRIX-METALLOPROTEINASE-9; NEUROINFLAMMATION; CASPASES; IMPACT	The aim of present study was to elucidate the role of Interleukin-10 (IL-10) in the neuroprotection of hyperbaric oxygen (HBO) against traumatic brain injury (TBI) in mice. The TBI in mice was induced by controlled cortical impact (CCI). HBO was given for 1 h at 2.0 absolute atmosphere (ATA) in 100% O-2. HBO enhanced the serumal and cerebral IL-10 protein levels in both sham-operated and TBI mice. HBO therapy after TBI reduced lesion volume, attenuated cerebral edema, improved neurological status including motor and cognitive function, inhibited apoptosis evidenced by decreased ratio of cleaved caspase-3 (C3) to pro-C3 and Bax expression and increased bcl-2 expression, and attenuated inflammation marked by reduced expression of IL-1 beta, IL-6, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1) and activity of matrix metalloproteinase-9 (MMP9). In addition, HBO after TBI improved the blood-brain barrier, and upregulated the expression of tight junction proteins including zonula occludens-1 (ZO-1) and claudin-5. IL-10 deficiency aggravated TBI-induced damage in the brain and abrogated the beneficial effects of HBO on neuroinflammation, apoptosis, and edema after TBI. IL-10 deficiency itself had no significant effect on brain water content and neurological status. In conclusion, IL-10 played an important role in the neuroprotection of HBO therapy against TBI in mice. (C) 2014 Published by Elsevier Ltd. on behalf of IBRO.	[Chen, X.; Duan, X. -S.; Xu, L. -J.; She, Z. -F.; Chen, W. -W.; Zheng, Z. -J.; Jiang, G. -D.] 113th Hosp PLA, Dept Hyperbar Oxygen, Ningbo 315040, Zhejiang, Peoples R China; [Zhao, J. -J.] 305th Hosp PLA, Dept Neurol, Beijing, Peoples R China		Jiang, GD (corresponding author), 113th Hosp PLA, Dept Hyperbar Oxygen, 337 Zhongshandong Rd, Ningbo 315040, Zhejiang, Peoples R China.	jianggd2013@hotmail.com					Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cua DJ, 2001, J IMMUNOL, V166, P602, DOI 10.4049/jimmunol.166.1.602; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frenkel D, 2005, J NEUROL SCI, V233, P125, DOI 10.1016/j.jns.2005.03.022; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu Zhan, 2006, Chin J Traumatol, V9, P168; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Londono D, 2011, J IMMUNOL, V186, P7176, DOI 10.4049/jimmunol.1100060; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Oshima T, 2001, MICROVASC RES, V61, P130, DOI 10.1006/mvre.2000.2288; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Perez-Espejo MA, 2009, NEUROCIRUGIA, V20, P449; Prakash A, 2012, J PEDIATR NEUROSCI, V7, P4, DOI 10.4103/1817-1745.97610; Qian L, 2006, J PHARMACOL EXP THER, V319, P44, DOI 10.1124/jpet.106.106351; Sahni T, 2012, BRIT J NEUROSURG, V26, P202, DOI 10.3109/02688697.2011.626879; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	35	64	70	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						235	243		10.1016/j.neuroscience.2013.11.036			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AE8VO	WOS:000334281200023	24291771				2022-02-06	
J	Zhang, MY; Shan, HY; Chang, P; Wang, T; Dong, WW; Chen, XP; Tao, LY				Zhang, Mingyang; Shan, Haiyan; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang			Hydrogen Sulfide Offers Neuroprotection on Traumatic Brain Injury in Parallel with Reduced Apoptosis and Autophagy in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; CYSTATHIONINE-BETA-SYNTHASE; CENTRAL-NERVOUS-SYSTEM; INDUCED CELL-DEATH; ALZHEIMERS-DISEASE; HEAD-INJURY; RAT MODEL; CONTRIBUTES; MECHANISMS; STRATEGIES	Hydrogen sulfide (H2S), a novel gaseous mediator, has been recognized as an important neuromodulator and neuroprotective agent in the central nervous system. The present study was undertaken to study the effects of exogenous H2S on traumatic brain injury (TBI) and the underlying mechanisms. The effects of exogenous H2S on TBI were examined by using measurement of brain edema, behavior assessment, propidium iodide (PI) staining, and Western blotting, respectively. Compared to TBI groups, H2S pretreatment had reduced brain edema, improved motor performance and ameliorated performance in Morris water maze test after TBI. Immunoblotting results showed that H2S pretreatment reversed TBI-induced cleavage of caspase-3 and decline of Bcl-2, suppressed LC3-II, Beclin-1 and Vps34 activation and maintained p62 level in injured cortex and hippocampus post TBI. The results suggest a protective effect and therapeutic potential of H2S in the treatment of brain injury and the protective effect against TBI may be associated with regulating apoptosis and autophagy.	[Zhang, Mingyang; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang] Soochow Univ, Coll Med, Dept Forens Sci, Suzhou, Peoples R China; [Zhang, Mingyang; Chang, Pan; Wang, Tao; Dong, Wenwen; Chen, Xiping; Tao, Luyang] Soochow Univ, Coll Med, Lab Brain Injury, Suzhou, Peoples R China; [Zhang, Mingyang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong, Peoples R China; [Shan, Haiyan] North Dist Suzhou Municipal Hosp, Dept Obstet & Gynecol, Suzhou, Peoples R China		Chen, XP (corresponding author), Soochow Univ, Coll Med, Dept Forens Sci, Suzhou, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Zhang, Mingyang/0000-0003-1612-0763	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872666, 81172911, 81301039]	This study was supported by grants 30872666, 81172911 and 81301039 from the National Natural Science Foundation of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 1996, J NEUROSCI, V16, P1066; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Enokido Y, 2005, FASEB J, V19, P1854, DOI 10.1096/fj.05-3724fje; Eto K, 2002, BIOCHEM BIOPH RES CO, V293, P1485, DOI 10.1016/S0006-291X(02)00422-9; Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020; Francis RC, 2011, ANESTHESIOLOGY, V115, P1012, DOI 10.1097/ALN.0b013e31823306cf; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kajta M, 2004, POL J PHARMACOL, V56, P689; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Karlsson O, 2011, BEHAV BRAIN RES, V219, P310, DOI 10.1016/j.bbr.2011.01.056; Kimura H, 2010, ANTIOXID REDOX SIGN, V12, P1111, DOI 10.1089/ars.2009.2919; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu YH, 2012, ANTIOXID REDOX SIGN, V17, P141, DOI 10.1089/ars.2011.4005; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Martelli A, 2012, MED RES REV, V32, P1093, DOI 10.1002/med.20234; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Qu K, 2006, STROKE, V37, P889, DOI 10.1161/01.STR.0000204184.34946.41; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wong PTH, 2006, J NEUROPATH EXP NEUR, V65, P109, DOI 10.1097/01.jnen.0000199571.96472.c7; Xuan AG, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-202; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang MY, 2013, NEUROCHEM RES, V38, P714, DOI 10.1007/s11064-013-0969-4; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	46	64	68	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2014	9	1							e87241	10.1371/journal.pone.0087241			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	297XI	WOS:000330288000203	24466346	Green Published, gold, Green Submitted			2022-02-06	
J	Carvalho, AF; Miskowiak, KK; Hyphantis, TN; Kohler, CA; Alves, GS; Bortolato, B; Sales, PMG; Machado-Vieira, R; Berk, M; McIntyre, RS				Carvalho, Andre F.; Miskowiak, Kamilla K.; Hyphantis, Thomas N.; Koehler, Cristiano A.; Alves, Gilberto S.; Bortolato, Beatrice; Sales, Paulo Marcelo G.; Machado-Vieira, Rodrigo; Berk, Michael; McIntyre, Roger S.			Cognitive Dysfunction in Depression - Pathophysiology and Novel Targets	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Brain-derived neurotrophic factor; cognition; cytokine; erythropoietin; inflammation; major depressive disorder; novel targets; oxidative stress; S-adenosyl-L-methionine	NITRIC-OXIDE SYNTHASE; TREATMENT-RESISTANT DEPRESSION; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; OXIDATIVE STRESS; DOUBLE-BLIND; N-ACETYLCYSTEINE; HIPPOCAMPAL VOLUME; GLUCOCORTICOID-RECEPTOR	Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing several domains, including memory, executive function, processing speed and attention. Cognitive deficits persist in a significant proportion of patients even in remission, compromising psychosocial functioning and workforce performance. While monoaminergic antidepressants may improve cognitive performance in MDD, most antidepressants have limited clinical efficacy. The overarching aims of this review were: (1) to synthesize extant literature on putative biological pathways related to cognitive dysfunction in MDD and (2) to review novel neurotherapeutic targets for cognitive enhancement in MDD. We found that reciprocal and overlapping biological pathways may contribute to cognitive dysfunction in MDD, including an hyperactive hypothalamic-pituitary-adrenal axis, an increase in oxidative and nitrosative stress, inflammation (e.g., enhanced production of pro-inflammatory cytokines), mitochondrial dysfunction, increased apoptosis as well as a diminished neurotrophic support. Several promising neurotherapeutic targets were identified such as minocycline, statins, anti-inflammatory compounds, N-acetylcysteine, omega-3 poliunsaturated fatty acids, erythropoietin, thiazolidinediones, glucagon-like peptide-1 analogues, S-adenosyl-l-methionine (SAMe), cocoa flavonols, creatine monohydrate and lithium. Erythropoietin and SAMe had pro-cognitive effects in randomized controlled trials (RCT) involving MDD patients. Despite having preclinical and/or preliminary evidences from trials suggesting possible efficacy as novel cognitive enhancing agents for MDD, no RCT to date was performed for most of the other therapeutic targets reviewed herein. In conclusion, multiple biological pathways are involved in cognitive dysfunction in MDD. RCTs testing genuinely novel pro-cognitive compounds for MDD are warranted.	[Carvalho, Andre F.; Alves, Gilberto S.; Sales, Paulo Marcelo G.] Univ Fed Ceara, Fac Med, Translat Psychiat Res Grp, BR-60430040 Fortaleza, Ceara, Brazil; [Miskowiak, Kamilla K.] Rigshosp, Copenhagen Univ Hosp, Psychiat Ctr Copenhagen, DK-2100 Copenhagen, Denmark; [Hyphantis, Thomas N.] Univ Ioaninna, Sch Med, Dept Psychiat, Ioaninna, Greece; [Koehler, Cristiano A.] Fed Univ Rio Grande Norte UFRN, Brain Inst ICe, Memory Res Lab, Natal, RN, Brazil; [Bortolato, Beatrice] Univ Padua, Dept Neurosci, Padua, Italy; [Machado-Vieira, Rodrigo] NIMH, Expt Therapeut & Pathophysiol Branch, Div Intramural Res Program, NIH, Bethesda, MD 20892 USA; [Berk, Michael] Deakin Univ, Sch Med, IMPACT Strateg Res Ctr, Geelong, Vic 3217, Australia; [Berk, Michael] Barwon Hlth, Geelong, Vic, Australia; [Berk, Michael] Univ Melbourne, Dept Psychiat, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Berk, Michael] Univ Melbourne, Orygen Youth Hlth Res Ctr, Parkville, Vic 3052, Australia; [McIntyre, Roger S.] Univ Toronto, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada; [McIntyre, Roger S.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [McIntyre, Roger S.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada		Carvalho, AF (corresponding author), Univ Fed Ceara, Fac Med, Dept Clin Med, Rua Prof Costa Mendes,1608,4o Andar, BR-60430040 Fortaleza, Ceara, Brazil.	andrefc7@terra.com.br	Kohler, Cristiano/A-6381-2013; McIntyre, Roger/AAU-1000-2020; SALES, PAULO M G/G-6575-2011; Machado-Vieira, Rodrigo/D-8293-2012; Berk, Michael/M-3585-2019; Berk, Michael/M-7891-2013	Kohler, Cristiano/0000-0003-0503-5264; McIntyre, Roger/0000-0003-4733-2523; SALES, PAULO M G/0000-0001-5958-2461; Machado-Vieira, Rodrigo/0000-0002-4830-1190; Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946; Miskowiak, Kamilla/0000-0003-2572-1384	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Level II)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	AFC is supported by a research fellowship award from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Level II). CAK is supported by a postdoctoral fellowship from CAPES.	Adcock KH, 2002, DEV NEUROSCI-BASEL, V24, P382, DOI 10.1159/000069043; Ahuja M, 2008, TOXICOLOGY, V244, P111, DOI 10.1016/j.tox.2007.11.003; Aizenstein HJ, 2009, AM J GERIAT PSYCHIAT, V17, P30, DOI 10.1097/JGP.0b013e31817b60af; Akpinar A, 2013, PROG NEURO-PSYCHOPH, V46, P120, DOI 10.1016/j.pnpbp.2013.07.003; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Alonso J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065858; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th; Anacker C, 2011, MOL PSYCHIATR, V16, P738, DOI 10.1038/mp.2011.26; Anderson G, 2014, CURR PHARM DESIGN, V20, P3812, DOI 10.2174/13816128113196660738; Arnone D, 2012, EUR NEUROPSYCHOPHARM, V22, P1, DOI 10.1016/j.euroneuro.2011.05.003; Bayramgurler D, 2013, PHYSIOL BEHAV, V119, P145, DOI 10.1016/j.physbeh.2013.06.010; Bergman J, 2013, CLIN NEUROPHARMACOL, V36, P73, DOI 10.1097/WNF.0b013e31828ef969; Berk M, 2014, J CLIN PSYCHIAT, V75, P628, DOI 10.4088/JCP.13m08454; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-200; Berk M, 2013, TRENDS PHARMACOL SCI, V34, P167, DOI 10.1016/j.tips.2013.01.001; Bhagwagar Z, 2008, INT J NEUROPSYCHOPH, V11, P255, DOI 10.1017/S1461145707007924; Bhagwagar Z, 2006, AM J PSYCHIAT, V163, P1580, DOI 10.1176/appi.ajp.163.9.1580; Bhattacharya P, 2014, LIFE SCI, V100, P97, DOI 10.1016/j.lfs.2014.01.085; Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35; Bora E, 2013, PSYCHOL MED, V43, P2017, DOI 10.1017/S0033291712002085; Bora E, 2012, J AFFECT DISORDERS, V138, P9, DOI 10.1016/j.jad.2011.03.049; Borre Y, 2012, EUR J PHARMACOL, V697, P59, DOI 10.1016/j.ejphar.2012.09.005; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Bufalino C, 2013, BRAIN BEHAV IMMUN, V31, P31, DOI 10.1016/j.bbi.2012.04.009; Buist-Bouwman MA, 2008, ACTA PSYCHIAT SCAND, V118, P451, DOI 10.1111/j.1600-0447.2008.01285.x; Bukh Jens Drachmann, 2011, Clin Pract Epidemiol Ment Health, V7, P140, DOI 10.2174/1745017901107010140; Cao L, 2012, NEUROSCIENCE, V220, P85, DOI 10.1016/j.neuroscience.2012.06.044; Carloni S, 2014, J PINEAL RES, V57, P192, DOI 10.1111/jpi.12156; Carvalho AF, 2014, PSYCHOTHER PSYCHOSOM, V83, P70, DOI 10.1159/000357500; Carvalho LA, 2008, STRESS, V11, P411, DOI 10.1080/10253890701850759; Caspi A, 2010, AM J PSYCHIAT, V167, P509, DOI 10.1176/appi.ajp.2010.09101452; Cassano P, 2006, PHARMACOGENOMICS J, V6, P381, DOI 10.1038/sj.tpj.6500385; Catena-Dell'Osso M, 2011, CURR MED CHEM, V18, P245, DOI 10.2174/092986711794088353; Celik C, 2010, PROG NEURO-PSYCHOPH, V34, P372, DOI 10.1016/j.pnpbp.2010.01.002; Chakravarty S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063302; Chen FH, 2013, SYNAPSE, V67, P127, DOI 10.1002/syn.21622; Christensen MV, 2006, NORD J PSYCHIAT, V60, P79, DOI 10.1080/08039480600600300; Christian KM, 2014, ANNU REV NEUROSCI, V37, P243, DOI 10.1146/annurev-neuro-071013-014134; Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009; Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646; Cumurcu BE, 2009, PSYCHIAT CLIN NEUROS, V63, P639, DOI 10.1111/j.1440-1819.2009.02004.x; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; Dantzer R, 2009, IMMUNOL ALLERGY CLIN, V29, P247, DOI 10.1016/j.iac.2009.02.002; de Quervain DJF, 2000, NAT NEUROSCI, V3, P313, DOI 10.1038/73873; Dean OM, 2012, PSYCHIAT CLIN NEUROS, V66, P514, DOI 10.1111/j.1440-1819.2012.02392.x; Della FP, 2013, METAB BRAIN DIS, V28, P93, DOI 10.1007/s11011-012-9375-x; Dias-Ferreira E, 2009, SCIENCE, V325, P621, DOI 10.1126/science.1171203; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Dong SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031211; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dunn AJ, 2005, NEUROSCI BIOBEHAV R, V29, P891, DOI 10.1016/j.neubiorev.2005.03.023; Elenkov IJ, 2006, NEUROIMMUNOMODULAT, V13, P257, DOI 10.1159/000104853; Fanous AH, 2004, NEUROTOX RES, V6, P43, DOI 10.1007/BF03033295; Faridhosseini F, 2014, HUM PSYCHOPHARM CLIN, V29, P216, DOI 10.1002/hup.2401; Fava M, 2012, J PSYCHIATR RES, V46, P1553, DOI 10.1016/j.jpsychires.2012.08.013; Mello BSF, 2013, J PSYCHIATR RES, V47, P1521, DOI 10.1016/j.jpsychires.2013.06.008; Flint J, 2014, NEURON, V81, P484, DOI [10.1016/j.neuron.2014.01.027, 10.1016/j.neuron.2014.02.033]; Fossati P, 2002, J AFFECT DISORDERS, V68, P261, DOI 10.1016/S0165-0327(00)00362-1; Galecki P, 2007, PSYCHIATR POL, V41, P615; Galecki P, 2014, PSYCHIAT RES, V215, P488, DOI 10.1016/j.psychres.2013.12.017; Galecki P, 2012, J AFFECT DISORDERS, V138, P360, DOI 10.1016/j.jad.2012.01.016; Galecki P, 2009, HUM PSYCHOPHARM CLIN, V24, P277, DOI 10.1002/hup.1014; Gao SF, 2014, PSYCHONEUROENDOCRINO, V47, P136, DOI 10.1016/j.psyneuen.2014.05.009; Gao Y, 2013, INT J GERIATR PSYCH, V28, P441, DOI 10.1002/gps.3845; Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8; Ghanizadeh A, 2013, DEPRESS ANXIETY, V30, P1084, DOI 10.1002/da.22195; Gold PW, 2013, MOL PSYCHIATR, V18, P154, DOI 10.1038/mp.2012.167; Goncalves JF, 2010, CHEM-BIOL INTERACT, V186, P53, DOI 10.1016/j.cbi.2010.04.011; Gos T, 2013, J PSYCHIATR RES, V47, P1694, DOI 10.1016/j.jpsychires.2013.07.005; Gould E, 1997, J NEUROSCI, V17, P2492; Grosso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096905; Hajek T, 2012, J PSYCHIATR NEUROSCI, V37, P333, DOI 10.1503/jpn.110143; Hasselbalch BJ, 2012, NEUROPSYCHOLOGY, V26, P642, DOI 10.1037/a0029301; Hasselbalch BJ, 2011, J AFFECT DISORDERS, V134, P20, DOI 10.1016/j.jad.2010.11.011; Heiser P, 2008, EUR NEUROPSYCHOPHARM, V18, P860, DOI 10.1016/j.euroneuro.2008.07.003; Herken H, 2007, ARCH MED RES, V38, P247, DOI 10.1016/j.arcmed.2006.10.005; Herrera-Guzman I, 2010, J AFFECT DISORDERS, V123, P341, DOI 10.1016/j.jad.2009.10.009; Herrera-Guzman I, 2009, J PSYCHIATR RES, V43, P855, DOI 10.1016/j.jpsychires.2008.10.015; Hinwood M, 2013, CEREB CORTEX, V23, P1784, DOI 10.1093/cercor/bhs151; Hock C, 2000, MOL PSYCHIATR, V5, P510, DOI 10.1038/sj.mp.4000743; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Homberg JR, 2014, NEUROSCI BIOBEHAV R, V43, P35, DOI 10.1016/j.neubiorev.2014.03.012; Hurley LL, 2013, NEUROTOX RES, V23, P131, DOI 10.1007/s12640-012-9348-1; Ikenouchi-Sugita A, 2009, PROG NEURO-PSYCHOPH, V33, P1451, DOI 10.1016/j.pnpbp.2009.07.028; Iseme RA, 2014, NEUROSCI BIOBEHAV R, V40, P62, DOI 10.1016/j.neubiorev.2014.01.008; Jaeger J, 2006, PSYCHIAT RES, V145, P39, DOI 10.1016/j.psychres.2005.11.011; Jang SW, 2010, P NATL ACAD SCI USA, V107, P3876, DOI 10.1073/pnas.0912531107; Juan WS, 2014, J PINEAL RES; Juruena MF, 2014, EPILEPSY BEHAV, V38, P148, DOI 10.1016/j.yebeh.2013.10.020; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Kendler KS, 2014, AM J PSYCHIAT, V171, P426, DOI 10.1176/appi.ajp.2013.13101375; Kernt M, 2010, CLIN OPHTHALMOL, V4, P591; Kessler RC, 2013, ANNU REV PUBL HEALTH, V34, P119, DOI 10.1146/annurev-publhealth-031912-114409; Khairova RA, 2009, INT J NEUROPSYCHOPH, V12, P561, DOI 10.1017/S1461145709009924; Kilic FS, 2012, NEUROSCIENCES, V17, P39; Kim SW, 2010, NEUROTOX RES, V17, P39, DOI 10.1007/s12640-009-9075-4; Kim SS, 2004, ARCH PHARM RES, V27, P314, DOI 10.1007/BF02980066; Klengel T, 2013, NAT NEUROSCI, V16, P33, DOI 10.1038/nn.3275; Krab LC, 2008, JAMA-J AM MED ASSOC, V300, P287, DOI 10.1001/jama.300.3.287; Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155; Krishnan R, 2007, BRIT J DERMATOL, V157, P1275, DOI 10.1111/j.1365-2133.2007.08205.x; Ladd CO, 2004, BIOL PSYCHIAT, V55, P367, DOI 10.1016/j.biopsych.2003.10.007; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Lampe IK, 2004, PSYCHIAT RES, V125, P73, DOI 10.1016/j.psychres.2003.12.004; Landro NI, 2001, NEUROPSY NEUROPSY BE, V14, P233; Larsen MH, 2010, J PSYCHIATR RES, V44, P808, DOI 10.1016/j.jpsychires.2010.01.005; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lee BH, 2007, J AFFECT DISORDERS, V101, P239, DOI 10.1016/j.jad.2006.11.005; Levkovitz Y, 2012, J AFFECT DISORDERS, V136, P1174, DOI 10.1016/j.jad.2011.04.059; Levkovitz Y, 2010, J CLIN PSYCHIAT, V71, P138, DOI 10.4088/JCP.08m04666yel; Lin PY, 2014, PHARMACOL BIOCHEM BE, V124, P174, DOI 10.1016/j.pbb.2014.06.006; Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105; Liu Y, 2012, J AFFECT DISORDERS, V139, P230, DOI 10.1016/j.jad.2011.08.003; Lopresti AL, 2012, J PSYCHOPHARMACOL, V26, P1512, DOI 10.1177/0269881112458732; Luca M, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/230797; Ludka FK, 2013, EUR NEUROPSYCHOPHARM, V23, P400, DOI 10.1016/j.euroneuro.2012.05.005; Madhoo M, 2014, NEUROPSYCHOPHARMACOL, V39, P1388, DOI 10.1038/npp.2013.334; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P702, DOI 10.1016/j.pnpbp.2010.12.017; MAES M, 1991, ACTA PSYCHIAT SCAND, V84, P379, DOI 10.1111/j.1600-0447.1991.tb03163.x; Maes M, 2013, J AFFECT DISORDERS, V149, P23, DOI 10.1016/j.jad.2012.06.039; Maes M, 2012, PSYCHIAT RES, V196, P243, DOI 10.1016/j.psychres.2011.09.029; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014; Maes M, 2009, NEUROENDOCRINOL LETT, V30, P715; Maes M, 2009, METAB BRAIN DIS, V24, P27, DOI 10.1007/s11011-008-9118-1; Malhi GS, 2013, CNS DRUGS, V27, P135, DOI 10.1007/s40263-013-0039-0; Marazziti D, 2011, CURR MED CHEM, V18, P4715, DOI 10.2174/092986711797379221; MARCOS T, 1994, J AFFECT DISORDERS, V32, P133, DOI 10.1016/0165-0327(94)90071-X; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Mauer S, 2014, AUST NZ J PSYCHIAT, V48, P809, DOI 10.1177/0004867414536932; Mazereeuw G, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.014; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; McEwen BS, 2010, ANN NY ACAD SCI, V1204, pE38, DOI 10.1111/j.1749-6632.2010.05568.x; McIntyre R. S., 2014, INT J NEUROPSYCHOPH, V30, P1; McIntyre RS, 2007, EXPERT OPIN PHARMACO, V8, P1615, DOI 10.1517/14656566.8.11.1615; McIntyre RS, 2013, DEPRESS ANXIETY, V30, P515, DOI 10.1002/da.22063; McIntyre RS, 2013, BEHAV BRAIN RES, V237, P164, DOI 10.1016/j.bbr.2012.09.021; McIntyre RS, 2010, ADV THER, V27, P63, DOI 10.1007/s12325-010-0011-z; McKinnon MC, 2009, J PSYCHIATR NEUROSCI, V34, P41; McMorris T, 2006, PSYCHOPHARMACOLOGY, V185, P93, DOI 10.1007/s00213-005-0269-z; Michel TM, 2007, PSYCHIAT RES, V151, P145, DOI 10.1016/j.psychres.2006.04.013; Michel TM, 2010, WORLD J BIOL PSYCHIA, V11, P314, DOI 10.3109/15622970802123695; Miracle AD, 2006, NEUROBIOL LEARN MEM, V85, P213, DOI 10.1016/j.nlm.2005.10.005; Miskowiak K, 2008, EXP BRAIN RES, V184, P313, DOI 10.1007/s00221-007-1102-1; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Miskowiak KW, 2014, NEUROPSYCHOPHARMACOL, V39, P1399, DOI 10.1038/npp.2013.335; Mohamed RH, 2011, BRAIN RES BULL, V86, P22, DOI 10.1016/j.brainresbull.2011.07.001; Molendijk ML, 2014, MOL PSYCHIATR, V19, P791, DOI 10.1038/mp.2013.105; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Montezuma K, 2012, NEUROPHARMACOLOGY, V62, P485, DOI 10.1016/j.neuropharm.2011.09.004; Mowla Arash, 2008, Depress Anxiety, V25, pE92, DOI 10.1002/da.20343; Moylan S, 2013, MOL PSYCHIATR, V18, P595, DOI 10.1038/mp.2012.33; Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007; Mueller A, 2011, NEUROPSYCHOPHARMACOL, V36, P1332, DOI 10.1038/npp.2011.11; Murri MB, 2014, PSYCHONEUROENDOCRINO, V41, P46, DOI 10.1016/j.psyneuen.2013.12.004; Musselman D, 2013, NEUROPSYCHOPHARMACOL, V38, P1921, DOI 10.1038/npp.2013.85; Myint AM, 2003, MED HYPOTHESES, V61, P519, DOI 10.1016/S0306-9877(03)00207-X; Na KS, 2014, PROG NEURO-PSYCHOPH, V48, P79, DOI 10.1016/j.pnpbp.2013.09.006; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; Nakasujja N, 2013, NEUROLOGY, V80, P196, DOI 10.1212/WNL.0b013e31827b9121; NEMEROFF CB, 1992, ARCH GEN PSYCHIAT, V49, P384; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; Neumeister A, 2005, BIOL PSYCHIAT, V57, P935, DOI 10.1016/j.biopsych.2005.01.016; Newcomer JW, 1999, ARCH GEN PSYCHIAT, V56, P527, DOI 10.1001/archpsyc.56.6.527; Nicoletti VG, 2005, NEUROCHEM RES, V30, P737, DOI 10.1007/s11064-005-6867-7; Nierenberg AA, 2013, AUST NZ J PSYCHIAT, V47, P26, DOI 10.1177/0004867412449303; Noble M, 1996, PERSPECT DEV NEUROBI, V3, P121; O'Neil A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-154; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Oliveira RMW, 2008, BRAZ J MED BIOL RES, V41, P333, DOI 10.1590/S0100-879X2008000400012; Orio L, 2010, NEUROTOX RES, V18, P187, DOI 10.1007/s12640-009-9120-3; Ormel J, 2013, NEUROSCI BIOBEHAV R, V37, P59, DOI 10.1016/j.neubiorev.2012.09.004; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Oxenkrug G, 2012, AGING DIS, V3, P330; Palta P, 2014, PSYCHOSOM MED, V76, P12, DOI 10.1097/PSY.0000000000000009; Papakostas GI, 2010, AM J PSYCHIAT, V167, P942, DOI 10.1176/appi.ajp.2009.09081198; Pariante CM, 2001, BIOL PSYCHIAT, V49, P391, DOI 10.1016/S0006-3223(00)01088-X; Parsaik AK, 2014, J AFFECT DISORDERS, V160, P62, DOI 10.1016/j.jad.2013.11.026; Pasco JA, 2010, PSYCHOTHER PSYCHOSOM, V79, P323, DOI 10.1159/000319530; Pearce EF, 2014, ANN PHARMACOTHER, V48, P758, DOI 10.1177/1060028014528305; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; Post RM, 2007, NEUROSCI BIOBEHAV R, V31, P858, DOI 10.1016/j.neubiorev.2007.04.003; Price JF, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1198; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Raison CL, 2003, AM J PSYCHIAT, V160, P1554, DOI 10.1176/appi.ajp.160.9.1554; Ravnkilde B, 2002, SCAND J PSYCHOL, V43, P239, DOI 10.1111/1467-9450.00292; Rigucci S, 2010, WORLD J BIOL PSYCHIA, V11, P165, DOI [10.3109/15622970903131571, 10.1080/15622970903131571]; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Roitman S, 2007, BIPOLAR DISORD, V9, P754, DOI 10.1111/j.1399-5618.2007.00532.x; Rothermundt M, 2001, J AFFECT DISORDERS, V66, P89, DOI 10.1016/S0165-0327(00)00321-9; ROY A, 1981, ARCH GEN PSYCHIAT, V38, P301; Sacktor N, 2011, NEUROLOGY, V77, P1135, DOI 10.1212/WNL.0b013e31822f0412; Sanmukhani J, 2014, PHYTOTHER RES, V28, P579, DOI 10.1002/ptr.5025; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sarandol A, 2007, HUM PSYCHOPHARM CLIN, V22, P67, DOI 10.1002/hup.829; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10-58; Schildknecht S, 2011, J BIOL CHEM, V286, P4991, DOI 10.1074/jbc.M110.169565; Seo JS, 2012, J NEUROSCI, V32, P9690, DOI 10.1523/JNEUROSCI.0794-12.2012; Sepanjnia K, 2012, NEUROPSYCHOPHARMACOL, V37, P2093, DOI 10.1038/npp.2012.58; Shea A, 2005, PSYCHONEUROENDOCRINO, V30, P162, DOI 10.1016/j.psyneuen.2004.07.001; Sievers C, 2014, EUR NEUROPSYCHOPHARM, V24, P890, DOI 10.1016/j.euroneuro.2014.01.008; Simons CJP, 2009, ACTA PSYCHIAT SCAND, V120, P45, DOI 10.1111/j.1600-0447.2008.01339.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Slavich GM, 2011, J PSYCHIATR RES, V45, P1146, DOI 10.1016/j.jpsychires.2011.03.004; Smaga I, 2012, PROG NEURO-PSYCHOPH, V39, P280, DOI 10.1016/j.pnpbp.2012.06.018; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; Soczynska JK, 2012, BEHAV BRAIN RES, V235, P302, DOI 10.1016/j.bbr.2012.07.026; Sokolov AN, 2013, NEUROSCI BIOBEHAV R, V37, P2445, DOI 10.1016/j.neubiorev.2013.06.013; Srivastava N, 2002, J AFFECT DISORDERS, V72, P45, DOI 10.1016/S0165-0327(01)00421-9; Stafford L, 2011, J CLIN PSYCHIAT, V72, P1229, DOI 10.4088/JCP.09m05825blu; Stefanescu C, 2012, J AFFECT DISORDERS, V143, P34, DOI 10.1016/j.jad.2012.05.022; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Stotland NL, 2012, PSYCHIAT CLIN N AM, V35, P37, DOI 10.1016/j.psc.2011.11.007; Stroud CB, 2011, J ABNORM PSYCHOL, V120, P142, DOI 10.1037/a0021659; Swiger KJ, 2013, MAYO CLIN PROC, V88, P1213, DOI 10.1016/j.mayocp.2013.07.013; Takebayashi M, 2010, J NEURAL TRANSM, V117, P1119, DOI 10.1007/s00702-010-0452-1; Talarowska M, 2015, ADV MED SCI-POLAND, V60, P1, DOI 10.1016/j.advms.2014.06.001; Talarowska Monika, 2014, Med Sci Monit, V20, P110, DOI 10.12659/MSM.889853; Talarowska M, 2012, NEUROSCI LETT, V510, P127, DOI 10.1016/j.neulet.2012.01.018; Tomaz VS, 2014, NEUROSCIENCE, V268, P236, DOI 10.1016/j.neuroscience.2014.03.025; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Tseng PT, 2013, PROG NEURO-PSYCHOPH, V40, P334, DOI 10.1016/j.pnpbp.2012.09.009; Turner CA, 2012, NEURON, V76, P160, DOI 10.1016/j.neuron.2012.08.037; Udina M, 2012, J CLIN PSYCHIAT, V73, P1128, DOI 10.4088/JCP.12r07694; van der Vaart T, 2013, LANCET NEUROL, V12, P1076, DOI 10.1016/S1474-4422(13)70227-8; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Voloboueva LA, 2011, J NEUROSCI RES, V89, P1989, DOI 10.1002/jnr.22768; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Wagner S, 2012, ACTA PSYCHIAT SCAND, V125, P281, DOI 10.1111/j.1600-0447.2011.01762.x; Wang YP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-95; Wang Y, 2011, NEUROSCI LETT, V499, P74, DOI 10.1016/j.neulet.2011.05.035; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Willner P, 2013, NEUROSCI BIOBEHAV R, V37, P2331, DOI 10.1016/j.neubiorev.2012.12.007; Wirtz PH, 2014, J AM COLL CARDIOL, V63, P2297, DOI 10.1016/j.jacc.2014.02.580; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Xie L, 2009, INT IMMUNOPHARMACOL, V9, P575, DOI 10.1016/j.intimp.2009.01.025; Yamamoto T, 2012, APPL NEUROPSYCH-ADUL, V19, P183, DOI 10.1080/09084282.2011.643959; Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025; Yi SY, 2012, PSYCHIAT RES, V200, P318, DOI 10.1016/j.psychres.2012.05.035; You JM, 2009, CAN J PHYSIOL PHARM, V87, P440, DOI [10.1139/Y09-027, 10.1139/y09-027]; Yuen EY, 2012, NEURON, V73, P962, DOI 10.1016/j.neuron.2011.12.033; Zannas AS, 2014, GENES BRAIN BEHAV, V13, P25, DOI 10.1111/gbb.12104; Zell R, 1997, MOL CELL BIOCHEM, V177, P61, DOI 10.1023/A:1006896832582; Zhang M, 2006, ACTA PHARMACOL SIN, V27, P1071, DOI 10.1111/j.1745-7254.2006.00322.x; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhou JF, 2008, J PINEAL RES, V45, P157, DOI 10.1111/j.1600-079X.2008.00570.x; Zhou W, 2014, EUR PSYCHIAT, V29, P419, DOI 10.1016/j.eurpsy.2013.10.005; Zhu FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093966; Zimmermann P, 2011, AM J PSYCHIAT, V168, P1107, DOI 10.1176/appi.ajp.2011.10111577; Zunszain PA, 2011, PROG NEURO-PSYCHOPH, V35, P722, DOI 10.1016/j.pnpbp.2010.04.011	257	64	66	1	49	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	10					1819	1835					17	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	CA0GG	WOS:000348594400017	25470397				2022-02-06	
J	Poole, VN; Abbas, K; Shenk, TE; Breedlove, EL; Breedlove, KM; Robinson, ME; Leverenz, LJ; Nauman, EA; Talavage, TM; Dydak, U				Poole, Victoria N.; Abbas, Kausar; Shenk, Trey E.; Breedlove, Evan L.; Breedlove, Katherine M.; Robinson, Meghan E.; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.; Dydak, Ulrike			MR Spectroscopic Evidence of Brain Injury in the Non-Diagnosed Collision Sport Athlete	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; METABOLIC-CHANGES; IN-VIVO; CHOLINE METABOLITES; HEAD-INJURY; CONCUSSION; GLUTAMINE; CHILDREN	With growing evidence of long-term neurological damage in individuals enduring repetitive head trauma, it is critical to detect lower-level damage accumulation for the early diagnosis of injury in at-risk populations. Proton magnetic resonance spectroscopic scans of the dorsolateral prefrontal cortex and primary motor cortex were collected from high school American (gridiron) football athletes, prior to and during their competition seasons. Although no concussions were diagnosed, significant metabolic deviations from baseline and non-collision sport controls were revealed. Overall the findings indicate underlying biochemical changes, consequential to repetitive hits, which have previously gone unnoticed due to a lack of traditional neurological symptoms.	[Poole, Victoria N.; Robinson, Meghan E.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Poole, Victoria N.; Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Abbas, Kausar; Shenk, Trey E.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Dydak, Ulrike] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA; [Dydak, Ulrike] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA		Talavage, TM (corresponding author), 465 Northwestern Ave, W Lafayette, IN 47907 USA.	tmt@purdue.edu	Abbas, Kausar/ABA-1318-2021; Abbas, Kausar/ABA-3670-2021	Abbas, Kausar/0000-0001-5352-149X; Abbas, Kausar/0000-0001-5352-149X; Talavage, Thomas/0000-0003-4977-6398; Poole, Victoria/0000-0003-0974-2564	Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health	This work was supported by the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health [to TMT, LJL, EAN].	Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Associations N. F. o. S. H. S., 2009, HIGH SCH ATHL PART S; Babb SM, 2004, PSYCHIAT RES-NEUROIM, V130, P1, DOI 10.1016/S0925-4927(03)00104-5; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698, DOI 10.1152/ajpregu.1999.277.3.R698; Erickson KI, 2012, BRAIN BEHAV, V2, P32, DOI 10.1002/brb3.30; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gonzales MM, 2013, BRAIN TOPOGR, V26, P126, DOI 10.1007/s10548-012-0248-8; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maddock RJ, 2011, NEUROIMAGE, V57, P1324, DOI 10.1016/j.neuroimage.2011.05.048; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mountford C, 2006, J MAGN RESON IMAGING, V24, P459, DOI 10.1002/jmri.20668; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tan J, 1998, MAGN RESON MED, V39, P1005, DOI 10.1002/mrm.1910390619; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van der Graaf M, 2010, EUR BIOPHYS J BIOPHY, V39, P527, DOI 10.1007/s00249-009-0517-y; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	49	64	64	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2014	39	6					459	473		10.1080/87565641.2014.940619			15	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AO0PL	WOS:000341012400003	25144258				2022-02-06	
J	Washington, PM; Morffy, N; Parsadanian, M; Zapple, DN; Burns, MP				Washington, Patricia M.; Morffy, Nicholas; Parsadanian, Maia; Zapple, David N.; Burns, Mark P.			Experimental Traumatic Brain Injury Induces Rapid Aggregation and Oligomerization of Amyloid-Beta in an Alzheimer's Disease Mouse Model	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; beta amyloid	CONTROLLED CORTICAL IMPACT; A-BETA; PRECURSOR PROTEIN; HEAD-INJURY; TRANSGENIC MICE; APOLIPOPROTEIN E4; INDUCED INCREASES; PEPTIDE; DEPOSITION; ACCUMULATION	Soluble amyloid-beta (A) oligomers are hypothesized to be the pathogenic species in Alzheimer's disease (AD), and increased levels of oligomers in the brain subsequent to traumatic brain injury (TBI) may exacerbate secondary injury pathways and underlie increased risk of developing AD in later life. To determine whether TBI causes A aggregation and oligomerization in the brain, we exposed triple transgenic AD model mice to controlled cortical impact injury and measured levels of soluble, insoluble, and oligomeric A by enzyme-linked immunosorbent assay (ELISA) at 1, 3, and 7 days postinjury. TBI rapidly increased levels of both soluble and insoluble A40 and A42 in the injured cortex at 1 day postinjury. We confirmed previous findings that identified damaged axons as a major site of A accumulation using both immunohistochemistry and biochemistry. We also report that soluble A oligomers were significantly increased in the injured cortex, as demonstrated by both ELISA and Western blot. Interestingly, the mouse brain is able to rapidly clear trauma-induced A, with both soluble and insoluble A species returning to sham levels by 7 days postinjury. In conclusion, we demonstrate that TBI causes acute accumulation and aggregation of A in the brain, including the formation of low- and high-molecular-weight A oligomers. The formation and aggregation of A into toxic species acutely after injury may play a role in secondary injury cascades after trauma and, chronically, may contribute to increased risk of developing AD in later life.	[Washington, Patricia M.; Morffy, Nicholas; Parsadanian, Maia; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA; [Zapple, David N.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20007 USA.	mpb37@georgetown.edu		Morffy, Nicholas/0000-0003-3170-2032; Burns, Mark P/0000-0003-4750-2000	National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081068, R03NS067417]; Cosmos Club Foundation's Young Scholars Grant Program; Georgetown University Medical Center Graduate Student Organization's Student Research Grants Program;  [T32NS041218]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R01NS081068, R03NS067417] Funding Source: NIH RePORTER	The project described above was supported by R01NS081068 and R03NS067417 (to M. P. B.) from the National Institute of Neurological Disorders and Stroke (NINDS) and T32NS041218 (to P. M. W.; principal investigators, Drs. Jean Wrathall and Kathleen Maguire-Zeiss), the Cosmos Club Foundation's Young Scholars Grant Program (to P. M. W.), and the Georgetown University Medical Center Graduate Student Organization's Student Research Grants Program (to P. M. W.). The authors thank Drs. R. Scott Turner and Hyang-Sook Hoe for providing 3 x Tg AD model mice and Dr. Paul Mathews (Nathan S. Kline Institute, Orangeburg, NY) for C1/6.1 Ab.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li SM, 2013, NEURON, V77, P929, DOI 10.1016/j.neuron.2012.12.040; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pryor NE, 2012, INT J MOL SCI, V13, P3038, DOI 10.3390/ijms13033038; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565	60	64	64	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					125	134		10.1089/neu.2013.3017			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500011	24050316	Green Published			2022-02-06	
J	Zou, HC; Brayer, SW; Hurwitz, M; Niyonkuru, C; Fowler, LE; Wagner, AK				Zou, Huichao; Brayer, Samuel W.; Hurwitz, Maxwell; Niyonkuru, Christian; Fowler, Lorraine E.; Wagner, Amy K.			Neuroprotective, Neuroplastic, and Neurobehavioral Effects of Daily Treatment With Levetiracetam in Experimental Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; glutamate transporter; levitiracetam; neuroprotection; neuroplasticity; neuroinflammation	GLUTAMATE TRANSPORTER GLT-1; INTRAVENOUS LEVETIRACETAM; WATER MAZE; PHENYTOIN; PROPHYLAXIS; MODEL; PERFORMANCE; EXPRESSION; SEIZURES; SUBTYPES	Background. Prophylactic treatment with antiepileptic drugs (AEDs) has been recommended to prevent early seizure onset in patients with traumatic brain injury (TBI). However, the potential neuroprotective and/or detrimental effects of prophylactic AED treatment on behavioral and cognitive function after TBI are not well studied. Objective. To investigate the effects of a novel AED, levitiracetam (LEV), on behavioral and cognitive function after experimental TBI in rats. Methods. Adult male rats were administered LEV (intraperitoneal 50 mg/kg) or vehicle (saline; SL) daily for 20 days beginning 1 day after controlled cortical impact (CCI; 2.8 mm; 4 m/s) or sham surgery. Beam performance (days 1-6), Y-maze (day 7), and Morris water maze (days 14-19) postinjury testing was assessed. Results. Daily LEV treatment improved motor function, increased novel arm exploration in the Y-maze, elicited greater hippocampal cell sparing, and decreased contusion volumes compared with CCI/SL rats. Daily LEV administration also reversed a TBI-induced decrease in regional glutamate transporter expression and neuroplastic marker proteins present 20 days post-CCI. Also, daily LEV treatment decreased regional IL-1 expression after TBI. Conclusions. These results suggest that daily LEV treatment has beneficial effects on histological, molecular, and behavioral elements of neurological recovery after TBI, in part, via modulation of neuroinflammatory and excitatory pathways.	[Zou, Huichao; Brayer, Samuel W.; Hurwitz, Maxwell; Niyonkuru, Christian; Fowler, Lorraine E.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Zou, Huichao; Brayer, Samuel W.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Wagner, AK (corresponding author), Univ Pittsburgh, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu		Canham, Lorraine/0000-0002-9444-4125	University of Pittsburgh Department of Physical Medicine and Rehabilitation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the University of Pittsburgh Department of Physical Medicine and Rehabilitation.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bell KFS, 2007, J NEUROSCI, V27, P10810, DOI 10.1523/JNEUROSCI.3269-07.2007; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Crepeau AZ, 2010, EXPERT REV NEUROTHER, V10, P159, DOI [10.1586/ern.10.5, 10.1586/ERN.10.3]; Da Cunha C, 2003, NEUROBIOL LEARN MEM, V79, P236, DOI 10.1016/S1074-7427(03)00008-X; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; De Smedt T, 2007, CNS DRUG REV, V13, P43, DOI 10.1111/j.1527-3458.2007.00004.x; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Furuta A, 1997, J NEUROSCI, V17, P8363; Gee JR, 2005, INT J BIOCHEM CELL B, V37, P1145, DOI 10.1016/j.biocel.2004.10.004; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Harris J, 2012, J CEREB BLOOD FLOW M, V31, P2122; HAUSER WA, 1990, NEW ENGL J MED, V323, P540, DOI 10.1056/NEJM199008233230809; Hoh TE, 1997, BEHAV NEUROSCI, V111, P1285, DOI 10.1037/0735-7044.111.6.1285; Hurwitz M, 2011, J NEUROTRAUM, V28, pA103; Kazerooni R, 2010, CLINICOECONOMIC OUTC, V2, P15; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Lyoo IK, 2009, ARCH GEN PSYCHIAT, V66, P878, DOI 10.1001/archgenpsychiatry.2009.86; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; Pagni Carlo Alberto, 2006, Expert Rev Neurother, V6, P1223, DOI 10.1586/14737175.6.8.1223; Palmada M., 1998, FRONT BIOSCI, V3, P701; Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f; Prow NA, 2008, J NEUROCHEM, V105, P1276, DOI 10.1111/j.1471-4159.2008.05230.x; PULLIAINEN V, 1995, EPILEPSIA, V36, P1195, DOI 10.1111/j.1528-1157.1995.tb01062.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Steinbaugh LA, 2012, EPILEPSY BEHAV, V23, P280, DOI 10.1016/j.yebeh.2011.12.005; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Takeuchi H, 2008, EXP NEUROL, V214, P144, DOI 10.1016/j.expneurol.2008.08.001; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Xing XC, 2011, BIOORG MED CHEM LETT, V21, P5774, DOI 10.1016/j.bmcl.2011.08.009	45	64	66	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV	2013	27	9					878	888		10.1177/1545968313491007			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	229IL	WOS:000325256000012	23812605				2022-02-06	
J	Yang, SH; Gustafson, J; Gangidine, M; Stepien, D; Schuster, R; Pritts, TA; Goodman, MD; Remick, DG; Lentsch, AB				Yang, Sung H.; Gustafson, Josh; Gangidine, Matt; Stepien, David; Schuster, Rebecca; Pritts, Timothy A.; Goodman, Michael D.; Remick, Daniel G.; Lentsch, Alex B.			A murine model of mild traumatic brain injury exhibiting cognitive and motor deficits	JOURNAL OF SURGICAL RESEARCH			English	Article						TBI; Inflammation; Combat casualty care; Trauma; Cytokines; Chemokines	CLOSED-HEAD INJURY; AXONAL INJURY; INTERLEUKIN-6; SEPSIS; MORTALITY; RECOVERY; DISEASE; IMPACT; IL-6	Background: Mild traumatic brain injury (TBI) is a serious public health concern affecting more than 1.7 million people in the United States annually. Mild TBI is difficult to diagnose and is clinically associated with impaired motor coordination and cognition. Methods: We subjected mice to a mild TBI (mTBI-1 or mTBI-2) induced by a weight drop model. We assessed brain injury histologically and biochemically, the latter by serum neuron-specific enolase and glial fibrillary acidic protein. Systemic and brain inflammation were measured by cytokine array. We determined blood-brain barrier integrity by cerebral vascular leakage of micromolecular and macromolecular fluorescent molecules. We evaluated mice using a rotarod device and novel object recognition to measure motor coordination and cognition, respectively. Results: Mice undergoing mTBI-1 or mTBI-2 had significant deficits in motor coordination and cognition for several days after injury compared with controls. Furthermore, both mTBI-1 and mTBI-2 caused micromolecular leakage in the blood-brain barrier, whereas only mTBI-2 caused macromolecular leakage. Serum neuron-specific enolase and glial fibrillary acidic protein were elevated acutely and corresponded to the degree of injury, but returned to baseline within 24 h. Serum cytokines interleukin-6 and keratinocyte-derived chemokine were significantly increased within 90 min of TBI. Interleukin-6 levels correlated with the degree of injury. Conclusions: The current study provides a reproducible model of mild TBI in mice that exhibits pathologic features of mild TBI in humans. Furthermore, our data suggest that serum cytokines, such as IL-6, may be effective biomarkers for severity of head injury. (C) 2013 Elsevier Inc. All rights reserved.	[Yang, Sung H.; Gustafson, Josh; Gangidine, Matt; Schuster, Rebecca; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.] Univ Cincinnati, Dept Surg, Inst Mil Med, Cincinnati, OH 45267 USA; [Gustafson, Josh] Boonshoft Sch Med, Dept Surg, Dayton, OH USA; [Stepien, David; Remick, Daniel G.] Boston Univ, Dept Pathol, Boston, MA 02215 USA		Lentsch, AB (corresponding author), Univ Cincinnati, Dept Surg, Inst Mil Med, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Stepien, David/0000-0002-3521-6210; Pritts, Timothy/0000-0003-2495-3255	United States Air ForceUnited States Department of Defense [FA8650-10-2-6B01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	Supported by United States Air Force grant FA8650-10-2-6B01 and National Institutes of Health training grant T32 GM08478.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul M, 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Michalski D, 2010, BRAIN RES, V1359, P186, DOI 10.1016/j.brainres.2010.08.045; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morey RA, 2012, HUM BRAIN M IN PRESS; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PATEL RT, 1994, BRIT J SURG, V81, P1306, DOI 10.1002/bjs.1800810914; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	29	64	65	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2013	184	2					981	988		10.1016/j.jss.2013.03.075			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	215XE	WOS:000324243500046	23622728	Green Accepted			2022-02-06	
J	Baalman, KL; Cotton, RJ; Rasband, SN; Rasband, MN				Baalman, Kelli L.; Cotton, R. James; Rasband, S. Neil; Rasband, Matthew N.			Blast Wave Exposure Impairs Memory and Decreases Axon Initial Segment Length	JOURNAL OF NEUROTRAUMA			English	Article						axon initial segment; ion channel; traumatic brain injury	TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY; NEURONAL INJURY; SODIUM-CHANNELS; RATS; OVERPRESSURE; CYTOSKELETON; NEUROTRAUMA; TETRODOTOXIN; MAINTENANCE	Exposure to a blast wave has been proposed to cause mild traumatic brain injury (mTBI), with symptoms including altered cognition, memory, and behavior. This idea, however, remains controversial, and the mechanisms of blast-induced brain injury remain unknown. To begin to resolve these questions, we constructed a simple compressed air shock tube, placed rats inside the tube, and exposed them to a highly reproducible and controlled blast wave. Consistent with the generation of a mild injury, 2 weeks after exposure to the blast, we found that motor performance was unaffected, and a panel of common injury markers showed little or no significant changes in expression in the cortex, corpus callosum, or hippocampus. Similarly, we were unable to detect elevated spectrin breakdown products in brains collected from blast-exposed rats. Using an object recognition task, however, we found that rats exposed to a blast wave spent significantly less time exploring a novel object when compared with control rats. Intriguingly, we also observed a significant shortening of the axon initial segment (AIS) in both the cortex and hippocampus of blast-exposed rats, suggesting altered neuronal excitability after exposure to a blast. A computational model showed that shortening the AIS increased both threshold and the interspike interval of repetitively firing neurons. These results support the conclusion that exposure to a single blast wave can lead to mTBI with accompanying cognitive impairment and subcellular changes in the molecular organization of neurons.	[Baalman, Kelli L.; Cotton, R. James; Rasband, Matthew N.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Rasband, S. Neil] Brigham Young Univ, Dept Phys & Astron, Provo, UT 84602 USA		Rasband, MN (corresponding author), Baylor Coll Med, Dept Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	rasband@bcm.edu		Cotton, R. James/0000-0001-5714-1400; Rasband, Matthew/0000-0001-8184-2477	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0145]	We thank Ms. Eva Ng and Yanhong Liu for technical help. We thank Cameron Cowan for help measuring the optokinetic response of rats. This work was supported by grant W81XWH-08-2-0145 from the Department of Defense.	Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Buffington SA, 2011, EUR J NEUROSCI, V34, P1609, DOI 10.1111/j.1460-9568.2011.07875.x; Burggraf D, 2008, BRAIN RES, V1189, P189, DOI 10.1016/j.brainres.2007.10.085; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Delcour M, 2012, BEHAV BRAIN RES, V232, P233, DOI 10.1016/j.bbr.2012.03.029; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Galiano MR, 2012, CELL, V149, P1125, DOI 10.1016/j.cell.2012.03.039; Gerstner W, 1997, P NATL ACAD SCI USA, V94, P12740, DOI 10.1073/pnas.94.24.12740; Grubb MS, 2011, J NEUROSCI, V31, P16049, DOI 10.1523/JNEUROSCI.4064-11.2011; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jeong H.K., 2011, PLOS ONE, V5; Kaphzan H, 2011, J NEUROSCI, V31, P17637, DOI 10.1523/JNEUROSCI.4162-11.2011; Kole MHP, 2008, NAT NEUROSCI, V11, P178, DOI 10.1038/nn2040; Kuba H, 2010, NATURE, V465, P1075, DOI 10.1038/nature09087; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Li XY, 2011, EMBO J, V30, P4825, DOI 10.1038/emboj.2011.376; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Ogawa Y, 2006, J NEUROSCI, V26, P5230, DOI 10.1523/JNEUROSCI.0425-06.2006; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rasband MN, 2010, NAT REV NEUROSCI; Rathbun DL, 2007, J NEUROPHYSIOL, V98, P911, DOI 10.1152/jn.00802.2006; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schafer DP, 2004, J NEUROSCI, V24, P3176, DOI 10.1523/JNEUROSCI.5427-03.2004; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wimmer VC, 2010, J PHYSIOL-LONDON, V588, P1829, DOI 10.1113/jphysiol.2010.188417; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yang Y, 2007, J CELL BIOL, V176, P509, DOI 10.1083/jcb.200610128	50	64	64	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		741	751		10.1089/neu.2012.2478			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600006	23025758	Green Published			2022-02-06	
J	Waszkielewicz, AM; Gunia, A; Szkaradek, N; Sloczynska, K; Krupinska, S; Marona, H				Waszkielewicz, A. M.; Gunia, A.; Szkaradek, N.; Sloczynska, K.; Krupinska, S.; Marona, H.			Ion Channels as Drug Targets in Central Nervous System Disorders	CURRENT MEDICINAL CHEMISTRY			English	Article						ASIC; central nervous system; CNS; KCNQ; ion channels; NMDA; P2X; TRP	GATED SODIUM-CHANNELS; D-ASPARTATE RECEPTOR; TARANTULA TOXIN PSALMOTOXIN-1; PERIPHERAL NEUROPATHIC PAIN; GLYCINE ANTAGONIST GV150526; ACID-SENSING ION-CHANNEL-1; SUBTYPE-SELECTIVE AGONIST; TRAUMATIC BRAIN-INJURY; TRANSGENIC MOUSE MODEL; ISCHEMIC CELL-DEATH	Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery process led towards specific channel subtypes. An example is Na+ channels, whose subtypes 1.3 and 1.7-1.9 are responsible for pain, and 1.1 and 1.2 - for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowledge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca2+ channels are not any more divided to T, L, N, P/Q, and R, but they are described as Ca(v)1.1-Ca(v)3.3, with even newer nomenclature alpha 1A-alpha 1I and alpha 1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving premises for new types of analgesic drugs.	[Waszkielewicz, A. M.; Gunia, A.; Szkaradek, N.; Sloczynska, K.; Krupinska, S.; Marona, H.] Jagiellonian Univ, Fac Pharm, Coll Med, Dept Bioorgan Chem,Chair Organ Chem, PL-30688 Krakow, Poland		Waszkielewicz, AM (corresponding author), Jagiellonian Univ, Fac Pharm, Coll Med, Dept Bioorgan Chem,Chair Organ Chem, 9 Med St, PL-30688 Krakow, Poland.	awaszkie@cm-uj.krakow.pl		L Londoner, Kenneth/0000-0001-9085-3813; Gunia-Krzyzak, Agnieszka/0000-0003-4162-4760; Marona, Henryk/0000-0002-3815-4174; Sloczynska, Karolina/0000-0002-7366-2676; Waszkielewicz, Anna/0000-0002-2871-9418	European Regional Development Fund through the Innovative Economy Program	This publication is supported by the European Regional Development Fund through the Innovative Economy Program.	Aarsland D, 2009, LANCET NEUROL, V8, P613, DOI 10.1016/S1474-4422(09)70146-2; Abrams J, 2006, NAT REV DRUG DISCOV, V5, P453, DOI 10.1038/nrd2069; Abu-Arafeh I, 2012, DEV MED CHILD NEUROL, V54, P204, DOI 10.1111/j.1469-8749.2011.04152.x; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Almeida L, 2007, NEUROTHERAPEUTICS, V4, P88, DOI 10.1016/j.nurt.2006.10.005; Anand R, 2010, CLIN NEUROPHARMACOL, V33, P297, DOI 10.1097/WNF.0b013e3181f8d501; Anderson SM, 2008, NAT NEUROSCI, V11, P344, DOI 10.1038/nn2054; Andries M, 2007, NEUROBIOL DIS, V25, P8, DOI 10.1016/j.nbd.2006.08.018; Anger T, 2001, J MED CHEM, V44, P115, DOI 10.1021/jm000155h; Arias C, 2002, EXP NEUROL, V177, P284, DOI 10.1006/exnr.2002.7988; Arroyo S, 2007, NEUROTHERAPEUTICS, V4, P155, DOI 10.1016/j.nurt.2006.11.006; Atack JR, 2011, J PSYCHOPHARMACOL, V25, P314, DOI 10.1177/0269881109354927; Atack JR, 2006, J PHARMACOL EXP THER, V316, P410, DOI 10.1124/jpet.105.089920; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Barajas RF, 2010, EPILEPSIA, V51, P473, DOI 10.1111/j.1528-1167.2009.02287.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Belardetti F, 2010, FUTURE MED CHEM, V2, P791, DOI 10.4155/FMC.10.30; Belforte JE, 2010, NAT NEUROSCI, V13, P76, DOI 10.1038/nn.2447; BENNETT DA, 1990, PROG CLIN BIOL RES, V361, P519; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044; Bezencon C, 2007, CHEM SENSES, V32, P41, DOI 10.1093/chemse/bjl034; Bialer M, 2010, EPILEPSY RES, V92, P89, DOI 10.1016/j.eplepsyres.2010.09.001; Bialer M, 2010, NAT REV DRUG DISCOV, V9, P68, DOI 10.1038/nrd2997; Bialer M, 2009, EPILEPSY RES, V83, P1, DOI 10.1016/j.eplepsyres.2008.09.005; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Black JA, 2008, J NEUROL SCI, V274, P57, DOI 10.1016/j.jns.2008.04.001; Blackshaw LA, 2010, GUT, V59, P126, DOI 10.1136/gut.2009.179523; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Blumenfeld H, 2005, EPILEPSIA, V46, P21, DOI 10.1111/j.1528-1167.2005.00311.x; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bollimuntha S, 2005, J BIOL CHEM, V280, P2132, DOI 10.1074/jbc.M407384200; Bonifacio MJ, 2001, EPILEPSIA, V42, P600, DOI 10.1046/j.1528-1157.2001.43600.x; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Brown DA, 2009, BRIT J PHARMACOL, V156, P1185, DOI 10.1111/j.1476-5381.2009.00111.x; Brown ML, 1997, J MED CHEM, V40, P602, DOI 10.1021/jm960692v; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Burnstock G, 2011, ADV PHARMACOL, V61, P333, DOI 10.1016/B978-0-12-385526-8.00011-4; Burnstock G, 2010, ACTA PHYSIOL, V199, P93, DOI 10.1111/j.1748-1716.2010.02114.x; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Cain SM, 2010, CHANNELS, V4, P475, DOI 10.4161/chan.4.6.14106; Carnally SM, 2008, BIOCHEM BIOPH RES CO, V372, P752, DOI 10.1016/j.bbrc.2008.05.100; Catterall WA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003947; Cavaliere F, 2001, NEUROCHEM INT, V38, P199, DOI 10.1016/S0197-0186(00)00087-5; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Cavaliere F, 2001, NEUROCHEM INT, V38, P189, DOI 10.1016/S0197-0186(00)00088-7; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chahine M, 2008, CNS NEUROL DISORD-DR, V7, P144, DOI 10.2174/187152708784083830; Chahl LA, 2007, BBA-MOL BASIS DIS, V1772, P968, DOI 10.1016/j.bbadis.2007.05.003; Chahl LA, 2011, ADV EXP MED BIOL, V704, P987, DOI 10.1007/978-94-007-0265-3_51; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chazot PL, 1997, J NEUROCHEM, V69, P2138; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; Chebib M, 2009, J PHARMACOL EXP THER, V328, P448, DOI 10.1124/jpet.108.146464; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Chen XM, 2005, J GEN PHYSIOL, V126, P71, DOI 10.1085/jgp.200509303; Chen XM, 2010, EUR J PHARMACOL, V648, P15, DOI 10.1016/j.ejphar.2010.09.005; Chen XM, 2010, NEUROPHARMACOLOGY, V58, P1045, DOI 10.1016/j.neuropharm.2010.01.011; Cheng W, 2010, PROTEIN CELL, V1, P802, DOI 10.1007/s13238-010-0108-9; Chevalier M, 2006, EUR J NEUROSCI, V23, P2321, DOI 10.1111/j.1460-9568.2006.04761.x; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Christensen T, 2005, BASIC CLIN PHARMACOL, V96, P316, DOI 10.1111/j.1742-7843.2005.pto960407.x; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Clayton DA, 2002, J NEUROSCI, V22, P3628; Coddou C, 2011, REV NEUROSCIENCE, V22, P335, DOI 10.1515/RNS.2011.014; Conti F, 1997, BRAZ J MED BIOL RES, V30, P555, DOI 10.1590/S0100-879X1997000500001; Cope DW, 2005, J NEUROSCI, V25, P11553, DOI 10.1523/JNEUROSCI.3362-05.2005; Coryell MW, 2009, J NEUROSCI, V29, P5381, DOI 10.1523/JNEUROSCI.0360-09.2009; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; de Haas SL, 2008, J PSYCHOPHARMACOL, V22, P24, DOI 10.1177/0269881107082108; de Haas SL, 2009, J PSYCHOPHARMACOL, V23, P625, DOI 10.1177/0269881108092595; de Hass SL, 2007, J PSYCHOPHARMACOL, V21, P374, DOI 10.1177/0269881106072343; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; DeSarro G, 1996, PHARMACOL BIOCHEM BE, V55, P281, DOI 10.1016/S0091-3057(96)00085-8; Deval E, 2011, J NEUROSCI, V31, P6059, DOI 10.1523/JNEUROSCI.5266-10.2011; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Devinsky O, 2002, SEIZURE-EUR J EPILEP, V11, P371, DOI 10.1053/seiz.2001.0669; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Dib-Hajj SD, 2009, BRAIN RES REV, V60, P65, DOI 10.1016/j.brainresrev.2008.12.005; Dibbens LM, 2004, HUM MOL GENET, V13, P1315, DOI 10.1093/hmg/ddh146; DiFabio R, 1997, J MED CHEM, V40, P841, DOI 10.1021/jm960644a; Dingledine R, 1999, PHARMACOL REV, V51, P7; Diochot S, 2007, TOXICON, V49, P271, DOI 10.1016/j.toxicon.2006.09.026; Diochot S, 2004, EMBO J, V23, P1516, DOI 10.1038/sj.emboj.7600177; Dong XP, 2010, J NEUROCHEM, V113, P313, DOI 10.1111/j.1471-4159.2010.06626.x; Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Duan B, 2007, J NEUROSCI, V27, P11139, DOI 10.1523/JNEUROSCI.3364-07.2007; Dube GR, 2005, PAIN, V117, P88, DOI 10.1016/j.pain.2005.05.021; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; Duplantier AJ, 2011, BIOORG MED CHEM LETT, V21, P3708, DOI 10.1016/j.bmcl.2011.04.077; Dyker AG, 1999, STROKE, V30, P986, DOI 10.1161/01.STR.30.5.986; Dyker AG, 1999, STROKE, V30, P2038, DOI 10.1161/01.STR.30.10.2038; Eikermann-Haerter K, 2010, CURR NEUROL NEUROSCI, V10, P167, DOI 10.1007/s11910-010-0099-1; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Ettaiche M, 2009, INVEST OPHTH VIS SCI, V50, P2417, DOI 10.1167/iovs.08-3028; Fatemi SH, 2009, SCHIZOPHRENIA BULL, V35, P528, DOI 10.1093/schbul/sbn187; Feng HJ, 2010, PHARMACEUTICALS, V3, P3461, DOI 10.3390/ph3113461; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Fitzgerald PB, 2010, CURR OPIN INVEST DR, V11, P92; Fletcher CF, 2001, FASEB J, V15, P1288, DOI 10.1096/fj.00-0562fje; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Froestl W, 2011, FUTURE MED CHEM, V3, P163, DOI 10.4155/FMC.10.285; Gao XM, 2000, AM J PSYCHIAT, V157, P1141, DOI 10.1176/appi.ajp.157.7.1141; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Gardoni F, 2002, J NEUROCHEM, V80, P438, DOI 10.1046/j.0022-3042.2001.00713.x; Garza A, 2010, J PHARMACOL EXP THER, V332, P489, DOI 10.1124/jpet.109.152884; Geffen Y, 2009, EUR NEUROPSYCHOPHARM, V19, P1, DOI 10.1016/j.euroneuro.2008.07.002; Gerlach M, 1996, BRAIN RES, V741, P142, DOI 10.1016/S0006-8993(96)00915-8; Ghafari M, 2011, BEHAV BRAIN RES, V221, P142, DOI 10.1016/j.bbr.2011.02.042; Gill R, 2002, J PHARMACOL EXP THER, V302, P940, DOI 10.1124/jpet.102.034322; GOFF DC, 1995, AM J PSYCHIAT, V152, P1213; Goff DC, 2012, SCHIZOPHRENIA BULL, V38, P936, DOI 10.1093/schbul/sbs012; Gottesmann C, 2002, NEUROSCIENCE, V111, P231, DOI 10.1016/S0306-4522(02)00034-9; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; Griebel G, 2003, CNS DRUG REV, V9, P3, DOI 10.1111/j.1527-3458.2003.tb00241.x; Griebel G, 1999, PHARMACOL BIOCHEM BE, V62, P689, DOI 10.1016/S0091-3057(98)00209-3; Grimwood S, 1999, NEUROREPORT, V10, P461, DOI 10.1097/00001756-199902250-00004; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; Gu QH, 2010, PHARMACEUTICALS, V3, P1411, DOI 10.3390/ph3051411; Guadalupe A., 2008, PHYSL MINIREV, V3, P25; Guan YZ, 2011, CLIN THER, V33, P159, DOI 10.1016/j.clinthera.2011.02.007; Gutman GA, 2005, PHARMACOL REV, V57, P473, DOI 10.1124/pr.57.4.10; Haines WR, 2001, J NEUROSCI, V21, P5885, DOI 10.1523/JNEUROSCI.21-16-05885.2001; Hains BC, 2003, J NEUROSCI, V23, P8881; Haley EC, 2005, STROKE, V36, P1006, DOI 10.1161/01.STR.0000163053.77982.8d; Halonen T, 1999, EPILEPSY RES, V34, P251, DOI 10.1016/S0920-1211(98)00122-3; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; Hansen HH, 2006, J PHARMACOL EXP THER, V318, P1006, DOI 10.1124/jpet.106.106757; Harnmarstrom AKM, 2002, EUR BIOPHYS J BIOPHY, V31, P323, DOI 10.1007/s00249-002-0218-2; Harty TP, 2000, EPILEPSY RES, V39, P47, DOI 10.1016/S0920-1211(99)00108-4; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Heresco-Levy U, 1998, INT J NEUROPSYCHOPH, V1, P131, DOI 10.1017/S1461145798001242; Hernandez CC, 2008, J PHYSIOL-LONDON, V586, P1811, DOI 10.1113/jphysiol.2007.148304; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Hildebrand MS, 2004, HEARING RES, V190, P149, DOI 10.1016/S0378-5955(04)00015-2; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Howard RJ, 2007, NEURON, V53, P663, DOI 10.1016/j.neuron.2007.02.010; Hracsko Z, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-28; Iftinca M C, 2011, J Med Life, V4, P126; Jacobson KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/jm020046y; Jacobson Kenneth A, 2006, Novartis Found Symp, V276, P58; Jahr H, 2005, BIOCHEM BIOPH RES CO, V337, P349, DOI 10.1016/j.bbrc.2005.09.054; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jarvis MF, 2009, NEUROPHARMACOLOGY, V56, P208, DOI 10.1016/j.neuropharm.2008.06.067; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jones-Davis DM, 2003, CURR OPIN PHARMACOL, V3, P12, DOI 10.1016/S1471-4892(02)00015-2; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7; Kahlig KM, 2010, BRIT J PHARMACOL, V161, P1414, DOI 10.1111/j.1476-5381.2010.00976.x; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; Khakh BS, 2001, PHARMACOL REV, V53, P107; Khan HN, 2012, EPILEPSY RES, V98, P62, DOI 10.1016/j.eplepsyres.2011.08.016; Kharlamov A, 2002, EXP BRAIN RES, V147, P353, DOI 10.1007/s00221-002-1251-1; Khosravani H, 2006, PHYSIOL REV, V86, P941, DOI 10.1152/physrev.00002.2006; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KIRSCH GE, 1993, J GEN PHYSIOL, V102, P797, DOI 10.1085/jgp.102.5.797; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kullmann DM, 2005, PROG BIOPHYS MOL BIO, V87, P33, DOI 10.1016/j.pbiomolbio.2004.06.003; Kuo CC, 1998, MOL PHARMACOL, V54, P712; KUO CC, 1994, MOL PHARMACOL, V46, P716; Kyle DJ, 2007, J MED CHEM, V50, P2583, DOI 10.1021/jm061005v; Laposky AD, 2001, NEUROREPORT, V12, P4143, DOI 10.1097/00001756-200112210-00056; Large CH, 2012, EPILEPSIA, V53, P425, DOI 10.1111/j.1528-1167.2011.03364.x; Large CH, 2009, EPILEPSY RES, V85, P96, DOI 10.1016/j.eplepsyres.2009.02.018; Larsson V, 2010, INT J GERIATR PSYCH, V25, P1030, DOI 10.1002/gps.2506; Le Feuvre RA, 2003, J CEREBR BLOOD F MET, V23, P381, DOI 10.1097/01.WCB.0000048519.34839.97; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lees KR, 2001, CEREBROVASC DIS, V11, P20, DOI 10.1159/000047607; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Lermontova NN, 2000, B EXP BIOL MED+, V129, P544, DOI 10.1007/BF02434871; Lessard CB, 2005, CELL SIGNAL, V17, P437, DOI 10.1016/j.cellsig.2004.09.005; Li MQ, 2012, CELL CALCIUM, V51, P486, DOI 10.1016/j.ceca.2012.04.014; Li MH, 2010, J PHYSIOL-LONDON, V588, P3883, DOI 10.1113/jphysiol.2010.192922; Licata SC, 2005, J PHARMACOL EXP THER, V313, P1118, DOI 10.1124/jpet.104.081612; Licata SC, 2010, NEUROPHARMACOLOGY, V58, P357, DOI 10.1016/j.neuropharm.2009.10.004; Lipkind GM, 2005, MOL PHARMACOL, V68, P1611, DOI 10.1124/mol.105.014803; Lipkind GM, 2010, MOL PHARMACOL, V78, P631, DOI 10.1124/mol.110.064683; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Litvinenko I V, 2010, Neurosci Behav Physiol, V40, P149, DOI 10.1007/s11055-009-9244-1; Liu G, 2003, NEUROPHARMACOLOGY, V44, P413, DOI 10.1016/S0028-3908(02)00400-8; Liu Y, 2009, EPILEPSY RES, V83, P66, DOI 10.1016/j.eplepsyres.2008.09.006; Ljungstrom T, 2003, PFLUG ARCH EUR J PHY, V446, P684, DOI 10.1007/s00424-003-1111-2; Loscher W, 2011, SEIZURE-EUR J EPILEP, V20, P359, DOI 10.1016/j.seizure.2011.01.003; Loscher W, 2002, CNS DRUGS, V16, P669; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Lu XY, 2006, P NATL ACAD SCI USA, V103, P1593, DOI 10.1073/pnas.0508901103; Luszczki J, 2009, J NEURAL TRANSM, V116, P57, DOI 10.1007/s00702-008-0152-2; Lv RJ, 2011, EPILEPSY RES, V96, P74, DOI 10.1016/j.eplepsyres.2011.05.002; Lydiard RB, 2006, J CLIN SLEEP MED, V2, P309; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MacDonald JF, 2006, TRENDS NEUROSCI, V29, P75, DOI 10.1016/j.tins.2005.12.001; MADDEN KP, 1993, STROKE, V24, P1068, DOI 10.1161/01.STR.24.7.1068; Main MJ, 2000, MOL PHARMACOL, V58, P253, DOI 10.1124/mol.58.2.253; Majoie HJM, 2006, EPILEPSY RES, V71, P135, DOI 10.1016/j.eplepsyres.2006.06.003; Malek R, 2003, POL J PHARMACOL, V55, P691; Mantegazza M, 2010, LANCET NEUROL, V9, P413, DOI 10.1016/S1474-4422(10)70059-4; Maren S, 2009, CELL, V139, P867, DOI 10.1016/j.cell.2009.11.008; Martin MS, 2007, HUM MOL GENET, V16, P2892, DOI 10.1093/hmg/ddm248; Mathiasen L, 2005, PSYCHOPHARMACOLOGY, V182, P475, DOI 10.1007/s00213-005-0119-z; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Mazzuca M, 2007, NAT NEUROSCI, V10, P943, DOI 10.1038/nn1940; McDonald S, 2011, AM J HEALTH-SYST PH, V68, P2335, DOI 10.2146/ajhp110134; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Mellergard P, 2012, J NEUROTRAUM, V29, P112, DOI 10.1089/neu.2010.1732; Metman LV, 2002, NEUROLOGY, V59, P694; Mitchell IJ, 1997, NEUROSCI BIOBEHAV R, V21, P469, DOI 10.1016/S0149-7634(96)00036-X; Mohammadianinejad SE, 2011, CLIN NEUROPHARMACOL, V34, P174, DOI 10.1097/WNF.0b013e318225140c; Molliver DC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-35; Moon DE, 2010, CLIN THER, V32, P2370, DOI 10.1016/j.clinthera.2011.01.014; Morales I, 2007, AM J PHYSIOL-CELL PH, V292, pC1934, DOI 10.1152/ajpcell.00593.2006; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nakayama J, 2009, BRAIN DEV-JPN, V31, P359, DOI 10.1016/j.braindev.2008.11.014; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nehlig A, 2003, EPILEPSY RES, V52, P253, DOI 10.1016/S0920-1211(02)00236-X; Nelson MT, 2006, CURR PHARM DESIGN, V12, P2189, DOI 10.2174/138161206777585184; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Ng CKL, 2011, FUTURE MED CHEM, V3, P197, DOI 10.4155/FMC.10.286; Nicholson E, 2009, J NEUROIMMUNOL, V215, P25, DOI 10.1016/j.jneuroim.2009.07.009; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; Nicolaidis R, 2005, NEUROCHEM RES, V30, P385, DOI 10.1007/s11064-005-2613-4; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-218; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nutt JG, 2008, MOVEMENT DISORD, V23, P1860, DOI 10.1002/mds.22169; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Omori Y, 2009, J PHARMACOL SCI, V109, P532, DOI 10.1254/jphs.08319FP; Ondo WG, 2011, PARKINSONISM RELAT D, V17, P156, DOI 10.1016/j.parkreldis.2010.12.003; Otto JE, 2004, EPILEPSIA, V45, P1009, DOI 10.1111/j.0013-9580.2004.65703.x; Palfi S, 1997, EXP NEUROL, V146, P135, DOI 10.1006/exnr.1997.6520; Paoletti P, 2007, CURR OPIN PHARMACOL, V7, P39, DOI 10.1016/j.coph.2006.08.011; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Patino GA, 2011, J NEUROSCI, V31, P14577, DOI 10.1523/JNEUROSCI.0361-11.2011; Patino GA, 2010, NEUROSCI LETT, V486, P53, DOI 10.1016/j.neulet.2010.06.050; Payandeh J, 2012, NATURE, V486, P135, DOI 10.1038/nature11077; Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Perez-Otano I, 2001, J NEUROSCI, V21, P1228; Perret D, 2009, NEUROTHERAPEUTICS, V6, P679, DOI 10.1016/j.nurt.2009.07.006; Perucca E, 1997, PHARMACOL RES, V35, P241, DOI 10.1006/phrs.1997.0124; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; PIGGOTT MA, 1992, BRAIN RES, V588, P277, DOI 10.1016/0006-8993(92)91586-4; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Pischalnikova AV, 2009, J NEUROIMMUNE PHARM, V4, P71, DOI 10.1007/s11481-008-9130-6; Pongs O., 2008, V44, P145, DOI 10.1007/400_2007_032; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Qi JS, 2006, J PHYSIOL-LONDON, V577, P579, DOI 10.1113/jphysiol.2006.113134; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; Rappold PM, 2006, BRAIN RES, V1089, P171, DOI 10.1016/j.brainres.2006.03.040; REDDY NL, 1994, J MED CHEM, V37, P260, DOI 10.1021/jm00028a009; Reggiani A, 2001, EUR J PHARMACOL, V419, P147, DOI 10.1016/S0014-2999(01)00948-7; Richards MC, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013938; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Roedding AS, 2012, BIPOLAR DISORD, V14, P151, DOI 10.1111/j.1399-5618.2012.01003.x; Roeloffs R, 2008, J PHARMACOL EXP THER, V326, P818, DOI 10.1124/jpet.108.137794; Romagnoli R, 2008, EXPERT OPIN THER TAR, V12, P647, DOI [10.1517/14728222.12.5.647, 10.1517/14728222.12.5.647 ]; Rosenberg R, 2007, J CLIN SLEEP MED, V3, P374; Rowlett JK, 2005, P NATL ACAD SCI USA, V102, P915, DOI 10.1073/pnas.0405621102; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Rush AM, 2005, J PHYSIOL-LONDON, V564, P803, DOI 10.1113/jphysiol.2005.083089; Russo E, 2004, NEUROPHARMACOLOGY, V46, P865, DOI 10.1016/j.neuropharm.2003.11.028; Ryan DP, 2010, NEURON, V68, P282, DOI 10.1016/j.neuron.2010.10.008; Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008; Sawada H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015298; Schabitz WR, 2000, STROKE, V31, P1709, DOI 10.1161/01.STR.31.7.1709; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Scharf MB, 2007, SLEEP, V30, P743, DOI 10.1093/sleep/30.6.743; Selvaraj S, 2009, CELL CALCIUM, V46, P209, DOI 10.1016/j.ceca.2009.07.008; Semel D, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-85; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Shibuya I, 1999, J PHYSIOL-LONDON, V514, P351, DOI 10.1111/j.1469-7793.1999.351ae.x; Shimada S, 2006, ARCH HISTOL CYTOL, V69, P227, DOI 10.1679/aohc.69.227; Shoulson I, 2001, NEUROLOGY, V56, P455; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sitnikova E, 2010, EPILEPSY RES, V89, P17, DOI 10.1016/j.eplepsyres.2009.09.005; Smith MR, 1998, J NEUROSCI, V18, P6093; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Sotty F, 2009, J PHARMACOL EXP THER, V328, P951, DOI 10.1124/jpet.108.146944; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; Stephen LJ, 2011, CNS DRUGS, V25, P89, DOI 10.2165/11584860-000000000-00000; Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874; Strupp M, 2007, NEUROTHERAPEUTICS, V4, P267, DOI 10.1016/j.nurt.2007.01.014; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Subasinghe NL, 2012, BIOORG MED CHEM LETT, V22, P4080, DOI 10.1016/j.bmcl.2012.04.075; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun GC, 2007, EPILEPSIA, V48, P774, DOI 10.1111/j.1528-1167.2007.01001.x; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; Tan J, 2011, MOL VIS, V17, P3300; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tarnawa Istvan, 2007, Recent Pat CNS Drug Discov, V2, P57, DOI 10.2174/157488907779561754; Taverna S, 1998, EPILEPSY RES, V32, P304, DOI 10.1016/S0920-1211(98)00060-6; Taylor M, 2003, PSYCHOL MED, V33, P387, DOI 10.1017/S0033291702006876; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; Tolino LA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.202366; Tomlinson SE, 2009, CLIN NEUROPHYSIOL, V120, P1768, DOI 10.1016/j.clinph.2009.07.003; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Tottene A, 2009, NEURON, V61, P762, DOI 10.1016/j.neuron.2009.01.027; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Trudeau MM, 2006, J MED GENET, V43, P527, DOI 10.1136/jmg.2005.035667; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Ugawa S, 2007, BIOCHEM BIOPH RES CO, V363, P203, DOI 10.1016/j.bbrc.2007.08.133; Urbani A, 2000, EUR J NEUROSCI, V12, P3567, DOI 10.1046/j.1460-9568.2000.00242.x; Vacher H, 2008, PHYSIOL REV, V88, P1407, DOI 10.1152/physrev.00002.2008; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vergo S, 2011, BRAIN, V134, P571, DOI 10.1093/brain/awq337; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Volonte C, 1996, J NEUROSCI RES, V45, P183; Volonte C, 1999, NEUROPHARMACOLOGY, V38, P1335, DOI 10.1016/S0028-3908(99)00034-9; Vreugdenhil M, 1999, EPILEPSIA, V40, P1512, DOI 10.1111/j.1528-1157.1999.tb02034.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waszkielewicz AM, 2011, CURR MED CHEM, V18, P4344; Watanabe H, 2000, J NEUROCHEM, V75, P28, DOI 10.1046/j.1471-4159.2000.0750028.x; Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO;2-G; Weiergraber M, 2010, BRAIN RES REV, V62, P245, DOI 10.1016/j.brainresrev.2009.12.005; Weiner MW, 2011, ALZHEIMERS DEMENT, V7, P425, DOI 10.1016/j.jalz.2010.09.003; Weir GA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-116; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Whitaker WRJ, 2001, NEUROSCIENCE, V106, P275, DOI 10.1016/S0306-4522(01)00212-3; Wickenden AD, 2008, MOL PHARMACOL, V73, P977, DOI 10.1124/mol.107.043216; Wickenden AD, 2000, MOL PHARMACOL, V58, P591, DOI 10.1124/mol.58.3.591; Wimmer VC, 2010, J PHYSIOL-LONDON, V588, P1829, DOI 10.1113/jphysiol.2010.188417; Wolfel M, 2003, J NEUROSCI, V23, P7059, DOI 10.1523/JNEUROSCI.23-18-07059.2003; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wulff H, 2008, CHEM REV, V108, P1744, DOI 10.1021/cr078234p; Wulff H, 2007, CURR OPIN DRUG DISC, V10, P438; Xie XM, 2001, PFLUG ARCH EUR J PHY, V441, P425, DOI 10.1007/s004240000448; Xiong QJ, 2008, TRENDS PHARMACOL SCI, V29, P99, DOI 10.1016/j.tips.2007.11.010; Yamamoto S, 2007, BBA-MOL BASIS DIS, V1772, P958, DOI 10.1016/j.bbadis.2007.03.006; Yan BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022440; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118; YASUMATSU H, 1994, BRIT J PHARMACOL, V111, P1170, DOI 10.1111/j.1476-5381.1994.tb14868.x; Ye Q, 2011, NEUROSCI LETT, V487, P394, DOI 10.1016/j.neulet.2010.10.064; Yiangou YG, 2001, EUR J GASTROEN HEPAT, V13, P891, DOI 10.1097/00042737-200108000-00003; Yokoo H, 1998, N-S ARCH PHARMACOL, V357, P526, DOI 10.1007/PL00005203; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zamponi, 2012, WIRES MEMBR TRANSP S, V1, P433, DOI DOI 10.1002/WMTS.38; Zamponi GW, 2010, PFLUG ARCH EUR J PHY, V460, P395, DOI 10.1007/s00424-009-0772-x; Zamponi GW, 2009, BIOORG MED CHEM LETT, V19, P6467, DOI 10.1016/j.bmcl.2009.09.008; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhan XJ, 2000, J NEUROSCI, V20, P3909, DOI 10.1523/JNEUROSCI.20-10-03909.2000; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029; Zoladz PR, 2006, PHARMACOL BIOCHEM BE, V85, P298, DOI 10.1016/j.pbb.2006.08.011; ZONA C, 1990, EXP BRAIN RES, V81, P313	378	64	66	0	60	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.	APR	2013	20	10					1241	1285					45	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	112TN	WOS:000316616600005	23409712				2022-02-06	
J	Alvarez, TL; Kim, EH; Vicci, VR; Dhar, SK; Biswal, BB; Barrett, AM				Alvarez, Tara L.; Kim, Eun H.; Vicci, Vincent R.; Dhar, Sunil K.; Biswal, Bharat B.; Barrett, A. M.			Concurrent Vision Dysfunctions in Convergence Insufficiency With Traumatic Brain Injury	OPTOMETRY AND VISION SCIENCE			English	Article						traumatic brain injury; oculomotor dysfunction; binocular vision; convergence insufficiency; visual dysfunction; visual impairment; visual acuity; mechanism of injury; vestibular dysfunction	FUNCTIONAL INDEPENDENCE MEASURE; DIFFUSE AXONAL INJURY; CRITICAL FLICKER FREQUENCY; POLYTRAUMA NETWORK SITE; VERGENCE EYE-MOVEMENTS; OCULOMOTOR NERVE PALSY; MINOR HEAD TRAUMA; VISUAL FUNCTION; AC/A RATIO; BINOCULAR DYSFUNCTIONS	Purpose. This study assessed the prevalence of convergence insufficiency (CI) with and without simultaneous vision dysfunctions within the traumatic brain injury (TBI) sample population because although CI is commonly reported with TBI, the prevalence of concurrent visual dysfunctions with CI in TBI is unknown. Methods. A retrospective analysis of 557 medical records from TBI civilian patients was conducted. Patients were all evaluated by a single optometrist. Visual acuity, oculomotor function, binocular vision function, accommodation, visual fields, ocular health, and vestibular function were assessed. Statistical comparisons between the CI and non-CI, as well as inpatient and outpatient subgroups, were conducted using chi(2) and Z tests. Results. Approximately 9% of the TBI sample had CI without the following simultaneous diagnoses: saccade or pursuit dysfunction; third, fourth, or sixth cranial nerve palsy; visual field deficit; visual spatial inattention/neglect; vestibular dysfunction; or nystagmus. Photophobia with CI was observed in 16.3% (21 of 130), and vestibular dysfunction with CI was observed in 18.5% (24 of 130) of the CI subgroup. Convergence insufficiency and cranial nerve palsies were common and yielded prevalence rates of 23.3% (130 of 557) and 26.9% (150 of 557), respectively, within the TBI sample. Accommodative dysfunction was common within the nonpresbyopic TBI sample, with a prevalence of 24.4% (76 of 314). Visual field deficits or unilateral visual spatial inattention/neglect was observed within 29.6% (80 of 270) of the TBI inpatient subgroup and was significantly more prevalent compared with that of the outpatient subgroup (p < 0.001). Most TBI patients had visual acuities of 20/60 or better in the TBI sample (85%; 473 of 557). Conclusions. Convergence insufficiency without simultaneous visual or vestibular dysfunctions was observed in about 9% of the visually symptomatic TBI civilian population studied. A thorough visual and vestibular examination is recommended for all TBI patients. (Optom Vis Sci 2012; 89: 1740-1751)	[Alvarez, Tara L.; Kim, Eun H.; Biswal, Bharat B.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Vicci, Vincent R.] Kessler Inst Rehabil, W Orange, NJ USA; [Dhar, Sunil K.] New Jersey Inst Technol, Ctr Appl Math & Stat, Dept Math Sci, Newark, NJ 07102 USA; [Barrett, A. M.] Kessler Fdn, W Orange, NJ USA		Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu	Barrett, A.M./ABG-4475-2021	Barrett, A.M./0000-0002-0789-2887; Alvarez, Tara/0000-0002-8797-1613	NSF CAREERNational Science Foundation (NSF)NSF - Office of the Director (OD) [BES-044713]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS055808, 5R01NS049176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055808, R01NS049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG032088] Funding Source: NIH RePORTER	Supported in part by NSF CAREER BES-044713 to T. L. A., NIH R01NS055808 to A. M. B., and 5R01NS049176 to B. B. B. The authors thank John Semmlow, PhD, and Norbert Elliot, PhD, for comments on the article and writing style and Mooyeon Oh-Park, MD, for summarizing the Kessler Institute TBI FIM statistics.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; Barrett BT, 2009, OPHTHAL PHYSL OPT, V29, P4, DOI 10.1111/j.1475-1313.2008.00607.x; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brautaset RL, 2006, INVEST OPHTH VIS SCI, V47, P2876, DOI 10.1167/iovs.04-1372; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Martinez PC, 2009, OPTOMETRY, V80, P702, DOI 10.1016/j.optm.2009.06.011; Chang TTL, 2007, BRAIN INJURY, V21, P1055, DOI 10.1080/02699050701591437; Chen CC, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.016311; Chen YF, 2010, J MED BIOL ENG, V30, P1; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Cooper JS, 2011, QUICK REFERENCE GUID; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dhaliwal A, 2006, J NEURO-OPHTHALMOL, V26, P4, DOI 10.1097/01.wno.0000204661.48806.1d; Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60; Eslinger PJ, 2007, BRAIN INJURY MED PRI, P779; Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326; Fukushima K, 1996, NEUROSCI RES, V25, P391; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Granet DB, 2005, STRABISMUS, V13, P163, DOI 10.1080/09273970500455436; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hammond FM, 2010, EUR J PHYS REHAB MED, V46, P545; HOFFMAN LG, 1980, J AM OPTOM ASSOC, V51, P119; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUGHES A, 1967, BRIT J OPHTHALMOL, V51, P786, DOI 10.1136/bjo.51.11.786; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Kaas JH, 1989, CHANGING CONCEPTS VI; Kaas JH, 2008, BRAIN RES BULL, V75, P384, DOI 10.1016/j.brainresbull.2007.10.009; Kaido T, 2006, J CLIN NEUROSCI, V13, P852, DOI 10.1016/j.jocn.2005.08.020; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Krishnan M, 2011, ARCH CLIN NEUROPSYCH, V26, P176, DOI 10.1093/arclin/acr010; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lara F, 2001, OPHTHAL PHYSL OPT, V21, P70, DOI 10.1046/j.1475-1313.2001.00540.x; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; LETOURNEAU JE, 1979, AM J OPTOM PHYS OPT, V56, P18; Levy RL, 2005, NEUROLOGY, V65, P169, DOI 10.1212/01.wnl.0000167288.10702.03; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mutti DO, 2000, INVEST OPHTH VIS SCI, V41, P2469; National Data and Statistical Center, 2012, TRAUM BRAIN INJ MOD; Numminen HJ, 2011, EUR J NEUROL, V18, P460, DOI 10.1111/j.1468-1331.2010.03179.x; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pankhania SR, 2011, STRABISMUS, V19, P52, DOI 10.3109/09273972.2011.578192; Pielmaier L, 2011, BRAIN INJURY, V25, P259, DOI 10.3109/02699052.2010.542429; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; Rosenfield M, 2000, OPHTHAL PHYSL OPT, V20, P207, DOI 10.1046/j.1475-1313.2000.00494.x; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P1169, DOI 10.1097/OPX.0b013e3181baad13; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Rouse MW, 1999, OPTOMETRY VISION SCI, V76, P643, DOI 10.1097/00006324-199909000-00022; Rutner D, 2006, BRAIN INJURY, V20, P1079, DOI 10.1080/02699050600909904; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Sandhaug M, 2011, J NEUROLOGICAL RES, V1, P48; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Scheiman M, 2006, OPTOMETRY VISION SCI, V83, P857, DOI 10.1097/01.opx.0000245513.51878.26; Scheiman M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006768.pub2; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P420, DOI 10.1097/OPX.0b013e31819fa712; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schrupp LE, 2009, OPTOMETRY, V80, P642, DOI 10.1016/j.optm.2009.04.097; Serra A, 2011, CURR OPIN NEUROL, V24, P32, DOI 10.1097/WCO.0b013e328341eebd; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Tanielian T, 2008, STOP LOSS NATION WEI; Taub MB, 2006, REV OPTOM, V3, P49; Thurman DJ, 2001, HEAD TRAUMA, P327; Warren M, 2009, AM J OCCUP THER, V63, P626, DOI 10.5014/ajot.63.5.626; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; West T.J.D., 2007, REBUILDING TRUST IND	92	64	64	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-5488			OPTOMETRY VISION SCI	Optom. Vis. Sci.	DEC	2012	89	12					1740	1751		10.1097/OPX.0b013e3182772dce			12	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	049TJ	WOS:000312006000017	23190716	Green Accepted			2022-02-06	
J	Chatelle, C; Majerus, S; Whyte, J; Laureys, S; Schnakers, C				Chatelle, Camille; Majerus, Steve; Whyte, John; Laureys, Steven; Schnakers, Caroline			A sensitive scale to assess nociceptive pain in patients with disorders of consciousness	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							STATE; STIMULI; COMA	Objective To determine the sensitivity of the Nociception Coma Scale (NCS), the first scale developed to assess nociceptive pain in vegetative state and minimally conscious state patients, in comparing behavioural changes in response to noxious versus non-noxious stimulation. Methods The NCS was administered to assess patients' responses in three conditions: (1) baseline (observation of spontaneous behaviours), (2) non-noxious/tactile stimulation (taps on the patient's shoulder), and (3) noxious stimulation (pressure on the nail bed). Results We included 64 patients (27 vegetative state and 37 minimally conscious state; age range 20-82 years; 22 traumatic brain injury; 21 in the acute stage). The NCS total scores and subscores (motor, verbal and facial) were higher for the noxious versus the non-noxious stimulation conditions. We did not observe a difference between the non-noxious and the noxious stimulation conditions for the visual subscale. We also found a NCS cut-off value of 4 differentiating the patients receiving a noxious stimulation from patients receiving a non-noxious stimulation. The exclusion of the visual subscale increased the cut-off sensitivity (from 46% to 73%; specificity of 97% and accuracy of 85%). Conclusion We propose a new version of the NCS excluding the visual subscale, the NCS-R, which constitutes a highly sensitive tool to assess responses to nociceptive pain in severely brain injured patients.	[Chatelle, Camille; Laureys, Steven; Schnakers, Caroline] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Chatelle, Camille; Laureys, Steven; Schnakers, Caroline] Univ Hosp Liege, Dept Neurol, Liege, Belgium; [Majerus, Steve; Schnakers, Caroline] Univ Liege, Dept Cognit Sci, B-4000 Liege, Belgium; [Whyte, John] Moss Rehabil Res Inst, Philadelphia, PA USA		Schnakers, C (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B30, B-4000 Liege, Belgium.	c.schnakers@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Majerus, Steve/D-4678-2009	Laureys, Steven/0000-0002-3096-3807; Chatelle, Camille/0000-0002-7526-2107; Majerus, Steve/0000-0002-8206-8097; Whyte, John/0000-0002-4381-1474	Belgian Federal Public Health; National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; James S. McDonnell Foundation; Mind Science Foundation; European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action [ARC 06/11-340]; Public Utility Foundation 'Universite Europeenne du Travail', 'Fondazione Europea di Ricerca Biomedica'; University of LiegeUniversity of Liege	This study was supported by the Belgian Federal Public Health, the National Funds for Scientific Research (FNRS), James S. McDonnell Foundation, Mind Science Foundation, European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action (ARC 06/11-340), Public Utility Foundation 'Universite Europeenne du Travail', 'Fondazione Europea di Ricerca Biomedica' and the University of Liege. CS is postdoctoral researcher, CC is research fellow, and SM and SL are senior research associates at FNRS.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Hummel P, 2006, SEMIN FETAL NEONAT M, V11, P237, DOI 10.1016/j.siny.2006.02.004; IASP, 1994, CLASS CHRON PAIN S3; Kupers R, 2006, LANCET NEUROL, V5, P1033, DOI 10.1016/S1474-4422(06)70624-X; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Lawrence J, 1993, Neonatal Netw, V12, P59; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Merkel S I, 1997, Pediatr Nurs, V23, P293; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; TEASDALE G, 1974, LANCET, V2, P81; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3	20	64	70	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1233	1237		10.1136/jnnp-2012-302987			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700024	22906615	Green Submitted			2022-02-06	
J	Phelan, HA; Wolf, SE; Norwood, SH; Aldy, K; Brakenridge, SC; Eastman, AL; Madden, CJ; Nakonezny, PA; Yang, L; Chason, DP; Arbique, GM; Berne, J; Minei, JP				Phelan, Herb A.; Wolf, Steven E.; Norwood, Scott H.; Aldy, Kim; Brakenridge, Scott C.; Eastman, Alexander L.; Madden, Christopher J.; Nakonezny, Paul A.; Yang, Lisa; Chason, David P.; Arbique, Gary M.; Berne, John; Minei, Joseph P.			A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Brain injury; venous thromboembolism; prophylaxis; enoxaparin; randomized trial	MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM PROPHYLAXIS; INTRACRANIAL HEMORRHAGE; VEIN THROMBOSIS; SAFETY; AGREEMENT; HEAD; VARIANCE; EFFICACY	BACKGROUND: Our group has created an algorithm for venous thromboembolism prophylaxis after traumatic brain injury (TB!), which stratifies patients into low, moderate, and high risk for spontaneous injury progression and tailors a prophylaxis regimen to each arm. We present the results of the Delayed Versus Early Enoxaparin Prophylaxis I study, a double-blind, placebo-controlled, randomized pilot trial on the low-risk arm. METHODS: In this two-institution study, patients presenting within 6 hours of injury with prespecified small TBI patterns and stable scans at 24 hours after injury were randomized to receive enoxaparin 30 mg bid or placebo from 24 to 96 hours after injury in a double-blind fashion. An additional computed tomography scan was obtained on all subjects 24 hours after starting treatment (and therefore 48 hours after injury). The primary end point was the radiographic worsening of TBI; secondary end points were venous thromboembolism occurrence and extracranial hemorrhagic complications. RESULTS: A total of 683 consecutive patients with TBI were screened during the 28 center months. The most common exclusions were for injuries larger than the prespecified criteria (n = 199) and preinjury anticoagulant use (n = 138). Sixty-two patients were randomized to enoxaparin (n = 34) or placebo (n = 28). Subclinical, radiographic TBI progression rates on the scans performed 48 hours after injury and 24 hours after start of treatment were 5.9% (95% confidence interval [CI], 0.7-19.7%) for enoxaparin and 3.6% (95% CI, 0.1-18.3%) for placebo, a treatment effect difference of 2.3% (95% CI, -14.42-16.5%). No clinical TBI progressions occurred. One deep vein thrombosis occurred in the placebo arm. CONCLUSION: TBI progression rates after starting enoxaparin in small, stable injuries 24 hours after injury are similar to those of placebo and are subclinical. The next Delayed Versus Early Enoxaparin Prophylaxis studies will assess efficacy of this practice in a powered study on the low-risk arm and a pilot trial of safety of a 72-hour time point in the moderate-risk arm. (J Trauma Acute Care Surg. 2012;73: 1434-1441. Copyright (C) 2012 by Lippincott Williams & Wilkins) LEVEL OF EVIDENCE: Therapeutic study, level II.	[Phelan, Herb A.; Wolf, Steven E.; Aldy, Kim; Eastman, Alexander L.; Minei, Joseph P.] UT SW Med Ctr, Div Burns Trauma Crit Care, Dept Surg, Parkland Mem Hosp, Dallas, TX 75390 USA; [Norwood, Scott H.] Univ S Florida, Sch Med, Dept Surg, Hudson, FL USA; [Brakenridge, Scott C.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Madden, Christopher J.] UT SW Med Ctr, Parkland Mem Hosp, Dept Neurosurg, Dallas, TX 75390 USA; [Nakonezny, Paul A.] UT SW Med Ctr, Dept Clin Sci, Div Biostat, Dallas, TX 75390 USA; [Yang, Lisa; Chason, David P.] UT SW Med Ctr, Parkland Mem Hosp, Dept Radiol, Div Neuroradiol, Dallas, TX 75390 USA; [Arbique, Gary M.] UT SW Med Ctr, Dept Radiol, Dallas, TX 75390 USA; [Berne, John] E Texas Med Ctr, Dept Surg, Tyler, TX USA		Phelan, HA (corresponding author), UT SW Med Ctr, Div Burns Trauma Crit Care, Dept Surg, Parkland Mem Hosp, 5323 Harry Hines Blvd,E5-508A, Dallas, TX 75390 USA.	herb.phelan@utsouthwestern.edu	Brakenridge, Scott/AAD-6691-2019	Brakenridge, Scott/0000-0002-7327-3718; Wolf, Steven/0000-0003-2972-3440	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER		Chow S-C, 2004, DESIGN ANAL CLIN TRI; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Fleiss JH., 1981, STAT METHODS RATES P; FLEISS JL, 1979, PSYCHOL BULL, V86, P974, DOI 10.1037/0033-2909.86.5.974; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Gwet K, 2002, STAT METHODS INTERRA, P1; Gwet KL, 2008, BRIT J MATH STAT PSY, V61, P29, DOI 10.1348/000711006X126600; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Minshall CT, 2011, J TRAUMA, V71, P396, DOI 10.1097/TA.0b013e31822734c9; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, pS122, DOI 10.1097/TA.0b013e3182606327; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; US Department of Health and Human Services, 1998, ICH TOP E9 GUID IND	25	64	66	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1434	1441		10.1097/TA.0b013e31825ac49e			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	058FV	WOS:000312620400013	22914079				2022-02-06	
J	Goodman, J; Leong, KC; Packard, MG				Goodman, Jarid; Leong, Kah-Chung; Packard, Mark G.			Emotional modulation of multiple memory systems: implications for the neurobiology of post-traumatic stress disorder	REVIEWS IN THE NEUROSCIENCES			English	Article						anxiety; brain; memory; stress; posttraumatic stress disorder	CEREBRAL-BLOOD-FLOW; OBSESSIVE-COMPULSIVE DISORDER; RESPONSE LEARNING-STRATEGIES; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL VOLUME; CAUDATE-NUCLEUS; DORSAL STRIATUM; NEUROGENIC AMNESIA; DRUG-ADDICTION; LIFE EVENTS	In lower animals and humans, stress/anxiety can enhance dorsal striatal-dependent habit memory, at the expense of hippocampal-dependent cognitive memory. The present review considers the potential for this 'stress/anxiety-induced habit bias' to explain some aspects of post-traumatic stress disorder (PTSD). In rats, anxiety induced by peripheral or intra-amygdala infusions of anxiogenic drugs can enhance habit memory and impair cognitive memory. In tasks in which both habit and cognitive memory processes may provide a learned solution, stress and drug-induced anxiety favors the use of habit memory. The effect of stress and anxiety on the use of multiple memory systems in rats depends on the functional integrity of the basolateral amygdala. Thus, under robust emotional arousal, amygdala activation can modulate the relative use of memory systems in a manner that favors habit memory. We propose a similar mechanism may underlie the development and persistence of some PTSD symptoms. The traumatic memories of PTSD patients can be deficient in hippocampus-dependent contextual or autobiographical aspects, and enhanced in responding to trauma related cues, which we suggest may reflect increased involvement of the dorsal striatum. We briefly consider the potential role of a stress/anxiety-induced habit bias with regard to other psychopathologies, including obsessive-compulsive disorder and drug addiction.	[Goodman, Jarid; Leong, Kah-Chung; Packard, Mark G.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA		Packard, MG (corresponding author), Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.	mgp@psyc.tamu.edu					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armony JL, 2005, AM J PSYCHIAT, V162, P1961, DOI 10.1176/appi.ajp.162.10.1961; Astur RS, 2006, CYBERPSYCHOL BEHAV, V9, P234, DOI 10.1089/cpb.2006.9.234; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Berardi A, 2012, REV NEUROSCIENCE, V23, P645, DOI 10.1515/revneuro-2012-0054; Bohbot VD, 2007, J NEUROSCI, V27, P10078, DOI 10.1523/JNEUROSCI.1763-07.2007; Bohbot VD, 2011, NEUROBIOL LEARN MEM, V96, P173, DOI 10.1016/j.nlm.2011.04.007; Bonne O, 2001, AM J PSYCHIAT, V158, P1248, DOI 10.1176/appi.ajp.158.8.1248; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bremner JD, 2006, ANN NY ACAD SCI, V1071, P80, DOI 10.1196/annals.1364.008; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 2001, HIPPOCAMPUS, V11, P75, DOI 10.1002/hipo.1023; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI 10.1016/S0272-7358(03)00033-3; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Britton JC, 2005, BIOL PSYCHIAT, V57, P832, DOI 10.1016/j.biopsych.2004.12.025; Brunet A, 2008, J PSYCHIATR RES, V42, P503, DOI 10.1016/j.jpsychires.2007.05.006; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Bryant RA, 2005, CNS SPECTRUMS, V10, P116, DOI 10.1017/S1092852900019453; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Carrion VG, 2001, BIOL PSYCHIAT, V50, P943, DOI 10.1016/S0006-3223(01)01218-5; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Cromer KR, 2007, BEHAV RES THER, V45, P2581, DOI 10.1016/j.brat.2007.06.005; Cromer KR, 2007, BEHAV RES THER, V45, P1683, DOI 10.1016/j.brat.2006.08.018; Davidson S.M., 1980, BEHAV MED CHANGING H, P410; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Del Casale A, 2011, NEUROPSYCHOBIOLOGY, V64, P61, DOI 10.1159/000325223; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; Dickie EW, 2008, NEUROPSYCHOLOGIA, V46, P1522, DOI 10.1016/j.neuropsychologia.2008.01.007; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 2010, INT J PSYCHOPHYSIOL, V78, P27, DOI 10.1016/j.ijpsycho.2010.04.009; Elliott AE, 2008, NEUROBIOL LEARN MEM, V90, P616, DOI 10.1016/j.nlm.2008.06.012; Evans C, 2007, J CONSULT CLIN PSYCH, V75, P134, DOI 10.1037/0022-006X.75.1.134; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; EYSENCK HJ, 1976, BEHAV RES THER, V14, P251, DOI 10.1016/0005-7967(76)90001-2; FAMULARO R, 1988, AM J DIS CHILD, V142, P1244, DOI 10.1001/archpedi.1988.02150110122036; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Ferragud A, 2010, BEHAV BRAIN RES, V210, P134, DOI 10.1016/j.bbr.2010.02.013; Ferreira TL, 2008, NEUROSCIENCE, V153, P84, DOI 10.1016/j.neuroscience.2008.02.013; Ferreira TL, 2003, BRAIN RES, V987, P17, DOI 10.1016/S0006-8993(03)03217-7; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOA EB, 1992, PSYCHOL BULL, V112, P218, DOI 10.1037/0033-2909.112.2.218; Francati V, 2007, DEPRESS ANXIETY, V24, P202, DOI 10.1002/da.20208; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Gillan CM, 2011, AM J PSYCHIAT, V168, P718, DOI 10.1176/appi.ajp.2011.10071062; Glantz M., 1992, VULNERABILITY DRUG A, P200; Golier JA, 2005, PSYCHIAT RES-NEUROIM, V139, P53, DOI 10.1016/j.pscychresns.2005.02.007; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUY AP, 1985, NEUROPSYCHOBIOLOGY, V13, P194, DOI 10.1159/000118187; Halligan SL, 2002, J BEHAV THER EXP PSY, V33, P73, DOI 10.1016/S0005-7916(02)00014-9; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; Happle R, 2005, J AM ACAD DERMATOL, V52, P157, DOI 10.1016/j.jaad.2004.07.060; Harrison PA, 1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6; Hawley WR, 2011, BEHAV BRAIN RES, V216, P525, DOI 10.1016/j.bbr.2010.08.028; HIGGINS RL, 1975, J ABNORM PSYCHOL, V84, P644, DOI 10.1037/0021-843X.84.6.644; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; Horton A.M., 1991, ARCH CLIN NEUROPSYCH, V6, P195; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Hull C., 1943, PRINCIPLES BEHAV; KESNER RP, 1998, NEUROBIOLOGY LEARNIN, P361; Kim JJ, 2001, J NEUROSCI, V21, P5222, DOI 10.1523/JNEUROSCI.21-14-05222.2001; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kindt M, 2008, J BEHAV THER EXP PSY, V39, P546, DOI 10.1016/j.jbtep.2007.12.003; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Koss MP, 1996, J ABNORM PSYCHOL, V105, P421, DOI 10.1037/0021-843X.105.3.421; Krauseneck T, 2010, PSYCHOL MED, V40, P861, DOI 10.1017/S0033291709990614; Krikorian R, 1998, J NEUROPSYCH CLIN N, V10, P359, DOI 10.1176/jnp.10.3.359; Landau D, 2011, J ANXIETY DISORD, V25, P192, DOI 10.1016/j.janxdis.2010.09.002; Laposa JM, 2012, J BEHAV THER EXP PSY, V43, P877, DOI 10.1016/j.jbtep.2011.12.007; Layton B, 2002, J NEUROPSYCH CLIN N, V14, P254, DOI 10.1176/jnp.14.3.254; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629; Lee T, 2009, NEUROREPORT, V20, P1554, DOI 10.1097/WNR.0b013e328332bb09; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lindauer RJL, 2004, BIOL PSYCHIAT, V56, P853, DOI 10.1016/j.biopsych.2004.08.003; Linnman C, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-8; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; McDonald RJ, 2004, NEUROBIOL LEARN MEM, V82, P333, DOI 10.1016/j.nlm.2004.05.009; McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McKinnon AC, 2008, BEHAV RES THER, V46, P766, DOI 10.1016/j.brat.2008.02.008; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Mechanic MB, 1998, J CONSULT CLIN PSYCH, V66, P948, DOI 10.1037/0022-006X.66.6.948; Merz CJ, 2010, BEHAV NEUROSCI, V124, P288, DOI 10.1037/a0018942; Mickleborough MJS, 2011, J PSYCHIATR NEUROSCI, V36, P6, DOI 10.1503/jpn.080188; Milad MR, 2012, TRENDS COGN SCI, V16, P43, DOI 10.1016/j.tics.2011.11.003; Mishkin M., 1984, NEUROPSYCHOL MEM, V1984, P287; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; Mowrer OH, 1960, LEARNING THEORY BEHA; Nadel L, 1998, CURR DIR PSYCHOL SCI, V7, P154, DOI 10.1111/1467-8721.ep10836842; NAGY J, 1979, NEUROPHARMACOLOGY, V18, P573, DOI 10.1016/0028-3908(79)90104-7; Nardo D, 2011, PSYCHOL MED, V41, P2549, DOI 10.1017/S0033291711000912; NEWCOMB MD, 1988, J ABNORM PSYCHOL, V97, P64, DOI 10.1037/0021-843X.97.1.64; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Osuch EA, 2001, BIOL PSYCHIAT, V50, P246, DOI 10.1016/S0006-3223(01)01107-6; Osuch EA, 2008, BIOL PSYCHIAT, V64, P327, DOI 10.1016/j.biopsych.2008.03.010; Packard MG, 2009, NEUROSCIENCE, V164, P457, DOI 10.1016/j.neuroscience.2009.07.054; Packard MG, 2010, HBK BEHAV NEUROSCI, V20, P561; Packard MG, 2009, BRAIN RES, V1293, P121, DOI 10.1016/j.brainres.2009.03.029; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; PACKARD MG, 1994, P NATL ACAD SCI USA, V91, P8477, DOI 10.1073/pnas.91.18.8477; Packard MG, 2004, NEUROBIOL LEARN MEM, V82, P243, DOI 10.1016/j.nlm.2004.06.008; PACKARD MG, 1989, J NEUROSCI, V9, P1465; PACKARD MG, 1991, BEHAV NEUROSCI, V105, P295, DOI 10.1037/0735-7044.105.2.295; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Packard MG, 2001, CURR OPIN NEUROBIOL, V11, P752, DOI 10.1016/S0959-4388(01)00280-X; Packard MG, 1997, BEHAV NEUROSCI, V111, P543, DOI 10.1037/0735-7044.111.3.543; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P278, DOI 10.1006/nlme.1996.0033; Packard MG, 1998, NEUROBIOL LEARN MEM, V69, P163, DOI 10.1006/nlme.1997.3815; Papagni SA, 2011, STRESS, V14, P227, DOI 10.3109/10253890.2010.522279; Pederson CL, 2004, J TRAUMA STRESS, V17, P37, DOI 10.1023/B:JOTS.0000014674.84517.46; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Pitman R.K., 2000, NEW COGNITIVE NEUROS, P687; Pitman RK, 2005, CNS SPECTRUMS, V10, P99, DOI 10.1017/S109285290001943X; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Pitman RK, 2001, HIPPOCAMPUS, V11, P73, DOI 10.1002/hipo.1022; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Podoll K, 2000, FORTSCHR NEUROL PSYC, V68, P458, DOI 10.1055/s-2000-7736; Podoll K, 2000, NEUROL PSYCHIAT BR, V8, P33; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Protopopescu X, 2005, BIOL PSYCHIAT, V57, P464, DOI 10.1016/j.biopsych.2004.12.026; Rasmusson AM, 1997, ANN NY ACAD SCI, V821, P332, DOI 10.1111/j.1749-6632.1997.tb48290.x; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Regambal MJ, 2012, J BEHAV THER EXP PSY, V43, P947, DOI 10.1016/j.jbtep.2012.02.003; Roozendaal B, 1996, BRAIN RES, V709, P243, DOI 10.1016/0006-8993(95)01305-9; Roozendaal B, 1997, EUR J NEUROSCI, V9, P76, DOI 10.1111/j.1460-9568.1997.tb01355.x; SANDERS SK, 1991, BRAIN RES, V567, P101, DOI 10.1016/0006-8993(91)91441-3; Sasson Y, 2005, PSYCHIAT RES, V135, P145, DOI 10.1016/j.psychres.2004.05.026; SCHEELKRUGER J, 1982, EUR J PHARMACOL, V82, P115, DOI 10.1016/0014-2999(82)90564-7; Schroeder JP, 2002, HIPPOCAMPUS, V12, P280, DOI 10.1002/hipo.10024; Schwabe L, 2008, NEUROBIOL LEARN MEM, V90, P495, DOI 10.1016/j.nlm.2008.07.015; Schwabe L, 2007, LEARN MEMORY, V14, P109, DOI 10.1101/lm.435807; Schwabe L, 2011, EXP CLIN PSYCHOPHARM, V19, P53, DOI 10.1037/a0022212; Schwabe L, 2010, NEUROBIOL LEARN MEM, V93, P183, DOI 10.1016/j.nlm.2009.09.009; Schwabe L, 2009, J NEUROSCI, V29, P7191, DOI 10.1523/JNEUROSCI.0979-09.2009; Schwabe L, 2009, LEARN MEMORY, V16, P110, DOI 10.1101/lm.1257509; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; SHIFFMAN S, 1982, J CONSULT CLIN PSYCH, V50, P71, DOI 10.1037/0022-006X.50.1.71; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Siegmund A, 2006, ANN NY ACAD SCI, V1071, P324, DOI 10.1196/annals.1364.025; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Steidl S, 2006, LEARN MEMORY, V13, P650, DOI 10.1101/lm.324406; Steidl S, 2011, EMOTION, V11, P12, DOI 10.1037/a0020288; Strawn JR, 2008, DEPRESS ANXIETY, V25, P260, DOI 10.1002/da.20292; Thomas KGF, 2010, S AFR J PSYCHOL, V40, P32, DOI 10.1177/008124631004000104; Tichenor V, 1996, J CONSULT CLIN PSYCH, V64, P1054, DOI 10.1037/0022-006X.64.5.1054; Tolin DF, 2010, DEPRESS ANXIETY, V27, P829, DOI 10.1002/da.20684; Tolman EdwardC., 1932, PURPOSIVE BEHAV ANIM; Tricomi E, 2009, EUR J NEUROSCI, V29, P2225, DOI 10.1111/j.1460-9568.2009.06796.x; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; VANDERKOLK BA, 1995, J TRAUMA STRESS, V8, P505, DOI 10.1002/jts.2490080402; Vermetten E, 2007, PSYCHOPHARMACOL BULL, V40, P8; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Werner NS, 2008, J PSYCHIATR RES, V43, P309, DOI 10.1016/j.jpsychires.2008.03.011; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008; White DA, 2001, PSYCHOPHARMACOLOGY, V154, P169, DOI 10.1007/s002130000649; White NM, 1996, ADDICTION, V91, P921, DOI 10.1111/j.1360-0443.1996.tb03586.x; White NM, 2003, BEHAV BRAIN RES, V142, P99, DOI 10.1016/S0166-4328(02)00402-3; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Wingard JC, 2008, BEHAV BRAIN RES, V193, P126, DOI 10.1016/j.bbr.2008.05.002; Wolpe J, 1952, B J PSYCHOL-GEN SECT, V43, P243, DOI 10.1111/j.2044-8295.1952.tb00347.x; Yovell Y, 2003, CNS SPECTRUMS, V8, P676, DOI 10.1017/S1092852900008865	179	64	65	1	37	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	NOV	2012	23	5-6			SI		627	643		10.1515/revneuro-2012-0049			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	083IM	WOS:000314456900014	23001314				2022-02-06	
J	von Steinbuechel, N; Wilson, L; Gibbons, H; Muehlan, H; Schmidt, H; Schmidt, S; Sasse, N; Koskinen, S; Sarajuuri, J; Hofer, S; Bullinger, M; Maas, A; Neugebauer, E; Powell, J; von Wild, K; Zitnay, G; Bakx, W; Christensen, AL; Formisano, R; Hawthorne, G; Truelle, JL				von Steinbuechel, Nicole; Wilson, Lindsay; Gibbons, Henning; Muehlan, Holger; Schmidt, Holger; Schmidt, Silke; Sasse, Nadine; Koskinen, Sanna; Sarajuuri, Jaana; Hoefer, Stefan; Bullinger, Monika; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; von Wild, Klaus; Zitnay, George; Bakx, Wilbert; Christensen, Anne-Lise; Formisano, Rita; Hawthorne, Graeme; Truelle, Jean-Luc			QOLIBRI Overall Scale: a brief index of health-related quality of life after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SATISFACTION	Background The Quality of Life after Brain Injury (QOLIBRI) scale is a recently developed instrument that provides a profile of health-related quality of life (HRQoL) in domains typically affected by brain injury. However, for global assessment it is desirable to have a brief summary measure. This study examined a 6-item QOLIBRI Overall Scale (QOLIBRI-OS), and considered whether it could provide an index of HRQoL after traumatic brain injury (TBI). Methods The properties of the QOLIBRI-OS were studied in a sample of 792 participants with TBI recruited from centres in nine countries covering six languages. An examination of construct validity was undertaken on a subsample of 153 participants recruited in Germany who had been assessed on two relevant brief quality of life measures, the Satisfaction With Life Scale and the Quality of Life Visual Analogue Scale. Results The reliability of the QOLIBRI-OS was good (Cronbach's a 0.86, test-retest reliability =0.81) and similar in participants with higher and lower cognitive performance. Factor analysis indicated that the scale is unidimensional. Rasch analysis also showed a satisfactory fit with this model. The QOLIBRI-OS correlates highly with the total score from the full QOLIBRI scale (r=0.87). Moderate to strong relationships were found among the QOLIBRI-OS and the Extended Glasgow Outcome Scale, Short-Form-36, and Hospital Anxiety and Depression scale (r=0.54 to -0.76). The QOLIBRI-OS showed good construct validity in the TBI group. Conclusions The QOLIBRI-OS assesses a similar construct to the QOLIBRI total score and can be used as a brief index of HRQoL for TBI.	[Wilson, Lindsay] Univ Stirling, Dept Psychol, Div Psychol, Stirling FK9 4LA, Scotland; [von Steinbuechel, Nicole; Gibbons, Henning; Sasse, Nadine] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany; [Muehlan, Holger] Ernst Moritz Arndt Univ Greifswald, Dept Hlth & Prevent, Greifswald, Germany; [Schmidt, Holger; Schmidt, Silke] Univ Med Ctr, Dept Neurol, Gottingen, Germany; [Koskinen, Sanna; Sarajuuri, Jaana] Kapyla Rehabil Ctr, Unit Clin Neuropsychol & Psychol, Helsinki, Finland; [Hoefer, Stefan] Innsbruck Med Univ, Dept Med Psychol, Innsbruck, Austria; [Bullinger, Monika] Univ Hamburg, Inst & Poliklin Med Psychol, Hamburg, Germany; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Neugebauer, Edmund] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany; [Powell, Jane] Univ London, Dept Psychol, London, England; [von Wild, Klaus] Univ Munster, Munster, Germany; [Zitnay, George] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Bakx, Wilbert] Maastricht Univ, Adelante Adult Rehabil Ctr, Maastricht, Netherlands; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Cognit & Memory, Copenhagen, Denmark; [Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Hawthorne, Graeme] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [Truelle, Jean-Luc] Univ Hosp Garches, Rehabil Dept, Garches, France		Wilson, L (corresponding author), Univ Stirling, Dept Psychol, Div Psychol, Stirling FK9 4LA, Scotland.	jtlw1@stir.ac.uk	Hofer, Stefan/B-8393-2008; Hofer, Stefan/N-8253-2019; Maas, Andrew IR/C-5584-2013; Sarajuuri, Jaana/AAD-8665-2019; Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Maas, Andrew IR/0000-0003-1612-1264; Sarajuuri, Jaana/0000-0002-6432-0295; Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Koskinen, Sanna/0000-0002-3453-5084	ZNS-Hannelore Kohl Foundation, Germany [2008014]; Victorian Transport Accident Commission [D114]; Italian Ministry of HealthMinistry of Health, Italy [RF08.31]	This work was supported by research grant 2008014 from the ZNS-Hannelore Kohl Foundation, Germany. The Australian data were collected under grant D114 from the Victorian Transport Accident Commission. Italian data were collected under grant RF08.31 from the Italian Ministry of Health.	Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Brown M, 2004, ARCH PHYS MED REHAB, V85, pS13, DOI 10.1016/j.apmr.2003.08.110; Cohen J., 2013, STAT POWER ANAL BEHA; de Boer AGEM, 2004, QUAL LIFE RES, V13, P311, DOI 10.1023/B:QURE.0000018499.64574.1f; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Fleiss JL, 1986, RELIABILITY MEASUREM, DOI DOI 10.1002/9781118032923; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gregg PM, 2001, SOC INDIC RES, V54, P1, DOI 10.1023/A:1007221030609; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; Moosbrugger H., 2007, TESTTHEORIE FRAGEBOG, V2; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Riemsma R P, 2001, Health Technol Assess, V5, P1; Smith AB, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-33; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; United States Food and Drug Administration, 2009, GUID IND PAT REP OUT; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	64	64	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1041	1047		10.1136/jnnp-2012-302361			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600005	22851609				2022-02-06	
J	King, D; Clark, T; Gissane, C				King, Doug; Clark, Trevor; Gissane, Conor			Use of a rapid visual screening tool for the assessment of concussion in amateur rugby league: A pilot study	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Vision; Eye movements; Sports-related concussion; King-Devick test	SPORTS-RELATED CONCUSSION; RELIABILITY; SYMPTOMS; TESTS	Aim: This study undertook to use the K-D sideline test with the SCAT2 to see if concussions could be identified in amateur rugby league players over a representative competition period. Method: A prospective cohort study was conducted on two teams participating in an amateur rugby league. All players were tested for signs of concussion utilising the K-D test and players with longer times than their baseline scores undertook a further concussion assessment with the SCAT2. Results: Five athletes with suspected concussion were evaluated by K-D testing. Three concussions were associated with witnessed events during the matches and two athletes were identified by the team medic as having longer K-D time scores incidentally post-match compared to baseline. Post-match K-D scores for all concussed athletes were worse than baseline for those with reported or witnessed concussion events (7 s; 5.0-7.1; p = 0.025) and for those identified incidentally (>5 s; 8.9-9.1 s). Both groups also reported more symptoms on the PCSS (a part of the SCAT2) post-match. Discussion: In this rugby cohort, the K-D test was not only useful in identifying changes in players with witnessed head trauma, but in identifying changes in players with an un-witnessed suspected concussion. (c) 2012 Elsevier B.V. All rights reserved.	[King, Doug] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Sport & Recreat, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Clark, Trevor] Massey Univ, Res Ctr Maori Hlth & Dev, Te Pumanawa Hauora, Wellington, New Zealand; [Gissane, Conor] St Marys Univ Coll, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England		King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@autac.nz	Gissane, Conor/I-3661-2019	Gissane, Conor/0000-0003-4677-3853; Clark, Dr Trevor/0000-0002-2853-0068			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; King DA, 2009, NZ J SPORTS MED, V36, P6; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020	20	64	65	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	SEP 15	2012	320	1-2					16	21		10.1016/j.jns.2012.05.049			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	000JC	WOS:000308381600004	22694977				2022-02-06	
J	Cocker, PJ; Hosking, JG; Benoit, J; Winstanley, CA				Cocker, Paul J.; Hosking, Jay G.; Benoit, James; Winstanley, Catharine A.			Sensitivity to Cognitive Effort Mediates Psychostimulant Effects on a Novel Rodent Cost/Benefit Decision-Making Task	NEUROPSYCHOPHARMACOLOGY			English	Article						cognitive effort; cost/benefit decision making; individual differences; amphetamine; caffeine; rat	REACTION-TIME-TASK; NUCLEUS-ACCUMBENS DOPAMINE; TRAUMATIC BRAIN-INJURY; D-AMPHETAMINE; PREFRONTAL CORTEX; ATTENTIONAL PERFORMANCE; ACETYLCHOLINE-RELEASE; CARDIOVASCULAR-RESPONSE; CORTICAL ACETYLCHOLINE; SUSTAINED ATTENTION	Amotivational states and insufficient recruitment of mental effort have been observed in a variety of clinical populations, including depression, traumatic brain injury, post-traumatic stress disorder, and attention deficit hyperactivity disorder. Previous rodent models of effort-based decision making have utilized physical costs whereas human studies of effort are primarily cognitive in nature, and it is unclear whether the two types of effortful decision making are underpinned by the same neurobiological processes. We therefore designed a novel rat cognitive effort task (rCET) based on the 5-choice serial reaction time task, a well-validated measure of attention and impulsivity. Within each trial of the rCET, rats are given the choice between an easy or hard visuospatial discrimination, and successful hard trials are rewarded with double the number of sugar pellets. Similar to previous human studies, stable individual variation in choice behavior was observed, with 'workers' choosing hard trials significantly more than their 'slacker' counterparts. Whereas workers 'slacked off in response to administration of amphetamine and caffeine, slackers 'worked harder' under amphetamine, but not caffeine. Conversely, these stimulants increased motor impulsivity in all animals. Ethanol did not affect animals' choice but invigorated behavior. In sum, we have shown for the first time that rats are differentially sensitive to cognitive effort when making decisions, independent of other processes such as impulsivity, and these baseline differences can influence the cognitive response to psychostimulants. Such findings could inform our understanding of impairments in effort-based decision making and contribute to treatment development. Neuropsychopharmacology (2012) 37, 1825-1837; doi:10.1038/npp.2012.30; published online 28 March 2012	[Cocker, Paul J.; Hosking, Jay G.; Benoit, James; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada		Winstanley, CA (corresponding author), Univ British Columbia, Dept Psychol, 2136 West Mall, Vancouver, BC V6T 1Z4, Canada.	jayhosking@psych.ubc.ca	Winstanley, Catharine/K-5003-2015	Winstanley, Catharine/0000-0001-7032-4471; Cocker, Paul/0000-0002-2957-2884	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; CIHRCanadian Institutes of Health Research (CIHR); University of British Columbia's University; Pacific Century Graduate Scholarship	This work was supported by an operating grant awarded to CAW from the Canadian Institutes for Health Research (CIHR). CAW also receives salary support through the Michael Smith Foundation for Health Research and the CIHR New Investigator Award program. JGH was supported by the University of British Columbia's University Graduate Fellowship and the Pacific Century Graduate Scholarship.	ANDERSON KJ, 1994, J PERS SOC PSYCHOL, V67, P334, DOI 10.1037/0022-3514.67.2.334; Bardgett ME, 2009, BEHAV NEUROSCI, V123, P242, DOI 10.1037/a0014625; Barnes A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006626; Bizarro L, 2004, BEHAV PHARMACOL, V15, P195, DOI 10.1097/01.fbp.0000131574.61491.50; Bizarro L, 2003, DRUG ALCOHOL DEPEN, V72, P287, DOI 10.1016/j.drugalcdep.2003.08.004; Botvinick MM, 2009, COGN AFFECT BEHAV NE, V9, P16, DOI 10.3758/CABN.9.1.16; Brunye TT, 2010, BRAIN COGNITION, V72, P181, DOI 10.1016/j.bandc.2009.07.013; Cardinal RN, 2006, ANOVA BEHAV SCI RES, p[xvi, 448]; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chudasama Y, 2006, BIOL PSYCHOL, V73, P19, DOI 10.1016/j.biopsycho.2006.01.005; Chudasama Y, 2004, LEARN MEMORY, V11, P78, DOI 10.1101/lm.70904; COHEN RM, 1982, ARCH GEN PSYCHIAT, V39, P593; COLE BJ, 1987, PSYCHOPHARMACOLOGY, V91, P458, DOI 10.1007/BF00216011; Collins LE, 2012, PHARMACOL BIOCHEM BE, V100, P498, DOI 10.1016/j.pbb.2011.10.015; Cousins MS, 1996, BEHAV BRAIN RES, V74, P189, DOI 10.1016/0166-4328(95)00151-4; COUSINS MS, 1994, PSYCHOPHARMACOLOGY, V116, P529, DOI 10.1007/BF02247489; Croxson PL, 2009, J NEUROSCI, V29, P4531, DOI 10.1523/JNEUROSCI.4515-08.2009; Dalley JW, 2004, CEREB CORTEX, V14, P922, DOI 10.1093/cercor/bhh052; Dalley JW, 2001, J NEUROSCI, V21, P4908, DOI 10.1523/JNEUROSCI.21-13-04908.2001; de Wit H, 2000, BEHAV NEUROSCI, V114, P830, DOI 10.1037//0735-7044.114.4.830; de Wit H, 2002, NEUROPSYCHOPHARMACOL, V27, P813, DOI 10.1016/S0893-133X(02)00343-3; Drummer OH, 2003, FORENSIC SCI INT, V134, P154, DOI 10.1016/S0379-0738(03)00134-8; Egeland J, 2010, J LEARN DISABIL-US, V43, P430, DOI 10.1177/0022219409355473; Field M, 2010, ALCOHOL CLIN EXP RES, V34, P1346, DOI 10.1111/j.1530-0277.2010.01218.x; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; Floresco SB, 2008, NEUROPSYCHOPHARMACOL, V33, P1966, DOI 10.1038/sj.npp.1301565; Floresco SB, 2007, CEREB CORTEX, V17, P251, DOI 10.1093/cercor/bhj143; Floresco SB, 2008, COGN AFFECT BEHAV NE, V8, P375, DOI 10.3758/CABN.8.4.375; Ghods-Sharifi S, 2009, J NEUROSCI, V29, P5251, DOI 10.1523/JNEUROSCI.0315-09.2009; Givens B, 1997, PSYCHOPHARMACOLOGY, V129, P135, DOI 10.1007/s002130050173; Gold JI, 2007, ANNU REV NEUROSCI, V30, P535, DOI 10.1146/annurev.neuro.29.051605.113038; Hammar A, 2003, J INT NEUROPSYCH SOC, V9, P954, DOI 10.1017/S1355617703960152; Hammar A, 2011, NORD J PSYCHIAT, V65, P74, DOI 10.3109/08039488.2010.494311; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Higgins GA, 2007, BEHAV BRAIN RES, V185, P32, DOI 10.1016/j.bbr.2007.07.013; Himmelheber AM, 2000, COGNITIVE BRAIN RES, V9, P313, DOI 10.1016/S0926-6410(00)00012-4; Holdstock L, 2000, ALCOHOL CLIN EXP RES, V24, P789, DOI 10.1111/j.1530-0277.2000.tb02057.x; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Jones-Cage C, 2012, PSYCHOPHARMACOLOGY, V220, P205, DOI 10.1007/s00213-011-2467-1; Kitzbichler MG, 2011, J NEUROSCI, V31, P8259, DOI 10.1523/JNEUROSCI.0440-11.2011; Kool W, 2010, J EXP PSYCHOL GEN, V139, P665, DOI 10.1037/a0020198; Kurniawan IT, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00081; Lawrie SM, 1997, PSYCHOL MED, V27, P995, DOI 10.1017/S0033291797005370; Lazarus M, 2011, J NEUROSCI, V31, P10067, DOI 10.1523/JNEUROSCI.6730-10.2011; McGaughy J, 2002, J NEUROSCI, V22, P1905, DOI 10.1523/JNEUROSCI.22-05-01905.2002; McGuire JT, 2010, P NATL ACAD SCI USA, V107, P7922, DOI 10.1073/pnas.0910662107; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mitchell MR, 2011, PSYCHOPHARMACOLOGY, V218, P703, DOI 10.1007/s00213-011-2363-8; Mukherjee S, 2011, CLIN NEUROPHYSIOL, V122, P2059, DOI 10.1016/j.clinph.2011.02.032; Naccache L, 2005, NEUROPSYCHOLOGIA, V43, P1318, DOI 10.1016/j.neuropsychologia.2004.11.024; Nakamura K, 2001, PHARMACOL BIOCHEM BE, V68, P65, DOI 10.1016/S0091-3057(00)00440-8; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; Passetti F, 2000, EUR J NEUROSCI, V12, P3051, DOI 10.1046/j.1460-9568.2000.00183.x; Paterson NE, 2011, NEUROSCI RES, V69, P41, DOI 10.1016/j.neures.2010.10.001; Peeling P, 2007, ADV PHYSIOL EDUC, V31, P332, DOI 10.1152/advan.00003.2007; REVELLE W, 1980, J EXP PSYCHOL GEN, V109, P1, DOI 10.1037//0096-3445.109.1.1; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rudebeck PH, 2006, NAT NEUROSCI, V9, P1161, DOI 10.1038/nn1756; Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014; SALAMONE JD, 1994, BEHAV BRAIN RES, V65, P221, DOI 10.1016/0166-4328(94)90108-2; Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9; Shah AK, 2008, PSYCHOL BULL, V134, P207, DOI 10.1037/0033-2909.134.2.207; SHALEV A, 1990, PSYCHOSOMATICS, V31, P197, DOI 10.1016/S0033-3182(90)72195-0; Silber BY, 2006, PSYCHOPHARMACOLOGY, V187, P154, DOI 10.1007/s00213-006-0410-7; Smit AS, 2004, ACTA PSYCHOL, V115, P35, DOI 10.1016/j.actpsy.2003.11.001; St Onge JR, 2010, PSYCHOPHARMACOLOGY, V211, P209, DOI 10.1007/s00213-010-1883-y; Stolerman IP, 2009, BEHAV PHARMACOL, V20, P742, DOI 10.1097/FBP.0b013e328333b290; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Treadway MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006598; Van Dort CJ, 2009, J NEUROSCI, V29, P871, DOI 10.1523/JNEUROSCI.4111-08.2009; Wallman Karen E, 2007, Res Sports Med, V15, P47, DOI 10.1080/15438620601184331; Walton ME, 2003, J NEUROSCI, V23, P6475; White TL, 2007, EXP CLIN PSYCHOPHARM, V15, P599, DOI 10.1037/1064-1297.15.6.599; Winstanley CA, 2003, PSYCHOPHARMACOLOGY, V167, P304, DOI 10.1007/s00213-003-1398-x; Winstanley CA, 2011, BRIT J PHARMACOL, V164, P1301, DOI 10.1111/j.1476-5381.2011.01323.x; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Wright RA, 2003, PSYCHOPHYSIOLOGY, V40, P98, DOI 10.1111/1469-8986.00010; Wright RA, 2008, INT J PSYCHOPHYSIOL, V69, P127, DOI 10.1016/j.ijpsycho.2008.04.002; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62	81	64	65	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUL	2012	37	8					1825	1837		10.1038/npp.2012.30			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	960EZ	WOS:000305372100006	22453140	Bronze, Green Published			2022-02-06	
J	Lu, J; Ng, KC; Ling, G; Wu, J; Poon, DJF; Kan, EM; Tan, MH; Wu, YJ; Li, P; Moochhala, S; Yap, E; Lee, LKH; Teo, M; Yeh, IB; Sergio, DMB; Chua, F; Kumar, SD; Ling, EA				Lu, Jia; Ng, Kian Chye; Ling, Geoffrey; Wu, Jian; Poon, David Jia Fei; Kan, Enci Mary; Tan, Mui Hong; Wu, Ya Jun; Li, Ping; Moochhala, Shabbir; Yap, Eric; Lee, Lionel Kim Hock; Teo, Melissa; Yeh, Ing Berne; Sergio, Darvi Michell Bufete; Chua, Frederic; Kumar, Srinivasan Dinesh; Ling, Eng-Ang			Effect of Blast Exposure on the Brain Structure and Cognition in Macaca fascicularis	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; immunohistochemistry; magnetic resonance imaging; models of injury; traumatic brain injury	DIFFUSE AXONAL INJURY; PROINFLAMMATORY CYTOKINES; MICROGLIA; CELL; PRESSURE; NEURONS; PROTEIN; TRAUMA; DAMAGE; EXPRESSION	Blast injury to the brain is one of the major causes of death and can also significantly affect cognition and physical and psychological skills in survivors of blast. The complex mechanisms via which blast injury causes impairment of cognition and other symptoms are poorly understood. In this study, we investigated the effects of varying degrees of primary blast overpressure (BOP; 80 and 200 kPa) on the pathophysiological and magnetic resonance imaging (MRI) changes and neurocognitive performance as assessed by the monkey Cambridge Neuropsychological Test Automated Battery (mCANTAB) in non-human primates (NHP). The study aimed to examine the effects of neurobehavioral and histopathological changes in NHP. MRI and histopathology revealed ultrastructural changes in the brain, notably in the Purkinje neurons in the cerebellum and pyramidal neurons in the hippocampus, which were most vulnerable to the blast. The results correlated well with the behavioral changes and changes in motor coordination and working memory of the affected monkeys. In addition, there was white matter damage affecting myelinated axons, astrocytic hypertrophy, and increased aquaporin-4 (AQP-4) expression in astrocytes, suggesting cerebral edema. Increased apoptosis appeared to involve astrocytes and oligodendrocytes in the animals following blast exposure. The small sample size could have contributed to the non-significant outcome in cognitive performance post-blast and limited quantitative analyses. Nevertheless, the study has provided initial descriptive changes for establishing a primary BOP threshold for brain injury to serve as a useful platform for future investigations that aim to estimate brain injury potential and set safe limits of exposure.	[Lu, Jia] DSO Natl Labs, Def Med & Environm Res Inst, Combat Care Lab, Singapore 117510, Singapore; [Ling, Geoffrey] DARPA, Arlington, VA USA; [Lu, Jia; Wu, Ya Jun; Li, Ping; Kumar, Srinivasan Dinesh; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117595, Singapore; [Yeh, Ing Berne] Alexandra Hosp, Dept Radiol, Singapore, Singapore; [Sergio, Darvi Michell Bufete] Singapore Gen Hosp, Singhlth Expt Med Ctr, Singapore 0316, Singapore		Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, Combat Care Lab, 27 Med Dr, Singapore 117510, Singapore.	ljia@dso.org.sg	Srinivasan, Dinesh Kumar/A-9872-2008; Lee, Lionel/F-3394-2015; Srinivasan, Dinesh Kumar/P-6528-2019; Srinivasan, Dinesh Kumar/E-6383-2017	Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Srinivasan, Dinesh Kumar/0000-0001-6535-5441; Sergio, Darvi Michell/0000-0002-5480-8094; MOOCHHALA, SHABBIR/0000-0003-4521-3192; Wu, Yajun/0000-0001-9598-4433	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	This study was supported by a research grant from Phase I of the PREVENT blast research program from the Defense Advanced Research Projects Agency (DARPA).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Barenberg P, 2001, NEUROSCI RES, V40, P245, DOI 10.1016/S0168-0102(01)00234-6; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cemak I., 1997, INT REV ARMED FORCES, V70, P114; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Deng YY, 2008, BRAIN PATHOL, V18, P387, DOI 10.1111/j.1750-3639.2008.00138.x; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dobbie C.B., 1963, PREBANSHEE CALIBRATI, P62; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; FIFKOVA E, 1985, CELL MOL NEUROBIOL, V5, P47, DOI 10.1007/BF00711085; Fray PJ, 1996, NEUROTOXICOL TERATOL, V18, P499, DOI 10.1016/0892-0362(96)00027-X; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Hausmann R, 2007, INT J LEGAL MED, V121, P175, DOI 10.1007/s00414-006-0122-x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson D.L., 1998, BLAST OVERPRESSURE S; Johnson D.L., 1993, BLAST OVERPRESSURE S; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C, 2005, NEUROSCIENCE, V135, P1217, DOI 10.1016/j.neuroscience.2005.06.023; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; LLINAS R, 1989, EUR J NEUROSCI, V1, P587, DOI 10.1111/j.1460-9568.1989.tb00365.x; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Lukoyanov NV, 2006, BEHAV BRAIN RES, V173, P229, DOI 10.1016/j.bbr.2006.06.026; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Meme W, 2006, FASEB J, V20, P494, DOI 10.1096/fj.05-4297fje; Molteni E, 2008, ANN BIOMED ENG, V36, P1216, DOI 10.1007/s10439-008-9506-z; Nag Sukriti, 2003, Methods Mol Med, V89, P133; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Obhi SS, 2002, MOTOR CONTROL, V6, P319, DOI 10.1123/mcj.6.4.319; Olney JW, 2004, ANESTHESIOLOGY, V101, P273, DOI 10.1097/00000542-200408000-00004; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Risling M, 2002, FOIR0757SE SWED DEF, P1; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Soriano SG, 2005, ANESTHESIOLOGY, V102, P866, DOI 10.1097/00000542-200504000-00030; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; Wu J, 2008, ACTA NEUROCHIR SUPPL, V105, P59; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	61	64	65	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1434	1454		10.1089/neu.2010.1591			21	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600017	21639720				2022-02-06	
J	Wang, YF; Song, JH; Denisova, JV; Park, WM; Fontes, JD; Belousov, AB				Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.; Park, Won-Mee; Fontes, Joseph D.; Belousov, Andrei B.			Neuronal Gap Junction Coupling Is Regulated by Glutamate and Plays Critical Role in Cell Death during Neuronal Injury	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; IN-VIVO; EPILEPTIFORM ACTIVITY; ELECTRICAL SYNAPSES; RECEPTOR AGONIST; GLOBAL-ISCHEMIA; RAT NEOCORTEX; EXPRESSION; ACTIVATION	In the mammalian CNS, excessive release of glutamate and overactivation of glutamate receptors are responsible for the secondary (delayed) neuronal death following neuronal injury, including ischemia, traumatic brain injury (TBI), and epilepsy. The coupling of neurons by gap junctions (electrical synapses) increases during neuronal injury. We report here that the ischemic increase in neuronal gap junction coupling is regulated by glutamate via group II metabotropic glutamate receptors (mGluRs). Specifically, using electrotonic coupling, Western blots, and siRNA in the mouse somatosensory cortex in vivo and in vitro, we demonstrate that activation of group II mGluRs increases background levels of neuronal gap junction coupling and expression of connexin 36 (Cx36) (neuronal gap junction protein), and inactivation of group II mGluRs prevents the ischemia-mediated increases in the coupling and Cx36 expression. We also show that the regulation is via cAMP/PKA (cAMP-dependent protein kinase)-dependent signaling and posttranscriptional control of Cx36 expression and that other glutamate receptors are not involved in these regulatory mechanisms. Furthermore, using the analysis of neuronal death, we show that inactivation of group II mGluRs or genetic elimination of Cx36 both dramatically reduce ischemia-mediated neuronal death in vitro and in vivo. Similar results are obtained using in vitro models of TBI and epilepsy. Our results indicate that neuronal gap junction coupling is a critical component of glutamate-dependent neuronal death. They also suggest that causal link among group II mGluR function, neuronal gap junction coupling, and neuronal death has a universal character and operates in different types of neuronal injuries.	[Wang, Yongfu; Song, Ji-Hoon; Denisova, Janna V.; Park, Won-Mee; Belousov, Andrei B.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Fontes, Joseph D.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA		Belousov, AB (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 2146 W 39th Ave, Kansas City, KS 66160 USA.	abelousov@kumc.edu		Fontes, Joseph/0000-0003-4796-343X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS064256, HD002528]; University of Kansas Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064256] Funding Source: NIH RePORTER	This work was supported by NIH Grant R01 NS064256 and the University of Kansas Medical Center funds (A.B.B.). Core support was provided by NIH Grant HD002528. We are grateful to Drs. D. Paul and M. Feller for providing us with the Cx36 knock-out mice and Dr. R. Nudo for help with establishing ischemic models.	[Anonymous], STROKE, V25, P2085; [Anonymous], STROKE, V25, P2089; Arumugam H, 2005, NAT NEUROSCI, V8, P1720, DOI 10.1038/nn1588; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Beraudi A, 2007, EXP EYE RES, V84, P544, DOI 10.1016/j.exer.2006.11.008; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Conn PJ, 2005, NAT REV NEUROSCI, V6, P787, DOI 10.1038/nrn1763; CONNORS BW, 1983, J NEUROSCI, V3, P773; Cusato K, 2006, CELL DEATH DIFFER, V13, P1707, DOI 10.1038/sj.cdd.4401876; Cusato K, 2003, J NEUROSCI, V23, P6413; Danesh-Meyer HV, 2008, J CLIN NEUROSCI, V15, P1253, DOI 10.1016/j.jocn.2008.08.002; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; de Pina-Benabou MH, 2005, STROKE, V36, P2232, DOI 10.1161/01.STR.0000182239.75969.d8; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Gajda Z, 2003, EPILEPSIA, V44, P1596, DOI 10.1111/j.0013-9580.2003.25803.x; Garrett FG, 2008, NEURON GLIA BIOL, V4, P295, DOI 10.1017/S1740925X09990093; Hatton GI, 1998, CELL BIOL INT, V22, P765, DOI 10.1006/cbir.1998.0386; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hormuzdi SG, 2001, NEURON, V31, P487, DOI 10.1016/S0896-6273(01)00387-7; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; Lobner D, 1994, DIPYRIDAMOLE INCREAS, V390, P38; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Oguro K, 2001, J NEUROSCI, V21, P7534, DOI 10.1523/JNEUROSCI.21-19-07534.2001; Park WM, 2011, J NEUROSCI, V31, P5909, DOI 10.1523/JNEUROSCI.6787-10.2011; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Peixoto PM, 2009, BIOCH BIOPHYS RES CO; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; Personius K, 2001, CELL COMMUN ADHES, V8, P329, DOI 10.3109/15419060109080748; Rash JE, 2000, P NATL ACAD SCI USA, V97, P7573, DOI 10.1073/pnas.97.13.7573; Samoilova M, 2003, J NEUROCHEM, V86, P687, DOI 10.1046/j.1471-4159.2003.01893.x; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Thompson RJ, 2008, SCIENCE, V322, P1555, DOI 10.1126/science.1165209; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaccari JCDR, 2007, J NEUROPHYSIOL, V98, P2878, DOI 10.1152/jn.00362.2007; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; Wang YF, 2010, J NEUROPHYSIOL, V104, P3551, DOI 10.1152/jn.00656.2010; Wong M, 2001, DEV BRAIN RES, V128, P113, DOI 10.1016/S0165-3806(01)00149-3; Yoshioka H, 2009, NEUROSCI LETT, V461, P266, DOI 10.1016/j.neulet.2009.06.056	48	64	68	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 11	2012	32	2					713	725		10.1523/JNEUROSCI.3872-11.2012			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	876QE	WOS:000299121800033	22238107	Green Published, Green Accepted, Bronze			2022-02-06	
J	Donnell, AJ; Kim, MS; Silva, MA; Vanderploeg, RD				Donnell, Alison J.; Kim, Michelle S.; Silva, Marc A.; Vanderploeg, Rodney D.			Incidence of Postconcussion Symptoms in Psychiatric Diagnostic Groups, Mild Traumatic Brain Injury, and Comorbid Conditions	CLINICAL NEUROPSYCHOLOGIST			English	Article						Head injuries; Psychiatric diagnoses; Veterans' health	POST-CONCUSSION SYMPTOMS; BLAST	The constellation of physical, cognitive, and emotional symptoms, collectively known as postconcussion syndrome (PCS), is not uniquely associated with concussion, making the etiology of chronic postconcussion symptoms controversial. The current study compared percentages of individuals meeting symptom-based criteria for PCS in a population-based sample of veterans composed of subgroups with various psychiatric diagnoses, a history of mild traumatic brain injury (MTBI), and healthy controls. Participants were identified from 4462 randomly sampled male U. S. Army veterans who served during the Vietnam era. Only 32% of veterans with a history of MTBI met DSM-IV symptom criteria for PCS as compared to 40% of those diagnosed with post-traumatic stress disorder (PTSD), 50% with generalized anxiety disorder (GAD), 57% with major depressive disorder (MDD), and 91% with somatization disorder. Results were consistent with existing literature showing that the PCS symptoms are not unique to concussion, and also provide important base-rate information for neuropsychologists practicing in both clinical and personal injury forensic settings.	[Vanderploeg, Rodney D.] James A Haley Vet Hosp, Psychol Serv 116B, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Donnell, Alison J.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Donnell, Alison J.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.] James A Haley Vet Hosp, HSR&D RR&D Ctr Excellence Maximizing Rehabil Outc, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Neurosci, Tampa, FL USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Dept Mental Hlth & Behav Sci, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov	Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Veterans Affairs, or U.S. Government.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 1988, JAMA, V259, P2701; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Faul M, 2010, TRAUMATIC BRAIN INJU; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GREIFFENSTEIN MF, 2005, FORENSIC NEUROPSYCHO, P29; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Larrabee, 2005, FORENSIC NEUROPSYCHO, P209; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; McCrea M. A., 2007, OXFORD WORKSHOP SERI; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Robins L.N., 1987, DIAGNOSTIC INTERVIEW; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; World Health Organization, 2004, ICD 10 INT STAT CLAS	32	64	64	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	7					1092	1101		10.1080/13854046.2012.713984			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	027DE	WOS:000310331200003	22935025				2022-02-06	
J	VandeVord, PJ; Bolander, R; Sajja, VSSS; Hay, K; Bir, CA				VandeVord, Pamela J.; Bolander, Richard; Sajja, Venkata Siva Sai Sujith; Hay, Kathryn; Bir, Cynthia A.			Mild Neurotrauma Indicates a Range-Specific Pressure Response to Low Level Shock Wave Exposure	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Blast; Neurotrauma; Injury mechanism; Brain	TRAUMATIC BRAIN-INJURY; SPATIAL WORKING-MEMORY; WATER MAZE PERFORMANCE; DENTATE GYRUS; ADULT NEUROGENESIS; INTRACRANIAL-PRESSURE; CORTICAL-NEURONS; BLAST INJURY; FLUORO-JADE; AMYGDALA	Identifying the level of overpressure required to create physiological deficits is vital to advance prevention, diagnostic, and treatment strategies for individuals exposed to blasts. In this study, a rodent model of primary blast neurotrauma was employed to determine the pressure at which acute neurological alterations occurred. Rats were exposed to a single low intensity shock wave at a pressure of 0, 97, 117, or 153 kPa. Following exposure, rats were assessed for acute cognitive alterations using the Morris water maze and motor dysfunction using the horizontal ladder test. Subsequently, histological analyses of three brain regions ( primary motor cortex, the hippocampal dentate gyrus region, and the posteromedial cortical amygdala) were conducted. Histological parameters included measuring the levels of glial fibrillary acidic protein (GFAP) to identify astrocyte activation, cleaved caspase-3 for early apoptosis identification and Fluoro-Jade B (FJB) which labels degenerating neurons within the brain tissue. The results demonstrated that an exposure to a single 117 kPa shock wave revealed a significant change in overall neurological deficits when compared to controls and the other pressures. The animals showed significant alterations in water maze parameters and a histological increase in the number of GFAP, caspase-3, and FJB-positive cells. It is suggested that when exposed to a low level shock wave, there may be a biomechanical response elicited by a specific pressure range which can cause low level neurological deficits within the rat. These data indicate that neurotrauma induced from a shock wave may lead to cognitive deficits in short-term learning and memory of rats. Additional histological evidence supports significant and diffuse glial activation and cellular damage. Further investigation into the biomechanical aspects of shock wave exposure is required to elucidate this pressure range-specific phenomenon.	[VandeVord, Pamela J.; Bolander, Richard; Sajja, Venkata Siva Sai Sujith; Hay, Kathryn; Bir, Cynthia A.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [VandeVord, Pamela J.] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA		VandeVord, PJ (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	pvord@wayne.edu; dt8583@wayne.edu; dz2837@wayne.edu; du7030@wayne.edu; cbir@wayne.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Bir, Cynthia/0000-0002-0777-0951	United States Office of Naval ResearchOffice of Naval Research [N000140810585]	The authors would like to thank Samantha Staley, James Kopacz, and Drs. Alessandra Dal Cengio Leonardi, Bin Wu, and Li Mao for their technical assistance. This research was partially supported by the United States Office of Naval Research grant Award Number N000140810585.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R., 2011, ANN BIOMED ENG  0707; Caberlotto L, 2000, J CHEM NEUROANAT, V20, P327, DOI 10.1016/S0891-0618(00)00107-1; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Ciraulo DL, 2006, J AM COLL SURGEONS, V203, P942, DOI 10.1016/j.jamcollsurg.2006.07.028; CLEMEDSON C.-J., 1957, ACTA PATHOL ET MICROBIOL SCAND, V40, P89; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Davies RR, 2005, BRAIN, V128, P1984, DOI 10.1093/brain/awh582; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Fraticelli-Torres A. I., 2010, ETHN DIS S1, V20, pS1; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Fuster JM, 2002, J NEUROCYTOL, V31, P373, DOI 10.1023/A:1024190429920; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Hernandez-Rabaza V, 2007, BRAIN RES BULL, V72, P315, DOI 10.1016/j.brainresbull.2007.01.013; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hong Jun, 2002, Chin J Traumatol, V5, P36; Jenkins TA, 2006, NEUROSCIENCE, V137, P747, DOI 10.1016/j.neuroscience.2005.09.034; Kamnaksh A., 2011, J NEUROTRAUMA, V23; Kesner RP, 2007, PROG BRAIN RES, V163, P567, DOI 10.1016/S0079-6123(07)63030-1; Kirby E. D., 2011, MOL PSYCHIAT    0614; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leong SY, 2011, NEUROCHEM INT, V59, P382, DOI 10.1016/j.neuint.2010.12.024; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Niewoehner B, 2007, EUR J NEUROSCI, V25, P837, DOI 10.1111/j.1460-9568.2007.05312.x; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wurm F, 2007, STROKE, V38, P2833, DOI 10.1161/STROKEAHA.107.485524; Zhang L., 2006, J BIOMECH, V39, pS163	63	64	65	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		227	236		10.1007/s10439-011-0420-4			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700020	21994066				2022-02-06	
J	Max, JE; Keatley, E; Wilde, EA; Bigler, ED; Levin, HS; Schachar, RJ; Saunders, A; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Yang, TT				Max, Jeffrey E.; Keatley, Eva; Wilde, Elisabeth A.; Bigler, Erin D.; Levin, Harvey S.; Schachar, Russell J.; Saunders, Ann; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Yang, Tony T.			Anxiety Disorders in Children and Adolescents in the First Six Months After Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSONALITY-CHANGE; RELIABILITY; VALIDITY; MOOD; NEUROBIOLOGY; PREDICTORS; DEPRESSION; SCHEDULE	The study's objective was to assess the nature, rate, predictive factors, and neuroimaging correlates of novel (new-onset) definite anxiety disorders and novel definite/subclinical anxiety disorders (in a broader group of children with at least subclinical anxiety disorders) after traumatic brain injury (TBI). Children with TBI from consecutive admissions to five trauma centers were enrolled and studied with psychiatric interviews soon after injury (baseline) and again 6 months post-injury. Novel definite anxiety disorder and novel definite/subclinical anxiety disorders were heterogeneous and occurred in 8.5% (N = 12) and 17% (N = 24) of participants, respectively, in the first 6 months after injury. Novel definite anxiety disorder was significantly associated with younger age at injury and tended to be associated with novel depressive disorder, as well as lesions of the superior frontal gyrus. Novel definite/subclinical anxiety disorder was significantly associated with concurrent psychiatric problems of personality change due to TBI and novel definite/subclinical depressive disorder, as well as with lesions of the superior frontal gyrus and a trend-association with frontal lobe white-matter lesions. These findings suggest that anxiety after childhood TBI may be part of a broader problem of affective dysregulation related to damaged dorsal frontal lobe and frontal white-matter systems, with younger children being at greatest risk for developing novel anxiety disorder after TBI. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:29-39)	[Max, Jeffrey E.; Keatley, Eva; Yang, Tony T.] Univ Calif San Diego, Dept Psychiat, Childrens Hosp & Hlth Ctr, San Diego, CA 92103 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Schachar, Russell J.] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr, Dept Pediat, Houston, TX USA; [Saunders, Ann] Univ Texas Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA		Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800, R01MH085734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kendler KS, 2008, PSYCHOL MED, V38, P1001, DOI 10.1017/S0033291707001821; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Mathew SJ, 2008, AM J MED GENET C, V148C, P89, DOI 10.1002/ajmg.c.30172; Max J. E., 2005, J AM ACAD CHILD ADOL, V44, P435; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Ressler KJ, 2007, NAT NEUROSCI, V10, P1116, DOI 10.1038/nn1944; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	34	64	64	1	18	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2011	23	1					29	39		10.1176/appi.neuropsych.23.1.29			11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	717VY	WOS:000287076700029	21304136				2022-02-06	
J	McCoy, B; Sharma, R; Ochi, A; Go, C; Otsubo, H; Hutchison, JS; Atenafu, EG; Hahn, CD				McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hutchison, James S.; Atenafu, Eshetu G.; Hahn, Cecil D.			Predictors of nonconvulsive seizures among critically ill children	EPILEPSIA			English	Article						Continuous EEG monitoring; Intensive care; Pediatrics	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; PRESSURE; PATTERNS; INCREASE	Purpose: Continuous electroencephalography (EEG) monitoring is a valuable tool for the detection of seizures among critically ill children, in particular when these seizures occur without clinical signs: termed nonconvulsive seizures. Continuous EEG monitoring is a limited resource in many centers. We sought to identify which critically ill children most frequently experience nonconvulsive seizures, and thus may particularly benefit from continuous EEG monitoring. Methods: Single-center review was undertaken of consecutive diagnostic continuous EEG (cEEG) recordings performed in our pediatric and neonatal intensive care units (ICUs). We examined the indications for monitoring, the clinical characteristics of monitored patients, the occurrence and timing of seizures, and clinical and EEG characteristics associated with nonconvulsive seizures. Key Findings: One hundred twenty-one patients underwent diagnostic continuous EEG monitoring, for a mean duration of 26 h. Seizures were detected in 32% of these patients, of which 90% experienced some nonconvulsive seizures, and 72% experienced exclusively nonconvulsive seizures. Patients with nonconvulsive seizures had significantly greater odds of having acute epilepsy, acute structural brain injury, prior in-hospital convulsive seizures, and the presence of interictal epileptiform abnormalities on EEG. Significance: Seizures are common among critically ill children undergoing diagnostic cEEG monitoring. The great majority of these seizures are nonconvulsive, requiring EEG for their detection. Predictors of nonconvulsive seizures include acute epilepsy, acute structural brain injury, prior in-hospital convulsive seizures, and interictal epileptiform abnormalities on EEG. These findings can help inform future allocation of limited cEEG monitoring resources to those patients at greatest risk for nonconvulsive seizures.	[McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hahn, Cecil D.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [McCoy, Blathnaid; Sharma, Rohit; Ochi, Ayako; Go, Cristina; Otsubo, Hiroshi; Hutchison, James S.; Hahn, Cecil D.] Univ Toronto, Toronto, ON, Canada; [Hutchison, James S.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Atenafu, Eshetu G.] Univ Hlth Network, Princess Margaret Hosp, Dept Biostat, Toronto, ON, Canada		Hahn, CD (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cecil.hahn@sickkids.ca	Hahn, Cecil D./F-6218-2011; Hahn, Cecil/J-3372-2016; Atenafu, Eshetu G./H-7520-2019	Hahn, Cecil D./0000-0002-0887-8761; Hahn, Cecil/0000-0002-0887-8761; Atenafu, Eshetu G./0000-0002-4613-3680	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Hospital for Sick Children Foundation; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Ontario Neurotrauma Foundation; Physicians Services Incorporated Foundation; Victoria Neurotrauma Initiative; Hospital for Sick Children Research Institute	Dr Hutchison has received research support from the National Institutes of Health, The Hospital for Sick Children Foundation, the Canada Foundation for Innovation, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Ontario Neurotrauma Foundation, the Physicians Services Incorporated Foundation, and the Victoria Neurotrauma Initiative. Dr Hahn has received research support from The Hospital for Sick Children Research Institute, The Hospital for Sick Children Foundation, the Canadian Institutes of Health Research, and the Physicians Services Incorporated Foundation.	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WERTHEIM D, 1994, ARCH DIS CHILD-FETAL, V71, pF97, DOI 10.1136/fn.71.2.F97; Young GB, 1996, NEUROLOGY, V47, P83	22	64	65	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2011	52	11					1973	1978		10.1111/j.1528-1167.2011.03291.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	848KE	WOS:000297049700011	22003955				2022-02-06	
J	Molloy, C; Conroy, RM; Cotter, DR; Cannon, M				Molloy, Charlene; Conroy, Ronan M.; Cotter, David R.; Cannon, Mary			Is Traumatic Brain Injury A Risk Factor for Schizophrenia? A Meta-Analysis of Case-Controlled Population-Based Studies	SCHIZOPHRENIA BULLETIN			English	Article						traumatic brain injury; psychosis; systematic review; meta-analysis	HEAD-INJURY; PSYCHIATRIC-ILLNESS; PSYCHOSIS; ASSOCIATION; DISORDER; CHILDHOOD; EPILEPSY	Traumatic brain injury (TBI) is known to lead to a range of adverse psychiatric sequelae but the question of whether TBI is a risk factor for psychosis and, in particular, schizophrenia remains unclear. Studies examining this issue have yielded conflicting results. We carried out a systematic review of the literature on TBI and psychosis in order to identify all population-based controlled studies which provide estimates of risk for schizophrenia following TBI. Odds ratios (ORs) were combined using random effects meta-analysis. Our literature search yielded 172 studies which were considered to be potentially relevant. From these, we identified 9 studies that could provide estimates of risk in the form of ORs. The pooled analysis revealed a significant association between TBI and schizophrenia (OR = 1.65; 95% CI = 1.17-2.32), with significant heterogeneity between the studies. Estimates from the family studies (OR = 2.8: 95% CI =1.76-4.47) were higher than those from the cohort/nested case-control studies (OR = 1.42: 95% CI = 1.02-1.97) by a factor of almost 2. There did not appear to be a dose-response relationship between severity of head injury and subsequent risk of schizophrenia. This meta-analysis supports an increased risk of schizophrenia following TBI, with a larger effect in those with a genetic predisposition to psychosis. Further epidemiological and neuroscientific studies to elucidate the mechanisms underlying this association are warranted.	[Cannon, Mary] Beaumont Hosp, Dept Psychiat, Royal Coll Surg Ireland, Educ & Res Ctr, Dublin 9, Ireland; [Conroy, Ronan M.] Royal Coll Surgeons Ireland, Dept Epidemiol & Biostat, Dublin 2, Ireland		Cannon, M (corresponding author), Beaumont Hosp, Dept Psychiat, Royal Coll Surg Ireland, Educ & Res Ctr, Dublin 9, Ireland.	marycannon@rcsi.ie	cotter, david r/D-8249-2012; Cannon, Mary/D-8227-2012; Conroy, Ronan/C-6416-2008	Cannon, Mary/0000-0002-0910-299X; Conroy, Ronan/0000-0001-5983-8682; cotter, david/0000-0003-4308-0648	European CommunityEuropean Commission [HEALTH-F2-2009-241909]; Health Research Board Ireland [CSA/2004/1]; NARSAD Essel FoundationNARSAD; Stanley Medical Research Institute; Health Research Board Ireland; NARSADNARSAD; Science Foundation IrelandScience Foundation IrelandEuropean Commission	European Community's Seventh Framework Program (HEALTH-F2-2009-241909; Project EU-GEI). M. C. is supported by a Clinician Scientist Award from the Health Research Board Ireland (CSA/2004/1) and also recieves support from a 2009 NARSAD Essel Foundation Independent Investigator Award and The Stanley Medical Research Institute. D. C. is supported by the Health Research Board Ireland, NARSAD, Science Foundation Ireland, and the Stanley Medical Research Institute.	AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cannon M, 2005, SCHIZOPHR RES, V79, P5, DOI 10.1016/j.schres.2005.05.027; Cannon M, 2002, ARCH GEN PSYCHIAT, V59, P449, DOI 10.1001/archpsyc.59.5.449; Chen Y-H, 2010, PSYCHOL MED     0922, DOI [10.1017/S00332917, DOI 10.1017/S00332917]; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; Davison K, 1969, BRIT J PSYCHIAT, pS113; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fleminger S., 2009, LISHMANS ORGANIC PSY, P167; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kim E, 2008, CURR OPIN PSYCHIATR, V21, P286, DOI 10.1097/YCO.0b013e3282fbcd21; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rutten BPF, 2009, SCHIZOPHRENIA BULL, V35, P1045, DOI 10.1093/schbul/sbp104; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; StataCorp, 2007, STAT STAT SOFTW REL; Sundram F, 2010, BRIT J PSYCHIAT, V197, P482, DOI 10.1192/bjp.bp.110.080218; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; van Os J, 2008, SCHIZOPHRENIA BULL, V34, P1066, DOI 10.1093/schbul/sbn117; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	30	64	69	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2011	37	6					1104	1110		10.1093/schbul/sbr091			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	836ZD	WOS:000296158100004	21813439	Bronze, Green Published			2022-02-06	
J	Work, SS; Colamonico, JA; Bradley, WG; Kaye, RE				Work, Susan S.; Colamonico, Jennifer A.; Bradley, Walter G.; Kaye, Randall E.			Pseudobulbar affect: an under-recognized and under-treated neurological disorder	ADVANCES IN THERAPY			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; diagnosis; multiple sclerosis; Parkinson's disease; prevalence; pseudobulbar affect; stroke; traumatic brain injury; treatment	AMYOTROPHIC-LATERAL-SCLEROSIS; EMOTIONAL EXPRESSION DISORDER; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; POSTSTROKE DEPRESSION; MOVEMENT-DISORDERS; ALZHEIMERS-DISEASE; LESION LOCATION; DOUBLE-BLIND; STROKE	Pseudobulbar affect (PBA) is a neurologic syndrome of emotional affect disinhibition, characterized by uncontrollable, exaggerated, and often inappropriate emotional outbursts, which may cause severe distress, embarrassment, and social dysfunction. However, the US prevalence of PBA remains unknown. An online survey was conducted primarily to estimate the US prevalence of PBA in patients with the six most commonly associated conditions: Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury. Invitations to participate were randomly sent online to adults (aged a parts per thousand yen18 years) registered in the Harris Poll Online Panel who were patients or belonged to a household with a patient diagnosed with one of the six conditions (identified through previous screening by Harris Interactive). Participants were screened for PBA using the Pathological Laughing and Crying Scale (PLACS) and the Center for Neurologic Study-Lability Scale (CNS-LS). PBA estimates were made using a cut-off score of a parts per thousand yen13 on the PLACS and two different cut-off thresholds on the CNS-LS, a lower one of a parts per thousand yen13 and a more rigorous one of a parts per thousand yen21. Existing US prevalence data for the six underlying conditions were used to estimate US prevalence of PBA. Of 38,000 individuals invited to participate, 8876 responded (23%) and 2318 (26%) completed the questionnaire. Mean prevalence of PBA across all six conditions was 10.1%, 9.4%, and 37.5% with the PLACS a parts per thousand yen13, CNS-LS a parts per thousand yen21, and CNS-LS a parts per thousand yen13 thresholds, respectively. Using disease population estimates from government agencies and professional organizations, the estimated US population with PBA ranged from 1.8 to 7.1 million. Among patients who discussed their laughing and/or crying episodes with a physician, 41% were diagnosed, and about half received a medication for their episodes. The overall prevalence of PBA was estimated to be about 10% across these commonly associated underlying neurological conditions and appears to be under-recognized.	[Work, Susan S.; Kaye, Randall E.] Avanir Pharmaceut Inc, Aliso Viejo, CA 92656 USA; [Colamonico, Jennifer A.] Harris Interact, Healthcare & Policy Res, New York, NY 10013 USA; [Bradley, Walter G.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA		Work, SS (corresponding author), Avanir Pharmaceut Inc, 101 Enterprise,Suite 300, Aliso Viejo, CA 92656 USA.	SWork@avanir.com			Avanir Pharmaceuticals	Avanir Pharmaceuticals commissioned this survey from Harris Interactive. Walter Bradley is Professor and Chairman Emeritus of the Department of Neurology, Miller School of Medicine, University of Miami. Susan Work and Randall Kaye are employees of Avanir Pharmaceuticals. Susan Work is Senior Director, Market Research and Analytics. Randall Kaye is the Senior Vice President of Medical Affairs. Jennifer A. Colamonico is Senior Vice President of Healthcare Research at Harris Interactive. The authors would like to thank Shawn Wade, Vice President of Market Strategies International, for his assistance with this manuscript when he was still employed by Harris Interactive. Editorial assistance in the preparation of the manuscript was provided by the Curry Rockefeller Group, LLC. Support for this assistance was funded by Avanir Pharmaceuticals.	ALS Association, WHO GETS ALS; American Stroke Association American Heart Association, HEART DIS STROK STAT; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; *AV PHARM INC, 2010, NEUD DEXTR HYDR QUIN; *AV PHARM INC, 2006, DAT FIL; BARNES R, 1982, AM J PSYCHIAT, V139, P1170; Brooks BR, 2004, NEUROLOGY, V63, P1364; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; *CDC, 2006, WHAT AR LONG TERM OU; Choi-Kwon S, 2002, CEREBROVASC DIS, V13, P31, DOI 10.1159/000047743; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; Dark FL, 1996, AUST NZ J PSYCHIAT, V30, P472, DOI 10.3109/00048679609065020; Deming WE, 1940, ANN MATH STAT, V11, P427, DOI 10.1214/aoms/1177731829; Duda JE, 2007, CNS SPECTRUMS, V12, P6, DOI 10.1017/S1092852900025955; Faul M, 2010, TRAUMATIC BRAIN INJU; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GREEN RL, 1987, AM J PSYCHIAT, V144, P442; GUBBAY SS, 1985, J NEUROL, V232, P295, DOI 10.1007/BF00313868; Haupt M, 1996, Int Psychogeriatr, V8 Suppl 3, P409; HIER DB, NEUROLOGY CLIN PRACT; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, J NEUROL, V249, P805, DOI 10.1007/s00415-002-0714-4; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langworthy OR, 1941, AM J PSYCHIAT, V98, P243, DOI 10.1176/ajp.98.2.243; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller RG, 2009, ANN NEUROL, V65, pS24, DOI 10.1002/ana.21556; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; National Institute of Neurological Disorders and Stroke (NINDS) NIH, DEM HOP RES; National MS Society, MS WHO GETS MS; Panitch HS, 2006, ANN NEUROL, V59, P780, DOI 10.1002/ana.20828; *PARK DIS FDN, FREQ ASK QUEST PARK; Parvizi J, 2009, J NEUROPSYCH CLIN N, V21, P75, DOI 10.1176/appi.neuropsych.21.1.75; Petracca GM, 2009, J NEUROPSYCH CLIN N, V21, P406, DOI 10.1176/appi.neuropsych.21.4.406; Phuong L, 2009, PARKINSONISM RELAT D, V15, P511, DOI 10.1016/j.parkreldis.2009.01.001; Pioro EP, 2010, ANN NEUROL, V68, P693, DOI 10.1002/ana.22093; Pleis John R, 2003, Vital Health Stat 10, P1; Poeck K, 1969, Ger Med Mon, V14, P394; POECK K, 1985, HDB CLIN NEUROLOGY, V45; PRATT RTC, 1951, J NEUROL NEUROSUR PS, V14, P326, DOI 10.1136/jnnp.14.4.326; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Rosen H, 2008, DRUG TODAY, V44, P661, DOI 10.1358/dot.2008.44.9.1258664; ROWLAND LP, 2000, ARCH NEUROL-CHICAGO, V57, P1084; Sato T, 2002, AM J PSYCHIAT, V159, P968, DOI 10.1176/appi.ajp.159.6.968; Schafer JL, 1997, ANAL INCOMPLETE MULT; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; Siddiqui MS, 2009, WORLD J BIOL PSYCHIA, V10, P234, DOI 10.1080/15622970701639445; Smi CK, 2006, STROKE, V37, P156, DOI 10.1161/01.STR.0000190892.93663.e2; Smith RA, 2004, MULT SCLER, V10, P1; Smith RA, 2006, ANN NEUROL, V60, pS50; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; Strowd RE, 2010, J NEUROL, V257, P1382, DOI 10.1007/s00415-010-5550-3; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tang WK, 2009, J INT NEUROPSYCH SOC, V15, P62, DOI 10.1017/S1355617708090061; Tang WK, 2004, J NEUROL, V251, P865, DOI 10.1007/s00415-004-0450-z; TARIOT PN, 1995, AM J PSYCHIAT, V152, P1349; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; *US CENS BUR POP D, US POPCLOCK PROJ; WALLIN MT, 2004, NEUROLOGY CLIN PRACT, P776; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006; Zimmerman EK, 2007, COGN BEHAV NEUROL, V20, P79, DOI 10.1097/WNN.0b013e31804c700b	70	64	69	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X			ADV THER	Adv. Ther.	JUL	2011	28	7					586	601		10.1007/s12325-011-0031-3			16	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	799KP	WOS:000293285900006	21660634	Bronze			2022-02-06	
J	Ghosh, M; Yang, YJ; Rothstein, JD; Robinson, MB				Ghosh, Mausam; Yang, Yongjie; Rothstein, Jeffrey D.; Robinson, Michael B.			Nuclear Factor-kappa B Contributes to Neuron-Dependent Induction of Glutamate Transporter-1 Expression in Astrocytes	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; AMINO-ACID CARRIER-1; UP-REGULATION; NEURON/ASTROCYTE COCULTURES; GLT-1/EAAT2 SUBTYPE; HIPPOCAMPAL-NEURONS; ISCHEMIC TOLERANCE; SIGNALING PATHWAYS; DOWN-REGULATION; MICE LACKING	The glutamate transporter-1 [GLT-1 (excitatory amino acid transporter 2)] subtype of glutamate transporter ensures crisp excitatory signaling and limits excitotoxicity in the CNS. Astrocytic expression of GLT-1 is regulated during development, by neuronal activity, and in neurodegenerative diseases. Although neurons activate astrocytic expression of GLT-1, the mechanisms involved have not been identified. In the present study, astrocytes from transgenic mice that express enhanced green fluorescent protein (eGFP) under the control of a bacterial artificial chromosome (BAC) containing a very large region of DNA surrounding the GLT-1 gene (BAC GLT-1 eGFP mice) were used to assess the role of nuclear factor-kappa B (NF-kappa B) in neuron-dependent activation of the GLT-1 promoter. We provide evidence that neurons activate NF-kappa B signaling in astrocytes. Transduction of astrocytes from the BAC GLT-1 eGFP mice with dominant-negative inhibitors of NF-kappa B signaling completely blocked neuron-dependent activation of a NF-kappa B reporter construct and attenuated induction of eGFP. Exogenous expression of p65 and/or p50 NF-kappa B subunits induced expression of eGFP or GLT-1 and increased GLT-1-mediated transport activity. Using wild-type and mutant GLT-1 promoter reporter constructs, we found that NF-kappa B sites at -583 or -251 relative to the transcription start site were required for neuron-dependent reporter activation. Electrophoretic mobility shift and supershift assays reveal that p65 and p50 interact with these same sites ex vivo. Finally, chromatin immunoprecipitation showed that p65 and p50 interact with these sites in adult cortex, but not in kidney (a tissue that expresses no detectable GLT-1). Together, these studies strongly suggest that NF-kappa B contributes to neuron-dependent regulation of astrocytic GLT-1 transcription.	[Ghosh, Mausam; Robinson, Michael B.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Robinson, Michael B.] Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; [Yang, Yongjie; Rothstein, Jeffrey D.] Johns Hopkins Univ, Dept Neurol & Neurosci, Baltimore, MD 21205 USA		Robinson, MB (corresponding author), 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@mail.med.upenn.edu	rothstein, jeffrey d/C-9470-2013		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036465] Funding Source: NIH RePORTER	This work was supported by NIH Grant NS36465 to M. B. R. and J.D.R. We thank Dr. Dean Ballard (Vanderbilt University School of Medicine) for the dominant-negative constructs of I kappa B alpha; Olga Zelanaia and Janice Watch for subcloning some of these cDNAs into the lentiviral backbone; and Dr. Judy Grinspan (Children's Hospital of Philadelphia) for providing the A2B5 hybridoma supernatant. We thank members of the Robinson laboratory for their advice and suggestion with this project.	Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brooks-Kayal AR, 1998, NEUROCHEM INT, V33, P95, DOI 10.1016/S0197-0186(98)00018-7; Caccamo D, 2005, EXP NEUROL, V193, P377, DOI 10.1016/j.expneurol.2005.01.014; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Dabir DV, 2006, J NEUROSCI, V26, P644, DOI 10.1523/JNEUROSCI.3861-05.2006; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Denis-Donini S, 2008, J NEUROSCI, V28, P3911, DOI 10.1523/JNEUROSCI.0148-08.2008; Furuta A, 1997, J NEUROSCI, V17, P8363; Ganel R, 2006, NEUROBIOL DIS, V21, P556, DOI 10.1016/j.nbd.2005.08.014; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Gegelashvili G, 1996, NEUROREPORT, V8, P261, DOI 10.1097/00001756-199612200-00052; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; Gonzalez MI, 2007, J NEUROCHEM, V103, P1917, DOI 10.1111/j.1471-4159.2007.04881.x; Gonzalez MI, 2007, J BIOL CHEM, V282, P29855, DOI 10.1074/jbc.M704738200; Gutierrez H, 2008, J NEUROSCI, V28, P8246, DOI 10.1523/JNEUROSCI.1941-08.2008; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hein C, 2001, EUR J NEUROSCI, V13, P1839, DOI 10.1046/j.0953-816x.2001.01559.x; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kawahara K, 2005, GLIA, V49, P349, DOI 10.1002/glia.20114; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; Li LB, 2006, J NEUROCHEM, V97, P759, DOI 10.1111/j.1471-4159.2006.03743.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mathern GW, 1999, NEUROLOGY, V52, P453, DOI 10.1212/WNL.52.3.453; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Mennerick S, 1998, J NEUROSCI, V18, P4490; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Perego C, 2000, J NEUROCHEM, V75, P1076, DOI 10.1046/j.1471-4159.2000.0751076.x; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rawls SM, 2007, BRIT J PHARMACOL, V151, P1095, DOI 10.1038/sj.bjp.0707309; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rodriguez-Kern A, 2003, NEUROCHEM INT, V43, P363, DOI 10.1016/S0197-0186(03)00023-8; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saura J, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-26; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; Shayakul C, 1997, AM J PHYSIOL-RENAL, V273, pF1023, DOI 10.1152/ajprenal.1997.273.6.F1023; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Sheldon AL, 2008, NEUROCHEM INT, V53, P296, DOI 10.1016/j.neuint.2008.07.010; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Swanson RA, 1997, J NEUROSCI, V17, P932; Tai YH, 2008, NEUROSCIENCE, V153, P823, DOI 10.1016/j.neuroscience.2008.02.055; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; Watson Deborah J, 2003, Methods Mol Med, V76, P383; Weller ML, 2008, NEUROSCIENCE, V155, P1204, DOI 10.1016/j.neuroscience.2008.05.059; Yamada T, 2006, NEUROCHEM RES, V31, P49, DOI 10.1007/s11064-005-9077-4; Yang YJ, 2009, NEURON, V61, P880, DOI 10.1016/j.neuron.2009.02.010; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667	72	64	65	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 22	2011	31	25					9159	9169		10.1523/JNEUROSCI.0302-11.2011			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	782AT	WOS:000291980500012	21697367	Bronze, Green Accepted, Green Published			2022-02-06	
J	Griesbach, GS				Griesbach, Grace S.			Exercise After Traumatic Brain Injury: Is it a Double-Edged Sword?	PM&R			English	Article							NEUROTROPHIC FACTOR EXPRESSION; LONG-TERM POTENTIATION; SENSORIMOTOR CORTEX LESIONS; FLUID PERCUSSION INJURY; NECROSIS-FACTOR-ALPHA; TRKB MESSENGER-RNA; MINOR HEAD-INJURY; VOLUNTARY EXERCISE; SYNAPTIC-PLASTICITY; PHYSICAL-ACTIVITY	This article describes the effects of exercise on neural plasticity after traumatic brain injury (TBI). There is strong evidence that indicates that exercise has neuroprotective effects by activating specific neuronal circuits and increasing molecules that enhance synaptic plasticity. Findings obtained from experimental models of TBI are discussed to support the use of exercise as a rehabilitative tool. These studies indicate that injury characteristics are likely to influence the time window for therapeutic exercise. Results of human and animal studies suggest that premature postconcussive exercise may be deleterious by exacerbating postconcussive symptomatology and disrupting restorative processes. A better understanding of the mechanisms that influence exercise after TBI will contribute to improving guidelines for the return to exercise activities and to the successful use of exercise as a therapeutic tool. PM R 2011;3:S64-S72	[Griesbach, Grace S.] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Griesbach, Grace S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N5061960]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	Research support: National Institute of Neurological Disorders and Stroke award N5061960 and The UCLA Brain Injury Research Center.	Adlard PA, 2004, NEUROSCIENCE, V124, P985, DOI 10.1016/j.neuroscience.2003.12.039; Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Ang ET, 2004, NEUROSCIENCE, V129, P337, DOI 10.1016/j.neuroscience.2004.06.087; Ashman TA, 2006, MT SINAI J MED, V73, P999; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Berninger B, 1999, LEARN MEMORY, V6, P232; Booth FW, 2002, J APPL PHYSIOL, V93, P3, DOI 10.1152/japplphysiol.00073.2002; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ding YH, 2006, ACTA NEUROPATHOL, V112, P74, DOI 10.1007/s00401-006-0076-6; Ding YH, 2006, CURR NEUROVASC RES, V3, P263, DOI 10.2174/156720206778792911; Ding YH, 2006, CURR NEUROVASC RES, V3, P15, DOI 10.2174/156720206775541787; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Fukunaga K, 1999, JPN J PHARMACOL, V79, P7, DOI 10.1254/jjp.79.7; Garcia C, 2003, NEUROSCIENCE, V119, P721, DOI 10.1016/S0306-4522(03)00192-1; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Itoh T, 2010, J NEURAL TRANSM 1006; Ivanco TL, 2000, NEUROPHARMACOLOGY, V39, P765, DOI 10.1016/S0028-3908(00)00004-6; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kozisek ME, 2008, PHARMACOL THERAPEUT, V117, P30, DOI 10.1016/j.pharmthera.2007.07.001; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matthews VB, 2009, DIABETOLOGIA, V52, P1409, DOI 10.1007/s00125-009-1364-1; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nibuya M, 1999, NEUROSCI LETT, V267, P81, DOI 10.1016/S0304-3940(99)00335-3; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Pan YX, 2007, HYPERTENSION, V49, P519, DOI 10.1161/01.HYP.0000256955.74461.93; Pardridge WM, 2002, ADV EXP MED BIOL, V513, P397; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Pitts EV, 2006, INT ANESTHESIOL CLIN, V44, P21, DOI 10.1097/00004311-200604420-00004; POWELL KE, 1985, PUBLIC HEALTH REP, V100, P118; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Rhyu IJ, 2010, NEUROSCIENCE, V167, P1239, DOI 10.1016/j.neuroscience.2010.03.003; Rimmer JH, 2010, AM J PHYS MED REHAB, V89, P249, DOI 10.1097/PHM.0b013e3181c9fa9d; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Russo-Neustadt A, 1999, NEUROPSYCHOPHARMACOL, V21, P679, DOI 10.1016/S0893-133X(99)00059-7; Russo-Neustadt A, 2001, BEHAV BRAIN RES, V120, P87, DOI 10.1016/S0166-4328(00)00364-8; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Schuit AJ, 2001, MED SCI SPORT EXER, V33, P772; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Seifert T, 2010, AM J PHYSIOL-REG I, V298, pR372, DOI 10.1152/ajpregu.00525.2009; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2; Tajiri N, 2010, BRAIN RES, V1310, P200, DOI 10.1016/j.brainres.2009.10.075; Tang SW, 2008, NEUROSCI LETT, V431, P62, DOI 10.1016/j.neulet.2007.11.019; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Ueyama T, 1997, NEUROSCI RES, V28, P103, DOI 10.1016/S0168-0102(97)00030-8; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vaidya VA, 1999, NEUROSCI LETT, V262, P1, DOI 10.1016/S0304-3940(99)00006-3; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZAFRA F, 1992, J NEUROSCI, V12, P4793	155	64	68	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2011	3	6		S			S64	S72		10.1016/j.pmrj.2011.02.008			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	961BB	WOS:000305437800011	21703583				2022-02-06	
J	Hua, F; Wang, J; Ishrat, T; Wei, WJ; Atif, F; Sayeed, I; Stein, DG				Hua, Fang; Wang, Jun; Ishrat, Tauheed; Wei, Wenjing; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.			Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone	JOURNAL OF NEUROINFLAMMATION			English	Article						Toll-like receptors progesterone; traumatic brain injury; inflammation; mouse	INTESTINAL INFLAMMATORY RESPONSE; MUCOSA STRUCTURE ALTERATIONS; CEREBRAL EDEMA; INNATE; ACTIVATION; MECHANISMS; CYTOKINES; SIGNAL	Background: Traumatic brain injury (TBI) causes acute inflammatory responses that result in an enduring cascade of secondary neuronal loss and behavioral impairments. It has been reported that progesterone (PROG) can inhibit the increase of some inflammatory cytokines and inflammation-related factors induced by TBI. Toll-like receptors (TLRs) play a critical role in the induction and regulation of immune/inflammatory responses. Therefore, in the present study, we examined the genomic profiles of TLR-mediated pathways in traumatically injured brain and PROG's effects on these genes. Methods: Bilateral cortical impact injury to the medial frontal cortex was induced in C57BL/6J mice. PROG was injected (i.p., 16 mg/kg body weight) at 1 and 6 h after surgery. Twenty-four hours post-surgery, mice were killed and peri-contusional brain tissue was harvested for genomic detection and protein measurement. RT-PCR arrays were used to measure the mRNA of 84 genes in TLR-mediated pathways. Western blot, ELISA and immunohistochemistry were used to confirm the protein expression of genes of interest. Results: We found that 2 TLRs (TLR1 and 2), 5 adaptor/interacting proteins (CD14, MD-1, HSPA1a, PGRP and Ticam2) and 13 target genes (Ccl2, Csf3, IL1a, IL1b, IL1r1, IL6, IL-10, TNFa, Tnfrsf1a, Cebpb, Clec4e, Ptgs2 and Cxcl10) were significantly up-regulated after injury. Administration of PROG significantly down-regulated three of the 13 increased target genes after TBI (Ccl-2, IL-1b and Cxcl-10), but did not inhibit the expression of any of the detected TLRs and adaptor/interacting proteins. Rather, PROG up-regulated the expression of one TLR (TLR9), 5 adaptor/interacting proteins, 5 effectors and 10 downstream target genes. We confirmed that Ccl-2, Cxcl-10, TLR2 and TLR9 proteins were expressed in brain tissue, a finding consistent with our observations of mRNA expression. Conclusion: The results demonstrate that TBI can increase gene expression in TLR-mediated pathways. PROG does not down-regulate the increased TLRs or their adaptor proteins in traumatically injured brain. Reduction of the observed inflammatory cytokines by PROG does not appear to be the result of inhibiting TLRs or their adaptors in the acute stage of TBI.	[Hua, Fang; Wang, Jun; Ishrat, Tauheed; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Sch Med, Atlanta, GA 30322 USA; [Wei, Wenjing] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA		Hua, F (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, Sch Med, 1365B Clifton Rd, Atlanta, GA 30322 USA.	fhua2@emory.edu	Stein, Donald/AAJ-5139-2020		AHA National Program SDG [0830481N]; Emory University URC [2009-002]; Department of Pediatric Cardiovascular Surgery at the Children's Hospital of Atlanta; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS048451, 1R01HD061971]; Emory Biomarker Service Center; Neuronal Imaging Core of the Emory Neuroscience NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS055077]; BHR Pharma; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS055077, R01NS048451] Funding Source: NIH RePORTER	This work was supported by AHA National Program SDG 0830481N to FH, Emory University URC Grant (2009-002) to FH, research funding from the Department of Pediatric Cardiovascular Surgery at the Children's Hospital of Atlanta and NIH 5R01NS048451 and 1R01HD061971 to DGS. This research was also supported in part by the Emory Biomarker Service Center and the Neuronal Imaging Core of the Emory Neuroscience NINDS core facilities grant (P30NS055077). A portion of this research was supported by a gift from BHR Pharma.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; Brightbill HD, 2000, IMMUNOLOGY, V101, P1, DOI 10.1046/j.1365-2567.2000.00093.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Chase MA, 2007, J IMMUNOL, V179, P6318, DOI 10.4049/jimmunol.179.9.6318; Chen G, 2008, J SURG RES, V147, P92, DOI 10.1016/j.jss.2007.05.029; Crack PJ, 2007, IMMUNOL CELL BIOL, V85, P476, DOI 10.1038/sj.icb.7100103; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Feng D, 2007, J INT MED RES, V35, P644, DOI 10.1177/147323000703500509; Gao Y, 2009, BIOMED PHARMACOTHER, V63, P442, DOI 10.1016/j.biopha.2008.06.028; Harburger LL, 2009, NEUROSCIENCE, V160, P6, DOI 10.1016/j.neuroscience.2009.02.024; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hua F, 2007, J NEUROIMMUNOL, V190, P101, DOI 10.1016/j.jneuroim.2007.08.014; Hua F, 2009, BRAIN RES, V1262, P100, DOI 10.1016/j.brainres.2009.01.018; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Jenkins KA, 2010, CYTOKINE, V49, P237, DOI 10.1016/j.cyto.2009.01.009; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kimoto M, 2003, SCAND J INFECT DIS, V35, P568, DOI 10.1080/00365540310015700; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; Letiembre M, 2009, NEUROBIOL AGING, V30, P759, DOI 10.1016/j.neurobiolaging.2007.08.018; Marsh BJ, 2009, NEUROSCIENCE, V158, P1007, DOI 10.1016/j.neuroscience.2008.07.067; Mishra BB, 2006, J NEUROIMMUNOL, V181, P46, DOI 10.1016/j.jneuroim.2006.07.019; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Naert G, 2009, J INNATE IMMUN, V1, P480, DOI 10.1159/000225990; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Prat A, 2005, CURR OPIN NEUROL, V18, P225, DOI 10.1097/01.wco.0000169737.99040.31; Rohe HJ, 2009, PHARMACOL THERAPEUT, V121, P14, DOI 10.1016/j.pharmthera.2008.09.006; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shimada M, 2008, DEVELOPMENT, V135, P2001, DOI 10.1242/dev.020461; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Stevens SL, 2008, J CEREBR BLOOD F MET, V28, P1040, DOI 10.1038/sj.jcbfm.9600606; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Wang JY, 2007, INT J IMMUNOGENET, V34, P407, DOI 10.1111/j.1744-313X.2007.00711.x; Wright DW, 2008, BRAIN INJURY, V22, P107, DOI 10.1080/02699050701867399; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	64	66	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAY 8	2011	8								42	10.1186/1742-2094-8-42			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	767MH	WOS:000290860200001	21549006	gold, Green Published			2022-02-06	
J	Beauchamp, MH; Ditchfield, M; Maller, JJ; Catroppa, C; Godfrey, C; Rosenfeld, JV; Kean, MJ; Anderson, VA				Beauchamp, M. H.; Ditchfield, M.; Maller, J. J.; Catroppa, C.; Godfrey, C.; Rosenfeld, J. V.; Kean, M. J.; Anderson, V. A.			Hippocampus, amygdala and global brain changes 10 years after childhood traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Brain injury; MRI; Hippocampus; Amygdala; Morphometry; Children	CLOSED-HEAD-INJURY; DIFFUSION-TENSOR; QUANTITATIVE-ANALYSIS; LONGITUDINAL CHANGES; MAJOR DEPRESSION; CORPUS-CALLOSUM; MEMORY FUNCTION; CHILDREN; ATROPHY; MRI	Traumatic brain injury (TBI) in children results in damage to the developing brain, particularly in severely injured individuals. Little is known, however, of the long-term structural aspects of the brain following childhood TBI. This study investigated the integrity of the brain 10 years post-TBI using magnetic resonance imaging volumetrics in a sample of 49 participants with mild, moderate and severe TB!, evaluated against a normative sample of 20 individuals from a pediatric database with comparable age and gender distribution. Structural integrity was investigated in gray and white matter, and by manually segmenting two regions of interest (hippocampus, amygdala), potentially vulnerable to the effects of childhood TBI. The results indicate that more severe injuries caused a reduction in gray and white brain matter, while all TBI severity levels resulted in increased volumes of cerebrospinal fluid and smaller hippocampal volumes. In addition, enlarged amygdala volumes were detected in severely injured patients compared to their mild and moderate counterparts, suggesting that childhood TBI may disrupt the development of certain brain regions through diffuse pathological changes. The findings highlight the lasting impact of childhood TBI on the brain and the importance of monitoring brain structure in the long-term after early injury. (C) 2010 ISDN. Published by Elsevier Ltd. All rights reserved.	[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Beauchamp, M. H.; Ditchfield, M.; Catroppa, C.; Godfrey, C.; Kean, M. J.; Anderson, V. A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Ditchfield, M.] Monash Univ, Dept Med, Clayton, Vic 3800, Australia; [Ditchfield, M.] Monash Med Ctr, Melbourne, Vic, Australia; [Maller, J. J.] Monash Univ, Alfred Psychiat Res Ctr, Clayton, Vic 3800, Australia; [Catroppa, C.; Anderson, V. A.] Univ Melbourne, Melbourne, Vic 3010, Australia; [Catroppa, C.; Kean, M. J.; Anderson, V. A.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosenfeld, J. V.] Monash Univ, Dept Surg, Clayton, Vic 3800, Australia; [Rosenfeld, J. V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia		Anderson, VA (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Rosenfeld, Jeffrey V/B-7249-2011; Maller, Jerome J/H-4963-2014; Catroppa, Cathy/AAX-9458-2021	Maller, Jerome J/0000-0003-4685-1508; Catroppa, Cathy/0000-0002-9750-0436	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [284518]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Thrasher Research Fund; Lynne Quayle Charitable Fund; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-HD02-3343, N01-MH9-0002, N01-NS-9-2314, -2315, -2316, -2317, -2319, -2320]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [N01HD023343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [N01MH090002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER	This work was supported by the National Health and Medical Research Council (project grant no. 284518) and by the Canadian Institutes of Health Research, Thrasher Research Fund, and Lynne Quayle Charitable Fund (MHB). The funding sources were not involved in the study design, collection, analysis or interpretation of data or writing of the manuscript.; Comparison group data used in the preparation of this article were obtained from the Pediatric MRI Data Repository (third release, 10/2009) created by the NIH MRI Study of Normal Brain Development. This is a multi-site, longitudinal study of typically developing children, from ages newborn through young adulthood, conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01-HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://www.bic.mni.mcgill.ca/nihpd/info/participating_centers.html.	Adolphs R, 2006, BRAIN RES, V1079, P25, DOI 10.1016/j.brainres.2005.12.127; Adolphs R, 2003, ANN NY ACAD SCI, V985, P326; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Brierley B, 2002, BRAIN RES REV, V39, P84, DOI 10.1016/S0165-0173(02)00160-1; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; COFFEY CE, 1991, PSYCHOPATHOLOGY BRAI; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Daniel A., 1983, POWER PRIVILEGE PRES; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DUVERNOY H, 1998, HUMAN HIPPOCAMPUS AT; Duvernoy HM., 1998, HUMAN HIPPOCAMPUS FU; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Frodl T, 2003, BIOL PSYCHIAT, V53, P338, DOI 10.1016/S0006-3223(02)01474-9; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Hajek T, 2009, J AFFECT DISORDERS, V115, P395, DOI 10.1016/j.jad.2008.10.007; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Howard MA, 2000, NEUROREPORT, V11, P2931, DOI 10.1097/00001756-200009110-00020; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Lange C, 2004, PSYCHOL MED, V34, P1059, DOI 10.1017/S0033291703001806; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2007, PSYCHIAT RES-NEUROIM, V156, P185, DOI 10.1016/j.pscychresns.2007.06.005; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sisk CL, 2004, NAT NEUROSCI, V7, P1040, DOI 10.1038/nn1326; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tottenham N, 2010, DEVELOPMENTAL SCI, V13, P46, DOI 10.1111/j.1467-7687.2009.00852.x; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Verger K, 2001, BRAIN INJURY, V15, P211; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P1521, DOI 10.1001/archneur.1997.00550240071015; Weniger G, 2006, J AFFECT DISORDERS, V94, P219, DOI 10.1016/j.jad.2006.04.017; Whitford TJ, 2007, HUM BRAIN MAPP, V28, P228, DOI 10.1002/hbm.20273; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	61	64	65	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	2011	29	2					137	143		10.1016/j.ijdevneu.2010.12.003			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	735IT	WOS:000288408200005	21147212				2022-02-06	
J	Wells, TS; Miller, SC; Adler, AB; Engel, CC; Smith, TC; Fairbank, JA				Wells, Timothy S.; Miller, Shannon C.; Adler, Amy B.; Engel, Charles C.; Smith, Tyler C.; Fairbank, John A.			Mental health impact of the Iraq and Afghanistan conflicts: A review of US research, service provision, and programmatic responses	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NATIONAL-GUARD SOLDIERS; D-CYCLOSERINE; WAR VETERANS; PRIMARY-CARE; LONGITUDINAL ASSESSMENT; MILITARY PERSONNEL; GENDER-DIFFERENCES; EXPOSURE THERAPY	Although documentation that war inflicts psychological casualties dates back to the American Civil War and earlier, most research began after the Vietnam conflict, when studies focused on post-traumatic stress disorder (PTSD). With ongoing conflicts in Iraq and Afghanistan, there has been significant research to illuminate the epidemiology of war-related psychological casualties. Significant findings include an appreciation for the role combat plays in the development of mental disorders, including PTSD and traumatic brain injury (TBI). Recent research has endeavoured to understand and improve psychological resilience to temper potentially adverse mental health effects of military service in the theatre of combat operations. Over 2 million US service members have now deployed and returned over 3 million times to the Iraq and Afghanistan conflicts. Mental health providers in the Departments of Defense and Veterans Affairs healthcare systems have consequently observed steep increases in mental health service use among these personnel. The Departments have responded aggressively to bolster staffing levels, increase capacity, improve available services, and anticipate future needs. Scientists and clinicians continue efforts to understand the determinants, prevention, recognition, and treatment of combat-related mental disorders.	[Wells, Timothy S.; Smith, Tyler C.] USN, Ctr Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92106 USA; [Miller, Shannon C.] USAF, Vulnerabil Anal Branch, Res Lab, Wright Patterson AFB, OH 45433 USA; [Miller, Shannon C.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; [Miller, Shannon C.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA; [Adler, Amy B.] USA, Med Res Unit Europe, Walter Reed Army Inst Res, Heidelberg, Germany; [Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD USA; [Engel, Charles C.] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Deployment Hlth Clin Ctr, Washington, DC 20307 USA; [Fairbank, John A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Fairbank, John A.] Mid Atlantic VISN 6 Mental Illness Res Educ & Cli, Durham, NC USA		Wells, TS (corresponding author), USN, Ctr Deployment Hlth Res, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	timothy.wells@med.navy.mil	Fairbank, John/F-8972-2013	Fairbank, John/0000-0003-2604-7256; Engel, Charles/0000-0002-9232-3389			ADLER AB, 2007, BATTL TRAIN SYST SUP; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; *ASS SECR DEF HLTH, 2010, MENT HLTH ASS MEMB A; BILMES LJ, 2010, TRUE COST WAR; Bliese P.D., 2011, DEPLOYMENT PSYCHOL E, P103; Bliese P.D., 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; BLIESE PD, 2006, MILITARY LIFE PSYCHO, V2, P213; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804; Bowles SV, 2010, MIL MED, V175, P382, DOI 10.7205/MILMED-D-10-00099; Britt TW, 2004, MIL MED, V169, P541, DOI 10.7205/MILMED.169.7.541; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Casey GW, 2011, AM PSYCHOL, V66, P1, DOI 10.1037/a0021930; Chwastiak LA, 2010, PSYCHOSOM MED, V72, P817, DOI 10.1097/PSY.0b013e3181eb33e9; Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420; COZZA SJ, 2005, PTSD RES Q, V16, P1; *DEP VET AFF, 2010, MENT HLTH EFF SERV A; Dickstein BD, 2010, MIL MED, V175, P482, DOI 10.7205/MILMED-D-09-00178; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Engel CC, 2005, GEN HOSP PSYCHIAT, V27, P158, DOI 10.1016/j.genhosppsych.2005.01.001; ENGEL CC, 2009, S 6 TEL MENT HLTH RE; Engel CC, 2008, MIL MED, V173, P935, DOI 10.7205/MILMED.173.10.935; Felker B, 2008, MIL MED, V173, P155, DOI 10.7205/MILMED.173.2.155; French LM, 2009, J HEAD TRAUMA REHAB, V24, P1, DOI 10.1097/HTR.0b013e318197a14c; Gillham JE, 2007, J CONSULT CLIN PSYCH, V75, P9, DOI 10.1037/0022-006x.75.1.9; GIWERTZ AH, 2010, J CONSULT CLIN PSYCH, V78, P599; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guastella AJ, 2008, BIOL PSYCHIAT, V63, P544, DOI 10.1016/j.biopsych.2007.11.011; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69315-X; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; INSEL TR, 2010, RES ACTIVITIES NATL; *IOM, 2010, RET HOM IR AFGH PREL, P94; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jacobson IG, 2009, AM J EPIDEMIOL, V169, P415, DOI 10.1093/aje/kwn366; Kang H., 2008, ANAL VA HLTH CARE UT; Kang HK, 2009, J OCCUP ENVIRON MED, V51, P401, DOI 10.1097/JOM.0b013e3181a2feeb; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Kline A, 2010, AM J PUBLIC HEALTH, V100, P276, DOI 10.2105/AJPH.2009.162925; Kulka RA, 1990, TRAUMA VIETNAM WAR G; LeardMann CA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-437; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; LEEDHAM CS, 1993, MIL MED, V158, P508, DOI 10.1093/milmed/158.8.508; Lester PB, 2011, AM PSYCHOL, V66, P77, DOI 10.1037/a0022083; Litz BT, 2007, AM J PSYCHIAT, V164, P1676, DOI 10.1176/appi.ajp.2007.06122057; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; MAGUEN S, 2006, MILITARY LIFE PSYCHO, V2, P141; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Maguen S, 2010, J TRAUMA STRESS, V23, P86, DOI 10.1002/jts.20434; MANSFIELD AJ, 2010, ANN M SOC EP RES SEA; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; McHugh RK, 2010, AM PSYCHOL, V65, P73, DOI 10.1037/a0018121; *MHAT 2, 2005, OP IR FREED OIF 2 ME; *MHAT 5, 2008, MENT HLTH ADV TEAM M; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MUNSEY C, 2009, MONITOR PSYCHOL, V40, P13; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ouimette P., 2010, MEASURING PTSD COURS, V16, P19, DOI DOI 10.1177/1534765610368570; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Rundell JR, 2006, GEN HOSP PSYCHIAT, V28, P352, DOI 10.1016/j.genhosppsych.2006.04.006; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; SCHWAB KA, 2003, ENCY NEUROLOGICAL SC, P438; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stiglitz J.E., 2008, 3 TRILLION DOLLAR WA; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; THOMAS JL, 2007, 2007 AM PSYCH ASS AN; Unutzer J, 2002, PSYCHIATR SERV, V53, P671, DOI 10.1176/appi.ps.53.6.671; *USA, 2008, REP SURG GEN TRAUM B; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P603, DOI 10.1001/archpsyc.62.6.603; Warner CH, 2011, DEPLOYMENT PSYCHOL E, P35, DOI DOI 10.1037/12300-002; WEATHERS R, 2009, EFFECTIVE TREATMENTS, P23; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432; Wojcik BE, 2009, MIL MED, V174, P1010, DOI 10.7205/MILMED-D-01-6108; Zeiss AM, 2008, J CLIN PSYCHOL MED S, V15, P73, DOI 10.1007/s10880-008-9100-4; 2010, MED SURVEILLANCE MON, V17, P18	91	64	65	0	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0954-0261	1369-1627		INT REV PSYCHIATR	Int. Rev. Psych.		2011	23	2					144	152		10.3109/09540261.2011.558833			9	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	755PO	WOS:000289946800004	21521083				2022-02-06	
J	Kline, AE; McAloon, RL; Henderson, KA; Bansal, UK; Ganti, BM; Ahmed, RH; Gibbs, RB; Sozda, CN				Kline, Anthony E.; McAloon, Rose L.; Henderson, Kate A.; Bansal, Utsav K.; Ganti, Bhaskar M.; Ahmed, Rashid H.; Gibbs, Robert B.; Sozda, Christopher N.			Evaluation of a Combined Therapeutic Regimen of 8-OH-DPAT and Environmental Enrichment after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						beam-walking; behavior; controlled cortical impact; ChAT; 5-HT1A receptor agonist; functional recovery; hippocampus; learning and memory; Morris water maze; traumatic brain injury	RECEPTOR AGONIST 8-OH-DPAT; CONTROLLED CORTICAL IMPACT; FOREBRAIN CHOLINE-ACETYLTRANSFERASE; COGNITIVE DEFICITS; GROWTH-FACTOR; MODERATE HYPOTHERMIA; UNITED-STATES; NEUROBEHAVIORAL BENEFIT; CONTUSION INJURY; CLINICAL-TRIALS	When provided individually, both the serotonin (5-HT1A)-receptor agonist 8-hydroxy-2-(di-n-propylamino)te-tralin (8-OH-DPAT) and environmental enrichment (EE) enhance behavioral outcome and reduce histopathology after experimental traumatic brain injury (TBI). The aim of this study was to determine whether combining these therapies would yield greater benefit than either used alone. Anesthetized adult male rats received a cortical impact or sham injury and then were randomly assigned to enriched or standard (STD) housing, where either 8-OH-DPAT (0.1 mg/kg) or vehicle (1.0 mL/kg) was administered intraperitoneally once daily for 3 weeks. Motor and cognitive assessments were conducted on post-injury days 1-5 and 14-19, respectively. CA1/CA3 neurons and choline acetyltransferase-positive (ChAT(+)) medial septal cells were quantified at 3 weeks. 8-OH-DPAT and EE attenuated CA3 and ChAT(+) cell loss. Both therapies also enhanced motor recovery, acquisition of spatial learning, and memory retention, as verified by reduced times to traverse the beam and to locate an escape platform in the water maze, and a greater percentage of time spent searching in the target quadrant during a probe trial in the TBI+STD+8-OH-DPAT, TBI+EE+8-OH-DPAT, and TBI+EE+vehicle groups versus the TBI+STD+vehicle group (p <= 0.0016). No statistical distinctions were revealed between the TBI+EE+8-OH-DPAT and TBI+EE+vehicle groups in functional outcome or CA1/CA3 cell survival, but there were significantly more ChAT(+) cells in the former (p=0.003). These data suggest that a combined therapeutic regimen of 8-OH-DPAT and EE reduces TBI-induced ChAT(+) cell loss, but does not enhance hippocampal cell survival or neurobehavioral performance beyond that of either treatment alone. The findings underscore the complexity of combinational therapies and of elucidating potential targets for TBI.	[Kline, Anthony E.; McAloon, Rose L.; Henderson, Kate A.; Bansal, Utsav K.; Ganti, Bhaskar M.; Ahmed, Rashid H.; Sozda, Christopher N.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants HD046700 and NS060005, awarded to A.E.K.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon C. Edward, 2009, P385, DOI 10.1007/978-1-60327-185-1_33; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujii T, 1997, BRAIN RES, V761, P244, DOI 10.1016/S0006-8993(97)00325-9; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Gibbs RB, 2002, HORM BEHAV, V42, P245, DOI 10.1006/hbeh.2002.1825; Gibbs RB, 2000, NEUROSCIENCE, V101, P931, DOI 10.1016/S0306-4522(00)00433-4; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Johnson DA, 2002, BRAIN RES, V943, P132, DOI 10.1016/S0006-8993(02)02623-9; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; Lanari A, 2006, MECH AGEING DEV, V127, P158, DOI 10.1016/j.mad.2005.09.016; Lazaris A, 2003, BRAIN RES, V967, P181, DOI 10.1016/S0006-8993(02)04272-5; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Menku A, 2003, NEUROSURG REV, V26, P288, DOI 10.1007/s10143-003-0277-6; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mufson Elliott J, 2008, Expert Rev Neurother, V8, P1703, DOI 10.1586/14737175.8.11.1703; National Research Council, 1996, GUID CAR US LAB AN; Oosterink BJ, 2003, NEUROREPORT, V14, P57, DOI 10.1097/00001756-200301200-00011; Paban V, 2005, NEUROSCIENCE, V132, P13, DOI 10.1016/j.neuroscience.2004.11.024; PARK GAS, 1992, NEUROSCI LETT, V143, P259, DOI 10.1016/0304-3940(92)90278-F; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Roloff EV, 1999, CELL MOL LIFE SCI, V55, P601, DOI 10.1007/s000180050318; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Row BW, 2007, BEHAV BRAIN RES, V177, P308, DOI 10.1016/j.bbr.2006.11.028; RYLETT RJ, 1993, PROG BRAIN RES, V98, P161; Sarter M, 2003, NEUROBIOL LEARN MEM, V80, P245, DOI 10.1016/S1074-7427(03)00070-4; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Segovia G, 2009, J NEURAL TRANSM, V116, P1007, DOI 10.1007/s00702-009-0214-0; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; WU DH, 1994, J NEUROCHEM, V62, P1653; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	91	64	65	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2021	2032		10.1089/neu.2010.1535			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500009	21028935	Green Published			2022-02-06	
J	Tin, ST; Woodward, A; Ameratunga, S				Tin, Sandar Tin; Woodward, Alistair; Ameratunga, Shanthi			Injuries to pedal cyclists on New Zealand roads, 1988-2007	BMC PUBLIC HEALTH			English	Article							PUBLIC HOSPITAL DISCHARGES; BICYCLISTS; TRAUMA; WALKING; SCHOOL; ENVIRONMENT; FATALITIES; SEVERITY; ACCURACY; CHILDREN	Background: The risk of injury is one of the major barriers to engaging in cycling. We investigated exposure-based rates and profiles of traffic injuries sustained by pedal cyclists that resulted in death or hospital inpatient treatment in New Zealand, one of the most car dependent countries. Methods: Pedal cyclist traffic injuries were identified from the Mortality Collection and the National Minimum Dataset. Total time spent cycling was used as the measure of exposure and computed from National Household Travel Surveys. Analyses were undertaken for the periods 1988-91, 1996-99 and 2003-07 in relation to other major road users and by age, gender and body region affected. A modified Barell matrix was used to characterise the profiles of pedal cyclist injuries by body region affected and nature of injury. Results: Cyclists had the second highest rate of traffic injuries compared to other major road user categories and the rate increased from 1996-99 to 2003-07. During 2003-07, 31 injuries occurred per million hours spent cycling. Non-collision crashes (40%) and collisions with a car, pick-up truck or van (26%) accounted for two thirds of the cycling injuries. Children and adolescents aged under 15 years were at the highest risk, particularly of non-collision crashes. The rate of traumatic brain injuries fell from 1988-91 to 1996-99; however, injuries to other body parts increased steadily. Traumatic brain injuries were most common in collision cases whereas upper extremity fractures were most common in other crashes. Conclusions: The burden of fatal and hospitalised injuries among pedal cyclists is considerable and has been increasing over the last decade. This underscores the development of road safety and injury prevention programmes for cyclists alongside the cycling promotion strategies.	[Tin, Sandar Tin; Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand		Tin, ST (corresponding author), Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand.	s.tintin@auckland.ac.nz	Tin, Sandar Tin/I-6392-2019	Tin, Sandar Tin/0000-0002-7303-061X; Ameratunga, Shanthi/0000-0001-8042-2251; Woodward, Alistair/0000-0001-5425-6018			Aharonson-Daniel L, 2005, INJURY PREV, V11, P197, DOI 10.1136/ip.2005.008227; Aharonson-Daniel L, 2003, INJURY PREV, V9, P156, DOI 10.1136/ip.9.2.156; AHARONSONDANIEL L, 2003, P INT COLL EFF INJ S, V4, P1026; Ahlbom A, 1993, BIOSTATISTICS EPIDEM; [Anonymous], INT CLASSIFICATION D; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bostrom L, 2001, J TRAUMA, V50, P900, DOI 10.1097/00005373-200105000-00021; Cavill N., 2007, CYCLING HLTH WHATS E; Civil I, 2003, INJURY, V34, P740, DOI 10.1016/j.injury.2003.08.013; Clark DE, 2006, INJURY PREV, V12, P111, DOI 10.1136/ip.2005.010058; *COMM MED ASP AUT, 1971, JAMA-J AM MED ASSOC, V215, P277; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cryer C, 2008, DEV INDICATORS INJUR; *CTC, 1997, BARR CYCL PERSP EX P; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Davie G, 2008, INJURY PREV, V14, P319, DOI 10.1136/ip.2007.017954; Davison K. K., 2008, Preventing Chronic Disease, V5, pA100; DOW N, 2001, TRENDS CYCLIST INJUR; GILBERT K, 1994, BRIT MED J, V308, P1534, DOI 10.1136/bmj.308.6943.1534; HAWLEY DA, 1995, J FORENSIC SCI, V40, P205; Jacobsen PL, 2015, INJURY PREV, V21, P271, DOI 10.1136/ip.9.3.205rep; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Johansson LA, 2002, J EPIDEMIOL COMMUN H, V56, P301, DOI 10.1136/jech.56.4.301; Kearns RA, 2003, AREA, V35, P285, DOI 10.1111/1475-4762.00177; Kerr J, 2006, MED SCI SPORT EXER, V38, P787, DOI 10.1249/01.mss.0000210208.63565.73; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Langley J, 2002, INJ PREV, V8, P332, DOI 10.1136/ip.8.4.332; Langley JD, 2003, INJURY PREV, V9, P376, DOI 10.1136/ip.9.4.376; LANGLEY JD, 1995, METHOD INFORM MED, V34, P340; LANGLOIS JA, 1995, INT J EPIDEMIOL, V24, P136, DOI 10.1093/ije/24.1.136; Meuleners LB, 2007, ACCIDENT ANAL PREV, V39, P1222, DOI 10.1016/j.aap.2007.03.006; *MIN TRANSP, 2010, COMP TRAV MOD HOUS T; *MIN TRANSP, 1999, DUTCH BIC MAST PLAN; *MIN TRANSP, 2010, DRIV TRAV CARS VANS; *MIN TRANSP, 2007, SUST SAF LAND TRANSP; *MIN TRANSP, 2009, CYCL CRASH FACT SHEE; Ministry of Transport, 2000, NZ TRAV TRENDS NZ HO, P1989; Ministry of Transport, 2010, SAF JOURN NZ ROAD SA, P3; Missoni E, 2003, CROAT MED J, V44, P610; *NZ TRANSP AG, 2008, CYCL SKILLS TRAIN GU; OFALLEN C, 2007, 338 LAND TRANSP NZ; OFALLEN C, 2001, WALKING SCH BUS NETW; OSTROM M, 1993, INT J EPIDEMIOL, V22, P483, DOI 10.1093/ije/22.3.483; PEARCE L, 1998, CYCLING HLTH NATION; Richter M, 2007, J TRAUMA, V62, P1118, DOI 10.1097/01.ta.0000221060.78894.cb; ROWE BH, 1995, CAN MED ASSOC J, V152, P45; SCOTT D, 2005, INJURY B, V86; Sport and Recreation New Zealand, 2008, SPORT RECR PHYS ACT; *SPORT RECR NZ, 2007, SPARC FACTS 97 01; Stutts JC, 1999, ACCIDENT ANAL PREV, V31, P505, DOI 10.1016/S0001-4575(99)00007-X; Timperio A, 2004, PREV MED, V38, P39, DOI 10.1016/j.ypmed.2003.09.026; Tin ST, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-64; Wardlaw M, 2002, TRAFFIC ENG CONTR, V43, P420; Wen LM, 2008, HEALTH EDUC RES, V23, P325, DOI 10.1093/her/cym043; Zavoski R, 1995, Conn Med, V59, P3; NZ MOTOR VEHICLE REG; NZ BICYCLE IMPORT ST; [No title captured]; NZ HOUSEHOLD TRAVEL	59	64	64	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	OCT 30	2010	10								655	10.1186/1471-2458-10-655			10	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	683FT	WOS:000284458200001	21034490	Green Published, gold			2022-02-06	
J	Pietrzak, RH; Goldstein, MB; Malley, JC; Rivers, AJ; Johnson, DC; Morgan, CA; Southwick, SM				Pietrzak, Robert H.; Goldstein, Marc B.; Malley, James C.; Rivers, Alison J.; Johnson, Douglas C.; Morgan, Charles A., III; Southwick, Steven M.			Posttraumatic growth in Veterans of Operations Enduring Freedom and Iraqi Freedom	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Posttraumatic stress disorder; Trauma; Posttraumatic growth; Veterans; Social support; Psychosocial; Resilience	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; STRESS-DISORDER; SOCIAL SUPPORT; RESILIENCE INVENTORY; DEPLOYMENT RISK; POSITIVE CHANGE; WAR; SYMPTOMS; SOLDIERS	Objective: A growing body of research has examined the prevalence and correlates of psychopathology, mild traumatic brain injury, and related problems in Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF-OIF). While these studies help characterize the deleterious effects of combat, no known study has examined factors that may enhance posttraumatic growth or positive changes experienced as a result of combat in this population. Method: A total of 272 predominantly older Reservist/National Guard OEF-OIF Veterans completed an anonymous mail survey that assessed combat exposure, psychopathology, psychosocial functioning, social support, and posttraumatic growth. Results: Seventy-two percent of the sample endorsed a significant degree of posttraumatic growth in at least one of the areas assessed, the most common of which were changing priorities about what is important in life (52.2%), being able to better appreciate each day (51.1%), and being better able to handle difficulties (48.5%). Hierarchical regression analysis revealed that younger age, greater posttraumatic stress disorder (PTSD) symptoms, and increased perceptions of unit member support and effort/perseverance were significantly associated with posttraumatic growth. Respondents with PTSD scored higher on an overall measure of posttraumatic growth and on items reflecting appreciation of life and personal strength. Limitations: This study is limited by a relatively low survey return rate and employment of an abbreviated measure of posttraumatic growth. Conclusions: Results of this study suggest that interventions to bolster unit member support and to enhance perceptions of effort and perseverance may help promote posttraumatic growth in OEF-OIF Veterans. (C) 2010 Elsevier B.V. All rights reserved.	[Pietrzak, Robert H.; Rivers, Alison J.; Morgan, Charles A., III; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Rivers, Alison J.; Morgan, Charles A., III; Southwick, Steven M.] VA Connecticut Healthcare Syst, Resilience Lab, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA; [Goldstein, Marc B.] Cent Connecticut State Univ, Dept Psychol, New Britain, CT 06050 USA; [Malley, James C.] Cent Connecticut State Univ, Dept Counseling & Family Therapy, New Britain, CT 06050 USA; [Johnson, Douglas C.] Univ Calif San Diego, Sch Med, Naval Hlth Res Ctr, San Diego, CA 92103 USA; [Johnson, Douglas C.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA		Pietrzak, RH (corresponding author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave 151E, West Haven, CT 06516 USA.	robert.pietrzak@yale.edu			State of Connecticut; Department of Mental Health and Addiction Services; National Center for PTSD	We thank the veterans who participated in this survey. We appreciate the assistance of the Center for Public Policy and Social Research at Central Connecticut State University and the Connecticut Department of Veterans' Affairs in conducting this research. This work was supported by grants from the State of Connecticut, the Department of Mental Health and Addiction Services, the National Center for PTSD, and a private gift.	ALDWIN CM, 1994, PSYCHOL AGING, V9, P34, DOI 10.1037/0882-7974.9.1.34; Bellizzi KM, 2006, HEALTH PSYCHOL, V25, P47, DOI 10.1037/0278-6133.25.1.47; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cadell S, 2003, AM J ORTHOPSYCHIAT, V73, P281, DOI 10.1037/0002-9432.73.3.279; Calhoun LG, 2000, J TRAUMA STRESS, V13, P521, DOI 10.1023/A:1007745627077; Cieslak R, 2009, ANXIETY STRESS COPIN, V22, P449, DOI 10.1080/10615800802403815; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Dekel R, 2009, HEALTH SOC WORK, V34, P87, DOI 10.1093/hsw/34.2.87; Dirik G, 2008, J CLIN PSYCHOL MED S, V15, P193, DOI 10.1007/s10880-008-9115-x; Duckworth AL, 2005, ANNU REV CLIN PSYCHO, V1, P629, DOI 10.1146/annurev.clinpsy.1.102803.144154; ELDER GH, 1989, J PERS, V57, P311, DOI 10.1111/j.1467-6494.1989.tb00485.x; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fava GA, 2005, PSYCHOTHER PSYCHOSOM, V74, P26, DOI 10.1159/000082023; Feder A, 2008, PSYCHIATRY, V71, P359, DOI 10.1521/psyc.2008.71.4.359; Fontana A, 1998, J TRAUMA STRESS, V11, P485, DOI 10.1023/A:1024452612412; Forstmeier S, 2009, AM J GERIAT PSYCHIAT, V17, P1030, DOI 10.1097/JGP.0b013e3181ab8b36; Gangstad B, 2009, REHABIL PSYCHOL, V54, P69, DOI 10.1037/a0014639; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Levine SZ, 2009, J TRAUMA STRESS, V22, P282, DOI 10.1002/jts.20409; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; McCaslin SE, 2009, J TRAUMA STRESS, V22, P334, DOI 10.1002/jts.20426; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Park CL, 1996, J PERS, V64, P71, DOI 10.1111/j.1467-6494.1996.tb00815.x; Park CL, 2008, AM J ORTHOPSYCHIAT, V78, P300, DOI 10.1037/a0014054; Peterson C, 2008, J TRAUMA STRESS, V21, P214, DOI 10.1002/jts.20332; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Powell S, 2003, J CLIN PSYCHOL, V59, P71, DOI 10.1002/jclp.10117; Rosenbach C, 2008, J BURN CARE RES, V29, P638, DOI 10.1097/BCR.0b013e31817de275; Schorr Y.H., 2002, ANN M INT SOC TRAUM; Schroevers MJ, 2010, PSYCHO-ONCOLOGY, V19, P46, DOI 10.1002/pon.1501; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; Solomon Z, 2007, J TRAUMA STRESS, V20, P303, DOI 10.1002/jts.20216; Swickert R, 2009, J HEALTH PSYCHOL, V14, P387, DOI 10.1177/1359105308101677; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers F.W., 1991, PTSD CHECKLIST MILIT; Widows MR, 2005, HEALTH PSYCHOL, V24, P266, DOI 10.1037/0278-6133.24.3.266; Zoellner T, 2006, CLIN PSYCHOL REV, V26, P626, DOI 10.1016/j.cpr.2006.01.008	45	64	66	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	OCT	2010	126	1-2					230	235		10.1016/j.jad.2010.03.021			6	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	658KD	WOS:000282488000029	20399504				2022-02-06	
J	Krahulik, D; Zapletalova, J; Frysak, Z; Vaverka, M				Krahulik, David; Zapletalova, Jirina; Frysak, Zdenek; Vaverka, Miroslav			Dysfunction of hypothalamic-hypophysial axis after traumatic brain injury in adults	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypopituitarism; hypothalamic-hypophysial axis	SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; NATURAL-HISTORY; HYPOPITUITARISM; DEPRESSION; PREVALENCE; RISK	Object. Traumatic brain injury (TBI) is a major cause of serious morbidity and mortality. The incidence is 100-500/100,000 inhabitants/year. Chronic pituitary dysfunction is increasingly recognized after TBI. To define the incidence of endocrine dysfunction and risk factors, the authors describe a prospectively assessed group of patients in whom they documented hormonal functions, early diagnosis, and treatment of neuroendocrine dysfunction after TBI. Methods. Patients aged 18-65 years were prospectively observed from the time of injury to 1 year postinjury; the Glasgow Coma Scale score ranged from 3 to 14. Patients underwent evaluation of hormonal function at the time of injury and at 3, 6, and 12 months postinjury. Magnetic resonance imaging was also conducted at 1 year postinjury. Results. During the study period, 89 patients were observed. The mean age of the patients was 36 years, there were 23 women, and the median Glasgow Coma Scale score was 7. Nineteen patients (21%) had primary hormonal dysfunction. Major deficits included growth hormone dysfunction, hypogonadism, and diabetes insipidus. Patients in whom the deficiency was major had a worse Glasgow Outcome Scale score, and MR imaging demonstrated empty sella syndrome more often than in patients without a deficit. Conclusions. To the authors' knowledge, this is the third largest study of its kind worldwide. The incidence of chronic hypopituitarism after TBI was higher than the authors expected. After TBI, patients are usually observed on the neurological and rehabilitative wards, and endocrine dysfunction can be overlooked. This dysfunction can be life threatening and other clinical symptoms can worsen the neurological deficit, extend the duration of physiotherapy, and lead to mental illness. The authors recommend routine pituitary hormone testing after moderate or severe TBI within 6 months and 1 year of injury. (DOI: 10.3171/2009.10.JNS09930)	[Krahulik, David; Vaverka, Miroslav] Fac Hosp, Neurosurg Clin, Olomouc, Czech Republic; [Zapletalova, Jirina] Fac Hosp, Dept Paediat, Olomouc, Czech Republic; [Frysak, Zdenek] Fac Hosp, Internal Clin 3, Olomouc, Czech Republic		Krahulik, D (corresponding author), IP Pavlova 6, Olomouc 77900, Czech Republic.	david.krahulik@fnol.cz		David, Krahulik/0000-0002-4907-7960			Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1963, SCI BASIS MED ANN, V84, P83; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308	22	64	67	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					581	584		10.3171/2009.10.JNS09930			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100022	19929195				2022-02-06	
J	Zweifel, C; Katan, M; Schuetz, P; Siegemund, M; Morgenthaler, NG; Merlo, A; Mueller, B; Christ-Crain, M				Zweifel, Christian; Katan, Mira; Schuetz, Philipp; Siegemund, Martin; Morgenthaler, Nils G.; Merlo, Adrian; Mueller, Beat; Christ-Crain, Mirjam			Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage	BMC NEUROLOGY			English	Article							CORTICOTROPIN-RELEASING HORMONE; TRAUMATIC BRAIN-INJURY; VASOPRESSIN PRECURSOR; STABLE PEPTIDE; REGULATORY MECHANISMS; ANTIDIURETIC-HORMONE; PROGNOSTIC MARKER; CEREBRAL-ISCHEMIA; GRADING SCALE; V-2 RECEPTORS	Background: Spontaneous intracerebral hemorrhage (ICH) accounts for a high mortality and morbidity. Early prediction of outcome is crucial for optimized care and treatment decision. Copeptin, the C-terminal part of provasopressin, has emerged as a new prognostic marker in a variety of diseases, but its prognostic value in ICH is unknown. Methods: In 40 consecutive patients who were admitted to the hospital within 72 hours after a spontaneous ICH, the plasma copeptin level was measured with a sandwich immunoassay upon admission. The prognostic value of copeptin to predict 30 day mortality and functional outcome after 90 days was assessed. A favorable outcome was defined as a Barthel score above 85 and a score below 3 on the Modified Rankin Scale. Results: Copeptin correlated positively with hematoma volume (r = 0.32, p < 0.05) and negatively with the Glasgow Coma Scale (GCS) on admission (r = -0.35, p < 0.05). Copeptin levels were higher in patients who died within 30 days than in 30-day survivors (179.0 pmol/l (IQR 33.7-566.0) vs. 12.9 pmol/l (IQR 5.2-42.8), p = 0.003). Copeptin levels were also higher in patients with an unfavorable functional outcome at 90 days compared to patients with a favorable outcome (32.4 pmol/l (IQR 9.5-97.8) vs. 11.9 pmol/l (IQR 3.2-19.8), p = 0.04). For the prediction of death, receiver-operating-characteristics analysis revealed an area under the curve (AUC) for copeptin of 0.88 (95% CI 0.75-1.00). The predictive value of the copeptin concentration was thus similar to that of GCS (AUC 0.82 (95% CI 0.59-1.00) p = 0.53), of the ICH Score (AUC 0.89, (95% CI 0.76-1.00), p = 0.94) and the ICH Grading Scale (AUC 0.86 (95% CI 0.69-1.00), p = 0.81). Conclusions: Copeptin is a new prognostic marker in patients with an ICH. If this finding can be confirmed in larger studies, copeptin might be an additional valuable tool for risk stratification and decision-making in the acute phase of ICH.	[Katan, Mira; Schuetz, Philipp; Mueller, Beat; Christ-Crain, Mirjam] Univ Basel Hosp, Dept Endocrinol & Clin Nutr, CH-4031 Basel, Switzerland; [Zweifel, Christian; Merlo, Adrian] Univ Basel Hosp, Dept Neurosurg, CH-4031 Basel, Switzerland; [Katan, Mira] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Siegemund, Martin] Univ Basel Hosp, Dept Anesthesia, Operat Intens Care Unit, CH-4031 Basel, Switzerland; [Morgenthaler, Nils G.] Ctr Biotechnol, BRAHMS Aktiengesell, Dept Res, D-16761 Hennigsdorf, Germany; [Mueller, Beat] Dept Internal Med, CH-5001 Aarau, Switzerland		Christ-Crain, M (corresponding author), Univ Basel Hosp, Dept Endocrinol & Clin Nutr, Petersgraben 4, CH-4031 Basel, Switzerland.	Christ-Crain@unibas.ch	Mueller, Beat/G-2662-2012; Siegemund, Martin/AAM-8929-2020; schuetz, philipp/C-8475-2013	Siegemund, Martin/0000-0002-2013-4140; schuetz, philipp/0000-0001-6400-4949; Christ-Crain, Mirjam/0000-0002-6336-0965; Katan, Mira/0000-0002-9265-8066	Departments of Endocrinology and Neurology of the University Hospital of Basel, Switzerland; University of Basel; Swiss National FoundationSwiss National Science Foundation (SNSF) [PP00P3-123346]	We are grateful to the nurses, ward physicians, and patients who participated in the study, the Departments of Neurosurgery, Neurology, and Anesthesia, the emergency unit. We thank the staff of the central laboratory of the University Hospital Basel, particularly Melanie Wieland and Heike Freidank, for their help and technical support. This study was supported by in-house grants from the Departments of Endocrinology and Neurology of the University Hospital of Basel, Switzerland as well as by a research grant for young scientist from the University of Basel (to MK) and further by research grants from the Swiss National Foundation (PP00P3-123346, to MCC). We thank Dr. Ethan Taub for proof-reading our manuscript.	Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90; Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112; Ariesen MJ, 2005, J NEUROL NEUROSUR PS, V76, P839, DOI 10.1136/jnnp.2004.048223; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Delgado P, 2007, NEUROLOGIA, V22, P448; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad; Fenske W, 2009, J CLIN ENDOCR METAB, V94, P123, DOI 10.1210/jc.2008-1426; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Goldstein LB, 2004, STROKE, V35, P1941, DOI 10.1161/01.STR.0000135225.80898.1c; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Itoi K, 2004, J NEUROENDOCRINOL, V16, P348, DOI 10.1111/j.0953-8194.2004.01172.x; Itoi K, 1998, ENDOCR J, V45, P13, DOI 10.1507/endocrj.45.13; Katan M, 2008, NEUROENDOCRINOL LETT, V29, P341; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Khan SQ, 2007, CIRCULATION, V115, P2103, DOI 10.1161/CIRCULATIONAHA.106.685503; KLEINDIENST A, 2006, ACTA NEUROCHIR SUPP, V221, P224; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; MAHONEY F I, 1965, Md State Med J, V14, P61; Mendelow AD, 2005, LANCET, V365, P387; Molnar AH, 2008, ACTA NEUROCHIR, V150, P265, DOI 10.1007/s00701-007-1400-1; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2008, TRENDS ENDOCRIN MET, V19, P43, DOI 10.1016/j.tem.2007.11.001; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Ranger GS, 2002, INT J CLIN PRACT, V56, P777; RANKIN J, 1957, Scott Med J, V2, P200; Robertson GL, 2001, ENDOCRIN METAB CLIN, V30, P671, DOI 10.1016/S0889-8529(05)70207-3; Ruiz-Sandoval JL, 2007, STROKE, V38, P1641, DOI 10.1161/STROKEAHA.106.478222; Sacco RL, 2006, NAT CLIN PRACT NEURO, V2, P577, DOI 10.1038/ncpneuro0345; Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Xu Miao, 2007, Chin J Traumatol, V10, P90	36	64	66	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	MAY 26	2010	10								34	10.1186/1471-2377-10-34			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	626AZ	WOS:000279939400001	20504314	gold, Green Published			2022-02-06	
J	Beirowski, B; Nogradi, A; Babetto, E; Garcia-Alias, G; Coleman, MP				Beirowski, Bogdan; Nogradi, Antal; Babetto, Elisabetta; Garcia-Alias, Guillermo; Coleman, Michael P.			Mechanisms of Axonal Spheroid Formation in Central Nervous System Wallerian Degeneration	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon; Axonal degeneration; Axonal transport; Neuroaxonal dystrophy; Neurodegeneration; Neuroprotection	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; OPTIC-NERVE; MOUSE MODEL; PERIPHERAL-NERVE; SELF-DESTRUCTION; SODIUM-CHANNELS; CALCIUM INFLUX	Wallerian degeneration of the CNS is accompanied by axonal dystrophy or swelling. To understand the mechanisms by which swellings arise, we studied their spatiotemporal dynamics, ultrastructure, composition, and the conditions that affect their formation in vivo and ex vivo. In contrast to peripheral nerve axons, lesioned optic nerve (ON) axons in vivo developed focal swellings asynchronously within 6 hours, long before there is any axon fragmentation. Axons in ON, spinal cord dorsal column, and corpus callosum all showed marked gradients with more swellings in proximal regions of their distal stumps early after lesion. Time-lapse imaging of a validated ex vivo system showed that multiple focal swellings arise after around 1 hour close to the injury site, followed by anterograde wave-like progression on continuous ON axon stumps. Swellings were largely stable but occasionally seemed to fuse with neighboring swellings. Their ultrastructural appearances resembled disease-associated spheroids. Although accumulation of axonal markers suggested transport deficits, large accumulations of mitochondria were not observed. Early swelling formation was decreased in Wld(S) gene-expressing rodents and by removing extracellular calcium. Several pharmacologic agents that inhibit axon loss in vitro and/or in vivo also prevented early formation of axonal spheroids in acute ON explants. Because axonal swellings are hallmarks of many neurodegenerative conditions, these data suggest that they are a manifestation of Wallerian-like degeneration in some cases. Thus, Wallerian-like degeneration may be a more common component mechanism in CNS diseases than previously thought.	[Beirowski, Bogdan; Babetto, Elisabetta; Coleman, Michael P.] Babraham Inst, Cambridge, England; [Nogradi, Antal] Univ Szeged, Dept Ophthalmol, Neuromorphol Lab, Szeged, Hungary; [Garcia-Alias, Guillermo; Coleman, Michael P.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 1TN, England		Beirowski, B (corresponding author), Washington Univ, Sch Med, Dept Genet, 660 S Euclid Ave, St Louis, MO 63110 USA.	bbeirowski@wustl.edu	Garcia-Alias, Guillermo/AAB-8595-2021; Nogradi, Antal/A-7045-2008	Nogradi, Antal/0000-0002-0520-5350; Babetto, Elisabetta/0000-0002-6385-8288	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF-LPD 9901/8-128]; Wellcome TrustWellcome TrustEuropean Commission [069652/Z/02/Z]	Supported by Biotechnology and Biological Sciences Research Council, Grant No. BMBF-LPD 9901/8-128 from the German Federal Ministry of Education and Research (to B. B.), and Grant No. 069652/Z/02/Z from the Wellcome Trust (to A.N.)	Adalbert R, 2009, BRAIN, V132, P402, DOI 10.1093/brain/awn312; Agrawal SK, 1996, J NEUROSCI, V16, P545; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Beirowski B, 2008, EUR J NEUROSCI, V28, P1166, DOI 10.1111/j.1460-9568.2008.06426.x; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; BUCKMASTER EA, 1995, EUR J NEUROSCI, V7, P1596, DOI 10.1111/j.1460-9568.1995.tb01155.x; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2005, J NEUROL SCI, V233, P133, DOI 10.1016/j.jns.2005.03.028; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Couto LA, 2004, J NEUROSCI RES, V77, P410, DOI 10.1002/jnr.20170; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GEORGE R, 1994, J NEUROCYTOL, V23, P657, DOI 10.1007/BF01181641; Giordana MT, 2002, NEUROPATH APPL NEURO, V28, P35, DOI 10.1046/j.1365-2990.2002.00372.x; Glass JD, 2002, J NEUROL SCI, V196, P9, DOI 10.1016/S0022-510X(02)00013-8; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Irvine KA, 2006, J NEUROIMMUNOL, V175, P69, DOI 10.1016/j.jneuroim.2006.03.002; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; LAWSON LJ, 1994, J NEUROCYTOL, V23, P729, DOI 10.1007/BF01268086; Liberski PP, 1999, ACTA NEUROPATHOL, V97, P329, DOI 10.1007/s004010050995; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Mancardi G, 2001, J NEUROL SCI, V184, P41, DOI 10.1016/S0022-510X(00)00490-1; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCarran WJ, 2007, J NEUROSCI, V27, P4220, DOI 10.1523/JNEUROSCI.5542-06.2007; Medana I, 2001, AM J PATHOL, V159, P809, DOI 10.1016/S0002-9440(10)61755-5; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mi WQ, 2005, BRAIN, V128, P405, DOI 10.1093/brain/awh368; Miller BR, 2009, NAT NEUROSCI, V12, P387, DOI 10.1038/nn.2290; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; Moeller JJ, 2008, ACTA NEUROPATHOL, V116, P331, DOI 10.1007/s00401-008-0362-6; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nishiyama J, 2007, AUTOPHAGY, V3, P591, DOI 10.4161/auto.4964; NIXON RA, 1986, J NEUROSCI, V6, P1252; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ohara S, 2004, EXP NEUROL, V187, P289, DOI 10.1016/j.expneurol.2004.03.002; OKAMOTO K, 1990, ACTA NEUROPATHOL, V80, P222, DOI 10.1007/BF00308929; Ouardouz M, 2003, NEURON, V40, P53, DOI 10.1016/j.neuron.2003.08.016; Oya Y, 1998, ACTA NEUROPATHOL, V96, P29, DOI 10.1007/s004010050857; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1992, EUR J NEUROSCI, V4, P1000, DOI 10.1111/j.1460-9568.1992.tb00126.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Ramaglia V, 2008, AM J PATHOL, V172, P1043, DOI 10.2353/ajpath.2008.070660; Ramon y Cajal, 1928, DEGENERATION REGENER; Ren Y, 2000, J NEUROSCI METH, V102, P165, DOI 10.1016/S0165-0270(00)00304-6; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Sasaki S, 1999, ACTA NEUROPATHOL, V97, P463, DOI 10.1007/s004010051015; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Saxena S, 2007, PROG NEUROBIOL, V83, P174, DOI 10.1016/j.pneurobio.2007.07.007; SCHLAEPFER WW, 1977, BRAIN RES, V136, P1, DOI 10.1016/0006-8993(77)90126-3; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Teng YD, 1997, J NEUROSCI, V17, P4359; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSAO JW, 1994, EUR J NEUROSCI, V6, P516, DOI 10.1111/j.1460-9568.1994.tb00295.x; Tseng KW, 2008, J COMP NEUROL, V507, P1053, DOI 10.1002/cne.21606; Valverde F, 1998, GOLGI ATLAS OF THE POSTNATAL MOUSE BRAIN, P1; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Wirths O, 2007, NEUROBIOL AGING, V28, P1689, DOI 10.1016/j.neurobiolaging.2006.07.021; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Yang Y, 2007, EUR J NEUROSCI, V26, P2979, DOI 10.1111/j.1460-9568.2007.05914.x; Yue ZY, 2008, AUTOPHAGY, V4, P94, DOI 10.4161/auto.5202; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	100	64	65	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2010	69	5					455	472		10.1097/NEN.0b013e3181da84db			18	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	594WV	WOS:000277571500004	20418780	Bronze			2022-02-06	
J	Geary, EK; Kraus, MF; Pliskin, NH; Little, DM				Geary, Elizabeth K.; Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.			Verbal learning differences in chronic mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Diffusion tensor imaging; Single trial learning	POST-CONCUSSIONAL SYNDROME; DIFFUSION-TENSOR; WHITE-MATTER; HEAD-INJURY; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL ASSESSMENT; ECOLOGICAL VALIDITY; SYMPTOMS; DEFICITS; MEMORY	Following mild traumatic brain injury (TBI), a percentage of individuals report chronic memory and attention difficulties. Traditional neuropsychological assessments often fail to find evidence for such complaints. We hypothesized that mild TB! patients may, in fact, experience subtle cognitive deficits that reflect diminished initial acquisition that can be explained by changes in cerebral white matter microstructure. In the data presented here, a sample of nonlitigating and gainfully employed mild TBI patients demonstrated statistically significant differences from age and education matched control participants in performance on the first trial of a verbal learning task. Performance on this trial was associated with reduced fractional anisotropy in the uncinate fasciculus and the superior longitudinal fasciculus providing an anatomical correlate for the cognitive findings. Mild TBI patients were not impaired relative to control participants on total learning or memory composite variables. Performance on the first learning trial was not related to any psychological variables including mood. We concluded that patients with mild TBI demonstrate diminished verbal learning that is not often interpreted in standard neuropsychological assessment. (ENS, 2010, 16, 506-516.)	[Geary, Elizabeth K.; Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL 60612 USA; [Geary, Elizabeth K.; Little, Deborah M.] Univ Illinois, Coll Med, Ctr Stroke Res, Chicago, IL 60612 USA; [Kraus, Marilyn F.; Pliskin, Neil H.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA; [Kraus, Marilyn F.; Pliskin, Neil H.; Little, Deborah M.] Univ Illinois, Coll Med, Ctr Cognit Med, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Anat, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Ophthalmol, Chicago, IL 60612 USA; [Little, Deborah M.] Univ Illinois, Coll Med, Dept Psychol, Chicago, IL 60612 USA		Little, DM (corresponding author), Univ Illinois, Coll Med, Dept Neurol, MC 796,912 S Wood St 855 N, Chicago, IL 60612 USA.	little@uic.edu			NIH, National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH068787]; Marshall Goldberg Traumatic Brain Injury Fund; Department of Defense/Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT 075675]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH068787] Funding Source: NIH RePORTER	This work is supported in part by NIH grant K23 MH068787 from the National Institute of Mental Health (MFK), the Marshall Goldberg Traumatic Brain Injury Fund (DML), and a grant from the Department of Defense/Congressionally Directed Medical Research Program grant PT 075675. The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the University of Illinois at Chicago. Department of Defense, or the National Institute of Mental Health. We thank Dr. Xiaohong Joe Zhou for providing the pulse sequence used to collect the DT1 data.	ANDERSON JR, 1982, PSYCHOL REV, V89, P369, DOI 10.1037/0033-295X.89.4.369; BAUER R, 2003, AMNESIC DISORDERS; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Breier JI, 2008, AM J NEURORADIOL, V29, P483, DOI 10.3174/ajnr.A0846; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chan AS, 2000, SCHIZOPHR RES, V41, P431, DOI 10.1016/S0920-9964(99)00078-X; Cho H, 2008, J KOREAN MED SCI, V23, P477, DOI 10.3346/jkms.2008.23.3.477; Delis D, 2000, CALIFORNIA VERBAL LE; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gold BT, 2007, NEUROPSYCHOLOGIA, V45, P2439, DOI 10.1016/j.neuropsychologia.2007.04.011; Gongvatana A, 2007, J NEUROPSYCH CLIN N, V19, P36, DOI 10.1176/appi.neuropsych.19.1.36; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Ivory SJ, 1999, NEUROPSYCHOLOGIA, V37, P817, DOI 10.1016/S0028-3932(98)00131-6; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; LOGAN GD, 1988, PSYCHOL REV, V95, P492, DOI 10.1037/0033-295X.95.4.492; LUEK SP, 1976, MEM COGNITION, V4, P476, DOI 10.3758/BF03213207; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Poonawalla AH, 2004, J MAGN RESON IMAGING, V19, P489, DOI 10.1002/jmri.20020; Rao SL, 1997, NIMHANS J, V15, P157; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ribeiro F, 2007, J CLIN EXP NEUROPSYC, V29, P187, DOI 10.1080/13803390600629775; Ropper AH., 2005, ADAMS VICTORS PRINCI; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Silverberg ND, 2009, J INT NEUROPSYCH SOC, V15, P94, DOI 10.1017/S1355617708090139; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale TW, 1997, BRIT MED J, V315, P569; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; WILLIAMS CW, 1993, PSYCHOL REP, V72, P483, DOI 10.2466/pr0.1993.72.2.483; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RL, 2009, J HEAD TRAUMA REHAB, V24, P88, DOI 10.1097/HTR.0b013e31819b118a; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	77	64	66	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2010	16	3					506	516		10.1017/S135561771000010X			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	594ZA	WOS:000277579000011	20188015				2022-02-06	
J	Hinton-Bayre, AD				Hinton-Bayre, Anton D.			Deriving Reliable Change Statistics from Test-Retest Normative Data: Comparison of Models and Mathematical Expressions	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Norms; normative studies; Practice effects; reliable change; Statistical methods	SPORT CONCUSSION RESEARCH; CHANGE FORMULA QUERY; NEUROPSYCHOLOGICAL CHANGE; CLINICAL-SIGNIFICANCE; REGRESSION EQUATIONS; CLASSICAL APPROACH; EPILEPSY SURGERY; STANDARD ERROR; TEST-SCORES; JACOBSON	The use of reliable change (RC) statistics to determine whether an individual has significantly improved or deteriorated on retesting is growing rapidly in clinical neuropsychology. This paper demonstrates how with only basic test-retest data and a series of simple expressions, the clinician/researcher can implement the majority of contemporary RC model(s). Though sharing a fundamental structure, RC models vary in how they derive predicted retest scores and standard error terms. Published test-retest normative data and a simple case study are presented to demonstrate how to calculate several well-known RC scores. The paper highlights the circumstances under which models will diverge in the estimation of RC. Most importantly variations in individual's performance relative to controls at initial testing, practice effects, inequality of control variability from test to retest, and degree of reliability will see systematic and predictable disagreement among models. More generally, the limitations and opportunities of RC methodology were discussed. Although a consensus on preferred model continues to be debated, the comparison of RC models in clinical samples is encouraged.	[Hinton-Bayre, Anton D.] Univ Queensland, Sch Med, Princess Alexandra Hosp, Dept Surg, Brisbane, Qld, Australia		Hinton-Bayre, AD (corresponding author), Univ Queensland, Princess Alexandra Hosp, Sch Med, Dept Surg, 199 Ipswich Rd, Woolloongabba, Qld 4102, Australia.	anton.hb@hotmail.com					Abramson IS, 2000, J INT NEUROPSYCH SOC, V6, P365, DOI 10.1017/S1355617700633131; BOYKO EJ, 1990, J CLIN EPIDEMIOL, V43, P851, DOI 10.1016/0895-4356(90)90068-Z; Charter RA, 1996, PERCEPT MOTOR SKILL, V82, P1139, DOI 10.2466/pms.1996.82.3c.1139; Charter RA, 2000, J PSYCHOEDUC ASSESS, V18, P125, DOI 10.1177/073428290001800203; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; CHRISTENSEN L, 1986, BEHAV THER, V17, P305, DOI 10.1016/S0005-7894(86)80060-0; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hinton-Bayre A, 2000, J INT NEUROPSYCH SOC, V6, P362, DOI 10.1017/S1355617700633118; Hinton-Bayre AD, 2005, J INT NEUROPSYCH SOC, V11, P788, DOI 10.1017/S1355617705050940; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Maassen GH, 2006, BRIT J SPORT MED, V40, P829, DOI 10.1136/bjsm.2005.023713; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Maassen GH, 2005, BRIT J SPORT MED, V39, P483, DOI 10.1136/bjsm.2004.015594; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Sherman EMS, 2003, J INT NEUROPSYCH SOC, V9, P879, DOI 10.1017/S1355617703960085; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Temkin NR, 2004, J INT NEUROPSYCH SOC, V10, P899, DOI 10.1017/S1355617704106115; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008	28	64	64	1	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					244	256		10.1093/arclin/acq008			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	587MC	WOS:000276995600010	20197293	Bronze, Green Published			2022-02-06	
J	Halamek, J; Bocharova, V; Chinnapareddy, S; Windmiller, JR; Strack, G; Chuang, MC; Zhou, J; Santhosh, P; Ramirez, GV; Arugula, MA; Wang, J; Katz, E				Halamek, Jan; Bocharova, Vera; Chinnapareddy, Soujanya; Windmiller, Joshua Ray; Strack, Guinevere; Chuang, Min-Chieh; Zhou, Jian; Santhosh, Padmanabhan; Ramirez, Gabriela V.; Arugula, Mary A.; Wang, Joseph; Katz, Evgeny			Multi-enzyme logic network architectures for assessing injuries: digital processing of biomarkers	MOLECULAR BIOSYSTEMS			English	Article							TRAUMATIC BRAIN-INJURY; MOLECULAR LOGIC; BIOCHEMICAL LOGIC; GATES; ENZYME; INFORMATION; NAND; NOR; NOREPINEPHRINE; FLUORESCENCE	A multi-enzyme biocatalytic cascade processing simultaneously five biomarkers characteristic of traumatic brain injury (TBI) and soft tissue injury (STI) was developed. The system operates as a digital biosensor based on concerted function of 8 Boolean AND logic gates, resulting in the decision about the physiological conditions based on the logic analysis of complex patterns of the biomarkers. The system represents the first example of a multi-step/multi-enzyme biosensor with the built-in logic for the analysis of complex combinations of biochemical inputs. The approach is based on recent advances in enzyme-based biocomputing systems and the present paper demonstrates the potential applicability of biocomputing for developing novel digital biosensor networks.	[Windmiller, Joshua Ray; Chuang, Min-Chieh; Santhosh, Padmanabhan; Ramirez, Gabriela V.; Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Halamek, Jan; Bocharova, Vera; Chinnapareddy, Soujanya; Strack, Guinevere; Zhou, Jian; Arugula, Mary A.; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA		Wang, J (corresponding author), Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA.	josephwang@ucsd.edu; ekatz@clarkson.edu	Padmanabhan, Santhosh/A-6930-2009; Valdes-Ramirez, Gabriela/D-2053-2012; Wang, Joseph/C-6175-2011	Padmanabhan, Santhosh/0000-0003-2418-5284; Valdes Ramirez, Gabriela/0000-0002-9566-930X	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]	This work was supported by the Office of Naval Research (Award # N00014-08-1-1202).	Adamatzky A., 2007, UNCONVENTIONAL COMPU; Andreasson J, 2010, CHEM SOC REV, V39, P174, DOI 10.1039/b820280j; Arugula MA, 2009, 2009 SECOND INTERNATIONAL CONFERENCE ON ADVANCES IN CIRCUITS, ELECTRONICS AND MICRO-ELECTRONICS, P1, DOI 10.1109/CENICS.2009.8; Ashkenasy G, 2004, J AM CHEM SOC, V126, P11140, DOI 10.1021/ja046745c; Ashkenazi G, 1997, BIOSENS BIOELECTRON, V12, P85, DOI 10.1016/S0956-5663(97)87054-6; Baron R, 2006, J PHYS CHEM A, V110, P8548, DOI 10.1021/jp0568327; Baytekin HT, 2000, ORG LETT, V2, P1725, DOI 10.1021/ol005873c; Benenson Y, 2004, NATURE, V429, P423, DOI 10.1038/nature02551; Benenson Y, 2009, CURR OPIN BIOTECH, V20, P471, DOI 10.1016/j.copbio.2009.08.002; Benenson Y, 2009, MOL BIOSYST, V5, P675, DOI 10.1039/b902484k; Berger RP, 2006, CLIN PEDIATR EMERG M, V7, P186, DOI 10.1016/j.cpem.2006.06.001; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V4, P2066; Calude C. S., 2009, LECT NOTES COMPUTER, V5715; Ciosek P, 2007, ANALYST, V132, P963, DOI 10.1039/b705107g; Credi A, 2007, ANGEW CHEM INT EDIT, V46, P5472, DOI 10.1002/anie.200700879; Darehmiraki M, 2007, APPL MATH COMPUT, V187, P1033, DOI 10.1016/j.amc.2006.09.020; de Silva AP, 2007, COORDIN CHEM REV, V251, P1623, DOI 10.1016/j.ccr.2007.03.001; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; DE SILVA AP, 1993, NATURE, V364, P42, DOI 10.1038/364042a0; de Silva AP, 1997, J AM CHEM SOC, V119, P7891, DOI 10.1021/ja9712229; DE SILVA AP, 1994, J CHEM SOC CHEM COMM, P1213, DOI 10.1039/c39940001213; de Silva AP, 2002, CHEM-EUR J, V8, P4935, DOI 10.1002/1521-3765(20021104)8:21<4935::AID-CHEM4935>3.0.CO;2-2; de Silva AP, 1999, J AM CHEM SOC, V121, P1393, DOI 10.1021/ja982909b; de Sousa M, 2006, CHEM COMMUN, P2051, DOI 10.1039/b600932h; Deonarine AS, 2003, FUTURE GENER COMP SY, V19, P87, DOI 10.1016/S0167-739X(02)00110-3; Ezziane Z, 2006, NANOTECHNOLOGY, V17, pR27, DOI 10.1088/0957-4484/17/2/R01; Fu L, 2004, ADV COLLOID INTERFAC, V111, P133, DOI 10.1016/j.cis.2004.09.004; Gunnlaugsson T, 2000, CHEM COMMUN, P93, DOI 10.1039/a908951i; Gunnlaugsson T, 2001, J AM CHEM SOC, V123, P12866, DOI 10.1021/ja004316i; Halamek J, 2010, ANALYST, V135, P2249, DOI 10.1039/c0an00270d; Ji S, 1999, BIOSYSTEMS, V52, P123, DOI 10.1016/S0303-2647(99)00039-8; JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669; Kahan M, 2008, PHYSICA D, V237, P1165, DOI 10.1016/j.physd.2008.01.027; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Kim KJ, 2006, ARTIF LIFE, V12, P153, DOI 10.1162/106454606775186455; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; Lee JY, 2005, LECT NOTES COMPUT SC, V3384, P215; Li L, 2007, COLLOID SURFACE A, V304, P49, DOI 10.1016/j.colsurfa.2007.04.020; Liberman EA, 1996, BIOSYSTEMS, V38, P173, DOI 10.1016/0303-2647(95)01588-4; Luxami V, 2008, NEW J CHEM, V32, P2074, DOI 10.1039/b805558k; Manesh KM, 2009, BIOSENS BIOELECTRON, V24, P3569, DOI 10.1016/j.bios.2009.05.019; Maojo V, 2010, PEDIATR RES, V67, P481, DOI 10.1203/PDR.0b013e3181d6245e; Margulies D, 2009, J AM CHEM SOC, V131, P9142, DOI 10.1021/ja900848t; May EE, 2008, IEEE SENS J, V8, P1011, DOI 10.1109/JSEN.2008.923945; Munoz YJ, 2009, J EXP THEOR ARTIF IN, V21, P273, DOI 10.1080/09528130902823649; Niazov T, 2006, P NATL ACAD SCI USA, V103, P17160, DOI 10.1073/pnas.0608319103; Ogawa A, 2009, CHEM COMMUN, P4666, DOI 10.1039/b910288d; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Pischel U, 2007, ANGEW CHEM INT EDIT, V46, P4026, DOI 10.1002/anie.200603990; Pischel U, 2010, AUST J CHEM, V63, P148, DOI 10.1071/CH09460; Pita M, 2008, J AM CHEM SOC, V130, P36, DOI 10.1021/ja077908a; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; Qian JH, 2008, CHEM COMMUN, P4141, DOI 10.1039/b805876h; Reif JH, 2009, THEOR COMPUT SCI, V410, P1428, DOI 10.1016/j.tcs.2008.12.003; Rinaudo K, 2007, NAT BIOTECHNOL, V25, P795, DOI 10.1038/nbt1307; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Saghatelian A, 2003, J AM CHEM SOC, V125, P346, DOI 10.1021/ja029009m; Seminario JM, 1998, ANN NY ACAD SCI, V852, P68, DOI 10.1111/j.1749-6632.1998.tb09865.x; Simmel FC, 2007, NANOMEDICINE-UK, V2, P817, DOI 10.2217/17435889.2.6.817; Sivan S, 2003, BIOSYSTEMS, V70, P21, DOI 10.1016/S0303-2647(03)00039-X; Sivan S, 1999, BIOTECHNOL PROGR, V15, P964, DOI 10.1021/bp990075a; Staiano M, 2005, MOL BIOSYST, V1, P354, DOI 10.1039/b513385h; Stojanovic MN, 2005, BIOELECTRONICS: FROM THEORY TO APPLICATIONS, P427, DOI 10.1002/352760376X.ch14; Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Strack G, 2008, J AM CHEM SOC, V130, P4234, DOI 10.1021/ja7114713; Strack G, 2010, J PHYS CHEM LETT, V1, P839, DOI 10.1021/jz100070u; Straight SD, 2007, ADV FUNCT MATER, V17, P777, DOI 10.1002/adfm.200600802; Szacilowski K, 2008, CHEM REV, V108, P3481, DOI 10.1021/cr068403q; Tokarev I, 2009, ACS APPL MATER INTER, V1, P532, DOI 10.1021/am800251a; Turfan B, 2002, ORG LETT, V4, P2857, DOI 10.1021/ol026245t; Unger R, 2006, PROTEINS, V63, P53, DOI 10.1002/prot.20886; van Noort D, 2005, LECT NOTES COMPUT SC, V3384, P365; von Maltzahn G, 2007, J AM CHEM SOC, V129, P6064, DOI 10.1021/ja070461l; Wagner N, 2009, CHEM-EUR J, V15, P1765, DOI 10.1002/chem.200801850; Wang J, 2001, ELECTROANAL, V13, P13, DOI 10.1002/1521-4109(200101)13:1<13::AID-ELAN13>3.0.CO;2-F; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Wang ZX, 2005, ORG LETT, V7, P3669, DOI 10.1021/ol051211h; Win MN, 2008, SCIENCE, V322, P456, DOI 10.1126/science.1160311; Zauner KP, 2005, CRIT REV SOLID STATE, V30, P33, DOI 10.1080/10408430590918387; Zhou J, 2009, J PHYS CHEM B, V113, P16065, DOI 10.1021/jp9079052; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zong GQ, 2007, TETRAHEDRON LETT, V48, P3891, DOI 10.1016/j.tetlet.2007.03.139	86	64	64	1	25	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1742-206X	1742-2051		MOL BIOSYST	Mol. Biosyst.		2010	6	12					2554	2560		10.1039/c0mb00153h			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	676SD	WOS:000283937800023	20953502				2022-02-06	
J	Madathil, SK; Evans, HN; Saatman, KE				Madathil, Sindhu Kizhakke; Evans, Heather N.; Saatman, Kathryn E.			Temporal and Regional Changes in IGF-1/IGF-1R Signaling in the Mouse Brain after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						Akt; axonal injury; blood vessels; controlled cortical impact; neurotrophic factor	GROWTH-FACTOR-I; CENTRAL-NERVOUS-SYSTEM; HYPOXIC-ISCHEMIC INJURY; CORTICAL IMPACT INJURY; PROTEIN-KINASE-B; IGF-I; MESSENGER-RNA; RAT-BRAIN; GERBIL HIPPOCAMPUS; NEURONAL SURVIVAL	Although neurotrophic factors such as nerve growth factor, basic fibroblast growth factor, brain-derived neurotrophic factor, and neurotrophin 4/5 are elevated after traumatic brain injury (TBI), little is known about the endogenous response of insulin-like growth factor-1 (IGF-1). We evaluated IGF-1, IGF-1 receptor (IGF-1R), and total and phosphorylated Akt (p-Akt), a known downstream mediator of IGF-1 signaling, using ELISA, Western blotting, and immunohistochemistry at 1, 6, 24, 48, and 72 h following 0.5-mm controlled cortical impact brain injury in adult mice. IGF-1 was transiently upregulated in homogenates of injured cortex at 1 h, and cells with increased IGF-1 immunoreactivity were observed in and around the cortical contusion site up to 48 h. IGF-1R and total Akt levels in cortical homogenates were unchanged, although immunohistochemistry revealed regional changes. In contrast, serine p-Akt levels increased significantly in homogenates at 6 h post-injury. Interestingly, delayed increases in vascular IGF-1R, total Akt, and p-Akt immunostaining were observed in and around the cortical contusion. IGF-1 and its downstream mediators were also upregulated in the subcortical white matter. Our findings indicate that moderate TBI results in a brief induction of IGF-1 and its signaling components in the acute post-traumatic period. This may reflect an attempt at endogenous neuroprotection or repair.	[Madathil, Sindhu Kizhakke; Evans, Heather N.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Saatman, KE (corresponding author), Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045131, NS051220, NS058484]; Kentucky Spinal Cord and Brain Injury Research Trust;  [KSCHIRT 7-20]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, R01NS045131, P30NS051220] Funding Source: NIH RePORTER	We greatly appreciate the technical assistance with photo-microscopy and surgery/brain injury provided by Mary Jennes and Nathan Surles, respectively. This work was supported by National Institutes of Health grants NS045131, NS051220, and NS058484, KSCHIRT 7-20, and a Kentucky Spinal Cord and Brain Injury Research Trust fellowship to S. K. M.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Anderson MF, 2002, DEV BRAIN RES, V134, P115; ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; Beilharz EJ, 1998, MOL BRAIN RES, V59, P119, DOI 10.1016/S0169-328X(98)00122-3; BERGSTEDT K, 1993, J CEREBR BLOOD F MET, V13, P895, DOI 10.1038/jcbfm.1993.112; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; Brywe KG, 2005, EUR J NEUROSCI, V21, P1489, DOI 10.1111/j.1460-9568.2005.03982.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cao Y, 2003, J CEREBR BLOOD F MET, V23, P739, DOI 10.1097/01.WCB.0000067720.12805.6F; Chisalita SI, 2004, AM J PHYSIOL-ENDOC M, V286, pE896, DOI 10.1152/ajpendo.00327.2003; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Conte V., 2003, EUR J TRAUMA, V7, P335; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Guan J, 1996, NEUROREPORT, V7, P632, DOI 10.1097/00001756-199601310-00061; Guan J, 2000, BRAIN RES, V853, P163, DOI 10.1016/S0006-8993(99)02030-2; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hollis ER, 2009, EXP NEUROL, V215, P53, DOI 10.1016/j.expneurol.2008.09.014; Hung KS, 2007, J NEUROSURG-SPINE, V6, P35, DOI 10.3171/spi.2007.6.1.7; Hwang IK, 2004, NEUROCHEM INT, V45, P149, DOI 10.1016/j.neuint.2003.10.006; Janelidze S, 2001, NEUROBIOL DIS, V8, P147, DOI 10.1006/nbdi.2000.0325; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; Namura S, 2000, J CEREBR BLOOD F MET, V20, P1301, DOI 10.1097/00004647-200009000-00004; Niblock MM, 2000, J NEUROSCI, V20, P4165; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Reynolds AJ, 2000, BRAIN RES REV, V33, P169, DOI 10.1016/S0165-0173(00)00028-X; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Vincent AM, 2004, NEUROBIOL DIS, V16, P407, DOI 10.1016/j.nbd.2004.03.001; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WERTHER GA, 1990, MOL ENDOCRINOL, V4, P773, DOI 10.1210/mend-4-5-773; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Zeger M, 2007, GLIA, V55, P400, DOI 10.1002/glia.20469; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zheng WH, 2000, ADV RES NEURODEGENER, V8, P261	63	64	68	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					95	107		10.1089/neu.2009.1002			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200008	19751099	Green Published			2022-02-06	
J	Singh, M; Jeong, J; Hwang, D; Sungkarat, W; Gruen, P				Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya; Gruen, Peter			Novel diffusion tensor imaging methodology to detect and quantify injured regions and affected brain pathways in traumatic brain injury	MAGNETIC RESONANCE IMAGING			English	Article						Diffusion tensor imaging; Tractography; Normalization; Traumatic brain injury	WHITE-MATTER INJURY; AXONAL INJURY; SPATIAL NORMALIZATION; HEAD TRAUMA; FIBER TRACKING; DTI-TRACTOGRAPHY; MRI; ABNORMALITIES; STRATEGIES; TRACTS	Purpose: To develop and apply diffusion tensor imaging (DTI)-based normalization methodology for the detection and quantification of sites of traumatic brain injury (TBI) and the impact of injury along specific brain pathways in (a) individual TBI subjects and (b) a TBI group. Materials and Methods: Normalized DTI tractography was conducted in the native space of 12 TBI and 10 age-matched control subjects using the same number of seeds in each subject, distributed at anatomically equivalent locations. Whole-brain tracts from the control group were mapped onto the head of each TBI subject. Differences in the fractional anisotropy (FA) maps between each TBI subject and the control group were computed in a common space using a t test, transformed back to the individual TBI subject's head space, and thresholded to form regions of interest (ROIs) that were used to sort tracts from the control group and the individual TBI subject. Tract counts for a given ROI in each TBI subject were compared to group mean for the same ROI to quantify the impact of injury along affected pathways. The same procedure was used to compare the TBI group to the control group in a common space. Results: Sites of injury within individual TBI subjects and affected pathways included hippocampal/fomix, inferior fronto-occipital, inferior longitudinal fasciculus, corpus callosum (genu and splenium), cortico-spinal tracts and the uncinate fasciculus. Most of these regions were also detected in the group study. Conclusions: The DTI normalization methodology presented here enables automatic delineation of ROIs within the heads of individual subjects (or in a group). These ROIs not only localize and quantify the extent of injury, but also quantify the impact of injury on affected pathways in an individual or in a group of TBI subjects. (C) 2010 Elsevier Inc. All rights reserved.	[Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya] Univ So Calif, Dept Radiol, Los Angeles, CA 90089 USA; [Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA; [Gruen, Peter] Univ So Calif, Dept Neurol Surg, Los Angeles, CA 90033 USA		Singh, M (corresponding author), Univ So Calif, Dept Radiol, Los Angeles, CA 90089 USA.	msingh@usc.edu	Hwang, Darryl/M-7221-2019	Hwang, Darryl/0000-0002-1111-9176	USA Medical Research and Material Command [W81XWH-07-1-0015]; TATRC; NIA-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05142]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005142] Funding Source: NIH RePORTER	This research was supported by Contract No. W81XWH-07-1-0015 awarded by USA Medical Research and Material Command, TATRC, and partially supported by grant NIA-NIH P50 AG05142.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, HUM BRAIN MAPP, V9, P212, DOI 10.1002/(SICI)1097-0193(200004)9:4<212::AID-HBM3>3.0.CO;2-#; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CLAYDEN J, 2005, P ESMRMB 22 ANN M EU, P508; Clayden JD, 2006, NEUROIMAGE, V33, P482, DOI 10.1016/j.neuroimage.2006.07.016; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2002, NEUROIMAGE, V17, P592, DOI 10.1006/nimg.2002.1148; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2001, MAGN RESON MED, V46, P18, DOI 10.1002/mrm.1155; Mori S, 2000, ANN NEUROL, V47, P412, DOI 10.1002/1531-8249(200003)47:3<412::AID-ANA28>3.3.CO;2-8; Muller HP, 2007, PHYS MED BIOL, V52, pN99, DOI 10.1088/0031-9155/52/6/N01; Nair G, 2005, NEUROIMAGE, V28, P165, DOI 10.1016/j.neuroimage.2005.05.049; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2005, P SOC PHOTO-OPT INS, V5746, P138, DOI 10.1117/12.594721; SINGH M, 2008, P INT SOC MAG RESON, V16, P2269; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Tyszka JM, 2006, NEUROIMAGE, V29, P1058, DOI 10.1016/j.neuroimage.2005.08.037; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu DR, 2003, MAGN RESON MED, V50, P175, DOI 10.1002/mrm.10489; Zhang RL, 2003, NEUROSCIENCE, V116, P373, DOI 10.1016/S0306-4522(02)00696-6; Zhang T, 2008, 2008 IEEE INTERNATIONAL CONFERENCE ON VEHICULAR ELECTRONICS AND SAFETY, P1, DOI 10.1109/ISEE.2008.4562845	53	64	67	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	JAN	2010	28	1					22	40		10.1016/j.mri.2009.05.049			19	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	583BX	WOS:000276648600004	19608369	Green Accepted			2022-02-06	
J	Schonberger, M; Ponsford, J; Reutens, D; Beare, R; O'Sullivan, R				Schoenberger, Michael; Ponsford, Jennie; Reutens, David; Beare, Richard; O'Sullivan, Richard			The Relationship between Age, Injury Severity, and MRI Findings after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						age; aging; traumatic brain injury; magnetic resonance imaging; brain and lesion volumes	WHITE-MATTER; CEREBRAL ATROPHY; PROGNOSTIC VALUE; CNS INJURY; HEALTHY; ADULTS; DECLINE; VOLUME; INDEXES; LESIONS	Age and injury severity are among the most significant predictors of outcome after traumatic brain injury (TBI). However, only a few studies have investigated the association between, age, injury severity, and the extent of brain damage in TBI. The purpose of this study was to investigate the association between age, measures of injury severity, and brain lesion volumes, as well as viable brain volumes, following TBI. Ninety-eight individuals with mild to very severe TBI (75.5% male, mean age at injury 34.5 years) underwent a structural MRI scan, performed with a 1.5-Tesla machine, on average 2.3 years post-injury. Lesion volumes were highly skewed in their distribution and were dichotomized for statistical purposes. Measures of injury severity were Glasgow Coma Scale score (GCS) and duration of post-traumatic amnesia (PTA). Logistic regression analyses predicting lesion volumes, controlling for participants' gender, cause of injury, time from injury to MRI scan, and total brain volume, revealed that both older age and longer PTA were associated with larger lesion volumes in both grey and white matter in almost all brain regions. Older age was also associated with smaller viable grey matter volumes in most neo-cortical brain regions, while longer PTA was associated with smaller viable white matter volumes in most brain regions. The results suggest that older age worsens the impact of TBI on the brain. They also indicate the validity of duration of PTA as a measure of injury severity that is not just related to one particular injury location.	[Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia; [Reutens, David; Beare, Richard] Monash Univ, Dept Med, Monash Med Ctr, Clayton, Vic 3800, Australia; [Reutens, David] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Beare, Richard] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Richmond, Vic, Australia		Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Melbourne, Vic 3800, Australia.	michael_schoenberger@web.de	Reutens, David/C-7226-2018	Reutens, David/0000-0002-1652-9369; Beare, Richard/0000-0002-7530-5664			Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cook IA, 2004, AM J GERIAT PSYCHIAT, V12, P190, DOI 10.1176/appi.ajgp.12.2.190; DeCarli C, 2005, NEUROBIOL AGING, V26, P491, DOI 10.1016/j.neurobiolaging.2004.05.004; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Farace E, 2000, Neurosurg Focus, V8, pe6; Fotenos AF, 2005, NEUROLOGY, V64, P1032, DOI 10.1212/01.WNL.0000154530.72969.11; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Hedden T, 2005, CURR OPIN NEUROL, V18, P740, DOI 10.1097/01.wco.0000189875.29852.48; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinman JD, 2007, NEUROCHEM RES, V32, P2023, DOI 10.1007/s11064-007-9341-x; Hugenschmidt CE, 2008, CEREB CORTEX, V18, P433, DOI 10.1093/cercor/bhm080; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ketonen LM, 1998, NEUROL CLIN, V16, P581, DOI 10.1016/S0733-8619(05)70082-7; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kolb B, 1998, ANNU REV PSYCHOL, V49, P43, DOI 10.1146/annurev.psych.49.1.43; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Malloy P, 2007, CLIN NEUROPSYCHOL, V21, P73, DOI 10.1080/13854040500263583; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pfefferbaum A, 2005, NEUROIMAGE, V26, P891, DOI 10.1016/j.neuroimage.2005.02.034; Pieperhoff P, 2008, J NEUROSCI, V28, P828, DOI 10.1523/JNEUROSCI.3732-07.2008; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Resnick SM, 2003, J NEUROSCI, V23, P3295; Reuter-Lorenz PA, 2005, CURR OPIN NEUROBIOL, V15, P245, DOI 10.1016/j.conb.2005.03.016; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Soo CA., 2005, BRAIN IMPAIR, V6, P75, DOI [DOI 10.1375/BRIM.2005.6.2.75, 10.1375/brim.2005.6.2.75]; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; TEASDALE G, 1974, LANCET, V2, P81; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	55	64	66	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2157	2167		10.1089/neu.2009.0939			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200003	19624261				2022-02-06	
J	Brenner, LA; Homaifar, BY; Adler, LE; Wolfman, JH; Kemp, J				Brenner, Lisa A.; Homaifar, Beeta Y.; Adler, Lawrence E.; Wolfman, Jessica H.; Kemp, Jan			Suicidality and Veterans With a History of Traumatic Brain Injury: Precipitating Events, Protective Factors, and Prevention Strategies	REHABILITATION PSYCHOLOGY			English	Article						suicide; traumatic brain injury; Veterans; qualitative	PEOPLE; REHABILITATION; POPULATION; HEALTH; IRAQ	Objectives: To increase understanding regarding precipitating and preventative factors of suicidal behavior and to highlight past experiences and recommendations regarding services aimed at suicide prevention among Veterans with a history of traumatic brain injury (TBI). Study Design: Qualitative. Participants: Sample of 13 Veterans with a history of TBI, and a history of clinically significant suicidal ideation or behavior. Method: In-person interviews were conducted and data were analyzed using a hermeneutic approach. Results: Shared precipitants noted included loss-of-self post-TBI, cognitive sequelae, and psychiatric and emotional disturbances. Common protective factors noted included social supports, a sense of purpose regarding the future, religion and spirituality, and mental health care. Means of improving care were also identified (e.g., increasing the availability of services and mental health professionals' knowledge regarding TBI, providing more structured treatment). Conclusions: Findings highlight potential areas of importance in the assessment and treatment of suicidal Veterans with a history of TBI. Recommendations regarding means of improving care are also presented.	[Brenner, Lisa A.] VA Eastern Colorado Hlth Care Syst, MIRECC, VISN 19, Denver, CO 80220 USA; [Homaifar, Beeta Y.; Adler, Lawrence E.] Univ Colorado, Sch Med, Dept Psychiat, MIRECC,VISN 19, Denver, CO 80262 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Wolfman, Jessica H.] Drexel Univ, MIRECC, VISN 19, Philadelphia, PA 19104 USA; [Kemp, Jan] VA Off Mental Hlth Serv, VISN Ctr Excellence 2, Canandaigua, NY USA		Brenner, LA (corresponding author), VA Eastern Colorado Hlth Care Syst, MIRECC, VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Brenner, Lisa A./AAG-2442-2019				Brenner L.A., 2008, J MENTAL HEALTH COUN, V30, P211, DOI [10.17744/mehc.30.3.n6418tm72231j606, DOI 10.17744/MEHC.30.3.N6418TM72231J606]; BRENNER LA, WAR SUICIDE IN PRESS; BRENNER LA, 2008, BRAIN INJURY PROFESS, V5, P26; Chwalisz K, 2008, REHABIL PSYCHOL, V53, P387, DOI 10.1037/a0012998; Crabtree B. F., 1999, DOING QUALITATIVE RE; Crisp R., 1993, DISABIL HANDICAP SOC, V8, P393, DOI DOI 10.1080/02674649366780371; Crist JD, 2003, NURS RES, V52, P202, DOI 10.1097/00006199-200305000-00011; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; *DEP VET AFF, 2004, VETEESA138 SP DEP VE; Epston, 1990, NARRATIVE MEANS THER; Haynes SN, 1995, PSYCHOL ASSESSMENT, V7, P238, DOI 10.1037/1040-3590.7.3.238; Hesse-Biber S., 2003, APPROACHES QUALITATI; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; KINSELLA EA, 2006, FQS FORUM QUALITATIV, V7; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Lakeman R, 2008, J ADV NURS, V64, P114, DOI 10.1111/j.1365-2648.2008.04773.x; Lorge E, 2008, ARMY RESPONDS RISING; Malone KM, 2000, AM J PSYCHIAT, V157, P1084, DOI 10.1176/appi.ajp.157.7.1084; Maris R, 2000, COMPREHENSIVE TXB SU, V1st; Miklowitz D. J., 1997, BIPOLAR DISORDER FAM; Moscicki E. K., 1999, HARVARD MED SCH GUID, P40; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Paterson M, 2005, QUAL REP, V10, P339; Patterson ME., 2002, COLLECTING ANAL QUAL; PEAKE JB, 2008, STATEMENT PRESENTATI; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; Rubin H., 1995, QUALITATIVE INTERVIE; Rudd MD, 2006, SUICIDE LIFE-THREAT, V36, P255, DOI 10.1521/suli.2006.36.3.255; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; STANLEY B, 2008, SAFETY PLAN TR UNPUB; Strauss A., 1990, BASICS QUALITATIVE R; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ., 1995, GUIDELINES SURVEILLA; World Health Organization, 2007, INT CLASS FUNCT DIS	42	64	64	0	11	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					390	397		10.1037/a0017802			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	526YF	WOS:000272331600005	19929120				2022-02-06	
J	Dobscha, SK; Clark, ME; Morasco, BJ; Freeman, M; Campbell, R; Helfand, M				Dobscha, Steven K.; Clark, Michael E.; Morasco, Benjamin J.; Freeman, Michele; Campbell, Rose; Helfand, Mark			Systematic Review of the Literature on Pain in Patients with Polytrauma Including Traumatic Brain Injury	PAIN MEDICINE			English	Article						Pain; Multiple Trauma; Blast Injuries; Traumatic Brain Injury; Veterans	PERIPHERAL-NERVE LESIONS; LONG-TERM OUTCOMES; INTRATHECAL BACLOFEN THERAPY; HEAD-INJURY; MULTIPLE TRAUMA; MAJOR TRAUMA; FOLLOW-UP; FUNCTIONAL CONSEQUENCES; SPASTIC HYPERTONIA; RISK-FACTORS	Objective. To review the literature addressing the assessment and management of pain in patients with polytraumatic injuries including traumatic brain injury (TBI) and blast-related headache, and to identify patient, clinician and systems factors associated with pain-related outcomes. Design. Systematic review. Methods. We conducted searches in MEDLINE of literature published from 1950 through July 2008. Due to a limited number of studies using controls or comparators, we included observational and rigorous qualitative studies. We systematically rated the quality of systematic reviews, cohort, and case-control design studies. Results. One systematic review, 93 observational studies, and one qualitative research study met inclusion criteria. The literature search yielded no published studies that assessed measures of pain intensity or pain-related functional interference among patients with cognitive deficits due to TBI, that compared patients with blast-related headache with patients with other types of headache, or that assessed treatments for blast-related headache pain. Studies on the association between TBI severity and pain reported mixed findings. There was limited evidence that the following factors are associated with pain among TBI patients: severity, location, and multiplicity of injuries; insomnia; fatigue; depression; and post-traumatic stress disorder. Conclusions. Very little evidence is currently available to guide pain assessment and treatment approaches in patients with polytrauma. Further research employing systematic observational as well as controlled intervention designs is clearly indicated.	[Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA; [Dobscha, Steven K.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97207 USA; [Clark, Michael E.] James A Haley Vet Affairs Hosp, Psychol Serv, Tampa, FL USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Psychol, Jacksonville, FL USA; [Clark, Michael E.] Univ S Florida, Coll Med, Dept Neurol, Jacksonville, FL USA; [Freeman, Michele; Campbell, Rose] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA; [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Helfand, Mark] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA		Dobscha, SK (corresponding author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Box 1034 P3MHADM, Portland, OR 97207 USA.	steven.dobscha@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration, Health Services Research and Development ServiceUS Department of Veterans Affairs [RCD 04129]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23DA023467-01A1]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K23DA023467] Funding Source: NIH RePORTER	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Project RCD 04129 (Dobscha), National Institutes of Health K23DA023467-01A1 (Morasco) and Evidence-based Practice Center funding which is supported by the Agency for Healthcare Research and Quality. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	ADELOYE A, 1971, PRACTITIONER, V206, P517; ANDY OJ, 1989, CLIN ELECTROENCEPHAL, V20, P24, DOI 10.1177/155005948902000107; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bergfeldt U, 2006, J REHABIL MED, V38, P166, DOI 10.1080/16501970500415348; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Brenneman FD, 1997, J TRAUMA, V42, P773, DOI 10.1097/00005373-199705000-00003; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Chen KW, 2004, J ALTERN COMPLEM MED, V10, P159, DOI 10.1089/107555304322849075; Childers MK, 1997, BRAIN INJURY, V11, P537, DOI 10.1080/713802187; CONCALVES J, 1994, STEREOT FUNCT NEUROS, V62, P108, DOI 10.1159/000098605; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Donnellan Clare P, 2006, Acupunct Med, V24, P129; Dougherty PJ, 1999, J BONE JOINT SURG AM, V81A, P1384, DOI 10.2106/00004623-199910000-00003; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fischer Hannah, 2009, US MILITARY CASUALTY; Fitzharris Michael, 2007, Traffic Inj Prev, V8, P309, DOI 10.1080/15389580701216533; Francisco GE, 2005, BRAIN INJURY, V19, P359, DOI 10.1080/02699050400003999; Francisco GE, 2007, BRAIN INJURY, V21, P335, DOI 10.1080/02699050701311018; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Frink M, 2007, INJURY, V38, P607, DOI 10.1016/j.injury.2006.12.021; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; Guttmann E, 1943, LANCET, V1, P10; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hebert JS, 2000, SPINE, V25, P55, DOI 10.1097/00007632-200001010-00011; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Jang SH, 2000, YONSEI MED J, V41, P536, DOI 10.3349/ymj.2000.41.4.536; KAY DWK, 1971, LANCET, V2, P1052; Lacoux PA, 2002, PAIN, V99, P309, DOI 10.1016/S0304-3959(02)00154-9; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Leung J, 2007, CLIN REHABIL, V21, P171, DOI 10.1177/0269215506070254; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; LEYTON N, 1951, Med Press, V226, P46; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Mkandawire NC, 2002, INJURY, V33, P111, DOI 10.1016/S0020-1383(01)00047-X; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Ribbers GM, 2001, ARCH PHYS MED REHAB, V82, P851, DOI 10.1053/apmr.2001.21911; Roganovic Z, 2006, NEUROSURGERY, V59, P1238, DOI 10.1227/01.NEU.0000245618.16979.32; Roganovic Z, 2006, NEUROSURGERY, V59, P1226, DOI 10.1227/01.NEU.0000245610.01732.32; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Shah RV, 2004, ARCH PHYS MED REHAB, V85, P1013, DOI 10.1016/j.apmr.2003.07.017; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; Tran T, 2002, FOOT ANKLE INT, V23, P340, DOI 10.1177/107110070202300409; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Turchin DC, 1999, J ORTHOP TRAUMA, V13, P1, DOI 10.1097/00005131-199901000-00001; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Urquhart DM, 2006, ANZ J SURG, V76, P600, DOI 10.1111/j.1445-2197.2006.03785.x; Verdolin MH, 2007, ANESTH ANALG, V104, P1557, DOI 10.1213/01.ane.0000264087.93163.bf; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wardell DW, 2006, J HOLIST NURS, V24, P231, DOI 10.1177/0898010106289840; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARDEN DL, 2005, 23 ANN NAT NEUR SOC; WILKINSON M, 1980, UPSALA J MED SCI, P48; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZACHARIAH SB, 1994, AM J MED SCI, V308, P38, DOI 10.1097/00000441-199407000-00009; Zelle BA, 2005, INJURY, V36, P169, DOI 10.1016/j.injury.2004.06.004	90	64	66	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	OCT	2009	10	7					1200	1217		10.1111/j.1526-4637.2009.00721.x			18	Anesthesiology; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; General & Internal Medicine	504BT	WOS:000270589100006	19818031	Green Accepted, Bronze			2022-02-06	
J	Broglio, SP; Sosnoff, JJ; Ferrara, MS				Broglio, Steven P.; Sosnoff, Jacob J.; Ferrara, Michael S.			The Relationship of Athlete-Reported Concussion Symptoms and Objective Measures of Neurocognitive Function and Postural Control	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport concussion; symptoms; balance; cognitive function	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; RECOVERY; SPORTS; SENSITIVITY; PERFORMANCE; VALIDITY; INJURY	Objective: Concussed athlete evaluations often include symptoms, balance, and neurocognitive assessments. We sought to identify the relationship between subjective symptom reports and objective clinical measures. Design: A retrospective assessment. Setting: A research laboratory. Patients: Concussed collegiate-level athletes (N = 32, 19.7 years) evaluated pre- and postinjury (less than 48 hours). Intervention: Each athlete completed an inventory of concussion-related symptoms, the NeuroCom Sensory Organization Test (SOT), and ImPACT neurocognitive assessment. Spearman correlations between balance symptoms and SOT scores and cognitive symptoms and ImPACT scores were completed. Main Outcome Measures: Symptoms related to balance and cognitive deficits, SOT composite balance and visual, vestibular, and somatosensory ratios, and ImPACT output scores. Results: Significant Spearman correlations were noted between reports of "dizziness" and the SOT composite balance (r(s) = -0.55) and vestibular ratio (r(s) = -0.50). Similarly, "balance problems" were significantly correlated with composite balance (r(s) = -0.52) and the somatosensory (r(s) = -0.41), visual (r(s) = -0.39), and vestibular ratios (r(s) = -0.57). The cognitive symptom of "feeling mentally foggy" and ImPACT variables of reaction time (r(s) = 0.36) and "difficulty concentrating" and verbal memory score (r(s) = -0.41) were significantly related. Finally, reports of "difficultly remembering" were significantly related to the verbal memory score (r(s) = -0.48) and reaction time (r(s) = 0.36). Conclusions: These findings indicate self-report symptoms are associated with athlete deficits in postural control and cognitive function. The moderate relationship between the symptom reports and the objective measures warrants the continued use of all measures. A reduction in the number of symptoms concussed athletes respond to may be justified to reduce redundancy.	[Broglio, Steven P.; Sosnoff, Jacob J.] Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA		Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DELATORRE JC, 2002, STROKE, V33, P1; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Karatas M, 2008, NEUROLOGIST, V14, P355, DOI 10.1097/NRL.0b013e31817533a3; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; VANKAMPEN DA, 2006, AM J SPORT MED, V30, P1	35	64	64	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2009	19	5					377	382		10.1097/JSM.0b013e3181b625fe			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	493DS	WOS:000269714200005	19741309				2022-02-06	
J	Viano, DC; Hamberger, A; Bolouri, H; Saljo, A				Viano, David C.; Hamberger, Anders; Bolouri, Hayde; Saljo, Annette			CONCUSSION IN PROFESSIONAL FOOTBALL: ANIMAL MODEL OF BRAIN INJURY-PART 15	NEUROSURGERY			English	Article						Animal models; Brain injury; Concussion; Head impact; Protective headgear; Recreation and sports	CLOSED-HEAD-INJURY; CONTROLLED CORTICAL IMPACT; ROTATIONAL ACCELERATION; AXONAL INJURY; PERCUSSION CONCUSSION; INTRACRANIAL-PRESSURE; SUBDURAL-HEMATOMA; GAME IMPACTS; RAT; BIOMECHANICS	OBJECTIVE: A concussion model was developed to study injury mechanisms, functional effects, treatment, and recovery. Concussions in National Football League football involve high-impact velocity (7.4-11.2 m/s) and rapid change in head velocity (Delta V) (5.4-9.0 m/s). Current animal models do not simulate these head impact conditions. METHODS: One hundred eight adult male Wistar rats weighing 280 to 350 g were used in ballistic impacts simulating 3 collision severities causing National Football League-type concussion. Pneumatic pressure accelerated a 50g impactor to velocities of 7.4, 9.3, and 11.2 m/s at the left side of the helmet-protected head. A thin layer of padding on the helmet controlled head acceleration, which was measured on the opposite side of the head, in line with the impact. Peak head acceleration, AV, impact duration, and energy transfer were determined. Fifty-four animals were exposed to single impact, with 18 each having 1, 4, or 10 days of survival. Similar tests were conducted on another 54 animals, which received 3 impacts at 6-hour intervals. An additional 72 animals were tested with a 100g impactor to study more serious brain injuries. Brains were perfused, and surface injuries were identified. RESULTS: The 50g impactor matches concussion conditions scaled to the rat. Impact velocity and head Delta V were within 1% and 3% of targets on average. Head acceleration reached 450g to 1750g without skull fracture. The test is repeatable and robust. Gross pathology was observed in 11%, 28%, and 33% of animals in the 7.4-, 9.3-, and 11.2-m/s single impacts, respectively. At 7.4 m/s, a single diameter area of less than 0.5 mm of fine petechial hemorrhage occurred on the brain surface in the parenchyma and meninges nearest the point of impact. At higher velocities, there were larger areas of bleeding, sometimes with subdural hemorrhage. When the 50g impactor tests were examined by logistic regression, greater energy transfer increased the probability of injury (odds ratio, 5.83; P = 0.01), as did 3 repeat impacts (odds ratio, 4.72; P = 0.002). The number of survival days decreased the probability of observing injury (odds ratio, 0.25 and 0.11 for 4 and 10 days, respectively, compared with 1 day). The 100g impactor produced more severe brain injuries. CONCLUSION: A concussion model was developed to simulate the high velocity of impact and rapid head Delta Vof concussions in National Football League players. The new procedure can be used to evaluate immediate and latent effects of concussion and more severe injury with greater impact mass.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Viano, David C.] Mild Traumat Brain Injury Comm, New York, NY USA; [Hamberger, Anders; Bolouri, Hayde; Saljo, Annette] Univ Gothenburg, Dept Anat & Cell Biol, Inst Biomed, Gothenburg, Sweden		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; ARMITAGE P, 1987, STAT METHODS MED RES, P410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ellingson Benjamin M., 2005, V41, P86; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Gremmelt A, 1995, ANAESTHESIST, V44, pS559; GURDJIAN ES, 1975, SURG GYNECOL OBSTET, V140, P845; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; HAMBERGER A, NEUROSURGERY, V64, P1172; Heath DL, 2001, J NEUROTRAUM, V18, P465, DOI 10.1089/089771501750171074; Holbourn AHS, 1943, LANCET, V2, P438; Hosmer D, 1989, APPL LOGISTIC REGRES; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN S, 1967, J TRAUM, V7, P493, DOI 10.1097/00005373-196707000-00001; MARGULIES SS, 1985, P IRCOBI AAAM C GOT, P13; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Rinder L, 1972, Scand J Rehabil Med, V4, P97; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, 1988, J BIOMECH, V21, P387, DOI 10.1016/0021-9290(88)90145-5; VIANO DC, 1999, CRASH PREV INJ CONTR, V1, P35; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	64	64	65	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1162	1173		10.1227/01.NEU.0000345863.99099.C7			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300035	19487897				2022-02-06	
J	Castriotta, RJ; Atanasov, S; Wilde, MC; Masel, BE; Lai, JM; Kuna, ST				Castriotta, Richard J.; Atanasov, Strahil; Wilde, Mark C.; Masel, Brent E.; Lai, Jenny M.; Kuna, Samuel T.			Treatment of Sleep Disorders after Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						Trauma; brain injury; hypersomnia; sleep apnea; narcolepsy; sleep disorders; MSLT; continuous positive airway pressure	EXCESSIVE DAYTIME SLEEPINESS; POSITIVE AIRWAY PRESSURE; APNEA-HYPOPNEA SYNDROME; MILD HEAD-INJURY; QUALITY-OF-LIFE; CPAP TREATMENT; RESIDUAL SLEEPINESS; DOUBLE-BLIND; MODAFINIL; PLACEBO	Study Objectives: Determine whether treatment of sleep disorders identified in brain injured adults would result in resolution of those sleep disorders and improvement of symptoms and daytime function. Methods: Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0.375 mg) for periodic limb movements in sleep (PLMS). Setting: Three academic medical centers. Participants: Fifty-seven (57) adults >= 3 months post traumatic brain injury (TBI). Measurements And Results: Abnormal sleep studies were found in 22 subjects (39%), of whom 13 (23%) had OSA, 2 (3%) had PTH, 3 (5%) had narcolepsy, 4 (7%) had PLMS, and 12 had objective excessive daytime sleepiness with MSLT score < 10 minutes. Apneas, hypopneas, and snoring were eliminated by CPAP in OSA subjects, but there was no significant change in MSLT scores. Periodic limb movements were eliminated with pramipexole. One of 3 narcolepsy subjects and 1 of 2 PTH subjects had resolution of hypersomnia with modafinil. There was no significant change in FOSQ, POMS, or PVT results after treatment. Conclusions: Treatment of sleep disorders after TBI may result in polysomnographic resolution without change in sleepiness or neuropsychological function.	[Castriotta, Richard J.] Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, Houston, TX 77030 USA; [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA; [Atanasov, Strahil] Univ Texas Med Branch Galveston, Galveston, TX USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA; [Kuna, Samuel T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA		Castriotta, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, 6431 Fannin St,MSB 1-274, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Castriotta, Richard/0000-0003-3502-4558			Agrawal A, 2008, J CLIN SLEEP MED, V4, P177; Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; *AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS; [Anonymous], 1997, SLEEP, V20, P406; Bardwell WA, 2001, SLEEP, V24, P905, DOI 10.1093/sleep/24.8.905; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Black J, 2003, RESP PHYSIOL NEUROBI, V136, P211, DOI 10.1016/S1569-9048(03)00083-1; Bonnet MH, 2006, J CLIN NEUROPHYSIOL, V23, P50, DOI 10.1097/01.wnp.0000190415.83841.17; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chami HA, 2008, CIRCULATION, V117, P2599, DOI 10.1161/CIRCULATIONAHA.107.717892; Coleman RM, 1982, SLEEPING WAKING DISO, P265; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dinges DF, 2003, SLEEP MED, V4, P393, DOI 10.1016/S1389-9457(03)00108-4; Dinges DF, 1997, SLEEP, V20, P267; Ellen RLB, 2006, J CLIN SLEEP MED, V2, P193; Gooneratne NS, 2003, J AM GERIATR SOC, V51, P642, DOI 10.1034/j.1600-0579.2003.00208.x; Hia KM, 2008, SLEEP, V31, P795; Hirshkowitz M, 2007, CNS DRUGS, V21, P407, DOI 10.2165/00023210-200721050-00004; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; Kingshott RN, 2001, AM J RESP CRIT CARE, V163, P918, DOI 10.1164/ajrccm.163.4.2005036; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Lenfant C, 2008, AM J THER, V15, P345, DOI 10.1097/MJT.0b013e31815fd0fe; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Macey PM, 2008, SLEEP, V31, P967; Marshall NS, 2008, SLEEP, V31, P1079; Marshall NS, 2006, THORAX, V61, P430, DOI 10.1136/thx.2005.050583; McNair D. M, 1971, MANUAL PROFILE MOOD; Monasterio C, 2001, AM J RESP CRIT CARE, V164, P939, DOI 10.1164/ajrccm.164.6.2008010; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Pandi-Perumal SR, 2006, BRAZ J MED BIOL RES, V39, P863, DOI 10.1590/S0100-879X2006000700003; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Weaver TE, 2003, SLEEP, V26, P727, DOI 10.1093/sleep/26.6.727; Weaver TE, 1997, SLEEP, V20, P835; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Young T, 2008, SLEEP, V31, P1071; Yu BH, 1999, J PSYCHIAT RES, V33, P427, DOI 10.1016/S0022-3956(99)00020-5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; [No title captured]	48	64	64	0	8	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389			J CLIN SLEEP MED	J. Clin. Sleep Med.	APR 15	2009	5	2					137	144					8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	499YN	WOS:000270262900009	19968047				2022-02-06	
J	McPherson, KM; Kayes, N; Weatherall, M				McPherson, Kathryn M.; Kayes, Nicola; Weatherall, Mark		Goals SR Res Grp	A pilot study of self-regulation informed goal setting in people with traumatic brain injury	CLINICAL REHABILITATION			English	Article							REHABILITATION; ATTAINMENT; MOTIVATION	Objective: To determine the acceptability and clinical application of two recently developed goal-setting interventions (Goal Management Training and Identity Oriented Goal Training) in people with traumatic brain injury. Design: A three parallel group, randomized controlled pilot study. Setting: Inpatient and community rehabilitation facilities. Subjects: Thirty-four people with moderate to severe traumatic brain injury (Goal Management Training, n = 12; Identity Oriented Goal Training, n = 10; usual care, n = 12) and their rehabilitation clinicians. Interventions: For both Goal Management Training and Identity Oriented Goal Training participants met face to face with their key worker weekly over a period of 6-8 weeks, during which time the key worker worked to engage them in goal setting and goal performance using the strategy prescribed by their group allocation. Usual care was provided to the other participants. Main measures: Largely qualitative using observation, individual interviews and focus groups. Participants also completed a Goal Attainment Scale at baseline, post intervention and at three months follow-up. Results: Both approaches were acceptable to the majority of participants with many reporting improved mood and goal attainment. Clinicians found working in a different way with patients both challenging and rewarding, with both experimental approaches enhancing a focus on the person's own goals. Identity Oriented Goal Training seemed particularly helpful in engaging people in the goal-setting process while Goal Management Training appeared particularly helpful in providing a structured framework for error prevention in attempting goal performance. Conclusion: These theoretically informed approaches to goal setting showed promise but were time intensive and at times difficult for practitioners to utilize.	[McPherson, Kathryn M.; Kayes, Nicola; Weatherall, Mark; Goals SR Res Grp] Natl Res Ctr Stroke, Appl Neurosci & Neurorehabil & Hlth & Rehabil Res, Sch Rehabil & Occupat Studies, Auckland, New Zealand		McPherson, KM (corresponding author), Natl Res Ctr Stroke, Appl Neurosci & Neurorehabil & Hlth & Rehabil Res, Sch Rehabil & Occupat Studies, Akoranga Dr Campus,AA Bldg,Room 263,Private Bag, Auckland, New Zealand.	Kathryn.McPherson@aut.ac.nz	Weatherall, Mark/Y-6824-2019	Weatherall, Mark/0000-0002-0051-9107; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand	This study was supported by the Health Research Council of New Zealand.	Ashford S, 2006, PHYSIOTHER RES INT, V11, P24, DOI 10.1002/pri.36; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Carver C.S., 1998, SELF REGULATION BEHA; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CYTRYNBAUM S, 1979, EVALUATION QUART, V3, P5, DOI 10.1177/0193841X7900300102; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Feigin V. L., 2007, HDB CLIN NEUROEPIDEM, P197; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Hellawell DJ, 1997, INT J REHABIL RES, V20, P345, DOI 10.1097/00004356-199712000-00001; JANE JA, 1982, CLIN NEUR, V29, P346; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Khan F, 2008, ARCH PHYS MED REHAB, V89, P652, DOI 10.1016/j.apmr.2007.09.049; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Locke E.A., 1990, THEORY GOAL SETTING; Locke EA, 2002, AM PSYCHOL, V57, P705, DOI 10.1037//0003-066X.57.9.705; Maclean N, 2000, SOC SCI MED, V50, P495; Medical Research Council, 2000, FRAM DEV EV RCTS COM; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Siegert RJ, 2005, DISABIL REHABIL, V27, P1493, DOI 10.1080/09638280500288401; Siegert RJ, 2004, DISABIL REHABIL, V26, P1175, DOI 10.1080/09638280410001724834; Tennant A, 2007, DISABIL REHABIL, V29, P1583, DOI 10.1080/09638280701618828; TORNER JC, 1996, EPIDEMIOLOGY CLOSED; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; World Health Organization, 2005, 55 SESS WHO REG COMM; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832	31	64	65	0	15	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2009	23	4					296	309		10.1177/0269215509102980			14	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	427YC	WOS:000264814000002	19293290				2022-02-06	
J	Toklu, HZ; Hakan, T; Biber, N; Solakolu, S; Ogunc, AV; Sener, G				Toklu, Hale Z.; Hakan, Tayfun; Biber, Necat; Solakolu, Seyhun; Oeguenc, Ayliz Velioglu; Sener, Goeksel			The protective effect of alpha lipoic acid against traumatic brain injury in rats	FREE RADICAL RESEARCH			English	Article						Alpha lipoic acid; brain injury; closed head; trauma; blood-brain barrier; oedema	ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN; NA+,K+-ATPASE ACTIVITY; METABOLIC ANTIOXIDANT; MELATONIN; MODEL; PATHOPHYSIOLOGY; NEUROPROTECTION	Traumatic brain injury (TBI) was induced by a weight-drop device using 300 g-1 m weight-height impact. The study groups were: control, alpha-lipoic acid (LA) (100 mg/kg, po), TBI, and TBI + LA (100 mg/kg, po). Forty-eight hours after the injury, neurological scores were measured and brain samples were taken for histological examination or determination of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) levels, myeloperoxidase (MPO) and Na+-K+ ATPase activities, whereas cytokines (TNF-, IL-1) were determined in blood. Brain oedema was evaluated by wet-dry weight method and blood-brain barrier (BBB) permeability was evaluated by Evans Blue (EB) extravasation. As a result, neurological scores mildly increased in trauma groups. Moreover, TBI caused a significant decrease in brain GSH and Na+-K+ ATPase activity, which was accompanied with significant increases in TBARS level, MPO activity and plasma proinflammatory cytokines. LA treatment reversed all these biochemical indices as well as histopathological alterations. TBI also caused a significant increase in brain water content and EB extravasation which were partially reversed by LA treatment. These findings suggest that LA exerts neuroprotection by preserving BBB permeability and by reducing brain oedema probably by its anti-inflammatory and antioxidant properties in the TBI model.	[Toklu, Hale Z.; Sener, Goeksel] Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey; [Hakan, Tayfun; Biber, Necat] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey; [Solakolu, Seyhun] Istanbul Univ, Sch Med, Dept Histol & Embriyol, Istanbul, Turkey; [Oeguenc, Ayliz Velioglu] Marmara Univ, Vocat Sch Hlth Related Sci, TR-34668 Istanbul, Turkey		Sener, G (corresponding author), Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey.	gsener@marmara.edu.tr	Toklu, Hale/AAR-2330-2020; Hakan, Tayfun/O-9979-2019; Hakan, Tayfun/P-8626-2015	Toklu, Hale/0000-0002-9797-3591; Hakan, Tayfun/0000-0003-1444-7076; Hakan, Tayfun/0000-0003-1444-7076; solakoglu, seyhun/0000-0002-1389-9639	Mikrogen Pharmaceuticals	The authors are grateful to Mikrogen Pharmaceuticals for supplying alpha lipoic acid.	Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arivazhagan P, 2002, EXP GERONTOL, V37, P803, DOI 10.1016/S0531-5565(02)00015-3; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Buege J A, 1978, Methods Enzymol, V52, P302; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chng HT, 2009, BRAIN RES, V1251, P80, DOI 10.1016/j.brainres.2008.11.025; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DAVIES GR, 1992, GUT, V33, P1467, DOI 10.1136/gut.33.11.1467; Dulundu E, 2007, PHARMACOLOGY, V79, P163, DOI 10.1159/000098953; Durmaz R, 2003, J NEUROL SCI, V215, P87, DOI 10.1016/S0022-510X(03)00207-7; ERECINSKA M, 1994, PROG NEUROBIOL, V43, P37, DOI 10.1016/0301-0082(94)90015-9; Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feng Dong-fu, 2004, Chin J Traumatol, V7, P148; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRISAR T, 1984, ANN NEUROL, V16, pS128, DOI 10.1002/ana.410160719; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; KIM YK, 1986, TOXICOL APPL PHARM, V86, P411, DOI 10.1016/0041-008X(86)90368-6; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kurella E, 1997, ANN NY ACAD SCI, V834, P661, DOI 10.1111/j.1749-6632.1997.tb52344.x; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makeeva AV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P76, DOI 10.1134/S0006297908010112; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Packer L, 1997, Adv Pharmacol, V38, P79; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Prahalathan C, 2006, TOXICOLOGY, V222, P225, DOI 10.1016/j.tox.2006.02.015; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rossol M, 1998, J AM INST CONSERV, V37, P231, DOI 10.2307/3179807; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Sehirli O, 2008, CLIN EXP PHARMACOL P, V35, P249, DOI 10.1111/j.1440-1681.2007.04810.x; Selvakumar E, 2006, CLIN CHIM ACTA, V367, P114, DOI 10.1016/j.cca.2005.11.034; Sener G, 2005, SURG TODAY, V35, P52, DOI 10.1007/s00595-004-2879-1; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shay KP, 2008, IUBMB LIFE, V60, P362, DOI 10.1002/iub.40; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smrcka M, 2007, BRATISL MED J, V108, P144; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Toklu HZ, 2008, J SURG RES, V145, P214, DOI 10.1016/j.jss.2007.03.072; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703; Yu SP, 2003, BIOCHEM PHARMACOL, V66, P1601, DOI 10.1016/S0006-2952(03)00531-8	62	64	65	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2009	43	7					658	667	PII 911687855	10.1080/10715760902988843			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	457ZS	WOS:000266979200003	19468925				2022-02-06	
J	Slemmer, JE; Zhu, C; Landshamer, S; Trabold, R; Grohm, J; Ardeshiri, A; Wagner, E; Sweeney, MI; Blomgren, K; Culmsee, C; Weber, JT; Plesnila, N				Slemmer, Jennifer E.; Zhu, Changlian; Landshamer, Stefan; Trabold, Raimund; Grohm, Julia; Ardeshiri, Ardavan; Wagner, Ernst; Sweeney, Marva I.; Blomgren, Klas; Culmsee, Carsten; Weber, John T.; Plesnila, Nikolaus			Causal Role of Apoptosis-Inducing Factor for Neuronal Cell Death Following Traumatic Brain Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FOCAL CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; CONTROLLED CORTICAL IMPACT; STRETCH-INDUCED INJURY; CNS INJURY; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; HIPPOCAMPAL CELLS; HYPOXIA-ISCHEMIA	Traumatic brain injury (TBI) consists of two phases: an immediate phase in which damage is caused as a direct result of the mechanical impact; and a late phase of altered biochemical events that results in delayed tissue damage and is therefore amenable to therapeutic treatment. Because the molecular mechanisms of delayed post-traumatic neuronal cell death are stiff poorly understood, we investigated whether apoptosis-inducing factor (AIF), a pro-apoptotic mitochondrial molecule and the key factor in the caspase-independent, cell death signaling pathway, plays a causal role in neuronal death following TBI. Using an in vitro model of neuronal stretch injury, we demonstrated that AN translocated from mitochondria to the nucleus of neurons displaying axonal disruption, chromatin condensation, and nuclear pyknosis in a caspase-independent manner, whereas astrocytes remained unaffected. Similar findings were observed following experimental TBI in mice, where AN translocation to die nucleus coincided with delayed neuronal cell death in both cortical and hippocampal neurons. Down-regulation of AIF in vitro by siRNA significantly reduced stretch-induced neuronal cell death by 67%, a finding corroborated in vivo using AIF-deficient harlequin mutant mice, where secondary contusion expansion was significantly reduced by 44%. Hence, our current findings demonstrate that caspase-independent, ALF-mediated signaling pathways significantly contribute to post-traumatic neuronal cell death and may therefore represent novel therapeutic targets for the treatment of TBI. (Am J Pathol 2008,173:1795-1805, DOI: 10.2353/ajpath.2008.080168)	[Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Physiol & Neurodegenerat, Dublin 2, Ireland; [Slemmer, Jennifer E.; Sweeney, Marva I.] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada; [Slemmer, Jennifer E.; Weber, John T.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Zhu, Changlian; Blomgren, Klas] Gothenburg Univ, Inst Neurosci & Physiol, Ctr Brain Repair & Rehab, S-41124 Gothenburg, Sweden; [Landshamer, Stefan; Wagner, Ernst; Culmsee, Carsten] Univ Munich, Dept Pharm, D-80539 Munich, Germany; [Trabold, Raimund; Ardeshiri, Ardavan; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, D-80539 Munich, Germany; [Trabold, Raimund; Ardeshiri, Ardavan; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Inst Surg Res, D-80539 Munich, Germany; [Grohm, Julia; Blomgren, Klas] Gothenburg Univ, Queen Silvia Childrens Hosp, Dept Pediat Oncol, S-41124 Gothenburg, Sweden; [Culmsee, Carsten] Univ Marburg, Inst Pharmacol & Toxicol, D-35032 Marburg, Germany; [Weber, John T.] Mem Univ Newfoundland, Sch Pharm, St John, NF, Canada		Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Neurodegenerat, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Wagner, Ernst/ABB-5976-2020; Plesnila, Nikolaus/T-7522-2019; Wagner, Ernst/A-7435-2012; Culmsee, Carsten/ABC-3120-2021	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015; Zhu, Changlian/0000-0002-5029-6730; Blomgren, Klas/0000-0002-0476-7271	Fakultatsforderprogramm fur Forschung und Lehre (FoFoLe) of the University of Munich; Erasmus MC; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Childhood Cancer FoundationEuropean Commission; Hersenstichting Nederland	Supported by the Fakultatsforderprogramm fur Forschung und Lehre (FoFoLe) of the University of Munich, a Breedtestrategie subsidie from Erasmus MC, the Swedish Research Council, the Swedish Childhood Cancer Foundation and Hersenstichting Nederland.	BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Chu CT, 2005, J NEUROCHEM, V94, P1685, DOI 10.1111/j.1471-4159.2005.03329.x; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Katayama Y, 1998, ACT NEUR S, V71, P289; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	54	64	70	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	DEC	2008	173	6					1795	1805		10.2353/ajpath.2008.080168			11	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	377LU	WOS:000261253500020	18988795	Green Published			2022-02-06	
J	Avants, B; Duda, JT; Kim, J; Zhang, H; Pluta, J; Gee, JC; Whyte, J				Avants, Brian; Duda, Jeffrey T.; Kim, Junghoon; Zhang, Hui; Pluta, John; Gee, James C.; Whyte, John			Multivariate Analysis of Structural and Diffusion Imaging in Traumatic Brain Injury	ACADEMIC RADIOLOGY			English	Article						Diffeomorphism; unbiased; traumatic brain injury; diffusion; morphometry	MILD COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; AXONAL INJURY; THALAMIC NUCLEI; HEAD-INJURY; CORTICOSPINAL TRACT; FIBER TRACTOGRAPHY; VEGETATIVE STATE; TEMPORAL-LOBE; TENSOR	Rationale and Objectives. Diffusion tensor (DT) and T1 structural magnetic resonance images provide unique and complementary tools for quantifying the living brain. We leverage both modalities in a diffeomorphic normalization method that unifies analysis of clinical datasets in a consistent and inherently multivariate (MV) statistical framework. We use this technique to study MV effects of traumatic brain injury (TBI). Materials and Methods. We contrast T1 and DT image-based measurements in the thalamus and hippocampus of 12 TBI survivors and nine matched controls normalized to a combined DT and T1 template space. The normalization method uses maps that are topology-preserving and unbiased. Normalization is based on the full tensor of information at each voxel and simultaneously, the similarity between high-resolution features derived from T1 data. The technique is termed symmetric normalization for MV neuroanatomy (SyNMN). Voxel-wise MV statistics on the local volume and mean diffusion are assessed with Hotelling's T-2 test with correction for multiple comparisons. Results. TBI significantly (false discovery rate P < .05) reduces volume and increases mean diffusion at coincident locations in the mediodorsal thalamus and anterior hippocampus. Conclusions: SyNMN reveals evidence that TBI compromises the limbic system. This TBI morphometry study and an additional performance evaluation contrasting SyNMN with other methods suggest that the DT component may aid normalization quality.	[Avants, Brian; Duda, Jeffrey T.; Zhang, Hui; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Pluta, John] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Kim, Junghoon; Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA		Duda, JT (corresponding author), Univ Penn, Dept Radiol, 3600 Market St,Suite 320, Philadelphia, PA 19104 USA.	stnava@gmail.com	Kennedy, Kristen M/B-4699-2008; Kim, Junghoon/A-6669-2012; Kim, Junghoon John/I-6702-2019	Kennedy, Kristen M/0000-0001-5373-9026; Kim, Junghoon John/0000-0001-5729-8993; avants, brian/0000-0002-4212-3362; Whyte, John/0000-0002-4381-1474; Zhang, Hui/0000-0002-5426-2140	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32 CA74781, T32 CA074781] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD039621, R24 HD39621] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [L40 DA025520] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS045839] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA074781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Ardekani BA, 2005, NEUROREPORT, V16, P1455, DOI 10.1097/01.wnr.0000177001.27569.06; Arsigny V, 2006, MAGN RESON MED, V56, P411, DOI 10.1002/mrm.20965; Avants B, 2003, LECT NOTES COMPUT SC, V2717, P21; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; AVANTS BB, 2006, MATH METHODS BIOMEDI; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beg MF, 2007, IEEE T MED IMAGING, V26, P1179, DOI 10.1109/TMI.2007.898813; CHAPPELL MH, 2006, J MAGN RESON IMAGING; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Duan Y, 2007, INT J BIOMED IMAGING, V2007, DOI 10.1155/2007/90216; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; FURLOW B, 2006, RADIOL TECHNOL, V78, P157; Furlow Bryant, 2006, Radiol Technol, V78, P145; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Hammers A, 2007, NEUROIMAGE, V36, P38, DOI 10.1016/j.neuroimage.2007.02.031; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hashimoto K, 2007, J REHABIL MED, V39, P418, DOI 10.2340/16501977-0065; Hermosillo G, 2002, INT J COMPUT VISION, V50, P329, DOI 10.1023/A:1020830525823; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kantarci K, 2001, RADIOLOGY, V219, P101, DOI 10.1148/radiology.219.1.r01ap14101; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kindlmann G, 2007, LECT NOTES COMPUT SC, V4791, P1; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langers DRM, 2007, NEUROIMAGE, V38, P43, DOI 10.1016/j.neuroimage.2007.07.031; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mangin JF, 2002, MED IMAGE ANAL, V6, P191, DOI 10.1016/S1361-8415(02)00079-8; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; McAllister, 1998, Semin Clin Neuropsychiatry, V3, P211; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller MI, 2005, P NATL ACAD SCI USA, V102, P9685, DOI 10.1073/pnas.0503892102; MILLER MI, 1993, P NATL ACAD SCI USA, V90, P11944, DOI 10.1073/pnas.90.24.11944; Miller MI, 2002, ANNU REV BIOMED ENG, V4, P375, DOI 10.1146/annurev.bioeng.4.092101.125733; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; O'Sullivan M, 2004, NEUROLOGY, V62, P702, DOI 10.1212/01.WNL.0000113760.72706.D2; Park HJ, 2003, NEUROIMAGE, V20, P1995, DOI 10.1016/j.neuroimage.2003.08.008; Ray KM, 2006, RADIOLOGY, V241, P197, DOI 10.1148/radiol.2411051051; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STUDHOLME C, 2008, MED IMAGE ANAL  0416; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Sydykova D, 2007, CEREB CORTEX, V17, P2276, DOI 10.1093/cercor/bhl136; Thirion JP, 1996, PROC CVPR IEEE, P245, DOI 10.1109/CVPR.1996.517081; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wiegell MR, 2003, NEUROIMAGE, V19, P391, DOI 10.1016/S1053-8119(03)00044-2; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; YAN C, 2005, TMI, V24, P1216; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yushkevich PA, 2007, NEUROIMAGE, V35, P1516, DOI 10.1016/j.neuroimage.2007.01.029; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	71	64	64	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	NOV	2008	15	11					1360	1375		10.1016/j.acra.2008.07.007			16	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	369PY	WOS:000260707600004	18995188	Green Accepted			2022-02-06	
J	Serbest, G; Burkhardt, MF; Siman, R; Raghupathi, R; Saatman, KE				Serbest, Gulyeter; Burkhardt, Matthew F.; Siman, Robert; Raghupathi, Ramesh; Saatman, Kathryn E.			Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice	NEUROCHEMICAL RESEARCH			English	Article						calpain; cytoskeleton; neurofilament; optic nerve; spectrin; tubulin; white matter	SPINAL-CORD-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; EXPERIMENTAL BRAIN-INJURY; CALPAIN I ACTIVATION; CLOSED-HEAD INJURY; NEUROFILAMENT PROTEINS; CATHEPSIN-D; SPECTRIN DEGRADATION; MEDIATED PROTEOLYSIS; BREAKDOWN PRODUCTS	To examine the time course and relative extent of proteolysis of neurofilament and tubulin proteins after traumatic axonal injury (TAI), anesthetized mice were subjected to optic nerve stretch injury. Immunohistochemistry confirmed neurofilament accumulation within axonal swellings at 4, 24, and 72 h postinjury (n = 4 injured and 2 sham per time point). Immunoblotting of optic nerve homogenates (n = 5 injured and 1 sham at 0.5, 4, 24 or 72 h) revealed calpain-mediated spectrin proteolytic fragments after injury. Protein levels for NF68 progressively decreased from 0.5 h to 24 h postinjury, while NF200 and alpha-tubulin levels decreased acutely (0.5-4 h), with a secondary decline at 72 h postinjury. These data demonstrate that diffusely distributed TAI is associated not only with a localized accumulation of neurofilament proteins, but also significant decreases in total cytoskeletal protein levels which may be mediated, in part, by calpains. Protection of the axonal cytoskeleton represents a potential therapeutic target for axonal damage associated with injury or neurodegenerative diseases.	Univ Kentucky, Dept Physiol Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA		Saatman, KE (corresponding author), Univ Kentucky, Dept Physiol Spinal Cord & Brain Injury Res Ctr, B367 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	k.saatman@uky.edu	Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS041561, R01NS048234, R01NS045131, T32NS043126] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS45131, R01 NS048234, R01-NS41561, T32-NS043126, R01 NS048234-01A2, P50-NS08803] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BANAYSCHWARTZ M, 1983, NEUROCHEM RES, V8, P51, DOI 10.1007/BF00965653; BANAYSCHWARTZ M, 1987, NEUROCHEM RES, V12, P361, DOI 10.1007/BF00993246; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Ellis RC, 2004, J NEUROCHEM, V88, P689, DOI 10.1046/j.1471-4159.2003.02197.x; Fournier AE, 1995, BIOCHEM CELL BIOL, V73, P659, DOI 10.1139/o95-073; GEDDES JW, 1995, NEUROBIOL AGING, V16, P651, DOI 10.1016/0197-4580(95)00062-J; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; Irving EA, 1997, MOL CHEM NEUROPATHOL, V30, P253, DOI 10.1007/BF02815102; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MOSKOWITZ PF, 1993, J NEUROSCI RES, V34, P129, DOI 10.1002/jnr.490340113; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAATMAN KE, 2007, HDB NEUROCHEMISTRY M; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STEPHENS RE, 1976, PHYSIOL REV, V56, P709, DOI 10.1152/physrev.1976.56.4.709; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	66	64	66	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	DEC	2007	32	12					2006	2014		10.1007/s11064-007-9318-9			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	226ZK	WOS:000250626800002	17401646				2022-02-06	
J	Couch, JR; Lipton, RB; Stewart, WF; Scher, AI				Couch, James R.; Lipton, Richard B.; Stewart, Walter F.; Scher, Ann I.			Head or neck injury increases the risk of chronic daily headache - A population-based study	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HEADACHE; MINOR HEAD; FREQUENT HEADACHE; PREVALENCE; CONCUSSION; SEVERITY; MIGRAINE	Objective: To evaluate the extent to which head and neck injury ( HANI) contributes to chronic daily headache ( CDH). Background: In prospective studies, head injury is associated with headache ( HA) that remains a problem at 12 to 24 months post- head injury in 20 to30% of patients. Of these, up to 30 to 50% manifest CDH. The degree to which head injury contributes to CDH has not been evaluated in a non- clinical population. We evaluate the relationship between lifetime occurrence of HANI and CDH in a randomly chosen population sample. Methods: Study participants are from the Frequent Headache Epidemiology Study. Cases with CDH ( >= 180 HA/ year) and a comparison group with episodic headache ( EH, 2 to 102 HA/ year) were identified from the general population. Subjects were asked about lifetime occurrence of HANI. HANI were further classified as potentially precipitating injuries ( PPI) if they occurred within 2 years of CDH onset for cases or in an equivalent 2- year period for EH controls. Results: Lifetime occurrence of HANI was more frequent in cases than controls for men ( adjusted OR = 3.1 [ 1.3 to 7.2]), women ( OR = 1.5 [ 0.97 to 2.3]), and overall ( OR = 1.7 [ 1.1 to 2.4]). The attributable risk was 15% ( 36% men, 11% women). Results were similar for PPI. The odds of CDH increased with the number of lifetime HANI in all groups ( p < 0.05 trend). Conclusions: Results suggest that head and neck injury ( HANI) accounts for approximately 15% of chronic daily headache ( CDH) cases in this non- clinical population. The relationship between HANI and CDH was not limited to injuries proximate to CDH onset. The lifetime risk of CDH increases with increasing number of HANI.	Univ Oklahoma, Sch Med, Dept Neurol, Oklahoma City, OK 73104 USA; Albert Einstein Coll Med, Dept Neurol Epidemiol Populat Hlth, Bronx, NY 10467 USA; Outcomes Res Inst, Danville, PA USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD USA		Couch, JR (corresponding author), Univ Oklahoma, Sch Med, Dept Neurol, 711 SL Yong Blvd,Room 209, Oklahoma City, OK 73104 USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011	Scher, Ann/0000-0003-4599-9834			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Berglund A, 2001, J CLIN EPIDEMIOL, V54, P851, DOI 10.1016/S0895-4356(00)00369-3; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; Cartlidge NEF, 1981, HEAD INJURY, P95; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Guttmann E, 1943, LANCET, V1, P10; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; KAY DWK, 1971, LANCET, V2, P1052; LANZI G, 1985, CEPHALALGIA, V5, P211, DOI 10.1046/j.1468-2982.1985.0504211.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Moscato Davide, 2005, J Headache Pain, V6, P284, DOI 10.1007/s10194-005-0208-8; Nestvold K, 2005, ACTA NEUROL SCAND, V112, P13, DOI 10.1111/j.1600-0404.2005.00344.x; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHECTER AL, 2001, WOLFFS HEADACHE OTHE, P108; Scher AI, 2003, NEUROLOGY, V60, P1366, DOI 10.1212/01.WNL.0000055873.71552.51; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Scher AI, 2003, PAIN, V106, P81, DOI 10.1016/S0304-3959(03)00293-8; Scher AI, 2004, NEUROLOGY, V63, P2022, DOI 10.1212/01.WNL.0000145760.37852.ED; Schrader H, 2006, EUR J NEUROL, V13, P1226, DOI 10.1111/j.1468-1331.2006.01481.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; Symonds CP, 1943, LANCET, V1, P7; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Wiendels NJ, 2006, CEPHALALGIA, V26, P1434, DOI 10.1111/j.1468-2982.2006.01210.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YOUNG WB, 2005, CHRONIC DAILY HEADAC	42	64	69	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 11	2007	69	11					1169	1177		10.1212/01.wnl.0000276985.07981.0a			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	208VA	WOS:000249346100014	17846416				2022-02-06	
J	Kurpius, D; Nolley, EP; Dailey, ME				Kurpius, Dana; Nolley, Eric P.; Dailey, Michael E.			Purines induce directed migration and rapid homing of microglia to injured pyramidal neurons in developing hippocampus	GLIA			English	Article						brain slice; ATP; time-lapse; motility; migration; CNS trauma	RAT-BRAIN; IN-VITRO; EXTRACELLULAR NUCLEOTIDES; P2Y(12) RECEPTOR; NERVOUS-SYSTEM; CELL-MIGRATION; SLICE CULTURES; GLIAL-CELLS; ACTIVATION; EXPRESSION	Traumatic CNS injury activates and mobilizes resident parenchymal microglia (MG), which rapidly accumulate near injured neurons where they transform into phagocytes. The mechanisms underlying this rapid 'homing' in situ are unknown. Using time-lapse confocal imaging in acutely excised neonatal hippocampal slices, we show that rapid accumulation of MG near somata of injured pyramidal neurons in the stratum pyramidale (SP) results from directed migration from tissue regions immediately adjacent to (< 200 mu m from) the SP. Time-lapse sequences also reveal a 'spreading activation wave' wherein MG situated progressively farther from the SP begin to migrate later and exhibit less directional migration toward the SP Because purines have been implicated in MG activation and chemotaxis, we tested whether ATP/ADP released from injured pyramidal neurons might account for these patterns of MG behavior. Indeed, application of apyrase, which degrades extracellular ATP/ADP, inhibits MG motility and homing to injured neurons in the SP Moreover, bath application of exogenous ATP/ADP disrupts MG homing by inducing directional migration toward the slice exterior and away from injured neurons. These results indicate that extracellular ATP/ADP is both necessary and sufficient to induce directional migration and rapid homing of neonatal MG to injured neurons in situ. Rapid, ATP/ADP-dependent MG homing may promote clearance of dead and dying cells and help limit secondary damage during the critical first few hours after neuronal injury. (c) 2007 Wiley-Liss, Inc.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA		Dailey, ME (corresponding author), Univ Iowa, Dept Biol Sci, 369 Biol Bldg, Iowa City, IA 52242 USA.	Michael-e-dailey@uiowa.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10 RR017941] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43468, R01 NS043468] Funding Source: Medline		Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Bianco F, 2005, BRAIN RES REV, V48, P144, DOI 10.1016/j.brainresrev.2004.12.004; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boucsein C, 2003, EUR J NEUROSCI, V17, P2267, DOI 10.1046/j.1460-9568.2003.02663.x; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Carbonell WS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-5; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; DAILEY ME, 2005, IMAGING NEUROSCIENCE, P1; Dalmau I, 1998, J COMP NEUROL, V398, P333, DOI 10.1002/(SICI)1096-9861(19980831)398:3<333::AID-CNE3>3.0.CO;2-0; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Duan YL, 2003, J NEUROBIOL, V57, P183, DOI 10.1002/neu.10262; DUBYAK GR, 1993, AM J PHYSIOL, V265, P577; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Franklin A, 2003, EUR J PHARMACOL, V474, P195, DOI 10.1016/S0014-2999(03)02074-0; Haas S, 1996, NEUROSCIENCE, V75, P257, DOI 10.1016/0306-4522(96)00270-9; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KURPIUS D, 2005, IMAGING NEUROSCIENCE, P425; Kurpius D, 2006, GLIA, V54, P58, DOI 10.1002/glia.20355; Maciejewski-Lenoir D, 1999, J IMMUNOL, V163, P1628; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; McLarnon JG, 2005, J NEUROSCI RES, V81, P349, DOI 10.1002/jnr.20475; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Nicholas RA, 2001, MOL PHARMACOL, V60, P416; Nolte C, 1997, EUR J NEUROSCI, V9, P1690, DOI 10.1111/j.1460-9568.1997.tb01526.x; NORENBERG W, 1994, BRIT J PHARMACOL, V111, P942; Petersen MA, 2004, GLIA, V46, P195, DOI 10.1002/glia.10362; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; Sasaki Y, 2003, GLIA, V44, P242, DOI 10.1002/glia.10293; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101; Xiang ZH, 2005, GLIA, V52, P119, DOI 10.1002/glia.20227; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	54	64	66	0	3	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0894-1491			GLIA	Glia	JUN	2007	55	8					873	884		10.1002/glia.20509			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	164IY	WOS:000246228300009	17405148				2022-02-06	
J	Cullen, DK; Lessing, MC; LaPlaca, MC				Cullen, D. Kacy; Lessing, M. Christian; LaPlaca, Michelle C.			Collagen-dependent neurite outgrowth and response to dynamic deformation in three-dimensional neuronal cultures	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						cell biomechanics; neurite outgrowth; hydrogel; in vitro; mechanotransduction; TBI	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; EXTRACELLULAR-MATRIX; MECHANICAL STRETCH; CELL-ADHESION; GEL STIFFNESS; AXONAL INJURY; NEURAL CELLS; 3 DIMENSIONS; INTEGRIN	In vitro models of brain injury that use thick 3-D cultures and control extracellular matrix constituents allow evaluation of cell-matrix interactions in a more physiologically relevant configuration than traditional 2-D cultures. We have developed a 3-D cell culture system consisting of primary rat cortical neurons distributed throughout thick (> 500 mu m) gels consisting of type IV collagen (Col) conjugated to agarose. Neuronal viability and neurite outgrowth were examined for a range of agarose (AG) percentages (1.0-3.0%) and initial collagen concentrations ([Col](i); 0-600 mu g/mL). In unmodified AG, 1.5% gels supported viable cultures with significant neurite outgrowth, which was not found at lower (<= 1.0%) concentrations. Varying [Col](i) in 1.25% AG revealed the formation of dense, 3-D neurite networks at [Col](i) of 300 mu g/mL, while neurons in unmodified AG and at higher [Col](i) (600 mu g/mL) exhibited significantly less neurite outgrowth; although, neuronal survival did not vary with [Col](i). The effect of [Col](i) on acute neuronal response following high magnitude, high rate shear deformation (0.50 strain, 30 s(-1) strain rate) was evaluated in 1.5% AG for [Col](i) of 30, 150, and 300 mu g/mL, which supported cultures with similar baseline viability and neurite outgrowth. Conjugation of Col to AG also increased the complex modulus of the hydrogel. Following high rate deformation, neuronal viability significantly decreased with increasing [Col](i), implicating cell-matrix adhesions in acute mechanotransduction events associated with traumatic loading. These results suggest interrelated roles for matrix mechanical properties and receptor-mediated cell-matrix interactions in neuronal viability, neurite outgrowth, and transduction of high rate deformation. This model system may be further exploited for the elucidation of mechanotransduction mechanisms and cellular pathology following mechanical insult.	Georgia Inst Technol, GT Emory Coulter Dept Biomed Engn, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Georgia Inst Technol, GT Emory Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014] Funding Source: Medline; NCIPC CDC HHS [R49/CE000191] Funding Source: Medline		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Anderson KL, 2004, J NEUROSCI RES, V75, P688, DOI 10.1002/jnr.20018; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; BELLAMKONDA R, 1995, J NEUROSCI RES, V41, P501, DOI 10.1002/jnr.490410409; BRADSHAW AD, 1995, DEVELOPMENT, V121, P3593; CARMELIET G, 1994, J CELL SCI, V107, P3379; Cavalcanti-Adam Elisabetta Ada, 2005, Prog Orthod, V6, P232; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danen EHJ, 2003, J PATHOL, V201, P632, DOI 10.1002/path.1472; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Dillon GP, 1998, J BIOMAT SCI-POLYM E, V9, P1049, DOI 10.1163/156856298X00325; Dodla MC, 2006, J BIOMED MATER RES A, V78A, P213, DOI 10.1002/jbm.a.30747; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Granet C, 1998, MED BIOL ENG COMPUT, V36, P513, DOI 10.1007/BF02523224; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HOFFMAN RM, 1993, STEM CELLS, V11, P105, DOI 10.1002/stem.5530110205; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kamm Roger D, 2004, Mech Chem Biosyst, V1, P201; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; KREWSON CE, 1994, BIOTECHNOL BIOENG, V43, P555, DOI 10.1002/bit.260430704; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Li BS, 2000, J NEUROSCI, V20, P6055, DOI 10.1523/JNEUROSCI.20-16-06055.2000; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; O'Connor SM, 2000, BIOSENS BIOELECTRON, V14, P871; O'Connor SM, 2001, NEUROSCI LETT, V304, P189, DOI 10.1016/S0304-3940(01)01769-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Schense JC, 2000, J BIOL CHEM, V275, P6813, DOI 10.1074/jbc.275.10.6813; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Smith DH, 1999, J NEUROSCI, V19, P4263; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOMASELLI KJ, 1991, ANN NY ACAD SCI, V633, P100; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wehrle-Haller B, 2003, J PATHOL, V200, P481, DOI 10.1002/path.1399; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Woerly S, 1996, NEUROSCI LETT, V205, P197, DOI 10.1016/0304-3940(96)12349-1; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Yu TT, 2005, BIOMATERIALS, V26, P1507, DOI 10.1016/j.biomaterials.2004.05.012; Yu XJ, 2001, J NEUROSCI RES, V66, P303, DOI 10.1002/jnr.1225	63	64	66	0	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2007	35	5					835	846		10.1007/s10439-007-9292-z			12	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	158TF	WOS:000245816900014	17385044				2022-02-06	
J	Mihalik, JP; McCaffrey, MA; Rivera, EM; Pardini, JE; Guskiewicz, KM; Collins, MW; Lovell, MR				Mihalik, Jason P.; McCaffrey, Meghan A.; Rivera, Eric M.; Pardini, Jamie E.; Guskiewicz, Kevin M.; Collins, Michael W.; Lovell, Mark R.			Effectiveness of mouthguards in reducing neurocognitive deficits following sports-related cerebral concussion	DENTAL TRAUMATOLOGY			English	Article						mild traumatic brain injury; high school athlete; concussion recovery; oral injury	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; NCAA CONCUSSION; ICE HOCKEY; RECOVERY; INJURIES; SOCCER; PERFORMANCE; FRACTURES; TRAUMA	Although it is widely accepted that mouthguards decrease the incidence of dental injuries, there is a controversy among sports medicine professionals as to the effectiveness of mouthguards in decreasing the incidence or severity of sports-related cerebral concussion (SRCC). While some experimental data suggest that this may be the case, there exist a number of reports suggesting that mouthguards do not serve this purpose. These conclusions have been drawn, however, without actually measuring the extent of neurocognitive dysfunction in athletes following sports-related concussion. The purpose of this study was to determine whether mouthguard use reduces the neurocognitive and symptomatic impairments that follow an injurious episode of SRCC. Preseason baseline data were collected as part of an ongoing clinical program that uses a computerized neurocognitive test to assess various faculties of brain function and symptoms reported at the time of testing. Follow-up testing from 180 student-athletes who had sustained an SRCC was analyzed for the purpose of this study. These athletes were separated into one of two groups: those who reported using mouthguards and those who did not. Neurocognitive testing was accomplished using the Immediate Post-Concussion and Assessment Test (ImPACT). Results suggest that neurocognitive deficits at the time of the athletes' first follow-up assessment did not differ between mouthguard users and non-users, suggesting that mouthguard use does little to reduce the severity of neurocognitive dysfunction and onset of symptoms following sports-related head trauma. However, an interesting finding in this study was that athletes experienced significantly lower neurocognitive test scores and reported higher symptom scores following SRCC regardless of mouthguard use. This emphasizes a thorough clinical evaluation of athletes that have sustained an SRCC. Although it was found in this study that mouthguard use does not decrease the severity of concussion, it is important to note that the use of mouthguards is paramount in reducing maxillofacial and dental trauma and their use should continue to be mandated by athletic associations and supported by all dental and sports medicine professionals.	Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Endodont, Chapel Hill, NC 27599 USA; Univ Pittsburgh, Med Ctr, Sports Med Concuss Program, Pittsburgh, PA USA		Mihalik, JP (corresponding author), Univ N Carolina, Sports Med Res Lab, CB 8700,Fetzer Gymnasium S Rd, Chapel Hill, NC 27599 USA.	jasonm@unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Blignaut J B, 1987, Br J Sports Med, V21, P5; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hawn KL, 2002, J ATHL TRAINING, V37, P204; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JONES NP, 1994, BRIT J SPORT MED, V28, P272, DOI 10.1136/bjsm.28.4.272; Kerr L, 1983, Clin Sports Med, V2, P115; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Levin L, 2003, DENT TRAUMATOL, V19, P237, DOI 10.1034/j.1600-9657.2003.00196.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mihalik JP, 2005, J ATHL TRAINING, V40, P116; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Padilla R, 1996, J Calif Dent Assoc, V24, P30; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey K F, 1999, Gen Dent, V47, P64; WOODMANSEY KF, 1999, GEN DENT, V47, P70	36	64	68	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2007	23	1					14	20		10.1111/j.1600-9657.2006.00488.x			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Dentistry, Oral Surgery & Medicine	125LM	WOS:000243443400004	17227375				2022-02-06	
J	Guilmette, TJ; Malia, LA; Mcquiggan, MD				Guilmette, Thomas J.; Malia, Laurie A.; Mcquiggan, Michael D.			Concussion understanding and management among New England high school football coaches	BRAIN INJURY			English	Article						concussion; football; football coaches	TRAUMATIC BRAIN-INJURY; MISCONCEPTIONS	Primary objective: To determine high school football coaches' understanding, management and sources of information of concussion at schools without a certified athletic trainer (ATC) or without one at practice. Research design: Anonymous survey of head football coaches at New England high schools. Methods and procedures: Surveys were mailed to 254 New England high school head football coaches. One hundred and nine ( 43%) surveys were returned, of which 62 respondents indicated there was no ATC either at the school or at practice. These 62 respondents were used for data analysis. Main outcomes and results: Coaching associations and conferences were the two most common sources of information received about concussion. Coaches were significantly more knowledgeable about concussion than a general public sample, from which data were available from a prior study. When given potential symptoms of concussion, 70 - 95% of coaches reported that they would consult a healthcare professional before allowing a player to return to action, consistent with most return-to-play guidelines. Conclusions: Participants demonstrated greater knowledge about concussions than the general public and most, but not all, coaches reported taking a conservative approach to concussion management. Ramifications of the results are discussed.	Providence Coll, Dept Psychol, Providence, RI 02918 USA; Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA; So New England Rehabil Ctr, Providence, RI USA		Guilmette, TJ (corresponding author), Providence Coll, Dept Psychol, Providence, RI 02918 USA.	tguilmet@providence.edu					BELL K, 2006, INTERNET J HLTH; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carek P J, 1999, J S C Med Assoc, V95, P420; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi S, 2006, SPORTS NEUROPSYCHOLO, P71; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McKeag DB, 2003, JAMA-J AM MED ASSOC, V290, P2604, DOI 10.1001/jama.290.19.2604; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; *NAT FED STAT HIGH, GUID MAN HEAD TRAUM; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Tonino PM, 2004, PHYSICIAN SPORTSMED, V32, P37, DOI 10.3810/psm.2004.02.123; *US DEP HHS CDCP, 2005, 0998262 US DEP HHS C; VANGSNESS C, 1994, AM J SPORT MED, V22, P719, DOI 10.1177/036354659402200524; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	23	64	64	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1039	1047		10.1080/02699050701633080			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600006	17891566				2022-02-06	
J	Herrmann, BL; Rehder, J; Kahlke, S; Wiedemayer, H; Doerfler, A; Ischebeck, W; Laumer, R; Forsting, M; Stolke, D; Mann, K				Herrmann, B. L.; Rehder, J.; Kahlke, S.; Wiedemayer, H.; Doerfler, A.; Ischebeck, W.; Laumer, R.; Forsting, M.; Stolke, D.; Mann, K.			Hypopituitarism following severe traumatic brain injury	EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES			English	Article						severe traumatic brain injury; hypopituitarism	GROWTH-HORMONE; PITUITARY DYSFUNCTION; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; TSH RESPONSE; REHABILITATION; INVOLVEMENT; DEFICIENCY; METABOLISM; GLUCOSE	Although hypopituitarism is a known complication of traumatic head injury, it may be under-recognized due to its subtle clinical manifestations. To address this issue, we determine the prevalence of neuroendocrine abnormalities in patients rehabilitating from severe traumatic brain injury (Glasgow Coma Scale <= 8). 76 patients (mean age 39 +/- 14 yr; range 18-65; 53 males and 23 females; BMI 25.8 +/- 4.2 kg/m(2); mean +/- SD) with a severe traumatic brain injury, an average of 22 10 months before this study (median, 20 months), underwent a series of standard endocrine tests, including TSH, free T4, T4, T3, prolactin, testosterone (males), estradiol (females), cortisol, ACTH, GH, and IGF-I. All subjects also underwent GH response to GHRH + arginine. Growth hormone deficiency (GHD) was defined as a GH response < 9 mu g/L to GHRH + arginine and was confirmed by ITT (< 3 mu g/L). Pituitary deficiency was shown in 24 % of the patients (18/76). 8 % (n = 6) had GHD (GH-peak range [GHRH + arginine]: 2.8 - 6.3 mu g/L; GH-peak range [ITT]: 1.5 - 2.2 mu g/L; IGF-I range: 62 - 174 mu g/L). 17 % (n = 13) had hypogonadism (total testosterone < 9.5 nmol/L and low gonadotropins in 12 males; low estradiol, and low gonadotropins in 1 female). Total testosterone levels did not correlate with BMI or age. 2 males with hypogonadism also showed a mild hyperprolactinemia (33 and 41 ng/ml). 3 % (n = 2) patients had partial ACTH-deficiency (cortisol-peak [ITT] 392 and 417 nmol/L) and 3 % (n = 2) had TSH-deficiency. In summary, we have found hypopituitarism in one-fourth of patients with predominantly secondary hypogonadism and GHD. These findings strongly suggest that patients who suffer head trauma must routinely include neuroendocrine evaluations.	Technol Ctr Bochum, Inst Cardiodiabet, D-44799 Bochum, Germany; Univ Hosp Essen, Dept Endocrinol, Essen, Germany; Univ Hosp Essen, Dept Neurosurg, Essen, Germany; Univ Hosp Essen, Dept Neuroradiol, Essen, Germany; Univ Witten Herdecke, Clin Neurosurg Rehabil, D-5810 Witten, Germany; Univ Essen Gesamthsch, Dept Neurosurg, Alfried Krupp Clin, Essen, Germany		Herrmann, BL (corresponding author), Technol Ctr Bochum, Inst Cardiodiabet, Univ Str 142, D-44799 Bochum, Germany.	herrmann@kardio-diabetes.biz	Forsting, Michael/C-6925-2013				Abs R, 2003, EUR J ENDOCRINOL, V148, pS3, DOI 10.1530/eje.0.148S003; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BENGTSSON BA, 1990, HORM RES, V33, P19, DOI 10.1159/000181579; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Coiro V, 2000, J INVEST MED, V48, P133; EDWARDS OM, 1986, MEDICINE, V65, P281; Goni MJ, 1997, METABOLISM, V46, P1305, DOI 10.1016/S0026-0495(97)90235-3; Herrmann BL, 2004, HORM METAB RES, V36, P54, DOI 10.1055/s-2004-814199; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MULLER EE, 1987, PHYSIOL REV, V67, P962, DOI 10.1152/physrev.1987.67.3.962; Radetti G, 2000, J ENDOCRINOL INVEST, V23, P744, DOI 10.1007/BF03345064; Rees P, 2001, LANCET, V358, P1812, DOI 10.1016/S0140-6736(01)06814-3; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; Seidell JC, 2000, EUR J CLIN NUTR, V54, pS33, DOI 10.1038/sj.ejcn.1601023; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Webster JB, 1997, ARCH PHYS MED REHAB, V78, P314, DOI 10.1016/S0003-9993(97)90040-X	30	64	65	0	4	JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH	STUTTGART	RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY	0947-7349	1439-3646		EXP CLIN ENDOCR DIAB	Exp. Clin. Endocrinol. Diabet.	JUN	2006	114	6					316	321		10.1055/s-2006-924254			6	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	068GA	WOS:000239359500006	16868891				2022-02-06	
J	Davis, DP; Serrano, JA; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, Daniel P.; Serrano, Jennifer A.; Vilke, Gaty M.; Sise, Michael J.; Kennedy, Frank; Eastman, A. Brent; Velky, Thomas; Hoyt, David B.			The predictive value of field versus arrival Glasgow coma scale score and TRISS calculations in moderate-to-severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma		Glasgow Coma Scale; traumatic brain injury; TRISS; paramedic; predictive value	RAPID-SEQUENCE INTUBATION; EMERGENCY CARE; MORTALITY; IMPACT; PATIENT; TEAM; AIR	Background: Glasgow Coma Scale (GCS) scores are widely used to quantify level of consciousness in the prehospital environment. The predictive value of field versus arrival GCS is not well defined but has tremendous implications with regard to triage and therapeutic decisions as well as the use of various predictive scoring systems, such as Trauma Score and Injury Severity Score (TRISS). This study explores the predictive value of field GCS (fGCS) and arrival GCS (aGCS) as well as TRISS calculations using field (fTRISS) and arrival (aTRISS) data in patients with moderate-to-severe traumatic brain injury (TBI). Methods: Major trauma victims with head Abbreviated Injury Scores of 3 or greater were identified from our county trauma registry over a 16-year period. The predictive ability of fGCS with regard to aGCS was explored using univariate statistics and linear regression modeling. The difference between aGCS and fGCS was also modeled against mortality and the composite endpoint using logistic regression, adjusting for fGCS. The predictive value of preadmission GCS (pGCS), defined as either fGCS or aGCS in nonintubated patients without a documented fGCS, with regard to mortality and a composite endpoint representing the need for neurosurgical care (death, craniotomy, invasive intracranial pressure monitoring, or intensive care unit care > 48 hours) was determined using receiver-operator curve (ROC) analysis. Finally, fTRISS and aTRISS predicted survival values were compared with each other and to observed survival. Results: A total of 12,882 patients were included. Mean values for fGCS and aGCS were similar (11.4 and 11.5, respectively, p = 0.336), and a strong correlation (r(2) = 0.67, 95 % CI 0.66-0.69, p < 0.0001) was observed between them. The difference between fGCS and aGCS was also predictive of outcome after adjusting for fGCS. Good predictive ability was observed for pGCS with regard to both mortality and neurosurgical intervention. Both fTRISS and aTRISS predicted survival values were nearly identical to observed survival. Observed and fTRISS predicted survival were nearly identical in patients undergoing prehospital intubation. Conclusions: Values for fGCS are highly predictive of aGCS, and both are associated with outcome from TBI. A change in GCS from the field to arrival is highly predictive of outcome. The use of field data for TRISS calculations appears to be a valid methodological approach, even in severely injured TBI patients undergoing prehospital intubation.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; Mercy Air Med Serv, San Diego, CA USA; Scripps Mercy Hosp, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps La Jolla Hosp, La Jolla, CA USA; Palomar Hosp, Escondido, CA USA		Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net					Amin AP, 2000, SURGERY, V127, P245, DOI 10.1067/msy.2000.104296; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BOYD CR, 1989, J TRAUMA, V29, P789, DOI 10.1097/00005373-198906000-00015; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Jacobs L M, 1999, Conn Med, V63, P677; Larson JT, 2004, J TRAUMA, V56, P89, DOI 10.1097/01.TA.0000061163.35582.A5; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; TEASDALE G, 1982, SCOT MED J, V27, P7, DOI 10.1177/003693308202700103; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X	33	64	66	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2006	60	5					985	990		10.1097/01.ta.0000205860.96209.1c			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	044NB	WOS:000237678100017	16688059				2022-02-06	
J	Marmarou, CR; Povlishock, JT				Marmarou, CR; Povlishock, JT			Administration of the immunophilin ligand FK506 differentially attenuates neurofilament compaction and impaired axonal transport in injured axons following diffuse traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; axonal damage; amyloid precursor protein (APP); immunophilin ligands; FK506; neurofilament compaction (NFC)	TRANSIENT FOCAL ISCHEMIA; CYCLOSPORINE-A; POSTTRAUMATIC HYPOTHERMIA; IMMUNOSUPPRESSANT FK506; CYTOSKELETAL CHANGES; DAMAGE; RAT; PROTEOLYSIS; MODEL; BETA	Traumatic axonal injury (TAI) following traumatic brain injury (TBI) remains a clinical problem for which no effective treatment exists. TAI was thought to involve intraaxonal changes that universally led to impaired axonal transport (IAT), disconnection and axonal bulb formation. However, recent, immunocytochemical studies employing antibodies to amyloid precursor protein (APP), a marker of IAT and antibodies to neurofilament compaction (NFC), RM014, demonstrated that NFC typically occurs independent of IAT, indicating the existence of different populations of damaged axons. FK506 administration has been shown to attenuate IAT. However, in light of the above, the ability of FK506 to attenuate axonal damage demonstrating NFC requires evaluation. The Current study explored the potential of FK506 to attenuate both populations of damaged axons. Rats were administered FK506 (3 mg/kg) or vehicle 30 min preinjury. Three hours post-TBI, tissue was prepared for the visualization of TAI using antibodies targeting IAT (APP) or NFC (RM014) or a combined labeling strategy. Confirming previous reports, FK506 treatment reduced the number of axons demonstrating IAT in the CSpT, from 411 +/- 54.70 to 91.00 +/- 33.87 (P <= 0.05) and in the ML from 78.62 +/- 16.87 to 41.00 +/- 5.80 (P <= 0.05). FK506 treatment failed to reduce the number of axons demonstrating NFC in either the CSpT or ML. FK506's failure to attenuate NFC suggests that additional therapeutic agents may be necessary to blunt the full burden of TAL Because FK506 targets IAT, calcineurin appears to be a major target for neuroprotection in damaged axons demonstrating IAT. (c) 2005 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jpovlish@hse.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS7288, NS-20193] Funding Source: Medline		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; Arii T, 2001, NEUROL RES, V23, P755, DOI 10.1179/016164101101199135; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUKI A, 2001, J NEUROTRAUM, V18, P1171; Butcher SP, 1997, J NEUROSCI, V17, P6939; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lofvenberg L, 1999, FEBS LETT, V443, P89, DOI 10.1016/S0014-5793(98)01697-4; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Nito C, 2004, BRAIN RES, V1008, P179, DOI 10.1016/j.brainres.2004.02.031; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OKONKWO DO, 2002, IMMUNOSUPPRESSANT AN, P263; PANNESE E, 1984, ACTA ANAT, V118, P193; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shields DC, 1997, EXP EYE RES, V65, P15, DOI 10.1006/exer.1997.0286; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Stys PK, 2002, NEUROSCI LETT, V328, P150, DOI 10.1016/S0304-3940(02)00469-X; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; UEDA Y, 2001, J NEUROTRAUM, V18, P1179; WATSON D, 1991, J NEUROSCI RES, V30, P226, DOI 10.1002/jnr.490300123; WITGEN BM, 2002, J NEUROTRAUM, V18, P1171	64	64	67	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					353	362		10.1016/j.expneurol.2005.10.003			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	009RV	WOS:000235131000011	16297913				2022-02-06	
J	Seyfried, D; Ding, J; Han, YX; Li, Y; Chen, JL; Chopp, M				Seyfried, D; Ding, J; Han, YX; Li, Y; Chen, JL; Chopp, M			Effects of intravenous administration of human bone marrow stromal cells after intracerebral hemorrhage in rats	JOURNAL OF NEUROSURGERY			English	Article						bone marrow stromal cell; intracerebral hemorrhage; neural regeneration; rat	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; NONHEMATOPOIETIC TISSUES; PROGENITOR CELLS; STROKE; TRANSPLANTATION; SYNAPTOGENESIS; MOUSE; MICE	Object. The goal of this study was to investigate whether human bone marrow stromal cells (hBMSCs) administered by intravenous injection have a beneficial effect on outcome after intracerebral hemorrhage (ICH) in rats. Methods. An ICH was induced in 54 adult male Wistar rats by a stereotactically guided injection of autologous blood into the right striatum. Intravenous infusion of the hBMSCs (3, 5, or 8 million cells) was performed I day after ICH, and for each dose group there was a control group that received injections of vehicle. Neurological function, which was evaluated using the Neurological Severity Score (NSS) and the corner turn test, was tested before and at 1, 7, and 14 days after ICH. After 14 days of survival, the area of encephalomalacia was calculated and histochemical labeling was performed. For all three groups, there were no statistical differences in either the NSS or corner turn tests after I day. After 7 and 14 days, however, the three groups that received the hBMSCs showed significant improvement in functional scores compared with the control group. In addition, after 14 days there was significantly more striatal tissue loss in the placebo groups compared with each of the three treatment groups. The region of injury in the treated animals demonstrated a significantly increased presence of hBMSCs, immature neurons, neuronal migration, synaptogenesis, and newly formed DNA. Conclusions. Intravenous administration of hBMSCs significantly improves neurological function in rats subjected to ICH. This improvement in the treated animals is associated with reduced tissue loss and increased local presence of the hBMSCs, mitotic activity, immature neurons, synaptogenesis, and neuronal migration.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA		Seyfried, D (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsdos@neuro.hfh.edu					ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; BENNETT JH, 1991, J CELL SCI, V99, P131; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gong C, 2001, NEUROSURGERY, V48, P875, DOI 10.1097/00006123-200104000-00037; Hua Y, 2002, J CEREBR BLOOD F MET, V22, P55, DOI 10.1097/00004647-200201000-00007; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1999, OSTEOARTHR CARTILAGE, V7, P364, DOI 10.1053/joca.1998.0213; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Villars F, 2000, J CELL BIOCHEM, V79, P672, DOI 10.1002/1097-4644(20001215)79:4<672::AID-JCB150>3.0.CO;2-2; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang ZG, 2004, NEUROIMAGE, V23, P281, DOI 10.1016/j.neuroimage.2004.05.019; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	31	64	73	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2006	104	2					313	318		10.3171/jns.2006.104.2.313			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	009CY	WOS:000235090000021	16509507				2022-02-06	
J	Ward, H; Shum, D; McKinlay, L; Baker-Tweney, S; Wallace, G				Ward, H; Shum, D; McKinlay, L; Baker-Tweney, S; Wallace, G			Development of prospective memory: Tasks based on the prefrontal-lobe model	CHILD NEUROPSYCHOLOGY			English	Article						prospective memory; children; prefrontal-lobe model	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; WORKING-MEMORY; FRONTAL-LOBE; EXPLICIT MEMORY; PERFORMANCE; CHILDREN; EVENT; TIME; DEFICITS	This study investigated the development of prospective memory using tasks based on the prefrontal-lobe model. Three groups each of 30 children, adolescents, and young adults were compared on prospective-memory performance using ongoing tasks with two levels of cognitive demand (low and high), and two levels of importance (unstressed and stressed) of remembering prospective cues. The Self-Ordered Pointing Task (SOPT), Stroop Color Word Interference Test, and Tower of London were also used to assess relationships between prospective memory and prefrontal-lobe functions. The children remembered fewer prospective cues than either the adolescents or adults, but the adolescents and adults remembered equally well. This trend increased significantly as the cognitive demand of the ongoing tasks increased. However, stressing or not stressing the importance of remembering made no difference to prospective-memory performance. Performance on the SOPT and Stroop Colour Word Interference predicted performance on the high- but not on the low-demand condition. These findings implicate the maturation of the brain's prefrontal region in the development of prospective memory.	Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia; Griffith Univ, Appl Cognit Neurosci Res Ctr, Nathan, Qld 4111, Australia; Royal Childrens Hosp, Brisbane, Qld, Australia; Mater Childrens Hosp, Brisbane, Qld, Australia		Ward, H (corresponding author), Griffith Univ, Sch Appl Psychol, Brisbane, Qld 4111, Australia.	h.ward@griffith.edu.au	Shum, David/A-3914-2008; Wallace, Geoff/H-1252-2013	Shum, David/0000-0002-4810-9262; Wallace, Geoff/0000-0001-9306-3542; McKinlay, Lynne/0000-0002-6677-0628			CECI SJ, 1985, CHILD DEV, V56, P152, DOI 10.2307/1130182; *CEDR CORP, 1996, SUP LAB PRO EXP LAB; CLUTTERBUCK PM, 1990, ART TEACHING SPELLIN; DAIGNEAULT S, 1993, J CLIN EXP NEUROPSYC, V15, P881, DOI 10.1080/01688639308402605; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; ELLIS JA, 1993, MEMORY, V10, P7; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gevins A, 1998, HUM FACTORS, V40, P79, DOI 10.1518/001872098779480578; Golden C, 2000, NEUROPSYCHOLOGICAL I; Golden CJ., 1978, STROOP COLOUR WORD T; Hanes KR, 1996, ARCH CLIN NEUROPSYCH, V11, P185, DOI 10.1016/0887-6177(95)00034-8; HARRIS JE, 1983, EVERYDAY MEMORY ACTI, P71; HITCH GJ, 1988, MEM COGNITION, V16, P120, DOI 10.3758/BF03213479; HITCH GJ, 1989, MEM COGNITION, V17, P175, DOI 10.3758/BF03197067; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kidder DP, 1997, AGING NEUROPSYCHOL C, V4, P93, DOI 10.1080/13825589708256639; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kvavilashvili L, 1998, APPL COGNITIVE PSYCH, V12, P533, DOI 10.1002/(SICI)1099-0720(1998120)12:6<533::AID-ACP538>3.0.CO;2-1; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Leech Geoffrey., 2001, WORD FREQUENCIES WRI; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Mateer C., 1997, CHILDHOOD TRAUMATIC, P153; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McDaniel M.A., 1996, PROSPECT MEM THEORY, P115; McGann D, 2002, MEM COGNITION, V30, P1021, DOI 10.3758/BF03194320; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; OReilly R.C., 1996, PROSPECTIVE MEMORY T, P267; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; Passolunghi MC, 1995, INT J BEHAV DEV, V18, P631, DOI 10.1177/016502549501800404; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Psychological Corporation, 1999, WECHSL ABBR SCAL INT; RUSSO R, 1995, J EXP CHILD PSYCHOL, V59, P566, DOI 10.1006/jecp.1995.1026; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHALLICE T, 1996, PROSPECTIVE MEMORY T, P319; Shimamura A.P., 1994, NEUROPSYCHOLOGY, V8, P408, DOI DOI 10.1037/0894-4105.8.3.408; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Shum D, 2000, BRAIN COGNITION, V44, P59; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P141; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; SNODGRASS JG, 1989, IMPLICIT MEMORY, P259; SOMERVILLE SC, 1983, J GENET PSYCHOL, V143, P87, DOI 10.1080/00221325.1983.10533537; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; Tunstall J., 1999, THESIS GRIFFITH U BR; Uttl B, 1997, J CLIN EXP NEUROPSYC, V19, P405, DOI 10.1080/01688639708403869; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson KM, 2001, J LEARN DISABIL-US, V34, P237, DOI 10.1177/002221940103400304; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3	63	64	65	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2005	11	6					527	549		10.1080/09297040490920186			23	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	987ZY	WOS:000233557900004	16306026				2022-02-06	
J	Cutler, SM; Pettus, EH; Hoffman, SW; Stein, DG				Cutler, SM; Pettus, EH; Hoffman, SW; Stein, DG			Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						progesterone; withdrawal; traumatic brain injury (TBI); apoptosis; inflammation; anxiety	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVITY; HORMONE REPLACEMENT; CORTICAL CONTUSION; GABA(A) RECEPTOR; ACTIVATION; PROTECTS; ANXIETY; MECHANISM; DURATION	Systemic injections of the neurosteroid progesterone improve cognitive recovery after traumatic brain injury (TBI) and stroke, and decrease molecular indicators of neuronal damage. Suddenly withdrawing progesterone after repeated dosing (PW) exacerbates ischemia and causes increased anxiety, seizure susceptibility, and excitotoxicity. Adult male Sprague-Dawley rats received either bilateral medial frontal cortex contusions or sham surgery. Injections were administered at 1 and 6 h post-injury, then every 24 h for 7 days. Vehicle-treated rats received 2-hydroxypropyl-beta-cyclodextrin (HBC). Acute PW (AW) rats received a full 16 mg/ml of progesterone for 7 days, and tapered PW (TW) rats received 5 days at full dosage, then 2 days with progressively halved dosages. Anxiety behaviors were observed pre- and post-surgery, and compared to levels at the peak of withdrawal. AW rats with lesions exhibited significantly more anxiety than any other treatment group, while both lesion- and sham-operated TW rats were indistinguishable from vehicle-treated intact animals. After behavioral tests were complete, the brains were extracted and prepared for Western blotting. TNF alpha, cFos, Caspase-3, and NF kappa B, among others, were investigated. While all progesterone treatments resulted in improved molecular recovery, TW animals had significantly fewer active markers for apoptosis and inflammation than AW animals. In conclusion, although progesterone treatment decreases inflammation and apoptosis, acute withdrawal increases activity in some apoptotic and inflammatory pathways and increases anxiety behavior during the acute healing phase. A tapered withdrawal of the hormone further enhances short-term recovery after TBI. (c) 2005 Elsevier Inc. All rights reserved.	Dept Emergency Med, Clin B, Atlanta, GA 30322 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA		Cutler, SM (corresponding author), Dept Emergency Med, Clin B, B5-301,1365 Clifton Rd, Atlanta, GA 30322 USA.	gt7812c@mail.gatech.edu	Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N538664, 1R01N540825] Funding Source: Medline		Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brenner RM, 2002, ANN NY ACAD SCI, V955, P60, DOI 10.1111/j.1749-6632.2002.tb02766.x; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burleson MH, 1998, PSYCHOSOM MED, V60, P17, DOI 10.1097/00006842-199801000-00004; Challis JRG, 1999, J PERINAT MED, V27, P26, DOI 10.1515/JPM.1999.003; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi SH, 2001, PSYCHOSOM MED, V63, P822, DOI 10.1097/00006842-200109000-00016; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; DAVIS WW, 1968, J BIOL CHEM, V243, P5153; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GALLO MA, 1993, PHARMACOL BIOCHEM BE, V46, P897, DOI 10.1016/0091-3057(93)90219-J; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gulinello M, 2003, EUR J NEUROSCI, V17, P641, DOI 10.1046/j.1460-9568.2003.02479.x; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; NAKAMURA T, 1974, ACTA ENDOCRINOL-COP, V75, P410, DOI 10.1530/acta.0.0750410; Oinonen KA, 2002, J AFFECT DISORDERS, V70, P229, DOI 10.1016/S0165-0327(01)00356-1; Pan B S, 1997, Sheng Li Ke Xue Jin Zhan, V28, P101; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 2002, STEROIDS, V67, P519, DOI 10.1016/S0039-128X(01)00170-2; Tremollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107; Wallace AE, 1999, RESTOR NEUROL NEUROS, V14, P35; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355	37	64	66	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2005	195	2					423	429		10.1016/j.expneurol.2005.06.003			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	968VI	WOS:000232190600016	16039652				2022-02-06	
J	Bandak, FA				Bandak, FA			Shaken baby syndrome: A biomechanics analysis of injury mechanisms	FORENSIC SCIENCE INTERNATIONAL			English	Article						injury; infant shaken; baby; rotational; acceleration/deceleration; syndrome; neck	PERMANENT BRAIN-DAMAGE; SUBDURAL HAEMATOMA; MENTAL-RETARDATION; WHIPLASH INJURY; CHILDREN; INFANTS; SHAKING; YOUNGER	Traumatic infant shaking has been associated with the shaken baby syndrome (SBS) diagnosis without verification of the operative mechanisms of injury. Intensities for SBS have been expressed only in qualitative, unsubstantiated terms usually referring to acceleration/deceleration rotational injury and relating to falls from great heights onto hard surfaces or from severe motor vehicle crashes. We conducted an injury biomechanics analysis of the reported SBS levels of rotational velocity and acceleration of the head for their injury effects on the infant head-neck. Resulting forces were compared with experimental data on the structural failure limits of the cervical spine in several animal models as well as human neonate cadaver models. We have determined that an infant head subjected to the levels of rotational velocity and acceleration called for in the SBS literature, would experience forces on the infant neck far exceeding the limits for structural failure of the cervical spine. Furthermore, shaking cervical spine injury can occur at much lower levels of head velocity and acceleration than those reported for the SBS. These findings are consistent with the physical laws of injury biomechanics as well as our collective understanding of the fragile infant cervical spine from (1) clinical obstetric experience, (2) automotive medicine and crash safety experience, and (3) common parental experience. The findings are not, however, consistent with the current clinical SBS experience and are in stark contradiction with the reported rarity of cervical spine injury in children diagnosed with SBS. In light of the implications of these findings on child protection and their social and medico-legal significance, a re-evaluation of the current diagnostic criteria for the SBS and its application is suggested. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med A1036, Bethesda, MD 20814 USA		Bandak, FA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med A1036, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	fbandak@usuhs.mil					American Academy of Pediatrics, 2001, PEDIATRICS, V108; BANDAK FA, 1996, TRAUMATIC BRAIN INJU, P139; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Ching R P, 2001, Stapp Car Crash J, V45, P329; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNCAN M, 1874, BRIT MED J, V2, P763; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; JENNY C, 2002, 30 INT WORKSH PONT V, P129; JOHNSON WH, 1961, RADIOGRAPHIC ANATOMY; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Mayer R., 1999, INJ BIOM RES P 27 IN, P87; Nuckley D., 2000, INJ SCI RES P 28 INT, P85; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1969, LANCET, V2, P237; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; QUAYLE K, 1997, PEDIATRICS, V99; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; STERN WE, 1959, AM J OBSTET GYNECOL, V78, P498, DOI 10.1016/0002-9378(59)90520-4	22	64	68	1	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	JUN 30	2005	151	1					71	79		10.1016/j.forsciint.2005.02.033			9	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	941YV	WOS:000230251000010	15885948				2022-02-06	
J	Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Feuer, H				Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Feuer, H			Concussion in professional football: Players returning to the same game - Part 7	NEUROSURGERY			English	Article						concussion; concussion guidelines; epidemiology; injury surveillance; sport injury; traumatic brain injury	NCAA CONCUSSION; INJURIES; IMPACTS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and outcome of players who were concussed and either returned immediately or were rested and returned to the same game in the National Football League (NFL). METHODS: From 1996 to 2001, concussions were recorded by NFL teams by use of a special standardized reporting form filled out by team physicians. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Action taken after concussion was recorded for 887 patients. RESULTS: There were 135 players (15.2%) who returned immediately and 304 (34.3%) who rested and returned to the same game after concussion. There were few differences by player position or team activity about the injury or action taken. However, the mean number of signs and symptoms progressively increased from those who returned immediately (1.52), rested and returned to play (2.07), were removed from play (3.51), or were hospitalized (6.55). Immediate recall problems (odds ratio [OR], 1.93; confidence interval [01, 1.26-2.94], memory problems (OR, 1.52; Cl, 1.06-2.19), and the number of signs and symptoms (OR, 1.39; Cl, 1.25-1.55) were predictive of removal from play or hospitalization. There was no statistical association between return to play in the same game and a subsequent concussion or a more serious concussion involving 7+ days out. CONCLUSION: Players who are concussed and return to the same game have fewer initial signs and symptoms than those removed from play. Return to play does not involve a significant risk of a second injury either in the same game or during the season. The current decision-making of NFL team physicians seems appropriate for return to the game after a concussion, when the player has become asymptomatic and does not have memory or cognitive problems.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProHLTH Care Assoc LLP, Lake Success, NY USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Wayne State Univ, Ctr Healthcare Effect Res, Dept Psychiat & Behav Neurosci, Detroit, MI USA; Indianapolis Neurosurg Grp, Indianapolis, IN USA		Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; *COL MED SOC, 1991, REPORT SPORTS MED CO; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958	18	64	65	1	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2005	56	1					79	90		10.1227/01.NEU.0000150180.16552.8D			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	884FD	WOS:000226069300029	28184620				2022-02-06	
J	Reiter, ER; DiNardo, LJ; Costanzo, RM				Reiter, ER; DiNardo, LJ; Costanzo, RM			Effects of head injury on olfaction and taste	OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA			English	Article							SMELL IDENTIFICATION TEST; POST-TRAUMATIC ANOSMIA; OF-PENNSYLVANIA SMELL; BRAIN INJURY; DYSFUNCTION; DISORDERS; NERVE; UNIVERSITY; AGEUSIA; BULB	Reports of olfactory or gustatory disturbances date back to the 1800s. Today, head injuries are sustained from traumatic events such as motor vehicle accidents, falls, and assault. A significant percentage of head-injured patients will experience changes in olfaction, or, less commonly, gustation. An understanding of the mechanisms of posttraumatic olfactory and gustatory dysfunction will help physicians better detect patients with such deficits, determine their prognosis for recovery, and provide appropriate treatment and counseling. Such measures may be important to patients in limiting the impact of their sensory loss on their quality of life and rehabilitation.	Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Otolaryngol Head & Neck Surg, Richmond, VA 23298 USA		Costanzo, RM (corresponding author), Virginia Commonwealth Univ, Dept Physiol, 1101 E Marshall St, Richmond, VA 23298 USA.	rcostanz@mail.2.vcu.edu		Costanzo, Richard/0000-0002-6839-3520	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000165] Funding Source: NIH RePORTER		Aiba T, 1998, ACTA OTO-LARYNGOL, P202; ALHADY MRA, 1990, J LARYNGOL OTOL, V104, P927, DOI 10.1017/S0022215100114410; ANDERSSON BGJ, 2002, GUIDES EVALUATION PE; Auerbach SH, 1989, TRAUMATIC BRAIN INJU; Bartoshuk L, 1989, Ear Nose Throat J, V68, P331; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; CAIN WS, 1987, AM IND HYG ASSOC J, V48, P47; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Cerf B, 1998, ANN NY ACAD SCI, V855, P575, DOI 10.1111/j.1749-6632.1998.tb10627.x; COMBARROS O, 1994, EUR NEUROL, V34, P344, DOI 10.1159/000117076; CONE JE, 1991, ENVIRON HEALTH PERSP, V95, P53, DOI 10.2307/3431106; Costanzo R. M., 1995, NEUROL DIS, P493; Costanzo R. M., 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Costanzo RM, 1986, CLIN MEASUREMENTS TA, P565; Costanzo RM, 1991, SMELL TASTE HLTH DIS, P711; Darrouzet V, 2001, OTOLARYNG HEAD NECK, V125, P77, DOI 10.1067/mhn.2001.116182; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Delank K.-W., 1998, Rhinology (Utrecht), V36, P15; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Doty RL, 1995, CHEM SENSES, V20, P645, DOI 10.1093/chemse/20.6.645; DUFFY V B, 1989, Ear Nose and Throat Journal, V68, P395; EBY TL, 1988, LARYNGOSCOPE, V98, P717; Formaker BK, 1998, ANN NY ACAD SCI, V855, P776, DOI 10.1111/j.1749-6632.1998.tb10657.x; Frank M.E., 1991, SMELL TASTE HLTH DIS, P503; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Fujikane M, 1999, Rinsho Shinkeigaku, V39, P771; Green P, 2001, NEUROREHABILITATION, V16, P237; HENKIN RI, 1971, J AMER MED ASSOC, V217, P434, DOI 10.1001/jama.217.4.434; HERBERHOLD C, 1980, LARYNG RHINOL OTOL V, V59, P570, DOI 10.1055/s-2007-1008898; HEYWOOD PG, 1986, AM J OTOLARYNG, V7, P194, DOI 10.1016/S0196-0709(86)80006-0; Ikeda K, 1995, TOHOKU J EXP MED, V177, P343, DOI 10.1620/tjem.177.343; Ikeda K, 1999, Auris Nasus Larynx, V26, P435, DOI 10.1016/S0385-8146(99)00023-1; INAMITSU M, 1990, J LARYNGOL OTOL, V104, P959, DOI 10.1017/S0022215100114483; Kalavrezos ND, 2000, J ROY COLL SURG EDIN, V45, P359; KEMINK JL, 1989, ARCH OTOLARYNGOL, V115, P661; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; Koster NL, 1996, BRAIN RES, V724, P117, DOI 10.1016/0006-8993(96)00281-8; Lawless H, 1983, Trans Pa Acad Ophthalmol Otolaryngol, V36, P190; LEGG JW, 1873, LANCET, V2, P659, DOI DOI 10.1016/S0140-6736(02)66313-5; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MATTES RD, 1994, J AM DIET ASSOC, V94, P50, DOI 10.1016/0002-8223(94)92041-9; MAY M, 1981, LARYNGOSCOPE, V91, P2092; MILLER IJ, 1990, PHYSIOL BEHAV, V47, P1213, DOI 10.1016/0031-9384(90)90374-D; Miwa T, 2001, ARCH OTOLARYNGOL, V127, P497, DOI 10.1001/archotol.127.5.497; MORAN DT, 1985, ARCH OTOLARYNGOL, V111, P122; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Obrebowski A, 1976, Otolaryngol Pol, V30, P391; Obrebowski A, 1977, Czas Stomatol, V30, P343; Renzi G, 2002, ANN PLAS SURG, V48, P355, DOI 10.1097/00000637-200204000-00003; ROTCH TM, 1878, BOSTON MED SURG J, V99, P130; Rousseaux M, 1996, STROKE, V27, P2328, DOI 10.1161/01.STR.27.12.2328; Saito T, 2001, ORL-J OTO-RHIN-LARYN, V63, P359, DOI 10.1159/000055774; Saito T, 2001, LARYNGOSCOPE, V111, P2064, DOI 10.1097/00005537-200111000-00037; SAKAI SC, 1984, SEMIN HEAR, V5, P157; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Scrivani SJ, 2000, J ORAL MAXIL SURG, V58, P3, DOI 10.1016/S0278-2391(00)80003-8; Seiden AM, 2001, LARYNGOSCOPE, V111, P9, DOI 10.1097/00005537-200101000-00002; SEMIRA C, 1957, MINERVA OTORINOLARIN, V7, P3; Sofferman PA, 1993, SURG EAR TEMPORAL BO, P329; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SUMNER D, 1967, BRAIN, V90, P187, DOI 10.1093/brain/90.1.187; Sumner D, 1975, HDB CLIN NEUROLOGY, P1; Sunada I, 1995, NEURORADIOLOGY, V37, P659; TAKAGI SF, 1987, ANN NY ACAD SCI, V510, P113; Temmel AFP, 2002, ARCH OTOLARYNGOL, V128, P635, DOI 10.1001/archotol.128.6.635; Van Toller S, 1999, CHEM SENSES, V24, P705, DOI 10.1093/chemse/24.6.705; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Yamauchi Y, 1995, Nihon Jibiinkoka Gakkai Kaiho, V98, P119; Yee KK, 1998, CHEM SENSES, V23, P513, DOI 10.1093/chemse/23.5.513; YEE KK, 1995, PHYSIOL BEHAV, V58, P959, DOI 10.1016/0031-9384(95)00159-G; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	75	64	65	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0030-6665	1557-8259		OTOLARYNG CLIN N AM	Otolaryngol. Clin. N. Am.	DEC	2004	37	6					1167	+		10.1016/j.otc.2004.06.005			19	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	881KW	WOS:000225867400006	15563909				2022-02-06	
J	Shore, PM; Thomas, NJ; Clark, RSB; Adelson, PD; Wisniewski, SR; Janesko, KL; Bayir, H; Jackson, EK; Kochanek, PM				Shore, PM; Thomas, NJ; Clark, RSB; Adelson, PD; Wisniewski, SR; Janesko, KL; Bayir, H; Jackson, EK; Kochanek, PM			Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: Effect on biochemical markers	JOURNAL OF NEUROTRAUMA			English	Article						head injury; interleukin-6; neuron-specific enolase; pediatrics; s100B; vascular endothelial growth factor; ventriculostomy	ENDOTHELIAL GROWTH-FACTOR; INTERLEUKIN-6; GLUTAMATE	Drainage of cerebrospinal fluid (CSF) is routinely used in the treatment of severe traumatic brain injury (TBI), either continuously or intermittently in response to increases in intracranial pressure (ICP). There has been little study of the effect of CSF drainage method on the biochemistry, pathophysiology or outcome of TBI in adults or children. Having previously reported that a variety of markers of injury or repair increase in CSF after severe TBI, we chose to evaluate directly the effect of CSF drainage method on the biochemistry and volume of CSF drained as well as ICP. We hypothesized that concentrations of these markers would be similar in CSF drained continuously vs intermittently. We compared CSF levels of markers of neuronal injury (neuron specific enolase, [NSE]), glial injury (s100B), inflammation (interleukin-6 [IL-6]), and regeneration (vascular endothelial growth factor [VEGF]) (measured by ELISA) in 80 CSF samples from 19 severely injured children whose CSF was drained continuously (n = 13) versus intermittently (n = 6) as part of standard care in two institutions. Compared to continuous CSF drainage, intermittent drainage of CSF was associated with twofold greater CSF concentrations of NSE, s100B, IL-6 and VEGF (P < 0.05) and with about half the volume of CSF removal than continuous drainage (P = 0.002). The resulting elimination (concentration x volume) of these biochemicals, however, was not influenced by drainage method. Patients treated with continuous drainage had lower mean ICPs than those with intermittent drainage (13.6 +/- 0.69 vs. 21.8 +/- 0.95 mm Hg,p < 0.0001). We conclude that the method of CSF drainage greatly affects concentrations of CSF markers after TBI and may influence ICP. The influence of method on CSF marker concentration must be kept in mind when interpreting studies of CSF biomarkers. The striking difference in biomarker concentration, CSF volume drained, and ICP suggests the need for a randomized trial directly comparing these two approaches in infants and children with severe TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Penn State Univ, Coll Med, Penn State Childrens Hosp, Div Pediat Crit Care Med, Hershey, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol & Med, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Wisniewski, Stephen/0000-0002-3877-9860; Thomas, Neal/0000-0002-7991-7510	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, NS 38087] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, R01NS038087, P20NS030318] Funding Source: NIH RePORTER		BAYIR H, 2001, MO CL BI CC, V2, P115; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergsneider M, 2001, NEUROSURG CLIN N AM, V12, P631, DOI 10.1016/S1042-3680(18)30021-4; CUTLER RWP, 1968, BRAIN, V91, P707, DOI 10.1093/brain/91.4.707; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; MORGANTIKOSSMANN MC, 2001, MO CL BI CC, V2, P99; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Yamamoto T, 1999, ACT NEUR S, V75, P17	13	64	65	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1113	1122					10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900001	15453982				2022-02-06	
J	Robertson, CL				Robertson, CL			Mitochondrial dysfunction contributes to cell death following traumatic brain injury in adult and immature animals	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article; Proceedings Paper	Mitochondria and Neuroprotection Symposium	APR 16-19, 2004	Ft Lauderdale, FL			brain mitochondria; development; pediatric; cytochrome c; bcl-2; membrane permeability transition; apoptosis	CYTOCHROME-C RELEASE; DEVELOPING RAT-BRAIN; CYCLOSPORINE-A; OXIDATIVE-PHOSPHORYLATION; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; CASPASE ACTIVATION; AXONAL INJURY; HEAD-INJURY; DAMAGE	Secondary injury following traumatic brain injury (TBI) is characterized by a variety of pathophysiologic cascades. Many of these cascades can have significant detrimental effects on cerebral mitochondria. These include exposure of neurons to excitotoxic levels of excitatory neurotransmitters with intracellular calcium influx, generation of reactive oxygen species, and production of peptides that participate in apoptotic cell death. Both experimental and clinical TBI studies have documented mitochondrial dysfunction, and animal studies suggest this dysfunction begins early and may persist for days following injury. Furthermore, interventions targeting mitochondrial mechanisms have shown neuroprotection after TBI. Continued evaluation and understanding of mitochondrial mechanisms contributing to neuronal cell death and survival after TBI is indicated. In addition, important underlying factors, such as brain maturation, that influence mitochondrial function should be studied. The ability to identify, target, and manipulate mitochondrial dysfunction may lead to the development of novel therapies for the treatment of adult and pediatric TBI.	Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA		Robertson, CL (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 22 S Greene St,S5D18, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 42805] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		AEESSANDRI B, 2002, J NEUROTRAUM, V19, P829; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; CDC, 1999, TRAUM BRAIN INJ US R; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DIENEL G, 1977, BIOCHIM BIOPHYS ACTA, V496, P484, DOI 10.1016/0304-4165(77)90330-0; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lai YC, 2003, CRIT CARE MED, V31, pA12; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; MILSTEIN JM, 1968, J NEUROCHEM, V15, P411, DOI 10.1111/j.1471-4159.1968.tb11627.x; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; MURTHY M R, 1963, Biochim Biophys Acta, V74, P51, DOI 10.1016/0006-3002(63)91328-3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PETTUS EH, 1996, BRAIN RES, V25, P1; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; SITKIEWICZ D, 1982, J NEUROCHEM, V39, P1308, DOI 10.1111/j.1471-4159.1982.tb12571.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STRANGE CJ, 2003, CRIT CARE MED, V31, pA12; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	64	65	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	AUG	2004	36	4					363	368		10.1023/B:JOBB.0000041769.06954.e4			6	Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biophysics; Cell Biology	854PR	WOS:000223916300018	15377873				2022-02-06	
J	Ederoth, P; Tunblad, K; Bouw, R; Lundberg, CJF; Ungerstedt, U; Nordstrom, CH; Hammarlund-Udenaes, M				Ederoth, P; Tunblad, K; Bouw, R; Lundberg, CJF; Ungerstedt, U; Nordstrom, CH; Hammarlund-Udenaes, M			Blood-brain barrier transport of morphine in patients with severe brain trauma	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2000	SAN FRANCISCO, CA	Amer Soc Anaesthesiologists		blood-brain barrier; brain injury; human; microdialysis; morphine; pharmacokinetics	IN-VIVO MICRODIALYSIS; P-GLYCOPROTEIN; INTRACEREBRAL MICRODIALYSIS; RESISTANCE; ANESTHESIA; STATE	Aims In experimental studies, morphine pharmacokinetics is different in the brain compared with other tissues due to the properties of the blood-brain barrier, including action of efflux pumps. It was hypothesized in this clinical study that active efflux of morphine occurs also in human brain, and that brain injury would alter cerebral morphine pharmacokinetics. Methods Patients with traumatic brain injury, equipped with one to three microdialysis catheters in the brain and one in abdominal subcutaneous fat for metabolic monitoring, were studied. The cerebral catheter locations were classified as 'better' and 'worse' brain tissue, referring to the degree of injury. Morphine (10 mg) was infused intravenously over a 10-min period in seven patients in the intensive care setting. Tissue and plasma morphine concentrations were obtained during the subsequent 3-h period with microdialysis and regular blood sampling. Results The area under the concentration-time curve (AUC) ratio of unbound morphine in brain tissue to plasma was 0.64 (95% confidence interval 0.40, 0.87) in 'better' brain tissue (P < 0.05 vs. the subcutaneous fat/plasma ratio), 0.78 (0.49, 1.07) in 'worse' brain tissue and 1.00 (0.86, 1.13) in subcutaneous fat. The terminal half-life and T-max were longer in the brain vs. plasma and fat, respectively. The relative recovery for morphine was higher in 'better' than in 'worse' brain tissue. The T-max value tended to be shorter in 'worse' brain tissue. Conclusions The unbound AUC ratio below unity in the 'better' human brain tissue demonstrates an active efflux of morphine across the blood-brain barrier. The 'worse' brain tissue shows a decrease in relative recovery for morphine and in some cases also an increase in permeability for morphine over the blood-brain barrier.	Univ Lund Hosp, Dept Anaesthesiol & Intens Care, SE-22185 Lund, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Univ Lund Hosp, Dept Clin Neurosci, SE-22185 Lund, Sweden		Ederoth, P (corresponding author), Univ Lund Hosp, Dept Anaesthesiol & Intens Care, SE-22185 Lund, Sweden.	per.ederoth@swipnet.se		Lundberg, Johan/0000-0002-3021-1795			Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; BONICA JJ, 1990, MANAGEMENT PAIN, P368; Bouw MR, 1998, PHARMACEUT RES, V15, P1673, DOI 10.1023/A:1011992125204; Bouw MR, 2000, PHARMACEUT RES, V17, P1220, DOI 10.1023/A:1026414713509; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Chen KC, 2002, J NEUROCHEM, V81, P108, DOI 10.1046/j.1471-4159.2002.00793.x; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; JOEL SP, 1988, J CHROMATOGR-BIOMED, V430, P394, DOI 10.1016/S0378-4347(00)83176-X; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stain-Texier F, 1999, BRIT J PHARMACOL, V128, P917, DOI 10.1038/sj.bjp.0702873; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Tunblad K, 2003, PHARMACEUT RES, V20, P618, DOI 10.1023/A:1023250900462; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; van den Nieuwenhuyzen MCO, 2000, CLIN PHARMACOKINET, V38, P181, DOI 10.2165/00003088-200038020-00003; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804; [No title captured]	25	64	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	APR	2004	57	4					427	435		10.1046/j.1365-2125.2003.02032.x			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pharmacology & Pharmacy	804AY	WOS:000220272800008	15025740	Green Published, Bronze			2022-02-06	
J	Luis, CA; Vanderploeg, RD; Curtiss, G				Luis, CA; Vanderploeg, RD; Curtiss, G			Predictors of postconcussion symptom complex in community dwelling male veterans	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; head injury; minor; neurobehavioral manifestations; mental disorders; social support; sequelae	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; DIAGNOSTIC INTERVIEW SCHEDULE; DIFFUSE AXONAL INJURY; COMPLAINT BASE RATES; UNITED-STATES; CONCUSSION; RECOVERY; STRESS; CONSEQUENCES	The presence of a persistent postconcussion symptom complex (PPCSC) was examined in a non-referred sample of male veterans with a history of mild head injury and a comparison group without a history of head injury., Hierarchical logistic regression procedures were used to determine possible predictors of PPCSC using variables supported by previous research (i.e., preexisting psychiatric difficulties, demographic and social support variables, and history of an accidental injurious event). Although PPCSC was common in all groups (23% of the total sample), a significantly greater proportion of individuals in the mild head injury with loss of consciousness group (37.2%) had PPCSC compared with three other groups (head injury without loss of consciousness = 26.1%; motor vehicle accident without head injury = 23%; and control = 17.3%). However, the most salient predictors of PPCSC were early life psychiatric difficulties such as anxiety or depression, limited social support, lower intelligence, and interactions among these variables. The predictive value of loss of consciousness was significant, but low (1.4% of unique variance). The findings provide support for the premise that PPCSC is mediated in part by individual resilience, preexisting psychological status, and psychosocial support.	James A Haley Vet Hosp, Psychiat Serv 116B, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychiat Serv 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				Accordino M.P., 2000, J MENTAL HEALTH COUN, V22, P268; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; [Anonymous], 1988, JAMA, V259, P2701; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BRYANT R, 1999, J NERV MENT DIS, V5, P302; *CDC, 1989, HLTH STAT VIETN VET, V4; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CURTISS G, 2001, M AM PSYCH ASS SAN F; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DeMaris A, 2002, SOCIOL METHOD RES, V31, P27, DOI 10.1177/0049124102031001002; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GOLDBERG L, 1990, PSYCHOPATHOLOGY, V23, P15, DOI 10.1159/000284632; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GRONWALL D, 1989, ASSESSMENT BEHAV CON, V7; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hathaway S.R., 1983, MINNESOTA MULTIPHASI; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kaemmer, 1989, MINNESOTA MULTIPHASI; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCKELVEY RD, 1975, J MATH SOCIOL, V4, P103, DOI 10.1080/0022250X.1975.9989847; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Timmerman IGH, 1998, BEHAV RES THER, V36, P863, DOI 10.1016/S0005-7967(98)00053-9; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD F, 1984, INT J PSYCHIAT MED, V14, P277; World Health Organization, 2004, ICD 10 INT STAT CLAS; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; [No title captured]	76	64	64	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2003	9	7					1001	1015		10.1017/S1355617703970044			15	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	735RW	WOS:000186129200004	14738282				2022-02-06	
J	Besson, VC; Croci, N; Boulu, RG; Plotkine, M; Marchand-Verrecchia, C				Besson, VC; Croci, N; Boulu, RG; Plotkine, M; Marchand-Verrecchia, C			Deleterious poly (ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat	BRAIN RESEARCH			English	Article						3-nitrotyrosine; 3-aminobenzamide; neuroprotection; poly(ADP-ribose)polymerase-1; peroxynitrite; traumatic brain injury	DNA STRAND-BREAKS; MIDDLE CEREBRAL-ARTERY; SPINAL-CORD INJURY; POLY(ADP-RIBOSE) POLYMERASE; NITRIC-OXIDE; OXIDATIVE STRESS; CELL-DEATH; TYROSINE NITRATION; RIBOSE POLYMERASE; ISCHEMIC-INJURY	Traumatic brain injury produces nitric oxide and reactive oxygen species. Peroxynitrite, resulting from the combination of nitric oxide and superoxide anions, triggers DNA strand breaks, leading to the activation of poly(ADP-ribose)polymerase-1. As excessive activation of this enzyme induces cell death, we examined the production of nitrosative stress, the activation of poly(ADP-ribose)polymerase-1, and the role of this enzyme in the outcomes of traumatic brain injury produced by fluid percussion in rats. Immunohistochemistry showed that 3-nitrotyrosine, an indicator of nitrosative stress, and poly(ADP-ribose), a marker of poly(ADP-ribose)polymerase-1 activation, were present as early as 30 min post-injury, and that persisted for 72 h. The poly(ADP-ribose)polymerase inhibitor, 3-aminobenzamide, at 10 and 30 mg/kg, significantly improved the neurological deficit, with a 60% reduction in the brain lesion volume and inhibition of poly(ADP-ribose)polyinerase-1 activation. Thus, poly(ADP-ribose)polyinerase-1 is involved in the neurological consequences of traumatic brain injury and may be a promising therapeutic target in clinical treatment of acute brain trauma. (C) 2003 Elsevier B.V. All rights reserved.	Univ Paris 05, Pharmacol Lab, F-75006 Paris, France		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, 4 Ave Observ, F-75006 Paris, France.		besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020	besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380			Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cookson MR, 1999, BRAIN PATHOL, V9, P165; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Love S, 1999, BRAIN PATHOL, V9, P119; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5	52	64	64	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 31	2003	989	1					58	66		10.1016/S0006-8993(03)03362-6			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733GL	WOS:000185991500008	14519512				2022-02-06	
J	Cory, CZ; Jones, MD				Cory, CZ; Jones, MD			Can shaking alone cause fatal brain injury? A biomechanical assessment of the Duhaime shaken baby syndrome model	MEDICINE SCIENCE AND THE LAW			English	Article							INFLICTED HEAD-INJURY; DIFFUSE AXONAL INJURY; IMPACT; INFANTS; WHIPLASH; NEUROPATHOLOGY; DAMAGE	A biomechanical model of a one-month old baby was designed and tested by Duhaime and co-workers in 1987 in an attempt to assess the biomechanics of the shaken baby syndrome (SBS). The study implied that pure shaking alone cannot cause fatal head injuries, a factor which has been applied in criminal courts. In an attempt to test the validity of the model a preliminary study was undertaken in which a replica was constructed and tested. The broad description of the design and construction of the Duhaime model allowed for variations and therefore uncertainties in its reproduction. It was postulated therefore that differences in certain parameters may increase angular head accelerations. To further investigate this observation, an adjustable replica model was developed and tested. The results indicated that certain parameter changes in the model did in fact lead to an increase in angular head acceleration. When these parameter changes were combined and an injurious shake pattern was employed, using maximum physical effort, the angular head acceleration results exceeded the original Duhaime et al. (1987) results and spanned two scaled tolerance limits for concussion. Additionally, literature suggests that the tolerance limits used to assess the shaking simulation results in the original study may not be reliable. Results from our study were closer to the internal head injury, subdural haematoma, tolerance limits. A series of end point impacts were identified in the shake cycles, therefore, an impact-based head injury measure (Head Injury Criterion - HIC) was utilized to assess their severity. Seven out of ten tests conducted resulted in HIC values exceeding the tolerance limits (critical load value, Sturtz, 1980) suggested for children. At this present stage the authors conclude that it cannot be categorically stated, from a biomechanical perspective, that pure shaking cannot cause fatal head injuries in an infant. Parameters identified in this study require further investigation to assess the accuracy of simulation and increase the biofidelity of the models before further conclusions can be drawn. There must now be sufficient doubt in the reliability of the Duhaime et al. (1987) biomechanical study to warrant the exclusion of such testimony in cases of suspected shaken baby syndrome.	Univ Wales Coll Cardiff, Cardiff Sch Engn, Med Engn Res Ctr, Cardiff CF24 0YF, S Glam, Wales		Cory, CZ (corresponding author), Univ Wales Coll Cardiff, Cardiff Sch Engn, Med Engn Res Ctr, The Parade,POB 925, Cardiff CF24 0YF, S Glam, Wales.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Beusenberg M., 1993, 933104 SAE; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; BUNDEZ DL, 1994, J FOR SCI, V41, P411; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Cory CZ, 2001, FORENSIC SCI INT, V123, P89, DOI 10.1016/S0379-0738(01)00523-0; CORY CZ, 2001, THESIS U WALES CARDI; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duhaime AC, 1996, PEDIAT TRAUMA FORENS, V4, P73; DUHAIME AC, 1998, COMMUNICATION; ELNER SG, 1996, J FOR SCI, V41, P114; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1956, P 11 STAPP CAR CRASH; INGRAHAM FD, 1972, AJDC, V124, P161; IRWIN AL, 1972, 973317 SAE; JACOBI G, 1986, J FOR SCI, V41, P114; JANSSEN EG, 1991, 35 STAPP CAR CRASH C; Klinich K.D., 1996, TECHNIQUES DEV CHILD; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MARGULIES SS, 1999, COMMUNICATION; MASSICOTTE SJ, 1991, J FOR SCI, V41, P114; MUNGER CE, 1993, J FOR SCI, V41, P114; Norris B., 1995, CHILDATA HDB CHILD M; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PHEASANT ST, 1986, CHILDATA HDB CHILD M; PRANGE MT, 1999, P 43 STAPP CAR CRASH, P333; PRASAD P, 1985, 851246 SAE; RAO N, 1988, J FOR SCI, V41, P114; Snyder RG, 1977, ANTHROPOMETRY INFANT; STEENBEKKERS LPA, 1993, CHILDATA HDB CHILD M; Sturtz G, 1980, 24 STAPP CAR CRASH C; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Thibault LE, 1985, P 4 EXP SAF VEH C NE	44	64	64	0	7	CHILTERN PUBLISHING	BEACONSFIELD	34 AYLESBURY END, BEACONSFIELD HP9 1LW, BUCKS, ENGLAND	0025-8024			MED SCI LAW	Med. Sci. Law	OCT	2003	43	4					317	333		10.1258/rsmmsl.43.4.317			17	Law; Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Government & Law; Legal Medicine; Pathology	752LD	WOS:000187161200006	14655963				2022-02-06	
J	Rancan, M; Morganti-Kossmann, MC; Barnum, TR; Saft, T; Schmidt, TOI; Ertel, WG; Stahel, PF				Rancan, M; Morganti-Kossmann, MC; Barnum, TR; Saft, T; Schmidt, TOI; Ertel, WG; Stahel, PF			Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	19th International Complement Workshop Meeting	SEP 22-26, 2002	PALERMO, ITALY			traumatic brain injury; complement; neuroinflammation; blood; brain barrier; transgenic mice	TRAUMATIC BRAIN INJURY; BARRIER DYSFUNCTION; ACTIVATION; PROTEIN; RATS; ACCUMULATION; EXPRESSION; FLUID	The role of intracerebral complement activation after traumatic brain injury remains unclear. In this study, the authors demonstrate that transgenic mice with astrocyte-targeted expression of the soluble complement inhibitor sCrry have a significantly reduced neurologic impairment and improved blood-brain barrier function after closed head injury compared with wild-type C57BL/6 littermates. This work further implicates the complement system as a participant in secondary progression of brain damage after head trauma and provides a strong rationale for future studies of posttraumatic pharmacologic complement inhibition.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Alfred Hosp, Dept Trauma Surg, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA		Stahel, PF (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Dept Trauma & Reconstruct Surg, Hindenburgdamm 30, D-12200 Berlin, Germany.			Morganti-Kossmann, Cristina/0000-0002-0807-2063	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038901] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38901] Funding Source: Medline		Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Davoust N, 1999, J IMMUNOL, V163, P6551; FOLEY S, 1993, EUR J IMMUNOL, V23, P1381, DOI 10.1002/eji.1830230630; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 2002, PRACTICE GEN SURG, P101; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morganti-Kossmann M.C., 2002, IMMUNE INFLAMMATORY, P106; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	22	64	65	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2003	23	9					1070	1074		10.1097/01.WCB.0000084250.20114.2C			5	Endocrinology & Metabolism; Hematology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	718KQ	WOS:000185144800008	12973023	Bronze			2022-02-06	
J	Chiaretti, A; Piastra, M; Polidori, G; Di Rocco, C; Caresta, E; Antonelli, A; Amendola, T; Aloe, L				Chiaretti, A; Piastra, M; Polidori, G; Di Rocco, C; Caresta, E; Antonelli, A; Amendola, T; Aloe, L			Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						nerve growth factor; brain-derived neurotrophic factor; glia-derived neurotrophic factor; traumatic brain injury; Glasgow Coma Scale; Glasgow Outcome Score	NERVE GROWTH-FACTOR; CEREBROSPINAL-FLUID; HEAD-INJURY; ALZHEIMER PATIENT; RAT HIPPOCAMPUS; FACTOR PROTECTS; MESSENGER-RNA; ADULT-RAT; NEURONS; RECEPTORS	Objectives: We evaluated the neurotrophic factors [nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glia-derived neurotrophic factor (GDNF)] expression and their association with the severity and outcome of children with traumatic brain injury. Design: Prospective observational clinical study. Setting: Pediatric intensive care unit. Patients: Fourteen children with severe head injury; 12 controls with obstructive hydrocephalus. Measurement: Cerebrospinal fluid (CSF) and plasma samples were collected 2 h (T1) and 24 h (T2) after head injury. Neurotrophic factor levels were measured using an immunoenzymatic assay. Main results: In patients, neurotrophic factor mean levels were significantly different in both CSF and plasma, showing high levels of BDNF compared to NGF and GDNF. Considering T1 and T2 expression, in the CSF the level of NGF increased from 3.5 +/- 0.4 pg/ml to 48.2 +/- 11.7 pg/ml (p<0.001); BDNF decreased from 4854.0 +/- 1303.7 pg/ml to 593.0 +/- 114.8 pg/ml (p<0.001), while GDNF did not undergo significant variations. In plasma, no significant changes were observed. Regarding severity and outcome, BDNF levels showed a sharp peak after head injury, but the only significant association was between NGF expression in the CSF and a good outcome versus a poor outcome (p=0.007). Conclusions: The variations in neurotrophic factor levels reflect an endogenous attempt at neuroprotection against biochemical and molecular changes after traumatic head injury. BDNF represents an early marker of brain injury, while NGF expression in the CSF was indicative of a good outcome and the role of this neurotrophin in the treatment of children with severe head injury may be hypothesized.	Univ Sacred Heart, Sch Med, Pediat Intens Care Unit, Policlin Gemelli, I-00168 Rome, Italy; CNR, Inst Neurobiol, I-00137 Rome, Italy		Chiaretti, A (corresponding author), Univ Sacred Heart, Sch Med, Pediat Intens Care Unit, Policlin Gemelli, Largo Gemelli 1, I-00168 Rome, Italy.						Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Aronica E, 2001, ACTA NEUROPATHOL, V101, P383; Azmitia EC, 2001, BRAIN DEV-JPN, V23, pS1, DOI 10.1016/S0387-7604(01)00368-0; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FISHER W, 1987, NATURE, V329, P65; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; HASHIMOTO Y, 1992, NEUROSCI LETT, V139, P45, DOI 10.1016/0304-3940(92)90853-Y; HEFTI F, 1986, J NEUROSCI, V6, P2155; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Ikeda T, 2000, ACTA NEUROPATHOL, V100, P161, DOI 10.1007/s004019900162; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Kanai M, 2002, TOHOKU J EXP MED, V196, P241, DOI 10.1620/tjem.196.241; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; Kim JY, 2002, EPILEPSIA, V43, P220, DOI 10.1046/j.1528-1157.43.s.5.33.x; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lappalainen R, 1996, J CHILD NEUROL, V11, P296, DOI 10.1177/088307389601100407; LAUTERBORN JC, 1993, NEUROREPORT, V5, P273, DOI 10.1097/00001756-199312000-00023; Lee TH, 1998, STROKE, V29, P1687, DOI 10.1161/01.STR.29.8.1687; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Lui VCH, 2002, LAB INVEST, V82, P703, DOI 10.1097/01.LAB.0000017364.13014.AE; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nelson KB, 2001, ANN NEUROL, V49, P597, DOI 10.1002/ana.1024; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Seguier-Lipszyc E, 2001, J UROLOGY, V165, P2269, DOI 10.1016/S0022-5347(05)66182-4; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Tokunaga Y, 2002, PEDIATR NEUROL, V27, P102, DOI 10.1016/S0887-8994(02)00387-9	54	64	66	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	AUG	2003	29	8					1329	1338		10.1007/s00134-003-1852-6			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720HQ	WOS:000185255700020	12845427				2022-02-06	
J	Chiaravalloti, ND; Christodoulou, C; Demaree, HA; DeLuca, J				Chiaravalloti, ND; Christodoulou, C; Demaree, HA; DeLuca, J			Differentiating simple versus complex processing speed: Influence on new learning and memory performance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CHRONIC-FATIGUE-SYNDROME; CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; SERIAL ADDITION TEST; MULTIPLE-SCLEROSIS; WORKING-MEMORY; RHEUMATOID-ARTHRITIS; CONSTRUCT-VALIDITY; REVISED CRITERIA; NORMAL EGYPTIANS	The current study was designed to examine how the construct of human information processing speed is conceptualized and measured, while also examining the influence of information processing speed on higher cognitive processes (i.e., learning). A mixed medical sample of 92 subjects participated in this study. Subjects underwent a broad-based neuropsychological evaluation, including measures of verbal and visuospatial new learning, spatial and verbal working memory, simple reaction time, choice reaction time, and information processing speed. Principal components factor analysis with varimax rotation resulted in a three-factor solution, comprised of: (1) simple speed/reaction time, (2) complex information processing and new learning, and (3) working memory. Notably, this factor solution identified 2 distinct forms of processing speed-simple and complex information processing speeds. In contrast to the abundance of literature grouping these two constructs together under one term (i.e., processing speed), these results indicate simple and complex speed to be distinct constructs assessed with different neuropsychological instruments. While the expected relationship between complex information processing capacities and working memory abilities was evident in this study, information processing speed also showed a significant relationship with new learning ability. The implications of this intriguing relationship are discussed.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA; Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA		DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Demaree, Heath/0000-0001-9655-8882	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052810] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH 52810-01A1] Funding Source: Medline		ANDERSON BO, 1989, SURGERY, V106, P347; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A.D., 1994, NEUROPSYCHOLOGY, V8, P485, DOI [10.1037/0894-4105.8.4.485, DOI 10.1037/0894-4105.8.4.485]; BAKER LA, 1991, BEHAV GENET, V21, P351, DOI 10.1007/BF01065972; BARBIZET J, 1968, INT J NEUROL, V7, P44; BARRETT P, 1986, INTELLIGENCE, V10, P9, DOI 10.1016/0160-2896(86)90025-5; BARTLE EJ, 1988, SURGERY, V104, P311; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Bryan J, 1996, PSYCHOL AGING, V11, P3, DOI 10.1037/0882-7974.11.1.3; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CHANNON S, 1993, PSYCHOL MED, V23, P87, DOI 10.1017/S0033291700038873; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; Elwan O, 1996, J NEUROL SCI, V136, P73, DOI 10.1016/0022-510X(95)00292-A; Elwan O, 1997, J NEUROL SCI, V148, P79, DOI 10.1016/S0022-510X(96)05336-1; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOLD AE, 1995, PSYCHOPHARMACOLOGY, V119, P325, DOI 10.1007/BF02246299; GOLD AE, 1995, PHYSIOL BEHAV, V58, P501, DOI 10.1016/0031-9384(95)00085-W; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gronwall D, 1974, PSYCHOL EFFECTS CONC; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; Johnson SK, 1996, PERCEPT MOTOR SKILL, V83, P51, DOI 10.2466/pms.1996.83.1.51; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kessels RPC, 1998, ACTA NEUROL SCAND, V97, P188; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KLOVE H, 1987, J CLIN EXP NEUROPSYC, V9, P297, DOI 10.1080/01688638708402792; KRUPP LB, 1994, ARCH NEUROL-CHICAGO, V51, P705, DOI 10.1001/archneur.1994.00540190089021; LAIDLAW TM, 1993, INT J CLIN EXP HYP, V41, P97, DOI 10.1080/00207149308414541; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVINE G, 1987, PERS INDIV DIFFER, V8, P599, DOI 10.1016/0191-8869(87)90057-2; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LITIVAN I, 1985, ARCH NEUROL-CHICAGO, V45, P281; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; Martin SE, 1996, AM J RESP CRIT CARE, V153, P1328, DOI 10.1164/ajrccm.153.4.8616562; Michiels V, 1996, J CLIN EXP NEUROPSYC, V18, P666, DOI 10.1080/01688639608408290; Michiels V, 1999, J CLIN EXP NEUROPSYC, V21, P709, DOI 10.1076/jcen.21.5.709.875; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prevey ML, 1998, EPILEPSY RES, V30, P1, DOI 10.1016/S0920-1211(97)00091-0; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RASMUSSEN K, 1993, AM J IND MED, V24, P553, DOI 10.1002/ajim.4700240506; ROEDIGER HL, 1980, MEM COGNITION, V8, P231, DOI 10.3758/BF03197611; RUCHKIN DS, 1994, BRAIN, V117, P289, DOI 10.1093/brain/117.2.289; Salthouse T. A., 1993, J GERONTOL B-PSYCHOL, V48, P245; SALTHOUSE TA, 1994, J EXP PSYCHOL LEARN, V20, P1486, DOI 10.1037/0278-7393.20.6.1486; Salthouse TA, 1985, THEORY COGNITIVE AGI, V28th; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; Thomas L, 1996, SEIZURE, V5, P205, DOI 10.1016/S1059-1311(96)80037-9; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; TIERSKY LA, 1998, CLIN NEUROPSYCHOL, V12, P1; UZZELL BP, 1986, J CLIN EXP NEUROPSYC, V8, P581, DOI 10.1080/01688638608405177; Valley V, 1981, Rev Electroencephalogr Neurophysiol Clin, V11, P133, DOI 10.1016/S0370-4475(81)80044-5; Weersink EJM, 1997, AM J RESP CRIT CARE, V156, P1144, DOI 10.1164/ajrccm.156.4.9701001; Wiens AN, 1997, J CLIN EXP NEUROPSYC, V19, P473, DOI 10.1080/01688639708403737	69	64	64	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2003	25	4					489	501		10.1076/jcen.25.4.489.13878			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	683GY	WOS:000183141300005	12911103				2022-02-06	
J	Faden, AI; Knoblach, SM; Cernak, I; Fan, L; Vink, R; Araldi, GL; Fricke, ST; Roth, BL; Kozikowski, AP				Faden, AI; Knoblach, SM; Cernak, I; Fan, L; Vink, R; Araldi, GL; Fricke, ST; Roth, BL; Kozikowski, AP			Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRH analogs; neuroprotection; traumatic brain injury; necrosis; apoptosis	THYROTROPIN-RELEASING-HORMONE; CONTROLLED CORTICAL IMPACT; FREE MAGNESIUM; CELL-DEATH; NEURONAL APOPTOSIS; TRH; CONTRIBUTES; ACTIVATION; DEFICITS; MODEL	The authors developed a novel diketopiperazine that shows neuroprotective activity in a variety of in vitro models, as well as in a clinically relevant experimental model of traumatic brain injury (TBI) in rats. Treatment with 1-ARA-35b (35b), a cyclized dipeptide derived from a modified thyrotropin-releasing hormone (TRH) analog, significantly reduced cell death associated with necrosis (maitotoxin), apoptosis (staurosporine), or mechanical injury in neuronalglial cocultures. Rats subjected to lateral fluid percussion-induced TBI and then treated with 1 mg/kg intravenous 35b thirty minutes after trauma showed significantly improved motor recovery and spatial learning compared with vehicle-treated controls. Treatment also significantly reduced lesion volumes as shown by magnetic resonance imaging, and decreased the number of TUNEL-positive neurons observed in ipsilateral hippocampus. Unlike TRH or traditional TRH analogs, 35b treatment did not change mean arterial pressure, body temperature, or thyroid- stimulating hormone release, and did not have analeptic activity. Moreover, in contrast to TRH or typical TRH analogs, 35b administration after TBI did not alter free-magnesium concentration or cellular bioenergetic state. Receptor-binding studies showed that 35b did not act with high affinity at 50 classical receptors, channels, or transporters. Thus, 35b shows none of the typical physiologic actions associated with TRH, but possesses neuroprotective actions in vivo and in vitro, and appears to attenuate both necrotic and apoptotic cell death.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; Case Western Reserve Univ, Sch Med, NIMH, Psychoact Drug Screening Program, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44109 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room Ep-12, Washington, DC 20057 USA.	fadena@georgetown.edu	Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008; Vink, Robert/S-5616-2019; Roth, Bryan L/F-3928-2010	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02 MH 01366] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 41119-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02MH001366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; ANDREWS JS, 1984, PHARMACOL BIOCHEM BE, V21, P715, DOI 10.1016/S0091-3057(84)80008-8; ANDREWS JS, 1983, REGUL PEPTIDES, V7, P373, DOI 10.1016/0167-0115(83)90109-X; BASSIRI RM, 1973, J CLIN INVEST, V52, P1616, DOI 10.1172/JCI107339; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1996, NEUROTRAUMA, P1479; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; Kraus J, 1996, NEUROTRAUMA, P13; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; OLSON GL, 1995, J MED CHEM, V38, P2866, DOI 10.1021/jm00015a009; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Shvachkin Iu P, 1989, Biull Eksp Biol Med, V108, P671; SIESJO BK, 1981, EUR NEUROL, V20, P194, DOI 10.1159/000115233; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; Vink R, 1996, J NEUROCHEM, V66, P2477; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	55	64	64	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2003	23	3					342	354		10.1097/01.WCB.0000046143.31247.FD			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	652VH	WOS:000181401200009	12621309	Bronze			2022-02-06	
J	Cross, NE; Glantz, MJ				Cross, NE; Glantz, MJ			Neurologic complications of radiation therapy	NEUROLOGIC CLINICS			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TEMPORAL-LOBE NECROSIS; INDUCED BRAIN-INJURY; INDUCED OPTIC NEUROPATHY; LONG-TERM SURVIVORS; BREAST-CANCER; MALIGNANT GLIOMAS; CEREBRAL NECROSIS; BRACHIAL-PLEXUS; NERVOUS-SYSTEM	Radiation therapy is a mainstay of cancer treatment, particularly for patients with nervous system tumors. Like most cancer treatments, radiation is nonspecifically cytotoxic. As a result, when radiation therapy is used to treat primary or metastatic nervous system cancers or non-nervous system malignancies located close to neural structures (eg, head and neck cancers or mediastinal Hodgkin disease), treatment must be carefully crafted and doses and fraction sizes curtailed to prevent injury to the adjacent normal nervous system. A dramatic example of radiation-related nervous system injury, cerebral radionecrosis, was originally described in 1930, soon after radiation was first used therapeutically for brain tumors [1]. Since that time, a spectrum of injuries involving central and peripheral nervous system structures has been identified. Despite this heightened awareness, the neurologic complications of radiation therapy continue to occur because individual tolerances to radiation are variable, safe radiation thresholds are not precisely known (and may be altered by concurrent chemotherapy, pre-existing disease, and variations in tumor anatomy), and intentional "overdoses" may be given with curative or long-term palliative intent. The incidence of radiation-related nervous system injury seems to be increasing as conventional radiation therapy techniques are being applied more aggressively, new approaches (such as hyperfractionated radiation therapy, concurrent chemo- and radiotherapy, and radiosurgery) are becoming commonplace, and patients are surviving longer. Accurate diagnosis based on clinical manifestations is critical to exclude other potentially treatable total doses, higher fraction size, and larger volumes of treated nervous system [2]. Among the acute complications, acute radiation encephalopathy is now uncommon because of careful radiation treatment planning and the judicious use of corticosteroids. In contrast, fatigue and other nonspecific side effects associated with conventional and stereotactic cranial irradiation (Box 1) occur in the majority of patients. Except for subacute myelopathy, which is seen in up to 15% of patients treated with mantle irradiation for Hodgkin disease, the subacute complications of nervous system irradiation are also uncommon. In contrast to the acute and subacute complications of radiation, late radiation effects are relatively common. Delayed cerebral radionecrosis occurs in approximately 5% of patients receiving more than 5000 cGy of cranial irradiation, although the actual incidence is dose and fraction size dependent (Fig. 1A, B; Fig. 2A, B). Hypertension, diabetes, concomitant chemotherapy (particularly with known radiosensitizing agents) [3-7], accelerated hyperfractionated radiation [8], stereotactic radiosurgery, and interstitial brachytherapy increase the frequency and accelerate the time course of this form of late-radiation-related injury. Up to 20% of patients receiving stereotactic radiosurgery [9] and as many as 80% of patients undergoing interstitial brachytherapy develop symptomatic radionecrosis, usually 3 to 12 months after treatment [10]. Radiation-related white matter changes are extremely common on CT and MRI scans [11,12], and as many as 20% of patients with these radiographic correlates of diffuse late brain injury develop frank radiation-induced dementia [ 13] (Fig. 3A-D). The incidence is greatest in patients receiving whole-brain radiation therapy with fractions greater than 200 cGy and in patients surviving more than I year. Concurrent methotrexate or nitrosourea chemotherapy may increase the risk. Subtle, nonprogressive personality and cognitive changes are even more frequent and are more pronounced in children and in those over 60 years of age. The manifestations of radiation-induced endocrine dysfunction are often subtle and difficult to distinguish from other treatment- and tumor-related with regard to prognosis and therapeutic options, and competing diagnoses with very different natural histories and therapies often mask or mimic the signs and symptoms of radiation-related nervous system injury. The ability to efficiently negotiate this complicated differential diagnostic landscape allows for early diagnosis of tumor recurrence or an alternative etiology, prompt institution of appropriate therapy, avoidance of unnecessary diagnostic studies, and confident prognostication for patients and families. Even after the diagnosis of a radiation-related complication is made, continued vigilance for additional sites or manifestations of radiation injury is mandatory. Meanwhile, further research into treatment, prevention, and the causes of individual susceptibility to radiation injury are essential.	Univ Massachusetts, Dept Med, Berkshire Med Ctr, Pittsfield, MA 01201 USA; Stiefel Res Inst, Oak Hill, NY 12460 USA		Glantz, MJ (corresponding author), Univ Massachusetts, Dept Med, Berkshire Med Ctr, 725 N St, Pittsfield, MA 01201 USA.	mjg@massmed.org					Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Akiyama K, 2001, NEUROL MED-CHIR, V41, P590, DOI 10.2176/nmc.41.590; Arlt W, 1997, NEUROLOGY, V49, P498, DOI 10.1212/WNL.49.2.498; ARMSTRONG C, 1995, J CLIN ONCOL, V13, P2263, DOI 10.1200/JCO.1995.13.9.2263; ARONEN HJ, 1995, ACTA RADIOL, V36, P520; ATKINSON JLD, 1989, NEUROSURGERY, V24, P171, DOI 10.1227/00006123-198902000-00004; Belka C, 2001, BRIT J CANCER, V85, P1233, DOI 10.1054/bjoc.2001.2100; BERGER PS, 1977, CANCER, V40, P152, DOI 10.1002/1097-0142(197707)40:1<152::AID-CNCR2820400125>3.0.CO;2-E; BEYER RA, 1986, NEUROLOGY, V36, P1173, DOI 10.1212/WNL.36.9.1173; BURGER PC, 1979, CANCER, V44, P1256, DOI 10.1002/1097-0142(197910)44:4<1256::AID-CNCR2820440415>3.0.CO;2-T; CHANG SM, 1995, NEUROSURGERY, V36, P685, DOI 10.1227/00006123-199504000-00007; Cheng KM, 2001, J NEURO-ONCOL, V51, P143, DOI 10.1023/A:1010631112015; Chong VFH, 2001, EUR RADIOL, V11, P317, DOI 10.1007/s003300000548; Chuba PJ, 1997, CANCER-AM CANCER SOC, V80, P2005, DOI 10.1002/(SICI)1097-0142(19971115)80:10<2005::AID-CNCR19>3.0.CO;2-0; CONSTINE LS, 1993, NEW ENGL J MED, V328, P87, DOI 10.1056/NEJM199301143280203; CORN BW, 1994, CANCER, V74, P2828, DOI 10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; DICHIRO G, 1988, AM J ROENTGENOL, V150, P189, DOI 10.2214/ajr.150.1.189; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FELDMANN E, 1986, ARCH NEUROL-CHICAGO, V43, P1227, DOI 10.1001/archneur.1986.00520120011009; FENKETASUBRAMAN.N, 2001, NEUROLOGY S3, V56, pA37; FIKE JR, 1995, INT J RADIAT ONCOL, V32, P1035, DOI 10.1016/0360-3016(95)00030-3; FISHER AW, 1930, DTSCH Z CHIR, V227, P475; Fouladi M, 2000, J CLIN ONCOL, V18, P824, DOI 10.1200/JCO.2000.18.4.824; Gavazzi C, 2001, LANCET, V357, P1410, DOI 10.1016/S0140-6736(00)04565-7; GERARD JM, 1989, NEUROLOGY, V39, P450, DOI 10.1212/WNL.39.3.450; GLANTZ MJ, 1994, NEUROLOGY, V44, P2020, DOI 10.1212/WNL.44.11.2020; GOLDWEIN JW, 1987, MED PEDIATR ONCOL, V15, P89, DOI 10.1002/mpo.2950150208; GROSSMAN H, 1994, NEUROPSY NEUROPSY BE, V7, P125; GUTIN PH, 1991, INT J RADIAT ONCOL, V21, P601, DOI 10.1016/0360-3016(91)90676-U; GUY J, 1991, J NEUROSURG, V74, P426, DOI 10.3171/jns.1991.74.3.0426; Hallahan DE, 1999, ONCOLOGY-NY, V13, P71; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; HOROWITZ SL, 1983, CAN J NEUROL SCI, V10, P56, DOI 10.1017/S0317167100044589; HUDGINS PA, 1992, AM J NEURORADIOL, V13, P235; Jenkin D, 1998, MED PEDIATR ONCOL, V31, P506, DOI 10.1002/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.0.CO;2-X; Karlsson P, 1998, RADIAT RES, V150, P357, DOI 10.2307/3579984; Kilgore S, 2001, NEUROLOGY, V56, pA409; KIMURA H, 1995, INT J RADIAT ONCOL, V33, P627, DOI 10.1016/0360-3016(95)00205-D; KLINE LB, 1985, OPHTHALMOLOGY, V92, P1118; KORI SH, 1981, NEUROLOGY, V31, P45, DOI 10.1212/WNL.31.1.45; Kumar AJ, 2000, RADIOLOGY, V217, P377, DOI 10.1148/radiology.217.2.r00nv36377; Larson JJ, 1998, J NEUROSURG, V88, P51, DOI 10.3171/jns.1998.88.1.0051; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; LEE AWM, 1988, CANCER-AM CANCER SOC, V61, P1535, DOI 10.1002/1097-0142(19880415)61:8<1535::AID-CNCR2820610809>3.0.CO;2-E; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; LEQUANG C, 1989, HAND CLIN, V5, P23; Levin N, 2001, NEUROLOGY, V56, pA476; Little MP, 1998, INT J CANCER, V78, P269, DOI 10.1002/(SICI)1097-0215(19981029)78:3<269::AID-IJC1>3.0.CO;2-T; LOFTUS CM, 1987, ARCH NEUROL-CHICAGO, V44, P711, DOI 10.1001/archneur.1987.00520190023011; Loning L, 2000, BLOOD, V95, P2770, DOI 10.1182/blood.V95.9.2770.009k16_2770_2775; MACK EE, 1993, J NEUROSURG, V79, P28, DOI 10.3171/jns.1993.79.1.0028; Malone S, 2000, INT J RADIAT ONCOL, V47, P185, DOI 10.1016/S0360-3016(99)00554-4; MARKS JE, 1985, PROG EXP TUMOR RES, V29, P210; Meyers CA, 2000, ONCOLOGY-NY, V14, P75; MURROS KE, 1989, ARCH NEUROL-CHICAGO, V46, P449, DOI 10.1001/archneur.1989.00520400109029; MUSA BS, 1995, BRIT J NEUROSURG, V9, P629, DOI 10.1080/02688699550040918; O'Connor MM, 2000, NEUROSURGERY, V46, P138, DOI 10.1093/neurosurgery/46.1.138; OLDFIELD EH, 1990, J NEUROSURG, V72, P737, DOI 10.3171/jns.1990.72.5.0737; OLSEN NK, 1993, INT J RADIAT ONCOL, V26, P43, DOI 10.1016/0360-3016(93)90171-Q; PAYNE R, 1986, NEUROLOGY, V36, P329; Peacock J, 2000, RADIOTHER ONCOL, V55, P173, DOI 10.1016/S0167-8140(00)00173-0; Peters LJ, 1996, CANCER, V77, P2379, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2379::AID-CNCR29>3.0.CO;2-T; PRATT RA, 1977, SURG NEUROL, V7, P117; Rauhut F, 2002, ACTA NEUROCHIR, V144, P37, DOI 10.1007/s701-002-8272-8; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; Rose SR, 1999, J CLIN ENDOCR METAB, V84, P4472, DOI 10.1210/jc.84.12.4472; ROSENBLUM MK, 1989, J NEURO-ONCOL, V7, P269; ROTTENBERG DA, 1977, ANN NEUROL, V1, P339, DOI 10.1002/ana.410010406; Russo C, 1999, INT J RADIAT ONCOL, V44, P85, DOI 10.1016/S0360-3016(98)00514-8; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; Schagen SB, 2001, J NEURO-ONCOL, V51, P159, DOI 10.1023/A:1010635229762; SCHULTHEISS TE, 1988, INT J RADIAT ONCOL, V14, P27, DOI 10.1016/0360-3016(88)90046-6; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHWARTZ RB, 1991, AM J NEURORADIOL, V12, P1187; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Thiessen B, 1998, ARCH NEUROL-CHICAGO, V55, P705, DOI 10.1001/archneur.55.5.705; THOMAS JE, 1985, NEUROLOGY, V35, P1; Tikka T, 2001, J NEUROCHEM, V78, P1409, DOI 10.1046/j.1471-4159.2001.00543.x; TSANG RW, 1993, CANCER-AM CANCER SOC, V72, P2227, DOI 10.1002/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I; Tsui EYK, 2001, EUR J RADIOL, V39, P133, DOI 10.1016/S0720-048X(01)00328-X; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Walter AW, 1998, J CLIN ONCOL, V16, P3761, DOI 10.1200/JCO.1998.16.12.3761; WALTHER PJ, 1987, CANCER, V60, P2170, DOI 10.1002/1097-0142(19871101)60:9<2170::AID-CNCR2820600909>3.0.CO;2-N; Wehbe T, 1998, J NEURO-ONCOL, V39, P245, DOI 10.1023/A:1005710710418; WEN PY, 1994, CANCER-AM CANCER SOC, V73, P3029, DOI 10.1002/1097-0142(19940615)73:12<3029::AID-CNCR2820731222>3.0.CO;2-4; WILSON CB, 1992, CLIN NEUR, V38, P49; ZIMMERMAN CF, 1990, AM J OPHTHALMOL, V110, P389, DOI 10.1016/S0002-9394(14)77019-9	92	64	67	0	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2003	21	1					249	+	PII S0733-8619(02)00031-2	10.1016/S0733-8619(02)00031-2			31	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	641EK	WOS:000180731700011	12690652				2022-02-06	
J	Beghi, E				Beghi, E			Overview of studies to prevent posttraumatic epilepsy	EPILEPSIA			English	Article						epilepsy; prophylaxis; brain injury; anticonvulsant drug; clinical trial	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC EPILEPSY; ANTIEPILEPTIC DRUGS; BRAIN INJURY; HEAD-INJURY; SEIZURES; CARBAMAZEPINE; PROPHYLAXIS; FAILURE; TRIALS	Purpose: Prevention of posttraumatic epilepsy (PTE) is of primary importance to reduce the degree of functional morbidity following traumatic brain injury (TBI). However, the effects of antiepileptic drugs (AEDs) in patients with TBI must be assessed separately in terms of prevention and control of provoked seizures (which include immediate and early posttraumatic seizures) and prevention of subsequent unprovoked seizures (late posttraumatic seizures or PTE). Methods: Potential mechanisms for prevention of epileptogenesis as well as reports and systematic reviews were evaluated to determine strategies and results of attempts to reduce or prevent the development of epilepsy following TBI. Results: In observational studies, after a period ranging from 6 months to 13 years, the proportion of cases developing seizures was 0-10% in patients receiving treatment compared to 2-50% in those who were left untreated. In randomized clinical trials, the difference between active treatment [phenytoin (PHT), phenobarbital, or carbamazepine (CBZ)} and placebo was less remarkable after a follow-up ranging from 3 to 60 months and was virtually lacking for the prevention of PTE. In a Cochrane systematic review of 890 patients from 10 RCTs assessing PHT or CBZ, the pooled relative risk (RR) for prevention of early seizures was 0.33 (95% Cl 0.21-0.52). By contrast, the RR for prevention of late seizures was 1.28 (95% Cl 0.90-1.81). Mortality and neurological disability were similar in the two treatment groups. The use of PHT was followed by an increased (nonsignificant) risk of skin rashes. In addition, cognitive performance was significantly affected by PHT in severely injured patients at 1 month and treatment withdrawal was followed by improvement in cognitive function. Conclusions: The failure to influence the risk of PTE in studies of patients with TBI are similar to findings of meta-analysis of randomized clinical trials on seizure prevention in other conditions, such as febrile seizures, cerebral malaria, craniotomy, and excessive alcohol intake. For these reasons, the prophylactic use of AEDs should be short-lasting and limited to the prevention of immediate and early seizures. Chronic treatment should be considered only after a diagnosis of PTE.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy		Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; BIRKMAYER W, 1951, WIEN KLIN WOCHENSCHR, V63, P603; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; COLLINS MA, 1986, ALKALOIDS, V27, P323; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Hernandez TD, 1997, TRENDS PHARMACOL SCI, V18, P59, DOI 10.1016/S0165-6147(96)01027-9; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; HOMAN RW, 1987, NEUROLOGY, V37, P1620, DOI 10.1212/WNL.37.10.1620; JENNETT B, 1975, EPILEPSY NONMISSILE; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; MURRI L, 1992, ITAL J NEUROL SCI, V13, P755, DOI 10.1007/BF02229161; MURRI L, 1980, ITAL J NEUROL SCI, V1, P225; MUSICCO M, 1993, NEUROLOGY, V43, P478; PECHADRE JC, 1991, PRESSE MED, V20, P841; PRICE D, 1980, ROYAL SOC MED INT C, P23; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; Schiller NG, 1997, IDENTITIES-GLOB STUD, V4, P1; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SMITH DB, 1987, EPILEPSIA, V28, pS50, DOI 10.1111/j.1528-1157.1987.tb05778.x; Temkin Nancy R., 1998, V76, P179; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; TEMKIN NR, EPILEPSIA S10, V44, P18; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x; [No title captured]	41	64	68	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2003	44			10			21	26		10.1046/j.1528-1157.44.s10.1.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733YK	WOS:000186028100005	14511391	Bronze			2022-02-06	
J	Mattioli, C; Beretta, L; Gerevini, S; Veglia, F; Citerio, G; Cormio, M; Stocchetti, N				Mattioli, C; Beretta, L; Gerevini, S; Veglia, F; Citerio, G; Cormio, M; Stocchetti, N			Traumatic subarachnoid hemorrhage on the computerized tomography scan obtained at admission: a multicenter assessment of the accuracy of diagnosis and the potential impact on patient outcome	JOURNAL OF NEUROSURGERY			English	Article						head injury; subarachnoid hemorrhage; computerized tomography; outcome	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; CT SCAN; VASOSPASM; COMA	Object. The goal of this study was fourfold: 1) to determine the incidence of traumatic subarachnoid hemorrhage (tSAH) in patients with traumatic brain injury (TBI); 2) to verify agreement in the diagnosis of tSAH in a multicenter study; 3) to assess the incidence of tSAH on the outcome of the patient; and 4) to establish whether tSAH itself leads to an unfavorable outcome or whether it is a sign of major brain trauma associated with severe posttraumatic lesions. Methods. Computerized tomography (CT) scans obtained in 169 head-injured patients on admission to 12 Italian intensive care units during a 3-month period were examined. The scans were collected for neuroradiological review and were used for the analysis together with data from a multicenter database (Neurolink). A review committee found a high incidence of tSAH (61%) in patients with TBI and a moderate agreement among centers (K = 0.57). Significant associations were observed between the presence and grading of tSAH and patient outcomes, and between the presence of tSAH and the severity of the CT findings. Logistic regression analysis showed that the presence of tSAH and its grading alone do not assume statistical significance in the prediction of unfavorable outcome. Conclusions. Traumatic SAH frequently occurs in patients with TBI, but it is difficult to detect and grade. Traumatic SAH is associated with more severe CT findings and a worse patient outcome.	IRCCS H San Raffaele, Dept Neuroradiol, Neurointens Care Unit, Milan, Italy; Inst Sci Interchange Fdn, ISI, Turin, Italy; H S Gerardo, Intens Care Unit, Monza, Italy; IRCCS H Policlin, Milan, Italy		Mattioli, C (corresponding author), Osped San Raffaele, Via Olgettina 60, Milan, Italy.		Gerevini, Simonetta/AAL-9594-2020; Veglia, Fabrizio/K-1958-2016; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017	Gerevini, Simonetta/0000-0002-2374-194X; Veglia, Fabrizio/0000-0002-9378-8874; Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834			BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ESKESEN V, 1987, ACTA NEUROCHIR, V87, P54, DOI 10.1007/BF02076017; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREYTAG E, 1963, ARCH PATHOL, V75, P402; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; SIMONSEN J, 1963, J Forensic Sci, V8, P97; Svensson E, 1996, NEUROL RES, V18, P487; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TEASDALE G, 1974, LANCET, V2, P81; VANGIJN J, 1982, NEURORADIOLOGY, V23, P153, DOI 10.1007/BF00347559; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	32	64	68	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2003	98	1					37	42		10.3171/jns.2003.98.1.0037			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	636NY	WOS:000180463700008	12546350				2022-02-06	
J	Webbe, FM; Ochs, SR				Webbe, FM; Ochs, SR			Recency and frequency of soccer heading interact to decrease neurocognitive performance	APPLIED NEUROPSYCHOLOGY			English	Article; Proceedings Paper	20th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 15-18, 2000	ORLANDO, FL	Natl Acad Neuropsychol		soccer; traumatic brain injury; athletic participation; neuropsychology; sport psychology	TRAUMATIC BRAIN-INJURY; CONCUSSION; RECOVERY; SPORT	This study investigated the role of heading recency interacting with heading frequency in determining neuropsychological deficits associated with heading the ball during soccer play. Sixty-four high-ability male soccer players ages 16 to 34 completed the California Verbal Learning Test (CVLT), the Trailmaking Test, the Paced Auditory Serial Addition Test (PASAT), the Facial Recognition Test, the Rey-Osterrieth Complex Figure, and the Shipley Scales. Heading recency interacted with heading frequency, such that players with the highest self-reported estimates of heading who also experienced heading within the previous 7 days scored significantly lower on CVLT, Shipley, Trailmaking, and PASAT than other combinations of heading and recency. Although strict ball-to-head contacts could not be isolated as sufficient to cause this interaction, these results increase the weight of evidence that heading behavior is problematic for causing at least transient cognitive impairment.	Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA		Webbe, FM (corresponding author), Florida Inst Technol, Sch Psychol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	webb@fit.edu	Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Almquist J, 2001, ATHLET THER TODAY, V6, P13, DOI 10.1123/att.6.1.13; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT, 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Delis DC, 1987, CALIFORNIA VERBAL LE; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ERLANGER D, IN PRESS J NEUROSURG; FRENGUELLI A, 1991, J CRANIO MAXILL SURG, V19, P178, DOI 10.1016/S1010-5182(05)80309-9; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kawanishi A, 1999, NEUROL MED-CHIR, V39, P231, DOI 10.2176/nmc.39.231; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Taylor L B, 1969, Clin Neurosurg, V16, P269; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]; WITOL AD, IN PRESS ARCH CLIN N; Zachary R. A., 1986, SHIPLEY I LIVING SCA; 2001, NCAA NEWS       0312, P6	41	64	64	0	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					31	41		10.1207/S15324826AN1001_5			11	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900005	12734073				2022-02-06	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Children's brain injury: a postal follow-up of 525 children from one health region in the UK	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; ADOLESCENTS; MOTOR; AGE; REHABILITATION; CHILDHOOD; INFANTS	Primary objectives: To follow-up a population of children admitted to one Hospital Trust with traumatic brain injury (TBI), and compare outcomes following mild TBI with outcomes following moderate or severe TBI. Research design: Population-based postal questionnaire survey. Methods and procedures: Questionnaires were mailed to parents of all 974 surviving children on a register of paediatric TBI admissions, 525 completed questionnaires were returned (56.2%). Most children (419) had suffered mild TBI, 57 moderate, and 49 severe. Main outcomes and results: Thirty per cent of parents received no information on post-injury symptoms, and clinical follow-up was limited. Statistically significant differences were observed between mild and moderate/severe groups for cognitive, social, emotional, and mobility problems. Nevertheless, similar to20% of the mild group suffered from poor concentration, personality change and educational problems post-injury. Few schools (20%) made special provision for children returning after injury. Conclusions: Children can have long-lasting and wide-ranging sequelae following TBI. Information should be routinely given to parents and schools after brain injury.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				*BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; Emanuelson I, 1998, INJURY, V29, P193, DOI 10.1016/S0020-1383(97)00177-0; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES GS, 1994, NUCL MED BIOL, V21, P117, DOI 10.1016/0969-8051(94)90138-4; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; *N STAFF HLTH AUTH, 1994, HLTH N STAFF ANN REP; NORUSIS MJ, 1998, SPSS 8 0 GUIDE DATA; O'Flaherty SJ, 2000, ARCH PHYS MED REHAB, V81, P723, DOI 10.1016/S0003-9993(00)90100-X; Parmelee D X, 1989, Psychiatr Med, V7, P11; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; Schootman M, 1999, BRAIN INJURY, V13, P995; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; STILWELL J, 1998, REPORT NATL TRAUMATI; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO	34	64	67	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2002	16	11					969	985		10.1080/02699050210147239			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500004	12443547	Green Submitted			2022-02-06	
J	Huynh, T; Messer, M; Sing, RF; Miles, W; Jacobs, DG; Thomason, MH				Huynh, T; Messer, M; Sing, RF; Miles, W; Jacobs, DG; Thomason, MH			Positive end-expiratory pressure alters intracranial and cerebral perfusion pressure in severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MA	Amer Assoc Surg Trauma		intracranial; cerebral; airway; positive end-expiratory pressure (PEEP); oxygen transport	RESPIRATORY-DISTRESS-SYNDROME; OXYGEN DELIVERY; CLINICAL-TRIAL; PEEP; RESUSCITATION; MANAGEMENT; MORTALITY; VALUES; INDEX	Background. Optimizing intracranial pressure (ICP) and cerebral perfusion pressure (CPP) is important in the management of severe traumatic brain injury (TBI). In trauma patients with TBI and respiratory dysfunction, positive end-expiratory pressure (PEEP) is often required to support oxygenation. Increases in PEEP may lead to reduced CPP. We hypothesized that increases in PEEP are associated with compromised hemodynamics and altered cerebral perfusion. Methods: Twenty patients (mean Injury Severity Score of 28) with TBI (Glasgow Coma Scale score < 8) were examined. All required simultaneous ICP and hemodynamic monitoring. Data were categorized on the basis of PEEP levels. Variables included central venous pressure, pulmonary artery occlusion pressure, cardiac index, oxygen delivery, and oxygen consumption indices. Differences were assessed using Kruskal-Wallis analysis of variance. Results: Data were expressed as mean +/- SE. As PEEP increased from 0 to 5, to 6 to 10 and 11 to 15 cm H2O, ICP decreased from 14.7 +/- 0.2 to 13.6 +/- 0.2 and 13.1 +/- 0.3 mm Hg, respectively. Concurrently, CPP improved from 77.5 +/- 0.3 to 80.1 +/- 0.5 and 78.9 +/- 0.7 mm Hg. As central venous pressure (5.9 +/- 0.1, 8.3 +/- 0.2, and 12.0 +/- 0.3 min Hg) and pulmonary artery occlusion pressure (8.3 +/- 0.2, 11.6 +/- 0.4, and 15.6 +/- 0.4 mm Hg) increased with rising levels of PEEP, cardiac index, oxygen delivery, and oxygen consumption indices remained unaffected. Overall mortality was 30%. Conclusion: In trauma patients with severe TBI, the strategy of increasing PEEP to optimize oxygenation is not associated with reduced cerebral perfusion or compromised oxygen transport.	Carolinas Med Ctr, Dept Surg, Div Trauma Surg Crit Care, Charlotte, NC 28232 USA		Huynh, T (corresponding author), Carolinas Med Ctr, FH Sammy Ross Jr Trauma Ctr, Trauma Crit Care Serv, Dept Gen Surg, Charlotte, NC 28232 USA.	toan.huynh@carolinashealthcare.org					AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; APUZZO MLJ, 1977, J NEUROSURG, V46, P227, DOI 10.3171/jns.1977.46.2.0227; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; Chang MC, 1999, NEW HORIZ-SCI PRACT, V7, P35; Cheatham ML, 1998, CRIT CARE MED, V26, P1801, DOI 10.1097/00003246-199811000-00017; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Clarke JP, 1997, INTENS CARE MED, V23, P106, DOI 10.1007/s001340050298; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COOPER KR, 1985, J NEUROSURG, V63, P552, DOI 10.3171/jns.1985.63.4.0552; Diebel LN, 1997, J TRAUMA, V42, P585, DOI 10.1097/00005373-199704000-00002; DIRUSSO SM, 1995, CRIT CARE MED, V23, P1485, DOI 10.1097/00003246-199509000-00008; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Marini JJ, 1996, CLIN CHEST MED, V17, P555, DOI 10.1016/S0272-5231(05)70331-2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; ROPPER AH, 1982, NEUROLOGY, V32, P1288, DOI 10.1212/WNL.32.11.1288; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHAPIRO HM, 1978, J TRAUMA, V18, P254, DOI 10.1097/00005373-197804000-00005; YU M, 1999, NEW HORIZ, V7, P45; Yu MH, 1998, CRIT CARE MED, V26, P1011, DOI 10.1097/00003246-199806000-00018	26	64	73	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					488	492		10.1097/00005373-200209000-00016			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	599GA	WOS:000178324700021	12352486				2022-02-06	
J	Hanson, JA; Deliganis, AV; Baxter, AB; Cohen, WA; Linnau, KF; Wilson, AJ; Mann, FA				Hanson, JA; Deliganis, AV; Baxter, AB; Cohen, WA; Linnau, KF; Wilson, AJ; Mann, FA			Radiologic and clinical spectrum of occipital condyle fractures: Retrospective review of 107 consecutive fractures in 95 patients	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							TRAUMATIC OCCIPITOVERTEBRAL DISSOCIATION; ATLANTOOCCIPITAL DISLOCATION; LATERAL RADIOGRAPHS; AVULSION FRACTURE; SUPINE SUBJECTS; CT; DIAGNOSIS; CLIVUS	OBJECTIVE. We proposed to characterize the radiologic spectrum of occipital condyle fractures in a large series of patients and to correlate fracture pathology with neurosurgical treatment and patient outcome. MATERIALS AND METHODS. We conducted a retrospective review of the findings on conventional radiography. CT, and MR imaging in 95 patients with 107 occipital condyle fractures. We described fracture patterns according to two previously published classification systems. Clinical findings, neurosurgical management, and patient outcome were obtained.. from the medical records. RESULTS. Inferomedial avulsions (Anderson and Montesano type III) were the most common type of occipital condyle fracture, constituting 80 (75%) of 107 overall fractures. Unilateral occipital condyle fractures were found in 73 (77%) of 95 patients, and 58 patients were treated nonoperatively; occipitocervical fusion was required in nine patients for complex C1-C2 injuries, and six patients died. Bilateral occipital condyle fractures or occipitoatlantoaxial joint injuries were seen in 22 (23%) of 95 patients. Occipitocervical fusion or halo traction for the craniocervical junction was required in 12 patients, all of whom had CT evidence of bilateral occipitoatlantoaxial joint disruption and six of whom showed normal craniocervical relationships on conventional radiographs. Six patients with nondisplaced fractures were treated nonoperatively, and four patients died. Thirty (32%) of 95 patients showed continued disability, whereas 55 (57.5%) of 95 patients had good outcomes at 1 month. Associated cervical spine injuries were present in 29 (31%) of 95 patients. CONCLUSION. Given their associated traumatic brain and cervical spine injuries, occipital condyle fractures are markers of high-energy traumas. That conventional radiographs alone may miss up to half of the patients with acute craniocervical instability has not been well established. Avulsion fracture type and fracture displacement are associated with both injury mechanism and the need for surgical stabilization. In this series. most unilateral occipital condyle fractures were treated nonoperatively, whereas bilateral occipitoatlantoaxial joint injuries with findings of instability usually required surgical stabilization.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Radiol, Seattle, WA 98104 USA		Mann, FA (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Radiol, 325 9th Ave,Box 359728, Seattle, WA 98104 USA.						ADAMS VI, 1992, J FORENSIC SCI, V37, P556; AHUJA A, 1994, SURG NEUROL, V41, P112, DOI 10.1016/0090-3019(94)90107-4; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BLACKSIN MF, 1995, AM J ROENTGENOL, V165, P1201, DOI 10.2214/ajr.165.5.7572503; Bloom AI, 1997, CLIN RADIOL, V52, P198, DOI 10.1016/S0009-9260(97)80273-5; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; BUNDSCHUH CV, 1992, SPINE, V17, P245, DOI 10.1097/00007632-199202000-00024; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; Deliganis AV, 2000, RADIOGRAPHICS, V20, pS237, DOI 10.1148/radiographics.20.suppl_1.g00oc23s237; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; HARRIS JH, 1994, AM J ROENTGENOL, V162, P881, DOI 10.2214/ajr.162.4.8141012; HARRIS JH, 1994, AM J ROENTGENOL, V162, P887, DOI 10.2214/ajr.162.4.8141013; JONES DN, 1990, AM J NEURORADIOL, V11, P1181; Leone A, 2000, RADIOLOGY, V216, P635, DOI 10.1148/radiology.216.3.r00se23635; LINK TM, 1995, RADIOLOGY, V196, P741, DOI 10.1148/radiology.196.3.7644638; MIRVIS SE, 1988, RADIOLOGY, V166, P807, DOI 10.1148/radiology.166.3.3277249; Noble ER, 1996, AM J NEURORADIOL, V17, P507; SATERNUS KS, 1987, Z RECHTSMED, V99, P95; Tanabe M, 1999, NEUROL MED-CHIR, V39, P358, DOI 10.2176/nmc.39.358; Tuli S, 1997, NEUROSURGERY, V41, P368, DOI 10.1097/00006123-199708000-00006; Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091; VOIGT GE, 1974, J TRAUMA, V14, P494, DOI 10.1097/00005373-197406000-00006; VONAHLGREN P, 1964, ROFO FORTSCHR RONTG, V101, P202; WASSERBERG J, 1995, NEURORADIOLOGY, V37, P370; WERNE S, 1957, ACTA ORTHOP SCAND S, V23, pS1; WHITE AA, 1990, CLIN BIOMECHANICS SP, P192; WILLAUSCHUS WG, 1995, SPINE, V20, P2493, DOI 10.1097/00007632-199512000-00006	29	64	66	1	5	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA	0361-803X			AM J ROENTGENOL	Am. J. Roentgenol.	MAY	2002	178	5					1261	1268		10.2214/ajr.178.5.1781261			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	543AA	WOS:000175077200040	11959743				2022-02-06	
J	von Oettingen, G; Bergholt, B; Gyldensted, C; Astrup, J				von Oettingen, G; Bergholt, B; Gyldensted, C; Astrup, J			Blood flow and ischemia within traumatic cerebral contusions	NEUROSURGERY			English	Article						contusion; head injury; ischemia; regional cerebral blood flow; xenon-enhanced computed tomography	HEAD-INJURY; XENON-CT; INTRACRANIAL HYPERTENSION; FOCAL ISCHEMIA; PRESSURE; PATHOPHYSIOLOGY; TOMOGRAPHY; METABOLISM; INHALATION	OBJECTIVE: To provide evidence of irreversible ischemia in cerebral contusions among patients with severe traumatic brain injuries and to clarify the potential viability of tissue in the pericontusional zone, quantitative regional cerebral blood flow (rCBF) measurements obtained with the xenon-enhanced computed tomographic method were correlated with the areas of contusions, by using image fusion. METHODS: rCBF measurements obtained during the acute phase (mean, 2 d after injury; range, 0-10 d) were statistically correlated with the extent of tissue necrosis identified as focal atrophy on late follow-up computed tomographic scans (mean time after the xenon-enhanced computed tomographic cerebral blood flow investigation, 265 d; range, 30-1047 d). RESULTS: Seventeen patients exhibited 26 traumatic contusions. All contusions progressed to late focal atrophic areas on the follow-up computed tomographic scans. The rCBF values within the traumatic contusions ranged from 0.5 to 22.0 ml/100 g/min, with a mean of 5.9 +/- 5.9 ml/100 g/min. The contusions exhibited a specific rCBF profile, presenting as a core of severe lethal ischemia surrounded by variable but gradually increasing perfusion with increasing distance from the ischemic core. CONCLUSION: The ischemic profile of the contusions, with a pericontusional zone of low rCBF, presents the potential risk of secondary ischemic insults, similar to the risk in the ischemic penumbral zones surrounding areas of acute ischemic stroke.	Aarhus Univ Hosp, Dept Neurosurg, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Neuroradiol, DK-8000 Aarhus C, Denmark		von Oettingen, G (corresponding author), Aarhus Univ Hosp, Dept Neurosurg, Noerebrogade 44, DK-8000 Aarhus C, Denmark.	von_oettingen@dadlnet.dk					ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock RM, 2000, J NEUROTRAUM, V17, P449; FATOUROS PP, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P73; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HOLL K, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P41; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KASHIWAGI S, 1986, Electromedica (English Edition), V54, P136; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MEYER JS, 1980, AM J ROENTGENOL, V135, P239, DOI 10.2214/ajr.135.2.239; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Obrist WD, 1998, J CEREBR BLOOD F MET, V18, P1192, DOI 10.1097/00004647-199811000-00005; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; POLACIN A, 1991, MED PHYS, V18, P1025, DOI 10.1118/1.596738; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; von Oettingen G, 2000, J NEUROSCI METH, V95, P159, DOI 10.1016/S0165-0270(99)00179-X; von Oettingen G, 2000, NEURORADIOLOGY, V42, P168, DOI 10.1007/s002340050039; YONAS H, 1988, STROKE, V19, P228, DOI 10.1161/01.STR.19.2.228; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010	34	64	64	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2002	50	4					781	788		10.1097/00006123-200204000-00019			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	539DQ	WOS:000174855100027	11904029				2022-02-06	
J	Hiott, DW; Labbate, L				Hiott, DW; Labbate, L			Anxiety disorders associated with traumatic brain injuries	NEUROREHABILITATION			English	Article						traumatic brain injury; obsessive compulsive disorder; posttraumatic stress disorder; panic disorder; generalized anxiety disorder	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; PANIC DISORDER; CONSEQUENCES; INDIVIDUALS; DEPRESSION; TOMOGRAPHY; LESIONS	Anxiety disorders are common in the general population and may be even more common in people with traumatic brain injuries. This article presents a review of the literature on anxiety disorders as a result of traumatic brain injury, specifically post-traumatic stress disorder, generalized anxiety disorder, obsessive compulsive disorder, and panic disorder. Our current understanding suggests that the increased frequency of anxiety disorders after TBI may reflect an overlap between brain regions vulnerable to traumatic brain injury, and the neural circuitry of these disorders. Issues regarding treatment are largely anecdotal, and much remains unsettled. More research is needed, both in terms of diagnosis and treatment.	Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson VAMC, Charleston, SC 29425 USA		Hiott, DW (corresponding author), Med Univ S Carolina, Dept Psychiat, 67 President St,5 South, Charleston, SC 29412 USA.	hiottdw@musc.edu					Adler A, 1943, J AMER MED ASSOC, V123, P1098, DOI 10.1001/jama.1943.02840520014004; American Psychiatric Association, 1994, DIAGN STAT MAN; Berthier ML, 1996, NEUROLOGY, V47, P353, DOI 10.1212/WNL.47.2.353; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bisaga A, 1998, AM J PSYCHIAT, V155, P1178, DOI 10.1176/ajp.155.9.1178; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Childers MK, 1998, BRAIN INJURY, V12, P613; Coplan JD, 1998, BIOL PSYCHIAT, V44, P1264, DOI 10.1016/S0006-3223(98)00300-X; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Epstein Richard S., 1994, P285; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fischer H, 1998, NEUROSCI LETT, V251, P137, DOI 10.1016/S0304-3940(98)00503-5; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Griffith J P, 1998, W V Med J, V94, P198; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Javanmard M, 1999, BIOL PSYCHIAT, V45, P872, DOI 10.1016/S0006-3223(98)00348-5; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1996, BRAIN INJURY, V10, P55; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Khouzam HR, 1998, GEN HOSP PSYCHIAT, V20, P62, DOI 10.1016/S0163-8343(97)00097-2; KLONOFF H, 1971, PERCEPT MOTOR SKILL, V32, P603, DOI 10.2466/pms.1971.32.2.603; LEWIS A, 2001, P ROY SOC MED, V35, P607; Malizia AL, 1998, ARCH GEN PSYCHIAT, V55, P715, DOI 10.1001/archpsyc.55.8.715; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; MELTZER H, 1995, REPORTS OFFICE POPUL, V1; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Saxena S, 1998, BRIT J PSYCHIAT, V173, P26; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SooMeng K, 1997, INT J CLIN PRACT, V51, P336; Van der Linden G, 2000, PROG NEURO-PSYCHOPH, V24, P419, DOI 10.1016/S0278-5846(99)00109-8; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; YUDOFSKY SC, APA ANN REV, V4, P142; Zohar J, 2000, ACTA PSYCHIAT SCAND, V101, P39, DOI 10.1111/j.1600-0447.2000.tb10947.x; [No title captured]	44	64	66	2	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2002	17	4					345	355					11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200008	12547982				2022-02-06	
J	McCrory, P				McCrory, P			Do mouthguards prevent concussion?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							OROFACIAL INJURIES; PREVALENCE; MANAGEMENT; ATTITUDES; WORLD; TEAM		Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia		McCrory, P (corresponding author), Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				Banky J, 1999, J Sci Med Sport, V2, P20, DOI 10.1016/S1440-2440(99)80181-9; Blignaut J B, 1987, Br J Sports Med, V21, P5; CARLOS TA, 1938, ORAL HYG, V28, P1580; CHAPMAN P, 1991, AUST J SCI MED SPORT, V22, P113; Chapman P, 1985, AUST J SCI MED SPORT, V3, P170; Chapman P J, 1990, Br J Sports Med, V24, P156; Chapman P J, 1985, Br J Sports Med, V19, P93; Chapman P J, 1988, Br J Sports Med, V22, P98; Chapman P J, 1985, Br J Sports Med, V19, P34; CHAPMAN PJ, 1993, BRIT J SPORT MED, V27, P197, DOI 10.1136/bjsm.27.3.197; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; CHAPMAN PJ, 1989, AUST DENT J, V34, P36, DOI 10.1111/j.1834-7819.1989.tb03003.x; CHAPMAN PJ, 1985, AUST DENT J, V30, P364, DOI 10.1111/j.1834-7819.1985.tb02533.x; CHAPMAN PJ, 1986, AUST J SCI MED SPORT, V18, P3; Chapman PJ, 1985, AUST J SCI MED SPORT, V17, P15; CHAPMAN PJ, 1983, SPORT HLTH, V1, P13; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GENNARELLI TA, 1993, J EMERG MED, V1, P5; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; JACOBS WH, 1938, ORAL HYGIENE, V28, P1152; Jennings D C, 1990, Br J Sports Med, V24, P159; Kay E J, 1990, Br J Sports Med, V24, P271; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; MAESTRELLODEMOYA MG, 1989, J DENT CHILD, V56, P36; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1990, SPORTS NEUROLOGY; REED RV, 1994, BRIT DENT J, V176, P478, DOI 10.1038/sj.bdj.4808485; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; STOKES AN, 1991, NZ J SPORTS MED, V19, P66; WEHNER PJ, 1965, DENT CLIN N AM, P493	32	64	67	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2001	35	2					81	82		10.1136/bjsm.35.2.81			2	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	418GC	WOS:000167881700003	11273965	Green Published, Bronze			2022-02-06	
J	Segalowitz, SJ; Bernstein, DM; Lawson, S				Segalowitz, SJ; Bernstein, DM; Lawson, S			P300 event-related potential decrements in well-functioning university students with mild head injury	BRAIN AND COGNITION			English	Article							AUDITORY-STIMULI; TASK-DIFFICULTY; REACTION-TIME; CONCUSSION; SYMPTOMS; LATENCY; ATTENTION; DISABILITIES; DETERMINANTS; RECOGNITION	We compared the performance of 10 well-functioning university students who had experienced a mild head injury (MHI) an average of 6.4 years previously and IZ controls on a series of standard psychometric tests of attention, memory, and thinking and on a series of auditory oddball vigilance tasks to which we also took event-related potentials (ERPs). The MHI and Control groups performed equivalently on all the psychometric tasks and on self-report questionnaires of everyday memory and attention difficulties. The MHI group performed more slowly and with lower accuracy on only the most difficult of the oddball tasks, yet they showed substantially and significantly reduced P300 amplitudes and subsequent attentuation on all the oddball tasks. both easy and difficult. There were no alterations of N1. P2. and N2 components. These data suggest that despite excellent behavioral recovery, subtle information processing deficits involving attention nevertheless may persist long after the original injury and may not he apparent on a variety of standard psychometric measures. (C) 2001 Academic Press.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada		Segalowitz, SJ (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.						BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BRAUN C, 1990, PSYCHOPHYSIOLOGY, V27, pS19; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V23, P1; CAMPBELL K, 1990, EEG S, V41; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DYWAN J, 1994, PSYCHOL AGING, V9, P568, DOI 10.1037/0882-7974.9.4.568; FORD JM, 1994, BIOL PSYCHIAT, V35, P96, DOI 10.1016/0006-3223(94)91198-3; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; GAILLARD AWK, 1977, PSYCHOPHYSIOLOGY, V14, P563, DOI 10.1111/j.1469-8986.1977.tb01200.x; Granovsky Y, 1998, EVOKED POTENTIAL, V108, P554, DOI 10.1016/S0168-5597(98)00036-7; GRONWALL D, 1975, LANCET, V2, P995; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Houlihan M, 1998, INTELLIGENCE, V26, P9, DOI 10.1016/S0160-2896(99)80049-X; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Knight R.T., 1990, EVENT RELATED BRAIN, P3; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVINE MJ, 1988, COGNITIVE REHABI MAR, P14; Marshall LF, 1989, MILD HEAD INJURY, P276; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PARASURAMAN R, 1982, PERCEPT PSYCHOPHYS, V31, P1, DOI 10.3758/BF03206196; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RITTER W, 1982, SCIENCE, V218, P909, DOI 10.1126/science.7134983; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TECCE JJ, 1976, ELECTROEN CLIN NEURO, V41, P277, DOI 10.1016/0013-4694(76)90120-6; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Wechsler, 1997, WECHSLER ADULT INTEL; WOODCOCK RW, 1977, WOODCOCKJOHNSON PSYC	48	64	68	0	7	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	APR	2001	45	3					342	356		10.1006/brcg.2000.1263			15	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	427PQ	WOS:000168415100003	11305878				2022-02-06	
J	Garnett, MR; Corkill, RG; Blamire, AM; Rajagopalan, B; Manners, DN; Young, JD; Styles, P; Cadoux-Hudson, TAD				Garnett, MR; Corkill, RG; Blamire, AM; Rajagopalan, B; Manners, DN; Young, JD; Styles, P; Cadoux-Hudson, TAD			Altered cellular metabolism following traumatic brain injury: A magnetic resonance spectroscopy study	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; magnesium; magnetic resonance spectroscopy; metabolism; phosphorus; proton; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; FREE MAGNESIUM CONCENTRATION; FOCAL CEREBRAL-ISCHEMIA; P-31 NMR-SPECTROSCOPY; MR SPECTROSCOPY; PHOSPHATE-METABOLISM; INTRACRANIAL TUMORS; INITIAL EXPERIENCE; ENERGY-METABOLISM	Experimental studies have reported early reductions in pH, phosphocreatine, and free intracellular magnesium following traumatic brain injury using phosphorus magnetic resonance spectroscopy. Paradoxically, in clinical studies there is some evidence for an increase in the pH in the subacute stage following traumatic brain injury. We therefore performed phosphorus magnetic resonance spectroscopy on seven patients in the subacute stage (mean 9 days postinjury) following traumatic brain injury to assess cellular metabolism. In areas of normal-appearing white matter, the pH was significantly alkaline (patients 7.09 +/- 0.04 [mean +/- SD], controls 7.01 +/- 0.04, p = 0.008), the phosphocreatine to inorganic phosphate ratio (PCr/Pi) was significantly increased (patients 4.03 +/- 1.18, controls 2.64 +/- 0.71, p = 0.03), the inorganic phosphate to adenosine triphosphate ratio (Pi/ATP) was significantly reduced (patients 0.37 +/- 0.10, controls 0.56 +/- 0.19, p = 0.04), and the PCr/ATP ratio was nonsignificantly increased (patients 1.53 +/- 0.29, controls 1.34 +/- 0.19, p = 0.14) in patients compared to controls. Furthermore, the calculated free intracellular magnesium was significantly increased in the patients compared to the controls (patients 0.33 +/- 0.09 mM, controls 0.22 +/- 0.09 mM, p = 0.03). Proton spectra, acquired from similar regions showed a significant reduction in N-acetylaspartate (patients 9.64 +/- 2.49 units, controls 12.84 +/- 2.35 units, p = 0.03) and a significant increase in choline compounds (patients 7.96 +/- 1.02, controls 6.67 +/- 1.01 units, p = 0.03). No lactate was visible in any patient or control spectrum. The alterations in metabolism observed in these patients could not be explained by ongoing ischemia but might be secondary to a loss of normal cellular homeostasis or a relative alteration in the cellular population, in particular an increase in the glial cell density, in these regions.	John Radcliffe Hosp, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Neurosurg, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Neurol, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Anaesthet, Oxford OX3 9DU, England		Garnett, MR (corresponding author), John Radcliffe Hosp, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England.	Mg@bioch.ox.ac.uk	Young, John D/M-9756-2016; Manners, David N/J-2415-2012; Blamire, Andrew/AAU-6100-2021	Manners, David N/0000-0002-2404-1101; Young, John Duncan/0000-0002-6838-4835; Blamire, Andrew/0000-0002-8749-1257			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; BOTTOMLEY PA, 1986, RADIOLOGY, V160, P763, DOI 10.1148/radiology.160.3.3737915; BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/j.1749-6632.1987.tb32915.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; BRUHN H, 1989, RADIOLOGY, V172, P541, DOI 10.1148/radiology.172.2.2748837; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; CADOUXHUDSON TAD, 1989, BRIT J CANCER, V60, P430, DOI 10.1038/bjc.1989.300; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gillard JH, 1996, AM J NEURORADIOL, V17, P873; GUNTHER T, 1981, ARTERY, V9, P167; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAASE A, 1985, PHYS MED BIOL, V30, P341, DOI 10.1088/0031-9155/30/4/008; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HEINDEL W, 1988, J COMPUT ASSIST TOMO, V12, P907, DOI 10.1097/00004728-198811000-00001; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HUBESCH B, 1990, RADIOLOGY, V174, P401, DOI 10.1148/radiology.174.2.2296651; HUGG JW, 1992, MAGN RESON IMAGING, V10, P227, DOI 10.1016/0730-725X(92)90483-G; HUGG JW, 1992, J CEREBR BLOOD F MET, V12, P734, DOI 10.1038/jcbfm.1992.104; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENNETT B, 1975, LANCET, V1, P480; LANFERMANN H, 1995, RADIOLOGY, V196, P203, DOI 10.1148/radiology.196.1.7784568; LEVINE SR, 1992, RADIOLOGY, V185, P537, DOI 10.1148/radiology.185.2.1410369; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTOSH TK, 1988, J NEUROTRAUM, V5, P17; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; NOAT G, 1970, EUR J BIOCHEM, V13, P347, DOI 10.1111/j.1432-1033.1970.tb00937.x; OTTO M, 1974, EUR J BIOCHEM, V49, P169, DOI 10.1111/j.1432-1033.1974.tb03822.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; RANGO M, 1990, ANN NEUROL, V28, P661, DOI 10.1002/ana.410280510; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SAPPEYMARINIER D, 1992, RADIOLOGY, V182, P29, DOI 10.1148/radiology.182.1.1727305; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; van den Boogaart A, 1997, MAGN RESON CHEM, V35, pS146, DOI 10.1002/(SICI)1097-458X(199712)35:13<S146::AID-OMR196>3.0.CO;2-X; VANDENBOOGART A, 1997, USERS GUIDE MAGNETIC; VANDERVEEN JWC, 1988, MAGNET RESON MED, V6, P92, DOI 10.1002/mrm.1910060111; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Welch K M, 1990, Funct Neurol, V5, P21; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	59	64	66	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					231	240		10.1089/08977150151070838			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000001	11284544				2022-02-06	
J	Goldstein, FC; Levin, HS; Goldman, WP; Clark, AN; Altonen, TK				Goldstein, FC; Levin, HS; Goldman, WP; Clark, AN; Altonen, TK			Cognitive and neurobehavioral functioning after mild versus moderate traumatic brain injury in older adults	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; aging; cognitive functioning; depression	CLOSED-HEAD INJURY; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; FOLLOW-UP; RECOVERY; AGE; CONSEQUENCES; COMA; CLASSIFICATION; PREDICTORS	This study evaluated the early cognitive and neurobehavioral outcomes of older adults with mild versus moderate traumatic brain injury (TBI). Thirty-five patients who were age 50 years and older and sustained mild or moderate TBI were prospectively recruited from acute care hospitals. Patients were administered cognitive and neurobehavioral measures up to 2 months post-injury. Demographically comparable control participants received the same measures. Patients and controls did not have previous histories of substance abuse, neuropsychiatric disturbance, dementia, or neurologic illness. Moderate TBI patients performed significantly poorer than mild TBI patients and controls on most cognitive measures, whereas the mild patients performed comparably to controls. In contrast, both mild and moderate patients exhibited significantly greater depression and anxiety/somatic concern than controls. The results indicate that the classification of TBI as mild versus moderate is prognostically meaningful as applied to older adults. The findings extend previous investigations in young adults by demonstrating a relatively good cognitive outcome on objective measures, but subjective complaints after a single, uncomplicated mild TBI in older persons.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA; Emory Univ, Wesley Woods Ctr, Atlanta, GA USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX USA		Goldstein, FC (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G30051, R49/CCR612707-01] Funding Source: Medline		AharonPeretz J, 1997, BRAIN INJURY, V11, P871; BALTES PB, 1996, LIFESPAN DEV INDIVID, P427; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kraus JF, 1987, HEAD INJURY, V2, P1; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Libon DJ, 1996, CLIN NEUROPSYCHOL, V10, P237, DOI 10.1080/13854049608406686; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PRIGATANO GP, 1987, NEUROPSYCHOLOGICAL R, P335; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; *US BUR CENS, 1997, STAT ABSTR US 1997; US War Department, 1944, ARM IND TEST BATT MA; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson BA, 1998, CURR OPIN NEUROBIOL, V8, P281, DOI 10.1016/S0959-4388(98)80152-9; YSEVAGE JA, 1983, J PSYCHIAT RES, V17, P37; ZASLER ND, 1997, ARCH PHYSICAL MED RE, V78, P512	67	64	66	0	13	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-4930 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2001	7	3					373	383		10.1017/S1355617701733115			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	427VA	WOS:000168425100011	11311038				2022-02-06	
J	Hall, CD; Smith, AL; Keele, SW				Hall, CD; Smith, AL; Keele, SW			The impact of aerobic activity on cognitive function in older adults: A new synthesis based on the concept of executive control	EUROPEAN JOURNAL OF COGNITIVE PSYCHOLOGY			English	Article							CEREBRAL BLOOD-FLOW; PHYSICAL-ACTIVITY LEVEL; CLOSED-HEAD INJURY; REACTION-TIME; PREFRONTAL CORTEX; AGE-DIFFERENCES; EXERCISE; PERFORMANCE; FITNESS; HEALTH	Numerous reaction time studies have suggested that age-related declines in cognitive function might be ameliorated by lifestyles involving aerobic activity or by interventionist programmes of aerobic exercise. These studies are far from conclusive, however, reflecting a failure to factor out cognitive from sensory and motor processes. Following a critical review of the literature, we report on recent developments that differentiate cognitive processes involving executive vs non-executive control, the former being associated with frontal lobe function. Three key studies suggest that aerobic exercise primarily improves executive control.	Univ Oregon, Dept Psychol, Eugene, OR 97405 USA; Univ Texas, Austin, TX 78712 USA; Purdue Univ, W Lafayette, IN 47907 USA; Univ Oregon, Eugene, OR 97403 USA		Keele, SW (corresponding author), Univ Oregon, Dept Psychol, Eugene, OR 97405 USA.		Smith, Alan L./I-5124-2015	Smith, Alan L./0000-0003-2267-7293			ABOUREZK T, 1995, J AGING PHYS ACTIV, V3, P251, DOI 10.1123/japa.3.3.251; ALLPORT A, 1994, ATTENTION PERFORM, V15, P421; *AM COLL SPORTS ME, 1986, GUID GRAD EX PRESCR; BAYLOR AM, 1988, J GERONTOL, V43, pP121, DOI 10.1093/geronj/43.5.P121; BIRREN JE, 1965, BEHAV AGING NERVOUS, V7, P191; BLUMENTHAL JA, 1991, J GERONTOL, V46, P352; Bouchard C, 1995, RES Q EXERCISE SPORT, V66, P268, DOI 10.1080/02701367.1995.10607911; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; CLARKSONSMITH L, 1989, PSYCHOL AGING, V4, P183, DOI 10.1037/0882-7974.4.2.183; DONDERS FC, 1969, ACTA PSYCHOL, V30, P412, DOI 10.1016/0001-6918(69)90065-1; Dustman R. E., 1994, Journal of Aging and Physical Activity, V2, P143; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; EMERY CF, 1995, GERONTOLOGIST, V35, P378, DOI 10.1093/geront/35.3.378; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Frith CD, 2000, ATTENTION PERFORMANC, VXVIII; Gregoire J, 1997, AGING NEUROPSYCHOL C, V4, P140, DOI 10.1080/13825589708256642; GUR RC, 1987, ARCH GEN PSYCHIAT, V44, P617; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; Keele S.W., 1973, ATTENTION HUMAN PERF; KEELE SW, 1985, HDB PERCEPTION PERFO; KEELE SW, 2000, ATTENTION PERFORMANC, V18; KERR B, 1993, ANN M PSYCH SOC WASH; Konishi S, 1998, NAT NEUROSCI, V1, P80, DOI 10.1038/283; KRAMER AE, IN PRESS HUMAN FACTO; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kray J, 2000, PSYCHOL AGING, V15, P126, DOI 10.1037//0882-7974.15.1.126; Lee IM, 1995, RES Q EXERCISE SPORT, V66, P286, DOI 10.1080/02701367.1995.10607913; LINDENBERGER U, 1993, PSYCHOL AGING, V8, P207, DOI 10.1037/0882-7974.8.2.207; LUPINACCI NS, 1993, RES Q EXERCISE SPORT, V64, P144, DOI 10.1080/02701367.1993.10608791; MADDEN DJ, 1989, PSYCHOL AGING, V4, P307, DOI 10.1037/0882-7974.4.3.307; MAYR U, 1993, J EXP PSYCHOL LEARN, V19, P1297, DOI 10.1037/0278-7393.19.6.1297; Mayr U, 1996, COGNITION, V59, P61, DOI 10.1016/0010-0277(95)00689-3; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; MEYER DE, 1998, COGN NEUR SOC SAN FR; MEYERSON J, 1990, PSYCHOL REV, V97, P475; Monsell S., 2000, ATTENTION PERFORMANC, V18; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; PANTON LB, 1990, J GERONTOL, V41, P645; PETRIDES M, 2000, ATTENTION PERFORMANC, V18; Posner, 1978, CHRONOMETRIC EXPLORA; RIKLI R, 1986, J GERONTOL, V41, P645, DOI 10.1093/geronj/41.5.645; RIKLI RE, 1991, RES Q EXERCISE SPORT, V62, P61, DOI 10.1080/02701367.1991.10607519; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Rogers RD, 1998, BRAIN, V121, P815, DOI 10.1093/brain/121.5.815; SALTHOUSE TA, 1985, THEORY COGNITIVE AGI, P249; SHAW TG, 1984, NEUROLOGY, V34, P855, DOI 10.1212/WNL.34.7.855; SHAY KA, 1992, PSYCHOL AGING, V7, P15, DOI 10.1037/0882-7974.7.1.15; SPECTOR A, 1976, AM J PSYCHOL, V89, P669, DOI 10.2307/1421465; SPIRDUSO WW, 1975, J GERONTOL, V30, P435, DOI 10.1093/geronj/30.4.435; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STERNBERG S, 1969, AM SCI, V57, P521; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Chronic Disease Prevention & President's Council on Physical Fitness, 1996, PHYS ACT HLTH REP SU; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; Vuori I, 1995, RES Q EXERCISE SPORT, V66, P276, DOI 10.1080/02701367.1995.10607912; WARREN LR, 1985, J GERONTOL, V40, P53, DOI 10.1093/geronj/40.1.53; WEISS AD, 1965, J GERONTOL, V20, P60, DOI 10.1093/geronj/20.1.60; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; WHITEHURST M, 1991, PERCEPT MOTOR SKILL, V72, P251, DOI 10.2466/PMS.72.1.251-256	61	64	65	1	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0954-1446			EUR J COGN PSYCHOL	Eur. J. Cogn. Psychol.	MAR-JUN	2001	13	1-2					279	300		10.1080/09541440042000313			22	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	425EF	WOS:000168274800014					2022-02-06	
J	Yeates, KO; Taylor, HG; Barry, CT; Drotar, D; Wade, SL; Stancin, T				Yeates, KO; Taylor, HG; Barry, CT; Drotar, D; Wade, SL; Stancin, T			Neurobehavioral symptoms in childhood closed-head injuries: Changes in prevalence and correlates during the first year postinjury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						closed-head injury; children; neurobehavioral symptoms	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; FAMILY BURDEN; CHILDREN; RELIABILITY; PREDICTORS; SEVERITY; ADOLESCENTS; RECOVERY; VALIDITY	Objective: To examine changes in the prevalence and correlates of neurobehavioral symptoms during the first year following childhood closed-head injuries (CHIs). Methods: Participants included 31 children with severe CHIs, 38 with moderate CHIs, and 53 with orthopedic injuries (Ols). Children and their families were assessed shortly after injury and at 6- and 12-month follow-ups. Parents rated 15 symptoms classified as either cognitive/somatic (C/S) or emotional/behavioral (E/B). Results: Both kinds of symptoms were more common in the CHI groups than in the OI group. C/S symptoms declined in the CHI groups over time, whereas E/B symptoms became relatively more common. Measures of injury severity, children's premorbid behavioral adjustment, and concurrent cognitive functioning predicted C/S symptoms. E/B symptoms were predicted by injury severity, concurrent cognitive functioning soon after the injury, and concurrent parent and family functioning later in time. Both types of symptoms contributed to the prediction of perceived family burden, with the relationships strengthening over time. Conclusions: The findings indicate that the prevalence and correlates of,neurobehavioral symptoms in childhood CHIs vary as a function of symptom type and time since injury.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Metrohlth Med Ctr, Cleveland, OH USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 RO1 NS36335] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Achenbach TM, 1991, MANUAL CHILD BEHAV C; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 2013, STAT POWER ANAL BEHA; Delis D, 1994, MANUAL CALIFORNIA VE; Demellweek C, 1998, OX MED PUBL, P207; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DROTAR D, 1995, J CLIN CHILD PSYCHOL, V24, P184, DOI 10.1207/s15374424jccp2402_6; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; JENNETT B, 1975, LANCET, V1, P480; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; MOOS R, 1988, LIFE STRESSORS SOCIA; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; MYERS JL, 1982, PSYCHOL BULL, V92, P517, DOI 10.1037/0033-2909.92.2.517; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	42	64	64	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	MAR	2001	26	2					79	91		10.1093/jpepsy/26.2.79			13	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	408KZ	WOS:000167326500002	11181884	Bronze			2022-02-06	
J	Berger, MM; Reymond, MJ; Shenkin, A; Rey, F; Wardle, C; Cayeux, C; Schindler, C; Chiolero, RL				Berger, MM; Reymond, MJ; Shenkin, A; Rey, F; Wardle, C; Cayeux, C; Schindler, C; Chiolero, RL			Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial	INTENSIVE CARE MEDICINE			English	Article						trauma; critically ill; selenium; supplementation; thyroid hormone; non-thyroidal illness	EUTHYROID SICK SYNDROME; CRITICALLY ILL PATIENTS; FREE-RADICALS; HEAD-INJURY; HORMONE METABOLISM; MAJOR TRAUMA; BRAIN INJURY; THYROXINE; ILLNESS; SERUM	Objective:To investigate whether early selenium (Se) supplementation can modify the post-traumatic alterations of thyroid hormone metabolism, since the first week after trauma is characterised by low plasma Se and negative Se balances. Design: Prospective, placebo-controlled randomised supplementation trial. Setting: Surgical ICU in a tertiary university hospital. Patients: Thirty-one critically ill trauma patients aged 42 +/- 16 years (mean +/- SD), with severe multiple injury (Injury Severity Score 30 +/- 7). Intervention: Supplementation during the first 5 days after injury with either Se or placebo. The selenium group was further randomised to receive daily 500 mug Se, with or without 150 mg alpha -tocopherol (AT) and 13 mg zinc supplements. The placebo group received the vehicle. Circulating Se, AT, zinc, and thyroid hormones were determined on D0 (= day 0, admission), D1, D2, D5, D10, and D20. Results: Plasma Se, low on DO, normalised from D1 in the selenium group; total T4 and T3 increased more and faster after D2 (P = 0.04 and 0.08), reverse T3 rising less between D0 and D2 (P = 0.05). Conclusions: Selenium supplements increased the circulating Se levels. Supplementation was associated with modest changes in thyroid hormones, with an earlier normalisation of T4 and reverse T3 plasma levels. The addition of AT and zinc did not produce any additional change.	CHU Vaudois, CH-1011 Lausanne, Switzerland; Royal Liverpool Univ Hosp, Liverpool, Merseyside, England		Berger, MM (corresponding author), CHU Vaudois, BH08-660, CH-1011 Lausanne, Switzerland.						BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; Berger MM, 1998, AM J CLIN NUTR, V68, P365, DOI 10.1093/ajcn/68.2.365; Berger MM, 1996, J TRAUMA, V40, P103, DOI 10.1097/00005373-199601000-00019; Berger MM, 1996, INTENS CARE MED, V22, P575, DOI 10.1007/BF01708099; Bertin-Maghit M, 2000, INTENS CARE MED, V26, P800, DOI 10.1007/s001340051250; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bratter P, 1996, J TRACE ELEM MED BIO, V10, P163; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Chopra IJ, 1997, J CLIN ENDOCR METAB, V82, P329, DOI 10.1210/jc.82.2.329; CONTEMPRE B, 1992, CLIN ENDOCRINOL, V36, P579, DOI 10.1111/j.1365-2265.1992.tb02268.x; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; DOCTER R, 1993, CLIN ENDOCRINOL, V39, P499, DOI 10.1111/j.1365-2265.1993.tb02401.x; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Forceville X, 1998, CRIT CARE MED, V26, P1536, DOI 10.1097/00003246-199809000-00021; HAWKER FH, 1990, CRIT CARE MED, V18, P442, DOI 10.1097/00003246-199004000-00020; HUANG TS, 1987, ENDOCRINOLOGY, V121, P498, DOI 10.1210/endo-121-2-498; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kohrle J, 2000, Rev Endocr Metab Disord, V1, P49, DOI 10.1023/A:1010012419869; Kohrle J, 1996, ACTA MED AUST, V23, P17; KOHRLE J, 1994, EXP CLIN ENDOCRINOL, V102, P63; LEHMANN J, 1982, CLIN CHEM, V28, P1784; MCLARTY DG, 1975, LANCET, V2, P275; NOVITZKY D, 1992, J HEART LUNG TRANSPL, V11, pS196; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; VANELLA A, 1993, NEUROCHEM RES, V18, P1337, DOI 10.1007/BF00975056; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YANG G, 1994, J TRACE ELEM ELECT H, V8, P159; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	35	64	64	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2001	27	1					91	100		10.1007/s001340000757			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	400XJ	WOS:000166897700016	11280679				2022-02-06	
J	Sohlberg, MM; Mateer, CA				Sohlberg, MM; Mateer, CA			Improving attention and managing attentional problems - Adapting rehabilitation techniques to adults with ADD	ADULT ATTENTION DEFICIT DISORDER	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article						attention training; compensatory strategies; self-regulation; neuroplasticity; rehabilitation	TRAUMATIC BRAIN INJURY; TRAINING-PROGRAM; HEAD-INJURY; CHILDREN; INTERVENTION; DEFICITS; DAMAGE	Research and clinical experience in the field of brain injury rehabilitation have focused quite extensively on the need and potential to retrain attentional skills that are commonly affected by acquired brain injury. Four approaches to managing attention impairments that have emerged from this literature include attention process training, training use of strategies and environmental support, training use of external aids, and the provision of psychosocial support. Most often, several of these will be used in combination. For example, a therapy regimen might include attention process training emphasizing specific components of attention (e.g., sustained attention), in conjunction with training in pacing techniques, and psychosocial support, where the client keeps behavioral logs and discusses insights gained from tracking attention successes and attention lapses. Although there are as yet little data with regard to the effectiveness of these approaches in adults with developmental disorders of attention, there is a growing literature suggesting they may be effective in children and adolescents with ADHD. Further investigation of the application of such techniques in adults with a wide variety of attention disorders, including developmental disorders, would be valuable.	Univ Victoria, Dept Psychol, Victoria, BC, Canada; Univ Oregon, Eugene, OR 97403 USA		Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC, Canada.						ADAMS A, 1982, READ RES QUART, V18, P27, DOI 10.2307/747537; ANDREWS J R, 1986, Seminars in Speech and Language, V7, P359, DOI 10.1055/s-0028-1085234; Baddeley A.D., 1986, WORKING MEMORY; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R; Diller L, 1974, REHABILITATION MONOG, V50; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; GRONWALL D, 1991, NEUROPSYCHOLOGY, V5, P235; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kerns KA, 1999, DEV NEUROPSYCHOL, V16, P273, DOI 10.1207/S15326942DN1602_9; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; MAPOU R, 1995, COGNITIVE FRAMEWORK; Mateer C.A., 1990, COGNITIVE REHABILITA; Mateer C.A., 1992, REHABILITATION POSTC; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Mateer C. A., 1997, NEUROPSYCHOLOGICAL R; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mateer CA, 2000, BRAIN COGNITION, V42, P106, DOI 10.1006/brcg.1999.1175; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NEIMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Semrud-Clikeman M, 1999, J LEARN DISABIL-US, V32, P581, DOI 10.1177/002221949903200609; SEMRUDCLIKEMAN M, 26 ANN INT NEUR SOC; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; Sohlberg M. M, 1989, COGNITIVE REHABILITA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1998, BRAIN INJURY, V12, P333; Sohlberg MM., 2000, NEUROPSYCHOLOGICAL M, P137; SOHLBERG MM, 2000, EVALUATION ATTENTION; SOHLBERG MM, 1994, THESIS ASS NEUROPSYC; STURM W, 1993, DEV ASSESSMENT REHAB; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; THOMSON JB, 2000, NEUROPSYCHOLOGICAL M, P233; THOMSON JB, 1995, 23 ANN M INT NEUR SO; Williams D.J., 1989, THESIS U WASHINGTON; WINOGRAD P, 1988, LEARNING STUDY STRAT; Wood R L, 1987, Int Disabil Stud, V9, P149	46	64	67	0	69	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923			ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	931						359	375					17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	BT11H	WOS:000172009700021	11462753				2022-02-06	
J	Reinert, M; Khaldi, A; Zauner, A; Doppenberg, E; Choi, S; Bullock, R				Reinert, M; Khaldi, A; Zauner, A; Doppenberg, E; Choi, S; Bullock, R			High level of extracellular potassium and its correlates after severe head injury: relationship to high intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						potassium; glutamate; lactate; cerebral blood flow; severe head injury; intracranial pressure	TRAUMATIC BRAIN INJURY; CORTICAL SPREADING DEPRESSION; NEUROPIL GLIAL-CELLS; CEREBRAL-ISCHEMIA; MITOCHONDRIAL DYSFUNCTION; GLUTAMATE UPTAKE; NEURAL TISSUE; LACTATE; GLUCOSE; RAT	Object. Disturbed ionic and neurotransmitter homeostasis are now recognized as probably the most important mechanisms contributing to the development of secondary brain swelling after traumatic brain injury (TBI). Evidence obtained in animal models indicates that posttraumatic neuronal excitation by excitatory amino acids leads to an increase in extracellular potassium, probably due to ion channel activation. The purpose of this study was therefore to measure dialysate potassium in severely head injured patients and to correlate these results with measurements of intracranial pressure (ICP), patient outcome, and levels of dialysate glutamate and lactate, and cerebral blood flow (CBF) to determine the role of ischemia in this posttraumatic ion dysfunction. Methods. Eighty-five patients with severe TBI (Glasgow Coma Scale Score < 8) were treated according to an intensive ICP management-focused protocol. All patients underwent intracerebral microdialyis. Dialysate potassium levels were analyzed using flame photometry, and dialysate glutamate and dialysate lactate levels were measured using high-performance liquid chromatography and an enzyme-linked amperometric method in 72 and 84 patients, respectively. Cerebral blood flow studies (stable xenon computerized tomography scanning) were performed in 59 patients. In approximately 20% of the patients, dialysate potassium values were increased (dialysate potassium > 1.8 mM) for 3 hours or more. A mean amount of dialysate potassium greater than 2 mM throughout the entire monitoring period was associated with ICP above 30 mm Hg and fatal outcome, as were progressively rising levels of dialysate potassium. The presence of dialysate potassium correlated positively with dialysate glutamate (p < 00001) and lactate (p < 0.0001) levels. Dialysate potassium was significantly inversely correlated with reduced CBF (p = 0.019). Conclusions. Dialysate potassium was increased after TBI in 20% of measurements. High levels of dialysate potassium were associated with increased ICP and poor outcome. The simultaneous increase in dialysate potassium, together with dialysate glutamate and lactate, supports the concept that glutamate induces ionic flux and consequently increases ICP, which the authors speculate may be due to astrocytic swelling. Reduced CBF was also significantly correlated with increased levels of dialysate potassium. This may be due to either cell swelling or altered vasoreactivity in cerebral blood vessels caused by higher levels of potassium after trauma. Additional studies in which potassium-sensitive microelectrodes are used are needed to validate these ionic events more clearly.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	mreinert@insel.ch	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P012587] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Armstead WM, 1998, AM J PHYSIOL-HEART C, V274, pH1674, DOI 10.1152/ajpheart.1998.274.5.H1674; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; BALLANYI K, 1990, GLIA, V3, P151, DOI 10.1002/glia.440030302; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1995, NEUROCHEMICAL MONITO; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; Forsyth R, 1996, DEV NEUROSCI-BASEL, V18, P360, DOI 10.1159/000111429; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HIROTA H, 1995, NEUROL RES, V17, P94, DOI 10.1080/01616412.1995.11740294; HOSSMAN K, 1977, ACTA PHYSL SCAND, V113, P437; JENNETT B, 1975, LANCET, V1, P480; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMPSKI O, 1991, ANN NY ACAD SCI, V633, P306; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; KUFFLER SW, 1967, PROC R SOC SER B-BIO, V168, P1, DOI 10.1098/rspb.1967.0047; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; NICHOLLS JG, 1992, NEURON BRAIN CELLULA; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Schousboe A, 1997, GLIA, V21, P99; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; TEASDALE G, 1974, LANCET, V2, P81; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WUTTKE WA, 1990, J NEUROPHYSIOL, V63, P1089, DOI 10.1152/jn.1990.63.5.1089; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	45	64	67	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					800	807		10.3171/jns.2000.93.5.0800			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800011	11059661				2022-02-06	
J	Strauss, DJ; Ashwal, S; Day, SM; Shavelle, RM				Strauss, DJ; Ashwal, S; Day, SM; Shavelle, RM			Life expectancy of children in vegetative and minimally conscious states	PEDIATRIC NEUROLOGY			English	Article							LONG-TERM SURVIVAL; CEREBRAL-PALSY; MENTAL-RETARDATION; NATURAL-HISTORY; CNS INJURIES; BRAIN INJURY; PERSISTENT; SCOLIOSIS; MORTALITY; DIFFICULTIES	We determined estimates of survival in children, 3-15 years of age, in the vegetative state (VS) (n = 564), immobile minimally conscious state (MCS) (n = 705), and mobile MCS (n = 3,806), Data were extracted from the annual Client Development Evaluation Reports of the California Department of Developmental Services between 1988 and 1997 using the operational definitions for these three states on the basis of 15 descriptive behavioral categories. Patients were also categorized according to the following four etiologies: acquired (traumatic and nontraumatic) brain injury; perinatal/genetic; degenerative; and unknown/undetermined, The percentage of patients surviving 8 Sears was 63%, 65%, and 81%, for the VS, immobile MCS, and mobile MCS, respectively. Children in the VS and MCSs with acquired brain injury had lower mortality rates and those with degenerative diseases the highest mortality rates. We observed little difference in survival between patients in the VS and immobile MCS, suggesting that the presence of consciousness is not a critical variable in determining life expectancy. Furthermore, survival was much greater for patients in the mobile MCS than for those in the immobile MCS, suggesting that mobility is more important in predicting survival than the level of consciousness. (C) 2000 by Elsevier Science Inc. All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, 11175 Campus St,Coleman Pavil, Loma Linda, CA 92350 USA.		Day, Steven/P-1002-2019	Day, Steven/0000-0001-8305-5813; Day, Marc/0000-0002-1711-3963			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Broder Andrew J, 1995, Univ Detroit Mercy Law Rev, V72, P787; *CAL DEP DEV SERV, 1978, CLIENT DEV EV REP; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Collett D., 1994, MODELLING SURVIVAL D; Cranford RE, 1998, GERIATRICS, V53, pS70; DETOLEDO J, 1994, BRAIN INJURY, V8, P607, DOI 10.3109/02699059409151013; DeToledo JC, 1999, BRAIN INJURY, V13, P39, DOI 10.1080/026990599121863; Eyman RK, 1996, DIAGNOSIS MANAGEMENT, P543; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Gillon R, 1998, J MED ETHICS, V24, P75, DOI 10.1136/jme.24.2.75; HAIG AJ, 1994, NEW ENGL J MED, V331, P1380; HARRIS CW, 1982, INTERRATER RELIABILI; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Hosmer D, 1989, APPL LOGISTIC REGRES; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; KOHDA E, 1994, ACTA OTO-LARYNGOL, P11; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Majd ME, 1997, SPINE, V22, P1461, DOI 10.1097/00007632-199707010-00007; Martin Bonnie J. W., 1994, Dysphagia, V9, P1; McLean SAM, 1999, J CLIN PATHOL, V52, P490, DOI 10.1136/jcp.52.7.490; MINDERHOUD JM, 1985, NED TIJDSCHR GENEES, V29, P2385; Nelson L J, 1999, J Contemp Health Law Policy, V15, P427; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Piguet O, 1999, BRAIN INJURY, V13, P829, DOI 10.1080/026990599121223; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Saito N, 1998, LANCET, V351, P1687, DOI 10.1016/S0140-6736(98)01302-6; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; Strauss D, 1998, J Insur Med, V30, P96; Strauss D, 1998, DEV MED CHILD NEUROL, V40, P369; Strauss D, 1996, AM J MENT RETARD, V101, P26; Strauss D, 1998, MENT RETARD, V36, P360, DOI 10.1352/0047-6765(1998)036<0360:MOAWDD>2.0.CO;2; Strauss D, 1997, PEDIATRICS, V99, P358, DOI 10.1542/peds.99.3.358; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; WIDAMAN KF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; Zafonte RD, 1996, NEUROREHABILITATION, V6, P19, DOI 10.3233/NRE-1996-6104; [No title captured]; 1996, ASP CONS C	53	64	66	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	OCT	2000	23	4					312	319		10.1016/S0887-8994(00)00194-6			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	372FQ	WOS:000165224000003	11068163	Green Published			2022-02-06	
J	Painter, TJ; Chaljub, G; Sethi, R; Singh, H; Gelman, B				Painter, TJ; Chaljub, G; Sethi, R; Singh, H; Gelman, B			Intracranial and intraspinal meningeal melanocytosis	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							NEUROCUTANEOUS MELANOSIS; DIAGNOSTIC-CRITERIA; FEATURES; MR	We describe a 35-year-old man with a history of remote closed head injury who presented with new neurologic deficits. A noncontrast head CT scan showed hyperattenuation involving both temporal lobes, frontal lobes, basal meninges, and cerebellum. A subsequent contrast-enhanced MR examination of the brain showed enhancement in the basal cisterns extending into the upper cervical spine and throughout the spinal canal. Gross, histologic, and immunohistochemical analysis revealed meningeal melanocytoma.	Univ Texas, Med Branch, Dept Radiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77550 USA		Chaljub, G (corresponding author), Univ Texas, Med Branch, Dept Radiol, 301 Univ Blvd, Galveston, TX 77555 USA.						AICHNER F, 1982, CANCER-AM CANCER SOC, V50, P1751, DOI 10.1002/1097-0142(19821101)50:9<1751::AID-CNCR2820500918>3.0.CO;2-Q; Alwatban J, 1997, J COMPUT ASSIST TOMO, V21, P38, DOI 10.1097/00004728-199701000-00008; DEMIRCI A, 1995, AM J NEURORADIOL, V16, P603; FAILLACE WJ, 1984, J NEUROSURG, V61, P782, DOI 10.3171/jns.1984.61.4.0782; FOX H, 1964, ARCH DIS CHILD, V39, P508, DOI 10.1136/adc.39.207.508; JELLINGER K, 1988, ACTA NEUROCHIR, V94, P78, DOI 10.1007/BF01406621; LACH B, 1988, NEUROSURGERY, V22, P773, DOI 10.1227/00006123-198804000-00030; LEANEY BJ, 1985, J NEUROSURG, V62, P148, DOI 10.3171/jns.1985.62.1.0148; LITOFSKY NS, 1992, NEUROSURGERY, V31, P945, DOI 10.1227/00006123-199211000-00019; NAUL LG, 1991, AM J NEURORADIOL, V12, P315; Ruelle A, 1996, NEUROSURG REV, V19, P39, DOI 10.1007/BF00346608; TATAGIBA M, 1992, NEUROSURGERY, V31, P958, DOI 10.1227/00006123-199211000-00023; UEMATSU Y, 1992, J NEUROSURG, V76, P705, DOI 10.3171/jns.1992.76.4.0705; Vanzieleghem BD, 1999, AM J NEURORADIOL, V20, P457	14	64	71	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	AUG	2000	21	7					1349	1353					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	369FG	WOS:000165054800033	10954294				2022-02-06	
J	McGowan, JC; Yang, JH; Plotkin, RC; Grossman, RI; Umile, EM; Cecil, KM; Bagley, LJ				McGowan, JC; Yang, JH; Plotkin, RC; Grossman, RI; Umile, EM; Cecil, KM; Bagley, LJ			Magnetization transfer imaging in the detection of injury associated with mild head trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	6th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 17-25, 1998	SYDNEY, AUSTRALIA	Int Soc Magnet Resonance Med			APPEARING WHITE-MATTER; MULTIPLE-SCLEROSIS LESIONS; DIFFUSE AXONAL INJURY; HISTOPATHOLOGIC CORRELATION; BRAIN INJURY; MR; SPECTROSCOPY; PIG	BACKGROUND AND PURPOSE: Most traumatic brain injuries are classified as mild, yet in many instances cognitive deficits result, The purpose of this study was to investigate possible relationships between quantitative magnetization transfer imaging (MTI) and neurocognitive findings in a cohort of patients with mild head trauma but negative findings on conventional MR images. METHODS: We examined 13 patients and 10 healthy volunteers with a standard MR protocol including fast spin-echo and gradient-echo imaging, to which was added quantitative MTI, MTI was performed with a modified gradient-echo sequence incorporating pulsed, off-resonance saturation. Both region-of-interest analysis and contour plots were obtained from the MTI data. A subgroup of nine patients was examined with a battery of neuropsychological tests, comprising 25 measures of neurocognitive ability. RESULTS: The magnetization transfer ratio (MTR) in the splenium of the corpus callosum was lower in the patient group as compared with the control group, but no significant reduction in MTR was found in the pens. Individual regional MTR values were significantly reduced in two cases, and contour plot analysis revealed focal areas of abnormality in the splenium of four patients. All the patients showed impairment on at least three measures of the neuropsychological test battery, and in two cases a significant correlation was found between regional MTR values and neuropsychological performance. CONCLUSION: Our results suggest that MTI and contour plot analysis may add sensitivity to the MR imaging examination of patients with traumatic brain injury.	Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Rehabil Med, Philadelphia, PA 19104 USA		McGowan, JC (corresponding author), Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.			Cecil, Kim/0000-0001-8233-5485	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS029029, P01NS008803, P50NS008803, R01NS029029, R55NS034353, R29NS034353] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29029, NS08803, NS34353] Funding Source: Medline		Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; Filippi M, 1997, J NEUROL SCI, V147, P151, DOI 10.1016/S0022-510X(96)05322-1; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GILROY J, 1982, BASIC NEUROLOGY, P329; GOMORI JM, 1993, AM J NEURORADIOL, V14, P871; HENKELMAN RM, 1993, MAGNET RESON MED, V29, P759, DOI 10.1002/mrm.1910290607; HIEHLE JF, 1995, AM J NEURORADIOL, V16, P69; HIEHLE JF, 1994, MAGNET RESON MED, V32, P285, DOI 10.1002/mrm.1910320303; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Long C. J., 1992, HDB HEAD TRAUMA ACUT; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; MCGOWAN JC, 1994, MAGNET RESON MED, V32, P517, DOI 10.1002/mrm.1910320415; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Petrella JR, 1996, AM J NEURORADIOL, V17, P1041; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; van Buchem MA, 1998, NEUROLOGY, V50, P1609, DOI 10.1212/WNL.50.6.1609; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	26	64	67	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2000	21	5					875	880					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	313CU	WOS:000086983400014	10815663				2022-02-06	
J	Cohen, IR; Schwartz, M				Cohen, IR; Schwartz, M			Autoimmune maintenance and neuroprotection of the central nervous system	JOURNAL OF NEUROIMMUNOLOGY			English	Article						central nervous system; central nervous system injury; autoimmune maintenance	TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; GROWTH-FACTOR; BASIC-PROTEIN; ENCEPHALOMYELITIS; LYMPHOCYTES; RECEPTOR; REGENERATION; MECHANISMS; EXPRESSION	The genesis of immune privilege high in the evolutionary tree suggests that immune privilege is necessary, if not advantageous for the progressive development of the CNS. Upon reaching a certain degree of complexity, it seems as if the CNS was obliged to restrain the immune system from penetrating the blood-brain barrier. CNS autoimmunity against myelin proteins is known to be a contributory factor in the pathophysiology of multiple sclerosis and in the animal model of experimental autoimmune encephalomyelitis (EAE) (Wekerle, 1993). Such autoimmunity has therefore been regarded as detrimental and hence obviously undesirable. However, recent findings in our laboratory suggest that T-cell autoimmunity to CNS self-antigens (Moalem et al., 1999), if expressed at the right time and the right place, can do much good in the CNS. We shall review the experiments briefly, and then discuss their implications for our understanding of immune privilege and CNS maintenance after injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel		Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Cohen, Irun R/B-3542-2009				Agrawal SK, 1996, J NEUROSCI, V16, P545; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BIRK O, 1999, IN PRESS P NATL ACA; BURNET M, 1959, CLONAL SELECTION THE; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1999, IN PRESS TENDING ADA; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAUBEN E, 1999, IN PRESS LANCET; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LIU DX, 1994, J NEUROCHEM, V62, P37; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; MOALEM G, 1999, UNPUB AUTOIMMUNE T C; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1998, NEUROSCIENTIST, V4, P71, DOI 10.1177/107385849800400203; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RANSOM BR, 1990, STROKE, V21, P52; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SANNER CA, 1994, J NEUROSCI, V14, P6472; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Wekerle H, 1993, Curr Opin Neurobiol, V3, P779, DOI 10.1016/0959-4388(93)90153-P; YAROM Y, 1983, NATURE, V303, P246, DOI 10.1038/303246a0; Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451	37	64	66	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	DEC	1999	100	1-2					111	114		10.1016/S0165-5728(99)00190-3			4	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	284XE	WOS:000085357500013	10695721				2022-02-06	
J	Azouvi, P; Jokic, C; Attal, N; Denys, P; Markabi, S; Bussel, B				Azouvi, P; Jokic, C; Attal, N; Denys, P; Markabi, S; Bussel, B			Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial	BRAIN INJURY			English	Article							SCALE; SEQUELAE; PATIENT; CLINICIAN; EFFICACY	Ten patients presenting agitation and anger outbursts at Various stages following a severe closed head injury, were treated in a prospective open trial with carbamazepine, with doses ranging from 400 to 800 mg per day, during 8 weeks. Group analysis demonstrated a statistically significant improvement of a score made up from six target items from the neurobehavioural rating scale. Improvement mainly concerned irritability and disinhibition. A statistically significant improvement was also found with the Agitated Behaviour Scale. Social functioning, as assessed by family or staff ratings of the Katz Adjustment Scale, also significantly improved. No modification of global cognitive functioning was found with the Mini Mental Status Examination. Individual analysis demonstrated that the beneficial effect was important in five cases, moderate in three patients and negligible in two cases. It is concluded that carbamazepine might help to reduce agitated behaviour in brain-injured patients. However, response to treatment demonstrated an important inter-individual variability.	Raymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France; Ctr Hosp, Dept Neurol Rehabil, Auyay Sur Odon, France; Hop La Pitie Salpetriere, Ctr Marguerite Bottard, Paris, France; Lab Ciba Geigy, Rueil Malmaison, France		Azouvi, P (corresponding author), Raymond Poincare Hosp, Dept Neurol Rehabil, F-92380 Garches, France.			DENYS, Pierre/0000-0002-4831-6499			ANTON RF, 1986, J CLIN PSYCHOPHARM, V6, P232; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; ESSA M, 1986, J CLIN PSYCHOPHARM, V6, P234; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1990, INT DRUG THERAPY NEW, V25, P28; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; NEPPE VM, 1982, LANCET, V2, P334; OKUMA T, 1979, PSYCHOPHARMACOLOGY, V66, P211, DOI 10.1007/BF00428308; POURCHER E, 1994, AM J PSYCHIAT, V151, P150; PRIGATANO GP, 1987, NEUROBEHAVIORAL RECO, P155; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; TEASDALE G, 1974, LANCET, V2, P81	23	64	64	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					797	804		10.1080/026990599121188			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800005	10576463				2022-02-06	
J	Ishikawa, M; Sekizuka, E; Sato, S; Yamaguchi, N; Inamasu, J; Bertalanffy, H; Kawase, T				Ishikawa, M; Sekizuka, E; Sato, S; Yamaguchi, N; Inamasu, J; Bertalanffy, H; Kawase, T			Effects of moderate hypothermia on leukocyte-endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion	STROKE			English	Article						hypothermia; leukocytes; middle cerebral artery; occlusion; reperfusion injury	ISCHEMIC CELL-DAMAGE; TRAUMATIC BRAIN INJURY; INTRAISCHEMIC HYPOTHERMIA; REPERFUSION INJURY; MESENTERIC VENULES; MILD HYPOTHERMIA; FOCAL ISCHEMIA; NEUTROPHIL; ADHESION; MICROCIRCULATION	Background and Purpose-It has been demonstrated that moderate hypothermia attenuates brain damage, but the mechanism whereby this is achieved has not been clearly shown. Recently, the role of leukocytes as mediators of secondary brain damage after brain ischemia has been discussed. The aim of this study is to examine the effects of moderate hypothermia on leukocyte-endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion (MCAO). Methods-Rhodamine 6G-labeled leukocytes in brain surface were visualized with intravital fluorescence videomicroscopy through a closed cranial window. We analyzed the number of leukocytes adhering to the venular and arteriolar endothelium before ischemic insult and up to 3 hours after reperfusion. Rats were divided into 4 experimental groups. Group I (n=6) consisted of sham-operated animals. Groups II (n=6) and III (n=6) received left MCAO for 1 hour under normothermia (36 degrees C to 37 degrees C, group II) and under moderate hypothermia (30 degrees C to 32 degrees C, group III). Group IV (n=4) received left common carotid artery occlusion for 1 hour under normothermia. Results-The number of adhering leukocytes in venules in groups II and IV increased significantly (P<0.001) after reperfusion compared with the group I, but that in group III did not increase significantly (P>0.05). The number of adhering leukocytes in arterioles in group II increased significantly (P<0.01) compared with the other groups, although the adhering leukocytes were not as numerous as those seen in venules. Conclusions-It is demonstrated that hypothermia attenuates adhering leukocytes in venules and arterioles after reperfusion of MCAO. The inhibition of the leukocyte function may be an important factor in the neuroprotective effect of hypothermia.	Saitama Natl Hosp, Dept Neurosurg, Moroyama, Saitama, Japan; Saitama Natl Hosp, Dept Internal Med, Moroyama, Saitama, Japan; Keio Univ, Sch Med, Dept Neurosurg, Tokyo 160, Japan; Univ Marburg, Dept Neurosurg, Marburg, Germany		Ishikawa, M (corresponding author), Philipps Univ Hosp, Dept Neurosurg, Baldingerstr, D-35033 Marbury, Germany.		Inamasu, Joji/R-7314-2019				AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK WM, 1994, STROKE, V25, P1411, DOI 10.1161/01.STR.25.7.1411; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Del Zoppo GJ., 1995, PHYSL PATHOPHYSIOLOG, P408; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIRNAGL U, 1994, STROKE, V25, P1028, DOI 10.1161/01.STR.25.5.1028; GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GUTE D, 1995, PHYSL PATHOPHYSIOLOG, P359; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Iigo Y, 1997, AM J PHYSIOL-HEART C, V273, pH138, DOI 10.1152/ajpheart.1997.273.1.H138; INAMASU J, 1997, J CEREB BLOOD FLOW M, V17, pS702; Ishikawa M, 1998, MICROVASC RES, V56, P166, DOI 10.1006/mvre.1998.2100; Ishikawa M, 1999, NEUROSURGERY, V44, P156, DOI 10.1097/00006123-199901000-00096; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MAYROVITZ HN, 1980, MICROVASC RES, V20, P264, DOI 10.1016/0026-2862(80)90028-X; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; MORII S, 1986, J CEREBR BLOOD F MET, V6, P34, DOI 10.1038/jcbfm.1986.5; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NAZZIOLA E, 1992, MICROVASC RES, V44, P127, DOI 10.1016/0026-2862(92)90076-2; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; SEKIZUKA E, 1991, GASTROINTESTINAL FUN, V9, P93; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Tomita M, 1996, ACT NEUR S, V66, P32; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; VILLRINGER A, 1991, MICROVASC RES, V42, P305, DOI 10.1016/0026-2862(91)90064-I; Wass CT, 1996, INT ANESTHESIOL CLIN, V34, P95, DOI 10.1097/00004311-199603440-00008; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	47	64	71	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	1999	30	8					1679	1685		10.1161/01.STR.30.8.1679			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	224JM	WOS:000081894300035	10436121	Bronze			2022-02-06	
J	Kennan, HT; Brundage, SI; Thompson, DC; Maier, RV; Rivara, FP				Kennan, HT; Brundage, SI; Thompson, DC; Maier, RV; Rivara, FP			Does the Face Protect the Brain? A case-control study of traumatic brain injury and facial fractures	ARCHIVES OF SURGERY			English	Article							HEAD-INJURIES	Background: The relationship between facial fractures and traumatic brain injury is controversial. Some studies show an increased risk of brain injury with the presence of facial fractures while others claim that facial fractures protect against brain injury. Objective: To examine the association between facial fractures and traumatic brain injuries. Design: Case-control study. Setting: Subjects were recruited from the emergency departments of 7 hospitals in the Seattle, Wash, area. Patients: Three thousand eight hundred forty-nine injured bicyclists and 5 scene deaths were identified from March 1, 1992, to August 31, 1994, with complete data available on 3388 bicyclists. Interventions: None. Results: The study group was composed of 1602 cases with injuries to the head, face, or brain and 1540 control subjects. There were 203 bicyclists with traumatic brain injuries, of whom 62 had an identifiable intracranial injury and 141 suffered a concussion. A total of 81 patients sustained facial fractures. The odds ratio for the risk of intracranial injury associated with facial fractures after adjustment for significant confounders was 9.9 (95% confidence interval, 5.1-19.3). The effect was less strong but still present when all traumatic brain injuries including concussions were considered (odds ratio, 2;95% confidence interval, 1.1-3.7). No association was found for concussion only. Conclusions: This study demonstrates no evidence that facial fractures help prevent traumatic brain injury. Data indicate that facial fractures are markers for increased risk of brain injury.	Univ Washington, Harborview Injury Prevent & Res Ctr, Dept Pediat & Epidemiol, Seattle, WA 98104 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA		Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Dept Pediat & Epidemiol, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@u.washington.edu					BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; CANNELL H, 1982, BRIT J ORAL SURG, V20, P183, DOI 10.1016/S0007-117X(82)80036-X; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; TURVEY TA, 1977, J ORAL SURG, V35, P887	6	64	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	JAN	1999	134	1					14	17		10.1001/archsurg.134.1.14			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	157GR	WOS:000078053500003	9927123	Bronze			2022-02-06	
J	Juneja, G; Czyrny, JJ; Linn, RT				Juneja, G; Czyrny, JJ; Linn, RT			Admission balance and outcomes of patients admitted for acute inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						balance; rehabilitation; functional outcomes; length of stay	ELDERLY PATIENTS; ACUTE STROKE; PROGNOSIS	The objective of the study contained herein was to evaluate the clinical use of the Berg Balance Scale in a heterogeneous acute inpatient rehabilitation population and to assess the relationship between balance scores at admission and rehabilitation outcomes, including functional gain and length of stay. This was a prospective study of 45 patients with diagnoses including stroke (n = 15), traumatic brain injury (n = 19), and other impairments (n = 11) who were admitted for acute inpatient rehabilitation. Functional ability was evaluated with the Functional Independence Measure (FIM(TM)) instrument, and balance was measured using the 14-item Berg Balance Scale. These measures were assessed both at admission to and discharge from inpatient rehabilitation. Correlation and multiple regression analyses were used to determine the relationship between balance and functional ability scores at admission and rehabilitation outcomes at discharge, including length of stay, functional gain, and efficiency. Analyses of variance comparing impairment groups indicated that patients with traumatic brain injury were younger than the stroke and other groups, but there were no group differences on FIM or balance scores at admission or discharge. There were no significant group differences for any of the outcome measures. When the impairment groups were collapsed into a single heterogeneous group, multiple regression analyses demonstrated that the sitting unsupported item score at admission accounted for 27% of the variation in length of stay, once demographic influences were controlled. The FIM efficiency score was predicted best by the total Berg Balance Scale score, with 22% of the variance accounted for. In contrast, balance scores did not provide predictive information about the FIM gain score beyond that already provided by the FIM-Total score at admission, which accounted for 10% of the variance once demographics were controlled. Balance scores collected at admission to inpatient rehabilitation, in whole and in part, were shown to account for moderate amounts of variation in length of stay and the FIM efficiency score. For several of the rehabilitation outcomes, balance scores at admission accounted for more variation than scores on the FIM instrument. These findings suggest that routine assessment of balance at admission to inpatient rehabilitation may enhance the ability to predict rehabilitation outcomes beyond that provided by assessment of functional status alone.	SUNY Buffalo, Dept Rehabil Med, Sch Med & Biomed Sci, Buffalo, NY 14260 USA		Czyrny, JJ (corresponding author), Erie Cty Med Ctr & Labs, 462 Grider St, Buffalo, NY 14215 USA.						BERG K, 1989, Physiotherapy Canada, V41, P240; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; BOBATH B, 1965, ABNORMAL POSTURAL RE; BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; Brunnstrom S., 1970, MOVEMENT THERAPY HEM; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gabell A, 1982, Physiotherapy, V68, P286; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; *SPSS INC, 1996, SPSS WIND REL 7 0; *STAT U NY BUFF, 1996, GUID UN DAT SET MED; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P980, DOI 10.1016/S0003-9993(97)90061-7; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; WADE DT, 1983, ARCH PHYS MED REHAB, V64, P24; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WING AM, 1993, ARCH PHYS MED REHAB, V74, P292; [No title captured]	22	64	73	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP-OCT	1998	77	5					388	393		10.1097/00002060-199809000-00005			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	132DA	WOS:000076613900005	9798829				2022-02-06	
J	Strauss, DJ; Shavelle, RM; Anderson, TW				Strauss, DJ; Shavelle, RM; Anderson, TW			Long-term survival of children and adolescents after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; SEVERE MENTAL-RETARDATION; LIFE EXPECTANCY; MORTALITY; PEOPLE	Objective: To obtain information on long-term mortality risk and life expectancy after traumatic brain injury (TBI), to improve planning and for counseling patients and their families. In contrast to the literature for spinal cord injury and other disabilities, there have been few such reports for TBI. Design: Records were reviewed on 946 persons aged 5 to 21 years who had sustained TBI. All were patients who subsequently received disability services in California, 1987 to 1995. Results: The chief predictors of mortality were basic functional skills such as mobility and self-feeding. After the initial high-risk period, mortality risk for TBI was much lower than for similarly functioning persons with cerebral palsy (a comparison group), although after 10 years the two sets of mortality rates had largely converged. For high-functioning persons, life expectancies were only 3 to 5 years shorter than for the general population. By contrast, the remaining life expectancy for those without mobility 6 months after injury was only 15 years. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada		Strauss, DJ (corresponding author), Univ Calif Riverside, Dept Stat, Riverside, CA 92521 USA.						Agresti A., 1990, CATEGORICAL DATA ANA; ARIAS M, 1983, PACIFIC STATE ARCH, V8, P28; ASHWAL S, 1994, PEDIATR NEUROL, V10, P27, DOI 10.1016/0887-8994(94)90063-9; *CAL DEP DEV SERV, 1978, CLIENT DEV EV REP; Collett D., 1994, MODELING SURVIVAL DA; *CONT SOFTW SYST I, 1995, INT CLASS DIS; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; EYMAN RK, 1993, AM J DIS CHILD, V147, P329, DOI 10.1001/archpedi.1993.02160270091029; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; GEISLER WO, 1977, PARAPLEGIA, V14, P262, DOI 10.1038/sc.1976.44; HARRIS CW, 1982, UCLA MENTAL RETARDAT; Hartkopp A, 1997, SPINAL CORD, V35, P76, DOI 10.1038/sj.sc.3100351; HUTTON JL, 1994, BRIT MED J, V309, P431, DOI 10.1136/bmj.309.6952.431; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MacKenzie E J, 1989, Md Med J, V38, P725; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Schoen R, 1988, MODELING MULTIGROUP; Strauss D, 1997, J PEDIATR-US, V131, P712, DOI 10.1016/S0022-3476(97)70098-2; Strauss D, 1996, AM J PUBLIC HEALTH, V86, P1422, DOI 10.2105/AJPH.86.10.1422; Strauss D, 1996, AM J MENT RETARD, V101, P26; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; WIDAMAN KF, 1984, 92 ANN M AM PSYCH AS; WIDAMAN KF, 1985, 109 ANN M AM ASS MEN; [No title captured]	30	64	64	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1998	79	9					1095	1100		10.1016/S0003-9993(98)90177-0			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	118FX	WOS:000075828700013	9749690				2022-02-06	
J	Christman, CW; Salvant, JB; Walker, SA; Povlishock, JT				Christman, CW; Salvant, JB; Walker, SA; Povlishock, JT			Characterization of a prolonged regenerative attempt by diffusely injured axons following traumatic brain injury in adult cat: a light and electron microscopic immunocytochemical study	ACTA NEUROPATHOLOGICA			English	Article						regeneration; diffuse axonal injury; GAP43; neurofilament; ultrastructure	RAT SPINAL-CORD; NERVE GROWTH-FACTOR; HEAD-INJURY; NEUROFILAMENT SUBUNITS; CNS NEURONS; GAP-43; ANTIBODIES; LESIONS; HUMANS; EXPRESSION	Traumatic brain injury in animals and humans is well known to cause axonal damage diffusely scattered throughout the brain without evidence of other brain parenchymal change. This observation has prompted some to posit that such damaged axons are well positioned to mount a regenerative attempt. The present study uses an immunocytochemical marker specific for regenerating neurites to explore this issue. Further, in an attempt to expedite and enhance any potential regenerative effort, this study evaluates the efficacy of intrathecally applied nerve growth factor. Three sets of experiments were performed in adult cats. One group of animals was subjected to moderate fluid percussion brain injury and followed for 7 or 14 days post injury, with the continuous intraventricular infusion of nerve growth factor delivered by implanted osmotic pumps. These animals were compared to a second group of time-matched, sham-operated animals receiving artificial cerebrospinal fluid infusion. To assess axonal damage immunohistochemical staining for the low molecular weight neurofilament subunit (NF-L) was carried out using an NR4 monoclonal antibody. To localize axons exhibiting a regenerative response immunohistochemical staining for the growth associated protein GAP43 was employed. In sham controls, at the light microscopic level NF-L-immunoreactive axonal swellings were numerous at 7 days, but by 14 days post injury their frequency declined markedly. In contrast, GAP43-immunoreactive, disconnected reactive axonal swellings were rarely observed at 7 days but were numerous at 14 days. Ultrastructural analysis at 14 days post injury of carefully matched sections revealed reactive axons demonstrating sprouting consistent with a regenerative effort. Analysis of tissue from animals of 14 days of survival indicated that supplementation with nerve growth factor did not appear to enhance the capacity of damaged brain axons to mount a regenerative attempt. Rather, it appears that regenerative efforts seen reflect a spontaneous response. A third group of adult cats, subjected to the same injury but not subjected to osmotic pump implantation was allowed to survive for 22-28 days. Animals in this group also demonstrated GAP43 immunoreactivity in reactive axonal swellings in the brain stem. This study demonstrates that diffusely injured axons can mount a sustained regenerative attempt that is associated with a reorganization of their cytoskeleton and accompanied by an up-regulation of growth-associated proteins.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT SURG, DIV NEUROL SURG, RICHMOND, VA 23298 USA						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BARRON KD, 1989, J NEUROSCI RES, V22, P331, DOI 10.1002/jnr.490220313; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; BURRY RW, 1992, J NEUROCYTOL, V21, P413, DOI 10.1007/BF01191506; CAMPBELL G, 1992, J NEUROCYTOL, V21, P755, DOI 10.1007/BF01237903; CAMPBELL G, 1991, EXP BRAIN RES, V87, P67; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COGGESHALL RE, 1991, NEUROSCI LETT, V131, P37, DOI 10.1016/0304-3940(91)90331-M; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; GILSON BC, 1974, CELL TISSUE RES, V149, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; LAMPERT P, 1964, LAB INVEST, V13, P825; LAMPERT PW, 1967, J NEUROPATH EXP NEUR, V26, P345, DOI 10.1097/00005072-196707000-00001; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LI Y, 1994, J NEUROSCI, V14, P4050; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; OESTREICHER AB, 1988, BRAIN RES BULL, V21, P713, DOI 10.1016/0361-9230(88)90037-8; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; PEREZPOLO JR, 1990, MOL NEUROBIOL, V4, P57, DOI 10.1007/BF02935585; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Reier P J, 1988, Adv Neurol, V47, P87; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SORENSEN JC, 1992, EXP BRAIN RES, V92, P299; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TONDER N, 1990, PROG BRAIN RES, V83, P391; VANDENPOL AN, 1994, J COMP NEUROL, V349, P244, DOI 10.1002/cne.903490207; WILLIAMS DK, 1994, DEV BRAIN RES, V81, P89, DOI 10.1016/0165-3806(94)90071-X; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	39	64	64	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	OCT	1997	94	4					329	337		10.1007/s004010050715			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	XZ298	WOS:A1997XZ29800005	9341933				2022-02-06	
J	Gemma, M; Cozzi, S; Tommasino, C; Mungo, M; Calvi, MR; Cipriani, A; Garancini, MP				Gemma, M; Cozzi, S; Tommasino, C; Mungo, M; Calvi, MR; Cipriani, A; Garancini, MP			7.5% hypertonic saline versus 20% mannitol during elective neurosurgical supratentorial procedures	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-of-Neurosurgical-Anesthesia-and-Critical-Care	OCT, 1995	ATLANTA, GA	Soc Neurosurg Anesthesia & Crit Care		intracranial pressure; neuroanesthesia; hypertonic saline; mannitol; elective neurosurgery; intraoperative brain bulk	CENTRAL PONTINE MYELINOLYSIS; CEREBRAL OXYGEN DELIVERY; TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; INTRACRANIAL-PRESSURE; ISOVOLEMIC HEMODILUTION; FLUID RESUSCITATION; CEREBROSPINAL-FLUID; 3-PERCENT SALINE; RENAL-FAILURE	This prospective randomized clinical study was designed to compare the effects of equal volumes of 7.5% hypertonic saline solution (HS) or 20% mannitol (M) on brain bulk and lumbar cerebrospinal fluid pressure (CSFP) during elective neurosurgical procedures (aneurysm, arteriovenous malformation, or tumor). After informed consent, 50 American Society of Anesthesiologists physical Status I (ASA I) patients were randomly assigned to M (n = 25) or HS (n = 25) groups. Anesthesia protocol was identical for both, and variables monitored included mean arterial blood pressure (MAP), heart rate (HR), central venous pressure(CVP), CSF pressure (CSFP), arterial blood gases (PaCO2 30-35 mm Hg), serum sodium, potassium, and osmolality, and diuresis. The study period started before hypertonic solution administration (To) and ended at the opening of the dura mater or 60 min after T-0. Data were assessed with repeated measures analysis of variance and Student t test with Bonferroni correction (p less than or equal to 0.05). MAP and CVP were the same in the two groups. After treatment, osmolality increased, and the increase at T-15 was higher in HS treated patients [316.6 +/- 9.3 vs. 304.0 +/- 12.0 (SD) mOsmol/kg; p < 0.001]. Sodium decreased after M and increased after HS. During the study, brain bulk was always considered satisfactory. CSFP was not different between M and I-IS groups and significantly decreased over time (p = 0.0056) with no difference between treatments. The results of the present study demonstrate that hypertonic saline is as effective as mannitol in reducing the brain bulk and the CSFP during elective neu rosurgical procedures under general anesthesia.	UNIV MILAN,IRCCS H SAN RAFFAELE ANESTHESIA,DEPT ANESTHESIOL,SECT NEUROANESTHESIA & INTENS CARE,I-20132 MILAN,ITALY					Gemma, Marco/0000-0002-9543-3831; Tommasino, Concezione/0000-0001-8856-6866			AVIRAM A, 1967, AM J MED, V42, P648, DOI 10.1016/0002-9343(67)90066-6; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BORGES HF, 1982, ARCH INTERN MED, V142, P63, DOI 10.1001/archinte.142.1.63; DIMATTIO J, 1975, PFLUG ARCH EUR J PHY, V359, P253, DOI 10.1007/BF00587383; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; Earley L E, 1972, CLIN DISORDERS FLUID, P95; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; FOXWORTHY JC, 1990, J NEUROSURG ANESTH, V2, P256, DOI 10.1097/00008506-199012000-00002; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GOTO T, 1993, CLIN ANESTHESIA PROC, P368; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; LAURENO R, 1983, ANN NEUROL, V13, P232, DOI 10.1002/ana.410130303; LAYON J, 1987, ANESTH ANALG, V66, P154; NORENBERG MD, 1982, ANN NEUROL, V11, P128, DOI 10.1002/ana.410110204; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; RAPOPORT SI, 1972, AM J PHYSIOL, V223, P323, DOI 10.1152/ajplegacy.1972.223.2.323; RAVUSSIN P, 1988, J NEUROSURG, V69, P869, DOI 10.3171/jns.1988.69.6.0869; SAHAR A, 1978, EXP NEUROL, V60, P584, DOI 10.1016/0014-4886(78)90012-2; SCHACKFORD SR, 1987, SURG GYNECOL OBSTET, V164, P127; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SCHELLER MS, 1991, J NEUROSURG ANESTH, V3, P291, DOI 10.1097/00008506-199112000-00009; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1988, SURGERY, V104, P553; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Tommasino C, 1992, Minerva Anestesiol, V58, P35; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; TOMMASINO C, 1995, FUNDAMENTALS NEUROAN, P133; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; WHELAN TV, 1984, ARCH INTERN MED, V144, P2053, DOI 10.1001/archinte.144.10.2053; WHITLEY JM, 1991, J NEUROSURG ANESTH, V3, P47, DOI 10.1097/00008506-199103000-00008; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	39	64	67	1	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	1997	9	4					329	334		10.1097/00008506-199710000-00007			6	Anesthesiology; Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	YC944	WOS:A1997YC94400007	9339405				2022-02-06	
J	Forbes, ML; Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Wisniewski, SR; Kelsey, SF; DeKosky, ST; Graham, SH; Marion, DW; Ho, C				Forbes, ML; Hendrich, KS; Kochanek, PM; Williams, DS; Schiding, JK; Wisniewski, SR; Kelsey, SF; DeKosky, ST; Graham, SH; Marion, DW; Ho, C			Assessment of cerebral blood flow and CO2 reactivity after controlled cortical impact by perfusion magnetic resonance imaging using arterial spin-labeling in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	4th Scientific Meeting and Exhibition of the International-Society-for-Magnetic-Resonance-in-Medicine	APR 27-MAY 03, 1996	NEW YORK, NY	Int Soc Magnet Resonance Med		traumatic brain injury; magnetic resonance imaging; perfusion; rat; controlled cortical impact	EXPERIMENTAL BRAIN INJURY; CARBON-DIOXIDE; HEAD-INJURY; FOCAL ISCHEMIA; WATER; INVERSION; MODEL; OXIDE	We measured CBF and CO, reactivity after traumatic brain injury (TBI) produced by controlled cortical impact (CCI) using magnetic resonance imaging (MRI) and spin-labeled carotid artery water protons as an endogenous tracer. Fourteen Sprague-Dawley rats divided into TBI (CCI; 4.02 +/- 0.14 m/s velocity; 2.5 mm deformation), sham, and control groups were studied 24 hours after TBI or surgery. Perfusion maps were generated during normocarbia (PaCO2 30 to 40 mm Hg) and hypocarbia (PaCO2 15 to 25 mm Hg). During normocarbia, CBF was reduced within a cortical region of interest (ROI, injured versus contralateral) after TBI (200 +/- 82 versus 296 +/- 65 mL.100 g(-1).min(-1), P < 0.05). Within a contusion-enriched ROI, CBF was reduced after TBI (142 +/- 73 versus 280 +/- 64 mL.100 g(-1).min(-1), P < 0.05). Cerebral blood flow in the sham group was modestly reduced (212 +/- 112 versus 262 +/- 118 mL.100 g(-1).min(-1), P < 0.05). Also, TBI widened the distribution of CBF in injured and contralateral cortex. Hypocarbia reduced cortical CBF in control (48%), sham (45%), and TBI rats (48%) versus normocarbia, P < 0.05. In the contusion-enriched ROI, only controls showed a significant reduction in CBF, suggesting blunted CO2 reactivity in the sham and TBI group. CO2 reactivity was reduced in the sham (13%) and TBI (30%) groups within the cortical ROI (versus contralateral cortex). These values were increased twofold within the contusion-enriched ROI but were not statistically significant. After TBI, hypocarbia narrowed the CBF distribution in the injured cortex. We conclude that perfusion MRI using arterial spin-labeling is feasible for the serial, noninvasive measurement of CBF and CO2 reactivity in rats.	SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROSURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; CARNEGIE MELLON UNIV, PITTSBURGH NMR CTR BIOMED RES, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT SCI BIOL, PITTSBURGH, PA 15213 USA				Marion, Donald/AAR-5749-2021; Ho, Chien/O-6112-2016; Forbes, MD, FAAP, Michael/C-4110-2009; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Forbes, MD, FAAP, Michael/0000-0002-2612-5392; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-03631, RR-10962] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [R01RR010962, P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON WT, 1986, MAGN RESON MED, V3, P454, DOI 10.1002/mrm.1910030311; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GINSBERG MD, 1987, CEREBRAL BLOOD FLOW, P299; GJEDDE A, 1977, ACTA PHYSIOL SCAND, V100, P273, DOI 10.1111/j.1748-1716.1977.tb05950.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HEILAND S, 1995, J CEREB BLOOD FLOW M, V15, pS58; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JIANG Q, 1994, J CEREBR BLOOD F MET, V14, P732, DOI 10.1038/jcbfm.1994.94; JONES SC, 1982, J COMPUT ASSIST TOMO, V6, P116, DOI 10.1097/00004728-198202000-00020; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEE JG, 1995, ANESTH ANALG, V80, P696, DOI 10.1097/00000539-199504000-00008; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; REITH W, 1994, ACTA NEUROCHIR, V131, P151, DOI 10.1007/BF01401466; SIESJO BK, 1983, J CEREBR BLOOD F MET, V3, P478, DOI 10.1038/jcbfm.1983.74; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Strupp JP, 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; WALSH EG, 1994, MAGNET RESON MED, V31, P147, DOI 10.1002/mrm.1910310208; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WARNER DS, 1987, CEREBRAL BLOOD FLOW, P288; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P4220; WILLIAMS DS, 1993, MAGNET RESON MED, V30, P361, DOI 10.1002/mrm.1910300314; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; ZHANG WG, 1992, MAGNET RESON MED, V25, P362, DOI 10.1002/mrm.1910250216; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	36	64	65	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	1997	17	8					865	874		10.1097/00004647-199708000-00005			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	XU902	WOS:A1997XU90200005	9290584				2022-02-06	
J	Bramlett, HM; Green, EJ; Dietrich, WD				Bramlett, HM; Green, EJ; Dietrich, WD			Hippocampally dependent and independent chronic spatial navigational deficits following parasagittal fluid percussion brain injury in the rat	BRAIN RESEARCH			English	Article						head injury; hippocampus; learning and memory; Morris water maze; rat	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; VENTRICULAR DILATION; LONG-TERM; MEMORY; PLACE; RECOVERY; LESIONS; DAMAGE; IMPAIRMENTS	Previous reports have documented spatial navigational deficits following experimental traumatic brain injury (TBI), although the majority of the work to date has involved assessment at acute intervals following TBI, and has focused on tasks sensitive to hippocampal dysfunction. The present experiments were designed to investigate the chronic consequences of TBI, and the possible contribution of extrahippocampal dysfunction to TBI-induced spatial navigational deficits, in a moderate parasagittal fluid percussion TBI model. In Experiment 1, animals were pre-trained in a water maze, subjected to TBI or sham procedures, and re-evaluated in the water maze 48 h following the insult. Six to 8 weeks following TBI, the same animals were required to navigate to a different platform location. TBI animals exhibited significant deficits in retention of previously learned spatial information at the 48 h interval, and marginally impaired acquisition of a novel platform location during the chronic test sessions. In Experiment 2, animals were required to navigate to novel spatial locations using cued (to evaluate extrahippocampal function) as well as non-cued variants of the water maze task during the 8 week period following the insult. Injured animals exhibited deficits in both tasks which gradually diminished over the course of testing. The results of these experiments indicate that moderate TBI is accompanied by both retention and acquisition deficits, and that some of the navigational deficits observed in the water maze can be attributed to extrahippocampal damage. The possible recovery of spatial navigational ability following parasagittal TBI at moderate intensities is also discussed. (C) 1997 Elsevier Science B.V.	UNIV MIAMI,DEPT PSYCHOL,CORAL GABLES,FL 33124; UNIV MIAMI,NEUROTRAUMA RES CTR,MIAMI,FL 33136; UNIV MIAMI,DEPT NEUROL,MIAMI,FL 33136						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAMLETT HM, 1996, SOC NEUR ABSTR, P231; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS HR, 1993, J NEUROTRAUM, V10, P405; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P176; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MARMAROU A, 1985, BRAIN EDEMA, P88; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUTHERLAND RJ, 1988, PSYCHOBIOLOGY, V16, P157; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; WHISHAW IQ, 1985, PHYSIOL BEHAV, V35, P139, DOI 10.1016/0031-9384(85)90186-6; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZILLES L, 1985, CORTEX RAT STEREOTAX; [No title captured]	43	64	65	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 11	1997	762	1-2					195	202		10.1016/S0006-8993(97)00387-9			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XL775	WOS:A1997XL77500022	9262173				2022-02-06	
J	Gabella, B; Hoffman, RE; Marine, WW; Stallones, L				Gabella, B; Hoffman, RE; Marine, WW; Stallones, L			Urban and rural traumatic brain injuries in Colorado	ANNALS OF EPIDEMIOLOGY			English	Article						rural population; urban population; surveillance; head injuries; mortality rates	MOTOR-VEHICLE CRASHES; HEAD-INJURY; EPIDEMIOLOGY; MORTALITY; SEVERITY; TRENDS; POPULATION; COMMUNITY; COUNTY; DEATHS	PURPOSE: The purpose of this study was to compare and contrast the epidemiology of traumatic brain injury among urban and rural residents of Colorado. METHODS: Cases of traumatic brain injury (ICD 800, 801, 803, 804, 850-854) for 1991 and 1992 from the Colorado surveillance system of hospitalized and fatal traumatic brain injuries were used. Urban cases resided in counties designated by the U.S. Census Bureau as metropolitan statistical areas (MSA). Rural cases were divided into two groups: ''rural, nonremote,'' if the country of residence was adjacent to an MSA county or if it had a population of 2500, and ''rural, remote,'' if not. and ''rural, remote,'' if not. RESULTS: Average annual age-adjusted rates of hospitalized and fatal traumatic brain injury varied significantly from 97.8 per 100,000 population for the most urban group to 172.1 per 100,000 population for the residents of rural, remote counties. Similarly, total mortality ranged from 18.1 per 100,000 population among residents of the most urban counties to 33.8 among residents of rural, remote counties. Prehospital mortality ranged from 10.0 to 27.7 traumatic brain injuries per 100,000 population. CONCLUSIONS: These results provide justification for expanding efforts to prevent traumatic brain injury to include the small, but high-risk group of residents in rural areas. (C) 1997 by Elsevier Science Inc.	UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262; COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT ENVIRONM HLTH,FT COLLINS,CO 80523		Gabella, B (corresponding author), COLORADO DEPT PUBL HLTH & ENVIRONM,DCEEDIEA3,4300 CHERRY CREEK DR S,DENVER,CO 80222, USA.		Stallones, Lorann/AAC-6248-2021	Stallones, Lorann/0000-0001-7616-582X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U59/CCU803364] Funding Source: Medline		*AM HOSP ASS, 1994, AHA PROF US HOSP DAT, pR33; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BAKER SP, 1992, INJURY FACT BOOK, P28; CHEN B, 1995, J TRAUMA, V38, P228, DOI 10.1097/00005373-199502000-00014; CHIANG CL, 1961, VITAL STAT SPECIAL R, V47; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; *HLTH STAT VIT REC, 1992, RED OCC INJ DEATH RU, P1; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEEFER S, 1989, INJURY COLORADO BASE, V75, P106; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MACKENZIE EJ, 1990, AM J PUBLIC HEALTH, V80, P217, DOI 10.2105/AJPH.80.2.217; RICKETTS TC, 1994, GEOGRAPHIC METHODS H; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STALLONES L, 1990, SUICIDE LIFE-THREAT, V20, P156; STALLONES L, 1992, J RURAL HEALTH, V8, P139; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US BUR CENS, 1990, 1990 CENS POP HOUS P; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	27	64	64	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	1047-2797			ANN EPIDEMIOL	Ann. Epidemiol.	APR	1997	7	3					207	212		10.1016/S1047-2797(96)00150-0			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	WX578	WOS:A1997WX57800008	9141644				2022-02-06	
J	McDermott, KL; Raghupathi, R; Fernandez, SC; Saatman, KE; Protter, AA; Finklestein, SP; Sinson, G; Smith, DH; McIntosh, TK				McDermott, KL; Raghupathi, R; Fernandez, SC; Saatman, KE; Protter, AA; Finklestein, SP; Sinson, G; Smith, DH; McIntosh, TK			Delayed administration of basic fibroblast growth factor (bFGF) attenuates cognitive dysfunction following parasagittal fluid percussion brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						basic fibroblast growth factor; cognition; fluid-percussion injury; neurotrophic factors; traumatic brain injury	CEREBRAL BLOOD-FLOW; FIMBRIA FORNIX TRANSECTION; FACTOR PROMOTES SURVIVAL; CHOLINERGIC NEURONS; HEAD-INJURY; EXCITOTOXIC LESIONS; NERVE; ISCHEMIA; DEATH; HIPPOCAMPUS	The present study evaluates the therapeutic effects of delayed administration of bFGF on cognitive dysfunction and histopathological damage following lateral fluid-percussion (FP) brain injury, Male Sprague-Dawley rats were trained to learn a visuospatial task in a Morris Water Maze (MWM) paradigm and then were anesthetized and subjected to either FP brain injury of moderate severity (2.5-2.8 atm, n = 32) or surgery without brain injury (n = 10), Twenty-four hours postinjury, an infusion cannula connected to a mini-osmotic pump was implanted into the area of maximal cortical injury to continuously infuse either bFGF (2.0 g) or vehicle for 7 days, Treatment with bFGF significantly attenuated posttraumatic memory dysfunction in the MWM at 8 days postinjury when compared to vehicle treatment (p < 0.05). The cortical lesion and significant cell loss in the ipsilateral CA3 region of the hippocampus, produced by FP injury, was not affected by bFGF treatment, However, immunohistochemical evaluation of glial fibrillary acidic protein revealed a trend toward increased astrocytosis in the injured cortex of bFGF-treated animals compared to vehicle-treated animals (p < 0.1). These results indicate that bFGF may be efficacious in attenuating cognitive dysfunction associated with traumatic brain injury.	UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; MASSACHUSETTS GEN HOSP,DEPT NEUROL,CNS GROWTH FACTOR RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; SCIOS NOVA INC,MT VIEW,CA 94043				Raghupathi, Ramesh/AAX-5538-2021; smith, douglas/A-1321-2007		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		AKANEYA Y, 1993, J CEREBR BLOOD F MET, V13, P1029, DOI 10.1038/jcbfm.1993.130; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ARAUJO DM, 1993, J NEUROCHEM, V61, P899, DOI 10.1111/j.1471-4159.1993.tb03601.x; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CASPER D, 1995, J NEUROCHEM, V65, P1016; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIETRICH DW, 1996, J NEUROTRAUM, V13, P309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALL ED, 1988, STROKE, V19, P340, DOI 10.1161/01.STR.19.3.340; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; ISHIHARA A, 1992, JPN J PHARMACOL, V59, P7, DOI 10.1254/jjp.59.7; JIANG N, 1996, IN PRESS J NEUROLOG; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; KIMELBERG HK, 1982, HEAD INJURY BASIC CL, P31; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mair R G, 1994, Rev Neurosci, V5, P105; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OTTO D, 1989, J NEUROSCI RES, V22, P83, DOI 10.1002/jnr.490220111; OTTO D, 1987, NEUROSCI LETT, V83, P156, DOI 10.1016/0304-3940(87)90233-3; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; Pierce JES, 1996, J NEUROSCI, V16, P1083; RAY J, 1994, J NEUROSCI, V14, P3548; REGLI L, 1994, BRAIN RES, V665, P155, DOI 10.1016/0006-8993(94)91167-3; ROSENBLATT S, 1994, J CEREBR BLOOD F MET, V14, P70, DOI 10.1038/jcbfm.1994.11; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROTRAUMA S, V10, pS62; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SWEETNAM PM, 1991, J NEUROCHEM, V57, P237, DOI 10.1111/j.1471-4159.1991.tb02121.x; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YUAN X, 1981, J NEUROTRAUM, V5, P289; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	66	64	65	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1997	14	4					191	200		10.1089/neu.1997.14.191			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WY593	WOS:A1997WY59300002	9151768				2022-02-06	
J	BeitYannai, E; Kohen, R; Horowitz, M; Trembovler, V; Shohami, E				BeitYannai, E; Kohen, R; Horowitz, M; Trembovler, V; Shohami, E			Changes of biological reducing activity in rat brain following closed head injury: A cyclic voltammetry study in normal and heat-acclimated rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						biological oxidation potential; cyclic voltammetry; closed head injury; reactive oxygen species	OXYGEN RADICALS; DAMAGE; ANTIOXIDANT; MECHANISMS; ISCHEMIA; TRAUMA	Reactive oxygen species (ROS) are normally generated in the brain during metabolism, and their production is enhanced by various insults. Low molecular weight antioxidants (LMWA) are one of the defense mechanisms of the living cell against ROS. The reducing capacity of brain tissue (total LMWA) was measured by cyclic vol tammetry (CV), which records biological oxidation potential specific to the type of scavenger(s) present and anodic current intensity (I-a), which depends on scavenger concentration. In the present study, the reducing capacity of rat brain following closed head injury (CHI) was measured. In addition, CV of heat-acclimated traumatized rats was used to correlate endogenous cerebroprotection after CHI with LMWA activity. Sham-injured rat brains displayed two anodic potentials: at 350 +/- 50 mV (I-a = 0.75 +/- 0.06 mu A/mg protein) and at 750 +/- 50 mV (I-a = 1.00 +/- 0.05 mu A/mg protein). Following CHI, the anodic waves appeared at the same potentials as in the sham animals. However, within 5 min of CHI, the total reducing capacity was transiently decreased by 40% (p < 0.01). A second dip was detected at 24 h (60%, p < 0.005). By 48 h and at 7 days, the I-a levels normalized. The acclimated rats displayed anodic potentials identical to those of normothermic rats. However, the I-a of both potentials was lower (60% of control, p < 0.001). The I-a profile after CHI was the direct opposite of the normothermic I,profile: no immediate decrease of I-a and an increase from 4 h and up to 7 days (40-50%, p < 0.001). We suggest that the lowered levels of LMWA in the post-CHI period reflect their consumption due to overproduction of free radicals. The augmented concentration of LMWA found in the brain of the heat-acclimated rats suggests that these rats are better able to cope with these harmful radicals, resulting in a more favorable outcome following CHI.	HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHARMACOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHARM, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH PHARM, DEPT PHYSIOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH MED, IL-91120 JERUSALEM, ISRAEL				Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			BAETHMANN A, 1989, NEUROSURG ANESTHESIO, V2, P567; Bard A.J., 1980, ELECTROCHEMICAL METH, P316; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; CHAN PH, 1989, CELLULAR ANTIOXIDANT, P89; CHEVION S, 1996, IN PRESS FREE RAD BI; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DIRNAGL U, 1995, J CEREBR BLOOD F MET, V15, P929, DOI 10.1038/jcbfm.1995.118; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GREEF R, 1990, HARWOOD SERIES PHYSI, P183; HADAS H, 1989, INT CONGR SER, V871, P395; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; HIGSON FK, 1988, FREE RADICAL RES COM, V5, P107, DOI 10.3109/10715768809066918; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V81, P103, DOI 10.1016/0300-9629(85)90274-9; HOROWITZ M, 1986, J MOL CELL CARDIOL, V18, P511, DOI 10.1016/S0022-2828(86)80916-6; HOROWITZ M, 1989, MILESTONES ENV PHYSL, P31; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; KOHEN R, 1992, EXP GERONTOL, V27, P161, DOI 10.1016/0531-5565(92)90040-7; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LEVI E, 1993, J APPL PHYSIOL, V75, P833, DOI 10.1152/jappl.1993.75.2.833; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHINAR E, 1983, J BIOL CHEM, V258, P4778; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; SHOHAMI E, 1989, J NEUROCHEM, V53, P541; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Yukido I, 1990, NEUROSURGERY, V27, P1	33	64	64	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1997	17	3					273	279		10.1097/00004647-199703000-00004			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	WQ178	WOS:A1997WQ17800004	9119900	Bronze			2022-02-06	
J	Fujiki, M; Zhang, ZY; Guth, L; Steward, O				Fujiki, M; Zhang, ZY; Guth, L; Steward, O			Genetic influences on cellular reactions to spinal cord injury: Activation of macrophages/microglia and astrocytes is delayed in mice carrying a mutation (Wld(s)) that causes delayed wallerian degeneration	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						inflammation; trauma; cytotoxicity; immunocytochemistry; regeneration; wound healing; scar	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; MONONUCLEAR PHAGOCYTES; ASTROGLIAL PROLIFERATION; AMEBOID MICROGLIA; TRAUMATIC INJURY; MAMMALIAN BRAIN; MESSENGER-RNA; ADULT-RATS; CNS	Reactive changes in macrophages/microglia and astrocytes were evaluated following spinal cord injury in normal mice of the C57BL/6J strain and in mice carrying a mutation (Wld(s)) which delays the onset of Wallerian degeneration in damaged axons. Crush injuries were produced at the T8 level by using an extradural approach; animals were allowed to survive for 2 days to 12 weeks, and spinal cords were prepared for immunocytochemistry using antibodies against Mad and glial fibrillary acidid protein (GFAP). In normal mice, Mad-positive macrophages accumulated at the injury site by 4 days and immunostaining of these cells peaked at 6-8 days. Cells in the gray matter near the crush site and in the ascending dorsal column also exhibited increased Mad staining that was prominent at 1 week and remained high at 2-4 weeks. In mice carrying the Wld(s) mutation, the accumulation of macrophages at the injury site and the increase in immunostaining of these cells were delayed, as were the increases in immunostaining in the gray matter and dorsal columns. Both normal and mutant mice exhibited pronounced increases in glial fibrillary acidic protein immunostaining at the edge of the crush site and for some distance both rostral and caudal to the injury; increased immunostaining was also prominent along the ascending dorsal columns. The center of the crush site, which contained connective tissue, remained completely unstained for GFAP. In normal mice, immunostaining for GFAP reached a peak at 1 week postinjury and then declined. In mice carrying the Wld(s) mutation, increases in GFAP immunostaining did not reach a peak until 2-3 weeks postinjury. These results indicate that activation of macrophages, microglia, and astrocytes is delayed and prolonged in mice carrying the Wld(s) mutation. (C) 1996 Wiley-Liss, Inc.	UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22908; COLL WILLIAM & MARY,DEPT BIOL,WILLIAMSBURG,VA 23185					Steward, Oswald/0000-0001-7069-8756	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21460, NS 32280] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032280, R01NS021460] Funding Source: NIH RePORTER		AGUAYO AJ, 1979, SOC NEUROSCI S, V4, P361; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1985, CELLULAR MOL BIOL LY, P815; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; GUTH L, 1994, EXP NEUROL, V126, P76, DOI 10.1006/exnr.1994.1043; GUTH L, 1985, EXP NEUROL, V88, P1, DOI 10.1016/0014-4886(85)90109-8; HOULGATTE R, 1989, J NEUROSCI RES, V24, P143, DOI 10.1002/jnr.490240204; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MOULIN V, 1995, EUR J CELL BIOL, V68, P1; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P408, DOI 10.1111/j.1460-9568.1990.tb00433.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; Ramon y Cajal S., 1913, DEGENERATION REGENER; Reier P., 1983, SPINAL CORD RECONSTR; Reier P.J., 1986, ASTROCYTES, V3, P263; REIER PJ, 1985, NEUROPATH APPL NEURO, V11, P81, DOI 10.1111/j.1365-2990.1985.tb00007.x; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1992, EXP NEUROL, V118, P340, DOI 10.1016/0014-4886(92)90192-S; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; Zhang ZY, 1996, J COMP NEUROL, V371, P485	46	64	64	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUL 29	1996	371	3					469	484					16	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	UZ738	WOS:A1996UZ73800009	8842900				2022-02-06	
J	Ommaya, AK; Ommaya, AK; Dannenberg, AL; Salazar, AM				Ommaya, AK; Ommaya, AK; Dannenberg, AL; Salazar, AM			Causation, incidence, and costs of traumatic brain injury in the US military medical system	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; epidemiology; costs; causes	CARE	Hospital discharge records from military facilities and private facilities reimbursed by Civilian Health and Medical Program of the Uniformed Services for fiscal year 1992 were reviewed to identify head injury admissions. Incidence rates, case fatality rates, causes of head injuries, and direct cost for hospital admissions were computed in this well-defined population. For fiscal year 1992, there were 5,568 hospitalized cases of noncombat head injury in the military medical system. The age-adjusted head injury rates for ages 15-44 years are higher in active-duty individuals compared with other beneficiaries (1.6 times greater for men and 2.5 times greater for women). The total cost for hospitalization in this population was $43 million. Private facility rehabilitation accounted for 26% of all private facility costs but only 6% of head injury cases. Firearms and motor vehicle crashes caused the most severe injuries for cases admitted to military facilities. Motor vehicle crashes, falls, and fighting accounted for 80% of the total military facility cost for head injuries, Military active-duty individuals are at increased risk for noncombat head injury. Prevention of head injury in military settings should focus on motor vehicle crashes, fist fights (assault), and falls.	GEORGE WASHINGTON UNIV,DEPT NEUROSURG,WASHINGTON,DC; JOHNS HOPKINS UNIV,SCH PUBL HLTH,INJURY PREVENT CTR,BALTIMORE,MD; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814		Ommaya, AK (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 7,ROOM 240,WASHINGTON,DC 20307, USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03 HS08414-01] Funding Source: Medline		ARMITAGE P, 1987, STATISTICAL METHODS, P459; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *COMM GOV OP, 1992, FRAUD AB HEAD INJ RE; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; *DEF MED INF MAN, 1993, CENTR RCMAS OSE US M; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; JOY SA, 1994, J TRAUMA, V37, P303, DOI 10.1097/00005373-199408000-00024; Kraus JF, 1993, HEAD INJURY, P1; MacKenzie E J, 1989, Md Med J, V38, P725; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; OMMAYA AK, 1983, HEAD NECK INJURY CRI, P248; RICE DH, 1989, CURRENT CONCEPTS HEA, P1; RIVARA FP, 1988, JAMA-J AM MED ASSOC, V260, P221; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251	16	64	64	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	1996	40	2					211	217		10.1097/00005373-199602000-00007			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	TW081	WOS:A1996TW08100007	8637068				2022-02-06	
J	KAY, T; CAVALLO, MM; EZRACHI, O; VAVAGIAKIS, P				KAY, T; CAVALLO, MM; EZRACHI, O; VAVAGIAKIS, P			THE HEAD-INJURY FAMILY INTERVIEW - A CLINICAL AND RESEARCH TOOL	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						FAMILY ASSESSMENT; TRAUMATIC BRAIN INJURY	RATING-SCALE	This article describes the Head Injury Family Interview (HI-FI), a five-part structured interview designed to gather clinical and research data on persons with head injury and their family members. The HI-FI was developed over a 10-year period at the Research and Training Center on Head Injury and Stroke of New York University Medical Center to track outcomes of persons recovering from traumatic brain injury, with input from both the injured person and significant others, and to document the impact of the injury on the family system. The structure, contents, rationale, and development of the interviews are described, as well as its clinical utility and research potential. In addition, the statistical properties of one particular instrument within the interview, the Problem Checklist, are detailed and data presented from a multi-center study.	ASSOC HELP RETARDED CHILDREN,TRAUMAT BRAIN INJURY SERV,NEW YORK,NY; ASSOC HELP RETARDED CHILDREN,TRAUMAT BRAIN INJURY COMMUNITY SUPPORT SERV,NEW YORK,NY; NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013		KAY, T (corresponding author), NYU MED CTR,RUSK INST REHABIL MED,NEW YORK,NY 10016, USA.						BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BISHOP D, 1989, J HEAD TRAUMA REHABI, V3, P16; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DEPOMPEI R, 1991, HEAD INJURY FAMILY M; HARVEY R, 1981, ARCH PHYS MED REHAB, V62, P109; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1991, HEAD INJURY FAMILY M; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; 1990, FUNCTIONAL INDEPENDE	13	64	64	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1995	10	2					12	31		10.1097/00001199-199504000-00004			20	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QR039	WOS:A1995QR03900004					2022-02-06	
J	WEBB, PM; GLUECKAUF, RL				WEBB, PM; GLUECKAUF, RL			THE EFFECTS OF DIRECT INVOLVEMENT IN GOAL-SETTING ON REHABILITATION OUTCOME FOR PERSONS WITH TRAUMATIC BRAIN INJURIES	REHABILITATION PSYCHOLOGY			English	Article								Sixteen adults with traumatic brain injuries participated in an eight-week goal setting training program designed to assess the effects of direct involvement in goal-setting on treatment outcome. Participants were randomly assigned to either a condition designed to facilitate high involvement (HI) in goal setting or to a low involvement (LI) condition. From pretesting to posttesting, both HI and LI participants significantly improved in attaining their goals. However, at the two-month follow-up, HI participants maintained gains from pretesting, whereas LI participants regressed to their pretesting level.			WEBB, PM (corresponding author), INDIANA UNIV PURDUE UNIV,PURDUE SCH SCI,DEPT PSYCHOL,402 N BLACKFORD ST,LD 3124,INDIANAPOLIS,IN 46202, USA.						CARLSON P, 1980, 88TH ANN M AM PSYCH; DUBBERT PM, 1984, BEHAV RES THER, V22, P227, DOI 10.1016/0005-7967(84)90003-2; EMMERSON GJ, 1988, COUNS PSYCHOL, V16, P261, DOI 10.1177/0011000088162007; EREZ M, 1985, ACAD MANAGE J, V28, P50, DOI 10.2307/256061; EREZ M, 1986, J APPL PSYCHOL, V71, P591, DOI 10.1037/0021-9010.71.4.591; FRANCE K, 1985, CRISIS INTERVENTION, V14, P11; GLUECKAUF RL, 1992, REHABIL PSYCHOL, V37, P291, DOI 10.1037/h0079109; GLUECKAUF RL, 1992, J CONSULT CLIN PSYCH, V60, P419, DOI 10.1037/0022-006X.60.3.419; GOLDSTEIN G, 1983, REHABILITATION BRAIN; GUARE JC, 1989, DIABETES CARE, V12, P500, DOI 10.2337/diacare.12.7.500; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KOVICH K, 1988, HEAD INJURY GUIDE FU, P27; LAFERRIERE L, 1978, AM J COMMUN PSYCHOL, V6, P271, DOI 10.1007/BF00894357; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LLOYD C, 1986, Occupational Therapy in Mental Health, V6, P19; LYNCH WJ, 1981, ARCH PHYS MED REHAB, V62, P223; Priddy D A, 1988, Brain Inj, V2, P249, DOI 10.3109/02699058809150949; ROESSLER R, 1976, PERSONAL ACHIEVEMENT; TREISCHMANN RB, 1974, ARCH PHYSICAL MED RE, V55, P556; WILLER B, 1976, J CLIN PSYCHOL, V32, P687, DOI 10.1002/1097-4679(197607)32:3<687::AID-JCLP2270320343>3.0.CO;2-V; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9; [No title captured]	23	64	66	0	8	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FAL	1994	39	3					179	188		10.1037/h0080321			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	PR338	WOS:A1994PR33800003					2022-02-06	
J	MILLIS, SR; RICKER, JH				MILLIS, SR; RICKER, JH			VERBAL-LEARNING PATTERNS IN MODERATE AND SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PARKINSONS-DISEASE; HEAD-INJURY; COMA	Previous studies that have examined performances on the California Verbal Learning Test (CVLT) among individuals with traumatic brain injury (TBI) have found differing levels of performance. Differential patterns of performance, however, have only been inferred. The present investigation sought to determine empirically if differential patterns of performance could be discerned in a TBI sample of 65 subjects with CVLT variables. The CVLT variables were selected based on the instrument's factor structure. Cluster analysis yielded four distinct subtypes of brain-injured individuals. The Active subtype demonstrated impaired unassisted retrieval, but used active encoding strategies and showed relatively intact ability to store novel information. The Disorganized subtype demonstrated an inconsistent, haphazard learning style along with deficits in encoding. The Passive subtype was marked by an overreliance on a serial clustering strategy as well as impaired encoding and/or consolidation. The Deficient subtype was the most impaired of all groups, exhibiting a slowed rate of acquisition, passive learning style, and significant impairment in encoding. Implications for rehabilitation are discussed.			MILLIS, SR (corresponding author), WAYNE STATE UNIV,SCH MED,REHABIL INST MICHIGAN,DEPT REHABIL PSYCHOL & NEUROPSYCHOL,261 MACK BLVD,DETROIT,MI 48201, USA.			Ricker, Joseph/0000-0003-3415-991X			AFIFI AA, 1990, COMPUTER AIDED MULTI; BROWN RG, 1988, BRAIN, V111, P323, DOI 10.1093/brain/111.2.323; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Crosson B., 1992, SUBCORTICAL FUNCTION; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; FRIDLUND AJ, 1987, IBM USER GUIDE CLVT; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; HUMMEL TJ, 1971, PSYCHOL BULL, V76, P49, DOI 10.1037/h0031323; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; STEVENS J, 1992, APPLIED MULTIVARIATE; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; [No title captured], DOI DOI 10.1037/1040-3590.3.1.19; [No title captured]	21	64	64	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1994	16	4					498	507		10.1080/01688639408402661			10	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	NW682	WOS:A1994NW68200002	7962354				2022-02-06	
J	NEWCOMBE, F; RABBITT, P; BRIGGS, M				NEWCOMBE, F; RABBITT, P; BRIGGS, M			MINOR HEAD-INJURY - PATHOPHYSIOLOGICAL OR IATROGENIC SEQUELAE	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; MILD CONCUSSION; REACTION-TIME; RECOVERY; LONG	This study addresses the possibility that cognitive sequelae-albeit of a transient or minor character-can be associated with mild head injury. Twenty men (aged 16-30 years of age), whose post-traumatic amnesia did not exceed eight hours, were examined within 48 hours of their accident and again one month later. This unselected sample had no previous history of head injury. A control group of 20 men of similar socioeconomic background, was selected from medical wards (where they had been admitted for orthopaedic treatment or a minor operation). They were also retested one month after the first examination. Neuropsychological tests were selected to measure abilities often compromised after significant head injury, namely memory and attention. The experimental component consisted of the fractionation of a complex skill (paced addition) to probe for deficits at different stages of information processing: perception and input into storage; search for and retrieval of information from working memory; and paced and unpaced addition. In general, no significant difference was found between the experimental and control groups, with the possible exception of an initial decrement on two working memory tasks: probe digits and a keeping track task (where the subject has to keep in mind and update a number of variables at the same time). The keeping track paradigm, ostensibly of ecological relevance, may well be worth further exploration in memory research, and in studies of more severely head-injured patients. It is further suggested that the appropriate management and counselling of mildly head-injured patients may help to avert symptoms that are of psychological rather than pathophysiological origin.	UNIV MANCHESTER,AGE & COGNIT PERFORMANCE RES CTR,MANCHESTER,ENGLAND		NEWCOMBE, F (corresponding author), RADCLIFFE INFIRM,DEPT NEUROSURG,OXFORD OX2 6HE,ENGLAND.						[Anonymous], 1942, Proc R Soc Med, V35, P601; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BADDELEY AD, 1982, AGING-US, V19, P141; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOWER GH, 1976, Q J EXP PSYCHOL, V28, P511, DOI 10.1080/14640747608400579; BROOKS D N, 1975, Cortex, V11, P329; BROOKS N, 1984, CLOSED HEAD INJURY P; CURRY H, 1981, 7TH INT C NEUR SURG; DEELMAN BG, 1990, TRAUMATIC BRAIN INJU; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENKINS A, 1986, LANCET, V2, P445; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Levin HS., 1982, NEUROBEHAVIORAL CONS; LIDVALL JHF, 1974, ACTA NEUROL SCAN S56, V50, P1; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; ODDY MJ, THESIS U LONDON LOND; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Panting A, 1972, REHABILITATION, V38, P33; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENBAUM M, 1978, SCAND J REHABIL MED, V10, P1; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; SAMPSON H, 1956, CAN J PSYCHOLOGY, V10, P219, DOI 10.1037/h0083679; SAMPSON H, 1958, CAN J PSYCHOLOGY, V12, P7, DOI 10.1037/h0083724; SHEPARD RN, 1961, J EXP PSYCHOL, V62, P302, DOI 10.1037/h0048606; SHORES EA, 1986, MED J AUSTRALIA, V144, P596; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1974, LANCET, V2, P81; THOMAS CM, 1977, THESIS OXFORD U OXFO; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, NEUROBEHAVIOURAL REC, P398; WAUGH NC, 1965, PSYCHOL REV, V72, P89, DOI 10.1037/h0021797; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; YNTEMA DB, 1960, J EXP PSYCHOL, V60, P18, DOI 10.1037/h0040055; [No title captured]; [No title captured]	50	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1994	57	6					709	716		10.1136/jnnp.57.6.709			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	NP425	WOS:A1994NP42500009	8006652	hybrid, Green Published			2022-02-06	
J	SLICK, D; HOPP, G; STRAUSS, E; HUNTER, M; PINCH, D				SLICK, D; HOPP, G; STRAUSS, E; HUNTER, M; PINCH, D			DETECTING DISSIMULATION - PROFILES OF SIMULATED MALINGERERS, TRAUMATIC BRAIN-INJURY PATIENTS, AND NORMAL CONTROLS ON A REVISED VERSION OF HISCOCK AND HISCOCKS FORCED-CHOICE MEMORY TEST	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD TRAUMA; BELIEVABLE DEFICITS; TASK; PERFORMANCE; INDIVIDUALS; COMPLAINTS; PROSPECTS; VALIDITY	A computer-administered memory test was given to normal subjects instructed to feign brain damage, normal controls, and traumatic brain-injured (TBI) patients with complaints of memory dysfunction. The test, a revised version of an instrument developed by Hiscock and Hiscock(1989), employed forced, two-choice recognition of previously presented five-digit numbers. Two levels of item difficulty and three retention intervals were used. Control and TBI subjects performed at near ceiling level on easy items and items with short retention intervals. Feigning subjects performed worse than TBI and control subjects at all levels of item difficulty and all retention intervals. Subject groups were maximally distinguishable from one another by performance on difficult items and items with the longest retention interval. All TBI patients performed at or above chance level. Only 15% of the feigning subjects performed below chance level on any section of the test. Jack-knifed discriminant function analysis correctly classified 83% of all subjects into their respective groups. Although evaluation of patient performance relative to chance probability is useful for indicating the presence of extremely exaggerated memory deficits, criteria derived from sample distributions of group scores were superior for evaluation of motivation in less obvious cases. The Victoria Revision may be useful for detecting true memory deficit as well as dissimulation.			SLICK, D (corresponding author), UNIV VICTORIA, DEPT PSYCHOL, POB 3050, VICTORIA V8W 3P5, BC, CANADA.						BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; BICKART WT, 1991, J FORENSIC PSYCHOL, V9, P3; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DAVIDSON H, 1991, ANN M INT NEUROPSYCH; FAUST D, 1990, J CONSULT CLIN PSYCH, V58, P248, DOI 10.1037/0022-006X.58.2.248; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK CK, 1993, ANN M INT NEUROPSYCH; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; Puri M. L., 1971, NONPARAMETRIC METHOD; Rey A., 1964, EXAMEN CLIN PSYCHOL; SCHRETLEN D, 1991, PSYCHOL ASSESSMENT, V3, P67; SLICK DJ, 1992, UNPUB VICTORIA REVIS; Spreen O, 1991, COMPENDIUM NEUROPSYC; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; WILKINSON L, 1990, SYSTAT SYSTEM STATIS	30	64	65	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					472	481		10.1080/01688639408402657			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400015	7929714				2022-02-06	
J	TOULMOND, S; DUVAL, D; SERRANO, A; SCATTON, B; BENAVIDES, J				TOULMOND, S; DUVAL, D; SERRANO, A; SCATTON, B; BENAVIDES, J			BIOCHEMICAL AND HISTOLOGICAL ALTERATIONS INDUCED BY FLUID PERCUSSION BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article						FLUID PERCUSSION; BRAIN TRAUMA; LESION VOLUME; NEURONAL ALTERATION; GLIAL ACTIVATION	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; MAGNETIC-RESONANCE; MODEL; QUANTIFICATION; RESPONSES; ISCHEMIA; DAMAGE; TRAUMA; PH	In the present study we have characterized the time-course of the histopathological and biochemical alterations resulting from mechanical brain injury caused by lateral fluid percussion centered over the parietal cortex in the rat. The injury device used was an HPLC pump coupled to a solenoid valve which delivered a constant and short lasting (10 ms) impact pressure (1.6 atm). This traumatic procedure resulted in an accumulation of blood in the subarachnoid space and cortical edema art 4-24 h post-trauma. From 4 h after injury, cortical neurons exhibited a pathologic appearance and phagocytic cells invaded the brain parenchyma. At 3 and 7 days post-injury, complete neuronal loss was observed in the parietal cortex around the impact site. In the ipsilateral cortex, the time-course of histologically assessed neuronal loss and phagocytic/glial activation paralleled the time-course of the loss of omega1-2 (benzodiazepine) sites (a neuronal marker) and of the increase in p sites (peripheral-type benzodiazepine binding sites; a glial/macrophage marker). Neuronal loss and increase in the density of the glial/macrophage biochemical marker were also observed in the hippocampus but not in the contralateral cortex or in other subcortical structures, suggesting a selective vulnerability of the hippocampus to this traumatic procedure. There was a very good spatial correlation between the histological alterations and the changes in the density of the neuronal and glial/macrophage biochemical markers (as assessed by autoradiography). The volume of the lesion, integrated from the surface of the lesion measured at 10 coronal levels cut at a 1 mm interval and stained with haemalum and eosin, represented 32.9 +/- 1.7 mm3. There was a very small inter-experimental variation in this volume. These results demonstrate the feasibility of monitoring the extent of traumatic brain damage induced by fluid percussion by measuring the volume of the lesion.	SYNTHELAB RECH LERS,DEPT BIOL,31 AV PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE								BENAVIDES J, 1990, BRAIN RES, V522, P275, DOI 10.1016/0006-8993(90)91472-S; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMEDIUK P, 1988, Journal of Neurotrauma, V5, P105, DOI 10.1089/neu.1988.5.105; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lindgren S., 1965, BIOPHYSIK, V2, P20; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757	26	64	65	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	1993	620	1					24	31		10.1016/0006-8993(93)90266-P			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LR731	WOS:A1993LR73100004	7691381				2022-02-06	
J	GAINOTTI, G				GAINOTTI, G			EMOTIONAL AND PSYCHOSOCIAL PROBLEMS AFTER BRAIN INJURY	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BLUNT HEAD-INJURY; FOLLOW-UP; STROKE PATIENTS; RELATIVES VIEW; MOOD DISORDERS; REHABILITATION; UNAWARENESS; DEPRESSION; DETERMINANTS; ANOSOGNOSIA	Emotional and psychosocial disorders of brain-damaged patients have a strong impact upon the outcome of the rehabilitation. However, owing to methodological difficulties, and to the intrinsic complexity of such disorders, these issues have received only a limited amount of interest. The aim of this paper is to try to disentangle some of the major factors underlying these disturbances, making a schematic distinction between three main categories: (1) neurological factors; (2) psychological (or psychodynamic) factors; (3) psychosocial factors. Emotional disorders stem directly from neurological factors when they result from the disruption of specific neural mechanisms subserving the modulation and control of emotional and social behaviour. Patients with severe traumatic head injury are, in general, the more prototypical instances of this category, as in them the lesion usually involves some of the most important cortical components of the limbic system. According to some authors, poststroke depression should also be included in this category. Psychological or psychodynamic factors, on the other hand, consist of those personal attitudes towards the disability that result from an implicit or explicit awareness of the defect and of its implications as to the future quality of life of the patient. These factors are linked to the personality of the patient, to their life-style and to their whole system of values. Finally, psychosocial factors can be considered as the interconnected set of consequences that the handicap, resulting from the functional impairment, will produce on the patient's social activities and on their network of social relationships. An important component of this category consists of the burden that the cognitive and personality change produced by the lesion represents for the close relatives of the patient, of their reaction to this burden, and of the influence that these reactions can have on the process of recovery.	CATHOLIC UNIV SACRED HEART,POLICLIN GEMELLI,INST NEUROL,I-00168 ROME,ITALY				G, Gainotti/AAD-6504-2022				ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALAJOUANINE T, 1956, BRAIN, V79, P1, DOI 10.1093/brain/79.1.1; ALAJOUANINE T, 1964, DISORDERS COMMUNICAT, P204; ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Anton G., 1899, ARCH PSYCHIAT NERVEN, V32, P86, DOI DOI 10.1007/BF02126945; BABINSKI MJ, 1914, REV NEUROL, V12, P845; BARRE JA, 1923, REV NEUROL, V29, P500; Ben-Yishay Y, 1990, REHABILITATION ADULT; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown J. W., 1977, MIND BRAIN CONSCIOUS; Critchley M., 1949, T OPHTHALMOLOGICAL S, V69, P95; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; FINSET A, 1988, CEREBRAL HEMISPHERE, P51; FOLSTEIN MF, 1977, J NEUROL NEUROSUR PS, V40, P1018, DOI 10.1136/jnnp.40.10.1018; Gainotti G, 1972, Cortex, V8, P41; GAINOTTI G, 1969, NEUROPSYCHOLOGIA, V7, P195, DOI 10.1016/0028-3932(69)90017-7; Gainotti G, 1992, NEUROPSYCHOLOGICAL R; Gainotti G, 1968, ANN NEUROLOGIA PSICH, V62, P1; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GJONE R, 1972, BRIT MED J, V4, P2; GOLDSTEIN K, 1948, LANGUAGE LANGUAGE DI; GRCEVIC N, 1988, SCAND J REHAB MED S, V17, P25; Hackett T P, 1969, Ann N Y Acad Sci, V164, P802, DOI 10.1111/j.1749-6632.1969.tb14095.x; Hamburg DA, 1953, PSYCHIATR, V16, P1; HURWITZ LJ, 1972, BRIT MED J, V1, P94; HYMAN MD, 1972, ARCH PHYS MED REHAB, V53, P217; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KERTESZ A, 1985, SPEECH LANGUAGE EVAL, P83; Kinsbourne M, 1989, EMOTIONS DUAL BRAIN, P248; KINSELLA G, 1978, MANAGEMENT APHASIA, P26; KINSELLA GJ, 1979, SCAND J REHABIL MED, V11, P129; KOEHLER PJ, 1986, J NEUROL SCI, V75, P255, DOI 10.1016/0022-510X(86)90073-0; Korsakoff S., 1889, REV PHILOS, V5, P501; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LEWIN W, 1976, BRIT MED J, V2, P1533; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LIPSEY JR, 1984, LANCET, V1, P297; LIPSEY JR, 1986, AM J PSYCHIAT, V143, P527; LIPSEY JR, 1985, AM J PSYCHIAT, V142, P527; MALONE RL, 1970, BRIT J DISORD COMMUN, V5, P174; MALONE RL, 1969, J SPEECH HEAR DISORD, V34, P146, DOI 10.1044/jshd.3402.146; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Moore R. Y., 1984, HDB CHEM NEUROANAT 1, V2, P123; NATHANSON M, 1952, AMA ARCH NEUROL PSY, V68, P380, DOI 10.1001/archneurpsyc.1952.02320210090010; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199112000-00004, DOI 10.1097/00001199-199112000-00004]; ROBINSON R G, 1989, Journal of Geriatric Psychiatry, V22, P1; ROBINSON RG, 1984, STROKE, V15, P510, DOI 10.1161/01.STR.15.3.510; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; ROBINSON RG, 1982, STROKE, V13, P635, DOI 10.1161/01.STR.13.5.635; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Schilder P, 1934, AM J PSYCHIAT, V91, P155, DOI 10.1176/ajp.91.1.155; SMITH BH, 1978, NEUROSURGERY, V3, P257; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Starkstein S. E., 1988, APHASIOLOGY, V2, P1, DOI [10.1080/02687038808248883, DOI 10.1080/02687038808248883]; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V154, P170, DOI 10.1192/bjp.154.2.170; TANNER DC, 1988, APHASIOLOGY, V2, P79; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TRIESCHMANN RB, 1980, SPINAL CORD INJURIES; Von Monakow A, 1885, ARCH PSYCHIAT, V16, P151, DOI DOI 10.1007/BF02227304; VONHAGEN KO, 1937, B LOS ANGELES NEUROL, V4, P41; WAHRBORG P, 1988, GOTEBORG PSYCHOL REP, V18, P1; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEDDELL RA, 1987, SCAND J REHABIL MED, V19, P93; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; 1980, STATISTICAL MANUAL M	84	64	65	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		1993	3	3					259	277		10.1080/09602019308401440			19	Neurosciences; Psychology	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	MC377	WOS:A1993MC37700004					2022-02-06	
J	MENDELSOHN, D; LEVIN, HS; BRUCE, D; LILLY, M; HARWARD, H; CULHANE, KA; EISENBERG, HM				MENDELSOHN, D; LEVIN, HS; BRUCE, D; LILLY, M; HARWARD, H; CULHANE, KA; EISENBERG, HM			LATE MRI AFTER HEAD-INJURY IN CHILDREN - RELATIONSHIP TO CLINICAL-FEATURES AND OUTCOME	CHILDS NERVOUS SYSTEM			English	Article						HEAD INJURY; OUTCOME; MAGNETIC RESONANCE IMAGING; FRONTAL LOBES; CHILDREN	MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; BRAIN INJURIES; TRAUMA; LESIONS; MILD; CT	To characterize the brain pathology in relation to long-term outcome after pediatric head injury, 55 children were studied by magnetic resonance imaging (MRI) at least 3 months after sustaining moderate to severe closed head injury (CHI). Thirty-nine of the patients had abnormal signal intensity consistent with residual brain lesions, including 28 children with lesions involving the frontal lobes. The clinical features of children with frontal lesions, extrafrontal lesions, and diffuse injury were compared. The analysis disclosed that children with frontal lobe lesions were more frequently disabled than children who sustained diffuse injury. Our MRI findings indicate that residual brain lesions are more common after moderate to severe CHI in children than previously thought and that the frontal lobes are most frequently involved. Further investigation is indicated to elucidate whether distinctive cognitive and behavioral sequelae are associated with frontal lobe lesions in children.	UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75230; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75230						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1978, J NEUROSURG, V48, P688; Damasio H., 1989, LESION ANAL NEUROPSY; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; EBISU T, 1989, SURG NEUROL, V31, P261, DOI 10.1016/0090-3019(89)90049-9; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1909, NEUROSURGERY, V24, P223; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1974, LANCET, V2, P81; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	25	64	64	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	DEC	1992	8	8					445	452		10.1007/BF00274405			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	KH026	WOS:A1992KH02600004	1288853				2022-02-06	
J	Xian, PP; Hei, Y; Wang, R; Wang, T; Yang, JL; Li, JY; Di, ZL; Liu, ZQ; Baskys, A; Liu, WP; Wu, SX; Long, QF				Xian, Panpan; Hei, Yue; Wang, Rui; Wang, Tian; Yang, Junle; Li, Jianying; Di, Zhengli; Liu, Zhiqin; Baskys, Andrius; Liu, Weiping; Wu, Shengxi; Long, Qianfa			Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice	THERANOSTICS			English	Article						MSC-Exo; astrocyte alterations; calcium signaling; Nrf2-NF-kappa B signaling; Nanotherapy	BONE-MARROW; ACTIVATION; NEUROINFLAMMATION; PATHWAY; STIMULATION; INHIBITION; PLASTICITY; IL-1-BETA; SYSTEM; MSCS	Mesenchymal stem cell-derived exosomes (MSC-Exo) have robust anti-inflammatory effects in the treatment of neurological diseases such as epilepsy, stroke, or traumatic brain injury. While astrocytes are thought to be mediators of these effects, their precise role remains poorly understood. To address this issue, we investigated the putative therapeutic effects and mechanism of MSC-Exo on inflammation-induced alterations in astrocytes. Methods: Lipopolysaccharide (LPS)-stimulated hippocampal astrocytes in primary culture were treated with MSC-Exo, which were also administered in pilocarpine-induced status epilepticus (SE) mice. Exosomal integration, reactive astrogliosis, inflammatory responses, calcium signaling, and mitochondrial membrane potentials (MMP) were monitored. To experimentally probe the molecular mechanism of MSC-Exo actions on the inflammation-induced astrocytic activation, we inhibited the nuclear factor erythroid-derived 2, like 2 (Nrf2, a key mediator in neuroinflammation and oxidative stress) by sgRNA (in vitro) or ML385 (Nrf2 inhibitor) in vivo. Results: MSC-Exo were incorporated into hippocampal astrocytes as well as attenuated reactive astrogliosis and inflammatory responses in vitro and in vivo. Also, MSC-Exo ameliorated LPS-induced aberrant calcium signaling and mitochondrial dysfunction in culture, and SE-induced learning and memory impairments in mice. Furthermore, the putative therapeutic effects of MSC-Exo on inflammation-induced astrocytic activation (e.g., reduced reactive astrogliosis, NF-kappa B deactivation) were weakened by Nrf2 inhibition. Conclusions: Our results show that MSC-Exo ameliorate inflammation-induced astrocyte alterations and that the Nrf2-NF-kappa B signaling pathway is involved in regulating astrocyte activation in mice. These data suggest the promising potential of MSC-Exo as a nanotherapeutic agent for the treatment of neurological diseases with hippocampal astrocyte alterations.	[Xian, Panpan; Wang, Tian; Baskys, Andrius; Long, Qianfa] Xian Cent Hosp, Miniinvas Neurosurg & Translat Med Ctr, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China; [Hei, Yue; Yang, Junle; Li, Jianying; Liu, Weiping] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 17 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Wang, Rui; Wu, Shengxi] Fourth Mil Med Univ, Sch Basic Med, Dept Neurobiol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Di, Zhengli; Liu, Zhiqin] Xian Cent Hosp, Dept Neurol, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China; [Baskys, Andrius] Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA		Long, QF (corresponding author), Xian Cent Hosp, Miniinvas Neurosurg & Translat Med Ctr, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China.; Wu, SX (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Dept Neurobiol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	shengxi@fmmu.edu.cn; lonva@live.cn	; Long, Qianfa/F-6461-2017	Zhiqin, Liu/0000-0003-2328-4897; Long, Qianfa/0000-0001-8848-9688	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871084]; key R&D Projects of Shaanxi Province [2018ZDXM-SF-046]; Major Projects of Xi'an Medical Research [201805104YX12SF38(1)]; Xi'an Science and Technology Project [2017115SF/YX009]	This work was supported by grants from National Natural Science Foundation of China (81871084), key R&D Projects of Shaanxi Province (2018ZDXM-SF-046), Major Projects of Xi'an Medical Research (201805104YX12SF38(1)) and Xi'an Science and Technology Project (2017115SF/YX009). We also thank Dr. Iqbal Ali for her English language editing services.	[Anonymous], 2011, GUIDE CARE USE LAB A; Arena A, 2019, BRAIN PATHOL, V29, P351, DOI 10.1111/bpa.12661; Bebensee DF, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3064016; Cayce JM, 2014, CELL CALCIUM, V55, P183, DOI 10.1016/j.ceca.2014.01.004; Cheli VT, 2016, GLIA, V64, P1396, DOI 10.1002/glia.23013; Chen JK, 2017, EUR J PHARMACOL, V806, P1, DOI 10.1016/j.ejphar.2017.03.025; Choi JH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01444; Dendrou CA, 2016, NAT REV NEUROL, V12, P685, DOI 10.1038/nrneurol.2016.171; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Dominguez-Prieto MD, 2018, J ALZHEIMERS DIS, V65, P1109, DOI 10.3233/JAD-180332; Draheim T, 2016, GLIA, V64, P2219, DOI 10.1002/glia.23058; Drommelschmidt K, 2017, BRAIN BEHAV IMMUN, V60, P220, DOI 10.1016/j.bbi.2016.11.011; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; Friedman A, 2011, EPILEPSIA, V52, P33, DOI 10.1111/j.1528-1167.2011.03034.x; Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001; Gerard F, 2012, BRAIN RES, V1473, P1, DOI 10.1016/j.brainres.2012.07.032; Haskew-Layton RE, 2010, P NATL ACAD SCI USA, V107, P17385, DOI 10.1073/pnas.1003996107; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Hung CC, 2016, J NEUROSCI, V36, P2027, DOI 10.1523/JNEUROSCI.3457-15.2016; Kelic S, 2001, MOL CELL NEUROSCI, V17, P551, DOI 10.1006/mcne.2000.0955; Kornilov R, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2017.1422674; Lai RC, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.29828; Levy S, 2014, IMMUNOL RES, V58, P179, DOI 10.1007/s12026-014-8490-7; Li YX, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1278-2; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Long Q, 2015, NEUROSCIENCE, V311, P464, DOI 10.1016/j.neuroscience.2015.10.055; Long QF, 2017, AGING DIS, V8, P301, DOI 10.14336/AD.2016.1018; Long Q, 2017, P NATL ACAD SCI USA, V114, pE3536, DOI 10.1073/pnas.1703920114; Lu XF, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-46; Muller MS, 2014, GLIA, V62, P526, DOI 10.1002/glia.22623; Mustaly-Kalimi S, 2018, ANTIOXID REDOX SIGN, V29, P1158, DOI 10.1089/ars.2017.7266; Narayanan SV, 2018, TRANSL STROKE RES, V9, P99, DOI 10.1007/s12975-017-0574-y; Nikolic L, 2018, GLIA, V66, P2673, DOI 10.1002/glia.23519; Niquet J, 2016, EPILEPSIA, V57, P1406, DOI 10.1111/epi.13480; Niranjan R, 2014, MOL NEUROBIOL, V49, P28, DOI 10.1007/s12035-013-8483-x; Ouali Alami N, 2018, EMBO J, V37, DOI 10.15252/embj.201798697; Pacheco SM, 2018, CELL MOL NEUROBIOL, V38, P1107, DOI 10.1007/s10571-018-0581-x; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Patel H, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0967-6; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Roberts-Dalton HD, 2017, NANOSCALE, V9, P13693, DOI 10.1039/c7nr04128d; Shang FQ, 2017, THERANOSTICS, V7, P4370, DOI 10.7150/thno.19888; Shanmugam G, 2017, REDOX BIOL, V12, P937, DOI 10.1016/j.redox.2017.04.038; Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5; Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005; Sivandzade F, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.017; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Tjalkens Ronald B, 2017, Adv Neurobiol, V18, P159, DOI 10.1007/978-3-319-60189-2_8; Vargas-Sanchez Karina, 2018, Oncotarget, V9, P26954, DOI 10.18632/oncotarget.25485; Verkhratsky A, 2016, PROG NEUROBIOL, V144, P188, DOI 10.1016/j.pneurobio.2015.09.003; Wang L, 2018, CELL PHYSIOL BIOCHEM, V50, P1535, DOI 10.1159/000494652; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wegierski T, 2018, CELL CALCIUM, V74, P102, DOI 10.1016/j.ceca.2018.07.001; Xie XT, 2012, BIOMATERIALS, V33, P7008, DOI 10.1016/j.biomaterials.2012.06.058; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yang Y, 2019, REDOX BIOL, V20, P157, DOI 10.1016/j.redox.2018.09.019; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5	66	63	65	14	32	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2019	9	20					5956	5975		10.7150/thno.33872			20	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	IR7DP	WOS:000481601200017	31534531	Green Published, gold	Y	N	2022-02-06	
J	Darby, RR; Horn, A; Cushman, F; Fox, MD				Darby, R. Ryan; Horn, Andreas; Cushman, Fiery; Fox, Michael D.			Lesion network localization of criminal behavior	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						morality; functional connectivity; criminality; sociopathy; lesion	TRAUMATIC BRAIN-INJURY; MORAL JUDGMENT; FRONTOTEMPORAL DEMENTIA; PREFRONTAL CORTEX; DECISION-MAKING; ACQUIRED SOCIOPATHY; ULTIMATUM GAME; CONNECTIVITY; DAMAGE; PSYCHOPATHY	Following brain lesions, previously normal patients sometimes exhibit criminal behavior. Although rare, these cases can lend unique insight into the neurobiological substrate of criminality. Here we present a systematic mapping of lesions with known temporal association to criminal behavior, identifying 17 lesion cases. The lesion sites were spatially heterogeneous, including the medial prefrontal cortex, orbitofrontal cortex, and different locations within the bilateral temporal lobes. No single brain region was damaged in all cases. Because lesion-induced symptoms can come from sites connected to the lesion location and not just the lesion location itself, we also identified brain regions functionally connected to each lesion location. This technique, termed lesion network mapping, has recently identified regions involved in symptom generation across a variety of lesion-induced disorders. All lesions were functionally connected to the same network of brain regions. This criminality-associated connectivity pattern was unique compared with lesions causing four other neuropsychiatric syndromes. This network includes regions involved in morality, value-based decision making, and theory of mind, but not regions involved in cognitive control or empathy. Finally, we replicated our results in a separate cohort of 23 cases in which a temporal relationship between brain lesions and criminal behavior was implied but not definitive. Our results suggest that lesions in criminals occur in different brain locations but localize to a unique resting state network, providing insight into the neurobiology of criminal behavior.	[Darby, R. Ryan] Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA; [Darby, R. Ryan; Horn, Andreas; Fox, Michael D.] Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Darby, R. Ryan; Horn, Andreas; Fox, Michael D.] Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Div Cognit Neurol, Boston, MA 02115 USA; [Darby, R. Ryan; Fox, Michael D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Darby, R. Ryan] Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA 02478 USA; [Horn, Andreas] Charite, Dept Neurol, Movement Disorder & Neuromodulat Unit, D-10117 Berlin, Germany; [Cushman, Fiery] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Fox, Michael D.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA		Darby, RR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Div Cognit Neurol, Boston, MA 02115 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Darby, RR (corresponding author), Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA 02478 USA.; Fox, MD (corresponding author), Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.	darby.ryan@gmail.com; foxmdphd@gmail.com	Horn, Andreas GR/B-8988-2017; Fox, Michael D./AAZ-3928-2020; Horn, Andreas/R-6528-2017	Horn, Andreas GR/0000-0002-0695-6025; Fox, Michael D./0000-0001-8848-6399; Horn, Andreas/0000-0002-0695-6025; Cushman, Fiery/0000-0002-6929-9982	Sidney R. Baer, Jr. Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS083741]; Dystonia Foundation; Nancy Lurie Marks Foundation; Alzheimer's AssociationAlzheimer's Association; BrightFocus FoundationBrightFocus Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS083741] Funding Source: NIH RePORTER	We thank Joshua Greene and Danilo Bzdok for sharing data. This work was supported by funding from the Sidney R. Baer, Jr. Foundation (R.R.D. and M.D.F.), the National Institutes of Health Grant K23NS083741 (to M.D.F.), the Dystonia Foundation (M.D.F.), the Nancy Lurie Marks Foundation (M.D.F.), the Alzheimer's Association (R.R.D.), and the BrightFocus Foundation (R.R.D.).	Adolphs R, 2016, NEURON, V90, P1151, DOI 10.1016/j.neuron.2016.05.014; Anderson DA, 1999, J LAW ECON, V42, P611, DOI 10.1086/467436; Anderson NE, 2012, TRENDS COGN SCI, V16, P52, DOI 10.1016/j.tics.2011.11.008; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Baron-Cohen S, 2013, SCI EVIL EMPATHY ORI; Batts S, 2009, BEHAV SCI LAW, V27, P261, DOI 10.1002/bsl.857; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Boes AD, 2015, BRAIN, V138, P3061, DOI 10.1093/brain/awv228; Braun Claude M J, 2008, Cogn Neuropsychiatry, V13, P296, DOI 10.1080/13546800802088580; Buckholtz JW, 2015, CURR OPIN BEHAV SCI, V3, P122, DOI 10.1016/j.cobeha.2015.03.004; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Cushman F, 2013, PERS SOC PSYCHOL REV, V17, P273, DOI 10.1177/1088868313495594; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Darby R. R., 2016, AJOB NEUROSCI, V7, P193, DOI [10.1080/21507740.2016.1236044, DOI 10.1080/21507740.2016.1236044]; Darby RR, 2017, BRAIN, V140, DOI 10.1093/brain/awx125; Darby RR, 2017, BRAIN, V140, P497, DOI 10.1093/brain/aww288; de Oliveira-Souza R, 2008, NEUROIMAGE, V40, P1202, DOI 10.1016/j.neuroimage.2007.12.054; DENNO DW, 2015, BC L REV, V56, P493; Diehl-Schmid J, 2013, COGN BEHAV NEUROL, V26, P73, DOI 10.1097/WNN.0b013e31829cff11; Eickhoff SB, 2009, HUM BRAIN MAPP, V30, P2907, DOI 10.1002/hbm.20718; Ermer E, 2012, J ABNORM PSYCHOL, V121, P649, DOI 10.1037/a0026371; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Feng CL, 2015, HUM BRAIN MAPP, V36, P591, DOI 10.1002/hbm.22649; Fischer DB, 2016, NEUROLOGY, V87, P2427, DOI 10.1212/WNL.0000000000003404; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fumagalli M, 2012, BRAIN, V135, P2006, DOI 10.1093/brain/awr334; Glenn AL, 2014, NAT REV NEUROSCI, V15, P54, DOI 10.1038/nrn3640; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Horn A, 2017, ANN NEUROL, V82, P67, DOI 10.1002/ana.24974; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Koenigs M, 2012, SOC COGN AFFECT NEUR, V7, P708, DOI 10.1093/scan/nsr048; Koenigs M, 2010, NEUROPSYCHOLOGIA, V48, P2198, DOI 10.1016/j.neuropsychologia.2010.04.012; Laganiere S, 2016, NEUROLOGY, V86, P2187, DOI 10.1212/WNL.0000000000002741; Liljegren M, 2015, JAMA NEUROL, V72, P295, DOI 10.1001/jamaneurol.2014.3781; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Mendez MF, 2005, COGN BEHAV NEUROL, V18, P193, DOI 10.1097/01.wnn.0000191292.17964.bb; Mendez MF, 2005, DEMENT GERIATR COGN, V20, P99, DOI 10.1159/000086474; Monakow C, 1914, LOKALISATION GROSSHI; Motzkin JC, 2011, J NEUROSCI, V31, P17348, DOI 10.1523/JNEUROSCI.4215-11.2011; O'Callaghan C, 2016, BRAIN, V139, P204, DOI 10.1093/brain/awv315; Pardini M, 2011, NEUROLOGY, V76, P1038, DOI 10.1212/WNL.0b013e318211c33e; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; Sutterer MJ, 2016, CORTEX, V78, P31, DOI 10.1016/j.cortex.2016.02.002; Taber-Thomas BC, 2014, BRAIN, V137, P1254, DOI 10.1093/brain/awt377; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Young L, 2007, P NATL ACAD SCI USA, V104, P8235, DOI 10.1073/pnas.0701408104	56	63	63	4	44	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 16	2018	115	3					601	606		10.1073/pnas.1706587115			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FT3ZS	WOS:000423091400059	29255017	hybrid, Green Published			2022-02-06	
J	Wright, DK; O'Brien, TJ; Shultz, SR; Mychasiuk, R				Wright, David K.; O'Brien, Terence J.; Shultz, Sandy R.; Mychasiuk, Richelle			Sex matters: repetitive mild traumatic brain injury in adolescent rats	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							MYELIN BASIC-PROTEIN; HYPERPHOSPHORYLATED TAU; PROFESSIONAL FOOTBALL; CONCUSSION SYMPTOMS; EXECUTIVE FUNCTION; CORPUS-CALLOSUM; SODIUM SELENATE; WHITE-MATTER; ANIMAL-MODEL; NEUROINFLAMMATION	Objective: Whether sex differences contribute to the heterogeneity of mild traumatic brain injury (mTBI) and repeated mTBI (RmTBI) outcomes in adolescents is unknown. Therefore, this study examined changes in, and differences between, male and female rats following single mTBI and RmTBI. Methods: Rats were given a single mTBI, RmTBI (i.e., 3x), or sham injuries. Injuries were administered using a lateral impact model that mimics forces common in human mTBI. After the final injury, rats underwent extensive behavioral testing to examine cognition, motor function, and anxiety- and depressive-like behavior. Postmortem analyses investigated gene expression and structural changes in the brain. Results: Many of the outcomes exhibited a sex-dependent response to RmTBI. While all rats given RmTBI had deficits in balance, motor coordination, locomotion, and anxiety- like behavior, only male rats given RmTBI had short-term working memory deficits, whereas only females given RmTBI had increased depressive-like behavior. Volumetric and diffusion weighted MRI analyses found that while RmTBI-induced atrophy of the prefrontal cortex was greater in female rats, only the male rats exhibited worse white matter integrity in the corpus callosum following RmTBI. Sex-dependent changes in brain expression of mRNA for glial fibrillary acidic protein, myelin basic protein, and tau protein were also observed following injury. Interpretation: These findings suggest that in adolescent mTBI, sex matters; and future studies incorporating both male and females are warranted to provide a greater understanding of injury prognosis and better inform clinical practice.	[Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Mychasiuk, Richelle] Univ Calgary, Alberta Childrens Hosp Res Inst, Dept Psychol, Calgary, AB, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Dept Psychol, Alberta Childrens Hosp Res Inst, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB, Canada.	rmmychas@ucalgary.ca	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021	O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651	Alberta Children's Hospital Research Foundation; Integrated Concussion Research Program; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The authors thank the Alberta Children's Hospital Research Foundation, the Integrated Concussion Research Program and the National Health and Medical Research Council for funding. We acknowledge the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.	Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chisholm NC, 2016, NEUROBIOL DIS, V85, P245, DOI 10.1016/j.nbd.2015.03.028; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Elder GA, 1999, J CELL BIOL, V146, P181; Faul M, 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gerbeding J, 2003, C MILD TRAUM BRAIN I; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gur RC, 1999, J NEUROSCI, V19, P4065; Gyengesi E, 2014, BRAIN STRUCT FUNCT, V219, P539, DOI 10.1007/s00429-013-0516-8; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kooy RF, 2001, EUR J HUM GENET, V9, P153, DOI 10.1038/sj.ejhg.5200606; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Mayer C, 2010, P NATL ACAD SCI USA, V107, P22693, DOI 10.1073/pnas.1012406108; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2016, NEUROSCI BIOBEHAV R, V70, P189, DOI 10.1016/j.neubiorev.2016.07.013; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Romeo RD, 2002, NEUROSCI BIOBEHAV R, V26, P381, DOI 10.1016/S0149-7634(02)00009-X; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Rowe RK, 2016, DEV NEUROSCI-BASEL, V38, P195, DOI 10.1159/000446773; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Rzeczkowska PA, 2014, NEUROENDOCRINOLOGY, V99, P139, DOI 10.1159/000362559; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharma P, 2017, NEUROBIOL DIS, V104, P33, DOI 10.1016/j.nbd.2017.04.022; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wright D, 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5204; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	74	63	63	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	SEP	2017	4	9					640	654		10.1002/acn3.441			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG2IX	WOS:000409921800004	28904986	Green Published, gold			2022-02-06	
J	Yanguas-Casas, N; Barreda-Manso, MA; Nieto-Sampedro, M; Romero-Ramirez, L				Yanguas-Casas, Natalia; Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel; Romero-Ramirez, Lorenzo			TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							BETA SIGNALING PLAYS; TAUROURSODEOXYCHOLIC ACID; SPINAL-CORD; LEUKOCYTE RECRUITMENT; URSODEOXYCHOLIC ACID; ACTIVATED MICROGLIA; IMMUNE-RESPONSES; GENE-EXPRESSION; NITRIC-OXIDE; IN-VITRO	Bile acids are steroid acids found in the bile of mammals. The bile acid conjugate tauroursodeoxycholic acid (TUDCA) is neuroprotective in different animal models of stroke and neurological diseases. We have previously shown that TUDCA has anti-inflammatory effects on glial cell cultures and in a mouse model of acute neuroinflammation. We show now that microglial cells (central nervous system resident macrophages) express the G protein-coupled bile acid receptor 1/Takeda G protein-coupled receptor 5 (GPBAR1/TGR5) in vivo and in vitro. TUDCA binding to GPBAR1/TGR5 caused an increase in intracellular cAMP levels in microglia that induced anti-inflammatory markers, while reducing pro-inflammatory ones. This anti-inflammatory effect of TUDCA was inhibited by small interference RNA for GPBAR1/TGR5 receptor, as well as by treatment with a protein kinase A (PKA) inhibitor. In the mouse model of acute neuroinflammation, treating the animals with TUDCA was clearly anti-inflammatory. TUDCA biased the microglial phenotype in vivo and in vitro toward the anti-inflammatory. The bile acid receptor GPBAR1/TGR5 could be a new therapeutic target for pathologies coursing with neuroinflammation and microglia activation, such as traumatic brain injuries, stroke, or neurodegenerative diseases. TUDCA and other GPBAR1/TGR5 agonists need to be further investigated, to determine their potential in attenuating the neuropathologies associated with microglia activation. J. Cell. Physiol. 232: 2231-2245, 2017. (c) 2016 Wiley Periodicals, Inc.	[Yanguas-Casas, Natalia; Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel] Inst Cajal CSIC, Dept Neurobiol Func & Sistemas, Madrid, Spain; [Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel; Romero-Ramirez, Lorenzo] Hosp Nacl Paraplej SESCAM, Unidad Neurol Expt, Toledo, Spain		Romero-Ramirez, L (corresponding author), Hosp Nacl Paraplej SESCAM, Unidad Neurol Expt, Lab Plasticidad Neural, Finca Peraleda S-N, Toledo 45071, Spain.	lromeroramirez@sescam.jccm.es	Barreda-Manso, M.Asuncion/ABF-8918-2020; Casas, Natalia Yanguas/AAB-6704-2019	Barreda-Manso, M.Asuncion/0000-0003-4127-2101; Casas, Natalia Yanguas/0000-0003-4368-0176	Spanish Ministry of Science and InnovationSpanish Government [SAF2009-11257]; Spanish Ministry of Economics and CompetitivenessSpanish Government [SAF2012-40126]; FISCAM-Comunidad de Castilla-La Mancha [PI2008/19, PI2009/51]	Contract grant sponsor: Spanish Ministry of Science and Innovation;; Contract grant number: SAF2009-11257.; Contract grant sponsor: Spanish Ministry of Economics and Competitiveness;; Contract grant number: SAF2012-40126.; Contract grant sponsor: FISCAM-Comunidad de Castilla-La Mancha;; Contract grant numbers: PI2008/19, PI2009/51.	Ackerman HD, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00263; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aloisi F, 2001, ANN MED, V33, P510, DOI 10.3109/07853890108995960; Bala V, 2011, GASTROENTEROLOGY, V140, pS147; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Bryan L, 2008, BBA-MOL CELL BIOL L, V1781, P459, DOI 10.1016/j.bbalip.2008.04.008; Castro-Caldas M, 2012, MOL NEUROBIOL, V46, P475, DOI 10.1007/s12035-012-8295-4; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Dello Russo C, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-9; Dent P, 2005, HEPATOLOGY, V42, P1291, DOI 10.1002/hep.20942; DEWIT H, 1994, BLOOD, V84, P608; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elia AE, 2015, EUR J NEUROL, V22, pE78, DOI 10.1111/ene.12756; FABRY Z, 1995, J IMMUNOL, V155, P325; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31; Grin'kina NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036475; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Jensen DD, 2013, J BIOL CHEM, V288, P22942, DOI 10.1074/jbc.M113.455774; Joo SS, 2004, ARCH PHARM RES, V27, P954, DOI 10.1007/BF02975850; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; Keitel V, 2008, BIOCHEM BIOPH RES CO, V372, P78, DOI 10.1016/j.bbrc.2008.04.171; Keitel V, 2010, GLIA, V58, P1794, DOI 10.1002/glia.21049; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lavoie B, 2010, J PHYSIOL-LONDON, V588, P3295, DOI 10.1113/jphysiol.2010.192146; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lewis ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100883; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; Magnus T, 2005, J NEUROSCI, V25, P2537, DOI 10.1523/JNEUROSCI.4794-04.2005; Mano N, 2004, J LIPID RES, V45, P295, DOI 10.1194/jlr.M300369-JLR200; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; McMillin M, 2015, J NEUROCHEM, V135, P565, DOI 10.1111/jnc.13243; Moon EY, 2005, J NEUROSCI RES, V81, P38, DOI 10.1002/jnr.20535; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nunes AF, 2012, MOL NEUROBIOL, V45, P440, DOI 10.1007/s12035-012-8256-y; Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Quinn M, 2012, J CELL SCI R, V3, P7, DOI [10.4172/2157-7013.1000-113, DOI 10.4172/2157-7013.1000-113]; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sato H, 2008, J MED CHEM, V51, P1831, DOI 10.1021/jm7015864; Standiford TJ, 2011, ONCOGENE, V30, P2475, DOI 10.1038/onc.2010.619; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Wu FJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0316-6; Yanguas-Casas N, 2017, MOL NEUROBIOL, V54, P6737, DOI 10.1007/s12035-016-0142-6; Yanguas-Casas N, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-50; Yoneno K, 2013, IMMUNOLOGY, V139, P19, DOI 10.1111/imm.12045; Zhou H, 2006, J IMMUNOL, V177, P8103, DOI 10.4049/jimmunol.177.11.8103; Zhou XL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-210	67	63	63	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	AUG	2017	232	8					2231	2245		10.1002/jcp.25742			15	Cell Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Physiology	ET0SF	WOS:000399973200030	27987324				2022-02-06	
J	Palacios, EM; Yuh, EL; Chang, YS; Yue, JK; Schnyer, DM; Okonkwo, DO; Valadka, AB; Gordon, WA; Maas, AIR; Vassar, M; Manley, GT; Mukherjee, P				Palacios, Eva M.; Yuh, Esther L.; Chang, Yi-Shin; Yue, John K.; Schnyer, David M.; Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik			Resting-State Functional Connectivity Alterations Associated with Six-Month Outcomes in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive and behavioral outcome; rsfMRI; TBI	DEFAULT-MODE NETWORK; CONCUSSED INDIVIDUALS; FMRI; DISRUPTION; ROBUST; MRI	Brain lesions are subtle or absent in most patients with mild traumatic brain injury (mTBI) and the standard clinical criteria are not reliable for predicting long-term outcome. This study investigates resting-state functional MRI (rsfMRI) to assess semiacute alterations in brain connectivity and its relationship with outcome measures assessed 6 months after injury. Seventy-five mTBI patients were recruited as part of the prospective multicenter Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) pilot study and compared with matched 47 healthy subjects. Patients were classified following radiological criteria: CT/MRI positive, evidence of lesions; CT/MRI negative, without evidence of brain lesions. rsfMRI data were acquired and then processed using probabilistic independent component analysis. We compared the functional connectivity of the resting-state networks (RSNs) between patients and controls, as well as group differences in the interactions between RSNs, and related both to cognitive and behavioral performance at 6 months post-injury. Alterations were found in the spatial maps of the RSNs between mTBI patients and healthy controls in networks involved in behavioral and cognition processes. These alterations were predictive of mTBI patients' outcomes at 6 months post-injury. Moreover, different patterns of reduced network interactions were found between the CT/MRI positive and CT/MRI negative patients and the control group. These rsfMRI results demonstrate that even mTBI patients not showing brain lesions on conventional CT/MRI scans can have alterations of functional connectivity at the semiacute stage that help explain their outcomes. These results suggest rsfMRI as a sensitive biomarker both for early diagnosis and for prediction of the cognitive and behavioral performance of these patients.	[Palacios, Eva M.; Yuh, Esther L.; Chang, Yi-Shin; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0946,185 Berry St, San Francisco, CA 94107 USA; [Yue, John K.; Vassar, Mary; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yue, John K.; Vassar, Mary; Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Yuh, Esther L.; Yue, John K.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik] San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94110 USA; [Yuh, Esther L.; Yue, John K.; Vassar, Mary; Manley, Geoffrey T.; Mukherjee, Pratik] Ctr Trauma, San Francisco, CA USA; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Gordon, Wayne A.] Ichan Sch Med Mt Sinai, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium		Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0946,185 Berry St, San Francisco, CA 94107 USA.	pratik.mukherjee@ucsf.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021; Maas, Andrew IR/C-5584-2013	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Maas, Andrew IR/0000-0003-1612-1264	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069409, NS069409-02S1, NS60776]; Department of Defense United States Army Medical Research Acquisition ActivityUnited States Department of Defense [W81XWH-13-1-0441]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409, R01NS060776] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) grants NS069409 and NS069409-02S1 (principal investigator [PI]: G.T.M.) and NS60776 (PI: P.M.) and Department of Defense United States Army Medical Research Acquisition Activity W81XWH-13-1-0441 (PI: G.T.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke (NINDS) or the NIH.	Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2012, NEUROIMAGE, V62, P1137, DOI 10.1016/j.neuroimage.2011.10.035; Di X, 2015, J NEUROPHYSIOL, V114, P2785, DOI 10.1152/jn.00893.2014; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Griffanti L, 2014, NEUROIMAGE, V95, P232, DOI 10.1016/j.neuroimage.2014.03.034; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Roiser J.P, 2016, MINIMUM STAT STAN DA; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smallwood J, 2012, BRAIN RES, V1428, P60, DOI 10.1016/j.brainres.2011.03.072; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2015, NAT NEUROSCI, V18, P1565, DOI 10.1038/nn.4125; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spreng RN, 2014, J NEUROSCI, V34, P14108, DOI 10.1523/JNEUROSCI.2815-14.2014; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; van Schouwenburg MR, 2010, J NEUROSCI, V30, P9910, DOI 10.1523/JNEUROSCI.1111-10.2010; Vatansever D, 2017, HUM BRAIN MAPP, V38, P41, DOI 10.1002/hbm.23341; Vatansever D, 2015, J NEUROSCI, V35, P15254, DOI 10.1523/JNEUROSCI.2135-15.2015; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	36	63	65	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1546	1557		10.1089/neu.2016.4752			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500006	28085565	Green Submitted, Green Published			2022-02-06	
J	Ljungqvist, J; Zetterberg, H; Mitsis, M; Blennow, K; Skoglund, T				Ljungqvist, Johan; Zetterberg, Henrik; Mitsis, Marios; Blennow, Kaj; Skoglund, Thomas			Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomarkers; DTI; MRI; TBI	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; SCALE; GUIDELINES; DAMAGE	Diffuse axonal injury (DAI) is an important cause of morbidity in patients with traumatic brain injury (TBI). There is currently no simple and reliable technique for early identification of patients with DAI, or to prognosticate long-term outcome in this patient group. In the present study, we examined acute serum concentrations of neurofilament light (NFL) in nine patients with severe TBI and DAI using a novel ultrasensitive single molecule array (Simoa) assay. The relationships between the NFL concentrations and MRI in the acute stage as well as clinical outcome and magnetic resonance diffusion tensor imaging (MR-DTI) parameters at 12 months were analyzed. We found that the mean NFL concentrations among the patients displayed a 30-fold increase compared with controls, and that NFL completely discriminated between the patients and controls. We also found a relationship between serum NFL and MR-DTI parameters, with higher NFL concentrations in patients with higher trace (R-2=0.79) and lower fractional anisotropy (FA) (R (2)=0.83). These results suggest that serum NFL may be a valuable blood biomarker for TBI, reflecting the severity of DAI.	[Ljungqvist, Johan; Skoglund, Thomas] Univ Gothenburg, Sahlgrenska Acad, Dept Neurosurg, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden; [Mitsis, Marios] Univ Gothenburg, Sahlgrenska Acad, Dept Neuroradiol, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England		Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se			Health and Medical Care Committee of Vastra Gotaland; Foundation for Medical Imaging in Memory of Erik Lysholm; Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Torsten Soderberg Foundation	This work was supported by grants from the Health and Medical Care Committee of Vastra Gotaland, the Foundation for Medical Imaging in Memory of Erik Lysholm, the Swedish Research Council, the European Research Council, the Knut and Alice Wallenberg Foundation, and the Torsten Soderberg Foundation. We thank Dr. Asgeir Jakola for his support with the statistical analysis.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bettermann K, 2012, RSC DRUG DISCOV, V24, P1, DOI 10.1039/9781849734745-00001; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Oliver J., 2016, J NEUROTRAUMA; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Studerus-Germann AM, 2016, INT J NEUROSCI, V126, P289, DOI 10.3109/00207454.2015.1033620; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	20	63	64	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2017	34	5					1124	1127		10.1089/neu.2016.4496			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EM6EI	WOS:000395405200016	27539721	Green Submitted			2022-02-06	
J	Yorke, AM; Smith, L; Babcock, M; Alsalaheen, B				Yorke, Amy M.; Smith, Laura; Babcock, Mitch; Alsalaheen, Bara			Validity and Reliability of the Vestibular/Ocular Motor Screening and Associations With Common Concussion Screening Tools	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; vestibular; balance; ocular motor	SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; KING-DEVICK TEST; FOOTBALL PLAYERS; REHABILITATION; MANAGEMENT; EPIDEMIOLOGY; CONVERGENCE; ADOLESCENTS; STATEMENT	Background: Sustaining a concussion commonly results in vestibular impairments that may be associated with balance deficits. To screen for vestibular impairments after a concussion, the Vestibular/Ocular Motor Screening (VOMS) tool was developed. The relationship between the VOMS and other concussion screening tools, such as the Balance Error Scoring System (BESS) and King-Devick (K-D), have not been explored. Hypotheses: (1) VOMS would provide reliable results and not provoke symptoms in healthy adolescents and (2) VOMS test items would measure related aspects of vestibular function that are not measured through the BESS or K-D. Study Design: Cross-sectional, descriptive. Methods: A total of 105 healthy adolescents (53 male, 52 female; mean age, 15.4 years) completed the VOMS, BESS, and K-D tests. A subsample of 21 adolescents (16 male, 5 female; mean age, 15.5 years) completed the VOMS twice. Results: The median total symptom score for all 7 VOMS items was 0 (0- 5). The majority of the individual VOMS test items total symptom scores demonstrated a significant correlation with each other (r(s) = 0.25-0.66, P < 0.02). The individual VOMS items did not demonstrate a significant relationship to the BESS or K-D. VOMS items demonstrated high agreement in total symptom scores between testing trials, with near point convergence (NPC) distance demonstrating an intraclass correlation coefficient (ICC) of 0.95 (95% CI, 0.89-0.98; P < 0.001). The MDC95 (minimal detectable change with 95 confidence) for NPC distance was 4 cm. Conclusion: The VOMS did not provoke vestibular symptoms in healthy adolescents. The VOMS items measured unique aspects of vestibular function other than those measured by the BESS or K-D with good reliability.	[Yorke, Amy M.; Smith, Laura; Babcock, Mitch; Alsalaheen, Bara] Univ Michigan Flint, Phys Therapy Dept, 303 East Kearsley,2157 William S White, Flint, MI 48502 USA; [Alsalaheen, Bara] Univ Michigan Ann Arbor, Dept Neurol, Ann Arbor, MI USA; [Alsalaheen, Bara] Univ Michigan Hlth Syst, Michigan NeuroSport, Ann Arbor, MI USA		Alsalaheen, B (corresponding author), Univ Michigan Flint, Phys Therapy Dept, 303 East Kearsley,2157 William S White, Flint, MI 48502 USA.	alsalahe@umflint.edu	Yorke, Amy/Q-4091-2019	Yorke, Amy/0000-0003-4998-0313			Alsalaheen B, 2016, SCAND J MED SCI SPOR, V26, P235, DOI 10.1111/sms.12628; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2015, PHYSICIAN SPORTSMED, V43, P221, DOI 10.1080/00913847.2015.1040717; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta K.M., 2016, CONCUSSION, V1, pCNC8; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Kandel E. R., 2000, PRINCIPLES NEURAL SC, V4; Khanna NK, 2015, SPORTS HEALTH, V7, P341, DOI 10.1177/1941738115571508; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Portney L.G., 2009, FDN CLIN RES APPL PR, V3rd ed.; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5	37	63	63	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2017	9	2					174	180		10.1177/1941738116678411			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EY5WQ	WOS:000404052200011	27834667	Green Published			2022-02-06	
J	Garcia-Mesa, Y; Jay, TR; Checkley, MA; Luttge, B; Dobrowolski, C; Valadkhan, S; Landreth, GE; Karn, J; Alvarez-Carbonell, D				Garcia-Mesa, Yoelvis; Jay, Taylor R.; Checkley, Mary Ann; Luttge, Benjamin; Dobrowolski, Curtis; Valadkhan, Saba; Landreth, Gary E.; Karn, Jonathan; Alvarez-Carbonell, David			Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system	JOURNAL OF NEUROVIROLOGY			English	Article						Microglia; HIV regulation; HIV-associated neurocognitive disorders; NeuroAIDS	HUMAN-IMMUNODEFICIENCY-VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; AIDS DEMENTIA COMPLEX; INFLAMMATORY FACTOR-I; ACIDIC PROTEIN GFAP; LARGE T-ANTIGEN; NF-KAPPA-B; RAMIFIED MICROGLIA; CELL-LINES	The major reservoirs for HIV in the CNS are in the microglia, perivascular macrophages, and to a lesser extent, astrocytes. To study the molecular events controlling HIV expression in the microglia, we developed a reliable and robust method to immortalize microglial cells from primary glia from fresh CNS tissues and commercially available frozen glial cells. Primary human cells, including cells obtained from adult brain tissue, were transformed with lentiviral vectors expressing SV40 T antigen or a combination of SVR40 T antigen and hTERT. The immortalized cells have microglia-like morphology and express key microglial surface markers including CD11b, TGF beta R, and P2RY12. Importantly, these cells were confirmed to be of human origin by sequencing. The RNA expression profiles identified by RNA-seq are also characteristic of microglial cells. Furthermore, the cells demonstrate the expected migratory and phagocytic activity, and the capacity to mount an inflammatory response characteristic of primary microglia. The immortalization method has also been successfully applied to a wide range of microglia from other species (macaque, rat, and mouse). To investigate different aspects of HIV molecular regulation in CNS, the cells have been superinfected with HIV reporter viruses and latently infected clones have been selected that reactive HIV in response to inflammatory signals. The cell lines we have developed and rigorously characterized will provide an invaluable resource for the study of HIV infection in microglial cells as well as studies of microglial cell function.	[Garcia-Mesa, Yoelvis; Checkley, Mary Ann; Luttge, Benjamin; Dobrowolski, Curtis; Karn, Jonathan; Alvarez-Carbonell, David] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Jay, Taylor R.; Landreth, Gary E.] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; [Valadkhan, Saba] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA		Alvarez-Carbonell, D (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.	yxg146@case.edu; trj29@case.edu; mxc567@case.edu; bxl244@case.edu; cxd108@case.edu; sxv46@case.edu; ge12@case.edu; jxk153@case.edu; dxa150@case.edu	Valadkhan, Saba/G-7271-2012	Valadkhan, Saba/0000-0002-6859-4883; Jay, Taylor/0000-0003-3878-7059; dobrowolski, Curtis/0000-0001-6576-8318	 [R01 DA036171];  [DP1 DA028869]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DP1DA028869, R01DA036171] Funding Source: NIH RePORTER	We thank past and present members of the Karn laboratory: Stephanie Milne, Biswajit Das, Uri Mbonye, Kien Nguyen, Meenakshi Shukla, Paul Wille, Amy Graham, Julia Freedman, Julian Wong, Hongxia Mao, and Michael Greenberg for gifts of the materials, help, and useful discussions. We also thank Kamel Khalili (Temple), Brandon Harvey (NIDA), Kurt Hauser (VCU), and Janice Clements (JHU) for the useful discussions and materials. We thank Scott J. Howell (CWRU Visual Sciences) for the help with the time-lapse experiments, the CWRU Genomics Core for the RNA sequencing services, and the CWRU/UH Center for AIDS Research (P30 AI36219) for the flow cytometry services. This work was supported by R01 DA036171 and DP1 DA028869 (JK).	Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Alvarez-Carbonell D, 2016, TOLL LIKE RECE UNPUB; Babas T, 2003, J VIROL, V77, P208, DOI 10.1128/JVI.77.1.208-216.2003; Banati RB, 2003, BRIT MED BULL, V65, P121, DOI 10.1093/bmb/65.1.121; Becher B, 1996, GLIA, V18, P1; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; BOOTH PL, 1991, BRAIN RES, V548, P163, DOI 10.1016/0006-8993(91)91118-K; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Carrol ED, 2007, JAIDS-J ACQ IMM DEF, V44, P443, DOI 10.1097/QAI.0b013e31802f8390; Chugh P, 2007, J MOL BIOL, V366, P67, DOI 10.1016/j.jmb.2006.11.011; Churchill MJ, 2009, ANN NEUROL, V66, P253, DOI 10.1002/ana.21697; CONANT K, 1994, ADV NEUROIMMUNOL, V4, P287, DOI 10.1016/S0960-5428(06)80269-X; Darmanis S, 2015, P NATL ACAD SCI USA, V112, P7285, DOI 10.1073/pnas.1507125112; Dissing-Olesen L, 2007, NEUROSCIENCE, V149, P112, DOI 10.1016/j.neuroscience.2007.06.037; Dominguez E, 2008, J NEUROCHEM, V107, P50, DOI 10.1111/j.1471-4159.2008.05566.x; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Etemad S, 2012, J NEUROSCI METH, V209, P79, DOI 10.1016/j.jneumeth.2012.05.025; Eugenin EA, 2007, J NEUROSCI, V27, P12844, DOI 10.1523/JNEUROSCI.4154-07.2007; Eyo UB, 2013, J NEUROIMMUNE PHARM, V8, P494, DOI 10.1007/s11481-013-9434-z; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Fonken LK, 2015, BRAIN BEHAV IMMUN, V45, P171, DOI 10.1016/j.bbi.2014.11.009; FORD AL, 1995, J IMMUNOL, V154, P4309; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gorry PR, 2003, CURR HIV RES, V1, P463, DOI 10.2174/1570162033485122; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hazleton JE, 2010, HIV AIDS-RES PALLIAT, V2, P39; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hinojosa AE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-77; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hu WH, 2014, P NATL ACAD SCI USA, V111, P11461, DOI 10.1073/pnas.1405186111; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; Jadhav VS, 2014, J NEUROCHEM, V131, P803, DOI 10.1111/jnc.12933; Janabi N, 1998, GLIA, V23, P304; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Johnson EA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-41; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kaminska B, 2015, BIOCH BIOPHYS ACTA; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khorooshi R, 2015, ACTA NEUROPATHOL, V130, P107, DOI 10.1007/s00401-015-1418-z; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kim YK, 2006, EMBO J, V25, P3596, DOI 10.1038/sj.emboj.7601248; Kothur K, 2016, CYTOKINE, V77, P227, DOI 10.1016/j.cyto.2015.10.001; Kowal K, 2011, FOLIA HISTOCHEM CYTO, V49, P365, DOI 10.5603/FHC.2011.0052; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; Lane BR, 2001, J VIROL, V75, P8195, DOI 10.1128/JVI.75.17.8195-8202.2001; Lee KM, 2004, CYTOTECHNOLOGY, V45, P33, DOI 10.1007/s10616-004-5123-3; LEE SHC, 1993, AM J PATHOL, V143, P1032; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Lisi L, 2015, J NEUROCHEM; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Martin S, 2003, J NEUROSCI, V23, P1198, DOI 10.1523/JNEUROSCI.23-04-01198.2003; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nagai A, 2005, J NEUROSCI RES, V81, P342, DOI 10.1002/jnr.20478; Nagai A, 2001, NEUROBIOL DIS, V8, P1057, DOI 10.1006/nbdi.2001.0437; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Parajuli B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-268; Paris JJ, 2015, BEHAV BRAIN RES, V291, P209, DOI 10.1016/j.bbr.2015.05.021; Pearson R, 2008, J VIROL, V82, P12291, DOI 10.1128/JVI.01383-08; PERESS NS, 1993, J NEUROIMMUNOL, V48, P71, DOI 10.1016/0165-5728(93)90060-C; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rawat P, 2016, J NEUROVIROL; Roberts ES, 2004, J NEUROPATH EXP NEUR, V63, P1255, DOI 10.1093/jnen/63.12.1255; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; ROESSMANN U, 1980, BRAIN RES, V200, P13, DOI 10.1016/0006-8993(80)91090-2; Sanchez-Guajardo V, 2013, ASN NEURO, V5, P113, DOI 10.1042/AN20120066; Satoh JI, 2015, NEUROPATHOLOGY; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; SHARER LR, 1986, HUM PATHOL, V17, P271, DOI 10.1016/S0046-8177(83)80220-2; Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154; Slepko N, 1996, GLIA, V16, P241; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tsuda M, 2009, P NATL ACAD SCI USA, V106, P8032, DOI 10.1073/pnas.0810420106; TUIJNMAN WB, 1993, APMIS, V101, P319, DOI 10.1111/j.1699-0463.1993.tb00117.x; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; Watkins CC, 2015, HIV AIDS-RES PALLIAT, V7, P35, DOI 10.2147/HIV.S39665; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wires ES, 2012, J NEUROVIROL, V18, P400, DOI 10.1007/s13365-012-0103-4; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Zhou MA, 2013, BRAIN RES, V1506, P105, DOI 10.1016/j.brainres.2013.02.010	97	63	65	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1355-0284	1538-2443		J NEUROVIROL	J. Neurovirol.	FEB	2017	23	1					47	66		10.1007/s13365-016-0499-3			20	Neurosciences; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Virology	EM0MB	WOS:000395011300004	27873219	Green Published, hybrid			2022-02-06	
J	Nixdorf, I; Frank, R; Beckmann, J				Nixdorf, Insa; Frank, Raphael; Beckmann, Juergen			Comparison of Athletes' Proneness to Depressive Symptoms in Individual and Team Sports: Research on Psychological Mediators in Junior Elite Athletes	FRONTIERS IN PSYCHOLOGY			English	Article						depression; junior elite athletes; team sports; individual sports; attribution	SOCCER PLAYERS; SELF-ESTEEM; PERFECTIONISM; PREVALENCE; BURNOUT; RISK; COHESION; GENDER; HEALTH; CONCUSSION	Depression among elite athletes is a topic of increasing interest and public awareness. Currently, empirical data on elite athletes' depressive symptoms are rare. Recent results indicate sport-related mechanisms and effects on depression prevalence in elite athlete samples; specific factors associated with depression include overtraining, injury, and failure in competition. One such effect is that athletes competing in individual sports were found to be more prone to depressive symptoms than athletes competing in team sports. The present study examined this effect by testing three possible, psychological mediators based on theoretical and empirical assumptions: namely, cohesion in team or training groups; perception of perfectionistic expectations from others; and negative attribution after failure. In a cross-sectional study, 199 German junior elite athletes (M-age = 14.96; SD = 1.56) participated and completed questionnaires on perfectionism, cohesion, attribution after failure, and depressive symptoms. Mediation analysis using path analysis with bootstrapping was used for data analysis. As expected, athletes in individual sports showed higher scores in depression than athletes in team sports [t(197) = 2.05; p < 0.05; d = 0.30]. Furthermore, negative attribution after failure was associated with individual sports (beta = 0.27; p < 0.001), as well as with the dependent variable depression (beta = 0.26; p < 0.01). Mediation hypothesis was supported by a significant indirect effect (beta = 0.07; p < 0.05). Negative attribution after failure mediated the relationship between individual sports and depression scores. Neither cohesion nor perfectionism met essential criteria to serve as mediators: cohesion was not elevated in either team or individual sports, and perfectionism was positively related to team sports. The results support the assumption of previous findings on sport specific mechanisms (here the effect between individual and team sports) contributing to depressive symptoms among elite athletes. Additionally, attribution after failure seems to play an important role in this regard and could be considered in further research and practitioners in the field of sport psychology.	[Nixdorf, Insa; Frank, Raphael; Beckmann, Juergen] Tech Univ Munich, Dept Sport Psychol, D-80290 Munich, Germany		Nixdorf, I (corresponding author), Tech Univ Munich, Dept Sport Psychol, D-80290 Munich, Germany.	insa.nixdorf@tum.de	Nixdorf, Raphael/J-7289-2016	Nixdorf, Raphael/0000-0002-3512-8819; Beckmann, Juergen/0000-0001-7238-4646	German Federal Institute of Sport Science (Bundesinstitut fur Sportwissenschitft) [IIA1-071001/14-15]; German Federal Institute of Sport Science (BISp); German Research Foundation (DFG)German Research Foundation (DFG); Technical University of Munich (TUM)	The present study was funded (grant number: IIA1-071001/14-15) by the German Federal Institute of Sport Science (Bundesinstitut fur Sportwissenschitft; BISp) based on a decision of the German Bundestag. This work was supported by the German Research Foundation (DFG) and the Technical University of Munich (TUM) in the framework of the Open Access Publishing Program.	ABRAMSON LY, 1989, PSYCHOL REV, V96, P358, DOI 10.1037/0033-295X.96.2.358; Alloy LB, 2006, J ABNORM PSYCHOL, V115, P145, DOI 10.1037/0021-843X.115.1.145; Appaneal RN, 2009, J SPORT EXERCISE PSY, V31, P60, DOI 10.1123/jsep.31.1.60; Armstrong LE, 2002, SPORTS MED, V32, P185, DOI 10.2165/00007256-200232030-00003; Armstrong S, 2009, J AM COLL HEALTH, V57, P521, DOI 10.3200/JACH.57.5.521-526; Ashby JS, 2002, J COUNS DEV, V80, P197, DOI 10.1002/j.1556-6678.2002.tb00183.x; Au ACY, 2009, ADOLESCENCE, V44, P851; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; CARRON AV, 1985, J SPORT PSYCHOL, V7, P244, DOI 10.1123/jsp.7.3.244; Enns MW., 2002, PERFECTIONISM THEORY, P33, DOI DOI 10.1037/10458-002; Evans MB, 2015, SCAND J MED SCI SPOR, V25, pE139, DOI 10.1111/sms.12235; Evans MB, 2012, CAN PSYCHOL, V53, P301, DOI 10.1037/a0030202; Flett G.L., 2002, PERFECTIONISM THEORY, P5; Frank R, 2013, DEUT Z SPORTMED, V64, P320, DOI 10.5960/dzsm.2013.088; FROST RO, 1990, COGNITIVE THER RES, V14, P449, DOI 10.1007/BF01172967; Gotwals JK, 2012, CAN PSYCHOL, V53, P263, DOI 10.1037/a0030288; Gouttebarge V, 2015, OCCUP MED-OXFORD, V65, P190, DOI 10.1093/occmed/kqu202; Gulliver A, 2015, J SCI MED SPORT, V18, P255, DOI 10.1016/j.jsams.2014.04.006; Hammond T, 2013, CLIN J SPORT MED, V23, P273, DOI 10.1097/JSM.0b013e318287b870; Hanrahan S.J., 1990, AUST J SCI MED SPORT, V22, P97; Hanrahan S. J., 2008, ADV SPORT PSYCHOL, P99; Hanrahan SJ, 2009, J SCI MED SPORT, V12, P508, DOI 10.1016/j.jsams.2008.01.005; Hautzinger M., 2011, ALLGEMEINE DEPRESSIO, V2nd; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; HEWITT PL, 1991, J ABNORM PSYCHOL, V100, P98, DOI 10.1037/0021-843X.100.1.98; HEWITT PL, 1991, J PERS SOC PSYCHOL, V60, P456, DOI 10.1037/0022-3514.60.3.456; Hill AP, 2008, PSYCHOL SPORT EXERC, V9, P630, DOI 10.1016/j.psychsport.2007.09.004; Hill AP, 2013, J SPORT EXERCISE PSY, V35, P18, DOI 10.1123/jsep.35.1.18; HULL JG, 1991, J PERS SOC PSYCHOL, V61, P85, DOI 10.1037/0022-3514.61.1.85; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Jacobi F, 2004, PSYCHOL MED, V34, P597, DOI 10.1017/S0033291703001399; Jowett GE, 2013, SPORT EXERC PERFORM, V2, P48, DOI 10.1037/a0029770; Junge A., 2016, BMJ OPEN SPORT EXERC, V2, pE000087, DOI [10.1136/bmjsem-2015-000087, DOI 10.1136/BMJSEM-2015-000087]; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Madigan DJ, 2015, J SPORT EXERCISE PSY, V37, P305, DOI 10.1123/jsep.2014-0266; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Martin K. A., 1997, Journal of Sport Behavior, V20, P435; Nixdorf I, 2013, J CLIN SPORT PSYCHOL, V7, P313, DOI 10.1123/jcsp.7.4.313; Norton PJ, 2000, DEPRESS ANXIETY, V12, P193, DOI 10.1002/1520-6394(2000)12:4<193::AID-DA2>3.0.CO;2-X; Ohlert J, 2012, INT J SPORT EXERC PS, V10, P39, DOI 10.1080/1612197X.2012.645129; PUFFER JC, 1992, CLIN SPORT MED, V11, P327; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCANLAN TK, 1984, PSYCHOL F SPORT, P118; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Stoeber J., 2004, HALLESCHE BERICHTE P, V7; Stoeber J, 2006, PERS SOC PSYCHOL REV, V10, P295, DOI 10.1207/s15327957pspr1004_2; Tracy JL, 2004, PSYCHOL INQ, V15, P103, DOI 10.1207/s15327965pli1502_01; van de Pol PKC, 2015, J APPL SOC PSYCHOL, V45, P697, DOI 10.1111/jasp.12331; Widmeyer W. N., 1992, ADV SPORT PSYCHOL, P163; Wolanin A, 2016, BRIT J SPORT MED, V50, P167, DOI 10.1136/bjsports-2015-095756; Wolanin A, 2015, CURR SPORT MED REP, V14, P56, DOI 10.1249/JSR.0000000000000123; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b	53	63	65	6	40	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	JUN 17	2016	7								893	10.3389/fpsyg.2016.00893			8	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	DO7JF	WOS:000377957900002	27378988	gold, Green Published			2022-02-06	
J	Kovacs, GG; Lutz, MI; Ricken, G; Strobel, T; Hoftberger, R; Preusser, M; Regelsberger, G; Honigschnabl, S; Reiner, A; Fischer, P; Budka, H; Hainfellner, JA				Kovacs, Gabor G.; Lutz, Mirjam I.; Ricken, Gerda; Stroebel, Thomas; Hoeftberger, Romana; Preusser, Matthias; Regelsberger, Guenther; Hoenigschnabl, Selma; Reiner, Angelika; Fischer, Peter; Budka, Herbert; Hainfellner, Johannes A.			Dura mater is a potential source of A beta seeds	ACTA NEUROPATHOLOGICA			English	Article						Alzheimer disease; Amyloid-beta; Dura mater; Iatrogenic Creutzfeldt-Jakob disease; Prion; Propagon	CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; ALPHA-SYNUCLEIN PATHOLOGY; CREUTZFELDT-JAKOB-DISEASE; ALZHEIMERS-DISEASE; UNRESOLVED QUESTIONS; NEURODEGENERATIVE DISEASES; APOLIPOPROTEIN-E; TAU; PROPAGATION	Deposition of amyloid-beta (A beta) in the brain parenchyma and vessels is one of the hallmarks of Alzheimer disease (AD). Recent observations of A beta deposition in iatrogenic Creutzfeldt-Jakob disease (iCJD) after dural grafting or treatment with pituitary extracts raised concerns whether A beta is capable of transmitting disease as seen in prion diseases by the disease-associated prion protein. To address this issue, we re-sampled and re-evaluated archival material, including the grafted dura mater of two cases with iCJD (28 and 33-years-old) without mutations in the A beta PP, PSEN1 and PSEN2 genes, and carrying epsilon 3/epsilon 3 alleles of the APOE gene. In addition, we evaluated 84 dura mater samples obtained at autopsy (mean age 84.9 +/- A 0.3) in the community-based VITA study for the presence of A beta deposition. We show that the dura mater may harbor A beta deposits (13 %) in the form of cerebral amyloid angiopathy or amorphous aggregates. In both iCJD cases, the grafted dura mater had accumulated A beta. The morphology and distribution pattern of cerebral A beta deposition together with the lack of tau pathology distinguishes the A beta proteinopathy in iCJD from AD, from that seen in young individuals without cognitive decline carrying one or two APOE4 alleles, and from that related to traumatic brain injury. Our novel findings of A beta deposits in the dura mater, including the grafted dura, and the distinct cerebral A beta distribution in iCJD support the seeding properties of A beta. However, in contrast to prion diseases, our study suggests that such A beta seeding is unable to reproduce the full clinicopathological phenotype of AD.	[Kovacs, Gabor G.; Lutz, Mirjam I.; Ricken, Gerda; Stroebel, Thomas; Hoeftberger, Romana; Regelsberger, Guenther; Budka, Herbert; Hainfellner, Johannes A.] Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Preusser, Matthias] Med Univ Vienna, Dept Med 1, Vienna, Austria; [Preusser, Matthias] Med Univ Vienna, Ctr Comprehens Canc, CNS Unit, Vienna, Austria; [Hoenigschnabl, Selma; Reiner, Angelika] Danube Hosp Vienna, Inst Pathol, Vienna, Austria; [Fischer, Peter] Danube Hosp, Med Res Soc Vienna, Dept Psychiat, DC, Vienna, Austria; [Budka, Herbert] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland		Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511; Preusser, Matthias/0000-0003-3541-2315; Regelsberger, Gunther/0000-0002-3233-1491	Medical University of Vienna; Ludwig Boltzmann Institute of Ageing Research; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [278486]; Federal Ministry of Health, Austria	Open access funding provided by Medical University of Vienna. The Vienna Trans-Danube Ageing (VITA) study was supported and organized by the Ludwig Boltzmann Institute of Ageing Research. The neuropathology study was supported by the European Commission's 7th Framework Programme under GA No 278486, "DEVELAGE". The Austrian Reference Centre for Human Prion Diseases is supported by the Federal Ministry of Health, Austria.	Aho L, 2010, J ALZHEIMERS DIS, V20, P1015, DOI 10.3233/JAD-2010-091681; Alafuzoff I, 2009, ACTA NEUROPATHOL, V117, P309, DOI 10.1007/s00401-009-0485-4; ANDRES KH, 1967, Z ZELLFORSCH MIK ANA, V79, P272, DOI 10.1007/BF00369291; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x; Bohl J, 1989, Prog Clin Biol Res, V317, P1007; Braak H, 2015, BRAIN, V138, P2814, DOI 10.1093/brain/awv236; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; Carare RO, 2013, NEUROPATH APPL NEURO, V39, P593, DOI 10.1111/nan.12042; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cupidi C, 2010, J ALZHEIMERS DIS, V19, P57, DOI 10.3233/JAD-2010-1205; DELAERE P, 1991, ACTA NEUROPATHOL, V81, P328, DOI 10.1007/BF00305876; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Eisele YS, 2016, ACTA NEUROPATHOL, V131, P5, DOI 10.1007/s00401-015-1516-y; Fischer P, 2002, J NEURAL TRANSM-SUPP, P105; FOLDI M, 1968, ANGIOLOGICA, V5, P250; Frontzek K, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14287; Ghoshal N, 2009, ARCH NEUROL-CHICAGO, V66, P1240, DOI 10.1001/archneurol.2009.224; Grinberg LT, 2009, NEUROPATH APPL NEURO, V35, P406, DOI [10.1111/j.1365-2990.2008.00997.x, 10.1111/j.1365-2990.2009.00997.x]; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Irwin DJ, 2013, JAMA NEUROL, V70, P462, DOI 10.1001/jamaneurol.2013.1933; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Keable A, 2016, BBA-MOL BASIS DIS, V1862, P1037, DOI 10.1016/j.bbadis.2015.08.024; KIDA S, 1993, NEUROPATH APPL NEURO, V19, P480, DOI 10.1111/j.1365-2990.1993.tb00476.x; Kovacs G.G., 2013, PRIONS DIS, P103; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2015, NEUROBIOL AGING, V36, P3100, DOI 10.1016/j.neurobiolaging.2015.07.018; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Kovacs GG, 2011, ACTA NEUROPATHOL, V121, P39, DOI 10.1007/s00401-010-0713-y; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lewis J, 2016, ACTA NEUROPATHOL, V131, P27, DOI 10.1007/s00401-015-1507-z; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Metsaars WP, 2003, NEUROBIOL AGING, V24, P563, DOI 10.1016/S0197-4580(02)00134-3; Murakami T, 2014, VET PATHOL, V51, P363, DOI 10.1177/0300985813511128; Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8; Pletnikova O, 2015, COGN BEHAV NEUROL, V28, P144, DOI 10.1097/WNN.0000000000000071; Preusser M, 2006, J NEUROL NEUROSUR PS, V77, P413, DOI 10.1136/jnnp.2005.070805; Reiniger L, 2011, ACTA NEUROPATHOL, V121, P5, DOI 10.1007/s00401-010-0691-0; ROLAND J, 1987, SURG RADIOL ANAT, V9, P43, DOI 10.1007/BF02116853; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Stratmann K, 2016, BRAIN PATHOL, V26, P371, DOI 10.1111/bpa.12289; Thal DR, 2008, ACTA NEUROPATHOL, V115, P599, DOI 10.1007/s00401-008-0366-2; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Thal DR, 2002, J NEUROPATH EXP NEUR, V61, P282, DOI 10.1093/jnen/61.3.282; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uchihara T, 2016, ACTA NEUROPATHOL, V131, P1, DOI 10.1007/s00401-015-1517-x; Uchihara T, 2016, ACTA NEUROPATHOL, V131, P49, DOI 10.1007/s00401-015-1485-1; Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x	57	63	63	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2016	131	6					911	923		10.1007/s00401-016-1565-x			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DM3WM	WOS:000376277400009	27016065	Green Published, hybrid			2022-02-06	
J	Barlow, KM				Barlow, Karen M.			Postconcussion Syndrome: A Review	JOURNAL OF CHILD NEUROLOGY			English	Article						mild traumatic brain injury; children; pathophysiology; outcome; management	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; GOOD-OLD-DAYS; TRANSCRANIAL MAGNETIC STIMULATION; SLEEP-WAKE DISTURBANCES; TENSOR IMAGING FINDINGS; QUALITY-OF-LIFE; SEX-DIFFERENCES	Postconcussion syndrome is a symptom complex with a wide range of somatic, cognitive, sleep, and affective features, and is the most common consequence of traumatic brain injury. Between 14% and 29% of children with mild traumatic brain injury will continue to have postconcussion symptoms at 3 months, but the pathophysiological mechanisms driving this is poorly understood. The relative contribution of injury factors to postconcussion syndrome decreases over time and, instead, premorbid factors become important predictors of symptom persistence by 3 to 6 months postinjury. The differential diagnoses include headache disorder, cervical injury, anxiety, depression, somatization, vestibular dysfunction, and visual dysfunction. The long-term outcome for most children is good, although there is significant morbidity in the short term. Management strategies target problematic symptoms such as headaches, sleep and mood disturbances, and cognitive complaints.	[Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Pediat & Clin Neurosci, Calgary, AB, Canada		Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Hosp, Dept Pediat & Clin Neurosci, 2888 Shaganappi Trail NW, Calgary, AB, Canada.	karen.barlow@albertahealthservices.ca	Meijer, Anna/K-5118-2016; Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507	Alberta Children's Hospital Foundation; Clinical Neurotrauma Grant Canadian Institutes of Health Research [293375]; Faculty of Medicine, University of Calgary (Internal Award)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Alberta Children's Hospital Foundation Clinical Neurotrauma Grant Canadian Institutes of Health Research (Grant number 293375) Faculty of Medicine, University of Calgary (Internal Award).	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050150209156; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Daviss WB, 2006, J CHILD PSYCHOL PSYC, V47, P927, DOI 10.1111/j.1469-7610.2006.01646.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Manber R, 2008, SLEEP, V31, P489, DOI 10.1093/sleep/31.4.489; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Miano S, 2008, NEUROL SCI, V29, P285, DOI 10.1007/s10072-008-0983-5; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Owens JA, 2000, SLEEP, V23, P1043; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Pickering A, 2012, EMERG MED J, V29, P451, DOI 10.1136/emj.2010.094755; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Senior HEJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-89; Shahim P, 2014, JAMA NEUROL; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Simon R, 2005, J CLIN ONCOL, V23, P7332, DOI 10.1200/JCO.2005.02.8712; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wolfson AR, 2003, SLEEP, V26, P213, DOI 10.1093/sleep/26.2.213; WOOD A, 1995, J CHILD PSYCHOL PSYC, V36, P327, DOI 10.1111/j.1469-7610.1995.tb01828.x; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yaeger K, 2014, AM J ROENTGENOL, V202, P614, DOI 10.2214/AJR.13.11091; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	118	63	64	2	35	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JAN	2016	31	1			SI		57	67		10.1177/0883073814543305			11	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	CY8HW	WOS:000366650400006	25330797				2022-02-06	
J	Rabinowitz, AR; Li, XQ; McCauley, SR; Wilde, EA; Barnes, A; Hanten, G; Mendez, D; McCarthy, JJ; Levin, HS				Rabinowitz, Amanda R.; Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Mendez, Donna; McCarthy, James J.; Levin, Harvey S.			Prevalence and Predictors of Poor Recovery from Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; human studies; recovery; traumatic brain injury	POST-CONCUSSION SYMPTOMS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; COGNITIVE RESERVE; OLDER-ADULTS; PRACTICAL SCALE; OUTCOMES; DISORDER; SEX	Although most patients with mild traumatic brain injury (mTBI) recover within 3 months, a subgroup of patients experience persistent symptoms. Yet, the prevalence and predictors of persistent dysfunction in patients with mTBI remain poorly understood. In a longitudinal study, we evaluated predictors of symptomatic and cognitive dysfunction in adolescents and young adults with mTBI, compared with two control groupspatients with orthopedic injuries and healthy uninjured individuals. Outcomes were assessed at 3 months post-injury. Poor symptomatic outcome was defined as exhibiting a symptom score higher than 90% of the orthopedic control (OC) group, and poor cognitive outcome was defined as exhibiting cognitive performance poorer than 90% of the OC group. At 3 months post-injury, more than half of the patients with mTBI (52%) exhibited persistently elevated symptoms, and more than a third (36.4%) exhibited poor cognitive outcome. The rate of high symptom report in mTBI was markedly greater than that of typically developing (13%) and OC (17%) groups; the proportion of those with poor cognitive performance in the mTBI group exceeded that of typically developing controls (15.8%), but was similar to that of the OC group (34.9%). Older age at injury, female sex, and acute symptom report were predictors of poor symptomatic outcome at 3 months. Socioeconomic status was the only significant predictor of poor cognitive outcome at 3 months.	[Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Mendez, Donna; McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA		Rabinowitz, AR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Goddard Labs 306, 3710 Hamilton Walk, Philadelphia, PA 19104 USA.	rabinowitz.a@gmail.com	Meijer, Anna/K-5118-2016		P01 [NS056202]; Department of Veterans AffairsUS Department of Veterans Affairs [B6812C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This project was supported by P01 Grant NS056202 (PI: Douglas Smith, M.D.). H.L., S.M., and E.W. were also supported by the Department of Veterans Affairs Grant B6812C "Neurorehabilitation: Neurons to Networks (N:N2N) Center of Excellence."	Arnold C, 2014, LANCET NEUROL, V13, P136, DOI 10.1016/S1474-4422(13)70287-4; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUAL MEMORY; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Derogatis L.R., 1993, BSI BRIEF SYMPTOM IN; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, TRAUMATIC BRAIN INJU, P1; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Hanten G, 2013, J NEUROTRAUM, V30, P618, DOI 10.1089/neu.2012.2392; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith A., 1982, SYMBOL DIGIT MODALIT; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	61	63	63	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1488	1496		10.1089/neu.2014.3555			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500007	25970233	Green Published			2022-02-06	
J	Strain, JF; Womack, KB; Didehbani, N; Spence, JS; Conover, H; Hart, J; Kraut, MA; Cullum, CM				Strain, Jeremy F.; Womack, Kyle B.; Didehbani, Nyaz; Spence, Jeffrey S.; Conover, Heather; Hart, John, Jr.; Kraut, Michael A.; Cullum, C. Munro			Imaging Correlates of Memory and Concussion History in Retired National Football League Athletes	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; HIPPOCAMPAL HEAD ATROPHY; ALZHEIMERS-DISEASE; DEPRESSIVE SYMPTOMS; VOLUME; IMPACT; SEGMENTATION; ASSOCIATION; DYSFUNCTION	IMPORTANCE To our knowledge, this is the first study to show an association between concussion, cognition, and anatomical structural brain changes across the age spectrum in former National Football League athletes. OBJECTIVE To assess the relationship of hippocampal volume, memory performance, and the influence of concussion history in retired National Football League athletes with and without mild cognitive impairment (MCI). DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study assessed differences between groups, mean hippocampal volumes, and memory performance by computing age quintiles based on group-specific linear regression models corrected for multiple comparisons for both athletes and control participants. The study was conducted starting in November 2010 and is ongoing at a research center in the northern region of Texas. This current analysis was conducted from October 9, 2013, to August 21, 2014. Participants included 28 retired National Football League athletes, 8 of whom had MCI and a history of concussion, 21 cognitively healthy control participants, and 6 control participants with MCI without concussion. MAIN OUTCOMES AND MEASURES Hippocampal volume, age, California Verbal Learning Test scores, and the number of grade 3 (G3) concussions. In addition, the number of games played was examined as an objective variable pertaining to football history. RESULTS The mean (SD) age was 58.1 (13) years for the 28 former athletes and 59.0 (12) years for the 27 control participants. Retired athletes with concussion history but without cognitive impairment had normal but significantly lower California Verbal Learning Test scores compared with control participants (mean [SD], 52.5 [8] vs 60.24 [7]; P = .002); those with a concussion history and MCI performed worse (mean [SD], 37 [8.62]) compared with both control participants (P < .001) and athletes without memory impairment (P < .001). Among the athletes, 17 had a G3 concussion and 11 did not. Older retired athletes with at least 1 G3 concussion had significantly smaller bilateral hippocampal volumes compared with control participants at the 40th age percentile (left, P = .04; right, P = .03), 60th percentile (left, P = .009; right, P = .01), and 80th percentile (left, P = .001; right, P = .002) and a smaller right hippocampal volume compared with athletes without a G3 concussion at the 40th percentile (P = .03), 60th percentile (P = .02), and 80th percentile (P = .02). Athletes with a history of G3 concussion were more likely to have MCI (7 of 7) compared with retired athletes without a history of G3 concussion (1 of 5) older than 63 years (P = .01). In addition, the left hippocampal volume in retired athletes with MCI and concussion was significantly smaller compared with control participants with MCI (P = .03). CONCLUSION AND RELEVANCE Prior concussion that results in loss of consciousness is a risk factor for increased hippocampal atrophy and the development of MCI. In individuals with MCI, hippocampal volume loss appears greater among those with a history of concussion.	[Strain, Jeremy F.; Didehbani, Nyaz; Spence, Jeffrey S.; Conover, Heather; Hart, John, Jr.; Kraut, Michael A.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA; [Womack, Kyle B.; Hart, John, Jr.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Womack, Kyle B.; Hart, John, Jr.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Kraut, Michael A.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA		Cullum, CM (corresponding author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	munro.cullum@utsouthwestern.edu	Womack, Kyle/O-5422-2018; Cullum, C. Munro/AAC-2496-2019	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Didehbani, Nyaz/0000-0001-6121-5759	BrainHealth Institute for Athletes at the Center for BrainHealth; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30Ag12300-19]; University of Texas at Dallas; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG012300] Funding Source: NIH RePORTER	This project was supported by the BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at The University of Texas at Dallas, and grant P30Ag12300-19 from the National Institute on Aging.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blasko I, 2008, NEUROBIOL AGING, V29, P1, DOI 10.1016/j.neurobiolaging.2006.09.002; Buffalo EA, 1998, HIPPOCAMPUS, V8, P330, DOI 10.1002/(SICI)1098-1063(1998)8:4<330::AID-HIPO3>3.0.CO;2-L; Chen KHM, 2010, BRAIN COGNITION, V72, P400, DOI 10.1016/j.bandc.2009.11.007; Chetelat G, 2003, BRAIN, V126, P1955, DOI 10.1093/brain/awg196; Convit A, 1997, NEUROBIOL AGING, V18, P131, DOI 10.1016/S0197-4580(97)00001-8; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Devanand DP, 2007, NEUROLOGY, V68, P828, DOI 10.1212/01.wnl.0000256697.20968.d7; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Du AT, 2001, J NEUROL NEUROSUR PS, V71, P441, DOI 10.1136/jnnp.71.4.441; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Ibarretxe-Bilbao N, 2008, J NEUROL, V255, P1324, DOI 10.1007/s00415-008-0885-8; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaplan E, 1983, BOSTON NAMING TEST; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kraut MA, 2002, J COGNITIVE NEUROSCI, V14, P24, DOI 10.1162/089892902317205294; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Loring D W, 1990, Arch Clin Neuropsychol, V5, P1, DOI 10.1016/0887-6177(90)90002-7; Lucarelli RT, 2013, AM J NEURORADIOL, V34, P752, DOI 10.3174/ajnr.A3308; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2014, J NEUROL NEUROPHYSIO, V5, P1; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Vanderploeg RD, 2014, J CLIN EXP NEUROPSYC, V36, P58, DOI 10.1080/13803395.2013.864600; Vythilingam M, 2005, PSYCHIAT RES-NEUROIM, V139, P89, DOI 10.1016/j.pscychresns.2005.04.003; Whitwell JL, 2001, AM J NEURORADIOL, V22, P1483; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	49	63	63	1	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUL	2015	72	7					773	780		10.1001/jamaneurol.2015.0206			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM8EP	WOS:000357931000010	25985094	Green Accepted, Bronze			2022-02-06	
J	Mangat, HS; Chiu, YL; Gerber, LM; Alimi, M; Ghajar, J; Hartl, R				Mangat, Halinder S.; Chiu, Ya-Lin; Gerber, Linda M.; Alimi, Marjan; Ghajar, Jamshid; Haertl, Roger			Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypertonic saline; mannitol; intracranial pressure; ICP burden	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; BLOOD-FLOW; SODIUM-CHLORIDE; MANNITOL; HYPERTENSION; ICP; HYPERNATREMIA; EXPERIENCE; REDUCTION	OBJECT Increased intracranial pressure (ICP) in patients with traumatic brain injury (TBI) is associated with a higher mortality rate and poor outcome. Mannitol and hypertonic saline (HIS) have both been used to treat high ICP, but it is unclear which one is more effective. Here, the authors compare the effect of mannitol versus HTS on lowering the cumulative and daily ICP burdens after severe TBI. METHODS The Brain Trauma Foundation TBI-trac New York State database was used for this retrospective study. Patients with severe TBI and intracranial hypertension who received only 1 type of hyperosmotic agent, mannitol or HIS, were included. Patients in the 2 groups were individually matched for Glasgow Coma Scale score (GCS), pupillary reactivity, craniotomy, occurrence of hypotension on Day 1, and the day of ICP monitor insertion. Patients with missing or erroneous data were excluded. Cumulative and daily ICP burdens were used as primary outcome measures. The cumulative ICP burden was defined as the total number of days with an ICP of > 25 mm Hg, expressed as a percentage of the total number of days of ICP monitoring. The daily ICP burden was calculated as the mean daily duration of an ICP of > 25 mm Hg, expressed as the number of hours per day. The numbers of intensive care unit (ICU) days, numbers of days with ICP monitoring, and 2-week mortality rates were also compared between the groups. A 2-sample t-test or chi-square test was used to compare independent samples. The Wilcoxon signed-rank or Cochran-Mantel-Haenszel test was used for comparing matched samples. RESULTS A total of 35 patients who received only HTS and 477 who received only mannitol after severe TBI were identified. Eight patients in the HTS group were excluded because of erroneous or missing data, and 2 other patients did not have matches in the mannitol group. The remaining 25 patients were matched 1:1. Twenty-four patients received 3% HTS, and 1 received 23.4% HTS as bolus therapy. All 25 patients in the mannitol group received 20% mannitol. The mean cumulative ICP burden (15.52% [HIS] vs 36.5% [mannitol]; p = 0.003) and the mean (SD) daily ICP burden (0.3 +/- 0.6 hours/day [HIS] vs 1.3 +/- 1.3 hours/day [mannitol]; p = 0.001) were significantly lower in the HIS group. The mean ( SD) number of ICU days was significantly lower in the HIS group than in the mannitol group (8.5 +/- 2.1 vs 9.8 +/- 0.6, respectively; p = 0.004), whereas there was no difference in the numbers of days of ICP monitoring (p = 0.09). There were no significant differences between the cumulative median doses of HIS and mannitol (p = 0.19). The 2-week mortality rate was lower in the HIS group, but the difference was not statistically significant (p = 0.56). CONCLUSIONS HIS given as bolus therapy was more effective than mannitol in lowering the cumulative and daily ICP burdens after severe TBI. Patients in the HIS group had significantly lower number of ICU days. The 2-week mortality rates were not statistically different between the 2 groups.	[Mangat, Halinder S.] Weill Cornell Brain & Spine Ctr, Dept Neurol, New York, NY USA; [Mangat, Halinder S.; Alimi, Marjan; Ghajar, Jamshid; Haertl, Roger] Weill Cornell Brain & Spine Ctr, Dept Neurol Surg, New York, NY USA; [Chiu, Ya-Lin; Gerber, Linda M.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA; [Gerber, Linda M.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Mangat, Halinder S.; Alimi, Marjan; Haertl, Roger] NewYork Presbyterian Hosp, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA		Mangat, HS (corresponding author), Weill Cornell Med Coll, Dept Neurol, Div Neurocrit Care, 525 E 68 St,F-610, New York, NY 10065 USA.	hsm9001@med.cornell.edu	Mangat, HALINDER/AAN-9153-2020	Mangat, HALINDER/0000-0003-3426-2001	New York State Department of Health, the Brain Trauma Foundation; NewYork-Presbyterian Hospital TBI fund; Clinical Translational Science Center, National Center for Advancing Translational Sciences [UL1-TR000457-06]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER	We thank the New York State Department of Health, the Brain Trauma Foundation, and the NewYork-Presbyterian Hospital TBI fund for their financial support. We gratefully acknowledge additional support from Clinical Translational Science Center, National Center for Advancing Translational Sciences, grant no. UL1-TR000457-06.	Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons AANS/CNS Joint Section on Neurotrauma and Critical Care, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Cohen J., 2013, STAT POWER ANAL BEHA; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; FLURY BK, 1986, AM STAT, V40, P249, DOI 10.2307/2684560; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hartl R, 1997, ACT NEUR S, V70, P40; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jones PA, 2005, ACT NEUR S, V95, P29; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; ROSENBAUM PR, 1989, J AM STAT ASSOC, V84, P1024, DOI 10.2307/2290079; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wainwright Mark S, 2012, Acta Neurochir Suppl, V114, P67, DOI 10.1007/978-3-7091-0956-4_12; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; WILLERSON JT, 1975, CIRCULATION, V51, P1095, DOI 10.1161/01.CIR.51.6.1095; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011	56	63	69	1	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2015	122	1					202	210		10.3171/2014.10.JNS132545			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AX5DQ	WOS:000346947600029	25380107	Bronze			2022-02-06	
J	Olenick, M; Flowers, M; Diaz, VJ				Olenick, Maria; Flowers, Monica; Diaz, Valerie J.			US veterans and their unique issues: enhancing health care professional awareness	ADVANCES IN MEDICAL EDUCATION AND PRACTICE			English	Article						veterans; veteran health care; veteran health issues; veteran content		United States veterans are a multifaceted population with a distinct culture that includes, but is not limited to, values, customs, ethos, selfless duty, codes of conduct, implicit patterns of communication, and obedience to command. Veterans experience mental health disorders, substance use disorders, post-traumatic stress, and traumatic brain injury at disproportionate rates compared to their civilian counterparts. Eighteen to 22 American veterans commit suicide daily and young veterans aged 18-44 are most at risk. Health care professionals must be aware of patients' military history and be able to recognize suicide-risk factors, regardless of age. Advancement in medical technology has allowed servicemen to survive their injuries but, for many, at the cost of a traumatic limb amputation and associated mental scarring. Health care professionals must be able to address physical safety concerns, as well as, emotional health of veterans. Approximately 49,933 American veterans are homeless and face the same difficulties as non-veterans in addition to service-related matters. Separation from military service and issues related to complex multiple deployments are among specifically identified veteran issues. Successful veteran reintegration into civilian life rests upon providing veterans with training that builds on their military knowledge and skill, employment post-separation from service, homelessness prevention, and mental health programs that promote civilian transition. Preparing health care providers to meet the complex needs of a vast veteran population can be facilitated by implementing veteran content into curricula that includes veteran patient simulations and case studies, and utilizes veteran clinical faculty.	[Olenick, Maria; Flowers, Monica; Diaz, Valerie J.] Florida Int Univ, Nicole Wertheim Coll Nursing & Hlth Sci, 11200 8th St,AHC3-329, Miami, FL 33199 USA; [Diaz, Valerie J.] US Navy, Nurse Corps, Operat Hlth Support Unit Jacksonville, Jacksonville, FL USA		Olenick, M (corresponding author), Florida Int Univ, Nicole Wertheim Coll Nursing & Hlth Sci, 11200 8th St,AHC3-329, Miami, FL 33199 USA.	molenick@fiu.edu	Olenick, maria/AAM-9991-2020		Division of Nursing and Public Health, Bureau of Health Workforce, Health Resources and Services Administration; Department of Health and Human Services, Veterans' Bachelor of Science Degree in Nursing Program (VBSN) [UF1HP26980]	This project was supported by funds from the Division of Nursing and Public Health, Bureau of Health Workforce, Health Resources and Services Administration. Department of Health and Human Services Grant UF1HP26980, Veterans' Bachelor of Science Degree in Nursing Program (VBSN).	American Academy of Colleges of Nursing (AACN) [homepage on the Internet], JOIN FORC ENH VET CA; [Anonymous], 2005, THERAPY PRACTICE; APA American Psychiatric Association, 2013, POSTTR STRESS DIS; Federation of American Scientists, 2015, GUID MIL CAS STAT OP; Fontana A, 2008, J NERV MENT DIS, V196, P513, DOI 10.1097/NMD.0b013e31817cf6e6; Institute of Medicine, 2014, VET AG OR UPD 2012; Johnson BS, 2013, AM J NURS, V113, P24, DOI 10.1097/01.NAJ.0000431913.50226.83; Kemp J, 2012, SUICIDE DATA REPORT; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; National Alliance on Mental Illness (NAMI), 2009, DEPR VET FACT SHEET; National Coalition for Homeless Veterans (NCHV), FAQ HOM VET; United States Department of Veterans Affairs, SEL VET HLTH ADM CHA; US Department of Veteran Affairs, UND TRAUM BRAIN INJ; US Department of Veteran Affairs, MIL EXP; US Department of Veterans Affairs, VA HLTH CAR UT REC V; Veterans Health Administration, 2008, COLL CAR DEPR PRIM C	16	63	63	1	9	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-7258			ADV MED EDUC PRACT	Adv. Med. Educ. Pract.		2015	6						635	639		10.2147/AMEP.S89479			5	Education, Scientific Disciplines	Emerging Sources Citation Index (ESCI)	Education & Educational Research	DA6BB	WOS:000367885600003	26664252	Green Published, Green Submitted, gold			2022-02-06	
J	Huang, L; Wong, SN; Snyder, EY; Hamblin, MH; Lee, JP				Huang, Lei; Wong, Sunnie; Snyder, Evan Y.; Hamblin, Milton H.; Lee, Jean-Pyo			Human neural stem cells rapidly ameliorate symptomatic inflammation in early-stage ischemic-reperfusion cerebral injury	STEM CELL RESEARCH & THERAPY			English	Article							BLOOD-BRAIN-BARRIER; MATRIX-METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; ARTERY OCCLUSION; TRAUMATIC BRAIN; STROKE; RAT; PROTEIN; MICE; MATRIX-METALLOPROTEINASE-9	Introduction: Clinically, a good deal of injury from stroke results from ischemic-reperfusion. There is a loss of cerebral parenchyma and its associated cells, disruption of neuronal connections, compromise of the blood-brain barrier, and inflammation. We tested whether exogenously engrafted human neural stem cells could migrate rapidly and extensively to damaged regions, following transplantation into a neurogenic site where migration cues are already underway during stroke onset, then counteract a number of these pathological processes. Methods: One day post-injury, we injected human neural stem cells (hNSCs) into the ipsilesional hippocampus of a mouse model of stroke with middle cerebral artery occlusion to induce focal ischemia followed by reperfusion (MCAO/R). The time frame for hNSC transplantation corresponded to upregulation of endogenous proinflammatory cytokines. We examined the effect of hNSC transplantation on pathological processes and behavioral dysfunction 48 hours post-injury. Results: Twenty-four hours after transplantation, engrafted hNSCs had migrated extensively to the lesion, and infarct volume was reduced relative to MCAO/R controls. The behavioral deficits seen in MCAO/R controls were also significantly improved. Given this rapid response, we hypothesized that the mechanisms underlying therapeutic activity were anti-inflammatory rather than due to cell replacement. In support of this idea, in hNSC-transplanted mice we observed reduced microglial activation, decreased expression of proinflammatory factors (tumor necrosis factor-alpha, interleukin (IL)-6, IL-1 beta, monocyte chemotactic protein-1, macrophage inflammatory protein-1 alpha) and adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1), and amelioration of blood-brain barrier damage. Conclusions: While long-term effects of engrafted hNSCs on the amelioration of ischemic stroke-induced behavioral dysfunction in a rodent model have been reported, our study is the first to show rapid, beneficial impacts on behavioral function (within 24 hours) upon early delivery of hNSCs into the hippocampus.	[Huang, Lei; Wong, Sunnie; Hamblin, Milton H.; Lee, Jean-Pyo] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA; [Snyder, Evan Y.; Lee, Jean-Pyo] Ctr Neurosci Aging & Stem Cells, Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA		Lee, JP (corresponding author), Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave,SL-99, New Orleans, LA 70112 USA.	jeanpyol@tulane.edu			Tulane Center for Stem Cell Research and Regenerative Medicine	We thank Dr. Gary Rosenberg, University of New Mexico, for his helpful scientific discussions and Courtney Louvre and Justin Chen, Tulane University, for technical assistance. This work was supported by startup funds from the Tulane Center for Stem Cell Research and Regenerative Medicine.	Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Clark WM, 1997, NEUROL RES, V19, P641; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; Emanueli C, 2003, BRIT J PHARMACOL, V140, P614, DOI 10.1038/sj.bjp.0705458; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hu Xueyou, 2010, J Vis Exp, DOI 10.3791/2445; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jeyakumar M, 2009, STEM CELLS, V27, P2362, DOI 10.1002/stem.163; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishiro K, 2012, NEUROSCIENCE, V205, P39, DOI 10.1016/j.neuroscience.2011.12.042; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; O'Neill M J, 2001, Curr Protoc Neurosci, VChapter 9, DOI [10.1002/0471142301.ns0905s12, 10.1002/0471142301.ns0906s12]; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Quinn LP, 2007, J NEUROSCI METH, V164, P43, DOI 10.1016/j.jneumeth.2007.03.021; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tureyen K, 2004, J NEUROSCI METH, V139, P203, DOI 10.1016/j.jneumeth.2004.04.029; Virley D, 2000, J CEREBR BLOOD F MET, V20, P563, DOI 10.1097/00004647-200003000-00015; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212	44	63	67	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1757-6512		STEM CELL RES THER	Stem Cell Res. Ther.	NOV 23	2014	5								129	10.1186/scrt519			16	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	AY2OB	WOS:000347428300001	25418536	gold, Green Published			2022-02-06	
J	Proto, DA; Pastorek, NJ; Miller, BI; Romesser, JM; Sim, AH; Linck, JF				Proto, Daniel A.; Pastorek, Nicholas J.; Miller, Brian I.; Romesser, Jennifer M.; Sim, Anita H.; Linck, John F.			The Dangers of Failing One or More Performance Validity Tests in Individuals Claiming Mild Traumatic Brain Injury-Related Postconcussive Symptoms	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild TBI; Effort; Performance validity; Neuropsychological assessment	RESPONSE BIAS SCALE; MALINGERING DETECTION; TEST FAILURE; VALIDATION; RECOGNITION; INDICATORS; EDUCATION; BATTERY; ISSUES; NORMS	Evaluating performance validity is important in any neuropsychological assessment, and prior research recommends a threshold for invalid performance of two or more performance validity test (PVT) failures. However, extant findings also indicate that failing a single PVT is associated with significant changes in neuropsychological performance. The current study sought to determine if there is an appreciable difference in neuropsychological testing results between individuals failing different numbers of PVTs. In a sample of veterans with reported histories of mild traumatic brain injury (mTBI; N = 178), analyses revealed that individuals failing only one PVT performed significantly worse than individuals failing no PVTs on measures of verbal learning and memory, processing speed, and cognitive flexibility. Additionally, individuals failing one versus two PVTs significantly differed only on delayed free recall scores. The current findings suggest that failure of even one PVT should elicit consideration of performance invalidity, particularly in individuals with histories of mTBI.	[Proto, Daniel A.; Miller, Brian I.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Proto, Daniel A.; Miller, Brian I.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Romesser, Jennifer M.] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA; [Sim, Anita H.] Minneapolis Vet Affairs Hlth Care Syst, Dept Phys Med & Rehabil, Minneapolis, MN USA; [Linck, John F.] Oklahoma City Vet Affairs Med Ctr, Oklahoma City, OK USA		Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.	nicholas.pastorek@va.gov		Pastorek, Nicholas/0000-0002-9290-380X	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks [B6812C]; Minnesota Veterans Medical Research & Education Foundation	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI-Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks; Minnesota Veterans Medical Research & Education Foundation. No pharmaceutical or corporate funding was used in the preparation of this manuscript or collection of data.	Allen L., 1997, CARB 97 MANUAL COMPU; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 2013, STAT POWER ANAL BEHA; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Gouvier WD, 1999, STUD NEUROPSYCHOL DE, P27; Gouvier WD, 1998, CRIT ISS NE, P55; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K. W., 2007, ASSESSMENT MALINGERE; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2014, ARCH CLIN NEUROPSYCH, V29, P224, DOI 10.1093/arclin/acu001; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TEST MEMORY MALINGER; *US GOV ACC OFF, 2008, GAO08276; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Webb JW, 2012, CLIN NEUROPSYCHOL, V26, P1377, DOI 10.1080/13854046.2012.728248; Wechsler, 2008, WAIS 4 ADM SCORING M; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Young JC, 2011, ARCH CLIN NEUROPSYCH, V26, P194, DOI 10.1093/arclin/acr015	57	63	63	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2014	29	7					614	624		10.1093/arclin/acu044			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AU9DA	WOS:000345890600002	25252598	Green Published, hybrid, Green Submitted			2022-02-06	
J	Assis, LC; Straliotto, MR; Engel, D; Hort, MA; Dutra, RC; De Bem, AF				Assis, L. C.; Straliotto, M. R.; Engel, D.; Hort, M. A.; Dutra, R. C.; De Bem, A. F.			beta-CARYOPHYLLENE PROTECTS THE C6 GLIOMA CELLS AGAINST GLUTAMATE-INDUCED EXCITOTOXICITY THROUGH THE NRF2 PATHWAY	NEUROSCIENCE			English	Article						beta-caryophyllene; C6 cell line; glutamate; Nrf2 pathway; CB2R	MITOCHONDRIAL PERMEABILITY TRANSITION; AMYOTROPHIC-LATERAL-SCLEROSIS; DEXTRAN SULFATE SODIUM; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; IN-VITRO; NEUROLOGICAL DISEASES; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; INDUCED APOPTOSIS	beta-Caryophyllene (BCP), a natural bicyclic sesquiterpene present in several essential oils, displays analgesic and anti-inflammatory properties in vitro and in vivo. Astrocytes are a major class of glial cells that regulate extracellular ion balance, repair and scarring processes in the CNS following neuroinflammatory conditions and traumatic injuries. This study sought to determine the protective effect of BCP against glutamate (Glu)-induced cytotoxicity in the C6 glioma cell line on neurochemical parameters as well as their biochemical mechanism. Glu increases intracellular reactive oxygen species (ROS) production and induces mitochondrial dysfunction as well as decreasing antioxidant defenses such as glutathione (GSH) and glutathione peroxidase activity. BCP prevented C6 cells from Glu-induced cytotoxicity by modulating the cellular antioxidant response, mainly by inhibiting ROS production and reestablishing the mitochondrial membrane potential (Delta Psi(m)). Moreover, BCP per se induced the nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) which was reflected by improvement in the cellular GSH antioxidant system. Taken together, our results suggest that cytoprotective effects of BCP were mediated by the amelioration of cellular antioxidant responses via Nrf2 activation, which is, in part, dependent on cannabinoid receptor type 2 (CB2R) activation. This functional nonpsychoactive CB2R ligand, could represent an important molecule for protection of glial cells against oxidative stress induced by glutamate. (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Assis, L. C.; Straliotto, M. R.; Engel, D.; Hort, M. A.; De Bem, A. F.] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Bioquim, Florianopolis, SC, Brazil; [Dutra, R. C.] Univ Fed Santa Catarina, Lab Autoimunidade & Imunofarmacol, BR-88900000 Ararangua, SC, Brazil; [Dutra, R. C.] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Farmacol, BR-88900000 Ararangua, SC, Brazil		Dutra, RC (corresponding author), Univ Fed Santa Catarina, Lab Autoimunidade & Imunofarmacol, Campus Ararangua, BR-88900000 Ararangua, SC, Brazil.	rafaelcdutra@gmail.com	Dutra, Rafael C/F-8452-2012; Engel, Daiane F./AAN-9044-2020; de, Andreza/AAA-1523-2019; Hort, Mariana/T-7377-2019	Dutra, Rafael C/0000-0002-6938-2161; Engel, Daiane F./0000-0002-1950-196X; de, Andreza/0000-0003-1090-5244; Hort, Mariana/0000-0001-5877-3506	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) in BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) in BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC)/PRONEX in Brazil; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This work was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and the Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC)/PRONEX, all in Brazil. LCA and MRS are PhD students in neuroscience and biochemistry, respectively, receiving grants from CAPES. AFB is supported by a research fellowship from CNPq.	Akerboom T P, 1981, Methods Enzymol, V77, P373; Alonso-Alconada D, 2012, NEUROCHEM RES, V37, P161, DOI 10.1007/s11064-011-0594-z; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Astani A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep187; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Batkai S, 2007, FASEB J, V21, P1788, DOI 10.1096/fj.06-7451com; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bento AF, 2011, AM J PATHOL, V178, P1153, DOI 10.1016/j.ajpath.2010.11.052; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhaskaran MD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010683; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Chen J, 2005, NEUROSCI LETT, V389, P99, DOI 10.1016/j.neulet.2005.07.028; Choi IY, 2000, GLIA, V31, P155, DOI 10.1002/1098-1136(200008)31:2<155::AID-GLIA70>3.0.CO;2-1; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Contartese A, 2012, PHARMACOL RES, V66, P555, DOI 10.1016/j.phrs.2012.08.003; Dasgupta A, 2007, FREE RADICAL BIO MED, V42, P617, DOI 10.1016/j.freeradbiomed.2006.11.030; Dingledine R, 1999, PHARMACOL REV, V51, P7; Downer EJ, 2011, THESCIENTIFICWORLDJO, V11, P855, DOI 10.1100/tsw.2011.84; Elmann A, 2009, J AGR FOOD CHEM, V57, P6636, DOI 10.1021/jf901162f; Farber NB, 1998, PROG BRAIN RES, V116, P421, DOI 10.1016/S0079-6123(08)60453-7; Farooqui T, 2009, MECH AGEING DEV, V130, P203, DOI 10.1016/j.mad.2008.11.006; Fernandez-Checa JC, 2010, SIGNALING PATHWAYS IN LIVER DISEASES, SECOND EDITION, P439, DOI 10.1007/978-3-642-00150-5_29; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Fernandez-Lopez D, 2006, PEDIATR RES, V60, P169, DOI 10.1203/01.pdr.0000228839.00122.6c; Fischedick JT, 2012, PLANTA MED, V78, P1725, DOI 10.1055/s-0032-1315241; Fujimura M, 2014, ARCH TOXICOL, V88, P109, DOI 10.1007/s00204-013-1089-2; Gautier CA, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-22; Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105; Ghelardini C, 2001, FARMACO, V56, P387, DOI 10.1016/S0014-827X(01)01092-8; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; Heales SJR, 2002, NEUROCHEM INT, V40, P469, DOI 10.1016/S0197-0186(01)00117-6; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; Ibrahim SM, 2001, BRAIN, V124, P1927, DOI 10.1093/brain/124.10.1927; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420; Jing X, 2013, TOXICOL APPL PHARM, V273, P672, DOI 10.1016/j.taap.2013.10.018; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Jou MJ, 2008, ADV DRUG DELIVER REV, V60, P1512, DOI 10.1016/j.addr.2008.06.004; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Kawakami N, 2005, J IMMUNOL, V175, P69, DOI 10.4049/jimmunol.175.1.69; Keum YS, 2003, PHARM RES-DORDR, V20, P1351, DOI 10.1023/A:1025737622815; Kim C, 2013, MOL CARCINOG; Kimball ES, 2006, AM J PHYSIOL-GASTR L, V291, pG364, DOI 10.1152/ajpgi.00407.2005; Kulawiak B, 2012, MITOCHONDRION, V12, P169, DOI 10.1016/j.mito.2011.12.001; Lee HG, 2009, BRAIN RES, V1249, P244, DOI 10.1016/j.brainres.2008.10.055; Lee M, 2010, FASEB J, V24, P2533, DOI 10.1096/fj.09-149997; Li Q, 2013, CELL PHYSIOL BIOCHEM, V31, P693, DOI 10.1159/000350088; Lin SX, 2011, ASN NEURO, V3, DOI 10.1042/AN20100033; Lipton SA, 2008, NAT NEUROSCI, V11, P381, DOI 10.1038/nn0408-381; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; McElnea EM, 2011, MOL VIS, V17, P1182; Mockute D, 2001, PHYTOCHEMISTRY, V57, P65, DOI 10.1016/S0031-9422(00)00474-X; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Niciu MJ, 2012, PHARMACOL BIOCHEM BE, V100, P656, DOI 10.1016/j.pbb.2011.08.008; Olney JW, 1990, CAN DIS WKLY REP, V16, P57; Onyango Isaac G., 2006, Current Alzheimer Research, V3, P339, DOI 10.2174/156720506778249489; Palazuelos J, 2008, J BIOL CHEM, V283, P13320, DOI 10.1074/jbc.M707960200; Paquet M, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-9; Prat A, 2005, ARCH NEUROL-CHICAGO, V62, P795, DOI 10.1001/archneur.62.5.795; Quincozes-Santos A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064372; Quincozes-Santos A, 2009, NEUROTOX RES, V16, P30, DOI 10.1007/s12640-009-9042-0; Rae MG, 2004, NEUROPHARMACOLOGY, V46, P1057, DOI 10.1016/j.neuropharm.2004.02.002; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Sevcik MA, 2005, J PAIN, V6, P771, DOI 10.1016/j.jpain.2005.06.010; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Sibbald B, 2005, CAN MED ASSOC J, V172, P1672, DOI 10.1503/cmaj.050628; Singh Mrinalini, 2013, Biomed Res Int, V2013, P569206, DOI 10.1155/2013/569206; Siqueira JM, 2009, CANCER CHEMOTH PHARM, V64, P529, DOI 10.1007/s00280-008-0901-9; Sohn JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026625; Sun R, 2012, FOLIA NEUROPATHOL, V50, P270, DOI 10.5114/fn.2012.30527; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Van Damme P, 2007, P NATL ACAD SCI USA, V104, P14825, DOI 10.1073/pnas.0705046104; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Weng CJ, 2011, NEW BIOTECHNOL, V28, P767, DOI 10.1016/j.nbt.2011.05.003; Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yeh CT, 2006, J NUTR, V136, P11, DOI 10.1093/jn/136.1.11; Yokote H, 2008, AM J PATHOL, V173, P1714, DOI 10.2353/ajpath.2008.080622; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058	84	63	63	2	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 24	2014	279						220	231		10.1016/j.neuroscience.2014.08.043			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR5ON	WOS:000343633800017	25194788				2022-02-06	
J	Salottolo, K; Levy, AS; Slone, DS; Mains, CW; Bar-Or, D				Salottolo, Kristin; Levy, A. Stewart; Slone, Denetta S.; Mains, Charles W.; Bar-Or, David			The Effect of Age on Glasgow Coma Scale Score in Patients With Traumatic Brain Injury	JAMA SURGERY			English	Article							SUBDURAL-HEMATOMA; ELDERLY-PATIENTS; SEVERITY SCORE; MORTALITY; PERFORMANCE; PREDICTION; IMPACT; RISK	IMPORTANCE The Glasgow Coma Scale (GCS) is used frequently to define the extent of neurologic injury in patients with a traumatic brain injury (TBI). Whether age affects the predictive ability of the GCS for severity of TBI (determined by the Abbreviated Injury Scale [AIS] score) remains unknown. OBJECTIVE To investigate the effect of age on the association between the GCS and anatomic TBI severity. DESIGN, SETTING, AND PARTICIPANTS We examined all patients with a TBI, defined by diagnostic codes 850 to 854 from the International Classification of Diseases, Ninth Revision, Clinical Modification, who were admitted to 2 level I trauma centers from January 1, 2008, through December 31, 2012. EXPOSURES We compared elderly (-65 years) and younger (18-64 years) adults with TBI. MAIN OUTCOMES AND MEASURES We examined differences by age in GCS category (defined by emergency department GCS as severe [3-8], moderate [9-12], or mild [13-15]) at each level of TBI severity (head AIS score, 1 [minor] to 5 [critical]). Cochran-Armitage X-2 trend tests and stepwise multivariate linear and logistic regression models were used. RESULTS During the study period, 6710 patients had a TBI (aged <65 years, 73.17%). Significant differences in GCS category by age occurred at each AIS score (P <= .01 for all). In particular, among patients with an AIS score of 5, most of the elderly patients (56.33%) had a mild neurologic deficit (GCS score, 13-15), whereas most of the younger patients (63.28%) had a severe neurologic deficit (GCS score, 3-8). After adjustment, the younger adults had increased odds of presenting with a severe neurologic deficit (GCS score, 3-8) at each of the following AIS scores: 1, 4.2 (95% CI, 1.0-17.6; P = .05); 2, 2.0 (1.0-3.7; P = .04); 3, 2.0 (1.2-3.5; P = .01); 4, 4.6 (2.8-7.5; P < .001); and 5, 3.1 (2.1-4.6; P < .001). The interaction between age and GCS for anatomic TBI severity remained significant after adjustment (estimate, -0.11; P = .005). CONCLUSIONS AND RELEVANCE Age affects the relationship between the GCS score and anatomic TBI severity. Elderly TBI patients have better GCS scores than younger TBI patients with similar TBI severity. These findings have implications for TBI outcomes research and for protocols and research selection criteria that use the GCS.	[Salottolo, Kristin; Slone, Denetta S.; Bar-Or, David] Swedish Med Ctr, Dept Trauma Res, Englewood, CO 80113 USA; [Salottolo, Kristin; Mains, Charles W.; Bar-Or, David] St Anthony Hosp, Dept Trauma Res, Lakewood, CO USA; [Levy, A. Stewart] St Anthony Hosp, Lakewood, CO USA; [Slone, Denetta S.; Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Dept Biomed Sci, Aurora, CO USA		Bar-Or, D (corresponding author), Swedish Med Ctr, Dept Trauma Res, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@ampiopharma.com	Bar-Or, David/AAE-9328-2020		St Anthony Hospital;  [Swedish Medical Center]	This study was supported by St Anthony Hospital and Swedish Medical Center.	Adam Williams Initiative, EST HIGH STAND CAR T; Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; American College of Surgeons Committee on Trauma, 2008, ATLS STUD COURS MAN; [Anonymous], 1971, JAMA, V215, P277; Association for the Advancement of Automotive Medicine, 2007, ABBR INJ SCAL 2005 R; Association for the Advancement of Automotive Medicine, 2011, AIS; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Emergency Medical and Trauma Services Section, 2011, COL TRAUM REG INCL E; Faul M, 2010, TRAUMATIC BRAIN INJU; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Horikawa E, 2005, INTERNAL MED, V44, P717, DOI 10.2169/internalmedicine.44.717; Karnath B, 2004, GERIATRICS, V59, P18; Kim HJ, 2012, J KOREAN NEUROSURG S, V51, P24, DOI 10.3340/jkns.2012.51.1.24; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Lesko MM, 2013, J NEUROTRAUM, V30, P17, DOI 10.1089/neu.2012.2438; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sheridan PL, 2007, DEMENT GERIATR COGN, V24, P125, DOI 10.1159/000105126; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Timiras P., 2003, PHYSL BASIS AGING GE, P99, DOI DOI 10.1161/01.ATV.0000173418.42264.19; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b	46	63	64	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUL	2014	149	7					727	734		10.1001/jamasurg.2014.13			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AN8DV	WOS:000340833800020	24899145	Bronze			2022-02-06	
J	Jamieson, M; Cullen, B; McGee-Lennon, M; Brewster, S; Evans, JJ				Jamieson, Matthew; Cullen, Breda; McGee-Lennon, Marilyn; Brewster, Stephen; Evans, Jonathan J.			The efficacy of cognitive prosthetic technology for people with memory impairments: A systematic review and meta-analysis	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Memory aid; Assistive technology; Memory impairment; Cognitive rehabilitation; Brain injury; Degenerative disease	TRAUMATIC BRAIN-INJURY; ASSISTIVE TECHNOLOGY; ELECTRONIC MEMORY; PAGING SYSTEM; REHABILITATION; AID; INDIVIDUALS; DEFICITS; QUALITY; DESIGN	Technology can compensate for memory impairment. The efficacy of assistive technology for people with memory difficulties and the methodology of selected studies are assessed. A systematic search was performed and all studies that investigated the impact of technology on memory performance for adults with impaired memory resulting from acquired brain injury (ABI) or a degenerative disease were included. Two 10-point scales were used to compare each study to an ideally reported single case experimental design (SCED) study (SCED scale; Tate et al., 2008) or randomised control group study (PEDro-P scale; Maher, Sherrington, Herbert, Moseley, & Elkins, 2003). Thirty-two SCED (mean = 5.9 on the SCED scale) and 11 group studies (mean = 4.45 on the PEDro-P scale) were found. Baseline and intervention performance for each participant in the SCED studies was re-calculated using non-overlap of all pairs (Parker & Vannest, 2009) giving a mean score of 0.85 on a 0 to 1 scale (17 studies, n = 36). A meta-analysis of the efficacy of technology vs. control in seven group studies gave a large effect size (d = 1.27) (n = 147). It was concluded that prosthetic technology can improve performance on everyday tasks requiring memory. There is a specific need for investigations of technology for people with degenerative diseases.	[Jamieson, Matthew; Cullen, Breda; Evans, Jonathan J.] Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow G12 0XH, Lanark, Scotland; [Jamieson, Matthew; McGee-Lennon, Marilyn; Brewster, Stephen] Univ Glasgow, Glasgow Interact Syst Grp, Sch Comp Sci, Glasgow G12 0XH, Lanark, Scotland		Jamieson, M (corresponding author), Univ Glasgow, Acad Ctr, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	m.jamieson.1@research.gla.ac.uk	Cullen, Breda/C-9154-2012; Cullen, Breda/N-3449-2019; brewster, stephen/J-9003-2017	Cullen, Breda/0000-0002-7259-9505; Cullen, Breda/0000-0002-7259-9505; brewster, stephen/0000-0001-9720-3899; Lennon, Marilyn/0000-0003-3271-2400	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1232093] Funding Source: researchfish	This paper was written during a doctorate studentship which is funded by the Medical Research Council.	Bharucha AJ, 2009, AM J GERIAT PSYCHIAT, V17, P88, DOI 10.1097/JGP.0b013e318187dde5; Boman IL, 2010, DISABIL REHABIL-ASSI, V5, P339, DOI 10.3109/17483100903131777; Burke DT, 2001, J HEAD TRAUMA REHAB, V16, P284, DOI 10.1097/00001199-200106000-00007; BUSSE RT, 1995, J SCHOOL PSYCHOL, V33, P269, DOI 10.1016/0022-4405(95)00014-D; Caprani N, 2006, PSYCHNOLOGY J, V4, P205; Chang Y. J., 2011, PERS UBIQUIT COMPUT, V17, P1; Chang YJ, 2011, RES DEV DISABIL, V32, P2669, DOI 10.1016/j.ridd.2011.06.006; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 2013, STAT POWER ANAL BEHA; De Joode EA, 2013, NEUROPSYCHOL REHABIL, V23, P133, DOI 10.1080/09602011.2012.726632; de Joode E, 2010, CLIN REHABIL, V24, P701, DOI 10.1177/0269215510367551; DEVAUL RW, 2000, CHI 2000 WORKSH SIT; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gentry T, 2008, AM J OCCUP THER, V62, P18, DOI 10.5014/ajot.62.1.18; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gillespie A, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI 10.1017/S1355617711001548; Hodges S, 2006, LECT NOTES COMPUT SC, V4206, P177; Jin ZX, 2007, PROCEEDINGS OF THE 2007 INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE AND ENGINEERING - MANAGEMENT AND ORGANIZATION STUDIES SECTION, P933; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KIRSCH NL, 1988, ICAART 88 ANN C ARL; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Klarborg B, 2012, ACCIDENT ANAL PREV, V48, P57, DOI 10.1016/j.aap.2011.05.004; Labelle KL, 2006, AM J OCCUP THER, V60, P442, DOI 10.5014/ajot.60.4.442; Lemoncello R, 2011, NEUROPSYCHOL REHABIL, V21, P825, DOI 10.1080/09602011.2011.618661; Lemoncello R, 2011, DISABIL REHABIL-ASSI, V6, P440, DOI 10.3109/17483107.2010.542571; Maher CG, 2003, PHYS THER REHABIL J, V83, P713, DOI 10.1093/ptj/83.8.713; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McBurney D.H., 2009, RES METHODS; McDonald A, 2011, NEUROPSYCHOL REHABIL, V21, P784, DOI 10.1080/09602011.2011.598405; Mihailidis A, 2004, IEEE T INF TECHNOL B, V8, P238, DOI 10.1109/TITB.2004.834386; Mihailidis A., 2000, TECHNOLOGY DISABILIT, V13, P23, DOI DOI 10.3233/TAD-2000-13104; Mihailidis Alex, 2008, BMC Geriatr, V8, P28, DOI 10.1186/1471-2318-8-28; O'Neill B, 2010, NEUROPSYCHOL REHABIL, V20, P509, DOI 10.1080/09602010903519652; O'Neill B, 2008, J ASSIST TECHNOL, V2, P22, DOI 10.1108/17549450200800015; O'Neill L., 2013, SOCIAL CARE NEURODIS, V4, P17, DOI DOI 10.1108/20420911311302281; Oriani M, 2003, AGING MENT HEALTH, V7, P22, DOI 10.1080/1360786021000045863; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Svoboda E, 2012, NEUROPSYCHOL REHABIL, V22, P408, DOI 10.1080/09602011.2011.652498; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tellis Winston, 2013, QUALITATIVE REPORT, V3; Thone-Otto AIT, 2003, INT J PSYCHOL, V38, P236, DOI 10.1080/00207590344000169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Van Hulle A, 2006, BRAIN INJURY, V20, P101, DOI 10.1080/02699050500309684; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Waldron B., 2012, IRISH J PSYCHOL, V33, P37; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	61	63	63	1	32	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN-AUG	2014	24	3-4					419	444		10.1080/09602011.2013.825632			26	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	AJ9LN	WOS:000338032300008	23957379				2022-02-06	
J	Huang, XL; Zhang, F; Wang, Y; Sun, XL; Choi, KY; Liu, DB; Choi, JS; Shin, TH; Cheon, J; Niu, G; Chen, XY				Huang, Xinglu; Zhang, Fan; Wang, Yu; Sun, Xiaolian; Choi, Ki Young; Liu, Dingbin; Choi, Jin-sil; Shin, Tae-Hyun; Cheon, Jinwoo; Niu, Gang; Chen, Xiaoyuan			Design Considerations of Iron-Based Nanoclusters for Noninvasive Tracking of Mesenchymal Stem Cell Homing	ACS NANO			English	Article						mesenchymal stem cell; homing; iron oxide nanoparticle; magnetic resonance imaging; CXCR4/SDF-1 alpha	INFARCTED MYOCARDIUM; CXCR4 EXPRESSION; MRI CONTRAST; IN-VITRO; MIGRATION; NANOPARTICLES; ENGRAFTMENT; CHEMOKINE; RECEPTOR; MICE	Stem-cell-based therapies have attracted considerable interest in regenerative medicine and ontological research. However, a major limitation of systemic delivery of stem cells is the low homing efficiency to the target site. Here, we report a serendipitous finding that various iron-based magnetic nanoparticles (MNPs) actively augment chemokine receptor CXCR4 expression of bone-marrow-derived mesenchymal stem cells (MSCs). On the basis of this observation, we designed an iron-based nanocluster that can effectively label MSCs, improve cell homing efficiency, and track the fate of the cells in vivo. Using this nanocluster, the labeled MSCs were accurately monitored by magnetic resonance imaging and improved the homing to both traumatic brain Injury and glioblastoma models as compared to unlabeled MSCs. Our findings provide a simple and safe method for imaging and targeted delivery of stem cells and extend the potential applications of iron-based MNPs in regenerative medicine and oncology.	[Huang, Xinglu; Zhang, Fan; Wang, Yu; Sun, Xiaolian; Choi, Ki Young; Liu, Dingbin; Niu, Gang; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA; [Zhang, Fan] Xiamen Univ, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen, Peoples R China; [Choi, Jin-sil; Shin, Tae-Hyun; Cheon, Jinwoo] Yonsei Univ, Dept Chem, Seoul 120749, South Korea		Chen, XY (corresponding author), NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA.	shawn.chen@nih.gov	Choi, Jin-sil/AAD-1076-2021; CHOI, KI YOUNG/Q-7177-2016; Chen, Xiaoyuan/D-1860-2014	CHOI, KI YOUNG/0000-0002-4207-2665; Chen, Xiaoyuan/0000-0002-9622-0870	National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); Department of Defense (DOD) Center for Neuroscience and Regenerative Medicine (CNRM); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER	This work was supported, in part, by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), and by the Department of Defense (DOD) Center for Neuroscience and Regenerative Medicine (CNRM).	Andrews M, 2012, BIOMETALS, V25, P749, DOI 10.1007/s10534-012-9543-9; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen M, 2004, J AM CHEM SOC, V126, P8394, DOI 10.1021/ja047648m; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; Cho MH, 2012, NAT MATER, V11, P1038, DOI [10.1038/nmat3430, 10.1038/NMAT3430]; Choi KY, 2012, BIOMATERIALS, V33, P6186, DOI 10.1016/j.biomaterials.2012.05.029; Choi KY, 2010, BIOMATERIALS, V31, P106, DOI 10.1016/j.biomaterials.2009.09.030; Chung TH, 2011, ACS NANO, V5, P9807, DOI 10.1021/nn2033902; Dong F, 2012, CIRCULATION, V126, P314, DOI 10.1161/CIRCULATIONAHA.111.082453; Fleming RE, 2012, NEW ENGL J MED, V366, P348, DOI 10.1056/NEJMra1004967; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; Huang XL, 2014, BIOMATERIALS, V35, P856, DOI 10.1016/j.biomaterials.2013.10.027; Huang XL, 2013, BIOMATERIALS, V34, P1772, DOI 10.1016/j.biomaterials.2012.11.032; Huang XL, 2012, ANGEW CHEM INT EDIT, V51, P1625, DOI 10.1002/anie.201107795; Jang JT, 2009, ANGEW CHEM INT EDIT, V48, P1234, DOI 10.1002/anie.200805149; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Khan Wasim S, 2012, J Stem Cells, V7, P87; Kim HS, 2010, NMR BIOMED, V23, P514, DOI 10.1002/nbm.1487; Kircher MF, 2011, NAT REV CLIN ONCOL, V8, P677, DOI 10.1038/nrclinonc.2011.141; Li F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064771; Liu G, 2011, SMALL, V7, P2742, DOI 10.1002/smll.201100825; Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008-5472.CAN-09-1912; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Matsumoto Y, 2008, MAGN RESON IMAGING, V26, P994, DOI 10.1016/j.mri.2008.01.039; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005; Pantopoulos K, 2012, BIOCHEMISTRY-US, V51, P5705, DOI 10.1021/bi300752r; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Ruster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood-2006-05-025098; Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852; Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Voswinkel J, 2013, CLIN REV ALLERG IMMU, V45, P180, DOI 10.1007/s12016-012-8347-6; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Xie J, 2013, CELL IMMUNOL, V281, P68, DOI 10.1016/j.cellimm.2013.02.001; Zhang DS, 2008, J MOL CELL CARDIOL, V44, P281, DOI 10.1016/j.yjmcc.2007.11.010; Zhang F, 2012, BIOMATERIALS, V33, P5414, DOI 10.1016/j.biomaterials.2012.04.032; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	63	66	6	93	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	MAY	2014	8	5					4403	4414		10.1021/nn4062726			12	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	AI1UM	WOS:000336640600031	24754735	hybrid, Green Published			2022-02-06	
J	Jorge, RE; Arciniegas, DB				Jorge, Ricardo E.; Arciniegas, David B.			Mood Disorders After TBI	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Mood disorders; Depressive disorders	TRAUMATIC BRAIN-INJURY; SEROTONIN TRANSPORTER POLYMORPHISMS; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; AGGRESSIVE-BEHAVIOR; BIPOLAR DISORDER; AXIS-I; MANIA; ASSOCIATION; SYMPTOMS	In this article, we examine the epidemiology and risk factors for the development of the most common mood disorders observed in the aftermath of TBI: depressive disorders and bipolar spectrum disorders. We describe the classification approach and diagnostic criteria proposed in the fifth edition of the Diagnostic and Statistical Manual for Mental Disorders. We also examine the differential diagnosis of post-TBI mood disorders and describe the mainstay of the evaluation process. Finally, we place a special emphasis on the analysis of the different therapeutic options and provide guidelines for the appropriate management of these conditions.	[Jorge, Ricardo E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Mental Hlth Care Line, Houston, TX 77030 USA; [Jorge, Ricardo E.; Arciniegas, David B.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA		Jorge, RE (corresponding author), One Baylor Plaza, Houston, TX 77030 USA.	jorge@bcm.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH065134, R01MH53592, R01 MH65134 01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055827] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065134, R01MH053592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055827] Funding Source: NIH RePORTER		Alper K, 2007, BIOL PSYCHIAT, V62, P345, DOI 10.1016/j.biopsych.2006.09.023; *AM PSYCH ASS, 1995, AM J PSYCHIAT S, V152, P63; American Psychiatric Association, 2010, TREATM PAT MAJ DEPR; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arango V, 2003, J PSYCHIATR RES, V37, P375, DOI 10.1016/S0022-3956(03)00048-7; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Binder EB, 2004, NAT GENET, V36, P1319, DOI 10.1038/ng1479; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Daniels JP, 2008, J CLIN PSYCHIAT, V69, P497, DOI 10.4088/JCP.v69n0324a; Dealberto MJ, 2008, BIPOLAR DISORD, V10, P111, DOI 10.1111/j.1399-5618.2008.00523.x; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2001, AM J PSYCHIAT, V158, P575, DOI 10.1176/appi.ajp.158.4.575; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hirschfeld R., 2002, GUIDELINE WATCH PRAC; Hornstein A, 1989, J Neuropsychiatry Clin Neurosci, V1, P446; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kant R, 1998, BRAIN INJURY, V12, P661, DOI 10.1080/026990598122223; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lasky-Su JA, 2005, AM J MED GENET B, V133B, P110, DOI 10.1016/j.ajmg.b.30104; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lotrich FE, 2004, PSYCHIAT GENET, V14, P121, DOI 10.1097/00041444-200409000-00001; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Oster TJ, 2007, CNS SPECTRUMS, V12, P764, DOI 10.1017/S1092852900015455; Patkar AA, 2002, PSYCHIAT RES, V110, P103, DOI 10.1016/S0165-1781(02)00098-7; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Reza MF, 2007, NEUROPSYCHOL REHABIL, V17, P723, DOI 10.1080/09602010601082441; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sen S, 2004, BIOL PSYCHIAT, V55, P244, DOI 10.1016/j.biopsych.2003.08.006; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith GS, 2004, NEUROPSYCHOPHARMACOL, V29, P2226, DOI 10.1038/sj.npp.1300552; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Sun HS, 2004, GENES BRAIN BEHAV, V3, P328, DOI 10.1111/j.1601-183X.2004.00085.x; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tunbridge E, 2004, SYNAPSE, V51, P112, DOI 10.1002/syn.10286; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429; Zubenko GS, 2003, AM J MED GENET B, V123B, P1, DOI 10.1002/ajmg.b.20073	88	63	65	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					13	+		10.1016/j.psc.2013.11.005			18	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	AD8UM	WOS:000333541200003	24529421	Green Accepted			2022-02-06	
J	Heldt, SA; Elberger, AJ; Deng, Y; Guley, NH; Del Mar, N; Rogers, J; Choi, GW; Ferrell, J; Rex, TS; Honig, MG; Reiner, A				Heldt, Scott A.; Elberger, Andrea J.; Deng, Yunping; Guley, Natalie H.; Del Mar, Nobel; Rogers, Joshua; Choi, Gy Won; Ferrell, Jessica; Rex, Tonia S.; Honig, Marcia G.; Reiner, Anton			A novel closed-head model of mild traumatic brain injury caused by primary overpressure blast to the cranium produces sustained emotional deficits in mice	FRONTIERS IN NEUROLOGY			English	Article						mild TBI; anxiety; fear; depression; mice		Emotional disorders are a common outcome from mild traumatic brain injury (TBI) in humans, but their pathophysiological basis is poorly understood. We have developed a mouse model of closed-head blast injury using an air pressure wave delivered to a small area on one side of the cranium, to create mild TBI. We found that 20-psi blasts in 3-month-old C57BL/6 male mice yielded no obvious behavioral or histological evidence of brain injury, while 25-40 psi blasts produced transient anxiety in an open field arena but little histological evidence of brain damage. By contrast, 50-60 psi blasts resulted in anxiety-like behavior in an open field arena that became more evident with time after blast. In additional behavioral tests conducted 2-8 weeks after blast, 50-60 psi mice also demonstrated increased acoustic startle, perseverance of learned fear, and enhanced contextual fear, as well as depression-like behavior and diminished prepulse inhibition. We found no evident cerebral pathology, but did observe scattered axonal degeneration in brain sections from 50 to 60 psi mice 3-8 weeks after blast. Thus, the TBI caused by single 50-60 psi blasts in mice exhibits the minimal neuronal loss coupled to "diffuse" axonal injury characteristic of human mild TBI. A reduction in the abundance of a subpopulation of excitatory projection neurons in basolateral amygdala enriched in Thy1 was, however, observed. The reported link of this neuronal population to fear suppression suggests their damage by mild TBI may contribute to the heightened anxiety and fearfulness observed after blast in our mice. Our overpressure air blast model of concussion in mice will enable further studies of the mechanisms underlying the diverse emotional deficits seen after mild TBI.	[Heldt, Scott A.; Elberger, Andrea J.; Deng, Yunping; Guley, Natalie H.; Del Mar, Nobel; Rogers, Joshua; Choi, Gy Won; Ferrell, Jessica; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, 855 Monroe Av, Memphis, TN 38163 USA; [Rex, Tonia S.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA; [Rex, Tonia S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN 37235 USA		Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, 855 Monroe Av, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	University of Tennessee Neuroscience Institute; Methodist Hospitals Endowed Professorship in Neuroscience; DoDUnited States Department of Defense [W81XWH-10-1-0528]; Research to Prevent Blindness Career Development AwardResearch to Prevent Blindness (RPB); Research to Prevent Blindness Unrestricted Funds; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS081370] Funding Source: NIH RePORTER	The technical assistance of Drs. Rafiq Islam, Danielle Howell, Marion Joni, and Rhonda Williams is gratefully acknowledged. Supported by The University of Tennessee Neuroscience Institute (Anton Reiner, Andrea J. Elberger), The Methodist Hospitals Endowed Professorship in Neuroscience (Anton Reiner), DoD grant W81XWH-10-1-0528 (Tonia S. Rex), Research to Prevent Blindness Career Development Award (Tonia S. Rex), and Research to Prevent Blindness Unrestricted Funds (Drs. Fleming and Sternberg).	Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Baisley SK, 2011, PHYSIOL BEHAV, V104, P796, DOI 10.1016/j.physbeh.2011.08.001; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; Dragatsis I, 2009, NEUROBIOL DIS, V33, P315, DOI 10.1016/j.nbd.2008.10.009; Drai D, 2001, NEUROSCI BIOBEHAV R, V25, P409, DOI 10.1016/S0149-7634(01)00022-7; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gorski JA, 2002, J NEUROSCI, V22, P6309; Grillon C, 1996, PSYCHIAT RES, V64, P169, DOI 10.1016/S0165-1781(96)02942-3; Heldt S, 2000, BEHAV NEUROSCI, V114, P749, DOI 10.1037//0735-7044.114.4.719; Heldt SA, 2006, BRAIN RES, V1073, P229, DOI 10.1016/j.brainres.2005.12.053; Heldt SA, 2004, NEUROPSYCHOPHARMACOL, V29, P1610, DOI 10.1038/sj.npp.1300468; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; HOF PR, 1990, J COMP NEUROL, V301, P44, DOI 10.1002/cne.903010105; Holstein DH, 2010, J AFFECT DISORDERS, V126, P188, DOI 10.1016/j.jad.2010.02.122; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Kafkafi N, 2003, BEHAV NEUROSCI, V117, P464, DOI 10.1037/0735-7044.117.3.464; Kafkafi N, 2001, J NEUROSCI METH, V109, P111, DOI 10.1016/S0165-0270(01)00392-2; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; King CE, 1997, NEUROREPORT, V8, P1663; Kohl S, 2013, J PSYCHIATR RES, V47, P445, DOI 10.1016/j.jpsychires.2012.11.018; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lipkind D, 2004, J APPL PHYSIOL, V97, P347, DOI 10.1152/japplphysiol.00148.2004; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meade CA, 2002, J COMP NEUROL, V449, P241, DOI 10.1002/cne.10295; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Pollak DD, 2010, ANN MED, V42, P252, DOI 10.3109/07853891003769957; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reiner A, 2012, BRAIN RES, V1473, P161, DOI 10.1016/j.brainres.2012.07.026; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2007, J COMP NEUROL, V505, P603, DOI 10.1002/cne.21515; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Yan HC, 2010, NEUROSCI BULL, V26, P327, DOI 10.1007/s12264-010-0323-7	73	63	63	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								2	10.3389/fneur.2014.00002			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300002	24478749	Green Published, gold			2022-02-06	
J	Iverson, GL				Iverson, Grant L.			Chronic traumatic encephalopathy and risk of suicide in former athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Sporting injuries	CHRONIC PAIN; LIFE EVENTS; BEHAVIOR; DISEASE; ASSOCIATION; AGGRESSION; DEPRESSION; MORTALITY; DEMENTIA; ADULTS	Background In the initial autopsy case studies of chronic traumatic encephalopathy (CTE), some researchers have concluded that the proteinopathy associated with CTE is the underlying cause of suicidality and completed suicide in former athletes. Methods A review of the literature on contact sports and risk of completed suicide revealed only one epidemiological study with direct relevant data. Results There are no published cross-sectional, epidemiological or prospective studies showing a relation between contact sports and risk of suicide. One published epidemiological study suggests that retired National Football League players have lower rates of death by suicide than the general population. Outside of sports, there is a mature body of evidence suggesting that the causes of suicide are complex, multifactorial and difficult to predict in individual cases. Conclusions Future research might establish a clear causal connection between the proteinopathy of CTE and suicide. At present, however, there is insufficient scientific evidence to conclude that there is a strong causal relationship between the presence of these proteinopathies and suicide in former athletes. Additional research is needed to determine the extent to which the neuropathology of CTE is a possible mediator or moderator variable associated with suicide.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA		Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, 79-96 13th St, Charlestown, MA 02129 USA.	giverson@partners.org		Iverson, Grant/0000-0001-7348-9570	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alcohol Beverage Medical Research Council; Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs; Vancouver Coastal Health Research Institute; Roche Diagnostics Canada	GLI has been reimbursed by the government, professional scientific bodies and commercial organisations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences and symposiums. He has received research funding from several test publishing companies, including ImPACT Applications, Inc, CNS Vital Signs, and Psychological Assessment Resources (PAR, Inc). He is a co-investigator, collaborator or consultant on grants relating to mild TBI funded by several organisations, including, but not limited to, the Canadian Institute of Health Research, Alcohol Beverage Medical Research Council, Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs, Vancouver Coastal Health Research Institute and Roche Diagnostics Canada.	Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Barr B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5142; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beghi M, 2010, CURR OPIN PSYCHIATR, V23, P349, DOI 10.1097/YCO.0b013e32833ad783; Bruffaerts R, 2010, BRIT J PSYCHIAT, V197, P20, DOI 10.1192/bjp.bp.109.074716; Centers for Disease Control and Prevention (CDC), 1800, MMWR Morb Mortal Wkly Rep, V62, P321; Chang SS, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5239; Chang SS, 2009, SOC SCI MED, V68, P1322, DOI 10.1016/j.socscimed.2009.01.010; Conner KR, 2012, DRUG ALCOHOL DEPEN, V120, P155, DOI 10.1016/j.drugalcdep.2011.07.013; Conner KR, 2004, AM J GERIAT PSYCHIAT, V12, P37, DOI 10.1176/appi.ajgp.12.1.37; Conner KR, 2001, SUICIDE LIFE-THREAT, V31, P367, DOI 10.1521/suli.31.4.367.22048; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Conwell Y, 2010, INT J GERIATR PSYCH, V25, P371, DOI 10.1002/gps.2348; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Fassberg MM, 2012, INT J ENV RES PUB HE, V9, P722, DOI 10.3390/ijerph9030722; Foster T, 2011, ARCH SUICIDE RES, V15, P1, DOI 10.1080/13811118.2011.540213; Frith D., 2001, SILENCE HEART CRICKE; Gardner A., 2013, BRIT J SPORT MED; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gelber RP, 2012, CURR ALZHEIMER RES, V9, P664; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Hundertmark J, 2007, AUSTRALAS PSYCHIATRY, V15, P509, DOI 10.1080/10398560701458210; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Lindqvist AS, 2013, SCAND J MED SCI SPOR, DOI [10.1111/sms.12122., DOI 10.1111/SMS.12122.[]; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McGirr Alexander, 2007, Curr Psychiatry Rep, V9, P460, DOI 10.1007/s11920-007-0062-2; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Ohayon MM, 2010, J PSYCHIATR RES, V44, P454, DOI 10.1016/j.jpsychires.2009.10.013; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parssinen M, 2000, INT J SPORTS MED, V21, P225, DOI 10.1055/s-2000-304; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Scott KM, 2010, PSYCHOSOM MED, V72, P712, DOI 10.1097/PSY.0b013e3181e3333d; Smith G, 2011, PERCEPT MOTOR SKILL, V112, P55, DOI 10.2466/07.PMS.112.1.55-60; Snowdon DA, 2003, ANN INTERN MED, V139, P450, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00014; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Von Korff M, 2005, PAIN, V113, P331, DOI 10.1016/j.pain.2004.11.010; White L, 2009, J ALZHEIMERS DIS, V18, P713, DOI 10.3233/JAD-2009-1178	56	63	63	2	43	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					162	U174		10.1136/bjsports-2013-092935			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	276KK	WOS:000328749000021	24178363				2022-02-06	
J	Watanabe, J; Shetty, AK; Hattiangady, B; Kim, DK; Foraker, JE; Nishida, H; Prockop, DJ				Watanabe, Jun; Shetty, Ashok K.; Hattiangady, Bharathi; Kim, Dong-Ki; Foraker, Jessica E.; Nishida, Hidetaka; Prockop, Darwin J.			Administration of TSG-6 improves memory after traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						TSG-6; Mesenchymal stem cells; Traumatic brain injury; Blood brain barrier; Neutrophils; Matrix metalloproteinase	INTER-ALPHA-INHIBITOR; FACTOR-STIMULATED GENE-6; STEM-CELLS; STROMAL CELLS; LINK MODULE; STEM/PROGENITOR CELLS; INFLAMMATORY DAMAGE; INNATE IMMUNITY; HEAVY-CHAINS; PROTEIN	Traumatic brain injury (TBI) causes multiple long-term defects including a loss of working memory that is frequently incapacitating. Administrations of mesenchymal stem/stromal cells (MSCs) previously produced beneficial effects in models of TBI as well as other disease models. In several models, the beneficial effects were explained by the MSCs being activated to express TSG-6, a multifunctional protein that modulates inflammation. In a mouse model of TB!, we found the initial mild phase of the inflammatory response persisted for at least 24 h and was followed by secondary severe response that peaked at 3 days. Intravenous human MSCs or TSG-6 during initial mild phase decreased neutrophil extravasation, expression of matrix metalloproteinase 9 by endothelial cells and neutrophils, and the subsequent blood brain barrier leakage in secondary phase. Administration of TSG-6 also decreased the lesion size at 2 weeks. Importantly, the acute administration of TSG-6 within 24 h of TBI was followed 6 to 10 weeks later by improvements in memory, depressive-like behavior and the number of newly born-neurons. The data suggested that acute administration of TSG-6 may be an effective therapy for decreasing some of the long-term consequences of TBI. (C) 2013 Elsevier Inc. All rights reserved.	[Watanabe, Jun; Shetty, Ashok K.; Hattiangady, Bharathi; Kim, Dong-Ki; Foraker, Jessica E.; Nishida, Hidetaka; Prockop, Darwin J.] Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, Temple, TX 76502 USA		Prockop, DJ (corresponding author), Scott & White Mem Hosp & Clin, Texas A&M Hlth Sci Ctr, Coll Med, Inst Regenerat Med, 5701 Airport Rd, Temple, TX 76502 USA.	Prockop@medicine.tamhsc.edu	Shetty, Ashok/AAT-7273-2020; Shetty, Ashok K/A-2428-2008	Shetty, Ashok/0000-0001-5049-6671; Shetty, Ashok K/0000-0001-5049-6671; Hattiangady, Bharathi/0000-0002-0432-1894; Tulloch, Jessica/0000-0002-6737-2525	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40OD011050]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40OD011050] Funding Source: NIH RePORTER	This study is supported in part by NIH grant P40OD011050.	Baranova NS, 2011, J BIOL CHEM, V286, P25675, DOI 10.1074/jbc.M111.247395; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Edwards P, 2005, LANCET, V365, P1957; Flach A, 2000, OPHTHALMOLOGY, V107, P1224, DOI 10.1016/S0161-6420(00)00223-2; Foraker JE, 2011, J NEUROCHEM, V119, P1052, DOI 10.1111/j.1471-4159.2011.07511.x; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Kohman RA, 2013, BRAIN BEHAV IMMUN, V27, P22, DOI 10.1016/j.bbi.2012.09.003; Kovesdi E., 2012, FRONT NEUROL, V3, P1; Kuznetsova SA, 2005, J BIOL CHEM, V280, P30899, DOI 10.1074/jbc.M500701200; Kuznetsova SA, 2008, MATRIX BIOL, V27, P201, DOI 10.1016/j.matbio.2007.10.003; Leali D, 2012, ARTERIOSCL THROM VAS, V32, P696, DOI 10.1161/ATVBAHA.111.243998; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lin JC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1129; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Mihara Y, 2011, J MOL NEUROSCI, V43, P162, DOI 10.1007/s12031-010-9438-6; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nagyeri G, 2011, J BIOL CHEM, V286, P23559, DOI 10.1074/jbc.M111.222026; Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Parihar VK, 2011, MOL PSYCHIATR, V16, P171, DOI 10.1038/mp.2009.130; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Prockop DJ, 2007, CLIN PHARMACOL THER, V82, P241, DOI 10.1038/sj.clpt.6100313; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Rao MS, 2005, EUR J NEUROSCI, V21, P464, DOI 10.1111/j.1460-9568.2005.03853.x; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rawson RA, 1943, AM J PHYSIOL, V138, P0708, DOI 10.1152/ajplegacy.1943.138.5.708; Rivest Serge, 2011, Expert Rev Neurother, V11, P783, DOI 10.1586/ern.11.64; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Scavenius C, 2011, BBA-PROTEINS PROTEOM, V1814, P1624, DOI 10.1016/j.bbapap.2011.08.017; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Uccelli A, 2010, CURR OPIN IMMUNOL, V22, P768, DOI 10.1016/j.coi.2010.10.012; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Wolfe Margaret, 2008, V449, P3, DOI 10.1007/978-1-60327-169-1_1; Zhang SZ, 2012, J BIOL CHEM, V287, P12433, DOI 10.1074/jbc.M112.342873; Zietlow R, 2008, CELL TISSUE RES, V331, P301, DOI 10.1007/s00441-007-0488-1	64	63	69	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2013	59						86	99		10.1016/j.nbd.2013.06.017			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	221MV	WOS:000324663900009	23851308	Green Accepted			2022-02-06	
J	Berthelson, L; Mulchan, SS; Odland, AP; Miller, LJ; Mittenberg, W				Berthelson, Lena; Mulchan, Siddika S.; Odland, Anthony P.; Miller, Lori J.; Mittenberg, Wiley			False positive diagnosis of malingering due to the use of multiple effort tests	BRAIN INJURY			English	Article						Base rate; effort tests; malingering; medicolegal; symptom exaggeration; symptom validity	VALIDITY TEST-PERFORMANCE; NEUROPSYCHOLOGICAL TEST BATTERIES; ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; RELIABLE DIGIT SPAN; 15-ITEM MEMORY TEST; BASE RATES; NEUROCOGNITIVE DYSFUNCTION; HEALTHY-ADULTS; RESPONSE BIAS	Objective: Effort indicators are used to determine if neuropsychological test results are valid measures of a patient's cognitive abilities. The use of multiple effort measures is often advocated, but the false positive rate for multiple indicators depends on the number of measures used and the correlation among indicators. This study presents a meta-analysis of correlations among effort measures. False positive rates for multiple correlated indicators are then estimated using Monte Carlo simulations. Methods: a literature search of published studies identified 22 independent samples in which 407 correlations among 31 effort measures were available in 3564 participants with normal effort. Participants were patients with neurological or psychiatric disorders and healthy volunteers. Results: Meta-analysis showed a mean correlation among effort indicators of 0.31. Monte Carlo simulation based on a 15% false positive rate for individual indicators showed that, when 10 effort indicators are used together, 38% of patients with valid performance will be incorrectly identified as malingering if two failures is the diagnostic standard. Failure on five of 10 measures is required for a false positive rate of 10% or less. If five effort indicators are interpreted, a false positive rate of 19% results when two test failures are assumed to characterize poor effort and failure on three measures is required to maintain 90% specificity. Conclusions: False positive rates for effort tests increase significantly as the number of indicators that are administered is increased.	[Berthelson, Lena; Mulchan, Siddika S.; Mittenberg, Wiley] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA; [Odland, Anthony P.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Miller, Lori J.] Eastern Washington Univ, Belmont, WA USA		Mittenberg, W (corresponding author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.	wiley@nova.edu					AEgisdottir S, 2006, COUNS PSYCHOL, V34, P341, DOI 10.1177/0011000005285875; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P725, DOI 10.1093/arclin/acs071; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Decker SL, 2012, ARCH CLIN NEUROPSYCH, V27, P69, DOI 10.1093/arclin/acr088; Ferguson GA, 1971, STAT ANAL PSYCHOL ED, P81; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Grove WM, 2000, PSYCHOL ASSESSMENT, V12, P19, DOI 10.1037/1040-3590.12.1.19; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Holdnack J, 2009, ADV CLIN SOLUTIONS C; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; McGlinchey R, REDUCED EFFORT UNPUB; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; METROPOLIS N, 1987, LOS ALAMOS SCI, V15, P125, DOI DOI 10.1128/JCM.05092-11; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Perna R, 2013, APPL NEUROP IN PRESS; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Rienstra A, 2010, ARCH CLIN NEUROPSYCH, V25, P371, DOI 10.1093/arclin/acq035; Rosenfeld B., 2010, INT J FORENSIC MENT, V9, P63, DOI DOI 10.1080/14999013.2010.499559; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Strutt AM, 2011, CLIN NEUROPSYCHOL, V25, P1253, DOI 10.1080/13854046.2011.609839; Sweet JJ, 2009, NEUROPSYCHOLOGY MALI, P568; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063	43	63	64	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					909	916		10.3109/02699052.2013.793400			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200019	23782260				2022-02-06	
J	Madathil, SK; Carlson, SW; Brelsfoard, JM; Ye, P; D'Ercole, AJ; Saatman, KE				Madathil, Sindhu K.; Carlson, Shaun W.; Brelsfoard, Jennifer M.; Ye, Ping; D'Ercole, A. Joseph; Saatman, Kathryn E.			Astrocyte-Specific Overexpression of Insulin-Like Growth Factor-1 Protects Hippocampal Neurons and Reduces Behavioral Deficits following Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; IGF-I; FLUID-PERCUSSION; GLIAL SCAR; OLIGODENDROCYTE DEVELOPMENT; CASPASE-3 ACTIVATION; REACTIVE ASTROCYTES	Traumatic brain injury (TBI) survivors often suffer from long-lasting cognitive impairment that stems from hippocampal injury. Systemic administration of insulin-like growth factor-1 (IGF-1), a polypeptide growth factor known to play vital roles in neuronal survival, has been shown to attenuate posttraumatic cognitive and motor dysfunction. However, its neuroprotective effects in TBI have not been examined. To this end, moderate or severe contusion brain injury was induced in mice with conditional (postnatal) overexpression of IGF-1 using the controlled cortical impact (CCI) injury model. CCI brain injury produces robust reactive astrocytosis in regions of neuronal damage such as the hippocampus. We exploited this regional astrocytosis by linking expression of hIGF-1 to the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter, effectively targeting IGF-1 delivery to vulnerable neurons. Following brain injury, IGF-1Tg mice exhibited a progressive increase in hippocampal IGF-1 levels which was coupled with enhanced hippocampal reactive astrocytosis and significantly greater GFAP levels relative to WT mice. IGF-1 overexpression stimulated Akt phosphorylation and reduced acute (1 and 3d) hippocampal neurodegeneration, culminating in greater neuron survival at 10d after CCI injury. Hippocampal neuroprotection achieved by IGF-1 overexpression was accompanied by improved motor and cognitive function in brain-injured mice. These data provide strong support for the therapeutic efficacy of increased brain levels of IGF-1 in the setting of TBI.	[Madathil, Sindhu K.; Carlson, Shaun W.; Brelsfoard, Jennifer M.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40508 USA; [Ye, Ping; D'Ercole, A. Joseph] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA		Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40508 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012	Carlson, Shaun/0000-0002-1413-5075	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS058484, NS072302, NS051220]; Kentucky Spinal Cord and Head Injury Research Trust [KSCHIRT 7-20]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072302] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) NS058484, NS072302, and NS051220, and KSCHIRT 7-20 Kentucky Spinal Cord and Head Injury Research Trust fellowship to SKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; Brywe KG, 2005, EUR J NEUROSCI, V21, P1489, DOI 10.1111/j.1460-9568.2005.03982.x; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Cao Y, 2003, J CEREBR BLOOD F MET, V23, P739, DOI 10.1097/01.WCB.0000067720.12805.6F; Cheng BX, 2011, MOL CELL NEUROSCI, V47, P181, DOI 10.1016/j.mcn.2011.04.002; CHERNAUSEK SD, 1993, J NEUROSCI RES, V34, P189, DOI 10.1002/jnr.490340206; Conte V., 2003, EUR J TRAUMA, V7, P335; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Delaney CL, 1999, J NEUROBIOL, V41, P540, DOI 10.1002/(SICI)1097-4695(199912)41:4<540::AID-NEU9>3.0.CO;2-P; Delaney CL, 2001, J NEUROPATH EXP NEUR, V60, P147, DOI 10.1093/jnen/60.2.147; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fletcher L, 2009, J NEUROSURG, V111, P164, DOI 10.3171/2009.2.JNS081199; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Giralt A, 2010, GENE THER, V17, P1294, DOI 10.1038/gt.2010.71; Giralt A, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-71; Goddard DR, 1999, J NEUROSCI RES, V57, P74, DOI 10.1002/(SICI)1097-4547(19990701)57:1<74::AID-JNR8>3.0.CO;2-O; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Horwood JM, 2006, EUR J NEUROSCI, V23, P3375, DOI 10.1111/j.1460-9568.2006.04859.x; Hunsaker MR, 2008, BEHAV BRAIN RES, V188, P310, DOI 10.1016/j.bbr.2007.11.015; Karpova A, 2006, NEUROSCIENCE, V137, P833, DOI 10.1016/j.neuroscience.2005.10.012; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kesner RP, 2007, PROG BRAIN RES, V163, P567, DOI 10.1016/S0079-6123(07)63030-1; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Lin SY, 2011, BRAIN RES, V1385, P246, DOI 10.1016/j.brainres.2011.02.013; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; McMorris FA, 1996, BRAIN PATHOL, V6, P313, DOI 10.1111/j.1750-3639.1996.tb00858.x; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Takadera T, 1999, J NEUROCHEM, V73, P548, DOI 10.1046/j.1471-4159.1999.0730548.x; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zheng WH, 2000, ADV RES NEURODEGENER, V8, P261; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801; Zhu W, 2009, J CEREBR BLOOD F MET, V29, P1528, DOI 10.1038/jcbfm.2009.75	74	63	63	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2013	8	6							e67204	10.1371/journal.pone.0067204			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IX	WOS:000321150000044	23826235	Green Published, Green Submitted, gold			2022-02-06	
J	Miller, DM; Singh, IN; Wang, JA; Hall, ED				Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Nrf2; Mitochondria; Oxidative damage; Lipid peroxidation; 4-Hydroxy-2-nonenal; Free radicals	TRAUMATIC BRAIN-INJURY; TRANSCRIPTION FACTOR NRF2; COMPLEX-II INHIBITION; SPINAL-CORD-INJURY; OXIDATIVE STRESS; NITRIC-OXIDE; ALKENAL/ONE OXIDOREDUCTASE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; IN-VITRO	The transcription factor NF-E2-related factor 2 (Nrf2) mediates transcription of antioxidant/cytoprotective genes by binding to the antioxidant-response element (ARE) within DNA. Upregulation of these genes constitutes a pleiotropic cytoprotective defense pathway, which has been shown to produce neuroprotection in numerous models by decreasing lipid peroxidation (LP) as measured by the neurotoxic LP by-product 4-hydroxynonenal (4-HNE). As neuronal mitochondria have previously been shown to be susceptible to insult-induced LP-mediated oxidative damage, we sought to mechanistically investigate whether Nrf2-ARE activation in vivo could protect mitochondria from subsequent 4-HNE exposure ex vivo. Young adult male CF-1 mice were administered one of two known Nrf2-ARE activators as single intraperitoneal doses-sulforaphane (SFP; 5.0 mg/kg) or carnosic acid (CA; 1.0 mg/kg)-or their respective vehicles 48 h before Ficoll isolation of rat cerebral cortical mitochondria. Purified mitochondria were then exposed ex vivo to 4-HNE for 15 min. at 37 degrees C which we showed to cause a concentration-related inhibition of mitochondrial respiration together with covalent binding of 4-HNE to mitochondrial proteins. We chose a 30 mu M concentration of 4-HNE, which produced an approximately 50% inhibition of complex I- or complex II-driven respiration, to assess whether prior in vivo Nrf2-ARE-activating compounds would increase the resistance of the isolated, cortical mitochondria to 4-HNE's mitotoxic effects. Administration of either compound significantly increased (p < 0.05) expression of heme oxygenase-1 mRNA in cortical tissue 48 h postadministration, verifying that both compounds were capable of inducing the Nrf2-ARE pathway. Moreover, the prior in vivo administration of SFP and CA significantly (p < 0.05) attenuated 4-HNE-induced inhibition of mitochondrial respiration for complex I, but only carnosic acid acted to protect complex II. Furthermore, both CA and SFP significantly (p < 0.05) reduced the amount of 4-HNE bound to mitochondrial proteins as determined by Western blot. These results demonstrate the capability of in vivo Nrf2-ARE induction to protect from 4-HNE toxicity to cortical mitochondria ex vivo. Ongoing studies will determine the therapeutic efficacy of Nrf2-ARE activators to attenuate traumatic brain injury-induced pathophysiology. (C) 2013 Elsevier Inc. All rights reserved.	[Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Miller, Darren M.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St BBSRB Room B477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		Kentucky Spinal Cord 82 Head Injury Research Trust;  [NIH-NIDA 1T32 DA022738];  [NIH-NINDS 2P30 NS051220-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, T32NS077889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by Grants NIH-NIDA 1T32 DA022738 and NIH-NINDS 2P30 NS051220-01 and funds from the Kentucky Spinal Cord 82 Head Injury Research Trust.	Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bosken J.M., 2012, ANIMAL MODELS NEUROL, P347; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Dick RA, 2001, J BIOL CHEM, V276, P40803, DOI 10.1074/jbc.M105487200; Greco T, 2011, FREE RADICAL BIO MED, V51, P2164, DOI 10.1016/j.freeradbiomed.2011.09.017; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; Hall E. D, 1996, NEUROSURGERY, P505; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Innamorato NG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011838; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; Kraft AD, 2007, EXP NEUROL, V207, P107, DOI 10.1016/j.expneurol.2007.05.026; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pettazzoni P, 2011, FREE RADICAL BIO MED, V51, P1610, DOI 10.1016/j.freeradbiomed.2011.07.009; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Yu X, 2006, J BIOL CHEM, V281, P26245, DOI 10.1074/jbc.M604620200; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	51	63	64	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	APR	2013	57						1	9		10.1016/j.freeradbiomed.2012.12.011			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	105AC	WOS:000316037000001	23275005	Green Accepted			2022-02-06	
J	Gatson, JW; Liu, MM; Abdelfattah, K; Wigginton, JG; Smith, S; Wolf, S; Minei, JP				Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Minei, Joseph P.			Resveratrol decreases inflammation in the brain of mice with mild traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						TBI; Resveratrol; microglia; IL-6; IL-12; mice	COGNITIVE DEFICITS; LIPID-PEROXIDATION; AXONAL INJURY; ADULT-RAT; NEUROGENESIS; ACTIVATION; CELLS; MODEL	BACKGROUND: Following a mild traumatic brain injury (TBI) event, the secondary brain injury that persists after the initial blow to the head consists of excitotoxicity, decreased cerebral glucose levels, oxidant injury, mitochondrial dysfunction, inflammation, and neuronal cell death. To date, there are no effective interventions used at decreasing secondary brain injury after mild TBI. METHODS: In this study, male mice were treated with either placebo or resveratrol (100 mg/kg) at 5 minutes and 12 hours after mild TBI. The mice were injured using the controlled cortical impact device. In this closed-head model, a midline incision was made to access the skull and the impactor tip was aligned on the sagittal suture midway between the bregma and lambda sutures. The mice were injured at a depth of 2.0 mm, velocity of 4 m/s, and a delay time of 100 milliseconds. At 72 hours following injury, the animals were intracardially perfused with 0.9% saline followed by 10% phosphate-buffered formalin. The whole brain was removed, sliced, and stained for microglial activation (Iba1). In addition, using the enzyme-linked immunosorbent assay, tissue levels of interleukin 6 (IL-6) and IL-12 were measured in the cerebral cortex and hippocampus. RESULTS: In this study, we found that in the placebo treatment group, there was a significant increase in Iba1 staining in the brain. The levels of microglial activation was reduced by resveratrol in the cerebral cortex (p < 0.001), corpus callosum (p < 0.001), and dentate gyrus (p < 0.005) brain regions after mild TBI. In addition to Iba1, resveratrol decreased the brain levels of IL-6 (p < 0.0001) and IL-12 (p < 0.004), which were observed in the hippocampus of the placebo group. In our model, no increase of IL-6 or IL-12 was observed in the cerebral cortex following TBI. CONCLUSION: Resveratrol given acutely after TBI results in a decrease in neuroinflammation. These results suggest that resveratrol may be beneficial in reducing secondary brain injury after experiencing a mild TBI. (J Trauma Acute Care Surg. 2013; 74: 470-475. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, Dallas, TX 75390 USA		Gatson, JW (corresponding author), Dept Surg, Div Burn Trauma Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsouthwestern.edu		Wolf, Steven/0000-0003-2972-3440; Wigginton, Jane/0000-0002-8561-3492	Department Of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas	This study was supported by the Department Of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza CC, 2001, J ATHL TRAINING, V36, P228; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hao HD, 2004, J MED FOOD, V7, P290, DOI 10.1089/jmf.2004.7.290; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Kasdallah-Grissa A, 2006, ALCOHOL ALCOHOLISM, V41, P236, DOI 10.1093/alcalc/agh256; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; MAYEVSKY A, 1974, BRAIN RES, V65, P529, DOI 10.1016/0006-8993(74)90243-1; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Redell JB, 2012, J NEUROTRAUM, V29, P2283; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Washington PM, 2012, J NEUROTRAUMA; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; ZALESKA MM, 1985, NEUROCHEM RES, V10, P397, DOI 10.1007/BF00964608; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; ZHUANG H, 2003, ANN NY ACAD SCI, V993, P287, DOI DOI 10.1111/J.1749-6632.2003.TB07531.X	32	63	66	2	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					470	474		10.1097/TA.0b013e31827e1f51			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	108UH	WOS:000316321200033	23354240				2022-02-06	
J	Legrand, A; Jeanjean, P; Delanghe, F; Peltier, J; Lecat, B; Dupont, H				Legrand, Aurelien; Jeanjean, Patrick; Delanghe, Fanny; Peltier, Johann; Lecat, Benoit; Dupont, Herve			Estimation of optic nerve sheath diameter on an initial brain computed tomography scan can contribute prognostic information in traumatic brain injury patients	CRITICAL CARE			English	Article							RAISED INTRACRANIAL-PRESSURE; OCULAR SONOGRAPHY; ULTRASOUND; HYPERTENSION; ULTRASONOGRAPHY; VALIDATION; ACCURACY	Introduction: The aim of this study was to evaluate the prognostic value of optic nerve sheath diameter (ONSD) measured on the initial brain computed tomography (CT) scan for intensive care unit (ICU) mortality in severe traumatic brain injury (TBI) patients. Methods: A prospective observational study of all severe TBI patients admitted to a neurosurgical ICU (over a 10-month period). Demographic and clinical data and brain CT scan results were recorded. ONSD for each eye was measured on the initial CT scan. The group of ICU survivors was compared to non-survivors. Glasgow Outcome Scale (GOS) was evaluated six months after ICU discharge. Results: Seventy-seven patients were included (age: 43 +/- 18; 81% males; mean Injury Severity Score: 35 +/- 15; ICU mortality: 28.5% (n = 22)). Mean ONSD on the initial brain CT scan was 7.8 +/- 0.1 mm in non-survivors vs. 6.8 +/- 0.1 mm in survivors (P < 0.001). The operative value of ONSD was a good predictor of mortality (area under the curve: 0.805). An ONSD cutoff >= 7.3 had a sensitivity of 86.4% and a specificity of 74.6% and was independently associated with mortality in this population (adjusted odds ratio 95% confidence interval: 22.7 (3.2 to 159.6), P = 0.002). There was a relationship between initial ONSD values and six-month GOS (P = 0.03). Conclusions: ONSD measured on the initial brain CT scan is independently associated with ICU mortality rate (when >= 7.3 mm) in severe TBI patients.	[Legrand, Aurelien; Jeanjean, Patrick; Delanghe, Fanny; Lecat, Benoit; Dupont, Herve] Amiens Univ Hosp, Dept Anaesthesiol & Crit Care Med, Neurosurg Intens Care Unit, F-80054 Amiens, France; [Peltier, Johann] Amiens Univ Hosp, Dept Neurosurg, F-80054 Amiens, France; [Dupont, Herve] Jules Verne Univ Picardy, INSERM U 1088, F-80036 Amiens, France		Dupont, H (corresponding author), Amiens Univ Hosp, Dept Anaesthesiol & Crit Care Med, Neurosurg Intens Care Unit, Pl Victor Pauchet, F-80054 Amiens, France.	dupont.herve@chu-amiens.fr	Dupont, Herve/D-1259-2010				BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Carenini BB, 2002, ACTA OPHTHALMOL SCAN, V80, P40; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clavier N, 2000, PRISE CHARGE TRAUMAT; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Ditillo M, 2011, J TRAUMA, V71, P373; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI [10.1186/cc6893, 10.1186/cc7006]; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; GIBBY WA, 1993, AM J ROENTGENOL, V160, P143, DOI 10.2214/ajr.160.1.8416612; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jaggi GP, 2012, BRIT J OPHTHALMOL, V96, P53, DOI 10.1136/bjo.2010.199224; JENNETT B, 1975, LANCET, V1, P480; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Kramer LA, 2012, RADIOLOGY, V263, P819, DOI 10.1148/radiol.12111986; Lagreze WA, 2007, INVEST OPHTH VIS SCI, V48, P1913, DOI 10.1167/iovs.06-1075; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Ozgen A, 1998, AM J ROENTGENOL, V170, P1093, DOI 10.2214/ajr.170.4.9530066; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Watanabe A, 2008, J NEUROSURG, V109, P255, DOI 10.3171/JNS/2008/109/8/0255; Watanabe Y, 2006, J NEUROSURG, V105, P190, DOI 10.3171/sup.2006.105.7.190	43	63	65	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	2							R61	10.1186/cc12589			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264OG	WOS:000327887300026	23536993	Green Published, gold			2022-02-06	
J	Clayton, EH; Genin, GM; Bayly, PV				Clayton, Erik H.; Genin, Guy M.; Bayly, Philip V.			Transmission, attenuation and reflection of shear waves in the human brain	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						traumatic brain injury; magnetic resonance imaging; MR elastography; displacement; strain; blast	MAGNETIC-RESONANCE ELASTOGRAPHY; ACOUSTIC STRAIN WAVES; DIFFUSE AXONAL INJURY; MR ELASTOGRAPHY; VISCOELASTIC PROPERTIES; HEAD INJURY; DEFORMATION; ACCELERATION; IMPACT; FLOW	Traumatic brain injuries (TBIs) are caused by acceleration of the skull or exposure to explosive blast, but the processes by which mechanical loads lead to neurological injury remain poorly understood. We adapted motion-sensitive magnetic resonance imaging methods to measure the motion of the human brain in vivo as the skull was exposed to harmonic pressure excitation (45, 60 and 80 Hz). We analysed displacement fields to quantify the transmission, attenuation and reflection of distortional (shear) waves as well as viscoelastic material properties. Results suggest that internal membranes, such as the falx cerebri and the tentorium cerebelli, play a key role in reflecting and focusing shear waves within the brain. The skull acts as a low-pass filter over the range of frequencies studied. Transmissibility of pressure waves through the skull decreases and shear wave attenuation increases with increasing frequency. The skull and brain function mechanically as an integral structure that insulates internal anatomic features; these results are valuable for building and validating mathematical models of this complex and important structural system.	[Clayton, Erik H.; Genin, Guy M.; Bayly, Philip V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Bayly, Philip V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA		Clayton, EH (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr,Campus Box 1185, St Louis, MO 63130 USA.	clayton@wustl.edu		Bayly, Philip/0000-0003-4303-0704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support for this study was provided by NIH grant R01 NS055951 (Bayly). The authors gratefully acknowledge Dr Bradley Bolster and Dr Agus Priatna at Siemens Healthcare for supporting MR pulse sequence development as well as technologists Glenn Foster, Scott Love and Mark Nolte at Washington University's Center for Clinical Imaging Research for assistance with MRI data acquisition.	Abney TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022063; Auld B. A., 1990, ACOUSTIC FIELDS WAVE; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Braun J, 2001, MAGN RESON IMAGING, V19, P703, DOI 10.1016/S0730-725X(01)00387-3; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; EHMAN RL, 1990, MAGNET RESON MED, V14, P293, DOI 10.1002/mrm.1910140214; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Grimm R. C., 2006, MRE WAVE VERSION 1 J; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Hamhaber U, 2010, J MAGN RESON IMAGING, V32, P577, DOI 10.1002/jmri.22294; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Holbourn AHS, 1943, LANCET, V2, P438; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; KNUTSSON H, 1994, IEEE IMAGE PROC, P36, DOI 10.1109/ICIP.1994.413270; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse SA, 2000, PHYS MED BIOL, V45, P1579, DOI 10.1088/0031-9155/45/6/313; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCracken P, 2004, LECT NOTES COMPUT SC, V3217, P1081; McCracken P. J., 2003, MR ELASTOGRAPHY STUD, P799; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MORAN PR, 1991, RADIOLOGY, V180, P115, DOI 10.1148/radiology.180.1.2052676; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, MAGN RESON MED, V36, P266, DOI 10.1002/mrm.1910360214; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; PERMAN WH, 1986, J COMPUT ASSIST TOMO, V10, P473; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Sinkus R, 2000, PHYS MED BIOL, V45, P1649, DOI 10.1088/0031-9155/45/6/317; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Streitberger KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029888; Streitberger KJ, 2011, NMR BIOMED, V24, P385, DOI 10.1002/nbm.1602; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Whitham G.B., 1974, LINEAR NONLINEAR WAV; Wuerfel J, 2010, NEUROIMAGE, V49, P2520, DOI 10.1016/j.neuroimage.2009.06.018; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034	48	63	64	0	28	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	NOV 7	2012	9	76					2899	2910		10.1098/rsif.2012.0325			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XD	WOS:000309269100014	22675163	Bronze, Green Published			2022-02-06	
J	Leopold, A; Krueger, F; dal Monte, O; Pardini, M; Pulaski, SJ; Solomon, J; Grafman, J				Leopold, Anne; Krueger, Frank; dal Monte, Olga; Pardini, Matteo; Pulaski, Sarah J.; Solomon, Jeffrey; Grafman, Jordan			Damage to the left ventromedial prefrontal cortex impacts affective theory of mind	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						affective theory of mind; ventromedial prefrontal cortex; traumatic brain injury; emotional intelligence; empathy	EMOTIONAL INTELLIGENCE; BRAIN-LESIONS; RHESUS-MONKEY; FALSE BELIEF; HEAD-INJURY; DISSOCIATION; IMPAIRMENTS; EMPATHY; DEPRESSION; AUTISM	Studies investigating theory of mind (ToM) abilities (i.e. ability to understand and predict others' mental states) have revealed that affective and cognitive functions play a significant role and that each of those functions are associated with distinct neural networks. Cognitive facets of ToM have implicated the medial prefrontal cortex, temporo-parietal junction and the anterior paracingulate cortex, whereas affective facets have implicated the ventromedial prefrontal cortex (vmPFC). Although the vmPFC has repeatedly shown to be critical for affective functions, knowledge regarding the exact role of the left and right vmPFC in affective ToM is still obscure. Here, we compared performances of 30 patients with left, right and bilateral vmPFC lesions to two comparison groups (one without and one with brain injuries) on the Faux Pas Recognition task measuring the facets of ToM. We also investigated whether any deficits may be associated with other emotional measures, namely emotional empathy and emotional intelligence. Our results extend earlier findings by showing that the vmPFC is associated with abilities in affective ToM. More importantly, our results revealed that the left, and not the right vmPFC as indicated previously, is involved in affective ToM and that this deficit is associated with emotional intelligence.	[Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ 07052 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [dal Monte, Olga] Univ Turin, Dept Neuropsychol, Turin, Italy; [dal Monte, Olga] Henry M Jackson Fdn, Rockville, MD USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Solomon, Jeffrey] Med Numer, Germantown, MD USA; [Leopold, Anne; dal Monte, Olga; Pulaski, Sarah J.] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Leopold, Anne] Univ Utrecht, Dept Social & Hlth Psychol, Utrecht, Netherlands		Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	FKrueger@gmu.edu; jgrafman@kesslerfoundation.org	Dal Monte, Olga/P-3759-2018; Pardini, Matteo/F-8414-2010	Dal Monte, Olga/0000-0002-7823-4769; Pardini, Matteo/0000-0002-4740-1982; Grafman, Jordan H./0000-0001-8645-4457	National Naval Medical Center; U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U. S. Government. The authors are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities. We are grateful to S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding and G. Tasick for their invaluable help with the testing of participants and organization of this study. The work was supported by the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study), grant number: DAMD17-01-1-0675.	Acuna BD, 2002, CEREB CORTEX, V12, P1312, DOI 10.1093/cercor/12.12.1312; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; [Anonymous], 2006, SPSS WIND REL 14 0 1; [Anonymous], 1960, ARMED FORCES QUALIFI; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; Critchley HD, 2000, J NEUROSCI, V20, P3033; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1093/neucas/5.4.345; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Goel V, 2004, BRAIN, V127, P783, DOI 10.1093/brain/awh086; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Goel V, 2003, NEUROIMAGE, V20, P2314, DOI 10.1016/j.neuroimage.2003.07.027; Goel V, 2000, NEUROIMAGE, V12, P504, DOI 10.1006/nimg.2000.0636; Goel V, 2007, CEREB CORTEX, V17, P2245, DOI 10.1093/cercor/bhl132; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; KAPLAN E, 1976, BOSTON NAMING TEST; Knauff M, 2003, J COGNITIVE NEUROSCI, V15, P559, DOI 10.1162/089892903321662949; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Koenigs M, 2009, NEUROSCI LETT, V459, P88, DOI 10.1016/j.neulet.2009.04.063; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; Krueger F, 2009, TRENDS COGN SCI, V13, P103, DOI 10.1016/j.tics.2008.12.005; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mayer J.D., 2002, TEST VERSION 2 0 USE; Mayer JD, 2004, PSYCHOL INQ, V15, P197, DOI 10.1207/s15327965pli1503_02; Mayer JD, 2008, AM PSYCHOL, V63, P503, DOI 10.1037/0003-066X.63.6.503; Mayer JD, 2001, EMOTION, V1, P232, DOI 10.1037//1528-3542.1.3.232; Miller SA, 2009, PSYCHOL BULL, V135, P749, DOI 10.1037/a0016854; PANDYA DN, 1969, BRAIN RES, V15, P594, DOI 10.1016/0006-8993(69)90193-0; PERNER J, 1987, BRIT J DEV PSYCHOL, V5, P125, DOI 10.1111/j.2044-835X.1987.tb01048.x; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Reverberi C, 2005, NEUROPSYCHOLOGIA, V43, P460, DOI 10.1016/j.neuropsychologia.2004.06.008; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Sabbagh MA, 2004, BRAIN COGNITION, V55, P209, DOI 10.1016/j.bandc.2003.04.002; Sabbagh MA, 1999, BRAIN LANG, V70, P29, DOI 10.1006/brln.1999.2139; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2006, SOC NEUROSCI-UK, V1, P149, DOI 10.1080/17470910600985589; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2007, PSYCHIAT RES, V149, P11, DOI 10.1016/j.psychres.2005.10.018; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Singer T, 2006, NEUROSCI BIOBEHAV R, V30, P855, DOI 10.1016/j.neubiorev.2006.06.011; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Strenziok M, 2011, SOC COGN AFFECT NEUR, V6, P2, DOI 10.1093/scan/nsp036; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; VANHOESEN GW, 1975, BRAIN RES, V95, P25, DOI 10.1016/0006-8993(75)90205-X; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D., 1997, MEASUREMENT ADULT IN; Wellman H. M., 1990, CHILDS THEORY MIND; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	72	63	64	1	56	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	NOV	2012	7	8					871	880		10.1093/scan/nsr071			10	Neurosciences; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	045BZ	WOS:000311671100001	22021651	Green Published, hybrid			2022-02-06	
J	Oddo, M; Levine, JM; Kumar, M; Iglesias, K; Frangos, S; Maloney-Wilensky, E; Le Roux, PD				Oddo, Mauro; Levine, Joshua M.; Kumar, Monisha; Iglesias, Katia; Frangos, Suzanne; Maloney-Wilensky, Eileen; Le Roux, Peter D.			Anemia and brain oxygen after severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Hemoglobin; Brain tissue oxygen tension; Anemia; Traumatic brain injury; Cerebral oxygenation; Clinical study; Humans; Outcome; Brain oxygen; Brain injury	BLOOD-CELL TRANSFUSION; TISSUE OXYGEN; HEAD-INJURY; HEMODILUTIONAL ANEMIA; CEREBRAL OXYGENATION; TENSION; CLASSIFICATION; MORTALITY; PERFUSION; DELIVERY	To investigate the relationship between hemoglobin (Hgb) and brain tissue oxygen tension (PbtO(2)) after severe traumatic brain injury (TBI) and to examine its impact on outcome. This was a retrospective analysis of a prospective cohort of severe TBI patients whose PbtO(2) was monitored. The relationship between Hgb-categorized into four quartiles (a parts per thousand currency sign9; 9-10; 10.1-11; > 11 g/dl)-and PbtO(2) was analyzed using mixed-effects models. Anemia with compromised PbtO(2) was defined as episodes of Hgb a parts per thousand currency sign 9 g/dl with simultaneous PbtO(2) < 20 mmHg. Outcome was assessed at 30 days using the Glasgow outcome score (GOS), dichotomized as favorable (GOS 4-5) vs. unfavorable (GOS 1-3). We analyzed 474 simultaneous Hgb and PbtO(2) samples from 80 patients (mean age 44 +/- A 20 years, median GCS 4 (3-7)). Using Hgb > 11 g/dl as the reference level, and controlling for important physiologic covariates (CPP, PaO2, PaCO2), Hgb a parts per thousand currency sign 9 g/dl was the only Hgb level that was associated with lower PbtO(2) (coefficient -6.53 (95 % CI -9.13; -3.94), p < 0.001). Anemia with simultaneous PbtO(2) < 20 mmHg, but not anemia alone, increased the risk of unfavorable outcome (odds ratio 6.24 (95 % CI 1.61; 24.22), p = 0.008), controlling for age, GCS, Marshall CT grade, and APACHE II score. In this cohort of severe TBI patients whose PbtO(2) was monitored, a Hgb level no greater than 9 g/dl was associated with compromised PbtO(2). Anemia with simultaneous compromised PbtO(2), but not anemia alone, was a risk factor for unfavorable outcome, irrespective of injury severity.	[Oddo, Mauro] CHU Vaudois, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Oddo, Mauro; Levine, Joshua M.; Kumar, Monisha; Frangos, Suzanne; Maloney-Wilensky, Eileen; Le Roux, Peter D.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Iglesias, Katia] Univ Lausanne Hosp, CHUV, Inst Social & Prevent Med, Fac Biol & Med, CH-1011 Lausanne, Switzerland		Oddo, M (corresponding author), CHU Vaudois, Dept Intens Care Med, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Society of Intensive Care Medicine (ECCRN Clinical Research Award); Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by grants from the Swiss National Science Foundation (grant no. 320030_138191) and the European Society of Intensive Care Medicine (ECCRN Clinical Research Award 2010) (to M. O.), and the Integra Foundation and the Mary Elisabeth Groff Surgical and Medical Research Trust (to P.D.L.).	Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Dexter F, 1997, BRIT J ANAESTH, V79, P346, DOI 10.1093/bja/79.3.346; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hare Gregory M T, 2004, Curr Opin Anaesthesiol, V17, P363, DOI 10.1097/00001503-200410000-00003; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Rigamonti A, 2008, BRIT J ANAESTH, V100, P357, DOI 10.1093/bja/aem401; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, V4, P5103; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023	35	63	66	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2012	38	9					1497	1504		10.1007/s00134-012-2593-1			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992GT	WOS:000307764300011	22584800	Green Submitted			2022-02-06	
J	Natale, JE; Joseph, JG; Rogers, AJ; Mahajan, P; Cooper, A; Wisner, DH; Miskin, ML; Hoyle, JD; Atabaki, SM; Dayan, PS; Holmes, JF; Kuppermann, N				Natale, JoAnne E.; Joseph, Jill G.; Rogers, Alexander J.; Mahajan, Prashant; Cooper, Arthur; Wisner, David H.; Miskin, Michelle L.; Hoyle, John D., Jr.; Atabaki, Shireen M.; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		PECARN	Cranial Computed Tomography Use Among Children With Minor Blunt Head Trauma	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							DEPARTMENT WAIT TIMES; EMERGENCY-DEPARTMENT; ETHNIC DISPARITIES; BRAIN-INJURY; HEALTH-CARE; RACE/ETHNICITY; RACE; ASSOCIATION; QUALITY; RISKS	Objective: To determine if patient race/ethnicity is independently associated with cranial computed tomography (CT) use among children with minor blunt head trauma. Design: Secondary analysis of a prospective cohort study. Setting: Pediatric research network of 25 North American emergency departments. Patients: In total, 42 412 children younger than 18 years were seen within 24 hours of minor blunt head trauma. Of these, 39 717 were of documented white non-Hispanic, black non-Hispanic, or Hispanic race/ethnicity. Using a previously validated clinical prediction rule, we classified each child's risk for clinically important traumatic brain injury to describe injury severity. Because no meaningful differences in cranial CT rates were observed between children of black non-Hispanic race/ethnicity vs Hispanic race/ethnicity, we combined these 2 groups. Main Outcome Measure: Cranial CT use in the emergency department, stratified by race/ethnicity. Results: In total, 13 793 children (34.7%) underwent cranial CT. The odds of undergoing cranial CT among children with minor blunt head trauma who were at higher risk for clinically important traumatic brain injury did not differ by race/ethnicity. In adjusted analyses, children of black non-Hispanic or Hispanic race/ethnicity had lower odds of undergoing cranial CT among those who were at intermediate risk (odds ratio, 0.86; 95% CI, 0.78-0.96) or lowest risk (odds ratio, 0.72; 95% CI, 0.65-0.80) for clinically important traumatic brain injury. Regardless of risk for clinically important traumatic brain injury, parental anxiety and request was commonly cited by physicians as an important influence for ordering cranial CT in children of white non-Hispanic race/ethnicity. Conclusions: Disparities may arise from the overuse of cranial CT among patients of nonminority races/ethnicities. Further studies should focus on explaining how medically irrelevant factors, such as patient race/ethnicity, can affect physician decision making, resulting in exposure of children to unnecessary health care risks.	[Natale, JoAnne E.; Kuppermann, Nathan] Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA; [Wisner, David H.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA; [Joseph, Jill G.] Univ Calif Davis, Betty Irene Moore Sch Nursing, Sacramento, CA 95817 USA; [Rogers, Alexander J.] Univ Michigan, Med Ctr, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Rogers, Alexander J.] Univ Michigan, Med Ctr, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; [Mahajan, Prashant] Childrens Hosp Michigan, Dept Pediat, Detroit, MI 48201 USA; [Mahajan, Prashant] Childrens Hosp Michigan, Dept Emergency Med, Detroit, MI 48201 USA; [Hoyle, John D., Jr.] Michigan State Univ, Helen DeVos Childrens Hosp, Dept Emergency Med, E Lansing, MI 48824 USA; [Cooper, Arthur] Columbia Univ, Coll Phys & Surg, Harlem Hosp Ctr, Dept Pediat Surg, New York, NY USA; [Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Dept Pediat Emergency Med, New York, NY USA; [Miskin, Michelle L.] Data Coordinating Ctr, Pediat Emergency Care Appl Res Network, Salt Lake City, UT USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA		Natale, JE (corresponding author), Univ Calif Davis, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	joanne.natale@ucdmc.ucdavis.edu		Tsung, James/0000-0002-4718-8325	Health Resources and Services Administration's Maternal and Child Health Bureau [R40MC02461, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]; Emergency Medical Services for Children; Division of Research, Education, and Training	This work was supported by grant R40MC02461 from the Health Resources and Services Administration's Maternal and Child Health Bureau, Emergency Medical Services for Children, and Division of Research, Education, and Training. The Pediatric Emergency Care Applied Research Network is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the Health Resources and Services Administration's Maternal and Child Health Bureau and Emergency Medical Services for Children.	Akinbami Lara J, 2011, NCHS Data Brief, P1; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Berdahl T, 2010, ACAD PEDIATR, V10, P95, DOI 10.1016/j.acap.2009.12.005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Chamberlain JM, 2007, PEDIATRICS, V119, pE1319, DOI 10.1542/peds.2006-2309; Faul M, 2010, TRAUMATIC BRAIN INJU; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Guagliardo MF, 2003, ACAD EMERG MED, V10, P1218, DOI 10.1197/S1069-6563(03)00492-5; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; James CA, 2005, PEDIATRICS, V115, pE310, DOI 10.1542/peds.2004-1541; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; Park CY, 2009, HEALTH SERV RES, V44, P2022, DOI 10.1111/j.1475-6773.2009.01020.x; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Richardson LD, 2003, ACAD EMERG MED, V10, P1184, DOI 10.1197/S1069-6563(03)00487-1; Richardson LP, 2003, ARCH PEDIAT ADOL MED, V157, P984, DOI 10.1001/archpedi.157.10.984; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Takakuwa KM, 2010, AM J ROENTGENOL, V195, P1151, DOI 10.2214/AJR.09.3847; Tamayo-Sarver JH, 2003, AM J PUBLIC HEALTH, V93, P2067, DOI 10.2105/AJPH.93.12.2067; Walsh-Kelly CM, 2008, PEDIATR EMERG CARE, V24, P505, DOI 10.1097/PEC.0b013e318180fdcb; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Wu BU, 2009, AM J GASTROENTEROL, V104, P1668, DOI 10.1038/ajg.2009.189; Yen K, 2003, ANN EMERG MED, V42, P41, DOI 10.1067/mem.2003.230	27	63	63	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	AUG	2012	166	8					732	737					6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	984KU	WOS:000307189300008	22869404				2022-02-06	
J	van Leeuwen, N; Lingsma, HF; Perel, P; Lecky, F; Roozenbeek, B; Lu, J; Shakur, H; Weir, J; Steyerberg, EW; Maas, AIR				van Leeuwen, Nikki; Lingsma, Hester F.; Perel, Pablo; Lecky, Fiona; Roozenbeek, Bob; Lu, Juan; Shakur, Haleema; Weir, James; Steyerberg, Ewout W.; Maas, Andrew I. R.		Int Mission Prognosis Clinical; Corticosteroid Randomization; Trauma Audit Res Network	Prognostic Value of Major Extracranial Injury in Traumatic Brain Injury: An Individual Patient Data Meta-analysis in 39 274 Patients	NEUROSURGERY			English	Article						Acute care; Extracranial injury; Meta-analysis; Prognosis; Trauma; Traumatic brain injury	HEAD-INJURY; MISSING VALUES; IMPUTATION; MORTALITY; DESIGN; MODELS; TRENDS; CARE	BACKGROUND: Major extracranial injury (MEI) is common in traumatic brain injury (TBI) patients, but the effect on outcome is controversial. OBJECTIVE: To assess the prognostic value of MEI on mortality after TBI in an individual patient data meta-analysis of 3 observational TBI studies (International Mission on Prognosis and Clinical Trial Design in TBI [IMPACT]), a randomized controlled trial (Corticosteroid Randomization After Significant Head Injury [CRASH]), and a trauma registry (Trauma Audit and Research Network [TARN]). METHODS: MEI (extracranial injury with an Abbreviated Injury Scale >= 3 or requiring hospital admission) was related to mortality with logistic regression analysis, adjusted for age, Glasgow Coma Scale motor score, and pupil reactivity and stratified by TBI severity. We pooled odds ratios (ORs) with random-effects meta-analysis. RESULTS: We included 39 274 patients. Mortality was 25%, and 32% had MEI. MEI was a strong predictor for mortality in TARN, with adjusted odds ratios of 2.81 (95% confidence interval [CI], 2.44-3.23) in mild, 2.18 (95% CI, 1.80-2.65) in moderate, and 2.14 (95% CI, 1.95-2.35) in severe TBI patients. The prognostic effect was smaller in IMPACT and CRASH, with pooled adjusted odds ratios of 2.14 (95% CI, 0.93-4.91) in mild, 1.46 (95% CI, 1.14-1.85) in moderate, and 1.18 (95% CI, 1.03-1.55) in severe TBI. When patients who died within 6 hours after injury were excluded from TARN, the effect of MEI was comparable with IMPACT and CRASH. CONCLUSION: MEI is an important prognostic factor for mortality in TBI patients. However, the effect varies by population, which explains the controversy in the literature. The strength of the effect is smaller in patients with more severe brain injury and depends on time of inclusion in a study.	[van Leeuwen, Nikki; Lingsma, Hester F.; Roozenbeek, Bob; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Perel, Pablo; Shakur, Haleema] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, London WC1, England; [Lecky, Fiona] Hope Hosp, Trauma Audit & Res Network, Manchester, Lancs, England; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Weir, James] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland		Lingsma, HF (corresponding author), POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	IBIS, NEUROCRITICOS/C-1805-2016; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; /0000-0002-2342-301X; Lu, Juan/0000-0002-5389-7603; Shakur-Still, Haleema/0000-0002-6511-109X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-42691]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Grant support was provided by National Institutes of Health NS-42691. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Braet V, 2002, EMERG MED J, V19, P510; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015	18	63	64	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	APR	2012	70	4					811	818		10.1227/NEU.0b013e318235d640			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	914FF	WOS:000301934000028	21904253	Bronze			2022-02-06	
J	Andelic, N; Anke, A; Skandsen, T; Sigurdardottir, S; Sandhaug, M; Ader, T; Roe, C				Andelic, N.; Anke, A.; Skandsen, T.; Sigurdardottir, S.; Sandhaug, M.; Ader, T.; Roe, C.			Incidence of Hospital-Admitted Severe Traumatic Brain Injury and In-Hospital Fatality in Norway: A National Cohort Study	NEUROEPIDEMIOLOGY			English	Article						Severe traumatic brain injury; Hospital admissions; Adults; epidemiology; Incidence National cohort study; Case-fatality rate	HEAD-INJURY; NORDIC COUNTRIES; EPIDEMIOLOGY; POPULATION; MORTALITY; MANAGEMENT; OUTCOMES; IMPACT; CLASSIFICATION; EUROPE	Aims: The aims of this study were to assess the incidence of hospital-admitted severe traumatic brain injury (TBI) in the adult population in Norway, and to determine whether there were differences in the epidemiological characteristics of severe TBI between rural and urban regions. Methods: A prospective population-based study on adults with severe TBI admitted to the Norwegian Trauma Referral Centres during the 2-year period (2009-2010). The electronic patient register was searched weekly for ICD-10 diagnoses of intracranial injuries (S06.0-S06.9) to identify patients. Severe TBI was defined as lowest unsedated Glasgow Coma Scale Score <= 8 during the first 24 h after injury. Results: The annual age-adjusted incidence was estimated at 5.2/100,000 in 2009 and 4.1/100,000 in 2010. The highest frequency of hospitalized patients was found among the youngest and the oldest age groups. The most common causes of injury were falls and transport accidents. The highest in-hospital case-fatality rate was found among the oldest patients. There were consistent epidemiological characteristics of severe TBI from both rural and urban regions. Conclusions:The incidence of hospital-admitted patients with severe TBI in this national study supports the declining incidence of TBI reported internationally. No major differences were found in epidemiological characteristics between the urban and rural parts of Norway. Copyright (C) 2012 S. Karger AG, Basel	[Andelic, N.; Roe, C.] Oslo Univ Hosp, Dept Phys Med & Rehabil, NO-0424 Oslo, Norway; [Anke, A.] Univ Hosp N Norway, Div Rehabil, Tromso, Norway; [Anke, A.] Univ Tromso, Inst Clin Med, Fac Hlth Sci, Tromso, Norway; [Skandsen, T.] St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, T.] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway; [Sigurdardottir, S.] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Sandhaug, M.] Sorlandet Hosp, Res Unit, Dept Phys Med & Rehabil, Kristiansand, Norway; [Ader, T.] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Roe, C.] Univ Oslo, Fac Med, Oslo, Norway		Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, NO-0424 Oslo, Norway.	nadand@ous-hf.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406	Norwegian Research CouncilResearch Council of NorwayEuropean Commission	The authors would like to thank the Neurosurgical Department of Stavanger University Hospital for all their help with registrations from their patient registers. Thanks to Unn Manskow, Beate Holmquist Karlsen and Stine Borgen Lund for valuable help with data collection. Special thanks are extended to the Norwegian Patient Registry for personal communication/overview of the ICD-10 diagnoses for patients admitted to the Norwegian hospitals in 2009. This study was supported by grants from the Norwegian Research Council.	Andelic N, 2010, J TRAUMA MANAG OUTCO, V26, P4; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Annoni J M, 1992, Disabil Rehabil, V14, P23; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gerber Linda M, 2009, J Trauma Manag Outcomes, V3, P9, DOI 10.1186/1752-2897-3-9; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelly DF, 2001, WORLD J SURG, V25, P1179; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norwegian Institute for Alcohol and Drug Research, 2006, ALC DRUGS NORW, P28; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Skandsen T, 2010, MODERATE SEVERE TRAU; Sollid S, 2009, EMERG MED J, V26, P769, DOI 10.1136/emj.2008.061630; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Strand Bjorn Heine, 2003, Tidsskr Nor Laegeforen, V123, P2849; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x	40	63	64	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	38	4					259	267		10.1159/000338032			9	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Neurosciences & Neurology	963XV	WOS:000305659200011	22678449	Bronze			2022-02-06	
J	Goldman, SM; Kamel, F; Ross, GW; Jewell, SA; Bhudhikanok, GS; Umbach, D; Marras, C; Hauser, RA; Jankovic, J; Factor, SA; Bressman, S; Lyons, KE; Meng, C; Korell, M; Roucoux, DF; Hoppin, JA; Sandler, DP; Langston, JW; Tanner, CM				Goldman, Samuel M.; Kamel, Freya; Ross, G. Webster; Jewell, Sarah A.; Bhudhikanok, Grace S.; Umbach, David; Marras, Connie; Hauser, Robert A.; Jankovic, Joseph; Factor, Stewart A.; Bressman, Susan; Lyons, Kelly E.; Meng, Cheryl; Korell, Monica; Roucoux, Diana F.; Hoppin, Jane A.; Sandler, Dale P.; Langston, J. William; Tanner, Caroline M.			Head injury, alpha-synuclein Rep1, and Parkinson's disease	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL RISK-FACTORS; INFLAMMATORY RESPONSE; AMYLOID-BETA; CELL-DEATH; EXPRESSION; ACCUMULATION; PATHOGENESIS; ASSOCIATION; VARIABILITY	Objective: To test the hypothesis that variability in SNCA Rep1, a polymorphic dinucleotide microsatellite in the promoter region of the gene encoding a-synuclein, modifies the association between head injury and Parkinson's disease (PD) risk. Methods: Participants in the Farming and Movement Evaluation (FAME) and the Study of Environmental Association and Risk of Parkinsonism using Case-Control Historical Interviews (SEARCH), 2 independent case-control studies, were genotyped for Rep1 and interviewed regarding head injuries with loss of consciousness or concussion prior to Parkinson's disease (PD) diagnosis. Logistic regression modeling adjusted for potential confounding variables and tested interaction between Rep1 genotype and head injury. Results: Consistent with prior reports, relative to medium-length Rep1, short Rep1 genotype was associated with reduced PD risk (pooled odds ratio [OR], 0.7; 95% confidence interval [CI], 0.5-0.9), and long Rep1 with increased risk (pooled OR, 1.4; 95% CI, 0.95-2.2). Overall, head injury was not significantly associated with PD (pooled OR, 1.3; 95% CI, 0.9-1.8). However, head injury was strongly associated with PD in those with long Rep1 (FAME OR, 5.4; 95% CI, 1.5-19; SEARCH OR, 2.3; 95% CI, 0.6-9.2; pooled OR, 3.5; 95% CI 1.4-9.2, p-interaction 0.02). Individuals with both head injury and long Rep1 were diagnosed 4.9 years earlier than those with neither risk factor (p 0.03). Interpretation: While head injury alone was not associated with PD risk, our data suggest head injury may initiate and/ or accelerate neurodegeneration when levels of synuclein are high, as in those with Rep1 expansion. Given the high population frequency of head injury, independent verification of these results is essential. ANN NEUROL 2012; 71: 40-48	[Goldman, Samuel M.; Jewell, Sarah A.; Bhudhikanok, Grace S.; Meng, Cheryl; Korell, Monica; Roucoux, Diana F.; Langston, J. William; Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA 94085 USA; [Kamel, Freya; Hoppin, Jane A.; Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA; [Umbach, David] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA; [Ross, G. Webster] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA; [Jewell, Sarah A.] German Ctr Neurodegenerat Dis, DZNE, Bonn, Germany; [Marras, Connie] Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Hauser, Robert A.] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Bressman, Susan] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA; [Lyons, Kelly E.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA		Goldman, SM (corresponding author), Parkinsons Inst, 675 Almanor Ave, Sunnyvale, CA 94085 USA.	sgoldman@thepi.org	Hauser, Robert/I-5372-2012; Goldman, Samuel/A-2225-2014	Jewell, Sarah/0000-0002-9877-2599; Goldman, Samuel/0000-0002-3039-9927; Hoppin, Jane/0000-0001-8456-0969; Sandler, Dale/0000-0002-6776-0018	NIH (National Institute of Environmental Health Sciences [NIEHS])United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01-ES044007, Z01-ES049030, R01-ES10803, U54 ES012077, NCI Z01-CP010119]; Michael J. Fox Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [Z01CP010119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES049004, ZIAES049030, ZIAES044007] Funding Source: NIH RePORTER	This research was supported in part by the Intramural Research Program of the NIH (National Institute of Environmental Health Sciences [NIEHS] Z01-ES044007, Z01-ES049030, R01-ES10803 (C. M. T.), U54 ES012077 (C. M. T., J.W.L.); NCI Z01-CP010119); Michael J. Fox Foundation (C. M. T., J. W. L.); Parkinson's Unity Walk; James and Sharron Clark. SEARCH was supported by an unrestricted grant from a group of current and former manufacturers of welding consumables awarded to The Parkinson's Institute.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Alavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Caudle WM, 2009, EXP NEUROL, V220, P230, DOI 10.1016/j.expneurol.2009.09.027; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; Cronin KD, 2009, HUM MOL GENET, V18, P3274, DOI 10.1093/hmg/ddp265; DeMichele G, 1996, MOVEMENT DISORD, V11, P17, DOI 10.1002/mds.870110105; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dufty BM, 2007, AM J PATHOL, V170, P1725, DOI 10.2353/ajpath.2007.061232; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Faul M, 2010, TRAUMATIC BRAIN INJU; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Fuchs J, 2008, FASEB J, V22, P1327, DOI 10.1096/fj.07-9348com; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kay DM, 2008, AM J MED GENET B, V147B, P1222, DOI 10.1002/ajmg.b.30758; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lee JK, 2009, J NEUROIMMUNE PHARM, V4, P419, DOI 10.1007/s11481-009-9176-0; Linnertz C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007480; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; MARTYN CN, 1995, J NEUROL SCI, V132, P201, DOI 10.1016/0022-510X(95)00148-U; McCann SJ, 1998, NEUROEPIDEMIOLOGY, V17, P310, DOI 10.1159/000026185; McCormack AL, 2009, CURR PROTEIN PEPT SC, V10, P476, DOI 10.2174/138920309789351912; McCulloch CC, 2008, HUM GENET, V123, P257, DOI 10.1007/s00439-008-0466-z; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORANO A, 1994, ACTA NEUROL SCAND, V89, P164; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Norris EH, 2005, ANTIOXID REDOX SIGN, V7, P673; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Ross OA, 2008, ANN NEUROL, V63, P743, DOI 10.1002/ana.21380; Rugbjerg Kathrine, 2008, BMJ, V337, pa2494, DOI 10.1136/bmj.a2494; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Siebert H, 2010, J NEUROCHEM, V114, P1007, DOI 10.1111/j.1471-4159.2010.06832.x; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Spangenberg S, 2009, PARKINSONISM RELAT D, V15, P12, DOI 10.1016/j.parkreldis.2008.02.004; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Tanner CM, 2009, ARCH NEUROL-CHICAGO, V66, P1106, DOI 10.1001/archneurol.2009.195; Tanner CM, 2008, PARKINSONS DIS DIAGN, P387; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; Tsai CH, 2002, CLIN NEUROL NEUROSUR, V104, P328, DOI 10.1016/S0303-8467(02)00027-6; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wilms H, 2009, INT J IMMUNOPATH PH, V22, P897, DOI 10.1177/039463200902200405; Yao XL, 2008, J NEUROCHEM, V104, P353, DOI 10.1111/j.1471-4159.2007.04970.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	68	63	64	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2012	71	1					40	48		10.1002/ana.22499			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	880MW	WOS:000299412200008	22275250	Green Accepted			2022-02-06	
J	Hoffmann, M; Lefering, R; Rueger, JM; Kolb, JP; Izbicki, JR; Ruecker, AH; Rupprecht, M; Lehmann, W				Hoffmann, M.; Lefering, R.; Rueger, J. M.; Kolb, J. P.; Izbicki, J. R.; Ruecker, A. H.; Rupprecht, M.; Lehmann, W.		German Soc Trauma Surg	Pupil evaluation in addition to Glasgow Coma Scale components in prediction of traumatic brain injury and mortality	BRITISH JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; SCORE; MODELS	Background: Early diagnosis and prediction of traumatic brain injury (TBI) is essential for determining treatment strategies and allocating resources. This study evaluated the predictive accuracy of Glasgow Coma Scale (GCS) verbal, motor and eye components alone, or in addition to pupil size and reactivity, for TBI. Methods: A retrospective cohort analysis of data from 51 425 severely injured patients registered in the Trauma Registry of the German Society for Trauma Surgery from 1993 to 2009 was undertaken. Only directly admitted patients alive on admission and with complete data on GCS, pupil size and pupil reactivity were included. The unadjusted predictive roles of GCS components and pupil parameters, alone or in combination, were modelled using area under the receiver operating characteristic (AUROC) curve analyses and multivariable logistic regression regarding presence of TBI and death. Results: Some 24 115 patients fulfilled the study inclusion criteria. Best accuracy for outcome prediction was found for pupil reactivity (AUROC 0.770, 95 per cent confidence interval 0.761 to 0.779) and GCS motor component (AUROC 0.797, 0.788 to 0.805), with less accuracy for GCS eye and verbal components. The combination of pupil reactivity and GCS motor component (AUROC 0.822, 0.814 to 0.830) outmatched the predictive accuracy of GCS alone (AUROC 0.808, 0.800 to 0.815). Pupil reactivity and size were significantly correlated (r(s) = 0.56, P < 0.001). Patients displaying both unequal pupils and fixed pupils were most likely to have TBI (95.1 per cent of 283 patients). Good outcome (Glasgow Outcome Scale score 4 or more) was documented for only 1929 patients (8.0 per cent) showing fixed and bilateral dilated pupils. Conclusion: The best predictive accuracy for presence of TBI was obtained using the GCS components. Pupil reactivity together with the GCS motor component performed best in predicting death.	[Hoffmann, M.; Rueger, J. M.; Kolb, J. P.; Ruecker, A. H.; Rupprecht, M.; Lehmann, W.] Univ Hosp Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Univ Med Ctr Hamburg, D-20246 Hamburg, Germany; [Izbicki, J. R.] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Lefering, R.] Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med, Cologne, Germany		Hoffmann, M (corresponding author), Univ Hosp Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Univ Med Ctr Hamburg, Martinistr 52, D-20246 Hamburg, Germany.	mi.hoffmann@uke.de	Lehmann, Wolfgang/H-3555-2012				Alkhoury F, 2011, AM SURGEON, V77, P277; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; de Jongh MAC, 2011, BRIT J SURG, V98, P790, DOI 10.1002/bjs.7436; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Duncan R, 2009, J EMERG MED, V37, P451, DOI 10.1016/j.jemermed.2008.11.026; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Jain S, 2008, INJURY, V39, P598, DOI 10.1016/j.injury.2007.06.003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Klein KU, 2010, BEST PRACT RES-CLIN, V24, P535, DOI 10.1016/j.bpa.2010.10.008; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; Namiki J, 2011, CLIN NEUROL NEUROSUR, V113, P393, DOI 10.1016/j.clineuro.2011.01.001; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Rehn M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-17; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; TEASDALE G, 1974, LANCET, V2, P81; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Varon J, 2011, AM J EMERG MED	24	63	64	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0007-1323			BRIT J SURG	Br. J. Surg.	JAN	2012	99			1			122	130		10.1002/bjs.7707			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	930PG	WOS:000303151000020	22441866				2022-02-06	
J	Cullen, DK; Vernekar, VN; LaPlaca, MC				Cullen, D. Kacy; Vernekar, Varadraj N.; LaPlaca, Michelle C.			Trauma-Induced Plasmalemma Disruptions in Three-Dimensional Neural Cultures Are Dependent on Strain Modality and Rate	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; cell mechanics; compression; injury biomechanics; membrane permeability; neuron; neurotrauma; shear; strain rate; 3-D culture; traumatic brain injury	DIFFUSE AXONAL INJURY; BRAIN-INJURY; NEURONAL INJURY; MEMBRANE DISRUPTION; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; CNS INJURY; CELL-DEATH; CALCIUM; MECHANISMS	Traumatic brain injury (TBI) results from cell dysfunction or death following supra-threshold physical loading. Neural plasmalemma compromise has been observed following traumatic neural insults; however, the biomechanical thresholds and time-course of such disruptions remain poorly understood. In order to investigate trauma-induced membrane disruptions, we induced dynamic strain fields (0.50 shear or compressive strain at 1, 10, or 30 sec(-1) strain rate) in 3-D neuronal-astrocytic co-cultures (>500 mu m thick). Impermeant dyes were present during mechanical loading and entered cells in a strain rate-dependent manner for both shear and compression. Real-time imaging revealed increased membrane permeability in a sub-population of cells immediately upon deformation. Alterations in cell membrane permeability, however, were transient and biphasic over the ensuing hour post-insult, suggesting initial membrane damage and rapid repair, followed by a phase of secondary membrane degradation. At 48 h post-insult, cell death increased significantly in the high-strain-rate group, but not after quasi-static loading, suggesting that cell survival relates to the initial extent of transient structural compromise. Cells were more sensitive to bulk shear deformation than compression with respect to acute permeability changes and subsequent cell survival. These results provide insight into the temporally varying alterations in membrane stability following traumatic loading and provide a basis for elucidating physical cellular tolerances.	[LaPlaca, Michelle C.] Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; [Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Vernekar, Varadraj N.; LaPlaca, Michelle C.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Petit Inst Bioengn & Biosci, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			National Science Foundation (NSF)National Science Foundation (NSF) [BES-0093830, EEC-9731643]; National Institutes of Health/National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014]; Southern Consortium for Injury Biomechanics at the University of Alabama Birmingham-Injury Control Research Center through National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000191]; National Highway Traffic Safety Administration [TNH22-01-H-07551]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER	The authors thank Drs. Albert King and Liying Zhang at Wayne State University for finite element modeling, Dr. Crystal M. Simon for input regarding experimental design and data analysis, and Christopher E. Gonzales and Rebekah M. Hamrick for technical assistance. This work was partially supported by the National Science Foundation (NSF) (CAREER Award BES-0093830), National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering (EB001014), NSF (EEC-9731643), and the Southern Consortium for Injury Biomechanics at the University of Alabama Birmingham-Injury Control Research Center, through a grant from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, award R49/CE000191, and Cooperative Agreement TNH22-01-H-07551 with the National Highway Traffic Safety Administration. This work made use of shared facilities from the Georgia Tech/Emory Center (GTEC) for the Engineering of Living Tissues, an ERC (EEC-9731643).	Adibhatla RM, 2008, BMB REP, V41, P560, DOI 10.5483/BMBRep.2008.41.8.560; Adibhatla RM, 2006, AAPS J, V8, pE314; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holbourn AHS, 1943, LANCET, V2, P438; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Irons HR, 2008, J NEURAL ENG, V5, P333, DOI 10.1088/1741-2560/5/3/006; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liao SL, 2001, NEUROREPORT, V12, P3519, DOI 10.1097/00001756-200111160-00029; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McNeil PL, 2000, J CELL SCI, V113, P1891; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; Nehrt A, 2007, NEUROSCIENCE, V146, P1504, DOI 10.1016/j.neuroscience.2007.02.015; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Schlicher RK, 2006, ULTRASOUND MED BIOL, V32, P915, DOI 10.1016/j.ultrasmedbio.2006.02.1416; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Togo T, 2000, ZYGOTE, V8, pS31; Villa PG, 1998, J CELL SCI, V111, P713; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	61	63	64	0	15	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2219	2233		10.1089/neu.2011.1841			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600003	22023556	Green Published			2022-02-06	
J	MacGregor, AJ; Dougherty, AL; Galarneau, MR				MacGregor, Andrew J.; Dougherty, Amber L.; Galarneau, Michael R.			Injury-Specific Correlates of Combat-Related Traumatic Brain Injury in Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						combat; military; traumatic brain injury	SEVERITY SCORE; AFGHANISTAN; HEAD	Background: The prevalence of traumatic brain injury (TBI) has increased during the wars in Iraq and Afghanistan compared with 20th century military conflicts. The aim of this study was to elucidate injury-specific correlates of combat-related TBI that have yet to be clearly defined. Participants: Predominately Marine US service members who sustained brain injuries in Iraq between March 2004 and April 2008 identified from clinical records completed in the theater of combat operations (n = 2074). Main Outcome Measures: Severity of TBI was classified as mild, moderate, or severe. Injury-specific factors, such as injury mechanism and type, were abstracted from the clinical records and were compared with severity of TBI. Results: Of all TBIs observed in the sample, 89% were mild. Higher severity of TBI was associated with an increased likelihood of sustaining the injury by gunshot and a lower likelihood of helmet use. Improvised explosive devices were associated with a preponderance of mild TBIs, and frequency of injuries in locations in addition to the head was highest among those with moderate and severe TBIs. Concomitant injuries to the spine/back were associated with blast injury mechanisms. Conclusions: Most incidents of TBI occurring during Operation Iraqi Freedom are mild in severity and a result of blast mechanisms. Multiple injuries were common, particularly as severity of TBI increased. Further research is needed to determine effects of combat-related TBI on rehabilitative and adverse health outcomes.	[MacGregor, Andrew J.; Dougherty, Amber L.; Galarneau, Michael R.] USN, Hlth Res Ctr, San Diego, CA 92106 USA		Dougherty, AL (corresponding author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Navy Medicine Bureau of Medicine and Surgery, Washington, DC [60808]	This work was supported by the US Navy Medicine Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60808. The views and opinions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Commission on Professional Hospital Activities, 1977, INT CLASS DIS 9 REV; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dougherty AL, 2009, INJURY, V40, P772, DOI 10.1016/j.injury.2009.02.014; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; LINN S, 1993, INT J EPIDEMIOL, V22, P905, DOI 10.1093/ije/22.5.905; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	23	63	62	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					312	318		10.1097/HTR.0b013e3181e94404			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700008	20808241				2022-02-06	
J	Hillary, FG; Medaglia, JD; Gates, K; Molenaar, PC; Slocomb, J; Peechatka, A; Good, DC				Hillary, Frank G.; Medaglia, John D.; Gates, Kathleen; Molenaar, Peter C.; Slocomb, Julia; Peechatka, Alyssa; Good, David C.			Examining working memory task acquisition in a disrupted neural network	BRAIN			English	Article						brain injury; brain plasticity; connectivity; structural equation model; working memory	TRAUMATIC BRAIN-INJURY; COGNITIVE-CONTROL; FMRI; ACTIVATION; ATTENTION; DEFICITS; REORGANIZATION; PERFORMANCE; PLASTICITY; MODERATE	There is mounting literature that examines brain activation during tasks of working memory in individuals with neurological disorders such as traumatic brain injury. These studies represent a foundation for understanding the functional brain changes that occur after moderate and severe traumatic brain injury, but the focus on topographical brain-'activation' differences ignores potential alterations in how nodes communicate within a distributed neural network. The present study makes use of the most recently developed connectivity modelling (extended-unified structural equation model) to examine performance during a well-established working-memory task (the n-back) in individuals sustaining moderate and severe traumatic brain injury. The goal is to use the findings observed in topographical activation analysis as the basis for second-level effective connectivity modelling. Findings reveal important between-group differences in within-hemisphere connectivity during task acquisition, with the control sample demonstrating rapid within-left hemisphere connectivity increases and the traumatic brain injury sample demonstrating consistently elevated within-right hemisphere connectivity. These findings also point to important maturational effects from 'early' to 'late' during task performance, including diminished right prefrontal cortex involvement and an anterior to posterior shift in connectivity with increased task exposure. We anticipate that this approach to functional imaging data analysis represents an important future direction for understanding how neural plasticity is expressed in brain disorders.	[Hillary, Frank G.; Medaglia, John D.; Peechatka, Alyssa] Penn State Univ, Dept Psychol, University Pk, PA 16801 USA; [Hillary, Frank G.; Slocomb, Julia; Good, David C.] Hershey Med Ctr, Dept Neurol, Hershey, PA 16801 USA; [Gates, Kathleen; Molenaar, Peter C.] Dept Human Dev & Family Sci, University Pk, PA 17033 USA		Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, 223 Bruce V Moore Bldg, University Pk, PA 16802 USA.	fhillary@psu.edu	Hillary, Frank/AAN-8622-2021		New Jersey Commission on Brain Injury Research [0120090178]; Pennsylvania Tobacco Settlement Funds; Social Sciences Research Institute, PSU, University Park	New Jersey Commission on Brain Injury Research, Grant #: 0120090178; Pennsylvania Tobacco Settlement Funds; Social Sciences Research Institute, PSU, University Park.	Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Brett M, 2010, MNI BRAIN TALAIRACH; Brown TA., 2015, CONFIRMATORY FACTOR, V2; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209; Gates KM, 2010, NEUROIMAGE, V50, P1118, DOI 10.1016/j.neuroimage.2009.12.117; Gates KM, 2010, NEUROIMAGE, V54, P1151; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hillary F, 2001, ARCH CLIN NEUROPSYCH, V16, P171, DOI 10.1016/S0887-6177(00)00050-0; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Kim J, 2007, HUM BRAIN MAPP, V28, P85, DOI 10.1002/hbm.20259; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maguire EA, 2001, BRAIN, V124, P1156, DOI 10.1093/brain/124.6.1156; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mcintosh A., 1994, HUM BRAIN MAPP, V2, P2, DOI DOI 10.1002/HBM.460020104; Medaglia JD, HUM BRAIN M IN PRESS; Molenaar PCM., 2004, MEASUREMENT, V2, P201, DOI [10.1207/s15366359mea0204_1, DOI 10.1207/S15366359MEA0204_1]; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Oikonomou VP, 2010, IEEE T INF TECHNOL B, V14, P664, DOI 10.1109/TITB.2009.2039712; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Sarty GE, 2006, COMPUTING BRAIN ACTI; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Speck O, 2000, NEUROREPORT, V11, P2581, DOI 10.1097/00001756-200008030-00046; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; TEASDALE G, 1974, LANCET, V2, P81; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Wechlser D, 1997, DIGIT SPAN SUBTEST W; Wechlser D, 1997, INFORM SUBTEST WAIS; WORSLEY KJ, 1995, NEUROIMAGE, V2, P183, DOI 10.1006/nimg.1995.1024	47	63	64	1	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAY	2011	134		5				1555	1570		10.1093/brain/awr043			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	766WZ	WOS:000290818600032	21571783				2022-02-06	
J	Shojo, H; Kaneko, Y; Mabuchi, T; Kibayashi, K; Adachi, N; Borlongan, CV				Shojo, H.; Kaneko, Y.; Mabuchi, T.; Kibayashi, K.; Adachi, N.; Borlongan, C. V.			GENETIC AND HISTOLOGIC EVIDENCE IMPLICATES ROLE OF INFLAMMATION IN TRAUMATIC BRAIN INJURY-INDUCED APOPTOSIS IN THE RAT CEREBRAL CORTEX FOLLOWING MODERATE FLUID PERCUSSION INJURY	NEUROSCIENCE			English	Article						head trauma; brain injury model gene expression; apoptosis related genes; inflammation	MITOCHONDRIAL CYTOCHROME-C; CELL-DEATH; ALTERED EXPRESSION; MESSENGER-RNA; ACTIVATION; DAMAGE; TRANSLOCATION; LOCALIZATION; DYSFUNCTION; CASPASES	Traumatic brain injury (TBI) causes massive brain damage However, the secondary injury and temporal sequence of events with multiple mechanisms after the insult has not been elucidated Here we examined the occurrence of apoptosis and a causal relationship between inflammation and apoptosis in the TBI brain Following a lateral moderate fluid percussion injury model of TBI in adult rats, microarray analyses detected apparent changes in the expression levels of apoptosis related genes which revealed time-dependent expression patterns for 23 genes in the lateral cortex The upregulated 23 genes included inflammatory cytokines such as interleukin 1 (IL 1) alpha, IL 1 beta, and tumor necrotic factor (TNF) which immediately increased at 3 h following the injury Time dependent gene expression profile analyses showed that apoptosis was subsequently induced following inflammation These results taken together suggested changes in expression of apoptosis related genes may be associated with inflammatory response Accompanying this surge of cell death genes after TBI was a neurostructural pathologic hall mark of apoptosis characterized by leakage of cytochrome c into cytoplasm, DNA fragmentation and apoptotic cells in the lateral cortex of the impacted hemisphere Caspase-3 positive cells in the TBI brain were initially sporadic after 3 h, but these apoptotic cells subsequently increased and populated the cerebral cortex at 6 and 12 h, and gradually reached a plateau by 48 h Interestingly, the expression profile of CD68 macrophage labeled cells closely resembled that of apoptotic cells after TBI, including the role of inflammatory signaling pathway in the progression of apoptotic cell death These results taken together suggest that TBI induced upregulation of apoptosis related genes, concomitant with the detection of apoptotic brain pathology during the 3-48 h post-injury period, which may be likely mediated by inflammation Thera pies designed at abrogating apoptosis and/or inflammation may prove effective when initiated at this subacute TBI phase (C) 2010 IBRO Published by Elsevier Ltd All rights reserved	[Shojo, H.; Adachi, N.] Univ Yamanashi, Dept Legal Med, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan; [Shojo, H.; Kaneko, Y.; Borlongan, C. V.] Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Mabuchi, T.] Univ Yamanashi, Dept Biochem, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan; [Kibayashi, K.] Tokyo Womens Med Univ, Dept Legal Med, Shinjuku Ku, Tokyo 1628666, Japan		Shojo, H (corresponding author), Univ Yamanashi, Dept Legal Med, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.		Kazuhiko, Kibayashi/F-5173-2013; Borlongan, Cesar/I-5696-2012	Kazuhiko, Kibayashi/0000-0001-6510-5215; Borlongan, Cesar/0000-0002-2966-9782	Ministry of Education Culture Sports Sciences and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17790409, 19689015, 22390141]; James and Esther King Biomedical Research [09KB 01 23123, 1KG01 33966]	This study was supported by grants (17790409 19689015 and 22390141) from the Ministry of Education Culture Sports Sciences and Technology of Japan (Dr Shojo) USF Department of Neurosurgery and Brain Repair funds (Drs Kaneko and Borlongan) Dr Borlongan received funds from James and Esther King Biomedical Research Programs Grant Numbers 09KB 01 23123 and 1KG01 33966	Abbas AK, 2003, EFFECTOR MECH IMMUNE, P243; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Bruce A, 2002, CELL CYCLE PROGRAM 4, P1010; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cavallaro S, 2001, EUR J NEUROSCI, V13, P1809, DOI 10.1046/j.0953-816x.2001.01543.x; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Crawford FC, 2007, BRAIN RES, V1185, P45, DOI 10.1016/j.brainres.2007.09.042; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Ezcurra ALD, 2010, NEUROBIOL DIS, V37, P630, DOI 10.1016/j.nbd.2009.11.018; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Eilers A, 1998, J NEUROSCI, V18, P1713; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Manor T, 2008, NEUROL RES, V30, P1075, DOI 10.1179/174313208X346107; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Nagai A, 2005, J NEUROSCI RES, V81, P342, DOI 10.1002/jnr.20478; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Pedersen MO, 2009, BRAIN RES, V1271, P103, DOI 10.1016/j.brainres.2009.03.022; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; RINK A, 1995, AM J PATHOL, V147, P1575; SANES JR, 2000, DEV NERVOUS SYSTEM P, P1087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	56	63	67	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 29	2010	171	4					1273	1282		10.1016/j.neuroscience.2010.10.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	693NO	WOS:000285231000028	20950674				2022-02-06	
J	Lustenberger, T; Talving, P; Kobayashi, L; Barmparas, G; Inaba, K; Lam, L; Branco, BC; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Barmparas, Galinos; Inaba, Kenji; Lam, Lydia; Branco, Bernardino Castelo; Demetriades, Demetrios			Early Coagulopathy After Isolated Severe Traumatic Brain Injury: Relationship With Hypoperfusion Challenged	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Severe head injury; Traumatic brain injury; Early coagulopathy; Hypoperfusion; Base deficit; Lactate; Mortality	PROTEIN-C PATHWAY; HEAD-INJURY; COAGULATION DISORDERS; BASE DEFICIT	Introduction: The purpose of this study was to examine the incidence of tissue hypoperfusion in victims of severe traumatic brain injury (sTBI) and to determine the associations between hypoperfusion and TBI coagulopathy. Methods: This is a retrospective analysis of a prospectively collected cohort admitted to the surgical intensive care unit from June 2005 to December 2007 sustaining isolated sTBI, defined as sTBI [head Abbreviated Injury Scale (AIS) >= 3] with chest, abdomen, and extremity AIS <3. Criteria for TBI-associated early coagulopathy included isolated sTBI in conjunction with thrombocytopenia (platelet count <100,000 per mm(3)) or elevated international normalized ratio >1.2 or prolonged activated partial thromboplastin time >36 seconds at admission. Hypoperfusion was defined by the presence of an arterial base deficit (BD) >6 mmol/L. Univariate and multivariate analysis was performed to identify associations among hypoperfusion, coagulopathy, and mortality. Results: A total of 132 patients met the study criteria. TBI-associated early coagulopathy occurred in 48 patients (36.4%). With increasing head injury severity, the incidence of coagulopathy increased in a stepwise fashion. Mean BD values and mean lactate values were significantly higher among patients with coagulopathy compared with their noncoagulopathic counterparts at hospital admission. The coagulopathic cohort presented more frequently with a BD >6 mmol/L at admission (39.6% vs. 20.2%, p = 0.016). In the stepwise logistic regression analysis, head AIS = 5 and an admission BD >6 mmol/L were independently associated with early coagulopathy. Coagulopathy was associated with increased mortality in patients after blunt head trauma, adjusted odds ratio (95% confidence interval): 3.79 (1.06-13.51); adjusted p = 0.04. Conclusion: Hypoperfusion is an independent risk factor for the development of early coagulopathy in patients with isolated sTBI. Nevertheless, early coagulopathy after sTBI does not occur exclusively in patients experiencing tissue hypoperfusion.	[Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Barmparas, Galinos; Inaba, Kenji; Lam, Lydia; Branco, Bernardino Castelo; Demetriades, Demetrios] Los Angeles Cty Univ So Calif Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA USA		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp LAC USC,FACS, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Barmparas, Galinos/L-6530-2019; INABA, KENJI/AAC-8532-2020; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Martin MJ, 2006, AM J SURG, V191, P625, DOI 10.1016/j.amjsurg.2006.02.014; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schrieber M, 2007, J TRAUMA, V63, P1261; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	15	63	65	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1410	1414		10.1097/TA.0b013e3181cdae81			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	695RT	WOS:000285391000028	20404754				2022-02-06	
J	Wakade, C; Sukumari-Ramesh, S; Laird, MD; Dhandapani, KM; Vender, JR				Wakade, Chandramohan; Sukumari-Ramesh, Sangeetha; Laird, Melissa D.; Dhandapani, Krishnan M.; Vender, John R.			Delayed reduction in hippocampal postsynaptic density protein-95 expression temporally correlates with cognitive dysfunction following controlled cortical impact in mice	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; glutamate; synaptic plasticity; hippocampus	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MEMORY; ACTIVATION; HEMORRHAGE; CONTUSION; PATHOLOGY; MODERATE; NEURONS; ADULTS	Object. Traumatic brain injury (TBI) induces significant neurological damage, including deficits in learning and memory, which contribute to a poor clinical prognosis. Treatment options to limit cognitive decline and promote neurological recovery are lacking, in part due to a poor understanding of the secondary or delayed processes that contribute to brain injury. In the present study, the authors characterized the temporal and spatial changes in the expression of postsynaptic density protein-95 (PSD-95), a key scaffolding protein implicated in excitatory synaptic signaling, after controlled cortical impacts in mice. Neurological injury, as assessed by the open-field activity test and the novel object recognition test, was compared with changes in PSD-95 expression. Methods. Adult male CD-1 mice were subjected to controlled cortical impacts to simulate moderate TBI in humans. The spatial and temporal expression of PSD-95 was analyzed in the cerebral cortex and hippocampus at various time points following injury and sham operations. Neurological assessments were performed to compare changes in PSD-95 with cognitive deficits. Results. A significant decrease in PSD-95 expression was observed in the ipsilateral hippocampus beginning on Day 7 postinjury. The loss of PSD-95 corresponded with a concomitant reduction in immunoreactivity for NeuN (neuronal nuclei), a neuron-specific marker. Aside from the contused cortex, a significant loss of PSD-95 immunore-activity was not observed in the cerebral cortex. The delayed loss of hippocampal PSD-95 directly correlated with the onset of behavioral deficits, suggesting a possible causative role for PSD-95 in behavioral abnormalities following head trauma. Conclusions. A delayed loss of hippocampal synapses was observed following head trauma in mice. These data may suggest a cellular mechanism to explain the delayed learning and memory deficits in humans after TBI and provide a potential framework for further testing to implicate PSD-95 as a clinically relevant therapeutic target. (DOI: 10.3171/2010.3.JNS091212)	[Wakade, Chandramohan; Sukumari-Ramesh, Sangeetha; Laird, Melissa D.; Dhandapani, Krishnan M.; Vender, John R.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA		Vender, JR (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	jvender@mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135, PRE2250690]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	This work was supported in part by Grant No. NS065172 from the National Institutes of Health (NS065172) and Grant No. BGIA2300135 from the American Heart Association (K.M.D.) and by Fellowship No. PRE2250690 from the American Heart Association (M.D.L.).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cheng DM, 2006, MOL CELL PROTEOMICS, V5, P1158, DOI 10.1074/mcp.D500009-MCP200; Christoforidis GA, 2007, STROKE, V38, P1799, DOI 10.1161/STROKEAHA.106.472282; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fukaya M, 2000, J COMP NEUROL, V426, P572; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kingston PA, 1999, SYNAPSE, V32, P1, DOI 10.1002/(SICI)1098-2396(199904)32:1<1::AID-SYN1>3.0.CO;2-M; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Laird MD, 2010, J NEUROCHEM; Lin Y, 2004, J NEUROSCI, V24, P10138, DOI 10.1523/JNEUROSCI.3159-04.2004; Lin Y, 2006, P NATL ACAD SCI USA, V103, P19902, DOI 10.1073/pnas.0609924104; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sangeetha SR, 2009, ENDOCRINE, V35, P389, DOI 10.1007/s12020-009-9159-1; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410	41	63	64	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2010	113	6					1195	1201		10.3171/2010.3.JNS091212			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	684QX	WOS:000284565500011	20397893	Green Accepted			2022-02-06	
J	Blyth, BJ; Bazarian, JJ				Blyth, Brian J.; Bazarian, Jeffrey J.			Traumatic Alterations in Consciousness: Traumatic Brain Injury	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Article						Concussion; Trauma; Brain; Injury	POSTTRAUMATIC-STRESS-DISORDER; FIBRILLARY ACIDIC PROTEIN; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; RISK-FACTORS; 2ND IMPACT; PHARMACOLOGICAL-TREATMENT; PSYCHIATRIC-DISORDERS; INTRACRANIAL INJURY	Mild traumatic brain injury (mTBI) refers to the clinical condition of transient alteration of consciousness as a result of traumatic injury to the brain The priority of emergency care is to identify and facilitate the treatment of rare but potentially life-threatening intracranial injuries associated with mTBI through the judicious application of appropriate imaging studies and neurosurgical consultation. Although post-mTBI symptoms quickly and completely resolve in the vast majority of cases, a significant number of patients will complain of lasting problems that may cause significant disability Simple and early interventions such as patient education and appropriate referral can reduce the likelihood of chronic symptoms Although definitive evidence is lacking, mTBI is likely to be related to significant long-term sequelae such as Alzheimer disease and other neurode-generative processes.	[Blyth, Brian J.; Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Dept Emergency Med, Rochester, NY 14642 USA		Blyth, BJ (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Dept Emergency Med, 601 Elmwood Ave,Box 645, Rochester, NY 14642 USA.				National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HD051865-03]; Jahnigen Career Development Scholars Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051865] Funding Source: NIH RePORTER	This work was supported by Grant No 5R01HD051865-03 from the National Institutes of Health (J.J.B and B J B) and a Jahnigen Career Development Scholars Award (B J B)	Adams RD, 1997, PRINCIPLES NEUROLOGY, V6th; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J. David, 2004, Journal of Rehabilitation Medicine Supplement, P28; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *CONC MTBI WORK GR, VA DOD CLIN PRACT GU; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Hain TC, 2005, NEUROL CLIN, V23, P831, DOI 10.1016/j.ncl.2005.01.012; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1989, MILD HEAD INJURY, P54; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; IOM, 2009, GULF WAR HLTH, V7; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; IVERSON GL, 2007, POSTCONCUSSIVE DISOR; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; KATAYAMA Y, 1984, BRAIN RES, V299, P348, DOI 10.1016/0006-8993(84)90717-0; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Missler U, 1999, CLIN CHEM, V45, P138; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPA L, 2009, CRIT CARE MED, V38, P318; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; PYYKKO I, 1988, ACTA OTO-LARYNGOL, P77; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sagduyu K, 2002, J CLIN PSYCHIAT, V63, P594, DOI 10.4088/JCP.v63n0710a; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P35; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Singer R B, 2001, J Insur Med, V33, P42; Sosin DM, 1996, BRAIN INJURY, V10, P47; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; ZEE DS, 1985, ARCH OTOLARYNGOL, V111, P609	134	63	63	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8627	1558-0539		EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	AUG	2010	28	3					571	+		10.1016/j.emc.2010.03.003			26	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	649AN	WOS:000281737700010	20709244	Green Accepted			2022-02-06	
J	Fanconi, M; Lips, U				Fanconi, Manuela; Lips, Ulrich			Shaken baby syndrome in Switzerland: results of a prospective follow-up study, 2002-2007	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						Shaken baby syndrome; Non-accidental head injury; Traumatic brain hemorrhage; Incidence; Outcome	TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; YOUNG-CHILDREN; HEAD TRAUMA; RETINAL HEMORRHAGES; SUBDURAL HAEMATOMA; WHIPLASH INJURY; INFANTS; SHAKING; TRIGGER	Since the incidence of shaken baby syndrome in Switzerland was not known, we conducted a nationwide prospective follow-up study for a 5-year period (from 2002 to 2007). The data were collected through the Swiss Pediatric Surveillance Unit. Inclusion criteria were the presence, in a child a parts per thousand currency sign6 years of age, of 1) more than or equal to two clinical symptoms (altered consciousness, convulsions, respiratory irregularities, and bulging fontanel), 2) one eye finding (retinal hemorrhages, vitreous hemorrhages), 3) one MRI/CT finding (subdural hematoma, subarachnoid hematoma, and parenchymatous lesions), or 4) history of shaking. Exclusion criteria were age > 6 years or documented accident/disease explaining symptoms/findings. To describe outcome, we used the King's Outcome Scale for Childhood Head Injury (KOSCHI). 56 cases were reported from 13 of 26 Swiss cantons, representing 80% of the Swiss population; 49 cases met the inclusion criteria. Preponderance of male infants was high (31 male and 18 female); median age at admission was 4 months (1-58). Clinical symptoms were present in 42 infants, retinal/vitreous hemorrhages in 39 infants, and pathological brain/head imaging in 46 infants. In 13 cases, the caregivers admitted shaking the child. Outcomes (KOSCHI 1-5; n = 47 patients) were death (KOSCHI 1) 8 (17.7%), vegetative state (KOSCHI 2) 0, severe disability (KOSCHI 3) 11 (22.2%), moderate disability (KOSCHI 4) 14 (31.1%), and good recovery (KOSCHI 5) 14 (28.8%). Based on these data, the incidence of shaken baby syndrome in Switzerland is 14 per 100 000 live births, which corresponds to the incidence in other Western countries. Demographic characteristics and outcomes of Swiss patients were comparable to published studies.	[Fanconi, Manuela; Lips, Ulrich] Univ Childrens Hosp Zurich, Child Protect Grp, CH-8032 Zurich, Switzerland		Lips, U (corresponding author), Univ Childrens Hosp Zurich, Child Protect Grp, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	ulrich.lips@kispi.uzh.ch					Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Mungan NK, 2007, CURR OPIN OPHTHALMOL, V18, P392, DOI 10.1097/ICU.0b013e3282a167f0; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1969, LANCET, V2, P237; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923	30	63	65	1	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	AUG	2010	169	8					1023	1028		10.1007/s00431-010-1175-x			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	614SU	WOS:000279080800017	20213304	Green Submitted			2022-02-06	
J	Dumont, TM; Visioni, AJ; Rughani, AI; Tranmer, BI; Crookes, B				Dumont, Travis M.; Visioni, Agostino J.; Rughani, Anand I.; Tranmer, Bruce I.; Crookes, Bruce			Inappropriate Prehospital Ventilation in Severe Traumatic Brain Injury Increases In-Hospital Mortality	JOURNAL OF NEUROTRAUMA			English	Article						brain injury guidelines; hyperventilation; prehospital; traumatic brain injury	CEREBRAL-BLOOD-FLOW; HEAD-INJURY; CARBON-DIOXIDE; PRESSURE AUTOREGULATION; HEMORRHAGIC-SHOCK; HYPERVENTILATION; OXYGENATION; CIRCULATION; METABOLISM; MANAGEMENT	In the setting of acute brainstem herniation in traumatic brain injury (TBI), the use of hyperventilation to reduce intracranial pressure may be life-saving. However, undue use of hyperventilation is thought to increase the incidence of secondary brain injury through direct reduction of cerebral blood flow. This is a retrospective review determining the effect of prehospital hyperventilation on in-hospital mortality following severe TBI. All trauma patients admitted directly to a single level 1 trauma center from January 2000 to January 2007 with an initial Glasgow Coma Scale (GCS) score <= 8 were included in the study (n = 77). Patients without documented or with late (> 20 min) arterial blood gas at presentation (n = 12) were excluded from the study. The remaining population (n = 65) was sorted into three groups based on the initial partial pressure of carbon dioxide: hypocarbic (Pco(2) < 35mm Hg), normocarbic (Pco(2) 35-45mm Hg), and hypercarbic (Pco(2) > 45mm Hg). Outcome was based on mortality during hospital admission. Survival was found to be related to admission Pco(2) in head trauma patients requiring intubation (p = 0.045). Patients with normocarbia on presenting arterial blood gas testing had in-hospital mortality of 15%, significantly improved over patients presenting with hypocarbia (in-hospital mortality 77%) or hypercarbia (in-hospital mortality 61%). Although there are many reports of the negative impact of prophylactic hyperventilation following severe TBI, this modality is frequently utilized in the prehospital setting. Our results suggest that abnormal Pco2 on presentation after severe head trauma is correlated with increased in-hospital mortality. We advocate normoventilation in the prehospital setting.	[Dumont, Travis M.; Visioni, Agostino J.; Rughani, Anand I.; Tranmer, Bruce I.] Univ Vermont, Coll Med, Dept Surg, Div Neurosurg, Burlington, VT 05401 USA; [Crookes, Bruce] Univ Vermont, Coll Med, Dept Surg, Div Trauma Surg, Burlington, VT 05401 USA		Dumont, TM (corresponding author), Univ Vermont, Coll Med, Dept Surg, Div Neurosurg, Fletcher 5th Floor, Burlington, VT 05401 USA.	Travis.Dumont@vtmednet.org					*AM ASS NEUR SURG, 2006, J NEUROTRAUM, V17, P513; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS87; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P573; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; [Anonymous], 2000, J Neurotrauma, V17, P563; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bhende M S, 2001, Prehosp Emerg Care, V5, P208, DOI 10.1080/10903120190940146; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Deakin CD, 2004, J TRAUMA, V57, P65, DOI 10.1097/01.TA.0000103984.70306.22; Deem S, 2006, RESP CARE, V51, P357; di Bartolomeo S, 2003, EUR J EMERG MED, V10, P268, DOI 10.1097/01.mej.0000103466.32882.7b; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; GORDON E, 1971, ACTA ANAESTH SCAND, V15, P193, DOI 10.1111/j.1399-6576.1971.tb05461.x; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Lal Dave, 2003, Prehosp Disaster Med, V18, P20; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROSSANDA M, 1972, EUR NEUROL, V8, P169, DOI 10.1159/000114573; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; TEASDALE G, 1974, LANCET, V2, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VICARIO SJ, 1983, ANN EMERG MED, V12, P145, DOI 10.1016/S0196-0644(83)80554-X; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	45	63	65	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1233	1241		10.1089/neu.2009.1216			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100008	20373856				2022-02-06	
J	Soane, L; Dai, WL; Fiskum, G; Bambrick, LL				Soane, Lucian; Dai, Wei Li; Fiskum, Gary; Bambrick, Linda L.			Sulforaphane Protects Immature Hippocampal Neurons Against Death Caused by Exposure to Hemin or to Oxygen and Glucose Deprivation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Nrf2; oxidative stress; ischemia/reperfusion; hemin; hippocampus	TRAUMATIC BRAIN-INJURY; ANTIOXIDANT RESPONSE ELEMENT; OXIDATIVE STRESS; INTRACEREBRAL HEMORRHAGE; NAD(P)H-QUINONE REDUCTASE; TRANSCRIPTION FACTOR; CEREBRAL-ISCHEMIA; DT-DIAPHORASE; NRF2; ASTROCYTES	Oxidative stress is a mediator of cell death following cerebral ischemia/reperfusion and heme toxicity, which can be an important pathogenic factor in acute brain injury. Induced expression of phase II detoxification enzymes through activation of the antioxidant response element (ARE)/Nrf2 pathway has emerged as a promising approach for neuroprotection. Little is known, however, about the neuroprotective potential of this strategy against injury in immature brain cells. In this study, we tested the hypothesis that sulforaphane (SFP), a naturally occurring isothiocyanate that is also a known activator of the ARE/Nrf2 antioxidant pathway, can protect immature neurons from oxidative stress-induced death. The hypothesis was tested with primary mouse hippocampal neurons exposed to either 02 and glucose deprivation (OGD) or hemin. Treatment of immature neurons with SFP immediately after the OGD during reoxygenation was effective in protecting immature neurons from delayed cell death. Exposure of immature hippocampal neurons to hemin induced significant cell death, and both pre- and cotreatment with SFP were remarkably effective in blocking cytotoxicity. RT-PCR analysis indicated that several Nrf2-dependent cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO1), and glutamate-cysteine ligase modifier subunit (GCLM), which is involved in glutathione biosynthesis, were up-regulated following SFP treatment both in control neurons and following exposure to OGD and hemin. These results indicate that SFP activates the ARE/Nrf2 pathway of antioxidant defense and protects immature neurons from death caused by stress paradigms relevant to those associated with ischemic and traumatic injury to the immature brain. (C) 2009 Wiley-Liss, Inc.	[Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Anesthesiol Res Labs,Dept Anesthesiol, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Anesthesiol Res Labs,Dept Anesthesiol, 685 W Baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			DODUnited States Department of Defense [DAMD17-03-1-0745]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HD16596]; Maryland State Stein Cell Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER	Contract grant sponsor: DOD; Contract grant number: DAMD17-03-1-0745 (to L.L.B.); Contract grant sponsor: NIH; Contract gram number: P01 HD16596 (to G.F.); Contract grant sponsor: Maryland State Stein Cell Grant (to G.F.).	Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Danilov CA, 2008, GLIA, V56, P801, DOI 10.1002/glia.20655; Danilov CA, 2009, GLIA, V57, P645, DOI 10.1002/glia.20793; Gamet-Payrastre L, 2006, CURR CANCER DRUG TAR, V6, P135, DOI 10.2174/156800906776056509; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Kalda A, 1998, NEUROSCI LETT, V240, P21, DOI 10.1016/S0304-3940(97)00914-2; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Le W, 1999, J NEUROSCI RES, V56, P652; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Levy YS, 2002, NEUROTOX RES, V4, DOI 10.1080/1029842021000045624; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIND C, 1990, METHOD ENZYMOL, V186, P287; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Marrot L, 2008, PIGM CELL MELANOMA R, V21, P79, DOI 10.1111/j.1755-148X.2007.00424.x; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Platt JL, 1998, NAT MED, V4, P1364, DOI 10.1038/3947; PROCHASKA HJ, 1987, J BIOL CHEM, V262, P1931; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Satoh T, 2006, P NATL ACAD SCI USA, V103, P768, DOI 10.1073/pnas.0505723102; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Soane L, 2008, J NEUROSCI RES, V86, P1267, DOI 10.1002/jnr.21584; Song LY, 2007, J NEUROSCI RES, V85, P2186, DOI 10.1002/jnr.21367; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	40	63	74	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1355	1363		10.1002/jnr.22307			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	575ZK	WOS:000276112600020	19998483	Green Accepted			2022-02-06	
J	Granger, CV; Markello, SJ; Graham, JE; Deutsch, A; Reistetter, TA; Ottenbacher, KJ				Granger, Carl V.; Markello, Samuel J.; Graham, James E.; Deutsch, Anne; Reistetter, Timothy A.; Ottenbacher, Kenneth J.			The Uniform Data System for Medical Rehabilitation Report of Patients with Traumatic Brain Injury Discharged from Rehabilitation Programs in 2000-2007	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Rehabilitation Outcomes; Benchmark; Quality Improvement; Traumatic Brain Injury	FUNCTIONAL INDEPENDENCE MEASURE; 1ST ADMISSIONS; STROKE; PAYMENT	Granger CV, Markello SJ, Graham JE, Deutsch A, Reistetter TA, Ottenbacher KJ: The Uniform Data System for Medical Rehabilitation: Report of patients with traumatic brain injury discharged from rehabilitation programs in 2000-2007. Am J Phys Med Rehabil 2010;89:265-278. Objective: To provide benchmarking information for a large national sample of patients receiving inpatient rehabilitation after traumatic brain injury. Design: Secondary data analysis from 893 medical rehabilitation facilities located in the United States that contributed information to the Uniform Data System for Medical Rehabilitation from January 2000 through December 2007. Variables analyzed included demographic information (age, sex, marital status, race or ethnicity, prehospital living setting, and discharge setting), hospitalization information (length of stay, program interruptions, payer, onset date, rehabilitation impairment group, Internation Classification of Diseases-9th revision codes for admitting diagnosis, and co-morbidities), and functional status information (FIM instrument [FIM] ratings at admission and discharge, FIM efficiency, FIM gain). Results: Descriptive statistics from 101,188 patients showed length of stay decreasing from a mean of 22.7 (+/-20.5) days to 16.6 (+/-14.8) days during the 8-yr study period. FIM total admission and discharge ratings also decreased. Mean admission ratings decreased from 58.6 (+/-24.7) to 54.8 (+/-21.2). Mean discharge ratings decreased from 92.4 (+/-24.2) to 85.0 (+/-24.0). Accordingly, mean functional independence measure change decreased from 33.8 (+/-20.5) to 30.2 (+/-18.4). The percentage of patients discharged to the community settings ranged from 81.3% in 2000 to 74.1% in 2007. All results are likely influenced by various policy changes affecting classification or documentation processes or both. Conclusions: National rehabilitation data from persons with traumatic brain injury in 2000-2007 indicate that patients are spending less time in an inpatient care setting than in the previous years and are experiencing improvements in functional independence during their stay. In addition, a majority of patients are discharged to community settings after inpatient rehabilitation.	[Graham, James E.; Ottenbacher, Kenneth J.] Univ Texas Galveston, Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Granger, Carl V.; Markello, Samuel J.] Uniform Data Syst Med Rehabil, Buffalo, NY USA; Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Chicago, IL 60611 USA; [Deutsch, Anne] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Reistetter, Timothy A.] E Carolina Univ, Dept Occupat Therapy, Greenville, NC USA		Ottenbacher, KJ (corresponding author), Univ Texas Galveston, Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.		Deutsch, Anne/B-7530-2017	Deutsch, Anne/0000-0003-2290-7757; Ottenbacher, Kenneth/0000-0001-5990-3982	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G080163, H133F090030]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055929] Funding Source: NIH RePORTER	This work was funded in part by grants H133G080163 (to KJO) and H133F090030 (to JEG) from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education. The FIM instrument is a registered trademark of the Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc. Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.	Carter GM, 2003, HEALTH CARE FINANC R, V24, P25; CARTER GM, 2002, EXECUTIVE SUMMARY AN; Deutsch A, 2002, AM J PHYS MED REHAB, V81, P133, DOI 10.1097/00002060-200202000-00010; Deutsch A, 2008, ARCH PHYS MED REHAB, V89, P2274, DOI 10.1016/j.apmr.2008.06.014; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fiedler RC, 1997, AM J PHYS MED REHAB, V76, P76, DOI 10.1097/00002060-199701000-00017; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P69, DOI 10.1097/00002060-199801000-00013; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P62, DOI 10.1097/00002060-199501000-00011; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; *IRF PAI, 2001, TRAIN MAN; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; UB Foundation Activities, 2004, INP REH FAC PAT ASS; 2003, FED REG, V68, P45674	23	63	63	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2010	89	4					265	278		10.1097/PHM.0b013e3181d3eb20			14	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	584CA	WOS:000276726400001	20299850	Green Accepted			2022-02-06	
J	Potts, MB; Adwanikar, H; Noble-Haeusslein, LJ				Potts, Matthew B.; Adwanikar, Hita; Noble-Haeusslein, Linda J.			Models of Traumatic Cerebellar Injury	CEREBELLUM			English	Article						Cerebellum; Traumatic brain injury; Animal model	DIFFUSE BRAIN INJURY; PURKINJE-CELL VULNERABILITY; LATERAL FLUID PERCUSSION; HEAD-INJURY; ROTATIONAL ACCELERATION; RAT CEREBELLUM; PARASAGITTAL ZONES; AXONAL INJURY; TIME-COURSE; ALDOLASE-C	Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Studies of human TBI demonstrate that the cerebellum is sometimes affected even when the initial mechanical insult is directed to the cerebral cortex. Some of the components of TBI, including ataxia, postural instability, tremor, impairments in balance and fine motor skills, and even cognitive deficits, may be attributed in part to cerebellar damage. Animal models of TBI have begun to explore the vulnerability of the cerebellum. In this paper, we review the clinical presentation, pathogenesis, and putative mechanisms underlying cerebellar damage with an emphasis on experimental models that have been used to further elucidate this poorly understood but important aspect of TBI. Animal models of indirect (supratentorial) trauma to the cerebellum, including fluid percussion, controlled cortical impact, weight drop impact acceleration, and rotational acceleration injuries, are considered. In addition, we describe models that produce direct trauma to the cerebellum as well as those that reproduce specific components of TBI including axotomy, stab injury, in vitro stretch injury, and excitotoxicity. Overall, these models reveal robust characteristics of cerebellar damage including regionally specific Purkinje cell injury or loss, activation of glia in a distinct spatial pattern, and traumatic axonal injury. Further research is needed to better understand the mechanisms underlying the pathogenesis of cerebellar trauma, and the experimental models discussed here offer an important first step toward achieving that objective.	[Potts, Matthew B.; Adwanikar, Hita; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA		Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 521 Parnassus Ave,Room C-224,Box 0520, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS NS050159.	Ai JL, 2004, PHARMACOLOGY, V71, P192, DOI 10.1159/000078085; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Alavi A, 1997, J NUCL MED, V38, P1717; Allen GV, 2001, NEUROSCIENCE, V102, P603, DOI 10.1016/S0306-4522(00)00519-4; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BOWER AJ, 1981, J NEUROSCI METH, V4, P181, DOI 10.1016/0165-0270(81)90052-2; Braga LW, 2007, J CHILD NEUROL, V22, P1084, DOI 10.1177/0883073807306246; Bramanti P, 1994, J Neurosurg Sci, V38, P117; BUCKI A, 2006, ACTA NEUROCHIR WIEN, V148, P93; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carulli D, 2004, PROG NEUROBIOL, V72, P373, DOI 10.1016/j.pneurobio.2004.03.007; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHEN S, 1994, EXP NEUROL, V126, P270, DOI 10.1006/exnr.1994.1064; Culic M, 2005, ACTA NEUROBIOL EXP, V65, P11; Dayer A, 1998, Eur J Paediatr Neurol, V2, P109, DOI 10.1016/S1090-3798(98)80026-3; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hattori N, 2003, J NUCL MED, V44, P1709; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; HOLMES G, 2007, BRAIN, V130, P4; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu Y, 2007, J CEREBR BLOOD F MET, V27, P1724, DOI 10.1038/sj.jcbfm.9600467; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; Lupi A, 2007, CLIN NUCL MED, V32, P445, DOI 10.1097/RLU.0b013e3180537621; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATSCHKE J, 1943, PEDIATR NEUROSURG, V4, P330; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; Newberg AB, 2000, CLIN NUCL MED, V25, P431, DOI 10.1097/00003072-200006000-00008; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OHearn E, 1997, J NEUROSCI, V17, P8828; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rossi F, 2006, CEREBELLUM, V5, P174, DOI 10.1080/14734220600786444; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sherrard RM, 1997, NEUROREPORT, V8, P3225, DOI 10.1097/00001756-199710200-00008; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2007, EUR J NEUROSCI, V26, P649, DOI 10.1111/j.1460-9568.2007.05708.x; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; VANGIJN J, 1904, BRAIN, V27, P522; Welsh JP, 2002, ADV NEUROL, V89, P331; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Xu ZJ, 2000, TOXICOL SCI, V57, P95, DOI 10.1093/toxsci/57.1.95	87	63	66	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1473-4222	1473-4230		CEREBELLUM	Cerebellum	SEP	2009	8	3					211	221		10.1007/s12311-009-0114-8			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	489PP	WOS:000269433200008	19495901	Green Published, hybrid, Green Submitted			2022-02-06	
J	DeJong, G; Horn, SD; Smout, RJ; Tian, WQ; Putman, K; Gassaway, J				DeJong, Gerben; Horn, Susan D.; Smout, Randall J.; Tian, Wenqiang; Putman, Koen; Gassaway, Julie			Joint Replacement Rehabilitation Outcomes on Discharge From Skilled Nursing Facilities and Inpatient Rehabilitation Facilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	84th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 03-07, 2007	Washington, DC	Amer Cong Rehabil Med		Arthroplasty, replacement, hip; Arthroplasty, replacement, knee; Rehabilitation; Skilled nursing facilities	FUNCTIONAL ASSESSMENT SCALES; TRAUMATIC BRAIN-INJURY; TOTAL KNEE REPLACEMENT; HOSPITAL VOLUME; HIP FRACTURE; INDEPENDENCE MEASURE; ELECTIVE HIP; CARE; ARTHROPLASTY; OBESITY	DeJong G, Horn SD, Smout RJ, Tian W, Putman K, Gassaway J. Joint replacement rehabilitation outcomes on discharge from skilled nursing facilities and inpatient rehabilitation facilities. Arch Phys Med Rehabil 2009;90: 1284-96. Objective: To compare functional outcomes at discharge across postacute settings. Design: Prospective observational cohort study. Setting: Eleven inpatient rehabilitation facilities (IRFs), 8 freestanding skilled nursing facilities (SNFs), and 1 hospital-based SNF from across the United States. Participants: Consecutively enrolled patients (N=2152): patients with knee replacement (n=1401) and patients with hip replacement (n=751). Interventions: None; examination of existing practice patterns. Main Outcome Measure: FIM discharge motor score. Results: Freestanding SNF patients entered with higher motor FIM scores and left with higher scores than did IRF patients. IRF patients, however, achieved larger motor FIM gains and achieved them in a shorter time. In multivariate models controlling for patient differences and onset days, IRFs were associated with better discharge motor outcomes, but the overall setting effect was not large. The largest motor FIM differences were between medium-volume IRFs and low-volume freestanding SNFs: 4.6 motor FIM points for patients with knee replacement and 7.3 motor FIM points for patients with hip replacement. Other differences between settings were much smaller. Multivariate models explained between a third and a half of the variance in outcome. Conclusions: As a group, IRFs had better motor FIM outcomes than did SNFs, but the size of the IRF advantage was not large. Other important facility and practice characteristics also were associated with discharge outcomes after joint replacement rehabilitation. Earlier and more intensive rehabilitation was associated with better outcomes. The volume of joint replacement patients seen by a facility also plays a part: medium-volume facilities among both SNFs and IRFs had better outcomes.	[DeJong, Gerben; Tian, Wenqiang; Putman, Koen] Natl Rehabil Hosp, Ctr Postacute Studies, Washington, DC 20010 USA; [Horn, Susan D.; Smout, Randall J.; Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Putman, Koen] Vrije Univ Brussel, Dept Med Sociol & Hlth Sci, Brussels, Belgium		DeJong, G (corresponding author), Natl Rehabil Hosp, Ctr Postacute Studies, 102 Irving St, Washington, DC 20010 USA.	DeJong@MedStar.net	Putman, Koen/ABG-6361-2021; Putman, Koen/D-4334-2009	Putman, Koen/0000-0002-7235-3759			Amin AK, 2006, J BONE JOINT SURG BR, V88B, P335, DOI 10.1302/0301-620X.88B3.16488; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Battaglia TC, 2006, CLIN ORTHOP RELAT R, P28, DOI 10.1097/01.blo.0000218743.99741.f0; Buntin MB, 2005, COMP MEDICARE SPENDI, P1; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1306, DOI 10.1016/j.apmr.2009.04.003; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1297, DOI 10.1016/j.apmr.2008.12.029; Deutsch A, 2005, MED CARE, V43, P892, DOI 10.1097/01.mlr.0000173591.23310.d5; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; Durairaj L, 2005, CHEST, V128, P1682, DOI 10.1378/chest.128.3.1682; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILTON B, 1987, UNIFORM DATA SYSTEM; Hamilton BB, 1999, ARCH PHYS MED REHAB, V80, P385, DOI 10.1016/S0003-9993(99)90274-5; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamoui N, 2006, OBES SURG, V16, P35, DOI 10.1381/096089206775222140; Hervey SL, 2003, J BONE JOINT SURG AM, V85A, P1775, DOI 10.2106/00004623-200309000-00017; Homboe ES, 2006, MED CARE, V44, P1073, DOI 10.1097/01.mlr.0000233685.22497.cf; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Jette DU, 2005, ARCH PHYS MED REHAB, V86, P373, DOI 10.1016/j.apmr.2004.10.018; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; Kane RL, 1998, J AM GERIATR SOC, V46, P1525, DOI 10.1111/j.1532-5415.1998.tb01537.x; Kane RL, 2000, HEALTH SERV RES, V35, P615; Kane RL, 2007, ARCH PHYS MED REHAB, V88, P1500, DOI 10.1016/j.apmr.2007.06.015; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Lyman S, 2005, CLIN ORTHOP RELAT R, P132, DOI 10.1097/01.blo.0000150571.51381.9a; Mahomed NN, 2000, J RHEUMATOL, V27, P1753; *MED PAYM ADV COMM, 2008, C MED PAYM POL, P153; *MED PAYM ADV COMM, 2005, PAYM POST CAR, P105; Merrill C, 2007, HOSP STAYS INVOLVING; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; Munin MC, 2005, ARCH PHYS MED REHAB, V86, P367, DOI 10.1016/j.apmr.2004.10.004; Nallamothu BK, 2005, ARCH INTERN MED, V165, P333, DOI 10.1001/archinte.165.3.333; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Stickles B, 2001, OBES RES, V9, P219, DOI 10.1038/oby.2001.24; Sung VW, 2006, AM J OBSTET GYNECOL, V195, P1778, DOI 10.1016/j.ajog.2006.07.015; Tian WQ, 2009, ARCH PHYS MED REHAB, V90, P1260, DOI 10.1016/j.apmr.2008.10.035; Tribe KL, 2005, CHRONIC ILLN, V1, P289, DOI 10.1179/174239505X72011; *US GEN ACC OFF, 2005, MOR SPEC CRIT NEED C; Vincent HK, 2007, OBESITY, V15, P522, DOI 10.1038/oby.2007.551; Vitale MA, 2005, J PEDIATR ORTHOPED, V25, P393, DOI 10.1097/01.bpo.0000153880.05314.be; Walsh MB, 2006, AM J PHYS MED REHAB, V85, P1, DOI 10.1097/01.phm.0000197538.33707.d9; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	49	63	65	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2009	90	8					1284	1296		10.1016/j.apmr.2009.02.009			13	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	483PY	WOS:000268981000004	19651262				2022-02-06	
J	Jackson, JC; Mitchell, N; Hopkins, RO				Jackson, James C.; Mitchell, Nathaniel; Hopkins, Ramona O.			Cognitive Functioning, Mental Health, and Quality of Life in ICU Survivors: An Overview	CRITICAL CARE CLINICS			English	Article						Cognitive impairments; Critical illness; Critical care outcomes; Psychiatric disorders; Quality of life	INTENSIVE-CARE-UNIT; POSTTRAUMATIC-STRESS-DISORDER; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TRAUMATIC BRAIN INJURY; CRITICAL ILLNESS; RISK-FACTORS; DELIRIUM; OUTCOMES; MEMORY	Critical illness can and often does lead to significant cognitive impairment and to the development of psychological disorders. These conditions are persistent and, although they improve with time, often fail to completely abate. Although the functional correlates of cognitive and psychological morbidity (depression, anxiety, and posttraumatic stress disorder) have been studied, they may include poor quality of life, inability to return to work or to work at previously established levels, and inability to function effectively in emotional and interpersonal domains. The potential etiologies of cognitive impairment and psychological morbidity in ICU survivors are particularly poorly understood and may vary widely across patients. Potential contributors may include the potentially toxic effects of sedatives and narcotics, delirium, hypoxia, glucose dysregulation, metabolic derangements, and inflammation. Patients with preexisting vulnerabilities, including predisposing genetic factors, and frail elderly populations may be at particular risk for emergence of acceleration of conditions such as mild cognitive impairment.	[Jackson, James C.; Mitchell, Nathaniel] Vanderbilt Univ, Sch Med, Med Ctr, Ctr Hlth Serv Res, Nashville, TN 37232 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Div Pulm & Crit Care, Murray, UT USA		Jackson, JC (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Ctr Hlth Serv Res, 6th Floor MCE,Suite 6100, Nashville, TN 37232 USA.	james.c.jackson@vanderbilt.edu					ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; [Anonymous], 1988, LANCET, V2, P349; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Capuzzo M, 2005, Minerva Anestesiol, V71, P167; Capuzzo M, 2004, CRIT CARE, V8, pR48, DOI 10.1186/cc2416; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; Dowdy DW, 2008, CRIT CARE MED, V36, P2726, DOI 10.1097/CCM.0b013e31818781f5; Dowdy DW, 2009, CRIT CARE MED, V37, P1702, DOI 10.1097/CCM.0b013e31819fea55; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Eikelenboom P, 1999, DEMENT GERIATR COGN, V10, P319, DOI 10.1159/000017162; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; Fong TG, 2006, J GERONTOL A-BIOL, V61, P1294, DOI 10.1093/gerona/61.12.1294; FOREMAN M, 2004, PRIMARY PSYCHIAT, V11, P46; Galanakis P, 2001, INT J GERIATR PSYCH, V16, P349, DOI 10.1002/gps.327; Girard TD, 2006, DURATION DELIRIUM PA, pA739; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; Hopkins R. O., 2005, P AM THORAC SOC, V2, pA36; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2005, CURR OPIN CRIT CARE, V11, P369, DOI 10.1097/01.ccx.0000166399.88635.a5; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 2000, MEMORY, V8, P81; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; Katz IR, 1996, AM J GERIAT PSYCHIAT, V4, P1, DOI 10.1097/00019442-199624410-00001; Klein E, 2003, CAN J PSYCHIAT, V48, P28, DOI 10.1177/070674370304800106; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lyketsos CG, 2005, AM J GERIAT PSYCHIAT, V13, P656, DOI 10.1176/appi.ajgp.13.8.656; MacLullich AMJ, 2009, INT REV PSYCHIATR, V21, P30, DOI 10.1080/09540260802675031; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Pandharipande P, 2005, CURR OPIN CRIT CARE, V11, P360; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Parkin AJ, 1999, CURR BIOL, V9, pR582, DOI 10.1016/S0960-9822(99)80378-9; Pollack MH, 1996, AM J PSYCHIAT, V153, P110; Pomara N, 2005, ARCH GEN PSYCHIAT, V62, P209, DOI 10.1001/archpsyc.62.2.209; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P411, DOI 10.1176/appi.psy.46.5.411; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P508, DOI 10.1176/appi.psy.46.6.508; Sessler CN, 2001, CHEST, V120, P1390, DOI 10.1378/chest.120.4.1390; Silverstone PH, 1996, J NERV MENT DIS, V184, P43, DOI 10.1097/00005053-199601000-00008; Silverstone PH, 1996, CAN J PSYCHIAT, V41, P67, DOI 10.1177/070674379604100202; Skodol A E, 1999, Semin Clin Neuropsychiatry, V4, P64; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Starr JM, 1996, J AM GERIATR SOC, V44, P411, DOI 10.1111/j.1532-5415.1996.tb06412.x; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; STRAUSS JS, 1981, PSYCHIAT RES, V4, P333, DOI 10.1016/0165-1781(81)90035-4; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teunissen CE, 2003, J NEUROIMMUNOL, V134, P142, DOI 10.1016/S0165-5728(02)00398-3; Toshima MT, 1992, J CARDIOPULM REHABIL, V12, P261; Trzepacz P T, 2000, Semin Clin Neuropsychiatry, V5, P132; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7	85	63	64	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JUL	2009	25	3					615	+		10.1016/j.ccc.2009.04.005			15	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	479ZB	WOS:000268699900014	19576534				2022-02-06	
J	Iverson, GL; Langlois, JA; McCrea, MA; Kelly, JP				Iverson, Grant L.; Langlois, Jean A.; McCrea, Michael A.; Kelly, James P.			CHALLENGES ASSOCIATED WITH POST-DEPLOYMENT SCREENING FOR MILD TRAUMATIC BRAIN INJURY IN MILITARY PERSONNEL	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild Traumatic Brain Injury; Military; Screening; Epidemiology	POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; CONCUSSION; IRAQ; METAANALYSIS; AFGHANISTAN; DISORDER; CARE	There is ongoing debate regarding the epidemiology of mild traumatic brain injury (MTBI) in military personnel. Accurate and timely estimates of the incidence of brain injury and the prevalence of long-term problems associated with brain injuries among active duty service members and veterans are essential for (a) operational planning, and (b) to allocate sufficient resources for rehabilitation and ongoing services and supports. The purpose of this article is to discuss challenges associated with post-deployment screening for MTBI. Multiple screening methods have been used in military, Veterans Affairs, and independent studies, which complicate cross-study comparisons of the resulting epidemiological data. We believe that post-deployment screening is important and necessary-but no screening methodology will be flawless, and false positives and false negatives are inevitable. Additional research is necessary to refine the sequential screening methodology, with the goal of minimizing false negatives during initial post-deployment screening and minimizing false positives during follow-up evaluations.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Langlois, Jean A.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [McCrea, Michael A.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Kelly, James P.] Univ Colorado, Dept Neurosurg, Denver Sch Med, Denver, CO 80202 USA; [Kelly, James P.] Univ Colorado, Dept Phys Med & Rehabil, Denver Sch Med, Denver, CO 80202 USA; [Kelly, James P.] Def Ctr Excellence Psychol Hlth, Natl Intrepid Ctr Excellence, Washington, DC USA; [Kelly, James P.] US Dept Def, TBI, Washington, DC 20305 USA		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Drazen JM, 2005, NEW ENGL J MED, V352, P2121, DOI 10.1056/NEJMe048332; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; General Accounting Office, 2008, GAO08276; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KANG H, 2007, ANAL VA HLTH CARE UT; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; *MENT HLTH ADV TEA, 2008, MHAT V OP IR FREED 0; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604	24	63	63	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	8					1299	1314		10.1080/13854040903153902			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	524KF	WOS:000272141500005	19882473				2022-02-06	
J	Lefering, R; Paffrath, T; Linker, R; Bouillon, B; Neugebauer, EAM				Lefering, Rolf; Paffrath, Thomas; Linker, Ralph; Bouillon, Bertil; Neugebauer, Edmund A. M.		Deutsch Gesellsch Unfallchirurg	Head Injury and Outcome-What Influence do Concomitant Injuries Have?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Trauma Registry Meeting	2006	Munich, GERMANY			Wounds and injuries; Head injury; Score systems; Outcome; Mortality	MULTIPLE-ORGAN FAILURE; TRAUMATIC BRAIN-INJURY; SEVERITY SCORE; MORTALITY; CARE	Background. Severe head injury (HI) is known to be a major determinant of mortality in patients with multiple injuries but additional injuries also contribute to the clinical outcome. The Trauma Registry of the German Society for Trauma Surgery offers sufficient data for comparative outcome analysis in relation to the injury pattern. Methods: A total of 21,356 cases from Trauma Registry of the German Society for Trauma Surgery with complete data for pattern of injury (Abbreviated Injury Scale [AIS], Injury Severity Score), the incidence of hospital mortality, organ failure, sepsis, duration of hospital stay, and intubation-free days. Maximum AIS severity of HI, including brain, skull, face, and cervical spine, and injuries to the torso and/or extremities (TEI) were used for comparative subgroup analysis. Results: Overall mortality rate was 13.7% (mean age, 41.3 years; 72.6% men; mean Injury Severity Score, 24.4). Patients with relevant HI (AIS(HI) >= 3) were found to have a higher mortality rate (22.1 %) than patients with relevant TEI (12.9%). In all HI severity subgroups mortality increased consistently by about 5% with TEI of grade 4, and by 15% with TEI of grade 5, but no increase is observed for lower severity grades. The incidence of organ failure (overall 31.4%), multiple organ failure (15.0%), and sepsis (9.9%) are mainly influenced by the severity of TEI. Intubation-free days are equally influenced by both types of injuries of grade 3 or higher. Conclusions: Mortality in patients with severe trauma is mainly determined by the severity of HI, while TEI contribute consistently only from AIS grade 4 or higher.	[Lefering, Rolf; Neugebauer, Edmund A. M.] Univ Witten Herdecke, IFOM Inst Res Operat Med, D-51109 Cologne, Germany; [Paffrath, Thomas; Bouillon, Bertil] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Linker, Ralph] Orthoped Med Practice Ctr, Zell Mosel, Germany		Lefering, R (corresponding author), Univ Witten Herdecke, IFOM Inst Res Operat Med, Campus Cologne Merheim,Bldg 38,Ostmerheimer St 20, D-51109 Cologne, Germany.	rolf.lefering@ifom-uni-wh.de					Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL AIS 19; Baethmann A, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P169; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baltas I, 1998, J Neurosurg Sci, V42, P85; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Dutton RP, 2006, J TRAUMA, V60, pS70, DOI 10.1097/01.ta.0000200856.47545.64; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; Lefering R, 2002, LANGENBECK ARCH SURG, V387, P14, DOI 10.1007/s00423-001-0269-3; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; PAPE HC, 2000, EUR J TRAUMA, V1, P233; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RAUM MR, 2001, EUR J TRAUMA, V27, P110; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; [No title captured]	26	63	64	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1036	1044		10.1097/TA.0b013e318184ee48			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	372DD	WOS:000260881000012	19001971				2022-02-06	
J	Jagannathan, J; Okonkwo, DO; Yeoh, HK; Dumont, AS; Saulle, D; Raizlip, J; Barth, JT; Jane, JA; Jane, JA				Jagannathan, Jay; Okonkwo, David O.; Yeoh, Hian Kwang; Dumont, Aaron S.; Saulle, Dwight; Raizlip, Julie; Barth, Jeffrey T.; Jane, John A., Sr.; Jane, John A., Jr.			Long-term outcomes and prognostic factors in pediatric patients with severe traumatic brain injury and elevated intracranial pressure	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; management strategy; outcomes; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SOMATOSENSORY-EVOKED POTENTIALS; SEVERE HEAD-INJURY; COMA DATA-BANK; BLOOD-FLOW; CHILDREN; HYPERTENSION; EXPERIENCE; VENTRICULOSTOMY; CRANIECTOMY	Object. The management strategics and outcomes in pediatric patients with elevated intracranial pressure (ICP) following severe traumatic brain injury (TBI) are examined in this study. Methods. This study was a retrospective review of a prospectively acquired pediatric trauma database. More than 750 pediatric patients with brain injury were seen over a 10-year period. Records were retrospectively reviewed to determine interventions for correcting ICP, and surviving patients were contacted prospectively to determine functional status and quality of life. Only patients with 2 years of follow-up were included in the study. Results. Ninety-six pediatric patients (age range 3-18 years) were identified with a Glasgow Coma Scale score < 8 and elevated ICP > 20 mm Hg on presentation. The mean injury severity score was 65 (range 30-100). All patients were treated using a standardized head injury protocol. The mean time course until peak ICP was 69 hours postinjury (range 2-196 hours). Intracranial pressure control was achieved in 82 patients (85%). Methods employed to achieve ICP control included maximal medical therapy (sedation, hyperosmolar therapy, and paralysis) in 34 patients (35%), ventriculostomy in 23 patients (24%). and surgery in 39 patients (41%). Fourteen patients (15%) had refractory ICP despite all interventions, and all of these patients died. Seventy-two patients (75%) were discharged from the hospital, whereas 24 (25%) died during hospitalization. Univariate and multivariate analysis revealed that the presence of vascular injury, refractory ICP, and cisternal effacement at presentation had the highest correlation with subsequent death (p < 0.05). Mean follow-up was 53 months (range 11-126 months). Three patients died during the follow-up period (2 due to infections and I committed Suicide). The mean 2-year Glasgow Outcome Scale score was 4 (median 4, range 1-5). The mean patient competency rating at follow-up was 4.13 out of 5 (median 4.5, range 1-4.8). Univariate analysis revealed that the extent of intracranial and Systemic injuries had the highest correlation with long-term quality of life (p < 0.05). Conclusions. Controlling elevated ICP is an important factor in patient survival following severe pediatric TBI. The modality used for ICP control appears to be less important. Long-term follow-up is essential to determine neurocognitive sequelae associated with TBI.	[Jagannathan, Jay; Yeoh, Hian Kwang; Dumont, Aaron S.; Saulle, Dwight; Jane, John A., Sr.; Jane, John A., Jr.] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA 22908 USA; [Raizlip, Julie; Jane, John A., Jr.] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; [Barth, Jeffrey T.] Univ Virginia Hlth Syst, Dept Psychiat Med, Charlottesville, VA 22908 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA		Jane, JA (corresponding author), Univ Virginia Hlth Syst, Dept Neurosurg, POB 800212, Charlottesville, VA 22908 USA.	jaj2k@virginia.edu	Jane, John/AAY-3201-2021				Adelson P D, 2000, Clin Neurosurg, V47, P319; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Artru F, 1990, Agressologie, V31, P367; BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chugani H T, 1999, Adv Neurol, V81, P241; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Hamilton KL, 2002, EXP PHYSIOL, V87, P437, DOI 10.1111/j.1469-445X.2002.tb00056.x; Hammer MD, 2006, SURG CLIN N AM, V86, P1541, DOI 10.1016/j.suc.2006.08.002; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Jones PA, 2005, ACT NEUR S, V95, P29; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; MARSHALL LF, 1975, J NEUROSURG, V43, P308, DOI 10.3171/jns.1975.43.3.0308; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; OBRIEN JF, 1991, ANN EMERG MED, V20, P644, DOI 10.1016/S0196-0644(05)82384-4; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Pople IK, 1996, PEDIATR NEUROSURG, V25, P1, DOI 10.1159/000121088; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Savitsky EA, 2000, AM J EMERG MED, V18, P96, DOI 10.1016/S0735-6757(00)90060-3; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; Vigue B, 2000, INTENS CARE MED, V26, P722, DOI 10.1007/s001340051238; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	49	63	68	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2008	2	4					240	249		10.3171/PED.2008.2.10.240			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	353ET	WOS:000259549600004	18831656				2022-02-06	
J	Morgalla, MH; Will, BE; Roser, F; Tatagiba, M				Morgalla, Matthias H.; Will, Bernd E.; Roser, Florian; Tatagiba, Marcos			Do long-term results justify decompressive craniectomy after severe traumatic brain injury?	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; intracranial pressure; intracranial pressure monitoring; neuromonitoring; transcranial Doppler ultrasonography	SURGICAL DECOMPRESSION; CEREBRAL EDEMA; HEAD-INJURY; MANAGEMENT; CHILDREN; ICP	Object. A decompressive craniectomy can be a life-saving procedure to relieve critically increased intracranial pressure. The survival of a patient is important as well as the subsequent and long-term quality of life. In this paper the authors' goal was to investigate whether long-term clinical results justify the use of a decompressive craniectomy. Methods. Thirty-three patient,, (20 males and 13 females) with a mean age of 36.3 years (range 13-60 years) with severe traumatic brain injury (Grades III and IV) and subsequent massive brain swelling were examined. For postoperative assessment the Barthel Index was used. A Surgical intervention was based on the following criteria: I) The intracranial pressure Could not be controlled by conservative treatment and constantly exceeded 30 rum Hg (cerebral perfusion pressure < 50 mm Hg). 2) Transcranial Doppler ultrasonography revealed only a systolic flow pattern or systolic peaks. 3) There were no other major injuries. 4) The patient was not older than 60 years. Results. One-fifth of all patients died and one-fifth remained in a vegetative state. Mild deficits were seen in 6 of 33 patients. A full rehabilitation (Barthel Index 90-100) was achieved in 13 patients (39.4%). Five patients could resume their former occupation, and another 4 had to change jobs. Conclusions. Age remains to be one of the most important exclusion factors. Decompressive craniectomy provided good clinical results in nearly 40% of patients who were otherwise most likely to die. Therefore, long-term results justify the use of decompressive craniectomy in this case series.	[Morgalla, Matthias H.; Will, Bernd E.; Roser, Florian; Tatagiba, Marcos] Univ Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany		Morgalla, MH (corresponding author), Univ Tubingen, Dept Neurosurg, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	matthias.morgalla@med.uni-tuebingen.de		Roser, Florian/0000-0002-7854-6789			Carmelo A, 2002, ACT NEUR S, V81, P109; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; Kunze E, 1998, ACT NEUR S, V71, P16; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schaller B, 2002, Swiss Surg, V8, P145, DOI 10.1024/1023-9332.8.4.145; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Spagnuolo E, 2004, NEUROCIRUGIA, V15, P36; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	25	63	66	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					685	690		10.3171/JNS/2008/109/10/0685			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100014	18826356				2022-02-06	
J	Mothe, AJ; Tator, CH				Mothe, Andrea J.; Tator, Charles H.			Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination	EXPERIMENTAL NEUROLOGY			English	Article						neural stem/progenitor cells; transplantation; spinal cord; myelination; focal demyelination lesions; shiverer mouse	CENTRAL-NERVOUS-SYSTEM; SHIVERER MOUSE-BRAIN; CNS STEM-CELLS; ADULT-RAT; PRECURSOR CELLS; ADHESION MOLECULE; COMPRESSION INJURY; TYPE-1 ASTROCYTES; MUTANT MOUSE; REMYELINATION	Stein cell therapy is a promising approach for remyelination strategies in demyelinating and traumatic disorders of the spinal cord. Self-renewing neural stem/progenitor cells (NSPCs) reside in the adult mammalian brain and spinal cord. We transplanted NSPCs derived from the adult spinal cord of transgenic rats into two models of focal demyelination and congenital dysmyelination. Focal demyelination was induced by X-irradiation and ethidium bromide injection (X-EB); and dysmyelination was in adult shiverer mutant mice, which lack compact CNS myelin. We examined the differentiation potential and myelinogenic capacity of NSPCs transplanted into the spinal cord. In X-EB lesions, the transplanted cells primarily differentiated along an oligodendrocyte lineage but only some of the oligodendrocytic Progeny remyelinated host axons. In this glial-free lesion, NSPCs also differentiated into cells with Schwann-like features based on ultrastructure, expression of Schwann cell markers, and generation of peripheral myelin. in contrast, after transplantation into the spinal cord of adult shiverer mice, the majority of the NSPCs expressed an oligodendrocytic phenotype which myelinated the dysmyelinated CNS axons forming compact myelin, and none had Schwann cell-like features. This is the first Study to examine the differentiation and myelinogenic capacity of adult Spinal Cord stem/progenitors in focal demyelination and dysmyelination of the adult rodent spinal cord. Our findings demonstrate that these NSPCs have the inherent plasticity to differentiate into oligodendrocytes OF Schwann-like cells depending oil the host environment, and that both cell types are capable of myelinating axons in the demyelinated and dysmyelinated adult spinal Cord. (C) 2008 Elsevier Inc. All rights reserved.	[Mothe, Andrea J.; Tator, Charles H.] Toronto Western Res Inst, Krembil Neurosci Ctr, Div Genet & Dev, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A8, Canada		Mothe, AJ (corresponding author), Toronto Western Res Inst, Krembil Neurosci Ctr, Div Genet & Dev, Toronto, ON M5T 2S8, Canada.	amothe@uhnres.utoronto.ca			Christopher Reeve Paralysis Foundation; MS Society of Canada; International Foundation of Research in Paraplegia; CIHR NETCanadian Institutes of Health Research (CIHR); Ontario Neurotrauma Foundation; CIHRCanadian Institutes of Health Research (CIHR)	This work was supported by operating grants to C.H.T from the Christopher Reeve Paralysis Foundation, MS Society of Canada, International Foundation of Research in Paraplegia, and in part by CIHR NET team grant. A. J. M. was supported by fellowships from the Ontario Neurotrauma Foundation and CIHR. We thank Linda Lee and Rita van Bendegem for the technical assistance and Iris Kulbatski for Culturing some of the cells used for the focal demyelination transplantation experiments. We thank Dr. Armand Keating and Dr. Xinghua Wang of the Cell Therapy Program, Princess Margaret Hospital and Ontario Cancer Institute, for maintaining the transgenic rat colony. We thank Bob Kuba and Dr. Richard Hill of the Division of Applied Molecular Oncology, Princess Margaret Hospital and Ontario Cancer Institute, for their help with the X-irradiation of rats. We thank Sheer Ramjohn and Dr. Patrick Shannon of the Department of Cellular and Molecular Pathology, University of Toronto, for their help with the ultrastructural analysis. We thank Stephanie Tung for her assistance with cell Counts and Dr. Juan Archelos for the gift of P0 antibody.	Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bhat RV, 1996, GLIA, V17, P169; BLAKEMORE WF, 1989, J NEUROCYTOL, V18, P519, DOI 10.1007/BF01474547; Blakemore WF, 2005, NEUROPATH APPL NEURO, V31, P1, DOI 10.1111/j.1365-2990.2005.00637.x; Blakemore WF, 2003, EXP NEUROL, V184, P955, DOI 10.1016/S0014-4886(03)00347-9; BLAKEMORE WF, 1978, NEUROPATH APPL NEURO, V4, P47, DOI 10.1111/j.1365-2990.1978.tb00528.x; BLAKEMORE WF, 1982, NEUROPATH APPL NEURO, V8, P365, DOI 10.1111/j.1365-2990.1982.tb00305.x; BRUNI JE, 1987, ACTA ANAT, V128, P265; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; CHERNOFF GF, 1981, J HERED, V72, P128, DOI 10.1093/oxfordjournals.jhered.a109442; CRANG AJ, 1992, J NEUROIMMUNOL, V40, P243, DOI 10.1016/0165-5728(92)90140-G; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Dervan AG, 2003, J COMP NEUROL, V458, P293, DOI 10.1002/cne.10594; DROMARD C, J NEUROSCI RES; Eftekharpour E, 2007, J NEUROSCI, V27, P3416, DOI 10.1523/JNEUROSCI.0273-07.2007; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; FRANKLIN RJM, 1991, J NEUROCYTOL, V20, P420, DOI 10.1007/BF01355538; Gajavelli S, 2004, EXP NEUROL, V188, P205, DOI 10.1016/j.expneurol.2004.03.026; GUMPEL M, 1989, DEV NEUROSCI-BASEL, V11, P132, DOI 10.1159/000111894; Hakamata Y, 2001, BIOCHEM BIOPH RES CO, V286, P779, DOI 10.1006/bbrc.2001.5452; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Horky LL, 2006, J COMP NEUROL, V498, P525, DOI 10.1002/cne.21065; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; KOHSAKA S, 1986, BRAIN RES, V372, P137, DOI 10.1016/0006-8993(86)91466-6; Kulbatski I, 2007, J HISTOCHEM CYTOCHEM, V55, P209, DOI 10.1369/jhc.6A7020.2006; LACHAPELLE F, 1994, EUR J NEUROSCI, V6, P814, DOI 10.1111/j.1460-9568.1994.tb00992.x; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; LUBETZKI C, 1988, J NEUROL SCI, V88, P161, DOI 10.1016/0022-510X(88)90214-6; Martens DJ, 2002, EUR J NEUROSCI, V16, P1045, DOI 10.1046/j.1460-9568.2002.02181.x; McKenzie IA, 2006, J NEUROSCI, V26, P6651, DOI 10.1523/JNEUROSCI.1007-06.2006; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Mothe AJ, 2005, J HISTOCHEM CYTOCHEM, V53, P1215, DOI 10.1369/jhc.5A6639.2005; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; MOTHE AJ, CELL TRANSP IN PRESS; Mujtaba T, 1998, DEV BIOL, V200, P1, DOI 10.1006/dbio.1998.8913; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; NORDLANDER RH, 1978, J COMP NEUROL, V180, P349, DOI 10.1002/cne.901800211; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; Parr AM, 2007, J NEUROTRAUM, V24, P835, DOI 10.1089/neu.2006.3771; Pfeifer K, 2006, REGEN MED, V1, P255, DOI 10.2217/17460751.1.2.255; PRIVAT A, 1979, NEUROSCI LETT, V12, P107, DOI 10.1016/0304-3940(79)91489-7; Radtke C, 2007, INT J DEV NEUROSCI, V25, P149, DOI 10.1016/j.ijdevneu.2007.02.002; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sasaki M, 2006, J NEUROSCI, V26, P1803, DOI 10.1523/JNEUROSCI.3611-05.2006; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Takahashi M, 2003, J NEUROPATH EXP NEUR, V62, P185, DOI 10.1093/jnen/62.2.185; Talbott JF, 2006, GLIA, V54, P147, DOI 10.1002/glia.20369; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vacanti MP, 2001, TRANSPLANT P, V33, P592, DOI 10.1016/S0041-1345(00)02158-8; VAQUERO J, 1981, ACTA NEUROCHIR, V59, P209, DOI 10.1007/BF01406350; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Weiss S, 1996, J NEUROSCI, V16, P7599; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	68	63	71	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2008	213	1					176	190		10.1016/j.expneurol.2008.05.024			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	344QX	WOS:000258943500022	18586031				2022-02-06	
J	Zlotnik, A; Gurevich, B; Cherniavsky, E; Tkachov, S; Matuzani-Ruban, A; Leon, A; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gurevich, Boris; Cherniavsky, Evgenia; Tkachov, Sergei; Matuzani-Ruban, Angela; Leon, Avner; Shapira, Yoram; Teichberg, Vivian I.			The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury	NEUROCHEMICAL RESEARCH			English	Article						glutamate; excitotoxicity; blood glutamate levels; blood glutamate scavenging; oxaloacetate; pyruvate; glutamate-pyruvate transaminase; closed head injury; stroke; neuroprotection; brain to blood glutamate efflux; neurological outcome; antioxidant activity; intravenous injection	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; NERVOUS-SYSTEM NEURONS; CEREBROSPINAL-FLUID; CORTICAL CONTUSION; HYDROGEN-PEROXIDE; PROTECTS NEURONS; CEREBRAL-CORTEX; BARRIER CHANGES; CELL-DEATH	The removal of excess glutamate from brain fluids after acute insults such as closed head injury (CHI) and stroke is expected to prevent excitotoxicity and the ensuing long lasting neurological deficits. Since blood glutamate scavenging accelerates the removal of excess glutamate from brain into blood and causes neuroprotection, we have evaluated here whether the neuroprotective properties of pyruvate could be partly accounted to its blood glutamate scavenging activity. The neurological outcome of rats after CHI improved significantly when treated with intravenous pyruvate (0.9 mmoles/100 g) but not with pyruvate administered together with glutamate. Pyruvate, at 5 mu mole/100 g rat was neither protective not able to decrease blood glutamate but displayed the latter two properties when combined with 60 mu g/100 g of glutamate-pyruvate transaminase. Since the neurological recovery from CHI was correlated with the decrease of blood glutamate levels, we conclude that pyruvate blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms.	[Matuzani-Ruban, Angela; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Cherniavsky, Evgenia] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Radiol, IL-84105 Beer Sheva, Israel; [Zlotnik, Alexander; Gurevich, Boris; Tkachov, Sergei; Leon, Avner; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel		Teichberg, VI (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	vivian.teichberg@weizman.ac.il		Ruban, Angela/0000-0003-1091-8854			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; BERL S, 1962, J BIOL CHEM, V237, P2562; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; CAVALLINI L, 1990, J MOL CELL CARDIOL, V22, P143, DOI 10.1016/0022-2828(90)91111-J; CONN AR, 1982, AM J PHYSIOL, V243, pE272, DOI 10.1152/ajpendo.1982.243.4.E272; Crestanello JA, 1998, SURGERY, V124, P92, DOI 10.1016/S0039-6060(98)70080-7; Desagher S, 1997, J NEUROSCI, V17, P9060; Dobsak P, 1999, J CARDIOVASC PHARM, V34, P651, DOI 10.1097/00005344-199911000-00005; EIMERL S, 1995, J NEUROCHEM, V65, P739; FACCI L, 1985, J NEUROSCI RES, V14, P293, DOI 10.1002/jnr.490140302; GOODWIN TW, 1952, BIOCHEM J, V51, P708, DOI 10.1042/bj0510708; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Koura SS, 1998, ACT NEUR S, V71, P244; Lee JY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0002.2001; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854, DOI 10.1152/ajpheart.2001.281.2.H854; Nakamichi N, 2005, J NEUROCHEM, V93, P84, DOI 10.1111/j.1471-4159.2005.02999.x; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450, DOI 10.1152/ajplegacy.1973.224.6.1450; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Ruiz F, 1998, NEUROREPORT, V9, P1277; SELAK I, 1985, J NEUROSCI, V5, P23; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wada M, 2006, BRAIN RES, V1081, P92, DOI 10.1016/j.brainres.2006.01.084; Wang XF, 2001, J NEUROSCI, V21, P3322, DOI 10.1523/JNEUROSCI.21-10-03322.2001; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	45	63	63	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	JUN	2008	33	6					1044	1050		10.1007/s11064-007-9548-x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	288CW	WOS:000254964800011	18080187				2022-02-06	
J	Nadler, Y; Alexandrovich, A; Grigorladis, N; Hartmann, T; Rao, KSJ; Shohami, E; Stein, R				Nadler, Yasmine; Alexandrovich, Alexander; Grigorladis, Nikolaos; Hartmann, Tobias; Rao, Kosagi S. Jagannatha; Shohami, Esther; Stein, Reuven			Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury	GLIA			English	Article						closed head injury; brain-stabbing; presenilin; nicastrin; astrocytes; microglia	CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-SECRETASE; MOUSE-BRAIN; REACTIVE ASTROCYTES; GLIAL SCAR; IMMUNOHISTOCHEMICAL ANALYSIS; MISSENSE MUTATIONS; ERBB-4 RECEPTOR	gamma-Secretase is an aspartyl protease composed of four proteins: presenilin (PS), nicastrin (Net), APH1, and PEN2. These proteins assemble into a membrane complex that cleaves a variety of substrates within the transmembrane domain. The gamma-secretase cleavage products play an important role in various biological processes such as embryonic development and Alzheimer's disease (AD). The major role of gamma-secretase in brain pathology has been linked to AD and to the production of the amyloid P-peptide. However, little is known about the possible role of gamma-secretase following acute brain insult. Here we examined by immunostaining the expression patterns of two gamma-secretase components, PSI and Net, in three paradigms of brain insult in mice: closed head injury, intracerebroventricular injection of LPS, and brain stabbing. Our results show that in naive and sham-injured brains expression of PS1 and Net is restricted mainly to neurons. However, following insult, the expression of both proteins is also observed in nonneuronal cells, consisting of activated astrocytes and microglia. Furthermore, the proteins are coexpressed within the same astrocytes and microglia, implying that these cells exhibit an enhanced gamma-secretase activity following brain damage. In view of the important role played by astrocytes and microglia in brain disorders, our findings suggest that gamma-secretase may participate in brain damage and repair processes by regulating astrocyte and microglia activation and/or function. (C) 2008 Wiley-Liss, Inc.	[Nadler, Yasmine; Stein, Reuven] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; [Alexandrovich, Alexander; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Grigorladis, Nikolaos] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol B, GR-54636 Thessaloniki, Greece; [Grigorladis, Nikolaos] Aristotle Univ Thessaloniki, Lab Expt Neurol, GR-54636 Thessaloniki, Greece; [Hartmann, Tobias] Univ Saarland, Uniklinikum Homburg, D-6600 Saarbrucken, Germany; [Rao, Kosagi S. Jagannatha] Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysore 570013, Karnataka, India		Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	reuvens@post.tau.ac.il	Kosagisharaf, Jagannatha Rao/N-6788-2014; Hartmann, Tobias/AAB-8297-2022	Kosagisharaf, Jagannatha Rao/0000-0003-4290-7666; Hartmann, Tobias/0000-0001-7481-6430			Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Blanchard V, 1997, BRAIN RES, V758, P209, DOI 10.1016/S0006-8993(97)00231-X; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; De Strooper B, 2005, CELL, V122, P318, DOI 10.1016/j.cell.2005.07.021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dewji NN, 2004, P NATL ACAD SCI USA, V101, P1057, DOI 10.1073/pnas.0307290101; Diehlmann A, 1999, J NEUROSCI RES, V56, P405; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Grandbarbe L, 2007, GLIA, V55, P1519, DOI 10.1002/glia.20553; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hartlage-Rubsamen M, 2003, GLIA, V41, P169, DOI 10.1002/glia.10178; Heales SJR, 2004, NEUROCHEM RES, V29, P513, DOI 10.1023/B:NERE.0000014822.69384.0f; Hebert SS, 2004, NEUROBIOL DIS, V17, P260, DOI 10.1016/j.nbd.2004.08.002; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P1009, DOI 10.1097/00005072-199709000-00006; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kim KS, 1997, BRAIN RES, V757, P159, DOI 10.1016/S0006-8993(97)00243-6; KODAM A, IN PRESS NEUROBIOL A; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; Lee J, 2002, NEUROMOL MED, V2, P29; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lin CH, 2006, EXP NEUROL, V201, P225, DOI 10.1016/j.expneurol.2006.04.014; Logan A, 2002, ADV EXP MED BIOL, V513, P115; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Magnus T, 2007, J NEUROSCI RES, V85, P2126, DOI 10.1002/jnr.21368; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marchetti B, 2005, TRENDS PHARMACOL SCI, V26, P517, DOI 10.1016/j.tips.2005.08.007; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; Miake H, 1999, ACTA NEUROPATHOL, V98, P337, DOI 10.1007/s004010051090; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pennypacker KR, 1999, BRAIN RES BULL, V48, P539, DOI 10.1016/S0361-9230(99)00031-3; Pitsi D, 2004, J BIOL CHEM, V279, P25333, DOI 10.1074/jbc.M312710200; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramirez MJ, 2001, BRAIN RES, V907, P222, DOI 10.1016/S0006-8993(01)02580-X; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rossner S, 2005, J NEUROCHEM, V92, P226, DOI 10.1111/j.1471-4159.2004.02857.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Siman R, 2004, NEUROSCIENCE, V129, P615, DOI 10.1016/j.neuroscience.2004.08.028; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tanimukai H, 1998, MOL BRAIN RES, V54, P212, DOI 10.1016/S0169-328X(97)00337-9; Toninelli GF, 2003, NEUROREPORT, V14, P917, DOI 10.1097/01.wnr.0000069962.11849.e6; Uchihara T, 2006, NEUROBIOL AGING, V27, P88, DOI 10.1016/j.neurobiolaging.2004.12.011; Uchihara T, 1996, ACTA NEUROPATHOL, V92, P325, DOI 10.1007/s004010050526; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weggen S, 1998, NEUROREPORT, V9, P3279; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamada T, 1997, EXP NEUROL, V148, P10, DOI 10.1006/exnr.1997.6661; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	86	63	64	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2008	56	5					552	567		10.1002/glia.20638			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	275KM	WOS:000254070300007	18240300				2022-02-06	
J	Staudenmayer, KL; Diaz-Arrastia, R; de Oliveira, A; Gentilello, LM; Shafi, S				Staudenmayer, Kristan L.; Diaz-Arrastia, Ramon; de Oliveira, Ana; Gentilello, Larry M.; Shafi, Shahid			Ethnic disparities in long-term function outcomes after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		traumatic brain injury; ethnic disparities	ACUTE MYOCARDIAL-INFARCTION; IMPACT; TRANSPLANTATION; RACE	Objective: Ethnic disparities in access to acute rehabilitation and in long-term global neurologic outcomes after traumatic brain injury (TBI) have been previously documented. The current study was undertaken to determine whether there are specific types of functional deficits that disproportionately affect ethnic minorities after TBI. Methods: The TBI Clinical Trials Network is a National Institutes of Health-funded multicenter prospective study. Local data from trauma centers in a single ethnically diverse major metropolitan study site were analyzed. Functional outcomes were measured in 211 patients with blunt TBI (head Abbreviated Injury Scale score 3-5) who were alive !,6 months after discharge using the Functional Status Examination (FSE), which measures outcome in 10 functional domains and compares current functional status to preinjury status. For each domain, patients were classified as functionally independent (FSE score 1, 2) or dependent upon others (FSE score 3, 4). Ethnic minorities (n = 66) were compared with non-Hispanic whites (n = 145), with p < 0.05 considered significant. Results: The two groups had similar injury severity (head Abbreviated Injury Scale score, initial Glasgow Coma Scale score, Injury Severity Score) and were equally likely to be placed in rehabilitation after trauma center discharge (minorities 51%, whites 46%, p = 0.28). Minority patients experienced worse long-term functional outcomes in all domains, which reached statistical significance in post-TBI standard of living, engagement in leisure activities, and return to work or school. Conclusions: Ethnic minorities with TBI suffer worse long-term deficits in three specific functional domains. TBI rehabilitation programs should target these specific areas to reduce disparities in functional outcomes in ethnic minorities.	[Gentilello, Larry M.; Shafi, Shahid] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma & Crit Care, Dallas, TX 75390 USA; [Staudenmayer, Kristan L.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Diaz-Arrastia, Ramon; de Oliveira, Ana] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA		Shafi, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma & Crit Care, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Barnhart JM, 2003, ARCH INTERN MED, V163, P461, DOI 10.1001/archinte.163.4.461; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; COLLINS KS, 1999, US MINORITY HLTH CHA; Delano BG, 1997, ASAIO J, V43, pM861; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Flattery Maureen P, 2004, J Cult Divers, V11, P25; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Syed M, 2000, AM HEART J, V140, P643, DOI 10.1067/mhj.2000.109644; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; *US DHHS, 2005, NAT HEALTHC DISP REP; Venkat A, 2003, ACAD EMERG MED, V10, P1199, DOI 10.1197/S1069-6563(03)00490-1; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; [No title captured]	24	63	63	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1364	1369		10.1097/TA.0b013e31815b897b			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	243AU	WOS:000251768100031	18212662				2022-02-06	
J	Klose, M; Watt, T; Brennum, J; Feldt-Rasmussen, U				Klose, M.; Watt, T.; Brennum, J.; Feldt-Rasmussen, U.			Posttraumatic hypopituitarism is associated with an unfavorable body composition and lipid profile, and decreased quality of life 12 months after injury	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE DEFICIENCY; BASE-LINE; QOL-AGHDA; FACTOR-I; ADULTS; REPLACEMENT; HEALTH; GH	Objective: Our objective was to describe body composition, lipid profile, and health-related quality of life (HRQL) in patients with traumatic brain injury (TBI) in relation to the development of post-traumatic hypopituitarism. Design: This is a cross-sectional evaluation with a nested prospective substudy. Patients: The cross-sectional cohort included 104 hospitalized patients with TBI [26 females/78 males; median age 41 yr (range 18 64); body mass index (BMI) 25 kg/m(2) (range 17 -39); and severity, mild (Glasgow Coma Scale score (GCS) 13 -15) n = 44, moderate (GCS 9 -12) n = 20, and severe (GCS < 9) n = 40)]. A nested cohort of 46 patients was followed prospectively. Measurements: BMI, waist circumference, lipid profile, total-and regional-fat mass were assessed 3 and 12 months (prospective) or only 12 months (cross-sectional) posttraumatically. HRQL questionnaires (Nottingham Health Profile, EuroQoL-5D, and the GH deficiency (GHD) specific instrument, Quality of Life Assessment of GHD in Adults) were completed "pre-traumatically," 3 and 12 months (prospective), or only 12 months (cross-sectional) posttraumatically. Results: Patients with posttraumatic hypopituitarism had higher age-, gender-, and BMI-adjusted 12-month low-density lipoprotein-cholesterol, waist circumference, and total fat mass (P < 0.05 in all cases), and a higher increase in total cholesterol (P = 0.01) during follow-up compared with sufficient patients. These findings were unrelated to 12-month IGF-I and IGF-I SD scores. Hypopituitary patients also had worse age, BMI, and TBI severity adjusted overall EuroQoL-5D visual analog scale (P = 0.03) and Quality of Life Assessment of GHD in Adults (P = 0.01) scores, and worse Nottingham Health Profile dimension scores of sleep (P = 0.03), energy (P = 0.02), and social isolation (P = 0.04), compared with patients with an intact pituitary function. Conclusion: Posttraumatic hypopituitarism was an independent predictor of the classical phenotypical features of hypopituitarism, including an unfavorable lipid and body composition profile, as well as worsened HRQL.	Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Glostrup Hosp, Dept Neurosurg, DK-2600 Glostrup, Denmark		Klose, M (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	mcklose@hotmail.com	Watt, Torquil/ABC-3252-2020	Watt, Torquil/0000-0002-6001-7440; Brennum, Jannick/0000-0002-7961-0156			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Carroll PV, 1997, EUR J ENDOCRINOL, V137, P146, DOI 10.1530/eje.0.1370146; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Coons SJ, 2000, PHARMACOECONOMICS, V17, P13, DOI 10.2165/00019053-200017010-00002; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; *GROWTH RES SOC WO, 1998, J CLIN ENDOCR METAB, V87, P379; HAMMOND FM, 2006, J HEAD TRAUMA REHAB, V64, P481; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; KANE R, 2006, UNDERSTANDING HLTH C, P377; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Maiter D, 2006, EUR J ENDOCRINOL, V155, P253, DOI 10.1530/eje.1.02209; MARDH G, 1994, ENDOCRINOLOGY MET SA, V1, P43; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; McMillan CV, 2003, CLIN ENDOCRINOL, V59, P467, DOI 10.1046/j.1365-2265.2003.01870.x; Montazeri Ali, 2003, Health Qual Life Outcomes, V1, P19, DOI 10.1186/1477-7525-1-19; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Stahl Elisabeth, 2005, Health Qual Life Outcomes, V3, P56, DOI 10.1186/1477-7525-3-56; Stewart PM, 2001, HORM RES, V56, P1, DOI 10.1159/000048126; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THORSEN H, 1995, DAN MED BULL, V42, P105; Thorsen Hanne, 1993, Scandinavian Journal of Primary Health Care, V11, P124, DOI 10.3109/02813439308994914; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wiren L, 2000, CLIN ENDOCRINOL, V52, P143, DOI 10.1046/j.1365-2265.2000.00899.x	38	63	65	0	4	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2007	92	10					3861	3868		10.1210/jc.2007-0901			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	220HS	WOS:000250148400017	17652217	Bronze			2022-02-06	
J	Clausen, F; Lorant, T; Lewen, A; Hillered, L				Clausen, Fredrik; Lorant, Tomas; Lewen, Anders; Hillered, Lars			T lymphocyte trafficking: A novel target for neuroprotection in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; neuroprotection; reactive oxygen species; S-PBN; T lymphocytes; traumatic brain injury	S-PBN; CELLS; ACTIVATION; EXPRESSION; ADHESION; STROKE; RECRUITMENT; NXY-059; EDEMA; RAT	Infiltration of T lymphocytes is a key feature in transplant rejection and in several autoimmune disorders, but the role of T lymphocytes in traumatic brain injury (TBI) is largely unknown. Here we studied trafficking of immune cells in the brain after experimental TBI. We found that scavenging of reactive oxygen species (ROS) at the endothelial level dramatically reduced the infiltration of activated T lymphocytes. Immune cell infiltration was studied 12 h to 7 days after controlled cortical contusion in rats by ex vivo propagation of T lymphocytes (TcR+, CD8(+)), neutrophils (MPO+), and macrophages/microglia (ED-1(+)) from biopsies taken from injured cortex and analyzed by flow cytometry, as well as by quantitative immunohistochemistry. T lymphocyte and neutrophil infiltration peaked at 24 h and macrophages/ microglia at 7 days post-injury. Pretreatment with 2-sulfophenylN-tert-butylnitrone( S-PBN) produced a dramatic reduction of TcR+T lymphocytes and a significantly smaller attenuation of neutrophil infiltration at 24 h post-injury, but did not affect CD8(+) T lymphocytes or macrophages/microglia. S-PBN significantly reduced the expression of the endothelial adhesion molecules ICAM-1 and VCAM at 24 h for following TBI. We conclude that ROS inhibition at the endothelial level influenced T lymphocyte and neutrophil infiltration following TBI. We submit that the reduction of T lymphocyte infiltration is a key feature in improving TBI outcome after S-PBN treatment. Our data suggest that targeting T lymphocyte trafficking to the injured brain at the microvascular level is a novel concept of neuroprotection in TBI and warrants further exploration.	Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Uppsala, Sweden; Univ Uppsala Hosp, Sect Transplantat Surg, Dept Surg Sci, Uppsala, Sweden		Hillered, L (corresponding author), Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Entrance 85,2nd floor, Uppsala, Sweden.	Lars.Hillered@neurokir.uu.se	Lorant, Tomas/AAU-2490-2020; Lewen, Anders/A-5156-2013	Lorant, Tomas/0000-0002-2466-6259; Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417; Hillered, Lars/0000-0002-2808-9292			Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chaudhary P, 2006, J NEUROIMMUNOL, V175, P87, DOI 10.1016/j.jneuroim.2006.03.007; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; CLAUSEN F, 2003, NAT NEUR S; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Harris AK, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-49; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lorant T, 2002, XENOTRANSPLANTATION, V9, P209, DOI 10.1034/j.1399-3089.2002.01060.x; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marshall JWB, 2003, STROKE, V34, P2228, DOI 10.1161/01.STR.0000087790.79851.A8; MAYER TG, 1985, J IMMUNOL, V134, P258; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Potts Mathew B, 2006, NeuroRx, V3, P143; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004	34	63	66	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1295	1307		10.1089/neu.2006.0258			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500001	17711391				2022-02-06	
J	Tian, DS; Dong, Q; Pan, DJ; He, Y; Yu, ZY; Xie, MJ; Wang, W				Tian, Dai-shi; Dong, Qianq; Pan, Deng-ji; He, Yi; Yu, Zhi-yuan; Xie, Min-jie; Wang, Wei			Attenuation of astrogliosis by suppressing of microglial proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury model	BRAIN RESEARCH			English	Article						cell cycle; spinal cord injury; microglial proliferation; glial interaction; astrogliosis	NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY RESPONSE; MESSENGER-RNA; EXPRESSION; CYTOKINES; ACTIVATION; BRAIN; REGENERATION; DEATH	Microglial activation/proliferation and reactive astrogliosis are commonly observed and have been considered to be closely relevant pathological processes during spinal cord injury (SCI). However, the molecular mechanisms underlying this micro glial-astroglial interaction are still poorly understood. We showed recently that the continuous injection of the cell cycle inhibitor olomoucine not only markedly suppressed microglial proliferation and associated release of pro-inflammatory cytokines, but also attenuated astroglial scar formation and the lesion cavity and mitigated the functional deficits in rat SCI animal model. in this study, we asked whether microglial activation/proliferation plays an initial role and also necessary in maintaining astrogliosis in SCI model. Our results showed that traumatic induced microglial activation/proliferation precedes astrogliosis, and the up-regulated GFAP expression at both mRNA and protein levels was temporally posterior to the microglial activation. Furthermore, when the cell cycle inhibitor olomoucine was administered only once 1 h post-SCI that should selectively suppress microglial proliferation, the subsequent SCI induced increase in GFAP expression at 1, 2 and 4 weeks was significantly attenuated, suggesting that microglial activation/proliferation played an important role for the later onset astrogliosis after SCI. Consistent with the results that microglial proliferation always precedes astroglial proliferation and there is at present no evidence of other astroglial precursors, which as always does not mean that they will not be uncovered by further searching, and in view of the fact that micro glial- derived pro-inflammatory cytokines promote astrogliosis as we reported recently, these findings together suggest that by release of cytokines and other soluble products, the early onset microglial activation/proliferation can significantly influence the subsequent development of reactive astrogliosis and glial scar formation in SCI animal model. (C) 2007 Elsevier B.V. All rights reserved.	Huazhong Univ Sci & Technol, Dept Neurol, Affiliated Tongji hosp, Tongji Med Coll, Wuhan 430030, Peoples R China; Fudan Univ, Dept Neurol, Huashan Hosp, Coll Med, Shanghai 200040, Peoples R China; Huazhong Univ Sci & Technol, Dept Med Record, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China		Wang, W (corresponding author), Huazhong Univ Sci & Technol, Dept Neurol, Affiliated Tongji hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.	wwang_tjh@yahoo.com.cn	TIAN, DAISHI/A-8744-2018				Balasingam V, 1996, GLIA, V18, P11, DOI 10.1002/(SICI)1098-1136(199609)18:1<11::AID-GLIA2>3.3.CO;2-C; Balasingam V, 1996, J NEUROSCI, V16, P2945; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fernandes A, 2006, J NEUROCHEM, V96, P1667, DOI 10.1111/j.1471-4159.2006.03680.x; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; GUILLAUD P, 1991, CELL PROLIFERAT, V24, P481, DOI 10.1111/j.1365-2184.1991.tb01176.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Iravani MM, 2005, EUR J NEUROSCI, V22, P317, DOI 10.1111/j.1460-9568.2005.04220.x; Ito T, 1997, ACTA NEUROPATHOL, V93, P13; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; Kuno R, 2006, BRAIN RES, V1116, P12, DOI 10.1016/j.brainres.2006.07.120; Little AR, 2001, NEUROTOXICOLOGY, V22, P607, DOI 10.1016/S0161-813X(01)00032-8; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Moynagh PN, 2005, J ANAT, V207, P265, DOI 10.1111/j.1469-7580.2005.00445.x; Penkowa M, 2002, EXP NEUROL, V176, P308, DOI 10.1006/exnr.2002.7968; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Rohl C, 2007, BRAIN RES, V1129, P43, DOI 10.1016/j.brainres.2006.10.057; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schultz J, 2004, AM J PATHOL, V165, P671, DOI 10.1016/S0002-9440(10)63331-7; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325; Xu M, 2005, BRAIN RES, V1055, P137, DOI 10.1016/j.brainres.2005.07.003; Zai LJ, 2005, BRAIN RES, V1052, P147, DOI 10.1016/j.brainres.2005.05.071	45	63	64	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2007	1154						206	214		10.1016/j.brainres.2007.04.005			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	187OK	WOS:000247857400023	17482149				2022-02-06	
J	Hendricks, HT; Geurts, ACH; van Ginneken, BC; Heeren, AJ; Vos, PE				Hendricks, Henk T.; Geurts, A. C. H.; van Ginneken, Bart C.; Heeren, Anita J.; Vos, Pieter E.			Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury	CLINICAL REHABILITATION			English	Article							CHILDREN	Objective: To assess brain injury severity, autonomic dysregulation and systemic infection as risk factors for the occurrence of heterotopic ossification in patients with severe traumatic brain injury. Design: Historic cohort study. Setting: Radboud University Medical Centre. Subjects: All consecutively admitted patients with severe traumatic brain injury (admission Glasgow Coma Scale score 8 or less) during the years 2002-2003. Main measures: The development of clinically relevant heterotopic ossification, defined as painful swelling of joints with redness and decreased range of motion, confirmed radiographically. Results: Seventy-six (64%) of the 119 patients survived and were eligible for further follow-up. Nine patients (12%) developed 20 symptomatic heterotopic ossifications, in one or more joints. Patients with heterotopic ossification had sustained more severe brain injuries, compared to the group without heterotopic ossification. The mean coma duration in the heterotopic ossification group was 28.11 days (SD 20.20) versus 7.54 days (SD 7.47) in the patients without heterotopic ossification (P < 0.001). The occurrence of autonomic dysregulation (relative risk (RR) 59.55, 95% confidence interval (Cl) 8.39-422.36), diffuse axonal injury (RR 20.68, 95% Cl 4.92-86.91), spasticity (RR 16.96, 95% Cl 3.96-72.57) and systemic infection (RR 13.12, 95% Cl 3.01-57.17) were all associated with an increased risk of developing symptomatic heterotopic ossification. However, only autonomic dysregulation had a high positive (88.9%, 95% Cl 51.7-99.7) and negative (98.5%, 95% Cl 91.9-99.9) predictive value with regard to heterotopic ossification. Conclusions: The occurrence of autonomic dysregulation may predict the chance of developing heterotopic ossification in patients with severe head injury.	Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Inst Neurol, Nijmegen, Netherlands		Hendricks, HT (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, POB 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Geurts, Alexander/H-8032-2014; Vos, Pieter/A-6043-2012	Geurts, Alexander/0000-0001-7478-1119; 			Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; Fransen M, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001160.PUB2; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goodman TA, 1997, ARTHRITIS RHEUM, V40, P1619, DOI 10.1002/art.1780400911; Guo Y, 2002, ARCH PHYS MED REHAB, V83, P855, DOI 10.1053/apmr.2002.32440; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; Jacobs JWG, 1999, RHEUMATOLOGY, V38, P1145, DOI 10.1093/rheumatology/38.11.1145; Lane JE, 2002, POSTGRAD MED J, V78, P494, DOI 10.1136/pmj.78.922.494; LIND M, 1995, CYTOKINE, V7, P78, DOI 10.1006/cyto.1995.1010; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Sebastiani GD, 2002, CLIN RHEUMATOL, V21, P173, DOI 10.1007/PL00011219; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; TOW APE, 1995, PARAPLEGIA, V33, P170, DOI 10.1038/sc.1995.38; Zeilig G, 2006, ARCH PHYS MED REHAB, V87, P92, DOI 10.1016/j.apmr.2005.07.308	21	63	70	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JUN	2007	21	6					545	553		10.1177/0269215507075260			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	193BE	WOS:000248247500006	17613585				2022-02-06	
J	Parikh, S; Koch, M; Narayan, RK				Parikh, Samir; Koch, Marcella; Narayan, Raj K.			Traumatic Brain Injury	INTERNATIONAL ANESTHESIOLOGY CLINICS			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL HEMATOMA; SECONDARY; COMA; DISABILITY; MANAGEMENT; MORTALITY; CHILDREN; CONSEQUENCES; HYPOTHERMIA		[Parikh, Samir; Koch, Marcella; Narayan, Raj K.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Parikh, S (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, 231 Albert Sabin Way,POB 670515, Cincinnati, OH 45267 USA.	SAMIR.PARIKH2@UC.EDU					ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Armstrong BD, 2003, J NEUROSCI RES, V74, P240, DOI 10.1002/jnr.10750; Barbaccia J J, 2001, Curr Opin Anaesthesiol, V14, P227, DOI 10.1097/00001503-200104000-00016; BLYTH B, 1981, NEW ZEAL MED J, V93, P267; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Diaz-Marchan PJ, 1996, NEUROTRAUMA, P140; Fodstad H, 2006, NEUROSURGERY, V59, P1132, DOI 10.1227/01.NEU.0000245582.08532.7C; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; GENSEMER IB, 1988, J TRAUMA, V28, P44, DOI 10.1097/00005373-198801000-00006; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Gottschling S, 2005, PEDIATR ANESTH, V15, P1006, DOI 10.1111/j.1460-9592.2004.01562.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; JANE JA, 1982, CLIN NEUR, V29, P346; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Joshi J, 2001, ANESTHESIA NEUROSURG, P19; Kelly DF, 1996, NEUROTRAUMA, P81; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; Lindenberg R, 1971, PATHOLOGY NERVOUS SY, V2, P1705; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MACIVER IN, 1958, LANCET, V1, P390; MALONEY AFJ, 1969, BRIT J SURG, V56, P23, DOI 10.1002/bjs.1800560106; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roberts I., 1999, COCHRANE DB SYST REV, V3; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEMKIN NR, 1996, NEUROTRAUMA, P611; Valadka AB, 1996, NEUROTRAUMA, P122; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wedekind C, 2002, MUSCLE NERVE, V26, P270, DOI 10.1002/mus.10187; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wysocki J, 2005, SKULL BASE-INTERD AP, V15, P99, DOI 10.1055/s-2005-870593; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	73	63	73	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0020-5907	1537-1913		INT ANESTHESIOL CLIN	Int. Anesthesiol. Clin.	SUM	2007	45	3					119	135		10.1097/AIA.0b013e318078cfe7			17	Anesthesiology	Emerging Sources Citation Index (ESCI)	Anesthesiology	V3I2C	WOS:000218278900008	17622833				2022-02-06	
J	Chen, SY; Atkins, CM; Liu, CLL; Alonso, OF; Dietrich, WD; Hu, BR				Chen, Shaoyi; Atkins, Coleen M.; Liu, Chunli L.; Alonso, Ofelia F.; Dietrich, W. Dalton; Hu, Bingren R.			Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						mTOR; protein synthesis; ribosomal protein S6; synaptic plasticity; translation factor; traumatic brain injury	TRANSIENT CEREBRAL-ISCHEMIA; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; PROTEIN-SYNTHESIS; S6 KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNAS; CELL-SIZE; PHOSPHORYLATION; TRANSLATION	In response to traumatic brain injury ( TBI), neurons initiate neuroplastic processes through the activation of intracellular signaling pathways. However, the molecular mechanisms underlying neuroplasticity after TBI are poorly understood. To study this, we utilized the fluid-percussion brain injury ( FPI) model to investigate alterations in the mammalian target of rapamycin ( mTOR) signaling pathways in response to TBI. Mammalian target of rapamycin stimulates mRNA translation through phosphorylation of eukaryotic initiation factor 4E binding protein-1 (4E-BP1), p70 ribosomal S6 kinase (p70S6K), and ribosomal protein S6 (rpS6). These pathways coordinate cell growth and neuroplasticity via dendritic protein synthesis. Rats received sham surgery or moderate parasagittal FPI on the right side of the parietal cortex, followed by 15 mins, 30 mins, 4 h, 24 h, or 72 h of recovery. Using Western blot analysis, we found that mTOR, p70S6K, rpS6, and 4E-BP1 phosphorylation levels were significantly increased in the ipsilateral parietal cortex and hippocampus from 30 mins to 24 h after TBI, whereas total protein levels were unchanged. Using confocal microscopy to localize these changes, we found that rpS6 phosphorylation was increased in the parietal cortex and all subregions of the hippocampus. In accordance with these results, eIF4E, a key, rate- limiting mRNA translation factor, was also phosphorylated by mitogen-activated protein kinase-interacting kinase 1 (Mnk1) 15 mins after TBI. Together, these results suggest that changes in mRNA translation may be one mechanism that neurons use to respond to trauma and may contribute to the neuroplastic changes observed after TBI.	Univ Miami, Miller Sch Med, Dept Neurol, Neurochem Lab Brain Injury, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Neurochem Lab Brain Injury, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Hu, BR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Neurochem Lab Brain Injury, POB 16960, Miami, FL 33136 USA.	bhu@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040407, R29NS036810, P50NS030291, R56NS036810, R01NS036810] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36810, NS40407, NS30291] Funding Source: Medline		ATKINS CM, 2006, IN PRESS J CEREB BLO; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cheli V, 2006, J NEUROCHEM, V97, P68, DOI 10.1111/j.1471-4159.2005.03592.x; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FERRARI S, 1991, J BIOL CHEM, V266, P22770; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gong R, 2006, J BIOL CHEM, V281, P18802, DOI 10.1074/jbc.M512524200; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Langlois J.A., 2004, TRAUMATIC BRAIN INJU, P1; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005	42	63	67	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2007	27	5					939	949		10.1038/sj.jcbfm.9600393			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	161FG	WOS:000245999300006	16955078	Bronze			2022-02-06	
J	Marino, S; Zei, E; Battaglini, M; Vittori, C; Buscalferri, A; Bramanti, P; Federico, A; De Stefano, N				Marino, Silvia; Zei, Ettore; Battaglini, Marco; Vittori, Cesare; Buscalferri, Antonella; Bramanti, Placido; Federico, Antonio; De Stefano, Nicola			Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CLOSED-HEAD INJURY; N-ACETYLASPARTATE; AXONAL INJURY; WHITE-MATTER; IN-VIVO; PRACTICAL SCALE; H-1 MRS; DAMAGE; DISABILITY	Background: Conventional MRI can provide critical information for care of patients with traumatic brain injury (TBI), but MRI abnormalities rarely correlate to clinical severity and outcome. Previous magnetic resonance spectroscopy studies have reported clinically relevant brain metabolic changes in patients with TBI. However, these changes were often assessed a few to several days after the trauma, with a consequent variation of the metabolic pattern due to temporal changes. Methods: Proton magnetic resonance spectroscopic imaging (H-1-MRSI) examinations were performed in 10 patients with TBI 48-72 h after the trauma, to obtain early measurements of central brain levels of N-acetylaspartate (NAA), choline (Cho), creatine (Cr) and lactate (La). Metabolite values were expressed as ratios to (1) a metabolic pattern, given by the sum of the resonance intensities of all metabolites detected in the same voxel and (2) intravoxel Cr. Results: NAA ratios were found to be significantly lower in patients with TBI than in normal controls. In contrast, Cho ratios were significantly higher in patients with TBI than in normal controls. Increased La levels were found in 5 of 10 patients with TBI. Both NAA and La values correlated closely with those of the Glasgow Coma Scale at presentation (r = 0.73 and 20.62, respectively; p<0.01 for both) and the Glasgow Outcome Scale at 3 months (r = 20.79 and 0.79, respectively; p<0.01 for both). Conclusion: Spectroscopic measures of neuro-axonal damage occurring soon after a brain trauma are clinically relevant. Significant increases in cerebral La level also may be detected when H-1-MRSI is performed early after the trauma and, at this stage, can represent a reliable index of injury severity and disease outcome in patients with TBI.	Univ Siena, Dept Neurol & Behav Sci, Neurol & Neurometab Unit, I-53100 Siena, Italy; IRCCS, Ctr Neurol Bonino Pulejo, Messina, Italy; Univ Siena, Dept Anesthesia & Intens Care, I-53100 Siena, Italy		De Stefano, N (corresponding author), Univ Siena, Dept Neurol & Behav Sci, Neurol & Neurometab Unit, Viale Bracci 2, I-53100 Siena, Italy.	destefano@unisi.it	Marino, Silvia/T-5118-2019; Bramanti, Placido/K-5117-2016	Marino, Silvia/0000-0002-1088-6808; Vittori, Cesare/0000-0001-8631-9853; de stefano, nicola/0000-0003-4930-7639; federico, antonio/0000-0002-5246-1621			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arnold DL, 1996, MR SPECTROSCOPY CLIN, P139; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barantin L, 1997, MAGN RESON MED, V38, P179, DOI 10.1002/mrm.1910380203; Bjartmar C, 2002, ANN NEUROL, V51, P51, DOI 10.1002/ana.10052; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; De Stefano N, 2001, ARCH NEUROL-CHICAGO, V58, P65, DOI 10.1001/archneur.58.1.65; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; JENNETT B, 1975, LANCET, V1, P480; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; Pelletier D, 2002, MAGN RESON IMAGING, V20, P599, DOI 10.1016/S0730-725X(02)00533-7; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRICHARD JW, 1991, NMR BIOMED, V4, P99, DOI 10.1002/nbm.1940040212; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; TEASDALE G, 1974, LANCET, V2, P81; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	41	63	68	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2007	78	5					501	507		10.1136/jnnp.2006.099796			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	156YO	WOS:000245686000016	17088335	Green Published			2022-02-06	
J	Phipps, S; Richardson, P				Phipps, Shawn; Richardson, Pamela			Occupational therapy outcomes for clients with traumatic brain injury and stroke using the Canadian occupational performance measure	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							SELF-IDENTIFIED GOALS; ACHIEVEMENT; ADULTS	The purpose of this study was to determine whether 155 ethnically diverse clients with traumatic brain injury (TBI) and stroke (cerebrovascular accident; CVA) who received occupational therapy services perceived that they reached self-identified goals related to tasks of daily lite as measured by the Canadian Occupational Performance Measure (COPM). This study found that a statistically and clinically significant change in self-perceived performance and satisfaction with tasks of daily life occurred at the end of a client-centered occupational therapy program (p <.001). There were no significant differences in performance and satisfaction between the TBI and CVA groups. However, the group with right CVA reported a higher level of satisfaction with performance in daily activities than the group with left CVA (p =.03). The COPM process can effectively assist clients with neurological impairments in identifying meaningful occupational performance goals, The occupational therapist also can use the COPM to design occupation-based and client-centered intervention programs and measure occupational therapy outcomes.	Rancho Los Amigos Natl Rehabil Ctr, Dept Occupat Therapy & Recreat Therapy, Downey, CA 90242 USA; Calif State Univ Dominguez Hills, Dept Occupat Therapy, Carson, CA 90747 USA; San Jose State Univ, Dept Occupat Therapy, San Jose, CA 95192 USA		Phipps, S (corresponding author), Rancho Los Amigos Natl Rehabil Ctr, Dept Occupat Therapy & Recreat Therapy, 7601 E Imperial Highway, Downey, CA 90242 USA.	sphipps@ladhs.org; pamrichardson@sbcglobal.net					ARNADOTTIR G, 1990, BRAIN BEHAV ASSESING, P188; Baum CM, 1997, AM J OCCUP THER, V51, P277, DOI 10.5014/ajot.51.4.277; Bodiam C., 1999, BRIT J OCCUP THER, V62, P123, DOI [10.1177/030802269906200310, DOI 10.1177/030802269906200310]; BOSCH J, 1995, THESIS MCMASTER U HA; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Chenq Ya-Hsin, 2002, Occup Ther Int, V9, P167, DOI 10.1002/oti.163; *COMM ACCR REH FAC, 2006, STAND MAN ORG SERV P; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Gagne DE, 2003, AM J OCCUP THER, V57, P215, DOI 10.5014/ajot.57.2.215; Guidetti Susanne, 2002, Occup Ther Int, V9, P257, DOI 10.1002/oti.168; Jansa J., 2004, WORLD FED OCCUP THER, V50, P18; *JOINT COMM ACCR H, 1991, AMH APPL MAN HOSP, V2; Law M, 1994, Can J Occup Ther, V61, P191; LAW M, 1998, CLIENT CENTERED OCCU; Maitra KK, 2006, AM J OCCUP THER, V60, P298, DOI 10.5014/ajot.60.3.298; McColl M A, 2000, Can J Occup Ther, V67, P22; McColl MA., 2003, THEORETICAL BASIS OC; Melville LL, 2002, AM J OCCUP THER, V56, P650, DOI 10.5014/ajot.56.6.650; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Pollock N., 2005, CANADIAN OCCUPATIONA; Rosa SA, 2005, AM J OCCUP THER, V59, P198, DOI 10.5014/ajot.59.2.198; SANFORD J, 1994, C AM SOC AG SAN FRAN; Sumsion T, 2000, Can J Occup Ther, V67, P15; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Vining Radomski M, 2000, PHYS DISABILITIES SP, V23, P1; Wilkins S, 2001, Can J Occup Ther, V68, P70; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 2003, DISABIL REHABIL, V25, P497, DOI 10.1080/0963828031000090560; Youngstrom MJ, 2002, AM J OCCUP THER, V56, P609	31	63	63	1	17	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	MAY-JUN	2007	61	3					328	334		10.5014/ajot.61.3.328			7	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	169ML	WOS:000246596200009	17569390				2022-02-06	
J	Molcanyi, M; Riess, P; Bentz, K; Maegele, M; Hescheler, J; Schafke, B; Trapp, T; Neugebauer, E; Klug, N; Schafer, U				Molcanyi, Marek; Riess, Peter; Bentz, Kristine; Maegele, Marc; Hescheler, Juergen; Schaefke, Bernhard; Trapp, Thorsten; Neugebauer, Edmund; Klug, Norfrid; Schaefer, Ute			Trauma-associated inflammatory response impairs embryonic stem cell survival and integration after implantation into injured rat brain	JOURNAL OF NEUROTRAUMA			English	Article						cell therapy; fluid percussion injury; macrophages; Sprague-Dawley rats	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; GROWTH-FACTOR; IN-VIVO; NEURAL TRANSPLANTATION; EXPERIMENTAL STROKE; COMPLEMENT-SYSTEM; STAB WOUNDS; ADULT-RAT; FLUID	Pluripotent embryonic stem cells were shown to survive and differentiate into mature neuronal cells after implantation in experimental models of Parkinson disease and cerebral ischemia. Embryonic stem cell transplantation has also been proposed as a potential therapy for cerebral trauma, characteristic of massive loss of multiple cell types due to primary insult and secondary sequelae. Green fluorescent protein (GFP)-transfected murine embryonic stem cells were implanted into the ipsi or contralateral cortex of male Sprague-Dawley rats 72 h after fluid-percussion injury. Animals were sacrificed at day 5 or week 7 postimplantation. Brain sections were examined using conventional and fluorescent double-labelling immunohistochemistry. Five days after implantation, clusters of GFP-positive cells undergoing partial differentiation along neuronal pathway, were detected at the implantation site. However, after 7 weeks, only a few GFP-positive cells were found, indicating an extensive loss of stem cells during this time period. For the first time, we proved the observed cell loss to be mediated via phagocytosis of implanted cells by activated macrophages. Cerebral trauma, induced 3 days prior to implantation, has activated the inflammatory potential of otherwise immunologically privileged tissue. Subsequent cell implantation was accompanied by reactive astrogliosis, activation of microglia, as well as a massive invasion of macrophages into transplantation sites even if the grafts were placed into contralateral healthy hemispheres, remote from the traumatic lesion. Our results demonstrate a significant post-traumatic inflammatory response, which impairs survival and integration of implanted stem cells and has generally not been taken into account in designs of previous transplantation studies.	Univ Witten Herdecke, IFOM, Fac Med, D-51109 Cologne, Germany; Univ Witten Herdecke, Hosp Merheim, Fac Med, Dept Trauma & Orthoped Surg, Cologne, Germany; Univ Cologne, Clin Neurosurg, Fac Med, Cologne, Germany; Univ Cologne, Dept Neurophysiol, Fac Med, Cologne, Germany; Natl Res Ctr Environm & Hlth, Inst Dev Genet, Munich, Germany; Max Planck Inst Neurol Res, Cologne, Germany; Univ Dusseldorf, Fac Med, Inst Transplantat Diagnost & Cell Therapeut, D-4000 Dusseldorf, Germany		Schafer, U (corresponding author), Univ Witten Herdecke, IFOM, Fac Med, Ostmerheimerstr 200, D-51109 Cologne, Germany.	u.schaefer@uni-koeln.de					Arnhold S, 2000, J NEUROSURG, V93, P1026, DOI 10.3171/jns.2000.93.6.1026; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Erdo Franciska, 2004, Orvosi Hetilap, V145, P1307; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kleinschnitz C, 2003, J CEREBR BLOOD F MET, V23, P1356, DOI 10.1097/01.WCB.0000090505.76664.DB; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Li PY, 2005, ARCH NEUROL-CHICAGO, V62, P223, DOI 10.1001/archneur.62.2.223; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Prasad ML, 1999, AM J SURG PATHOL, V23, P176, DOI 10.1097/00000478-199902000-00006; Rausch M, 2001, MAGNET RESON MED, V46, P1018, DOI 10.1002/mrm.1290; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saleh A, 2004, NMR BIOMED, V17, P163, DOI 10.1002/nbm.881; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schroeter M, 2003, MOL BRAIN RES, V117, P1, DOI 10.1016/S0169-328X(03)00255-9; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Wang X, 2004, ACTA NEUROCHIR SUPPL, V89, P49; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009	45	63	66	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					625	637		10.1089/neu.2006.0180			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000005	17439346				2022-02-06	
J	Douglas, JM; Bracy, CA; Snow, PC				Douglas, Jacinta M.; Bracy, Christine A.; Snow, Pamela C.			Measuring perceived communicative ability after traumatic brain injury: Reliability and validity of the La Trobe Communication Questionnaire	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; communication disorders; language tests; outcome assessment; rehabilitation; reliability and validity	CLOSED HEAD-INJURY; DISCOURSE ASSESSMENT; AWARENESS; ADULTS; DEFICITS	Objective: Further psychometric evaluation of a measure designed to assess communication ability after traumatic brain injury (TBI). Design: Internal consistency, test-retest reliability, and validity for self-report and close-other versions of the tool were evaluated. Participants: Eighty-eight adults with severe TBI (mean posttraumatic amnesia 53.12 days) and 71 close others (relatives or friends). Measure: The La Trobe Communication Questionnaire (LCQ), a 30-item questionnaire that measures cognitive-communication ability from multiple perspectives. Results: Internal consistency coefficients were above 0.9 and test-retest reliability exceeded 0.80. The questionnaire was sensitive to the effect of severity of injury. Conclusion: The La Trobe Communication Questionnaire is a promising tool for measuring perceived communication ability in adults with severe TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia; La Trobe Univ, Sch Publ Hlth, Bundoora, Vic 3086, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Damico J. S., 1985, COMMUNICATION SKILLS, P165; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Fleming JM, 1996, BRAIN INJURY, V10, P1; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GILLIES S, 1990, PERCEPTIONS COMMUNIC; Godfrey H.P.D., 1993, J CLIN EXP PSYCHOL, V15, P530; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; KREUTZER J, 1999, NEUROBEHAV FUNCTIONI; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1986, NEUROPSYCHOL REHAB B; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Selltiz C, 1976, RES METHODS SOCIAL R; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Ylvisaker M., 2001, LANGUAGE INTERVENTIO; [No title captured]	34	63	63	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					31	38		10.1097/00001199-200701000-00004			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400004	17235229				2022-02-06	
J	Ho, J; Kleiven, S				Ho, Johnson; Kleiven, Svein			Dynamic response of the brain with vasculature: A three-dimensional computational study	JOURNAL OF BIOMECHANICS			English	Article						human head model; finite element analysis; cerebral blood vessels; traumatic brain injury	HUMAN HEAD; INJURY; IMPACT; SIZE	To date, the influence of the vasculature on the dynamic response of the brain has not been studied with a complete three-dimensional (3D) finite element head model. In this study, short duration rotational (10,000 rad/s(2) with a duration of 5 ms) and translational (100 G with a duration of 5 ms) acceleration impulses were applied to the 3D finite element models to study the dynamic response of the brain. The hypothesis of this study was that due to the convoluted organization and non-linear material properties of cerebral vasculature, the difference in maximum principle strain between models with and without vasculature should be minimal. The effects of non-linear material properties and the convoluted structure of the vasculature were examined by comparing the results from the 3D finite element models. The peak average strain reduction in a model with non-linear elastic vasculature and a model with linear elastic vasculature compared to a model without vasculature was 2% and 5%, respectively, indicating that the influence of the vasculature on the dynamic response of the brain is minimal. (c) 2007 Elsevier Ltd. All rights reserved.	Royal Inst Technol, Sch Technol Hlth, Div Neuron Engn, Stockholm, Sweden		Ho, J (corresponding author), Royal Inst Technol, Sch Technol Hlth, Div Neuron Engn, Stockholm, Sweden.	johnsonh@kth.se; sveink@kth.se	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Ho, Johnson/0000-0001-9785-2071			ALDMAN B, 1981, P HEAD NECK INJ CRIT; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; BAIN BC, 2000, J BIOMECH ENG, V16, P615; CHALUPNIK JD, 1971, 7111 ME U WASH; DONNELLY BR, 1998, P 26 INT WORKSH, P47; ESTES MS, 1970, 70BHF13 ASME; Fung Y.C., 1981, BIOMECHANICS MECH PR; HOLBOURN AHS, 1943, MECH HEAD INJURIES, P438; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; *LIV SOFTW TECHN C, 2003, LSDYNA KEYWORD USERS; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; *MATH WORKS INC, 1994, MATH WORKS MATLAB RE; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Monson K. L., 2001, THESIS U CALIFORNIA; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; OMORI K, 2000, P 2000 ASME INT MECH; Parnaik Yednesh, 2004, Stapp Car Crash J, V48, P259; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; ZHOU C, 1994, 942314 SAE	30	63	65	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2007	40	13					3006	3012		10.1016/j.jbiomech.2007.02.011			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	222EB	WOS:000250277800023	17433331				2022-02-06	
J	Wang, Y; Moges, H; Bharucha, Y; Symes, A				Wang, Yu; Moges, Helina; Bharucha, Yasmin; Symes, Aviva			Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; glial scar; gliosis; transforming growth factor-beta; Smad3	TRANSFORMING-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; CHONDROITIN SULFATE PROTEOGLYCANS; FIBRILLARY ACIDIC PROTEIN; ADULT-RAT BRAIN; TGF-BETA; REACTIVE ASTROCYTES; NG2 PROTEOGLYCAN; GLIAL SCAR; EXTRACELLULAR-MATRIX	Following central nervous system injury, adult mammalian neurons do not regenerate through regions of scar formation. This regenerative failure is due in part to the inhibitory environment of the glial scar at the lesion site. Following injury, transforming growth factor beta (TGF-beta) is strongly induced and is important to many aspects of the response to injury, including deposition of extracellular matrix (ECM) in the glial scar. However, the pathways through which TGF-beta signals to mediate these effects are not known. In order to examine the contribution of the TGF-beta-induced transcription factor, Smad3, to formation of the glial scar after traumatic brain injury, we utilized mice that do not express Smad3. We report that Smad3 null mice heal stab wounds to the cerebral cortex more rapidly than do wild-type mice. In Smad3 null mice many aspects of glial scar formation and the immune response to injury were altered. Fewer neutrophils, macrophages/microglia, NG2-positive cells and GFA-beta-positive cells were detected immediately around the lesion in Smad3 null mice. Expression of fibronectin and laminin was also reduced. Injury-induced cell proliferation was significantly lower in Smad3 null mice around the lesion. There was no overall difference between wild-type and Smad3 null mice in immunoreactivity for TGF-beta(1) after injury. Thus, our experiments suggest that TGF-beta signaling through Smad3 contributes significantly to the immune response and scar formation after cortical stab wound injury, delaying recovery through multiple mechanisms. Published by Elsevier Inc.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA		Symes, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Asymes@usuhs.mil	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939			Abraham S, 2003, VIROLOGY, V309, P196, DOI 10.1016/S0042-6822(03)00112-0; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CUI W, 1996, GROWTH FACTORS CYTOK, P319; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; GAGELIN C, 1995, GLIA, V13, P283, DOI 10.1002/glia.440130405; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kawata Y, 2002, J BIOL CHEM, V277, P11375, DOI 10.1074/jbc.M111284200; King VR, 2004, NEUROSCIENCE, V126, P173, DOI 10.1016/j.neuroscience.2004.03.035; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; Konig HG, 2005, J CELL BIOL, V168, P1077, DOI 10.1083/jcb.200407027; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; KROHN K, 1995, J NEUROIMMUNOL, V56, P53, DOI 10.1016/0165-5728(94)00133-9; Krohn K, 1999, J NEUROCHEM, V72, P1353, DOI 10.1046/j.1471-4159.1999.721353.x; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Sousa VD, 2004, EUR J NEUROSCI, V19, P1721, DOI 10.1111/j.1460.9568.2004.03249.x; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weiss JM, 1998, J NEUROIMMUNOL, V91, P190, DOI 10.1016/S0165-5728(98)00183-0; Wickelgren I, 2002, SCIENCE, V297, P178, DOI 10.1126/science.297.5579.178; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; WyssCoray T, 1997, J NEUROIMMUNOL, V77, P45, DOI 10.1016/S0165-5728(97)00049-0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhu Y, 2000, BRAIN RES, V866, P286, DOI 10.1016/S0006-8993(00)02240-X; Zuo J, 2002, EXP NEUROL, V176, P221, DOI 10.1006/exnr.2002.7922	87	63	70	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					168	184		10.1016/j.expneurol.2006.08.006			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	123NU	WOS:000243303400019	16996058				2022-02-06	
J	Zhang, L; Heier, LA; Zimmerman, RD; Jordan, B; Ulug, AM				Zhang, L.; Heier, L. A.; Zimmerman, R. D.; Jordan, B.; Ulug, A. M.			Diffusion anisotropy changes in the brains of professional boxers	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD INJURY; WHITE-MATTER; FIBER TRACKING; TENSOR; DAMAGE; TRACT	BACKGROUND AND PURPOSE: Professional boxing may result in brain injury. We hypothesize that quantitative MR diffusion imaging may be useful in determining early white matter changes. METHODS: Forty-nine professional boxers (age 30 +/- 4.5 years) and 19 healthy control subjects (age 32 +/- 9.5 years) were imaged on a clinical 1.5T scanner. None of the subjects had neurologic disorder or deficit. The average diffusion constant (D-av) and diffusion anisotropy (FA) were determined pixel by pixel. Regional diffusion measurements were done in the corpus callosum (CC) and internal capsule (IC). The whole brain diffusion constant (BDav) was also determined. Student t test was used to analyze the diffusion difference between boxers and the healthy control subjects. P < .05 was considered statistically significant. RESULTS: Of the 49 professional boxers, 42 had normal conventional MRIs. The remaining 7 boxers had abnormal MR imaging findings dominated by nonspecific white matter disease. There was a significant difference in diffusion and anisotropy measurements in all the boxers compared with the healthy control subjects. In the boxer group, BDav increased and FA decreased significantly in the CC and posterior limb of IC. The measured FA and D-av inversely correlated in regions of CC and IC in boxers but not in healthy control subjects. BDav also robustly correlated with both FA and D-av in the splenium of CC in boxers. CONCLUSION: Increased BID., and the decreased FA in the CC and IC may represent preclinical signs of subtle brain injury in professional boxers.	Cornell Univ, Weill Med Coll, Dept Radiol, New York, NY 10021 USA; New York State Athlet Commiss, New York, NY USA; Burke Rehabil Hosp, White Plains, NY USA		Ulug, AM (corresponding author), Cornell Univ, Weill Med Coll, Dept Radiol, Box 141,1300 York Ave, New York, NY 10021 USA.	ulug@ieee.org	Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Chun T, 2000, AM J NEURORADIOL, V21, P1078; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BMJ-BRIT MED J, P105; Fernando MS, 2004, NEUROPATH APPL NEURO, V30, P385, DOI 10.1111/j.1365-2990.2004.00550.x; Higano S, 2001, AM J NEURORADIOL, V22, P456; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; LeBihan D, 1995, NMR BIOMED, V8, P375; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; Lee SK, 2004, NEUROIMAGE, V22, P1826, DOI 10.1016/j.neuroimage.2004.04.028; Mamata H, 2004, NEUROCHEM INT, V45, P553, DOI 10.1016/j.neuint.2003.11.014; MOODY DM, 1988, AM J NEURORADIOL, V9, P1051; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Nicholl JP, 1995, BRIT J SPORT MED, V29, P232, DOI 10.1136/bjsm.29.4.232; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; Ross J, 2000, HAEMOPHILIA, V6, P41; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sotak CH, 2004, NEUROCHEM INT, V45, P569, DOI 10.1016/j.neuint.2003.11.010; Spriggs M, 2004, J MED ETHICS, V30, P515, DOI 10.1136/jme.2003.003541; Ulug AM, 1999, AM J NEURORADIOL, V20, P1044; Ulug AM, 2004, J MAGN RESON IMAGING, V19, P34, DOI 10.1002/jmri.10433; Ulug AM, 1999, JMRI-J MAGN RESON IM, V9, P804; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; WAKANA S, 2004, RADIOLOGY, P230; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Yamada K, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085827.54986.89; Yamada K, 2003, RADIOLOGY, V227, P295, DOI 10.1148/radiol.2271020313; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	40	63	64	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	OCT	2006	27	9					2000	2004					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	095OE	WOS:000241316400043	17032883				2022-02-06	
J	Falo, MC; Fillmore, HL; Reeves, TM; Phillips, LL				Falo, M. C.; Fillmore, H. L.; Reeves, T. M.; Phillips, L. L.			Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						matrix metalloproteinase; synaptogenesis; hippocampus; neurotrauma	COMBINED FLUID PERCUSSION; ENTORHINAL CORTICAL LESION; DENTATE-GYRUS; EXTRACELLULAR-MATRIX; MMP-3 EXPRESSION; PROTEOLYTIC CLEAVAGE; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; UP-REGULATION; RAT-BRAIN	The interaction between extracellular matrix (ECM) and regulatory matrix metalloproteinases (MMPs) is important in establishing and maintaining synaptic connectivity. By using fluid percussion traumatic brain injury (TBI) and combined TBI and bilateral entorhinal cortical lesion (TBI + BEC), we previously demonstrated that hippocampal stromelysin-1 (MMP-3) expression and activity increased during synaptic plasticity. We now report a temporal analysis of MMP-3 protein and mRNA response to TBI during both degenerative (2 day) and regenerative (7, 15 day) phases of reactive synaptogenesis. MMP-3 expression during successful synaptic reorganization (following unilateral entorhinal cortical lesion; UEC) was compared with MMP-3 expression when normal synaptogenesis fails (after combined TBI + BEC insult). Increased expression of MMP-3 protein and message was observed in both models at 2 days postinjury, and immuohistochemical (IHC) colocalization suggested that reactive astrocytes contribute to that increase. By 7 days postinjury, model differences in MMP-3 were observed. UEC MMP-3 mRNA was equivalent to control, and MMP-3 protein was reduced within the deafferented region. In contrast, enzyme mRNA remained elevated in the maladaptive TBI + BEC model, accompanied by persistent cellular labeling of MMP-3 protein. At 15 days survival, MMP-3 mRNA was normalized in each model, but enzyme protein remained higher than paired controls. When TBI + BEC recovery was enhanced by the N-methyl-D-aspartate antagonist MK-801, 7-day MMP-3 mRNA was significantly reduced. Similarly, MMP inhibition with FN-439 reduced the persistent spatial learning deficits associated with TBI + BEC insult. These results suggest that MMP-3 might differentially affect the sequential phases of reactive synaptogenesis and exhibit an altered pattern when recovery is perturbed. (c) 2006 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Neurosurg, Richmond, VA USA		Phillips, LL (corresponding author), Virginia Commonwealth Univ, Ctr Med, Sch Med, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	llphilli@vcu.edu		Fillmore, Helen/0000-0003-4131-579X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS044372, NS-44372] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NSO-07288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS044372, R01NS044372] Funding Source: NIH RePORTER		Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; BEJARANO PA, 1988, BIOCHEM J, V256, P413, DOI 10.1042/bj2560413; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; Chernoff EAG, 2000, WOUND REPAIR REGEN, V8, P282, DOI 10.1046/j.1524-475x.2000.00282.x; Cuzner ML, 1996, J NEUROPATH EXP NEUR, V55, P1194, DOI 10.1097/00005072-199612000-00002; D'Souza CA, 2002, J BIOL CHEM, V277, P13589, DOI 10.1074/jbc.M108817200; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Falo MC, 2003, J NEUROTRAUM, V20, P1124; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; Mayer J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-52; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; OKADA Y, 1987, J RHEUMATOL, V14, P41; Phillips LL, 2004, J NEUROTRAUM, V21, P1321; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 2003, J NEUROSCI, V23, P10182; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; VanSaun M, 2000, J NEUROBIOL, V43, P140, DOI 10.1002/(SICI)1097-4695(200005)43:2<140::AID-NEU4>3.3.CO;2-B; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Witek-Zawada B, 2003, J PHYSIOL PHARMACOL, V54, P489; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	47	63	66	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP	2006	84	4					768	781		10.1002/jnr.20986			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	080YI	WOS:000240284000007	16862547				2022-02-06	
J	Richards, EM; Rosenthal, RE; Kristian, T; Fiskum, G				Richards, Erica M.; Rosenthal, Robert E.; Kristian, Tibor; Fiskum, Gary			Postischemic hyperoxia reduces hippocampal pyruvate dehydrogenase activity	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						mitochondria; hyperoxia; nitrotyrosine; normoxia; oxidative stress; global ischemia; selective vulnerability; free radicals	FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; SELECTIVE NEURONAL VULNERABILITY; MANGANESE SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN-INJURY; CANINE CARDIAC-ARREST; PROTEIN NITRATION; OXIDATIVE STRESS; MASS-SPECTROMETRY	The pyruvate dehydrogenase complex (PDHC) is a mitochondrial matrix enzyme that catalyzes the oxidative decarboxylation of pyruvate and represents the sole bridge between anaerobic and aerobic cerebral energy metabolism. Previous studies demonstrating loss of PDHC enzyme activity and immunoreactivity during reperfusion after cerebral ischemia suggest that oxidative modifications are involved. This study tested the hypothesis that hyperoxic reperfusion exacerbates loss of PDHC enzyme activity, possibly due to tyrosine nitration or S-nitrosation. We used a clinically relevant canine ventricular fibrillation cardiac arrest model in which, after resuscitation and ventilation on either 100% O-2 (hyperoxic) or 21-30% O-2 (normoxic), animals were sacrificed at 2 h reperfusion and the brains removed for enzyme activity and immunoreactivity measurements. Animals resuscitated under hyperoxic conditions exhibited decreased PDHC activity and elevated 3-nitrotyrosine immunoreactivity in the hippocampus but not the cortex, compared to nonischemic controls. These measures were unchanged in normoxic animals. In vitro exposure of purified PDHC to peroxynitrite resulted in a dose-dependent loss of activity and increased nitrotyrosine immunoreactivity. These results support the hypothesis that oxidative stress contributes to loss of hippocampal PDHC activity during cerebral ischemia and reperfusion and suggest that PDHC is a target of peroxynitrite. (c) 2006 Elsevier Inc. All rights reserved.	Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Program Trauma, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA.	gfisk001@umaryland.edu	Kristian, Tibor/I-5697-2019; Kristian, Tibor/U-6497-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050653, U01 NS049425, R21 NS050653, NS049425, U01 NS049425-03, NS34152, R01 NS034152-12, R01 NS034152] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152, R21NS050653, U01NS049425] Funding Source: NIH RePORTER		AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Alonso D, 2002, J COMP NEUROL, V443, P183, DOI 10.1002/cne.10111; Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dohi K, 2003, ACT NEUR S, V86, P87; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; ELNAGEH KM, 1988, J NEUROCHEM, V51, P1482, DOI 10.1111/j.1471-4159.1988.tb01115.x; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; FISKUM G, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P487; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gonzalez D, 2004, J BIOL CHEM, V279, P43345, DOI 10.1074/jbc.M401889200; Haga KK, 2003, BRAIN RES, V993, P42, DOI 10.1016/j.brainres.2003.08.063; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hoehn T, 2003, PEDIATR RES, V54, P179, DOI 10.1203/01.PDR.0000075220.17631.F1; Hurtado O, 2003, FASEB J, V17, P2082, DOI 10.1096/fj.02-1086fje; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kanski J, 2005, J BIOL CHEM, V280, P24261, DOI 10.1074/jbc.M501773200; Kim HY, 2005, ANN NEUROL, V57, P571, DOI 10.1002/ana.20430; Krajewska M, 2004, EXP NEUROL, V189, P261, DOI 10.1016/j.expneurol.2004.05.020; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Kusumoto M, 1996, J NEUROCHEM, V67, P1613; Lei BP, 1999, BRAIN RES PROTOC, V4, P415, DOI 10.1016/S1385-299X(99)00047-1; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Liu SM, 2004, J CEREBR BLOOD F MET, V24, P343, DOI 10.1097/01.WCB.0000110047.43905.01; Liu YB, 1998, STROKE, V29, P1679, DOI 10.1161/01.STR.29.8.1679; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MICKEL HS, 1987, STROKE, V18, P426, DOI 10.1161/01.STR.18.2.426; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; Ohtaki H, 2003, ACT NEUR S, V86, P97; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; POON HF, NEUROBIOL AGING; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rhee KY, 2005, P NATL ACAD SCI USA, V102, P467, DOI 10.1073/pnas.0406133102; ROSENTHAL M, 1995, J CEREBR BLOOD F MET, V15, P655, DOI 10.1038/jcbfm.1995.81; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Sasaki T, 2001, Keio J Med, V50, P182; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Shirakura T, 2005, BIOL PHARM BULL, V28, P1658, DOI 10.1248/bpb.28.1658; SIMS NR, 1992, NEUROCHEM RES, V17, P923, DOI 10.1007/BF00993269; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; Takeda Y, 2004, J CEREBR BLOOD F MET, V24, P986, DOI 10.1097/01.WCB.0000127966.84050.61; Takizawa S, 2002, J CEREBR BLOOD F MET, V22, P50, DOI 10.1097/00004647-200201000-00006; Tan S, 2001, FREE RADICAL BIO MED, V30, P1045, DOI 10.1016/S0891-5849(01)00499-3; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VasquezVivar J, 1997, CHEM RES TOXICOL, V10, P786, DOI 10.1021/tx970031g; VERECZKI V, J CEREB BLOOD FLOW M; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Zaidan E, 1998, J NEUROCHEM, V70, P233; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545; ZWEMER CF, 1994, RESUSCITATION, V27, P267; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4	78	63	63	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUN 1	2006	40	11					1960	1970		10.1016/j.freeradbiomed.2006.01.022			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	050QP	WOS:000238103300009	16716897	Green Accepted			2022-02-06	
J	Chapman, SB; Gamino, JF; Cook, LG; Hanten, G; Li, XQ; Levin, HS				Chapman, SB; Gamino, JF; Cook, LG; Hanten, G; Li, XQ; Levin, HS			Impaired discourse gist and working memory in children after brain injury	BRAIN AND LANGUAGE			English	Article						discourse; language; brain injury; children; gist; cognition; summary; top down processing; working memory; memory	CLOSED-HEAD-INJURY; COMPREHENSION; RETRIEVAL; RECALL	Emerging evidence suggests that a traumatic brain injury (TBI) in childhood may disrupt the ability to abstract the central meaning or gist-based memory from connected language (discourse). The current study adopts a novel approach to elucidate the role of immediate and working memory processes in producing a cohesive and coherent gist-based text in the form of a summary in children with mild and severe TBI as compared to typically developing children, ages 8-14 years at test. Both TBI groups showed decreased performance on a summary production task as well as retrieval of specific content from a long narrative. Working memory on n-back tasks was also impaired in children with severe TBI, whereas immediate memory performance for recall of a simple word list in both TBI groups was comparable to controls. Interestingly, working memory, but not simple immediate memory for a word list, was significantly correlated with summarization ability and ability to recall discourse content. (c) 2005 Elsevier Inc. All rights reserved.	Univ Texas, Inst Biomed Sci & Technol, Ctr BrainHlth, Dallas, TX 75230 USA; Baylor Coll Med, Houston, TX 77030 USA		Chapman, SB (corresponding author), Univ Texas, Inst Biomed Sci & Technol, Ctr BrainHlth, Dallas, TX 75230 USA.	schapman@utdallas.edu					Adams C, 1997, J GERONTOL B-PSYCHOL, V52, pP187, DOI 10.1093/geronb/52B.4.P187; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; BARTLETT R, 1936, REMEMBERING; Brainerd CJ, 1998, DEV PSYCHOL, V34, P342, DOI 10.1037/0012-1649.34.2.342; BROWN AL, 1983, J VERB LEARN VERB BE, V22, P1, DOI 10.1016/S0022-5371(83)80002-4; Caspari I, 2000, J NEUROLINGUIST, V13, P15, DOI 10.1016/S0911-6044(99)00009-3; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Engle RW, 2004, PSYCHOL LEARN MOTIV, V44, P145; Ferstl EC, 1999, BRAIN LANG, V70, P385, DOI 10.1006/brln.1999.2151; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Graesser AC, 1997, ANNU REV PSYCHOL, V48, P163, DOI 10.1146/annurev.psych.48.1.163; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; JOHNSON NS, 1983, CHILDRENS LANGUAGE, P314; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Lehman S, 2002, J EDUC PSYCHOL, V94, P738, DOI 10.1037//0022-0663.94.4.738; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LYTTINEN S, 1998, ED PSYCHOL, V18, P157; MALONE LD, 1992, EXCEPT CHILDREN, V58, P270, DOI 10.1177/001440299105800309; Radvansky GA, 1999, J EXP PSYCHOL GEN, V128, P563, DOI 10.1037/0096-3445.128.4.563; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Schacter D. L., 2002, 7 SINS MEMORY MIND F; Singer M, 1996, MEM COGNITION, V24, P733, DOI 10.3758/BF03201098; Singer M, 2001, DISCOURSE PROCESS, V31, P27, DOI 10.1207/S15326950dp3101_2; St George M, 1999, BRAIN, V122, P1317, DOI 10.1093/brain/122.7.1317; STEIN BL, 1992, J READING BEHAV, V24, P217, DOI 10.1080/10862969209547773; TANNOCK R, 1995, J ABNORM CHILD PSYCH, V23, P235, DOI 10.1007/BF01447091; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; VANDIJK TA, 1995, DISCOURSE COMPREHENSION, P383; WITTROCK MC, 1990, AM EDUC RES J, V27, P489, DOI 10.3102/00028312027003489; [No title captured]	44	63	64	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	MAY	2006	97	2					178	188		10.1016/j.bandl.2005.10.002			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	040EG	WOS:000237361200005	16288805				2022-02-06	
J	DeRidder, MN; Simon, MJ; Siman, R; Auberson, YP; Raghupathi, R; Meaney, DF				DeRidder, MN; Simon, MJ; Siman, R; Auberson, YP; Raghupathi, R; Meaney, DF			Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; organotypic; hippocampus; caspase-3; calpain; N-methyl-D-aspartate receptor	METHYL-D-ASPARTATE; EXPERIMENTAL BRAIN-INJURY; CORTICAL IMPACT INJURY; CELL-DEATH; NEURONAL APOPTOSIS; HEAD-INJURY; COGNITIVE DEFICITS; TEMPORAL PROFILE; RAT; NECROSIS	Apoptotic or necrotic cell death in the hippocampus is a major factor underlying the cognitive impairments following traumatic brain injury. In this study, we examined if traumatic mechanical injury would produce regional activation of calpain and caspase-3 in the in vitro hippocampus and studied how the mechanically induced activation of NR2A and NR2B containing N-methyl-D-aspartate receptors (NMDARs) affects the activation of these proteases following mechanical injury. Following a 75% stretch, significant levels of activated caspase-3 and calpain-mediated spectrin breakdown products were evident only in cells within the dentate gyrus, and little co-localization of the markers was identified within individual cells. After 100% stretch, only calpain activation was observed, localized to the CA3 subregion 24 It after stretch. At moderate injury, levels, both caspase-3 and calpain activation was attenuated by blocking NR2B containing NMDARs prior to stretch or by blocking all NMDARs prior to stretch injury. Treatment with an NR2A selective NMDAR antagonist had little effect on either activated caspase-3 or Ab38 immunoreactivity following moderate injury but resulted in the appearance of activated caspase-3 in the dentate gyrus following severe mechanical stretch. Together, these studies suggest that the injury induced activation of NR2A containing NMDARs functions as a pro-survival signal, while the activation of NR2B containing NMDARs is a competing, anti-survival, signal following mechanical injury to the hippocampus. (c) 2005 Elsevier file. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,Room 105E,Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Auberson, Yves/AAF-6538-2019; Raghupathi, Ramesh/AAX-5538-2021	Auberson, Yves/0000-0001-5800-4811; Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS35712, R01 NS 41699] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Auberson YP, 2002, BIOORG MED CHEM LETT, V12, P1099, DOI 10.1016/S0960-894X(02)00074-4; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clouse AK, 2003, J NEUROTRAUM, V20, P1109; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Krebs C, 2003, J NEUROSCI, V23, P3364; Lesort M, 1997, NEUROSCI LETT, V221, P213, DOI 10.1016/S0304-3940(96)13310-3; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Papachristou GI, 2005, CLIN LAB MED, V25, P17, DOI 10.1016/j.cll.2004.12.003; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sattler R, 1998, J NEUROCHEM, V71, P2349; Schipke CG, 2001, FASEB J, V15, P1270, DOI 10.1096/fj.00-0439fje; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tenneti L, 1998, J NEUROCHEM, V71, P946; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Tovar KR, 1999, J NEUROSCI, V19, P4180; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	61	63	67	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2006	22	1					165	176		10.1016/j.nbd.2005.10.011			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029WN	WOS:000236595200017	16356733				2022-02-06	
J	Sumanont, Y; Murakami, Y; Tohda, M; Vajragupta, O; Watanabe, H; Matsumoto, K				Sumanont, Y; Murakami, Y; Tohda, M; Vajragupta, O; Watanabe, H; Matsumoto, K			Prevention of kainic acid-induced changes in nitric oxide level and neuronal cell damage in the rat hippocampus by manganese complexes of curcumin and diacetylcurcumin	LIFE SCIENCES			English	Article						curcumin; manganese complex; nitric oxide; kainic acid; neurotoxicity	KAINATE-INDUCED EXCITOTOXICITY; RADICAL SCAVENGING ABILITY; SUPEROXIDE-DISMUTASE; STATUS EPILEPTICUS; GLUTAMATE RELEASE; BRAIN; SEIZURES; NEUROTOXICITY; MECHANISMS; MICRODIALYSIS	Curcumin is a natural antioxidant isolated from the medicinal plant Curcuma longa Linn. We previously reported that manganese complexes of curcumin (Cp-Mn) and diacetylcurcumin (DiAc-Cp-Mn) exhibited potent superoxide dismutase (SOD)-like activity in an in vitro assay. Nitric oxide (NO) is a free radial playing a multifaceted role in the brain and its excessive production is known to induce neurotoxicity. Here, we examined the in vivo effect of Cp-Mn and DiAc-Cp-Mn on NO levels enhanced by kainic acid (KA) and L-arginine (L-Arg) in the hippocampi of awake rats using a microdialysis technique. Injection of KA (10 mg/kg, i.p.) and L-Arg (1000 mg/kg, i.p.) significantly increased the concentration of NO and Cp-Mn and DiAc-Cp-Mn (50 mg/kg, i.p.) significantly reversed the effects of KA and L-Arg without affecting the basal NO concentration. Following KA-induced seizures, severe neuronal cell damage was observed in the CA1 and CA3 subfields of hippocampal 3 days after KA administration. Pretreatment with Cp-Mn and DiAc-Cp-Mn (50 mg/kg, i.p.) significantly attenuated KA-induced neuronal cell death in both CA1 and CA3 regions of rat hippocampus compared with vehicle control, and Cp-Mn and DiAc-Cp-Mn showed more potent neuroprotective effect than their parent compounds, curcumin and diacetylcurcumin. These results suggest that Cp-Mn and DiAc-Cp-Mn protect against KA-induced neuronal cell death by suppression of KA-induced increase in NO levels probably by their NO scavenging activity and antioxidative activity. Cp-Mn and DiAc-Cp-Mn have an advantage to be neuroprotective agents in the treatment of acute brain pathologies associated with NO-induced neurotoxicity and oxidative stress-induced neuronal damage such as epilepsy, stroke and traumatic brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Toyama Med & Pharmaceut Univ, 21st COE Program, Inst Nat Med, Div Med Pharmacol, Toyama 9300194, Japan; Mahidol Univ, Fac Pharm, Dept Pharmaceut Chem, Bangkok 10400, Thailand; Toyama Med & Pharmaceut Univ, 21st COE Program, Toyama 9300194, Japan		Matsumoto, K (corresponding author), Toyama Med & Pharmaceut Univ, 21st COE Program, Inst Nat Med, Div Med Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	mkinzo@ms.toyama-mpu.ac.jp	CHULIKHIT, Yaowared/ABC-2153-2021; Vajragupta, Opa/AAU-8700-2021; vajragupta, opa/R-6616-2019	CHULIKHIT, Yaowared/0000-0001-7317-8721; Vajragupta, Opa/0000-0003-3313-0621; Matsumoto, Kinzo/0000-0002-2420-9621			BAGETTA G, 1995, NEURODEGENERATION, V4, P43, DOI 10.1006/neur.1995.0005; Bagetta G, 1995, EUR J PHARMACOL, V294, P341, DOI 10.1016/0014-2999(95)00689-3; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Das KC, 2002, BIOCHEM BIOPH RES CO, V295, P62, DOI 10.1016/S0006-291X(02)00633-2; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Hara S, 2004, NEUROSCI LETT, V366, P302, DOI 10.1016/j.neulet.2004.05.055; Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702; Jones PA, 1998, NEUROSCI LETT, V249, P75, DOI 10.1016/S0304-3940(98)00372-3; Kashihara K, 1998, NEUROSCI RES, V32, P189, DOI 10.1016/S0168-0102(98)00086-8; Kim HC, 2000, BRAIN RES, V853, P215, DOI 10.1016/S0006-8993(99)02254-4; Lian XY, 2005, EPILEPSIA, V46, P15, DOI 10.1111/j.0013-9580.2005.40904.x; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; Maj R, 1998, EUR J PHARMACOL, V359, P27, DOI 10.1016/S0014-2999(98)00554-8; Masuda T, 2001, J AGR FOOD CHEM, V49, P2539, DOI 10.1021/jf001442x; Matsumoto K, 1999, BRAIN RES, V839, P74, DOI 10.1016/S0006-8993(99)01715-1; Milatovic D, 2002, BRAIN RES, V957, P330, DOI 10.1016/S0006-8993(02)03669-7; Milatovic D, 2001, BRAIN RES, V912, P67, DOI 10.1016/S0006-8993(01)02657-9; Montecot C, 1998, NEUROSCIENCE, V84, P791, DOI 10.1016/S0306-4522(97)00566-6; Montecot C, 1997, J CEREBR BLOOD F MET, V17, P94, DOI 10.1097/00004647-199701000-00012; Murakami Y, 2000, BEHAV BRAIN RES, V109, P83, DOI 10.1016/S0166-4328(99)00162-X; Najm IM, 1998, BRAIN RES, V810, P72, DOI 10.1016/S0006-8993(98)00886-5; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; REDDY ACP, 1994, MOL CELL BIOCHEM, V137, P1, DOI 10.1007/BF00926033; Shin EJ, 2004, CLIN EXP PHARMACOL P, V31, P320, DOI 10.1111/j.1440-1681.2004.03990.x; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Sumanont Y, 2004, BIOL PHARM BULL, V27, P170, DOI 10.1248/bpb.27.170; UNNIKRISHNAN MK, 1995, MOL CELL BIOCHEM, V146, P35, DOI 10.1007/BF00926878; Vajragupta O, 2004, FREE RADICAL RES, V38, P303, DOI 10.1080/10715760310001643339; Vajragupta O, 2003, FREE RADICAL BIO MED, V35, P1632, DOI 10.1016/j.freeradbiomed.2003.09.011; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I	39	63	70	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAR 13	2006	78	16					1884	1891		10.1016/j.lfs.2005.08.028			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	022WC	WOS:000236085800015	16266725				2022-02-06	
J	Curtis, KL; Greve, KW; Bianchini, KJ; Brennan, A				Curtis, KL; Greve, KW; Bianchini, KJ; Brennan, A			California verbal learning test indicators of malingered neurocognitive dysfunction - Sensitivity and specificity in traumatic brain injury	ASSESSMENT			English	Article; Proceedings Paper	24th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 17-20, 2004	Seattle, WA	Natl Acad Neuropsychol		malingering; memory; neuropsychological assessment; traumatic brain injury; diagnostic accuracy	ADULT INTELLIGENCE SCALE; CARD SORTING TEST; HEAD-INJURY; RESPONSE BIAS; BASE RATES; IDENTIFICATION; PERFORMANCE; VALIDATION	The present study used well-defined traumatic brain injury (TBI) and mixed neurological (other than TBI) and psychiatric samples to examine the specificity and sensitivity to Malingered Neurocognitive Dysfunction (MND) of four individual California Verbal Learning Test (CVLT) variables and eight composite CVLT malingering indicators. Participants were 275 traumatic brain injury and 352 general clinical patients seen for neuropsychological evaluation. The TBI patients were assigned to one of five groups using the Slick, Sherman, and Iverson (1999) criteria: no incentive, incentive only, suspect, and malingering (both Probable MND and Definite MND). Within TBI, persons with the strongest evidence for malingering (Probable and Definite) had the most extreme scores. Good sensitivity (approximately 50%) in the context of excellent specificity (> 95%) was found in the TBI samples. Issues related to the appropriate clinical application of these data are discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Univ New Orleans, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEZAK MD, 2004, NEURO PSYCHOL ASSESS; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1997, M INT NEUR SOC BERG; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671	34	63	63	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2006	13	1					46	61		10.1177/1073191105285210			16	Psychology, Clinical	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	014LV	WOS:000235482600004	16443718				2022-02-06	
J	Louin, G; Marchand-Verrecchia, C; Palmier, B; Plotkine, M; Jafarian-Tehrani, M				Louin, G; Marchand-Verrecchia, C; Palmier, B; Plotkine, M; Jafarian-Tehrani, M			Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury	NEUROPHARMACOLOGY			English	Article						nitric oxide synthase; fluid percussion brain injury; aminoguanidine; L-NIL; 1400W; cerebral edema; neurological score; rat	ACUTE LUNG INJURY; BARRIER BREAKDOWN; DETRIMENTAL ROLE; NOS ACTIVITY; COLD INJURY; IN-VIVO; RATS; AMINOGUANIDINE; EXPRESSION; INFLAMMATION	The role of inducible nitric oxide synthase (iNOS) in cerebral edema and neurological deficit following traumatic brain injury (TBI) is not yet clear-cut. Therefore, the aim of this study was to investigate the effect of three different iNOS inhibitors on cerebral edema and functional outcome after TBI. First, the time courses of blood-brain barrier (BBB) breakdown, cerebral edema, and neurological deficit were studied in a rat model of fluid percussion-induced TBI. The permeability of BBB to Evans blue was increased from I It to 24 h after TBI. Consistently, a significant increase in brain water content (BWC) was observed at 6 and 24 h post-TBI. A deficit in sensorimotor neurological functions was also observed from 6 It to 7 days with a maximum 24 h after TBI. Second, a single dose of aminoguanidine (AG; 100 mg/kg, i.p.), L-N-iminoethyl-lysine (L-NIL; 20 mg/kg, i.p.), or N-[3-(aminomethyl)benzyl]acetamide (1400W; 20 mg/kg, s.c.) was administered at 6 It post-TBI. Treatment with AG reduced by 71% the increase in BWC evaluated at 24 h, while L-NIL and 1400W had no effect. In contrast, the three iNOS inhibitors reduced the neurological deficit from 30% to 40%. Third, 1400W (20 mg/kg, s.c.) was administered at 5 min, 8 and 16 h post-TBI. Although this treatment paradigm had no effect on cerebral edema evaluated at 24 h, it significantly reduced the neurological deficit and iNOS activity. In conclusion, iNOS contributes to post-TBI neurological deficit but not to cerebral edema. The beneficial effect of iNOS inhibitors is not due to their anti-edematous effect, and the reduction of cerebral edema by AG is unlikely related to iNOS inhibition. The 6 h therapeutic window of iNOS inhibitors could allow their use in the treatment of functional deficit at the acute phase of TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75270 Paris 06, France		Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75270 Paris 06, France.	mehrnaz.jafarian@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arkovitz MS, 1996, J PEDIATR SURG, V31, P1009, DOI 10.1016/S0022-3468(96)90075-5; Arnbrosini A, 2005, J NEUROSCI METH, V144, P183, DOI 10.1016/j.jbeumeth.2004.11.002; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bucci M, 2005, P NATL ACAD SCI USA, V102, P904, DOI 10.1073/pnas.0408906102; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Evans SM, 2003, EUR J PHARMACOL, V461, P63, DOI 10.1016/S0014-2999(02)02959-X; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Handy RLC, 1998, BRIT J PHARMACOL, V123, P1119, DOI 10.1038/sj.bjp.0701735; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harkin DW, 2004, J SURG RES, V120, P230, DOI 10.1016/j.jss.2004.03.011; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nag S, 2000, ACT NEUR S, V76, P65; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Yildiz G, 1998, BRIT J PHARMACOL, V124, P905, DOI 10.1038/sj.bjp.0701924; Young RJ, 2000, BIOORG MED CHEM LETT, V10, P597, DOI 10.1016/S0960-894X(00)00055-X; Zhang L, 2003, J APPL PHYSIOL, V94, P1473, DOI 10.1152/japplphysiol.00789.2002	46	63	65	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2006	50	2					182	190		10.1016/j.neuropharm.2005.08.020			9	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	014RP	WOS:000235497900006	16242164				2022-02-06	
J	Nelson, NW; Sweet, JJ; Demakis, GJ				Nelson, NW; Sweet, JJ; Demakis, GJ			Meta-analysis of the MMPI-2 fake bad scale: Utility in forensic practice	CLINICAL NEUROPSYCHOLOGIST			English	Article							VALIDITY SCALES; LEES-HALEY; CONSTRUCT-VALIDITY; MCMI-II; LITIGANTS; SYMPTOMATOLOGY; PROFILES; SYMPTOMS; DISORDER; STANDARD	Some clinical researchers disagree regarding the clinical utility of the MMPI-2 Fake Bad scale (FBS) within forensic and clinical settings. The present meta-analysis summarizes weighted effect size differences among the FBS and other commonly used validity scales (L, F, K, Fb, Fp, F-K, O-S, Ds2, Dsr2) in symptom overreporting and comparison groups. Forty studies that included FBS were identified through exploration of online databases, perusal of published references, and communication with primary authors. Nineteen of the 40 studies met restrictive inclusion criteria, resulting in a pooled sample size of 3664 (1615 overreporting participants and 2049 comparison participants). The largest grand effect sizes were observed for FBS (.96), followed by O-S (.88), Dsr2 (.79), F- K (.69), and the F- scale (.63). Significant within-scale variability was observed for seven validity scales, including FBS (Q = 119.11, p < .001). Several subsequent FBS moderator analyses yielded moderate to large effect sizes and were statistically significant for level of cognitive effort, type of overreporting comparison group, and condition associated with overreporting (e.g., traumatic brain injury, posttraumatic stress, chronic pain). Findings suggest that the FBS performs as well as, if not superior to, other validity scales in discriminating overreporting and comparison groups; the preponderance of the present literature supports the scale's use within forensic settings.	Evanston NW Healthcare Med Grp, Dept Psychiat & Behav Sci, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL USA; Univ N Carolina, Charlotte, NC 28223 USA		Sweet, JJ (corresponding author), Evanston NW Healthcare Med Grp, Dept Psychiat & Behav Sci, 909 Davis St,Suite 160, Evanston, IL 60201 USA.	j-sweet@northwestern.edu					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 2004, ARCH CLIN NEUROPSYCH, V19, P341, DOI 10.1016/j.acn.2003.12.003; ARNOLD G, 2005, 33 ANN M INT NEUR PS; Bagby RM, 2000, ASSESSMENT, V7, P55, DOI 10.1177/107319110000700104; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bury AS, 2002, PSYCHOL ASSESSMENT, V14, P472, DOI 10.1037//1040-3590.14.4.472; Butcher J, 1989, MANUAL ADM SCORING M; Butcher JN, 2003, ARCH CLIN NEUROPSYCH, V18, P473, DOI 10.1016/S0887-6177(02)00142-7; CHARLES T, 1999, DISS ABSTR INT, V60, P5221; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cramer KM, 1995, J CLIN PSYCHOL, V51, P831, DOI 10.1002/1097-4679(199511)51:6<831::AID-JCLP2270510616>3.0.CO;2-O; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Elhai JD, 2000, J PERS ASSESS, V75, P449, DOI 10.1207/S15327752JPA7503_06; Elhai JD, 2001, ASSESSMENT, V8, P221, DOI 10.1177/107319110100800210; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; Gough H.G., 1950, J CONSULT PSYCHOL, V14, P408, DOI [10.1037/h0054506, DOI 10.1037/H0054506]; Gough HG, 1957, CALIFORNIA PSYCHOL I; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; Greene R. L, 1991, MMPI 2 MMPI INTERPRE; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GREIFFENSTEIN MF, IN PRESS DETECTION N; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P337, DOI 10.1016/j.acn.2003.12.005; GREVE KW, CLIN NEUROPSYCHOLOGI; GRILLO J, 1994, J CLIN PSYCHOL, V50, P651, DOI 10.1002/1097-4679(199407)50:4<651::AID-JCLP2270500424>3.0.CO;2-C; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; HINOJOSA L, 1993, DISS ABSTR INT, V54, P2203; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; IVERSON GL, 1995, PSYCHOL ASSESSMENT, V7, P118, DOI 10.1037/1040-3590.7.1.118; Lanyon RI, 2002, J AM ACAD PSYCHIATRY, V30, P400; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Lees-Haley PR, 2004, ARCH CLIN NEUROPSYCH, V19, P333, DOI 10.1016/j.acn.2003.12.004; Lees-Haley PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Lipsey MW, 2001, PRACTICAL META ANAL; MCCARTHY J, 2005, 33 ANN M INT NEUR PS; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; MILLIS SR, 1995, 30 ANN S REC DEV US; Nelson NW, 2005, CLIN NEUROPSYCHOL, V19, P154; NELSON NW, IN PRESS J CLIN NEUR; Posthuma AB, 1998, PROF PSYCHOL-RES PR, V29, P437; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1995, ASSESSMENT, V2, P81, DOI DOI 10.1177/1073191195002001008; Rogers R., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; SCHMIDT FL, 2003, HDB PSYCHOL RES METH, V12; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Van Gaasbeek JK, 2001, ARCH CLIN NEUROPSYCH, V16, P813; WEGMAN TJ, 2005, 33 ANN M INT NEUR SO; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594	63	63	63	2	23	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2006	20	1					39	58		10.1080/13854040500459322			20	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	999OL	WOS:000234399000004	16393920				2022-02-06	
J	Stevens, RD; Bhardwaj, A				Stevens, RD; Bhardwaj, A			Approach to the comatose patient	CRITICAL CARE MEDICINE			English	Article						coma; vegetative state; hypoxic-ischemic encephalopathy; traumatic brain injury; neurologic diagnosis; outcome prediction	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; HERPES-SIMPLEX ENCEPHALITIS; MINIMALLY CONSCIOUS STATES; CHRONIC HEALTH EVALUATION; NEURON-SPECIFIC ENOLASE; ACUTE PHYSIOLOGY SCORE	Background: Coma is a medical emergency and may constitute a diagnostic and therapeutic challenge for the intensivist. Objective: To review currently available data on the etiology, diagnosis, and outcome of coma. To propose an evidence-based approach for the clinical management of the comatose patient. Data Source: Search of Medline and Cochrane databases; manual review of bibliographies from selected articles and monographs. Data Synthesis and Conclusions: Coma and other states of impaired consciousness are signs of extensive dysfunction or injury involving the brainstem, diencephalon, or cerebral cortex and are associated with a substantial risk of death and disability. Management of impaired consciousness includes prompt stabilization of vital physiologic functions to prevent secondary neurologic injury, etiological diagnosis, and the institution of brain-directed therapeutic or preventive measures. Neurologic prognosis is determined by the underlying etiology and may be predicted by the combination of clinical signs and electrophysiological tests.	Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Dept Anesthesiol Crit Care Med Neurol & Neurosurg, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA		Stevens, RD (corresponding author), Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Dept Anesthesiol Crit Care Med Neurol & Neurosurg, Baltimore, MD 21218 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 046379] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046379] Funding Source: NIH RePORTER		ACKERMANN H, 1995, FORTSCHR NEUROL PSYC, V63, P59, DOI 10.1055/s-2007-996603; ADAMS HP, 1985, NEUROLOGY, V35, P1263, DOI 10.1212/WNL.35.9.1263; AdelsonMitty J, 1997, INTENS CARE MED, V23, P749, DOI 10.1007/s001340050404; American Psychiatric Association, 1994, TASK FORC DSM 4 DIAG; American Psychiatric Association, 2000, TASK FORC DSM 4 DIAG; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bateman DE, 2001, J NEUROL NEUROSUR PS, V71, P13; Bates D, 2001, J NEUROL NEUROSUR PS, V71, P20; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER KJ, 1997, CURRENT THERAPY NEUR; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Burns A, 2004, J NEUROL NEUROSUR PS, V75, P362, DOI 10.1136/jnnp.2003.023366; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; Cartlidge N, 2001, J NEUROL NEUROSUR PS, V71, P18; Chalela JA, 2001, NEUROLOGY, V56, P481, DOI 10.1212/WNL.56.4.481; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHIEN LT, 1977, ARCH NEUROL-CHICAGO, V34, P361, DOI 10.1001/archneur.1977.00500180055011; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Coleman MR, 2005, J NEUROL NEUROSUR PS, V76, P432, DOI 10.1136/jnnp.2004.045930; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DAUBE JR, 1993, NEUROLOGY, V43, P625; Douglas NJ, 2001, J NEUROL NEUROSUR PS, V71, P3; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Finelli PF, 2004, J NEUROL NEUROSUR PS, V75, P1189, DOI 10.1136/jnnp.2003.030833; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Hasbun R, 2001, NEW ENGL J MED, V345, P1727, DOI 10.1056/NEJMoa010399; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hollinger P, 2000, J NEUROL, V247, P232, DOI 10.1007/s004150050573; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kaplan PW, 2004, J CLIN NEUROPHYSIOL, V21, P307; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; KARKELA J, 1992, CRIT CARE MED, V20, P378; Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kunze K, 2002, J NEUROL, V249, P1150, DOI 10.1007/s00415-002-0869-z; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Liu GT, 1999, NEUROSURG CLIN N AM, V10, P579, DOI 10.1016/S1042-3680(18)30159-1; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Mesulam MM, 2000, PRINCIPLES BEHAV COG; Metersky ML, 1997, CLIN INFECT DIS, V25, P285, DOI 10.1086/514531; MORUZZI G, 1995, J NEUROPSYCH CLIN N, V7, P251; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PLUM F, 1980, CONT NEUROLOGY SERIE, V19; Qureshi AI, 2000, CRIT CARE MED, V28, P984, DOI 10.1097/00003246-200004000-00012; Rafanan AL, 2000, CRIT CARE MED, V28, P1306, DOI 10.1097/00003246-200005000-00008; Restrepo L, 2002, STROKE, V33, P2909, DOI 10.1161/01.STR.0000040408.75704.15; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rordorf G, 2000, CRIT CARE MED, V28, P1301, DOI 10.1097/00003246-200005000-00007; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; SAMUELS MA, 1993, NEUROL CLIN, V11, P273, DOI 10.1016/S0733-8619(18)30153-1; SAUNDERS DE, 1995, STROKE, V26, P2272, DOI 10.1161/01.STR.26.12.2272; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEGATORE M, 1992, HEART LUNG, V21, P548; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; SMITH JB, 1975, MAYO CLIN PROC, V50, P469; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; Taylor MA, 2003, AM J PSYCHIAT, V160, P1233, DOI 10.1176/appi.ajp.160.7.1233; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; van de Beek D, 2004, NEW ENGL J MED, V351, P1849, DOI 10.1056/NEJMoa040845; Varelas PN, 2003, NEUROLOGY, V61, P702, DOI 10.1212/01.WNL.0000078812.36581.97; Vargas F, 2000, INTENS CARE MED, V26, P623, DOI 10.1007/s001340051213; Varon J, 2000, CHEST, V118, P214, DOI 10.1378/chest.118.1.214; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WIJDICKS EFM, 2002, CONT NEUROLOGY SERIE, V64; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; Wityk RJ, 2001, ARCH NEUROL-CHICAGO, V58, P571, DOI 10.1001/archneur.58.4.571; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; Young GB, 1999, ARCH NEUROL-CHICAGO, V56, P153, DOI 10.1001/archneur.56.2.153; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; ZIAI WC, 2004, HDB NEUROCRITICAL CA; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; 2002, NEUROSURGERY, V50, pS7	122	63	72	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2006	34	1					31	41		10.1097/01.CCM.0000194534.42661.9F			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999IB	WOS:000234381900005	16374153				2022-02-06	
J	Coates, BM; Vavilala, MS; Mack, CD; Muangman, S; Suz, P; Sharar, SR; Bulger, E; Lam, AM				Coates, BM; Vavilala, MS; Mack, CD; Muangman, S; Suz, P; Sharar, SR; Bulger, E; Lam, AM			Influence of definition and location of hypotension on outcome following severe pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						blood pressure; brain injury; pediatric trauma; children; head trauma; hemodynamics	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; BLOOD-PRESSURE; CEREBRAL AUTOREGULATION; CHILDREN; SURVIVAL; DAMAGE; RAT	Objective: To examine the influence of definition and location (field, emergency department, or pediatric intensive care unit) of hypotension on outcome following severe pediatric traumatic brain injury. Design: Retrospective cohort study. Setting: Harborview Medical Center (level I pediatric trauma center), Seattle, WA, over a 5-yr period between 1998 and 2003. Patients: Ninety-three children <14 yrs of age with traumatic brain injury following injury, head Abbreviated Injury Score >= 3, and pediatric intensive care unit admission Glasgow Coma Scale score <9 formed the analytic sample. Data sources included the Harborview Trauma Registry and hospital records. Interventions: None. Measurements and Main Results: The relationship between hypotension and outcome was examined comparing two definitions of hypotension: a) systolic blood pressure <5th percentile for age; and b) systolic blood pressure <90 mm Hg. Hospital discharge Glasgow Outcome Score <4 or disposition of either death or discharge to a skilled nursing facility was considered a poor outcome. Pediatric intensive care unit and hospital length of stay were also examined. Systolic blood pressure <5th percentile for age was more highly associated with poor hospital discharge Glasgow Outcome Score (p=.001), poor disposition (p=.02), pediatric intensive care unit length of stay (rate ratio 9.5; 95% confidence interval 6.7-12.3), and hospital length of stay (rate ratio 18.8; 95% confidence interval 14.0-23.5) than systolic blood pressure <90 mm Hg. Hypotension occurring in either the field or emergency department, but not in the pediatric intensive care unit, was associated with poor Glasgow Outcome Score (p=.008), poor disposition (p=.03), and hospital length of stay (rate ratio 18.7; 95% confidence interval 13.1-24.2). Conclusions: Early hypotension, defined as systolic blood pressure <5th percentile for age in the field and/or emergency department, was a better predictor of poor outcome than delayed hypotension or the use of systolic blood pressure <90 mm Hg.	Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Harborview Injury Prevent & Res Ctr, Seattle, WA USA		Coates, BM (corresponding author), Univ Washington, Sch Med, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD044632] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [K23044632] Funding Source: Medline		BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; BLUMENTHAL S, 1987, PEDIATRICS, V79, P1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DESWIET M, 1980, PEDIATRICS, V65, P1028; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; GENTLEMAN D, 1992, INT SURG, V77, P297; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Langlois JA, 2001, TRAUMATIC BRAIN INJU; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RULEY EJ, 1993, TXB CRITICAL CARE, P602; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	27	63	63	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	NOV	2005	33	11					2645	2650		10.1097/01.CCM.0000186417.19199.9B			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999XC	WOS:000234423500028	16276192	Green Accepted			2022-02-06	
J	Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J				Max, JE; Schachar, RJ; Levin, HS; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Saunders, A; Landis, J			Predictors of attention-deficit/hyperactivity disorder within 6 months after pediatric traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; secondary attention-deficit/hyperactivity disorder; orbitofrontal gyrus	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; CHILDREN; RELIABILITY; VALIDITY; LESIONS; SYMPTOMATOLOGY; ADOLESCENTS; SCHEDULE; ADHD	Objective: To assess the phenomenology and predictive factors of attention-deficit/hyperactivity disorder (ADHD) after traumatic brain injury (TBI), also called secondary ADHD (SADHD). Method: Children without preinjury ADHD 5-14 years old with TBI from consecutive admissions (n = 143) to five trauma centers were observed prospectively for 6 months (baseline and 6 months), with semistructured psychiatric interviews. Injury severity, lesion characteristics, and preinjury variables including psychiatric disorder, family psychiatric history, family psychiatric history of ADHD, family function, socioeconomic status, psychosocial adversity, and adaptive function were assessed with standardized instruments. Results: SADHD in the first 6 months after injury occurred in 18 of 115 (16%) of returning participants. All subtypes of ADHD occurred. Socioeconomic status (p = .041) and orbitofrontal gyrus lesions (p = .005) independently significantly predicted SADHD. Conclusions: These findings are consistent with research on developmental ADHD that implicate psychosocial factors and prefrontal structural and functional differences between those with and without the disorder.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Hosp Sick Children, Dept Psychiat, Res Inst, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Psychol, Res Inst, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX 77225 USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Univ Houston, Dept Educ Psychol, Houston, TX 77004 USA		Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Ciccetti D., 1984, VINELAND ADAPTIVE BE; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Damasio H., 1989, LESION ANAL NEUROPSY; FARAONE SV, 1995, J AM ACAD CHILD PSY, V34, P1001, DOI 10.1097/00004583-199508000-00009; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hesslinger B, 2002, NEUROSCI LETT, V328, P319, DOI 10.1016/S0304-3940(02)00554-2; HOLLINGSHEAD A, 1975, 4 FACOR INDEX SOCIAL; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Lee JS, 2005, HUM BRAIN MAPP, V24, P157, DOI 10.1002/hbm.20067; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8	29	63	63	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	OCT	2005	44	10					1032	1040		10.1097/01.chi.0000173293.05817.b1			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	967GD	WOS:000232078600014	16175108				2022-02-06	
J	Emery, DL; Fulp, CT; Saatman, KE; Schutz, C; Neugebauer, E; McIntosh, TK				Emery, DL; Fulp, CT; Saatman, KE; Schutz, C; Neugebauer, E; McIntosh, TK			Newly born granule cells in the dentate gyrus rapidly extend axons into the hippocampal CA3 region following experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						BrdU; hippocampus; mossy fiber pathway; neurogenesis; neuronal plasticity; progenitor cells; tract tracing; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; TRANSIENT GLOBAL-ISCHEMIA; NMDA RECEPTOR ACTIVATION; ADULT-RAT; STEM-CELLS; ENHANCED NEUROGENESIS; SPINAL-CORD; PSA-NCAM; PROLIFERATION; NEURONS	We investigated whether new neurons generated in the adult rat brain following lateral fluid percussion traumatic brain injury (TBI) are capable of projecting axons along the mossy fiber pathway to the CA3 region of the hippocampus. Dividing cells were labeled by intraperitoneal injection of bromodeoxyuridine (BrdU) on the day of surgery/injury, and neurons that extended axons to the CA3 region were retrogradely labeled by fluorescent tracers (FluoSpheres(R)), stereotactically injected into the CA3 region of both the ipsi- and contralateral hippocampus at I or 12 days following TBI (n = 12) or sham injury (n = 12) in anaesthetized rats. Animals (11 = 6 injured and n = 6 sham-injured controls per time point) were sacrificed at either 3 or 14 days post-injury. Another group of animals (n = 3) was subjected to experimental TBI and BrdU administration and sacrificed 3 days after TBI to be processed for BrdU and immunohistochemistry for polysialylated neural cell adhesion molecule (PSA-NCAM), a growth-related protein normally observed during CNS development. A fivefold bilateral increase in the number of mitotically active (BrdU+) cells was noted within the dentate gyrus when compared to uninjured controls as early as 3 days following TBI. A subgroup of dividing cells was also immunoreactive for PSA-NCAM at 3 days following TBI. By 2 weeks post-injury the number of BrdU+ cells within the dentate gyrus was increased twofold compared to the uninjured counterparts and a proportion of these newly generated cells showed cytoplasmic staining for the fluorescent tracer. These findings document rapid neurogenesis following TBI and show, for the first time, that newly generated granule neurons are capable of extending projections along the hippocampal mossy fiber pathway in the acute post-traumatic period.	Univ Kentucky, Spinal Cord & Brain Injury Ctr, Lexington, KY 40536 USA; Univ Penn, Sch Med, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Cologne, Dept Expt Surg, Cologne, Germany		Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Ctr, B367 BB3RB,741 S Limestone St, Lexington, KY 40536 USA.	K.Saatman@uky.edu	Schuetz, Christian/K-5234-2013	Schuetz, Christian/0000-0002-6828-4543	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40978, P50-NS08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-45131] Funding Source: Medline		Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Bender RA, 2003, HIPPOCAMPUS, V13, P399, DOI 10.1002/hipo.10089; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Grados-Munro EM, 2003, J NEUROSCI RES, V74, P479, DOI 10.1002/jnr.10803; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hastings NB, 2002, J COMP NEUROL, V452, P324, DOI 10.1002/cne.10386; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; HOUSE RM, 1992, PROTEUS, V9, P41; HOUSER CR, 1990, J NEUROSCI, V10, P267; HOUSER CR, 1992, EPILEPSY RES, P223; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KAPLAN SJ, 1984, ACM T DATABASE SYST, V9, P1, DOI 10.1145/348.318584; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Liu JL, 1998, J NEUROSCI, V18, P7768; Markakis EA, 1999, J COMP NEUROL, V406, P449; MATHERN GW, 1994, DEV BRAIN RES, V78, P70, DOI 10.1016/0165-3806(94)90011-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore N, 2002, J NEUROCHEM, V80, P111, DOI 10.1046/j.0022-3042.2001.00680.x; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nomura T, 2000, J NEUROSCI RES, V61, P588, DOI 10.1002/1097-4547(20000915)61:6<588::AID-JNR2>3.3.CO;2-D; Parent JM, 1999, J NEUROSCI, V19, P4508; Parent JM, 1997, J NEUROSCI, V17, P3727; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Radley JJ, 2003, BRAIN RES, V966, P1, DOI 10.1016/S0006-8993(02)03989-6; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; Scott BW, 1998, NEUROSCI LETT, V248, P73, DOI 10.1016/S0304-3940(98)00355-3; SEKI T, 1993, DEV BRAIN RES, V73, P141, DOI 10.1016/0165-3806(93)90056-G; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; SERESS L, 1992, EPILEPSY RES, P3; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; SHUMATE M, 1995, EPILEPSIA, V36, P503; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SLOVITER RS, 1991, J COMP NEUROL, V308, P381, DOI 10.1002/cne.903080306; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Soares HD, 1995, J NEUROSCI, V15, P8223; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; [No title captured]	83	63	66	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					978	988		10.1089/neu.2005.22.978			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600005	16156713				2022-02-06	
J	Maier, B; Laurer, HL; Rose, S; Buurman, WA; Marzi, I				Maier, B; Laurer, HL; Rose, S; Buurman, WA; Marzi, I			Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: A normative study	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; interleukin; plasma; reference value; soluble receptors	TRAUMATIC BRAIN INJURY; INTERCELLULAR-ADHESION MOLECULE-1; SOLUBLE E-SELECTIN; INFLAMMATORY RESPONSE; IMMUNE-RESPONSE; TNF RECEPTOR; INTERLEUKIN-8; CYTOKINES; SERUM; RELEASE	Numerous recent studies have reported a significant inflammatory reaction in the brain and the systemic circulation following traumatic brain injury (TBI), infection, or neoplasm of the brain with a sequential release of pro- and anti-inflammatory mediators. Although there is growing knowledge and understanding of the mechanisms leading to the often poor outcome of these patients, only a limited database exists on the physiological expression of pro- and anti-inflammatory cytokines and molecules in plasma and particularly in cerebrospinal fluid (CSF). Therefore, we analyzed paired plasma/CSF samples of healthy human volunteers for the physiological concentrations of Interleukin (IL)-6, IL-8, IL-10, soluble TNF-receptors (sTNF-R) p55 and p75, soluble ICAM (sICAM), and soluble E-selectin (sE-selectin). A physiological release of IL-6, IL-8, IL-10, and sTNF-R p55 and p75 was detected in plasma and CSF. In contrast, sICAM and sE-selectin were only detectable in plasma. Pro- and anti-inflammatory mediators exhibited different concentration patterns in plasma and CSF, suggesting a pro-inflammatory predisposition in the central nervous system.	Goethe Univ Frankfurt, Univ Hosp, Sch Med, Dept Trauma Hand & Reconstruct Surg, Frankfurt, Germany; Univ Maastricht, Dept Surg, Maastricht, Netherlands		Marzi, I (corresponding author), Goethe Univ Frankfurt, Klin Unfall Hand & Wiederherstellungschirurg, D-69590 Frankfurt, Germany.	marzi@trauma.uni-frankfurt.de					ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; AYALA A, 1991, AM J PHYSIOL, V260, pR167, DOI 10.1152/ajpregu.1991.260.1.R167; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bouma M, 1997, IMMUNOCHEMISTRY PRAC, P181; Brockhaus M, 1997, INTENS CARE MED, V23, P808, DOI 10.1007/s001340050416; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; ENGELBERTS I, 1992, CLIN IMMUNOL IMMUNOP, V65, P330, DOI 10.1016/0090-1229(92)90165-K; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Froon AHM, 1996, EUR J SURG, V162, P287; Handa Shoichi, 1992, Kurume Medical Journal, V39, P257; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kleine TO, 2003, BRAIN RES BULL, V61, P287, DOI 10.1016/S0361-9230(03)00092-3; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; LAW MM, 1994, J TRAUMA, V37, P100, DOI 10.1097/00005373-199407000-00017; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MAIER B, 1999, UNFALLCHIRURGIE, V25, P100; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Muller M, 2001, Eur J Ultrasound, V12, P203, DOI 10.1016/S0929-8266(00)00118-X; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Polin RS, 1998, J NEUROSURG, V89, P559, DOI 10.3171/jns.1998.89.4.0559; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; Spuler S, 1996, J NEUROIMMUNOL, V66, P57; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vinante F, 1998, BRIT J HAEMATOL, V102, P1025, DOI 10.1046/j.1365-2141.1998.00872.x; Woiciechowsky C, 1997, ACTA NEUROCHIR, V139, P619, DOI 10.1007/BF01411996	35	63	68	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					822	835		10.1089/neu.2005.22.822			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800009	16004584				2022-02-06	
J	Haley, SM; Raczek, AE; Coster, WJ; Dumas, HM; Fragala-Pinkham, MA				Haley, SM; Raczek, AE; Coster, WJ; Dumas, HM; Fragala-Pinkham, MA			Assessing mobility in children using a computer adaptive testing version of the Pediatric Evaluation of Disability Inventory	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						outcome assessment (health care); pediatrics; rehabilitation	ITEM RESPONSE THEORY; TRAUMATIC BRAIN INJURY; MEASURING OUTCOMES; REHABILITATION; SIMULATION; MODEL	Objective: To assess score agreement, validity, precision, and response burden of a prototype computerized adaptive testing (CAT) version of the Mobility Functional Skills Scale (Mob-CAT) of the Pediatric Evaluation of Disability Inventory (PEDI) as compared with the full 59-item version (Mob-59). Design: Computer simulation analysis of cross-sectional and longitudinal retrospective data; and cross-sectional prospective study. Setting: Pediatric rehabilitation hospital, including inpatient acute rehabilitation, day school program, outpatient clinics, community-based day care, preschool, and children's homes. Participants: Four hundred sixty-nine children with disabilities and 412 children with no disabilities (analytic sample); 41 children without disabilities and 39 with disabilities (cross-validation sample). Interventions: Not applicable. Main Outcome Measures: Summary scores from a prototype Mob-CAT application and versions using 15-, 10-, and 5-item stopping rules; scores from the Mob-59; and number of items and time (in seconds) to administer assessments. Results: Mob-CAT scores from both computer simulations (intraclass correlation coefficient [ICC] range, .94-.99) and field administrations (ICC = .98) were in high agreement with scores from the Mob-59. Using computer simulations of retrospective data, discriminant validity, and sensitivity to change of the Mob-CAT closely approximated that of the Mob-59, especially when using the 15- and 10-item stopping rule versions of the Mob-CAT. The Mob-CAT used no more than 15% of the items for any single administration, and required 20% of the time needed to administer the Mob-59. Conclusions: Comparable score estimates for the PEDI mobility scale can be obtained from CAT administrations, with losses in validity and precision for shorter forms, but with a considerable reduction in administration time.	Boston Univ, Hlth & Disabil Res Inst, Boston, MA 02215 USA; QualityMetr Inc, Lincoln, RI USA; Franciscan Childrens Hosp, Res Ctr Children Special Hlth Care Needs, Boston, MA USA		Haley, SM (corresponding author), Boston Univ, Hlth & Disabil Res Inst, 53 Bay State Rd, Boston, MA 02215 USA.	smhaley@bu.edu	Fragala-Pinkham, Maria/AAY-4354-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD045354, R43HD042388] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02 HD45354-01A1, R43 HD42388-01] Funding Source: Medline		ANDRICH D, 1998, RASCH MODELS MEASURE; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; Bjorner JB, 2003, QUAL LIFE RES, V12, P981, DOI 10.1023/A:1026123400242; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P1189, DOI 10.1016/S0895-4356(98)00111-5; Bjorner JB, 2003, QUAL LIFE RES, V12, P913, DOI 10.1023/A:1026163113446; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, P384, DOI 10.1053/apmr.2003.50006; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Dumas HM, 2001, BRAIN INJURY, V15, P891, DOI 10.1080/02699050110065691; Embretson S. E., 2000, ITEM RESPONSE THEORY, P123; Engelbert RH, 1997, PEDIAT PHYS THER, V9, P18; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Fischer GH, 1995, RASCH MODELS FDN REC; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; GOLDBERG MJ, 1991, J PEDIATR ORTHOPED, V11, P682; Granger C., 1996, CHILD SPINAL CORD IN, P709; Haley S, 1992, PEDIAT EVALUATION DI; HALEY SM, 1992, MED SPORT SCI, V36, P278; Haley SM, 2004, ARCH PHYS MED REHAB, V85, P661, DOI 10.1016/j.apmr.2003.08.097; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALEY SM, 1991, PHYS MED REH CLIN N, V2, P689; Haley SM, 1993, PHYS MED REH CLIN N, V4, P529, DOI [10.1016/S1047-9651(18)30568-0, DOI 10.1016/S1047-9651(18)30568-0]; HALEY SM, 2000, ORTHOP PHYS THER CLI, V9, P17; Hambleton RK., 1991, FUNDAMENTALS ITEM RE; Hays RD, 2000, MED CARE, V38, P28; Iyer LV, 2003, PHYS THER, V83, P888, DOI 10.1093/ptj/83.10.888; Kothari DH, 2003, PHYS THER, V83, P776, DOI 10.1093/ptj/83.9.776; Law M, 1999, ARCH PHYS MED REHAB, V80, P629, DOI 10.1016/S0003-9993(99)90164-8; Lollar DJ, 2000, ARCH PHYS MED REHAB, V81, pS46, DOI 10.1053/apmr.2000.20624; Ludlow L H, 2000, J Outcome Meas, V4, P482; Ludlow LH, 1996, EDUC PSYCHOL MEAS, V56, P122, DOI 10.1177/0013164496056001008; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MISLEVY RJ, 1986, J EDUC STAT, V11, P3, DOI 10.2307/1164846; Msall ME, 2002, PEDIATRICS, V109, P317, DOI 10.1542/peds.109.2.317; MUTHEN S, 1998, MPLUS USERS GUIDE; Nichols DS., 1996, PEDIATR PHYS THER, V8, P15, DOI DOI 10.1097/00001577-199600810-00004; Norrlin S, 2003, ACTA PAEDIATR, V92, P204; Ostensjo S, 2003, DEV MED CHILD NEUROL, V45, P603, DOI 10.1017/S0012162203001105; Ottenbacher KJ, 2000, AM J PHYS MED REHAB, V79, P114, DOI 10.1097/00002060-200003000-00002; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TJUR T, 1982, SCAND J STAT, V9, P23; Tsai PY, 2002, CHILD NERV SYST, V18, P48, DOI 10.1007/s00381-001-0531-6; Turk M., 1997, ASSESSING MED REHABI, P367; van der Linden W.J., 1997, HDB MODERN ITEM RESP; VERHELST ND, 1995, ONEPARAMETER LOGISTI; Wainer H., 2000, COMPUTERIZED ADAPTIV; Ware JE, 2003, QUAL LIFE RES, V12, P935, DOI 10.1023/A:1026115230284; Ware JE, 2003, ARCH PHYS MED REHAB, V84, pS43, DOI 10.1053/apmr.2003.50246; Ware JE, 2000, MED CARE, V38, P73; WARM TA, 1989, PSYCHOMETRIKA, V54, P427, DOI 10.1007/BF02294627; Wright FV, 1993, CAN J REHABIL, V7, P41; YEN WM, 1993, J EDUC MEAS, V30, P187, DOI 10.1111/j.1745-3984.1993.tb00423.x; YOUNG NL, 1995, J PEDIATR ORTHOPED, V15, P244	54	63	63	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					932	939		10.1016/j.apmr.2004.10.032			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	928NM	WOS:000229278500013	15895339				2022-02-06	
J	Mitrasinovic, OM; Grattan, A; Robinson, CC; Lapustea, NB; Poon, C; Ryan, H; Phong, C; Murphy, GM				Mitrasinovic, OM; Grattan, A; Robinson, CC; Lapustea, NB; Poon, C; Ryan, H; Phong, C; Murphy, GM			Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial-hippocampal organotypic coculture system	JOURNAL OF NEUROSCIENCE			English	Article						microglia; hippocampus; organotypic; M-CSF; excitotoxicity; neuroprotection; ribozyme; laser capture microdissection	METHYL-D-ASPARTATE; M-CSF RECEPTOR; IN-VITRO MODEL; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; MESSENGER-RNA; EXPRESSION; CELLS; ACTIVATION; NEUROTOXICITY	Microglia with increased expression of the macrophage colony-stimulating factor receptor (M-CSFR; c-fms) are found surrounding plaques in Alzheimer's disease ( AD) and in mouse models for AD and after ischemic or traumatic brain injury. Increased expression of M-CSFR causes microglia to adopt an activated state that results in proliferation, release of cytokines, and enhanced phagocytosis. To determine whether M-CSFR-induced microglial activation affects neuronal survival, we assembled a coculture system consisting of BV-2 microglia transfected to overexpress the M-CSFR and hippocampal organotypic slices treated with NMDA. Twenty-four hours after assembly of the coculture, microglia overexpressing M-CSFR proliferated at a higher rate than nontransfected control cells and exhibited enhanced migration toward NMDA-injured hippocampal cultures. Surprisingly, coculture with c-fms-transfected microglia resulted in a dramatic reduction in NMDA-induced neurotoxicity. Similar results were observed when cocultures were treated with the teratogen cyclophosphamide. Biolistic overexpression of M-CSFR on microglia endogenous to the organotypic culture also rescued neurons from excitotoxicity. Furthermore, c-fms-transfected microglia increased neuronal expression of macrophage colony-stimulating factor (M-CSF), the M-CSFR, and neurotrophin receptors in the NMDA-treated slices, as determined with laser capture microdissection. In the coculture system, direct contact between the exogenous microglia and the slice was necessary for neuroprotection. Finally, blocking expression of the M-CSF ligand by exogenous c-fms-transfected microglia with a hammerhead ribozyme compromised their neuroprotective properties. These results demonstrate a protective role for microglia overexpressing M-CSFR in our coculture system and suggest under certain circumstances, activated microglia can help rather than harm neurons subjected to excitotoxic and teratogen-induced injury.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA		Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Med Sch Lab Surge Bldg,Room P-104, Stanford, CA 94305 USA.	gmurphy@leland.stanford.edu	Poon, Chi Sun/H-4152-2015		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH057833] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH057833, MH 57833] Funding Source: Medline		Aschner M, 1999, ANNU REV PHARMACOL, V39, P151, DOI 10.1146/annurev.pharmtox.39.1.151; Bamberger ME, 2002, NEUROSCIENTIST, V8, P276, DOI 10.1177/1073858402008003013; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Berezovskaya O, 1996, ACTA NEUROPATHOL, V92, P479, DOI 10.1007/s004010050550; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Fixe P, 1997, EUR CYTOKINE NETW, V8, P125; Francis K, 1997, P NATL ACAD SCI USA, V94, P12258, DOI 10.1073/pnas.94.23.12258; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Glass JD, 2001, MICROSC RES TECHNIQ, V54, P95, DOI 10.1002/jemt.1124; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Haapasalo A, 2002, J BIOL CHEM, V277, P43160, DOI 10.1074/jbc.M205202200; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; Hao AJ, 2001, J NEUROSCI RES, V64, P79, DOI 10.1002/jnr.1056; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; KONDO K, 1995, NEUROSCI LETT, V188, P140, DOI 10.1016/0304-3940(95)11408-O; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Luder CGK, 1999, EXP PARASITOL, V93, P23, DOI 10.1006/expr.1999.4421; McGeer PL, 1998, J NEURAL TRANSM-SUPP, P159; McGeer PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969; Mitrasinovic OM, 2004, J NEUROSCI RES, V77, P420, DOI 10.1002/jnr.20168; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; Murase S, 1998, J NEUROSCI, V18, P10481; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schwartz M, 2004, TRENDS PHARMACOL SCI, V25, P407, DOI 10.1016/j.tips.2004.06.010; Schwartz M, 2003, TRENDS NEUROSCI, V26, P297, DOI 10.1016/S0166-2236(03)00126-7; Shaked I, 2004, J NEUROIMMUNOL, V146, P84, DOI 10.1016/j.jneuroim.2003.10.049; Smits HA, 2001, J IMMUNOL, V166, P6869, DOI 10.4049/jimmunol.166.11.6869; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333; UEMURA N, 1993, BLOOD, V82, P2634; Vincent VAM, 2002, J NEUROSCI RES, V69, P578, DOI 10.1002/jnr.10329; Vincent VAM, 2002, J NEUROCHEM, V82, P1388, DOI 10.1046/j.1471-4159.2002.01087.x; Wang MJ, 2002, EUR J NEUROSCI, V16, P2103, DOI 10.1046/j.1460-9568.2002.02290.x; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Watanabe H, 2000, NEUROSCI LETT, V289, P53, DOI 10.1016/S0304-3940(00)01252-0; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911; Yao GQ, 2003, ENDOCRINOLOGY, V144, P3677, DOI 10.1210/en.2002-221071; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	63	67	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 27	2005	25	17					4442	4451		10.1523/JNEUROSCI.0514-05.2005			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	920PP	WOS:000228702900025	15858070	Bronze, Green Published			2022-02-06	
J	McKee, JA; Brewer, RP; Macy, GE; Phillips-Bute, B; Campbell, KA; Borel, CO; Reynolds, JD; Warner, DS				McKee, JA; Brewer, RP; Macy, GE; Phillips-Bute, B; Campbell, KA; Borel, CO; Reynolds, JD; Warner, DS			Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia	CRITICAL CARE MEDICINE			English	Article						magnesium sulfate; neuroprotective agents; cerebrospinal fluid; subarachnoid hemorrhage; brain ischemia; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; IONIZED MAGNESIUM; CEREBRAL-ISCHEMIA; ACUTE STROKE; BLOOD-FLOW; IN-VITRO; RAT; PREECLAMPSIA; DEFICIENCY	Objective: Based on preclinical investigations, magnesium sulfate (MgSO4) has gained interest as a neuroprotective agent. However, the ability of peripherally administered MgSO4 to penetrate the blood-brain barrier is limited in normal brain. The current study measured the passage of intravenously administered Mg2+ into cerebrospinal fluid in patients with brain injury requiring ventricular drainage. Design: A prospective evaluation of the cerebrospinal fluid total and ionized magnesium concentration, [Mg2+], during sustained hypermagnesemia was performed. Setting: Neurosciences intensive care unit at a major teaching institution. Patients: Thirty patients with acute brain injury secondary to subarachnoid hemorrhage, traumatic brain injury, primary intracerebral hemorrhage, subdural hematoma, brain tumor, central nervous system infection, or ischemic stroke were studied. Interventions. Patients underwent 24 hrs of induced hypermagnesemia during which total and ionized cerebrospinal fluid [Mg2+] was measured. Serum [Mg2+] was adjusted to 2.1-2.5 mmol/L. Cerebrospinal fluid [Mg2+] was measured at baseline, at 12 and 24 hrs after onset of infusion, and at 12 hrs following infusion termination. Measurements and Main Results. At baseline, total (1.25 +/- 0.14 mmol/L) and ionized (0.80 +/- 0.10 mmol/L) cerebrospinal fluid [Mg2+] was greater than serum total (0.92 +/- 0.18 mmol/L) and ionized (0.63 +/- 0.07 mmol/L) [Mg2+] (p < .05). Total (1.43 +/- 0.13 mmol/L) and ionized (0.89 +/- 0.12 mmol/L) cerebrospinal fluid [Mg2+] was maximally increased by 15% and 11% relative to baseline, respectively, during induced hypermagnesemia (p < .05). Conclusions: Hypermagnesemia produced only marginal increases in total and ionized cerebrospinal fluid [Mg2+]. Regulation of cerebrospinal fluid [Mg2+] is largely maintained following acute brain injury and limits the brain bioavailability of MgSO4.	Duke Univ, Med Ctr, Neurosci Intens Care Unit, Durham, NC 27706 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27706 USA; Duke Univ, Sch Med, Med Ctr, Durham, NC 27706 USA		McKee, JA (corresponding author), Duke Univ, Med Ctr, Neurosci Intens Care Unit, Durham, NC 27706 USA.						Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; Belfort MA, 2003, NEW ENGL J MED, V348, P304, DOI 10.1056/NEJMoa021180; Boet R, 2000, NEUROSURGERY, V47, P602, DOI 10.1097/00006123-200009000-00014; Bradford Andrew, 2000, Curr Control Trials Cardiovasc Med, V1, P184, DOI 10.1186/CVM-1-3-184; Brewer RP, 2001, CLIN NEUROPHARMACOL, V24, P341, DOI 10.1097/00002826-200111000-00005; CHI OZ, 1990, ARCH INT PHARMACOD T, V304, P196; CHOI WW, 1991, AM J OBSTET GYNECOL, V164, P693, DOI 10.1016/S0002-9378(11)80048-7; CHUTKOW JG, 1974, NEUROLOGY, V24, P780, DOI 10.1212/WNL.24.8.780; FuchsBuder T, 1997, J NEUROSURG ANESTH, V9, P324, DOI 10.1097/00008506-199710000-00006; Gee JB, 2004, PEDIATR RES, V55, P93, DOI 10.1203/01.PDR.0000099771.39629.E5; Gee JB, 1999, PEDIATR RES, V46, P281, DOI 10.1203/00006450-199909000-00006; GHRIBI O, 1995, FUNDAM CLIN PHARM, V9, P141, DOI 10.1111/j.1472-8206.1995.tb00273.x; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HALLAK M, 1992, AM J OBSTET GYNECOL, V167, P1605, DOI 10.1016/0002-9378(92)91749-Z; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HUANG QF, 1994, AM J PHYSIOL, V266, pR158, DOI 10.1152/ajpregu.1994.266.1.R158; KEMP PA, 1993, CLIN SCI, V85, P175, DOI 10.1042/cs0850175; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Lampl Y, 2001, CLIN NEUROPHARMACOL, V24, P11, DOI 10.1097/00002826-200101000-00003; Lampl Y, 1998, J NEUROL, V245, P584, DOI 10.1007/s004150050249; Lees KR, 2004, LANCET, V363, P439, DOI 10.1016/S0140-6736(04)15490-1; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; MIURA K, 1988, Neurological Surgery, V16, P1251; Morris M E, 1992, Magnes Res, V5, P303; Muir KW, 1998, MAGNESIUM RES, V11, P43; Nelson RM, 2003, BRAIN RES, V964, P1, DOI 10.1016/S0006-8993(02)03691-0; OPPELT WW, 1963, AM J PHYSIOL, V205, P959, DOI 10.1152/ajplegacy.1963.205.5.959; Saver JL, 2002, STROKE, V33, P353; SCHANNE FAX, 1993, BIOCHIM BIOPHYS ACTA, V1158, P257, DOI 10.1016/0304-4165(93)90023-2; Sirin BH, 1998, EUR J CARDIO-THORAC, V14, P82, DOI 10.1016/S1010-7940(98)00140-7; SOMJEN G, 1966, J PHARMACOL EXP THER, V154, P652; Standley CA, 1996, OBSTET GYNECOL, V88, P184, DOI 10.1016/0029-7844(96)00144-5; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9; TORREGROSA G, 1994, J CARDIOVASC PHARM, V23, P1004, DOI 10.1097/00005344-199406000-00020; van den Bergh WM, 2003, ACTA NEUROCHIR, V145, P195, DOI 10.1007/s00701-002-1064-9; VANLINDE AM, 1991, METAB BRAIN DIS, V6, P199; Veyna RS, 2002, J NEUROSURG, V96, P510, DOI 10.3171/jns.2002.96.3.0510; ZOFKOVA I, 1993, HORM METAB RES, V25, P29, DOI 10.1055/s-2007-1002040; Zofkova I, 1995, Magnes Res, V8, P77	42	63	69	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2005	33	3					661	666		10.1097/01.ccm.0000156293.35868.b2			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907CD	WOS:000227691800026	15753761				2022-02-06	
J	Engstrom, M; Romner, B; Schalen, W; Reinstrup, P				Engstrom, M; Romner, B; Schalen, W; Reinstrup, P			Thrombocytopenia predicts progressive hemorrhage after head trauma	JOURNAL OF NEUROTRAUMA			English	Article						brain; contusion; progressive; TBI; thrombocytopenia; trauma	EARLY HEMOSTATIC THERAPY; INTRACEREBRAL HEMORRHAGE; BRAIN-INJURY; PLATELET-FUNCTION; COAGULOPATHY; COAGULATION; GUIDELINES; EPIDEMIOLOGY; MANAGEMENT; CHILDREN	Patients with traumatic brain injury (TBI) often show progression of hemorrhagic injuries (PHI) after admission to the hospital. This progression is correlated with poor outcome. In this study, we have investigated if thrombocytopenia was a risk factor for PHI. The study was performed on patients admitted to the hospital with severe TBI during year 2000. In total, 50 patients were admitted with severe TBI. Twenty-seven out of these had complete platelet counts at admission and 24 hours thereafter and were included for further study. We found thrombocytopenia at admission to be a risk factor for PHI (p = 0.008). We also found that the platelet count decreased more significantly during the first 24 h after injury in patients with PHI compared to patients without PHI (P = 0.009). A trend towards longer periods of mechanical ventilation in patients with PHI compared to patients without PHI was identified. These findings support a causal relationship between thrombocytopenia and PHI. The findings provide a rationale for future studies of hemostatic agents in the treatment of TBI in order to minimise complications caused by PHI.	Lund Univ Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden		Engstrom, M (corresponding author), Lund Univ Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden.	martin.engstrom@skane.se					Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BURCH JM, 1992, ANN SURG, V215, P476, DOI 10.1097/00000658-199205000-00010; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LITTLETON JM, 1982, ALCOHOL CLIN EXP RES, V6, P512, DOI 10.1111/j.1530-0277.1982.tb05015.x; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2002, NEUROL RES, V24, P19, DOI 10.1179/016164102101199495; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Mayer SA, 2002, INTENS CARE MED, V28, pS235, DOI 10.1007/s00134-002-1470-8; Mikhail J, 1999, AACN Clin Issues, V10, P85, DOI 10.1097/00044067-199902000-00008; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Serebruany VL, 2000, J THROMB THROMBOLYS, V9, P229, DOI 10.1023/A:1018762510842; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; ZOUCAS E, 1982, EUR SURG RES, V14, P33, DOI 10.1159/000128220	34	63	74	0	1	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					291	296		10.1089/neu.2005.22.291			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400008	15716634				2022-02-06	
J	Knight, RG; Harnett, M; Titov, N				Knight, RG; Harnett, M; Titov, N			The effects of traumatic brain injury on the predicted and actual performance of a test of prospective remembering	BRAIN INJURY			English	Article							PROSPECTIVE MEMORY; SELF-AWARENESS; DEFICITS; ADULTS; EVENT; FAILURE; DAMAGE; TIME	Primary objective: The aim of the present study was to assess prospective memory ( PM) with a video-based task using naturalistic stimuli, in a group with long-term disabilities resulting from traumatic brain injury (TBI). The specific focus of the research was on comparing the accuracy of the TBI and control groups' estimates of successful completion of the prospective memory tasks. Research design: A group of 25 persons with TBI and 20 matched controls were compared on the video-based test of prospective remembering, on a test of retrospective memory ( the Logical Memory sub-test of the Wechsler Memory Scale) and tests of executive dysfunction. Correlations between the neuropsychological and PM test scores were calculated and an item analysis of the PM test was undertaken. Procedures: For the PM test, participants were given a scenario involving a robbery, and a list of tasks to be completed in a nearby city centre. The instructions were given twice and on the second occasion they were asked to rate the likelihood of remembering each item. They then watched a videotaped segment showing the perspective of a person first driving and then walking through an unfamiliar city. Their task was to recall each instruction when a relevant cue appeared. Outcomes and results: The TBI group ratings of likelihood of recalling items were entirely equivalent to those made by the controls. On the PM test, however, their performance was significantly reduced. The performance of the TBI group on the PM test was correlated with scores on the Logical Memory and verbal fluency measures. Conclusions: The results showed that, although the TBI group performed more poorly on the PM task, their expectations about how much they would remember were comparable to those of the controls. The findings suggest that persons with TBI may have unrealistic expectations about how much they will remember in a novel situation. Awareness and acceptance of cognitive changes after TBI can be a significant issue for rehabilitation.	Univ Otago, Dept Psychol, Dunedin, New Zealand		Knight, RG (corresponding author), Univ Otago, Dept Psychol, Box 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz		Fountain, Mairead/0000-0003-0575-5368; Titov, Nickolai/0000-0002-7268-729X			Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Cherry KE, 2001, MEMORY, V9, P177, DOI 10.1080/09658210143000092; CICERONE KD, ARCH PHYSL MED REHAB, V81, P1596; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Katai S, 2003, J NEUROL NEUROSUR PS, V74, P704, DOI 10.1136/jnnp.74.6.704; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KRINSKY R, 1985, ACTA PSYCHOL, V58, P141, DOI 10.1016/0001-6918(85)90004-6; Marsh RL, 2000, APPL COGNITIVE PSYCH, V14, pS29, DOI 10.1002/acp.769.abs; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDermott K, 2004, APPL COGNITIVE PSYCH, V18, P349, DOI 10.1002/acp.977; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Perfect TJ, 1999, J EXP PSYCHOL-APPL, V5, P250, DOI 10.1037/1076-898X.5.3.250; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; Titov N, 2000, BRAIN INJURY, V14, P877; Titov N, 2001, APPL COGNITIVE PSYCH, V15, P61, DOI 10.1002/1099-0720(200101/02)15:1<61::AID-ACP689>3.0.CO;2-Y	35	63	70	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					19	27		10.1080/02699050410001720022			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600003	15762098				2022-02-06	
J	Le, TH; Mukherjee, P; Henry, RG; Berman, JI; Ware, M; Manley, GT				Le, TH; Mukherjee, P; Henry, RG; Berman, JI; Ware, M; Manley, GT			Diffusion tensor imaging with three-dimensional fiber tractography of traumatic axonal shearing injury: An imaging correlate for the posterior callosal "disconnection" syndrome: Case report	NEUROSURGERY			English	Article						corpus callosum; diffuse axonal injury; diffusion tensor imaging; fiber tractography; magnetic resonance imaging; traumatic brain injury; white matter			Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA		Le, TH (corresponding author), Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.		Ware, Marcus/E-4981-2011; Mukherjee, Pratik/A-5446-2008	Mukherjee, Pratik/0000-0001-7473-7409				0	63	64	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2005	56	1					189	189		10.1227/01.NEU.0000144846.00569.3A			1	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	884FD	WOS:000226069300057	15617604				2022-02-06	
J	Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D				Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D			Proton MR spectroscopy detected glutamate/glutamine is increased in children with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						children; glutamate; infants; spectroscopy; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; AMINO-ACID RELEASE; CLOSED-HEAD INJURY; VENTRICULAR CEREBROSPINAL-FLUID; PEDIATRIC INTENSIVE-CARE; CORTICAL IMPACT INJURY; IN-VIVO; METABOLITE CONCENTRATIONS; GLUTAMATE CONCENTRATIONS; RAT-BRAIN	Adults with traumatic brain injury (TBI) have been shown by invasive methods to have increased levels of the excitatory neurotransmitter glutamate. It is unclear whether glutamate release contributes to primary or secondary injury and whether its protracted elevation is predictive of a poor outcome. Preliminary studies at our institution in adults found that early increases in magnetic resonance spectroscopy (MRS)-detected glutamate/glutamine (Glx) were associated with poor outcomes. We therefore studied 38 children (mean age, 11 years; range, 1.6-17 years) who had TBI with quantitative short-echo time (STEAM, TE = 20 msec) proton MRS, a mean of 7 +/- 4 (range, 1-17) days after injury in order to determine if their occipital or parietal Glx levels correlated with the severity of injury or outcome. Occipital Glx was significantly increased in children with TBI compared to controls (13.5 +/- 2.4 vs. 10.7 +/- 1.8; p = 0.002), but there was no difference between children with good compared to poor outcomes as determined by the Pediatric Cerebral Performance Category Scale score at 6-12 months after injury. We also did not find a correlation between the amount of Glx and the initial Glasgow Coma Scale score, duration of coma, nor with changes in spectral metabolites, including N-acetyl aspartate, choline, and myoinositol. In part, this may have occurred because, in this study, most patients with poor outcomes were studied later than patients with good outcomes, potentially beyond the time frame for peak elevation of Glx after injury. Additional early and late studies of patients with varying degrees of injury are required to assess the importance to the pathophysiology of TBI of this excitatory neurotransmitter.	Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92350 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, 11175 Campus St,Rm A1120G, Loma Linda, CA 92350 USA.	sashwal@ahs.ilumc.edu					Alessandri B, 1999, ACT NEUR S, V75, P25; Antuono PG, 2001, NEUROLOGY, V56, P737, DOI 10.1212/WNL.56.6.737; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARTH TM, 1990, STROKE, V21, P153; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANIELSEN ER, 1999, MAGNETIC RESONANCE S; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gopinath SP, 2000, ACT NEUR S, V76, P437; Hajek M, 1997, EPILEPSY RES, V28, P245, DOI 10.1016/S0920-1211(97)00050-8; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HOLSHOUSER BA, 2003, P INT SOC MAG RESON, V11, P2032; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koura SS, 1998, ACT NEUR S, V71, P244; Kreis R, 2002, MAGNET RESON MED, V48, P949, DOI 10.1002/mrm.10304; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Lundbom NMI, 1999, AM J NEURORADIOL, V20, P1543; Malcon C, 2000, BRAIN RES, V860, P195, DOI 10.1016/S0006-8993(00)02038-2; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Miller SP, 2002, NEUROLOGY, V58, P542, DOI 10.1212/WNL.58.4.542; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Petroff O A, 2000, Adv Neurol, V83, P261; Petroff OAC, 1999, SEIZURE-EUR J EPILEP, V8, P120, DOI 10.1053/seiz.1999.0267; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Pu YL, 2000, AM J NEURORADIOL, V21, P203; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rothman DL, 1999, PHILOS T R SOC B, V354, P1165, DOI 10.1098/rstb.1999.0472; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Savic I, 2000, ACTA NEUROL SCAND, V102, P179, DOI 10.1034/j.1600-0404.2000.102003179.x; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Simister RJ, 2003, NEUROLOGY, V61, P897, DOI 10.1212/01.WNL.0000086903.69738.DC; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; Staub F, 1997, BRAIN RES, V766, P285, DOI 10.1016/S0006-8993(97)00751-8; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; TANAKA H, 1994, ACTA NEUROCHIR, P524; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Yamamoto T, 1999, ACT NEUR S, V75, P17; Zhang H, 2001, CLIN CHEM, V47, P1458; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	80	63	67	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1539	1552		10.1089/0897715042441756			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800002	15684647				2022-02-06	
J	Asplund, CA; McKeag, DB; Olsen, CH				Asplund, CA; McKeag, DB; Olsen, CH			Sport-related concussion - Factors associated with prolonged return to play	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; sports; symptoms; outcomes	BRAIN-INJURY; HIGH-SCHOOL; CONTACT-SPORTS; 2ND IMPACT; PERFORMANCE; COLLEGIATE; SEVERITY; DURATION; SYMPTOMS; MILD	Objective: To assess predictive value of concussion signs and symptoms based on return-to-play timelines. Design: Physician practice study without diagnosis that includes presentation, initial and subsequent treatment, and management of concussion. Setting: National multisite primary care sports medicine provider locations. Participants: Twenty-two providers at 18 sites; 101 athletes (91 men, 10 women in the following sports: 73 football, 8 basketball, 8 soccer, 3 wrestling, 2 lacrosse, 2 skiing, 5 others; 51 college, 44 high school, 4 professional, and 2 recreational). Main Outcome Measurements: Duration of symptoms, presence of clinical signs, and time to return to play following concussion. Results: One hundred one concussions were analyzed. Pearson chi(2) analysis of common early and late concussion symptoms revealed statistical significance (P < 0.05) of headache > 3 hours, difficulty concentrating > 3 hours, any retrograde amnesia or loss of consciousness, and return to play > 7 days. There appeared to be a trend in patients with posttraumatic amnesia toward poor outcome, but this was not statistically significant. Conclusions: When evaluating concussion, symptoms of headache > 3 hours, difficulty concentrating > 3 hours, retrograde amnesia, or loss of consciousness may indicate a more severe injury or prolonged recovery; great caution should be exercised before returning these athletes to play.	DeWitt Army Community Hosp, Dept Family Practice, Ft Belvoir, VA 22060 USA; Indiana Univ, Ctr Sports Med, Sch Med, Indianapolis, IN 47405 USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA		Asplund, CA (corresponding author), 5663 Marshall Rd, Ft Belvoir, VA 22060 USA.	chad.asplund@us.army.mil					CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; Long C J, 1983, Psychiatr Med, V1, P35; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory P, 1997, PHYSICIAN SPORTSMED, V25, P33, DOI 10.3810/psm.1997.02.1133; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	31	63	63	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2004	14	6					339	343		10.1097/00042752-200411000-00003			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	943BZ	WOS:000230328100003	15523205				2022-02-06	
J	Read, KM; Kufera, JA; Dischinger, PC; Kerns, TJ; Ho, SM; Burgess, AR; Burch, CA				Read, KM; Kufera, JA; Dischinger, PC; Kerns, TJ; Ho, SM; Burgess, AR; Burch, CA			Life-altering outcomes after lower extremity injury sustained in motor vehicle crashes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						lower extremity injury; psychosocial consequences; motor vehicle crash; outcomes; traumatic brain injury	MULTIPLE TRAUMA; DEPRESSION; ALCOHOLISM; RECOVERY; IMPACT; COSTS; SF-36; CAGE	Background. Lower extremity injuries (LEIs) sustained in vehicular crashes result in physical problems and unexpected psychosocial consequences. Their significance is diminished by low Abbreviated Injury Scale scores. Methods:. Drivers who sustained LEIs were identified as part of the Crash Injury Research and Engineering Network (CIREN) and interviewed during hospitalization, at 6 months, and at 1 year. All were occupants of newer vehicles with seatbelts and airbags. Results: Sixty-five patients were followed for 1 year. Injuries included mild brain injury (43%), ankle/foot fractures (55%), and bilateral injuries (37%). One year post-injury, 46% reported limitations in walking and 22% with ankle/foot fractures were unable to return to work. Depression (39%), cognitive problems (32%), and post-traumatic stress disorder (18%) were significant in the mild brain injury group. Conclusions. Long-lasting physical and psychological burdens may impede recovery and alter the lifestyle of patients with LEI. These issues need to be addressed by trauma center personnel.	Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, MSW, Baltimore, MD 21201 USA		Read, KM (corresponding author), Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, MSW, 701 W Pratt St,5th Floor, Baltimore, MD 21201 USA.	kread@som.umaryland.edu					Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Blanchard E. B., 1997, CRASH ASSESSMENT TRE; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Convit A, 2003, P NATL ACAD SCI USA, V100, P2019, DOI 10.1073/pnas.0336073100; DISCHINGER P, 1994, P INJ PREV BIOM S WA, P29; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; DISCHINGER PC, 1995, ACCIDENT ANAL PREV, V27, P601, DOI 10.1016/0001-4575(95)00002-H; DISCHINGER PC, 1994, SAE INT, P11; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Goldberg R J, 1993, R I Med, V76, P391; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Joint Commission on Accreditation of Health- care Organizations, 2000, PAIN ASS MAN ORG APP; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Loo GT, 1996, J TRAUMA, V41, P935, DOI 10.1097/00005373-199612000-00001; MacKenzie EJ, 2000, J ORTHOP TRAUMA, V14, P455, DOI 10.1097/00005131-200009000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MCCLURE R, 2000, P 3 INT C MEAS BURD; Nesse RE, 1996, AM FAM PHYSICIAN, V53, P2125; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; Soderstrom CA, 1997, J TRAUMA, V43, P962, DOI 10.1097/00005373-199712000-00017; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; *US DEP TRANSP, 2001, EFF OCC PROT SYSTM T; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; 2000, DIAGNOSTIC STAT MAN, P463; 2000, INT CLASSIFICATION D	29	63	64	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2004	57	4					815	823		10.1097/01.TA.0000136289.15303.44			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	871EN	WOS:000225112300026	15514536				2022-02-06	
J	Ehrlich, PF; Seidman, PS; Atallah, O; Haque, A; Helmkamp, J				Ehrlich, PF; Seidman, PS; Atallah, O; Haque, A; Helmkamp, J			Endotracheal intubations in rural pediatric trauma patients	JOURNAL OF PEDIATRIC SURGERY			English	Article						endotracheal intubation; prehospital intubation; pediatric trauma	ADVANCED LIFE-SUPPORT; PREHOSPITAL CARE; CHILDREN; EPIDEMIOLOGY; STATE; SYSTEM; INJURY; SCOOP; TRIAL; DEATH	Background/Purpose: Evidence from urban trauma centers questions the efficacy of pediatric field endotracheal intubations (ETIs). It is recognized that in the rural environment, discovery, transport delays, and a paucity of pediatric expertise contribute to higher pediatric trauma mortality rates compared with urban environments. The purpose of our study was to determine the effectiveness of field ETI in rural pediatric trauma patients. Methods: ETI attempts (field, referring hospital, trauma center [TC]) in trauma patients less than 19 years old were included. Prehospital and TC charts, including demographics, injury mechanism, indication, location, person performing, number of attempts, Glascow Coma Scale (GCS), complications from ETI, and outcome, were assessed. losing airway control (37%), closed head injury (36.1%), respiratory rate less than 10 or greater than 40 (11.2%), cardiopulmonary arrest (6.5%), respiratory arrest (4.6%), and airway obstruction 4.6%. Only 9.3% of children could not be oxygenated or ventilated by bag valve mask (BVM) before ETI. Twenty-three percent had complications directly related to ETI leg, aspiration). The relative risk of an airway complication was 2.5x higher with more then one ETI attempt (P<.05). Four percent of the airway complications occurred in TC, 29% (transferring hospital) and 66% (field, P<.05), respectively. Airway complications and multiple ETIs were associated with transport delay, lower GCS, longer hospital stay, and lower discharge GCS (P<.001) but independent of injury severity score, sex, age, and survival (P>.05). Results: Between 1991 and 2000, 105 of 2,907 patients met study criteria. Paramedics, trauma flight nurses (field ETIs), emergency physicians, surgeons, and anesthesiologists performed the ETI. One hundred fiftyfive ETIs (1 to 6 per patient) were attempted in 105 children. Fifty-seven percent of the ETIs were attempted in the field, 22% in transferring hospital, and 21% at the TC. Successful intubation on first attempt was 67% (field), 69% (referring hospital), and 95% (TC). Subsequent ETI attempts had failure rates of 50% (field) and 0% (referring hospital, TC). Indication for ETI included fear of. Conclusions: Multiple ETI attempts are associated with significant complications and may offer limited advantage over BVM and possibly may affect outcome. Indications for field intubations may require review especially in rural pediatric trauma. (C) 2004 Elsevier Inc. All rights reserved.	W Virginia Univ, Sch Med, Dept Pediat Surg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Anesthesia, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Ctr Rural Emergency Med, Morgantown, WV 26506 USA		Ehrlich, PF (corresponding author), Univ Michigan, CS Mott Childrens Hosp, F-3970,1500 E Med Ctr Dr,POB 0245, Ann Arbor, MI 48109 USA.						*AM COLL RHEUM, 1998, RHEUM PRINC CAR PHYS, P1; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S; CAYTEN CG, 1993, J TRAUMA, V35, P460, DOI 10.1097/00005373-199309000-00021; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; DAVIS DP, 2002, ANN M AM ASS SURG TR, V61, P104; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Ehrlich P F, 2002, W V Med J, V98, P66; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Glaeser P, 2000, JAMA-J AM MED ASSOC, V283, P797, DOI 10.1001/jama.283.6.797; GOLD CR, 1987, ANN EMERG MED, V16, P797, DOI 10.1016/S0196-0644(87)80578-4; Grossman DC, 1997, J TRAUMA, V42, P723, DOI 10.1097/00005373-199704000-00024; GROSSMAN DC, 1995, J TRAUMA, V38, P14, DOI 10.1097/00005373-199501000-00006; Hapgood R, 2001, Inj Prev, V7, P14, DOI 10.1136/ip.7.1.14; Hoyt DB, 2003, ANN SURG, V237, P161, DOI 10.1097/00000658-200302000-00002; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; Institute of Medicine (U.S.) . Committee on Pediatric Emergency Medical Services, 1993, EM MED SERV CHILDR; KATZ SH, 1998, ACAD EMERG MED, V5, P429; KRAUSZ MM, 1992, J TRAUMA, V33, P6, DOI 10.1097/00005373-199207000-00002; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; LOSEK J D, 1989, Pediatric Emergency Care, V5, P1, DOI 10.1097/00006565-198903000-00001; MATTOX KL, 1986, J TRAUMA, V26, P779, DOI 10.1097/00005373-198609000-00002; NAKAYAMA D, 1992, ANN SURG, V216, P201; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Parada MA, 2001, ACCIDENT ANAL PREV, V33, P139, DOI 10.1016/S0001-4575(00)00012-9; POTTER D, 1988, ANN EMERG MED, V17, P582, DOI 10.1016/S0196-0644(88)80397-4; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; RODGERS FB, 1999, J TRAUMA, V47, P802; Rogers FB, 2001, J TRAUMA, V50, P409, DOI 10.1097/00005373-200103000-00003; Sampalis JS, 1997, J TRAUMA, V43, P608, DOI 10.1097/00005373-199710000-00008; SANAKARAN K, 1985, ANN ROYAL COLL PHYS, V18, P135; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Smith GA, 1997, ANN EMERG MED, V29, P504, DOI 10.1016/S0196-0644(97)70224-5; STEWART RD, 1984, ANN EMERG MED, V13, P1032, DOI 10.1016/S0196-0644(84)80064-5; STRATTON SJ, 1991, ANN EMERG MED, V20, P1314, DOI 10.1016/S0196-0644(05)81073-X; Svenson JE, 1996, ANN EMERG MED, V27, P625, DOI 10.1016/S0196-0644(96)70167-1; Svenson JE, 1996, PEDIATR EMERG CARE, V12, P173, DOI 10.1097/00006565-199606000-00007; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006; VANE DW, 1993, J PEDIATR SURG, V28, P1295, DOI 10.1016/S0022-3468(05)80316-1	39	63	65	1	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	SEP	2004	39	9					1376	1380		10.1016/j.jpedsurg.2004.05.010			5	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	855HF	WOS:000223963300013	15359393				2022-02-06	
J	Brooks, BM; Rose, FD; Potter, J; Jayawardena, S; Morling, A				Brooks, BM; Rose, FD; Potter, J; Jayawardena, S; Morling, A			Assessing stroke patients' prospective memory using virtual reality	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; ENVIRONMENTS	There is a dearth of empirical evidence about prospective memory (remembering to perform actions in the future) in stroke patients. A probable reason for this is that it is difficult to perform a realistic and controlled assessment of prospective memory ability in a rehabilitation setting. Virtual reality may provide a solution to this difficulty by allowing prospective memory to be tested in a simulation of a real-life situation whilst retaining a laboratory level of scientific control. This exploratory study assessed the performance of stroke patients and age-matched control participants on event-, time- and activity-based prospective memory retrieval tasks in a personal computer-based virtual environment. Stroke patients were severely impaired at the event- and activity-based tasks compared with age-matched controls, but only marginally impaired at the time-based task. The additional knowledge gained from this form of assessment could direct rehabilitation more effectively towards specific impairments of individual patients.	Univ E London, Sch Psychol, London E15 4LZ, England; Kent & Canterbury Hosp, Stroke Rehabil Unit, Canterbury, Kent, England		Brooks, BM (corresponding author), Univ E London, Sch Psychol, London E15 4LZ, England.	b.m.brooks@uel.ac.uk					Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; DAVIES RC, 1998, P 2 EUR C DIS VIRT R, P61; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Maylor E. A., 1996, PROSPECTIVE MEMORY T, P173; Mendozzi L, 1998, CYBERPSYCHOL BEHAV, V1, P79; MORRIS RG, 2000, P INT C DIS VIRT REA, P189; NELSON HE, 1982, NATL ADULT READING; Rose D, 1999, PSYCHOLOGIST, V12, P550; Rose FD, 1999, DISABIL REHABIL, V21, P548; Titov N, 2000, BRAIN INJURY, V14, P877; WANN JP, 1997, VIRTUAL REALITY NEUR, P157; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	17	63	73	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2004	18	4					391	401		10.1080/02699050310001619855			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	765VB	WOS:000188304100005	14742152				2022-02-06	
J	Johnston, JJE; McGovern, SJ				Johnston, JJE; McGovern, SJ			Alcohol related falls: an interesting pattern of injuries	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; ETHANOL; LEVEL; RATS	Objective: To discover if there is a significant difference in the pattern and severity of injury sustained during falls in patients who have consumed alcohol and those who have not. To determine how pattern and severity of injury correlates with blood alcohol concentration. Method: A prospective quasi-randomised controlled study between November 2001 and July 2002. All healthy adults between 16 and 60 years who had fallen from standing height were included. A systematic history and examination permitted calculation of injury severity scores as per abbreviated injury scale update 1998. Blood alcohol concentrations were obtained from intoxicated patients with consent. Results: 351 healthy adult patients were included in the study, there were 238 in the no alcohol group, 113 had consumed alcohol and blood alcohol intake were obtained for 47. The alcohol group had a higher incidence of head injuries (46(48%) versus 22 (9%)) with a lower incidence of limb injuries (39 (39%) versus 183 (76%)) than the no alcohol group. There was a significant difference in the pattern of injury between the alcohol and no alcohol groups (chi(2), p<0.001) and there was a significant difference in the injury severity scores (p<0.001, Z=-2.5). In the alcohol group severity and pattern correlated with alcohol concentration at the time of injury. Patients with an alcohol concentration <2 g/l had mostly soft tissue limb injuries (58%), 2-2.5 mostly significant limb fractures (55%), and >2.5 mostly significant head injuries (90%). Conclusions: Alcohol related falls are more often associated with severe craniofacial injury. The severity of both limb and head injury is greater and correlates directly with blood alcohol concentration.	Ulster Hosp Dundonald, Dept Accid & Emergency, Belfast, Antrim, North Ireland		Johnston, JJE (corresponding author), Newcastle Gen Hosp, Dept Accid & Emergency, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	jeremyjejohnston@doctors.org.uk					*ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Cook L S, 1994, Acad Emerg Med, V1, P227; HINGSON R, 1993, ADDICTION, V88, P877, DOI 10.1111/j.1360-0443.1993.tb02105.x; HOLDFORD N, 1987, CLIN PHARMACOKINET, V13, P273; HONKANEN R, 1976, ANN CHIR GYNAECOL FE, V65, P287; HONKANEN R, 1990, INJURY, V21, P353, DOI 10.1016/0020-1383(90)90117-D; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kleemann Werner Johann, 1995, Blutalkohol, V32, P162; KNIGHT B, 1996, FORENSIC PATHOLOGY, P544; Roys MS, 2001, APPL ERGON, V32, P135, DOI 10.1016/S0003-6870(00)00049-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Tate PS, 1999, BRAIN INJURY, V13, P767; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	16	63	65	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	MAR 1	2004	21	2					185	188		10.1136/emj.2003.006130			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	778TB	WOS:000189255900014	14988344	Green Published, Bronze			2022-02-06	
J	Gates, MA; Coupe, VM; Torres, EM; Fricker-Gates, RA; Dunnett, SB				Gates, MA; Coupe, VM; Torres, EM; Fricker-Gates, RA; Dunnett, SB			Spatially and temporally restricted chemoattractive and chemorepulsive cues direct the formation of the nigro-striatal circuit	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						substantia nigra; dopamine neurons; rat; axon guidance; Parkinson's disease	LATERAL GANGLIONIC EMINENCE; AXON GUIDANCE; C-ELEGANS; DOPAMINE NEURONS; FIBER OUTGROWTH; SONIC HEDGEHOG; OPTIC TECTUM; CELL; MIDLINE; DROSOPHILA	Identifying cellular and molecular mechanisms that direct the formation of circuits during development is thought to be the key to reconstructing circuitry lost in adulthood to neurodegenerative disorders or common traumatic injuries. Here we have tested whether brain regions situated in and around the developing nigro-striatal pathway have particular chemoattractive or chemorepulsive effects on mesencephalic dopamine axons, and whether these effects are temporally restricted. Mesencephalic explants from embryonic day (E)12 rats were either cultured alone or with coexplants from the embryonic, postnatal or adult medial forebrain bundle region (MFB), striatum, cortex, brain stem or thalamus. Statistical analysis of axon growth responses revealed a potent chemoattraction to the early embryonic MFB (i.e. E12-15) that diminished (temporally) in concert with the emergence of chemoattraction to the striatum in the late embryonic period (i.e. E19+). Repulsive responses by dopaminergic axons were obvious in cocultures with embryonic brain stem and cortex, however, there was no effect by the thalamus. Such results suggest that the nigro-striatal circuit is formed via spatially and temporally distributed chemoattractive and chemorepulsive elements that: (i) orientate the circuit in a rostral direction (via brain stem repulsion); (ii) initiate outgrowth (via MFB attraction); (iii) prevent growth beyond the target region (via cortical repulsion); and (iv) facilitate target innervation (via striatal chemoattraction). Subsequent studies will focus on identifying genes responsible for these events so that their products may be exploited to increase the integration of neuronal transplants to the mature brain, or provide a means to (re)establish the nigro-striatal circuit in vivo.	Cardiff univ, Sch Biosci, Brain Repair Grp, Cardiff CF10 3US, S Glam, Wales		Gates, MA (corresponding author), Cardiff univ, Sch Biosci, Brain Repair Grp, Cardiff CF10 3US, S Glam, Wales.	gatesma@cf.ac.uk	Dunnett, Stephen B/A-5869-2010; Fricker, Gert/N-4157-2018	Dunnett, Stephen B/0000-0003-1826-1578; Fricker, Gert/0000-0003-3894-961X			Battye R, 1999, DEVELOPMENT, V126, P2475; Bayer S.A., 1991, NEOCORTICAL DEV; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; BRUNDIN P, 1986, DEV BRAIN RES, V24, P77, DOI 10.1016/0165-3806(86)90174-4; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; COSTANTINI LC, 1994, EXP NEUROL, V127, P219, DOI 10.1006/exnr.1994.1098; Coupe VM, 2002, EXP NEUROL, V175, P432; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; EmgardMattson M, 1997, CELL TRANSPLANT, V6, P277, DOI 10.1016/S0963-6897(97)00038-9; Friedman GC, 1996, J NEUROSCI, V16, P5498; Gates M A, 2000, Prog Brain Res, V127, P115; Gates MA, 1998, NEUROSCIENCE, V84, P1013, DOI 10.1016/S0306-4522(97)00512-5; Gates MA, 1996, J NEUROSCI, V16, P8005; Haque NSK, 1996, BRAIN RES, V712, P45, DOI 10.1016/0006-8993(95)01427-6; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Irving C, 2002, DEVELOPMENT, V129, P5389, DOI 10.1242/dev.00117; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Keleman K, 2002, CELL, V110, P415, DOI 10.1016/S0092-8674(02)00901-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Laywell ED, 1996, J NEUROSCI METH, V66, P99, DOI 10.1016/0165-0270(96)00008-8; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MOLNAR Z, 1995, TRENDS NEUROSCI, V18, P389, DOI 10.1016/0166-2236(95)93935-Q; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nakamura S, 2000, J NEUROSCI, V20, P4112; Ohtani N, 2003, J NEUROSCI, V23, P2840; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rosenblad C, 1996, NEUROSCIENCE, V75, P979; SAUER H, 1993, BRAIN RES, V626, P37, DOI 10.1016/0006-8993(93)90560-A; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Sinclair SR, 1996, NEUROREPORT, V7, P2547, DOI 10.1097/00001756-199611040-00029; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Super H, 1998, BRAIN RES REV, V27, P40, DOI 10.1016/S0165-0173(98)00005-8; Tanaka A, 2001, BRAIN RES, V912, P105, DOI 10.1016/S0006-8993(01)02726-3; Trousse F, 2001, DEVELOPMENT, V128, P3927; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011; YUREK DM, 1990, EXP NEUROL, V109, P191, DOI 10.1016/0014-4886(90)90073-2; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213; ZHOU HF, 1992, J COMP NEUROL, V317, P145, DOI 10.1002/cne.903170204; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	47	63	67	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2004	19	4					831	844		10.1111/j.1460-9568.2004.03213.x			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803TE	WOS:000220252600005	15009130				2022-02-06	
J	Currier, BL; Todd, LT; Maus, TP; Fisher, DR; Yaszemski, MJ				Currier, BL; Todd, LT; Maus, TP; Fisher, DR; Yaszemski, MJ			Anatomic relationship of the internal carotid artery to the C1 vertebra: A case report of cervical reconstruction for chordoma and pilot study to assess the risk of screw fixation of the atlas	SPINE			English	Article; Proceedings Paper	Meeting of the European Section of the Cervical-Spine-Research-Society	JUN, 2002	PARIS, FRANCE	Cerv Spine Res Soc, European Sect		internal carotid artery injury; atlantoaxial transarticular screws; C1 lateral mass screws; atlantoaxial fusion; preoperative computed tomography	ATLANTOAXIAL ARTHRODESIS; TRANSARTICULAR SCREWS; C1-C2 FUSION; SPINE; PLACEMENT; ACCURACY; INJURY	Study Design. A case of internal carotid artery impingement by the tip of a well- positioned C1 - C2 transarticular screw is presented along with a pilot study involving radiologic and anatomic evaluation of human cadaveric specimens. Objective. To raise awareness that the internal carotid artery may be in close proximity to the anterior aspect of the atlas and at risk of injury during placement of C1 - C2 transarticular screws or C1 lateral mass screws. Summary of Background Data. To our knowledge, no cases of internal carotid artery injury or impingement have been reported with screw fixation of the atlas. Methods. A case of internal carotid artery impingement by a C1 - C2 transarticular screw is presented. The C1 - C2 rotation appeared to place the internal carotid artery in the path of the screw, prompting a pilot study. Three fresh- frozen human cadaveric head and neck specimens were fixed in different degrees of rotation. Thinsection computed tomography of the specimens was obtained in the plane of the atlas. The frozen specimens were sectioned in the same plane as the computed tomography images. Measurements were taken to assess the location of the internal carotid artery relative to the anterior aspect of the atlas. Results. Cervical rotation does not have a predictable effect on the location of the internal carotid artery. Medial angulation of a screw placed in the lateral mass of C1 appears to increase the margin of safety for the internal carotid artery. The internal carotid artery varies in location and may be within 1 mm of the ideal exit point of a bicortical transarticular screw or a C1 lateral mass screw. Conclusions. The internal carotid artery is at risk during bicortical screw fixation of the atlas. We recommend a contrast- enhanced computed tomography to assess the location of the internal carotid artery before screw fixation of the atlas.	Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Radiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Anat, Rochester, MN 55905 USA		Currier, BL (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped Surg, 200 1st St SW, Rochester, MN 55905 USA.						ABOU MA, 1997, J BONE JOINT SURG BR, V79, P820; Apfelbaum Ronald I., 1994, Contemporary Neurosurgery, V16, P1; Bloch O, 2001, J NEUROSURG, V95, P74, DOI 10.3171/spi.2001.95.1.0074; Casey ATH, 1997, BRIT J NEUROSURG, V11, P508; CHRISTENSEN DM, 2000, 28 ANN M CERV SPIN R; Coric D, 1996, J NEUROSURG, V85, P340, DOI 10.3171/jns.1996.85.2.0340; DICKMAN CA, 1995, J NEUROSURG, V83, P248, DOI 10.3171/jns.1995.83.2.0248; Dickman CA, 1998, NEUROSURGERY, V43, P275, DOI 10.1097/00006123-199808000-00056; DULL ST, 1995, NEUROSURGERY, V37, P150, DOI 10.1227/00006123-199507000-00026; Ebraheim NA, 2000, SURG NEUROL, V53, P208, DOI 10.1016/S0090-3019(00)00160-9; Eleraky MA, 1998, J NEUROSURG, V89, P8, DOI 10.3171/jns.1998.89.1.0008; Farey ID, 1999, CLIN ORTHOP RELAT R, P126, DOI 10.1097/00003086-199902000-00013; Gebhard JS, 1998, SPINE, V23, P2185, DOI 10.1097/00007632-199810150-00008; Goel A, 1999, J NEUROSURG, V90, P376; Grant J. C. B., 1972, GRANTS ATLAS ANATOMY; GROB D, 1992, SPINE, V17, P480, DOI 10.1097/00007632-199205000-00003; GROB D, 1991, J BONE JOINT SURG BR, V73, P972, DOI 10.1302/0301-620X.73B6.1955447; Haid RW, 2001, NEUROSURGERY, V49, P65, DOI 10.1097/00006123-200107000-00010; Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014; Henriques T, 2000, SPINE, V25, P2877, DOI 10.1097/00007632-200011150-00007; JEANNERET B, 1992, J SPINAL DISORD, V5, P464, DOI 10.1097/00002517-199212000-00012; Jun BY, 1998, SPINE, V23, P1703, DOI 10.1097/00007632-199808010-00018; Kawaguchi Yoshiharu, 2002, J Orthop Sci, V7, P131, DOI 10.1007/s776-002-8434-y; Kazan S, 2000, CLIN ANAT, V13, P237, DOI 10.1002/1098-2353(2000)13:4<237::AID-CA2>3.0.CO;2-K; Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961; Magerl F, 1987, CERVICAL SPINE, P322; Mandel IM, 2000, SPINE, V25, P1542, DOI 10.1097/00007632-200006150-00014; McGraw R W, 1973, J Bone Joint Surg Br, V55, P482; Mitchell TC, 1999, J ORTHOP TRAUMA, V13, P483, DOI 10.1097/00005131-199909000-00004; Naderi S, 1998, SPINE, V23, P1946, DOI 10.1097/00007632-199809150-00005; Nishimura K, 1996, AM J ROENTGENOL, V166, P219, DOI 10.2214/ajr.166.1.8571894; OSGUTHORPE JD, 1981, OTOLARYNG HEAD NECK, V89, P758, DOI 10.1177/019459988108900513; Paramore CG, 1996, J NEUROSURG, V85, P221, DOI 10.3171/jns.1996.85.2.0221; PICCIARDELLI E, 1989, ARCH OTOLARYNGOL, V115, P519; Prabhu VC, 2001, SURG NEUROL, V55, P29, DOI 10.1016/S0090-3019(00)00338-4; SASSO RC, 1994, SPINE, V19, P2364, DOI 10.1097/00007632-199410150-00021; Song GS, 1997, J NEUROSURG, V87, P851, DOI 10.3171/jns.1997.87.6.0851; Welch WC, 1997, NEUROSURGERY, V40, P958, DOI 10.1097/00006123-199705000-00016; Wright NM, 1998, J NEUROSURG, V88, P634, DOI 10.3171/jns.1998.88.4.0634	39	63	70	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	NOV 15	2003	28	22					E461	E467		10.1097/01.BRS.0000092385.19307.9E			7	Clinical Neurology; Orthopedics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	744QD	WOS:000186642800013	14624095				2022-02-06	
J	Pilitsis, JG; Coplin, WM; O'Regan, MH; Wellwood, JM; Diaz, FG; Fairfax, MR; Michael, DB; Phillis, JW				Pilitsis, JG; Coplin, WM; O'Regan, MH; Wellwood, JM; Diaz, FG; Fairfax, MR; Michael, DB; Phillis, JW			Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						cerebral trauma; free fatty acids; phospholipases; patient outcome	RAT; LACTATE; CORTEX; DAMAGE	Free fatty acid (FFA) concentrations in cerebrospinal fluid (CSF) are recognized as markers of brain damage in animal studies. There is, however, relatively little information regarding FFA concentrations in human CSF in normal and pathological conditions. The present study examined FFA concentrations in CSF from 15 patients with traumatic brain injury (TBI) and compared the data with values obtained from 73 contemporary controls. Concentrations of specific FFAs from TBI patients, obtained within 48 It of the insult were significantly greater than those in the control group (arachidonic, docosahexaenoic and myristic, P < 0.001; oleic, palmitic, P < 0.01; linoleic, P < 0.05). Higher concentrations of total polyunsaturated fatty acids (P < 0.001) and of arachidonic, myristic and palmitic acids measured individually in CSF (P < 0.01) obtained I week after the insult were associated with a worse outcome at the time of hospital discharge using the Glasgow Outcome Scale. This preliminary investigation suggests that CSF FFA concentrations may be useful as a predictive marker of outcome following TBI. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Univ Detroit Mercy, Sch Dent, Dept Biomed Sci, Detroit, MI 48219 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA		Phillis, JW (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 5374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS38905] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038905] Funding Source: NIH RePORTER		Carman HM, 1998, BRAIN RES, V808, P116, DOI 10.1016/S0006-8993(98)00824-5; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pilitsis JG, 2001, NEUROCHEM RES, V26, P1265, DOI 10.1023/A:1014227231130; Saluja I, 1999, NEUROCHEM RES, V24, P669, DOI 10.1023/A:1021004525979; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	11	63	64	0	5	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 2	2003	349	2					136	138		10.1016/S0304-3940(03)00803-6			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	720ZT	WOS:000185293100017	12946571				2022-02-06	
J	Tuzson, AE; Granata, KP; Abel, MF				Tuzson, AE; Granata, KP; Abel, MF			Spastic velocity threshold constrains functional performance in cerebral palsy	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	7th Annual Meeting of the Gait-and-Clinical-Movement-Analysis-Society	APR 17-20, 2002	CHATTANOOGA, TENNESSEE	Gait & Clin Movement Anal Soc		cerebral palsy; gait; muscle spasticity; rehabilitation	MODIFIED ASHWORTH SCALE; STRETCH REFLEX THRESHOLD; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; MUSCLE SPASTICITY; MOVEMENT; RELIABILITY; EXCITABILITY; CHILDREN; ELBOW	Objectives: To evaluate a quantitative, velocity-based assessment of spasticity in the quadriceps and hamstrings muscles of children with cerebral palsy (CP) and to show the effects of spasticity in constraining knee velocities during fast gait. Design: A quantitative comparison of neuromuscular and biomechanical performance in patients with CP and controls without CP. Setting: Movement analysis laboratory within a university clinical referral center. Participants: A convenience sample of 18 ambulatory patients with CP and 11 control subjects without CP. Interventions: Not applicable. Main Outcome Measures: Spastic threshold velocity recorded from electromyographic response during passive isovelocity knee movement was compared with knee angular velocity during fast walking, Gross Motor Function Measure (GMFM) scores. and Ashworth Scale score. Results: Patients with measurable spasticity showed slower peak knee angular velocity during walking than patients without spasticity (P<.005). A significant correlation existed between spastic threshold velocity and peak knee angular velocity during fast walking (r=.85, P<.001). Spastic threshold velocity correlated significantly with GMFM (r=.58, P<.05) but not with Ashworth score. Conclusions: The velocity dependency of spasticity can be measured by electromyograph and dynamometer to determine spastic threshold velocity. Spastic threshold velocity correlated with limitations in joint angular velocity during walking and functional performance.	Univ Virginia, Kluge Childrens Rehabil Ctr, Mot Anal & Motor Performance Lab, Charlottesville, VA USA		Granata, KP (corresponding author), Virginia Polytech Inst & State Univ, Dept Engn Sci & Mech, Musculoskeletal Biomech Lab, 219 Norris Hall 0219, Blacksburg, VA 24061 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA092680] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-99-006-02, R24 HD039631-050001] Funding Source: Medline		Abel MF, 1996, J PEDIATR ORTHOPED, V16, P753, DOI 10.1097/01241398-199611000-00010; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; BERMAN B, 1990, AM J OCCUP THER, V44, P511, DOI 10.5014/ajot.44.6.511; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CAMPBELL SK, 1992, DIPLEGIC CHILD : EVALUATION AND MANAGEMENT, P221; CORCOS DM, 1986, BRAIN, V109, P1043, DOI 10.1093/brain/109.5.1043; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P112, DOI 10.1017/S0012162201001761; Engsberg JR, 1996, ARCH PHYS MED REHAB, V77, P594, DOI 10.1016/S0003-9993(96)90301-9; FELLOWS SJ, 1994, ANN NEUROL, V36, P397, DOI 10.1002/ana.410360311; GOLDKAMP O, 1984, ARCH PHYS MED REHAB, V65, P232; Haas BM, 1996, SPINAL CORD, V34, P560, DOI 10.1038/sc.1996.100; Jobin A, 2000, DEV MED CHILD NEUROL, V42, P531, DOI 10.1017/S0012162200001018; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KNUTSSON E, 1980, SCAND J REHABIL MED, V12, P93; KUMAN KC, 1994, NEW ENGL J MED, V330, P188; LANCE JW, 1980, NEUROLOGY, V30, P1303, DOI 10.1212/WNL.30.12.1303; LEVIN MF, 1994, BRAIN RES, V657, P23, DOI 10.1016/0006-8993(94)90949-0; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P116; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P290; Malouin F, 1997, SCAND J REHABIL MED, V29, P147; MCGEER T, 1990, INT J ROBOT RES, V9, P68, DOI DOI 10.1177/027836499000900206); Pandyan AD, 2001, CLIN BIOMECH, V16, P859, DOI 10.1016/S0268-0033(01)00084-5; PARK TS, 1992, NEW ENGL J MED, V326, P745; Phillips CA, 1997, COMPUT BIOL MED, V27, P309, DOI 10.1016/S0010-4825(97)00007-3; Priebe MM, 1996, ARCH PHYS MED REHAB, V77, P713, DOI 10.1016/S0003-9993(96)90014-3; ROSEN MG, 1992, AM J OBSTET GYNECOL, V167, P417, DOI 10.1016/S0002-9378(11)91422-7; Russell, 1993, GROSS MOTOR FUNCTION; THILMANN AF, 1991, BRAIN, V114, P233	30	63	64	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2003	84	9					1363	1368		10.1016/S0003-9993(03)00199-0			6	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	718WT	WOS:000185170000017	13680575	Green Accepted			2022-02-06	
J	Francisco, GE; Boake, C				Francisco, GE; Boake, C			Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: A preliminary study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	North American Stroke Meeting	AUG 15-18, 2001	SAN DIEGO, CA			cerebrovascular accident; drug therapy; muscle spasticity; rehabilitation; walking	UPPER EXTREMITY SPASTICITY; TRAUMATIC BRAIN-INJURY; BOTULINUM TOXIN; MOTOR CONTROL; STROKE; GAIT; HYPERTONIA; RECOVERY; INFUSION; TIZANIDINE	Objective: To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors. Design: Case series. Setting: Tertiary care center. Participants: Ten adults with poststroke hemiparesis who were ambulatory at the time of pump implantation. Interventions: Implantation of ITB pump after inadequate control of spasticity with other interventions. Time from stroke onset to implantation averaged 28.6 months (range, 9-55mo). Main Outcome Measures: Customary walking speed was measured from the time required to walk 50ft (15m) at a self-selected pace. Evaluators rated spastic hypertonia and functional mobility. Results: Statistically significant improvements occurred in walking speed, functional mobility ratings, and spasticity (P<.05) at a follow-up interval that averaged 8.9 months. Mean walking speed over 50ft improved from 36.6 to 52cm/s. Mean Modified Ashworth Scale scores in the muscles of the affected lower limb improved from 2.0 to 0.4. Normal muscle strength (5/5) was preserved in the unaffected limbs. Conclusions: This preliminary study suggests that ITB therapy, in combination with physical therapy, may improve walking speed and functional mobility in ambulatory individuals with poststroke spastic hemiplegia. (C) 2003 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Houston, TX USA; Inst Rehabil & Res, Houston, TX USA		Francisco, GE (corresponding author), 1333 Moursund, Houston, TX 77030 USA.	francg@tirr.tmc.edu					ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; [Anonymous], 1997, GUID UN DAT SET MED; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Francisco GE, 2002, AM J PHYS MED REHAB, V81, P355, DOI 10.1097/00002060-200205000-00007; FRANCISCO GE, 2001, ARCH PHYS MED REHAB, V82, pA1335; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; Gerszten PC, 1997, PEDIATR NEUROSURG, V27, P40, DOI 10.1159/000121223; Hal KM, 1997, J REHABILITATION OUT, V1, P63; Hesse S, 1996, STROKE, V27, P455, DOI 10.1161/01.STR.27.3.455; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; KNUTSSON E, 1979, BRAIN, V102, P405, DOI 10.1093/brain/102.2.405; Lamontagne A, 2001, ARCH PHYS MED REHAB, V82, P1696, DOI 10.1053/apmr.2001.26810; LATASH ML, 1990, J NEUROSURG, V72, P388, DOI 10.3171/jns.1990.72.3.0388; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; RICHARDS CL, 1996, GAIT POSTURE, V4, P149; RICHARDS CL, 1995, GAIT ANAL THEORY APP, P355; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Sylvester A, 2001, NEUROLOGY, V56, pA26; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; [No title captured]	34	63	67	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1194	1199		10.1016/S0003-9993(03)00134-5			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000015	12917859				2022-02-06	
J	Zazryn, TR; Finch, CF; McCrory, P				Zazryn, TR; Finch, CF; McCrory, P			A 16 year study of injuries to professional boxers in the state of Victoria, Australia	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BOXING INJURIES	Objectives: Concerns about the significant injury risks in boxers have been well documented. To inform the continuing debate, updated information about the risk of injury for participants, and suitable means of modifying or preventing these risks, need to be identified. Methods: Data describing all professional boxing fight outcomes and injuries sustained during competition, from August 1985 to August 2001, were obtained from the Victorian Professional Boxing and Combat Sports Board. Results: A total of 107 injuries were recorded from 427 fight participations, corresponding to an injury rate of 250.6 injuries per 1000 fight participations. The most commonly injured body region was the head/neck/face (89.8%), followed by the upper extremities (7.4%). Specifically, injuries to the eye region (45.8%) and concussion (15.9%) were the most common. About three quarters of all injuries were lacerations/open wounds or superficial. No information was available on the mechanism of injury. Conclusions: Future research should collect information on the mechanism of injury, as this is crucial for the development and implementation of effective injury prevention strategies. A suggested boxing injury report form is provided to facilitate this.	Monash Univ, Sch Med, Alfred Hosp, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia		Finch, CF (corresponding author), Monash Univ, Sch Med, Alfred Hosp, Dept Epidemiol & Prevent Med, Commercial Rd, Prahran, Vic 3181, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR SPORTS INJ, 1997, AUSTR SPORTS INJ DAT; Boxing Jordan B, 1996, EPIDEMIOLOGY SPORTS, P113; *BRIT MED ASS, 2002, BOX DEB; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; FINCH C, 1997, SPORTSAFE AUSTR NATL; GIOVINAZZO VJ, 1987, OPHTHALMOLOGY, V94, P587; JORDAN BD, 1990, PHYSICIAN SPORTSMED, V18, P81, DOI 10.1080/00913847.1990.11709974; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; MCCRORY P, 2001, CLIN SPORTS MED, P189; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; *NAT HLTH MED RES, 1994, BOX INJ, P38; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; SCOTT I, 2002, COUNTING INJURIES OU; WELCH MJ, 1986, PHYSICIAN SPORTSMED, V14, P81, DOI 10.1080/00913847.1986.11709169	17	63	67	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG 1	2003	37	4					321	324		10.1136/bjsm.37.4.321			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	706VB	WOS:000184474800013	12893717	Bronze, Green Published			2022-02-06	
J	Wennersten, A; Holmin, S; Mathiesen, T				Wennersten, A; Holmin, S; Mathiesen, T			Characterization of Bax and Bcl-2 in apoptosis after experimental traumatic brain injury in the rat	ACTA NEUROPATHOLOGICA			English	Article						Bax; Bcl-2; apoptosis; brain injury; trauma	INTRACEREBRAL INFLAMMATORY RESPONSE; CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; HEAD-INJURY; IN-VIVO; NEURONS; ISCHEMIA; OVEREXPRESSION; CONTUSIONS	This study was undertaken to fulfill the need for additional data on the dynamics of Bax and Bcl-2 expression in conjunction to the cell death that ensues following experimental brain contusion. Adult Sprague-Dawley rats were subjected to a unilateral experimental controlled cortical contusion and killed at 1, 2, 4, 6 and 10 days post injury (dpi). Cell death was examined by the terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) method together with immunohistochemistry for cellular markers. Expression of Bax and Bcl-2 were analyzed by immunohistochemistry and in situ hybridization. The number of TUNEL-positive cells was highest at 1 dpi and decreased with time. At all time points, 10-16% of the TUNEL-positive cells showed an apoptotic nuclear morphology. The apoptotic features were restricted to neurons and some inflammatory cells. Immunohistochemistry for Bax revealed a translocation of Bax from a diffuse to a granular distribution in neurons. An up-regulation of Bax mRNA at 6 dpi was discernible. This increase was associated with a statistically significant increase in number of cells with up-regulated and translocated Bax protein. Moreover, a statistically significant increase of Bcl-2 mRNA was detected at 10dpi. The potential window for antiapoptotic treatment to salvage neurons is wide. The susceptibility of neurons to necrosis and apoptosis through different pathways during a prolonged post-traumatic period indicate that different pharmacological strategies may be required at different time points after trauma.	Karolinska Inst, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden		Mathiesen, T (corresponding author), Karolinska Inst, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden.		mathiesen, tiit/ABC-3627-2021	Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070	46	63	73	0	5	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2003	105	3					281	288		10.1007/s00401-002-0649-y			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	652BN	WOS:000181359800013	12557016				2022-02-06	
J	Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V				Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V			Serum S-100B protein as a molecular marker in severe traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	International Symposium on Molecular Markers of Brain Damage - Current State and Future Perspectives	JUN 13-15, 2002	BREMEN, GERMANY			S-100 protein; severe head injury; prognosis; outcome	SEVERE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; CARDIAC-SURGERY; NEUROBIOCHEMICAL MARKERS; OUTCOME PREDICTION; CEREBRAL-ISCHEMIA; DAMAGE MARKERS; S100B PROTEIN; ACUTE STROKE; RELEASE	Purpose: There is growing evidence that S-100B protein may be used as a novel biochemical marker of brain cell damage. measured by a simple blood test. In this paper, we summarize the current knowledge about S-100B serum measurements in severe head injury and address actual controversies. Methods: The material of the present analysis consists of a MEDLINE literature search for S-100 and severe head injury from 1966 to 2003. Studies of S-100B in severe head injury were reviewed for their information about the potential clinical value of this marker. Results: A total of 18 clinical studies were identified and reviewed. Peak values of serum S-100B were demonstrated to have the highest correlation to any endpoint parameter. Admission values also have a significant correlation to injury severity and outcome but show a highly time dependent temporal course. There is extracranial release of S-100B in multitrauma patients in the first 48 hours, but the impact is limited as many studies have found a clear relationship between S-100B and injury severity, imaging findings and outcome. Conclusion: S-100B belongs to a new generation of molecular serum markers of brain damage. These markers will have potential as a surrogate outcome marker or monitoring parameters for both clinical and experimental settings.			Raabe, A (corresponding author), Univ Frankfurt, Dept Neurosurg, Neuroctr, Schleusenweg 2-16, D-60528 Frankfurt, Germany.						Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Bottiger BW, 2001, CIRCULATION, V103, P2694; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ikeda Y, 2001, NEUROSURG QUART, V11, P173, DOI 10.1097/00013414-200109000-00001; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; INGEBRIGTSEN T, IN PRESS BRAIN INJ; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; Marmarou A, 2000, ACT NEUR S, V76, P349; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	40	63	69	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2003	21	3-4					159	169					11	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745LV	WOS:000186690900008	14530578				2022-02-06	
S	Skaper, SD		Slikker, W; Andrews, RJ; Trembly, B		Skaper, SD			Poly(ADP-ribose) polymerase-1 in acute neuronal death and inflammation - A strategy for neuroprotection	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	6th International Conference on Neuroprotective Agents	SEP 15-19, 2002	HILTON HEAD ISL, SC			poly(ADP-ribose) polymerase; DNA repair; neurotoxicity; cerebral ischemia; neurodegeneration; neuroinflammation; neuroprotection	ADP-RIBOSE SYNTHETASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; DNA STRAND BREAKS; POTENT INHIBITOR; GLUTAMATE NEUROTOXICITY; REPERFUSION INJURY; GENE DISRUPTION; MICE DEFICIENT	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme that is activated primarily by DNA damage. Upon activation, the enzyme hydrolyzes NAD(+) to nicotinamide and transfers ADP ribose units to a variety of nuclear proteins, including histories and PARP-1 itself. This process is important in facilitating DNA repair. However, excessive activation of PARP-1 can lead to significant decrements in NAD(+), and ATP depletion, and cell death (suicide hypothesis). In response to cellular damage by oxygen radicals or excitotoxicity, a rapid and strong activation of PARP-1 occurs in neurons. Excessive PARP-1 activation is implicated in a variety of insults, including cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The use of PARP inhibitors has, therefore, been proposed as a protective therapy in decreasing excitotoxic neuronal cell death, as,well as ischemic and other tissue damage. Excitotoxic brain lesions initially result in the primary destruction of brain parenchyma and subsequently in secondary damage of neighboring neurons hours after the insult. This secondary damage of initially surviving neurons accounts for most of the volume of the infarcted area and the loss of brain function after a stroke. One major component of secondary neuronal damage is the migration of macrophages and microglial cells toward the sites of injury, where they produce large quantities of toxic cytokines and oxygen radicals. Recent evidence indicates that this microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may, therefore, be a promising strategy in protecting neurons from this secondary damage, as well. Studies demonstrating an important role for PARP-1 in the regulation of gene transcription have further increased the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenge the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. The hypothesis that PARI's might regulate cell fate as essential modulators of death and survival transcriptional programs is discussed with relation to nuclear factor kappaB and p53.	GlaxoSmithKline Res & Dev Ltd, Dept Neurophysiol & Cell Sci, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England		Skaper, SD (corresponding author), GlaxoSmithKline Res & Dev Ltd, Dept Neurophysiol & Cell Sci, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Stephen_Skaper-1@gsk.com					Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/0006-8993(96)00571-9; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Dawson Ted M., 1997, P319; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Drazen DL, 2001, MOL MED, V7, P761, DOI 10.1007/BF03401966; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; Lu X., 2001, Society for Neuroscience Abstracts, V27, P2025; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Mandir AS, 2000, J NEUROSCI, V20, P8005; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIWA M, 1971, J BIOL CHEM, V246, P6362; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shall S, 2001, MUTAT RES, V460, P1; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yang ZQ, 2000, SHOCK, V13, P60, DOI 10.1097/00024382-200013010-00011; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816	76	63	66	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-469-2; 1-57331-468-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2003	993						217	228		10.1111/j.1749-6632.2003.tb07532.x			12	Multidisciplinary Sciences; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BX10T	WOS:000184303000027	12853316				2022-02-06	
J	Tyor, WR; Avgeropoulos, N; Ohlandt, G; Hogan, EL				Tyor, WR; Avgeropoulos, N; Ohlandt, G; Hogan, EL			Treatment of spinal cord impact injury in the rat with transforming growth factor-beta	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						spinal cord injury; rats; mononuclear phagocytes; cytokines; transforming growth factor-beta	TUMOR-NECROSIS-FACTOR; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRAUMATIC INJURY; FACTOR-ALPHA; TNF-ALPHA; TGF-BETA; BRAIN; EXPRESSION; GROWTH-FACTOR-BETA-1; CYTOKINES	To investigate the contribution of cytokines, proinflammatory TNF-alpha and inhibitory TGF-beta, to spinal cord injury (SCI) in a rat model, two studies were performed using adult Sprague-Dawley rats which were injured at T9/T10. In the first study, rats were sacrificed at 1, 6, 24, 96 and 168 h after SCI for immunocytochemistry of coronal sections for the presence of mononuclear phagocytes, astrocytes, TNF-alpha and TGF-beta, among other markers. From intervening frozen sections, RNA was extracted for semiquantitative polymerase chain reaction (RTPCR) analysis of TNF-alpha and TGF-beta. In the second experiment, rats were treated with intravenous TGF-beta 30 min after injury and sacrificed at 6 and 48 h after injury. Spinal cord sections were immunocytochemically stained and RNA extracted for semiquantitative PCR as mentioned above, as well as quantitation of lesion volume. There were increases in mononuclear phagocytes and astrocytes, as early as 1 h after SCI, with steady progression over 168 h after injury. TNF-alpha and TGF-beta was produced locally by mononuclear phagocytes and astrocytes. There was an 18-h delay in peak mRNA production of TGF-beta compared to TNF-alpha. The treatment of SCI rats with TGF-beta reduced lesion volume by 50% at 48 h and this was associated with decreased accumulation of mononuclear phagocytes in and around the injury site. This reduction of mononuclear phagocyte numbers around the site of trauma would reduce their contribution to secondary injury. Published by Elsevier Science B.V.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA		Tyor, WR (corresponding author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031767] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31767] Funding Source: Medline		Aloisi F, 1999, J NEUROSCI RES, V56, P571; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; DACUNHA A, 1993, BRAIN RES, V631, P39, DOI 10.1016/0006-8993(93)91183-S; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Kitamura M, 1997, J IMMUNOL, V159, P1404; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; RACKE MK, 1991, J IMMUNOL, V146, P3012; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645, DOI 10.1002/jlb.62.5.645; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SOLIVEN B, 1992, J NEUROSCI, V12, P2665; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Tator C H, 1996, J Spinal Cord Med, V19, P206; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1997, NEUROIMMUNOLOGY CLIN, P3; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WARWICKDAVIES J, 1995, J IMMUNOL, V155, P3186; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410	28	63	73	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	AUG 15	2002	200	1-2					33	41	PII S0022-510X(02)00113-2	10.1016/S0022-510X(02)00113-2			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	584FY	WOS:000177457600005	12127673				2022-02-06	
J	Wagner, KR; Packard, BA; Hall, CL; Smulian, AG; Linke, MJ; de Courten-Myers, GM; Packard, LM; Hall, NC				Wagner, KR; Packard, BA; Hall, CL; Smulian, AG; Linke, MJ; de Courten-Myers, GM; Packard, LM; Hall, NC			Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma	DEVELOPMENTAL NEUROSCIENCE			English	Article						intracerebral hemorrhage; white matter; protein oxidation; heme oxygenase; pigs	EDEMA DEVELOPMENT; BRAIN-INJURY; IN-VIVO; HEMORRHAGE; ACCUMULATION; EXPRESSION; SUSCEPTIBILITY; MICROGLIA; CYTOKINE; THROMBIN	Spontaneous or traumatic intracerebral hemorrhage (ICH) in the white matter of neonates, children and adults causes significant mortality and morbidity. The detailed biochemical mechanisms through which blood damages white matter are poorly defined. Presently, we tested the hypothesis that ICH induces rapid oxidative stress in white matter. Also, since clot-derived plasma proteins accumulate in white matter after ICH and these proteins can induce oxidative stress in microglia in vitro, we determined whether the blood's plasma component alone induces oxidative stress. Lastly, since heme oxygenase-1 (HO-1) induction is highly sensitive to oxidative stress, we also examined white matter HO-1 gene expression. We infused either whole blood,or plasma (2.5 ml) into the frontal hemispheric white matter of pentobarbital-anesthetized pigs (similar to1 kg) over 15 min. We monitored and controlled physiologic variables and froze brains in situ between 1 and 24 h after ICH. White matter oxidative stress was determined by measuring protein carbonyl formation and HO-1 gene expression by RT-PCR. Protein carbonyl formation occurred rapidly in the white matter adjacent to both blood and plasma clots with significant elevations (3- to 4-fold) already 1 h after infusion. This increase remained through the first 24 h. HO-1 mRNA was rapidly induced in white matter with either whole blood or plasma infusions. These results demonstrate that not only whole blood but also its plasma component are capable of rapidly inducing oxidative stress in white matter. This rapid response, possibly in microglial cells, may contribute to white matter damage not only following ICH, but also in pathophysiological states in which blood-brain-barrier permeability to plasma proteins is increased. Copyright (C) 2002 S. Karger AG, Basel.	Dept Vet Affairs Med Ctr, Med Res Serv, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Grad Program Neurosci, Cincinnati, OH USA		Wagner, KR (corresponding author), Dept Vet Affairs Med Ctr, Res Serv 151, 3200 Vine St, Cincinnati, OH 45220 USA.	wagnerkr@email.uc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS30652] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030652] Funding Source: NIH RePORTER		Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Dean RT, 1997, BIOCHEM J, V324, P1; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dozois CM, 1997, VET IMMUNOL IMMUNOP, V58, P287, DOI 10.1016/S0165-2427(97)00039-1; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; Gebel JM, 1998, STROKE, V29, P563, DOI 10.1161/01.STR.29.3.563; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hall N, 1999, J NEUROCHEM, V72, pS33; Hall N, 1998, STROKE, V29, P273; Hall NC, 2000, CELL MOL BIOL, V46, P673; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; IBAS G, 1992, J NEUROTRAUMA S1, V9, pS265; JENKINS A, 1990, British Journal of Neurosurgery, V4, P45, DOI 10.3109/02688699009000681; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Lamb NJ, 1999, BIOCHEM J, V344, P153, DOI 10.1042/0264-6021:3440153; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matsuoka Y, 1999, NEUROPHARMACOLOGY, V38, P825, DOI 10.1016/S0028-3908(99)00020-9; Matz PG, 2001, J CEREBR BLOOD F MET, V21, P921, DOI 10.1097/00004647-200108000-00004; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McCord JM, 1998, SEMIN HEMATOL, V35, P5; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Nakaso K, 2000, NEUROSCI LETT, V293, P49, DOI 10.1016/S0304-3940(00)01491-9; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Packard B. A., 1999, Society for Neuroscience Abstracts, V25, P1849; Panahian N, 1999, J NEUROCHEM, V72, P1187; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Perlman JM, 1998, EARLY HUM DEV, V53, P99, DOI 10.1016/S0378-3782(98)00037-1; Richmon JD, 1998, BRAIN RES, V780, P108, DOI 10.1016/S0006-8993(97)01314-0; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Suzuki J, 1980, SPONTANEOUS INTRACER, P121; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wagner KR, 2001, STROKE, V32, P327; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; WAGNER KR, 2001, NEUROPROTECTION, P471; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580	49	63	65	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.	MAR-JUN	2002	24	2-3					154	160		10.1159/000065703			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	613QN	WOS:000179143100009	12401953				2022-02-06	
J	Cheney, JA; Weisser, JD; Bareyre, FM; Laurer, HL; Saatman, KE; Raghupathi, R; Gribkoff, V; Starrett, JE; McIntosh, TK				Cheney, JA; Weisser, JD; Bareyre, FM; Laurer, HL; Saatman, KE; Raghupathi, R; Gribkoff, V; Starrett, JE; McIntosh, TK			The maxi-K channel opener EMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BMS-204352; potassium channels; head injury; cerebral edema; neuromotor function; cognition	ACTIVATED POTASSIUM CHANNELS; CEREBELLAR GRANULE CELLS; NEUROBEHAVIORAL FUNCTION; AMINO-ACIDS; HEAD-INJURY; RAT-BRAIN; RILUZOLE; IMPROVES; RELEASE; CONSEQUENCES	Large-conductance, calcium-activated potassium (maxi-K) channels regulate neurotransmitter release and neuronal excitability, and openers of these channels have been shown to be neuroprotective in models of cerebral ischemia. The authors evaluated the effects of postinjury systemic administration of the maxi-K channel opener, BMS-204352, on behavioral and histologic outcome after lateral fluid percussion (PP) traumatic brain injury (TBI) in the rat. Anesthetized Sprague Dawley rats (n = 142) were subjected to moderate FP brain injury (n = 88) or surgery without injury(n = 54) and were randomized to receive a bolus of 0.1 mg/kg BMS-204352 (n = 26, injured; n = 18, sham), 0.03 mg/kg BMS-201352 (n = 25, injured; n = 18, sham), or 2% dimethyl sulfoxide (DMSO) in polyethylene glycol (vehicle, n = 27, injured; n = 18. sham) at IO minutes postinjury. One group of rats was tested for memory retention (Morris water maze) at 42 hours postinjury, then killed for evaluation of regional cerebral edema. A second group of injured/sham rats was assessed for neurologic motor function from 48 hours to 2 weeks postinjury and cortical lesion area. Administration of 0.1 mg/kg BMS-204352 improved neurologic motor function at 1 and 2 weeks postinjury (P < 0.05) and reduced the extent of cerebral edema in the ipsilateral hippocampus, thalamus, and adjacent cortex (P < 0.05). Administration of 0.03 mg/kg EMS-204352 significantly reduced cerebral edema in the ipsilateral thalamus (P < 0.05). No effects on cognitive function or cortical tissue loss were observed with either dose. These results suggest that the novel maxi-a channel opener BMS-204352 may be selectively beneficial in the treatment of experimental TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NSO8803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		ADAMS PR, 1982, NATURE, V296, P746, DOI 10.1038/296746a0; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BODIE H, 1993, J NEUROTRAUM, V10, pS161; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAGNI L, 1994, PFLUG ARCH EUR J PHY, V429, P176, DOI 10.1007/BF00374310; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRIBKOFF VK, 1997, ADV PHARMACOL, V37, P348; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; JALONEN T, 1990, BRAIN RES, V535, P33, DOI 10.1016/0006-8993(90)91820-7; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knaus HG, 1996, J NEUROSCI, V16, P955; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LIU GL, 1994, INT J TURBO JET ENG, V11, P53; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MCKAY MC, 1994, J NEUROPHYSIOL, V71, P1873, DOI 10.1152/jn.1994.71.5.1873; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POSTMUNSON DJ, 2000, P KEYST S POT CHANN, P57; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Smallwood I.M, 1996, HDB ORGANIC SOLVENT, P1; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stark J, 2000, INT SYMP MICROARCH, P57, DOI 10.1109/MICRO.2000.898058; Starrett JE, 1996, CURR PHARM DESIGN, V2, P413; Strobaek D, 1996, NEUROPHARMACOLOGY, V35, P903, DOI 10.1016/0028-3908(96)00096-2; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; YOSHIDA A, 1991, JPN J PHYSIOL, V41, P297, DOI 10.2170/jjphysiol.41.297; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	60	63	64	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2001	21	4					396	403		10.1097/00004647-200104000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	421PT	WOS:000168073300008	11323525	Bronze			2022-02-06	
J	Max, JE; Robertson, BAM; Lansing, AE				Max, JE; Robertson, BAM; Lansing, AE			The phenomenology of personality change due to traumatic brain injury in children and adolescents	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FRONTAL-LOBE DAMAGE; PSYCHIATRIC-DISORDERS; CHILDHOOD; IMPACT; SCALE	The authors aimed to contribute a clinically rich description of personality change due to traumatic brain injury (PC) in children. The sample consisted of consecutively injured children. Ninety-four subjects ages 5 to 14 years were assessed at the time of hospitalization after a traumatic brain injury (TBI). A standardized psychiatric interview, the Neuropsychiatric Rating Schedule, tons used to elicit symptoms of PC. PC occurred in 59% of severe (22/37) and 5% of mild/moderate (3/57) TBI subjects. Among the 37 severe TBI subjects, the labile subtype of PC was the most common (49%), followed by the aggressive and disinhibited subtypes (38% each), apathy (14%), and paranoia (5%). Also frequent in severe TBI was perseveration (35%). A detailed case example, numerous clinical vignettes of PC symptoms, and a tabulation of their frequencies provide clinicians a broader frame of reference for eliciting symptoms of PC.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA		Max, JE (corresponding author), Univ Calif San Diego, Childrens Hosp, 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 K08 MH01800-01] Funding Source: Medline		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P854; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, NEUROCASE, V3, P119; MILLS RAR, 1994, J CAN PETROL TECHNOL, V33, P5; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X	27	63	68	0	8	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2001	13	2					161	170		10.1176/appi.neuropsych.13.2.161			10	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	432JE	WOS:000168687800002	11449023				2022-02-06	
J	Zhang, LY; Yang, KH; King, AI				Zhang, LY; Yang, KH; King, AI			Biomechanics of neurotrauma	NEUROLOGICAL RESEARCH			English	Article						biomechanics; head impact; finite element modeling; traumatic minor brain injury	DIFFUSE AXONAL INJURY; CEREBRAL CONCUSSION; SUBDURAL-HEMATOMA; HEAD-INJURY; PRIMATE; IMPACT; MODEL	This paper reviews the traditional areas of impact biomechanics as they relate to brain injury caused by blunt impact. These areas are injury mechanisms, human response to impact, human tolerance to impact and the use of human surrogates. With the advent of high-speed computers, it is now possible to add computer models to the list of human surrogates that used to be limited to animals and human cadavers. The advantages and shortcomings of current computer models are discussed One of the computer models was used to predict the pressures and shear stresses developed in the brain and the extent of stretch of the bridging veins in the brains of American football players who sustained severe helmet-to-helmet head impact during the game. It was found that increases in intracranial pressure were more dependent on translational acceleration while the primary determinant for the development of shear stresses in the brain is rotational acceleration. Although the current head injury criterion is based almost entirely on translational acceleration, it is recommended that any new criterion should reflect the contribution of both translational and rotational acceleration.	Wayne State Univ, Bioengn Ctr, Detroit, MI 48202 USA		King, AI (corresponding author), Wayne State Univ, Bioengn Ctr, 818 W Hancock, Detroit, MI 48202 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503534-09] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; BYCROFT GN, 1973, J BIOMECH, V6, P487, DOI 10.1016/0021-9290(73)90007-9; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Ewing C. L., 1975, P 19 STAPP CAR CRASH; Gadd C. W., 1966, P 10 STAPP CAR CRASH; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Goldsmith W, 1989, P IRCOBI C 1989 SEPT, P1; GRONWALL D, 1975, LANCET, V2, P995; GROSS A G, 1958, J Aviat Med, V29, P725; Gurdjian E.S., 1945, MENTAL ADV DIS, V24, P28; GURDJIAN ES, 1961, J NEUROSURG, V18, P58, DOI 10.3171/jns.1961.18.1.0058; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1963, P 7 STAPP CAR CRASH, V35, P470; Hardy C. H., 1971, ELASTIC ANAL SKULL; HODGSON VR, 1973, 002 HS801 DOT NAT TE; HODGSON VR, 1969, P 13 STAPP CAR CRASH; Holbourn AHS, 1943, LANCET, V2, P438; Hosey R. R., 1982, FINITE ELEMENTS BIOM, P379; Huston J, 1975, P INT IRCOBI C BIOM, P153; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Lighthall J.W., 1989, P 12 INT TECHN C EXP, P627; LINDENBERG R, 1955, AM J PATHOL, V31, P297; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Nahum AM, 1977, P 21 STAPP CAR CRASH; Newman J.A., 1999, P INT RES C BIOM I 1, P17; Ommaya A. K., 1967, P 11 STAPP CAR CRASH; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1966, P 10 STAPP CAR CRASH; Ono K., 1980, P 24 STAPP CAR CRASH; Patrick LM, 1963, P 7 STAPP CAR CRASH, V36, P483; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PRINCERNAILLE Y, 1989, P 33 STAPP CAR CRASH; PUDENZ RH, 1946, J NEUROSURG, V3, P87; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; RUAN J, 1991, P 1 INJ PREV BIOM S, P97; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; STRICH SJ, 1961, LANCET, V2, P443; Tarriere C, 1987, HEAD INJURY MECHANIS, P47; Thibault L., 1971, P 15 STAPP CAR CRASH; THIBAULT LE, 1989, P 10 INT TECH C EXP; THIBAULT LE, 1985, P 29 STAPP CAR CRASH; Trosseille X., 1992, P 36 STAPP CAR CRASH; UNTERHARNSCHEID.FJ, 1971, P 15 STAPP CAR CRASH; Ward C, 1975, P 19 STAPP CAR CRASH; Ward C, 1980, P 24 STAPP CAR CRASH; Zhou C, 1995, P 39 STAPP CAR CRASH	56	63	64	0	12	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					144	156		10.1179/016164101101198488			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	422DX	WOS:000168104200006	11320593				2022-02-06	
J	de Kruijk, JR; Twijnstra, A; Leffers, P				de Kruijk, JR; Twijnstra, A; Leffers, P			Diagnostic criteria and differential diagnosis of mild traumatic brain injury	BRAIN INJURY			English	Article							MODERATE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; COMA-SCALE SCORE; COMPUTED-TOMOGRAPHY; MANAGEMENT; PROTEIN; CT; DAMAGE; SPECT; S-100	Brain injury is classified clinically as severe, moderate or mild brain injury characteristics, including admission Glasgow coma score, duration of unconsciousness and post-traumatic amnesia and any focal neurological findings. Most traumatic brain injuries are classified as mild traumatic brain injury (MTBI). Headache, nausea and dizziness are frequent symptoms after MTBI and may continue for weeks to months after the trauma. MTBI may also be complicated by intracranial injuries. Experimental animal models and post-mortem studies have shown axonal damage and dysfunction in MTBI. This damage is mostly localized in the frontal lobes. Serum S-100 and NSE have been reported to be markers for the severity of brain damage. In the literature, indications for radiodiagnostic evaluation following MTBI have been the subject of debate. Radiographs of the skull are used to exclude skull fractures, but are not useful for an evaluation of brain injury. Computed tomography of the brain seems to be the best way to exclude the development of relevant intracranial lesions. MTBI has a good clinical outcome, although a substantial group of patients develop post-concussional complaints (PCC). There is little information on the effectiveness of various methods suggested for reducing the frequency of PCC.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands		de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.		Leffers, Pieter/B-8642-2009				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN NI, 1993, NEUROLOGY, V42, P103; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; de Louw A, 1994, Ned Tijdschr Geneeskd, V138, P2197; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HADLEY D, 1995, ACTA NEUROLOGY BEL S, V95, P109; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; ICHISE M, 1994, J NUCL MED, V35, P217; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; JACOBS A, 1994, J NUCL MED, V35, P942; KAY T, 1992, Neurology, V42, P411; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRUGER J, 1991, NERVENARZT, V62, P226; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Masdeu J C, 1994, J Neuroimaging, V4, P177; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PERSSON I, 1986, STROKE, V18, P911; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 1994, Ned Tijdschr Geneeskd, V138, P2279; VANTHOOFT F, 1973, COMOTIO CEREBRI ANDE; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; [No title captured]	55	63	64	0	11	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2001	15	2					99	106		10.1080/026990501458335			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800002	11260760				2022-02-06	
J	Mu, XJ; Azbill, RD; Springer, JE				Mu, XJ; Azbill, RD; Springer, JE			Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						excitotoxicity; glucocorticoids; glutamate release; myelin; spinal cord trauma	NEUROPROTECTIVE AGENT RILUZOLE; AMYOTROPHIC-LATERAL-SCLEROSIS; NMDA RECEPTOR ANTAGONISTS; EXCITATORY AMINO-ACIDS; NERVOUS-SYSTEM INJURY; LIPID-PEROXIDATION; SODIUM-CHANNELS; GRANULE CELLS; BRAIN INJURY; TISSUE LOSS	The potential use of riluzole (a glutamate release inhibitor) alone or in combination with methylprednisolone (MP) in treating acute spinal cored injury (SCI) was examined. Rats received a contusion injury to the spinal cord using the NYU impactor and were treated with vehicle, riluzole (8 mg/kg), MP(30 mg/kg), or riluzole + MP at 2 and 4 h following injury. Animals continued to receive riluzole treatment (8 mg/kg) for a period of 1 week. The animals were then tested weekly for functional recovery using the BBB open field locomotor score. At the end of testing (6 weeks after injury), each spinal cord was examined for the amount of remaining tissue at the injury site and a myelination index was used to quantify remaining axons in the ventromedial white matter. In this study, only the combination treatment was found to significantly improve behavioral recovery as assessed using the BBB open field locomotor scale. In addition, the combination treatment promoted tissue sparing at the lesion epicenter, but had no clear effect on the index of myelnation. The results of this study clearly demonstrate the potential beneficial effects of a combination approach in the treatment of traumatic SCI.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, Lexington, KY 40536 USA		Mu, XJ (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Ctr Spinal Cord & Brain Injury Res, 800 Rose St, Lexington, KY 40536 USA.			Azbill, David/0000-0001-7989-1771	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040015, NS30248, NS40015] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030248, R01NS040015] Funding Source: NIH RePORTER		Agrawal SK, 1997, J NEUROSCI, V17, P1055; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; Bryson HM, 1996, DRUGS, V52, P549, DOI 10.2165/00003495-199652040-00010; CHERAMY A, 1992, NEUROSCI LETT, V147, P209, DOI 10.1016/0304-3940(92)90597-Z; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; COURATIER P, 1994, NEUROREPORT, V5, P1012, DOI 10.1097/00001756-199404000-00040; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DOBLE A, 1996, NEUROLOGY S4, V47, P233; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1997, EXP BRAIN RES, V113, P1, DOI 10.1007/BF02454136; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1992, N NEUROTRAUMA S1, V9, pS165; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; Huang CS, 1997, J PHARMACOL EXP THER, V282, P1280; HUBERT JP, 1994, BRIT J PHARMACOL, V113, P261, DOI 10.1111/j.1476-5381.1994.tb16203.x; ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; MALGOURIS C, 1994, NEUROSCI LETT, V177, P95, DOI 10.1016/0304-3940(94)90053-1; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; PRENEN GHM, 1988, EXP NEUROL, V99, P118, DOI 10.1016/0014-4886(88)90132-X; ROMETTINO S, 1991, EUR J PHARMACOL, V199, P371, DOI 10.1016/0014-2999(91)90503-I; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; Song JH, 1997, J PHARMACOL EXP THER, V282, P707; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Springer JE, 1997, J NEUROCHEM, V68, P2469; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Teng YD, 1997, J NEUROSCI, V17, P4359; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; Wokke J, 1996, LANCET, V348, P795, DOI 10.1016/S0140-6736(96)03181-9; Wrathall JR, 1998, J NEUROSCI, V18, P8780; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	59	63	66	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2000	17	9					773	780		10.1089/neu.2000.17.773			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	356LM	WOS:000089444800005	11011817				2022-02-06	
J	Verger, K; Junque, C; Jurado, MA; Tresserras, P; Bartumeus, F; Nogues, P; Poch, JM				Verger, K; Junque, C; Jurado, MA; Tresserras, P; Bartumeus, F; Nogues, P; Poch, JM			Age effects on long-term neuropsychological outcome in paediatric traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; CHILDREN; ADOLESCENTS; CHILDHOOD; MEMORY; PERFORMANCE; SEVERITY; RECOVERY	In order to investigate the relationship between age at injury and long-term neuropsychological impairment, 29 children and adolescents who sustained traumatic brain injury (TBI) were studied at least 6 years post-trauma. Tests of intellectual, memory, visuospatial and frontal lobe functions were administered to patients and 29 normal matched control subjects. Correlations between performance on neuropsychological tests and age showed the following direction: the younger the child when TBI was sustained, the worse the cognitive outcome. After controlling for injury severity, visuospatial functions remained related to age. Patients' performance differed significantly from chat of controls in half of the neuropsychological variables analysed. To further investigate the effects of age at injury, the sample was divided in two groups (TBI before and after age of 8) and then compared with their respective controls. Patients damaged earlier presented impaired intellectual and visuospatial functions. The results suggest that neuropsychological sequelae remain after at lease 6 years of evolution, and that there is an age at injury effect.	Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Barcelona 08035, Spain; Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain; Hosp Gen Valle Hebron, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Passeig Vall dHebron 171, Barcelona 08035, Spain.	cjunque@psi.ub.es	Junque, Carme/B-4400-2011; JURADO, MARIA ANGELES/E-1745-2011	Junque, Carme/0000-0002-6381-3063; JURADO, MARIA ANGELES/0000-0002-9403-1670			ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DANTA G, 1975, NEUROLOGY, V25, P43, DOI 10.1212/WNL.25.1.43; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Finger S., 1988, BRAIN INJURY RECOVER, P117; Golden C.J., 1994, STROOP TEST COLORES; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINGMA A, 1993, AM J PEDIAT HEMATOL, V15, P231; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MILLER EA, 1973, SCIENCE, V182, P304, DOI 10.1126/science.182.4109.304; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; REY A, 1987, THESIS TEA MADRID; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SMITH A, 1975, NEUROLOGY, V25, P813, DOI 10.1212/WNL.25.9.813; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476; WECHSLER D, 1976, ESCALA INTELIGENCIA; Wechsler D., 1993, ESCALA INTELIGENCIA	43	63	64	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2000	14	6					495	503					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600001	10887884				2022-02-06	
J	Ng, I; Yeo, TT; Tang, WY; Soong, R; Ng, PY; Smith, DR				Ng, I; Yeo, TT; Tang, WY; Soong, R; Ng, PY; Smith, DR			Apoptosis occurs after cerebral contusions in humans	NEUROSURGERY			English	Article						apoptosis; bax; bcl-2; cerebral contusions	TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; SEVERE HEAD-INJURY; NEURONAL APOPTOSIS; FRAGMENTED DNA; BCL-2 GENE; IN-VIVO; C-MYC; HYPOTHERMIA	OBJECTIVE: Animal model systems have shown that head trauma can induce cell death in regions of the brain away from the site of the impact via a process of apoptosis. We sought to determine whether there was evidence of cellular apoptosis in clinically collected materials from human head trauma patients, as well as to attempt to determine the pathway by which it may occur. METHODS: Thirty-one sequential specimens of brain tissue excised during emergency craniotomy for evacuation of cerebral contusions with mass effect were examined. Non-necrotic pericontusional tissues were detected in 11 samples. These were examined for the presence of apoptotic cells by the terminal deoxynucleotide transferase-mediated nick end labeling method as well as by immunohistochemistry to detect possible expression of the apoptosis-related genes p53, bcl-2, and bax. RESULTS: Bax expression was detected in all patients, whereas bcl-2 expression was noted in six patients, Terminal deoxynucleotide transferase-mediated nick end labeling-positive cells were noted in eight patients. One instance of p53-positive immunostaining was observed. Patients with bcl-2 expression had a better survival rate than patients in whom no bcl-2 expression was noted (P = 0.01). CONCLUSION: Although necrosis seemed to be the main finding in cerebral contusions, these results support the hypothesis that apoptosis does occur in patients after traumatic brain injury, and this may contribute to the secondary injury processes that are seen with head injury. Patients in whom anti-apoptotic bcl-2 is induced seem to have a better prognosis. This may have important clinical significance in the development of bcl-2 homologs or bax inhibitors to prevent apoptosis.	Tan Tock Seng Hosp, Brain & Spine Ctr, Mol Biol Lab, Singapore 308433, Singapore; Tan Tock Seng Hosp, Dept Neurosurg, Singapore 308433, Singapore		Smith, DR (corresponding author), Tan Tock Seng Hosp, Brain & Spine Ctr, Mol Biol Lab, Singapore 308433, Singapore.		Yeo, Tseng Tsai/U-8864-2017; Smith, Duncan R/C-6891-2011	Smith, Duncan R/0000-0002-6592-9852; Soong, Richie/0000-0002-0152-1225			ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Bauer J, 1995, CURR OPIN IMMUNOL, V7, P839, DOI 10.1016/0952-7915(95)80057-3; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DURE LS, 1995, EXP NEUROL, V133, P207, DOI 10.1006/exnr.1995.1023; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GAVNELI Y, 1992, J CELL BIOL, V119, P493; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Johnstone SA, 1998, ANN ONCOL, V9, P36; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Katoh K, 1996, NEUROSCI LETT, V216, P9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LINDENBERG R, 1971, PATHOLOGY NERVOUS SY, V2, P705; Liu XZ, 1997, J NEUROSCI, V17, P5395; MAJNO G, 1995, AM J PATHOL, V146, P3; MCCORMICK WF, 1983, CLIN NEUROSCIENCES, V3, P241; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moss SF, 1996, DIGEST DIS SCI, V41, P2238, DOI 10.1007/BF02071407; Namura S, 1998, J NEUROSCI, V18, P3659; NEMOTO EM, 1994, J NEUROSURG ANESTH, V6, P220; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Ogura E, 1999, ONCOL REP, V6, P365; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; RINK A, 1995, AM J PATHOL, V147, P1575; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SEARLE J, 1982, PATHOL ANNU, V17, P229; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DR, 1996, BRIT J CANCER, V74, P216, DOI 10.1038/bjc.1996.340; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	65	63	82	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2000	46	4					949	956		10.1097/00006123-200004000-00034			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	302HR	WOS:000086360100101	10764270				2022-02-06	
J	Chen, T; Qian, YZ; Di, X; Rice, A; Zhu, JP; Bullock, R				Chen, T; Qian, YZ; Di, X; Rice, A; Zhu, JP; Bullock, R			Lactate/glucose dynamics after rat fluid percussion brain injury	JOURNAL OF NEUROTRAUMA			English	Article						glucose; lactate; microdialysate; traumatic brain injury	EXCITATORY AMINO-ACIDS; CORTICAL EXTRACELLULAR LEVELS; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; SYNAPTIC FUNCTION; CONTUSION TRAUMA; HEAD-INJURY; CELL-DAMAGE; LACTATE; GLUCOSE	Traumatic brain injury (TBI) places enormous early energy demand on brain tissue to reinstate normal ionic balance. Clinical studies have demonstrated a decline in extracellular fluid (ECF) glucose and an increase in lactate after TBI. In vitro studies suggest that this increase in lactate is mediated by increased glutamate and may provide a metabolic substrate for neurons, to aid in ionic restoration. This led us to hypothesize that high ECF lactate may be beneficial in recovery following TBI, where major ionic flux has been shown to occur. In this study, we measured cerebral dialysate lactate and glucose, and arterial lactate and glucose, before and after rat lateral fluid percussion brain injury (FPI; 2.06 +/- 0.13 atm) with and without IV lactate infusion (100 mM x 0.65 mL/h X 5 h) to test the hypothesis that arterial lactate can influence ECF lactate. Dialysate lactate increased within 10 min following FPI, with higher values in the lactate infusion group. Following FPI, the dialysate lactate increase was 238% with lactate infusion versus 171% increase with saline infusion. Dialysate glucose fell immediately following FPI, with a more severe decline in the saline group. The glucose decrease was 231% greater in the IV saline group. Furthermore, in the lactate infusion group, the dialysate glucose levels recovered to baseline levels by 4 h after injury, whereas they remained depressed through out the experiment, in the saline infusion group. We conclude that arterial lactate augmentation can increase brain dialysate lactate, and result in more rapid recovery of dialysate glucose after FPI. This may indicate a beneficial role for lactate, that may be potentially useful in the clinical situation, after TBI.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH12587] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CROCKARD HA, 1972, EUR NEUROL, V8, P151, DOI 10.1159/000114569; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREWES LR, 1973, ARCH NEUROL-CHICAGO, V29, P385, DOI 10.1001/archneur.1973.00490300047005; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; FERNANDES J, 1982, LANCET, V1, P113; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; KNUDSEN GM, 1991, J CEREBR BLOOD F MET, V11, P581, DOI 10.1038/jcbfm.1991.107; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; METZEL E, 1971, ACTA NEUROCHIR, V25, P177, DOI 10.1007/BF01809099; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLDENDORF WH, 1971, EUR NEUROL, V6, P49, DOI 10.1159/000114465; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; SCHURR A, 1987, BRAIN RES, V421, P135, DOI 10.1016/0006-8993(87)91283-2; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SEITZ H D, 1976, Zeitschrift fuer Experimentelle Chirurgie, V9, P341; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; STITTSWORTH JD, 1993, BRAIN RES, V630, P21, DOI 10.1016/0006-8993(93)90637-3; TUAN XQ, 1993, J NEUROTRAUM, V10, P307; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	44	63	64	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					135	142		10.1089/neu.2000.17.135			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800003	10709871				2022-02-06	
J	Wiegner, S; Donders, J				Wiegner, S; Donders, J			Performance on the California Verbal Learning Test after traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CONFIRMATORY FACTOR-ANALYSIS; SEVERE HEAD-INJURY; STANDARDIZATION SAMPLE; MEMORY; SCALE; MODERATE; PATTERNS; CHILDREN; 1-YEAR; COMA	The California Verbal Learning Test (CVLT; Delis, Kramer, Kaplan, & Ober, 1987) data of 150 patients with traumatic brain injury (TBI) were evaluated to determine the latent underlying constructs as well as the possibility of performance subtypes with criterion validity. Confirmatory factor analysis of eight competing latent variable models suggested that a four-factor model (composed of Attention Span, Learning Efficiency, Delayed Recall, and Inaccurate Recall) fit the data relatively well. Two-stage cluster analysis of marker variables of each of these four factors suggested the presence of four reliable subtypes. Level of performance differences between these clusters were related to injury severity parameters. It is concluded that the CVLT is a sensitive and mulitfactorial measure of learning and memory after TBI. Specific recommendations for interpretation of clinically obtained CVLT profiles are provided.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Bentler PM, 1989, EQS STRUCTURAL EQUAT; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; BURTON DB, 1993, ARCH CLIN NEUROPSYCH, V8, P467, DOI 10.1016/0887-6177(93)90047-5; Burton DB, 1996, CHILD NEUROPSYCHOL, V2, P39, DOI 10.1080/09297049608401349; CERNY BA, 1977, MULTIVAR BEHAV RES, V12, P43, DOI 10.1207/s15327906mbr1201_3; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Delis DC, 1987, CALIFORNIA VERBAL LE; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DONDERS J, IN PRESS DEV NEUROPS; Gardner SD, 1998, BRAIN COGNITION, V37, P10; Gorsuch R.L., 1983, FACTOR ANAL; Hatcher L, 1994, STEP BY STEP APPROAC, P325; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MARTIN JA, 1987, CHILD DEV, V58, P33, DOI 10.1111/j.1467-8624.1987.tb03488.x; MILLIS SR, 1995, PERCEPT MOTOR SKILL, V80, P219, DOI 10.2466/pms.1995.80.1.219; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; NETEMEYER RG, 1990, J APPL PSYCHOL, V75, P148, DOI 10.1037/0021-9010.75.2.148; Rawlings J.O, 1988, APPL REGRESSION ANAL; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; SAS, 1989, SAS STAT US GUID VER, V1; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; TEASDALE G, 1974, LANCET, V2, P81; VANDERPLOEG RD, 1994, J CLIN EXP NEUROPSYC, V16, P243, DOI 10.1080/01688639408402635; Wechsler, 1997, WECHSLER ADULT INTEL; Welsch R, 1980, REGRESSION DIAGNOSTI; Wolfson, 1993, HALSTEAD REITAN NEUR; WOODARD JL, 1993, J CLIN EXP NEUROPSYC, V15, P968, DOI 10.1080/01688639308402611	34	63	63	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1999	21	2					159	170		10.1076/jcen.21.2.159.925			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	226CL	WOS:000082002700002	10425514				2022-02-06	
J	Machulda, MM; Bergquist, TF; Ito, V; Chew, S				Machulda, MM; Bergquist, TF; Ito, V; Chew, S			Relationship between stress, coping, and postconcussion symptoms in a healthy adult population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; POST-CONCUSSIVE SYMPTOMS; BASE RATES; IMPAIRMENT; SEQUELAE	Study 1 examined the association between intensity of postconcussive symptoms (PCS), impact of daily stress, and level of perceived stress order the past month in a group of healthy young adults. There was a significant relationship between intensity of PCS and impact of daily sl,ess, as well as level of perceived stress over the past month, independent of the frequency of stressful events experienced. Study 2 assessed the stability of the relationship between PCS nan stress. Subjects rated intensity of PCS, impact of daily stress, and level of perceived stress on two separate occasions approximately 1 month apart. The Perceived Stress Scale demonstrated high test-retest reliability. Significant relationships were again found between intensity of PCS wild level of perceived slr ess at both lime points, independent of the frequency of stressful events. These results suggest that persistent symptoms in some individuals with postconcussive syndrome may be doe, at least in parr, to individual differences in the perceived stress of incurring a mild traumatic brain injury. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Rehabil Inst Chicago, Chicago, IL 60611 USA; Samford Univ, Birmingham, AL USA		Machulda, MM (corresponding author), Rehabil Inst Chicago, Chicago, IL 60611 USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BRANTLEY PJ, 1988, J PSYCHOPATHOL BEHAV, V10, P75, DOI 10.1007/BF00962987; BRANTLEY PJ, 1987, J BEHAV MED, V10, P61, DOI 10.1007/BF00845128; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DOERING S, 1993, ARCH NEUROL-CHICAGO, V50, P617, DOI 10.1001/archneur.1993.00540060055018; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Folkman S., 1984, STRESS; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Holroyd K. A., 1982, HDB STRESS THEORETIC, P21; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KRAUS JF, 1989, MILD HEAD INJURY, P8; KURTZKE JF, 1993, CLIN NEUROLOGY, V4, P1; LAZARUS RS, 1990, PERSONALITY DIS, P97; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102	23	63	63	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	1998	13	5					415	424		10.1016/S0887-6177(97)00031-0			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	ZU448	WOS:000074198000001	14590606	Bronze			2022-02-06	
J	Hutchins, JB; Barger, SW				Hutchins, JB; Barger, SW			Why neurons die: Cell death in the nervous system	ANATOMICAL RECORD			English	Article						Alzheimer disease; apoptosis; calcium; free radicals; glutamate; Huntington disease; necrosis; Parkinson disease; stroke	NEUROTOXICITY; DEPRIVATION; DISEASE	It is likely that humans are born with all of the nerve cells (neurons) that will serve them throughout life, For all practical purposes, when our neurons die, they are lost forever. During nervous system development, about one-and-a-half times the adult number of neurons are created. These "extra" neurons are then destroyed or commit suicide. This process of programmed cell death occurs through a series of events termed apoptosis and is an appropriate and essential event during brain development. Later in life, inappropriate neuronal cell death may result from pathological causes such as traumatic injury, environmental toxins, cardiovascular disorders, infectious agents, or genetic diseases, In some cases, the death occurs through apoptosis, In other cases, cell death is random, irreversible, and uncontrollable; to distinguish it from the controlled, planned cell death of apoptosis, we call this necrotic cell death, Understanding the difference between apoptotic and necrotic cell death is essential for designing therapies which will prevent or limit inappropriate cell death in the nervous system. Anat. Rec, (NewAnat.): 253:79-90 1998. (C) 1998 Wiley-Liss, Inc.	Univ Mississippi, Med Ctr, Dept Neurol Res, University, MS 38677 USA; Univ Mississippi, Med Ctr, Dept Ophthalmol, University, MS 38677 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA		Hutchins, JB (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol Res, University, MS 38677 USA.			Barger, Steven/0000-0001-6049-6480			Barger S. W., 1995, CNS NEUROTRANSMITTER, V2, P273; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; CHALMERSREDMAN RME, 1997, INT REV NEUROBIOL, V40, P1; CHENG B, 1995, J NEUROSCI, V15, P7095; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Clarke Donald D., 1994, P645; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; HOLLAND A, 1994, ENVIRON VALUE, V3, P1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; OLNEY JW, 1994, PSYCHOPHARMACOL BULL, V30, P533; OLNEY JW, 1971, SCIENCE, V172, P294, DOI 10.1126/science.172.3980.294; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Tymianski M, 1996, ADV NEUROL, V71, P85; WARDMAN P, 1996, FREE RADICALS NATURE; Wyllie AH, 1997, BRIT MED BULL, V53, P451; ZHANG H, 1998, ANAT REC NEW ANAT, V253, P58	24	63	67	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0003-276X			ANAT REC	Anat. Rec.	JUN	1998	253	3					79	90		10.1002/(SICI)1097-0185(199806)253:3<79::AID-AR4>3.0.CO;2-9			12	Anatomy & Morphology	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology	106JD	WOS:000075125400004	9700393				2022-02-06	
J	Naredi, S; Eden, E; Zall, S; Stephensen, H; Rydenhag, B				Naredi, S; Eden, E; Zall, S; Stephensen, H; Rydenhag, B			A standardized neurosurgical/neurointensive therapy directed toward vasogenic edema after severe traumatic brain injury: clinical results	INTENSIVE CARE MEDICINE			English	Article						head injury; cerebral edema; cerebral perfusion pressure; blood-brain barrier	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; DIHYDROERGOTAMINE; CATECHOLAMINES; MANAGEMENT; LESIONS	Objective: Analysis of a standardized therapy focusing on prevention and treatment of vasogenic edema in patients suffering severe traumatic brain injury (TBI). Design: A retrospective analysis. Setting: Neurointensive care unit at Sahlgrenska University Hospital, Goteborg, Sweden. Patients: 38 patients with severe TBI were included. The median Glasgow Coma Score was 5 (range 3-8) and median age 27 years (range 5-70 years). Interventions: Measurement of intracranial pressure (ICP). Surgical evacuation of hematomas and contusions. Volume expansion aiming at normovolemia. Sedation with continuous intravenous infusion of low-dose thiopentone and reduction of stress response by clonidine, Normalization of capillary hydrostatic pressure by metoprolol and clonidine, If ICP and cerebral perfusion pressure (CPP) were not stabilized (ICP < 20 mmHg and CPP > 60 mm Hg), a continuous infusion of dihydroergotamine was added, In 4 patients a craniectomy was performed. Results: Of the 35 patients, 27 (71%) survived with good recovery or moderate disability 5 (13 %) survived with severe disability, 1 (3%) remained in a vegetative state, and 5 (13%) died. The mortality due to intracranial hypertension was 11% (4 patients), Conclusion: A therapy focusing on treatment of the assumed vasogenic edema in combination with aggressive neurosurgery resulted in an outcome as good as the best previously reported.	Univ Hosp No Sweden, Dept Anesthesiol & Intens Care, S-90185 Umea, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurosurg, S-41345 Goteborg, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Anesthesiol & Intens Care, S-41345 Goteborg, Sweden		Naredi, S (corresponding author), Univ Hosp No Sweden, Dept Anesthesiol & Intens Care, S-90185 Umea, Sweden.	Peter.Naredi@surgery.umu.se		Naredi, Silvana/0000-0002-4409-6089			ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER KR, 1985, J NEUROSURG, V63, P552, DOI 10.3171/jns.1985.63.4.0552; DIDIER P, 1990, CRIT CARE MED, V18, P392; ELL SR, 1991, INVEST RADIOL, V26, P499, DOI 10.1097/00004424-199105000-00022; Grande PO, 1996, ACTA ANAESTH SCAND, V40, P1255, DOI 10.1111/j.1399-6576.1996.tb05563.x; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GUIPTA VL, 1996, ACTA ANAESTH SCAND, V40, P389; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; ILLIEVICH UM, 1994, CURR OPIN ANAESTH, V7, P394; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; MILLER JD, 1995, NEUROTRAUMA, P61; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; STARMARK JE, 1996, TRAUMA CARE; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	29	63	65	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	1998	24	5					446	451		10.1007/s001340050594			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT544	WOS:000074098500008	9660259				2022-02-06	
J	Fukuda, K; Aihara, N; Sagar, SM; Sharp, FR; Pitts, LH; Honkaniemi, J; Noble, LJ				Fukuda, K; Aihara, N; Sagar, SM; Sharp, FR; Pitts, LH; Honkaniemi, J; Noble, LJ			Purkinje cell vulnerability to mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microglia; OX-42; PEP-19; Purkinje cell; traumatic brain injury	CEREBRAL-ISCHEMIA; C-FOS; PARASAGITTAL ZONES; MESSENGER-RNA; HEAD-INJURIES; RAT; PROTEIN; CEREBELLUM; MICROGLIA; MACROPHAGES	In this study we examined the cerebellar response to mild traumatic brain injury by assessing microglial activation and Purkinje cell loss, Activated microglia were identified using the antibodies OX-42 and ED-1 as well as isolectin B4. The anti-Purkinje cell antibody PEP-19 was used to evaluate Purkinje cell loss after injury, The mechanism of cell injury was examined using a monoclonal antibody to the inducible 72-kDa heat shock protein, A monoclonal antibody to the N-terminal sequence of Fos was used as a marker for neuronal activation, There was progressive activation of microglia in the cerebellar vermis within a few days after forebrain injury. In coronal sections the processes of activated microglia were oriented in ''stripes'' perpendicular to the cortical surface, In sagittal sections the activated microglia were in irregularly shaped clusters or in a fan-like distribution that radiated from the Purkinje cell layer toward the cortical surface. There was a significant loss of Purkinje cells 7 days postinjury as compared to the control group, There was no evidence of induction of heat shock protein in the cerebellum, In addition, there was no evidence of induction of c-Fos protein in either the cerebellar cortex or inferior olivary nuclei within the first 3 h after injury, These studies demonstrate that a fluid percussive impact to the forebrain results in cerebellar damage, The close anatomical association between activated microglia and Purkinje cells suggests that Purkinje cell injury is the cause of the microglial activation, The mechanism of Purkinje cell death, however, remains unclear.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94110						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ANDERSON G, 1978, EXP BRAIN RES, V35, P565; Brodal A., 1980, ADV ANAT EMBRYOL, V64, P1; BURT AM, 1993, TXB NEUROANATOMY, P349; CAVANAGH JB, 1994, NEUROPATH APPL NEURO, V20, P599, DOI 10.1111/j.1365-2990.1994.tb01014.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; GILMAN S, 1994, ANN NEUROL, V35, P3, DOI 10.1002/ana.410350103; Glickstein M, 1992, Curr Opin Neurobiol, V2, P802, DOI 10.1016/0959-4388(92)90137-A; GOENEWEGEN HJ, 1977, J COMP NEUROL, V174, P417; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS A, 1986, LANCET, V2, P445; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NAKKI R, 1995, J NEUROSCI, V15, P2097, DOI 10.1523/JNEUROSCI.15-03-02097.1995; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; OLSON JMM, 1987, NEUROSCIENCE, V22, P913, DOI 10.1016/0306-4522(87)92969-1; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMAS WE, 1992, BRAIN RES REV, V17, P61; VONLUBITZ DKJE, 1983, ACTA NEUROPATHOL, V61, P52, DOI 10.1007/BF00688386; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	49	63	63	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1996	13	5					255	266		10.1089/neu.1996.13.255			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UT295	WOS:A1996UT29500003	8797175				2022-02-06	
J	Heindl, UT; Laub, MC				Heindl, UT; Laub, MC			Outcome of persistent vegetative state following hypoxic or traumatic brain injury in children and adolescents	NEUROPEDIATRICS			English	Article						brain injury; children; epilepsy; cerebral hypoxia; ischemia; persistent vegetative state	CLOSED-HEAD-INJURY; PROLONGED POSTTRAUMATIC UNAWARENESS; COMA; UNCONSCIOUSNESS; CONSCIOUSNESS; PARAMETERS; RECOVERY	Persistent vegetative state (PVS, apallic syndrome) has become a significant medical and social problem. The outcome of young people with PVS is a matter of great interest. Therefore, we analysed the outcome of 127 children and adolescents who were in PVS for at least 30 days following traumatic (n = 82) or hypoxic (n = 45) brain injury. After 19 months of follow-up, 84% of the patients of the traumatic brain injury (TBI) group, but only 55% of the hypoxic brain injury (HBI) group had left PVS (p<0.001). The TBI patients regained consciousness earlier. Later than 9 months post trauma less than 5% of the patients of both groups left PVS. Hypoxic brain injury patients had a higher incidence of seizures (p = 0.01) and a higher seizure frequency. They had significantly more com plications like pneumonia, gastrointestinal disturbance or myositis ossificans (= heterotopic ossification). Posttraumatic hyperthermia and autonomic dysfunctions were correlated with worse outcome in the TBI group, but not in the HBI group. Thirteen patients (16%) with TBI became independent in everyday life versus only two (4 %) with HBI. These results underline the important contribution of hypoxia in severe and permanent brain impairment. They also may help to establish the prognosis of children in PVS.	BEHANDLUNGSZENTRUM VOGTAREUTH,ABT NEUROPADIATR,D-83569 VOGTAREUTH,GERMANY								ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ANDREWS K, 1993, BRIT MED J, V306, P1600, DOI 10.1136/bmj.306.6892.1600; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; Ashwal S, 1994, Adv Pediatr, V41, P195; ASHWAL S, 1992, ANN NEUROL, V32, P454; BARTKOWSKI HM, 1986, HEAD TRAUMA REHABIL, V1, P1; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BERNEY J, 1995, CHILD NERV SYST, V11, P256, DOI 10.1007/BF00301755; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; CHU HS, 1993, J FORMOS MED ASSOC, V92, P697; COLE G, 1984, BRIT MED J, V289, P1620, DOI 10.1136/bmj.289.6458.1620-c; D'Aleo G, 1994, Funct Neurol, V9, P189; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; FREEMAN EA, 1993, MED J AUSTRALIA, V159, P428, DOI 10.5694/j.1326-5377.1993.tb137943.x; GARNER C, 1994, PHYS MED REHAB KUROR, V4, P220; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; GROTE EH, 1993, UNFALLCHIRURG, V96, P609; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; KALLERT TW, 1994, FORTSCHR NEUROL PSYC, V62, P241, DOI 10.1055/s-2007-996674; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRETSCHMER E, 1940, NEUROL PSYCHIAT, V169, P576; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRIEL RL, 1994, PEDIATR NEUROL, V10, P207, DOI 10.1016/0887-8994(94)90024-8; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MAGUN JG, EPILEPSIESYNDROME TH; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1980, PEDIATRICS, V65, P477; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUIJS MBM, 1994, CLIN NEUROL NEUROSUR, V96, P273, DOI 10.1016/0303-8467(94)90114-7; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; SOUSTIEL JF, 1993, ELECTROEN CLIN NEURO, V87, P277, DOI 10.1016/0013-4694(93)90180-4; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; TURKSTRA LS, 1995, BRAIN INJURY, V9, P61, DOI 10.3109/02699059509004573; [No title captured]; 1995, ARCH PHYS MED REHAB, V76, P205; 1994, NEW ENGL J MED, V330, P1499; 1990, JAMA-J AM MED ASSOC, V263, P426; 1994, NEW ENGL J MED, V330, P1572	55	63	66	0	1	HIPPOKRATES VERLAG GMBH	STITTGART	PO BOX 30 05 04 RUDIGERSTRASSE 14, 70469 STITTGART, GERMANY	0174-304X			NEUROPEDIATRICS	Neuropediatrics	APR	1996	27	2					94	100		10.1055/s-2007-973756			7	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	UN784	WOS:A1996UN78400007	8737825				2022-02-06	
J	SUN, FY; FADEN, AI				SUN, FY; FADEN, AI			NEUROPROTECTIVE EFFECTS OF 619C89, A USE-DEPENDENT SODIUM-CHANNEL BLOCKER, IN RAT TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; SODIUM CHANNEL BLOCKER; GLUTAMATE RELEASE INHIBITOR; EXCITOTOXICITY; NEURONAL DAMAGE; MOTOR DEFICIT	EXCITATORY AMINO-ACIDS; TRANSIENT GLOBAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; SPINAL-CORD INJURY; CEREBRAL-ISCHEMIA; GLUTAMATE RELEASE; NMDA ANTAGONISTS; TRANSPORT SITES; MESSENGER-RNA	Release of the excitatory amino acid (EAA) neurotransmitter glutamate has been implicated in secondary tissue damage following central nervous system (CNS) trauma and ischemia. The present study evaluated the neuroprotective actions of 619C89, a sodium channel blocker that inhibits ischemia-induced glutamate release, on traumatic brain injury (TBI) in rats using a lateral fluid percussion model. Various motor-related behavioral outcomes were used to evaluate neurologic function. Glial fibrillary acidic protein (GFAP) immunostaining and Cresyl violet staining were used to assess the histological changes. Treatment with 619C89, at a dose of 30 mg/kg administered intravenously 15 min before brain injury, significantly attenuated behavioral deficits at 24 h and 1 week. At 2 weeks, neuronal loss in the CA1 and CA3 pyramidal cell layers of the hippocampus was significantly decreased by 619C89 administration. Treatment with this compound also significantly attenuated increases in GFAP-immunoreactivity in both ipsilateral and contralateral CA1 regions. The present results suggest a potential therapeutic role for sodium channel blockade and/or glutamate release inhibition in the treatment of TBI.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ALBERS GW, 1990, CLIN NEUROPHARMACOL, V13, P177, DOI 10.1097/00002826-199006000-00001; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; ANDERSON KJ, 1993, BRAIN RES, V622, P93, DOI 10.1016/0006-8993(93)90806-X; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BUCHAN AM, 1994, NEUROSCI LETT, V132, P255; BULLOCK R, 1994, J CEREBR BLOOD F MET, V14, P466, DOI 10.1038/jcbfm.1994.57; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADDIS BT, 1988, AM J ANAT, V183, P316, DOI 10.1002/aja.1001830405; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LIPTON SA, 1994, NEW ENGL J MED, V33, P613; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1990, BRAIN METAB REV, V2, P25; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; ORDY JM, 1993, EXP NEUROL, V119, P128, DOI 10.1006/exnr.1993.1014; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; Paxinos G, 1986, RAT BRAIN STEREOTAXI; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHARPIRA Y, 1990, J NEUROTRAUM, V7, P131; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SIMON RP, 1992, EXCITAOTRY AMINO ACI, P241; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	46	63	64	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 27	1995	673	1					133	140		10.1016/0006-8993(94)01413-C			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QJ682	WOS:A1995QJ68200017	7757466				2022-02-06	
J	SCHIFFER, D; GIORDANA, MT; CAVALLA, P; VIGLIANI, MC; ATTANASIO, A				SCHIFFER, D; GIORDANA, MT; CAVALLA, P; VIGLIANI, MC; ATTANASIO, A			IMMUNOHISTOCHEMISTRY OF GLIAL REACTION AFTER INJURY IN THE RAT - DOUBLE STAININGS AND MARKERS OF CELL-PROLIFERATION	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						BRAIN INJURY; GLIAL REACTION; GFAP AND VIMENTIN; BRDU-PCNA	FIBRILLARY ACIDIC PROTEIN; MESSENGER-RNA LEVELS; NERVOUS-SYSTEM; CEREBRAL-CORTEX; BRAIN INJURY; RADIAL GLIA; STAB WOUNDS; ADULT-RATS; ASTROCYTES; EXPRESSION	The astrocytic reaction in the rat after brain injury has been studied immunohistochemically for intermediate filaments (GFAP and vimentin), also with double staining procedures, and for markers of proliferation (BrdU and PCNA). GFAP-positive reactive astrocytes appeared around the lesion, where they were vimentin-positive and at a distance. BrdU and PCNA showed a high labelling index around the wound at day 2 and scattered positive nuclei were also found at a distance in the ipsilateral side. BrdU-positive astrocytes represented a minor fraction of GFAP- and vimentin-positive astrocytes. The expression of vimentin persisted at least 15 days after the lesion. Our results could suggest that distant reactive astrocytes originate through hypertrophy while those close to lesion arise by hyperplasia from mature or immature glial cells. The hypothesis is formulated that cells of the periventricular matrix contribute to the post-traumatic proliferative activity.			SCHIFFER, D (corresponding author), UNIV TURIN,DEPT NEUROL 2,VIA CHERASCO 15,I-10126 TURIN,ITALY.			vigliani, maria claudia/0000-0002-9026-7985; Cavalla, Paola/0000-0003-4589-4864			BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; FEDOROFF S, 1984, J NEUROSCI RES, V12, P15, DOI 10.1002/jnr.490120103; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; IKUTA F, 1991, NEUROPATHOLOGY BRAIN, P211; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEVITT P, 1981, J NEUROSCI, V1, P27, DOI 10.1523/JNEUROSCI.01-01-00027.1981; LUDWIN SK, 1985, LAB INVEST, V52, P20; LUDWIN SK, 1984, ACTA NEUROPATHOL, V63, P240, DOI 10.1007/BF00685250; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MILLER RH, 1986, J NEUROSCI, V6, P22; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; REYNERS H, 1986, J NEUROCYTOL, V15, P53, DOI 10.1007/BF02057904; SCHIFFER D, 1991, ACTA NEUROPATHOL, V83, P30, DOI 10.1007/BF00294427; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; STEWARD O, 1990, J NEUROSCI, V10, P2373; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309	28	63	64	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	1993	11	2					269	280		10.1016/0736-5748(93)90085-R			12	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	LD086	WOS:A1993LD08600016	7687086				2022-02-06	
J	HELLMANN, JR; SHOTT, SR; GOOTEE, MJ				HELLMANN, JR; SHOTT, SR; GOOTEE, MJ			IMPALEMENT INJURIES OF THE PALATE IN CHILDREN - REVIEW OF 131 CASES	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						PALATE; IMPALEMENT; NEUROLOGIC	INTERNAL CAROTID-ARTERY; THROMBOSIS; TRAUMA	Impalement injuries of the soft palate and oropharynx are common injuries especially in children. Devastating neurologic sequelae secondary to thrombus propagation in the internal carotid artery are rare but well-documented complications of these innocuous appearing injuries. Neurologic sequelae have been reported anywhere from 3 to 60 hours after the injury. Protocols that include hospitalization up to 72 hours have been advocated. In order to evaluate the effectiveness and practicality of such protocols, all hospital admissions for palate injuries in the past 17 years were reviewed. Of the 131 cases reviewed, no complications were discovered during hospitalization, nor were there any complications in these patients seen in follow up. Based on this review, the majority of soft plate and oropharyngeal impalement injuries can be managed on an outpatient basis. Parental counseling, similar to instructions given in instances of mild head trauma, as well as close follow up in the office are felt to be a more reasonable and as well as a safe treatment plan. A suggested instruction form is presented.	CHILDRENS HOSP MED CTR,DEPT PEDIAT OTOLARYNGOL & MAXILLOFACIAL SURG,BETHESDA & ELLAND AVE,CINCINNATI,OH 45229								ALPERS BJ, 1959, ARCH NEURO PSYCHIATR, V81, P409, DOI 10.1001/archneurpsyc.1959.02340160007002; BICKERSTAFF ER, 1964, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5401.82; BRAUDO M, 1956, BRIT MED J, V1, P665, DOI 10.1136/bmj.1.4968.665; Caldwell JA, 1936, AM J SURG, V32, P522; CRAWFORD B S, 1970, British Journal of Plastic Surgery, V23, P262, DOI 10.1016/S0007-1226(70)80052-2; FAIRBURN B, 1957, BRIT MED J, V2, P750, DOI 10.1136/bmj.2.5047.750; HELMUT D, 1983, PLAST RECONSTR SURG, V72, P656; HENGERER AS, 1984, LARYNGOSCOPE, V94, P1571; HOLYST J, 1976, ACTA NEUROCHIR, V33, P325, DOI 10.1007/BF01886680; MAINS B, 1989, J LARYNGOL OTOL, V103, P796, DOI 10.1017/S0022215100110126; MARTIN N, 1969, SOUTHERN MED J, V62, P103, DOI 10.1097/00007611-196901000-00023; MEYER JS, 1958, NEW ENGL J MED, V258, P151, DOI 10.1056/NEJM195801232580401; PITNER SE, 1966, NEW ENGL J MED, V274, P764, DOI 10.1056/NEJM196604072741403; SHANON E, 1972, ARCHIV OTOLARYNGOL, V96, P256; SHILLITO J, 1964, J NEUROSURG, V21, P540, DOI 10.3171/jns.1964.21.7.0540; TOWNE JB, 1972, ARCH SURG-CHICAGO, V104, P565; WOODHURST WB, 1980, NEUROSURGERY, V6, P559, DOI 10.1227/00006123-198005000-00012	17	63	65	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0165-5876			INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	MAR	1993	26	2					157	163		10.1016/0165-5876(93)90021-T			7	Otorhinolaryngology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology; Pediatrics	KP241	WOS:A1993KP24100007	8444557				2022-02-06	
J	ODER, W; GOLDENBERG, G; SPATT, J; PODREKA, I; BINDER, H; DEECKE, L				ODER, W; GOLDENBERG, G; SPATT, J; PODREKA, I; BINDER, H; DEECKE, L			BEHAVIORAL AND PSYCHOSOCIAL SEQUELAE OF SEVERE CLOSED HEAD-INJURY AND REGIONAL CEREBRAL BLOOD-FLOW - A SPECT STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SOCIAL RECOVERY; RELATIVES VIEW; FOLLOW-UP; TRAUMA	Thirty six patients (31 male, 5 female) who had suffered severe closed head injury were re-examined at an average of 39.3 (SD 12.8, range 7-66) months after the injury. Behavioural symptoms were measured using the Giessen test. The relatives' reports were used for data analysis to ensure that results were valid. The neurophysical impairment subscale of the Glasgow assessment schedule was completed by two neurologists, and the number connection test was completed by each patient. The adjective mood scale was completed by each relative. All patients were investigated by single photon emission computerised tomography (SPECT). Exploratory factor analysis using the principal components method was carried out separately for SPECT results and psychological measures and correlations were sought between the resulting factors. Factor analysis of the data from the Giessen test identified social isolation, disinhibition, and aggressive behaviour as major components of post-traumatic personality changes; it indicates that these behavioural features are independent of the level of neurological and neuropsychological impairment, which loaded on a single independent factor. Relatives' psychic health seemed to be relatively resistant to physical and cognitive disability and was mainly affected by disinhibitive behaviour. The highest correlation was between frontal flow indices and disinhibitive behaviour (p < 0.01): the severity of disinhibition increased with lower frontal flow rates. There was a significant but somewhat weaker correlation (p < 0.05) between flow indices of the left cerebral hemisphere and social isolation. Low flow values of the right brain regions were related to aggressive behaviour (p < 0.05). Neurological and cognitive impairment correlated negatively with the thalamus; worse neurological and cognitive performance indicated by raised scores on the neurophysical scale and on the number connection test was associated with low thalamic flow values. The results support the importance of lesion location in the production of post traumatic behavioural disorders.			ODER, W (corresponding author), UNIV VIENNA, NEUROL KLIN, DEPT NEUROL, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BECKMANN D, 1979, ERFAHRUNGEN GIESSEN; BEFCKMANN D, 1983, TEST INDIVIDUAL GRUP; BELLINI S, 1979, IEEE T ACOUST SPEECH, V27, P213, DOI 10.1109/TASSP.1979.1163232; Benson D.F., 1986, FRONTAL LOBES; Bond M. R., 1990, REHABILITATION ADULT, P179; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Brooks N., 1990, TRAUMATIC BRAIN INJU, P77; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; FAHY TJ, 1967, LANCET, V2, P475; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GOLDENBERG G, 1992, J NEUROL NEUROSURG P; HELL D, 1982, ARCH PSYCHIAT NERVEN, V232, P167, DOI 10.1007/BF00343697; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1990, REHABILITATION ADULT, P3; KING MA, 1984, J NUCL MED, V25, P1234; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lieberthal MM., 1979, HEPATIC COMA SYNDROM; Livingston M G, 1985, Int Rehabil Med, V7, P145; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MICHAEL C, 1987, UNTERSUCHUNG PERSONO; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PIGATRANO GP, 1986, NEUROPSYCHOL REHABIL, P29; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; PODREKA I, 1987, J NUCL MED, V28, P1657; Poewe W, 1983, J Neural Transm Suppl, V19, P215; POPROPEK AT, 1982, IEEE T NUCL SCI, V21, P1299; RICHTER J, 1991, PSYCHOPATHOLOGY, V24, P25, DOI 10.1159/000284693; Rimel RW, 1990, REHABILITATION ADULT, P8; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TASDALE G, 1984, CLOSED HEAD NIJURY P, P4; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Von Zerssen D., 1986, ASSESSMENT DEPRESSIO, P270; VONZERSSEN D, 1976, KLINISCHE BEURTEILUN; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood R., 1984, CLOSED HEAD INJURY P, P195; [No title captured]; [No title captured]	56	63	63	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1992	55	6					475	480		10.1136/jnnp.55.6.475			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	HZ150	WOS:A1992HZ15000012	1619415	Green Published, Bronze			2022-02-06	
J	MARTINEZARIZALA, A; GREEN, BA				MARTINEZARIZALA, A; GREEN, BA			HYPOTHERMIA IN SPINAL-CORD INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			BLOOD-FLOW; BRAIN TEMPERATURE; TISSUE OXYGEN; RAT-BRAIN; ISCHEMIA; TRAUMA; PROTECTION; ANESTHESIA; MONKEYS	Early investigations involving central nervous system (CNS) temperature lowering to protect against the detrimental effects of hypoxia and ischemia were based on the observation that hypothermia reduces brain metabolism and energy consumption. The protective effects of hypothermia have been demonstrated in numerous experimental models of cerebral ischemia and recently in models of brain trauma. These observations also led to the application of hypothermia, in the form of local spinal cord cooling (LSCC), in animal models of experimental spinal cord injury (SCI). Although some investigators have reported negative results in studies of LSCC following traumatic SCI, the majority of studies have noted beneficial effects. The favorable results in animal experimentation led to a limited number of cases where LSCC was used in the treatment of human SCI. However, results are difficult to interpret because (1) most investigators report only a small number of cases, (2) the studies lack a control population, (3) the time interval from injury to the application of cooling has been highly variable, and (4) several investigators combined drug treatments with LSCC. In these experiments, LSCC was achieved via perfusion with a cold solution or an epidural heat exchanger and the aim was to lower cord temperatures significantly (about 10-degrees-C). The application of the technique itself is fraught with difficulties. It requires acute surgery in a traumatized patient, a wide multilevel laminectomy, and minimizing the time interval between injury and the application of spinal cord cooling. Recent studies in experimental brain ischemia strongly suggest that a drastic lowering of CNS temperature may be unnecessary to lessen the degree of tissue damage occurring following an ischemic brain injury. It has been documented that modest temperature changes (1-3-degrees-C) can critically alter the extent of neuronal injury and blood-brain barrier alterations that occur in models of experimental brain ischemia. These findings are especially intriguing, since an earlier experimental SCI study showed a beneficial effect for normothermic perfusion of contused spinal cord tissue. If lowering brain temperature 1-3-degrees-C is sufficient to benefit compromised brain tissue, it is quite possible that this modest temperature change could also be beneficial to the injured spinal cord. Current investigations in our laboratories are addressing the applicability of these findings to experimental SCI.	UNIV MIAMI,SCH MED,DEPT NEUROL,MIAMI,FL 33136; UNIV MIAMI,SCH MED,DEPT NEUROL SURG,MIAMI,FL 33136		MARTINEZARIZALA, A (corresponding author), UNIV MIAMI,SCH MED,MIAMI PROJECT CURE PARALYSIS,R-48,1600 NW 10TH AVE,MIAMI,FL 33136, USA.						Albin M S, 1965, Surg Forum, V16, P423; ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; ALBIN MS, 1968, J NEUROSURG, V29, P113, DOI 10.3171/jns.1968.29.2.0113; BEATTIE EJ, 1953, SURG GYNECOL OBSTET, V96, P711; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Bricolo A, 1976, Surg Neurol, V6, P101; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Campbell J B, 1973, Surg Neurol, V1, P102; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DUCKER TB, 1978, SURG NEUROL, V10, P60; DUCKER TB, 1978, SURG NEUROL, V10, P64; DUCKER TB, 1969, J NEUROSURG, V30, P693; Eidelberg E, 1976, Surg Neurol, V6, P243; Green B A, 1973, Surg Forum, V24, P436; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; HOWITT MM, 1972, CAN J SURG, V15, P179; KELLY DL, 1970, J NEUROSURG, V33, P554, DOI 10.3171/jns.1970.33.5.0554; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; Kuchner E F, 1976, Surg Neurol, V6, P371; MARSHALL SB, 1956, ARCH SURG-CHICAGO, V72, P98; MEACHAM WF, 1973, SOUTH MED J, V66, P95, DOI 10.1097/00007611-197301000-00016; MICHENFELDER JD, 1976, ARCH NEUROL-CHICAGO, V33, P345, DOI 10.1001/archneur.1976.00500050031006; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; NEGRIN J, 1975, NEW YORK STATE J MED, V75, P2387; NOBLE LJ, 1987, EXP NEUROL, V95, P530, DOI 10.1016/0014-4886(87)90162-2; PONTIUS R G, 1955, Surg Forum, V5, P224; PONTIUS RG, 1954, SURGERY, V36, P33; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROSOMOFF HL, 1957, ARCH NEURO PSYCHIATR, V78, P454, DOI 10.1001/archneurpsyc.1957.02330410018002; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; ROSOMOFF HL, 1956, J NEUROSURG, V13, P244; SAKAMOTO T, 1989, AM J PHYSIOL, V257, pH785, DOI 10.1152/ajpheart.1989.257.3.H785; SAKAMOTO T, 1989, J NEUROSURG, V70, P780, DOI 10.3171/jns.1989.70.5.0780; SAKAMOTO T, 1990, NEUROSURGERY, V26, P958, DOI 10.1227/00006123-199006000-00006; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; SELKER R G, 1971, Surgical Forum (Chicago), V22, P411; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; TATOR CH, 1979, NEURAL TRAUMA, P363; THIENPRASIT P, 1975, J NEUROSURG, V42, P150, DOI 10.3171/jns.1975.42.2.0150; WELLS JD, 1978, SURG NEUROL, V10, P200; ZIELONKA J S, 1974, Surgical Forum (Chicago), V25, P434	50	63	63	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S497	S505					9	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900007	1613809				2022-02-06	
J	HACKL, JM; GOTTARDIS, M; WIESER, C; RUMPL, E; STADLER, C; SCHWARZ, S; MONKAYO, R				HACKL, JM; GOTTARDIS, M; WIESER, C; RUMPL, E; STADLER, C; SCHWARZ, S; MONKAYO, R			ENDOCRINE ABNORMALITIES IN SEVERE TRAUMATIC BRAIN INJURY - A CUE TO PROGNOSIS IN SEVERE CRANIOCEREBRAL TRAUMA	INTENSIVE CARE MEDICINE			English	Article						SEVERE CRANIOCEREBRAL TRAUMA; ADRENAL SYSTEM; GONADAL SYSTEM; THYROIDAL SYSTEM; HUMAN GROWTH HORMONE; INSULIN SYSTEM	CENTRAL NERVOUS-SYSTEM; LOW-THYROXINE STATE; GROWTH-HORMONE; HEAD-TRAUMA; SOMATOMEDIN ACTIVITY; PLASMA-CORTISOL; SOMATOSTATIN; SUPPRESSION; THYROTROPIN; METABOLISM	Patients with severe craniocerebral trauma (sCCT) display metabolic and endocrine changes. The question is raised whether hormonal patterns give cues to the prognosis of outcome or not. In 21 patients the function of the adrenocortical, gonadal, thyroid and human growth hormone (hGH)-insulin system was assessed. LH, FSH, TSH, prolactin and hGH were stimulated. 3 groups of patients were formed. Group I: patients in acute phase with a Glasgow Coma Score (GCS) more than 6 (group Ia) and less than 6 (group Ib). Group II: patients in transition to traumatic apallic syndrome (TAS). Group III: patients with full-blown or resolving TAS. The values of group Ia comprised low T3, T4 and testosterone, elevated insulin, normal hGH. Group Ib had hypothyroid T3 and T4 and an attenuated response of LH, TSH, prolactin and hGH to stimulation. Group III: there was seen an endocrine normalisation with elevated T4 and TBG and an altered response of hGH and prolactin to stimulation. Endocrine abnormalities were not helpful in predicting which course, either to better or to worse, a given patient would follow.	UNIV HOSP INNSBRUCK,DEPT ANAESTHESIA & GEN INTENS CARE MED,INNSBRUCK,AUSTRIA; UNIV HOSP INNSBRUCK,INST EXPTL PATHOL,INNSBRUCK,AUSTRIA; GEN HOSP KLAGENFURT,DEPT NEUROL,KLAGENFURT,AUSTRIA								BAES M, 1987, ENDOCRINOLOGY, V120, P280, DOI 10.1210/endo-120-1-280; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BRATUSCHMARREIN PR, 1987, J CLIN ENDOCR METAB, V55, P973; COATES CL, 1981, INJURY, V13, P100, DOI 10.1016/0020-1383(81)90042-5; DANIEL PM, 1959, LANCET, V2, P927; EVERSMANN I, 1978, ASIAT SPACE ENV MED, V49, P234; FISHER DA, 1980, ENDOCRINOLOGY, V107, P714, DOI 10.1210/endo-107-3-714; GERSTENBRAND F, 1967, TRAUMATISCHE APALLIS, P9; GNEHM H E, 1979, Helvetica Paediatrica Acta, V34, P529; GOBIET W, 1976, NEUROGENER SCHOCK, P91; GOTTARDIS M, 1988, INFUSIONSTHERAPIE, V15, P112; HACKL JM, 1986, ANAESTHESIST, V35, P171; HANSEN AP, 1975, SCAND J CLIN LAB INV, V35, P205; HARTIG W, 1986, J CLIN NUTR GASTROEN, V1, P255; HESCH RD, 1982, ACTA ENDOKRINOL STOF, V3, P24; HOEFFLER JP, 1987, ENDOCRINOLOGY, V120, P791, DOI 10.1210/endo-120-2-791; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUME DM, 1974, PRINCIPLES SURGERY, P1; JAMBART S, 1980, ACTA ENDOCRINOL-COP, V93, P264, DOI 10.1530/acta.0.0930264; JENNETT B, 1975, LANCET, V1, P480; Josten K U, 1980, Anasth Intensivther Notfallmed, V15, P213, DOI 10.1055/s-2007-1005141; KAPTEIN EM, 1981, J CLIN ENDOCR METAB, V53, P764, DOI 10.1210/jcem-53-4-764; KIRKPATRICK JR, 1987, NUTRITION, V3, P221; KIRVELA O, 1985, CLIN NUTR, V4, P39, DOI 10.1016/0261-5614(85)90036-6; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; MAREK J, 1981, ACTA ENDOCRINOL-COP, V96, P491, DOI 10.1530/acta.0.0960491; MARTIN JB, 1980, FED PROC, V39, P2902; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PHILLIPS LS, 1986, METABOLISM, V35, P78, DOI 10.1016/0026-0495(86)90100-9; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; RUMPL E, 1987, NEUROLOGISCHE PSYCHI, P563; SHAMOON H, 1981, J CLIN ENDOCR METAB, V52, P1235, DOI 10.1210/jcem-52-6-1235; SILER TM, 1974, J CLIN ENDOCR METAB, V38, P742, DOI 10.1210/jcem-38-5-742; STAUB JJ, 1978, SCHWEIZ MED WSCHR, V108, P1909; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904	35	63	66	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.		1991	17	1					25	29		10.1007/BF01708405			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB204	WOS:A1991FB20400006	2037721				2022-02-06	
J	VINK, R; MCINTOSH, TK; RHOMHANYI, R; FADEN, AI				VINK, R; MCINTOSH, TK; RHOMHANYI, R; FADEN, AI			OPIATE ANTAGONIST NALMEFENE IMPROVES INTRACELLULAR FREE MG-2+, BIOENERGETIC STATE, AND NEUROLOGIC OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROSCIENCE			English	Article									UNIV CONNECTICUT,CTR HLTH,DEPT SURG,FARMINGTON,CT 06032; UNIV CALIF SAN FRANCISCO,SCH MED,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143; VET ADM MED CTR,SAN FRANCISCO,CA 94121		VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT CHEM & BIOCHEM,TOWNSVILLE,QLD 4811,AUSTRALIA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; CHANCE B, 1986, FED PROC, V45, P2915; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Faden A I, 1988, Adv Neurol, V47, P531; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1990, IN PRESS J PHARM EXP; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1987, MAGNET RESON MED, V6, P37; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; 1984, NALMEFENE INFORMATIO	45	63	65	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	NOV	1990	10	11					3524	3530					7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EG885	WOS:A1990EG88500006	2230942				2022-02-06	
J	GORDON, E				GORDON, E			CONTROLLED RESPIRATION IN MANAGEMENT OF PATIENTS WITH TRAUMATIC BRAIN INJURIES	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article																	ALEXANDER SC, 1970, ANESTHESIOLOGY, V32, P60, DOI 10.1097/00000542-197001000-00013; Bottistini N, 1969, CEREBRAL BLOOD FLOW, P249; BOZZMARRUBINI M, 1965, AUG S AN INT PRAG; BRAWLEY BW, 1968, SCAND J CLIN LA S102; BROCK M, 1970, 1970 P PRINC C CER D; CAMPAN L, 1968, ANN ANESTH FRANC, V9, P4; CHAMBERLAIN JH, 1970, BRIT J ANAESTH, V42, P32, DOI 10.1093/bja/42.1.32; COTEV S, 1968, SCAND J CLIN LA S102, P111; GORDON E, 1970, ACTA ANAESTH SCAND, V14, P97, DOI 10.1111/j.1399-6576.1970.tb00763.x; GORDON E, 1968, ACTA ANAESTH SCAND, V12, P51, DOI 10.1111/j.1399-6576.1968.tb00411.x; GOTOH F, 1965, ARCH NEUROL-CHICAGO, V12, P410, DOI 10.1001/archneur.1965.00460280080008; GRANHOLM L, 1969, ACTA PHYSIOL SCAND, V77, P179, DOI 10.1111/j.1748-1716.1969.tb04562.x; GRANHOLM L, 1968, EXPERIENTIA, V24, P337, DOI 10.1007/BF02140806; HOEDTRASMUSSEN K, 1967, ARCH NEUROL-CHICAGO, V17, P271, DOI 10.1001/archneur.1967.00470270049007; HUANG CT, 1963, ARCH NEUROL-CHICAGO, V9, P545, DOI 10.1001/archneur.1963.00460110113012; HUNTER AR, 1964, LANCET, V1, P279; KIENLE G, 1969, CEREBRAL BLOOD FLOW, P132; KJALLQUI.A, 1969, ACTA PHYSIOL SCAND, V75, P267, DOI 10.1111/j.1748-1716.1969.tb04380.x; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUNDBERG L, 1959, ACTA PSYCH NEUR S139, P34; MEYER JS, 1960, ARCH NEUROL-CHICAGO, V3, P539, DOI 10.1001/archneur.1960.00450050059007; MEYER JS, 1969, CEREBRAL BLOOD FLOW, P199; PLUM F, 1968, AM J PHYSIOL, V215, P1240, DOI 10.1152/ajplegacy.1968.215.5.1240; ROSSANDA M, 1970, ACTA ANAESTH SCAND, V14, P173, DOI 10.1111/j.1399-6576.1970.tb00963.x; ROSSANDA M, 1966, ACTA ANAESTH SC  S23, P766; SOLOWAY M, 1968, ANESTHESIOLOGY, V29, P975, DOI 10.1097/00000542-196809000-00022; SUGIOKA K, 1960, ANESTHESIOLOGY, V21, P135, DOI 10.1097/00000542-196003000-00001; Symon L., 1968, SCAND J CLIN LA S102, V102, pXIII; THORN W, 1954, PFLUG ARCH GES PHYS, V258, P501, DOI 10.1007/BF00363713; VAPALATHI M, 1969, CEREBRAL BLOOD FLOW, P249	30	63	64	1	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.		1971	15	3					193	&		10.1111/j.1399-6576.1971.tb05461.x			0	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	K5975	WOS:A1971K597500005	5120955				2022-02-06	
J	Yue, JK; Yuh, EL; Korley, FK; Winkler, EA; Sun, XY; Puffer, RC; Deng, HS; Choy, W; Chandra, A; Taylor, SR; Ferguson, AR; Huie, JR; Rabinowitz, M; Puccio, AM; Mukherjee, P; Vassar, MJ; Wang, KKW; Diaz-Arrastia, R; Okonkwo, DO; Jain, S; Manley, GT; Adeoye, OM; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Dikmen, SS; Duhaime, AC; Ellenbogen, R; Feeser, VR; Foreman, B; Gardner, RC; Gaudette, E; Giacino, J; Goldman, D; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Kramer, J; Kreitzer, N; Levin, HS; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, TW; McCrea, M; Merchant, R; Nelson, L; Ngwenya, LB; Noel, F; Palacios, EM; Perl, D; Robertson, C; Rosand, J; Sander, A; Satris, GG; Schnyer, DM; Seabury, SA; Sherer, M; Stein, M; Temkin, NR; Toga, A; Valadka, AB; Vespa, P; Zafonte, R				Yue, John K.; Yuh, Esther L.; Korley, Frederick K.; Winkler, Ethan A.; Sun, Xiaoying; Puffer, Ross C.; Deng, Hansen; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Rabinowitz, Miri; Puccio, Ava M.; Mukherjee, Pratik; Vassar, Mary J.; Wang, Kevin K. W.; Diaz-Arrastia, Ramon; Okonkwo, David O.; Jain, Sonia; Manley, Geoffrey T.; Adeoye, Opeolu M.; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Dikmen, Sureyya S.; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Ramana; Foreman, Brandon; Gardner, Raquel C.; Gaudette, Etienne; Giacino, Joseph; Goldman, Dana; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Kramer, Joel; Kreitzer, Natalie; Levin, Harvey S.; Lindsell, Christopher; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas W.; McCrea, Michael; Merchant, Randall; Nelson, Lindsay; Ngwenya, Laura B.; Noel, Florence; Palacios, Eva M.; Perl, Daniel; Robertson, Claudia; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela G.; Schnyer, David M.; Seabury, Seth A.; Sherer, Mark; Stein, Murray; Temkin, Nancy R.; Toga, Arthur; Valadka, Alex B.; Vespa, Paul; Zafonte, Ross		TRACK-TBI Investigators	Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study	LANCET NEUROLOGY			English	Article							COMMON DATA ELEMENTS; FIBRILLARY ACIDIC PROTEIN; TERMINAL HYDROLASE-L1; TRANSFORMING RESEARCH; INTRACRANIAL LESIONS; CLINICAL KNOWLEDGE; MILD; BIOMARKERS; MODEL; S100B	Background After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on CT scan. Some patients with suspected TBI with normal CT findings show pathology on MRI. We assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings. Methods TRACK-TBI is a prospective cohort study that enrolled patients with TBI who had a clinically indicated head CT scan within 24 h of injury at 18 level 1 trauma centres in the USA. For this analysis, we included patients with normal CT findings (Glasgow Coma Scale score 13-15) who consented to venepuncture within 24 h post injury and who had an MRI scan 7-18 days post injury. We compared MRI findings in these patients with those of orthopaedic trauma controls and healthy controls recruited from the study sites. Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform. We used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 h (time between injury and venepuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 h of injury. The Dunn Kruskal-Wallis test was used to compare GFAP concentrations between MRI lesion types with Benjamini-Hochberg correction for multiple comparisons. This study is registered with ClinicalTrials.gov, number NCT02119182. Findings Between Feb 26,2014, and June 15, 2018, we recruited 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopaedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0.777 (95% CI 0.726-0.829) over 24 h. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL, 25-75th percentile 139.3-813.4), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL, 17.5-214.4), orthopaedic trauma controls (13.1 pg/mL, 6.9-20.0), and healthy controls (8.0 pg/mL, 3.0-14.0; all comparisons between patients with CT-negative MRI-positive findings and other groups p<0.0001). Interpretation Analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 h of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Yue, John K.; Winkler, Ethan A.; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Vassar, Mary J.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA; [Yue, John K.; Yuh, Esther L.; Winkler, Ethan A.; Choy, Winward; Chandra, Ankush; Taylor, Sabrina R.; Ferguson, Adam R.; Huie, J. Russell; Mukherjee, Pratik; Vassar, Mary J.; Manley, Geoffrey T.] Zudcerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA USA; [Korley, Frederick K.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Sun, Xiaoying; Jain, Sonia] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Puffer, Ross C.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA; [Puffer, Ross C.; Deng, Hansen; Rabinowitz, Miri; Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat & Neurosci, Gainesville, FL USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Ctr Neurodegenerat & Repair, Philadelphia, PA 19104 USA; [Adeoye, Opeolu M.; Foreman, Brandon; Kreitzer, Natalie; Ngwenya, Laura B.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, Baltimore, MD 21201 USA; [Boase, Kim; Chesnut, Randall; Dikmen, Sureyya S.; Ellenbogen, Richard; Machamer, Joan; Temkin, Nancy R.] Univ Washington, Seattle, WA 98195 USA; [Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Goldman, Dana; Seabury, Seth A.; Toga, Arthur] Univ Southern Calif, Los Angeles, CA 90089 USA; [Duhaime, Ann-Christine] Mass Gen Hosp, Boston, MA USA; [Feeser, V. Ramana; Merchant, Randall; Valadka, Alex B.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Gardner, Raquel C.; Hemphill, J. Claude; Kramer, Joel; Martin, Alastair; Palacios, Eva M.; Satris, Gabriela G.] Univ Calif San Francisco, San Francisco, CA 94110 USA; [Giacino, Joseph] Spaulding Rehabil Hosp, Boston, MA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar; Levin, Harvey S.; Noel, Florence; Robertson, Claudia; Sander, Angelle] Baylor Coll Med, Houston, TX 77030 USA; [Lindsell, Christopher] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Madden, Christopher] UT Southwestern, Dallas, TX USA; [McAllister, Thomas W.] Indiana Univ, Bloomington, IN 47405 USA; [McCrea, Michael; Nelson, Lindsay] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Schnyer, David M.] UT Austin, Austin, TX USA; [Stein, Murray] Univ Calif San Diego, San Diego, CA 92103 USA; [Vespa, Paul] Univ Calif Los Angeles, Los Angeles, CA USA; [Zafonte, Ross] Harvard Med Sch, Boston, MA 02115 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Schnyer, David/ABD-6372-2021; Hemphill, Claude/AAY-5630-2021; Giacino, Joseph/AAF-1952-2021; Badjatia, Neeraj/AAS-4855-2021; Goldman, Dana P/E-7667-2013; Yue, John/P-1348-2015	Schnyer, David/0000-0002-7472-2853; Hemphill, Claude/0000-0003-4019-7525; Giacino, Joseph/0000-0002-7916-9698; Goldman, Dana P/0000-0001-8498-6396; Bodien, Yelena/0000-0003-4858-2903; Wang, Kevin/0000-0002-9343-6473; Ferguson, Adam/0000-0001-7102-1608; Yue, John/0000-0001-9694-7722; Badjatia, Neeraj/0000-0003-1509-9034	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of DefenseUnited States Department of Defense	Funding National Institute of Neurological Disorders and Stroke and US Department of Defense.	Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Broussard JI, 2018, BRAIN INJURY, V32, P113, DOI 10.1080/02699052.2017.1380228; Carlson AP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10182; Chen HZ, 2017, J NEUROTRAUM, V34, P2291, DOI 10.1089/neu.2016.4870; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; Gill J, GLIAL FIBRILLARY ACI; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Luccichenti G, 2010, FUNCT NEUROL, V25, P109; Manley GT, 2017, J NEUROTRAUM, V34, P2721, DOI 10.1089/neu.2016.4729; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wayne PA, 2012, EVALUATION DETECTION; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	30	62	63	4	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					953	961		10.1016/S1474-4422(19)30282-0			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	WOS:000485784000020	31451409				2022-02-06	
J	Shin, J; Liu, ZH; Bai, WB; Liu, YH; Yan, Y; Xue, YG; Kandela, I; Pezhouh, M; MacEwan, MR; Huang, YG; Ray, WZ; Zhou, WD; Rogers, JA				Shin, Jiho; Liu, Zhonghe; Bai, Wubin; Liu, Yonghao; Yan, Ying; Xue, Yeguang; Kandela, Irawati; Pezhouh, Maryam; MacEwan, Matthew R.; Huang, Yonggang; Ray, Wilson Z.; Zhou, Weidong; Rogers, John A.			Bioresorbable optical sensor systems for monitoring of intracranial pressure and temperature	SCIENCE ADVANCES			English	Article							SILICON NANOMEMBRANES; FIBER; ELECTRONICS; DISSOLUTION; CHALLENGES; LAYERS	Continuous measurements of pressure and temperature within the intracranial, intraocular, and intravascular spaces provide essential diagnostic information for the treatment of traumatic brain injury, glaucoma, and cardiovascular diseases, respectively. Optical sensors are attractive because of their inherent compatibility with magnetic resonance imaging (MRI). Existing implantable optical components use permanent, nonresorbable materials that must be surgically extracted after use. Bioresorbable alternatives, introduced here, bypass this requirement, thereby eliminating the costs and risks of surgeries. Here, millimeter-scale bioresorbable Fabry-Perot interferometers and two dimensional photonic crystal structures enable precise, continuous measurements of pressure and temperature. Combined mechanical and optical simulations reveal the fundamental sensing mechanisms. In vitro studies and histopathological evaluations quantify the measurement accuracies, operational lifetimes, and biocompatibility of these systems. In vivo demonstrations establish clinically relevant performance attributes. The materials, device designs, and fabrication approaches outlined here establish broad foundational capabilities for diverse classes of bioresorbable optical sensors.	[Shin, Jiho] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; [Shin, Jiho] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Liu, Zhonghe; Liu, Yonghao; Zhou, Weidong] Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA; [Bai, Wubin; Xue, Yeguang; Huang, Yonggang; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Bai, Wubin; Rogers, John A.] Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA; [Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Kandela, Irawati] Northwestern Univ, Dev Therapeut Core, Evanston, IL 60208 USA; [Pezhouh, Maryam] Northwestern Univ, Feinberg Sch Med, Northwestern Med, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn Elect Engn & Comp Sci, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA		Zhou, WD (corresponding author), Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn Elect Engn & Comp Sci, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA.	wzhou@uta.edu; jrogers@northwestern.edu	Xue, Yeguang/B-8696-2015; Bai, Wubin/AAG-2382-2020; Rogers, John/L-2798-2016; Huang, Yonggang/B-6998-2009	Xue, Yeguang/0000-0002-1968-5092; Bai, Wubin/0000-0003-2872-5559; Liu, Zhonghe/0000-0002-9629-110X; Kandela, Irawati/0000-0002-8646-9357	Ryan Fellowship; Northwestern University International Institute for Nanotechnology; Cancer Center Support grant (National Cancer Institute) [P30 CA060553]; NSFNational Science Foundation (NSF) [1635443]; NSF PFI programNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [IIP-1827693]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA060553] Funding Source: NIH RePORTER	Y.X. acknowledges support from the Ryan Fellowship and the Northwestern University International Institute for Nanotechnology. I.K. acknowledges support from Cancer Center Support grant no. P30 CA060553 (National Cancer Institute) awarded to the Robert H. Lurie Comprehensive Cancer Center. Y.H. acknowledges support from the NSF (grant no. 1635443). W.Z. and J.A.R. acknowledge support from the NSF PFI program (grant no. IIP-1827693).	Annese VF, 2014, IEEE I C ELECT CIRC, P598, DOI 10.1109/ICECS.2014.7050056; Bai WB, 2018, ADV MATER, V30, DOI 10.1002/adma.201801584; Bhat YM, 2013, GASTROINTEST ENDOSC, V78, P209, DOI 10.1016/j.gie.2013.04.166; Boutry CM, 2018, NAT ELECTRON, V1, P314, DOI 10.1038/s41928-018-0071-7; Boutry CM, 2015, ADV MATER, V27, P6954, DOI 10.1002/adma.201502535; Boutry CM, 2012, PHILOS T R SOC A, V370, P2418, DOI 10.1098/rsta.2011.0439; Chamis AL, 2001, CIRCULATION, V104, P1029, DOI 10.1161/hc3401.095097; Choi M, 2015, ADV MATER, V27, P4081, DOI 10.1002/adma.201501603; Fang H, 2016, P NATL ACAD SCI USA, V113, P11682, DOI 10.1073/pnas.1605269113; Franta D, 2018, J APPL PHYS, V123, DOI 10.1063/1.5026195; Fu RX, 2018, ADV OPT MATER, V6, DOI 10.1002/adom.201700941; Ge YX, 2013, OPTIK, V124, P6946, DOI 10.1016/j.ijleo.2013.05.156; Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hecht E., 2002, OPTICS; Hwang SW, 2015, NANO LETT, V15, P2801, DOI 10.1021/nl503997m; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2012, SCIENCE, V337, P1640, DOI 10.1126/science.1226325; Jiang GQ, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/neuro.20.002.2010; Joannopoulos J., 2002, PHOTONIC CRYSTALS RO; Jung IW, 2009, IEEE LEOS ANN MTG, P761, DOI 10.1109/LEOS.2009.5343346; Kang SK, 2016, NATURE, V530, P71, DOI 10.1038/nature16492; Kang SK, 2015, ADV FUNCT MATER, V25, P1789, DOI 10.1002/adfm.201403469; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Karrock T, 2015, BIOMED OPT EXPRESS, V6, P4901, DOI 10.1364/BOE.6.004901; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee YK, 2017, ACS NANO, V11, P12562, DOI 10.1021/acsnano.7b06697; Leviton D. B., 2006, SPIE ASTRONOMICAL TE, V6273, P11; Li M, 2006, OPT EXPRESS, V14, P1497, DOI 10.1364/OE.14.001497; Liu V, 2012, COMPUT PHYS COMMUN, V183, P2233, DOI 10.1016/j.cpc.2012.04.026; Liu YH, 2017, OPT EXPRESS, V25, P10536, DOI 10.1364/OE.25.010536; Lu YR, 2011, PROC IEEE MICR ELECT, P621, DOI 10.1109/MEMSYS.2011.5734501; Luo MD, 2014, J MICROELECTROMECH S, V23, P4, DOI 10.1109/JMEMS.2013.2290111; Newcombe VFJ, 2008, J NEUROSURG, V109, P159, DOI 10.3171/JNS/2008/109/7/0159; Nizamoglu S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10374; Park B, 2011, IEEE SENS J, V11, P2643, DOI 10.1109/JSEN.2011.2153844; Phang I, 2016, SPINE, V41, pE605, DOI 10.1097/BRS.0000000000001334; Poeggel S, 2015, SENSORS-BASEL, V15, P17115, DOI 10.3390/s150717115; Rodriguez DAA, 2015, MED ENG PHYS, V37, P100, DOI 10.1016/j.medengphy.2014.11.004; Roguin A, 2008, EUROPACE, V10, P334, DOI 10.1093/europace/eun021; Shan DY, 2017, BIOMATERIALS, V143, P142, DOI 10.1016/j.biomaterials.2017.08.003; Shin JH, 2019, NAT BIOMED ENG, V3, P37, DOI 10.1038/s41551-018-0300-4; Sit AJ, 2009, J GLAUCOMA, V18, P272, DOI 10.1097/IJG.0b013e3181862490; Taffoni F, 2013, SENSORS-BASEL, V13, P14105, DOI 10.3390/s131014105; Vanhoestenberghe A, 2009, SENSOR REV, V29, P345, DOI 10.1108/02602280910986593; Watanabe H, 2004, INT J THERMOPHYS, V25, P221, DOI 10.1023/B:IJOT.0000022336.83719.43; Williams EJ, 1999, J NEUROSURG, V91, P706, DOI 10.3171/jns.1999.91.4.0706; Wu X, 2015, J MICROELECTROMECH S, V24, P968, DOI 10.1109/JMEMS.2014.2360859; Yin L, 2015, ADV MATER, V27, P1857, DOI 10.1002/adma.201404579; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Yu L, 2014, SENSORS-BASEL, V14, P20620, DOI 10.3390/s141120620; Zhou WD, 2014, PROG QUANT ELECTRON, V38, P1, DOI 10.1016/j.pquantelec.2014.01.001	52	62	64	16	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	2375-2548			SCI ADV	Sci. Adv.	JUL	2019	5	7							eaaw1899	10.1126/sciadv.aaw1899			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	IN6EO	WOS:000478770400055	31281889	Green Published, gold			2022-02-06	
J	Schonenberg, M; Wiedemann, E; Schneidt, A; Scheeff, J; Logemann, A; Keune, PM; Hautzinger, M				Schoenenberg, Michael; Wiedemann, Eva; Schneidt, Alexander; Scheeff, Jonathan; Logemann, Alexander; Keune, Philipp M.; Hautzinger, Martin			Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial	LANCET PSYCHIATRY			English	Article							DEFICIT/HYPERACTIVITY DISORDER; ADHD; CHILDREN; EEG; BRAIN	Background Many studies suggest that electroencephalographic (EEG) neurofeedback might be beneficial in the treatment of attention-deficit hyperactivity disorder (ADHD). However, numbers of well controlled studies are low and neurofeedback techniques are regarded as highly controversial. The present trial examined the efficacy (compared with sham neurofeedback) and efficiency (compared with meta-cognitive therapy) of a standard EEG neurofeedback protocol in adults with ADHD. Methods We did a concurrent, triple-blind, randomised, controlled trial using authorised deception in adults with ADHD from one centre (University of Tubingen) in Tubingen, Germany. Participants were eligible if they fulfilled the DSM-IV-TR criteria for ADHD, were aged between 18 years and 60 years, and had no or stable use of medication for at least 2 months with no intention to change. We excluded participants who had comorbid schizophrenia or schizoaffective disorder, bipolar disorder, borderline personality disorder, epilepsy, or traumatic brain injury; substance abuse or dependence; or current or planned other psychological treatment. Those eligible were randomly assigned to three groups: a neurofeedback group which received 30 verum theta-to-beta neurofeedback sessions over 15 weeks, a sham neurofeedback group which received 15 sham followed by 15 verum theta-to-beta neurofeedback sessions over 15 weeks, or a meta-cognitive group therapy group which received 12 sessions over 12 weeks. Participants were assigned equally to one of the three interventions through a computerised minimisation randomisation procedure stratified by sex, age, and baseline symptom severity of ADHD. Participants were masked as to whether they were receiving neurofeedback or sham neurofeedback, but those receiving metacognitive therapy were aware of their treatment. Clinical assessors (ie, those assessing outcomes) and research staff who did the neurofeedback training were masked to participants' randomisation status only for neurofeedback and sham neurofeedback. The primary outcome was symptom score on the Conners' adult ADHD rating scale, assessed before treatment, at midtreatment (after 8 weeks), after treatment (after 16 weeks), and 6 months later. All individuals with at least one observation after randomisation were included in the analyses. This trial is registered with ClinicalTrials.gov, number NCT01883765. Findings Between Feb 1, 2013, and Dec 1, 2015, 761 people were assessed for eligibility. 656 (86%) were excluded and 118 (15%) were eligible for participation in this study. Eligible participants were randomly assigned to neurofeedback (38 [32%]), sham neurofeedback (39 [33%]), or meta-cognitive therapy (41 [35%]). 37 (97%) individuals for neurofeedback, 38 (97%) for sham neurofeedback, and 38 (93%) for meta-cognitive therapy were included in analyses. Self-reported ADHD symptoms decreased substantially for all treatment groups (B=-2.58 [95% CI -3.48 to -1.68]; p< 0.0001) between pretreatment and the end of 6 month follow-up, independent of treatment condition (neurofeedback vs sham neurofeedback B=-0.89 [95% CI -2.14 to 0.37], p= 0.168; neurofeedback vs meta-cognitive therapy -0.30 [-1.55 to 0.95], p= 0.639). No treatment-related or trial-related serious adverse events were reported. Interpretation Our findings suggest that neurofeedback training is not superior to a sham condition or group psychotherapy. All three treatments were equivalently effective in reducing ADHD symptoms. This first randomised, sham-controlled trial did not show any specific effects of neurofeedback on ADHD symptoms in adults.	[Schoenenberg, Michael; Wiedemann, Eva; Schneidt, Alexander; Scheeff, Jonathan; Hautzinger, Martin] Univ Tubingen, Dept Clin Psychol & Psychotherapy, D-72076 Tubingen, Germany; [Logemann, Alexander] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary; [Keune, Philipp M.] Univ Bamberg, Dept Physiol Psychol, Bamberg, Germany; [Keune, Philipp M.] Klinikum Bayreuth, Dept Neurol, Bayreuth, Germany		Schonenberg, M (corresponding author), Univ Tubingen, Dept Clin Psychol & Psychotherapy, D-72076 Tubingen, Germany.	michael.schoenenberg@uni-tuebingen.de	Logemann, Alexander/I-3702-2019; Logemann, Herman NA/I-7443-2017; Keune, Philipp/AAZ-2837-2020	Logemann, Alexander/0000-0002-4147-1269; Logemann, Herman NA/0000-0002-4147-1269; 	German Research FoundationGerman Research Foundation (DFG)	German Research Foundation.	Arns M, 2014, BIOL PSYCHOL, V95, P108, DOI 10.1016/j.biopsycho.2013.11.013; Christiansen H, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00943; Cortese S, 2016, J AM ACAD CHILD PSY, V55, P444, DOI 10.1016/j.jaac.2016.03.007; Formann A. K., 2011, WIENER MATRIZEN TEST; Gevensleben H, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00846; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Haavik J, 2010, EXPERT REV NEUROTHER, V10, P1569, DOI 10.1586/ERN.10.149; Hautzinger M, 2006, BECK DEPRESSION INVE; Heyde G., 2000, INVENTORY COMPLEX AT; Hillard B, 2013, CLIN EEG NEUROSCI, V44, P193, DOI 10.1177/1550059412458262; KNYE M, 1996, CPT CONTINUOUS PERFO; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Lansbergen MM, 2011, J NEURAL TRANSM, V118, P275, DOI 10.1007/s00702-010-0524-2; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; LEHRL S, 1989, MULTIPLE CHOICE VOCA; Logemann HNA, 2010, NEUROSCI LETT, V479, P49, DOI 10.1016/j.neulet.2010.05.026; Martin AL, 2010, PAIN, V149, P208, DOI 10.1016/j.pain.2009.12.004; Meisel V, 2013, BIOL PSYCHOL, V94, P12, DOI 10.1016/j.biopsycho.2013.04.015; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Retz-Junginger P, 2002, NERVENARZT, V73, P830, DOI 10.1007/s00115-001-1215-x; Schotte CKW, 1998, PSYCHOL MED, V28, P1179, DOI 10.1017/S0033291798007041; Schuhfried G., 2000, WIENER TEST SYSTEM P; Schulz H, 2003, DIAGNOSTICA, V49, P83, DOI 10.1026//0012-1924.49.2.83; Sharma A, 2014, ANN PHARMACOTHER, V48, P209, DOI 10.1177/1060028013510699; Solanto MV, 2010, AM J PSYCHIAT, V167, P958, DOI 10.1176/appi.ajp.2009.09081123; Sparrow E, 1999, CONNERS ADULT ADHD R; Spielberger C.D., 1970, STAI MANUAL STATE TR; Stieglitz, 2008, HASE HOMBURG ADHD SC; Storebo OJ, 2012, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD009885, 10.1002/14651858.CD009885]; Thibault RT, 2016, CORTEX, V74, P247, DOI 10.1016/j.cortex.2015.10.024; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Wilens Timothy E, 2002, J Atten Disord, V5, P189; Zimmermann P, 2009, TEST ATTENTIONAL PER; Zuberer A, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00135	34	62	62	3	64	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2215-0374			LANCET PSYCHIAT	Lancet Psychiatry	SEP	2017	4	9					673	684		10.1016/S2215-0366(17)30291-2			12	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	FE7DW	WOS:000408368800027	28803030				2022-02-06	
J	Cheng, PC; Yin, P; Ning, PD; Wang, LJ; Cheng, XJ; Liu, YN; Schwebel, DC; Liu, JM; Qi, JL; Hu, GQ; Zhou, MG				Cheng, Peixia; Yin, Peng; Ning, Peishan; Wang, Lijun; Cheng, Xunjie; Liu, Yunning; Schwebel, David C.; Liu, Jiangmei; Qi, Jinlei; Hu, Guoqing; Zhou, Maigeng			Trends in traumatic brain injury mortality in China, 2006-2013: A population-based longitudinal study	PLOS MEDICINE			English	Article							ROAD TRAFFIC MORTALITY; OLDER WOMEN; NEW-ZEALAND; DEATH; EPIDEMIOLOGY; RISK; PREVENTION; BEHAVIORS; INCREASES; BALANCE	Background Traumatic brain injury (TBI) is a significant global public health problem, but has received minimal attention from researchers and policy-makers in low-and middle-income countries (LMICs). Epidemiological evidence of TBI morbidity and mortality is absent at the national level for most LMICs, including China. Using data from China's Disease Surveillance Points (DSPs) system, we conducted a population-based longitudinal analysis to examine TBI mortality, and mortality differences by sex, age group, location (urban/rural), and external cause of injury, from 1 January 2006 to 31 December 2013 in China. Method and findings Mortality data came from the national DSPs system of China, which has coded deaths using the International Classification of Diseases-10th Revision (ICD-10) since 2004. Crude and age-standardized mortality with 95% CIs were estimated using the census population in 2010 as a reference population. The Cochran-Armitage trend test was used to examine the significance of trends in mortality from 2006 to 2013. Negative binomial models were used to examine the associations of TBI mortality with location, sex, and age group. Subgroup analysis was performed by external cause of TBI. We found the following: (1) Age-adjusted TBI mortality increased from 13.23 per 100,000 population in 2006 to 17.06 per 100,000 population in 2008 and then began to fall slightly. In 2013, age-adjusted TBI mortality was 12.99 per 100,000 population (SE = 0.13). (2) Compared to females and urban residents, males and rural residents had higher TBI mortality risk, with adjusted mortality rate ratios of 2.57 and 1.71, respectively. TBI mortality increased substantially with older age. (3) Motor vehicle crashes and falls were the 2 leading causes of TBI mortality between 2006 and 2013. TBI deaths from motor vehicle crashes in children aged 0-14 years and adults aged 65 years and older were most often in pedestrians, and motorcyclists were the first or second leading category of road user for the other age groups. (4) TBI mortality attributed to motor vehicle crashes increased for pedestrians and motorcyclists in all 7 age groups from 2006 to 2013. Our analysis was limited by the availability and quality of data in the DSPs dataset, including lack of injury-related socio-economic factors, policy factors, and individual and behavioral factors. The dataset also may be incomplete in TBI death recording or contain misclassification of mortality data. Conclusions TBI constitutes a serious public health threat in China. Further studies should explore the reasons for the particularly high risk of TBI mortality among particular populations, as well as the reasons for recent increases in certain subgroups, and should develop solutions to address these challenges. Interventions proven to work in other cultures should be introduced and implemented nationwide. Examples of these in the domain of motor vehicle crashes include policy change and enforcement of laws concerning helmet use for motorcyclists and bicyclists, car seat and booster seat use for child motor vehicle passengers, speed limit and drunk driving laws, and alcohol ignition interlock use. Examples to prevent falls, especially among elderly individuals, include exercise programs, home modification to reduce fall risk, and multifaceted interventions to prevent falls in all age groups.	[Cheng, Peixia; Ning, Peishan; Cheng, Xunjie; Hu, Guoqing] Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Yin, Peng; Wang, Lijun; Liu, Yunning; Liu, Jiangmei; Qi, Jinlei; Zhou, Maigeng] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China; [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA		Hu, GQ (corresponding author), Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China.; Zhou, MG (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China.	huguoqing009@gmail.com; maigengzhou@126.com	Liu, You-Nian/G-2697-2013	Liu, You-Nian/0000-0002-7078-5937; Hu, Guoqing/0000-0002-5002-8015			Adams RS, 2013, SUBST USE MISUSE, V48, P821, DOI 10.3109/10826084.2013.797995; Alcorn T, 2011, LANCET, V378, P305, DOI 10.1016/S0140-6736(11)61153-7; [Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Asbridge M, 2010, ACCIDENT ANAL PREV, V42, P1408, DOI 10.1016/j.aap.2010.03.005; Barr GC, 2015, J EMERG MED, V48, P366, DOI 10.1016/j.jemermed.2014.09.055; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Chinese Center for Disease Control and Prevention National Center for Chronic and Noncommunicable Disease Control and Prevention, 2008, DAT SETS DEATH CAUS; Chinese Center for Disease Control and Prevention National Center for Chronic and Noncommunicable Disease Control and Prevention, 2013, DAT SETS DEATH CAUS; Coronado VG, 2011, MMWR SURVEILL SUMM, V60, P1; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; D'Souza AJ, 2008, J EPIDEMIOL COMMUN H, V62, P899, DOI 10.1136/jech.2007.068072; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Firsching R, 2001, WORLD J SURG, V25, P1221; Hu G, 2008, INJURY PREV, V14, P129, DOI 10.1136/ip.2007.017822; Hu GQ, 2011, B WORLD HEALTH ORGAN, V89, P41, DOI 10.2471/BLT.10.080317; Hu GQ, 2010, J RURAL HEALTH, V26, P73, DOI 10.1111/j.1748-0361.2009.00255.x; Hu GQ, 2009, LANCET, V373, P214, DOI 10.1016/S0140-6736(09)60068-4; Huang HL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153251; Huang YX, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1111; Hui Z, 2012, BIOMED ENVIRON SCI, V25, P483, DOI 10.3967/0895-3988.2012.04.015; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JUDGE JO, 1993, PHYS THER, V73, P254, DOI 10.1093/ptj/73.4.254; Kessaram T, 2016, DRUG ALCOHOL REV, V35, P412, DOI 10.1111/dar.12328; Li L, 2015, B WORLD HEALTH ORGAN, V93, P169, DOI 10.2471/BLT.14.139998; Liu Ming-bo, 2013, Zhonghua Liu Xing Bing Xue Za Zhi, V34, P985; LORD SR, 1993, ARCH PHYS MED REHAB, V74, P837, DOI 10.1016/0003-9993(93)90010-8; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; Mooney P, 2006, B WORLD HEALTH ORGAN, V84, P168; National Health and Family Planning Commission of the People's Republic of China, 2007, CHIN HLTH STAT YB 20; National Health and Family Planning Commission of the PRC, 2014, CHIN HLTH STAT YB 20; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Nicodemus KK, 2008, MOL PSYCHIATR, V13, P873, DOI 10.1038/sj.mp.4002153; Ning P, 2017, INJ PREV; Ning PS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164560; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reidy DE, 2016, INJURY PREV, V22, P370, DOI 10.1136/injuryprev-2015-041599; Riesch SK, 2013, INT J NURS STUD, V50, P1067, DOI 10.1016/j.ijnurstu.2012.10.012; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sasser SM, 2006, B WORLD HEALTH ORGAN, V84, P507, DOI 10.2471/BLT.06.033605; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Song SL, 2016, COMPUT J, V59, P91, DOI 10.1093/comjnl/bxv066; Statistical Consulting Group, NEG BIN REGR STAT AN; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tian DP, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0330-z; US Centers for Disease Control and Prevention, EXT CAUS INJ MORT MA; Vaaramo K, 2015, J NEUROTRAUM, V32, P1579, DOI 10.1089/neu.2014.3757; Varghese M., 2005, PREHOSPITAL TRAUMA C; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang Li-jun, 2007, Zhonghua Liu Xing Bing Xue Za Zhi, V28, P571; Wang Lin, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P1061; WHO, 2013, PED SAF ROAD SAF MAN; World Health Organization, 2013, MAK WALK SAF BRIEF O; World Health Organization, 2007, WHO GLOB REP FALLP; [杨冬立 Yang Dongli], 2013, [中国急救医学, Chinese Journal of Critical Care Medicine], V33, P1130; Yang G, 1992, Zhonghua Liu Xing Bing Xue Za Zhi, V13, P197; Yang Gonghuan, 2005, Popul Health Metr, V3, P3, DOI 10.1186/1478-7954-3-3; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HaoSu, 2016, Chinese Journal of Emergency Medicine, V25, P779; Zhang Y., 2016, J TRAUMA SURG, V18, P328; [张溢华 Zhang Yihua], 2014, [中华创伤杂志, Chinese Journal of Trauma], V30, P1215; Zhou Mai-geng, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P328; Zhou MaiGeng, 2010, Disease Surveillance, V25, P239	71	62	74	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002332	10.1371/journal.pmed.1002332			22	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC1QA	WOS:000406611200034	28700591	Green Published, Green Submitted, gold			2022-02-06	
J	Kroshus, E; Baugh, CM; Stein, CJ; Austin, SB; Calzo, JP				Kroshus, Emily; Baugh, Christine M.; Stein, Cynthia J.; Austin, S. Bryn; Calzo, Jerel P.			Concussion reporting, sex, and conformity to traditional gender norms in young adults	JOURNAL OF ADOLESCENCE			English	Article						Concussion; College; Sport; Gender; Help-seeking	STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; AGE-DIFFERENCES; INJURY; SPORT; FEMALE; RISK; SYMPTOMS; WOMEN; PAIN	This study assessed whether between-sex differences in concussion reporting intention and behavior among young adults are explained by the extent to which the individual conforms to traditional masculine norms that often characterize contemporary sport culture. A survey of college athletes in the United States (n = 328) found greater symptom reporting intention among females as compared to males, but no difference in their likelihood continued play while experiencing symptoms of a possible concussion. Greater conformity to the norms of risk-taking was associated with greater likelihood of continued play while symptomatic among female athletes but not among male athletes. These findings suggest that gendered behavior, rather than biologically determined sex, is an important consideration for concussion safety in this age group. Addressing elements of the contemporary sport ethos that reinforce risk taking in service of athletic achievement may be a relevant direction for interventions aimed at improving injury reporting among all athletes. (C) 2016 The Foundation for Professionals in Services for Adolescents. Published by Elsevier Ltd. All rights reserved.	[Kroshus, Emily] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Kroshus, Emily] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Baugh, Christine M.] Harborview Injury Prevent Res Ctr, Seattle, WA USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.; Stein, Cynthia J.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Austin, S. Bryn] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Austin, S. Bryn; Calzo, Jerel P.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Austin, S. Bryn; Calzo, Jerel P.] Boston Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA USA		Kroshus, E (corresponding author), 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@u.washington.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Calzo, Jerel/0000-0002-4656-1052			Abar C, 2008, ADDICT BEHAV, V33, P1360, DOI 10.1016/j.addbeh.2008.06.010; Ajzen I, 2011, HDB THEORIES SOCIAL, V1, P438, DOI [10.4135/9781446249215.n22, DOI 10.4135/9781446249215.N22]; Atkinson Michael, 2010, SEXUAL SPORTS RHETOR, P15; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; BLINDE EM, 1992, SOCIOL QUART, V33, P521, DOI 10.1111/j.1533-8525.1992.tb00141.x; Calzo JP, 2014, ANN BEHAV MED, V47, P17, DOI 10.1007/s12160-013-9570-y; Caudwell J., 1999, Journal of Sport and Social Issues, V23, P390, DOI 10.1177/0193723599234003; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Ezzell MB, 2009, SOC PROBL, V56, P111, DOI 10.1525/sp.2009.56.1.111; Fenton LT, 2010, RES Q EXERCISE SPORT, V81, P212; Figner B, 2009, J EXP PSYCHOL LEARN, V35, P709, DOI 10.1037/a0014983; Fogel C., 2011, CANADA SOCIAL SCI, V7, P1; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Halbert C., 1997, Journal of Sport and Social Issues, V21, P7, DOI 10.1177/019372397021001002; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson G. L., 2012, REHABILITATION REP; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2014, INT EPIDEMIOL, V1, P1; Kline Rex B., 2015, PRINCIPLES PRACTICE, P394; Kroshus E., 2015, ANN BEHAV MED; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lugasi T, 2011, J ADOLESCENT HEALTH, V48, P429, DOI 10.1016/j.jadohealth.2010.10.016; Mahalik J.R., 2003, PSYCHOL MEN MASCULIN, V4, P3, DOI [10.1037/1524-9220.4.1.3, DOI 10.1037/1524-9220.4.1.3]; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Malcom NL, 2006, J CONTEMP ETHNOGR, V35, P495, DOI 10.1177/0891241605283571; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCreary DR, 1996, SEX ROLES, V34, P507, DOI 10.1007/BF01545029; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McDermott R C., 2016, PSYCHOL MEN MASCULIN; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Morrongiello BA, 2000, J EXP CHILD PSYCHOL, V76, P89, DOI 10.1006/jecp.2000.2572; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Collegiate Athletic Association, 2014, DIV I STEER COMM GOV; Nixon H. L. II, 1992, Journal of Sport and Social Issues, V16, P127, DOI 10.1177/019372359201600208; NIXON HL, 1994, SOCIOL SPORT J, V11, P79, DOI 10.1123/ssj.11.1.79; Parent MC, 2013, PSYCHOL MEN MASCULIN, V14, P324, DOI 10.1037/a0027642; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Reyna VF, 2006, PSYCHOL SCI, P1, DOI 10.1111/j.1529-1006.2006.00026.x; Roderick M, 2006, SOCIOL HEALTH ILL, V28, P76, DOI 10.1111/j.1467-9566.2005.00483.x; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Sartore ML, 2009, SEX ROLES, V60, P100, DOI 10.1007/s11199-008-9502-7; Shakib S, 2002, SOCIOL PERSPECT, V45, P353, DOI 10.1525/sop.2002.45.4.353; Sisjord MK, 2009, INT REV SOCIOL SPORT, V44, P231, DOI 10.1177/1012690209335278; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Steinfeldt JA, 2011, PSYCHOL MEN MASCULIN, V12, P401, DOI 10.1037/a0023634; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Tracey J, 2003, J APPL SPORT PSYCHOL, V15, P279, DOI 10.1080/714044197; Vast RL, 2010, AUST PSYCHOL, V45, P132, DOI 10.1080/00050060903261538; Waldron JJ, 2005, QUEST, V57, P315, DOI 10.1080/00336297.2005.10491860; Young K., 1995, Journal of Sport and Social Issues, V19, P45, DOI 10.1177/019372395019001004; Zamarripa MX, 2003, J COUNS PSYCHOL, V50, P333, DOI 10.1037/0022-0167.50.3.333	66	62	61	2	26	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0140-1971	1095-9254		J ADOLESCENCE	J. Adolesc.	JAN	2017	54						110	119		10.1016/j.adolescence.2016.11.002			10	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	EI7KN	WOS:000392676700012	27984789				2022-02-06	
J	Thelin, EP; Jeppsson, E; Frostell, A; Svensson, M; Mondello, S; Bellander, BM; Nelson, DW				Thelin, Eric Peter; Jeppsson, Emma; Frostell, Arvid; Svensson, Mikael; Mondello, Stefania; Bellander, Bo-Michael; Nelson, David W.			Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity	CRITICAL CARE			English	Article						Traumatic brain injury; Biomarkers; S100B; Neuron-specific enolase; Outcome	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; GLASGOW COMA SCALE; SERUM S100B; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; HEAD-INJURY; S-100-BETA PROTEIN; PROGNOSTIC VALUE; PREDICTIVE-VALUE	Background: In order to improve assessment and outcome prediction in patients suffering from traumatic brain injury (TBI), cerebral protein levels in serum have been suggested as biomarkers of injury. However, despite much investigation, biomarkers have yet to reach broad clinical utility in TBI. This study is a 9-year follow-up and clinical experience of the two most studied proteins, neuron-specific enolase (NSE) and S100B, in a neuro-intensive care TBI population. Our aims were to investigate to what extent NSE and S100B, independently and in combination, could predict outcome, assess injury severity, and to investigate if the biomarker levels were influenced by extracranial factors. Methods: All patients treated at the neuro-intensive care unit at Karolinska University Hospital, Stockholm, Sweden between 2005 and 2013 with at least three measurements of serum S100B and NSE (sampled twice daily) were retrospectively included. In total, 417 patients fulfilled the criteria. Parameters were extracted from the computerized hospital charts. Glasgow Outcome Score (GOS) was used to assess long-term functional outcome. Univariate, and multivariate, regression models toward outcome and what explained the high levels of the biomarkers were performed. Nagelkerke's pseudo-R-2 was used to illustrate the explained variance of the different models. A sliding window assessed biomarker correlation to outcome and multitrauma over time. Results: S100B was found a better predictor of outcome as compared to NSE (area under the curve (AUC) samples, the first 48 hours had Nagelkerke's pseudo-R2 values of 0.132 and 0.038, respectively), where the information content of S100B peaks at approximately 1 day after trauma. In contrast, although both biomarkers were independently correlated to outcome, NSE had limited additional predictive capabilities in the presence of S100B in multivariate models, due to covariance between the two biomarkers (correlation coefficient 0.673 for AUC 48 hours). Moreover, NSE was to a greater extent correlated to multitrauma the first 48 hours following injury, whereas the effect of extracerebral trauma on S100B levels appears limited to the first 12 hours. Conclusions: While both biomarkers are independently correlated to long-term functional outcome, S100B is found a more accurate outcome predictor and possibly a more clinically useful biomarker than NSE for TBI patients.	[Thelin, Eric Peter; Jeppsson, Emma; Frostell, Arvid; Svensson, Mikael; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Nelson, David W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden		Thelin, EP (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	eric.thelin@ki.se	Svensson, Mikael/F-8662-2012; Thelin, Eric Peter/K-2144-2012; Viani, Rafael/V-1196-2018; Frostell, Arvid/ABG-5167-2021; Mondello, Stefania/A-1813-2012	Svensson, Mikael/0000-0003-1179-7003; Thelin, Eric Peter/0000-0002-2338-4364; Mondello, Stefania/0000-0002-8587-3614; Nelson, David/0000-0003-2530-8207	Karolinska InstitutetKarolinska Institutet; Stockholm CountyStockholm County Council; SENSUS Region Mellansverige	The study was founded by grants from the Karolinska Institutet and the Stockholm County (ALF funding) as well as funding from SENSUS Region Mellansverige. The funding bodies had no role in the design of the study, interpretation of the data or in the presentation results.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Committee on Trauma American College of Surgeons, 2008, ATLS ADV TRAUM LIF S, V8th; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gonzalez-Mao MC, 2011, CLIN LAB, V57, P587; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Karaoguz R, 2008, INT HEART J, V49, P553, DOI 10.1536/ihj.49.553; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; R Development Core Team, 2008, R LANG ENV STAT COMP; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Sogut O, 2010, J INT MED RES, V38, P1708, DOI 10.1177/147323001003800516; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; TEASDALE G, 1974, LANCET, V2, P81; Thelin E. P., 2015, EUR J TRAUMA EMERG S; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; [No title captured]	86	62	68	1	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 8	2016	20								285	10.1186/s13054-016-1450-y			15	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DV2AN	WOS:000382723300001	27604350	Green Published, gold			2022-02-06	
J	Trepanier, MO; Hopperton, KE; Orr, SK; Bazinet, RP				Trepanier, Marc-Olivier; Hopperton, Kathryn E.; Orr, Sarah K.; Bazinet, Richard P.			N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Neuroinflammation; Omega-3 polyunsaturated fatty acids; Brain; Cytokines; Microglia; Docosahexaenoic acid	SPINAL-CORD-INJURY; OLFACTORY BULBECTOMIZED RAT; GROWTH-FACTOR EXPRESSION; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; ETHYL-EICOSAPENTAENOATE; INFLAMMATORY RESPONSE; ALZHEIMERS-DISEASE; DOUBLE-BLIND; LIPID MEDIATORS	Neuroinflammation is a characteristic of a multitude of neurological and psychiatric disorders. Modulating inflammatory pathways offers a potential therapeutic target in these disorders. Omega-3 polyunsaturated fatty acids have anti-inflammatory and pro-resolving properties in the periphery, however, their effect on neuroinflammation is less studied. This review summarizes 61 animal studies that tested the effect of omega-3 polyunsaturated fatty acids on neuroinflammatory outcomes in vivo in various models including stroke, spinal cord injury, aging, Alzheimer's disease, Parkinson's disease, lipopolysaccharide and IL-113 injections, diabetes, neuropathic pain, traumatic brain injury, depression, surgically induced cognitive decline, whole body irradiation, amyotrophic lateral sclerosis, N-methyl-D-aspartate-induced excitotoxicity and lupus. The evidence presented in this review suggests anti-neuroinflammatory properties of omega-3 polyunsaturated fatty acids, however, it is not clear by which mechanism omega-3 polyunsaturated fatty acids exert their effect. Future research should aim to isolate the effect of omega-3 polyunsaturated fatty acids on neuroinflammatory signaling in vivo and elucidate the mechanisms underlying these effects. (C) 2016 Published by Elsevier B.V.	[Trepanier, Marc-Olivier; Hopperton, Kathryn E.; Orr, Sarah K.; Bazinet, Richard P.] Univ Toronto, Fac Med, Dept Nutr Sci, FitzGerald Bldg,150 Coll St,Room 306, Toronto, ON M5S 3E2, Canada		Bazinet, RP (corresponding author), Univ Toronto, Fac Med, Dept Nutr Sci, FitzGerald Bldg,150 Coll St,Room 306, Toronto, ON M5S 3E2, Canada.	richard.bazinet@utoronto.ca		Hopperton, Kathryn/0000-0003-0146-2744	Natural Sciences and Engineering Research Council of Canada, CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); Canadian Institutes of Health Research, CanadaCanadian Institutes of Health Research (CIHR)	This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada, Canada and the Canadian Institutes of Health Research, Canada to RPB. MOT received a studentship from the Natural Sciences and Engineering Research Council of Canada and RPB holds a Canada Research Chair in Brain Lipid Metabolism.	Alvarez-Nolting R, 2012, NEUROCHEM RES, V37, P105, DOI 10.1007/s11064-011-0588-x; Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192; Ballesteros-Zebadua P, 2012, CNS NEUROL DISORD-DR, V11, P937, DOI 10.2174/1871527311201070937; Banks WA, 2015, BRAIN BEHAV IMMUN, V44, P1, DOI 10.1016/j.bbi.2014.08.007; Barden A, 2014, J LIPID RES, V55, P2401, DOI 10.1194/jlr.M045583; Baron Ralf, 2009, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-540-79090-7_1; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Bazinet R.P., 2014, NAT REV NEUROSCI; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; BLACK KL, 1984, PROSTAG OTH LIPID M, V28, P545, DOI 10.1016/0090-6980(84)90243-0; Bousquet M, 2011, AGEING RES REV, V10, P453, DOI 10.1016/j.arr.2011.03.001; Bousquet M, 2011, J LIPID RES, V52, P263, DOI 10.1194/jlr.M011692; Breitner J, 2013, ALZHEIMERS DEMENT, V9, P714, DOI 10.1016/j.jalz.2012.11.012; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cai DS, 2013, TRENDS ENDOCRIN MET, V24, P40, DOI 10.1016/j.tem.2012.11.003; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Cohen SP, 2014, BMJ-BRIT MED J, V348, pf7656, DOI [10.1136/bmj.f7656, DOI 10.1136/BMJ.F7656]; Colas RA, 2014, AM J PHYSIOL-CELL PH, V307, pC39, DOI 10.1152/ajpcell.00024.2014; Crupi R, 2012, PREV MED, V54, pS103, DOI 10.1016/j.ypmed.2011.12.019; Crupi R, 2010, BIOL PSYCHIAT, V67, P558, DOI 10.1016/j.biopsych.2009.12.008; Dawczynski C, 2013, CLIN NUTR, V32, P686, DOI 10.1016/j.clnu.2012.12.010; Delpech J. C, 2014, NEUROPSYCHOPHARMACOL; DeMar JC, 2006, BBA-MOL CELL BIOL L, V1761, P1050, DOI 10.1016/j.bbalip.2006.06.006; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Eady TN, 2014, NEUROBIOL DIS, V62, P1, DOI 10.1016/j.nbd.2013.09.008; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Figueroa JD, 2012, J NEUROTRAUM, V29, P551, DOI 10.1089/neu.2011.2141; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Green JT, 2008, J LIPID RES, V49, P939, DOI 10.1194/jlr.R700017-JLR200; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison J. L., 2015, BRAIN BEHAV IMMUN; Hashimoto M, 2014, J PHARMACOL SCI, V124, P294, DOI 10.1254/jphs.13R14CP; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hjorth E, 2013, J ALZHEIMERS DIS, V35, P697, DOI 10.3233/JAD-130131; Hjorth E, 2012, CURR OPIN CLIN NUTR, V15, P134, DOI 10.1097/MCO.0b013e32835017cc; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Hooijmans CR, 2012, J ALZHEIMERS DIS, V28, P191, DOI 10.3233/JAD-2011-111217; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Igarashi M, 2007, J LIPID RES, V48, P1150, DOI 10.1194/jlr.M600549-JLR200; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Jaturapatporn D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006378.pub2; Ji AL, 2012, NEUROTOXICOLOGY, V33, P780, DOI 10.1016/j.neuro.2012.02.018; Jia D, 2014, NEUROSCIENCE, V258, P228, DOI 10.1016/j.neuroscience.2013.11.016; Kavanagh T, 2004, PROSTAG LEUKOTR ESS, V70, P391, DOI 10.1016/j.plefa.2003.12.014; Keleshian VL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095318; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kelly L, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.001; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Labrousse VF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036861; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lebbadi M, 2011, J ALZHEIMERS DIS, V27, P853, DOI 10.3233/JAD-2011-111010; Leonard BE, 2002, INT J NEUROPSYCHOPH, V5, P345, DOI 10.1017/S1461145702003140; Lim SN, 2013, NEUROBIOL DIS, V51, P104, DOI 10.1016/j.nbd.2012.10.021; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Lim SN, 2010, PROSTAG LEUKOTR ESS, V83, P193, DOI 10.1016/j.plefa.2010.08.003; Liu J.J, 2014, BRAIN RES; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Luchtman DW, 2012, BEHAV BRAIN RES, V226, P386, DOI 10.1016/j.bbr.2011.09.033; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Luo C., 2014, J LIPID RES; Lynch AM, 2007, NEUROBIOL AGING, V28, P845, DOI 10.1016/j.neurobiolaging.2006.04.006; Lynch AM, 2003, J BIOL CHEM, V278, P51075, DOI 10.1074/jbc.M307970200; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Martin DSD, 2002, J BIOL CHEM, V277, P34239, DOI 10.1074/jbc.M205289200; Mashour G.A., 2014, BR J ANAESTHESIA; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Meng QJ, 2010, EUR J PHARMACOL, V649, P127, DOI 10.1016/j.ejphar.2010.09.046; Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Mingam R, 2008, EUR J NEUROSCI, V28, P1877, DOI 10.1111/j.1460-9568.2008.06470.x; Minogue AM, 2007, J NEUROCHEM, V103, P914, DOI 10.1111/j.1471-4159.2007.04848.x; Mischoulon D, 2015, J CLIN PSYCHIAT, V76, P54, DOI 10.4088/JCP.14m08986; Moranis A, 2012, BRAIN BEHAV IMMUN, V26, P721, DOI 10.1016/j.bbi.2011.11.001; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Muntane G, 2010, NEUROCHEM INT, V56, P318, DOI 10.1016/j.neuint.2009.10.015; Myint AM, 2007, NEUROIMMUNOMODULAT, V14, P65, DOI 10.1159/000107420; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Okabe N, 2011, J STROKE CEREBROVASC, V20, P188, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.016; Orr SK, 2013, J NEUROCHEM, V127, P378, DOI 10.1111/jnc.12392; Orr SK, 2013, PROSTAG LEUKOTR ESS, V88, P97, DOI 10.1016/j.plefa.2012.05.008; Orr SK, 2010, NEUROCHEM RES, V35, P811, DOI 10.1007/s11064-010-0139-x; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Parrott MD, 2015, NEUROBIOL AGING, V36, P90, DOI 10.1016/j.neurobiolaging.2014.08.013; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI [10.1186/1742-2094-11-6, 10.1186/s12974-014-0136-0]; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rao JS, 2007, MOL PSYCHIATR, V12, P36, DOI 10.1038/sj.mp.4001888; Rees K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008454.pub2; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Schwartz M, 2014, EMBO J, V33, P7, DOI 10.1002/embj.201386609; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2013, CURR OPIN PHARMACOL, V13, P632, DOI 10.1016/j.coph.2013.05.012; Song C, 2004, J LIPID RES, V45, P1112, DOI [10.1194/jlr.M300526-JLR200, 10.1194/jlr.M300526-JLr200]; Song C, 2008, J NUTR, V138, P954, DOI 10.1093/jn/138.5.954; Song C, 2009, J NEUROSCI, V29, P14, DOI 10.1523/JNEUROSCI.3569-08.2009; Suridjan I., 2015, MOL PSYCHIAT; Taepavarapruk P, 2010, J NEUROCHEM, V112, P1054, DOI 10.1111/j.1471-4159.2009.06524.x; Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004; Terrando N, 2013, FASEB J, V27, P3564, DOI 10.1096/fj.13-230276; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Tian YG, 2015, BIOCHEM BIOPH RES CO, V460, P799, DOI 10.1016/j.bbrc.2015.03.109; Torkildsen O, 2012, ARCH NEUROL-CHICAGO, V69, P1044, DOI 10.1001/archneurol.2012.283; Trepanier MO, 2012, EPILEPSY RES, V99, P225, DOI 10.1016/j.eplepsyres.2011.12.001; Wang DM, 2014, EUR J PHARMACOL, V728, P59, DOI 10.1016/j.ejphar.2014.01.057; Wang J., 2014, J ALZHEIMERS DIS JAD; Wang X., 2014, ALZHEIMERS DEMENT J; Wang Y., 2014, INT J DISTRIBUTED SE, V2014, P1, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang Y, 2014, J CHROMATOGR A, V1359, P60, DOI 10.1016/j.chroma.2014.07.006; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu ZZ, 2013, ANN NEUROL, V74, P490, DOI 10.1002/ana.23928; Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yang DY, 2007, NEUROTOXICOLOGY, V28, P1220, DOI 10.1016/j.neuro.2007.08.003; Yates CM, 2014, PHARMACOL THERAPEUT, V141, P272, DOI 10.1016/j.pharmthera.2013.10.010; Yip PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061626; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhao YG, 2011, ABSTR APPL ANAL, DOI 10.1155/2011/390543	137	62	65	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 15	2016	785						187	206		10.1016/j.ejphar.2015.05.045			20	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DS4LP	WOS:000380752900021	26036964				2022-02-06	
J	Kwon, EJ; Skalak, M; Lo Bu, R; Bhatia, SN				Kwon, Ester J.; Skalak, Matthew; Lo Bu, Riana; Bhatia, Sangeeta N.			Neuron-Targeted Nanoparticle for siRNA Delivery to Traumatic Brain Injuries	ACS NANO			English	Article						traumatic brain injury; nucleic acid delivery; nanoparticle; peptide; neuron targeting	FOCUSED ULTRASOUND; GENE DELIVERY; CELL-DEATH; BLOOD; BARRIER; EXPRESSION; RECEPTOR; TUMORS; RATS; NEUROPROTECTION	Traumatic brain injuries (TBIs) affect 2.5 million Americans per year, and survivors of TBI can develop long-term impairments in physical, cognitive, and psychosocial functions. Currently, there are no treatments available to stop the long-term effects of TBI. Although the primary injury can only be prevented, there is an opportunity for intervention during the secondary injury, which persists over the course of hours to years after the initial injury. One promising strategy is to modulate destructive pathways using nucleic acid therapeutics, which can downregulate "undruggable" targets considered difficult to inhibit with small molecules; however, the delivery of these materials to the central nervous system is challenging. We engineered a neuron-targeting nanoparticle which can mediate intracellular trafficking of siRNA cargo and achieve silencing of mRNA and protein levels in cultured cells. We hypothesized that, soon after an injury, nanoparticles in the bloodstream may be able to infiltrate brain tissue in the vicinity of areas with a compromised blood brain barrier (BBB). We find that, when administered systemically into animals with brain injuries, neuron-targeted nanoparticles can accumulate into the tissue adjacent to the injured site and downregulate a therapeutic candidate.	[Kwon, Ester J.; Skalak, Matthew; Lo Bu, Riana; Bhatia, Sangeeta N.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Harvard MIT Div Hlth Sci & Technol, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Bhatia, Sangeeta N.] Harvard Med Sch, Boston, MA 02115 USA; [Bhatia, Sangeeta N.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Howard Hughes Med Inst, Cambridge, MA 02139 USA		Bhatia, SN (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Bhatia, SN (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Bhatia, SN (corresponding author), Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), Howard Hughes Med Inst, Cambridge, MA 02139 USA.	sbhatia@mit.edu		Kwon, Ester/0000-0002-6335-9681	Marie D. & Pierre Casimir-Lambert Fund; Koch Institute from the National Cancer Institute (Swanson Biotechnology Center) [P30-CA14051]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30-ES002109]; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [HR0011-13-2-0017]; Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32CA177094-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [F32CA177094, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES002109] Funding Source: NIH RePORTER	We thank the Koch Institute Swanson Biotechnology Center (MIT) for assistance with TEM imaging, specifically Dr. Dong Soo Yun, and tissue sectioning, specifically Michael Brown and Kathleen Cormier. We thank Dr. Heather Fleming (MIT) for critical reading and editing of the manuscript. This work was supported in part by the Marie D. & Pierre Casimir-Lambert Fund, and a Koch Institute Support Grant P30-CA14051 from the National Cancer Institute (Swanson Biotechnology Center) and a Core Center Grant P30-ES002109 from the National Institute of Environmental Health Sciences. This work was also supported by the Defense Advanced Research Projects Agency under Cooperative Agreement HR0011-13-2-0017. The content of the information within this document does not necessarily reflect the position or the policy of the government. E.J.K. acknowledges support from the Ruth L. Kirschstein National Research Service Award (1F32CA177094-01). S.N.B. is an HHMI Investigator.	Al-Jamal KT, 2011, P NATL ACAD SCI USA, V108, P10952, DOI 10.1073/pnas.1100930108; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102; Boeckle S, 2005, J GENE MED, V7, P1335, DOI 10.1002/jgm.783; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]; Cheng JJ, 2006, J MED CHEM, V49, P6522, DOI 10.1021/jm060736s; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi CHJ, 2010, P NATL ACAD SCI USA, V107, P1235, DOI 10.1073/pnas.0914140107; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; El Badawy AM, 2010, ENVIRON SCI TECHNOL, V44, P1260, DOI 10.1021/es902240k; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; HANHAM CA, 1993, J VIROL, V67, P530, DOI 10.1128/JVI.67.1.530-542.1993; Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kwon EJ, 2010, BIOMATERIALS, V31, P2417, DOI 10.1016/j.biomaterials.2009.11.086; Lafon M, 2005, J NEUROVIROL, V11, P82, DOI 10.1080/13550280590900427; Lee J, 2016, J CONTROL RELEASE, V223, P197, DOI 10.1016/j.jconrel.2015.12.051; Lin KY, 2014, NANO TODAY, V9, P550, DOI 10.1016/j.nantod.2014.09.001; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062905; Liu YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17543; Mulik RS, 2016, BIOMATERIALS, V83, P257, DOI 10.1016/j.biomaterials.2016.01.021; Nance E, 2014, J CONTROL RELEASE, V189, P123, DOI 10.1016/j.jconrel.2014.06.031; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Price L., 2016, TRANSLATIONAL RES TR; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ren Y, 2012, ACS NANO, V6, P8620, DOI 10.1021/nn301975s; Ren Y, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003778; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rungta RL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.65; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101; Schnell MJ, 2010, NAT REV MICROBIOL, V8, P51, DOI 10.1038/nrmicro2260; Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep22595; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	45	62	65	7	85	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	AUG	2016	10	8					7926	7933		10.1021/acsnano.6b03858			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	DU1HP	WOS:000381959100077	27429164	Green Accepted			2022-02-06	
J	David, CN; Frias, ES; Szu, JI; Vieira, PA; Hubbard, JA; Lovelace, J; Michael, M; Worth, D; McGovern, KE; Ethell, IM; Stanley, BG; Korzus, E; Fiacco, TA; Binder, DK; Wilson, EH				David, Clement N.; Frias, Elma S.; Szu, Jenny I.; Vieira, Philip A.; Hubbard, Jacqueline A.; Lovelace, Jonathan; Michael, Marena; Worth, Danielle; McGovern, Kathryn E.; Ethell, Iryna M.; Stanley, B. Glenn; Korzus, Edward; Fiacco, Todd A.; Binder, Devin K.; Wilson, Emma H.			GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite Toxoplasma gondii	PLOS PATHOGENS			English	Article							TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; REPRODUCING INCREASED DOPAMINE; AMYOTROPHIC-LATERAL-SCLEROSIS; TYROSINE-HYDROXYLASE ACTIVITY; ISCHEMIC CORTICAL PENUMBRA; REGULATED ANION CHANNELS; NF-KAPPA-B; ALZHEIMERS-DISEASE; TRANSPORTER GLT-1	The immune privileged nature of the CNS can make it vulnerable to chronic and latent infections. Little is known about the effects of lifelong brain infections, and thus inflammation, on the neurological health of the host. Toxoplasma gondii is a parasite that can infect any mammalian nucleated cell with average worldwide seroprevalence rates of 30%. Infection by Toxoplasma is characterized by the lifelong presence of parasitic cysts within neurons in the brain, requiring a competent immune system to prevent parasite reactivation and encephalitis. In the immunocompetent individual, Toxoplasma infection is largely asymptomatic, however many recent studies suggest a strong correlation with certain neurodegenerative and psychiatric disorders. Here, we demonstrate a significant reduction in the primary astrocytic glutamate transporter, GLT-1, following infection with Toxoplasma. Using microdialysis of the murine frontal cortex over the course of infection, a significant increase in extracellular concentrations of glutamate is observed. Consistent with glutamate dysregulation, analysis of neurons reveal changes in morphology including a reduction in dendritic spines, VGlut1 and NeuN immunoreactivity. Furthermore, behavioral testing and EEG recordings point to significant changes in neuronal output. Finally, these changes in neuronal connectivity are dependent on infection-induced downregulation of GLT-1 as treatment with the beta-lactam antibiotic ceftriaxone, rescues extracellular glutamate concentrations, neuronal pathology and function. Altogether, these data demonstrate that following an infection with T. gondii, the delicate regulation of glutamate by astrocytes is disrupted and accounts for a range of deficits observed in chronic infection.	[David, Clement N.; Frias, Elma S.; Szu, Jenny I.; Hubbard, Jacqueline A.; Michael, Marena; Worth, Danielle; McGovern, Kathryn E.; Ethell, Iryna M.; Binder, Devin K.; Wilson, Emma H.] Univ Calif Riverside, Sch Med, Div Biomed Sci, Riverside, CA 92521 USA; [Vieira, Philip A.; Lovelace, Jonathan; Stanley, B. Glenn; Korzus, Edward] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA; [Fiacco, Todd A.] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA		Wilson, EH (corresponding author), Univ Calif Riverside, Sch Med, Div Biomed Sci, Riverside, CA 92521 USA.	emmaw@ucr.edu		Vieira, Philip/0000-0003-0792-2836; Hubbard, Jacqueline/0000-0003-4092-7153; McGovern, Kathryn/0000-0001-8770-2619	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067231, NS072298]; UCR's Academic Senate and Office of Research; UCR's Graduate Division;  [NS082570];  [NS081243];  [R01MH106617]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH106617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072298, R21NS071160] Funding Source: NIH RePORTER	Funding to EHW was provided by NIH (NS067231; NS072298) and UCR's Academic Senate and Office of Research, to DKB by (NS082570; NS081243), to CND by UCR's Graduate Division, and to EK (R01MH106617). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032489; Babiloni C., 2015, INT J PSYCHOPHYSIOL; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; Berenreiterova M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028925; Brooks JM, 2015, MBIO, V6, DOI 10.1128/mBio.01428-15; BYLSMA FW, 1994, NEUROPSYCHOLOGIA, V32, P137, DOI 10.1016/0028-3932(94)90001-9; Cabral CM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005447; Carbone M, 2012, NEUROCHEM INT, V60, P31, DOI 10.1016/j.neuint.2011.10.017; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dass SAH, 2014, MOL ECOL, V23, P6114, DOI 10.1111/mec.12888; Dellacasa-Lindberg I, 2007, MICROBES INFECT, V9, P1291, DOI 10.1016/j.micinf.2007.06.003; Dickerson F, 2014, BIPOLAR DISORD, V16, P129, DOI 10.1111/bdi.12123; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; DURING MJ, 1993, LANCET, V341, P1607; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Fagard R, 1999, PARASITOLOGY, V15; FERGUSON DJP, 1994, PARASITOL RES, V80, P493, DOI 10.1007/BF00932696; FERGUSON DJP, 1987, VIRCHOWS ARCH A, V411, P39, DOI 10.1007/BF00734512; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; Flegr J, 2013, TRENDS PARASITOL, V29, P156, DOI 10.1016/j.pt.2013.01.007; Flegr J, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-72; Fontana A. C., 2015, J NEUROTRAUMA; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Gale SD, 2015, PARASITOLOGY, V142, P557, DOI 10.1017/S0031182014001577; GAZZINELLI R, 1992, J IMMUNOL, V149, P175; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Ghosh M, 2011, J NEUROSCI, V31, P9159, DOI 10.1523/JNEUROSCI.0302-11.2011; Giraudon P, 2009, REV NEUROL-FRANCE, V165, P789, DOI 10.1016/j.neurol.2009.07.004; Gonsette RE, 2008, J NEUROL SCI, V274, P48, DOI 10.1016/j.jns.2008.06.029; Gonzalez LE, 2007, BEHAV BRAIN RES, V177, P70, DOI 10.1016/j.bbr.2006.11.012; Gupta RK, 2014, NEUROCHEM RES, V39, P150, DOI 10.1007/s11064-013-1200-3; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; Halpain S, 2000, TRENDS NEUROSCI, V23, P141, DOI 10.1016/S0166-2236(00)01576-9; Hermes G, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-48; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.0.CO;2-N; Honjo K, 2009, ALZHEIMERS DEMENT, V5, P348, DOI 10.1016/j.jalz.2008.12.001; HUNTER CA, 1992, LAB INVEST, V67, P635; Hyzinski-Garcia MC, 2011, J NEUROCHEM, V118, P140, DOI 10.1111/j.1471-4159.2011.07289.x; Ji YF, 2013, GLIA, V61, P1959, DOI 10.1002/glia.22566; John B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000505; Kam JWY, 2013, J PSYCHIATR RES, V47, P1893, DOI 10.1016/j.jpsychires.2013.09.009; Kannan G, 2013, NEUROBIOL DIS, V57, P5, DOI 10.1016/j.nbd.2013.05.012; Kimelberg HK, 2006, GLIA, V54, P747, DOI 10.1002/glia.20423; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Kiryk A, 2008, NEUROTOX RES, V13, P19, DOI 10.1007/BF03033364; Kusbeci OY, 2011, ALZ DIS ASSOC DIS, V25, P1, DOI 10.1097/WAD.0b013e3181f73bc2; Lafferty KD, 2013, J EXP BIOL, V216, P56, DOI 10.1242/jeb.073668; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee M, 2013, NEUROSCIENCE, V229, P164, DOI 10.1016/j.neuroscience.2012.10.033; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Maragakis NJ, 2004, ANN NEUROL, V55, P469, DOI 10.1002/ana.20003; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; McConkey GA, 2015, INFECT IMMUN, V83, P3334, DOI 10.1128/IAI.00605-15; Mendy A, 2015, PARASITOLOGY, V142, P1221, DOI 10.1017/S0031182015000505; Mendy A, 2015, BRAIN BEHAV IMMUN, V45, P36, DOI 10.1016/j.bbi.2014.12.006; Mesci P, 2015, BRAIN, V138, P53, DOI 10.1093/brain/awu312; Miman O, 2010, NEUROSCI LETT, V475, P129, DOI 10.1016/j.neulet.2010.03.057; Miranda AS, 2010, BRAZ J MED BIOL RES, V43, P1173, DOI 10.1590/S0100-879X2010007500130; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Morel L, 2013, J BIOL CHEM, V288, P7105, DOI 10.1074/jbc.M112.410944; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; Parlog A, 2014, DIS MODEL MECH, V7, P459, DOI 10.1242/dmm.014183; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; PIANI D, 1994, J IMMUNOL, V152, P3578; Promeneur D, 2013, P NATL ACAD SCI USA, V110, P1035, DOI 10.1073/pnas.1220566110; Raju K, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa4312; Rao PSS, 2014, ALCOHOL ALCOHOLISM, V49, P390, DOI 10.1093/alcalc/agu019; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Schallier A, 2011, J ALZHEIMERS DIS, V24, P287, DOI 10.3233/JAD-2011-101005; Selemon LD, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.115; Soni N, 2014, PHARMACOL BIOCHEM BE, V127, P70, DOI 10.1016/j.pbb.2014.10.001; Strack A, 2002, ACTA NEUROPATHOL, V103, P458, DOI 10.1007/s00401-001-0491-7; Takahashi K, 2015, J EXP MED, V212, P319, DOI 10.1084/jem.20140413; Takaki J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-275; Tauber S C, 2008, Curr Mol Pharmacol, V1, P68; Torrey EF, 2012, SCHIZOPHRENIA BULL, V38, P642, DOI 10.1093/schbul/sbs043; Underhill SM, 2015, J NEUROSCI, V35, P5260, DOI 10.1523/JNEUROSCI.4365-14.2015; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vyas A, 2007, P NATL ACAD SCI USA, V104, P6442, DOI 10.1073/pnas.0608310104; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang ZT, 2015, INFECT IMMUN, V83, P1039, DOI 10.1128/IAI.02465-14; Wang ZT, 2015, INFECT IMMUN, V83, P3336, DOI 10.1128/IAI.00642-15; Watts E, 2015, MBIO, V6, DOI 10.1128/mBio.01155-15; Webster JP, 2006, P ROY SOC B-BIOL SCI, V273, P1023, DOI 10.1098/rspb.2005.3413; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson EH, 2005, J NEUROIMMUNOL, V165, P63, DOI 10.1016/j.jneuroim.2005.04.018; Wilson EH, 2004, INT J PARASITOL, V34, P543, DOI 10.1016/j.ijpara.2003.12.010; Wilson EH, 2009, IMMUNITY, V30, P300, DOI 10.1016/j.immuni.2008.12.013; Yamada T, 2006, NEUROCHEM RES, V31, P49, DOI 10.1007/s11064-005-9077-4; Yolken RH, 2001, CLIN INFECT DIS, V32, P842, DOI 10.1086/319221; Zhang YH, 2008, EXP NEUROL, V210, P514, DOI 10.1016/j.expneurol.2007.11.027	95	62	65	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7366	1553-7374		PLOS PATHOG	PLoS Pathog.	JUN	2016	12	6							e1005643	10.1371/journal.ppat.1005643			29	Microbiology; Parasitology; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Microbiology; Parasitology; Virology	DQ6WD	WOS:000379345300016	27281462	Green Submitted, gold, Green Published			2022-02-06	
J	Goswami, R; Dufort, P; Tartaglia, MC; Green, RE; Crawley, A; Tator, CH; Wennberg, R; Mikulis, DJ; Keightley, M; Davis, KD				Goswami, R.; Dufort, P.; Tartaglia, M. C.; Green, R. E.; Crawley, A.; Tator, C. H.; Wennberg, R.; Mikulis, D. J.; Keightley, M.; Davis, Karen D.			Frontotemporal correlates of impulsivity and machine learning in retired professional athletes with a history of multiple concussions	BRAIN STRUCTURE & FUNCTION			English	Article						Concussion; Impulsivity; Uncinate fasciculus; Cortical thickness; Connectivity; Machine learning	TRAUMATIC BRAIN-INJURY; ANTERIOR TEMPORAL-LOBE; SURFACE-BASED ANALYSIS; ORBITOFRONTAL CORTEX; DECISION-MAKING; SUSTAINED ATTENTION; PREFRONTAL CORTEX; LINEAR-MODELS; FRONTAL LOBES; SELECTION	The frontotemporal cortical network is associated with behaviours such as impulsivity and aggression. The health of the uncinate fasciculus (UF) that connects the orbitofrontal cortex (OFC) with the anterior temporal lobe (ATL) may be a crucial determinant of behavioural regulation. Behavioural changes can emerge after repeated concussion and thus we used MRI to examine the UF and connected gray matter as it relates to impulsivity and aggression in retired professional football players who had sustained multiple concussions. Behaviourally, athletes had faster reaction times and an increased error rate on a go/no-go task, and increased aggression and mania compared to controls. MRI revealed that the athletes had (1) cortical thinning of the ATL, (2) negative correlations of OFC thickness with aggression and task errors, indicative of impulsivity, (3) negative correlations of UF axial diffusivity with error rates and aggression, and (4) elevated resting-state functional connectivity between the ATL and OFC. Using machine learning, we found that UF diffusion imaging differentiates athletes from healthy controls with significant classifiers based on UF mean and radial diffusivity showing 79-84 % sensitivity and specificity, and 0.8 areas under the ROC curves. The spatial pattern of classifier weights revealed hot spots at the orbitofrontal and temporal ends of the UF. These data implicate the UF system in the pathological outcomes of repeated concussion as they relate to impulsive behaviour. Furthermore, a support vector machine has potential utility in the general assessment and diagnosis of brain abnormalities following concussion.	[Goswami, R.; Dufort, P.; Tartaglia, M. C.; Green, R. E.; Crawley, A.; Tator, C. H.; Wennberg, R.; Mikulis, D. J.; Keightley, M.; Davis, Karen D.] Toronto Western Hosp, Canadian Sports Concuss Project, Toronto, ON M5T 2S8, Canada; [Goswami, R.; Crawley, A.; Tator, C. H.; Mikulis, D. J.; Davis, Karen D.] Univ Hlth Network, Toronto Western Hosp, Div Brain Imaging & Behav Syst Neurosci, Toronto Western Res Inst, 399 Bathurst St,Room MP14-306, Toronto, ON M5T 2S8, Canada; [Dufort, P.; Crawley, A.; Mikulis, D. J.] Toronto Western Hosp, Dept Med Imaging, Toronto, ON M5T 2S8, Canada; [Dufort, P.; Crawley, A.; Mikulis, D. J.] Univ Toronto, Toronto, ON, Canada; [Tartaglia, M. C.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; [Tartaglia, M. C.; Wennberg, R.] Krembil Neurosci Ctr, Div Neurol, Toronto, ON, Canada; [Green, R. E.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5T 2S8, Canada; [Crawley, A.; Tator, C. H.; Mikulis, D. J.; Davis, Karen D.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Tator, C. H.] Toronto Western Hosp, Div Neurosurg, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Tator, C. H.; Davis, Karen D.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Keightley, M.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Keightley, M.] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada		Davis, KD (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Brain Imaging & Behav Syst Neurosci, Toronto Western Res Inst, 399 Bathurst St,Room MP14-306, Toronto, ON M5T 2S8, Canada.	kdavis@uhnres.utoronto.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Green, Robin/0000-0001-9451-3963	Physicians' Services Incorporated (PSI) Foundation; Canadian Sports Concussion Project, Toronto Western Hospital.; Canadian Football League Alumni Association	This research was supported by a Grant from The Physicians' Services Incorporated (PSI) Foundation and funds from the Canadian Sports Concussion Project, Toronto Western Hospital. We are very grateful to Leo Ezerins and the Canadian Football League Alumni Association for their support and aid in recruitment. Thank you to Brenda Colella and Mozhgan Khodadadi for neuropsychological data collection and administrative support, and MRI technologists Eugen Hlasny and Keith Ta for neuroimaging data collection.	Aribisala BS, 2010, LECT NOTES COMPUT SC, V6326, P51; Baldassarre L, 2012, P 2 INT WORKSH PATT; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Bi YC, 2011, CORTEX, V47, P575, DOI 10.1016/j.cortex.2009.12.002; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boyd Stephen, 2010, Foundations and Trends in Machine Learning, V3, P1, DOI 10.1561/2200000016; Brothers L., 1990, CONCEPTS NEUROSCIENC, V1, P27; Carter L, 2013, BRAIN COGNITION, V82, P35, DOI 10.1016/j.bandc.2013.02.002; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chen YW, 2006, STUD FUZZ SOFT COMP, V207, P315; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DICKMAN SJ, 1990, J PERS SOC PSYCHOL, V58, P95, DOI 10.1037/0022-3514.58.1.95; DREWE E A, 1975, Cortex, V11, P8; EBELING U, 1992, ACTA NEUROCHIR, V115, P143, DOI 10.1007/BF01406373; Efron B., 1994, INTRO BOOTSTRAP; Erpelding N, 2012, PAIN, V153, P1602, DOI 10.1016/j.pain.2012.03.012; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghashghaei H, 2007, NEUROIMAGE, V34, P905, DOI 10.1016/j.neuroimage.2006.09.046; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hastie T, 2009, ELEMENTS STAT LEARNI, V2nd, DOI 10.1007/978-0-387-84858-7; Haufe S, 2014, NEUROIMAGE, V87, P96, DOI 10.1016/j.neuroimage.2013.10.067; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Hoptman MJ, 2002, BIOL PSYCHIAT, V52, P9, DOI 10.1016/S0006-3223(02)01311-2; Hoptman MJ, 2004, NEUROREPORT, V15, P2467, DOI 10.1097/00001756-200411150-00007; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Kahnt T, 2012, J NEUROSCI, V32, P6240, DOI 10.1523/JNEUROSCI.0257-12.2012; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Matsuo K, 2009, HUM BRAIN MAPP, V30, P1188, DOI 10.1002/hbm.20588; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Moayedi M, 2011, NEUROIMAGE, V55, P277, DOI 10.1016/j.neuroimage.2010.12.013; Morey L.C., 2007, PERSONALITY ASSESSME; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Piguet O, 2011, LANCET NEUROL, V10, P162, DOI 10.1016/S1474-4422(10)70299-4; Potegal M, 2012, BEHAV BRAIN RES, V231, P386, DOI 10.1016/j.bbr.2011.10.049; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sakai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067391; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schoenbaum G, 2003, NEURON, V39, P855, DOI 10.1016/S0896-6273(03)00474-4; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Snowden JS, 2001, J NEUROL NEUROSUR PS, V70, P323, DOI 10.1136/jnnp.70.3.323; Soloff P, 2008, PSYCHIAT RES-NEUROIM, V164, P223, DOI 10.1016/j.pscychresns.2008.02.003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Strakowski SM, 2009, BIPOLAR DISORD, V11, P41, DOI 10.1111/j.1399-5618.2008.00658.x; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Swann AC, 2007, BIPOLAR DISORD, V9, P206, DOI 10.1111/j.1399-5618.2007.00357.x; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van Tol MJ, 2014, PSYCHOL MED, V44, P2053, DOI 10.1017/S0033291713002742; Vigil-Colet A, 2004, PERS INDIV DIFFER, V37, P1431, DOI 10.1016/j.paid.2004.01.013; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; WEIGER WA, 1988, J PSYCHIAT RES, V22, P85, DOI 10.1016/0022-3956(88)90073-8; Winstanley CA, 2004, J NEUROSCI, V24, P4718, DOI 10.1523/JNEUROSCI.5606-03.2004; Wong C, 2012, BRAIN RES, V1449, P94, DOI 10.1016/j.brainres.2012.02.017; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhou Y, 2013, P ISMRM, V21, P2688; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	91	62	62	3	13	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAY	2016	221	4					1911	1925		10.1007/s00429-015-1012-0			15	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anatomy & Morphology; Neurosciences & Neurology	DL3UJ	WOS:000375558600008	25721800	Green Published, hybrid			2022-02-06	
J	Nelson, LD; Guskiewicz, KM; Marshall, SW; Hammeke, T; Barr, W; Randolph, C; McCrea, MA				Nelson, Lindsay D.; Guskiewicz, Kevin M.; Marshall, Stephen W.; Hammeke, Thomas; Barr, William; Randolph, Christopher; McCrea, Michael A.			Multiple Self-Reported Concussions Are More Prevalent in Athletes With ADHD and Learning Disability	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						learning disability; concussion; standardized assessment of concussion; attention deficit	COLLEGIATE FOOTBALL PLAYERS; POSITION STATEMENT; RECOVERY-TIME; SPORT; INJURIES; HYPERACTIVITY; CHILDREN; PERFORMANCE; MANAGEMENT; DISORDERS	Objective: We evaluated how attention deficit-hyperactivity disorder (ADHD) and learning disability (LD) are associated with concussion history and performance on standard concussion assessment measures. Based on previous reports that developmental disorders are associated with increased injury proneness and poorer cognitive performance, we anticipated that ADHD and LD would be associated with increased history of concussion and poorer baseline performance on assessment measures. Design: Cross-sectional study. Setting: Clinical research center. Participants: The study sample aggregated data from two separate projects: the National Collegiate Athletic Association Concussion Study and Project Sideline. Interventions: We analyzed preseason baseline data from 8056 high school and collegiate athletes (predominantly male football players) enrolled in prior studies of sport-related concussion. Main Outcome Measures: Measures included demographic/health history, symptoms, and cognitive performance. Results: Attention deficit-hyperactivity disorder and LD were associated with 2.93 and 2.08 times the prevalence, respectively, of 3+ historical concussions (for comorbid ADHD/LD the prevalence ratio was 3.38). In players without histories of concussion, individuals with ADHD reported more baseline symptoms, and ADHD and LD were associated with poorer performance on baseline cognitive tests. Interactive effects were present between ADHD/LD status and concussion history for self-reported symptoms. Conclusions: Neurodevelopmental disorders and concussion history should be jointly considered in evaluating concussed players. Clinical Relevance: Clinical judgments of self-reported symptoms and cognitive performance should be adjusted based on athletes' individual preinjury baselines or comparison with appropriate normative samples.	[Nelson, Lindsay D.; Hammeke, Thomas; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; Hammeke, Thomas; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; [Guskiewicz, Kevin M.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Hammeke, Thomas] Milwaukee VA Med Ctr, Dept Mental Behav Hlth, Milwaukee, WI USA; [Barr, William] NYU, Sch Med, Dept Neurol, New York, NY USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Chicago, IL 60611 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, Div Neuropsychol, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.	linelson@mcw.edu		Barr, William/0000-0001-7711-7758	National Collegiate Athletic Association (NCAA); National Operating Committee on Standards for Athletic Equipment (NOCSAE); Center for Disease Control's National Center for Injury Prevention and Control; University of North Carolina Injury Prevention Research Center; Waukesha Memorial Hospital Foundation; National Academy of Neuropsychology; National Federation of State High School Associations; NFL Charities; Green Bay Packer Foundation; Milwaukee Bucks; Herbert H. Kohl Charities; Waukesha Service Club; Medical College of Wisconsin General Clinical Research Center from the National Institutes of Health [M01 RR00058]	Supported in part by funding from the National Collegiate Athletic Association (NCAA) and the National Operating Committee on Standards for Athletic Equipment (NOCSAE), Center for Disease Control's National Center for Injury Prevention and Control, University of North Carolina Injury Prevention Research Center, Waukesha Memorial Hospital Foundation, National Academy of Neuropsychology, National Federation of State High School Associations, NFL Charities, Green Bay Packer Foundation, Milwaukee Bucks, Herbert H. Kohl Charities, Waukesha Service Club, Michael Emme, and the Medical College of Wisconsin General Clinical Research Center (M01 RR00058 from the National Institutes of Health).	Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Brehaut JC, 2003, PEDIATRICS, V111, P262, DOI 10.1542/peds.111.2.262; Christoffel KK, 1996, PEDIATRICS, V97, P33; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DAVIDSON LL, 1987, J DEV BEHAV PEDIATR, V8, P335; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gillberg C, 2004, EUR CHILD ADOLES PSY, V13, P80, DOI 10.1007/s00787-004-1008-4; Golden CJ., 2002, STROOP COLOR WORD TE; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jerome L, 2003, CAN MED ASSOC J, V169, P16; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, OXFROD HDB IN PRESS; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reitan R, 1985, HALSTEAD REITAN NEUR; Smith A., 1982, SYMBOL DIGITS MODALI; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Wisniewska B, 2007, Adv Med Sci, V52 Suppl 1, P215	37	62	62	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2016	26	2					120	127		10.1097/JSM.0000000000000207			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	DF4DM	WOS:000371297600005	25915144	Green Accepted			2022-02-06	
J	Mychasiuk, R; Hehar, H; Candy, S; Ma, I; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Candy, Sydeny; Ma, Irene; Esser, Michael J.			The direction of the acceleration and rotational forces associated with mild traumatic brain injury in rodents effect behavioural and molecular outcomes	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Concussion; Prefrontal cortex; Hippocampus; qRT-PCR; Sprague Dawley rats	COLLEGIATE FOOTBALL PLAYERS; SEX-DIFFERENCES; WHITE-MATTER; PROFESSIONAL FOOTBALL; EXECUTIVE FUNCTION; AXONAL INJURY; HEAD-INJURY; SHORT-TERM; CONCUSSION; ATTENTION	Background: The translation of research to clinical application is only as good as the modelling platforms employed. This study sought to improve understanding of mild traumatic brain injury (mTBI), by examining the importance of acceleration and rotational force directions on behavioural and molecular outcomes. It is believed that many symptoms associated with concussive forms of mTBI are related to white matter and fibre tract damage. Given that rodents have significantly less white. matter, could changes in acceleration/rotational force directionality alter outcomes?. New method/comparison with existing methods: Comparison of mTBIs with two distinct injury platforms, the lateral impact (LI) device, which produces horizontal acceleration/rotation; or the modified weight drop (WD) device, which produces sagittal or vertical acceleration/rotation. Male and female rats underwent a behavioural test battery followed by analysis of 5 TBI-associated biomarkers (BDNF, Eno2, GFAP, MAPT, TERT) from the prefrontal cortex and hippocampus. Results: Acute behavioural impairments were similar for both injury models; animals exhibited increased time-to-wake, and deficits of balance and motor control. However, as the post-injury interval increased LI animals displayed deficits on tasks related to emotional functioning, whereas WD animals showed impairment in cognitive measures. Biomarker expression varied as a function of injury platform, sex, and brain region. Conclusion: just as with humans, the direction of the acceleration and rotational forces produced injuries in different networks and connections, resulting in altered functional deficits for rodents as well. These findings suggest that rodents are a valuable resource for the study of mTBI, when appropriately modelled. (C) 2015 Elsevier B.V. All rights reserved.	[Mychasiuk, Richelle; Hehar, Harleen; Candy, Sydeny; Ma, Irene; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			ACHRI; ACHF; Markin USRP for Health and Wellness	The authors would like to thank Craig Good and Lonnie Unger with Collision Analysis, Calgary AB, for their expertise in biomechanical engineering and the development of the Lateral Impact Device. The authors would also like to thank ACHRI, the ACHF, and the Markin USRP for Health and Wellness, for their financial contributions.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M, 2010, TRAUMATIC BRAIN INJU; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Gennarelli T.A., 1987, SAE TECH PAP; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gur RC, 1999, J NEUROSCI, V19, P4065; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; IQBAL K, 1986, LANCET, V2, P421; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kanaan RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038272; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Ventura-Antunes L, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00003; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Whishaw IQ, 2005, BEHAV LAB RAT HDB TE; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zilles K, 1985, CORTEL RAT STEREOTAX	56	62	62	1	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2016	257						168	178		10.1016/j.jneumeth.2015.10.002			11	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CY2FL	WOS:000366224100017	26484783				2022-02-06	
J	Unden, L; Calcagnile, O; Unden, J; Reinstrup, P; Bazarian, J				Unden, Linda; Calcagnile, Olga; Unden, Johan; Reinstrup, Peter; Bazarian, Jeff			Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults	BMC MEDICINE			English	Article						Biomarkers; Brain injury; Computed tomography; Decision rule; Guidelines; Head injury; Management; Mild traumatic brain injury; S100B/S100/S100BB; Traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; S100B; RULE; QUESTIONNAIRE; EPIDEMIOLOGY	Background: Acute management of traumatic brain injury (TBI), in particular mild TBI, focuses on the detection of the 5-7 % who may be harboring potentially life-threatening intracranial hemorrhage (IH) using CT scanning. Guidelines intending to reduce unnecessary head CT scans using available clinical variables to detect those at high IH risk have shown varying results. Recently, the Scandinavian Neurotrauma Committee (SNC) derived a new set of high-IH risk variables for adults with TBI using an evidence-based literature review. Unlike previous guidelines, the SNC guideline incorporates serum values of the brain protein S100B with clinical variables. Methods: We performed a nested cohort study of adults with mild TBI presenting to six emergency departments in New York and Pennsylvania within 6 h of injury. Patients were managed according to existing guidelines for CT selection. All patients underwent head CT scanning and serum S100B measurement, as well as prospective collection of clinical variables, as a requirement of the parent study. Using the SNC guidelines, S100B values and clinical variables were applied to these subjects, classifying each into one of five pre-defined severity categories, as well as predicting the need for head CT scanning to identify IH. This classification was then compared to actual head CT results to determine guideline sensitivity and specificity. Results: In total, 662 adults (mean age 42 years, range 18-96; 258 females, 549 Caucasians) were available for analysis; 36 (5 %) had IH on head CT scan. The SNC guidelines had a sensitivity of 97 % (95 % CI, 84-100 %) and a specificity of 34 % (95 % CI, 30-37 %) for the detection of IH on head CT. Application of the SNC guidelines would have resulted in a CT reduction of 32 % (211/662 patients). One patient with low-risk mild TBI and a S100B level under 0.10 mu g/L had a traumatic CT abnormality and would have been discharged with strict adherence to the guidelines. However, this patient did not need any intervention for the injury and had a good outcome. Conclusion: Using the SNC guideline could save approximately one third of CT scans in a pre-selected cohort of mild TBI patients with little or no impact on patient outcome.	[Unden, Linda] Lund Univ, S-20185 Lund, Sweden; [Calcagnile, Olga] Hallands Hosp, Dept Pediat Med, S-30185 Halmstad, Sweden; [Unden, Johan] Lund Univ, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden; [Reinstrup, Peter] Skane Univ Hosp, Dept Neuroanesthesia, S-20185 Lund, Sweden; [Reinstrup, Peter] Lund Univ, S-20185 Lund, Sweden; [Bazarian, Jeff] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA		Unden, J (corresponding author), Lund Univ, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com					Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Choi SJ, 2014, PEDIATR EMERG CARE, V30, P479, DOI 10.1097/PEC.0000000000000165; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Faul M, 2010, TRAUMATIC BRAIN INJU; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kelly JC, 2010, IRISH J MED SCI, V179, P557, DOI 10.1007/s11845-010-0499-x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833	25	62	62	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7015			BMC MED	BMC Med.	DEC 9	2015	13								292	10.1186/s12916-015-0533-y			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CY1KT	WOS:000366165800001	26645914	gold, Green Published			2022-02-06	
J	Frontera, JA; Curtis, JR; Nelson, JE; Campbell, M; Gabriel, M; Mosenthal, AC; Mulkerin, C; Puntillo, KA; Ray, DE; Bassett, R; Boss, RD; Lustbader, DR; Brasel, KJ; Weiss, SP; Weissman, DE				Frontera, Jennifer A.; Curtis, J. Randall; Nelson, Judith E.; Campbell, Margaret; Gabriel, Michelle; Mosenthal, Anne C.; Mulkerin, Colleen; Puntillo, Kathleen A.; Ray, Daniel E.; Bassett, Rick; Boss, Renee D.; Lustbader, Dana R.; Brasel, Karen J.; Weiss, Stefanie P.; Weissman, David E.		Improving Palliative Care ICU Proj	Integrating Palliative Care Into the Care of Neurocritically Ill Patients: A Report From the Improving Palliative Care in the ICU Project Advisory Board and the Center to Advance Palliative Care	CRITICAL CARE MEDICINE			English	Article						end-of-life care; intensive care unit; neurocritical care; neurointensive care unit; palliative care	TRAUMATIC BRAIN-INJURY; PRIMARY INTRACEREBRAL HEMORRHAGE; MIDDLE-CEREBRAL-ARTERY; REFRACTORY STATUS EPILEPTICUS; ADMISSION BLOOD-PRESSURE; ORGAN DONOR DONATION; OF-LIFE CARE; SUBARACHNOID HEMORRHAGE; PROGNOSTIC VALUE; DECISION-MAKING	Objectives: To describe unique features of neurocritical illness that are relevant to provision of high-quality palliative care; to discuss key prognostic aids and their limitations for neurocritical illnesses; to review challenges and strategies for establishing realistic goals of care for patients in the neuro-ICU; and to describe elements of best practice concerning symptom management, limitation of life support, and organ donation for the neurocritically ill. Data Sources: A search of PubMed and MEDLINE was conducted from inception through January 2015 for all English-language articles using the term "palliative care," "supportive care," "end-of-life care," "withdrawal of life-sustaining therapy," "limitation of life support," "prognosis," or "goals of care" together with "neurocritical care," "neurointensive care," "neurological," "stroke," "subarachnoid hemorrhage," "intracerebral hemorrhage," or "brain injury." Data Extraction and Synthesis: We reviewed the existing literature on delivery of palliative care in the neurointensive care unit setting, focusing on challenges and strategies for establishing realistic and appropriate goals of care, symptom management, organ donation, and other considerations related to use and limitation of life-sustaining therapies for neurocritically ill patients. Based on review of these articles and the experiences of our interdisciplinary/interprofessional expert advisory board, this report was prepared to guide critical care staff, palliative care specialists, and others who practice in this setting. Conclusions: Most neurocritically ill patients and their families face the sudden onset of devastating cognitive and functional changes that challenge clinicians to provide patient-centered palliative care within a complex and often uncertain prognostic environment. Application of palliative care principles concerning symptom relief, goal setting, and family emotional support will provide clinicians a framework to address decision making at a time of crisis that enhances patient/family autonomy and clinician professionalism.	[Frontera, Jennifer A.] Cleveland Clin, Neurol Inst, Cerebrovasc Ctr, Cleveland, OH 44106 USA; [Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; [Nelson, Judith E.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Nelson, Judith E.] Mem Sloan Kettering Canc Ctr, Dept Anesthesia & Crit Care, New York, NY 10021 USA; [Campbell, Margaret] Wayne State Univ, Coll Nursing, Detroit, MI 48202 USA; [Gabriel, Michelle] VA Palo Alto Hlth Care Syst, Off Qual Safety & Value, Palo Alto, CA USA; [Mosenthal, Anne C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ USA; [Mulkerin, Colleen] Hartford Hosp, Palliat Med & Social Work Serv, Hartford, CT 06115 USA; [Puntillo, Kathleen A.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; [Ray, Daniel E.] Lehigh Valley Hlth Network, Sect Palliat Med & Hosp Med, Allentown, PA USA; [Bassett, Rick] St Lukes Boise Med Ctr, Boise, ID USA; [Boss, Renee D.] Johns Hopkins Univ, Sch Med, Div Neonatal Perinatal Med, Baltimore, MD USA; [Lustbader, Dana R.] Hofstra North Shore Long Isl Jewish Hlth Syst, ProHEALTH, Lake Success, NY USA; [Brasel, Karen J.] Oregon Hlth & Sci Univ, Dept Surg, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA; [Weiss, Stefanie P.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; [Weissman, David E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA		Frontera, JA (corresponding author), Cleveland Clin, Neurol Inst, Cerebrovasc Ctr, Cleveland, OH 44106 USA.	frontej@ccf.org	Boss, Renee/AAN-4091-2020; Viani, Rafael/V-1196-2018	Curtis, J. Randall/0000-0001-9529-845X	Center to Advance Palliative Care; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute on Aging for the Improving Palliative Care in the ICU Project (Academic Career Leadership Award) [K07-034234]; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); Healthcare Foundation of New Jersey; Center for Health Quality and Innovation Quality Enterprise Risk Management program; National Institute on Aging (K07 Academic Career Leadership Award); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K07AG034234] Funding Source: NIH RePORTER	Supported, in part, by the Center to Advance Palliative Care.	Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Apatira L, 2008, ANN INTERN MED, V149, P861, DOI 10.7326/0003-4819-149-12-200812160-00005; Back A., 2009, MASTERING COMMUNICAT; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Benejam B, 2009, J NEUROL, V256, P1126, DOI 10.1007/s00415-009-5083-9; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Brieva J, 2013, CRIT CARE MED, V41, P2677, DOI 10.1097/CCM.0b013e3182987f38; BRODY H, 1981, JAMA-J AM MED ASSOC, V246, P1411, DOI 10.1001/jama.246.13.1411; Campbell ML, 2013, J PALLIAT MED, V16, P1255, DOI 10.1089/jpm.2013.0122; CARLBERG B, 1993, STROKE, V24, P1372, DOI 10.1161/01.STR.24.9.1372; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Cherny N I, 1994, J Palliat Care, V10, P31; CHRISTAKIS NA, 1999, DEATH FORETOLD PROPH; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; Clarke EB, 2003, CRIT CARE MED, V31, P2255, DOI 10.1097/01.CCM.0000084849.96385.85; Cook D, 2014, NEW ENGL J MED, V370, P2506, DOI 10.1056/NEJMra1208795; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Curtis JR, 2014, INTENS CARE MED, V40, P1374, DOI 10.1007/s00134-014-3421-6; Davis CG, 2013, REHABIL PSYCHOL, V58, P287, DOI 10.1037/a0033400; de Groot YJ, 2012, CRIT CARE MED, V40, P233, DOI 10.1097/CCM.0b013e31822f0633; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; Diringer MN, 1998, STROKE, V29, P1352, DOI 10.1161/01.STR.29.7.1352; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; DRAKE CG, 1988, J NEUROSURG, V68, P985; Ehlenbach WJ, 2013, CRIT CARE MED, V41, P1136, DOI 10.1097/CCM.0b013e31827c03eb; Engelberg RA, 2008, J CRIT CARE, V23, P565, DOI 10.1016/j.jcrc.2007.12.018; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Da Silva IRF, 2015, JAMA NEUROL, V72, P112, DOI 10.1001/jamaneurol.2014.3083; Flemming KD, 2001, CEREBROVASC DIS, V11, P183, DOI 10.1159/000047636; Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P1534, DOI 10.1136/jnnp.2004.055145; Fogelholm R, 1997, STROKE, V28, P1396, DOI 10.1161/01.STR.28.7.1396; Fried TR, 2007, J GEN INTERN MED, V22, P495, DOI 10.1007/s11606-007-0104-9; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Frontera JA, 2010, NEUROCRIT CARE, V12, P103, DOI 10.1007/s12028-009-9292-y; Frontera JA, 2010, NEUROCRIT CARE, V12, P111, DOI 10.1007/s12028-009-9294-9; GARDE A, 1983, EUR NEUROL, V22, P161, DOI 10.1159/000115555; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Goettler CE, 2010, J TRAUMA, V68, P1279, DOI 10.1097/TA.0b013e3181de3b99; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Grysiewicz RA, 2008, NEUROL CLIN, V26, P871, DOI 10.1016/j.ncl.2008.07.003; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hadley MN, 2013, NEUROSURGERY, V72, P40, DOI 10.1227/NEU.0b013e318276edda; Hankey GJ, 2007, NEUROLOGY, V68, P1583, DOI 10.1212/01.wnl.0000260967.77422.97; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Holloway RG, 2014, STROKE, V45, P1887, DOI 10.1161/STR.0000000000000015; Holloway RG, 2010, J PALLIAT MED, V13, P407, DOI 10.1089/jpm.2009.0278; Holzer M, 2002, NEW ENGL J MED, V346, P549; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Jauss M, 1999, J NEUROL, V246, P257, DOI 10.1007/s004150050344; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Kelso CM, 2007, J PALLIAT MED, V10, P118, DOI 10.1089/jpm.2006.0118; Kerr CW, 2014, AM J HOSP PALLIAT ME, V31, P105, DOI 10.1177/1049909112474111; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kong KH, 2014, NEUROREHABILITATION, V35, P221, DOI 10.3233/NRE-141110; Korfage IJ, 2007, QUAL LIFE RES, V16, P1627, DOI 10.1007/s11136-007-9265-6; Kowalski RG, 2004, JAMA-J AM MED ASSOC, V291, P866, DOI 10.1001/jama.291.7.866; Kowalski RG, 2013, NEUROCRIT CARE, V19, P269, DOI 10.1007/s12028-013-9929-8; Lee VH, 2014, NEUROCRIT CARE, V21, P14, DOI 10.1007/s12028-013-9952-9; Legriel S, 2008, INTENS CARE MED, V34, P476, DOI 10.1007/s00134-007-0915-5; Legriel S, 2010, CRIT CARE MED, V38, P2295, DOI 10.1097/CCM.0b013e3181f859a6; Levine D Z, 2001, Am J Kidney Dis, V38, P901, DOI 10.1053/ajkd.2001.27855; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Luce JM, 2001, MANAGING DEATH INTEN, P19; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Menikoff J., 2001, LAW BIOETHICS INTRO; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Murata Y, 1999, J NEUROL SCI, V167, P107, DOI 10.1016/S0022-510X(99)00150-1; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Naidech AM, 2009, NEUROCRIT CARE, V11, P45, DOI 10.1007/s12028-009-9186-z; Nelson JE, 2011, J HOSP PALLIAT NURS, V13, P89, DOI 10.1097/NJH.0b013e318203d9ff; Nelson JE, 2010, CRIT CARE MED, V38, P1765, DOI 10.1097/CCM.0b013e3181e8ad23; Nelson JE, 2010, CRIT CARE MED, V38, P808, DOI 10.1097/CCM.0b013e3181c5887c; Neurocritical Care Society, WHAT IS NEUR CAR; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nilsson OG, 2002, J NEUROSURG, V97, P531, DOI 10.3171/jns.2002.97.3.0531; Oshiro EM, 1997, NEUROSURGERY, V41, P140, DOI 10.1097/00006123-199707000-00029; Pullicino PM, 1997, NEUROLOGY, V49, P1090, DOI 10.1212/WNL.49.4.1090; Puntillo K, 2014, INTENS CARE MED, V40, P235, DOI 10.1007/s00134-013-3153-z; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Quill TE, 2011, JAMA-J AM MED ASSOC, V306, P1483, DOI 10.1001/jama.2011.1413; Qureshi AI, 2014, WORLD NEUROSURG, V82, pE579, DOI 10.1016/j.wneu.2014.07.008; Qureshi AI, 2013, MED CARE, V51, P1094, DOI 10.1097/MLR.0b013e3182a95db4; Rabinstein AA, 2002, NEUROLOGY, V58, P1367, DOI 10.1212/WNL.58.9.1367; Rabinstein AA, 2012, LANCET NEUROL, V11, P414, DOI 10.1016/S1474-4422(12)70060-1; RANKIN J, 1957, Scott Med J, V2, P200; Rincon F, 2013, NEUROCRIT CARE, V19, P95, DOI 10.1007/s12028-012-9793-y; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Rosenbaum BP, 2014, J CLIN NEUROSCI, V21, P1874, DOI 10.1016/j.jocn.2014.05.006; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; SALAZAR J, 1986, ACTA NEUROCHIR, V79, P80, DOI 10.1007/BF01407449; Scheunemann LP, 2012, AM J RESP CRIT CARE, V186, P480, DOI 10.1164/rccm.201204-0710CP; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shea AM, 2007, NEUROSURGERY, V61, P1131, DOI 10.1227/01.neu.0000306090.30517.ae; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Smith GP, 1998, CAMB Q HEALTHC ETHIC, V7, P382, DOI 10.1017/S0963180198704074; St Louis EK, 1998, NEUROLOGY, V51, P1364, DOI 10.1212/WNL.51.5.1364; St Louis EK, 2000, CAN J NEUROL SCI, V27, P32; Tealea E, 2013, CEREBROVASC DIS EXTR, V3, P97, DOI 10.1159/000351142; TEASDALE G, 1974, LANCET, V2, P81; Terayama Y, 1997, STROKE, V28, P1185, DOI 10.1161/01.STR.28.6.1185; Thompson DR, 2014, INTENS CARE MED, V40, P1372, DOI 10.1007/s00134-014-3422-5; Treece PD, 2004, CRIT CARE MED, V32, P1141, DOI 10.1097/01.CCM.0000125509.34805.0C; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Unroe KT, 2015, J AM MED DIR ASSOC, V16, P90, DOI 10.1016/j.jamda.2014.11.010; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Varelas PN, 2008, SEMIN NEUROL, V28, P726, DOI 10.1055/s-0028-1105969; Wee B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005177.pub2; Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835; Wendler D, 2011, ANN INTERN MED, V154, P336, DOI 10.7326/0003-4819-154-5-201103010-00008; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wijdicks EFM, 2006, MAYO CLIN PROC, V81, P1332, DOI 10.4065/81.10.1332; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342; Wijdicks EFM, 2006, NEUROLOGY, V66, P1300, DOI 10.1212/01.wnl.0000210497.62202.e9; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2004, CRIT CARE MED, V32, P2332, DOI 10.1097/01.CCM.0000145949.34618.E1; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72	145	62	63	8	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					1964	1977		10.1097/CCM.0000000000001131			14	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DC5JH	WOS:000369256800043	26154929	Green Accepted			2022-02-06	
J	Miller, JP; Sweet, JA; Bailey, CM; Munyon, CN; Luders, HO; Fastenau, PS				Miller, Jonathan P.; Sweet, Jennifer A.; Bailey, Christopher M.; Munyon, Charles N.; Luders, Hans O.; Fastenau, Philip S.			Visual-spatial memory may be enhanced with theta burst deep brain stimulation of the fornix: a preliminary investigation with four cases	BRAIN			English	Article						deep brain stimulation; memory; theta burst stimulation	GEORGIA COMPLEX FIGURES; BOSTON NAMING TEST; 5 ALTERNATE FORMS; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL TESTS; MEDICAL-COLLEGE; HIPPOCAMPUS; RAT; POTENTIATION; VALIDITY	Memory loss after brain injury can be a source of considerable morbidity, but there are presently few therapeutic options for restoring memory function. We have previously demonstrated that burst stimulation of the fornix is able to significantly improve memory in a rodent model of traumatic brain injury. The present study is a preliminary investigation with a small group of cases to explore whether theta burst stimulation of the fornix might improve memory in humans. Four individuals undergoing stereo-electroencephalography evaluation for drug-resistant epilepsy were enrolled. All participants were implanted with an electrode into the proximal fornix and dorsal hippocampal commissure on the language dominant (n = 3) or language non-dominant (n = 1) side, and stimulation of this electrode reliably produced a diffuse evoked potential in the head and body of the ipsilateral hippocampus. Each participant underwent testing of verbal memory (Rey Auditory-Verbal Learning Test), visual-spatial memory (Medical College of Georgia Complex Figure Test), and visual confrontational naming (Boston Naming Test Short Form) once per day over at least two consecutive days using novel test forms each day. For 50% of the trials, the fornix electrode was continuously stimulated using a burst pattern (200 Hz in 100 ms trains, five trains per second, 100 mu s, 7 mA) and was compared with sham stimulation. Participants and examiners were blinded to whether stimulation was active or not, and the order of stimulation was randomized. The small sample size precluded use of inferential statistics; therefore, data were analysed using descriptive statistics and graphic analysis. Burst stimulation of the fornix was not perceived by any of the participants but was associated with a robust reversible improvement in immediate and delayed performance on the Medical College of Georgia Complex Figure Test. There were no apparent differences on either Rey Auditory-Verbal Learning Test or Boston Naming Test. There was no apparent relationship between performance and side of stimulation (language dominant or non-dominant). There were no complications. Preliminary evidence in this small sample of patients with drug-resistant epilepsy suggests that theta burst stimulation of the fornix may be associated with improvement in visual-spatial memory.	[Miller, Jonathan P.; Sweet, Jennifer A.; Bailey, Christopher M.; Munyon, Charles N.; Luders, Hans O.; Fastenau, Philip S.] Univ Hosp Case Med Ctr, Neurol Inst, Cleveland, OH 44106 USA; [Miller, Jonathan P.; Sweet, Jennifer A.; Munyon, Charles N.] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, Cleveland, OH USA; [Bailey, Christopher M.; Luders, Hans O.; Fastenau, Philip S.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA		Miller, JP (corresponding author), Univ Hosp Case Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	Jonathan.Miller@UHHospitals.org		Miller, Jonathan/0000-0001-5441-1751	George R. and Constance P. Lincoln family	This project was supported in part by philanthropic support from the George R. and Constance P. Lincoln family.	Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Beglinger LJ, 2003, SCHIZOPHR RES, V62, P191, DOI 10.1016/S0920-9964(02)00425-5; De Ridder D, 2010, NEUROSURGERY, V66, P986, DOI 10.1227/01.NEU.0000368153.44883.B3; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; Fastenau PS, 2002, ARCH CLIN NEUROPSYCH, V17, P834; Fastenau PS, 2001, ARCH CLIN NEUROPSYCH, V16, P824; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P828, DOI 10.1076/jcen.20.6.828.1105; Fastenau PS, 1996, J CLIN EXP NEUROPSYC, V18, P462, DOI 10.1080/01688639608409003; Fastenau PS, 2002, J INT NEUROPSYCH SOC, V8, P151; Fontaine D, 2013, J ALZHEIMERS DIS, V34, P315, DOI 10.3233/JAD-121579; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; Hescham S, 2013, BRAIN STIMUL, V6, P72, DOI 10.1016/j.brs.2012.01.008; Kaplan E, 1983, BOSTON NAMING TEST; Knight J.A., 2003, HDB REY OSTERRIETH C; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Loring DW, 2008, J INT NEUROPSYCH SOC, V14, P394, DOI 10.1017/S1355617708080582; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Nadel L, 2013, J COGNITIVE NEUROSCI, V25, P22, DOI 10.1162/jocn_a_00313; Rey A., 1964, EXAMEN CLIN PSYCHOL; Shirvalkar PR, 2010, P NATL ACAD SCI USA, V107, P7054, DOI 10.1073/pnas.0911184107; Smith GS, 2012, ARCH NEUROL-CHICAGO, V69, P1141, DOI 10.1001/archneurol.2012.590; Soriano-Mas C, 2005, BEHAV BRAIN RES, V160, P141, DOI 10.1016/j.bbr.2004.11.025; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Sweet JA, 2014, HIPPOCAMPUS, V24, P1592, DOI 10.1002/hipo.22338; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; Yamashita H, 2008, PERCEPT MOTOR SKILL, V107, P45, DOI 10.2466/PMS.107.1.45-50; Yasugi M, 2010, PERCEPT MOTOR SKILL, V110, P181, DOI 10.2466/PMS.110.1.181-184	34	62	63	1	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL 1	2015	138		7				1833	1842		10.1093/brain/awv095			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN6HY	WOS:000358536600017	26106097	Bronze			2022-02-06	
J	Lu, CH; Petzold, A; Topping, J; Allen, K; Macdonald-Wallis, C; Clarke, J; Pearce, N; Kuhle, J; Giovannoni, G; Fratta, P; Sidle, K; Fish, M; Orrell, R; Howard, R; Greensmith, L; Malaspina, A				Lu, Ching-Hua; Petzold, Axel; Topping, Jo; Allen, Kezia; Macdonald-Wallis, Corrie; Clarke, Jan; Pearce, Neil; Kuhle, Jens; Giovannoni, Gavin; Fratta, Pietro; Sidle, Katie; Fish, Mark; Orrell, Richard; Howard, Robin; Greensmith, Linda; Malaspina, Andrea			Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SUBUNIT PNF-H; CEREBROSPINAL-FLUID; AXONAL DAMAGE; LIGHT LEVELS; ALS; CSF; SERUM; BIOMARKERS; ANTIBODIES	Objective To investigate the role of longitudinal plasma neurofilament heavy chain protein ( NfH) levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis ( ALS). Methods A cross-sectional study involving 136 clinically heterogeneous patients with ALS and 104 healthy and neurological controls was extended to include a prospective analysis of 74 of these ALS cases, with samplings at approximately 3-month intervals in a follow-up period of up to 3 years. We analysed the correlation between longitudinal NfH-phosphoform levels and disease progression. Temporal patterns of NfH changes were evaluated using multilevel linear regression. Results Baseline plasma NfH levels were higher than controls only in patients with ALS with short disease duration to baseline sampling. Compared with controls, fast-progressing patients with ALS, particularly those with a short diagnostic latency and disease duration, had higher plasma NfH levels at an early stage and lower levels closer to end-stage disease. Lower NfH levels between visits were associated with rapid functional deterioration. We also detected antibodies against NfH, NfH aggregates and NfH cleavage products. Conclusions Disease progression in ALS involves defined trajectories of plasma NfH levels, reflecting speed of neurological decline and survival. Intervisit plasma NfH changes are also indicative of disease progression. This study confirms that longitudinal measurements of NfH plasma levels are more informative than cross-sectional studies, where the time of sampling may represent a bias in the interpretation of the results. Autoantibodies against NfH aggregates and NfH cleavage products may explain the variable expression of plasma NfH with disease progression.	[Lu, Ching-Hua; Topping, Jo; Kuhle, Jens; Giovannoni, Gavin; Malaspina, Andrea] Queen Mary Univ London, Ctr Neurosci & Trauma, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England; [Lu, Ching-Hua; Greensmith, Linda] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England; [Petzold, Axel] UCL Inst Neurol, Dept Neuroinflammat, London, England; [Allen, Kezia; Malaspina, Andrea] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, Essex, England; [Macdonald-Wallis, Corrie; Howard, Robin] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Clarke, Jan; Orrell, Richard] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Pearce, Neil] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Fratta, Pietro] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Sidle, Katie] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Fish, Mark] Musgrove Pk Hosp, Clin Trial Unit, Taunton, Somerset, England; [Orrell, Richard] UCL Inst Neurol, Dept Clin Neurosci, London, England; [Greensmith, Linda] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England; [Malaspina, Andrea] North East London & Essex MND Care & Res Ctr, London, England		Malaspina, A (corresponding author), Queen Mary Univ London, Ctr Neurosci & Trauma, Blizard Inst, Barts & London Sch Med & Dent, 4 Newark St, London E1 2AT, England.	a.malaspina@qmul.ac.uk	Petzold, Axel/C-1090-2009; Fratta, Pietro/G-1296-2019	Petzold, Axel/0000-0002-0344-9749; Fratta, Pietro/0000-0002-8762-8188; Pearce, Neil/0000-0002-9938-7852; Macdonald-Wallis, Corrie/0000-0002-4447-3817	Motor Neurone Disease Association [Malaspina/Apr13/6097]; Barts and The London Charities [468/1714]; Brain Research Trust; European CommunityEuropean Commission; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1000287, MR/M008606/1, MR/K000608/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K000608/1, MR/M008606/1, G1000287] Funding Source: researchfish; Motor Neurone Disease Association [Fratta/Jan15/946-795] Funding Source: researchfish	This project was funded by The Motor Neurone Disease Association (Malaspina/Apr13/6097) and Barts and The London Charities (468/1714). LG is the Graham Watts Senior Research Fellow, funded by The Brain Research Trust and the European Community's Seventh Framework Programme (FP7/2007-2013).	Abou-Donia Mohamed B, 2013, J Toxicol Environ Health A, V76, P363, DOI 10.1080/15287394.2013.765369; Bowser R, 2011, NAT REV NEUROL, V7, P631, DOI 10.1038/nrneurol.2011.151; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Boylan KB, 2013, J NEUROL NEUROSUR PS, V84, P467, DOI 10.1136/jnnp-2012-303768; Brettschneider J, 2006, NEUROLOGY, V66, P852, DOI 10.1212/01.wnl.0000203120.85850.54; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Cellura E, 2012, CLIN NEUROL NEUROSUR, V114, P550, DOI 10.1016/j.clineuro.2011.11.026; Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P310, DOI 10.3109/17482960802566824; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Couratier P, 1998, J NEUROL SCI, V154, P137, DOI 10.1016/S0022-510X(97)00219-0; De Carvalho M, 2009, AMYOTROPH LATERAL SC, V10, P53, DOI 10.1080/17482960802521126; Fialova L, 2010, EUR J NEUROL, V17, P562, DOI 10.1111/j.1468-1331.2009.02853.x; Fialova L, 2013, J NEUROIMMUNOL, V259, P81, DOI 10.1016/j.jneuroim.2013.03.009; Ganesalingam J, 2011, J NEUROCHEM, V117, P528, DOI 10.1111/j.1471-4159.2011.07224.x; Iwasaki Y, 2002, CLIN NEUROL NEUROSUR, V104, P87, DOI 10.1016/S0303-8467(01)00188-3; Leckie G, 2013, J STAT SOFTW, V52, P1; Lu CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040998; Lu CH, 2011, J NEUROSCI METH, V195, P143, DOI 10.1016/j.jneumeth.2010.11.026; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Petzold A, 2010, ANN NEUROL, V68, P806, DOI 10.1002/ana.22169; Puentes F, 2014, J NEUROL NEUROSUR PS, V85, P274, DOI [10.1136/jnnp-2013-305494, 10.1136/jnnp-2013-307454]; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Stevenson L, 2014, AAPS J, V16, P83, DOI 10.1208/s12248-013-9542-y; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Touloumi G, 1999, STAT MED, V18, P1215; Turner MR, 2010, J NEUROL SCI, V294, P81, DOI 10.1016/j.jns.2010.03.028; Zetterberg H, 2007, EUR J NEUROL, V14, P1329, DOI 10.1111/j.1468-1331.2007.01972.x; Zoing MC, 2006, J CLIN NEUROSCI, V13, P78, DOI 10.1016/j.jocn.2004.04.011	35	62	63	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2015	86	5					565	573		10.1136/jnnp-2014-307672			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	CF8BR	WOS:000352780800018	25009280	Green Published, hybrid, Green Accepted			2022-02-06	
J	Sugarman, MA; Axelrod, BN				Sugarman, Michael A.; Axelrod, Bradley N.			Embedded Measures of Performance Validity Using Verbal Fluency Tests in a Clinical Sample	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						logistic regression; malingering; COWAT; effort	TRAUMATIC BRAIN-INJURY; PATTERNS	The objective of this study was to determine to what extent verbal fluency measures can be used as performance validity indicators during neuropsychological evaluation. Participants were clinically referred for neuropsychological evaluation in an urban-based Veteran's Affairs hospital. Participants were placed into 2 groups based on their objectively evaluated effort on performance validity tests (PVTs). Individuals who exhibited credible performance (n=431) failed 0 PVTs, and those with poor effort (n=192) failed 2 or more PVTs. All participants completed the Controlled Oral Word Association Test (COWAT) and Animals verbal fluency measures. We evaluated how well verbal fluency scores could discriminate between the 2 groups. Raw scores and T scores for Animals discriminated between the credible performance and poor-effort groups with 90% specificity and greater than 40% sensitivity. COWAT scores had lower sensitivity for detecting poor effort. A combination of FAS and Animals scores into logistic regression models yielded acceptable group classification, with 90% specificity and greater than 44% sensitivity. Verbal fluency measures can yield adequate detection of poor effort during neuropsychological evaluation. We provide suggested cut points and logistic regression models for predicting the probability of poor effort in our clinical setting and offer suggested cutoff scores to optimize sensitivity and specificity.	[Sugarman, Michael A.; Axelrod, Bradley N.] John D Dingell Vet Affairs Med Hosp, Dept Psychol, Detroit, MI USA; [Sugarman, Michael A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA		Sugarman, MA (corresponding author), Wayne State Univ, Dept Psychol, 7th Floor,5057 Woodward Ave, Detroit, MI 48202 USA.	Mike.Sugarman@wayne.edu					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Benton A., 1978, MULTILINGUAL APHASIA; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; Green P, 2004, GREENS MED SYMPTOM V; Heaton R. K., 2004, REVISED COMPREHENSIV; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lemeshow S, 2000, APPL LOGISTIC REGRES; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR., 2009, AM ACAD CLIN NEUROPS, P21; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D., 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 2008, WECHSLER ADULT INTEL	23	62	63	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					141	146		10.1080/23279095.2013.873439			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400009	25153155				2022-02-06	
J	Fenn, AM; Skendelas, JP; Moussa, DN; Muccigrosso, MM; Popovich, PG; Lifshitz, J; Eiferman, DS; Godbout, JP				Fenn, Ashley M.; Skendelas, John P.; Moussa, Daniel N.; Muccigrosso, Megan M.; Popovich, Phillip G.; Lifshitz, Jonathan; Eiferman, Daniel S.; Godbout, Jonathan P.			Methylene Blue Attenuates Traumatic Brain Injury-Associated Neuroinflammation and Acute Depressive-Like Behavior in Mice	JOURNAL OF NEUROTRAUMA			English	Article						intervention; cytokines; fluid percussion injury; recovery; microglia	QUINOLINIC ACID; NITRIC-OXIDE; AGED MICE; COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; WORKING-MEMORY; HEAD-INJURY; INFLAMMATION; ACTIVATION; EXPRESSION	Traumatic brain injury (TBI) is associated with cerebral edema, blood brain barrier breakdown, and neuroinflammation that contribute to the degree of injury severity and functional recovery. Unfortunately, there are no effective proactive treatments for limiting immediate or long-term consequences of TBI. Therefore, the objective of this study was to determine the efficacy of methylene blue (MB), an antioxidant agent, in reducing inflammation and behavioral complications associated with a diffuse brain injury. Here we show that immediate MB infusion (intravenous; 15-30 minutes after TBI) reduced cerebral edema, attenuated microglial activation and reduced neuroinflammation, and improved behavioral recovery after midline fluid percussion injury in mice. Specifically, TBI-associated edema and inflammatory gene expression in the hippocampus were significantly reduced by MB at 1 d post injury. Moreover, MB intervention attenuated TBI-induced inflammatory gene expression (interleukin [IL]-1 beta, tumor necrosis factor alpha) in enriched microglia/macrophages 1 d post injury. Cell culture experiments with lipopolysaccharide-activated BV2 microglia confirmed that MB treatment directly reduced IL-1 beta and increased IL-10 messenger ribonucleic acid in microglia. Last, functional recovery and depressive-like behavior were assessed up to one week after TBI. MB intervention did not prevent TBI-induced reductions in body weight or motor coordination 1-7 d post injury. Nonetheless, MB attenuated the development of acute depressive-like behavior at 7 d post injury. Taken together, immediate intervention with MB was effective in reducing neuroinflammation and improving behavioral recovery after diffuse brain injury. Thus, MB intervention may reduce life-threatening complications of TBI, including edema and neuroinflammation, and protect against the development of neuropsychiatric complications.	[Fenn, Ashley M.; Skendelas, John P.; Moussa, Daniel N.; Muccigrosso, Megan M.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA; [Eiferman, Daniel S.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Lifshitz, Jonathan] Univ Arizona, Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Child Hlth, Phoenix, AZ USA		Eiferman, DS (corresponding author), Ohio State Univ, 395 W 12th Ave,Suite 634, Columbus, OH 43210 USA.	daniel.eiferman@osumc.edu; jonathan.godbout@osumc.edu		Skendelas, John/0000-0002-3491-7568	Ohio State University by the Center for Brain and Spinal Cord Repair; Department of Surgery; College of Medicine Dean's Discovery Grant; OSU Presidential Fellowship	This work was supported by Ohio State University funding by the Center for Brain and Spinal Cord Repair (to JPG), Department of Surgery (to DSE), and a College of Medicine Dean's Discovery Grant (to JPG). AMF was supported by the OSU Presidential Fellowship. The authors thank Christopher Burnsides for his technical assistance, and Dr. Joseph Travers and Dr. Jason Nasse for use of their isoflurane setup and their technical assistance in developing an isoflurane system.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cardenas A, 2005, BRAIN RES REV, V50, P1, DOI 10.1016/j.brainresrev.2005.03.006; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; De Palma C, 2008, J NEUROCHEM, V106, P193, DOI 10.1111/j.1471-4159.2008.05351.x; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; Fenn A.M., 2013, BIOL PSYCHIAT; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Maslow AD, 2006, ANESTH ANALG, V103, P2, DOI 10.1213/01.ane.0000221261.25310.fe; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miclescu A, 2010, CRIT CARE MED, V38, P2199, DOI 10.1097/CCM.0b013e3181f26b0c; Miller AH., 2008, FOCUS, V6, P36; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morganti JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093650; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NHDS NHAMCS NVSS, 2010, INJ PREV CONTR TRAUM; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; Oz M, 2011, MED RES REV, V31, P93, DOI 10.1002/med.20177; Paciullo CA, 2010, PHARMACOTHERAPY, V30, P702, DOI 10.1592/phco.30.7.702; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Peter C, 2000, EUR J CLIN PHARMACOL, V56, P247, DOI 10.1007/s002280000124; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Richwine AF, 2008, PSYCHONEUROENDOCRINO, V33, P1369, DOI 10.1016/j.psyneuen.2008.08.003; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Schirmer RH, 2003, REDOX REP, V8, P272, DOI 10.1179/135100003225002899; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Steiner J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-94; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Vutskits L, 2008, ANESTHESIOLOGY, V108, P684, DOI 10.1097/ALN.0b013e3181684be4; Wang HE, 2013, PREHOSP EMERG CARE, V17, P8, DOI 10.3109/10903127.2012.722178; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yirmiya R, 2000, ANN NY ACAD SCI, V917, P478; ZEMBOWICZ A, 1992, P NATL ACAD SCI USA, V89, P2051, DOI 10.1073/pnas.89.6.2051; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	77	62	68	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					127	138		10.1089/neu.2014.3514			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700008	25070744	Green Published			2022-02-06	
J	Des Roches, CA; Balachandran, I; Ascenso, EM; Tripodis, Y; Kiran, S				Des Roches, Carrie A.; Balachandran, Isabel; Ascenso, Elsa M.; Tripodis, Yorghos; Kiran, Swathi			Effectiveness of an impairment-based individualized rehabilitation program using an iPad-based software platform	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						aphasia; stroke; traumatic brain injury; iPad-based rehabilitation; Constant Therapy; impairment-based; individualized rehabilitation	MILD COGNITIVE IMPAIRMENT; WORKING-MEMORY; LANGUAGE THERAPY; APHASIA; STROKE; INTENSITY; DEFICITS; POSTSTROKE; CONVERSION; SEVERITY	The delivery of tablet-based rehabilitation for individuals with post-stroke aphasia is relatively new, therefore, this study examined the effectiveness of an iPad-based therapy to demonstrate improvement in specific therapy tasks and how the tasks affect overall language and cognitive skills. Fifty-one individuals with aphasia due to a stroke or traumatic brain injury (TBI) were recruited to use an iPad-based software platform, Constant Therapy, for a 10 week therapy program. Participants were split into an experimental (N = 42) and control (N = 9) group. Both experimental and control participants received a 1 h clinic session with a clinician once a week, the experimental participants additionally practiced the therapy at home. Participants did not differ in the duration of the therapy and both groups of participants showed improvement over time in the tasks used for the therapy. However, experimental participants used the application more often and showed greater changes in accuracy and latency on the tasks than the control participants; experimental participants' severity level at baseline as measured by standardized tests of language and cognitive skills were a factor in improvement on the tasks. Subgroups of task co-improvement appear to occur between different language tasks, between different cognitive tasks, and across both domains. Finally, experimental participants showed more significant and positive changes due to therapy in their standardized tests than control participants. These results provide preliminary evidence for the usefulness of a tablet-based platform to deliver tailored language and cognitive therapy to individuals with aphasia.	[Des Roches, Carrie A.; Balachandran, Isabel; Ascenso, Elsa M.; Kiran, Swathi] Boston Univ, Speech Hearing & Language Sci Sargent Coll, Aphasia Res Lab, Boston, MA 02215 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA		Des Roches, CA (corresponding author), Boston Univ, Speech Hearing & Language Sci Sargent Coll, Aphasia Res Lab, 635 Commonwealth Ave,Rm 326, Boston, MA 02215 USA.	cadesroc@gmail.com	; Des Roches, Carrie/G-3314-2014	Tripodis, Yorghos/0000-0003-2190-7608; Des Roches, Carrie/0000-0001-5593-9347	Coulter Foundation for Translational Research	This project was funded by the Coulter Foundation for Translational Research. The authors thank Stephanie Keifer, Sahil Luthra, and Anna Kasdan for their contributions to the project and for their assistance in data collection.	Akerlund E, 2013, BRAIN INJURY, V27, P1649, DOI 10.3109/02699052.2013.830195; Allen L, 2012, TOP STROKE REHABIL, V19, P523, DOI 10.1310/tsr1906-523; Atticks A. H., 2012, GERONTOLOGY, V17, P84, DOI [10.1044/gero17.3.84, DOI 10.1044/GERO17.3.84]; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Barnes DE, 2009, ALZ DIS ASSOC DIS, V23, P205, DOI 10.1097/WAD.0b013e31819c6137; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Bowen A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4407; Brady MC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub3; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); Cherney Leora R., 2010, Seminars in Speech and Language, V31, P42, DOI 10.1055/s-0029-1244952; Doesborgh S, 2004, APHASIOLOGY, V18, P213, DOI 10.1080/02687030344000580; Fink RB, 2002, APHASIOLOGY, V16, P1061, DOI 10.1080/02687030244000400; Finn M, 2011, BRAIN IMPAIR, V12, P187; Goodglass H., 1983, REVISED BOSTON NAMIN; Helm-Estabrooks N., 2001, COGNITIVE LINGUISTIC; Holland AL, 2014, SEMIN SPEECH LANG, V35, P1, DOI 10.1055/s-0033-1362994; Hoover EL, 2014, SEMIN SPEECH LANG, V35, P25, DOI 10.1055/s-0033-1362990; Howard D, 1992, PYRAMIDS PALM TREES; Hussey EK, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00158; Johansson B, 2012, SCAND J OCCUP THER, V19, P176, DOI 10.3109/11038128.2011.603352; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kertesz A., 1982, W APHASIA BATTERY TE; Kiran S, 2005, APHASIOLOGY, V19, P53, DOI 10.1080/02687030444000633; Kiran S, 2001, APHASIOLOGY, V15, P855, DOI 10.1080/02687040143000258; Kiran S, 2014, SEMIN SPEECH LANG, V35, P38, DOI 10.1055/s-0033-1362995; Kohnert K, 2004, BRAIN LANG, V91, P294, DOI 10.1016/j.bandl.2004.04.001; Kurland J, 2014, SEMIN SPEECH LANG, V35, P51, DOI 10.1055/s-0033-1362991; Kurland J, 2014, SEMIN SPEECH LANG, V35, P3, DOI 10.1055/s-0033-1362989; Lee JB, 2009, APHASIOLOGY, V23, P885, DOI 10.1080/02687030802669534; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Pedersen PM, 2004, CEREBROVASC DIS, V17, P35, DOI 10.1159/000073896; Pedersen PM, 2001, APHASIOLOGY, V15, P151, DOI 10.1080/02687040042000106; Ralph MAL, 2010, NEUROPSYCHOL REHABIL, V20, P289, DOI 10.1080/09602010903237875; Ramsberger G, 2007, AM J SPEECH-LANG PAT, V16, P343, DOI 10.1044/1058-0360(2007/038); Ramsberger G, 2014, SEMIN SPEECH LANG, V35, P17, DOI 10.1055/s-0033-1362992; Raymer AM, 2008, J SPEECH LANG HEAR R, V51, pS259, DOI 10.1044/1092-4388(2008/020); Slevc LR, 2013, BEHAV BRAIN SCI, V36, P373, DOI 10.1017/S0140525X12002683; Szabo G, 2014, SEMIN SPEECH LANG, V35, P5, DOI 10.1055/s-0033-1362993; Teasell R, 2012, TOP STROKE REHABIL, V19, P457, DOI 10.1310/tsr1906-457; van de Sandt-Koenderman WME, 2011, INT J SPEECH-LANG PA, V13, P21, DOI 10.3109/17549507.2010.502973; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484	43	62	62	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JAN 5	2015	8								1015	10.3389/fnhum.2014.01015			29	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	AY3YO	WOS:000347515500001	25601831	Green Published, gold			2022-02-06	
J	Dal Monte, O; Schintu, S; Pardini, M; Berti, A; Wassermann, EM; Grafman, J; Krueger, F				Dal Monte, Olga; Schintu, Selene; Pardini, Matteo; Berti, Anna; Wassermann, Eric M.; Grafman, Jordan; Krueger, Frank			The left inferior frontal gyrus is crucial for reading the mind in the eyes: Brain lesion evidence	CORTEX			English	Article						RMET; Mental states; Voxel-based lesion symptom mapping; Traumatic brain injury; Semantic working memory	PREFRONTAL CORTEX; ARCUATE FASCICULUS; EMOTION RECOGNITION; COGNITIVE IMPAIRMENT; ASPERGER-SYNDROME; SOCIAL COGNITION; LOBE DAMAGE; INJURY; FMRI; LANGUAGE	Deficit in the ability to understand and predict the mental states of others is one of the central features of traumatic brain injury (TBI), leading to problems in social-daily life such as social withdrawal and the inability to maintain work or family relationships. Although several functional neuroimaging studies have identified a widely distributed brain network involved in the Reading the Mind in the Eyes Test (RMET), the necessary brain regions engaged in this capacity are still heavily debated. In this study, we combined the RMET with a whole-brain voxel-based lesion symptom mapping (VLSM) approach to identify brain regions necessary for adequate RMET performance in a large sample of patients with penetrating TBI (pTBI). Our results revealed that pTBI patients performed worse on the RMET compared to non-head injured controls, and impaired RMET performance was associated with lesions in the left inferior frontal gyms (IFG). Our findings suggest that the left IFG is a key region in reading the mind in the eyes, probably involved in a more general impairment of a semantic working memory system that facilitates reasoning about what others are feeling and thinking as expressed by the eyes. (C) 2014 Elsevier Ltd. All rights reserved.	[Dal Monte, Olga; Berti, Anna] Univ Turin, Dept Neuropsychol, Turin, Italy; [Schintu, Selene] Lyon Neurosci Res Ctr, CNRS, INSERM, ImpAct Team,UMR5292,U1028, Lyon, France; [Schintu, Selene] Univ UCBL Lyon 1, Lyon, France; [Pardini, Matteo] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet & Mat & Ch, Genoa, Italy; [Wassermann, Eric M.] Natl Inst Neurol Disorders & Stroke, Behav Neurol Unit, NIH, Bethesda, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, Chicago, IL 60611 USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA USA		Krueger, F (corresponding author), George Mason Univ, Dept Psychol, Mol Neurosci Dept, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	fkrueger@gmu.edu	Wassermann, Eric M./AAC-9064-2020; Dal Monte, Olga/P-3759-2018; Schintu, Selene/ABF-7032-2020; Pardini, Matteo/F-8414-2010	Wassermann, Eric M./0000-0003-0628-0210; Dal Monte, Olga/0000-0002-7823-4769; Schintu, Selene/0000-0002-6362-3905; Pardini, Matteo/0000-0002-4740-1982; Berti, Anna/0000-0001-9972-5543	U.S. National Institute of Neurological Disorders and Stroke Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	This study was conducted and supported by the U.S. National Institute of Neurological Disorders and Stroke Intramural Research Program and took place at the National Institutes of Health Clinical Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the U.S. Government. For further information about the Vietnam Head Injury Study, contact J.G. at jgrafman@northwestern.edu. We thank the NIH Clinical Center for the provision of their facilities and for their supportive services. We thank Sandra Bonifant, Michael Tiemey, Leila Glass, Lyanne Yozawitz, Carolee Noury, Vivien YJ Tsen, and Anne Leopold who worked tirelessly to test subjects and organize the study. As always, the authors are grateful to all of the Vietnam veterans and caregivers who participated in this study. Their unending commitment to improving the health care of veterans is the reason this study could be completed.	Adams RB, 2010, J COGNITIVE NEUROSCI, V22, P97, DOI 10.1162/jocn.2009.21187; Baglio F, 2012, J ALZHEIMERS DIS, V29, P25, DOI 10.3233/JAD-2011-111256; Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; Baron-Cohen S, 2006, BRAIN COGNITION, V61, P122, DOI 10.1016/j.bandc.2005.12.011; Beck, 1978, BECK DEPRESSION INVE; Brauer J, 2011, CEREB CORTEX, V21, P459, DOI 10.1093/cercor/bhq108; Castelli I, 2010, NEUROPSYCHOLOGIA, V48, P2586, DOI 10.1016/j.neuropsychologia.2010.05.005; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dal Monte O, 2013, SOC COGN AFFECT NEUR, V8, P632, DOI 10.1093/scan/nss041; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dick AS, 2012, BRAIN, V135, P3529, DOI 10.1093/brain/aws222; Friederici AD, 2009, TRENDS COGN SCI, V13, P175, DOI 10.1016/j.tics.2009.01.001; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; Glasser MF, 2008, CEREB CORTEX, V18, P2471, DOI 10.1093/cercor/bhn011; Goodglass H, 1997, J Int Neuropsychol Soc, V3, P128; Goodkind MS, 2012, HUM BRAIN MAPP, V33, P753, DOI 10.1002/hbm.21251; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Gross JJ, 1997, PSYCHOL AGING, V12, P590, DOI 10.1037/0882-7974.12.4.590; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hirao K, 2008, SCHIZOPHR RES, V105, P165, DOI 10.1016/j.schres.2008.07.021; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Jang SH, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00749; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; KAPLAN E, 1976, BOSTON NAMING TEST; Kawashima R, 1999, BRAIN, V122, P779, DOI 10.1093/brain/122.4.779; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kemp J, 2012, AGEING RES REV, V11, P199, DOI 10.1016/j.arr.2011.12.001; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Marchina S, 2011, STROKE, V42, P2251, DOI 10.1161/STROKEAHA.110.606103; Martin PI, 2009, BRAIN LANG, V111, P20, DOI 10.1016/j.bandl.2009.07.007; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McNeil M., 1994, REVISED TOKEN TEST; Moor BG, 2012, SOC COGN AFFECT NEUR, V7, P44, DOI 10.1093/scan/nsr020; Mori S, 2005, MRI ATLAS HUMAN WHIT; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Obler LK, 2010, BRAIN LANG, V113, P113, DOI [10.1016/j.bandl.2010.03.001, 10.1016/j.band1.2010.03.001]; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Poldrack RA, 1999, NEUROIMAGE, V10, P15, DOI 10.1006/nimg.1999.0441; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Rilling JK, 2008, NAT NEUROSCI, V11, P426, DOI 10.1038/nn2072; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1982, DOI 10.1152/jn.1996.75.5.1982; Russell TA, 2000, AM J PSYCHIAT, V157, P2040, DOI 10.1176/appi.ajp.157.12.2040; Sabbagh MA, 2004, J COGNITIVE NEUROSCI, V16, P415, DOI 10.1162/089892904322926755; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; Tsuchida A, 2012, CEREB CORTEX, V22, P2904, DOI 10.1093/cercor/bhr370; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; United States Department of Defense, 1960, ARM FORC QUAL TEST A; Wagner AD, 1998, BRAIN, V121, P1985, DOI 10.1093/brain/121.10.1985; Warrington E. K., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WECHSLER MEMORY SCAL; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	64	62	62	2	40	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	SEP	2014	58						9	17		10.1016/j.cortex.2014.05.002			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	AO6OA	WOS:000341470200002	24946302				2022-02-06	
J	Kelly, DF; Chaloner, C; Evans, D; Mathews, A; Cohan, P; Wang, C; Swerdloff, R; Sim, MS; Lee, J; Wright, MJ; Kernan, C; Barkhoudarian, G; Yuen, KCJ; Guskiewicz, K				Kelly, Daniel F.; Chaloner, Charlene; Evans, Diana; Mathews, Amy; Cohan, Pejman; Wang, Christina; Swerdloff, Ronald; Sim, Myung-Shin; Lee, Jihey; Wright, Mathew J.; Kernan, Claudia; Barkhoudarian, Garni; Yuen, Kevin C. J.; Guskiewicz, Kevin			Prevalence of Pituitary Hormone Dysfunction, Metabolic Syndrome, and Impaired Quality of Life in Retired Professional Football Players: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; hypogonadism; metabolic syndrome; mild traumatic brain injury; professional football	TRAUMATIC BRAIN-INJURY; GH REPLACEMENT THERAPY; BODY-MASS INDEX; GROWTH-HORMONE; DEFICIENT ADULTS; LONG-TERM; HYPOPITUITARY PATIENTS; RECURRENT CONCUSSION; SUBARACHNOID HEMORRHAGE; STIMULATION TESTS	Hypopituitarism is common after moderate and severe traumatic brain injury (TBI). Herein, we address the association between mild TBI (mTBI) and pituitary and metabolic function in retired football players. Retirees 30-65 years of age, with one or more years of National Football League (NFL) play and poor quality of life (QoL) based on Short Form 36 (SF-36) Mental Component Score (MCS) were prospectively enrolled. Pituitary hormonal and metabolic syndrome (MetS) testing was performed. Using a glucagon stimulation test, growth hormone deficiency (GHD) was defined with a standard cut point of 3 ng/mL and with a more stringent body mass index (BMI)-adjusted cut point. Subjects with and without hormonal deficiency (HD) were compared in terms of QoL, International Index of Erectile Function (IIEF) scores, metabolic parameters, and football career data. Of 74 subjects, 6 were excluded because of significant non-football-related TBIs. Of the remaining 68 subjects (mean age, 47.3 +/- 10.2 years; median NFL years, 5; median NFL concussions, 3; mean BMI, 33.8 +/- 6.0), 28 (41.2%) were GHD using a peak GH cutoff of < 3 ng/mL. However, with a BMI-adjusted definition of GHD, 13 of 68 (19.1%) were GHD. Using this BMI-adjusted definition, overall HD was found in 16 (23.5%) subjects: 10 (14.7%) with isolated GHD; 3 (4.4%) with isolated hypogonadism; and 3 (4.4%) with both GHD and hypogonadism. Subjects with HD had lower mean scores on the IIEF survey (p = 0.016) and trended toward lower scores on the SF-36 MCS (p = 0.113). MetS was present in 50% of subjects, including 5 of 6 (83%) with hypogonadism, and 29 of 62 (46.8%) without hypogonadism (p = 0.087). Age, BMI, median years in NFL, games played, number of concussions, and acknowledged use of performance-enhancing steroids were similar between HD and non-HD groups. In summary, in this cohort of retired NFL players with poor QoL, 23.5% had HD, including 19% with GHD (using a BMI-adjusted definition), 9% with hypogonadism, and 50% had MetS. Although the cause of HD is unclear, these results suggest that GHD and hypogonadism may contribute to poor QoL, erectile dysfunction, and MetS in this population. Further study of pituitary function is warranted in athletes sustaining repetitive mTBI.	[Kelly, Daniel F.; Chaloner, Charlene; Sim, Myung-Shin; Lee, Jihey; Barkhoudarian, Garni] St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, Santa Monica, CA 90404 USA; [Kelly, Daniel F.; Chaloner, Charlene; Sim, Myung-Shin; Lee, Jihey; Barkhoudarian, Garni] St Johns Hlth Ctr, John Wayne Canc Inst, Pituitary Disorders Program, Santa Monica, CA 90404 USA; [Evans, Diana; Wang, Christina; Swerdloff, Ronald; Wright, Mathew J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Evans, Diana; Wang, Christina; Swerdloff, Ronald; Wright, Mathew J.] Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Mathews, Amy; Guskiewicz, Kevin] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC USA; [Cohan, Pejman] UCLA Sch Med, Div Endocrinol, Dept Med, Los Angeles, CA USA; [Kernan, Claudia] UCLA Semel Inst Neurosci & Human Behav, Los Angeles, CA USA; [Yuen, Kevin C. J.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol, Portland, OR 97201 USA		Kelly, DF (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwci.org		Guskiewicz, Kevin/0000-0002-8682-2130	National Operating Committee on Standards for Athletic Equipment (NOCSAE); Pfizer, Inc.Pfizer; General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1 RR00425]; UCLA Clinical and Translational Science Institute at Los Angeles Biomedical Research Institute (LA BioMed) [1UL1TR000124]; Harbor-UCLA Medical Center; Endocrine, Metabolism and Nutrition Training Grant [T32 DK007571]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK007571] Funding Source: NIH RePORTER	This study was funded by the National Operating Committee on Standards for Athletic Equipment (NOCSAE) and by Pfizer, Inc., and, in part, by the General Clinical Research Center (MO1 RR00425) and the UCLA Clinical and Translational Science Institute (1UL1TR000124) at Los Angeles Biomedical Research Institute (LA BioMed) and Harbor-UCLA Medical Center, and the Endocrine, Metabolism and Nutrition Training Grant (T32 DK007571). The authors thank Andrew Leung and Mari Lajoie of the Endocrine and Metabolic Research Laboratory for the hormonal analyses and the nurses at the former GCRC (now the Clinical and Translational Research Center) at LA BioMed and Harbor-UCLA for their skillful nursing assistance.	Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Akanji AO, 2012, METAB SYNDR RELAT D, V10, P3, DOI 10.1089/met.2011.0083; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Allan CA, 2010, CURR OPIN ENDOCRINOL, V17, P224, DOI 10.1097/MED.0b013e3283398ee2; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Attanasio AF, 2010, J CLIN ENDOCR METAB, V95, P74, DOI 10.1210/jc.2009-1326; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Berg C, 2010, EUR J ENDOCRINOL, V162, P477, DOI 10.1530/EJE-09-0824; Blum WF, 2003, J CLIN ENDOCR METAB, V88, P4158, DOI 10.1210/jc.2002-021792; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Brand JS, 2011, INT J EPIDEMIOL, V40, P189, DOI 10.1093/ije/dyq158; Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P3995, DOI 10.1210/jc.2009-0438; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Conceicao FL, 2003, GROWTH HORM IGF RES, V13, P347, DOI 10.1016/S1096-6374(03)00124-2; Cook DM, 2009, ENDOCR PRACT, V15, P580, DOI 10.4158/EP.15.6.580; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Corona G, 2007, J SEX MED, V4, P1038, DOI 10.1111/j.1743-6109.2007.00529.x; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Di Somma C, 2010, J ENDOCRINOL INVEST, V33, P171, DOI [10.1007/BF03346577, 10.3275/6519]; Dubourg J, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11182; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Giusti M, 1998, EUR J CLIN INVEST, V28, P13; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOFFMAN DM, 1994, LANCET, V344, P482, DOI 10.1016/S0140-6736(94)91821-X; Hong JW, 2011, HORM METAB RES, V43, P48, DOI 10.1055/s-0030-1265217; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Howell S, 2001, HORM RES, V56, P86, DOI 10.1159/000048142; Ives JC, 2007, J ATHL TRAINING, V42, P431; KARLBERG J, 1995, ACTA OBSTET GYN SCAN, V74, P367, DOI 10.3109/00016349509024430; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; Laaksonen DE, 2005, J CLIN ENDOCR METAB, V90, P712, DOI 10.1210/jc.2004-0970; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mahajan T, 2004, EUR J ENDOCRINOL, V151, P325, DOI 10.1530/eje.0.1510325; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Mukherjee A, 2005, J CLIN ENDOCR METAB, V90, P1542, DOI 10.1210/jc.2004-0832; Oliveira CRP, 2011, ARQ BRAS CARDIOL, V97, P434, DOI 10.1590/S0066-782X2011001400012; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qoubaitary A, 2005, EXPERT OPIN PHARMACO, V6, P1493, DOI 10.1517/14656566.6.9.1493; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Scacchi M, 2010, EUR J ENDOCRINOL, V163, P201, DOI 10.1530/EJE-10-0160; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Vahl N, 1997, AM J PHYSIOL-ENDOC M, V272, pE1108, DOI 10.1152/ajpendo.1997.272.6.E1108; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; Wang C, 2011, DIABETES CARE, V34, P1669, DOI 10.2337/dc10-2339; Ware J., 2001, SF 36 PHYS MENTAL HL; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wiren L, 1998, CLIN ENDOCRINOL, V48, P613, DOI 10.1046/j.1365-2265.1998.00462.x; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	81	62	62	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1161	1171		10.1089/neu.2013.3212			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500005	24552537	Green Published, Green Submitted			2022-02-06	
J	Tulsky, DS; Carlozzi, N; Chiaravalloti, ND; Beaumont, JL; Kisala, PA; Mungas, D; Conway, K; Gershon, R				Tulsky, David S.; Carlozzi, Noelle; Chiaravalloti, Nancy D.; Beaumont, Jennifer L.; Kisala, Pamela A.; Mungas, Dan; Conway, Kevin; Gershon, Richard			NIH Toolbox Cognition Battery (NIHTB-CB): List Sorting Test to Measure Working Memory	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognition; Working memory; Memory; Short-term; Neuropsychological tests; Executive function; Adult	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; COMPLEX SPAN; SHORT-TERM; PERFORMANCE; INFORMATION; CAPACITY; ACTIVATION	The List Sorting Working Memory Test was designed to assess working memory (WM) as part of the NIH Toolbox Cognition Battery. List Sorting is a sequencing task requiring children and adults to sort and sequence stimuli that are presented visually and auditorily. Validation data are presented for 268 participants ages 20 to 85 years. A subset of participants (N = 89) was retested 7 to 21 days later. As expected, the List Sorting Test had moderately high correlations with other measures of working memory and executive functioning (convergent validity) but a low correlation with a test of receptive vocabulary (discriminant validity). Furthermore, List Sorting demonstrates expected changes over the age span and has excellent test-retest reliability. Collectively, these results provide initial support for the construct validity of the List Sorting Working Memory Measure as a measure of working memory. However, the relationship between the List Sorting Test and general executive function has yet to be determined.	[Tulsky, David S.] NYU, Rusk Inst, Dept Rehabil Med, Dept Orthoped Surg,Dept Gen Med,Langone Med Ctr, New York, NY 10016 USA; [Tulsky, David S.; Chiaravalloti, Nancy D.] Kessler Fdn, Spinal Cord Injury Lab, Neuropsychol & Neurosci Lab, West Orange, NJ USA; [Carlozzi, Noelle] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Beaumont, Jennifer L.; Gershon, Richard] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David S.; Kisala, Pamela A.] NYU, Rusk Inst, Dept Rehabil Med, Langone Med Ctr, New York, NY 10016 USA; [Mungas, Dan] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA; [Conway, Kevin] NIDA, Rockville, MD USA		Tulsky, DS (corresponding author), NYU, Rusk Inst, Dept Rehabil Med, Langone Med Ctr, Ambulatory Care Ctr 240 E 38th St,17th Floor, New York, NY 10016 USA.	david.tulsky@nyumc.org	Beaumont, Jennifer/AAA-2825-2020	Conway, Kevin/0000-0002-7638-339X; Chiaravalloti, Nancy/0000-0003-2943-7567; Beaumont, Jennifer/0000-0002-1484-260X; Tulsky, David/0000-0002-4335-4509	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [N01AG60007]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010220, P30AG010129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [N44AA002006] Funding Source: NIH RePORTER	Funding for this research was provided by contract number N01AG60007 from the National Institutes of Health. The authors have nothing to disclose.	Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; [Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A., 1987, WORKING MEMORY, V11; Baddeley A.D., 1986, WORKING MEMORY; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; Baddeley AD, 2002, EUR PSYCHOL, V7, P85, DOI 10.1027//1016-9040.7.2.85; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Beatty WW, 1996, J CLIN EXP NEUROPSYC, V18, P56, DOI 10.1080/01688639608408262; Belger A, 1998, HUM BRAIN MAPP, V6, P14, DOI 10.1002/(SICI)1097-0193(1998)6:1<14::AID-HBM2>3.0.CO;2-O; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conlin JA, 2005, J EXP CHILD PSYCHOL, V90, P303, DOI 10.1016/j.jecp.2004.12.001; Conway ARA, 2005, PSYCHON B REV, V12, P769, DOI 10.3758/BF03196772; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; Crosson B, 1999, NEUROPSYCHOLOGY, V13, P171, DOI 10.1037/0894-4105.13.2.171; Crowe SF, 2000, ASSESSMENT, V7, P113, DOI 10.1177/107319110000700202; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; de Jong PF, 1998, J EXP CHILD PSYCHOL, V70, P75, DOI 10.1006/jecp.1998.2451; de Jong PF, 2004, J EXP CHILD PSYCHOL, V88, P254, DOI 10.1016/j.jecp.2004.03.007; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Dunn, 2007, PPVT 4 PEABODY PICTU; Edin F, 2007, J COGNITIVE NEUROSCI, V19, P750, DOI 10.1162/jocn.2007.19.5.750; Edin F, 2009, P NATL ACAD SCI USA, V106, P6802, DOI 10.1073/pnas.0901894106; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GRIGSBY J, 1994, J NEUROL, V241, P125; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P134; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GROSSMAN M, 1994, NEUROPSY NEUROPSY BE, V7, P194; HASHER L, 1991, J EXP PSYCHOL LEARN, V17, P163, DOI 10.1037/0278-7393.17.1.163; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton R., 2000, WISCONSIN CARD SORTI; Hitch GJ, 2001, J EXP PSYCHOL GEN, V130, P184, DOI 10.1037//0096-3445.130.2.184; Hodes RJ, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e3182872e90; Hofmann W, 2012, TRENDS COGN SCI, V16, P174, DOI 10.1016/j.tics.2012.01.006; Jacobsen CF, 1935, ARCH NEURO PSYCHIATR, V33, P558, DOI 10.1001/archneurpsyc.1935.02250150108009; Jonides J., 1995, INVITATION COGNITIVE, V3, P215; Kirasic KC, 1996, PSYCHOL AGING, V11, P658, DOI 10.1037/0882-7974.11.4.658; Klingberg T, 1996, EUR J NEUROSCI, V8, P1965, DOI 10.1111/j.1460-9568.1996.tb01340.x; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Kwon H, 2002, P NATL ACAD SCI USA, V99, P13336, DOI 10.1073/pnas.162486399; KYLLONEN PC, 1990, INTELLIGENCE, V14, P389, DOI 10.1016/S0160-2896(05)80012-1; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Linden DEJ, 2007, NEUROSCIENTIST, V13, P257, DOI 10.1177/1073858406298480; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; Logie RH, 1996, WORKING MEMORY HUMAN, P31, DOI DOI 10.1093/ACPROF:OSO/9780195100990.003.0002; Manly J., 2003, CLIN INTERPRETATION, P181, DOI DOI 10.1016/B978-012703570-3/50010-9; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAuley T, 2011, J EXP CHILD PSYCHOL, V108, P453, DOI 10.1016/j.jecp.2010.08.009; McCabe DP, 2010, NEUROPSYCHOLOGY, V24, P222, DOI 10.1037/a0017619; MESSICK S, 1980, AM PSYCHOL, V35, P1012, DOI 10.1037/0003-066X.35.11.1012; MESSICK S, 1991, ENCY ED RES; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Milner B., 1964, FRONTAL GRANULAR COR, P313; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A., 1999, MODELS WORKING MEMOR; Mungas D, 2000, NEUROPSYCHOLOGY, V14, P209, DOI 10.1037//0894-4105.14.2.209; Newell A., 1972, HUMAN PROBLEM SOLVIN; Newell A, 1973, VISUAL INFORMATION P, P463; Orellana Gricel, 2013, Front Psychiatry, V4, P35, DOI 10.3389/fpsyt.2013.00035; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Pelphrey KA, 2003, ADV CHILD DEV BEHAV, V31, P173; Repovs G, 2006, NEUROSCIENCE, V139, P1, DOI 10.1016/j.neuroscience.2005.12.007; Riggs KJ, 2006, J EXP CHILD PSYCHOL, V95, P18, DOI 10.1016/j.jecp.2006.03.009; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Salthouse T. A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [10.1037/0894-4105.8.4.535, DOI 10.1037/0894-4105.8.4.535]; SALTHOUSE TA, 1989, J EXP PSYCHOL LEARN, V15, P507, DOI 10.1037/0278-7393.15.3.507; Scherf KS, 2006, J COGNITIVE NEUROSCI, V18, P1045, DOI 10.1162/jocn.2006.18.7.1045; Schmiedek F, 2009, J EXP PSYCHOL LEARN, V35, P1089, DOI 10.1037/a0015730; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tulsky D., 2003, CLIN INTERPRETATION, P43, DOI DOI 10.1016/B978-012703570-3/50006-7; Tulsky DS, 2013, MONOGR SOC RES CHILD, V78, P70, DOI 10.1111/mono.12035; Van Snellenberg JX, 2009, PSYCHIAT RES-NEUROIM, V174, P89, DOI 10.1016/j.pscychresns.2009.04.001; Vugs B, 2014, RES DEV DISABIL, V35, P62, DOI 10.1016/j.ridd.2013.10.022; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wechsler D, 1952, RANGE HUMAN CAPACITI; Wechsler D., 2008, WECHSLER ADULT INTEL; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Woods SP, 2009, NEUROPSYCHOL REV, V19, P152, DOI 10.1007/s11065-009-9102-5; You SC, 2014, MOVEMENT DISORD, V29, P405, DOI 10.1002/mds.25762; Zelazo PD, 2013, MONOGR SOC RES CHILD, V78, P16, DOI 10.1111/mono.12032; [No title captured], DOI DOI 10.1093/ACPROF:OSO/9780195100990.003.0004	104	62	62	6	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2014	20	6					599	610		10.1017/S135561771400040X			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AL7PH	WOS:000339326300004	24959983	Green Accepted			2022-02-06	
J	Velikonja, D; Tate, R; Ponsford, J; McIntyre, A; Janzen, S; Bayley, M				Velikonja, Diana; Tate, Robyn; Ponsford, Jennie; McIntyre, Amanda; Janzen, Shannon; Bayley, Mark		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part V: Memory	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; guidelines; knowledge translation; memory; neuropsychology; rehabilitation; therapeutic approaches for the treatment of central nervous system injury; traumatic brain injury	CLOSED-HEAD INJURY; RANDOMIZED CONTROLLED-TRIAL; FACE-NAME ASSOCIATIONS; OF-THE-LITERATURE; IMPAIRED PATIENTS; VANISHING CUES; ACUTE REHABILITATION; TRAINING-PROGRAM; EVERYDAY MEMORY; PAGING SYSTEM	Introduction: Traumatic brain injury results in complex cognitive sequelae. Impairments in memory are among the most common sequelae resulting in significant functional problems. An international team of researchers and clinicians (known as INCOG) was formed to develop recommendations for the management of impairments in memory. Methods: The experts met to select appropriate recommendations and then reviewed available literature to ensure recommendations were current. Decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials were developed. The team then prioritized recommendations for implementation and developed audit criteria to evaluate adherence to the best practice recommendations. Results: The recommendations for rehabilitation of memory impairments support the integration of internal and external compensatory strategies implemented using appropriate instructional techniques that consider functional relevance and important patient characteristics. Restorative strategies have regained significant popularity, given broader access to computer technology; however, evidence for efficacy of these techniques remains weak and the choice in using these should be guided by special considerations. Conclusion: There is good evidence for the integration of internal and external compensatory memory strategies that are implemented using instructional procedures for rehabilitation for memory impairments. The evidence for the efficacy of restorative strategies currently remains weak.	[Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON L8L 0A4, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Tate, Robyn; Ponsford, Jennie] NHMRC Ctr Res Excellence Traumat Brain Injury Psy, Sydney, NSW, Australia; [Tate, Robyn] Royal Rehabil Ctr, Sydney, NSW, Australia; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia; [Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [McIntyre, Amanda; Janzen, Shannon] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada		Velikonja, D (corresponding author), Hamilton Hlth Sci, Reg Rehabil Ctr, Acquired Brain Injury Program, 300 Wellington St North, Hamilton, ON L8L 0A4, Canada.	dvelikonja@svapsych.ca		Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University; Ontario Neurotrauma Foundation	The authors gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University, and the Ontario Neurotrauma Foundation for their support of this project.	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; [Anonymous], 2006, TRAUM BRAIN INJ DIAG; [Anonymous], AGREE ADV SCI PRACT; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Bentley P, 2003, NEUROIMAGE, V20, P58, DOI 10.1016/S1053-8119(03)00302-1; Bergman M M, 2000, Appl Neuropsychol, V7, P76, DOI 10.1207/S15324826AN0702_2; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; DILLER L, 1976, CLINICAL PSYCHOLOGIS, V29, P13; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Eakman AM, 2001, OCCUP THER J RES, V21, P109, DOI 10.1177/153944920102100205; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fernandez E, 2012, MEDICC REV, V14, P32, DOI 10.37757/MR2012V14.N4.8; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; Glisky EL, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P137; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Goldstein G, 1996, CLIN NEUROPSYCHOL, V10, P66, DOI 10.1080/13854049608406664; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Goverover Y, 2009, AM J OCCUP THER, V63, P543, DOI 10.5014/ajot.63.5.543; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grilli MD, 2011, NEUROPSYCHOL REHABIL, V21, P847, DOI 10.1080/09602011.2011.627263; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Haslam C, 2011, J CLIN EXP NEUROPSYC, V33, P432, DOI 10.1080/13803395.2010.533155; HAYMAN CAG, 1993, J COGNITIVE NEUROSCI, V5, P375, DOI 10.1162/jocn.1993.5.4.375; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Hux K, 2000, BRAIN INJURY, V14, P907; Jennett S M, 1991, Int Disabil Stud, V13, P83; Johansson B, 2012, SCAND J OCCUP THER, V19, P176, DOI 10.3109/11038128.2011.603352; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kapur N., 1994, MEMORY DISORDERS CLI; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kessler RC, 2010, INT J METH PSYCH RES, V19, P4, DOI 10.1002/mpr.310; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YW, 2009, CLIN NEUROPHARMACOL, V32, P63, DOI 10.1097/WNF.0b013e31816f1bc1; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Lebowitz MS, 2012, J REHABIL RES DEV, V49, P1547, DOI 10.1682/JRRD.2011.07.0133; Lemoncello R, 2011, NEUROPSYCHOL REHABIL, V21, P825, DOI 10.1080/09602011.2011.618661; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lloyd J, 2009, NEUROPSYCHOL REHABIL, V19, P98, DOI 10.1080/09602010802117392; Loranye H, 1974, MEMORY BOOK CLASSIC; Luria A. R, 1982, LANGUAGE COGNITION; Lynch B, 2002, J HEAD TRAUMA REHAB, V17, P446, DOI 10.1097/00001199-200210000-00006; Manasse NJ, 2005, BRAIN INJURY, V19, P633, DOI 10.1080/02699050400013667; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; McDonald A, 2011, NEUROPSYCHOL REHABIL, V21, P784, DOI 10.1080/09602011.2011.598405; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; MOLLOY M, 1984, AUST OCCUP THER J, V31, P20; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Page M, 2006, NEUROPSYCHOLOGIA, V44, P90, DOI 10.1016/j.neuropsychologia.2005.04.004; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; Pitel AL, 2006, BRAIN INJURY, V20, P1099, DOI 10.1080/02699050600909961; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Potvin MJ, 2011, NEUROPSYCHOL REHABIL, V21, P899, DOI 10.1080/09602011.2011.630882; Powell LE, 2012, NEUROPSYCHOL REHABIL, V22, P85, DOI 10.1080/09602011.2011.640466; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raskin SA, 2009, BRAIN IMPAIR, V10, P76, DOI 10.1375/brim.10.1.76; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Riley GA, 2000, NEUROPSYCHOL REHABIL, V10, P133, DOI 10.1080/096020100389219; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Schefft BK, 2008, APPL NEUROPSYCHOL, V15, P61, DOI 10.1080/09084280801917806; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 2011, J REHABIL MED, V43, P216, DOI 10.2340/16501977-0647; Silver JM, 2009, BRAIN INJURY, V23, P123, DOI 10.1080/02699050802649696; Sohlberg M. M., 2006, REV NEUROPSICOLOGIA, V1, P14; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Sumowski JF, 2010, J INT NEUROPSYCH SOC, V16, P1147, DOI 10.1017/S1355617710001128; Svoboda E, 2010, NEUROPSYCHOL REHABIL, V20, P562, DOI 10.1080/09602011003669918; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Taverni JP, 1998, BRAIN INJURY, V12, P77; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo O, 2009, BRAIN INJURY, V23, P548, DOI 10.1080/02699050902926275; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Wilson B, 2009, MEMORY REHABILITATIO; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1997, NEUROPSYCHOL REHABIL, V7, P43, DOI 10.1080/713755518; WILSON BA, 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI DOI 10.1080/09602019108401386; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	124	62	63	2	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					369	386		10.1097/HTR.0000000000000069			18	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300012	24984098				2022-02-06	
J	Hutchison, MG; Lawrence, DW; Cusimano, MD; Schweizer, TA				Hutchison, Michael G.; Lawrence, David W.; Cusimano, Michael D.; Schweizer, Tom A.			Head Trauma in Mixed Martial Arts	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						mixed martial arts (MMA); knockout; concussion; head injury; technical knockout; video analysis	CONCUSSION; INJURIES; VICTORIA; FOOTBALL; STATE; SPORT	Background: Mixed martial arts (MMA) is a full combative sport with a recent global increase in popularity despite significant scrutiny from medical associations. To date, the empirical research of the risk of head injuries associated with this sport is limited. Youth and amateur participation is growing, warranting investigation into the burden and mechanism of injuries associated with this sport. Purpose: (1) To determine the incidence, risk factors, and characteristics of knockouts (KOs) and technical knockouts (TKOs) from repetitive strikes in professional MMA; and (2) to identify the mechanisms of head trauma and the situational factors that lead to KOs and TKOs secondary to repetitive strikes through video analysis. Study Design: Descriptive epidemiology study. Methods: Competition data and video records for all KOs and TKOs from numbered Ultimate Fighting Championship MMA events (n = 844) between 2006 to 2012. Analyses included (1) multivariate logistic regression to investigate factors associated with an increased risk of sustaining a KO or TKO secondary to repetitive strikes and (2) video analysis of all KOs and TKOs secondary to repetitive strikes with descriptive statistics. Results: During the study period, the KO rate was 6.4 per 100 athlete-exposures (AEs) (12.7% of matches), and the rate of TKOs secondary to repetitive strikes was 9.5 per 100 AEs (19.1% of matches), for a combined incidence of match-ending head trauma of 15.9 per 100 AEs (31.9% of matches). Logistic regression identified that weight class, earlier time in a round, earlier round in a match, and older age were risk factors for both KOs and TKOs secondary to repetitive strikes. Match significance and previously sustained KOs or TKOs were also risk factors for KOs. Video analysis identified that all KOs were the result of direct impact to the head, most frequently a strike to the mandibular region (53.9%). The average time between the KO-strike and match stoppage was 3.5 seconds (range, 0-20 seconds), with losers sustaining an average of 2.6 additional strikes (range, 0-20 strikes) to the head. For TKOs secondary to strikes, in the 30-second interval immediately preceding match stoppage, losers sustained, on average, 18.5 strikes (range, 5-46 strikes), with 92.3% of these being strikes to the head. Conclusion: Rates of KOs and TKOs in MMA are higher than previously reported rates in other combative and contact sports. Public health authorities and physicians should be cognizant of the rates and mechanisms of head trauma. Preventive measures to lessen the risks of head trauma for those who elect to participate in MMA are described.	[Hutchison, Michael G.; Lawrence, David W.; Cusimano, Michael D.; Schweizer, Tom A.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada		Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	One or more of the authors has declared the following potential conflict of interest or source of funding: This study was funded through a grant from the Canadian Institutes of Health Research Strategic Teams in Applied Injury Research. The funding agency had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.	American Medical Association, H 470 965 ULT EXTR F; Australian Medical Association (WA), MIX MART ARTS MUST B; Bearak B, 2011, NY TIMES, pD1; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; Brown R, 2012, MINNESOTA COMBATIVE; Buse GJ, 2006, BRIT J SPORT MED, V40, P169, DOI 10.1136/bjsm.2005.021295; Canadian Medical Association, MIX MART ARTS MMA BA; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; George C, BOXING UPDATE BOARD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Kim M, 2010, SPORTS LAW J, V17, P49; Lawrence DW, 2014, CLIN J SPORT MED, V24, P397, DOI 10.1097/JSM.0000000000000047; Martin D, UFC 124 ATTENDANCE R; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Ngai KM, 2008, BRIT J SPORT MED, V42, P686, DOI 10.1136/bjsm.2007.044891; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pishna K, UFC 129 GATE RECEIPT; Rainey Charles E, 2009, N Am J Sports Phys Ther, V4, P190; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Ultimate Fighting Championship, SPORT; Ultimate Fighting Championship, WAYS WIN; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	28	62	62	2	38	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2014	42	6					1352	1358		10.1177/0363546514526151			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	AN6QO	WOS:000340721400018	24658345				2022-02-06	
J	Donovan, V; Kim, C; Anugerah, AK; Coats, JS; Oyoyo, U; Pardo, AC; Obenaus, A				Donovan, Virginia; Kim, Claudia; Anugerah, Ariana K.; Coats, Jacqueline S.; Oyoyo, Udochuwku; Pardo, Andrea C.; Obenaus, Andre			Repeated mild traumatic brain injury results in long-term white-matter disruption	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						axon caliber; bilateral injury; corpus callosum; diffusion tensor imaging; myelin	FLUID PERCUSSION INJURY; AXONAL INJURY; TEMPORAL WINDOW; MOUSE MODEL; IN-VIVO; DIFFUSION; VULNERABILITY; MICE; DEMYELINATION; SENSITIVITY	Mild traumatic brain injury (mTBI) is an increasing public health concern as repetitive injuries can exacerbate existing neuropathology and result in increased neurologic deficits. In contrast to other models of repeated mTBI (rmTBI), our study focused on long-term white-matter abnormalities after bilateral mTBIs induced 7 days apart. A controlled cortical impact (CCI) was used to induce an initial mTBI to the right cortex of Single and rmTBI Sprague Dawley rats, followed by a second injury to the left cortex of rmTBI animals. Shams received only a craniectomy. Ex vivo diffusion tensor imaging (DTI), transmission electron microscopy (TEM), and histology were performed on the anterior corpus callosum at 60 days after injury. The rmTBI animals showed a significant bilateral increase in radial diffusivity (myelin), while only modest changes in axial diffusivity (axonal) were seen between the groups. Further, the rmTBI group showed an increased g-ratio and axon caliber in addition to myelin sheath abnormalities using TEM. Our DTI results indicate ongoing myelin changes, while the TEM data show continuing axonal changes at 60 days after rmTBI. These data suggest that bilateral rmTBI induced 7 days apart leads to progressive alterations in white matter that are not observed after a single mTBI.	[Donovan, Virginia; Obenaus, Andre] Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; [Kim, Claudia; Anugerah, Ariana K.] Loma Linda Univ, Sch Med, Loma Linda, CA 92354 USA; [Coats, Jacqueline S.; Pardo, Andrea C.; Obenaus, Andre] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Oyoyo, Udochuwku] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA		Obenaus, A (corresponding author), Loma Linda Univ, Dept Pediat, 11175 Campus St,Room A1120, Loma Linda, CA 92354 USA.	aobenaus@llu.edu	Pardo, Andrea/B-4836-2017	Pardo, Andrea/0000-0001-7767-8539	NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014089]	The authors wish to acknowledge Douglas Hauser, Ernesto Barron, and the USC/Norris Cancer Center's Cell and Tissue Imaging Core facility (supported by NCI grant P30CA014089) for assistance with TEM tissue preparation and imaging. Additionally, the authors would like to thank Dr Monica J Carson and Bethann Martinez for helpful suggestions and Faisal Rashid for assistance with manual segmentation of regional DTI ROIs. We also thank Dr Richard Sun for use of the DTI software and helpful discussions.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Faul M, 2010, TRAUMATIC BRAIN INJU; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leigland LA, 2013, NEUROIMAGE, V83, P1081, DOI 10.1016/j.neuroimage.2013.07.068; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mnatsakanyan L, 2011, J NEURO-OPHTHALMOL, V31, P6, DOI 10.1097/WNO.0b013e3181fab1b4; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schnaar RL, 2009, J NEUROSCI RES, V87, P3267, DOI 10.1002/jnr.21992; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Sun SW, 2009, NEUROIMAGE, V44, P611, DOI 10.1016/j.neuroimage.2008.10.032; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zhang JY, 2012, MAGN RESON MED, V67, P750, DOI 10.1002/mrm.23032	45	62	62	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2014	34	4					715	723		10.1038/jcbfm.2014.6			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AE2AE	WOS:000333774900022	24473478	Bronze, Green Published			2022-02-06	
J	Giordano, C; Cloots, RJH; van Dommelen, JAW; Kleiven, S				Giordano, C.; Cloots, R. J. H.; van Dommelen, J. A. W.; Kleiven, S.			The influence of anisotropy on brain injury prediction	JOURNAL OF BIOMECHANICS			English	Article						Traumatic Brain Injury (TBI); Diffuse Axonal Injury (DAI); Anisotropy; Head model; Finite Element Method (FEM)	HEAD; MODEL; STEM	Traumatic Brain Injury (TBI) occurs when a mechanical insult produces damage to the brain and disrupts its normal function. Numerical head models are often used as tools to analyze TBIs and to measure injury based on mechanical parameters. However, the reliability of such models depends on the incorporation of an appropriate level of structural detail and accurate representation of the material behavior. Since recent studies have shown that several brain regions are characterized by a marked anisotropy, constitutive equations should account for the orientation-dependence within the brain. Nevertheless, in most of the current models brain tissue is considered as completely isotropic. To study the influence of the anisotropy on the mechanical response of the brain, a head model that incorporates the orientation of neural fibers is used and compared with a fully isotropic model. A simulation of a concussive impact based on a sport accident illustrates that significantly lowered strains in the axonal direction as well as increased maximum principal strains are detected for anisotropic regions of the brain. Thus, the orientation-dependence strongly affects the response of the brain tissue. When anisotropy of the whole brain is taken into account, deformation spreads out and white matter is particularly affected. The introduction of local axonal orientations and fiber distribution into the material model is crucial to reliably address the strains occurring during an impact and should be considered in numerical head models for potentially more accurate predictions of brain injury. (C) 2014 Elsevier Ltd. All rights reserved.	[Giordano, C.; Kleiven, S.] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, SE-14152 Huddinge, Sweden; [Cloots, R. J. H.; van Dommelen, J. A. W.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands		Giordano, C (corresponding author), Royal Inst Technol KTH, Sch Technol & Hlth, Div Neuron Engn, Alfred Nobels Alle 10, S-14152 Huddinge, Sweden.	chiara.giordano@sth.kth.se; sveink@kth.se					Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Chatelin S., 2011, J MECH BEHAV BIOMED; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Faul M, 2010, TRAUMATIC BRAIN INJU; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S., 2006, SCAND J FORENS SCI, V2, P73; Kleiven S., 2002, 20029 KUNGL TEKN HOG; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Newman J, 2000, P 44 STAPP CAR CRASH; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1	24	62	66	2	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAR 21	2014	47	5					1052	1059		10.1016/j.jbiomech.2013.12.036			8	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	AE6GG	WOS:000334088000017	24462379				2022-02-06	
J	Asemota, AO; George, BP; Cumpsty-Fowler, CJ; Haider, AH; Schneider, EB				Asemota, Anthony O.; George, Benjamin P.; Cumpsty-Fowler, Carolyn J.; Haider, Adil H.; Schneider, Eric B.			Race and Insurance Disparities in Discharge to Rehabilitation for Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						disparities; epidemiology; rehabilitation; traumatic brain injury	HEALTH-CARE; RACIAL DISPARITIES; ETHNIC DISPARITIES; COGNITIVE REHABILITATION; CULTURAL COMPETENCE; LANGUAGE BARRIERS; UNITED-STATES; OUTCOMES; MODERATE; SEVERITY	Post-acute inpatient rehabilitation services are associated with improved functional outcomes among persons with traumatic brain injury (TBI). We sought to investigate racial and insurance-based disparities in access to rehabilitation. Data from the Nationwide Inpatient Sample from 2005-2010 were analyzed using standard descriptive methods and multivariable logistic regression to assess race- and insurance-based differences in access to inpatient rehabilitation after TBI, controlling for patient- and hospital-level variables. Patients with moderate to severe TBI aged 18-64 years with complete data on race and insurance status discharged alive from inpatient care were eligible for study. Among 307,675 TBI survivors meeting study criteria and potentially eligible for discharge to rehabilitation, 66% were white, 12% black, 15% Hispanic, 2% Asian, and 5% other ethnic minorities. Most whites (70%), Asians (70%), blacks (59%), and many Hispanics (49%) had insurance. Compared with insured whites, insured blacks had reduced odds of discharge to rehabilitation (odds ratio [OR] 0.84; 95% confidence interval [CI] 0.75-0.95). Also, insured Hispanics (OR 0.52; 95% CI 0.44-0.60) and insured Asians (OR 0.54; 95% CI 0.39-0.73) were less likely to be discharged to rehabilitation than insured whites. Compared with insured whites, uninsured whites (OR 0.57; 95% CI 0.51-0.63), uninsured blacks (OR 0.33; 95% CI 0.26-0.42), uninsured Hispanics (OR 0.27; 95% CI 0.22-0.33), and uninsured Asians (OR 0.40; 95% CI 0.22-0.73) were less likely to be discharged to rehabilitation. Race and insurance are strong predictors of discharge to rehabilitation among adult TBI survivors in the United States. Efforts are needed to understand and eliminate disparities in access to rehabilitation after TBI.	[Asemota, Anthony O.] Johns Hopkins Sch Med, Dept Neurol Neurosurg, Baltimore, MD USA; [Asemota, Anthony O.; George, Benjamin P.; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, CSTOR, Baltimore, MD 21287 USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Cumpsty-Fowler, Carolyn J.] Johns Hopkins Univ, Sch Nursing, Dept Community Publ Hlth, Baltimore, MD 21287 USA; [Cumpsty-Fowler, Carolyn J.] Johns Hopkins Univ, Ctr Injury Res & Policy, Baltimore, MD 21287 USA; [Cumpsty-Fowler, Carolyn J.; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Sch Med, Dept Surg, Div Acute Care Surg & Adult Trauma, Baltimore, MD USA		Asemota, AO (corresponding author), Johns Hopkins Univ, Dept Surg, CSTOR, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	aasemota@jhsph.edu		George, Benjamin/0000-0001-9966-5632			Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; [Anonymous], 1999, JAMA, V282, P974; [Anonymous], 1997, ICDMAP 90 INJ SEV CO; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Baicker K, 2005, PERSPECT BIOL MED, V48, pS42; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2005, HEALTH AFFAIR, V24, P499, DOI 10.1377/hlthaff.24.2.499; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brach C, 2000, MED CARE RES REV, V57, P181, DOI 10.1177/107755800773743655; Casas-Zamora JA, 2004, AM J PUBLIC HEALTH, V94, P2055, DOI 10.2105/AJPH.94.12.2055; Chin MH, 2007, MED CARE RES REV, V64, p7S, DOI 10.1177/1077558707305413; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holmes GM, 2012, HEALTH SERV RES, V47, P1158, DOI 10.1111/j.1475-6773.2011.01363.x; Ibrahim SA, 2003, AM J PUBLIC HEALTH, V93, P1619, DOI 10.2105/AJPH.93.10.1619; Jacobs E, 2006, MILBANK Q, V84, P111, DOI 10.1111/j.1468-0009.2006.00440.x; Jacobs EA, 2004, AM J PUBLIC HEALTH, V94, P866, DOI 10.2105/AJPH.94.5.866; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; Millham F, 2009, WORLD J SURG, V33, P23, DOI 10.1007/s00268-008-9745-z; Nationwide Inpatient Sample, 2011, NAT INP SAMPL HEALTH; Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Sacks GD, 2011, J TRAUMA, V71, P1011, DOI 10.1097/TA.0b013e3182092c27; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sandhaug M, 2012, DISABIL REHABIL, V34, P904, DOI 10.3109/09638288.2011.626484; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Shen YC, 2010, AM J PUBLIC HEALTH, V100, P1462, DOI 10.2105/AJPH.2009.175828; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Wehman P, 2007, J HEAD TRAUMA REHAB, V22, P95, DOI 10.1097/01.HTR.0000265097.44683.22	49	62	62	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2057	2065		10.1089/neu.2013.3091			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500007	23972035	Green Published			2022-02-06	
J	Major, MJ; Fatone, S; Roth, EJ				Major, Matthew J.; Fatone, Stefania; Roth, Elliot J.			Validity and Reliability of the Berg Balance Scale for Community-Dwelling Persons With Lower-Limb Amputation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amputees; Outcome measures; Postural balance; Rehabilitation	FRENCHAY ACTIVITIES INDEX; 2-MINUTE WALK TEST; INPATIENT REHABILITATION; PSYCHOMETRIC PROPERTIES; PROSTHETIC MOBILITY; STANDING BALANCE; VASCULAR-DISEASE; ELDERLY-PEOPLE; BRAIN-INJURY; STROKE	Objective: To evaluate the validity and reliability of the Berg Balance Scale (BBS) for use in people with lower-limb amputation. Design: Cross-sectional study. Setting: Research laboratory. Participants: Individuals (N=30; age, 54 +/- 12y; 20 men) with unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3) lower-limb amputation of dysvascular (n=7), traumatic (n=14), infectious (n=6), or congenital (n=3) origin. Interventions: Not applicable. Main Outcome Measures: BBS, 2-minute walk test, L test, Prosthesis Evaluation Questionnaire-Mobility Subscale, Activities-specific Balance Confidence Scale, and Frenchay Activities Index; self-reported descriptors were also collected, including frequency of prosthesis use, number of falls in 12 months before the visit, fear of falling, and daily mobility aid use. Results: The BBS had high interrater reliability (intraclass correlation coefficient =.945) and internal consistency (alpha=.827). Relations between the BBS scores and those of other outcome measures were all statistically significant (P <=.001). Significant group differences in BBS scores were observed for fear of falling (P=.008) and mobility aid use (P<.001), but not for multiple (>= 2) falls in the previous 12 months (P=.381). BBS items involving reaching forward, turning 360 degrees, tandem standing, and standing on 1 leg had relatively greater frequencies of lower scores across participants. Conclusions: The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation, but it may not be able to discriminate between individuals with greater or lesser fall risk. Limitations in prosthetic motion and control may be responsible for the challenges experienced on items of lower performance. Future studies would be useful to assess the responsiveness of the BBS to interventions aimed at improving balance in individuals with lower-limb amputation. (C) 2013 by the American Congress of Rehabilitation Medicine	[Major, Matthew J.; Fatone, Stefania] Northwestern Univ, Prosthet Orthot Ctr, Chicago, IL 60611 USA; [Major, Matthew J.; Fatone, Stefania; Roth, Elliot J.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Roth, Elliot J.] Rehabil Inst Chicago, Chicago, IL 60611 USA		Major, MJ (corresponding author), Northwestern Univ, Prosthet Orthot Ctr, 680 N Lake Shore Dr,Suite 1100, Chicago, IL 60611 USA.	Matthew-Major@northwestern.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [3UL1RR025741]; National Institute on Disability and Rehabilitation Research [H133P110013, H133E080009]; David Rubin, MD, Enrichment Fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741] Funding Source: NIH RePORTER	Supported by National Institutes of Health (grant no. 3UL1RR025741), National Institute on Disability and Rehabilitation Research (grant nos. H133P110013 and H133E080009), and the David Rubin, MD, Enrichment Fund. The opinions contained in this article are those of the authors and do not necessarily reflect those of the US Department of Education or Health and Human Services.	Alzayer L, 2009, J NEUROL PHYS THER, V33, P136, DOI 10.1097/NPT.0b013e3181b51307; Andersson AG, 2006, J REHABIL MED, V38, P186, DOI 10.1080/16501970500478023; Askham J., 1990, REV RES FALLS ELDERL; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Brooks D, 2002, ARCH PHYS MED REHAB, V83, P1562, DOI 10.1053/apmr.2002.34600; Brooks D, 2001, ARCH PHYS MED REHAB, V82, P1478, DOI 10.1053/apmr.2001.25153; Buckley JG, 2002, AM J PHYS MED REHAB, V81, P13, DOI 10.1097/00002060-200201000-00004; Busse ME, 2009, J NEUROL NEUROSUR PS, V80, P88, DOI 10.1136/jnnp.2008.147793; CAMPBELL A J, 1981, Age and Ageing, V10, P264, DOI 10.1093/ageing/10.4.264; Cattaneo D, 2007, DISABIL REHABIL, V29, P1920, DOI 10.1080/09638280701191859; Cattaneo D, 2006, DISABIL REHABIL, V28, P789, DOI 10.1080/09638280500404289; Cohen J., 1988, J AM STAT ASSOC, V2, P19, DOI DOI 10.1016/B978-0-12-179060-8.50012-8; Cowley A, 2001, PHYS THER REV, V6, P5; Deathe AB, 2009, DISABIL REHABIL, V31, P1455, DOI 10.1080/09638280802639491; Deathe AB, 2005, PHYS THER, V85, P626, DOI 10.1093/ptj/85.7.626; Dibble Lee E, 2006, J Neurol Phys Ther, V30, P60; Dite W, 2007, ARCH PHYS MED REHAB, V88, P109, DOI 10.1016/j.apmr.2006.10.015; Ditunno JE, 2007, NEUROREHAB NEURAL RE, V21, P539, DOI 10.1177/1545968307301880; Duncan RP, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/237673; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feld JA, 2001, NEUROREHAB NEURAL RE, V15, P239, DOI 10.1177/154596830101500312; Franchignoni F, 2005, PARKINSONISM RELAT D, V11, P427, DOI 10.1016/j.parkreldis.2005.05.005; GEURTS ACH, 1992, SCAND J REHABIL MED, V24, P83; Gosselin S, 2008, J REHABIL MED, V40, P55, DOI 10.2340/16501977-0144; Halsaa KE, 2007, ARCH PHYS MED REHAB, V88, P94, DOI 10.1016/j.apmr.2006.10.016; HERMODSSON Y, 1994, PROSTHET ORTHOT INT, V18, P150; Hislop HJ, 1995, DANIELS WORTHINGHAMS; Hof AL, 2007, GAIT POSTURE, V25, P250, DOI 10.1016/j.gaitpost.2006.04.013; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Kavounoudias A, 2005, ARCH PHYS MED REHAB, V86, P633, DOI 10.1016/j.apmr.2004.10.030; Kerr GK, 2010, NEUROLOGY, V75, P116, DOI 10.1212/WNL.0b013e3181e7b688; Kulkarni J., 1996, PHYSIOTHERAPY, V2, P130, DOI DOI 10.1016/S0031-9406(05)66968-4]; Landers Merrill R, 2008, J Neurol Phys Ther, V32, P56, DOI 10.1097/NPT.0b013e3181761330; Learmonth YC, 2012, INT J REHABIL RES, V35, P69, DOI 10.1097/MRR.0b013e328350b65f; Leddy AL, 2011, PHYS THER, V91, P102, DOI 10.2522/ptj.20100113; Legro MW, 1998, ARCH PHYS MED REHAB, V79, P931, DOI 10.1016/S0003-9993(98)90090-9; Lemay JF, 2010, SPINAL CORD, V48, P245, DOI 10.1038/sc.2009.119; Lim LIIK, 2005, PARKINSONISM RELAT D, V11, P19, DOI 10.1016/j.parkreldis.2004.06.003; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Major MJ, 2012, J REHABIL RES DEV, V49, P815, DOI 10.1682/JRRD.2011.06.0108; Major MJ, 2013, GAIT POSTURE; Mao HF, 2002, STROKE, V33, P1022, DOI 10.1161/01.STR.0000012516.63191.C5; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Miller WC, 2004, CLIN REHABIL, V18, P414, DOI 10.1191/0269215504cr728oa; Miller WC, 2003, ARCH PHYS MED REHAB, V84, P656, DOI 10.1016/S0003-9993(03)04807-4; Miller WC, 2002, PHYS THER, V82, P856, DOI 10.1093/ptj/82.9.856; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1031, DOI 10.1053/apmr.2001.24295; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1238, DOI 10.1053/apmr.2001.25079; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1432, DOI 10.1053/apmr.2001.25987; Muir SW, 2008, PHYS THER, V88, P449, DOI 10.2522/ptj.20070251; Nadollek Heidi, 2002, Physiother Res Int, V7, P203, DOI 10.1002/pri.260; Nederhand MJ, 2012, CLIN BIOMECH, V27, P40, DOI 10.1016/j.clinbiomech.2011.07.008; Newstead Ann H, 2005, J Neurol Phys Ther, V29, P18; Nilsagard Y, 2009, CLIN REHABIL, V23, P259, DOI 10.1177/0269215508095087; NORKIN CC, 2003, MEASUREMENT JOINT MO; Norvell DC, 2011, J VASC SURG, V54, P412, DOI 10.1016/j.jvs.2011.01.046; Pauley T, 2006, AM J PHYS MED REHAB, V85, P521, DOI 10.1097/01.phm.0000219119.58965.8c; Pedrinelli A, 2002, PROSTHET ORTHOT INT, V26, P195, DOI 10.1080/03093640208726648; Persson CU, 2011, J REHABIL MED, V43, P348, DOI 10.2340/16501977-0677; Portney L.G., 2009, FDN CLIN RES APPL PR, V3rd ed.; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Quai TM, 2005, CLIN REHABIL, V19, P668, DOI 10.1191/0269215505cr857oa; Qutubuddin AA, 2005, ARCH PHYS MED REHAB, V86, P789, DOI 10.1016/j.apmr.2004.11.005; Rao AK, 2009, GAIT POSTURE, V29, P433, DOI 10.1016/j.gaitpost.2008.11.002; Raya MA, 2010, PROSTHET ORTHOT INT, V34, P73, DOI 10.3109/03093640903585008; Rougier PR, 2009, AM J PHYS MED REHAB, V88, P896, DOI 10.1097/PHM.0b013e3181b331af; Sahin Fusun, 2008, J Geriatr Phys Ther, V31, P32; Sawatzky B, 2007, ARCH PHYS MED REHAB, V88, P1423, DOI 10.1016/j.apmr.2007.08.005; Scalzo PL, 2009, ARQ NEURO-PSIQUIAT, V67, P831, DOI 10.1590/S0004-282X2009000500010; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Thorbahn LDB, 1996, PHYS THER, V76, P576, DOI 10.1093/ptj/76.6.576; Ulger O, 2009, TURK J PHYSIOTHER R, V20, P169; van Velzen JM, 2006, CLIN REHABIL, V20, P999, DOI 10.1177/0269215506070700; Vanicek N, 2009, ARCH PHYS MED REHAB, V90, P1018, DOI 10.1016/j.apmr.2008.12.024; Vincent C, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-68; Viton JM, 2000, PROSTHET ORTHOT INT, V24, P108, DOI 10.1080/03093640008726533; Vrieling AH, 2008, GAIT POSTURE, V28, P222, DOI 10.1016/j.gaitpost.2007.12.002; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5; Wee JY, 2003, ARCH PHYS MED REHAB, V84, P731, DOI 10.1016/S0003-9993(03)04940-7; Wirz M, 2010, NEUROREHAB NEURAL RE, V24, P70, DOI 10.1177/1545968309341059; Yazicioglu K, 2007, AM J PHYS MED REHAB, V86, P800, DOI 10.1097/PHM.0b013e318151fc74	88	62	64	0	60	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2194	2202		10.1016/j.apmr.2013.07.002			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	250KV	WOS:000326852600022	23856150				2022-02-06	
J	Whyte, J; Nakase-Richardson, R; Hammond, FM; McNamee, S; Giacino, JT; Kalmar, K; Greenwald, BD; Yablon, SA; Horn, LJ				Whyte, John; Nakase-Richardson, Risa; Hammond, Flora M.; McNamee, Shane; Giacino, Joseph T.; Kalmar, Kathleen; Greenwald, Brian D.; Yablon, Stuart A.; Horn, Lawrence J.			Functional Outcomes in Traumatic Disorders of Consciousness: 5-Year Outcomes From the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Cognition; Consciousness disorders; Minimally conscious state; Prognosis; Rehabilitation; Rehabilitation outcome; Traumatic brain injuries; Vegetative state	RECOVERY; ADMISSION; SCALE; STATE; COMA	Objective: To characterize the 5-year outcomes of patients with traumatic brain injury (TBI) not following commands when admitted to acute inpatient rehabilitation. Design: Secondary analysis of prospectively collected data from the National Institute on Disability and Rehabilitation Research funded Traumatic Brain Injury Model Systems (TRIMS). Setting: Inpatient rehabilitation hospitals participating in the TRIMS program. Participants: Patients (N=108) with TBI not following commands at admission to acute inpatient rehabilitation were divided into 2 groups (early recovery: followed commands before discharge [n=72]; late recovery: did not follow commands before discharge [n=36]). Interventions: Not applicable. Main Outcome Measures: FIM items. Results: For the early recovery group, depending on the FIM item, 8% to 21% of patients were functioning independently at discharge, increasing to 56% to 85% by 5 years postinjury. The proportion functioning independently increased from discharge to 1 year, 1 to 2 years, and 2 to 5 years. In the late recovery group, depending on the FIM item, 19% to 36% of patients were functioning independently by 5 years postinjury. The proportion of independent patients increased significantly from discharge to 1 year and from 1 to 2 years, but not from 2 to 5 years. Conclusions: Substantial proportions of patients admitted to acute inpatient rehabilitation before following commands recover independent functioning over as long as 5 years, particularly if they begin to follow commands before hospital discharge. (c) 2013 by the American Congress of Rehabilitation Medicine	[Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [McNamee, Shane] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Boston, MA USA; [Kalmar, Kathleen] JFK Johnson Rehabil Inst, Edison, NJ USA; [Greenwald, Brian D.] Mt Sinai Sch Med, New York, NY USA; [Yablon, Stuart A.] Univ Alberta, Edmonton, AB, Canada; [Yablon, Stuart A.] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Horn, Lawrence J.] Wayne State Univ, Detroit, MI USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A060038, H133A070040, H133A070042, H133A070030, H133A070033, H133A070027, H133A080044]; Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes [COE - HFP 09-156]	Supported by the National Institute on Disability and Rehabilitation Research, United States Department of Education (grant nos. H133A060038 [TBI Model System National Data and Statistical Center], H133A070040 [Moss TBI Model System], H133A070042 [Carolinas Traumatic Brain Injury Rehabilitation and Research System], H133A070030 [JFK-Johnson Rehabilitation Institute TBI Model System], H133A070033 [New York TBI Model System], H133A070027 [North Texas TBI Model System], H133A080044 [Southeastern Michigan TBI System]). The contents of the article do not necessarily represent the policy of the Department of Education, and endorsement by the Federal Government should not be assumed. Statistical support provided by the Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes (grant no. COE - HFP 09-156).	Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hammond F, 2009, J NEUROTRAUM, V26, pA83; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; 1994, J NEUROTRAUMA, V330, P1499; 1994, J NEUROTRAUMA, V330, P1572	16	62	62	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1855	1860		10.1016/j.apmr.2012.10.041			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	231TU	WOS:000325442100002	23732164				2022-02-06	
J	Ponsford, JL; Parcell, DL; Sinclair, KL; Roper, M; Rajaratnam, SMW				Ponsford, Jennie L.; Parcell, Diane L.; Sinclair, Kelly L.; Roper, Monique; Rajaratnam, Shantha M. W.			Changes in Sleep Patterns Following Traumatic Brain Injury: A Controlled Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep disturbance; sleep quality; excessive daytime sleepiness; depression; anxiety	DEPRESSION SCALE; HOSPITAL ANXIETY; DAYTIME SLEEPINESS; QUALITY INDEX; DISTURBANCE; FATIGUE; PREVALENCE; INSOMNIA; REHABILITATION; ASSOCIATION	Background. Sleep changes are frequently reported following traumatic brain injury (TBI) and have an impact on rehabilitation and quality of life following injury. Potential causes include injury to brain regions associated with sleep regulation, as well as secondary factors, including depression, anxiety, and pain. Understanding the nature and causes of sleep changes following TBI represents a vital step in developing effective treatments. Objective. The study aimed to investigate subjective sleep changes in a community-based sample of individuals with TBI in comparison with noninjured age- and sex-matched controls and to explore the impact of secondary factors (pain, anxiety, depression, employment) on these self-reported sleep changes. Methods: A total of 153 participants with mild to severe TBI and 128 noninjured controls completed self-report measures relating to their sleep quality, daytime sleepiness, mood, fatigue, and pain and completed a sleep diary each day for 7 days. Results. Compared with the noninjured controls, participants with TBI reported significantly poorer sleep quality and higher levels of daytime sleepiness; sleep diaries revealed longer sleep onset latency, poorer sleep efficiency, longer sleep duration, and more frequent daytime napping in the TBI group, as well as earlier bedtimes and greater total sleep duration. Anxiety, depression, and pain were associated with poorer sleep quality. Greater injury severity was also associated with a need for longer sleep time. Conclusion. These findings highlight the importance of assessing and addressing pain, anxiety, and depression as part of the process of treating TBI-related sleep disturbances.	[Ponsford, Jennie L.; Parcell, Diane L.; Sinclair, Kelly L.; Rajaratnam, Shantha M. W.] Monash Univ, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.; Sinclair, Kelly L.; Roper, Monique] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Fac Med Nursing & Hlth Sci, Clayton Campus, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]; Monash UniversityMonash University	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The projects described in the article received funding from the National Health and Medical Research Council (Project ID 334002) and Monash University.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Braekeland F, 1971, ARCH GEN PSYCHIAT, V24, P548; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cleeland CS, 1989, ISSUES PAIN MEASUREM, P391; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harris K, 2007, CLIN ONCOL-UK, V19, P523, DOI 10.1016/j.clon.2007.04.007; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Ponsford J., 2012, TRAUMATIC BRAIN INJU, V2nd Edition; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sinclair KL, 2014, BEHAV SLEEP MED, V12, P13, DOI 10.1080/15402002.2012.726203; Skilbeck C, 2011, BRAIN IMPAIR, V12, P22, DOI 10.1375/brim.12.1.22; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	62	63	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2013	27	7					613	621		10.1177/1545968313481283			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	190EW	WOS:000322323100004	23549523				2022-02-06	
J	Mihalik, JP; Register-Mihalik, J; Kerr, ZY; Marshall, SW; McCrea, MC; Guskiewicz, KM				Mihalik, Jason P.; Register-Mihalik, Johna; Kerr, Zachary Y.; Marshall, Stephen W.; McCrea, Michael C.; Guskiewicz, Kevin M.			Recovery of Posttraumatic Migraine Characteristics in Patients After Mild Traumatic Brain Injury	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						athlete; concussion; evaluation; headache; return-to-participation	COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; POSTURAL STABILITY; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; STANDARDIZED ASSESSMENT; NCAA CONCUSSION; EPIDEMIOLOGY; MANAGEMENT	Background: Headache-related symptoms may be predictive of delayed recovery in student athletes after sport-related concussion. Purpose and Hypothesis: To compare balance performance, cognitive function, and symptom recovery in concussed student athletes with no headache, those with posttraumatic headache, and those with characteristics of posttraumatic migraine following a sport-related concussion. It was hypothesized that those with posttraumatic migraine would take longer to recover on all clinical measures. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: A total of 296 student athletes who sustained sport-related concussions (migraine, 52; headache, 176; no headache, 68) were evaluated on measures of balance performance, cognition, and symptoms. Patients were categorized into posttraumatic migraine, posttraumatic headache, and no headache groups based on symptoms reported 1 day after injury. Serial testing was conducted with the Balance Error Scoring System, the Standardized Assessment of Concussion, and a graded symptom checklist to evaluate balance performance, cognition, and symptoms, respectively, at baseline, at the time of injury, after the event, and at days 1, 2, 3, 5, 7, and 90. Results: Student athletes with posttraumatic migraine experienced greater symptom severity scores than did those with posttraumatic headache and no headache at the time of injury, after the event, and through day 7 (P < .001 for all). By day 7, symptom severity scores reported by patients with posttraumatic migraine still demonstrated deficits relative to baseline (Delta = 5.6 +/- 1.2) compared with patients with headache (D = 20.8 +/- 0.7) and those with no headache (Delta = -1.4 +/- 1.1). Patients with headache experienced greater symptom severity scores than patients with no headache at the time of injury (P < . 001), after the event (P < .001), and at day 1 (P <. 001), day 2 (P = .005), and day 3 (P = .038). Much smaller differences were observed between the headache and no headache groups beyond day 3 (P > .05). There were no group differences on balance performance (P = .439) and cognitive testing (P = .200) over time. Female patients were 2.13 times more likely than males to report posttraumatic migraine characteristics after concussion. Conclusion: Posttraumatic migraine characteristics are related to prolonged symptom recovery after sport-related concussion. Clinicians should exercise caution in making decisions about return to participation for athletes with migraine-like symptoms given the increased short-term impairments and delayed symptom recovery we observed.	[Mihalik, Jason P.; Register-Mihalik, Johna; Kerr, Zachary Y.; Marshall, Stephen W.; McCrea, Michael C.; Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC 27599 USA		Mihalik, JP (corresponding author), 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743; Mihalik, Jason/0000-0001-6085-8322; Marshall, Stephen/0000-0002-2664-9233	National Collegiate Athletic Association (NCAA); National Operating Committee on Standards for Athletic Equipment (NOCSAE); National Centers for Injury Prevention and Control (NCIPC); University of North Carolina Injury Prevention Research Center	This research was funded in part by the National Collegiate Athletic Association (NCAA) and the National Operating Committee on Standards for Athletic Equipment (NOCSAE). Major funding came from the National Centers for Injury Prevention and Control (NCIPC) for the Concussion Prevention Initiative Study, and the University of North Carolina Injury Prevention Research Center contributed to the execution and success of this project.	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Couch JR, 2011, HEADACHE, V51, P33, DOI 10.1111/j.1526-4610.2010.01800.x; Ferrara Michael S., 2001, J Athl Train, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finkelstein E., 2006, INCIDENCE EC BURDEN; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Jackson JL, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5222; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MANDEL S, 1989, POSTGRAD MED, V85, P213; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Patel AV, 2007, J ATHL TRAINING, V42, P66; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344	45	62	62	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2013	41	7					1490	1496		10.1177/0363546513487982			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	301HS	WOS:000330524000009	23696213				2022-02-06	
J	Berdichevsky, Y; Dryer, AM; Saponjian, Y; Mahoney, MM; Pimentel, CA; Lucini, CA; Usenovic, M; Staley, KJ				Berdichevsky, Yevgeny; Dryer, Alexandra M.; Saponjian, Yero; Mahoney, Mark M.; Pimentel, Corrin A.; Lucini, Corrina A.; Usenovic, Marija; Staley, Kevin J.			PI3K-Akt Signaling Activates mTOR-Mediated Epileptogenesis in Organotypic Hippocampal Culture Model of Post-Traumatic Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; MAMMALIAN TARGET; STATUS EPILEPTICUS; INTERICTAL SPIKES; BRAIN-INJURY; MOUSE MODEL; CELL-DEATH; IN-VITRO; RAPAMYCIN; SEIZURES	mTOR is activated in epilepsy, but the mechanisms of mTOR activation in post-traumatic epileptogenesis are unknown. It is also not clear whether mTOR inhibition has an anti-epileptogenic, or merely anticonvulsive effect. The rat hippocampal organotypic culture model of post-traumatic epilepsy was used to study the effects of long-term (four weeks) inhibition of signaling pathways that interact with mTOR. Ictal activity was quantified by measurement of lactate production and electrical recordings, and cell death was quantified with lactate dehydrogenase (LDH) release measurements and Nissl-stained neuron counts. Lactate and LDH measurements were well correlated with electrographic activity and neuron counts, respectively. Inhibition of PI3K and Akt prevented activation of mTOR, and was as effective as inhibition of mTOR in reducing ictal activity and cell death. A dual inhibitor of PI3K and mTOR, NVP-BEZ235, was also effective. Inhibition of mTOR with rapamycin reduced axon sprouting. Late start of rapamycin treatment was effective in reducing epileptic activity and cell death, while early termination of rapamycin treatment did not result in increased epileptic activity or cell death. The conclusions of the study are as follows: (1) the organotypic hippocampal culture model of post-traumatic epilepsy comprises a rapid assay of anti-epileptogenic and neuroprotective activities and, in this model (2) mTOR activation depends on PI3K-Akt signaling, and (3) transient inhibition of mTOR has sustained effects on epilepsy.	[Berdichevsky, Yevgeny; Saponjian, Yero; Usenovic, Marija; Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA; [Berdichevsky, Yevgeny; Staley, Kevin J.] Harvard Univ, Sch Med, Boston, MA 02129 USA; [Dryer, Alexandra M.] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA; [Mahoney, Mark M.; Pimentel, Corrin A.; Lucini, Corrina A.] Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA		Staley, KJ (corresponding author), MGH Neurol, CNY 114,Room 2600,114 16th St, Charlestown, MA 02129 USA.	Staley.Kevin@mgh.harvard.edu		Berdichevsky, Yevgeny/0000-0001-7539-601X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS072258, R01 NS077908]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034700, R01NS034360, R21NS072258, R01NS077908] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grants R21 NS072258 and R01 NS077908 (National Institute of Neurological Disorders and Stroke).	Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borders EB, 2010, AM J HEALTH-SYST PH, V67, P2095, DOI 10.2146/ajhp100020; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Caron E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.108; Castillo M, 2001, AM J NEURORADIOL, V22, P152; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Chueh SCJ, 2005, TRANSPL INT, V18, P261, DOI 10.1111/j.1432-2277.2004.00039.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Crino PB, 2011, TRENDS MOL MED, V17, P734, DOI 10.1016/j.molmed.2011.07.008; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Daoud D, 2007, EPILEPSIA, V48, P834, DOI 10.1111/j.1528-1167.2006.00976.x; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DURING MJ, 1994, J NEUROCHEM, V62, P2356; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; FUJIKAWA DG, 1988, BRAIN RES, V454, P51; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Huang XX, 2010, NEUROBIOL DIS, V40, P193, DOI 10.1016/j.nbd.2010.05.024; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Lew FH, 2011, EPILEPSIA, V52, P2326, DOI 10.1111/j.1528-1167.2011.03315.x; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; McDaniel SS, 2011, NEUROSCI LETT, V497, P231, DOI 10.1016/j.neulet.2011.02.037; Mercimek-Mahmutoglu S, 2012, PEDIATRICS, V129, pE1368, DOI 10.1542/peds.2011-0123; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Ruegg S, 2007, EPILEPSY RES, V77, P85, DOI 10.1016/j.eplepsyres.2007.09.009; Sabolek HR, 2012, J NEUROSCI, V32, P3009, DOI 10.1523/JNEUROSCI.5853-11.2012; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sliwa A, 2012, NEUROSCI LETT, V509, P105, DOI 10.1016/j.neulet.2011.12.051; Staley BA, 2011, PEDIATRICS, V127, pE117, DOI 10.1542/peds.2010-0192; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Talos DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035885; Tang HY, 2012, BIOCHEM BIOPH RES CO, V420, P199, DOI 10.1016/j.bbrc.2012.02.143; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Ulfig N, 1998, CELL TISSUE RES, V291, P433, DOI 10.1007/s004410051013; van Vliet EA, 2012, EPILEPSIA, V53, P1254, DOI 10.1111/j.1528-1167.2012.03513.x; Wasterlain CG, 2010, NEUROCHEM RES, V35, P2193, DOI 10.1007/s11064-010-0339-4; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang B, 2012, EPILEPSIA, V53, P506, DOI 10.1111/j.1528-1167.2011.03384.x	44	62	65	0	20	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 22	2013	33	21					9056	9067		10.1523/JNEUROSCI.3870-12.2013			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	150LF	WOS:000319391200015	23699517	Bronze, Green Accepted, Green Published			2022-02-06	
J	Douglas, JM				Douglas, Jacinta M.			Conceptualizing self and maintaining social connection following severe traumatic brain injury	BRAIN INJURY			English	Article						Self-concept; identity; narrative self; rehabilitation; outcome; quality-of-life	QUALITY-OF-LIFE; HEAD-INJURY; PEOPLE; REHABILITATION; QUESTIONNAIRE; PERSPECTIVES; INTERVIEWS; EXPERIENCE; NARRATIVES; AWARENESS	Primary objective: To explore how adults who have sustained severe traumatic brain injury (TBI) conceptualize self several years after injury. Design: Self-conceptualization was explored from the perspective of the injured individual within a constructivist Grounded Theory approach using in-depth interviews. Qualitative analysis moved through a process of data-driven open and focused coding, identification of emergent self-related categories and exploration of relations between these categories. Participants: Sixteen men and four women with severe-very severe injury participated in the study. Severity of injury was indexed by either a Glasgow Coma Scale (GCS) score <= 8 or duration of post-traumatic amnesia (PTA) >= 14 days. At the time of interview, the average age of participants was 35.2 years and a minimum of 5 years had elapsed since injury. Main outcomes and results: Three main themes emerged from the data. The first two themes together described a model of self-concept. The third theme captured the insider's perspective on factors that had helped to create and maintain a sense of connection between self and society. Conclusion: Conceptualization of self after brain injury is a dynamic and multi-faceted process. Insight into the process can guide the development of therapeutic endeavours to facilitate the ongoing construction of self after severe TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au		Douglas, Jacinta/0000-0003-0940-6624	La Trobe University, Faculty of Health Sciences, Clinical Research Fellowship	This project was supported by a La Trobe University, Faculty of Health Sciences, Clinical Research Fellowship awarded to the author.	Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bluff R., 2005, QUALITATIVE RES HLTH, P147; Browne J., 2004, RES METHODS NURSING, P624; Campbell JD, 1996, J PERS SOC PSYCHOL, V70, P141, DOI 10.1037/0022-3514.70.1.141; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Carlsson E, 2007, QUAL HEALTH RES, V17, P1361, DOI 10.1177/1049732307306926; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Charmaz K., 2014, BROKERAGE CLOSURE IN; Charmaz K., 2009, DEV GROUNDED THEORY, P127; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Gracey F, 2008, NEUROPSYCHOL REHABIL, V18, P627, DOI 10.1080/09602010802041238; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P619, DOI 10.1016/0895-4356(94)00186-T; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Klein SB, 2010, WIRES COGN SCI, V1, P172, DOI 10.1002/wcs.25; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lloyd V, 2006, QUAL HEALTH RES, V16, P1386, DOI 10.1177/1049732306293846; McAdams D. P., 2006, IDENTITY STORY CREAT; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; Minichiello V., 2004, RES METHODS NURSING, V2nd; Morf C, 2005, SELF IDENTITY, V4, P97; Morse J.M., 2002, READ ME 1 USERS GUID; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ouellet MC, 2009, J HEAD TRAUMA REHAB, V24, P262, DOI 10.1097/HTR.0b013e3181a68b73; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; QSR International Pty Ltd, 2006, NVIVO QUAL DAT AN SO; Sabat Ayesha, 2006, S Afr J Commun Disord, V53, P17; Shaddon B., 2008, LIFE STORIES NARRATI; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stein KF, 1996, J PSYCHOTHER INTEGR, V6, P349, DOI 10.1037/h0101118; Suls J, 2002, CURR DIR PSYCHOL SCI, V11, P159, DOI 10.1111/1467-8721.00191; Suls J., 2000, HDB SOCIAL COMP; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; von Hippel W., 2005, SOCIAL OUTCAST OSTRA, P227; Whitbourne S.K., 2002, IDENTITY, V2, P29, DOI [DOI 10.1207/S1532706XID0201_, 10.1207/S1532706XID0201_03, DOI 10.1207/S1532706XID0201_03]; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; [No title captured], DOI DOI 10.1375/BRIM.7.2.107	59	62	62	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					60	74		10.3109/02699052.2012.722254			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300007	23252437				2022-02-06	
J	Siman, R; Giovannone, N; Hanten, G; Wilde, EA; McCauley, SR; Hunter, JV; Li, XQ; Levin, HS; Smith, DH				Siman, Robert; Giovannone, Nicholas; Hanten, Gerri; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Li, Xiaoqi; Levin, Harvey S.; Smith, Douglas H.			Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients	FRONTIERS IN NEUROLOGY			English	Article						surrogate marker; concussion; calpain; DTI; spectrin; diffuse axonal injury; prognostic marker; cognitive impairment		Although mild traumatic brain injury (mTBI), or concussion, is not typically associated with abnormalities on computed tomography (CT), it nevertheless causes persistent cognitive dysfunction for many patients. Consequently, new prognostic methods for mTBI are needed to identify at risk cases, especially at an early and potentially treatable stage. Here, we quantified plasma levels of the neurodegeneration biomarker calpain-cleaved alpha ll-spectrin N-terminal fragment (SNTF) from 38 participants with CT-negative mTBI, orthopedic injury (01), and normal uninjured controls (UCs) (age range 12-30 years), and compared them with findings from diffusion tensor imaging (DTI) and long-term cognitive assessment. SNTF levels were at least twice the lower limit of detection in 7 of 17 mTBI cases and in 3 of 13 01 cases, but in none of the UCs. An elevation in plasma SNTF corresponded with significant differences in fractional anisotropy and the apparent diffusion coefficient in the corpus callosum and uncinate fasciculus measured by DTI. Furthermore, increased plasma SNTF on the day of injury correlated significantly with cognitive impairment that persisted for at least 3 months, both across all study participants and also among the mTBI cases by themselves. The elevation in plasma SNTF in the subset of 01 cases, accompanied by corresponding white matter and cognitive abnormalities, raises the possibility of identifying undiagnosed cases of mTBI. These data suggest that the blood level of SNTF on the day of a CT-negative mTBI may identify a subset of patients at risk of white matter damage and persistent disability. SNTF could have prognostic and diagnostic utilities in the assessment and treatment of mTBI.	[Siman, Robert; Giovannone, Nicholas; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Hanten, Gerri; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA		Siman, R (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, 502 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Giovannone, Nicholas/0000-0001-5391-8729	National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-056202]	This research was supported by a grant from the National Institute of Neurologic Disorders and Stroke (P01 NS-056202 to Douglas H. Smith). We thank Amanda Barnes, Trevor Wu, Ana C. Vasquez, Melisa Frisby, Greg S. Vogt, Joshua Cooper, and Claudia Robertson for their essential contributions to enrolling patients and deriving plasma samples. We gratefully acknowledge the contribution of Ponnada Narayana and Vipulkumar S. Patel in implementation and execution of the imaging sequences, and Zili D. Chu for his role in data processing. We thank Shawn Roberts and Daphne Georlette of Meso Scale Diagnostics for providing the SECTOR Imager 2400 electrochemiluminescence reader and data analysis software, along with advice on their use. We thank the participants and their families for their involvement in this research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; BIJUR PE, 1990, PEDIATRICS, V86, P337; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hanten G, 2013, J NEUROTRAUM, V30, P618, DOI 10.1089/neu.2012.2392; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; Mabbott DJ, 2009, BRAIN RES, V1294, P80, DOI 10.1016/j.brainres.2009.07.046; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028938; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith, 1973, SYMBOL DIGIT MODALIT; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Sturgeon CM, 2011, ANN CLIN BIOCHEM, V48, P418, DOI 10.1258/acb.2011.011073; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Word Medical Association Declaration of Helsinki, 2001, B WORLD HEALTH ORGAN, V79, P373; YNTEMA DB, 1967, ACTA PSYCHOL, V27, P325, DOI 10.1016/0001-6918(67)90075-3; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	63	62	65	1	11	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								190	10.3389/fneur.2013.00190			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000186	24302918	gold, Green Published			2022-02-06	
J	Amenta, PS; Jallo, JI; Tuma, RF; Elliott, MB				Amenta, Peter S.; Jallo, Jack I.; Tuma, Ronald F.; Elliott, Melanie B.			A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						controlled cortical impact; blood-brain barrier; cannabinoid-2 receptor; endocannabinoid; traumatic brain injury; microglia	CONTROLLED CORTICAL IMPACT; CEREBRAL ISCHEMIC/REPERFUSION INJURY; FLUID PERCUSSION INJURY; SPINAL-CORD-INJURY; CB2 RECEPTOR; ENDOCANNABINOID SYSTEM; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; CELL-MIGRATION; MOUSE MODEL	After traumatic brain injury (TBI), inflammation participates in both the secondary injury cascades and the repair of the CNS, both of which are influenced by the endocannabinoid system. This study determined the effects of repeated treatment with a cannabinoid type 2 receptor (CB2R) agonist on bloodbrain barrier integrity, neuronal degeneration, and behavioral outcome in mice with TBI. We also looked for the presence of a prolonged treatment effect on the macrophage/microglial response to injury. C57BL/6 mice underwent controlled cortical impact (CCI) and received repeated treatments with a CB2R agonist, 0-1966, or vehicle. After euthanasia at 6 hr or 1, 2, 3, or 7 days postinjury, brains were removed for histochemical analysis. Bloodbrain barrier permeability changes were evaluated by using sodium fluorescein (NaF). Perilesional degenerating neurons, injury volumes, and macrophage/microglia cells were quantified by stereological methods. Rota-rod and open-field testing were performed to evaluate motor function and natural exploratory behavior in mice. 0-1966 Treatment resulted in a significant reduction in NaF uptake and number of degenerating neurons compared with the vehicle-treated group. 0-1966-Treated mice demonstrated improvement on rota-rod and open-field testing compared with vehicle-treated mice. These changes in CCI mice treated with 0-1966 were associated with a prolonged reduction in macrophage/microglia cell counts. In conclusion, repeated treatments with a CB2R agonist, 0-1966, result in attenuated bloodbrain barrier disruption and neuronal degeneration. In addition, repeated treatment with 0-1966 shows prolonged treatment effects on behavior and the macrophage/microglia cell response over several days. (c) 2012 Wiley Periodicals, Inc.	[Amenta, Peter S.; Jallo, Jack I.; Elliott, Melanie B.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Tuma, Ronald F.] Temple Univ, Dept Physiol, Philadelphia, PA 19122 USA		Elliott, MB (corresponding author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, 1025 Walnut St,Suite 516, Philadelphia, PA 19107 USA.	melanie.elliott@jefferson.edu		Jallo, Jack/0000-0002-5512-1729			Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Ashton JC, 2011, BRIT J PHARMACOL, V163, P1113, DOI 10.1111/j.1476-5381.2010.01139.x; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481-011-9291-6; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lapter S, 2009, ARTHRITIS RHEUM-US, V60, P3744, DOI 10.1002/art.25013; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leong S, 1992, GLIA, V7, P9; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Liao H, 2005, J BIOL CHEM, V280, P8316, DOI 10.1074/jbc.M412730200; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lombard C, 2007, CLIN IMMUNOL, V122, P259, DOI 10.1016/j.clim.2006.11.002; Malone DT, 2009, PHARMACOL BIOCHEM BE, V93, P91, DOI 10.1016/j.pbb.2009.04.010; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Mo FM, 2004, EUR J PHARMACOL, V489, P21, DOI 10.1016/j.ejphar.2004.02.034; Montecucco F, 2008, AM J PHYSIOL-HEART C, V294, pH1145, DOI 10.1152/ajpheart.01328.2007; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Phares TW, 2007, J IMMUNOL, V178, P7334, DOI 10.4049/jimmunol.178.11.7334; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sacerdote P, 2000, J NEUROIMMUNOL, V109, P155, DOI 10.1016/S0165-5728(00)00307-6; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Stokely ME, 2007, J NEUROSCI METH, V166, P217, DOI 10.1016/j.jneumeth.2007.07.010; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wieseler J, 2010, J NEUROSCI METH, V185, P236, DOI 10.1016/j.jneumeth.2009.10.006; Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zarruk JG, 2012, STROKE, V43, P211, DOI 10.1161/STROKEAHA.111.631044; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	82	62	63	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	DEC	2012	90	12					2293	2305		10.1002/jnr.23114			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	027FM	WOS:000310337300007	22903455				2022-02-06	
J	Farbota, KDM; Sodhi, A; Bendlin, BB; McLaren, DG; Xu, GF; Rowley, HA; Johnson, SC				Farbota, Kimberly D. M.; Sodhi, Aparna; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan; Rowley, Howard A.; Johnson, Sterling C.			Longitudinal Volumetric Changes following Traumatic Brain Injury: A Tensor-Based Morphometry Study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Longitudinal studies; Recovery of function; Brain injuries; humans; Neurosciences; Magnetic resonance imaging; Chronic brain injuries; Brain mapping; Apoptosis; Necrosis	INDUCED AXONAL INJURY; WALLERIAN DEGENERATION; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ATROPHY; MILD; AXOTOMY; PATHOBIOLOGY; AUTOPHAGY; ANIMALS	After traumatic injury, the brain undergoes a prolonged period of degenerative change that is paradoxically accompanied by cognitive recovery. The spatiotemporal pattern of atrophy and the specific relationships of atrophy to cognitive changes are ill understood. The present study used tensor-based morphometry and neuropsychological testing to examine brain volume loss in 17 traumatic brain injury (TBI) patients and 13 controls over a 4-year period. Patients were scanned at 2 months, 1 year, and 4 years post-injury. High-dimensional warping procedures were used to create change maps of each subject's brain for each of the two intervals. TBI patients experienced volume loss in both cortical areas and white matter regions during the first interval. We also observed continuing volume loss in extensive regions of white matter during the second interval. Neuropsychological correlations indicated that cognitive tasks were associated with subsequent volume loss in task-relevant regions. The extensive volume loss in brain white matter observed well beyond the first year post-injury suggests that the injured brain remains malleable for an extended period, and the neuropsychological relationships suggest that this volume loss may be associated with subtle cognitive improvements. (JINS, 2012, 18, 1006-1018)	[Farbota, Kimberly D. M.; Sodhi, Aparna; Bendlin, Barbara B.; McLaren, Donald G.; Xu, Guofan; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53792 USA; [Farbota, Kimberly D. M.; McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; [Sodhi, Aparna; Bendlin, Barbara B.; Xu, Guofan; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA		Farbota, KDM (corresponding author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, J5M-162 CSC,600 Highland Ave, Madison, WI 53792 USA.	kim.farbota@gmail.com		Bendlin, Barbara/0000-0002-0580-9875; Johnson, Sterling/0000-0002-8501-545X; McLaren, Donald/0000-0002-0566-4610	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH65723, AG000213]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000213] Funding Source: NIH RePORTER	This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213, and by the facilities and resources of the William S. Middleton Memorial Veterans Hospital. The authors declare no conflict of interest. The assistance of Robert Dempsey, MD, Jack Sherman, PhD, Tisha Kawahara, Taylor Schmitz, Lisa Newman, Amy Hawley, and Erik Kastman is greatly appreciated. We also greatly appreciate the support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where MR imaging took place. Donald McLaren, PhD, is now affiliated with Harvard University Medical School and the Massachusetts General Hospital, Department of Neurology. Finally, we thank all the patients who took part in this study. The contents of this study do not represent the views of the Department of Veterans Affairs or the United States Government.	Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Demir SO, 2006, BRAIN INJURY, V20, P1383, DOI 10.1080/02699050601081844; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Hua X, 2008, NEUROIMAGE, V41, P19, DOI 10.1016/j.neuroimage.2008.02.010; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; STERN B, 1985, SCAND J REHABIL MED, P27; Takeuchi S, 2011, ARCH NEUROL-CHICAGO, V68, P1090, DOI 10.1001/archneurol.2011.205; Tao GZ, 2009, J NEUROL SCI, V282, P39, DOI 10.1016/j.jns.2008.12.035; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	45	62	63	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2012	18	6					1006	1018		10.1017/S1355617712000835			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	048IT	WOS:000311905300008	22883443	Green Accepted			2022-02-06	
J	Sashindranath, M; Sales, E; Daglas, M; Freeman, R; Samson, AL; Cops, EJ; Beckham, S; Galle, A; McLean, C; Morganti-Kossmann, C; Rosenfeld, JV; Madani, R; Vassalli, JD; Su, EMJ; Lawrence, DA; Medcalf, RL				Sashindranath, Maithili; Sales, Eunice; Daglas, Maria; Freeman, Roxann; Samson, Andre L.; Cops, Elisa J.; Beckham, Simone; Galle, Adam; McLean, Catriona; Morganti-Kossmann, Cristina; Rosenfeld, Jeffrey V.; Madani, Rime; Vassalli, Jean-Dominique; Su, Enming J.; Lawrence, Daniel A.; Medcalf, Robert L.			The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans	BRAIN			English	Article						neurovascular unit; traumatic brain injury; tissue plasminogen activator; plasminogen activator inhibitor-1; matrix metalloproteinase-3	RECEPTOR-RELATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; FOCAL CEREBRAL-ISCHEMIA; MATRIX METALLOPROTEINASES; BARRIER BREAKDOWN; BLOOD; STROKE; TPA; EXPRESSION	The neurovascular unit provides a dynamic interface between the circulation and central nervous system. Disruption of neurovascular integrity occurs in numerous brain pathologies including neurotrauma and ischaemic stroke. Tissue plasminogen activator is a serine protease that converts plasminogen to plasmin, a protease that dissolves blood clots. Besides its role in fibrinolysis, tissue plasminogen activator is abundantly expressed in the brain where it mediates extracellular proteolysis. However, proteolytically active tissue plasminogen activator also promotes neurovascular disruption after ischaemic stroke; the molecular mechanisms of this process are still unclear. Tissue plasminogen activator is naturally inhibited by serine protease inhibitors (serpins): plasminogen activator inhibitor-1, neuroserpin or protease nexin-1 that results in the formation of serpin:protease complexes. Proteases and serpin:protease complexes are cleared through high-affinity binding to low-density lipoprotein receptors, but their binding to these receptors can also transmit extracellular signals across the plasma membrane. The matrix metalloproteinases are the second major proteolytic system in the mammalian brain, and like tissue plasminogen activators are pivotal to neurological function but can also degrade structures of the neurovascular unit after injury. Herein, we show that tissue plasminogen activator potentiates neurovascular damage in a dose-dependent manner in a mouse model of neurotrauma. Surprisingly, inhibition of activity following administration of plasminogen activator inhibitor-1 significantly increased cerebrovascular permeability. This led to our finding that formation of complexes between tissue plasminogen activator and plasminogen activator inhibitor-1 in the brain parenchyma facilitates post-traumatic cerebrovascular damage. We demonstrate that following trauma, the complex binds to low-density lipoprotein receptors, triggering the induction of matrix metalloproteinase-3. Accordingly, pharmacological inhibition of matrix metalloproteinase-3 attenuates neurovascular permeability and improves neurological function in injured mice. Our results are clinically relevant, because concentrations of tissue plasminogen activator: plasminogen activator inhibitor-1 complex and matrix metalloproteinase-3 are significantly elevated in cerebrospinal fluid of trauma patients and correlate with neurological outcome. In a separate study, we found that matrix metalloproteinase-3 and albumin, a marker of cerebrovascular damage, were significantly increased in brain tissue of patients with neurotrauma. Perturbation of neurovascular homeostasis causing oedema, inflammation and cell death is an important cause of acute and long-term neurological dysfunction after trauma. A role for the tissue plasminogen activator-matrix metalloproteinase axis in promoting neurovascular disruption after neurotrauma has not been described thus far. Targeting tissue plasminogen activator: plasminogen activator inhibitor-1 complex signalling or downstream matrix metalloproteinase-3 induction may provide viable therapeutic strategies to reduce cerebrovascular permeability after neurotrauma.	[Sashindranath, Maithili; Sales, Eunice; Daglas, Maria; Freeman, Roxann; Samson, Andre L.; Cops, Elisa J.; Beckham, Simone; Galle, Adam; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [McLean, Catriona] Alfred Hosp, Dept Pathol, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Surg, Melbourne, Vic 3004, Australia; [Madani, Rime; Vassalli, Jean-Dominique] Univ Geneva, Fac Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; [Su, Enming J.; Lawrence, Daniel A.] Univ Michigan, Div Cardiovasc Med, Dept Internal Med, Ann Arbor, MI 48109 USA		Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia.	robert.medcalf@monash.edu	Sashindranath, Maithili/AAI-7408-2021; Rosenfeld, Jeffrey V/B-7249-2011; Medcalf, Robert L/E-9632-2011	Sashindranath, Maithili/0000-0002-9712-4784; Daglas, Maria/0000-0002-9356-4061; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Samson, Andre/0000-0002-0637-2716; Lawrence, Daniel/0000-0003-3126-1935	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia [606660]; Victorian Neurotrauma Initiative [D0-34]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL55374, HL54710, HL089407]; Neurotrauma Tissue/Fluid Bank; Victorian Brain Bank Network; Mental Health Research Institute; Alfred Hospital; National Trauma Research Institute; Victorian Forensic Institute of Medicine; Victorian Neurotrauma Initiative; Transport Accident Commission (TAC); NHMRC of AustraliaNational Health and Medical Research Council of Australia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL054710, R01HL055374, P01HL089407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079639] Funding Source: NIH RePORTER	Grant numbers 606660 and D0-34 awarded to R.L.M from the National Health and Medical Research Council (NHMRC) of Australia and the Victorian Neurotrauma Initiative, respectively, and by grant numbers HL55374, HL54710, and HL089407 awarded to D. A. L from the National Institutes of Health. Tissues were received from the Neurotrauma Tissue/Fluid Bank, supported by the Victorian Brain Bank Network, Mental Health Research Institute, The Alfred Hospital, the National Trauma Research Institute, Victorian Forensic Institute of Medicine and funded by Victorian Neurotrauma Initiative, the Transport Accident Commission (TAC) and the NHMRC of Australia.	Alvarez JI, 2011, BBA-MOL BASIS DIS, V1812, P252, DOI 10.1016/j.bbadis.2010.06.017; Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fanne R Abu, 2010, NEUROPHARMACOLOGY, V58, P972, DOI DOI 10.1016/J.NEUROPHARM.2009.12.017; Gary AR, 2002, GLIA, V39, P279; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Gveric D, 2005, AM J PATHOL, V166, P1143, DOI 10.1016/S0002-9440(10)62334-6; Gveric D, 2003, BRAIN, V126, P1590, DOI 10.1093/brain/awg167; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Johansson L, 2000, STROKE, V31, P26, DOI 10.1161/01.STR.31.1.26; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Lemarchant S, 2012, NEUROPHARMACOLOGY, V62, P749, DOI 10.1016/j.neuropharm.2011.10.020; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Lo EH, 2004, STROKE, V35, P354, DOI 10.1161/01.STR.0000115164.80010.8A; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Macrez R, 2011, STROKE, V42, P2315, DOI 10.1161/STROKEAHA.110.606293; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nilsson TK, 2005, THROMB RES, V116, P249, DOI 10.1016/j.thromres.2004.12.005; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; PHILIPS M, 1984, BIOCHIM BIOPHYS ACTA, V802, P99, DOI 10.1016/0304-4165(84)90039-4; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Suzuki Y, 2007, J THROMB HAEMOST, V5, P1732, DOI 10.1111/j.1538-7836.2007.02628.x; Suzuki Y, 2009, BLOOD, V114, P3352, DOI 10.1182/blood-2009-02-203919; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Verma A, 2000, J HEAD TRAUMA REHAB, V15, P1149, DOI 10.1097/00001199-200010000-00008; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yang D, 2009, J NEUROSCI, V29, P8669, DOI 10.1523/JNEUROSCI.1117-09.2009; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zaheer Z, 2011, THER ADV CHRONIC DIS, V2, P119, DOI 10.1177/2040622310394032; Zhang C, 2009, J CEREBR BLOOD F MET, V29, P1946, DOI 10.1038/jcbfm.2009.174; Zhang C, 2009, AM J PATHOL, V174, P586, DOI 10.2353/ajpath.2009.080661; Zhang XH, 2007, AM J PATHOL, V171, P1281, DOI 10.2353/ajpath.2007.070472; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	49	62	64	0	31	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2012	135		11				3251	3264		10.1093/brain/aws178			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044SV	WOS:000311644800013	22822039	Green Published, Green Submitted, hybrid			2022-02-06	
J	Yi, JH; Katagiri, Y; Susarla, B; Figge, D; Symes, AJ; Geller, HM				Yi, Jae-Hyuk; Katagiri, Yasuhiro; Susarla, Bala; Figge, David; Symes, Aviva J.; Geller, Herbert M.			Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						chondroitin sulfate proteoglycan; traumatic brain injury; extracellular ma-trix; perineuronal nets	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; MONOCLONAL-ANTIBODY; GLIAL SCAR; PROTEOGLYCAN EXPRESSION; REACTIVE ASTROCYTES; PERINEURONAL NETS; NG2 PROTEOGLYCAN; ADULT-RAT; ARTICULAR-CARTILAGE	Chondroitin sulfate proteoglycans (CSPGs) play a pivotal role in many neuronal growth mechanisms including axon guidance and the modulation of repair processes following injury to the spinal cord or brain. Many actions of CSPGs in the central nervous system (CNS) are governed by the specific sulfation pattern on the glycosaminoglycan (GAG) chains attached to CSPG core proteins. To elucidate the role of CSPGs and sulfated GAG chains following traumatic brain injury (TBI), controlled cortical impact injury of mild to moderate severity was performed over the left sensory motor cortex in mice. Using immunoblotting and immunostaining, we found that TBI resulted in an increase in the CSPGs neurocan and NG2 expression in a tight band surrounding the injury core, which overlapped with the presence of 4-sulfated CS GAGs but not with 6-sulfated GAGs. This increase was observed as early as 7 days post injury (dpi), and persisted for up to 28 dpi. Labeling with markers against microglia/macrophages, NG2+ cells, fibroblasts, and astrocytes showed that these cells were all localized in the area, suggesting multiple origins of chondroitin-4-sulfate increase. TBI also caused a decrease in the expression of aggrecan and phosphacan in the pericontusional cortex with a concomitant reduction in the number of perineuronal nets. In summary, we describe a dual response in CSPGs whereby they may be actively involved in complex repair processes following TBI. J. Comp. Neurol. 520:32953313, 2012. (C) 2012 Wiley Periodicals, Inc.	[Yi, Jae-Hyuk; Katagiri, Yasuhiro; Figge, David; Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Cell Biol & Physiol Ctr, NIH, Bethesda, MD 20892 USA; [Yi, Jae-Hyuk; Susarla, Bala; Symes, Aviva J.; Geller, Herbert M.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Susarla, Bala; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA		Geller, HM (corresponding author), NHLBI, Dev Neurobiol Sect, Cell Biol & Physiol Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	geller@helix.nih.gov	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Geller, Herbert/0000-0002-7048-6144	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G175PD, G1709B]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZIAHL006135, ZICHL006019] Funding Source: NIH RePORTER	Grant sponsor: Center for Neuroscience and Regenerative Medicine; Grant numbers: G175PD (to H.M.G. and A.J.S.) and G1709B (postdoctoral fellowship to J.-H.Y.).	Andrews EM, 2012, EXP NEUROL, V235, P174, DOI 10.1016/j.expneurol.2011.09.008; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bartus K, 2012, EXP NEUROL, V235, P5, DOI 10.1016/j.expneurol.2011.08.008; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRAUER K, 1993, BRAIN RES, V631, P167, DOI 10.1016/0006-8993(93)91205-7; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bukhari N, 2011, J NEUROSCI, V31, P14931, DOI 10.1523/JNEUROSCI.3339-11.2011; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Carulli D, 2006, J COMP NEUROL, V494, P559, DOI 10.1002/cne.20822; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; Coulson-Thomas YA, 2008, J NEUROSCI METH, V171, P19, DOI 10.1016/j.jneumeth.2008.01.030; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Gama CI, 2006, NAT CHEM BIOL, V2, P467, DOI 10.1038/nchembio810; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Giamanco KA, 2010, NEUROSCIENCE, V170, P1314, DOI 10.1016/j.neuroscience.2010.08.032; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Horii-Hayashi N, 2008, CELL TISSUE RES, V334, P163, DOI 10.1007/s00441-008-0698-1; Horii-Hayashi N, 2010, NEUROSCI LETT, V483, P67, DOI 10.1016/j.neulet.2010.07.064; Hu HY, 2011, J COMP NEUROL, V519, P1320, DOI 10.1002/cne.22572; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Imagama S, 2011, J NEUROSCI, V31, P17091, DOI 10.1523/JNEUROSCI.5120-10.2011; Ishii M, 2008, GLYCOBIOLOGY, V18, P602, DOI 10.1093/glycob/cwn040; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Komitova M, 2011, GLIA, V59, P800, DOI 10.1002/glia.21152; Kwok JCF, 2011, DEV NEUROBIOL, V71, P1073, DOI 10.1002/dneu.20974; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; LEVINE JM, 1994, J NEUROSCI, V14, P4716; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Lin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021499; Lyck L, 2008, J HISTOCHEM CYTOCHEM, V56, P201, DOI 10.1369/jhc.7A7187.2007; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; MARK MP, 1989, DEV BIOL, V133, P475, DOI 10.1016/0012-1606(89)90051-1; Massey JM, 2008, EXP NEUROL, V209, P426, DOI 10.1016/j.expneurol.2007.03.029; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; Miyata S, 2004, BRAIN RES, V1017, P163, DOI 10.1016/j.brainres.2004.05.034; Morgenstern DA, 2003, MOL CELL NEUROSCI, V24, P787, DOI 10.1016/S1044-7431(03)00245-8; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakamura M, 2009, BRAIN RES, V1252, P117, DOI 10.1016/j.brainres.2008.11.022; Ohsawa K, 2000, J CELL SCI, V113, P3073; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; POOLE CA, 1991, J HISTOCHEM CYTOCHEM, V39, P1175, DOI 10.1177/39.9.1717545; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Sajad M, 2011, J MOL NEUROSCI, V43, P531, DOI 10.1007/s12031-010-9476-0; Sato Y, 2009, CURR STEM CELL RES T, V4, P200, DOI 10.2174/157488809789057419; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Shearer MC, 2003, MOL CELL NEUROSCI, V24, P913, DOI 10.1016/j.mcn.2003.09.004; Shimada IS, 2011, STROKE, V42, P3231, DOI 10.1161/STROKEAHA.111.623280; Shimazaki Y, 2005, J NEUROSCI RES, V82, P172, DOI 10.1002/jnr.20639; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stallcup WB, 2001, J CELL SCI, V114, P2315; Takahashi H, 2011, MOL CELL NEUROSCI, V47, P119, DOI 10.1016/j.mcn.2011.03.006; Velasco J, 2011, J BIOL CHEM, V286, P26016, DOI 10.1074/jbc.M110.208694; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wang H, 2008, J CELL SCI, V121, P3083, DOI 10.1242/jcs.032649; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; Yamamoto Y, 1995, EUR J HISTOCHEM, V39, P265; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang HQ, 2006, GLYCOBIOLOGY, V16, P702, DOI 10.1093/glycob/cwj115	77	62	62	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	OCT 15	2012	520	15					3295	3313		10.1002/cne.23156			19	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	993HV	WOS:000307849400001	22628090	Green Accepted			2022-02-06	
J	Schreiber, JM; Zelleke, T; Gaillard, WD; Kaulas, H; Dean, N; Carpenter, JL				Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Dean, Nathan; Carpenter, Jessica L.			Continuous Video EEG for Patients with Acute Encephalopathy in a Pediatric Intensive Care Unit	NEUROCRITICAL CARE			English	Article						Electroencephalogram (EEG); Seizure; Non-convulsive; Status epilepticus; Encephalopathy	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; CLINICAL-FEATURES; CHILDREN; PREVALENCE; ETIOLOGY	In this study, we aimed to determine the incidence of electrographic seizures among patients in a pediatric intensive care unit (PICU) presenting with acute encephalopathy. Risk factors and duration of continuous EEG monitoring needed to capture electrographic seizures were also assessed. Based on a NeuroICU clinical care pathway, all patients with acute encephalopathy admitted to the PICU are monitored with continuous video electroencephalogram (cVEEG) for 48 h or until the encephalopathy improves. Ninety-four consecutive patients included on the pathway over a year were identified. Mean age was 6.7 years (range 32 days-17.9 years). Data pertaining to patient clinical information and electrographic seizures, including non-convulsive seizures (NCS) and non-convulsive status epilepticus (NCSE), were extracted from a prospective database. Thirty percent (28/94) had seizures captured on cVEEG including 17 patients (18 %) with NCSE. Variables associated with electrographic seizures were age < 24 months and clinical seizure(s) prior to EEG placement. The first seizure captured on cVEEG occurred in the first 24 h for the majority of patients (97 %). Acute brain injury and electrographic seizures were associated with worse outcome. Electrographic seizures are common in pediatric patients with acute encephalopathy. This study supports the practice of cVEEG monitoring for at least 24 h in pediatric patients with acute encephalopathy, particularly if they are less then 24 months of age and/or if a clinical event suspicious for seizure precedes the encephalopathy.	[Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Carpenter, Jessica L.] George Washington Univ, Sch Med & Hlth Sci, Dept Epilepsy Neurophysiol & Crit Care Neurol, Washington, DC 20010 USA; [Schreiber, John M.; Zelleke, Tesfaye; Gaillard, William D.; Kaulas, Himanshu; Dean, Nathan; Carpenter, Jessica L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Dean, Nathan] George Washington Univ, Sch Med & Hlth Sci, Dept Crit Care Med, Washington, DC 20010 USA		Carpenter, JL (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Epilepsy Neurophysiol & Crit Care Neurol, 111 Michigan Ave NW, Washington, DC 20010 USA.	jcarpent@cnmc.org		Schreiber, John/0000-0003-0615-2497			Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Garcia-Filion P, 2012, J NEUROTRAUMA; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Husain AM, 2003, J NEUROL NEUROSUR PS, V74, P189, DOI 10.1136/jnnp.74.2.189; Hussain N, 2007, SEIZURE-EUR J EPILEP, V16, P305, DOI 10.1016/j.seizure.2007.01.007; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kuchta J, 2009, CENT EUR NEUROSURG, V70, P176, DOI 10.1055/s-0029-1224168; Narayanan JT, 2007, EPILEPSIA, V48, P900, DOI 10.1111/j.1528-1167.2007.01099.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	27	62	64	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					31	38		10.1007/s12028-012-9715-z			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000004	22565632				2022-02-06	
J	Choi, KE; Hall, CL; Sun, JM; Wei, L; Mohamad, O; Dix, TA; Yu, SP				Choi, Ko-Eun; Hall, Casey L.; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Dix, Thomas A.; Yu, Shan P.			A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice	FASEB JOURNAL			English	Article						neurotensin analog; brain protection; autophagy; sensorimotor function	MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; NEUROTENSIN ANALOG; BODY-TEMPERATURE; ARTERY INFARCTION; BRAIN TEMPERATURE; HYPOXIC-ISCHEMIA; EMERGING ROLE; ACUTE-PHASE	Compelling evidence from preclinical and clinical studies has shown that mild to moderate hypothermia is neuroprotective against ischemic stroke. Clinical applications of hypothermia therapy, however, have been hindered by current methods of physical cooling, which is generally inefficient and impractical in clinical situations. In this report, we demonstrate the potential of pharmacologically induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal ischemic model of adult mice. ABS-201 (1.5-2.5 mg/kg, i.p.) reduces body and brain temperature by 2-5 degrees C in 15-30 min in a dose-dependent manner without causing shivering or altering physiological parameters. Infarct volumes at 24 h after stroke are reduced by similar to 30-40% when PIH therapy is initiated either immediately after stroke induction or after 30-60 min delay. ABS-201 treatment increases bcl-2 expression, decreases caspase-3 activation, and TUNEL-positive cells in the peri-infarct region, and suppresses autophagic cell death compared to stroke controls. The PIH therapy using ABS-201 improves recovery of sensorimotor function as tested 21 d after stroke. These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising candidates for treatment of ischemic stroke and possibly for other ischemic or traumatic injuries. Choi, K.-E., Hall, C. L., Sun, J.-M., Wei, L., Mohamad, O., Dix, T. A., Yu, S. P. A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J. 26, 2799-2810 (2012). www.fasebj.org	[Choi, Ko-Eun; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Yu, Shan P.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Hall, Casey L.; Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.; Yu, Shan P.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut, Charleston, SC USA		Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Cir,Woodruff Mem Res Bldg,Ste 620, Atlanta, GA 30322 USA.	spyu@emory.edu			U.S. National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057255, NS058710, NS062097, R41NS073378, GM079044, MH65099]; Yerkes National Primate Center/NIH [P51]; NIH from National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R43GM079044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH065099, R41MH065099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057255, R41NS073378, R01NS058710, R01NS062097] Funding Source: NIH RePORTER	This work was supported by U.S. National Institutes of Health (NIH) grants NS057255, NS058710, NS062097, R41NS073378 (S.P.Y., L. W.), GM079044 (S.P.Y., T. A. D.), and MH65099 (T. A. D.) and by a Yerkes National Primate Center/NIH P51 pilot grant. This work was also supported by NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	BABCOCK AM, 1993, BRAIN RES BULL, V32, P373, DOI 10.1016/0361-9230(93)90202-M; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Dawaliby R, 2010, MOL BIOL CELL, V21, P4173, DOI 10.1091/mbc.E09-09-0782; Den Hertog H. M., 2009, COCHRANE DB SYST REV, V21; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Froehler MT, 2010, EXPERT REV CARDIOVAS, V8, P593, DOI [10.1586/erc.09.129, 10.1586/ERC.09.129]; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hammer MD, 2003, NEUROLOGIST, V9, P280, DOI 10.1097/01.nrl.0000094628.29312.2b; Hughes FM, 2010, J MED CHEM, V53, P4623, DOI 10.1021/jm100092s; Humeau A, 2007, MED BIOL ENG COMPUT, V45, P421, DOI 10.1007/s11517-007-0170-5; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Katz LM, 2001, ACAD EMERG MED, V8, P1115, DOI 10.1111/j.1553-2712.2001.tb01126.x; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lampe JW, 2011, ANNU REV MED, V62, P79, DOI 10.1146/annurev-med-052009-150512; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martinet W, 2006, AUTOPHAGY, V2, P55, DOI 10.4161/auto.2217; Miyazawa T, 2003, NEUROL RES, V25, P457, DOI 10.1179/016164103101201850; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650; Smith KE, 2011, BEHAV BRAIN RES, V224, P344, DOI 10.1016/j.bbr.2011.06.014; Sun J., 2011, SOC NEUR ANN M SESS; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427; Torok E, 2009, NEUROSURGERY, V65, P352, DOI 10.1227/01.NEU.0000345632.09882.FF; Torup L, 2003, NEUROSCI LETT, V351, P173, DOI 10.1016/j.neulet.2003.08.008; Tyler-McMahon BM, 2000, EUR J PHARMACOL, V390, P107, DOI 10.1016/S0014-2999(99)00877-8; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Yanagawa Y, 2002, RESUSCITATION, V53, P93, DOI 10.1016/S0300-9572(01)00499-3; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	69	62	64	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2799	2810		10.1096/fj.11-201822			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	WOS:000305912500009	22459147	Green Published			2022-02-06	
J	Menditto, VG; Lucci, M; Polonara, S; Pomponio, G; Gabrielli, A				Menditto, Vincenzo G.; Lucci, Moira; Polonara, Stefano; Pomponio, Giovanni; Gabrielli, Armando			Management of Minor Head Injury in Patients Receiving Oral Anticoagulant Therapy: A Prospective Study of a 24-Hour Observation Protocol	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; COMPUTED-TOMOGRAPHY; CT; RISK	Study objective: Patients receiving warfarin who experience minor head injury are at risk of intracranial hemorrhage, and optimal management after a single head computed tomography (CT) scan is unclear. We evaluate a protocol of 24-hour observation followed by a second head CT scan. Methods: In this prospective case series, we enrolled consecutive patients receiving warfarin and showing no intracranial lesions on a first CT scan after minor head injury treated at a Level II trauma center. We implemented a structured clinical pathway, including 24-hour observation and a CT scan performed before discharge. We then evaluated the frequency of death, admission, neurosurgery, and delayed intracranial hemorrhage. Results: We enrolled and observed 97 consecutive patients. Ten refused the second CT scan and were well during 30-day follow-up. Repeated CT scanning in the remaining 87 patients revealed a new hemorrhage lesion in 5 (6%), with 3 subsequently hospitalized and 1 receiving craniotomy. Two patients discharged after completing the study protocol with 2 negative CT scan results were admitted 2 and 8 days later with symptomatic subdural hematomas; neither received surgery. Two of the 5 patients with delayed bleeding at 24 hours had an initial international normalized ratio greater than 3.0, as did both patients with delayed bleeding beyond 24 hours. The relative risk of delayed hemorrhage with an initial international normalized ratio greater than 3.0 was 14 (95% confidence interval 4 to 49). Conclusion: For patients receiving warfarin who experience minor head injury and have a negative initial head CT scan result, a protocol of 24-hour observation followed by a second CT scan will identify most occurrences of delayed bleeding. An initial international normalized ratio greater than 3 suggests higher risk. [Ann Emerg Med. 2012;59:451-455.]	[Menditto, Vincenzo G.; Polonara, Stefano] Osped Riuniti Ancona, Emergency Dept, Ancona, Italy; [Lucci, Moira; Pomponio, Giovanni; Gabrielli, Armando] Univ Politecn Marche, Dept Internal Med, Ancona, Italy		Menditto, VG (corresponding author), Osped Riuniti Ancona, Emergency Dept, Ancona, Italy.	vincenzomenditto74@yahoo.it	menditto, vincenzo g/ABF-1651-2020; Gabrielli, Armando/AAC-3173-2019	menditto, vincenzo g/0000-0001-6231-2251; 			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leiblich A, 2011, EMERG MED J, V28, P115, DOI 10.1136/emj.2009.079442; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mascarenhas Lino, 2006, Neurosurgery, V59, pE1152; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Saab M, 1996, J ACCID EMERG MED, V13, P208; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	25	62	65	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2012	59	6					451	455		10.1016/j.annemergmed.2011.12.003			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	959HA	WOS:000305302300002	22244878				2022-02-06	
J	Li, YC; Xi, CH; An, YF; Dong, WH; Zhou, M				Li, Y-C.; Xi, C-H.; An, Y-F.; Dong, W-H.; Zhou, M.			Perioperative inflammatory response and protein S-100 beta concentrations - relationship with post-operative cognitive dysfunction in elderly patients	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MINOR SURGERY; SERUM-LEVELS; ANESTHESIA; NEUROINFLAMMATION; MARKERS; RISK	Background: One major concern in about one third of elder patients after total hip-replacement surgery is post-operative cognitive dysfunction (POCD). Previous studies have suggested that cognitive impairment is accompanied with changes in serum S-100 beta protein (S-100 beta) and inflammatory markers. Thus, the aim of the current study was to investigate the value of serum S-100 beta and interleukin(IL)-1 beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP) in reflecting POCD after total hip-replacement surgery. Methods: Forty-two elderly patients were enrolled, and 37 patients completed the follow-up. Serum S-100 beta protein and IL-1 beta, IL-6, TNF-alpha, and CRP were determined pre-operatively, as well as 1 h and 6 h post-operatively. Neuropsychological tests were performed pre-operatively, as well as on day 1, 3, and 7 post-operatively. Results: Seventeen (45.9%, 17/37) patients developed POCD 1 day after surgery, and three (8.1%, 3/37) developed POCD 7 days after surgery. [Correction added after publication 7 February 2012: in the preceding sentence (54.1%, 17/37) was corrected to (45.9%, 17/37)]. Patients with POCD 1 day after surgery had significantly higher serum levels of IL-6 at 6 h (135 +/- 32 pg/ml vs. 91 +/- 29 pg/ml, P < 0.05) and S-100b at 1 h (1872 +/- 385 pg/ml vs. 1289 +/- 143 pg/ml, P < 0.05. No significant post-operative change was detected in levels of TNF-alpha, IL-1, or CRP. Conclusion: The serum levels of pro-inflammatory marker IL-6 and S-100 beta protein increased after total hip-replacement in elderly patients, and such increase may serve as predicting parameters for the occurrence of POCD.	[Li, Y-C.; Xi, C-H.; An, Y-F.; Dong, W-H.; Zhou, M.] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Anesthesiol, Shanghai 200233, Peoples R China		Zhou, M (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Anesthesiol, 600 Yishan Rd, Shanghai 200233, Peoples R China.	zhoum@sjtu.edu.cn					Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Brickenkamp R, 1994, TEST D2 AUFMERKSAMKE; Cambell DN, 1993, ANAESTHESIA, V48, P422; Cao XZ, 2010, PROG NEURO-PSYCHOPH, V34, P1426, DOI 10.1016/j.pnpbp.2010.07.027; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Dijkstra JB, 1999, BRIT J ANAESTH, V82, P867, DOI 10.1093/bja/82.6.867; Evered L, 2011, ANESTH ANALG, V112, P1179, DOI 10.1213/ANE.0b013e318215217e; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Jawa Randeep S, 2011, J Intensive Care Med, V26, P73, DOI 10.1177/0885066610395679; Lemstra AW, 2008, INT J GERIATR PSYCH, V23, P943, DOI 10.1002/gps.2015; [李兴 LI Xing], 2009, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V25, P652; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Norkiene I, 2010, MEDICINA-LITHUANIA, V46, P460, DOI 10.3390/medicina46070066; Oswald W. D., 1997, ZAHLEN VERBINDUNGS T; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242, DOI 10.1093/oxfordjournals.bja.a013410; Rohan D, 2005, CAN J ANAESTH, V52, P137, DOI 10.1007/BF03027718; Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004; SEIDENBERG M, 1981, EPILEPSIA, V22, P75, DOI 10.1111/j.1528-1157.1981.tb04334.x; Sheeran P, 1997, BRIT J ANAESTH, V78, P201, DOI 10.1093/bja/78.2.201; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Sun TS, 2011, INJURY, V42, P707, DOI 10.1016/j.injury.2011.01.010; Tamura A, 2011, ANN THORAC CARDIOVAS, V17, P33, DOI 10.5761/atcs.oa.09.01518; Voronina TA, 2009, B EXP BIOL MED+, V148, P533, DOI 10.1007/s10517-010-0757-y; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wu CL, 2004, REGION ANESTH PAIN M, V29, P257, DOI 10.1016/j.rapm.2003.11.007	31	62	93	0	17	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2012	56	5					595	600		10.1111/j.1399-6576.2011.02616.x			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	923FD	WOS:000302603900010	22224444				2022-02-06	
J	Lethaus, B; Safi, Y; ter Laak-Poort, M; Kloss-Brandstatter, A; Banki, F; Robbenmenke, C; Steinseifer, U; Kessler, P				Lethaus, Bernd; Safi, Yara; ter Laak-Poort, Mariel; Kloss-Brandstaetter, Anita; Banki, Frans; Robbenmenke, Christian; Steinseifer, Ulrich; Kessler, Peter			Cranioplasty with Customized Titanium and PEEK Implants in a Mechanical Stress Model	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; in vivo studies; surgery; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; BONE FLAP; POLYETHERETHERKETONE; HYDROXYAPATITE; BIOCOMPATIBILITY; RECONSTRUCTION; BIOMECHANICS; PHOSPHATE; ALPHA	Large skull defects as a result of craniectomies due to cerebral insults, trauma, or tumors create functional and aesthetic disturbances for the patient. Cranioplasty with implants in these cases are an alternative to autogenous bone transplantation. In our clinic, customized titanium or optima poly-ether-ether ketone (PEEK) implants are used to reconstruct craniectomy defects. To compare the two materials we investigated the structural changes of the implants fixed to a sintered polyamide skull model under mechanical stress in four simplified models. In a standard testing machine, the models were subjected to a load under a quasi-static loading rate of 1.925 mm/min. Fractures of the PEEK implants occurred at a force of 24.2 and 24.5kN with a displacement of 8.4 and 8 mm. The titanium implants showed no deformation, but extensive damage was seen in the polyamide skull models. The highest pressures achieved were 45.8 and 50.9 kN. In a simplified model with quasi-static loading, both implants withstood forces that were higher than those capable of causing skull fractures. It seems that the mechanical properties of PEEK could provide better protection when used for cranioplasty in patients after craniectomy if reconstruction with autogenous bone is not possible.	[Lethaus, Bernd; Banki, Frans; Kessler, Peter] Maastricht Univ Med Ctr, Dept Craniomaxillofacial Surg, NL-3202 AZ Maastricht, Netherlands; [Safi, Yara; Robbenmenke, Christian; Steinseifer, Ulrich] Rhein Westfal TH Aachen, Dept Cardiovasc Engn, Inst Appl Med Engn, Helmholtz Inst, Aachen, Germany; [ter Laak-Poort, Mariel] Maastricht Univ Med Ctr, Dept Neurosurg, NL-3202 AZ Maastricht, Netherlands; [Kloss-Brandstaetter, Anita] Innsbruck Med Univ, Div Genet Epidemiol, Innsbruck, Austria		Lethaus, B (corresponding author), Maastricht Univ Med Ctr, Dept Craniomaxillofacial Surg, Postbus 5800, NL-3202 AZ Maastricht, Netherlands.	bernd.lethaus@mumc.nl	Lethaus, Bernd/AAC-3091-2021	Lethaus, Bernd/0000-0002-9619-9362			Abu Bakar MS, 2003, BIOMATERIALS, V24, P2245, DOI 10.1016/S0142-9612(03)00028-0; ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776; Baldo S, 2010, WORLD NEUROSURG, V73, P552, DOI 10.1016/j.wneu.2010.02.018; Baumeister S, 2008, PLAST RECONSTR SURG, V122, p195E, DOI 10.1097/PRS.0b013e3181858eee; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Eschbach L, 2000, Injury, V31 Suppl 4, P22; Got C., 1983, P 27 STAPP CAR CRASH; HAMPSON D, 1995, J BIOMECH, V28, P1; Hanasono MM, 2009, ANN PLAS SURG, V62, P653, DOI 10.1097/SAP.0b013e318184abc7; Hodgson V.R., 1971, P 16 STAPP CAR CRASH, P292; Inamasu J, 2010, J TRAUMA, V68, P183, DOI 10.1097/TA.0b013e3181c45384; Jagur-Grodzinski J, 1999, REACT FUNCT POLYM, V39, P99, DOI 10.1016/S1381-5148(98)00054-6; Kamyszek T, 2001, Mund Kiefer Gesichtschir, V5, P233, DOI 10.1007/s100060100317; Katzer A, 2002, BIOMATERIALS, V23, P1749, DOI 10.1016/S0142-9612(01)00300-3; KLEIN CPAT, 1994, BIOMATERIALS, V15, P146, DOI 10.1016/0142-9612(94)90264-X; Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013; Lethaus B., 2010, J CRANIOMAXILLOFAC S; Li LH, 2005, J BIOMED MATER RES A, V73A, P48, DOI 10.1002/jbm.a.30244; McElhaney J., 1972, HUMAN IMPACT TOLERAN, P85; MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142-9612(95)94906-2; NAHUM A, 1980, P 24 STAPP CAR CRASH; SAE, 1994, HUM MECH RESP CHAR, pJ1460; Schmidt M, 2007, CIRP ANN-MANUF TECHN, V56, P205, DOI 10.1016/j.cirp.2007.05.097; Schneider DC, 1972, P 16 STAPP CAR CRASH, P186; Scolozzi P, 2007, J CRANIOFAC SURG, V18, P224, DOI 10.1097/01.scs.0000249359.56417.7e; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Takano Y, 1999, J ORTHOP RES, V17, P59, DOI 10.1002/jor.1100170110; Toth JM, 2006, BIOMATERIALS, V27, P324, DOI 10.1016/j.biomaterials.2005.07.011; Turner CH, 1999, J BIOMECH, V32, P437, DOI 10.1016/S0021-9290(98)00177-8; Wiltfang J, 2002, J BIOMED MATER RES, V63, P115, DOI 10.1002/jbm.10084; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014	32	62	66	2	43	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1077	1083		10.1089/neu.2011.1794			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100006	22017579				2022-02-06	
J	Murphy, PR; Robertson, IH; Allen, D; Hester, R; O'Connell, RG				Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; Hester, Robert; O'Connell, Redmond G.			An electrophysiological signal that precisely tracks the emergence of error awareness	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						error positivity; EEG; error awareness; error processing; performance monitoring	ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; FUNCTIONAL-SIGNIFICANCE; ERP COMPONENTS; NEURAL BASIS; DYNAMICS; MECHANISMS; ATTENTION; DISCRIMINATION; POTENTIALS	Recent electrophysiological research has sought to elucidate the neural mechanisms necessary for the conscious awareness of action errors. Much of this work has focused on the error positivity (Pe), a neural signal that is specifically elicited by errors that have been consciously perceived. While awareness appears to be an essential prerequisite for eliciting the Pe, the precise functional role of this component has not been identified. Twenty-nine participants performed a novel variant of the Go/No-go Error Awareness Task (EAT) in which awareness of commission errors was indicated via a separate speeded manual response. Independent component analysis (ICA) was used to isolate the Pe from other stimulus- and response-evoked signals. Single-trial analysis revealed that Pe peak latency was highly correlated with the latency at which awareness was indicated. Furthermore, the Pe was more closely related to the timing of awareness than it was to the initial erroneous response. This finding was confirmed in a separate study which derived IC weights from a control condition in which no indication of awareness was required, thus ruling out motor confounds. A receiver-operating-characteristic (ROC) curve analysis showed that the Pe could reliably predict whether an error would be consciously perceived up to 400 ms before the average awareness response. Finally, Pe latency and amplitude were found to be significantly correlated with overall error awareness levels between subjects. Our data show for the first time that the temporal dynamics of the Pe trace the emergence of error awareness. These findings have important implications for interpreting the results of clinical EEG studies of error processing.	[Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; O'Connell, Redmond G.] Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; O'Connell, Redmond G.] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Hester, Robert] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic, Australia		Murphy, PR (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland.	murphyp7@tcd.ie	Hester, Robert/F-2097-2011	Hester, Robert/0000-0003-0982-8026; Murphy, Peter R/0000-0003-1963-185X; Robertson, Ian H/0000-0001-8637-561X; O'Connell, Redmond/0000-0001-6949-2793	Irish Research Council for Science, Engineering, and Technology (IRCSET)Irish Research Council for Science, Engineering and Technology; ARCAustralian Research Council [FT110100088]; EUEuropean Commission; Irish Government	This research was supported by an Irish Research Council for Science, Engineering, and Technology (IRCSET) "Embark Initiative" grant awarded to Peter R. Murphy, an ARC Fellowship to Robert Hester (FT110100088), and an IRCSET "Empower" Fellowship to Redmond G. O'Connell. The authors also acknowledge funding support via the HEA PRTLI Cycle 3 program of the EU Structural Funds and the Irish Government's National Development Plan 2002-2006. We thank Hugh Nolan and Simon Kelly for their assistance with aspects of data analysis and Misha Byrne for assistance with figure design.	Althaus M, 2010, BIOL PSYCHOL, V85, P19, DOI 10.1016/j.biopsycho.2010.04.007; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Bartholow BD, 2012, J ABNORM PSYCHOL, V121, P173, DOI 10.1037/a0023664; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Biehl SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028396; Bland AR, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00080; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brazil IA, 2009, BIOL PSYCHIAT, V65, P137, DOI 10.1016/j.biopsych.2008.08.011; Cavanagh JF, 2011, NAT NEUROSCI, V14, P1462, DOI 10.1038/nn.2925; Cavanagh JF, 2009, J NEUROSCI, V29, P98, DOI 10.1523/JNEUROSCI.4137-08.2009; Cohen MX, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00030; Cohen MX, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.054.2009; Colebatch JG, 2007, MOVEMENT DISORD, V22, P601, DOI 10.1002/mds.21323; Debener S, 2006, TRENDS COGN SCI, V10, P558, DOI 10.1016/j.tics.2006.09.010; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dhar M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019578; Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065; Eichele T, 2008, P NATL ACAD SCI USA, V105, P6173, DOI 10.1073/pnas.0708965105; Einhauser Wolfgang, 2010, Front Hum Neurosci, V4, P18, DOI 10.3389/fnhum.2010.00018; Endrass T, 2005, J PSYCHOPHYSIOL, V19, P275, DOI 10.1027/0269-8803.19.4.275; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 1995, EEG CL N SU, P287; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 1990, PSYCHOPHYSIOLOGICAL, V1, P192; Frank MJ, 2007, COGN AFFECT BEHAV NE, V7, P297, DOI 10.3758/CABN.7.4.297; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gold JI, 2007, ANNU REV NEUROSCI, V30, P535, DOI 10.1146/annurev.neuro.29.051605.113038; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2012, J NEUROSCI, V32, P2619, DOI 10.1523/JNEUROSCI.4052-11.2012; Holroyd C.B., 2004, COGNITIVE NEUROSCIEN, P219; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Hughes G, 2011, NEUROPSYCHOLOGIA, V49, P405, DOI 10.1016/j.neuropsychologia.2010.11.036; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P61, DOI 10.1016/j.ijpsycho.2011.02.001; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Leuthold H, 1999, CLIN NEUROPHYSIOL, V110, P342, DOI 10.1016/S1388-2457(98)00058-3; Luijten M, 2011, PHARMACOL BIOCHEM BE, V97, P514, DOI 10.1016/j.pbb.2010.10.012; Luu P, 2004, CLIN NEUROPHYSIOL, V115, P1821, DOI 10.1016/j.clinph.2004.03.031; Macdonald JSP, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00082; Makeig S, 2004, TRENDS COGN SCI, V8, P204, DOI 10.1016/j.tics.2004.03.008; Mintz AR, 2004, SCHIZOPHR RES, V67, P213, DOI 10.1016/S0920-9964(03)00047-1; Murphy PR, 2011, PSYCHOPHYSIOLOGY, V48, P1531, DOI 10.1111/j.1469-8986.2011.01226.x; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nolan H, 2010, J NEUROSCI METH, V192, P152, DOI 10.1016/j.jneumeth.2010.07.015; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connell RG, 2009, J NEUROSCI, V29, P8604, DOI 10.1523/JNEUROSCI.5967-08.2009; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Olvet DM, 2010, PSYCHIAT RES, V179, P30, DOI 10.1016/j.psychres.2010.06.008; Onton J, 2006, NEUROSCI BIOBEHAV R, V30, P808, DOI 10.1016/j.neubiorev.2006.06.007; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Perez VB, 2012, J ABNORM PSYCHOL, V121, P372, DOI 10.1037/a0025487; Peterburs J, 2012, NEUROPSYCHOLOGIA, V50, P379, DOI 10.1016/j.neuropsychologia.2011.12.009; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; RABBITT P, 1990, ERGONOMICS, V33, P1291, DOI 10.1080/00140139008925333; RABBITT P, 1981, Q J EXP PSYCHOL-A, V33, P223, DOI 10.1080/14640748108400790; RABBITT P, 1978, Q J EXP PSYCHOL, V30, P319, DOI 10.1080/14640747808400679; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RABBITT PMA, 1966, NATURE, V212, P438, DOI 10.1038/212438a0; Ratcliff R, 2010, J EXP PSYCHOL GEN, V139, P70, DOI 10.1037/a0018128; Ridderinkhof KR, 2009, PSYCHOPHYSIOLOGY, V46, P531, DOI 10.1111/j.1469-8986.2009.00790.x; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Roitman JD, 2002, J NEUROSCI, V22, P9475; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; Shalgi S, 2009, EUR J NEUROSCI, V29, P1522, DOI 10.1111/j.1460-9568.2009.06690.x; SPENCER KM, 2004, EVENT RELATED POTENT, P209; Steinhauser M, 2008, J EXP PSYCHOL HUMAN, V34, P158, DOI 10.1037/0096-1523.34.1.158; Steinhauser M, 2010, J NEUROSCI, V30, P15643, DOI 10.1523/JNEUROSCI.1899-10.2010; Ullsperger M, 2006, BRAIN RES, V1105, P102, DOI 10.1016/j.brainres.2006.01.007; Ullsperger M, 2010, BRAIN STRUCT FUNCT, V214, P629, DOI 10.1007/s00429-010-0261-1; van Boxtel GJM, 2005, J PSYCHOPHYSIOL, V19, P1, DOI 10.1027/0269-8803.19.1.1; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Viola FC, 2009, CLIN NEUROPHYSIOL, V120, P868, DOI 10.1016/j.clinph.2009.01.015; Wessel JR, 2011, J COGNITIVE NEUROSCI, V23, P3021, DOI 10.1162/jocn.2011.21635; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	78	62	62	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 28	2012	6								65	10.3389/fnhum.2012.00065			16	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	924ST	WOS:000302712300001	22470332	Green Published, gold			2022-02-06	
J	Li, ZY; Wang, B; Kan, ZS; Zhang, BL; Yang, Z; Chen, JL; Wang, D; Wei, HJ; Zhang, JN; Jiang, RC				Li, Zhanying; Wang, Bin; Kan, Zhisheng; Zhang, Baoliang; Yang, Zhuo; Chen, Jieli; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai			Progesterone Increases Circulating Endothelial Progenitor Cells and Induces Neural Regeneration after Traumatic Brain Injury in Aged Rats	JOURNAL OF NEUROTRAUMA			English	Article						aged rats; EPCs; neurological function; progesterone; TBI; vascular remodeling	CD34(+) CELLS; BEHAVIORAL ABNORMALITIES; THERAPEUTIC ANGIOGENESIS; INFLAMMATORY RESPONSE; CEREBRAL EDEMA; BLOOD-VESSELS; NEUROGENESIS; TRANSPLANTATION; VASCULOGENESIS; MOBILIZATION	Vascular remodeling plays a key role in neural regeneration in the injured brain. Circulating endothelial progenitor cells (EPCs) are a mediator of the vascular remodeling process. Previous studies have found that progesterone treatment of traumatic brain injury (TBI) decreases cerebral edema and cellular apoptosis and inhibits inflammation, which in concert promote neuroprotective effects in young adult rats. However, whether progesterone treatment regulates circulating EPC level and fosters vascular remodeling after TBI have not been investigated. In this study, we hypothesize that progesterone treatment following TBI increases circulating EPC levels and promotes vascular remodeling in the injured brain in aged rats. Male Wistar 20-month-old rats were subjected to a moderate unilateral parietal cortical contusion injury and were treated with or without progesterone (n =54/group). Progesterone was administered intraperitoneally at a dose of 16mg/kg at 1 h post-TBI and was subsequently injected subcutaneously daily for 14 days. Neurological functional tests and immnunostaining were performed. Circulating EPCs were measured by flow cytometry. Progesterone treatment significantly improved neurological outcome after TBI measured by the modified neurological severity score, Morris Water Maze and the long term potentiation in the hippocampus as well as increased the circulating EPC levels compared to TBI controls (p<0.05). Progesterone treatment also significantly increased CD34 and CD31 positive cell number and vessel density in the injured brain compared to TBI controls (p<0.05). These data indicate that progesterone treatment of TBI improves multiple neurological functional outcomes, increases the circulating EPC level, and facilitates vascular remodeling in the injured brain after TBI in aged rats.	[Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Li, Zhanying; Wang, Bin; Zhang, Baoliang; Wang, Dong; Wei, Huijie; Zhang, Jian-ning; Jiang, Rongcai] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Li, Zhanying; Kan, Zhisheng] Hebei United Univ, Kailuan Hosp, Dept Neurosurg, Tangshan, Peoples R China; [Yang, Zhuo] Nankai Univ, Coll Life Sci, Minist Educ, Sch Med,Key Lab Bioact Mat, Tianjin 300071, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA		Jiang, RC (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com; jianghope@gmail.com			National 973 Projects of ChinaNational Basic Research Program of China [2005CB522605]; Application Foundation and Advanced Technology [11JCZDJC18100]	We acknowledge Li Liu and Fanglian Chen in our laboratory for their excellent technical support. We also acknowledge Michael Chopp from Henry Ford Hospital and Jing-fei Dong from Baylor College of Medicine for their suggestions and editing on this manuscript. This work is supported by the National 973 Projects of China (grant 2005CB522605) and Tianjin Research Program of Application Foundation and Advanced Technology (grant 11JCZDJC18100).	Al-Jarrah M, 2010, NEUROREHABILITATION, V26, P369, DOI 10.3233/NRE-2010-0574; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Blann AD, 2006, THROMB HAEMOSTASIS, V95, P49, DOI 10.1160/TH05-07-0527; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bulut D, 2007, CLIN RES CARDIOL, V96, P258, DOI 10.1007/s00392-007-0494-z; Camara CC, 2010, BRAZ J MED BIOL RES, V43, P657, DOI 10.1590/S0100-879X2010007500050; Campagnolo P, 2010, CIRCULATION, V121, P1735, DOI 10.1161/CIRCULATIONAHA.109.899252; Carr BR, 1998, CONTRACEPTION, V58, p23S, DOI 10.1016/S0010-7824(98)00079-1; Chang EI, 2007, CIRCULATION, V116, P2818, DOI 10.1161/CIRCULATIONAHA.107.715847; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Edelberg JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS1199, DOI 10.2741/1166; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Frontczak-Baniewicz M, 2003, ACTA NEUROBIOL EXP, V63, P65; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Ishigami S, 2010, ANTICANCER RES, V30, P2453; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kawamoto A, 2006, CIRCULATION, V114, P2163, DOI 10.1161/CIRCULATIONAHA.106.644518; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kiernan TJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-66; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719; Lapergue B, 2007, PROG NEUROBIOL, V83, P349, DOI 10.1016/j.pneurobio.2007.08.001; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morris CL, 2003, BRIT J HAEMATOL, V120, P413, DOI 10.1046/j.1365-2141.2003.04107.x; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Okada S, 2008, DIABETES CARE, V31, P157, DOI 10.2337/dc07-1125; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rufaihah AJ, 2010, REGEN MED, V5, P231, DOI 10.2217/RME.09.83; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Senegaglia AC, 2010, EXP BIOL MED, V235, P119, DOI 10.1258/ebm.2009.009194; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stellos K, 2010, ARTERIOSCL THROM VAS, V30, P1127, DOI 10.1161/ATVBAHA.110.204370; Su ZJ, 2009, J NEUROTRAUM, V26, P1695, DOI 10.1089/neu.2008.0519; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tian F, 2009, BLOOD, V113, P5352, DOI 10.1182/blood-2008-08-173773; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Wang JX, 2010, CIRC RES, V106, P1904, DOI 10.1161/CIRCRESAHA.110.221762; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xing CH, 2009, J NEUROSCI RES, V87, P2571, DOI 10.1002/jnr.22076; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Yu H, 2008, CELL ADHES MIGR, V2, P254, DOI 10.4161/cam.2.4.6818; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	83	62	67	3	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					343	353		10.1089/neu.2011.1807			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300013	21534727	Green Published			2022-02-06	
J	Simpkins, JW; Singh, M; Brock, C; Etgen, AM				Simpkins, James W.; Singh, Meharvan; Brock, Courtney; Etgen, Anne M.			Neuroprotection and Estrogen Receptors	NEUROENDOCRINOLOGY			English	Article						Estradiol; Estrogens; Nonfeminizing estrogens; Estrogen receptor alpha; Estrogen receptor beta; Traumatic brain injury; Neuroprotection; Cerebral ischemia; Stroke; Spinal cord injury	ACTIVATED PROTEIN-KINASE; CONJUGATED EQUINE ESTROGENS; METABOTROPIC GLUTAMATE RECEPTORS; HORMONE REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; CEREBRAL-ARTERY OCCLUSION; HEALTH INITIATIVE MEMORY; BETA-ESTRADIOL PROTECTS; GROWTH-FACTOR-I; POSTMENOPAUSAL WOMEN	This review is intended to assess the state of current knowledge on the role of estrogen receptors (ERs) in the neuroprotective effects of estrogens in models for acute neuronal injury and death. We evaluate the overall evidence that estrogens are neuroprotective in acute injury and critically assess the role of ER alpha, ER beta, GPR 30, and nonreceptor-mediated mechanisms in these robust neuroprotective effects of this ovarian steroid hormone. We conclude that all three receptors, as well as nonreceptor-mediated mechanisms can be involved in neuroprotection, depending on the model used, the level of estrogen administrated, and the mode of administration of the steroid. Also, the signaling pathways used by both ER-dependent and ER-independent mechanisms to exert neuroprotection are considered. Finally, further studies that are needed to parse out the relative contribution of receptor versus nonreceptor-mediated signaling are discussed. Copyright (C) 2012 S. Karger AG, Basel	[Simpkins, James W.; Singh, Meharvan; Brock, Courtney] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA; [Etgen, Anne M.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA		Simpkins, JW (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, 3500 Camp Bowie Bvld, Ft Worth, TX 76107 USA.	james.simpkins@unthsc.edu		Singh, Meharvan/0000-0002-8072-1769	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG020494, P01 AG027956, P01 AG022550] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG020494, P01AG022550] Funding Source: NIH RePORTER		Abdelhamid R, 2011, ACS CHEM NEUROSCI, V2, P256, DOI 10.1021/cn100106a; Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Akama KT, 2003, J NEUROSCI, V23, P2333; Al Sweidi S, 2012, J NEUROENDOCRINOL, V24, P48, DOI 10.1111/j.1365-2826.2011.02193.x; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Amantea D, 2007, FEBS J, V274, P4464, DOI 10.1111/j.1742-4658.2007.05975.x; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 1999, GLIA, V26, P260; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; BISHOP J, 1994, MOL CELL NEUROSCI, V5, P303, DOI 10.1006/mcne.1994.1036; Bondar G, 2009, J NEUROSCI, V29, P15323, DOI 10.1523/JNEUROSCI.2107-09.2009; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Bryant DN, 2010, NEUROSCIENCE, V170, P1261, DOI 10.1016/j.neuroscience.2010.08.019; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290, DOI 10.1152/ajpheart.2000.278.1.H290; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Cimarosti H, 2006, NEUROCHEM RES, V31, P483, DOI 10.1007/s11064-006-9043-9; Clark RA, 1997, J ACQ IMMUN DEF SYND, V15, P341, DOI 10.1097/00042560-199708150-00003; Connell BJ, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/976951; Cordey M, 2005, BRAIN RES, V1045, P217, DOI 10.1016/j.brainres.2005.03.032; Crawford DK, 2010, BRAIN, V133, P2999, DOI 10.1093/brain/awq237; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; D'Astous M, 2006, MOL PHARMACOL, V69, P1492, DOI 10.1124/mol.105.018671; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Dai XN, 2007, NEUROPHARMACOLOGY, V52, P1124, DOI 10.1016/j.neuropharm.2006.11.012; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dhandapani KM, 2007, EXP GERONTOL, V42, P70, DOI 10.1016/j.exger.2006.06.032; Dominguez R, 2010, J NEUROSCI, V30, P12589, DOI 10.1523/JNEUROSCI.1038-10.2010; Donzelli A, 2010, J PHARMACOL SCI, V114, P158, DOI 10.1254/jphs.10164FP; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Elzer JG, 2010, J CEREBR BLOOD F MET, V30, P935, DOI 10.1038/jcbfm.2009.258; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Farr TD, 2007, BRAIN RES, V1185, P275, DOI 10.1016/j.brainres.2007.09.009; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Fugger HN, 2001, NEUROSCI LETT, V309, P207, DOI 10.1016/S0304-3940(01)02083-3; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Gamerdinger M, 2006, J NEUROCHEM, V97, P57, DOI 10.1111/j.1471-4159.2006.03675.x; Gingerich S, 2010, NEUROSCIENCE, V170, P54, DOI 10.1016/j.neuroscience.2010.06.076; Gorosito SV, 2008, NEUROSCIENCE, V154, P1173, DOI 10.1016/j.neuroscience.2008.05.001; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Grove-Strawser D, 2010, NEUROSCIENCE, V170, P1045, DOI 10.1016/j.neuroscience.2010.08.012; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Guo JB, 2010, J CEREBR BLOOD F MET, V30, P545, DOI 10.1038/jcbfm.2009.226; Hammond R, 2011, BRAIN RES, V1379, P53, DOI 10.1016/j.brainres.2010.11.098; Handa RJ, 2012, NEUROENDOCRINOLOGY, V96, P111, DOI 10.1159/000338397; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Henderson VW, 2010, PROG BRAIN RES, V182, P77, DOI 10.1016/S0079-6123(10)82003-5; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Horstink MWIM, 2003, ADV NEUROL, V91, P107; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Jover-Mengual T, 2010, BRAIN RES, V1321, P1, DOI 10.1016/j.brainres.2010.01.046; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kelly MJ, 2009, MOL CELL ENDOCRINOL, V308, P17, DOI 10.1016/j.mce.2009.03.008; Kramar EA, 2009, J NEUROSCI, V29, P12982, DOI 10.1523/JNEUROSCI.3059-09.2009; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Lewis DK, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.007; Liu R, 2007, NEUROSCI LETT, V415, P237, DOI 10.1016/j.neulet.2007.01.074; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583; Luciani P, 2008, ENDOCRINOLOGY, V149, P4256, DOI 10.1210/en.2007-1795; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marder K, 1998, NEUROLOGY, V50, P1141, DOI 10.1212/WNL.50.4.1141; Marin R, 2003, ANN NY ACAD SCI, V1007, P108, DOI 10.1196/annals.1286.011; Marin R, 2008, STEROIDS, V73, P992, DOI 10.1016/j.steroids.2007.12.007; Marin R, 2009, J STEROID BIOCHEM, V114, P2, DOI 10.1016/j.jsbmb.2008.12.014; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McDowell ML, 2011, NEUROCHEM INT, V59, P175, DOI 10.1016/j.neuint.2011.04.011; Meltser I, 2008, J CLIN INVEST, V118, P1563, DOI 10.1172/JCI32796; Mendelowitsch A, 1901, BRAIN RES, V200, P230; Mendez P, 2005, J ENDOCRINOL, V185, P11, DOI 10.1677/joe.1.06058; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Micevych PE, 2012, NEUROENDOCRINOLOGY, V96, P103, DOI 10.1159/000338400; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Milner TA, 2001, J COMP NEUROL, V429, P355; Mirshams N, 2011, NEUR M PLANN WASH SO; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mong JA, 2006, NEUROSCIENCE, V138, P967, DOI 10.1016/j.neuroscience.2005.10.017; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nishio M, 2004, NEUROSCI LETT, V355, P109, DOI 10.1016/j.neulet.2003.10.064; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; Perez E, 2005, DRUG DEVELOP RES, V66, P78, DOI 10.1002/ddr.20047; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Picciarelli-Lima P, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-51; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Raz L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027039; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2001, ANN NY ACAD SCI, V949, P203; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Richardson TE, 2011, ENDOCRINOLOGY, V152, P2742, DOI 10.1210/en.2011-0184; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Russo R, 2008, PROG BRAIN RES, V173, P583, DOI 10.1016/S0079-6123(08)01144-8; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Sawada M, 2000, J CEREBR BLOOD F MET, V20, P112, DOI 10.1097/00004647-200001000-00015; Scott E, 2012, FRONT NEUROENDOCRIN, V33, P85, DOI 10.1016/j.yfrne.2011.10.001; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Sherwin BB, 1997, NEUROLOGY, V48, pS21, DOI 10.1212/WNL.48.5_Suppl_7.21S; Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singh M, 2006, EXP BIOL MED, V231, P514; Singh M, 1999, J NEUROSCI, V19, P1179; Singh M, 2000, J NEUROSCI, V20, P1694; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Spampinato SF, 2012, MOL PHARMACOL, V81, P12, DOI 10.1124/mol.111.074021; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Srivastava DP, 2011, J NEUROSCI, V31, P16056, DOI 10.1523/JNEUROSCI.4097-11.2011; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1824, DOI 10.1038/jcbfm.2008.70; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wigginton JG, 2010, CRIT CARE MED, V38, pS620, DOI 10.1097/CCM.0b013e3181f243a9; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Xia Y, 2009, NEUROSCIENCE, V162, P292, DOI 10.1016/j.neuroscience.2009.04.068; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Yang SH, 2003, ANN NY ACAD SCI, V1007, P101, DOI 10.1196/annals.1286.010; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang QG, 2011, P NATL ACAD SCI USA, V108, pE617, DOI 10.1073/pnas.1104391108; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhao LZ, 2007, BRAIN RES, V1172, P48, DOI 10.1016/j.brainres.2007.06.092; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhou XH, 2007, DEV NEUROBIOL, V67, P603, DOI 10.1002/dneu.20373	159	62	64	2	23	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0028-3835	1423-0194		NEUROENDOCRINOLOGY	Neuroendocrinology		2012	96	2					119	130		10.1159/000338409			12	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	008SK	WOS:000308976700004	22538356	Green Accepted			2022-02-06	
J	Tham, SW; Palermo, TM; Vavilala, MS; Wang, J; Jaffe, KM; Koepsell, TD; Dorsch, A; Temkin, N; Durbin, D; Rivara, FP				Tham, See Wan; Palermo, Tonya M.; Vavilala, Monica S.; Wang, Jin; Jaffe, Kenneth M.; Koepsell, Thomas D.; Dorsch, Andrea; Temkin, Nancy; Durbin, Dennis; Rivara, Frederick P.			The Longitudinal Course, Risk Factors, and Impact of Sleep Disturbances in Children with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						pediatric; risk factors; sleep disturbances; traumatic brain injury	UNITED-STATES; FOLLOW-UP; POSTCONCUSSIVE SYMPTOMS; PAIN; PARTICIPATION; ADOLESCENTS; RELIABILITY; PERFORMANCE; PREVALENCE; INSOMNIA	This study aimed to examine the prevalence and trajectory of sleep disturbances and their associated risk factors in children up to 24 months following a traumatic brain injury (TBI). In addition, the longitudinal association between sleep disturbances and children's functional outcomes was assessed. This was a prospective study of a cohort of children with TBI and a comparison cohort of children with orthopedic injury (OI). Parental reports of pre-injury sleep disturbances were compared to reports of post-injury changes at 3, 12, and 24 months. Risk factors for sleep disturbances were examined, including severity of TBI, presence of psychosocial problems, and pain. Sleep disturbances were also examined as a predictor of children's functional outcomes in the areas of adaptive behavior skills and activity participation. Both cohorts (children with TBI and OI) displayed increased sleep disturbances after injury. However, children with TBI experienced higher severity and more prolonged duration of sleep disturbances compared to children with OI. Risk factors for disturbed sleep included mild TBI, psychosocial problems, and frequent pain. Sleep disturbances emerged as significant predictors of poorer functional outcomes in children with moderate or severe TBI. Children with TBI experienced persistent sleep disturbances over 24 months. Findings suggest a potential negative impact of disturbed sleep on children's functional outcomes, highlighting the need for further research on sleep in children with TBI.	[Tham, See Wan; Palermo, Tonya M.; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Palermo, Tonya M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dorsch, Andrea] Seattle Childrens Hosp, Dept Rehabil Psychol, Seattle, WA USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA		Tham, SW (corresponding author), Seattle Childrens Res Inst, M-S CW8-6,POB 5371, Seattle, WA 98145 USA.	see.tham@seattlechildrens.org	Durbin, Dennis/AAD-7829-2022		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM086270-03]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD060068] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER	Support for this project was provided by National Institutes of Health grant 5T32GM086270-03, and National Center for Injury Prevention and Control, Centers for Disease Control and Prevention grant R49 CE 001021.	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bartsch T, 2004, PAIN, V109, P367, DOI 10.1016/j.pain.2004.02.005; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cappuccio FP, 2008, SLEEP, V31, P619, DOI 10.1093/sleep/31.5.619; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chung KF, 2010, SLEEP MED, V11, P752, DOI 10.1016/j.sleep.2009.09.005; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Gregory AM, 2008, ARCH PEDIAT ADOL MED, V162, P330, DOI 10.1001/archpedi.162.4.330; Gregory AM, 2011, J AM ACAD CHILD PSY, V50, P499, DOI 10.1016/j.jaac.2011.02.003; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Huntley ED, 2007, J PEDIATR PSYCHOL, V32, P938, DOI 10.1093/jpepsy/jsm032; Hysing M, 2009, J PEDIATR PSYCHOL, V34, P665, DOI 10.1093/jpepsy/jsn095; Kashikar-Zuck S, 2010, RHEUMATOLOGY, V49, P2204, DOI 10.1093/rheumatology/keq254; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kelleher M., 1999, AMBULATORY CHILD HLT, V5, P225, DOI DOI 10.1016/J.JURO.2010.11.051; Kheirandish L, 2006, DEVELOPMENTAL SCI, V9, P388, DOI 10.1111/j.1467-7687.2006.00504.x; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Lewandowski A. S., 2011, PEDIAT CLIN N AM; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marr A. L., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; NCIPC, 2003, REP C MILD TRAUM BRA; Ohayon MM, 2005, J PSYCHIAT RES, V39, P151, DOI 10.1016/j.jpsychires.2004.07.001; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Richardson RD, 2005, ASSES EFF INTERV, V30, P51, DOI 10.1177/073724770503000407; Rivara F. P., 2011, PEDIATRICS; Rust JO., 2004, J PSYCHOEDUC ASSESS, V22, P367, DOI [10.1177/073428290402200407, DOI 10.1177/073428290402200407]; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sivertsen Borge, 2009, Child Adolesc Psychiatry Ment Health, V3, P22, DOI 10.1186/1753-2000-3-22; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Ward TM, 2010, SLEEP, V33, P252, DOI 10.1093/sleep/33.2.252; Wirrell E, 2005, DEV MED CHILD NEUROL, V47, P754, DOI 10.1017/S0012162205001581; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	55	62	62	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					154	161		10.1089/neu.2011.2126			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300018	22029569	Green Published			2022-02-06	
J	Yang, R; Fredman, G; Krishnamoorthy, S; Agrawal, N; Irimia, D; Piomelli, D; Serhan, CN				Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Agrawal, Nitin; Irimia, Daniel; Piomelli, Daniele; Serhan, Charles N.			Decoding Functional Metabolomics with Docosahexaenoyl Ethanolamide (DHEA) Identifies Novel Bioactive Signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID RECEPTOR; WHOLE-BLOOD; FATTY-ACIDS; ANANDAMIDE; ENDOCANNABINOIDS; PLATELETS; INJURY; BINDS; D1; INFLAMMATION	Neuroinflammation and traumatic brain injury involve activation of inflammatory cells and production of local pro-inflammatory mediators that can amplify tissue damage. Using LC-UV-MS-MS-based lipidomics in tandem with functional screening at the single-cell level in microfluidic chambers, we identified a series of novel bioactive oxygenated docosahexaenoyl ethanolamide( DHEA) derived products that regulated leukocyte motility. These included 10,17-dihydroxydocosahexaenoyl ethanolamide (10,17-diHDHEA) and 15-hydroxy-16(17)-epoxy-docosapentaenoyl ethanolamide (15-HEDPEA), each of which was an agonist of recombinant CB2 receptors with EC50 3.9 X 10(-10) and 1.0 X 10(-10)M. In human whole blood, 10,17-diHDHEA and 15-HEDPEA at concentrations as low as 10 pM each prevented formation of platelet-leukocyte aggregates involving either platelet-monocyte or platelet-polymorphonuclear leukocyte. In vivo, 15-HEDPEA was organ-protective in mouse reperfusion second organ injury. Together these results indicate that DHEA oxidative metabolism produces potent novel molecules with anti-inflammatory and organ-protective properties.	[Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Serhan, Charles N.] Brigham & Womens Hosp, Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Yang, Rong; Fredman, Gabrielle; Krishnamoorthy, Sriram; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Agrawal, Nitin; Irimia, Daniel] Shriners Hosp Children, Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02129 USA; [Agrawal, Nitin; Irimia, Daniel] Harvard Univ, Sch Med, Boston, MA 02129 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92617 USA; [Piomelli, Daniele] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92617 USA; [Piomelli, Daniele] Italian Inst Technol, I-16163 Genoa, Italy		Serhan, CN (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 829,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Yang, Rong/ABA-7587-2021; Irimia, Daniel/S-5404-2019; Irimia, Daniel/A-4095-2008	Irimia, Daniel/0000-0001-7347-2082; Irimia, Daniel/0000-0001-7347-2082; Yang, Rong/0000-0001-8837-0089	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS067686, RC2AT005909, R01DE019938]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [RC2AT005909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE019938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM092804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067686] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants R01NS067686 (to C. N. S.), RC2AT005909 (to C. N. S.), and R01DE019938 (to C. N. S. and D. I.).	Arnason BG, 2010, NEUROIMMUNE, V9, P1; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Berger A, 2001, P NATL ACAD SCI USA, V98, P6402, DOI 10.1073/pnas.101119098; Calder PC, 2010, P NUTR SOC, V69, P565, DOI 10.1017/S0029665110000157; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Dona M, 2008, BLOOD, V112, P848, DOI 10.1182/blood-2007-11-122598; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Franklin A, 2003, J NEUROSCI, V23, P7767; Furman MI, 2001, J AM COLL CARDIOL, V38, P1002, DOI 10.1016/S0735-1097(01)01485-1; Hassan IR, 2009, J IMMUNOL, V182, P3223, DOI 10.4049/jimmunol.0802064; Irimia D, 2006, LAB CHIP, V6, P191, DOI 10.1039/b511877h; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; KILGORE KS, 1999, REPERFUSION INJURY; Kim HY, 2011, BIOCHEM J, V435, P327, DOI 10.1042/BJ20102118; Kozak KR, 2002, PROSTAG LEUKOTR ESS, V66, P211, DOI 10.1054/plef.2001.0359; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Kumar V, 2004, ROBBINS COTRAN PATHO; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Nishiura H, 1996, J BIOL CHEM, V271, P878, DOI 10.1074/jbc.271.2.878; Olson KR, 2007, ASSAY DRUG DEV TECHN, V5, P137, DOI 10.1089/adt.2006.052; Pace-Asciak CR, 1999, ADV EXP MED BIOL, V447, P123; Pavlopoulos S, 2006, CURR PHARM DESIGN, V12, P1751, DOI 10.2174/138161206776873743; PREISSNER WC, 1983, BRIT J DERMATOL, V109, P1, DOI 10.1111/j.1365-2133.1983.tb03984.x; Qiu FH, 2000, P NATL ACAD SCI USA, V97, P4267, DOI 10.1073/pnas.97.8.4267; RINDER HM, 1991, BLOOD, V78, P1730; ROWLEY FA, 1998, EICOSANOIDS; Sarma J, 2002, CIRCULATION, V105, P2166, DOI 10.1161/01.CIR.0000015700.27754.6F; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541; Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; van Gils JM, 2009, J LEUKOCYTE BIOL, V85, P195, DOI 10.1189/jlb.0708400; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364; YANG R, 2011, CURR PR S94 IN PRESS; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	42	62	63	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2011	286	36					31532	31541		10.1074/jbc.M111.237990			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	814WI	WOS:000294487500048	21757729	Green Published, hybrid			2022-02-06	
J	Thiele, RH; Nemergut, EC; Lynch, C				Thiele, Robert H.; Nemergut, Edward C.; Lynch, Carl, III			The Clinical Implications of Isolated Alpha(1) Adrenergic Stimulation	ANESTHESIA AND ANALGESIA			English	Article							LEFT-VENTRICULAR FUNCTION; INHALED NITRIC-OXIDE; REGIONAL BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; SYSTEMIC VASCULAR-RESISTANCE; CEREBRAL PERFUSION-PRESSURE; INDUCED HYPERTENSION; SPINAL-ANESTHESIA; SEPTIC SHOCK; PHENYLEPHRINE INFUSIONS	Phenylephrine is a direct-acting, predominantly alpha(1) adrenergic receptor agonist used by anesthesiologists and intensivists to treat hypotension. A variety of physiologic studies suggest that alpha-agonists increase cardiac afterload, reduce venous compliance, and reduce renal bloodflow. The effects on gastrointestinal and cerebral perfusion are controversial. To better understand the effects of phenylephrine in a variety of clinical settings, we screened 463 articles on the basis of PubMed searches of "methoxamine," a long-acting alpha agonist, and "phenylephrine" (limited to human, randomized studies published in English), as well as citations found therein. Relevant articles, as well as those discovered in the peer-review process, were incorporated into this review. Phenylephrine has been studied as an antihypotensive drug in patients with severe aortic stenosis, as a treatment for decompensated tetralogy of Fallot and hypoxemia during 1-lung ventilation, as well as for the treatment of septic shock, traumatic brain injury, vasospasm status-postsubarachnoid hemorrhage, and hypotension during cesarean delivery. In specific instances (critical aortic stenosis, tetralogy of Fallot, hypotension during cesarean delivery) in which the regional effects of phenylephrine (e.g., decreased heart rate, favorable alterations in Q(p):Q(s) ratio, improved fetal oxygen supply: demand ratio) outweigh its global effects (e.g., decreased cardiac output), phenylephrine may be a rational pharmacologic choice. In pathophysiologic states in which no regional advantages are gained by using an alpha(1) agonist, alternative vasopressors should be sought. (Anesth Analg 2011;113:297-304)	[Thiele, Robert H.; Nemergut, Edward C.; Lynch, Carl, III] Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA		Thiele, RH (corresponding author), Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	rht7w@virginia.edu		Thiele, Robert/0000-0001-7262-0653			Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; Antonopoulos A, 2002, INT J CARDIOL, V84, P201, DOI 10.1016/S0167-5273(02)00146-8; APPLETON C, 1985, J PHARMACOL EXP THER, V233, P729; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; AWAN N, 1977, BRIT HEART J, V39, P651; BIGATELLO LM, 1994, ANESTHESIOLOGY, V80, P761, DOI 10.1097/00000542-199404000-00007; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brooker RF, 1997, ANESTHESIOLOGY, V86, P797, DOI 10.1097/00000542-199704000-00009; BUCKLAND MR, 1988, ANESTHESIOLOGY, V69, P116, DOI 10.1097/00000542-198807000-00021; Butterworth J, 2004, ANESTHESIOLOGY, V101, P1038, DOI 10.1097/00000542-200410000-00040; Charls LM, 2003, HEART LUNG, V32, P402, DOI 10.1016/j.hrtlng.2003.07.004; CHARLSON ME, 1989, ANN SURG, V210, P637, DOI 10.1097/00000658-198911000-00012; Cho S, 1996, ANESTHESIOLOGY, V85, P755, DOI 10.1097/00000542-199610000-00010; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; CRYSTAL GJ, 1991, ANESTH ANALG, V73, P283; CURIEL R, 1989, J CARDIOVASC PHARM, V14, P603, DOI 10.1097/00005344-198910000-00012; Dellinger R Phillip, 2008, Crit Care Med, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Doering EB, 1997, ANESTHESIOLOGY, V87, P18, DOI 10.1097/00000542-199707000-00004; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; EICHLER HG, 1989, J CLIN INVEST, V83, P108, DOI 10.1172/JCI113845; FLAMM SD, 1990, CIRCULATION, V81, P1550, DOI 10.1161/01.CIR.81.5.1550; Funk DJ, 2009, ANESTH ANALG, V108, P887, DOI 10.1213/ane.0b013e31818ffd99; Glantz SA, 2005, PRIMER BIOSTATISTICS; GOERTZ AW, 1993, ANESTH ANALG, V77, P227, DOI 10.1213/00000539-199377020-00004; GOERTZ AW, 1993, ANESTHESIOLOGY, V78, P834, DOI 10.1097/00000542-199305000-00005; GRANGSJO G, 1971, ACTA ANAESTH SCAND, V15, P71, DOI 10.1111/j.1399-6576.1971.tb00822.x; Greenberg M., 2005, HDB NEUROSURGERY, V6th; HAMID SK, 1992, ANAESTHESIA, V47, P490, DOI 10.1111/j.1365-2044.1992.tb02272.x; HARIK SI, 1981, J CEREBR BLOOD F MET, V1, P329, DOI 10.1038/jcbfm.1981.36; HEATH P, 1949, ARCH OPHTHALMOL-CHIC, V41, P172; HEYNDRICKX GR, 1976, AM J PHYSIOL, V231, P1579, DOI 10.1152/ajplegacy.1976.231.5.1579; HIRAKAWA S, 1984, JPN CIRC J, V48, P620, DOI 10.1253/jcj.48.620; HOFFBRAND BI, 1973, J PHARMACOL EXP THER, V184, P656; Holdcroft A, 2000, BRIT J ANAESTH, V85, P58, DOI 10.1093/bja/85.1.58; Joffe II, 1997, J AM SOC ECHOCARDIOG, V10, P717, DOI 10.1016/S0894-7317(97)70114-7; Kaplan J.A., 2008, ESSENTIALS CARDIAC A; Khaw KS, 2006, FETAL MATERNAL MED R, V17, P157; Kim DH, 2003, NEUROSURGERY, V53, P1044, DOI 10.1227/01.NEU.0000088567.59324.78; KITAGUCHI K, 1993, ANESTHESIOLOGY, V79, P704, DOI 10.1097/00000542-199310000-00011; KOBAYASHI H, 1985, CIRC RES, V56, P402, DOI 10.1161/01.RES.56.3.402; KOSNIK EJ, 1976, J NEUROSURG, V45, P148, DOI 10.3171/jns.1976.45.2.0148; LANDZBERG JS, 1991, CIRCULATION, V84, P1608, DOI 10.1161/01.CIR.84.4.1608; LANG RM, 1986, CIRCULATION, V74, P1114, DOI 10.1161/01.CIR.74.5.1114; Langesaeter E, 2008, ANESTHESIOLOGY, V109, P856, DOI 10.1097/ALN.0b013e31818a401f; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; LOEB HS, 1978, CIRCULATION, V57, P41, DOI 10.1161/01.CIR.57.1.41; MacDonald R Loch, 2006, Clin Neurosurg, V53, P257; MARINO RJ, 1975, ANESTHESIOLOGY, V43, P570, DOI 10.1097/00000542-197511000-00016; Mattox, 2007, SABISTON TXB SURG; Miller RD., 2010, MILLERS ANESTHESIA; MILLER RR, 1977, AM J CARDIOL, V40, P504, DOI 10.1016/0002-9149(77)90063-7; MIZUKI T, 1995, STROKE, V26, P2333, DOI 10.1161/01.STR.26.12.2333; Morelli A, 2008, SHOCK, V29, P446, DOI 10.1097/SHK.0b013e31815810ff; Morelli A, 2008, CRIT CARE, V12, DOI 10.1186/cc7121; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUIZELAAR JP, 1986, SURG NEUROL, V25, P317, DOI 10.1016/0090-3019(86)90205-3; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Myburgh J A, 2005, Crit Care Resusc, V7, P200; Ngan Kee WD, 2008, ANESTH ANALG, V107, P1295, DOI 10.1213/ane.0b013e31818065bc; NUDEL DB, 1976, PEDIATRICS, V58, P248; Nygren A, 2006, CRIT CARE MED, V34, P722, DOI 10.1097/01.CCM.0000201879.20281.C6; Oba Y, 2000, NEW ENGL J MED, V343, P813; ONEILL C, 1989, J NEURAL TRANSM-PARK, V1, P303, DOI 10.1007/BF02263484; Pang CCY, 2001, PHARMACOL THERAPEUT, V90, P179, DOI 10.1016/S0163-7258(01)00138-3; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; PROST JF, 1991, EUR RESPIR J, V4, P683; PUYBASSET L, 1994, INTENS CARE MED, V20, P319, DOI 10.1007/BF01720903; RALSTON DH, 1974, ANESTHESIOLOGY, V40, P354, DOI 10.1097/00000542-197404000-00009; Reich DL, 2002, ANESTH ANALG, V95, P273, DOI 10.1097/00000539-200208000-00003; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; ROSSAINT R, 1995, CHEST, V107, P1107, DOI 10.1378/chest.107.4.1107; Saager L, 2009, AM SOC AN ANN M 2009; SHARROCK NE, 1992, THROMB HAEMOSTASIS, V68, P436; Shinomiya Kayo, 2003, Journal of Medical Investigation, V50, P203; Smrcka M, 1998, NEUROSURGERY, V42, P617, DOI 10.1097/00006123-199803000-00032; SNELL RE, 1965, AM HEART J, V69, P529, DOI 10.1016/0002-8703(65)90424-2; Stevens RD, 2009, INTENS CARE MED, V35, P1556, DOI 10.1007/s00134-009-1533-1; Thiele RH, 2011, ANESTH ANALG, V113, P284, DOI 10.1213/ANE.0b013e3182124c0e; Treggiari MM, 2009, CURR OPIN CRIT CARE, V15, P83, DOI 10.1097/MCC.0b013e32832922d1; TUMAN KJ, 1995, J CARDIOTHOR VASC AN, V9, P2, DOI 10.1016/S1053-0770(05)80048-5; Varpula M, 2005, INTENS CARE MED, V31, P1066, DOI 10.1007/s00134-005-2688-z; WOODMAN OL, 1987, AM J PHYSIOL, V253, pH388, DOI 10.1152/ajpheart.1987.253.2.H388; YANG HT, 1994, J PHARMACOL EXP THER, V269, P732; ZIMMERMAN BG, 1963, J PHARMACOL EXP THER, V139, P290	89	62	65	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2011	113	2					297	304		10.1213/ANE.0b013e3182120ca5			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	796PQ	WOS:000293064500016	21519053				2022-02-06	
J	Erlandsson, A; Lin, CHA; Yu, FG; Morshead, CM				Erlandsson, Anna; Lin, Chia-Hsun Anthony; Yu, Fenggang; Morshead, Cindi M.			Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury	EXPERIMENTAL NEUROLOGY			English	Article						Neural stem cells; Immunosuppression; Stroke; Neurogenesis; Migration; Neurosphere; NOD/SCID; Cyclosporine; Functional recovery; Regeneration	TRAUMATIC BRAIN-INJURY; ADULT MAMMALIAN FOREBRAIN; SUBVENTRICULAR ZONE; CYCLOSPORINE-A; GROWTH-FACTOR; INDUCED NEUROGENESIS; DIRECTED MIGRATION; MOUSE BRAIN; CNS INJURY; STROKE	Recent work has demonstrated that self-repair in the adult brain can be augmented by the infusion of growth factors to activate endogenous neural precursor cells that contribute to new tissue formation and functional recovery in a model of stroke. Using both a genetic model and drug treatment, we demonstrate that immunosuppression mimics the effects of growth factor activation, including tissue regeneration, neural precursor cell migration and functional recovery following ischemic injury. In the absence of growth factor treatment, mice with a functional immune system develop a prominent cavity in the cortex underlying the ischemic injury. In untreated immunodeficient NOD/SCID mice, however, the cortical cavity forms but is then filled with regenerated cortical tissue containing glial cells and subependyma derived neural stem and progenitor cells that migrate from their niche lining the lateral ventricles. The daily administration of Cyclosporine A also results in endogenous neural precursor cell migration and regenerated cortical tissue at the site of the cortical injury. Different from growth factor-treated animals is the finding that the regenerated cortical tissue in immunosuppressed animals is devoid of new neurons. Interestingly, both the growth factor and immunosuppressed (NOD/SCID and Cyclosporine A) treated animals displayed functional behavioural recovery despite the lack of neurogenesis within the regenerated cortical tissue. This article is part of a Special Issue entitled "Interaction between repair, disease, & inflammation." (C) 2010 Elsevier Inc. All rights reserved.	[Erlandsson, Anna; Morshead, Cindi M.] Univ Toronto, Dept Surg, Div Anat, Donnelly Ctr, Toronto, ON M5S 3E1, Canada; [Lin, Chia-Hsun Anthony; Yu, Fenggang] Uppsala Univ, Dept Neurosci, Uppsala, Sweden		Morshead, CM (corresponding author), Univ Toronto, Dept Surg, Div Anat, Donnelly Ctr, 160 Coll St,1006, Toronto, ON M5S 3E1, Canada.	cindi.morshead@utoronto.ca			Stem Cell Network; Canadian Stroke Network; Heart and Stroke FoundationHeart & Stroke Foundation of Canada	The authors thank Amy Hoyles, Angela Kam and Vince Cheng for their technical expertise and contributions to the manuscript. AE is supported by the Stem Cell Network, CMM is supported by the Stem Cell Network, Canadian Stroke Network and the Heart and Stroke Foundation.	Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Craig CG, 1996, J NEUROSCI, V16, P2649; Cui X, 2009, J NEUROSCI RES, V87, P86, DOI 10.1002/jnr.21836; Ekdahl C.T., 2008, NEUROSCIENCE; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Guo JS, 2007, NEUROREPORT, V18, P863, DOI 10.1097/WNR.0b013e32811d6d36; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hunt J, 2010, J NEUROSCI, V30, P2888, DOI 10.1523/JNEUROSCI.5991-09.2010; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2008, J CEREBR BLOOD F MET, V28, P1574, DOI 10.1038/jcbfm.2008.47; Jakubs K, 2008, J NEUROSCI, V28, P12477, DOI 10.1523/JNEUROSCI.3240-08.2008; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; KERSCHENSTEINER M, 2008, NEUROSCIENCE; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lorke DE, 2008, HISTOCHEM CELL BIOL, V130, P693, DOI 10.1007/s00418-008-0463-2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maysami S, 2008, J CEREBR BLOOD F MET, V28, P1104, DOI 10.1038/jcbfm.2008.4; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mitchell BS, 1997, BRIT J BIOMED SCI, V54, P278; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morshead CM, 1998, DEVELOPMENT, V125, P2251; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Nonoyama S, 1996, Int Rev Immunol, V13, P289, DOI 10.3109/08830189609061753; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	45	62	64	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	2011	230	1			SI		48	57		10.1016/j.expneurol.2010.05.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	781BT	WOS:000291906300006	20685361				2022-02-06	
J	Li, YG; Lein, PJ; Liu, CM; Bruun, DA; Tewolde, T; Ford, G; Ford, BD				Li, Yonggang; Lein, Pamela J.; Liu, Cuimei; Bruun, Donald A.; Tewolde, Teclemichael; Ford, Gregory; Ford, Byron D.			Spatiotemporal pattern of neuronal injury induced by DFP in rats: A model for delayed neuronal cell death following acute OP intoxication	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Acute intoxication; Delayed neurotoxicity; DFP; Neuronal injury; Organophosphate; Rat model	CENTRAL-NERVOUS-SYSTEM; CHRONIC NEUROLOGICAL SEQUELAE; TRAUMATIC BRAIN INJURY; FLUORO-JADE-B; BEHAVIORAL DEFICITS; INDUCED SEIZURES; FOCAL ISCHEMIA; SOMAN; DEGENERATION; ORGANOPHOSPHATE	Organophosphate (OP) neurotoxins cause acute cholinergic toxicity and seizures resulting in delayed brain damage and persistent neurological symptoms. Testing novel strategies for protecting against delayed effects of acute OP intoxication has been hampered by the lack of appropriate animal models. In this study, we characterize the spatiotemporal pattern of cellular injury after acute intoxication with the OP diisopropylfluorophosphate (DFP). Adult male Sprague-Dawley rats received pyridostigmine (0.1 mg/kg, im) and atropine methylnitrate (20 mg/kg, im) prior to DFP (9 mg/kg, ip) administration. All DFP-treated animals exhibited moderate to severe seizures within minutes after DFP injection but survived up to 72 h. AChE activity was significantly depressed in the cortex, hippocampus, subcortical brain tissue and cerebellum at 1 h post-DFP injection and this inhibition persisted for up to 72 h. Analysis of neuronal injury by Fluoro-Jade B (FJB) labeling revealed delayed neuronal cell death in the hippocampus, cortex, amygdala and thalamus, but not the cerebellum, starting at 4 h and persisting until 72 h after DFP treatment, although temporal profiles varied between brain regions. At 24 h post-DFP injection, the pattern of FJB labeling corresponded to TUNEL staining in most brain regions, and FJB-positive cells displayed reduced NeuN immunoreactivity but were not immunopositive for astrocytic (GFAP), oligodendroglial (O4) or macrophage/microglial (ED1) markers, demonstrating that DFP causes a region-specific delayed neuronal injury mediated in part by apoptosis. These findings indicate the feasibility of this model for testing neuroprotective strategies, and provide insight regarding therapeutic windows for effective pharmacological intervention following acute OP intoxication. (C) 2011 Elsevier Inc. All rights reserved.	[Li, Yonggang; Liu, Cuimei; Tewolde, Teclemichael; Ford, Gregory; Ford, Byron D.] Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, Atlanta, GA 30310 USA; [Lein, Pamela J.; Bruun, Donald A.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; [Ford, Gregory] Morehouse Coll, Dept Biol, Atlanta, GA 30310 USA		Ford, BD (corresponding author), Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, 720 Westview Dr SW, Atlanta, GA 30310 USA.	bford@msm.edu		Lein, Pamela/0000-0001-7665-7584	National Institutes of Health Office of the DirectorUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS 057993]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12-RR03034]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS057993] Funding Source: NIH RePORTER	The research is supported by the CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Neurological Diseases and Stroke Grant Number U01 NS 057993 and Grants Number G12-RR03034 and G12-RR03034 from the National Center for Research Resources (NCRR) (BDF). The sponsor was involved in the study design but not in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Auta J, 2004, NEUROPHARMACOLOGY, V46, P397, DOI 10.1016/j.neuropharm.2003.09.010; Baille V, 2005, TOXICOLOGY, V215, P1, DOI 10.1016/j.tox.2005.05.028; Baille V, 2001, PHARMACOL BIOCHEM BE, V69, P561, DOI 10.1016/S0091-3057(01)00549-4; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; Collombet JM, 2007, NEUROTOXICOLOGY, V28, P38, DOI 10.1016/j.neuro.2006.07.011; Collombet JM, 2006, NEUROSCI LETT, V398, P337, DOI 10.1016/j.neulet.2006.01.029; Collombet JM, 2006, NEUROTOXICOLOGY, V27, P201, DOI 10.1016/j.neuro.2005.10.002; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Deshpande LS, 2010, TOXICOL SCI, V116, P623, DOI 10.1093/toxsci/kfq157; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gunnell D, 2003, INT J EPIDEMIOL, V32, P902, DOI 10.1093/ije/dyg307; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hoffman A, 2007, MIL MED, V172, P607, DOI 10.7205/MILMED.172.6.607; Jett DA, 2007, ANN NEUROL, V61, P9, DOI 10.1002/ana.21072; Kadriu B, 2009, TOXICOLOGY, V256, P164, DOI 10.1016/j.tox.2008.11.021; Kim YB, 1999, ENVIRON TOXICOL PHAR, V7, P147, DOI 10.1016/S1382-6689(99)00006-X; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; Kwong TC, 2002, THER DRUG MONIT, V24, P144, DOI 10.1097/00007691-200202000-00022; Leikin JB, 2002, CRIT CARE MED, V30, P2346, DOI 10.1097/00003246-200210000-00026; LEMERCIER G, 1983, ACTA NEUROPATHOL, V61, P123, DOI 10.1007/BF00697391; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MAZZONE A, 1995, HAEMATOLOGICA, V80, P161; MCDONOUGH JH, 1987, BRAIN RES, V435, P123, DOI 10.1016/0006-8993(87)91593-9; MCDONOUGH JH, 1995, NEUROTOXICOLOGY, V16, P123; McDonough JH, 1997, NEUROSCI BIOBEHAV R, V21, P559, DOI 10.1016/S0149-7634(96)00050-4; MCLEOD CG, 1985, FUND APPL TOXICOL, V5, pS10, DOI 10.1016/0272-0590(85)90110-1; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PETRAS JM, 1994, J EXP ANAL BEHAV, V61, P319, DOI 10.1901/jeab.1994.61-319; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; Schmued LC, 2003, BRAIN RES, V974, P127, DOI 10.1016/S0006-8993(03)02563-0; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCHREIBER SS, 1995, TRENDS NEUROSCI, V18, P446, DOI 10.1016/0166-2236(95)94495-Q; SHIH TM, 1991, NEUROSCI BIOBEHAV R, V15, P349; Shih TM, 2003, TOXICOL APPL PHARM, V188, P69, DOI 10.1016/S0041-008X(03)00019-X; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P731, DOI 10.2105/AJPH.84.5.731; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; WATSON N, 1992, BRIT J PHARMACOL, V105, P107, DOI 10.1111/j.1476-5381.1992.tb14219.x; Wesseling C, 2002, INT J OCCUP ENV HEAL, V8, P27, DOI 10.1179/oeh.2002.8.1.27; Wright LKM, 2010, NEUROTOXICOL TERATOL, V32, P329, DOI 10.1016/j.ntt.2009.12.006; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149	54	62	62	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	JUN 15	2011	253	3					261	269		10.1016/j.taap.2011.03.026			9	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	774FZ	WOS:000291372000010	21513723	Green Accepted			2022-02-06	
J	Zhao, QJ; Zhang, XG; Wang, LX				Zhao, Qing-Jv; Zhang, Xue-Guang; Wang, Le-Xin			Mild hypothermia therapy reduces blood glucose and lactate and improves neurologic outcomes in patients with severe traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Mild hypothermia; Traumatic brain injury; Lactate; Glucose; Neurologic outcome	MODERATE HYPOTHERMIA; HEAD-INJURY; PHASE-II; CHILDREN; PREDICTORS; MANAGEMENT; MORTALITY	Purpose: The study aimed to investigate the association between blood glucose or lactate and the outcomes of severe traumatic brain injury (TBI), and to evaluate the effect of mild hypothermia therapy on glucose and lactate levels. Methods: Eighty-one patients with TBI were randomly divided into normothermia (n = 41) and mild hypothermia (n = 40) group. Body temperature of hypothermia group was maintained at 32.7 degrees C for 72 hours. Arterial blood glucose and lactic acid were determined before and after hypothermia therapy. Glasgow Outcome Scale (GOS) score was assessed 3 months after the treatment. Results: The mean glucose (7.04 +/- 0.51 vs 9.71 +/- 1.63 mmol/L, P < .05) in the hypothermia group was lower than in the normothermia group after hypothermia therapy. There were more patients with good neurologic function (GOS 4-5) in the hypothermia group than in the normothermia group (75.0% vs 51.2%, P = .038). Multivariate regression analysis showed that blood glucose greater than 10 mmol/L (adjusted risk ratio, 5.7; 95% confidence interval, 1.4-13.2; P < .05) was an independent predictor for poor neurologic outcomes in these patients, and hypothermia therapy was an independent predictor for favorable outcomes (risk ratio, 4.9; 95% confidence interval, 1.0-15.6; P < .05). No significant association between lactate and GOS scores was identified in the multivariate analysis. Conclusion: Hyperglycemia after TBI was associated with poor clinical outcomes, but the predictive value of blood lactate level requires further investigation. Hypothermia therapy improves neurologic outcomes in patients with severe TBI, and reduction in blood glucose may be partially responsible for the improved outcomes. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.	[Wang, Le-Xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia; [Zhao, Qing-Jv; Zhang, Xue-Guang] Taishan Med Univ, Liaocheng Peoples Hosp, Dept Neurosurg, Tai An, Shandong, Peoples R China; [Zhao, Qing-Jv; Zhang, Xue-Guang] Taishan Med Univ, Liaocheng Clin Sch, Tai An, Shandong, Peoples R China		Wang, LX (corresponding author), Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia.	lwang@csu.edu.au					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Duke TD, 1997, INTENS CARE MED, V23, P684, DOI 10.1007/s001340050394; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Hatherill M, 2000, INTENS CARE MED, V26, P314, DOI 10.1007/s001340051155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jansen TC, 2009, CRIT CARE MED, V37, P2827, DOI 10.1097/CCM.0b013e3181a98899; Jansen TC, 2009, J TRAUMA, V66, P377, DOI 10.1097/TA.0b013e3181648e2f; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARGULIES DR, 1994, AM SURGEON, V60, P387; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Pittard AJ, 1999, ANN CLIN BIOCHEM, V36, P401, DOI 10.1177/000456329903600402; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50	21	62	68	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441			J CRIT CARE	J. Crit. Care	JUN	2011	26	3					311	315		10.1016/j.jcrc.2010.08.014			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MH	WOS:000291390200014	20889287				2022-02-06	
J	de Sousa, A; McDonald, S; Rushby, J; Li, S; Dimoska, A; James, C				de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte			Understanding deficits in empathy after traumatic brain injury: The role of affective responsivity	CORTEX			English	Article						Emotional empathy; Emotional responsivity; Traumatic brain injury; Facial mimicry; Skin conductance	SKIN-CONDUCTANCE RESPONSES; ANXIETY STRESS SCALES; FACIAL REACTIONS; EMOTIONAL EMPATHY; MIMICRY REACTIONS; MIRROR-NEURON; EXPRESSION; DEPRESSION; FACES; FEAR	People with traumatic brain injury (TBI) often find social situations challenging because they can no longer respond to the emotional state of the people they are with. Many also lack emotional empathy in their social interactions. But are these problems related? The present study addressed this question by examining psychophysiological indices of emotional responding, including facial electromyography (EMG) and skin conductance during exposure to happy and angry facial expressions, in addition to self-rated emotional empathy in 21 adults with severe TBI and 22 control participants. In comparison to control participants, those in the TBI group displayed a reduction in the ability to empathize emotionally, and showed reduced physiological responding to the emotional expression of anger. By contrast, the control group spontaneously mimicked the emotional expressions they were exposed to, regardless of affective valence, and also demonstrated higher skin conductance responsivity to angry faces. The data further suggested that a loss of emotional empathy plays a role in the emotional response deficits to angry facial expressions following TBI. The results have implications for understanding the impaired social functioning and poor quality of interpersonal relationships commonly seen as a consequence of TBI. (C) 2010 Elsevier Srl. All rights reserved.	[de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		de Sousa, A (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	adesousa@psy.unsw.edu.au	McDonald, Skye/G-4118-2014; Rushby, Jacqueline/D-1820-2010	McDonald, Skye/0000-0003-0723-6094; Rushby, Jacqueline/0000-0002-5018-638X; Li, Sophie/0000-0002-4762-6911			Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BAVELAS JB, 1986, J NONVERBAL BEHAV, V10, P102, DOI 10.1007/BF01000007; BAVELAS JB, 1988, HUM COMMUN RES, V14, P275, DOI 10.1111/j.1468-2958.1988.tb00158.x; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; de Wied M, 2006, J PSYCHIAT RES, V40, P112, DOI 10.1016/j.jpsychires.2005.08.003; Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221; Dimberg U, 1998, SCAND J PSYCHOL, V39, P39, DOI 10.1111/1467-9450.00054; DIMBERG U, 1990, BIOL PSYCHOL, V30, P151, DOI 10.1016/0301-0511(90)90024-Q; DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x; DIMBERG U, 1990, PSYCHOPHYSIOLOGY, V27, P481, DOI 10.1111/j.1469-8986.1990.tb01962.x; Dimberg U, 1996, PSYCHOPHYSIOLOGY, V33, pS34; Dimberg U, 2002, COGNITION EMOTION, V16, P449, DOI 10.1080/02699930143000356; Dimberg U., 1988, J PSYCHOPHYSIOL, V2, P277; Ekman P., 1976, PICTURES FACIAL AFFE; Elliot A., 1994, EMOTION CONTAGION; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ESTEVES F, 1994, PSYCHOPHYSIOLOGY, V31, P375, DOI 10.1111/j.1469-8986.1994.tb02446.x; ESTEVES F, 1994, COGNITION EMOTION, V8, P393, DOI 10.1080/02699939408408949; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoffman, 1984, EMOTIONS COGNITION B; Hoffman M.L., 2000, EMPATHY MORAL DEV IM, P63; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Kaplan JT, 2006, SOC NEUROSCI-UK, V1, P175, DOI 10.1080/17470910600985605; Long C. J., 1992, HDB HEAD TRAUMA ACUT; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Marks I.M., 1987, FEARS PHOBIAS RITUAL; Martin I, 1980, TECHNIQUES PSYCHOPHY, P4; McDonald S, 1999, J HEAD TRAUMA REHAB, V16, P612; McDonald S, 2011, J CLIN EXP NEUROPSYC, V33, P17, DOI 10.1080/13803391003761967; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; MEHRABIAN A, 1988, CURR PSYCHOL RES REV, V7, P221, DOI 10.1007/BF02686670; Mehrabian A., 2000, MANUAL BALANCED EMOT; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; Oddy M, 2003, HDB NEUROLOGICAL REH, P453; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Sanchez-Navarro JP, 2005, BEHAV NEUROSCI, V119, P87, DOI 10.1037/0735-7044.119.1.87; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Shamay-Tsoory SG, 2007, BRAIN, V130, P1663, DOI 10.1093/brain/awm093; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Sonnby-Borgstrom M, 2003, J NONVERBAL BEHAV, V27, P3, DOI 10.1023/A:1023608506243; Sweeny TD, 2009, J VISION, V9, DOI 10.1167/9.3.2; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tyler CW, 2006, J VISION, V6, P1117, DOI 10.1167/6.10.11; Westbury HR, 2008, BIOL PSYCHOL, V78, P66, DOI 10.1016/j.biopsycho.2007.12.009; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326	59	62	63	0	22	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	MAY	2011	47	5					526	535		10.1016/j.cortex.2010.02.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	754BW	WOS:000289827700004	20334857				2022-02-06	
J	Castellanos, NP; Leyva, I; Buldu, JM; Bajo, R; Paul, N; Cuesta, P; Ordonez, VE; Pascua, CL; Boccaletti, S; Maestu, F; del-Pozo, F				Castellanos, Nazareth P.; Leyva, Inmaculada; Buldu, Javier M.; Bajo, Ricardo; Paul, Nuria; Cuesta, Pablo; Ordonez, Victoria E.; Pascua, Cristina L.; Boccaletti, Stefano; Maestu, Fernando; del-Pozo, Francisco			Principles of recovery from traumatic brain injury: Reorganization of functional networks	NEUROIMAGE			English	Article						Magnetoencephalography (MEG); Functional connectivity; Graph theory; Traumatic brain injury (TBI); Plasticity	GRAPH-THEORETICAL ANALYSIS; COGNITIVE REHABILITATION; QUANTITATIVE-ANALYSIS; NEURONAL SYNCHRONY; TUMOR PATIENTS; CONNECTIVITY; OPTIMIZATION; DYNAMICS; COMMUNICATION; COMPLEXITY	Recovery after brain injury is an excellent platform to study the mechanism underlying brain plasticity, the reorganization of networks. Do complex network measures capture the physiological and cognitive alterations that occurred after a traumatic brain injury and its recovery? Patients as well as control subjects underwent resting-state MEG recording following injury and after neurorehabilitation. Next, network measures such as network strength, path length, efficiency, clustering and energetic cost were calculated. We show that these parameters restore, in many cases, to control ones after recovery, specifically in delta and alpha bands, and we design a model that gives some hints about how the functional networks modify their weights in the recovery process. Positive correlations between complex network measures and some of the general index of the WAIS-III test were found: changes in delta-based path-length and those in Performance IQ score, and alpha-based normalized global efficiency and Perceptual Organization Index. These results indicate that: 1) the principle of recovery depends on the spectral band, 2) the structure of the functional networks evolves in parallel to brain recovery with correlations with neuropsychological scales, and 3) energetic cost reveals an optimal principle of recovery. (C) 2010 Elsevier Inc. All rights reserved.	[Castellanos, Nazareth P.; Bajo, Ricardo; Cuesta, Pablo; Ordonez, Victoria E.; Maestu, Fernando; del-Pozo, Francisco] Tech Univ Madrid, Ctr Biomed Technol, Cognit & Computat Neurosci Lab, Madrid, Spain; [Leyva, Inmaculada; Buldu, Javier M.] Univ Rey Juan Carlos, Complex Syst Grp, Fuenlabrada, Spain; [Leyva, Inmaculada; Buldu, Javier M.] Tech Univ Madrid, Ctr Biomed Technol, Lab Biol Networks, Madrid, Spain; [Paul, Nuria] Univ Complutense Madrid, Sch Med, Dept Psychiat & Med Psychol, E-28040 Madrid, Spain; [Pascua, Cristina L.] Ctr Brain Injury Treatment LESCER, Madrid, Spain; [Boccaletti, Stefano] CNR, Inst Complex Syst, Florence, Italy		Castellanos, NP (corresponding author), Univ Politecn Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Campus Montegancedo, E-28660 Madrid, Spain.	nazareth@pluri.ucm.es	Boccaletti, Stefano/U-7603-2019; Buldu, Javier Martin/R-8167-2018; Buldu, Javier/N-5422-2014; maestu, fernando/M-7480-2019; Cuesta, Pablo/ABA-2284-2021; Leyva, I./M-1820-2013; Castellanos, Nazareth/AAA-8812-2020; Maestu, Fernando/E-3213-2012; Bajo, Ricardo/AAA-5541-2019; POZO GUERRERO, FRANCISCO DEL/H-6668-2015	Boccaletti, Stefano/0000-0002-5758-7012; Buldu, Javier/0000-0002-9345-599X; maestu, fernando/0000-0002-3195-0071; Cuesta, Pablo/0000-0002-8459-3354; Leyva, I./0000-0001-9634-5385; Maestu, Fernando/0000-0002-3195-0071; Bajo, Ricardo/0000-0003-0646-2962; Paul, Nuria/0000-0001-5462-6138; POZO GUERRERO, FRANCISCO DEL/0000-0001-9919-9125; Castellanos, Nazareth/0000-0002-3508-7316	MADRI.B; Obra Social CajaMadrid; MAPFRE; IMSERSO; Spanish Ministry of Science and TechnologySpanish Government [FIS2009-07072]; Community of MadridComunidad de Madrid [MODELICO-CM/S2009ESP-1691]	This work was supported by MADRI.B (CAMi+d+I project), Obra Social CajaMadrid, MAPFRE 2008 and IMSERSO (07-2008), the Spanish Ministry of Science and Technology (FIS2009-07072), and by the Community of Madrid under the R&D Program of activities MODELICO-CM/S2009ESP-1691. We are grateful to S. Aurtenetxe, O. Demuynck, J. Garcia-Pacios, and D. del Rio for their generous help. We would like to thank Dr. Juan Manuel Munoz Cespedes, who led this study. His ideas and personality will always be with us.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Alstott J, 2009, PLOS COMPUT BIOL, P5; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Beason-Held LL, 2009, BRAIN IMAGING BEHAV, V3, P123, DOI 10.1007/s11682-008-9054-z; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Braitenberg V., 1998, CORTEX STAT GEOMETRY; Bressler SL, 2002, CURR DIR PSYCHOL SCI, V11, P58, DOI 10.1111/1467-8721.00168; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Butz M, 2009, FRONT COMPUT NEUROSC, V3, DOI 10.3389/neuro.10.010.2009; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; Buzsaki Gyorgy, 2006, RHYTHMS BRAIN; Campo P, 2010, NEUROIMAGE, V49, P2807, DOI 10.1016/j.neuroimage.2009.10.024; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Cherniak C, 2004, P NATL ACAD SCI USA, V101, P1081, DOI 10.1073/pnas.0305212101; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Dall'Asta L, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/P04006; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Deuker L, 2009, NEUROIMAGE, V47, P1460, DOI 10.1016/j.neuroimage.2009.05.035; Dijkstra E. W, 1959, NUMER MATH, V1, P269, DOI [DOI 10.1007/BF01386390, 10.1007/BF01386390]; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fries P, 2009, NEURON, V64, P601, DOI 10.1016/j.neuron.2009.11.024; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GASSER T, 1982, ELECTROEN CLIN NEURO, V53, P119, DOI 10.1016/0013-4694(82)90112-2; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gong YC, 2009, ANN NY ACAD SCI, V1158, P82, DOI 10.1111/j.1749-6632.2008.03752.x; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guimera R, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/02/P02001; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Hellwig B, 2000, BIOL CYBERN, V82, P111, DOI 10.1007/PL00007964; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Klyachko VA, 2003, P NATL ACAD SCI USA, V100, P7937, DOI 10.1073/pnas.0932745100; Korzeniewska A, 2003, J NEUROSCI METH, V125, P195, DOI 10.1016/S0165-0270(03)00052-9; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li YH, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000395; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; NAKAMURA T, 2009, PLOS ONE, V14, P4; Palva JM, 2010, P NATL ACAD SCI USA, V107, P7580, DOI 10.1073/pnas.0913113107; Palva S, 2010, NEUROIMAGE, V49, P3257, DOI 10.1016/j.neuroimage.2009.11.031; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PIVIK RT, 1993, PSYCHOPHYSIOLOGY, V30, P547, DOI 10.1111/j.1469-8986.1993.tb02081.x; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schnitzler A, 2005, NAT REV NEUROSCI, V6, P285, DOI 10.1038/nrn1650; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Singer W, 2009, COGN NEURODYNAMICS, V3, P189, DOI 10.1007/s11571-009-9087-z; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; van den Heuvel MP, 2009, J NEUROSCI, V29, P7619, DOI 10.1523/JNEUROSCI.1443-09.2009; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	71	62	66	1	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2011	55	3					1189	1199		10.1016/j.neuroimage.2010.12.046			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	734DQ	WOS:000288313800032	21195199				2022-02-06	
J	Han, XG; Yang, N; Xu, YS; Zhu, JL; Chen, ZQ; Liu, ZJ; Dang, GT; Song, CL				Han, Xiaoguang; Yang, Ning; Xu, Yingsheng; Zhu, Jinglin; Chen, Zhongqiang; Liu, Zhongjun; Dang, Gengting; Song, Chunli			Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF	NEUROSCIENCE LETTERS			English	Article						Spinal cord injury; Simvastatin; Electrophysiology; Neurotrophin	TRAUMATIC BRAIN-INJURY; NEUROGENESIS; ATORVASTATIN; INCREASE; CELLS; RATS; TRANSPLANTATION; OVEREXPRESSION; ACTIVATION; SURVIVAL	The aim of this study was to determine the therapeutic efficacy of simvastatin treatment starting 1 day after spinal cord injury (SCI) in rat and to investigate the underlying mechanism. Spinal cord injury was induced in adult female Sprague-Dawley rats after laminectomy at T9-T10. Then additionally with sham group (laminectomy only) the SCI animals were randomly divided into 3 groups: vehicle-treated group; 5-mg/kg simvastatin-treated group; and 10-mg/kg simvastatin-treated group. Simvastatin or vehicle was administered orally at 1 day after SCI and then daily for 5 weeks. Locomotor functional recovery was assessed during 8 weeks postoperation by performing open-field locomotor test and inclined-plane test. At the end of study, motor evoked potentials (MEPs) and somatosensory evoked potentials (SEPs) were assessed to evaluate the integrity of spinal cord pathways. Then, the animals were killed, and 1-cm segments of spinal cord encompassing the injury site were removed for histopathological analysis. Immunohistochemistry was performed to observe the expression of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF) in the spinal cord. Results show that the simvastatin-treated animals showed significantly better locomotor function recovery, better electrophysiological outcome, less myelin loss, and higher expression of BDNF and GDNF. These findings suggest that simvastatin treatment starting 1 day after SCI can significantly improve locomotor recovery, and this neuro protective effect may be related to the upregulation of BDNF and GDNF. Therefore, simvastatin may be useful as a promising therapeutic agent for SCI. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Xu, Yingsheng] Peking Univ, Hosp 3, Dept Neurol, Beijing 100191, Peoples R China; [Han, Xiaoguang; Yang, Ning; Zhu, Jinglin; Chen, Zhongqiang; Liu, Zhongjun; Dang, Gengting; Song, Chunli] Peking Univ, Hosp 3, Dept Orthoped, Beijing 100191, Peoples R China		Xu, YS (corresponding author), Peking Univ, Hosp 3, Dept Neurol, Beijing 100191, Peoples R China.	xys@bjmu.edu.cn; schl@bjmu.edu.cn		Han, Xiaoguang/0000-0001-7477-3274	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30300352, 30772200]	This work was supported by the National Nature Science Foundation of China (30300352, 30772200).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Dery MA, 2009, NEUROSCI LETT, V453, P73, DOI 10.1016/j.neulet.2009.01.062; Garcia-Alias G, 2004, J NEUROSCI RES, V75, P632, DOI 10.1002/jnr.20029; Kao CH, 2008, RESUSCITATION, V77, P395, DOI 10.1016/j.resuscitation.2008.01.023; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Lee SI, 2009, J NEUROSCI RES, V87, P3186, DOI 10.1002/jnr.22149; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Mann CM, 2010, EXP NEUROL, V221, P285, DOI 10.1016/j.expneurol.2009.11.006; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Tolwani RJ, 2004, J NEUROSCI RES, V77, P662, DOI 10.1002/jnr.20181; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Zhang LQ, 2009, GLIA, V57, P1178, DOI 10.1002/glia.20840	21	62	71	4	26	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 10	2011	487	3					255	259		10.1016/j.neulet.2010.09.007			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	712WQ	WOS:000286697400001	20851742				2022-02-06	
J	Nishibe, M; Barbay, S; Guggenmos, D; Nudo, RJ				Nishibe, Mariko; Barbay, Scott; Guggenmos, David; Nudo, Randolph J.			Reorganization of Motor Cortex after Controlled Cortical Impact in Rats and Implications for Functional Recovery	JOURNAL OF NEUROTRAUMA			English	Article						behavioral recovery; cortical plasticity; intracortical microstimulation; motor impairment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ADULT SQUIRREL-MONKEYS; SENSORIMOTOR CORTEX; ISCHEMIC LESIONS; MOVEMENT REPRESENTATIONS; FORELIMB REPRESENTATION; STRUCTURAL PLASTICITY; STROKE; AREAS; PREMOTOR	We report the results of controlled cortical impact (CCI) centered on the caudal forelimb area (CFA) of rat motor cortex to determine the feasibility of examining cortical plasticity in a spared cortical motor area (rostral forelimb area, RFA). We compared the effects of three CCI parameter sets (groups CCI-1, CCI-2, and CCI-3) that differed in impactor surface shape, size, and location, on behavioral recovery and RFA structural and functional integrity. Forelimb deficits in the limb contralateral to the injury were evident in all three CCI groups assessed by skilled reach and footfault tasks that persisted throughout the 35-day post-CCI assessment period. Nissl-stained coronal sections revealed that the RFA was structurally intact. Intracortical microstimulation experiments conducted at 7 weeks post-CCI demonstrated that RFA was functionally viable. However, the size of the forelimb representation decreased significantly in CCI-1 compared to the control group. Subdivided into component movement categories, there was a significant group effect for proximal forelimb movements. The RFA area reduction and reorganization are discussed in relation to possible diaschisis, and to compensatory functional behavior, respectively. Also, an inverse correlation between the anterior extent of the lesion and the size of the RFA was identified and is discussed in relation to corticocortical connectivity. The results suggest that CCI can be applied to rat CFA while sparing RFA. This CCI model can contribute to our understanding of neural plasticity in premotor cortex as a substrate for functional motor recovery.	[Nishibe, Mariko; Barbay, Scott; Guggenmos, David; Nudo, Randolph J.] Univ Kansas, Med Ctr, Landon Ctr Aging, Kansas City, KS 66103 USA; [Barbay, Scott; Guggenmos, David; Nudo, Randolph J.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA; [Nishibe, Mariko] Univ Kansas, Med Ctr, Dept Phys Therapy & Rehabil Sci, Kansas City, KS 66103 USA		Nudo, RJ (corresponding author), Univ Kansas, Med Ctr, Landon Ctr Aging, 3599 W 36th Ave,MS1005, Kansas City, KS 66103 USA.	rnudo@kumc.edu	Nishibe, Mariko/AAP-2226-2020		Department of DefenseUnited States Department of Defense [W81XWH-08-1-0168]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030853]; University of Kansas; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS030853, R01NS030853] Funding Source: NIH RePORTER	We thank Dr. Yong-yue He for performing the CCI surgical procedures, and Dr. Pei-chun Beard for her technical assistance in histology. The work was supported by Department of Defense-Army Research Grant W81XWH-08-1-0168 (to R.J.N.), National Institutes of Health Grant NS030853 (to R.J.N.), and the University of Kansas Summer Research Fellowship (to M.N.).	Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Alaverdashvili M, 2008, BEHAV BRAIN RES, V188, P281, DOI 10.1016/j.bbr.2007.11.007; Alaverdashvili M, 2007, EUR J NEUROSCI, V25, P3442, DOI 10.1111/j.1460-9568.2007.05594.x; Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; Bury SD, 2002, J NEUROSCI, V22, P8597; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; Cirstea MC, 2000, BRAIN, V123, P940, DOI 10.1093/brain/123.5.940; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; Dancause N, 2006, CEREB CORTEX, V16, P1057; Dancause N, 2006, NEUROSCIENTIST, V12, P489, DOI 10.1177/1073858406292782; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eisner-Janowicz I, 2008, J NEUROPHYSIOL, V100, P1498, DOI 10.1152/jn.90447.2008; Fang PC, 2005, J COMP NEUROL, V490, P305, DOI 10.1002/cne.20665; Fang PC, 2010, STROKE, V41, P544, DOI 10.1161/STROKEAHA.109.572073; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Finger S, 2009, HDB CLIN NEUROL, V95, P833; Finger S., 1982, BRAIN DAMAGE RECOVER; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gilmour G, 2005, BEHAV BRAIN RES, V165, P98, DOI 10.1016/j.bbr.2005.06.027; GLEES P, 1949, J PHYSIOL-LONDON, V108, pP33; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KELLER A, 1993, CEREB CORTEX, V3, P430, DOI 10.1093/cercor/3.5.430; Kleim JA, 2003, NEURON, V40, P167, DOI 10.1016/S0896-6273(03)00592-0; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; MAO H, 2010, BIOMECH MODEL MECHAN; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nowak DA, 2009, NEUROREHAB NEURAL RE, V23, P641, DOI 10.1177/1545968309336661; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Nudo RJ, 2006, EVOLUTION NERVOUS SY, P373; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Rema V, 2003, J NEUROSCI, V23, P10378; ROUILLER EM, 1993, SOMATOSENS MOT RES, V10, P269, DOI 10.3109/08990229309028837; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SLAVIN MD, 1988, BRAIN INJURY RECOVER, P165; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stepniewska I, 2006, J COMP NEUROL, V495, P691, DOI 10.1002/cne.20906; Tennant KA, 2009, J NEUROSCI METH, V181, P18, DOI 10.1016/j.jneumeth.2009.04.009; von Monakow C., 1914, LOKALISATION GROSSHI; Voorhies AC, 2002, BEHAV BRAIN RES, V133, P237, DOI 10.1016/S0166-4328(02)00029-3; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	72	62	63	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2221	2232		10.1089/neu.2010.1456			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400011	20873958	Green Published			2022-02-06	
J	Laskowitz, DT; Song, PP; Wang, HC; Mace, B; Sullivan, PM; Vitek, MP; Dawson, HN				Laskowitz, Daniel T.; Song, Pingping; Wang, Haichen; Mace, Brian; Sullivan, Patrick M.; Vitek, Michael P.; Dawson, Hana N.			Traumatic Brain Injury Exacerbates Neurodegenerative Pathology: Improvement with an Apolipoprotein E-Based Therapeutic	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; amyloid; apolipoprotein E; microglia; pharmacogenomics; tau	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; E-BASED PEPTIDE; ALZHEIMERS-DISEASE; MOUSE MODEL; MURINE MODEL; SUBARACHNOID HEMORRHAGE; MICROGLIAL ACTIVATION; TARGETED REPLACEMENT; BETA-PEPTIDE	Cognitive impairment is common following traumatic brain injury (TBI), and neuroinflammatory mechanisms may predispose to the development of neurodegenerative disease. Apolipoprotein E (apoE) polymorphisms modify neuroinflammatory responses, and influence both outcome from acute brain injury and the risk of developing neurodegenerative disease. We demonstrate that TBI accelerates neurodegenerative pathology in double-transgenic animals expressing the common human apoE alleles and mutated amyloid precursor protein, and that pathology is exacerbated in the presence of the apoE4 allele. The administration of an apoE-mimetic peptide markedly reduced the development of neurodegenerative pathology in mice homozygous for apoE3 as well as apoE3/E4 heterozygotes. These results demonstrate that TBI accelerates the cardinal neuropathological features of neurodegenerative disease, and establishes the potential for apoE mimetic therapies in reducing pathology associated with neurodegeneration.	[Laskowitz, Daniel T.; Song, Pingping; Wang, Haichen; Vitek, Michael P.; Dawson, Hana N.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.; Vitek, Michael P.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Mace, Brian; Sullivan, Patrick M.] Duke Univ, Med Ctr, Dept Geriatr Med, Durham, NC 27710 USA; [Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC USA		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048; Mace, Brian/0000-0002-5478-6227	Institute for the Study of Aging; Alzheimer's AssociationAlzheimer's Association	This work was supported by a grant from the Institute for the Study of Aging (to D.T.L.) and the Alzheimer's Association (to M.P.V.). The mice were generously provided by Eli Lilly & Company. COG1410 was provided by Cognosci, Inc.	Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; DAWSON HN, 2010, NEUROSCIENC IN PRESS; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; GALLO G, 1994, AM J PATHOL, V145, P526; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gomez-Ramos P, 2007, J ALZHEIMERS DIS, V11, P53; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Misra V, 2001, Indian J Pathol Microbiol, V44, P271; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Szekely CA, 2008, NEUROLOGY, V70, P17, DOI 10.1212/01.wnl.0000284596.95156.48; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wilcock DM, 2006, NAT PROTOC, V1, P1591, DOI 10.1038/nprot.2006.277; Wirths O, 2004, J NEUROCHEM, V91, P513, DOI 10.1111/j.1471-4159.2004.02737.x; Wirths O, 2008, NEUROBIOL AGING, V29, P891, DOI 10.1016/j.neurobiolaging.2006.12.004; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	57	62	63	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1983	1995		10.1089/neu.2010.1396			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500006	20812776	Green Submitted			2022-02-06	
J	Ji, XT; Liu, WB; Xie, KL; Liu, WP; Qu, Y; Chao, XD; Chen, T; Zhou, J; Fei, Z				Ji, Xituan; Liu, Wenbo; Xie, Keliang; Liu, Weiping; Qu, Yan; Chao, Xiaodong; Chen, Tao; Zhou, Jun; Fei, Zhou			Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress	BRAIN RESEARCH			English	Article						Traumatic brain injury (TBI); Reactive oxygen species (ROS); Oxidative stress; Hydrogen gas	INTESTINAL ISCHEMIA/REPERFUSION; REPERFUSION INJURY; MICE; ISCHEMIA; IMPACT; INHALATION; BIOMARKERS; MARKERS; ACID	Traumatic brain injury (TBI) is a leading cause of mortality and disability among the young population. It has been shown that hydrogen gas (H(2)) exerts a therapeutic antioxidant activity by selectively reducing hydroxyl radical (center dot OH, the most cytotoxic ROS). Recently, we have found that H(2) inhalation significantly improved the survival rate and organ damage of septic mice. In the present study, we investigated the effectiveness of H(2) therapy on brain edema, blood brain barrier (BBB) breakdown, neurological dysfunction and injury volume in TBI-challenged rats. In addition, we investigated the effects of H(2) treatment on the changes of oxidative products and antioxidant enzymes in brain tissue of TBI-challenged rats. Hydrogen treatment was given by exposure to 2% H(2) from 5 min to 5 h after sham or TBI operation, respectively. Here, we found that TBI-challenged rats showed significant brain injuries characterized by the increase of BBB permeability, brain edema and lesion volume as well as neurological dysfunction, which was significantly attenuated by 2% H(2) treatment. In addition, we found that the decrease of oxidative products and the increase of endogenous antioxidant enzymatic activities in the brain tissue may be associated with the protective effects of H(2) treatment in TBI-challenged rats. The present study supports that H(2) inhalation may be a more effective therapeutic strategy for patients with TBI. (C) 2010 Elsevier B.V. All rights reserved.	[Ji, Xituan; Liu, Wenbo; Liu, Weiping; Qu, Yan; Chao, Xiaodong; Chen, Tao; Fei, Zhou] Fourth Mil Med Univ, Xiing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Prov, Peoples R China; [Xie, Keliang] Tianjin Med Univ, Gen Hosp, Dept Anesthesiol, Tianjin 300052, Peoples R China; [Zhou, Jun] Urumqi Gen Hosp PLA, Dept Pharm, Urumqi 830000, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Xiing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Prov, Peoples R China.	feizhou@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093/H0906]	This work was supported by research grants from the National Natural Science Foundation of China (no. 30930093/H0906).	Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Cai JM, 2008, NEUROSCI LETT, V441, P167, DOI 10.1016/j.neulet.2008.05.077; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088; George JF, 2010, KIDNEY INT, V77, P85, DOI 10.1038/ki.2009.432; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Kumar A, 2008, NEONATOLOGY, V94, P96, DOI 10.1159/000116633; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu DD, 2008, CRIT CARE MED, V36, P565, DOI 10.1097/01.CCM.0000299737.24338.5C; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Mao YF, 2009, BIOCHEM BIOPH RES CO, V381, P602, DOI 10.1016/j.bbrc.2009.02.105; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Matchett GA, 2009, BRAIN RES, V1259, P90, DOI 10.1016/j.brainres.2008.12.066; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ohta Shigeo, 2008, Nihon Ronen Igakkai Zasshi, V45, P355; Sakamoto M, 2002, NEUROL RES, V24, P301, DOI 10.1179/016164102101199783; Sato Y, 2008, BIOCHEM BIOPH RES CO, V375, P346, DOI 10.1016/j.bbrc.2008.08.020; Satpute RM, 2009, FOOD CHEM TOXICOL, V47, P2689, DOI 10.1016/j.fct.2009.06.007; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; XIE K, 2010, SHOCK           0323; Xie KL, 2010, SHOCK, V34, P90, DOI 10.1097/SHK.0b013e3181cdc4ae; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zheng XF, 2009, FREE RADICAL RES, V43, P478, DOI 10.1080/10715760902870603	39	62	67	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 1	2010	1354						196	205		10.1016/j.brainres.2010.07.038			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	654IT	WOS:000282162400021	20654594				2022-02-06	
J	Rughani, AI; Dumont, TM; Lu, ZY; Bongard, J; Horgan, MA; Penar, PL; Tranmer, BI				Rughani, Anand I.; Dumont, Travis M.; Lu, Zhenyu; Bongard, Josh; Horgan, Michael A.; Penar, Paul L.; Tranmer, Bruce I.			Use of an artificial neural network to predict head injury outcome	JOURNAL OF NEUROSURGERY			English	Article						artificial neural network; outcome prediction; head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LOGISTIC-REGRESSION; MODEL	Object. The authors describe the artificial neural network (ANN) as an innovative and powerful modeling tool that can be increasingly applied to develop predictive models in neurosurgery. They aimed to demonstrate the utility of an ANN in predicting survival following traumatic brain injury and compare its predictive ability with that of regression models and clinicians. Methods. The authors designed an ANN to predict in-hospital survival following traumatic brain injury. The model was generated with 11 clinical inputs and a single output. Using a subset of the National Trauma Database, the authors "trained" the model to predict outcome by providing the model with patients for whom 11 clinical inputs were paired with known outcomes, which allowed the ANN to "learn" the relevant relationships that predict outcome. The model was tested against actual outcomes in a novel subset of 100 patients derived from the same database. For comparison with traditional forms of modeling, 2 regression models were developed using the same training set and were evaluated on the same testing set. Lastly, the authors used the same 100-patient testing set to evaluate 5 neurosurgery residents and 4 neurosurgery staff physicians on their ability to predict survival on the basis of the same 11 data points that were provided to the ANN. The ANN was compared with the clinicians and the regression models in terms of accuracy, sensitivity, specificity, and discrimination. Results. Compared with regression models, the ANN was more accurate (p < 0.001), more sensitive (p < 0.001), as specific (p = 0.260), and more discriminating (p < 0.001). There was no difference between the neurosurgery residents and staff physicians, and all clinicians were pooled to compare with the 5 best neural networks. The ANNs were more accurate (p < 0.0001), more sensitive (p < 0.0001), as specific (p = 0.743), and more discriminating (p < 0.0001) than the clinicians. Conclusions. When given the same limited clinical information, the ANN significantly outperformed regression models and clinicians on multiple performance measures. While this paradigm certainly does not adequately reflect a real clinical scenario, this form of modeling could ultimately serve as a useful clinical decision support tool. As the model evolves to include more complex clinical variables, the performance gap over clinicians and logistic regression models will persist or, ideally, further increase. (DOI: 10.3171/2009.11.JNS09857)	[Rughani, Anand I.; Dumont, Travis M.; Horgan, Michael A.; Penar, Paul L.; Tranmer, Bruce I.] Univ Vermont, Div Neurosurg, Burlington, VT USA; [Lu, Zhenyu; Bongard, Josh] Univ Vermont, Dept Comp Sci, Burlington, VT USA		Rughani, AI (corresponding author), 111 Colchester Ave,Fletcher 5, Burlington, VT 05401 USA.	anand.rughani@vtmednet.org					BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; Bongard JC, 2005, IEEE T EVOLUT COMPUT, V9, P361, DOI 10.1109/TEVC.2005.850293; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Genkin A, 2007, TECHNOMETRICS, V49, P291, DOI 10.1198/004017007000000245; HAGEN MD, 1995, PRIMARY CARE, V22, P213; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hsu MH, 2005, STUD HEALTH TECHNOL, V116, P241; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Landwehr N, 2005, MACH LEARN, V59, P161, DOI 10.1007/s10994-005-0466-3; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; LU Z, 2008, P 2008 GECCO C COMP, P2047; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Segal ME, 2006, J HEAD TRAUMA REHAB, V21, P298, DOI 10.1097/00001199-200607000-00003; Seung H. S., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P287, DOI 10.1145/130385.130417	19	62	64	1	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					585	590		10.3171/2009.11.JNS09857			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100023	20020844				2022-02-06	
J	Whelan-Goodinson, R; Ponsford, JL; Schonberger, M; Johnston, L				Whelan-Goodinson, Rochelle; Ponsford, Jennie Louise; Schoenberger, Michael; Johnston, Lisa			Predictors of Psychiatric Disorders Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety disorders; brain injuries; depression; mental disorders; neuropsychology; substance-related disorders	MAJOR DEPRESSION; SUBSTANCE-ABUSE; MOOD DISORDERS; AXIS-I; NATURAL-HISTORY; HEAD-INJURY; ALCOHOL; CONSEQUENCES; DISABILITY; AGE	Objective: To investigate predictors of posttraumatic brain injury psychiatric disorders. Design: Retrospective, cross-sectional design with stratified random sampling of groups of patients on average 1 to 5 years postinjury. DSM-based diagnostic interviews of both traumatic brain injury (TBI) participant and informant. Participants: One hundred community-based participants, aged 19-74 years, with traumatic brain injury sustained 0.05-5.5 years previously. Setting: Community-based patients previously treated at a rehabilitation hospital. Main measure: The Structured Clinical Interview for DSM-IV diagnosis. Results: A psychiatric history was a high-risk factor for having the same disorder postinjury. However, the majority of cases of depression and anxiety were novel, suggesting that significant factors other than pre-TBI psychiatric status contribute to post-TBI psychiatric outcome. Female gender, lower education, and pain were also associated with postinjury depression and unemployment and older age with anxiety. Conclusion: Findings suggest that long-term screening and support are important for individuals with TBI, regardless of preinjury psychiatric status.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie Louise; Schoenberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic, Australia; [Johnston, Lisa] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie Louise] Epworth Med Fdn, Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17, Clayton, Vic, Australia.	jennie.ponsford@med.monash.edu.au					Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Burke B. L., 2004, J COGN PSYCHOTHER, V18, P309, DOI [10.1891/jcop.18.4.309.64002, DOI 10.1891/JC0P.18.4.309.64002]; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIRST MB, 2004, COMPUTER ASSISTED SC; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; PONSFORD J, 2004, MID M INT NEUR SOC A; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	62	63	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					320	329		10.1097/HTR.0b013e3181c8f8e7			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400004	20042983				2022-02-06	
J	Mannix, R; Bourgeois, FT; Schutzman, SA; Bernstein, A; Lee, LK				Mannix, Rebekah; Bourgeois, Florence T.; Schutzman, Sara A.; Bernstein, Ari; Lee, Lois K.			Neuroimaging for Pediatric Head Trauma: Do Patient and Hospital Characteristics Influence Who Gets Imaged?	ACADEMIC EMERGENCY MEDICINE			English	Article						craniocerebral trauma; diagnostic imaging; emergency service; hospital	EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; UNITED-STATES; INTRACRANIAL INJURY; RACIAL DISPARITIES; SPLENIC INJURIES; DECISION RULE; CHILDREN; RACE/ETHNICITY; CARE	P>Objectives: The objective was to identify patient, provider, and hospital characteristics associated with the use of neuroimaging in the evaluation of head trauma in children. Methods: This was a cross-sectional study of children (< 19 years of age) with head injuries from the National Hospital Ambulatory Medical Care Survey (NHAMCS) collected by the National Center for Health Statistics. NHAMCS collects data on approximately 25,000 visits annually to 600 randomly selected hospital emergency and outpatient departments. This study examined visits to U.S. emergency departments (EDs) between 2002 and 2006. Multivariable logistic regression was used to analyze characteristics associated with neuroimaging in children with head injuries. Results: There were 50,835 pediatric visits in the 5-year sample, of which 1,256 (2.5%, 95% confidence interval [CI] = 2.2% to 2.7%) were for head injury. Among these, 39% (95% CI = 34% to 43%) underwent evaluation with neuroimaging. In multivariable analyses, factors associated with neuroimaging included white race (odds ratio [OR] = 1.5, 95% CI = 1.02 to 2.1), older age (OR = 1.3, 95% CI = 1.1 to 1.5), presentation to a general hospital (vs. a pediatric hospital, OR = 2.4, 95% CI = 1.1 to 5.3), more emergent triage status (OR = 1.4, 95% CI = 1.1 to 1.8), admission or transfer (OR = 2.7, 95% CI = 1.4 to 5.3), and treatment by an attending physician (OR = 2.0, 95% CI = 1.1 to 3.7). The effect of race was mitigated at the pediatric hospitals compared to at the general hospitals (p < 0.001). Conclusions: In this study, patient race, age, and hospital-specific characteristics were associated with the frequency of neuroimaging in the evaluation of children with closed head injuries. Based on these results, focusing quality improvement initiatives on physicians at general hospitals may be an effective approach to decreasing rates of neuroimaging after pediatric head trauma.	[Mannix, Rebekah; Bourgeois, Florence T.; Schutzman, Sara A.; Bernstein, Ari; Lee, Lois K.] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA		Mannix, R (corresponding author), Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Bourgeois, Florence/H-6710-2016; Mannix, Rebekah/AAD-8702-2020	Bourgeois, Florence/0000-0001-7798-4560; 	National Institutes of Health through the Harvard School of Public Health [T32 MH073122-04]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH073122] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health through the Harvard School of Public Health Interdisciplinary Training Program in Neurodevelopmental Toxicology Award to Dr. Mannix (T32 MH073122-04).	Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P287, DOI 10.1093/phr/118.4.287; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bourgeois FT, 2008, ANN EMERG MED, V52, P599, DOI 10.1016/j.annemergmed.2008.03.012; Bowman SM, 2005, JAMA-J AM MED ASSOC, V294, P2611, DOI 10.1001/jama.294.20.2611; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Chamberlain JM, 2007, PEDIATRICS, V119, pE1319, DOI 10.1542/peds.2006-2309; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Guagliardo MF, 2003, ACAD EMERG MED, V10, P1218, DOI 10.1197/S1069-6563(03)00492-5; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hostetler MA, 2002, AM J EMERG MED, V20, P139, DOI 10.1053/ajem.2002.33002; James CA, 2005, PEDIATRICS, V115, pE310, DOI 10.1542/peds.2004-1541; Kalauokalani D, 2007, PAIN MED, V8, P17, DOI 10.1111/j.1526-4637.2007.00170.x; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mooney DP, 2006, J TRAUMA, V61, P330, DOI 10.1097/01.ta.0000226167.44892.1d; National Center for Health Statistics, 2009, AMB HLTH CAR DAT; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pines JM, 2009, ACAD EMERG MED, V16, P403, DOI 10.1111/j.1553-2712.2009.00381.x; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Tamayo-Sarver JH, 2003, ACAD EMERG MED, V10, P1239, DOI 10.1197/S1069-6563903)00494-9	27	62	62	1	5	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL 10	2010	17	7					694	700		10.1111/j.1553-2712.2010.00797.x			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	621VO	WOS:000279613400010	20653582	Green Accepted, Green Submitted			2022-02-06	
J	Bailey, CM; Samples, HL; Broshek, DK; Freeman, JR; Barth, JT				Bailey, Christopher M.; Samples, Hillary L.; Broshek, Donna K.; Freeman, Jason R.; Barth, Jeffrey T.			The Relationship Between Psychological Distress and Baseline Sports-Related Concussion Testing	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury; mild traumatic brain injury; neuropsychology; athlete; personality	HIGH-SCHOOL; NEUROPSYCHOLOGICAL DEFICITS; SEX-DIFFERENCES; SYMPTOMS; PERFORMANCE; RECOVERY; DEPRESSION; IMPAIRMENT; ANXIETY; IMPACT	Objective: This study examined the effect of psychological distress on neurocognitive performance measured during baseline concussion testing. Design: Archival data were utilized to examine correlations between personality testing and computerized baseline concussion testing. Significantly correlated personality measures were entered into linear regression analyses, predicting baseline concussion testing performance. Suicidal ideation was examined categorically. Setting: Athletes underwent testing and screening at a university athletic training facility. Participants: Participants included 47 collegiate football players 17 to 19 years old, the majority of whom were in their first year of college. Interventions: Participants were administered the Concussion Resolution Index (CRI), an internet-based neurocognitive test designed to monitor and manage both at-risk and concussed athletes. Participants took the Personality Assessment Inventory (PAI), a self-administered inventory designed to measure clinical syndromes, treatment considerations, and interpersonal style. Main Outcome Measures: Scales and subscales from the PAI were utilized to determine the influence psychological distress had on the CRI indices: simple reaction time, complex reaction time, and processing speed. Results: Analyses revealed several significant correlations among aspects of somatic concern, depression, anxiety, substance abuse, and suicidal ideation and CRI performance, each with at least a moderate effect. When entered into a linear regression, the block of combined psychological symptoms accounted for a significant amount of baseline CRI performance, with moderate to large effects (r(2) = 0.23-0.30). When examined categorically, participants with suicidal ideation showed significantly slower simple reaction time and complex reaction time, with a similar trend on processing speed. Conclusions: Given the possibility of obscured concussion deficits after injury, implications for premature return to play, and the need to target psychological distress outright, these findings heighten the clinical importance of screening for psychological distress during baseline and post-injury concussion evaluations.	[Bailey, Christopher M.] Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; [Samples, Hillary L.; Broshek, Donna K.; Freeman, Jason R.; Barth, Jeffrey T.] Univ Virginia Hlth Syst, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA		Bailey, CM (corresponding author), 11100 Euclid Ave,Mail Stop HAN 5040, Cleveland, OH 44106 USA.	christopher.bailey3@uhhospitals.org	Broshek, Donna/ABA-4208-2021	Broshek, Donna/0000-0002-7175-7815			Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Bailes JE, 2009, J INT NEUROPSYCH SOC, V15, P509, DOI 10.1017/S1355617709090936; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BARTH JT, 2002, ENCY HUMAN BRAIN, V3, P81; Barth JT, 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BREWER BW, 2001, COPING SPORT INJURIE, P1; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Butters MA, 2004, ARCH GEN PSYCHIAT, V61, P587, DOI 10.1001/archpsyc.61.6.587; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; EYSENCK MW, 1992, COGNITION EMOTION, V6, P409, DOI 10.1080/02699939208409696; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FURTADO JL, 2006, SPORTS NEUROPSYCHOLO, P287; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HARTLAGE S, 1993, PSYCHOL BULL, V113, P247, DOI 10.1037/0033-2909.113.2.247; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Morey, 1991, PERSONALITY ASSESSME; Nebes RD, 2000, PSYCHOL MED, V30, P679, DOI 10.1017/S0033291799001968; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; PUTUKIAN M, 2006, SPORTS NEUROPSYCHOLO, P297; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214	42	62	62	1	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2010	20	4					272	277		10.1097/JSM.0b013e3181e8f8d8			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	622EA	WOS:000279641800005	20606512				2022-02-06	
J	Lewis, SB; Wolper, R; Chi, YY; Miralia, L; Wang, Y; Yang, C; Shaw, G				Lewis, Stephen B.; Wolper, Regina; Chi, Yueh-Yun; Miralia, Lynn; Wang, Yong; Yang, Cui; Shaw, Gerry			Identification and Preliminary Characterization of Ubiquitin C Terminal Hydrolase 1 (UCHL1) as a Biomarker of Neuronal Loss in Aneurysmal Subarachnoid Hemorrhage	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurofilaments; NF-H; pNF-H; ubiquitin C-terminal hydrolase 1; UCHL1; S100 beta; biomarker; aneurysmal subarachnoid hemorrhage; vasospasm	NEUROFILAMENT HEAVY-CHAIN; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; AXONAL INJURY; NF-H; SERUM S100B; PNF-H; MARKERS; DAMAGE	By using two different approaches, ubiquitin C-terminal hydrolase 1 (UCHL1) was identified as a potential cerebrospinal fluid (CSF) biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage (ASAH) and presumably other CNS damage and disease states. Appropriate antibodies and a sensitive ELISA were generated, and the release of UCHL1 into CSF was compared with that of pNF-H and S100 beta in a cohort of 30 ASAH patients. Both UCHL1 and pNF-H showed persistent release into CSF in almost all patients in the second week postaneurysmal rupture (AR), and S100 beta levels rapidly declined to baseline levels in 23 of 30 patients. Seven of thirty patients showed persistently elevated S100 beta levels over the first 5 days post-AR and also had relatively higher levels of pNF-H and UCHL1 higher compared with the rest. These patients proved to have very poor outcomes, with 6 of 7 expiring. Patients who did reduce S100 beta levels tended to have a better outcome if pNF-H and UCHL1 levels were also lower, and elevated UCHL1 levels in the second week post-AR were particularly predictive of poor outcome. Acute coordinated releases of large amounts of UCHL1, pNF-H, and S100 beta in 16 of 30 patients were observed, suggesting sudden loss of brain tissues associated with secondary events. We conclude that measurement of the CSF levels of these proteins reveals details of ASAH progression and recovery and predicts patient outcome. (C) 2010 Wiley-Liss, Inc.	[Yang, Cui; Shaw, Gerry] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Lewis, Stephen B.; Wolper, Regina; Miralia, Lynn] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurol Surg, Gainesville, FL 32610 USA; [Wang, Yong; Shaw, Gerry] EnCor Biotechnol Inc, Gainesville, FL USA		Shaw, G (corresponding author), Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA.	shaw@mbi.ufl.edu	, Gerry/X-2377-2019; Chi, Yueh-Yun/AAL-6234-2020		General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1-RR00082]; Departments of Neurosurgery and Neuroscience, McKnight Brain Institute, University of Florida College of Medicine; EnCor Biotechnology Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER	Contract grant sponsor: General Clinical Research Center; Contract grant number: MO1-RR00082 (to S.B.L.); Contract grant sponsor: Departments of Neurosurgery and Neuroscience, McKnight Brain Institute, University of Florida College of Medicine; Contract grant sponsor: EnCor Biotechnology Inc.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Deisenhammer F, 2009, EUR J NEUROL, V16, P760, DOI 10.1111/j.1468-1331.2009.02595.x; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Gresle MM, 2008, J NEUROSCI RES, V86, P3548, DOI 10.1002/jnr.21803; Guy J, 2008, MOL VIS, V14, P2443; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2005, J NEUROTRAUM, V22, P407, DOI 10.1089/neu.2005.22.407; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Petzold A, 2009, MUSCLE NERVE, V40, P42, DOI 10.1002/mus.21239; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Sanchez-Pena P, 2008, CRIT CARE MED, V36, P2267, DOI 10.1097/CCM.0b013e3181809750; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; THOMPSON RJ, 1983, BRAIN RES, V278, P294; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	23	62	64	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2010	88	7					1475	1484		10.1002/jnr.22323			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	585VP	WOS:000276858600008	20077430				2022-02-06	
J	Haselkorn, ML; Shellington, DK; Jackson, EK; Vagni, VA; Janesko-Feldman, K; Dubey, RK; Gillespie, DG; Cheng, DM; Bell, MJ; Jenkins, LW; Homanics, GE; Schnermann, J; Kochanek, PM				Haselkorn, M. Lee; Shellington, David K.; Jackson, Edwin K.; Vagni, Vincent A.; Janesko-Feldman, Keri; Dubey, Raghvendra K.; Gillespie, Delbert G.; Cheng, Dongmei; Bell, Michael J.; Jenkins, Larry W.; Homanics, Gregg E.; Schnermann, Jurgen; Kochanek, Patrick M.			Adenosine A(1) Receptor Activation as a Brake on the Microglial Response after Experimental Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						adenosine; A(1) receptor; BV-2 cells; head injury; Iba-1; knockout; microglia; neurotrauma	CONTROLLED CORTICAL IMPACT; STATUS EPILEPTICUS; CEREBRAL-ISCHEMIA; MOUSE-BRAIN; CELLS; NEURODEGENERATION; ANTAGONISTS; SEIZURES; LACKING; RATS	We reported that adenosine A(1) receptor (A(1)AR) knockout (KO) mice develop lethal status epilepticus after experimental traumatic brain injury (TBI), which is not seen in wild-type (WT) mice. Studies in epilepsy, multiple sclerosis, and neuro-oncology suggest enhanced neuro-inflammation and/or neuronal death in A(1)AR KO. We hypothesized that A(1)AR deficiency exacerbates the microglial response and neuronal damage after TBI. A1AR KO and WT littermates were subjected to mild controlled cortical impact (3m/sec; 0.5mm depth) to left parietal cortex, an injury level below the acute seizure threshold in the KO. At 24 h or 7 days, mice were sacrificed and serial sections prepared. Iba-1 immunostaining was used to quantify microglia at 7 days. To assess neuronal injury, sections were stained with Fluoro-Jade C (FJC) at 24 h to evaluate neuronal death in the hippocampus and cresyl violet staining at 7 days to analyze cortical lesion volumes. We also studied the effects of adenosine receptor agonists and antagonists on H-3-thymidine uptake (proliferation index) by BV-2 cells (immortalized mouse microglial). There was no neuronal death in CA1 or CA3 quantified by FJC. A(1)AR KO mice exhibited enhanced microglial response; specifically, Iba-1 + microglia were increased 20-50% more in A1AR KO versus WT in ipsilateral cortex, CA3, and thalamus, and contralateral cortex, CA1, and thalamus (p<0.05). However, contusion and cortical volumes did not differ between KO and WT. Pharmacological studies in cultured BV-2 cells indicated that A(1)AR activation inhibits microglial proliferation. A(1)AR activation is an endogenous inhibitor of the microglial response to TBI, likely via inhibition of proliferation, and this may represent a therapeutic avenue to modulate microglia after TBI.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Cheng, Dongmei; Homanics, Gregg E.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Bell, Michael J.; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Homanics, Gregg E.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Dubey, Raghvendra K.; Gillespie, Delbert G.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; [Schnermann, Jurgen] NIDDKD, NIH, Bethesda, MD 20892 USA; [Dubey, Raghvendra K.] Univ Zurich Hosp, Dept Obstet & Gynecol, Clin Reprod Endocrinol, Zurich, Switzerland		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Homanics, Gregg/0000-0003-3641-8153; Dubey, Raghvendra/0000-0003-1000-7137; Shellington, David/0000-0001-6708-6978; Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 38087, NS 30318, DK 068575]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [32-64040.00, 320000-117998]; Oncosuisse [OCS-01551-08-2004]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318, R01NS038087] Funding Source: NIH RePORTER	We thank NIH NS 38087 (PMK), NS 30318 (PMK), DK 068575 (EKJ), Swiss National Science Foundation #32-64040.00 (RKD), 320000-117998 (RKD), and Oncosuisse OCS-01551-08-2004 (RKD) for support. We thank Marci Provins and Cara Mulhollen for assisting with manuscript preparation.	Avignone E, 2008, J NEUROSCI, V28, P9133, DOI 10.1523/JNEUROSCI.1820-08.2008; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Dare E, 2007, PHYSIOL BEHAV, V92, P15, DOI 10.1016/j.physbeh.2007.05.031; Dzhala V, 2000, ANN NEUROL, V48, P632, DOI 10.1002/1531-8249(200010)48:4<632::AID-ANA10>3.3.CO;2-V; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P37, DOI 10.1016/0197-0186(95)00137-9; Gimenez-Llort L, 2005, SYNAPSE, V57, P8, DOI 10.1002/syn.20146; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gundlfinger A, 2007, J PHYSIOL-LONDON, V582, P263, DOI 10.1113/jphysiol.2007.132613; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jacobson KA, 2001, HANDB EXP PHARM, V151, P129; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1139/y05-143; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; Olsson T, 2004, EUR J NEUROSCI, V20, P1197, DOI 10.1111/j.1460-9568.2004.03564.x; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Si QS, 1996, EXP NEUROL, V137, P345, DOI 10.1006/exnr.1996.0035; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Synowitz M, 2006, CANCER RES, V66, P8550, DOI 10.1158/0008-5472.CAN-06-0365; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; van Muijlwijk-Koezen JE, 2000, J MED CHEM, V43, P2227, DOI 10.1021/jm000002u; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0	36	62	64	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					901	910		10.1089/neu.2009.1075			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400012	20121416	Green Accepted, Green Published			2022-02-06	
J	McNamara, KCS; Lisembee, AM; Lifshitz, J				McNamara, Katelyn C. S.; Lisembee, Amanda M.; Lifshitz, Jonathan			The Whisker Nuisance Task Identifies a Late-Onset, Persistent Sensory Sensitivity in Diffuse Brain-Injured Rats	JOURNAL OF NEUROTRAUMA			English	Article						corticosterone; physical therapy; plasticity; rehabilitation	COGNITIVE FUNCTION; ENVIRONMENTAL ENRICHMENT; PLASTICITY; CORTEX; STIMULATION; EXPRESSION; RECOVERY; MOTOR; PAIN; ORGANIZATION	Post-traumatic morbidity reduces the quality of life for traumatic brain injury (TBI) survivors by altering neuropsychological function. After midline fluid percussion injury (FPI), diffuse pathology in the ventral posterior thalamus suggests that somatosensory whisker function may be impaired post-injury. The goals of the present study were to design and validate a task to detect injury-induced somatosensory morbidity (Experiment 1), and to evaluate preliminary applications of the task (Experiment 2). In Experiment 1, male Sprague-Dawley rats were subjected to moderate FPI (similar to 1.9 atm) or sham injury. Over an 8-week time course, the whiskers on both mystacial pads were stimulated manually with an applicator stick in an open field for three 5-min periods. Behavioral responses in this whisker nuisance task were recorded using objective criteria (max score = 16). Sham animals were ambivalent or soothed by whisker stimulation (4.0 +/- 0.8), whereas brain-injured rats showed aggravated responses at 1 week (6.7 +/- 0.9), which became significant at 4 weeks (9.5 +/- 0.5) and 8 weeks (8.4 +/- 1.1) compared to sham injury, indicating chronic injury-induced sensory sensitivity. Total free serum corticosterone levels indicated a significant stress response in brain-injured (125.0 +/- 17.7 ng/mL), but not uninjured animals (74.2 +/- 12.2 ng/mL) in response to whisker stimulation. In Experiment 2, to evaluate applications of the whisker nuisance task, four additional uninjured and brain-injured groups were subjected to mild brain injury only, shaved whiskers after moderate brain injury, repeated whisker nuisance task stimulation after moderate brain injury, or regular opportunities for tactile exploration of an enriched environment after moderate brain injury over 4 weeks post-injury. The whisker nuisance task has the sensitivity to detect mild brain injury (7.7 +/- 1.0), but morbidity was not mitigated by any of the neurorehabilitative interventions. Following diffuse brain injury, the whisker nuisance task is a promising tool to detect post-traumatic morbidity and the efficacy of therapeutic interventions that may restore discrete circuit function in brain-injured patients.	[Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Coll Med,Off B463, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Phys Med & Rehabil, Coll Med, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Coll Med,Off B463, Biomed & Biol Sci Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	JLifshitz@uky.edu			University of Kentucky; Experience Based Career Education (EBCE); University of Kentucky College of Medicine; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052, p30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS065052] Funding Source: NIH RePORTER	We are grateful to Dr. Mark A. Prendergast and his laboratory for assistance with the corticosterone assays. We thank Dr. Karin Westlund High and Dr. Fei Ma for their assistance in evaluating pressure sensitivity in the whisker pad. We are grateful to Dr. Michael T. Bardo and Ms. Emily D. Denehy for conducting the open-field behavioral analysis. Also, we wish to thank Experiences in Undergraduate Research and Kreative Activities (eUreka!), Students Promoting Undergraduate Research (SPUR), Kentucky Yang Researchers Program (KYRP), and National Conference for Undergraduate Research (NCUR) at the University of Kentucky as well as Experience Based Career Education (EBCE) for their continued support of undergraduate research. Supported, in part, by University of Kentucky College of Medicine, NIH NINDS R01 NS065052 and NIH NINDS p30 NS051220.	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERNARDO KL, 1987, J COMP NEUROL, V258, P542, DOI 10.1002/cne.902580406; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Brecht M, 1997, BEHAV BRAIN RES, V84, P81, DOI 10.1016/S0166-4328(97)83328-1; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Cromwell HC, 2008, CLIN EEG NEUROSCI, V39, P69, DOI 10.1177/155005940803900209; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DYCK RH, 2004, BEHAV LAB RAT; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Faisal AA, 2008, NAT REV NEUROSCI, V9, P292, DOI 10.1038/nrn2258; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Frostig RD, 2006, CURR OPIN NEUROBIOL, V16, P445, DOI 10.1016/j.conb.2006.06.001; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOLD BG, 1991, J NEUROSCI, V11, P943; GONZALEZ MF, 1985, J COMP NEUROL, V231, P457, DOI 10.1002/cne.902310405; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Henderson T. A., 1995, CEREBRAL CORTEX BARR, P123; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iarocci G, 2006, J AUTISM DEV DISORD, V36, P77, DOI 10.1007/s10803-005-0044-3; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; ISAAC WL, 1989, BEHAV NEUROSCI, V103, P345, DOI 10.1037/0735-7044.103.2.345; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; JOURDAN D, 1995, PAIN, V63, P237, DOI 10.1016/0304-3959(95)00049-X; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Krupa DJ, 2004, SCIENCE, V304, P1989, DOI 10.1126/science.1093318; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELZER P, 1985, BRAIN RES, V348, P229, DOI 10.1016/0006-8993(85)90441-X; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Ordyan N E, 1998, Neurosci Behav Physiol, V28, P22, DOI 10.1007/BF02461907; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 2001, HEAD TRAUMA, P281; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031-9384(99)00136-5; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Skouras E, 2009, RESTOR NEUROL NEUROS, V27, P237, DOI 10.3233/RNN-2009-0474; Vierck C J Jr, 2000, Prog Brain Res, V129, P411, DOI 10.1016/S0079-6123(00)29032-8; VOS BP, 1994, J NEUROSCI, V14, P2708; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Wooters TE, 2009, PSYCHOPHARMACOLOGY, V204, P551, DOI 10.1007/s00213-009-1487-6	80	62	62	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					695	706		10.1089/neu.2009.1237			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000004	20067394	Green Published			2022-02-06	
J	Lee, V; Ford, RL; Xing, W; Bunce, C; Foot, B				Lee, V.; Ford, R. L.; Xing, W.; Bunce, C.; Foot, B.			Surveillance of traumatic optic neuropathy in the UK	EYE			English	Article						TON; optic neuropathy; optic nerve injury; head injury; orbital fracture; BOSU	CONTROLLED-TRIAL; INDIRECT INJURY; NERVE TRAUMA; METHYLPREDNISOLONE; MANAGEMENT; CHILDREN; THERAPY	Aims The aim of this study is to provide epidemiological data on the incidence, aetiology, management, and visual outcome in traumatic optic neuropathy (TON) in the UK. Methods Patients with TON were identified prospectively by population-based active surveillance through the British Ophthalmic Surveillance Unit over a 2-year period with data obtained from an incident questionnaire and follow-up questionnaire sent to positive reporters. Results Incident and follow-up data were available on 121 and 97 (80%) patients, respectively. The minimum estimated incidence was 1.005 per million. Leading causes included falls (25.6%), road traffic accidents (RTAs) (21.5%), and assaults (20.7%). The median age was 31 years. There were 95 (78.5%) men. Presenting visual acuity (VA) was 6/60 or worse in 85 (70%) patients, with 43 patients (36%) with no perception of light. Associated injuries included 47 (39%) orbital wall fractures, 37 (31%) closed globe injuries, 23 (19%) ocular adnexal injuries, 23 (19%) skull fractures, and 18 (16%) intracranial bleeding. Sixty-five percent (75/116) received no acute treatment and 35% (41/116) received steroids and/or surgery. Of the treated group, 24% (8/33) and of the untreated group 20% (11/56) improved three lines or more of VA (P = 0.61). Prompt ophthalmic examination (P = 0.002), orbital fracture (P = 0.046), high Glasgow Coma Scale (GCS) score (P = 0.023), and poor initial VA (P = 0.009) were associated with increased likelihood of treatment. Poor initial VA (P < 0.001), orbital fracture (P = 0.004), and significant head injury (P = 0.038) were associated with poor visual outcome. Conclusions This study suggested that young men were at greatest risk of TON. We detected a trend towards conservative management of this condition in the UK. TON was associated with significant ocular, orbital, and head injuries that highlighted the need for multidisciplinary management. Eye (2010) 24, 240-250; doi: 10.1038/eye.2009.79; published online 1 May 2009	[Lee, V.; Ford, R. L.] Cent Middlesex Hosp, Cent Eye Serv, NW London NHS Trust, London NW10 7NS, England; [Xing, W.; Bunce, C.] Moorfields Eye Hosp NHS Fdn Trust, Dept Res & Dev, London, England; [Foot, B.] Royal Coll Ophthalmologists, London, England		Lee, V (corresponding author), Cent Middlesex Hosp, Cent Eye Serv, NW London NHS Trust, Acton Lane, London NW10 7NS, England.	vickielee@mac.com		Lee, Vickie/0000-0002-2963-5742; Bunce, Catey/0000-0002-0935-3713; Ford, Rebecca/0000-0001-6392-3097	British Ophthalmic Surveillance Unit; Central Middlesex Hospital Eye Clinic Fund	We are grateful for the support of the British Ophthalmic Surveillance Unit. The work was supported by a grant from the Central Middlesex Hospital Eye Clinic Fund. We thank the following ophthalmologists who have reported cases to this study: Mr J Acheson, Miss D AhKine, Mr S Ahmed, Mr RWAllchin, Mr ED Allen, Mr S Armstrong, Mr S Ataullah, Mr HR Atta, Mr HF Bacon, Mr R Bates, Miss K Belfer, Mr PD Black, Mrs T Blamires, Mr CR Bentley, Mr AK Brahma, Mr F Bremner, Mr MC Briggs, Mr MA Burdon, Miss SEP Burgess, Mr R Caesar, Mr IG Calder, Mr A Cassels-Brown, Mr JKT Chan, Mr PR Chaudhuri, Mr S Chawdhury, Mrs JK Chhina, Mr JR Clarke, Mr MD Cole, Mr A Coombes, Dr M Cooper, Mr R Dagres, Mr RB Dapling, Mr K Davey, Mr DV De Alwis, Mr JA Dunne, Miss O Earley, Miss BE Enoch, Dr J Ellis, Mr D Etchells, Mr MG Falcon, Mrs V Ferguson, Mr J Ferris, Mr DW Flanagan, Professor JV Forrester, Mr PD Fox, Mr DG Frazer, Mr LB Freeman, Mrs H Gaston, Dr ND George, Mr RA Gibson, Mr JT Gillow, Mr RHB Grey, Dr DJ Grierson, Mr PG Griffiths, Mr C Hammond, Miss J Harcourt, Mr R Haslett, Mr JM Hayward, Dr DJ Huggan, Mr C Illingworth, Mr A Jacks, Mr JSH Jacob, Miss CA Jones, Mr A Kamal, Mr WSS Karwatowski, Mr VV Kayarkar, Mr J Keenan, Miss G Larkin, Mr N Lee, Mr NP Litvin, Mr M Logendran, Mr V Long, Mr J Luck, Mr G Mackingtosh, Dr JR Mackinnon, Dr DC Manfield, Miss R Manners, Miss DC Mather, Mr BK McLeod, Mr JE Morgan, Mr SJ Morgan, Mr AP Moriarty, Mr CD Morsman, Mrs CE Morton, Mr G Naylor, Dr J Olsen, Mr V Pai, Dr S Patterson-Brown, Dr R Paul, Mr JC Pauw, Mrs I Pepper, Mr W Poon, Mr M Potts, Mr AP Plumb, Mr A Quinn, Mr C Rene, Mr P Riordan-Eva, Dr STD Roxburgh, Mr NJ Sarkies, Mr S Scotcher, Mr C Scott, Dr JA Scott, Mr RAH Scott, Mr PR Simcock, Mr DL Smerdon, Mr R Smith, Mr L Stevenson, Mr G Sturrock, Miss S Vickers, Mr AN Tadros, Mr A Tekriwal, Mr DM Tole, Mr A Toufeeq, Mr JM Twomey, Mr V Vampali, Mr AJ Vivian, Mr IMJ Wearne, Ms S Webber, Mr ST White, Dr Whittle, and Mr YF Yang.	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P291; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; Chadwick J., 1950, MED WORKS HIPPOCRATE, P260; Chou PI, 1996, NEURO-OPHTHALMOLOGY, V16, P325, DOI 10.3109/01658109609044636; Cook MW, 1996, ARCH OTOLARYNGOL, V122, P389; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; EDMUND J, 1963, ACTA OPHTHALMOL, V41, P693; Edwards P, 2005, LANCET, V365, P1957; Foot B, 2003, EYE, V17, P9, DOI 10.1038/sj.eye.6700233; FUJITANI T, 1986, JPN J OPHTHALMOL, V30, P125; Goldenberg-Cohen N, 2004, J AAPOS, V8, P20, DOI 10.1016/j.jaapos.2003.08.009; GROSS CE, 1981, J NEUROSURG, V55, P963, DOI 10.3171/jns.1981.55.6.0963; HALL ED, 1984, J NEUROSURG, V61, P805; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; LEVIN LA, 1994, OPHTHALMOLOGY, V101, P566; Levin LA, 2003, J NEURO-OPHTHALMOL, V23, P72, DOI 10.1097/00041327-200303000-00013; MAHAPATRA AK, 1993, PEDIATR NEUROSURG, V19, P34, DOI 10.1159/000120698; MAURIELLO JA, 1992, BRIT J OPHTHALMOL, V76, P349, DOI 10.1136/bjo.76.6.349; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Rajiniganth MG, 2003, ARCH OTOLARYNGOL, V129, P1203, DOI 10.1001/archotol.129.11.1203; SEIFF SR, 1990, OPHTHALMIC SURG LAS, V21, P389; Spencer Matthew T, 2003, Ann Emerg Med, V41, P410, DOI 10.1067/mem.2003.84; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; STEINSAPIR KD, 2005, COMP OPHTHALMOL UPDA, V6, P11; Steinsapir KDGR, 1998, WALSH HOYTS CLIN NEU, P715; TAKEHARA S, 1994, NEURORADIOLOGY, V36, P512, DOI 10.1007/BF00593510; TEASDALE G, 1974, LANCET, V2, P81; THACKER SB, 1986, AM J PREV MED, V2, P345; VOGT RL, 1983, AM J PUBLIC HEALTH, V73, P795, DOI 10.2105/AJPH.73.7.795; Wang BH, 2001, PLAST RECONSTR SURG, V107, P1655, DOI 10.1097/00006534-200106000-00003; Yang WG, 2004, ANN PLAS SURG, V52, P36, DOI 10.1097/01.sap.0000096442.82059.6d; Yu-Wai-Man P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005024.pub3; Yu-Wai-Man P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006032.pub2	43	62	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-222X	1476-5454		EYE	Eye	FEB	2010	24	2					240	250		10.1038/eye.2009.79			11	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	553WQ	WOS:000274397900006	19407847	Bronze			2022-02-06	
J	Oddo, M; Frangos, S; Maloney-Wilensky, E; Kofke, WA; Le Roux, PD; Levine, JM				Oddo, Mauro; Frangos, Suzanne; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Le Roux, Peter D.; Levine, Joshua M.			Effect of Shivering on Brain Tissue Oxygenation During Induced Normothermia in Patients With Severe Brain Injury	NEUROCRITICAL CARE			English	Article						Induced normothermia; Fever control; Temperature management; Surface cooling; Shivering; Brain tissue oxygenation; Brain injury; SAH; TBI; Neurointensive care; Neurocritical care	INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; CEREBRAL OXYGENATION; ADDITIVELY REDUCE; BODY-TEMPERATURE; CLINICAL-TRIAL; MEPERIDINE; THRESHOLD; HYPERTHERMIA; HYPOTHERMIA	Background We analyzed the impact of shivering on brain tissue oxygenation (PbtO(2)) during induced normothermia in patients with severe brain injury. Methods We studied patients with severe brain injury who developed shivering during induced normothermia. Induced normothermia was applied to treat refractory fever (body temperature [BT] >= 38.3 degrees C, refractory to conventional treatment) using a surface cooling device with computerized adjustment of patient BT target to 37 +/- 0.5 degrees C. PbtO(2), intracranial pressure, mean arterial pressure, cerebral perfusion pressure, and BT were monitored continuously. Circulating water temperature of the device system was measured to assess the intensity of cooling. Results Fifteen patients (10 with severe traumatic brain injury, 5 with aneurysmal subarachnoid hemorrhage) were treated with induced normothermia for an average of 5 +/- 2 days. Shivering caused a significant decrease in PbtO(2) levels both in SAH and TBI patients. Compared to baseline, shivering was associated with an overall reduction of PbtO(2) from 34.1 +/- 7.3 to 24.4 +/- 5.5 mmHg (P < 0.001). A significant correlation was found between the magnitude of shivering-associated decrease of PbtO(2) (Delta PbtO(2)) and circulating water temperature (R = 0.82, P < 0.001). Conclusion In patients with severe brain injury treated with induced normothermia, shivering was associated with a significant decrease of PbtO(2), which correlated with the intensity of cooling. Monitoring of therapeutic cooling with computerized thermoregulatory systems may help prevent shivering and optimize the management of induced normothermia. The clinical significance of shivering-induced decrease in brain tissue oxygenation remains to be determined.	[Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Oddo, Mauro; Frangos, Suzanne; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Le Roux, Peter D.; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Levine, JM (corresponding author), Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA.	mauro.oddo@chuv.ch; Joshua.Levine@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525			Badjatia N, 2007, NEUROCRIT CARE, V6, P186, DOI 10.1007/s12028-007-0011-2; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Bilotta F, 2001, ANAESTHESIA, V56, P514, DOI 10.1046/j.1365-2044.2001.02057.x; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CROSSLEY AWA, 1994, ANAESTHESIA, V49, P205; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Doufas AG, 2004, NEUROCRIT CARE, V1, P489, DOI 10.1385/NCC:1:4:489; Eberhart LHJ, 2005, ANESTH ANALG, V101, P1849, DOI [10.1213/O1.ANE.0000184128.41795.FE, 10.1213/01.ANE.0000184128.41795.FE]; Geocadin RG, 2005, NEUROCRIT CARE, V3, P63, DOI 10.1385/NCC:3:1:063; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Hata JS, 2008, NEUROCRIT CARE, V9, P37, DOI 10.1007/s12028-007-9015-1; Haugk M, 2007, RESUSCITATION, V75, P76, DOI 10.1016/j.resuscitation.2007.03.001; Holtzclaw Barbara J, 2004, AACN Clin Issues, V15, P267, DOI 10.1097/00044067-200404000-00012; IMRIE MM, 1990, BRIT J ANAESTH, V64, P346, DOI 10.1093/bja/64.3.346; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kurz A, 1997, ANESTHESIOLOGY, V86, P1046, DOI 10.1097/00000542-199705000-00007; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oddo M, 2009, STROKE, V40, P1913, DOI 10.1161/STROKEAHA.108.534115; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Sagir O, 2007, ACTA ANAESTH SCAND, V51, P44, DOI 10.1111/j.1399-6576.2006.01196.x; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; Tsai YC, 2001, ANESTH ANALG, V93, P1288, DOI 10.1097/00000539-200111000-00052; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	35	62	67	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2010	12	1					10	16		10.1007/s12028-009-9280-2			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	571HL	WOS:000275742800003	19821062				2022-02-06	
J	Inamasu, J; Kuramae, T; Nakatsukasa, M				Inamasu, Joji; Kuramae, Takumi; Nakatsukasa, Masashi			Does Difference in the Storage Method of Bone Flaps After Decompressive Craniectomy Affect the Incidence of Surgical Site Infection After Cranioplasty? Comparison Between Subcutaneous Pocket and Cryopreservation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Bone flap; Cranioplasty; Cryopreservation; Decompressive craniectomy; Subcutaneous pocket; Surgical site infection; Traumatic brain injury	DELAYED CRANIOPLASTY; GRAFT INFECTION; FROZEN; PRESERVATION	Background: After decompressive craniectomy for brain swelling, bone flaps need to be stored in a sterile fashion until cranioplasty. Temporary placement in a subcutaneous pocket (SP) and cryopreservation (CP) are the two commonly used methods for preserving bone flaps. Surgical site infection (SSI) is a serious complication of cranioplasty, and the storage method associated with a lower SSI incidence is favored. It is unclear, however, whether one storage method is superior to the other in terms of SSI prevention. Methods: During a 9-year period, 70 patients underwent decompressive craniectomy and subsequent cranioplasty. Bone flaps from 39 patients were stored using SP and those from the other 31 were stored using CP. Demographic data and SSI incidence was compared. Results: There were no significant demographic differences between the groups. SSI occurred in seven patients: 2 (5.1%) in the SP group and 5 (16.1%) in the CP group. The difference was not statistically significant (p = 0.23). When each group was further divided into two categories based oil etiology (traumatic brain injury [TBI] versus non-TBI), CP showed a significantly higher SSI incidence compared with SP (28.6% versus 0%, p = 0.02.) in the TBI category. However, the difference in incidence was not significant in the non-TBI category. Conclusions: SP and CP may be equally efficacious for storage of bone flails of non-TBI etiology; however, SP may be the storage method of choice for TBI. It remains to be verified in a prospective fashion whether SP is truly the better method of storing bone flaps in TBI.	[Inamasu, Joji; Kuramae, Takumi; Nakatsukasa, Masashi] Saiseikai Utsunomiya Hosp, Dept Neurosurg, Utsunomiya, Tochigi 3210974, Japan		Inamasu, J (corresponding author), Saiseikai Utsunomiya Hosp, Dept Neurosurg, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan.	ginamasu@aol.com	Inamasu, Joji/R-7314-2019				ACIKGOZ B, 1986, SURG NEUROL, V26, P557, DOI 10.1016/0090-3019(86)90339-3; Asano Y, 1993, No To Shinkei, V45, P1145; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Crotti F M, 1979, J Neurosurg Sci, V23, P289; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Ichinose T, 2007, NEUROL SURG TOKYO, V35, P151; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Missori P, 2003, ACTA NEUROCHIR, V145, P899, DOI 10.1007/s00701-003-0118-y; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Nakajima T, 1977, No Shinkei Geka, V5, P1329; OSAWA M, 1990, ACTA NEUROCHIR, V102, P38, DOI 10.1007/BF01402184; PACSAOGLU A, 1996, NEUROSURG REV, V19, P153; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Shimizu S, 2002, NEUROL SURG TOKYO, V30, P479; Tybor K, 2005, NEUROL NEUROCHIR POL, V39, P225; Tybor Krzysztof, 2005, Neurol Neurochir Pol, V39, P220; Yano H, 2006, J CRANIOFAC SURG, V17, P1076, DOI 10.1097/01.scs.0000244916.84511.b6; Zingale A, 2003, J Neurosurg Sci, V47, P137	23	62	64	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2010	68	1					183	187		10.1097/TA.0b013e3181c45384			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	543NR	WOS:000273585800035	20065773				2022-02-06	
J	Riley, RD; Steyerberg, EW				Riley, Richard D.; Steyerberg, Ewout W.			Meta-analysis of a binary outcome using individual participant data and aggregate data	RESEARCH SYNTHESIS METHODS			English	Article						meta-analysis; evidence synthesis; individual participant data (IPD); binary data; participant-level covariate	PATIENT DATA; META-REGRESSION; ECOLOGICAL BIAS; LEVEL; MODELS; ASSOCIATIONS; FRAMEWORK	In this paper, we develop meta-analysis models that synthesize a binary outcome from health-care studies while accounting for participant-level covariates. In particular, we show how to synthesize the observed event-risk across studies while accounting for the within-study association between participant-level covariates and individual event probability. The models are adapted for situations where studies provide individual participant data (IPD), or a mixture of IPD and aggregate data. We show that the availability of IPD is crucial in at least some studies; this allows one to model potentially complex within-study associations and separate them from across-study associations, so as to account for potential ecological bias and study-level confounding. The models can produce pertinent population-level and individual-level results, such as the pooled event-risk and the covariate-specific event probability for an individual. Application is made to 14 studies of traumatic brain injury, where IPD are available for four studies and the six-month mortality risk is synthesized in relation to individual age. The results show that as individual age increases the probability of six-month mortality also increases; further, the models reveal clear evidence of ecological bias, with the mean age in each study additionally influencing an individual's mortality probability. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Riley, Richard D.] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Med Stat, Birmingham B15 2TT, W Midlands, England; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Med Decis Making, NL-3000 CA Rotterdam, Netherlands		Riley, RD (corresponding author), Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Publ Hlth Bldg, Birmingham B15 2TT, W Midlands, England.	r.d.riley@bham.ac.uk	Riley, Richard David/ABE-5877-2020	Riley, Richard David/0000-0001-8699-0735	U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800808] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800808] Funding Source: researchfish	The work by E. W. Steyerberg on TBI is supported by the U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691). We thank the Editors, an Associate Editor, and two Reviewers for their constructive comments that have greatly improved the content of this paper.	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Barr DR, 1999, AM STAT, V53, P357, DOI 10.2307/2686057; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Berlin JA, 2002, STAT MED, V21, P371, DOI 10.1002/sim.1023; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Dwyer T, 2005, PAEDIATR PERINAT EP, V19, P48, DOI 10.1111/j.1365-3016.2005.00615.x; Goldstein H, 2000, J ROY STAT SOC C-APP, V49, P399, DOI 10.1111/1467-9876.00200; Greenland S, 2002, STAT MED, V21, P389, DOI 10.1002/sim.1024; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jackson C, 2006, STAT MED, V25, P2136, DOI 10.1002/sim.2370; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lee KJ, 2008, STAT MED, V27, P418, DOI 10.1002/sim.2897; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Mancl LA, 2000, J DENT RES, V79, P1778, DOI 10.1177/00220345000790100801; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; NEUHAUS JM, 1991, INT STAT REV, V59, P25, DOI 10.2307/1403572; Pinheiro J.C, 1995, J COMPUT GRAPH STAT, V4, P12, DOI 10.1080/10618600.1995.10474663; RICHARDSON S, 1987, INT J EPIDEMIOL, V16, P111, DOI 10.1093/ije/16.1.111; Riley RD, 2008, STAT MED, V27, P1870, DOI 10.1002/sim.3165; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2008, STAT MED, V27, P6111, DOI 10.1002/sim.3441; Schmid CH, 2004, J CLIN EPIDEMIOL, V57, P683, DOI 10.1016/j.jclinepi.2003.12.001; Simmonds MC, 2007, STAT MED, V26, P2982, DOI 10.1002/sim.2768; Simmonds MC, 2005, THESIS U CAMBRIDGE; SPIEGELHALTER DJ, 2003, BAYESIAN APPROACHES; Steyerberg EW, 2000, STAT MED, V19, P141, DOI 10.1002/(SICI)1097-0258(20000130)19:2<141::AID-SIM334>3.0.CO;2-O; Sutton AJ, 2008, STAT MED, V27, P651, DOI 10.1002/sim.2916; Thompson SG, 2005, LANCET, V365, P341, DOI 10.1016/S0140-6736(05)17790-3; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L; VACH W, 1991, AM J EPIDEMIOL, V134, P895, DOI 10.1093/oxfordjournals.aje.a116164; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zhou XH, 1999, STAT MED, V18, P557, DOI 10.1002/(SICI)1097-0258(19990315)18:5<557::AID-SIM53>3.0.CO;2-F	39	62	62	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1759-2879	1759-2887		RES SYNTH METHODS	Res. Synth. Methods	JAN-MAR	2010	1	1					2	19		10.1002/jrsm.4			18	Mathematical & Computational Biology; Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Science & Technology - Other Topics	V38ZC	WOS:000209380300002	26056090				2022-02-06	
J	Afari, N; Harder, LH; Madra, NJ; Heppner, PS; Moeller-Bertram, T; King, C; Baker, DG				Afari, Niloofar; Harder, Laura H.; Madra, Naju J.; Heppner, Pia S.; Moeller-Bertram, Tobias; King, Clay; Baker, Dewleen G.			PTSD, Combat Injury, and Headache in Veterans Returning From Iraq/Afghanistan	HEADACHE			English	Article						headache; posttraumatic stress disorder; combat; physical injury; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; CHRONIC PAIN; PREVALENCE; MIGRAINE; IMPACT; RACE; IRAQ; POPULATION; SYMPTOMS	Objective.- To examine the relationship between posttraumatic stress disorder, combat injury, and headache in Operation Iraqi Freedom and Operation Enduring Freedom veterans at the VA San Diego Healthcare System. Background.- Previous investigations suggest that a relationship between posttraumatic stress disorder and primary headache disorders exists and could be complicated by the contribution of physical injury, especially one that results in loss of consciousness. These associations have not been systematically examined in Operation Iraqi Freedom and Operation Enduring Freedom veterans. Methods.- In this observational cross-sectional study, a battery of self-report, standardized questionnaires was completed by 308 newly registered veterans between March and October 2006. The Davidson Trauma Scale was used to determine the degree of posttraumatic stress disorder symptoms and combat-related physical injury was assessed by self-report. The presence of headache was based on a symptom checklist measure and self-reported doctor diagnoses. Logistic regression analysis was performed to predict presence of headache and determine odds ratios and 95% confidence intervals associated with demographic, military, in-theatre, and mental health characteristics. Results.- About 40% of the veterans met the criteria for posttraumatic stress disorder; 40% self-reported current headache, 10% reported a physician diagnosis of migraine, 12% a physician diagnosis of tension-type headache, and 6% reported both types of headache. Results from the logistic regression model indicated that combat-related physical injury (odds ratio: 2.25; 95% confidence interval: 1.17-4.33) and posttraumatic stress disorder (odds ratio: 4.13; 95% confidence interval: 2.44-6.99) were independent predictors of self-reported headache. Additional analyses found that veterans with both tension and migraine headache had higher rates of posttraumatic stress disorder (chi-square [d.f. = 3] = 15.89; P = .001) whereas veterans with migraine headache alone had higher rates of combat-related physical injury (chi-square [d.f. = 9] = 22.00; P = .009). Conclusion.- Posttraumatic stress disorder and combat-related physical injury were related to higher rates of self-reported headache in newly returning veterans. Our finding that posttraumatic stress disorder and injury during combat are differentially related to migraine and tension-type headache, point to a complex relationship between physical and psychological trauma and headache. These findings have implications for a comprehensive approach to interventions for headache and the physical and psychological sequelae of trauma.	[Afari, Niloofar; Heppner, Pia S.; Baker, Dewleen G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Afari, Niloofar; Harder, Laura H.; Madra, Naju J.; Heppner, Pia S.; Moeller-Bertram, Tobias; King, Clay; Baker, Dewleen G.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Afari, Niloofar; Heppner, Pia S.; Moeller-Bertram, Tobias; Baker, Dewleen G.] Vet Affairs Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Moeller-Bertram, Tobias] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA		Afari, N (corresponding author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Mail Stop 0738, La Jolla, CA 92093 USA.		Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AR051524, U01DK082325]; Department of DefenseUnited States Department of Defense; VA research grants; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082325] Funding Source: NIH RePORTER	Dr. Afari is supported in part by the National Institute of Health (R01AR051524 and U01DK082325). Dr. Baker is supported in part by Department of Defense and VA research grants (Merit, HSR&D, and Cooperative Studies). Dr. Moeller-Bertram is supported in part by a grant from the Foundation for Anesthesia Education and Research. Drs. Afari, Heppner, Moeller-Bertram, and Baker are supported in part by the VA Center of Excellence for Stress and Mental Health. We appreciate the efforts and support of Mr. Michael Kilmer of the Social Work Service, and Mr. Glenn White and his staff at Member Services of the VA San Diego Healthcare System. Portions of this study were presented at the VA Mental Health Conference in July, 2008 and the 24th annual meeting of the International Society for Traumatic Stress Studies in November, 2008.	Adeney KL, 2006, AM J EPIDEMIOL, V163, pS221; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Boscarino JA, 2004, ANN NY ACAD SCI, V1032, P141, DOI 10.1196/annals.1314.011; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; Engel CC, 2006, PHILOS T R SOC B, V361, P707, DOI 10.1098/rstb.2006.1829; Gerber Y, 2007, MAYO CLIN PROC, V82, P933, DOI 10.4065/82.8.933; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Ifergane G, 2009, EUR J INTERN MED, V20, P182, DOI 10.1016/j.ejim.2008.05.001; Katon WJ, 2006, J TRAUMA STRESS, V19, P611, DOI 10.1002/jts.20147; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lyngberg AC, 2005, EUR J EPIDEMIOL, V20, P243, DOI 10.1007/s10654-004-6519-2; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; Moorman PG, 1999, ANN EPIDEMIOL, V9, P188, DOI 10.1016/S1047-2797(98)00057-X; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nash JM, 2006, HEADACHE, V46, P1377, DOI 10.1111/j.1526-4610.2006.00580.x; Orr SP, 2002, PSYCHIAT CLIN N AM, V25, P271, DOI 10.1016/S0193-953X(01)00007-7; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnurr Paula P, 2004, Adv Mind Body Med, V20, P18; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Wolfe J, 1999, PSYCHOSOM MED, V61, P532, DOI 10.1097/00006842-199907000-00018	37	62	62	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	OCT	2009	49	9					1267	1276		10.1111/j.1526-4610.2009.01517.x			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	500OC	WOS:000270311200003	19788469				2022-02-06	
J	Salim, A; Teixeira, P; Ley, EJ; DuBose, J; Inaba, K; Margulies, DR				Salim, Ali; Teixeira, Pedro; Ley, Eric J.; DuBose, Joseph; Inaba, Kenji; Margulies, Daniel R.			Serum Ethanol Levels: Predictor of Survival After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Alcohol; Traumatic brain injury; Outcome; Intoxication	753 CONSECUTIVE DEATHS; GLASGOW COMA SCALE; HEAD-INJURY; ALCOHOL-INTOXICATION; SUBSTANCE-ABUSE; HOSPITAL COURSE; SCORE; ASSOCIATION; PREVALENCE; PREVENTION	Background: Recent studies have suggested that moderate doses of ethanol (ETOH) before traumatic brain injury (TBI) may have a neuroprotective role. Objective: The objective of this study is to investigate the effects of serum ETOH levels on outcomes after TBI. Our hypothesis was that ETOH exposure is associated with improved survival in severe TBI patients and that the serum ETOH levels on admission correlate with survival. Methods: All patients sustaining severe TBI (head abbreviated injury score >= 3) admitted to the Surgical Intensive Care Unit at the Los Angeles County + University of Southern California Medical Center from January 2000 to December 2005 who had a serum ETOH level measured on admission were analyzed. Patients were classified into ETOH-positive and ETOH-negative groups, according to the serum ETOH levels and compared for differences in outcomes using logistic regression to adjust for clinically and statistically relevant confounding factors. Results: During the 5-year study period, 482 severe TBI patients admitted to the Surgical Intensive Care Unit at Los Angeles County + University of Southern California Medical Center had a serum ETOH level measured on admission. A total of 47% of severe TBI patients were tested for ETOH. ETOH levels were positive in 37% (179) and negative in 63% (303) of the TBI patients. The ETOH-positive group had a higher percentage of males (91% vs. 79%, p = 0.001), lower percentage of penetrating injuries (9% vs. 20%, p = 0.002), and lower injury severity score (25.7 +/- 11.5 vs. 28.4 +/- 14.1, p = 0.05). Overall mortality was significantly lower in the ETOH-positive group at 27% versus 40% (odds ratio = 0.55, 95% confidence interval: 0.37-0.82; p = 0.004). This survival benefit remained significant after multivariable analysis (adjusted odds ratio = 0.54, 95% confidence interval: 0.31-0.92; adjusted p = 0.02). The mean serum ETOH level was significantly higher for survivors than for nonsurvivors (0.11 +/- 0.21 vs. 0.05 +/- 0.10, p < 0.001). The serum ETOH levels significantly correlated with the probability of survival (r = 0.21, p < 0.001), but this correlation was not strong as shown by the low r value. Conclusion: The results of this study suggest that elevated ETOH serum levels are independently associated with higher survival in patients with severe traumatic brain injuries. Additional research is required to further investigate the mechanism and potential therapeutic implications of this association.	[Salim, Ali; Ley, Eric J.; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Teixeira, Pedro; DuBose, Joseph; Inaba, Kenji] Univ So Calif, Med Ctr, Div Trauma, Los Angeles, CA USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	INABA, KENJI/AAC-8532-2020; Teixeira, Pedro/H-2239-2011	Teixeira, Pedro/0000-0002-7258-7977			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Christensen M A, 2001, J Neurosci Nurs, V33, P184; Cornwell EE, 1998, AM SURGEON, V64, P461; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Flaherty S, 2003, J TRAUMA, V54, P70; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; Guidot DM, 2005, J INVEST MED, V53, P235, DOI 10.2310/6650.2005.53506; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HERVE C, 1986, J TRAUMA, V26, P1123, DOI 10.1097/00005373-198612000-00013; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; MILLER TR, 1994, ACCIDENT ANAL PREV, V26, P583, DOI 10.1016/0001-4575(94)90020-5; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; NHTSA, 2000, EC IMP MOT VEH CRASH; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TEASDALE G, 1974, LANCET, V2, P81; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1991, J TRAUMA, V31, P1271, DOI 10.1097/00005373-199109000-00012; Woolf PD, 1991, J TRAUMA, V31, P1275	51	62	65	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					697	703		10.1097/TA.0b013e3181b5dcf2			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	506BE	WOS:000270747000004	19820573				2022-02-06	
J	Sharma, S; Zhuang, Y; Ying, Z; Wu, A; Gomez-Pinilla, F				Sharma, S.; Zhuang, Y.; Ying, Z.; Wu, A.; Gomez-Pinilla, F.			DIETARY CURCUMIN SUPPLEMENTATION COUNTERACTS REDUCTION IN LEVELS OF MOLECULES INVOLVED IN ENERGY HOMEOSTASIS AFTER BRAIN TRAUMA	NEUROSCIENCE			English	Article						curcumin; energy homeostasis; traumatic brain injury	ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL CREATINE-KINASE; CYTOCHROME-C-OXIDASE; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; UNCOUPLING PROTEIN-2; SYNAPTIC PLASTICITY; CALORIE RESTRICTION; NEUROTROPHIC FACTOR	Traumatic brain injury (TBI) is followed by an energy crisis that compromises the capacity of the brain to cope with challenges, and often reduces cognitive ability. New research indicates that events that regulate energy homeostasis crucially impact synaptic function and this can compromise the capacity of the brain to respond to challenges during the acute and chronic phases of TBI. The goal of the present study is to determine the influence of the phenolic yellow curry pigment curcumin on molecular systems involved with the monitoring, balance, and transduction of cellular energy, in the hippocampus of animals exposed to mild fluid percussion injury (FPI). Young adult rats were exposed to a regular diet (RD) without or with 500 ppm curcumin (Cur) for four weeks, before an FPI was performed. The rats were assigned to four groups: RD/Sham, Cur/Sham, RD/FPI, and Cur/FPI. We found that FPI decreased the levels of AMP-activated protein kinase (AMPK), ubiquitous mitochondrial creatine kinase (uMtCK) and cytochrome c oxidase II (COX-II) in RD/FPI rats as compared to the RD/sham rats. The curcumin diet counteracted the effects of FPI and elevated the levels of AMPK, uMtCK, COX-II in Cur/FPI rats as compared to RD/sham rats. In addition, in the Cur/sham rats, AMPK and uMtCK increased compared to the RD/sham. Results show the potential of curcumin to regulate molecules involved in energy homeostasis following TBI. These studies may foster a new line of therapeutic treatments for TBI patients by endogenous upregulation of molecules important for functional recovery. (C) 2009 Published by Elsevier Ltd on behalf of IBRO.	[Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Physiol Sci, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Gomez-Pinilla, F.] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, Brain Injury Res Ctr, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu	Sharma, Sandeep/AAU-7050-2021; Sharma, Sandeep/A-9248-2011	Sharma, Sandeep/0000-0002-9680-7460; Sharma, Sandeep/0000-0002-9680-7460	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS50465]	Studies were supported by funds related to awards covered under National Institutes of Health, NS50465. We are also thankful to the Brain Injury Research Center, UCLA for their cooperation.	Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Arsenijevic D, 2007, J NEUROIMMUNOL, V186, P121, DOI 10.1016/j.jneuroim.2007.03.013; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Boero J, 2003, MOL CELL BIOCHEM, V244, P69, DOI 10.1023/A:1022409101641; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Bronner M, 2004, BIOCHEM J, V384, P295, DOI 10.1042/BJ20040955; Chen LL, 1995, J COMP NEUROL, V363, P389, DOI 10.1002/cne.903630305; Cheng G, 2003, BIOCHEM BIOPH RES CO, V308, P573, DOI 10.1016/S0006-291X(03)01409-8; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200; Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034; de Lange P, 2006, FASEB J, V20, DOI 10.1096/fj.06-6025fje; EPPENBERGER ME, 1967, NATURE, V214, P239, DOI 10.1038/214239a0; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; FRIEDMAN DL, 1994, J COMP NEUROL, V343, P500, DOI 10.1002/cne.903430311; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Horvath TL, 1999, J NEUROSCI, V19, P10417; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200; Kim-Han JS, 2005, ANTIOXID REDOX SIGN, V7, P1173, DOI 10.1089/ars.2005.7.1173; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NELSON C, 1994, PEDIATR RES, V36, P12, DOI 10.1203/00006450-199407001-00003; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nisoli E, 2006, J CELL SCI, V119, P2855, DOI 10.1242/jcs.03062; North RA, 2006, PFLUG ARCH EUR J PHY, V452, P479, DOI 10.1007/s00424-006-0060-y; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Richard D, 1999, INT J OBESITY, V23, pS53, DOI 10.1038/sj.ijo.0800947; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; ROJO M, 1991, J BIOL CHEM, V266, P20290; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sumanont Y, 2006, LIFE SCI, V78, P1884, DOI 10.1016/j.lfs.2005.08.028; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062; WHITTINGHAM TS, 1981, J NEUROCHEM, V37, P1618, DOI 10.1111/j.1471-4159.1981.tb06337.x; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117	63	62	64	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 21	2009	161	4					1037	1044		10.1016/j.neuroscience.2009.04.042			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	458EU	WOS:000266998600008	19393301	Green Accepted			2022-02-06	
J	Whiteneck, G; Gassaway, J; Dijkers, M; Jha, A				Whiteneck, Gale; Gassaway, Julie; Dijkers, Marcel; Jha, Amitabh			New Approach to Study the Contents and Outcomes of Spinal Cord Injury Rehabilitation: The SCIRehab Project	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Rehabilitation, physical; Outcomes research; Epidemiology; Practice-based evidence	LENGTH-OF-STAY; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; INPATIENT REHABILITATION; FUNCTIONAL STATUS; BLACK-BOX; NEUROLOGIC RECOVERY; PHYSICAL-THERAPY; MOTOR; SEVERITY	Background/Objective: Limited research evidence is available to show the effectiveness of the many specific interventions provided in spinal cord injury (SCI) rehabilitation; what is available typically focuses on effects of the full rehabilitation package but not specific therapy interventions, medical procedures, patient education, or counseling. Given the problems of conducting randomized controlled trials (RCTs) in rehabilitation, practice-based evidence (PBE) research has been suggested as an alternative methodology for identifying which rehabilitation interventions are associated most strongly with positive outcomes, after controlling for patient differences. Using the PBE research methodology, the SCIRehab project attempts to "open the black box" of acute SCI rehabilitation, provide detailed information on treatments delivered by all rehabilitation disciplines, and contribute to outcomes-based guidelines for clinical decision-making. Methods: The SCIRehab project includes 1,500 patients with acute SCI, consecutively admitted to 1 of 6 US inpatient rehabilitation facilities. Details of the rehabilitation process are captured by clinicians from multiple disciplines documenting their interventions in handheld personal digital assistants after sessions with their patients. Outcome data are abstracted from medical records (clinical outcomes data) and obtained from patient interviews at 6 and 12 months after injury. Extensive patient, injury, and other treatment characteristics are abstracted from medical records. SCIRehab is the first research project to collect detailed information on individual interventions offered by the full rehabilitation team. Results: SCIRehab is the first research project to collect detailed information on individual interventions offered by the full rehabilitation team. These findings are presented in a series of 9 articles. Conclusions: To date, SCIRehab's major contribution is a system for categorizing specific contributions of each discipline and a technology for documenting that detail. After data collection is complete, future manuscripts will relate those process elements to outcomes. The SCIRehab Project is an important step toward establishing outcomes-based guidelines for SCI rehabilitation.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Whiteneck, Gale; Jha, Amitabh] Craig Hosp, Englewood, CO USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA		Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	Department of EducationUS Department of Education; NIDRR [H133A060103, H133N060005, H133N060027]	The contents of this article were developed under grants from the Department of Education and NIDRR Grants H133A060103 and H133N060005 to Craig Hospital and H133N060027 to Mount Sinai School of Medicine. However, these contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the federal government.	Abeyta N, 2009, J SPINAL CORD MED, V32, P336, DOI 10.1080/10790268.2009.11760787; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Bode RK, 2004, ARCH PHYS MED REHAB, V85, P1901, DOI 10.1016/j.apmr.2004.02.023; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1488, DOI 10.1016/j.apmr.2003.10.010; Breasted J., 1930, E SMITH SURG PAPYRUS; Burnett DM, 2002, NEUROREHABILITATION, V17, P187; Burnett DM, 2001, ARCH PHYS MED REHAB, V82, P114, DOI 10.1053/apmr.2001.18042; Burns SP, 2005, J SPINAL CORD MED, V28, P33, DOI 10.1080/10790268.2005.11753796; Burns SP, 1997, ARCH PHYS MED REHAB, V78, P1169, DOI 10.1016/S0003-9993(97)90326-9; Cahow C, 2009, J SPINAL CORD MED, V32, P298, DOI 10.1080/10790268.2009.11760783; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; Celani MG, 2001, ARCH PHYS MED REHAB, V82, P589, DOI 10.1053/apmr.2001.21948; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; Conroy B, 2005, ARCH PHYS MED REHAB, V86, pS73, DOI 10.1016/j.apmr.2005.08.129; *CONS SPIN CORD ME, CLIN PRACT GUID; Curt A, 1998, ARCH PHYS MED REHAB, V79, P81, DOI 10.1016/S0003-9993(98)90213-1; DeJong G, 2004, ARCH PHYS MED REHAB, V85, P678, DOI 10.1016/j.apmr.2003.06.033; DeJong G, 2007, ANN C AM C REH MED O; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; ELTORAI I, 2003, HIST SPINAL CORD MED; Esselman PC, 2006, AM J PHYS MED REHAB, V85, P383, DOI 10.1097/01.phm.0000202095.51037.a3; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HORN S, 1997, ONCOL ISSUES, V12, P16; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Johnson K, 2009, J SPINAL CORD MED, V32, P329, DOI 10.1080/10790268.2009.11760786; Johnston MV, 2006, AM J PHYS MED REHAB, V85, P292, DOI 10.1097/01.phm.0000202079.58567.3b; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Latham NK, 2005, ARCH PHYS MED REHAB, V86, pS41, DOI 10.1016/j.apmr.2005.08.128; LAZAR RB, 1989, ARCH PHYS MED REHAB, V70, P819; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Mckinley William O, 2002, J Spinal Cord Med, V25, P28; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1253, DOI 10.1016/S0003-9993(99)90025-4; McKinley WO, 2001, AM J PHYS MED REHAB, V80, P693, DOI 10.1097/00002060-200109000-00010; McKinley WO, 2000, AM J PHYS MED REHAB, V79, P138, DOI 10.1097/00002060-200003000-00005; Meade MA, 2004, ARCH PHYS MED REHAB, V85, P368, DOI 10.1016/j.apmr.2003.06.008; Middleton JW, 1998, ARCH PHYS MED REHAB, V79, P1428, DOI 10.1016/S0003-9993(98)90239-8; Muslumanoglu L, 1997, SPINAL CORD, V35, P386, DOI 10.1038/sj.sc.3100406; *NAT SPIN CORD INJ, 2007 ANN REP SPIN CO; Natale A, 2009, J SPINAL CORD MED, V32, P270, DOI 10.1080/10790268.2009.11760781; National Spinal Cord Injury Statistical Center, 2008, SPIN CORD INJ FACTS; New PW, 2005, ARCH PHYS MED REHAB, V86, P250, DOI 10.1016/j.apmr.2004.04.028; Ozelie R, 2009, J SPINAL CORD MED, V32, P283, DOI 10.1080/10790268.2009.11760782; Pagliacci MC, 2003, ARCH PHYS MED REHAB, V84, P1266, DOI 10.1016/S0003-9993(03)00234-X; Pagliacci MC, 2003, SPINAL CORD, V41, P620, DOI 10.1038/sj.sc.3101521; Post MWM, 2005, J REHABIL RES DEV, V42, P75, DOI 10.1682/JRRD.2004.10.0133; Saboe LA, 1997, ARCH PHYS MED REHAB, V78, P644, DOI 10.1016/S0003-9993(97)90431-7; Schonherr MC, 1999, CLIN REHABIL, V13, P457, DOI 10.1191/026921599666105472; Scivoletto G, 2005, ARCH PHYS MED REHAB, V86, P512, DOI 10.1016/j.apmr.2004.05.021; Scivoletto G, 2004, CLIN REHABIL, V18, P709, DOI 10.1191/0269215504cr749oa; Scivoletto G, 2004, ARCH PHYS MED REHAB, V85, P485, DOI 10.1016/S0003-9993(03)00766-4; Seel R T, 2001, J Spinal Cord Med, V24, P241; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; SPIVAK JM, 1994, SPINE, V19, P2302, DOI 10.1097/00007632-199410150-00009; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Tooth L, 2003, SPINAL CORD, V41, P220, DOI 10.1038/sj.sc.3101433; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; *US AG HEALTHC QUA, 1996, 990034 AHCPR; van der Putten JMF, 2001, NEUROREHAB NEURAL RE, V15, P99, DOI 10.1177/154596830101500203; van Langeveld SA, 2008, ARCH PHYS MED REHAB, V89, P1454, DOI 10.1016/j.apmr.2007.12.044; van Langeveld Sacha A H B, 2008, J Neurol Phys Ther, V32, P2, DOI 10.1097/NPT.0b013e3181663533; Wade DT, 2001, CLIN REHABIL, V15, P229, DOI 10.1191/026921501677354949; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; Waters RL, 1998, ARCH PHYS MED REHAB, V79, P1237, DOI 10.1016/S0003-9993(98)90268-4; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Wilson C, 2009, J SPINAL CORD MED, V32, P319, DOI 10.1080/10790268.2009.11760785	82	62	63	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					251	259		10.1080/10790268.2009.11760779			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	474NF	WOS:000268290100006	19810627	Green Published			2022-02-06	
J	Bruce, JM; Echemendia, RJ				Bruce, Jared M.; Echemendia, Ruben J.			HISTORY OF MULTIPLE SELF-REPORTED CONCUSSIONS IS NOT ASSOCIATED WITH REDUCED COGNITIVE ABILITIES	NEUROSURGERY			English	Article						Cognition; Concussion; Mild traumatic brain injury; Neuropsychology	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HIGH-SCHOOL; PERFORMANCE; RECOVERY; PLAYERS; IMPACT	OBJECTIVE: The long-term impact of sports-related concussion is uncertain. Several studies using traditional neuropsychological measures have found a relationship between a previous history of concussion and reduced cognitive abilities. In contrast, studies using computerized neuropsychological measures have typically found no relationship between concussion history and cognition. In the present study, we examined the association between a self-reported concussion history and cognition using traditional and computer-based neuropsychological tests. METHODS: A computerized neuropsychological battery was administered to a sample of 858 collegiate male athletes. Of this sample, 298 athletes reported a history of concussion. A traditional neuropsychological battery was administered to a separate sample of 479 male collegiate athletes, 187 of whom reported a history of concussion. Finally, both a computerized and a traditional neuropsychological battery were administered to a third distinct sample of 175 male collegiate athletes, 57 of whom reported a history of concussion. Concussion history was assessed via self-report. None of the athletes had been concussed in the 6 months before testing. RESULTS: No significant association was found between self-reported concussion history and performance on either computerized or traditional neuropsychological tests. CONCLUSION: Findings suggest that athletes who report a distant history of concussion have minimal enduring neurocognitive deficits. Given conflicting findings in the literature, prospective studies that attempt to identify moderating factors are necessary to help determine who is at risk for long-term cognitive difficulties after concussion.	[Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA		Bruce, JM (corresponding author), Univ Missouri, Dept Psychol, 4825 Troost Bldg,Suite 111-G,5100 Rockhill Rd, Kansas City, MO 64110 USA.	brucejm@umkc.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BENTON AL, 1994, MULTILINGUAL APHASIA, P4409; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2004, NEUROLOGY, V63, P1516; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; REITAN R, 1985, HALSTEAD REITAN NEUR, P4409; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; SMITH A, 1973, SYMBOL DIGIT MODALIT, P4409; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TRENERRY M, 1989, STROOP NEUROLOGICAL, P4409; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	26	62	63	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2009	64	1					100	106		10.1227/01.NEU.0000336310.47513.C8			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	393MO	WOS:000262377600022	19145158				2022-02-06	
J	Lew, HL; Garvert, DW; Pogoda, TK; Hsu, PT; Devine, JM; White, DK; Myers, PJ; Goodrich, GL				Lew, Henry L.; Garvert, Donn W.; Pogoda, Terri K.; Hsu, Pei-Te; Devine, Jennifer M.; White, Daniel K.; Myers, Paula J.; Goodrich, Gregory L.			Auditory and visual impairments in patients with blast-related traumatic brain injury: Effect of dual sensory impairment on Functional Independence Measure	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast-related; brain injuries; dual sensory impairment; Functional Independence Measure; hearing; outcomes assessment; polytrauma; rehabilitation; sensory disorders; vision	HEARING; SOLDIERS; POPULATION; DEPRESSION; VISION; IRAQ	The frequencies of hearing impairment (HI), vision impairment (VI), or dual (hearing and vision) sensory impairment (DSI) in patients with blast-related traumatic brain injury (TBI) and their effects on functional recovery are not well documented. In this preliminary study of 175 patients admitted to a Polytrauma Rehabilitation Center, we completed hearing and vision examinations and obtained Functional Independence Measure (FIM) scores at admission and discharge for 62 patients with blast-related TBI. We diagnosed HI only, VI only, and DSI in 19%, 34%, and 32% of patients, respectively. Only 15% of the patients had no sensory impairment in either auditory or visual modality. An analysis of variance showed a group difference for the total and motor FIM scores at discharge (p < 0.04). Regression model analyses demonstrated that DSI significantly contributed to reduced gain in total (t = -2.25) and motor (t = -2.50) FIM scores (p < 0.05). Understanding the long-term consequences of sensory impairments in the functional recovery of patients with blast-related TBI requires further research.	[Lew, Henry L.; Hsu, Pei-Te; Devine, Jennifer M.] VA Boston Healthcare Syst, Dept Vet Affairs, Phys Med & Rehabil Serv, Boston, MA USA; [Lew, Henry L.; Hsu, Pei-Te] Harvard Univ, Sch Med, Boston, MA USA; [Lew, Henry L.] VA Boston Healthcare Syst, Def & Vet Brain Injury Ctr, Boston, MA USA; [Lew, Henry L.; Pogoda, Terri K.; Hsu, Pei-Te] VA Boston Healthcare Syst, Traumat Brain Injury Ctr Excellence, Boston, MA USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [White, Daniel K.] Boston Univ, Med Ctr, Boston, MA USA; [Myers, Paula J.] James A Haley Vet Hosp, Audiol Sect, Tampa, FL 33612 USA		Goodrich, GL (corresponding author), VA Palo Alto Hlth Care Syst, Psychol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	gregory.goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019; White, Daniel Kenta/AAE-8449-2021; Pogoda, Terri/F-6243-2012	White, Daniel Kenta/0000-0003-3792-4621; Pogoda, Terri/0000-0003-1397-8780	VA Merit ReviewUS Department of Veterans Affairs [BR5008]; Quality Enhancement Research Initiative [RRP 07-339]	This material was based on work supported in part by a VA Merit Review grant (BR5008) to Dr. Lew and a Quality Enhancement Research Initiative grant (RRP 07-339) to Dr. Goodrich.	Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368; CARHART R, 1959, J SPEECH HEAR DISORD, V24, P330, DOI 10.1044/jshd.2404.330; Centers for Disease Control and Prevention, INT CLASS DIS; Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Martin F.N., 1986, INTRO AUDIOLOGY; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Wong TY, 1997, SURV OPHTHALMOL, V41, P433, DOI 10.1016/S0039-6257(97)00022-2	22	62	65	0	11	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					819	826		10.1682/JRRD.2008.09.0129			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100013	20104405	Bronze			2022-02-06	
J	Peleg, G; Barak, O; Harel, Y; Rochberg, J; Hoofien, D				Peleg, Gil; Barak, Ohr; Harel, Yermi; Rochberg, Judith; Hoofien, Dan			Hope, dispositional optimism and severity of depression following traumatic brain injury	BRAIN INJURY			English	Article						Adult Hope Scale; Beck Depression Inventory; depression; hope; Life Orientation Test Revised; optimism; traumatic brain injury	MAJOR DEPRESSION; LIFE; HOPELESSNESS; INVENTORY; HEALTH; SATISFACTION; DISORDERS; DYSPHORIA; ANXIETY	Primary objective: To investigate the extent in which two coping variableshope and dispositional optimismare related to depression severity amongst individuals who have sustained traumatic brain injury (TBI). Methods and procedures: Sixty-five participants were administered the Beck Depression Inventory (BDI), the Adult Hope Scale (AHS), the Life Orientation Test-Revised (LOT-R) and a demographic and injury-related data questionnaire. In addition, relevant injury-related data was collected from the medical records. Main outcomes and results: High levels of depression were experienced in the study sample, while hope and dispositional optimism were significantly lower in comparison to the general population. The correlation patterns indicate that both hope and dispositional optimism negatively correlated with participants' depression levels and that they showed significant positive correlations with each other. In the case of mild depression, the hope-Pathways sub-scale of the AHS was the only variable negatively correlated to it, while in moderate-to-severe depression all coping variables were negatively correlated to it. Regression analysis revealed that the AHS and LOT-R, but not the demographic and injury-related variables, predicted depression severity. Conclusions: Clinical implications in referring persons with TBI with mild vs. severe depression to rehabilitation programmes are discussed.	[Peleg, Gil; Barak, Ohr] Tel Aviv Jaffa Acad Coll, Tel Aviv, Israel; [Barak, Ohr; Hoofien, Dan] Natl Inst Rehabil Persons Brain Injuries, Tel Aviv, Israel; [Harel, Yermi; Rochberg, Judith] Loewenstein Hosp Rehabil Ctr, Raanana, Israel; [Harel, Yermi] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Hoofien, Dan] Hebrew Univ Jerusalem, Jerusalem, Israel		Barak, O (corresponding author), Tel Aviv Jaffa Acad Coll, Dept Behav Sci, 14 Rabenu Yerucham St, IL-68182 Tel Aviv Jaffa, Israel.	obar@mta.ac.il			Tel-Aviv Jaffa academic college	This research was facilitated by a grant from the Tel-Aviv Jaffa academic college and support from the research and development funding of the national institute for the rehabilitation of persons with brain injuries in Israel.	Abramson LY, 2000, SCI OPTIMISM HOPE RE; Allison PJ, 2000, QUAL LIFE RES, V9, P951, DOI 10.1023/A:1008931906253; Arnau RC, 2007, J PERS, V75, P43, DOI 10.1111/j.1467-6494.2006.00432.x; Bailey TC, 2007, PSYCHOL REC, V57, P233, DOI 10.1007/BF03395574; Barry LC, 2007, PSYCHOSOM MED, V69, P115, DOI 10.1097/PSY.0b013e31802f2785; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bryan FB, 2004, J SOC CLIN PSYCHOL, V23, P273, DOI 10.1521/jscp.23.2.273.31018; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chang EC, 2001, PSYCHOL AGING, V16, P524, DOI 10.1037/0882-7974.16.3.524; Chang EC, 2001, J SOC CLIN PSYCHOL, V20, P117, DOI 10.1521/jscp.20.2.117.22262; CHANG EC, 2000, OPTIMISM PESSIMISM I; Cramer KM, 1998, PSYCHOL REP, V83, P1035, DOI 10.2466/PR0.83.7.1035-1041; Curry LA, 1997, J PERS SOC PSYCHOL, V73, P1257, DOI 10.1037/0022-3514.73.6.1257; DEMBER WN, 1989, CURR PSYCHOL RES REV, V8, P102, DOI 10.1007/BF02686675; DOBROV A, 1992, DISS ABSTR; ELLIOTT TR, 1991, J PERS SOC PSYCHOL, V61, P608, DOI 10.1037/0022-3514.61.4.608; Evans S, 2000, J PSYCHOSOM RES, V49, P157, DOI 10.1016/S0022-3999(00)00157-4; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hirsch JK, 2006, SUICIDE LIFE-THREAT, V36, P661, DOI 10.1521/suli.2006.36.6.661; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOROWITZ R, 1999, DISS ABSTR; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Klausner EJ, 1998, INT J GERIATR PSYCH, V13, P707, DOI 10.1002/(SICI)1099-1166(1998100)13:10<707::AID-GPS856>3.0.CO;2-Q; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kwon P, 2000, J PERS, V68, P199, DOI 10.1111/1467-6494.00095; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MELGES FT, 1969, ARCH GEN PSYCHIAT, V20, P690; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; MUIR CA, 1984, BEHAV ASSESSMENT REH; OLIVER JM, 1985, J CLIN PSYCHOL, V41, P469, DOI 10.1002/1097-4679(198507)41:4<469::AID-JCLP2270410405>3.0.CO;2-R; Pence L, 2007, J PAIN SYMPTOM MANAG, V33, P302, DOI 10.1016/j.jpainsymman.2006.08.010; PRIGATANO GP, 1999, NEUROPSYCHOLOGICAL R; RANGE LM, 1994, PSYCHOL REP, V75, P456, DOI 10.2466/pr0.1994.75.1.456; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schwartz B, 2002, J PERS SOC PSYCHOL, V83, P1178, DOI 10.1037//0022-3514.83.5.1178; Shahar G, 2008, J PERS ASSESS, V90, P61, DOI 10.1080/00223890701693751; Snyder CR, 1998, COGNITION EMOTION, V12, P807, DOI 10.1080/026999398379448; Snyder CR, 2000, COGNITIVE THER RES, V24, P747, DOI 10.1023/A:1005547730153; SNYDER CR, 1991, J PERS SOC PSYCHOL, V60, P570, DOI 10.1037/0022-3514.60.4.570; Snyder CR, 2002, J EDUC PSYCHOL, V94, P820, DOI 10.1037//0022-0663.94.4.820; Snyder CR, 2000, APPL PREV PSYCHOL, V9, P249, DOI 10.1016/S0962-1849(00)80003-7; SNYDER CR, 2000, OPTIMISM PESSIMISM I; Stanton AL, 2002, PSYCHO-ONCOLOGY, V11, P93, DOI 10.1002/pon.574; Thomas SA, 2006, BRIT J CLIN PSYCHOL, V45, P49, DOI 10.1348/014466505X34183	50	62	64	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	10					800	808	PII 914076473	10.1080/02699050903196696			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	485SP	WOS:000269144600003	19697168				2022-02-06	
J	Alexanian, AR; Maiman, DJ; Kurpad, SN; Gennarelli, TA				Alexanian, Arshak R.; Maiman, Dennis J.; Kurpad, Shekar N.; Gennarelli, Thomas A.			In Vitro and In Vivo Characterization of Neurally Modified Mesenchymal Stem Cells Induced by Epigenetic Modifiers and Neural Stem Cell Environment	STEM CELLS AND DEVELOPMENT			English	Article							MARROW STROMAL CELLS; ADULT SPINAL-CORD; NEURONAL DIFFERENTIATION; NONHEMATOPOIETIC TISSUES; MUSCLE REGENERATION; PROGENITOR CELLS; BONE; INDUCTION; PHENOTYPE; BRAIN	Mesenchymal stem cell (MSC)-mediated tissue regeneration is a promising strategy to treat several neurodegenerative diseases and traumatic injuries of the central nervous system. Bone marrow MSCs have great potential as therapeutic agents, since they are easy to isolate and expand and are capable of producing various cell types, including neural cells. Recently we developed a highly efficient methodology to produce neural stem-like and neural precursor-like cells from mice bone marrow-derived MSCs that eventually differentiate into neuronaland glial-like cells in vitro. The aim of this study is to further elucidate neural expression profile of neurally induced mesenchymal stem cells (NI-MSCs) and their ability to retain neural differentiation potential when grafted into the intact spinal cord of rats. To this end, we further characterized in vitro and in vivo properties of NI-MSCs by immunocytochemistry, Western blot, ELISA, and immunohistochemistry. Immunocytochemical data demonstrated that NI-MSCs express several mature neural markers such as B3T, GFAP MAP-2, NF-200, and NeuN, which were confirmed through Western blot. ELISA data showed that NI-MSCs release nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). In vivo studies demonstrated that grafted NI-MSCs survived after transplantation into intact spinal cord and produced cells that expressed neural markers. All these data suggest that neurally modified MSCs, induced by recently developed methodology, could be a potential source of cells to replace damaged neurons and glia in injured spinal cord, and/or to promote cell survival and axonal growth of host tissue.	[Alexanian, Arshak R.; Maiman, Dennis J.; Kurpad, Shekar N.; Gennarelli, Thomas A.] Vet Adm Med Ctr, Dept Neurosurg, Neurosci Res Labs, Milwaukee, WI 53295 USA		Alexanian, AR (corresponding author), Vet Adm Med Ctr, Dept Neurosurg, Neurosci Res Labs, Res 151,5000 W Natl Ave, Milwaukee, WI 53295 USA.	aalexan@mcw.edu	Kurpad, Shekar/V-2188-2019	Alexanian, Arshak/0000-0001-6107-9427	VA Medical Research and the Department of Neurosurgery	This work was supported by VA Medical Research and the Department of Neurosurgery. We thank Christy Stadig for technical assistance.	Alexanian AR, 2006, J NEUROSCI METH, V150, P41, DOI 10.1016/j.jneumeth.2005.05.024; Alexanian AR, 2005, EXP CELL RES, V310, P383, DOI 10.1016/j.yexcr.2005.08.015; Alexanian AR, 2007, J CELL BIOCHEM, V100, P362, DOI 10.1002/jcb.21029; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Bertani N, 2005, J CELL SCI, V118, P3925, DOI 10.1242/jcs.02511; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Corti S., 2003, Current Gene Therapy, V3, P247, DOI 10.2174/1566523034578375; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2005, EXPERT OPIN BIOL TH, V5, P427, DOI 10.1517/14712598.5.4.427; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Joannides A, 2003, J HEMATOTH STEM CELL, V12, P681, DOI 10.1089/15258160360732704; KATSETOS CD, 1994, ARCH PATHOL LAB MED, V118, P1002; Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756-200207020-00023; Kim SS, 2005, NEUROREPORT, V16, P1357, DOI 10.1097/01.wnr.0000175243.12966.f5; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102; Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Levy YS, 2003, J MOL NEUROSCI, V21, P121, DOI 10.1385/JMN:21:2:121; Long XX, 2005, STEM CELLS DEV, V14, P65, DOI 10.1089/scd.2005.14.65; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Mizuno S, 1996, EXP CELL RES, V227, P89, DOI 10.1006/excr.1996.0253; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Padovan CS, 2003, CELL TRANSPLANT, V12, P839, DOI 10.3727/000000003771000183; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qian LC, 2004, BIOMATERIALS, V25, P1331, DOI 10.1016/j.biomaterials.2003.08.013; Qu TY, 2004, RESTOR NEUROL NEUROS, V22, P459; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005-0636; UMEZAWA A, 1991, MOL CELL BIOL, V11, P920, DOI 10.1128/MCB.11.2.920; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yang Xiao-su, 2005, Zhonghua Yi Xue Za Zhi, V85, P1125; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	54	62	79	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	DEC	2008	17	6					1123	1130		10.1089/scd.2007.0212			8	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	380UL	WOS:000261490700012	18484898				2022-02-06	
J	Cohen, JE; Gomori, JM; Segal, R; Spivak, A; Margolin, E; Sviri, G; Raiz, G; Fraifeld, S; Spektor, S				Cohen, Jose E.; Gomori, John M.; Segal, Ricardo; Spivak, Alex; Margolin, Emil; Sviri, Gil; Raiz, Gustavo; Fraifeld, Shifra; Spektor, Sergey			Results of endovascular treatment of traumatic intracranial aneurysms	NEUROSURGERY			English	Article						cerebral aneurysm; embolization; intracranial hemorrhage; subarachnoid hemorrhage; traumatic brain injury	CEREBRAL-ARTERY ANEURYSM; GUNSHOT WOUNDS; HEAD; ANGIOGRAPHY; MANAGEMENT; CHILDHOOD; DIAGNOSIS; PITFALLS; VESSELS; INJURY	OBJECTIVE: To present results of early angiographic diagnosis and endovascular treatment of traumatic intracranial aneurysms (TICA). METHODS: From June 2002 to December 2006, diagnostic angiography was performed on patients with moderate to severe traumatic brain injury that involved a cranial base fracture or a penetrating brain injury with a tract from the penetrating agent that entered at the pterional area, went through the middle cerebral artery candelabra, and crossed the midline. TICAs were treated by various endovascular techniques during the same angiographic procedure. RESULTS: Thirty-four patients with traumatic brain injury underwent angiography (25 penetrating brain injuries, nine blunt injuries); 13 TICAs were diagnosed (10 penetrating brain injuries, three blunt injuries). The Glasgow Coma Scale score at diagnosis ranged from 5 to 15. Angiography was performed for screening in eight patients and for clinical indications in five patients; 11 TICAs were diagnosed before rupture. Seven aneurysms were located on branches of the middle cerebral artery, two on pericallosal branches of the anterior cerebral artery, and four on the internal carotid artery. No recanalization was detected in 12 patients. One patient treated with a bare stent and coiling had a growing intracavernous pseudoaneurysm; therefore, internal carotid artery occlusion with extracranial-intracranial microvascular bypass was performed. Six patients refused angiographic follow-up, but computed tomographic angiography has failed to show recanalization. No patient presented with delayed bleeding (mean follow-up, 2.6 yr). There were no procedure-related complications or mortality. CONCLUSION: Early angiographic diagnosis with immediate endovascular treatment provided an effective approach for TICA detection and management. Endovascular therapy is versatile and offers a valuable alternative to surgery, allowing early aneurysm exclusion with excellent results.	[Cohen, Jose E.] Hadassah Hebrew Univ Hosp, Dept Neurosurg, Sect Endovasc Neurosurg & Intervent Neuroradiol, Jerusalem, Israel; [Cohen, Jose E.; Gomori, John M.] Hadassah Hebrew Univ Hosp, Dept Radiol, Sect Endovasc Neurosurg & Intervent Neuroradiol, Jerusalem, Israel; [Sviri, Gil] Rambam Med Ctr, Dept Neurosurg, Haifa, Israel; [Raiz, Gustavo] Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel		Cohen, JE (corresponding author), Kiryat Hadassih,POB 12000, IL-91120 Jerusalem, Israel.	jcohenns@yahoo.com					AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; [Anonymous], 2001, J TRAUMA, V51, pS26; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CASEY ATH, 1994, BRIT J NEUROSURG, V8, P97, DOI 10.3109/02688699409002401; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; CROWELL RM, 1995, SURG MANAGEMENT NEUR, P377; Davis PC, 2007, AM J NEURORADIOL, V28, P1619; Eckard DA, 2000, AM J NEURORADIOL, V21, P137; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; Guillaume DJ, 2005, OPERATIVE NEUROSURGE, P1224; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; JINKINS JR, 1992, AM J ROENTGENOL, V159, P365, DOI 10.2214/ajr.159.2.1632358; Karamessini MT, 2004, EUR J RADIOL, V49, P212, DOI 10.1016/S0720-048X(03)00173-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; Kocer N, 2002, AM J NEURORADIOL, V23, P442; Larson P S, 2000, Neurosurg Focus, V8, pe4; Lath R, 2002, J CLIN NEUROSCI, V9, P466, DOI 10.1054/jocn.2001.1050; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Lylyk P, 2002, J NEUROSURG, V97, P1306, DOI 10.3171/jns.2002.97.6.1306; Martin NA, 1998, NEUROSURG CLIN N AM, V9, P897, DOI 10.1016/S1042-3680(18)30237-7; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; Quintana F, 1996, AM J NEURORADIOL, V17, P283; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; Raju BSV, 2001, NEUROL INDIA, V49, P295; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; Romijn M, 2008, AM J NEURORADIOL, V29, P134, DOI 10.3174/ajnr.A0741; ROSENTHAL G, 2005, OPERATIVE NEUROSURGE, P89; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; Tokunaga K, 2001, AM J NEURORADIOL, V22, P35; Uzan M, 1998, NEUROSURGERY, V43, P1314, DOI 10.1097/00006123-199812000-00024; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; Young N, 1999, NEURORADIOLOGY, V41, P93, DOI 10.1007/s002340050712	40	62	71	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2008	63	3					476	485		10.1227/01.NEU.0000324995.57376.79			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	354FZ	WOS:000259625600020	18812959				2022-02-06	
J	Loder, RT				Loder, Randall T.			The demographics of equestrian-related injuries in the United States: Injury patterns, orthopedic specific injuries, and avenues for injury prevention	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						equestrian; injury; demographics; predictors; body area; location	HORSE-RELATED INJURIES; ACCIDENTS; CHILDREN; SERIES	Background: It was the purpose of this study to review equestrian-related injuries using a large nation wide database and analyze predictors of significant injury. Methods: The National Electronic Surveillance System database was queried for equestrian injuries from 2002 to 2004. The presence of a fracture, dislocation, traumatic brain injury, musculoskeletal injury, orthopedic injury, and spinal injury, as well as injury mechanism, geographical location, and emergency room disposition were noted. Bivariate, cosinor seasonal, and multiple logistic regression analyses were performed. p < 0.01 was considered significant. Results: Emergency room visits because of equestrian-related injuries from 2002 to 2004 from the NEISS database were reviewed; there were 5,033 visits during this time span. The average age was 30.0 +/- 17.0 years; 66% were women. The injuries occurred at home (36%), recreation/sporting facility (30%), on a farm (19%), and other public property (12%). The injury was due to a fall (59%), thrown/bucked from the horse (22.0%), and while riding the horse (9%). The most common injuries were contusion/abrasions (31%), fractures (28%), sprain/strains (18%), traumatic brain injuries (12%), and lacerations (6%). The body area injured was the head and neck (24%), trunk (29%), upper extremity (30%), lower extremity (16%), and multiple locations (11%). Most injuries occurred in the summer. Predictors of hospital admission were age > 18 years, traumatic brain injury, fracture, or occurrence on other public property (odds ratios 1.4, 6.25, 7.7, and 1.5, respectively). Conclusions: The largest number of equestrian injuries occur in white females in the 2nd, 4th, and 5th decades of life. Serious injuries are due to failing or being bucked off a horse and most commonly occur at home or at a recreational/sporting facility. Prevention strategies (educational and passive protection equipment) should be especially targeted to this high risk group.	[Loder, Randall T.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA; [Loder, Randall T.] Indiana Univ, Dept Orthopaed Surg, Indiana Sch Med, Indiana, PA USA		Loder, RT (corresponding author), James Whitcomb Riley Hosp Children, Room 4250,702 Barnhill Dr, Indianapolis, IN 46202 USA.	rloder@iupui.edu			Garceau Professorship Endowment; Indiana University, Department of Orthopaedic Surgery; Rapp Pediatric Orthopaedic Research Endowment; Riley Children's Foundation, Indianapolis, Indiana	This research was supported in part by the Garceau Professorship Endowment, Indiana University, Department of Orthopaedic Surgery, and the Rapp Pediatric Orthopaedic Research Endowment, Riley Children's Foundation, Indianapolis, Indiana.	ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BROOKS WH, 1988, PHYSICIAN SPORTSMED, V16, P84, DOI 10.1080/00913847.1988.11709646; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; Dekker R, 2004, DISABIL REHABIL, V26, P91, DOI 10.1080/09638280310001629688; *DIV HAZ INJ DAT S, 2000, US CONS PROD SAF COM; Eveleth PB, 1990, WORLDWIDE VARIATION; Exadaktylos AK, 2002, EMERG MED J, V19, P573, DOI 10.1136/emj.19.6.573; FAURE A, 1990, COMPUT BIOL MED, V20, P319, DOI 10.1016/0010-4825(90)90011-D; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Frankel HL, 1998, AM SURGEON, V64, P151; Gabbe BJ, 2005, BRIT J SPORT MED, V39, P573, DOI 10.1136/bjsm.2004.015750; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; Hobbs Gregory D., 1994, Journal of Emergency Medicine, V12, P143, DOI 10.1016/0736-4679(94)90690-4; Holland AJA, 2001, MED J AUSTRALIA, V175, P609, DOI 10.5694/j.1326-5377.2001.tb143746.x; HOPKINS RS, 1989, AM J PREV MED, V5, P104, DOI 10.1016/S0749-3797(18)31112-7; Jagodzinski Tanya, 2005, WMJ, V104, P50; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCaig Linda F, 2004, Adv Data, P1; MILLS NJ, 1990, P INT RES C BIOM IMP, P155; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; MORBIDITY MWR, 1990, MMWR-MORBID MORTAL W, V39, P329; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Northey Glenda, 2003, N Z Med J, V116, pU601; OFarrell DA, 1997, BRIT J SPORT MED, V31, P249, DOI 10.1136/bjsm.31.3.249; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; REGAN PJ, 1991, INJURY, V22, P124, DOI 10.1016/0020-1383(91)90072-M; Roe D, 2003, AM J ORTHOPSYCHIAT, V73, P336, DOI 10.1037/0002-9432.73.3.334; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005; Whitlock MR, 1999, BRIT J SPORT MED, V33, P212, DOI 10.1136/bjsm.33.3.212	43	62	64	2	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2008	65	2					447	460		10.1097/TA.0b013e31817dac43			14	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	337US	WOS:000258461600042	18695484				2022-02-06	
J	Fabbri, A; Servadei, F; Marchesini, G; Stein, SC; Vandelli, A				Fabbri, A.; Servadei, F.; Marchesini, G.; Stein, S. C.; Vandelli, A.			Early predictors of unfavourable outcome in subjects with moderate head injury in the emergency department	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC SUBARACHNOID HEMORRHAGE; COMPUTED TOMOGRAPHIC SCAN; BRAIN-INJURY; PROGNOSTIC-FACTORS; MANAGEMENT; CT; ANTICOAGULATION; CARE; PROGRESSION; DIAGNOSIS	Background: Subjects with moderate head injury are a particular challenge for the emergency physician. They represent a heterogeneous population of subjects with large variability in injury severity, clinical course and outcome. We aimed to determine the early predictors of outcome of subjects with moderate head injury admitted to an Emergency Department (ED) of a general hospital linked via telemedicine to the Regional Neurosurgical Centre. Patients and methods: We reviewed, prospectively, 12 675 subjects attending the ED of a General Hospital between 1999 and 2005 for head injury. A total of 309 cases (2.4%) with an admission Glasgow Coma Scale (GCS) 9-13 were identified as having moderate head injury. The main outcome measure was an unfavourable outcome at 6 months after injury. The predictive value of a model based on main entry variables was evaluated by logistic regression analysis. Findings: 64.7% of subjects had a computed tomographic scan that was positive for intracranial injury, 16.5% needed a neurosurgical intervention, 14.6% had an unfavourable outcome at 6 months (death, permanent vegetative state, permanent severe disability). Six variables (basal skull fracture, subarachnoid haemorrhage, coagulopathy, subdural haematoma, modified Marshall category and GCS) predicted an unfavourable outcome at 6 months. This combination of variables predicts the 6-month outcome with high sensitivity (95.6%) and specificity (86.0%). Interpretation: A group of selected variables proves highly accurate in the prediction of unfavourable outcome at 6 months, when applied to subjects admitted to an ED of a General Hospital with moderate head injury.	[Fabbri, A.; Vandelli, A.] Presidio Ospedaliero Morgagni Pierantoni, Dipartimento Emergenza, I-47100 Forli, Italy; [Servadei, F.] Ospedale M Bufalini, Div Neurochirurg Traumatol, Cesena, Italy; [Marchesini, G.] Univ Bologna, Alma Mater Studiorum, Bologna, Italy; [Stein, S. C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Fabbri, A (corresponding author), Presidio Ospedaliero Morgagni Pierantoni, Dipartimento Emergenza, Azienda USL Forli,Via Forlanini 34, I-47100 Forli, Italy.	andrea.fabbri@formulatre.it	Fabbri, Andrea/K-9994-2016	Fabbri, Andrea/0000-0002-9837-4638; Marchesini, Giulio/0000-0003-2407-9860; Servadei, Franco/0000-0002-3595-3464			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; NORUSIS MJ, 1992, SPSS PC BASE SYSTEM; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; STEIN SC, 1996, NEUROTRAUMA, P755; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; ZWEIG MH, 1993, CLIN CHEM, V39, P561	40	62	63	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2008	79	5					567	573		10.1136/jnnp.2007.120162			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	287LK	WOS:000254918400017	17766433	Bronze			2022-02-06	
J	Friedemann-Sanchez, G; Sayer, NA; Pickett, T				Friedemann-Sanchez, Greta; Sayer, Nina A.; Pickett, Treven			Provider perspectives on rehabilitation of patients with polytrauma	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; caregivers; combat disorders; rehabilitation; rehabilitation centers.	TRAUMATIC BRAIN-INJURY; INJECTION-DRUG USE; RAPID ASSESSMENT; IRAQ; CARE; WAR; AFGHANISTAN; SOLDIERS; OUTCOMES; VICTIMS	Objectives: To describe, from the perspective of U.S. Department of Veterans Affairs (VA) polytrauma rehabilitation providers, (1) patients with combat-related polytrauma and their rehabilitation, (2) polytrauma patient family member involvement in rehabilitation, and (3) the impact on providers of providing polytrauma rehabilitation. Design: Qualitative study based on rapid assessment process methodology, which included semistructured interviews, observation, and use of a field liaison. Setting: The 4 VA polytrauma rehabilitation centers (PRCs). Participants: Fifty-six purposefully selected PRC providers and providers from consulting services. Interventions: Not applicable. Main Outcomes Measures: Provider self-report of polytrauma patient characteristics, polytrauma patient family member involvement in rehabilitation, and the impact of polytrauma rehabilitation on providers themselves. Results: According to PRC providers, polytrauma patients are younger than VA rehabilitation patients. Strong military identities affect rehabilitation needs and reactions to severe injury. The public and the media have particular interest in war-injured patients. Patients with blast-related polytrauma have unique constellations of visible (including amputations, craniectomies, and burns) and invisible (including traumatic brain injury, pain, and posttraumatic stress disorder) injuries. Providers have adjusted treatment strategies and involved services outside of rehabilitation because of this clinical complexity. Family members are intensely involved in rehabilitation and have service needs that may surpass those of families of rehabilitation patients without polytrauma. Sources of provider stress include new responsibilities, media attention, increased oversight, and emotional costs associated with treating severely injured young patients and their families. Providers also described the work as deeply rewarding. Conclusions: The VA should prioritize the identification or development and implementation of strategies to address family member needs and to monitor and ensure that PRC providers have access to appropriate resources. Future research should determine whether findings generalize to patients injured in other wars and to people who sustain polytraumatic injuries outside of a war zone, including victims of terrorist attacks.	[Friedemann-Sanchez, Greta] Univ Minnesota, Hubert H Humphrey Inst Publ Affairs, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Friedemann-Sanchez, Greta; Sayer, Nina A.] Ctr Chron Dis Outcomes Res VA Med Ctr, Minneapolis, MN USA; [Pickett, Treven] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Pickett, Treven] McGuire VA Med Ctr, Richmond, VA USA; [Pickett, Treven] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA		Friedemann-Sanchez, G (corresponding author), Univ Minnesota, Hubert H Humphrey Inst Publ Affairs, Humphrey Ctr 267, 301-19th Ave S, Minneapolis, MN 55455 USA.	frie0013@umn.edu	Sayer, Nina/E-3249-2016	Friedemann-Sanchez, Greta/0000-0002-0493-7218			Aharonson-Daniel L, 2005, SCAND J SURG, V94, P185, DOI 10.1177/145749690509400302; AMARA J, 2007, WORKING PAPER SERIES; Beach SR, 2005, J AM GERIATR SOC, V53, P255, DOI 10.1111/j.1532-5415.2005.53111.x; Beach SR, 2000, PSYCHOL AGING, V15, P259, DOI 10.1037//0882-7974.15.2.259; Beebe J, 2001, RAPID ASSESSMENT PRO; Burg M.M., 1994, ANN BEHAV MED, V46, P1097; CHAMBERS R, 1994, WORLD DEV, V22, P1253, DOI 10.1016/0305-750X(94)90003-5; Chatterjee A., 1996, Bulletin on Narcotics, V48, P11; Darkins A, 2008, ARCH PHYS MED REHAB, V89, P182, DOI 10.1016/j.apmr.2007.07.027; de Jong W, 1999, J DRUG ISSUES, V29, P843, DOI 10.1177/002204269902900406; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Eldar R, 2003, DISABIL REHABIL, V25, P1019, DOI 10.1080/0963828031000137739; Fitch, 2000, Int J Drug Policy, V11, P63, DOI 10.1016/S0955-3959(99)00056-0; Fitch C, 2004, SOC SCI MED, V59, P1819, DOI 10.1016/j.socscimed.2004.02.028; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GITTLESON J, 1998, RAPID ASSESSMENT PRO; Glaser B., 1967, DISCOVERY GROUNDED T; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; GUNTHER MS, 1994, AM J PSYCHOTHER, V48, P208, DOI 10.1176/appi.psychotherapy.1994.48.2.208; KLEVEN J, 2004, INJ CONTROL SAF PROM, V11, P1; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; MANDERSON L, 1992, SOC SCI MED, V35, P839, DOI 10.1016/0277-9536(92)90098-B; Menetrez Jennifer S, 2002, Phys Med Rehabil Clin N Am, V13, P67, DOI 10.1016/S1047-9651(03)00072-X; Needle RH, 2003, AM J PUBLIC HEALTH, V93, P970, DOI 10.2105/AJPH.93.6.970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; OSBORN M, 1988, AM J PHYS MED REHAB, V67, P275; Pape TLB, 2006, BRAIN INJURY, V20, P743, DOI 10.1080/02699050600676933; Patton MQ., 2015, QUALITATIVE RES EVAL, V4; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; Pearson R, 1989, Hygie, V8, P23; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Rusk H A, 1969, Arch Phys Med Rehabil, V50, P463; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SCHLENZ KC, 1995, AM J OCCUP THER, V49, P986, DOI 10.5014/ajot.49.10.986; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Scrimshaw NS, 1992, RAPID ASSESSMENT PRO; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Stimson GV, 2006, AM J PUBLIC HEALTH, V96, P288, DOI 10.2105/AJPH.2003.035899; Strauss A., 1990, BASICS QUALITATIVE R; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thorogood N, 2004, QUALITATIVE METHODS; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; Wittig PG, 2003, DISABIL REHABIL, V25, P97, DOI 10.1080/0963828021000024933; [No title captured]	53	62	65	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					171	178		10.1016/j.apmr.2007.10.017			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	249LB	WOS:000252228600029	18164350				2022-02-06	
J	Livingstone, SA; Skelton, RW				Livingstone, Sharon A.; Skelton, Ronald W.			Virtual environment navigation tasks and the assessment of cognitive deficits in individuals with brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						spatial navigation; traumatic brain injury; virtual reality; Morris water maze; hippocampus; learning and memory; spatial cognition; allocentric and egocentric strategies; wayfinding; landmark	UNILATERAL TEMPORAL LOBECTOMY; HUMAN SPATIAL NAVIGATION; MORRIS WATER MAZE; TOPOGRAPHICAL DISORIENTATION; HEAD-INJURY; HIPPOCAMPAL FUNCTION; ALZHEIMERS-DISEASE; MEMORY DEFICITS; FRONTAL LOBES; LESIONS	Navigation in real environments is often impaired by traumatic brain injury TBI). These deficits in wayfinding appear to be due to disruption of cognitive processes underlying navigation and may in turn be due to damage to the hippocampus and frontal lobes. These wayfinding problems after TBI were investigated using a virtual simulation of a Morris Water Maze (MWM), a standard test of hippocampal function in laboratory animals. The virtual environment consisted of a large virtual arena in a very large virtual room whose walls provided views of a naturalistic landscape. Eleven community-dwelling TBI survivors and 12 comparison participants, matched for gender, age and education were tested to see if they could find a location in the arena marked by one of the following: (a) a visible platform, (b) a single proximal object, (c) a single proximal object among seven other distracter objects, or (d) distal features inside and outside the room. The proximal objects allowed participants to use egocentric (body-centered) navigational strategies that rely on relatively simple stimulus-response associations. The absence of proximal cues forced the participants to rely on distal features of the environment (room walls, landscape elements) and tested their ability to use allocentric (world-based) navigational strategies requiring cognitive mapping. Results indicated that the navigation of TBI survivors was not impaired when the proximal cues were present but was impaired when proximal cues were absent. These results provide more evidence that the navigational deficit after TBI is due to an inability to form, remember or use cognitive maps. (C) 2007 Elsevier B.V. All rights reserved.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	skelton@uvic.ca	Skelton, Ronald/E-5605-2012				Aguirre GK, 1999, BRAIN, V122, P1613, DOI 10.1093/brain/122.9.1613; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Barrash J, 1998, J CLIN EXP NEUROPSYC, V20, P807, DOI 10.1076/jcen.20.6.807.1114; BARRASH J, 1994, DEV NEUROPSYCHOL, V10, P189, DOI 10.1080/87565649409540578; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Burgess N, 1999, HIPPOCAMPAL PARIETAL, P3; Cherrier MM, 2001, NEUROPSY NEUROPSY BE, V14, P159; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; GRUSSER O, 1991, GETTING LOST WORLD T, V12; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hamilton DA, 2004, BEHAV BRAIN RES, V154, P385, DOI 10.1016/j.bbr.2004.03.005; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs LF, 2003, PSYCHOL REV, V110, P285, DOI 10.1037/0033-295X.110.2.285; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; KOLB B, 1987, BEHAV BRAIN RES, V23, P127, DOI 10.1016/0166-4328(87)90050-7; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORROW L, 1988, NEUROPSYCHOLOGY SPAT, P5; Nadel L, 2004, NEUROPSYCHOLOGY, V18, P473, DOI 10.1037/0894-4105.18.3.473; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE O, 1978, HIPPOCAMPUS COGNITIV; PANG D, 1989, PHYS PATHOPHYSIOLOGY, P1; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; WILSON B, 1991, RIVERMEAD BEHAV MEMO, P1; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; WOLFKLEIN GP, 1989, J AM GERIATR SOC, V37, P730, DOI 10.1111/j.1532-5415.1989.tb02234.x	57	62	65	0	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	DEC 11	2007	185	1					21	31		10.1016/j.bbr.2007.07.015			11	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	232PF	WOS:000251030900003	17727970				2022-02-06	
J	Berrocal, Y; Pearse, DD; Singh, A; Andrade, CM; McBroom, JS; Puentes, R; Eaton, MJ				Berrocal, Yerko; Pearse, Damien D.; Singh, Amanpreet; Andrade, Christian M.; McBroom, Jordan S.; Puentes, Rocio; Eaton, Mary J.			Social and environmental enrichment improves sensory and motor recovery after severe contusive spinal cord injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						growth factors; locomotor function; sensory function; therapeutic approaches for the treatment of CNS; traumatic spinal cord injury	NEUROTROPHIC FACTOR BDNF; FUNCTIONAL RECOVERY; NEUROPATHIC PAIN; NERVE INJURY; EXERCISE; NEURONS; HEMISECTION; COMPLEXITY; EXPRESSION; THRESHOLD	Neuropathic pain and motor dysfunction are difficult problems following spinal cord injury (SCI). Social and environmental enrichment (SEE), which models much of the clinical rehabilitation environment for post-SCI persons, is the focus of the current investigation which examines the effects of multiple-housing and the addition of climbing spaces, improved bedding and crawl toys on the sensory and motor recovery following a severe contusive SCI. Efficacy was determined with sensory testing, open-field motor behavioral testing, lesion volume analysis and quantification of brain-derived neurotrophic factor (BDNF) in the lumbar spinal cord with and without SEE provided during the recovery period. Sensory and motor testing were performed weekly for 12 weeks following SCI. SEE significantly and permanently reversed cutaneous allodynia, but not thermal hyperalgesia, to near normal levels. The gross locomotor performance (BBB [Basso, Beattie, and Bresnahan] motor scores) significantly improved about two points. In addition, the BBB subscale scores were significantly improved nearly seven points by the end of the study. SEE also significantly improved foot rotation to normal levels and reduced gridwalk footfall errors nearly 50%, but had no effect on stride length or base of support dysfunctions. SEE significantly increased the total volume of a thoracic segment of cord encompassing the injury site at 12 weeks, by reducing cavitation and increasing both the volume of grey and white matter spared, compared to SCI alone. When BDNF levels were examined in the injured lumbar spinal cord, SEE significantly returned BDNF levels to near-normal. These data suggest that immediate use of SEE after contusive SCI is able to improve overall spinal cell survival and prevent much of the sensory and motor dysfunction that accompanies contusive SCI.	Miami VA Med Ctr, Miami, FL 33125 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL USA		Eaton, MJ (corresponding author), Miami VA Med Ctr, D806C 1201 NW 16th St, Miami, FL 33125 USA.	meaton@miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Berrocal, Yerko/0000-0002-1089-6563; Andrade, Christian/0000-0001-6470-0776			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Behrman AL, 2005, PHYS THER, V85, P1356, DOI 10.1093/ptj/85.12.1356; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; CELAS P, 2000, PAIN, V86, P95; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Conner JM, 1997, J NEUROSCI, V17, P2295; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; Drew GM, 2004, PAIN, V109, P379, DOI 10.1016/j.pain.2004.02.007; Eaton MJ, 2002, GENE THER, V9, P1387, DOI 10.1038/sj.gt.3301814; Engesser-Cesar C, 2005, J NEUROTRAUM, V22, P157, DOI 10.1089/neu.2005.22.157; Erschbamer MK, 2006, EXP NEUROL, V201, P154, DOI 10.1016/j.expneurol.2006.04.003; GARDNER EB, 1975, PHYSIOL BEHAV, V14, P321, DOI 10.1016/0031-9384(75)90040-2; Ginis KAM, 2003, REHABIL PSYCHOL, V48, P157, DOI 10.1037/0090-5550.48.3.157; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hains BC, 2003, BRAIN RES, V970, P238, DOI 10.1016/S0006-8993(03)02347-3; Hains BC, 2002, NEUROSCI LETT, V320, P125, DOI 10.1016/S0304-3940(02)00026-5; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HUNTLEY MJ, 1972, PHYSIOL BEHAV, V8, P725, DOI 10.1016/0031-9384(72)90103-5; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Ikeda O, 2002, J NEUROPATH EXP NEUR, V61, P142, DOI 10.1093/jnen/61.2.142; KATZ HB, 1984, EXP NEUROL, V83, P274, DOI 10.1016/0014-4886(84)90098-0; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Merighi A, 2004, PROG BRAIN RES, V146, P291, DOI 10.1016/S0079-6123(03)46019-6; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Miki K, 2000, NEUROSCI LETT, V278, P85, DOI 10.1016/S0304-3940(99)00908-8; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Moon LDF, 2006, RESTOR NEUROL NEUROS, V24, P147; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; PERREAU VM, 2005, GENE EXPRESSION, P107; PUGLISIALLEGRA S, 1983, PHARMACOL BIOCHEM BE, V19, P679, DOI 10.1016/0091-3057(83)90344-1; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Smith RR, 2006, J NEUROTRAUM, V23, P908, DOI 10.1089/neu.2006.23.908; Van Meeteren NLU, 2003, J NEUROTRAUM, V20, P1029, DOI 10.1089/089771503770195876; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; VIERCK CJ, 2000, NERVOUS SYSTEM PLAST, P411; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Yajima Y, 2002, BRAIN RES, V958, P338, DOI 10.1016/S0006-8993(02)03666-1; Yezierski R P, 2000, Prog Brain Res, V129, P429; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015; Ying Z, 2003, BRAIN RES, V987, P93, DOI 10.1016/S0006-8993(03)03258-X	50	62	64	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1761	1772		10.1089/neu.2007.0327			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500007	18001204				2022-02-06	
J	Pan, DS; Liu, WG; Yang, XF; Cao, F				Pan, De-Sheng; Liu, Wei-Guo; Yang, Xiao-Feng; Cao, Fei			Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury	BIOMEDICAL AND ENVIRONMENTAL SCIENCES			English	Article						traumatic brain injury; progesterone; inflammation	NF-KAPPA-B; EXPRESSION	Objective Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality in young people. Inflammatory cytokines play an important part in the pathophysiology of TBI. Recent studies demonstrate that progesterone significantly reduces cerebral edema and enhances functional recovery from TBI and stroke in several animal models. This study was designed to investigate the inhibitory effect of progesterone on inflammatory response after traumatic brain injury. Methods Progesterone was injected intraperitoneally using rats as a model of traumatic brain injury, and Western blot technique was applied to detect the expression of three inflammation-related factors: nuclear factor kappa B p65 (NF kappa B p65), glial fibrillary acidic protein (GFAP), and tumor necrosis factor-alpha (TNF-alpha). The water content of injured brain was also examined. A neurological severity score was recorded to evaluate the effect of progesterone on neurodeficit recovery. Results NF kappa B p65, GFAP, and TNF-alpha were increased in all injured animals. In rats treated with progesterone, the expression level of NF kappa B p65 and TNF-alpha were reduced significantly in comparison with vehicle-treated rats. However, progesterone did not alter the expression of GFAP in the injured rats. Progesterone also reduced the water content of injured brain and the lesion volume. In addition, progesterone-treated injured rats showed significant improvements in the Neurological Severity Score test, compared with vehicle-treated ones. Conclusions Progesterone inhibits the inflammatory response after experimental traumatic brain injury and mitigates the severity of brain damage.	Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China; Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China		Yang, XF (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China.	zjcswk@126.com					Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu ZZ, 2000, INT J DEV NEUROSCI, V18, P185, DOI 10.1016/S0736-5748(99)00087-8; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; STAMATOVIC SM, 2006, ACTA NEUROCHIR SUPPL, P444; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	17	62	64	0	12	CHINESE CENTER DISEASE CONTROL & PREVENTION	BEIJING	155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA	0895-3988			BIOMED ENVIRON SCI	Biomed. Environ. Sci.	OCT	2007	20	5					432	438					7	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	226UC	WOS:000250613000015	18188998				2022-02-06	
J	Holloway, R; Zhou, Z; Harvey, HB; Levasseur, JE; Rice, AC; Sun, D; Hamm, RJ; Bullock, MR				Holloway, R.; Zhou, Z.; Harvey, H. B.; Levasseur, J. E.; Rice, A. C.; Sun, D.; Hamm, R. J.; Bullock, M. R.			Effect of lactate therapy upon cognitive deficits after traumatic brain injury in the rat	ACTA NEUROCHIRURGICA			English	Article						L-lactate; cognitive deficits; ATP; TBI	CELL-DEATH; CREATINE-PHOSPHATE; OXYGEN-CONSUMPTION; N-ACETYLASPARTATE; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CARDIAC-MUSCLE; UNITED-STATES; METABOLISM; GLUCOSE	Background. In previous studies, it has been shown that intravenous lactate therapy can improve brain neurochemistry, adenosine triphosphate (ATP) generation and outcome after traumatic brain injury (TBI) in rats. In this study, we examined: (1) four L-lactate concentrations to determine the optimal therapeutic dose post TBI in terms of cognitive function; (2) ATP production after TBI for the L-lactate concentration found to be the optimal dose; (3) the possible production of lactic acidosis with the highest L-lactate concentration tested. Methods. Thirty minutes following a fluid percussion injury (FPI) over the left cerebral hemisphere, the animals received an intravenous infusion of 10, 28, 100, or 280mM L-lactate (n = 10 for each group) for 3h at a rate of 0.65ml/h. Shams and control injured animals received a saline infusion. At 11-15 days post injury, cognitive deficits were examined using the Morris Water Maze (MWM) test. Three groups of rats were used for ATP analysis: shams, injured + saline infusion, and injury + the optimal lactate dose as determined by the MWM (n = 4/group). Additionally, a group receiving 280mM L-lactate (n = 5) and one receiving a saline infusion (n = 3) were monitored for arterial blood variables and blood pressures. Findings. In the MWM test, only the 100mM L-lactate-treated injured animals showed a significant reduction in cognitive deficits when compared to saline-treated injured animals (p n 0.05). In the ATP study, injured animals without treatment had a 53% reduction in ATP level in the ipsilateral cortex, while animals with 100mM lactate treatment had a 28% reduction. (p n 0.05). No lactic acidosis was induced by the intravenous infusion of 280mM L-lactate. Conclusions. This study indicates that the intravenous infusion of 100mM L-lactate provided the optimal concentration of the substrate to ameliorate cognitive impairment, probably via the regeneration of ATP following TBI in rats.	Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Psychol, Richmond, VA USA; Second Shanghai Med Univ, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China		Holloway, R (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.	mbullock@mcvh-vcu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 12587-27] Funding Source: Medline		Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; BESSHO M, 1991, ANAL BIOCHEM, V192, P117, DOI 10.1016/0003-2697(91)90195-Y; Buck CR, 2003, EXP NEUROL, V181, P149, DOI 10.1016/S0014-4886(03)00043-8; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; DENNIS SC, 1978, BIOCHEM J, V172, P155, DOI 10.1042/bj1720155; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; IDSTROM JP, 1990, SCAND J CLIN LAB INV, V50, P541, DOI 10.3109/00365519009089169; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Keele CA, 1961, SAMSON WRIGHTS APPL; LEVASSEUR J, 1999, J NEUROTRAUM, V16, P991; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lopez JM, 2003, BIOCHEM J, V370, P1027, DOI 10.1042/BJ20021053; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Mahgoub MA, 1999, ANN THORAC SURG, V68, P22, DOI 10.1016/S0003-4975(99)00277-5; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nordstrom Carl-Henrik, 2003, Neurosurg Focus, V15, pE5; OHSUZU F, 1994, J MOL CELL CARDIOL, V26, P203, DOI 10.1006/jmcc.1994.1023; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Schurr A, 1998, DEV NEUROSCI-BASEL, V20, P348, DOI 10.1159/000017330; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thrivikraman KV, 2002, BRAIN RES PROTOC, V10, P84, DOI 10.1016/S1385-299X(02)00185-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Zeng JY, 2007, J CEREBR BLOOD F MET, V27, P304, DOI 10.1038/sj.jcbfm.9600335; Zhan C, 2006, PHARMACOL RES, V53, P303, DOI 10.1016/j.phrs.2005.12.008	52	62	64	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2007	149	9					919	927		10.1007/s00701-007-1241-y			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	204AT	WOS:000249015900019	17660938				2022-02-06	
J	Kalsotra, A; Zhao, J; Anakk, S; Dash, PK; Strobel, HW				Kalsotra, Auinash; Zhao, Jing; Anakk, Sayeepriyadarshini; Dash, Pramod K.; Strobel, Henry W.			Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood brain barrier; cytochrome P450 4Fs; cytokines; leukotriene B4 metabolism; pulmonary inflammation	LEUKOTRIENE B-4; OMEGA-HYDROXYLASES; BIOSYNTHESIS; MOBILIZATION; NEUTROPHILS; CHEMOTAXIS; EXPRESSION; RECEPTOR; RELEASE; SIGNALS	Traumatic brain injury is known to cause several secondary effects, which lead to multiple organ dysfunction syndrome. An acute systemic inflammatory response seems to play an integral role in the development of such complications providing the potential for massive secondary injury. We show that a contusion injury to the rat brain causes large migration of inflammatory cells ( especially macrophages and neutrophils) in the major airways and alveolar spaces at 24 h post-injury, which is associated with enhanced pulmonary leukotriene B-4 (LTB4) production within the lung. However, by 2 weeks after injury, a temporal switch occurs and the resolution of inflammation is underway. We provide evidence that 5-lipoxygenase and Cytochrome P450 4Fs (CYP4Fs), the respective enzymes responsible for LTB4 synthesis and breakdown, play crucial roles in setting the cellular concentration of LTB4. Activation of LTB4 breakdown via induction of CYP4Fs, predominantly in the lung tissue, serves as an endogenous signal to ameliorate further secondary damage. In addition, we show that CYP4Fs are localized primarily in the airways and pulmonary endothelium. Given the fact that adherence to the microvascular endothelium is an initial step in neutrophil diapedesis, the temporally regulated LTB4 clearance in the endothelium presents a novel focus for treatment of pulmonary inflammation after injury.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA		Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, Vivian L Smith Ctr Neurol Res, POB 20708,6431 Fannin St, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH070054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS044174] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH070054] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, R01 NS044174] Funding Source: Medline		Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; DENZLINGER C, 1985, SCIENCE, V230, P330, DOI 10.1126/science.4048937; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kalsotra A, 2003, FEBS LETT, V555, P236, DOI 10.1016/S0014-5793(03)01240-7; KALSOVSKY RA, 1993, AM J PHYSIOL, V264, pL401; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Marion D W, 1999, Clin Neurosurg, V45, P184; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; PAINE R, 1952, JAMA-J AM MED ASSOC, V149, P643, DOI 10.1001/jama.1952.02930240021008; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stubbe HD, 2004, J CEREBR BLOOD F MET, V24, P1400, DOI 10.1097/01.WCB.0000141516.61418.82; Tarlowe MH, 2003, J IMMUNOL, V171, P2066, DOI 10.4049/jimmunol.171.4.2066; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	40	62	64	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2007	27	5					963	974		10.1038/sj.jcbfm.9600396			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	161FG	WOS:000245999300008	16985506	Bronze			2022-02-06	
J	Spanos, GK; Wilde, EA; Bigler, ED; Cleavinger, HB; Fearing, MA; Levin, HS; Li, X; Hunter, JV				Spanos, G. K.; Wilde, E. A.; Bigler, E. D.; Cleavinger, H. B.; Fearing, M. A.; Levin, H. S.; Li, X.; Hunter, J. V.			Cerebellar atrophy after moderate-to-severe pediatric traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSE AXONAL INJURY; PREFRONTAL CORTEX; HEAD-INJURY; CHILDREN; VULNERABILITY; PROJECTIONS; PROTEIN; IMPACT; RAT; MRI	BACKGROUND AND PURPOSE: Although the cerebellum has not attracted the same degree of attention as cortical areas and the hippocampus in traumatic brain injury (TBI) literature, there is limited structural and functional imaging evidence that the cerebellum is also vulnerable to insult. The cerebellum is emerging as part of a frontocerebellar system that, when disrupted, results in significant cognitive and behavioral consequences, We hypothesized that cerebellar volume would be reduced in children following TBI and wished to examine the relation between the cerebellum and known sites of projection, including the prefrontal cortex, thalamus, and pons. MATERIALS AND METHODS: Quantitative MR imaging was used to measure cerebellar white and gray matter and lesion volumes 1-10 years following TBI in 16 children 9-16 years of age and 16 demographically matched typically developing children 9-16 yeas of age. Cerebellar volumes were also compared with volumetric data from other brain regions to which the cerebellum projects. RESULTS: A significant group difference was found in cerebellar white and gray matter volume, with children in the TBI group consistently exhibiting smaller volumes, Repeating the analysis after excluding children with focal cerebellar lesions revealed that significant group differences still remained for cerebellar white matter (WM). We also found a relation between the cerebellum and projection areas, including the dorsolateral prefrontal cortex, thalamus, and pons in 1 or both groups. CONCLUSION: Our finding of reduced cerebellar WM volume in children with TBI is consistent with evidence from experimental studies suggesting that the cerebellum and its related projection areas are highly vulnerable to fiber degeneration following traumatic insult.	Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Dartmouth Coll Sch Med, Dept Psychiat, W Lebanon, NH USA; Boston VA Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA		Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1790 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD35476, U19 HD035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889, NS-21889] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Allen G, 2005, NEUROIMAGE, V28, P39, DOI 10.1016/j.neuroimage.2005.06.013; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Diamond A, 2000, CHILD DEV, V71, P44, DOI 10.1111/1467-8624.00117; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Haber S, 2001, NEUROSCIENTIST, V7, P315, DOI 10.1177/107385840100700408; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hardan AY, 2001, J AM ACAD CHILD PSY, V40, P666, DOI 10.1097/00004583-200106000-00011; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Liu JS, 2000, NEUROSCI LETT, V282, P85, DOI 10.1016/S0304-3940(00)00865-X; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438, DOI 10.1523/JNEUROSCI.17-01-00438.1997; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Sullivan EV, 2003, ALCOHOL CLIN EXP RES, V27, P1409, DOI 10.1097/01.ALC.0000085586.91726.46; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	29	62	62	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2007	28	3					537	542					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	149PW	WOS:000245160100035	17353332				2022-02-06	
J	Lee, KH; Suh-Kim, H; Choi, JS; Jeun, SS; Kim, EJ; Kim, SS; Yoon, DH; Lee, BH				Lee, Kyung Hee; Suh-Kim, Haeyoung; Choi, Ji Soo; Jeun, Sin-Soo; Kim, Eun Jin; Kim, Sung-Soo; Yoon, Do Heum; Lee, Bae Hwan			Human mesenchymal stem cell transplantation promotes functional recovery following acute spinal cord injury in rats	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article						spinal cord injury; human mesenchymal stem cell; transplantation; behavioral test; electrophysiology	MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; CONTUSION MODEL; SENSORY AXONS; ADULT-RAT; IN-VITRO; DIFFERENTIATE; REGENERATION; GROWTH; ALLODYNIA	Many attempts have been made in animals to produce cellular regeneration in the spinal cord using a variety of transplanted cell types. The present study was to investigate whether transplantation of human mesenchymal stem cells (hMSCs) into the spinal cord after contusion injury promotes a functional outcome. Spinal cord injury (SCI) was induced using an NYU impactor and hMSCs were transplanted I week after SCI. Behavioral testing was performed weekly for 2 months. Somatosensory (SSEPs) and motor evoked potentials (MEPs) were recorded to determine functional recovery. Hindlimb performance was modestly improved in the transplanted group based on BBB scaling and pain tests. SSEP latencies in the transplanted group were significantly shorter than in the media-treated group. Pathologically, LacZ and hTau positive cells were located at the injury and adjacent sites. The data indicate improvement in functional outcome in animals treated with hMSC transplantation compared to media-treated animals.	Yonsei Univ, Coll Med, Dept Physiol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Res Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Ajou Univ, Sch Med, Dept Anat, Suwon 443721, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 443721, South Korea; Catholic Univ Korea, Coll Med, Dept Neurosurg, Seoul 137701, South Korea; Yonsei Univ, Coll Med, Dept Neurosurg, Seoul 120752, South Korea		Lee, BH (corresponding author), Yonsei Univ, Coll Med, Dept Physiol, Seoul 120752, South Korea.	bhlee@yumc.yonsei.ac.kr		Kim, Sung-Soo/0000-0003-3591-5932; Lee, Bae H./0000-0003-4719-9021; Suh-Kim, Haeyoung/0000-0001-8175-1209			Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Blesch A, 2003, J COMP NEUROL, V467, P403, DOI 10.1002/cne.10934; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Jones LL, 2003, J NEUROSCI, V23, P9276; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Lee KH, 2005, J NEUROTRAUM, V22, P575, DOI 10.1089/neu.2005.22.575; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindsey AE, 2000, NEUROREHAB NEURAL RE, V14, P287, DOI 10.1177/154596830001400405; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Qiu J, 2002, PROG BRAIN RES, V137, P381; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Tuszynski MH, 1999, CNS REGENERATION BAS; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yoon YW, 2004, SOMATOSENS MOT RES, V21, P25, DOI 10.1080/0899022042000201272; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004; Zurita M, 2006, NEUROSCI LETT, V402, P51, DOI 10.1016/j.neulet.2006.03.069	36	62	82	0	4	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400			ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2007	67	1					13	22					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	159YO	WOS:000245904000002	17474317				2022-02-06	
J	Max, JE; Levin, HS; Schachar, RJ; Landis, J; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M				Max, JE; Levin, HS; Schachar, RJ; Landis, J; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M			Predictors of personality change due to traumatic brain injury in children and adolescents six to twenty-four months after injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							FRONTAL-LOBE DAMAGE; PSYCHIATRIC-DISORDERS; RELIABILITY; VALIDITY; BEHAVIOR; SCHEDULE	Phenomenology and predictive factors of personality change due to traumatic brain injury (TBI) 6 to 24 months after injury was investigated in children, ages 5 to 14 years, enrolled from consecutive admissions and followed prospectively for 2 years. Injury and preinjury psychosocial variables were assessed. Personality change occurred in 13% of participants between 6 and 12 months after injury and 12% in the second year after injury. Severity of injury consistently predicted personality change, and preinjury adaptive function predicted personality change only in the second year postinjury. Lesions of the superior frontal gyrus were associated with personality change between 6 and 12 months following injury, after controlling for severity of injury and the presence of other brain lesions. Only lesions in the frontal lobe white matter were significantly related to personality change in the second year after injury. After childhood TBI, neural correlates of personality change evolve between 6 and 12 months and 12 to 24 months after injury. The data implicate the dorsal prefrontal cortex and frontal lobe white matter in the emergence of personality change involving the effortful or conscious regulation of affective states.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA USA; Baylor Coll Med, Dept Neurosurg, Dept Phys Med & Rehabil, Houston, TX USA; Univ Houston, Dept Educ Psychol, Houston, TX USA; Hosp Sick Children, Res Inst, Dept Psyhciat Brain & Behav Program, Toronto, ON, Canada; Univ Texas, Hlth Sci Ctr, Dept Psychiat, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX USA; Univ Texas, Ctr Brain Hlth, Dept Behav & Brain Sci, Dallas, TX USA		Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08 MH01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Biederman J, 1997, J AFFECT DISORDERS, V44, P177, DOI 10.1016/S0165-0327(97)00043-8; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Drevets WC, 2003, ANN NY ACAD SCI, V985, P420, DOI 10.1111/j.1749-6632.2003.tb07098.x; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LISHMAN WA, 1978, ORGANIC PSYCHIAT; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MAX JE, 2005, ADOLESCENT PSYCHIAT, V44, P435; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN, P107; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81	35	62	62	0	29	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2006	18	1					21	32		10.1176/appi.neuropsych.18.1.21			12	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	014YU	WOS:000235519900004	16525067				2022-02-06	
J	Cullen, DK; LaPlaca, MC				Cullen, D. Kacy; LaPlaca, Michelle C.			Neuronal response to high rate shear deformation depends on heterogeneity of the local strain field	JOURNAL OF NEUROTRAUMA			English	Article						cell mechanics; neuron; shear strain; strain rate; traumatic brain injury	IN-VITRO MODEL; TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; MECHANICAL STRETCH; MEMBRANE-PERMEABILITY; NEURAL TRAUMA; TISSUE; CULTURES	Many cellular models of traumatic brain injury (TBI) deform cells in a planar (2-D) configuration, a contrast from the three-dimensional (3-D) architecture of the brain, resulting in strain fields that may fail to represent the complex deformation patterns seen in vivo. Cells cultured in 3-D may more accurately represent in vivo cellular behavior than planar models due to differences in cytostructure, cell-cell/cell-matrix interactions and access to trophic factors; however, the effects of culture configuration on the response to high rate deformation have not been evaluated. We examined cell viability following a defined mechanical insult to primary cortical neurons distributed throughout a bioactive matrix (3-D) or in a monolayer sandwiched between layers of a bioactive matrix (2-D). After high rate loading (20 or 30 sec(-1); 0.50 strain), there was a significant decrease in neuron viability for both configurations versus unloaded control cultures; however, neurons in 3-D presented greater cell death based on matched bulk loading parameters. Computer simulations of bulk loading predicted local cellular strains, revealing that neurons in 3-D were subjected to a heterogeneous strain field simultaneously consisting of tensile, compressive and shear strains; conversely, neurons in 2-D experienced a less complex deformation regime varying mainly based on shear strains. These results show differential susceptibility to mechanical loading between neurons cultured in 2-D and 3-D that may be due to differences in cellular strain manifestation. Models of TBI that accurately represent the related cellular biomechanics and pathophysiology are important for the elucidation of cellular tolerances and the development of mechanistically driven intervention strategies.	Emory Univ, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Georgia Inst Technol,Lab Neuroengn, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Emory Univ, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Georgia Inst Technol,Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER		Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Cullen DK, 2005, J NEUROTRAUM, V22, P1250; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; Holbourn AHS, 1943, LANCET, V2, P438; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MIGHELI A, 1988, J NEUROSCI, V8, P1846; MILLER BE, 1985, CANCER RES, V45, P4200; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Sieg F, 1999, J NEUROTRAUM, V16, P1197, DOI 10.1089/neu.1999.16.1197; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1999, J NEUROSCI, V19, P4263; THIBAULT LE, 1989, 10 INT TECH C EXPT S; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397, DOI 10.1152/jappl.1989.67.1.397; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001	52	62	64	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1304	1319		10.1089/neu.2006.23.1304			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900003	16958583				2022-02-06	
J	Kim, YH; Ko, MH; Na, SY; Park, SH; Kim, KW				Kim, YH; Ko, MH; Na, SY; Park, SH; Kim, KW			Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study	CLINICAL REHABILITATION			English	Article							WORKING-MEMORY; ATTENTION; DEPRESSION; ADULT	Objectives: To determine the effect of a single dose of methylphenidate on the cognitive performance of patients with traumatic brain injury (TBI), and particularly on working memory and visuospatial attention. Design: A double-blind placebo-controlled study. The subjects were randomly divided into an experimental group taking methylphenidate and a control group taking a placebo. Setting: The Department of Rehabilitation Medicine of a university hospital. Subjects: Eighteen subjects with TBI (16 male and two female) were enrolled. Interventions: The patients were given 20 mg methylphenidate or a placebo. Cognitive assessments were performed at three times: before the medication as a baseline, 2 h after medication and at follow-up (48 h later). Main measures: Cognitive assessments consisted of working memory tasks and endogenous visuospatial attention tasks designed using SuperLabPro 2.0 software. Response accuracy and reaction time were measured. Results: There were significant improvements in response accuracy in the methylphenidate group compared with the placebo group for both the working memory and visuospatial attention tasks. A significant decrease in the reaction time was also observed in the methylphenidate group only for the working memory task. Conclusions: The administration of single-dose methylphenidate has an effect in improving cognitive functioning following a TBI. The effects were most prominent regarding the reaction time of the working memory.	Sungkyunkwan Univ, Sch Med, Dept Phys Med & Rehabil, Samsung Med Ctr,Stroke & Cerebrovasc Ctr, Seoul 135710, South Korea; Chonbuk Natl Univ, Dept Rehabil Med, Coll Med, Jeonju, South Korea; Chonbuk Natl Univ, Dept Pharmacol, Coll Med, Jeonju, South Korea		Kim, YH (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Phys Med & Rehabil, Samsung Med Ctr,Stroke & Cerebrovasc Ctr, 50 Ilwon Dong, Seoul 135710, South Korea.	yunkim@smc.samsung.co.kr	Kim, Yun Hee/F-4600-2014	Ko, Myoung-Hwan/0000-0002-0566-3677			Bontke CF, 1996, PHYS MED REHABILITAT, P1027; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Galynker I, 1997, J NEUROPSYCH CLIN N, V9, P231; GILMAN AG, 1985, PHARMACOL BASIS THER, P236; GOLDSTEIN LB, 2003, PHYS MED REH CLIN N, V14, P125; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Ilic TV, 2003, NEUROREPORT, V14, P773, DOI 10.1097/01.wnr.0000063251.41814.70; JOHNSON ML, 1992, AM J PHYS MED REHAB, V71, P239, DOI 10.1097/00002060-199208000-00008; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KEVIN SL, 1999, NEUROIMAGE, V10, P695; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; McFayden MP, 2002, DEV PSYCHOBIOL, V41, P123, DOI 10.1002/dev.10059; Mehta MA, 2000, J NEUROSCI, V20; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; Sekine Y, 2000, J CLIN PSYCHOPHARM, V20, P584, DOI 10.1097/00004714-200010000-00019; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Szobot CM, 2003, EUR J NUCL MED MOL I, V30, P423, DOI 10.1007/s00259-002-1082-0; Wax PM, 1997, J TOXICOL-CLIN TOXIC, V35, P203, DOI 10.3109/15563659709001195; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	30	62	62	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2006	20	1					24	30		10.1191/0269215506cr927oa			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	015CY	WOS:000235530700004	16502746				2022-02-06	
J	Mateer, CA; Sira, CS				Mateer, Catherine A.; Sira, Claire S.			Cognitive and emotional consequences of TBI: Intervention strategies for vocational rehabilitation	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			cognitive rehabilitation; vocational outcome; brain injury; rehabilitation; emotion	TRAUMATIC BRAIN-INJURY; MEMORY PERFORMANCE; EMPLOYMENT; AWARENESS; WORK; METAMEMORY; ADJUSTMENT; DEPRESSION; TASK	The effects of a traumatic brain injury on vocational outcome can be predicted on the basis of several factors. Environmental factors such as a supportive work environment, and person specific factors, including the client's age, premorbid occupation, injury variables, level of awareness, psychosocial adjustment, coping skills, and cognitive deficits have all been found to predict return to work following a traumatic brain injury. Some of these factors are amenable to treatment, and clinicians can impact clients' likelihood of returning to work by intervening in various ways. Through case studies and a literature review on the effectiveness of cognitive rehabilitation interventions, we have outlined specific strategies and recommendations for interventions. Cognitive rehabilitation strategies that address attention, memory and executive deficits can improve clients' abilities to manage workplace tasks and demands. Many clients continue to experience problems with social and emotional adjustment following a brain injury that impact return to work. Cognitive behavioural therapy is well suited for improving coping skills, helping clients to manage cognitive difficulties, and addressing more generalized anxiety and depression in the context of a brain injury.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Mateer, CA (corresponding author), Univ Victoria, Dept Psychol, POB 3050,STN CSC, Victoria, BC V8W 3P5, Canada.	cmateer@uvic.ca					BENYISHAY Y, 1989, NEUROPSYHCOLOGICAL T; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BRUSH JA, 1998, CLIN GERONTOLOGIST, V19, P51, DOI DOI 10.1300/J018V19N01_; CALLAHAN CD, 2001, REHABILITATION NEURO; CAVANAUGH JC, 1989, PSYCHOL AGING, V4, P365, DOI 10.1037/0882-7974.4.3.365; ELLIOTT E, 1989, PSYCHOL PERSPECTICES; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Heald Paul, 1998, J INTELL PROP L, V5, P415; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HERTZOG C, 1990, PSYCHOL AGING, V5, P215, DOI 10.1037/0882-7974.5.2.215; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; HULTSCH DF, 1988, COGNITIVE DEV ADULTH; Jonker C, 1997, EDUC GERONTOL, V23, P115, DOI 10.1080/0360127970230203; KAY T, 1989, ASSESSMENT BEHAV CON; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LACHMAN ME, 1992, J GERONTOL, V47, pP293, DOI 10.1093/geronj/47.5.P293; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1995, NEUROPSYCHOLOIGICAL; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MATEER CA, HDB CLIN NEUROPSYCHO; MCCUE M, 1998, HUMAN BRAIN FUNCT, P113; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1995, HDB MEMORY DISORDERS; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; REICH JH, 1991, J NERV MENT DIS, V179, P74, DOI 10.1097/00005053-199102000-00003; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; ROSENTHAL M, 1990, REHABILITATION ADULT; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg M., 2001, COGNITIVE REHABILITA; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON BA, 2002, NEUROPSYCHOLOGY MEMO	47	62	64	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					315	326					12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700006	17361048				2022-02-06	
J	McAvinue, L; O'Keeffe, F; McMackin, D; Robertson, IH				McAvinue, L; O'Keeffe, F; McMackin, D; Robertson, IH			Impaired sustained attention and error awareness in traumatic brain injury: Implications for insight	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SELF-AWARENESS; QUESTIONNAIRE; CINGULATE; FAILURES; DEFICITS; LESIONS; SYSTEM; TASK	The processes of error awareness and sustained attention were investigated in 18 traumatic brain injury (TBI) individuals and 16 matched control participants. In Experiment 1, we found that: (1) in comparison to controls, TBI participants displayed reduced sustained attention and awareness of error during the Sustained Attention to Response Task; (2) degree of error awareness was strongly correlated with sustained attention capacity, even with severity of injury partialed out; and (3) that error feedback significantly reduced errors. We replicated the finding of a correlation between error awareness and sustained attention capacity in Experiment 2 with a separate sample of 19 TBI participants and 20 controls. We conclude that TBI leads to impaired sustained attention and error awareness. The finding of a significant relationship between these two deficits in TBI suggests there may be a link between these two processes. Feedback on error improves sustained attention performance of control and TBI participants.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Beaumont Hosp, Dublin 9, Ireland		Robertson, IH (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	Ian.Robertson@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Kiehl KA, 2000, PSYCHOPHYSIOLOGY, V37, P216, DOI 10.1017/S0048577200990231; Lamme VAF, 2003, TRENDS COGN SCI, V7, P12, DOI 10.1016/S1364-6613(02)00013-X; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nelson H.E., 1982, NATL ADULT READING T; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	32	62	64	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2005	15	5					569	587		10.1080/09602010443000119			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	994ZM	WOS:000234069700001	16381141				2022-02-06	
J	Ponsford, J				Ponsford, J			Rehabilitation interventions after mild head injury	CURRENT OPINION IN NEUROLOGY			English	Article						concussion; intervention; mild head injury; mild traumatic brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ROUTINE FOLLOW-UP; CONCUSSION; ADULTS; IMPACT	Purpose of review This review examines current management and rehabilitation strategies for mild traumatic brain injury, with emphasis on the need to address multiple potential causative factors in order to enhance outcomes and to conduct more controlled efficacy studies. Recent findings Whilst most individuals who sustain mild traumatic brain injury make a good recovery, a proportion experience significant ongoing disability. In some cases this is due to diffuse axonal injury and cognitive impairment, but in others symptoms are exacerbated by factors such as pain,,stress, personality issues or litigation, or in children, previous head injury, behavioural or learning difficulties. Provision of information early after injury results in reduced symptom reporting in adults and children. There is also a need, however, to address these other factors in treatment. Psychological therapy using a cognitive behavioural approach may be helpful, but controlled evaluations of such interventions have been lacking. Recent uncontrolled studies have examined the impact of computer-mediated interventions to remediate visual and verbal processing and oculomotor problems and the impact of quantitative electroencephalog rap by. More rigorous efficacy studies of these approaches are needed. Guidelines for management of sports-related concussion and timing of return to play also require a more solid scientific basis. Summary The evidence base for management of mild traumatic brain injury is still very limited. There is a need to conduct more carefully controlled prospective studies and examine the influence of factors not directly related to the brain injury as a basis for formulating more uniform management guidelines.	Epworth Med Fdn, Dept Psychol, Epworth Rehabil Ctr, Richmond, Vic 3121, Australia; Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia		Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Epworth Rehabil Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au					Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bronfort G., 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001878.PUB2; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Friedman Jules M, 2004, Med Health R I, V87, P296; Horton A., 2002, MED SCI SPORTS EXERC, V34, P99; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McKerral M, 2005, J REHABIL MED, V37, P61, DOI 10.1080/16501970510026647; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MOORE C, 2004, NZ MED J, V117, P1046; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J. L., 1999, J HEAD TRAUMA REHAB, V14, P25; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rose JM, 2005, BRAIN INJURY, V19, P29, DOI 10.1080/02699050310001617361; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	36	62	62	0	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2005	18	6					692	697		10.1097/01.wco.0000186840.61431.44			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989MT	WOS:000233678800011	16280681				2022-02-06	
J	Machamer, J; Temkin, N; Fraser, R; Doctor, JN; Dikmen, S				Machamer, J; Temkin, N; Fraser, R; Doctor, JN; Dikmen, S			Stability of employment after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injuries; work; neuropsychology; risk factors; prognosis; outcome assessment (health care)	COMMUNITY INTEGRATION; RANDOMIZED-TRIAL; HEAD-INJURY; WORK; RETURN; PREDICTION; TBI; VALPROATE; MODERATE; MODEL	Although substantial information exists about factors related to who returns to work and time taken to return to work after traumatic brain injury (TBI), less is known about the stability of the work experience after the injury. One hundred sixty-five workers with complicated mild to severe traumatic brain injury were followed for 3 to 5 years postinjury. Work stability definitions included amount of time worked (amount of time worked divided by time observed postinjury) and maintenance of uninterrupted employment once a person returned to work. Amount of time worked was significantly and systematically related to brain injury severity, neuropsychological functioning at 1-month postinjury, and preinjury characteristics such as prior work stability and earnings. However, once persons returned to work, the ability to maintain uninterrupted employment was largely related to premorbid characteristics such as being older, higher income before the injury, or a preinjury job with benefits. It was also related to higher neuropsychological functioning at 1-month postinjury (reflecting the combined effects of premorbid functioning and traumatic brain injury severity), but not related to neurologic indices of severity.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA USA; Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	machamer@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01INS19643] Funding Source: Medline		Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McLeod A, 2004, OCCUP ENVIRON MED, V61, P414, DOI 10.1136/oem.2003.007336; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; *US DEP LAB, 2005, LOC AR UN STAT; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	29	62	62	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2005	11	7					807	816		10.1017/S135561770505099X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	000JT	WOS:000234458500002	16519260				2022-02-06	
J	Marmarou, CR; Walker, SA; Davis, CL; Povlishock, JT				Marmarou, CR; Walker, SA; Davis, CL; Povlishock, JT			Quantitative analysis of the relationship between intra-axonal neurofilament compaction and impaired axonal transport following diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amyloid pre-cursor protein (APP); neurofilament compaction (NFC); traumatic axonal injury (TAI); traumatic brain injury (TBI)	AMYLOID PRECURSOR PROTEIN; CYCLOSPORINE-A; BETA-APP; POSTTRAUMATIC HYPOTHERMIA; RETROGRADE CONVERSION; SPECTRIN PROTEOLYSIS; CORTICAL IMPACT; CALCIUM INFLUX; WHITE MATTER; NERVE-FIBERS	Traumatic axonal injury (TAI) following traumatic brain injury (TBI) contributes to morbidity and mortality. TAI involves intra-axonal changes assumed to progress to impaired axonal transport (IAT), disconnection, and axonal bulb formation. Immunocytochemical studies employing antibodies to amyloid precursor protein (APP), a marker of IAT and RMO14, a marker of neurofilament compaction (NFC), have shown that TAI involves both NFC and IAT, with the suggestion that NFC leads to IAT. Recently, new data has suggested that NFC may occur independently of IAT. The objective of this study was to determine quantitatively the precise relationship between NFC and IAT. Following TBI, rats were studied at 30 min, 3 h, and 24 h. Using single-label immunocytochemistry employing the antibodies RMO14, APP, or a combined labeling strategy targeting APP/RMO14 in aggregate, the immunoreactive (IR) profiles were counted in the corticospinal tract (CSpT) and medial lemniscus (ML). In the CSpT, the number of axons demonstrating RMO14-IR approximated the number of axons showing APP-IR, with the APP-IR population showing a significant increase over 24 h (p < 0.05). The sum of both single-label counts equaled the aggregate APP/RMO14 numbers, demonstrating little relationship between NFC and IAT. In the ML, 75% of fibers demonstrated a separation of APP-IR and NFC-IR; however, 25% of the ML fibers showed co-localization of APP-IR and RMO14. The results of these studies indicate that, in the majority of damaged axons, NFC is not associated with IAT. Our findings argue for the use of multiple markers when evaluating the extent of TAI or the efficacy of therapies targeting the treatment of TAI.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Ctr Hlth, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Ctr Hlth, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, T32NS007288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; He Xiaosheng, 1999, Chin J Traumatol, V2, P25; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; MALBOUISSON AMB, 1985, ANAT EMBRYOL, V171, P339, DOI 10.1007/BF00347022; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PANNESE E, 1984, ACTA ANAT, V118, P193; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 2001, HEAD TRAUMA, P281; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; PRICE RL, 1988, J NEUROCYTOL, V17, P55, DOI 10.1007/BF01735377; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; UEDA Y, 2001, J NEUROTRAUM, V18, P1179; WATSON D, 1991, J NEUROSCI RES, V30, P226, DOI 10.1002/jnr.490300123; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258	70	62	67	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1066	1080		10.1089/neu.2005.22.1066			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600004	16238484				2022-02-06	
J	Ozdemir, D; Tugyan, K; Uysal, N; Sonmez, U; Sonmez, A; Acikgoz, O; Ozdemir, N; Duman, M; Ozkan, H				Ozdemir, D; Tugyan, K; Uysal, N; Sonmez, U; Sonmez, A; Acikgoz, O; Ozdemir, N; Duman, M; Ozkan, H			Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; immature rat; spatial memory deficits; hippocampal neuron death; melatonin	BRAIN-INJURY; OXIDATIVE STRESS; CHILDREN; DYSFUNCTION; NEURODEGENERATION; VULNERABILITY; ADOLESCENTS; REDUCTION; APOPTOSIS; SYSTEM	It is well known that head trauma induces the cognitive dysfunction resulted from hippocampal damage. In the present study, we aimed to demonstrate the effect of melatonin on hippocampal damage and spatial memory deficits in 7-day-old rat pups subjected to contusion injury. Melatonin was injected intraperitoneally at the doses of 5 or 20 mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Spatial memory performance was assessed in the Morris water maze. Melatonin significantly attenuated trauma-induced neuronal death in hippocampal CA1, CA3 regions and dentate gyrus, and improved spatial memory deficits, which was equally effective at doses of 5-20 mg/kg. The present results suggest that melatonin is a highly promising agent for preventing the unfavorable outcomes of traumatic brain injury in young children. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Histol & Embryol, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Physiol, TR-35340 Izmir, Turkey; Ataturk Training & Res Hosp, Dept Neurosurg, Izmir, Turkey		Ozkan, H (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey.	hasan.ozkan@deu.edu.tr	Ozkan, Hasan/P-6128-2019; Duman, Murat/Q-2708-2019; Tugyan, Kazim/AAB-3849-2020; acikgoz, osman/C-8046-2012	Ozkan, Hasan/0000-0003-2542-7441; Uysal, Nazan/0000-0002-2348-7427; ACIKGOZ, OSMAN/0000-0003-1444-5847; Duman, Murat/0000-0001-6767-5748			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Amaral David G., 1995, P443; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Felderhoff-Mueser Ursula, 2000, Current Opinion in Neurology, V13, P141, DOI 10.1097/00019052-200004000-00005; Feng Z, 2004, J PINEAL RES, V37, P129, DOI 10.1111/j.1600-079X.2004.00144.x; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Shen YX, 2002, J PINEAL RES, V32, P173, DOI 10.1034/j.1600-079x.2002.1o850.x; Shen YX, 2001, ACTA PHARMACOL SIN, V22, P797; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941	34	62	65	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 16	2005	385	3					234	239		10.1016/j.neulet.2005.05.055			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952AE	WOS:000230972700012	15970378				2022-02-06	
J	Morali, G; Letechipia-Vallejo, G; Lopez-Loeza, E; Montes, P; Hernandez-Morales, L; Cervantes, M				Morali, G; Letechipia-Vallejo, G; Lopez-Loeza, E; Montes, P; Hernandez-Morales, L; Cervantes, M			Post-ischemic administration of progesterone in rats exerts neuroprotective effects on the hippocampus	NEUROSCIENCE LETTERS			English	Article						global cerebral ischemia; hippocampal pyramidal neurons; CA1; neuroprotection; progesterone; 4VO	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; DAMAGE; ISCHEMIA; PROTECTS; STROKE; MODEL; ACID	Progesterone is neuroprotective in models of focal or global ischemia when treatment starts either before the insult or at the onset of reperfusion. In these cases the steroid may act during the occurrence of the early pathophysiological events triggered by ischemia or reperfusion. As opposed to this condition, the aim of the present study was to assess the effect of delayed, post-injury administration of progesterone on the preservation of pyramidal neurons of the hippocampus of rats 21 days after been exposed to global ischemia by the four vessel occlusion model. Progesterone (8 mg/kg, i.v.) or its vehicle, were administered at 20 min, 2, 6, and 24 h after the end of ischemia. At histological examination, brains of the ischemic vehicle-treated rats showed a severe reduction of the population of pyramidal neurons in the CA1 and CA2 subfields (12% and 29% remaining neurons, respectively), and a less severe neuronal loss in the CA3 and CA4 subfields of the hippocampus (68% and 63% remaining neurons, respectively), as compared to rats exposed to sham procedures. They also showed a two-fold enlargement of the lateral ventricles and 33% shrinkage of the cerebral cortex as compared to the sham group. Progesterone treatment resulted in a significant preservation of pyramidal neurons in CA1 and CA2 (40% and 62% remaining neurons), with no ventricular dilation and only a mild (12%) cortical shrinkage. Results suggest that progesterone, is able to interfere with some late pathophysiological mechanisms leading both to selective neuronal damage in the hippocampal CA1 and CA2 subfields, and to shrinkage of the cerebral cortex. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	IMSS, CMN Siglo 21, Unidad Invest Med Farmacol, Mexico City 03100, DF, Mexico; Univ Michoacana, Fac Med, Morelia 58240, Michoacan, Mexico; IMSS, Ctr Invest Biomed Michoacan, Lab Neurofarmacol, Morelia 58240, Michoacan, Mexico		Morali, G (corresponding author), IMSS, CMN Siglo 21, Unidad Invest Med Farmacol, Eugenia 626 Girasol 302,Col Valle, Mexico City 03100, DF, Mexico.	gmorali@hotmail.com	Morali, Gabriela/AAH-8014-2020	Montes, Pedro/0000-0003-1630-5047			Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DOWNIE MM, 1983, BASIC STAT METHODS; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; GWAG BJ, 2002, METH NE FRO NEUROSCI, P79; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kraemer M, 2004, J NEUROIMAGING, V14, P265, DOI 10.1177/1051228404264950; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LUNA G, 1960, MANUAL HISTOLOGIC ST; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Roine R.O., 1997, CURRENT REV CEREBROV, P159; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarraf-Yazdi S, 1999, NEUROL DIS, V48, P243; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Siegel S., 1956, NONPARAMETRIC STAT B, pXVII, 312; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	32	62	65	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUL 15	2005	382	3					286	290		10.1016/j.neulet.2005.03.066			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	939IK	WOS:000230065800017	15885907				2022-02-06	
J	Hall, ED; Gibson, TR; Pavel, KM				Hall, ED; Gibson, TR; Pavel, KM			Lack of a gender difference in post-traumatic neurodegeneration in the mouse controlled cortical impact injury model	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; gender; mouse; neurodegeneration; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LIPID PEROXYL RADICALS; NITRIC-OXIDE; MITOCHONDRIAL DYSFUNCTION; SEXUAL-DIMORPHISM; ALPHA-TOCOPHEROL; BCL-2 EXPRESSION; SMOOTH-MUSCLE; HEAD-INJURY; ESTROGEN	Recent studies using a mouse model of weight-drop-induced "diffuse" traumatic brain injury (TBI) have demonstrated a substantial gender difference in the time course and magnitude of post-traumatic neurodegeneration following a severe level of injury. The time of maximal damage, as assessed by the de Olmos aminocupric silver staining method, occurred at 72 h in male mice, whereas the peak of neurodegeneration was not observed until 14 days in females and was less in magnitude compared to males. This difference, favoring females, has been postulated to relate to the neuroprotective actions of estrogen and progesterone. In the presently reported experiments, we compared the time course and peak of neurodegeneration in male and female mice after a severe level of "focal" controlled cortical impact (CCI; I mm, 3.5 m/sec) TBI using the same strain (CF-1) and weight (29-31 g) as employed in the "diffuse" TBI study. The volume of silver staining was measured using image analysis methods at 24, 48, and 72 h, and 1, 2 and 4 weeks. In male and female mice, a significant increase in neurodegeneration was observed at 24 h, and the volume was not significantly different between the two genders. In both gender groups, the maximal neurodegeneration was seen at 48 h after injury. Although the female mice exhibited a trend toward higher mean volumes of silver staining, this difference was not significantly different compared to males. Furthermore, the rate of resolution of staining between 48 h and 4 weeks was similar. However, injured females still exhibited a significantly higher volume of staining compared to sham, non-injured females at 4 weeks, whereas the difference in staining volume between sham and injured males was no longer significant at that time point. These results show that, following a "focal" CCI, there is no gender difference that favors females, in contrast to that seen with the "diffuse" injury paradigm. The disparity between the effects of gender in the two models may be due to the fact that, in the "focal" CCI model, the timing of post-traumatic neurodegeneration is significantly more rapid than that seen in the "diffuse" model, which may overwhelm the neuroprotective effects of estrogen and progesterone and obscure the appearance of a gender difference.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,B383 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013				Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL ED, 1995, NEUROSURGERY, V96, P505; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; MADDOX YT, 1987, J PHARMACOL EXP THER, V240, P392; McIntosh TK, 1996, LAB INVEST, V74, P315; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Pelligrino DA, 2001, JPN J PHARMACOL, V86, P137, DOI 10.1254/jjp.86.137; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; ZHANG A, 1992, BRIT J PHARMACOL, V105, P305, DOI 10.1111/j.1476-5381.1992.tb14250.x; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267	48	62	64	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					669	679		10.1089/neu.2005.22.669			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400006	15941376				2022-02-06	
J	Joseph, DK; Dutton, RP; Aarabi, B; Scalea, TM				Joseph, DK; Dutton, RP; Aarabi, B; Scalea, TM			Decompressive laparotomy to treat intractable intracranial hypertension after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2004	Minneapolis, MN	Amer Assoc Surg Trauma			ABDOMINAL COMPARTMENT SYNDROME; INTRAABDOMINAL PRESSURE	Introduction: Increases in intra-abdominal pressure (IAP) can cause increases in intracranial pressure (ICP). Recently, we noticed that abdominal fascial release could be useful in treating intracranial hypertension (ICH) after traumatic brain injury (TBI). We added this as an option in our treatment of TBI. Methods: In our institution, ICH is treated with an algorithm using osmolar therapy, CSF drainage and barbiturates. Patients with refractory ICH have routine measurement of IAP. If elevated, consideration is given to decompressive laparotomy. We retrospectively reviewed all patients admitted from January 2000 through July 2003 who had abdominal decompression to treat refractory ICH. Results: From 1/00 to 7/03, 17 patients underwent decompressive laparotomy for intractable ICH. Thirteen male and 4 females all sustained blunt injury. All had failed maximal therapy including 14 who had had decompressive craniectomy. Mean ICP was 30 +/- 8.1 mm Hg (range 20-40 mm Hg) before decompression. No patients had evidence of abdominal compartment syndrome (ACS). Before decompression mean IAP was 27.5 (+/- 5.2) mmHg (range 21-35 mm Hg). After abdominal decompression ICP dropped precipitously by at least 10 mm Hg to a mean of 17.5 (+/- 3.2) mmHg (range 10-25 mm Hg). In 6 patients the decrease in ICP was transient. All died. The remaining 11 had sustained decreases in ICP. All survived, made neurologic recovery and were discharged to a rehabilitation facility. Conclusion: Decompressive laparotomy can be a useful adjunct in the treatment of ICH failing maximal therapy following TBI. More work will need to be done to precise the exact indications for this therapy.	Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Sch Med,Program Trauma, Baltimore, MD 21201 USA		Scalea, TM (corresponding author), Univ Maryland, Med Syst, R Adams Cowley Shock Trauma Ctr, Sch Med,Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	tscalea@umm.edu					ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BARNES GE, 1985, AM J PHYSIOL, V248, pR208, DOI 10.1152/ajpregu.1985.248.2.R208; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; DIEBEL LN, 1992, J TRAUMA, V33, P45, DOI 10.1097/00005373-199207000-00010; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; HOLTHAUSEN UH, 1997, LANGENBECKS ARCH CHI, V114, P257; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Kopelman T, 2000, J TRAUMA, V49, P744, DOI 10.1097/00005373-200010000-00025; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Meier U, 2003, NEUROSURG QUART, V13, P113, DOI 10.1097/00013414-200306000-00006; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; MIGLIETTA M, IN PRESS J TRAUMA; MUTOH T, 1991, J APPL PHYSIOL, V70, P2611, DOI 10.1152/jappl.1991.70.6.2611; Saggi B, 1998, J TRAUMA, V45, P597, DOI 10.1097/00005373-199809000-00033; Saggi BH, 1999, J TRAUMA, V46, P646, DOI 10.1097/00005373-199904000-00014; SAGGI BH, 1998, J TRAUMA, V44, P248; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; Schob OM, 1996, AM J SURG, V172, P248, DOI 10.1016/S0002-9610(96)00101-8; STONE HH, 1977, ANN SURG, V186, P343, DOI 10.1097/00000658-197709000-00012; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	23	62	72	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2004	57	4					687	693		10.1097/01.TA.0000140645.84897.F2			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	871EN	WOS:000225112300001	15514520				2022-02-06	
J	McFadyen, BJ; Swaine, B; Dumas, D; Durand, A				McFadyen, BJ; Swaine, B; Dumas, D; Durand, A			Residual effects of a traumatic brain injury on locomotor capacity - A first study of spatiotemporal patterns during unobstructed and obstructed walking	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						biomechanics; brain injury; gait; locomotion; kinematics; rehabilitation	BALANCE DEFICITS; OBSTACLES; GAIT; REHABILITATION; ADJUSTMENTS; STROKE; PERFORMANCE; DISORDERS; RECOVERY; HEALTHY	Objectives: To understand the residual locomotor effects of a traumatic brain injury (TBI) on unobstructed and obstructed walking. Participants: Eight young, high-functioning adults with TBI and 4 healthy subjects. Main outcome measures: Spatiotemporal gait parameters and their relation to specific clinical measures of severity and locomotor and balance abilities. Results: Subjects with TBI walked slower and showed a tendency for greater foot clearances in all conditions. Slower walking was due to decreased stride lengths and not cadence, while higher foot clearances were due to placing the trailing foot farther from the obstacle and increasing hip flexion angles during avoidance. Conclusions: The results suggest that this highly functional TBI population used increased caution. Measures of injury severity did not provide simple predictions of locomotor ability, but the one-legged stance test with eyes closed correlated to walking capacity.	Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 1S8, Canada; Univ Laval, Dept Rehabil, Quebec City, PQ, Canada; Inst Readaptat Montreal, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; Univ Montreal, Sch Rehabil, Montreal, PQ, Canada; Quebec Rehabil Inst, Quebec City, PQ, Canada		McFadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Hamel, Quebec City, PQ G1M 1S8, Canada.			McFadyen, Bradford/0000-0003-1992-4927			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Begg RK, 1998, GAIT POSTURE, V7, P99, DOI 10.1016/S0966-6362(97)00039-8; Bent LR, 2002, EXP BRAIN RES, V146, P490, DOI 10.1007/s00221-002-1204-8; BERG K, 1989, Physiotherapy Canada, V41, P304; BRIGGS RC, 1989, PHYS THER, V69, P748, DOI 10.1093/ptj/69.9.748; CHEN HC, 1991, J GERONTOL, V46, pM196, DOI 10.1093/geronj/46.6.M196; DREW T, 1993, J NEUROPHYSIOL, V70, P179, DOI 10.1152/jn.1993.70.1.179; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Kalaska JF, 1997, CURR OPIN NEUROBIOL, V7, P849, DOI 10.1016/S0959-4388(97)80146-8; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McFadyen BJ, 1997, EXP BRAIN RES, V114, P500, DOI 10.1007/PL00005659; MCFADYEN BJ, 1993, HUM MOVEMENT SCI, V12, P259, DOI 10.1016/0167-9457(93)90019-L; MCFADYEN BJ, 1991, NEUROSCI RES COMMUN, V9, P37; McFayden BJ, 2002, J GERONTOL A-BIOL, V57, pB166, DOI 10.1093/gerona/57.4.B166; McIntosh L, 1999, J REHABIL OUTCOMES M, V3, P1; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Patla AE, 1996, J MOTOR BEHAV, V28, P35, DOI 10.1080/00222895.1996.9941731; PATLA AE, 1995, EXP BRAIN RES, V106, P499; PATLA AE, 1993, GAIT POSTURE, V1, P45, DOI 10.1016/0966-6362(93)90042-Y; PREFACE EA, 1999, J HEAD TRAUMA REHAB, V14, pR5; Said CM, 1999, ARCH PHYS MED REHAB, V80, P1054, DOI 10.1016/S0003-9993(99)90060-6; Said CM, 2001, ARCH PHYS MED REHAB, V82, P1712, DOI 10.1053/apmr.2001.26247; Schall JD, 2002, NEURON, V36, P309, DOI 10.1016/S0896-6273(02)00964-9; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; ShumwayCook A, 1997, PHYS THER, V77, P812, DOI 10.1093/ptj/77.8.812; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Warren WH, 2001, NAT NEUROSCI, V4, P213, DOI 10.1038/84054; Whitney SL, 2000, J VESTIBUL RES-EQUIL, V10, P99; Winter D.A., 1991, BIOMECHANICS MOTOR C; Yardley L, 2001, J ANXIETY DISORD, V15, P107, DOI 10.1016/S0887-6185(00)00045-1	35	62	63	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2003	18	6					512	525		10.1097/00001199-200311000-00005			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	747MX	WOS:000186809200005	14707881				2022-02-06	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Overview of the brain polyamine-stress-response: Regulation, development, and modulation by lithium and role in cell survival	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						behavior; cell death; hypothalamic-pituitary-adrenocortical axis; lithium; neuroprotection; neurotrauma; ornithine decarboxylase; putrescine; spermidine; spermine	ORNITHINE DECARBOXYLASE ACTIVITY; BIPOLAR AFFECTIVE-DISORDER; FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE-C; RAT-BRAIN; NERVOUS-SYSTEM; CORTICOSTERONE TREATMENT; SIGNAL-TRANSDUCTION; CHRONIC EXPOSURE; HEAT-SHOCK	An early transient increase in brain polyamine (PA) metabolism, termed the PA-stress-response (PSR), is a common reaction to stressful stimuli, including physical, emotional, and hormonal stressors, with a magnitude related to the stress intensity. In the extreme, traumatic injury can result in an incomplete PSR, with persistent accumulation of putrescine and eventual reduction in the concentrations of the higher polyamines (PAs), spermidine and spermine. Chronic intermittent application of stressors causes a recurrence of the brain PSR, but, in contrast, it leads to habituation of the response in the periphery ( liver). Severe continuous stress, however, may lead to accumulation of brain PAs. Long-term inhibition of PA synthesis depletes brain PAs and can result in altered emotional reactivity to stressors. Furthermore, the brain PSR, in contrast to the periphery, can be blocked by a long-term, but not by short-term, treatment with lithium, the most efficacious treatment of manic-depressive illness. The brain PSR is developmentally regulated, and the switch to the mature pattern coincides with the cessation of the "stress hyporesponsive period" in the hypothalamic-pituitary-adrenocortical (HPA) system. In contrast to the brain and liver, the PSR in the adrenal and thymus is down-regulated by acute stressors. Transient up-regulation of the PSR, as in the brain and liver, is implicated in cell survival while its down-regulation is implicated in cell death. Taken together, the findings indicate that the PSR is a dynamic process that varies with the type, intensity, and duration of stressors, and implicate this response as an adaptive mechanism in the reaction to stressful events. Under persistent stressful conditions, however, the PSR may be maladaptive as may be reflected by PA accumulation. This raises the hypothesis that proper regulation of brain PSR may be critical for neuronal function and for an appropriate behavioral response to stressors.	Assaf Harofeh Med Ctr, Neurosci Lab, IL-70300 Zerifin, Israel		Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Neurosci Lab, PO Beer Yaakov, IL-70300 Zerifin, Israel.	gmgilad@asaf.health.gov.il	Gilad, Gad M/E-7193-2010				Abraham I, 1997, J NEUROENDOCRINOL, V9, P713, DOI 10.1046/j.1365-2826.1997.00634.x; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; ANDERSON TR, 1975, BIOCHEM PHARMACOL, V24, P495, DOI 10.1016/0006-2952(75)90136-7; Anisman H, 1998, INT J DEV NEUROSCI, V16, P149, DOI 10.1016/S0736-5748(98)00025-2; ARMARIO A, 1988, NEUROENDOCRINOLOGY, V47, P263, DOI 10.1159/000124921; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Bohn M. C, 1984, NEUROBEHAVIORAL TERA, P365; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; CALDECOTTHAZARD S, 1991, SYNAPSE, V8, P185, DOI 10.1002/syn.890080306; COTTERRELL M, 1972, J NEUROCHEM, V19, P2151, DOI 10.1111/j.1471-4159.1972.tb05124.x; COUSIN MA, 1982, J NEUROCHEM, V38, P1296, DOI 10.1111/j.1471-4159.1982.tb07904.x; COX RH, 1985, J APPL PHYSIOL, V58, P1207, DOI 10.1152/jappl.1985.58.4.1207; DANZIN C, 1979, LIFE SCI, V24, P519, DOI 10.1016/0024-3205(79)90173-5; EBSTEIN RP, 1980, J PHARMACOL EXP THER, V213, P161; FERCHMIN PA, 1993, PHARMACOL BIOCHEM BE, V45, P967, DOI 10.1016/0091-3057(93)90149-N; FLAMIGNI F, 1986, J MOL CELL CARDIOL, V18, P3, DOI 10.1016/S0022-2828(86)80977-4; GILAD GM, 1995, MECH AGEING DEV, V78, P75, DOI 10.1016/0047-6374(94)01529-U; Gilad GM, 2002, BRAIN RES, V943, P23, DOI 10.1016/S0006-8993(02)02479-4; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GILAD GM, 1992, LIFE SCI, V50, pPL149, DOI 10.1016/0024-3205(92)90289-2; Gilad GM, 1998, INT J DEV NEUROSCI, V16, P271, DOI 10.1016/S0736-5748(98)00033-1; Gilad GM, 1996, J NEUROCHEM, V67, P1992; Gilad VH, 2001, BIOCHEM PHARMACOL, V61, P207, DOI 10.1016/S0006-2952(00)00517-7; Gilad VH, 2000, DEV BRAIN RES, V120, P255, DOI 10.1016/S0165-3806(00)00012-2; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; Goodwin F.K., 1990, MANIC DEPRESSIVE ILL; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Heim C, 1997, PSYCHOPHARMACOL BULL, V33, P185; HIETALA OA, 1983, BIOCHEM PHARMACOL, V32, P1581, DOI 10.1016/0006-2952(83)90331-3; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIRVONEN A, 1988, BIOCHIM BIOPHYS ACTA, V950, P229, DOI 10.1016/0167-4781(88)90015-2; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; JOPE RS, 1994, BIOCHEM PHARMACOL, V47, P429, DOI 10.1016/0006-2952(94)90172-4; KANBA S, 1991, NEUROPHARMACOLOGY, V30, P497, DOI 10.1016/0028-3908(91)90012-Z; Kuhn CM, 1998, INT J DEV NEUROSCI, V16, P261, DOI 10.1016/S0736-5748(98)00034-3; KVETNANKY R, 1979, AM J PHYSIOL, V246, pH457; LACHMAN HM, 1989, LIFE SCI, V45, P1413, DOI 10.1016/0024-3205(89)90031-3; LI PP, 1993, J NEUROCHEM, V61, P1722, DOI 10.1111/j.1471-4159.1993.tb09809.x; LUKKARAINEN J, 1995, EUR J NEUROSCI, V7, P1840, DOI 10.1111/j.1460-9568.1995.tb00704.x; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; MANJI HK, 1993, J NEUROCHEM, V61, P2303, DOI 10.1111/j.1471-4159.1993.tb07474.x; MARTIN A, 1994, J CHEM TECHNOL BIOT, V60, P7, DOI 10.1002/jctb.280600103; MARTON LJ, 1986, PHARMACEUT RES, V3, P311, DOI 10.1023/A:1016375705487; MASANA MI, 1992, J NEUROCHEM, V59, P200, DOI 10.1111/j.1471-4159.1992.tb08891.x; MATSUI I, 1980, BIOCHIM BIOPHYS ACTA, V633, P87, DOI 10.1016/0304-4165(80)90040-9; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORUZZI MS, 1993, MOL CELL BIOCHEM, V124, P1, DOI 10.1007/BF01096375; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; NISENBAUM LK, 1991, J NEUROSCI, V11, P1478; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; OBAYASHI M, 1992, BIOCHIM BIOPHYS ACTA, V1131, P41, DOI 10.1016/0167-4781(92)90096-I; PASCHEN W, 1988, NEUROCHEM PATHOL, V9, P1; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; POL O, 1992, PHARMACOL BIOCHEM BE, V42, P407, DOI 10.1016/0091-3057(92)90133-Z; PRINCE CR, 1984, BEHAV NEURAL BIOL, V42, P99, DOI 10.1016/S0163-1047(84)90942-7; RICHARDS JF, 1990, LIFE SCI, V47, P233, DOI 10.1016/0024-3205(90)90325-L; ROSELLINI RA, 1976, B PSYCHONOMIC SOC, V7, P251, DOI 10.3758/BF03337180; RUSSELL DH, 1974, J NEUROBIOL, V5, P349, DOI 10.1002/neu.480050406; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; SCHUBER F, 1989, BIOCHEM J, V260, P1; SCHUBERT T, 1991, PSYCHOPHARMACOLOGY, V104, P45, DOI 10.1007/BF02244552; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1991, Prog Drug Res, V37, P107; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SINGH SS, 1995, LIFE SCI, V57, P685, DOI 10.1016/0024-3205(95)00320-6; Soliman KFA, 1997, LIFE SCI, V60, P2383, DOI 10.1016/S0024-3205(97)00298-1; Sparapani M, 1997, BRAIN RES, V765, P164, DOI 10.1016/S0006-8993(97)00656-2; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TIZABI Y, 1989, NEUROSCI LETT, V105, P177, DOI 10.1016/0304-3940(89)90033-5; UMEMOTO S, 1994, NEUROSCI LETT, V167, P101, DOI 10.1016/0304-3940(94)91037-5; Wang SY, 1996, J NEUROSCI, V16, P836; WEISS JM, 1981, BRAIN RES REV, V3, P167, DOI 10.1016/0165-0173(81)90005-9; WEISS JM, 1975, PSYCHOSOM MED, V37, P522, DOI 10.1097/00006842-197511000-00006; WILLNER P, 1990, PHARMACOL THERAPEUT, V45, P425, DOI 10.1016/0163-7258(90)90076-E; WSTRARKMAN MN, 1999, BIOL PSYCHOL, V45, P1595; YOUNG LT, 1991, BRAIN RES, V553, P323, DOI 10.1016/0006-8993(91)90843-K; ZOLI M, 1991, NEUROSCI LETT, V132, P225, DOI 10.1016/0304-3940(91)90307-F	84	62	64	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	OCT	2003	23	4-5					637	649		10.1023/A:1025036532672			13	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	708UX	WOS:000184589000017	14514021				2022-02-06	
J	Gottshall, K; Drake, A; Gray, N; McDonald, E; Hoffer, ME				Gottshall, K; Drake, A; Gray, N; McDonald, E; Hoffer, ME			Objective vestibular tests as outcome measures in head injury patients	LARYNGOSCOPE			English	Article						traumatic brain injury; dynamic visual acuity; vestibular dysfunction	TRAUMATIC BRAIN-INJURY; DYNAMIC VISUAL-ACUITY; POSTCONCUSSION SYNDROME; DEPRESSION; CONCUSSION; MANAGEMENT; INVENTORY; DEFICITS; SCALE; COMA	Hypothesis: Dynamic visual acuity testing (DVAT) and the Dizziness Handicap Index (DHI) can be used as reliable outcome measures in patients after head injury. Background: Balance disorders are a significant disability after mild traumatic brain injury (TBI). Assessing when individuals can perform activities of daily living, return to work, and begin to play sports can be difficult to determine. Objective outcome measures that correlate with successful life skills can be useful in managing these patients. Methods. Fifty-three active duty individuals who suffered mild TBI underwent weekly DVAT testing and were administered a weekly DHI. Results in this group were compared with 46 control subjects who had not experienced TBI. In addition, weekly scores were compared with the patient's functional level, time to return to work, and time to perform all job related activities. Results. Individuals with TBI showed an overall increase of 42% in DVAT function over the first 4 weeks of testing, whereas controls showed an 8% increase. Concurrently, individuals with TBI averaged a 18-point improvement in DHI function, whereas control subjects showed no significant change in this score. Improvement in DVAT and DHI function correlated closely at the 1-week time point. Improvement in the patient's cognitive function, ability to return to activities of daily living, and ability to return to work gradually improved continuously. Conclusion: DVAT and the DHI can be used as reliable outcome measures in evaluating the progress of patients with balance disorders associated with TBI. These measures allow providers to make more reliable recommendations regarding such activities as returning to work.	US Dept Def, Spatial Orientat Ctr, Dept Otolaryngol, Naval Med Ctr San Diego, San Diego, CA 92134 USA; Def Vet Head Injury Program, San Diego, CA USA		Gottshall, K (corresponding author), US Dept Def, Spatial Orientat Ctr, Dept Otolaryngol, Naval Med Ctr San Diego, San Diego, CA 92134 USA.	krgottshall@nmcsd.med.navy.mil					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM C REH MED, 1993, HEAD TRAUMA REHABIL, V8, P86; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; *CDCP, 1999, TRAUM BRAIN INJ US; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Clark WD, 1998, HEALTH CARE FINANC R, V20, P1; Clendaniel RA, 2000, OTOLARYNG CLIN N AM, V33, P519, DOI 10.1016/S0030-6665(05)70225-5; Demer JL, 2001, ANN NY ACAD SCI, V942, P428; Demer JL, 1998, OTOLARYNG HEAD NECK, V119, P78, DOI 10.1016/S0194-5998(98)70176-7; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Flanagan S, 1999, MT SINAI J MED, V66, P152; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GRONWALL D, 1975, LANCET, V2, P995; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman SJ, 2001, ARCH OTOLARYNGOL, V127, P1205, DOI 10.1001/archotol.127.10.1205; Herdman SJ, 1998, AM J OTOL, V19, P790; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; KIRTANE MV, 1982, J LARYNGOL OTOL, V96, P521, DOI 10.1017/S0022215100092793; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lee MH, 1997, AVIAT SPACE ENVIR MD, V68, P111; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; *MICR TECHN, 1999, DVA TEST VERS 12 US, P1; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Schubert MC, 2001, ANN NY ACAD SCI, V942, P490; TEASDALE G, 1974, LANCET, V2, P81; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, P7; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whitney SL, 2000, OTOLARYNG CLIN N AM, V33, P659, DOI 10.1016/S0030-6665(05)70232-2; WRIGHT JH, 1983, HOSP COMMUNITY PSYCH, V34, P1119; Wright SC, 1998, AVIAT SPACE ENVIR MD, V69, P999	34	62	64	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0023-852X	1531-4995		LARYNGOSCOPE	Laryngoscope	OCT	2003	113	10					1746	1750		10.1097/00005537-200310000-00016			5	Medicine, Research & Experimental; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Research & Experimental Medicine; Otorhinolaryngology	731EL	WOS:000185871500015	14520100				2022-02-06	
J	Pardo, R; Andreolotti, AG; Ramos, B; Picatoste, F; Claro, E				Pardo, R; Andreolotti, AG; Ramos, B; Picatoste, F; Claro, E			Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; cell cycle arrest; ERK; GSK-3; lithium; MEK	CEREBELLAR GRANULE CELLS; GLYCOGEN-SYNTHASE KINASE-3; SUBGENUAL PREFRONTAL CORTEX; CEREBRAL-CORTICAL SLICES; CULTURED BRAIN NEURONS; AP-1 DNA-BINDING; INOSITOL MONOPHOSPHATASE; PROTEIN-KINASE; MOOD DISORDERS; GROWTH-FACTORS	Lithium is widely used in the treatment of bipolar disorder, but despite its proven therapeutic efficacy, the molecular mechanisms of action are not fully understood. The present study was undertaken to explore lithium effects of the MEK/ERK cascade of protein kinases in astrocytes and neurons. In asynchronously proliferating rat cortical astrocytes, lithium decreased time- and dose-dependently the phosphorylation of MEK and ERK, with 1 mM concentrations achieving 60 and 50% inhibition of ERK and MEK, respectively, after a 7-day exposure. Lithium also inhibited [H-3] thymidine incorporation into DNA and induced a G2/M cell cycle arrest. In serum-deprived, quiescent astrocytes, pre-exposure to lithium resulted in the inhibition of cell cycle re-entry as stimulated by the mitogen endothelin-1: under this experimental setting, lithium did not affect the rapid, peak phosphorylation of MEK taking place after 3-5 min, but was effective in inhibiting the long-term, sustained phosphorylation of MEK. Lithium inhibition of the astrocyte MEK/ERK pathway was independent of inositol depletion. Further, compound SB216763 inhibited Tau phosphorylation at Ser396 and stabilized cytosolic beta-catenin, consistent with the inhibition of glycogen synthase kinase-3beta (GSK-3beta), but failed to reproduce lithium effects on MEK and ERK phosphorylation and cell cycle arrest. In cerebellar granule neurons, millimolar concentrations of lithium enhanced MEK and ERK phosphorylation in a concentration-dependent manner, again through an inositol and GSK-3beta independent mechanism. These opposing effects in astrocytes and neurons make lithium treatment a promising strategy to favour neural repair and reduce reactive gliosis after traumatic injury.	Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain; Univ Extremadura, Dept Fisiol, E-06071 Badajoz, Spain		Claro, E (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Edifici M, E-08193 Bellaterra, Spain.		Claro, Enrique/D-5612-2009; Ramos, Belen/K-8067-2015	Claro, Enrique/0000-0002-7592-7906; Ramos, Belen/0000-0002-4577-2106			Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7; Atack JR, 1996, BRAIN RES REV, V22, P183; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Centeno F, 1998, NEUROREPORT, V9, P4199, DOI 10.1097/00001756-199812210-00036; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Chen RW, 2003, J NEUROCHEM, V84, P566, DOI 10.1046/j.1471-4159.2003.01548.x; CLARO E, 1993, J NEUROCHEM, V60, P2078, DOI 10.1111/j.1471-4159.1993.tb03492.x; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.t01-1-00251.x; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GODFREY PP, 1989, BIOCHEM J, V258, P621, DOI 10.1042/bj2580621; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hall AC, 2002, MOL CELL NEUROSCI, V20, P257, DOI 10.1006/mcne.2002.1117; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hashimoto R, 2003, NEUROSCIENCE, V117, P55, DOI 10.1016/S0306-4522(02)00577-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; Levine S, 2000, CELL PROLIFERAT, V33, P203, DOI 10.1046/j.1365-2184.2000.00170.x; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Masgrau R, 2000, J NEUROCHEM, V74, P818, DOI 10.1046/j.1471-4159.2000.740818.x; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nemeth ZH, 2002, J BIOL CHEM, V277, P7713, DOI 10.1074/jbc.M109711200; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; Ozaki N, 1997, J NEUROCHEM, V69, P2336; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Servitja JM, 2000, J NEUROCHEM, V75, P788, DOI 10.1046/j.1471-4159.2000.0750788.x; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; STANIMIROVIC DB, 1995, GLIA, V15, P119, DOI 10.1002/glia.440150204; Torreilles F, 2000, MOL BRAIN RES, V78, P181, DOI 10.1016/S0169-328X(00)00073-5; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	52	62	63	2	11	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					417	426		10.1046/j.1471-4159.2003.02015.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100015	14511119	Bronze			2022-02-06	
J	Goranson, TE; Graves, RE; Allison, D; La Freniere, R				Goranson, TE; Graves, RE; Allison, D; La Freniere, R			Community integration following multidisciplinary rehabilitation for traumatic brain injury	BRAIN INJURY			English	Article							COGNITIVE REHABILITATION; QUESTIONNAIRE; OUTCOMES; PREDICTION; PROGRAM; REGRESSION; DAMAGE	Primary objective : To determine the extent to which participation in a multidisciplinary rehabilitation programme and patient characteristics predict improvement in community integration following mild-to-moderate traumatic brain injury (TBI). Research design : A non-randomized case-control study was conducted employing a pre-test-post-test multiple regression design. Methods and procedures : Archival data for 42 patients with mild-to-moderate TBI who completed the Community Integration Questionnaire (CIQ) at intake and again 6-18 months later were analysed. Half the sample participated in an intensive outpatient rehabilitation programme that provided multi-modal interventions, while the other half received no rehabilitation. The two groups were matched on age, education and time since injury. Results : On the CIQ Home Integration scale, participation in rehabilitation and female gender predicted better outcome. On the Productivity scale, patients with a lower age at injury had better outcome. Outcome on both of these scales, as well as on the Social Integration scale, was predicted by the baseline pre-test score (initial severity). Conclusions : Overall, multidisciplinary rehabilitation appeared to increase personal independence. It is also concluded that: (1) multivariate analysis can reveal the relative importance of multiple predictors of outcome; (2) different predictors may predict different aspects of outcome; and (3) more sensitive and specific outcome measures are needed.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Gorge Rd Hosp, Dept Psychol, Victoria, BC, Canada; Gorge Rd Hosp, Dept Rehabil Med, Victoria, BC, Canada		Graves, RE (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.						ARANOW HU, 1987, J HEAD TRAUMA REHAB, V2, P24; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, pCH7; FORSYTHE AB, 1971, J PSYCHIAT RES, V8, P119, DOI 10.1016/0022-3956(71)90013-6; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MATEER CA, 1996, NEUROPHYSIOLOGY NEUR, V6, P12; NORUSIS MJ, 1999, SPSS BASE 10 0 USERS; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	32	62	62	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2003	17	9					759	774		10.1080/0269905031000088513			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691ML	WOS:000183610000003	12850942				2022-02-06	
J	Tinius, TP				Tinius, TP			The Integrated Visual and Auditory Continuous Performance Test as a neuropsychological measure	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mTBI; attention; brain injury; ADHD; head injury	CLOSED-HEAD-INJURY; REACTION-TIME; SUSTAINED ATTENTION	The Integrated Visual and Auditory (IVA) Continuous Performance Test (CPT) and Neuropsychological Impairment Scale (NIS) were completed by adults diagnosed with mild traumatic brain injury (mTBI), adults diagnosed with attention deficit hyperactivity disorder (ADHD), and controls. On the IVA CPT, the mTBI and ADHD groups performed significantly lower on the full and secondary scales for attention and response accuracy. For individual scales, the mTBI and ADHD groups showed lower performance on measures of reaction time, inattention, impulsivity, and variability of RT. The mTBI and ADHD groups showed similar patterns of performance on the IVA. On the NIS, the mTBI and ADHD groups reported more neuropsychological symptoms than the control group, and the mTBI group reported more neuropsychological symptoms than the ADHD group. The results are discussed in regard to changes in cognitive processing and sustained attention in individuals diagnosed with mTBI and ADHD. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	St Cloud State Univ, Dept Psychol, St Cloud, MN 56301 USA		Tinius, TP (corresponding author), St Cloud State Univ, Dept Psychol, 420 7th Ave S, St Cloud, MN 56301 USA.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Beck A.T., 1967, DEPRESSION CLIN; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; ERRICO AL, 1990, J CONSULT CLIN PSYCH, V1, P45; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gordon M, 1988, INSTRUCTION MANUAL G; Gronwall D, 1989, MILD HEAD INJURY, P153; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; LARRABEE GJ, 1996, ECOLOGICAL VALIDITY; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Miller E, 1970, Cortex, V6, P121; O'Donnell W., 1994, NEUROPSYCHOLOGICAL I; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Rimel R. W., 1981, NEUROSURGERY, V9, P35; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SANDFORD JA, 1995, MANUAL INTEGRATED VI; SOLHBERG MM, 1989, INTRO COGNITIVE REHA; Sparrow E, 1999, CONNERS ADULT ADHD R; Spielberger C.D., 1970, TEST MANUAL STATE TR; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMENEN AH, 1990, NEUROBEHAVORIAL RECO; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wechsler D, 1981, WECHSLER ADULT INTEL; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7	30	62	72	1	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2003	18	5					439	454	PII S0887-6177(02)00144-0	10.1016/S0887-6177(02)00144-0			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	689CB	WOS:000183473100001	14591441				2022-02-06	
J	Huebner, RA; Johnson, K; Bennett, CM; Schneck, C				Huebner, RA; Johnson, K; Bennett, CM; Schneck, C			Community participation and quality of life outcomes after adult traumatic brain injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	APR   18, 1999	INDIANAPOLIS, INDIANA	Amer Occupat Therapy Assoc		activity limitation; community integration; occupational performance	REHABILITATION; SATISFACTION; INTEGRATION; RECOVERY	OBJECTIVE. This study examined outcomes after traumatic brain injury in adults salient to occupational therapy. METHOD. Demographic data and Functional Independence Measure (FIM) scores from the inpatient rehabilitation stay were first gathered from a retrospective chart review. At follow-up, 25 adults, on average 21 months post-injury, completed measures of disability, community participation, quality of life, and satisfaction with occupational therapy during a telephone interview. Analysis of covariance was used to test the differences between pretest and posttest scores on the FIM; regression analysis and correlations were used to analyze predictions and relationships. RESULTS. Statistically significant improvements in FIM scores during rehabilitation were predictive of the level of long-term disability and community participation among participants. At follow-up, participants were often unemployed, depressed and withdrawn, and experienced limitations in decision making, hand use, bladder control, and community integration. Less disability and more community participation were related to higher quality of life. Satisfaction with occupational therapy, although high, was unrelated to most outcomes. CONCLUSION. Results support the premise that participation is associated with a high quality of lite, yet persons with brain injury have significant needs for long-term occupational therapy.	Eastern Kentucky Univ, Dept Occupat Therapy, Richmond, KY 40475 USA; Stepping Stones Communities, Louisville, KY USA; Mountainland Rehabil, Salt Lake City, UT USA		Huebner, RA (corresponding author), Kentucky Cabinet Families & Children, Off Secretary, Mail Stop 4W-B,275 E Main St, Frankfort, KY 40621 USA.						Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Brandt EN, 1997, ENABLING AM ASSESSIN; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Corcoran K., 1987, MEASURES CLIN PRACTI; DIJKERS MPJ, 2000, MEASURES SOCIAL O S2, V81, pS63; Evans RW, 1997, ARCH PHYS MED REHAB, V78, pS17, DOI 10.1016/S0003-9993(97)90151-9; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fisher TF, 1998, AM J OCCUP THER, V52, P785, DOI 10.5014/ajot.52.10.785; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; GUST T, 1982, QUALITY LIFE RATING; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Halstead LS, 2001, ARCH PHYS MED REHAB, V82, P149, DOI 10.1053/apmr.2001.22207; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holm MB, 2000, AM J OCCUP THER, V54, P575, DOI 10.5014/ajot.54.6.575; HUEBNER RA, 1998, J REHABILITATION OUT, V2, P8; JOHNSTON MV, 1994, ARCH PHYSICAL MED RE, V75, P2; Keith RA, 1998, ARCH PHYS MED REHAB, V79, P1122, DOI 10.1016/S0003-9993(98)90182-4; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; Macksoud M.S., 1992, J REFUG STUD, V5, P1, DOI [10.1093/jrs/5.1.1, DOI 10.1093/JRS/5.1.1]; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Nelson DL, 1996, AM J OCCUP THER, V50, P223, DOI 10.5014/ajot.50.3.223; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; *SPSS INC, 2001, STAT PROGR SOC SERV; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Watts J, 2000, J REHABILITATION OUT, V4, P55; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WHYTE J, 1998, REHABILITATION MED P, P1191; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; World Health Organization, 1999, INT CLASS FUNCT DIS; YOUNGSTROM MJ, 2000, UNPUB DRAFT 4; 1989, HLTH ACTIVITY LIMITA	41	62	67	0	4	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR-APR	2003	57	2					177	185		10.5014/ajot.57.2.177			9	Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Rehabilitation	654YV	WOS:000181525300007	12674309				2022-02-06	
J	Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Kochanek, PM				Berger, RP; Pierce, MC; Wisniewski, SR; Adelson, PD; Kochanek, PM			Serum S100B concentrations are increased after closed head injury in children: A preliminary study	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; pediatrics; S100B; traumatic brain injury	S-100 PROTEIN MEASUREMENTS; TRAUMATIC BRAIN-DAMAGE; MARKERS; AGE	Traumatic brain injury (TBI) is a leading cause of death and disability in children. The current gold standards for diagnosis of TBI after closed head injury (CHI) have limitations, particularly in cases of inflicted injury. S100B is a protein that is specific to astrocytes. Serum S100B concentrations are increased in adults after CHI; there are no studies of serum S100B after CHI in children. The goal of this study was to measure the serum concentrations of S100B in children inflicted and noninflicted mild, moderate, and severe CHI. CHI severity was defined by initial Glasgow Coma Scale score. Forty-five children aged 0-13 years with mild (n = 27), moderate (n = 6), and severe (n = 12) CHI were enrolled prospectively. Blood was obtained as soon as possible after injury (range: 0.5-15.25 h) and every 12 h for up to 5 days when vascular access was available. Single control samples were obtained from 16 children aged 0-11 years with isolated long-bone fractures. Twenty-two patients (49%), including both patients with inflicted CHI, had an abnormal initial serum S100B concentration where an abnormal concentration was defined as greater than mean control concentration plus two standard deviations. S100B was detectable more than 12 h after injury only in patients with severe CHI. We conclude that serum S100B is increased in almost half of children after mild, moderate, and severe inflicted and noninflicted CHI. The increase is transient, lasting less than 12 h after injury, except in children with severe injury. Future research will focus on the possibility of using serum S100B as a screening test for inflicted CHI.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Pierce, Mary Clyde/AAQ-3509-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline		DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976	12	62	62	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1405	1409		10.1089/089771502320914633			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500001	12490005				2022-02-06	
J	Carnevale, GJ; Anselmi, V; Busichio, K; Millis, SR				Carnevale, GJ; Anselmi, V; Busichio, K; Millis, SR			Changes in ratings of caregiver burden following a community-based behavior management program for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver burden; community-based behavior management program; traumatic brain injury	PERCEIVED STRESS; HEAD-INJURY; DISTRESS; INDIVIDUALS; HEALTH; NEEDS	Objective: This study examines the use of a community-delivered behavior management program for persons with traumatic brain injury and their caregivers and its effect on reduction of ratings of caregiver burden. Design: A control group was compared with an education only and education plus behavior management group with random assignment to conditions. Participants: Total number of participants was 27 persons with brain injury and their caregivers. Main Outcome Measures: Dependent measures were subscales of the Questionnaire on Resources and Stress (QRS) and an adapted version of the Maslach Burnout Inventory (MBI). Results: An analysis of covariance adjusting for baseline burden and stress ratings showed no significant change in these measures associated with treatment. Conclusions: The results are discussed in terms of the potential modifiability of caregiver burden, the small sample size, and the sensitivity of current measures of caregiver stress and burden to detect clinically meaningful change.	Kaiser Inst Rehabil, Dept Psychol Neuropsychol, E Orange, NJ 07018 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA		Carnevale, GJ (corresponding author), Kaiser Inst Rehabil, Dept Psychol Neuropsychol, 240 Cent Ave, E Orange, NJ 07018 USA.						Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; CARNEVALE GJ, 1995, NATURAL SETTING BEHA; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Holroyd J., 1987, MANUAL QUESTIONNAIRE; KAUSAR R, 1996, CLIN REHABIL, V10, P159; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Maslach C., 1996, MBI MASLACH BURNOUT; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Moules S, 1999, BRAIN INJURY, V13, P983; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751	25	62	63	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					83	95		10.1097/00001199-200204000-00002			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500002	11909508				2022-02-06	
J	Borgens, RB; Bohnert, D				Borgens, RB; Bohnert, D			Rapid recovery from spinal cord injury after subcutaneously administered polyethylene glycol	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nerve sealing; neurotrauma; PEG; polyethylene glycol; spinal cord injury; spinal recovery	APPLIED ELECTRIC-FIELDS; METHYLPREDNISOLONE; RECONNECTION; HEMISECTION; MEMBRANES; AXONS	Arguably a seminal event in most trauma and disease is the breakdown of the cell membrane. In most cells, this is first observed as a collapse of the axolemmas barrier properties allowing a derangement of ions to occur, leading to a progressive dissolution of the cell or its process. We have shown that an artificial sealing of mechanically damaged membranes by topical application of hydrophilic polymers such as polyethylene glycol (PEG) immediately restores variable levels of nerve impulse conduction through the lesion. This was documented by a rapid recovery of somatosensory evoked potential (SSEP) conduction, and by recovery of the cutaneous trunchi muscle (CTM) reflex in PEG-treated animals. The CTM reflex is a sensorimotor behavior dependent on an intact (and identified) white matter tract within the ventrolateral funiculus of the spinal cord, and is thus an excellent index of white matter integrity. We show that PEG can be safely introduced into the bloodstream by several routes of administration. Using a fluorescein decorated PEG, we demonstrate that the polymer specifically targets the hemorrhagic contusion of the adult guinea pig spinal cord when administered through the vasculature, but not intact regions of the spinal cord. A single subcutaneous injection (30% weight by weight in sterile saline) made 6 hr after a standardized spinal cord contusion in adult guinea pigs was sufficient to produce a rapid recovery of SSEP propagation through the lesion in only PEG-treated animals, accompanied by a statistically significant recovery of the CTM reflex. These data suggest that parenterally administered PEG may be a novel treatment for not only spinal injury, but head injury and stroke as well. (C) 2001 Wiley-Liss, Inc.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Inst Appl Neurol, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.	cpr@vet.purdue.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39288-02] Funding Source: Medline		Alberstone CD, 1999, SPINE SURG TECHNIQUE, P1; BITTNER GD, 1986, BRAIN RES, V367, P351, DOI 10.1016/0006-8993(86)91617-3; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DUERSTOCK BS, 2001, IN PRESS J EXPT BIO; EPSTEIN N, 1999, SPINE SURG, P1249; JOHNSON AJ, 1971, BRIT J HAEMATOL, V21, P21, DOI 10.1111/j.1365-2141.1971.tb03414.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; MALGREM L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280; MARKS JD, 2000, FASEB J, V15, P1107; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; POINTILLART V, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Working PK, 1997, ACS SYM SER, V680, P45; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	34	62	62	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2001	66	6					1179	1186					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	499GH	WOS:000172562500017	11746451				2022-02-06	
J	Marklund, N; Clausen, F; Lewander, T; Hillered, L				Marklund, N; Clausen, F; Lewander, T; Hillered, L			Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method	JOURNAL OF NEUROTRAUMA			English	Article						free radicals; 2-hydroxybenzoic acid (salicylate : 2-HBA); 4-hydroxybenzoic acid (4-HBA); microdialysis; reactive oxygen species; traumatic brain injury (TBI)	COMPRESSION CONTUSION TRAUMA; HYDROXYL RADICAL GENERATION; EXPERIMENTAL HEAD-INJURY; LIPID-PEROXIDATION; CAUTIONARY NOTE; SODIUM-SALICYLATE; OXIDATIVE STRESS; CELL-DEATH; ISCHEMIA; RELEASE	The detection of reactive oxygen species (ROS) after traumatic brain injury (TBI) is based on indirect methods due to the high reactivity and short half-life of ROS in biological tissue. The commonly used salicylate trapping method has several disadvantages making it unsuitable for human use. We have evaluated 4-hydroxybenzoic acid (4-HBA) together with microdialysis (MD) in the rat as an alternative method. 4-HBA forms one stable adduct, 3,4-dihydroxybenzoic acid (3,4-DHBA), when reacting with ROS and has not previously been used together with MD after TBI. Twenty-seven rats were used for the assessment of 3,4-DHBA production as an indicator of ROS formation in a controlled contusion injury model using intracerebral MD with 3 mM 4-HBA in the perfusate. For comparison, salicylate trapping was used in eight rats. TBI caused a 250 % increase of 3,4-DHBA that peaked at 30 min after injury in severely injured rats and remained significantly elevated as compared to baseline for 90 min after trauma. The mild injury level caused a 100% increase in 3,4-DHBA formation at 30 min after the injury. When the MD probe was placed in the perimeter of the injury site, no significant increase in ROS formation occurred. Salicylate trapping showed a similar increase in adduct formation after severe injury. In addition, high cortical concentrations of 4-HBA and salicylate were found. It is concluded that microdialysis with 4-HBA as a trapping agent appears to be a useful method for ROS detection in the rat with a potential clinical utility.	Univ Uppsala Hosp, Dept Neurosci & Neurosurg, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Psychiat, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci & Neurosurg, SE-75185 Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; CASADEBAIG F, 1991, THROMB RES, V64, P631, DOI 10.1016/0049-3848(91)90063-3; DEJANA E, 1983, THROMB RES, P153; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez MA, 1998, J PHARM PHARMACOL, V50, P1183, DOI 10.1111/j.2042-7158.1998.tb03332.x; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; Gido G, 2000, ACTA PHYSIOL SCAND, V168, P277; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; Halliwell B, 1997, FREE RADICAL RES, V27, P239, DOI 10.3109/10715769709065762; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Love S, 1999, BRAIN PATHOL, V9, P119; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MONTGOMERY J, 1995, FREE RADICAL BIO MED, V19, P927, DOI 10.1016/0891-5849(95)02004-T; Najbauer J, 2000, NEUROSCIENCE, V99, P107, DOI 10.1016/S0306-4522(00)00158-5; Nakagawa Y, 1999, BIOCHEM PHARMACOL, V58, P811, DOI 10.1016/S0006-2952(99)00147-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishio S, 1997, ACT NEUR S, V70, P84; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STAHLE L, 1991, MICRODIALYSIS NEUROS, P155; Ste-Marie L, 1999, FREE RADICAL BIO MED, V27, P997, DOI 10.1016/S0891-5849(99)00170-7; SteMarie L, 1996, ANAL BIOCHEM, V241, P67, DOI 10.1006/abio.1996.0379; TANAKA T, 1995, CANCER-AM CANCER SOC, V75, P1433, DOI 10.1002/1097-0142(19950315)75:6+<1433::AID-CNCR2820751507>3.0.CO;2-4; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; WATSON BD, 1993, PROG BRAIN RES, V96, P69; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WESTERGREN I, 1995, J NEUROCHEM, V64, P229; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	52	62	68	4	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2001	18	11					1217	1227		10.1089/089771501317095250			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	491KC	WOS:000172106700003	11721740				2022-02-06	
J	Meythaler, JA; Guin-Renfroe, S; Johnson, A; Brunner, RM				Meythaler, JA; Guin-Renfroe, S; Johnson, A; Brunner, RM			Prospective assessment of tizanidine for spasticity due to acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						baclofen; brain injuries; cerebral palsy; cerebrovascular accident; dystonia; muscle hypertonia; muscle spasticity; rehabilitation	INTRATHECAL BACLOFEN INFUSION; LONG-TERM; SPINAL SPASTICITY; DRUG-THERAPY; DOUBLE-BLIND; DYSTONIA; HEMIPLEGIA; HYPERTONIA; ORIGIN	Objective: To determine if orally delivered tizanidine will control spastic hypertonia due to acquired brain injury. Design: Randomized, double-blind, placebo-controlled, crossover design, with 2 8-week treatment arms separated by a 1-week washout period at baseline. Patients were randomly assigned to receive tizanidine or a matching placebo. Setting: Tertiary care outpatient and inpatient rehabilitation center attached to a university hospital. Participants: Seventeen persons recruited in a consecutive manner, 9 of whom had suffered a stroke and 8 a traumatic brain injury, and had more than 6 months of intractable spastic hypertonia. Intervention: Over a 6-week period, subjects were slowly titrated up to their maximum tolerated dose (up to 36mg/d). Following a 1-week drug taper and 1-week period in which no study drug was administered, patients were then crossed over to the other study medication following an identical titration regime. Main Outcome Measures: Subjects were evaluated for dose and effect throughout the trial as well as for side effects. Data for Ashworth rigidity scores, spasm scores, deep tendon reflex scores, and motor strength were collected on the affected upper extremity (UE) and lower extremity (LE). Differences over time were assessed via descriptive statistics, Friedman's analysis, and Wilcoxon's signed-rank. Data are reported as the mean +/- 1 standard deviation. Results: Following 4 weeks of treatment when subjects reached their maximal tolerated dosage, the average LE Ashworth score on the affected side decreased from 2.3 +/- 1.4 to 1.7 +/- 1.1 (p < .0001). The spasm score decreased from 1.0 +/- 0.9 to 0.5 +/- 0.8 (p = .0464), while the reflex score was not statistically significant decreasing from 2.2 +/- 1.0 to 2.0 +/- 1.1 (p = .0883). The average UE Ashworth score on the affected side decreased from 1.9 +/- 1.1 to 1.5 +/- 0.9 (p < .0001). There was no significant change in the UE spasm and reflex scores. While there were positive placebo effects on motor tone, the active drug was still significantly better than placebo for decreasing LE tone (p = .0006) and UE tone (p = .0007). With a reduction in motor tone, there was an increase in motor strength (p = .0089). The average dosage at 4 weeks was 25.2mg/d. Conclusion: Tizanidine is effective in decreasing the spastic hypertonia associated with acquired brain injury, which is dose-dependent. There are limitations on its use due to side effects related to drowsiness.	Univ Alabama Birmingham, Sch Med, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA		Meythaler, JA (corresponding author), Univ Alabama Birmingham, Sch Med, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, 619 19th St S, Birmingham, AL 35249 USA.	JMeythal@uab.edu					ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P68; Albright AL, 1996, NEUROSURGERY, V38, P934, DOI 10.1097/00006123-199605000-00015; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ASHBY P, 1974, J NEUROL NEUROSUR PS, V37, P1352, DOI 10.1136/jnnp.37.12.1352; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BES A, 1988, CURR MED RES OPIN, V10, P709, DOI 10.1185/03007998809111122; BodineFowler SC, 1996, MUSCLE NERVE, V19, P497, DOI 10.1002/mus.880190404; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Coward D M, 1994, Neurology, V44, pS6; DAVIES J, 1984, BRIT J PHARMACOL, V82, P409, DOI 10.1111/j.1476-5381.1984.tb10776.x; DELWAIDE PJ, 1994, NEUROLOGY, V44, P21; Delwaide PJ, 1994, NEUROLOGY S9, pS27; DONOVAN WH, 1988, ARCH PHYS MED REHAB, V69, P193; Ford B, 1996, ARCH NEUROL-CHICAGO, V53, P1241, DOI 10.1001/archneur.1996.00550120049016; Gekht AB, 1998, ZH NEVROPATOL PSIKH, V98, P22; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; Gracies JM, 1997, MUSCLE NERVE, pS92; GRANGER CV, 1993, GUIDE USE UNIFORM DA; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; KAMEYAMA T, 1986, EUR J PHARMACOL, V125, P257, DOI 10.1016/0014-2999(86)90035-X; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; LANG AE, 1992, CLIN NEUROPHARMACOL, V15, P142, DOI 10.1097/00002826-199204000-00008; LATASTE X, 1994, NEUROLOGY, V44, P53; Mann NH, 1991, J NEUROL REHABIL, V5, P51; *MED EC, 1999, PHYS DES REF, P617; MEDICI M, 1989, CURR MED RES OPIN, V11, P398, DOI 10.1185/03007998909110141; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 1997, J HEAD TRAUMA REHAB, V12, P87, DOI 10.1097/00001199-199702000-00012; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; MILANOV I, 1994, ACTA NEUROL SCAND, V89, P274; Milanov I G, 1992, Electromyogr Clin Neurophysiol, V32, P621; NANCE PW, 1994, NEUROLOGY, V44, P44; Patterson, 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROBERTS RC, 1994, NEUROLOGY, V44, P29; SAYERS AC, 1980, ARZNEIMITTEL-FORSCH, V30-1, P793; SMITH C, 1994, NEUROLOGY, V44, P34; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 1993, REHABILITATION MED P, P825; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96	43	62	67	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2001	82	9					1155	1163		10.1053/apmr.2001.25141			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	470LR	WOS:000170873900002	11552184				2022-02-06	
J	Mayer, SA; Commichau, C; Scarmeas, N; Presciutti, M; Bates, J; Copeland, D				Mayer, SA; Commichau, C; Scarmeas, N; Presciutti, M; Bates, J; Copeland, D			Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; ACUTE STROKE; BODY-TEMPERATURE; HYPERTHERMIA; WORSENS; CARE; UNIT	Objective: To evaluate the efficacy of an air-circulating cooling blanket for reducing body temperature in febrile neuro-ICU patients treated with acetaminophen. Methods: Two-hundred twenty consecutively admitted neuro-ICU patients whose tympanic membrane temperature reached or exceeded 101 degreesF (38.3 degreesC) were randomly assigned to receive acetaminophen (650 mg every 4 hours) alone (n = 107) or acetaminophen plus air blanket therapy (n = 113). After 24 hours of treatment, the authors compared the proportion of subjects who attained treatment success (T less than or equal to 99 degreesF) or treatment failure (T greater than or equal to 101 degreesF for 2 consecutive hours) using the chi (2) test and the time to reach these endpoints using Kaplan-Meier survival analysis. Main Results: Air blanket therapy resulted in a small increase in the proportion of subjects with treatment success (44% versus 36%, chi (2) p = 0.19, log rank p = 0.10) and a similar small reduction in the proportion of patients with treatment failure (42% versus 53%, chi (2) p = 0.11, log-rank p = 0.21), compared with treatment with acetaminophen alone. Approximately one third of patients in both groups remained febrile after randomization and "failed" after the first 2 hours of treatment. Twelve percent of patients assigned to air blanket therapy refused or were unable to tolerate treatment, compared with 2% of patients treated with acetaminophen alone (p = 0.005). Conclusions: Treatment with an air-circulating cooling blanket did not effectively reduce body temperature in febrile neuro-ICU patients treated with acetaminophen. More effective interventions are needed to maintain normothermia in patients at risk for fever-related brain damage.	Columbia Univ Coll Phys & Surg, Dept Neurol, Div Crit Care Neurol, New York, NY 10032 USA; New York Presbyterian Hosp, Columbia Presbyterian Med Ctr, Dept Nursing, New York, NY USA		Mayer, SA (corresponding author), Neurol Inst, 710 W 168th St,Unit 39, New York, NY 10032 USA.		Scarmeas, Nikolaos/AAD-2512-2020	Scarmeas, Nikolaos/0000-0001-6453-8908			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AMEER B, 1977, ANN INTERN MED, V87, P202, DOI 10.7326/0003-4819-87-2-202; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BUSTO R, 1987, J CEREB BLOOD FLOW M, V7, P129; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CLASEN RA, 1974, J NEUROSURG, V41, P576, DOI 10.3171/jns.1974.41.5.0576; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; DONE AK, 1983, AM J MED, V74, P27, DOI 10.1016/0002-9343(83)90525-9; ERICKSON RS, 1993, CRIT CARE MED, V21, P1528, DOI 10.1097/00003246-199310000-00022; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Guyton A. C, 1991, TXB MED PHYSL, P797; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; HOLTZCLAW BJ, 1992, HEART LUNG, V21, P482; ISAACS SN, 1990, AM J MED, V88, P31, DOI 10.1016/0002-9343(90)90124-V; KIELBLOCK AJ, 1986, S AFR MED J, V69, P378; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Klein NC, 1996, INFECT DIS CLIN N AM, V10, P211, DOI 10.1016/S0891-5520(05)70295-6; LEBOVITZ RM, 1975, EPILEPSIA, V16, P215, DOI 10.1111/j.1528-1157.1975.tb06050.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Morgan S P, 1990, J Neurosci Nurs, V22, P19; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; O'Grady NP, 1998, CRIT CARE MED, V26, P392, DOI 10.1097/00003246-199802000-00046; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Poblete B, 1997, BRIT J ANAESTH, V78, P123, DOI 10.1093/bja/78.2.123; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Schmitz T, 1995, Am J Crit Care, V4, P286; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WEINER JS, 1980, LANCET, V1, P507; WYNDHAM CH, 1959, J APPL PHYSIOL, V14, P771, DOI 10.1152/jappl.1959.14.5.771	33	62	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 13	2001	56	3					292	298		10.1212/WNL.56.3.292			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	401DK	WOS:000166911700004	11171891				2022-02-06	
J	Bareyre, FM; Saatman, KE; Raghupathi, R; McIntosh, TK				Bareyre, FM; Saatman, KE; Raghupathi, R; McIntosh, TK			Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion; lesion volume; magnesium chloride; neuroprotection; head injury	SODIUM-CHANNEL BLOCKER; CEREBRAL EDEMA; NEURONAL LOSS; HEAD TRAUMA; CALCIUM; NEUROTOXICITY; ACTIVATION; ANTAGONISM; EFFICACY; DECLINE	The neuroprotective effect of magnesium chloride (MgCl2), a compound previously demonstrated to improve behavioral and neurochemical outcome in several models of experimental brain injury, was evaluated in the present study. Male Sprague-Dawley rats were anesthetized and subjected to lateral fluid-percussion brain injury of moderate severity (2.5-2.8 atm), A cannula was implanted in the left femoral vein and at 1 h following injury, animals randomly received a 15 min i.v. infusion of either MgCl2 (125 mu mol/rat) or saline. A second group of animals received anesthesia, surgery, and either MgCl2 or vehicle to serve as uninjured (sham) controls, Two weeks following brain injury, animals were sacrificed, brains removed, and coronal sections were taken for quantitative analysis of cortical lesion volume and hippocampal CA(3) cell counts. Traumatic brain injury resulted in a lesion in the ipsilateral cortex and loss of pyramidal neurons in the CA3 region of the hippocampus in vehicle-treated animals (p < 0.01 vs. uninjured animals). Administration of MgCl2 significantly reduced the injury-induced damage in the cortex (p < 0.01) but did not alter posttraumatic cell loss in the CA(3) region of the ipsilateral hippocampus, The present study demonstrates that, in addition to its beneficial effects on behavioral outcome, MgCl2 treatment attenuates cortical histological damage when administered following traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline		Aikawa J.K., 1981, MAGNESIUM ITS BIOL S, V1st ed.; ALTURA B M, 1985, Magnesium, V4, P245; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GIBSON BL, 1985, NEUROSCI LETT, V57, P13, DOI 10.1016/0304-3940(85)90033-3; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEALTH DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Regan RF, 1998, J NEUROCHEM, V70, P77; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TASSANI V, 1995, BIOCHEM BIOPH RES CO, V207, P661, DOI 10.1006/bbrc.1995.1238; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Vink R, 1990, Magnes Res, V3, P163; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	64	62	63	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2000	17	11					1029	1039		10.1089/neu.2000.17.1029			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	374KY	WOS:000165345400003	11101206				2022-02-06	
J	Hofman, PAM; Nelemans, P; Kemerink, GJ; Wilmink, JT				Hofman, PAM; Nelemans, P; Kemerink, GJ; Wilmink, JT			Value of radiological diagnosis of skull fracture in the management of mild head injury: meta-analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; skull fracture; meta-analysis; radiological diognosis	SIGNIFICANT INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; RISK; PREDICTORS; EMERGENCY; ADMISSION; UTILITY; TESTS	Objectives-Head injury is a common event. Most patients sustain a mild head injury (MHI), and management depends on the risk of an intracranial haemorrhage (ICH). The value of a plain skull radiograph as a screening tool for ICH is controversial. The aim of this metaanalysis was to estimate and explain differences in reported sensitivity and specificity of the finding of a skull fracture for the diagnosis of ICH, in order to assess the value of the plain skull radiograph in the investigation of patients with MHI, and to estimate the prevalence of ICH in these patients. Method-After a systematic literature search 20 studies were selected that reported data on the prevalence of ICH after MHI and/or data on the diagnostic value of skull fracture for the diagnosis of ICH. The mean prevalence of ICH weighted for the sample size was determined. The sensitivity and specificity of different studies were combined using a summary receiver operator characteristic curve. Correlation analysis was used to determine factors that could explain the reported differences between studies. Results-The weighted mean prevalence of ICH after MHI is 0.083. The potential for verification bias and the percentage of patients who had suffered loss of consciousness or post-traumatic amnesia were the most significant factors explaining interstudy differences in sensitivity and specificity. Based on studies wherein at least 50% of patients had a CT study of the brain, the estimated sensitivity of a radiographic finding of skull fracture for the diagnosis of ICH is 0.38 with a corresponding specificity of 0.95. Conclusion-The plain skull radiograph is of little value in the initial assessment of MHI patients.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Maastricht, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Epidemiol, NL-6200 AZ Maastricht, Netherlands		Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.						Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; BEGG CB, 1988, RADIOLOGY, V167, P565, DOI 10.1148/radiology.167.2.3357976; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Bradburn MJ., 1998, STATA TECH B, V44, P4; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; EVANS KT, 1977, BRIT J RADIOL, V50, P299, DOI 10.1259/0007-1285-50-593-299; GALBRAITH S, 1981, LANCET, V2, P1350; GomezGallego F, 1996, FASEB J, V10, P153, DOI 10.1096/fasebj.10.1.8566536; GORMAN DF, 1987, ARCH EMERG MED, V4, P141; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hutchinson PJA, 1998, J ACCID EMERG MED, V15, P84; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121403; RAO R, 1991, J TRAUMA, V31, P801; RAO R, 1991, J TRAUMA, V31, P804; ROBERTS CJ, 1981, LANCET, V2, P791; Sackett DL., 1991, CLIN EPIDEMIOLOGY BA, V2; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; THILLAINAYAGAM K, 1987, INJURY, V18, P319, DOI 10.1016/0020-1383(87)90051-9; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	39	62	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2000	68	4					416	422		10.1136/jnnp.68.4.416			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	299AQ	WOS:000086174000005	10727475	Green Published, Bronze			2022-02-06	
J	Kogler, A; Lindfors, J; Odkvist, LM; Ledin, T				Kogler, A; Lindfors, J; Odkvist, LM; Ledin, T			Postural stability using different neck positions in normal subjects and patients with neck trauma	ACTA OTO-LARYNGOLOGICA			English	Article; Proceedings Paper	Meeting of the Collegium Oto-Rhino-Laryngologicum Amicitae Sacrum (CORLAS)	AUG 22-25, 1999	LYON, FRANCE			neck position; neck proprioceptors; postural control; whiplash injury	HEAD EXTENSION; POSTUROGRAPHY	Subjects with neck problems, such as whiplash injuries, often complain of disturbed equilibrium and, in some instances, provocation of the neck position can elicit such problems. The importance of neck proprioceptors for maintaining balance is gaining increased interest, moreover the function or malfunction of the otoliths may disturb equilibrium in certain head positions. The aim of the study was to create a reference material for postural control and its dependence on head position in healthy subjects and to compare this with a set of patients with known neck problems and associated vertiginous problems. A total of 32 healthy subjects (16 men, 16 women; age range 21-58 years) as well as 10 patients age range 27-62 years (mean 44 years) with neck problems and associated balance problems since a whiplash injury were tested For postural control using the EquiTest dynamic posturographic model. The normal subjects were initially split into four age groups in order to estimate the effects of age on performance. The postural stability was evaluated for dependence of support sur face conditions (stable or sway-referenced), visual input (eyes open or closed) and head position (neutral, left rotated, right rotated, extended backwards or flexed forward) using analysis of variance (ANOVA) with Tukey's post hoc test in case of a significant factor effect. As expected, visual cues as well as stable support surface improve postural stability (p < 0.001). Postural stability is statistically different in the head extended backwards condition compared with the other foul head positions (p < 0.001 in all cases) in both patients and controls. Eliminating this test condition from the analysis, only a slight (p < 0.05) difference between head forwards and head turned left remained. This pattern of results remained if the normal subjects were only split into two age groups instead of Four. Finally, the patient group exhibited significantly lower postural performance than all the groups of normal subjects (p < 0.01), but none of the normal groups differed significantly from each other. It is concluded that the postural control system is significantly challenged in the head extended backwards condition in both normal subjects and patients with previous whiplash injury and persistent neck problems. The patient group differed statistically from all groups of normal subjects, This suggests that neck problems impair postural control, and that the head extended position is a more challenging task for the postural system to adapt to. Whether this is due to utricular malpositioning, central integrative functions or cervical proprioceptive afferents is not within the scope of this study to answer.	Linkoping Univ Hosp, Dept ENT, SE-58185 Linkoping, Sweden		Ledin, T (corresponding author), Linkoping Univ Hosp, Dept ENT, SE-58185 Linkoping, Sweden.						Alund M, 1993, J Vestib Res, V3, P383; BARIN K, 1992, OTOLARYNG HEAD NECK, V106, P355, DOI 10.1177/019459989210600407; Barre J-A., 1926, REV NEUROL, V33, P1246; BRANDT T, 1981, ANN NY ACAD SCI, V374, P636, DOI 10.1111/j.1749-6632.1981.tb30907.x; DEJONG JMB, 1986, DISORDERS POSTURE GA, P185; ENBOM H, 1990, THESIS U HOSP LUND; Guez C, 1991, PRINCIPLES NEURAL SC, P596; HAMID MA, 1994, J VESTIB RES, V6, P481; JACKSON RT, 1991, ANN OTO RHINOL LARYN, V100, P63, DOI 10.1177/000348949110000110; Karlberg M, 1995, THESIS U HOSP LUND; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; PFALTZ CR, 1984, VERTIGO, P179; RYAN GMS, 1955, LANCET, V31, P1355; SHEEHAN S, 1960, NEUROLOGY, V10, P968, DOI 10.1212/WNL.10.11.968; SPITZER WO, 1995, SPINE S8, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; WILLIS WD, 1992, PHYSIOLOGY, P166	16	62	66	0	8	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-6489			ACTA OTO-LARYNGOL	Acta Oto-Laryngol.		2000	120	2					151	155					5	Otorhinolaryngology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	313JJ	WOS:000086996300009	11603761				2022-02-06	
J	Ewing-Cobbs, L; Prasad, M; Kramer, L; Landry, S				Ewing-Cobbs, L; Prasad, M; Kramer, L; Landry, S			Inflicted traumatic brain injury: Relationship of developmental outcome to severity of injury	PEDIATRIC NEUROSURGERY			English	Article						brain injury; cerebral infarction; child abuse; cognition; outcome; infants; children; shaken baby syndrome	HEAD-INJURY; YOUNG-CHILDREN; FOLLOW-UP; IMPACT SYNDROME; ABUSE; INFANTS; ADOLESCENTS; MECHANISMS; SEQUELAE; COMA	Inflicted traumatic brain injury (TBI) is a frequent consequence of physical child abuse in infants and children. Twenty-eight children who were 2-42 months of age when hospitalized for moderate to severe TBI were enrolled in a prospective, longitudinal study of neurobehavioral outcome following acquired brain injury. Relative to a comparison group, the children with inflicted TBI had significant deficits in cognitive, motor and behavioral domains when assessed with the Bayley Scales of Infant Development-II 1 and 3 months after the injury. Nearly half of the injured children showed persisting deficits in attention/arousal, emotional regulation and motor coordination. Greater injury severity, as indicated by lower coma scale scores, longer periods of unconsciousness and the presence of edema/cerebral infarctions was associated with poorer outcomes in all domains. Copyright (C) 2000 S. Karger AG, Basel.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	lewing@ped1.med.uth.tmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29462] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; ELMER E, 1977, PEDIATRICS, V59, P273; ELMER E, 1967, PEDIATRICS, V40, P596; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; EWINGCOBBS L, IN PRESS CHILDS NERV; FAMULARO R, 1992, CLIN PEDIATR, V31, P536, DOI 10.1177/000992289203100904; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; FITCH MJ, 1976, J PEDIATR PSYCHOL, V1, P32; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GOLDSON E, 1978, AM J DIS CHILD, V132, P790, DOI 10.1001/archpedi.1978.02120330062016; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Greer A L, 1981, J Med Syst, V5, P129, DOI 10.1007/BF02222066; HAHN YS, 1983, CHILD BRAIN, V10, P229; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.2307/1130130; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MORSE CW, 1970, AM J DIS CHILD, V120, P439, DOI 10.1001/archpedi.1970.02100100103011; OKUN A, 1994, DEV PSYCHOPATHOL, V6, P77, DOI 10.1017/S0954579400005897; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148; [No title captured]	40	62	63	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	NOV	1999	31	5					251	258		10.1159/000028872			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	288RC	WOS:000085576200006	10681680				2022-02-06	
J	Michaels, AJ; Michaels, CE; Zimmerman, MA; Smith, JS; Moon, CH; Peterson, C				Michaels, AJ; Michaels, CE; Zimmerman, MA; Smith, JS; Moon, CH; Peterson, C			Posttraumatic stress disorder in injured adults: Etiology by path analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	29th Annual Meeting of the Western-Trauma-Association	FEB 28-MAR 06, 1999	CRESTED BUTTE, COLORADO	Western Trauma Asso			MOTOR-VEHICLE ACCIDENTS; ROAD TRAFFIC ACCIDENTS; TRAUMA PATIENTS; PERITRAUMATIC DISSOCIATION; PSYCHIATRIC CONSEQUENCES; PREDICTORS; PTSD; VETERANS; RECOVERY; EVENTS	Objective: Posttraumatic Stress Disorder (PTSD) impairs outcome from injury. We present a path analysis of factors related to the development of PTSD in injured adults. Methods: A prospective cohort of 250 patients without severe neurotrauma was evaluated by interview during admission and by mailed self-report 6 months later. Data were gathered from the trauma registry (age, injury mechanism, and Injury Severity Score), social history (gender, income, education, and social support), and survey instruments. Baseline assessment used the Michigan Critical Events Perception Scale (peritraumatic dissociation and subjective threat to life), the Life Experience Survey (stressful exposure history), and the SF36 (general and mental health). PTSD at 6 months was identified with the civilian Mississippi Scale for PTSD. Data are listed as mean +/- SEM or percent (%). Path analysis was conducted by linear regression and significant (p < 0.05) variables are shown. Factors are listed with the standardized beta. A negative beta suggests a protective effect. Results: The 176 patients (72%) who completed the 6-month follow-up were 37.7 +/- 0.88 years old; 75% were men; and blunt (70%), penetrating (13.5%), and burn (16.4%) mechanisms caused the injuries. Assault was involved in 14.5% of the cases. Average income was $44,300 +/- 2,700/yr, education was 13.0 +/- 0.15 years, and Injury Severity Score was 13.9 +/- 0.50. A total of 42.3% of the patients developed PTSD. The 39.7% of the variance in PTSD explained by the model was due to intentional injury (beta = 0.27), male gender (beta = -0.21), age (beta = -0.20), peritraumatic dissociation (beta = 0.174), baseline mental health (beta = -0.21), and prior life-threatening illness (beta = -0.29). Peritraumatic dissociation was due to the patient's sense of threat to life (beta = -0.47), and threat was related to Injury Severity Score (beta = 0.2), assault(beta = 0.14), education (beta = -0.15), and age (beta = -0.19). Baseline SF36 mental health was related to social support (beta = 0.27) and income (beta = 0.21). Income was contingent on education (beta = 0.21). Conclusion: PTSD occurred in 42.3% of injured adults 6 months after trauma and was related to assault, dissociation, female gender, youth, poor mental health, and prior illness. By modeling PTSD, we may learn more of the etiology, risk stratification, and potentials for the treatment of this common and important morbidity of injury.	Legacy Emanuel Hosp, Dept Surg, Portland, OR USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Publ Hlth, Ann Arbor, MI 48109 USA		Michaels, AJ (corresponding author), Emanuel Hosp, Trauma Serv, 2801 Gantenbien Ave, Portland, OR 97227 USA.						American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN, V4th; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BREMNER JD, 1992, AM J PSYCHIAT, V149, P328; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; DEROGATIS LR, 1993, BSI BRIEF SYMPTOM IN; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EPSTEIN RS, 1993, J TRAUMA STRESS, V6, P451, DOI 10.1007/BF00974316; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; LANDSMAN IS, 1990, J BEHAV MED, V13, P561, DOI 10.1007/BF00844735; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Marmar CR, 1996, AM J PSYCHIAT, V153, P94; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; MICHAELS AJ, 1998, SURG FORUM, V49, P534; MICHAELS CE, 1997, ANN M INT SOC TRAUM; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Prigerson HG, 1999, J NERV MENT DIS, V187, P23, DOI 10.1097/00005053-199901000-00005; Richmond TS, 1998, J TRAUMA, V44, P635, DOI 10.1097/00005373-199804000-00012; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Taal LA, 1998, BURNS, V24, P285, DOI 10.1016/S0305-4179(98)00030-8; Taft CT, 1999, J TRAUMA STRESS, V12, P3, DOI 10.1023/A:1024786030358; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409; Ware J.E., 1993, SF 36 HLTH SURVEY MA	44	62	65	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	1999	47	5					867	873		10.1097/00005373-199911000-00009			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	254QM	WOS:000083623700008	10568714				2022-02-06	
J	Voller, B; Benke, T; Benedetto, K; Schnider, P; Auff, E; Aichner, F				Voller, B; Benke, T; Benedetto, K; Schnider, P; Auff, E; Aichner, F			Neuropsychological, MRI and EEG findings alter very mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; PRACTICAL SCALE; TOMOGRAPHY; DEFICITS; CT	Neuropsychological performance, magnetic resonance imaging (MRI) and electroencephalography (EEG) were investigated in 12 consecutive patients with very mild traumatic brain injury (MTBI) (Glasgow coma score 15) within 24 hours and 6 weeks after injury. The data were compared to 14 control subjects. There was a significant impairment in neuropsychological performance (verbal memory, arithmetic abilities and psychomotor reaction time) at onset and after 6 weeks, whereas verbal fluency and non-verbal memory lest revealed no significant differences matching the control values. In MRI scans, three patients showed traumatic lesions (slight epidural haematoma, haemorrhagic contusions and white matter lesions indicating diffuse axonal injury). In the EEG recordings, no generalized slowing or focal changes were found. Structural and functional impairment can be identified using neuroimaging and neuropsychological examination, even in very MTBI patients.	Univ Vienna, Dept Neurol, Div Neurorehabil, A-1090 Vienna, Austria; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Trauma Surg, A-6020 Innsbruck, Austria; Landesnervenklin Linz, Dept Neurol, Linz, Austria		Voller, B (corresponding author), Univ Vienna, Dept Neurol, Div Neurorehabil, Wahringergurtel 18-20, A-1090 Vienna, Austria.	bernhard.voller@akh-wien.ac.at		Voller, Bernhard/0000-0001-5809-874X			Adams J.H., 1990, HDB CLIN NEUROLOGY, V13, P43; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BENZER A, 1987, NOTFALLMEDIZIN, V13, P41; Delis DC, 1987, CALIFORNIA VERBAL LE; DENMAN SB, 1984, CLIN ASSESMENT IMMED; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; ILMBGER J, 1992, MUNCHNER GEDACHTNIST; JENKINS A, 1986, LANCET, V2, P445; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	25	62	62	0	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					821	827		10.1080/026990599121214			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800008	10576466				2022-02-06	
J	Ciresi, DL; Cali, RF; Senagore, AJ				Ciresi, DL; Cali, RF; Senagore, AJ			Abdominal closure using nonabsorbable mesh after massive resuscitation prevents abdominal compartment syndrome and gastrointestinal fistula	AMERICAN SURGEON			English	Article; Proceedings Paper	Midwest Surgical Association Meeting	AUG 16-18, 1998	MACKINAC ISL, MICHIGAN	Midwest Surg Assoc			CRITICALLY ILL PATIENTS; VACUUM PACK; EXPERIENCE; MANAGEMENT; PRESSURE; TRAUMA	Patients who receive high-volume resuscitation after massive abdominopelvic trauma, or emergent repair of a ruptured abdominal aortic aneurysm (RAAA), are at a significant risk for postoperative abdominal compartment syndrome (ACS). Absorbable prosthetic closure of the abdominal wall has been recommended as a means of managing ACS. However, use of absorbable prosthetic has been associated with very high rates of intestinal fistula formation and ventral hernia formation. The purpose of this study was to retrospectively review our experience with the use of nonabsorbable prosthetic abdominal closures in patients with documented ACS or at high risk for ACS. All patients managed by this technique from July 1995 through July 1997 after repair of ruptured abdominal aortic aneurysm or massive abdominopelvic trauma were evaluated. A total of 18 patients were identified: 15 primary prosthetic placements (Gore-Tex (TM) patch, 12; Marlex (TM) mesh, 2; and silastic mesh, 1) and 3 delayed prosthetic placements for ACS (Gore-Tex (TM), 1 and Marlex (TM), 2). The mortality rate was 22 per cent (4 of 18) and resulted from multisystem organ failure (2 patients), cardiac arrest 1 hour postoperatively (1 patient), and severe closed head injury (1 patient). Secondary closure and prosthetic removal was possible in 16 of 18 patients, including the 2 patients who died of multisystem organ failure within the same hospitalization. Delayed abdominal closure at a subsequent admission was performed in two cases. This same patient developed an enterocutaneous fistula 2 months after discharge. Importantly, only 1 of 18 closed in this manner developed ACS requiring reoperation. The results indicate that use of a nonabsorbable prosthetic, particularly with Gore-Tex (TM), is efficacious in the prevention of postoperative ACS in high-risk patients, while it enhances the possibility for delayed abdominal closure and minimizes the risk of gastrointestinal fistulization associated with other techniques.	Michigan State Univ, Ctr Surg Educ, Grand Rapids, MI 49503 USA; Michigan State Univ, Div Trauma, Grand Rapids, MI 49503 USA; Michigan State Univ, Div Vasc Surg, Grand Rapids, MI 49503 USA		Senagore, AJ (corresponding author), Michigan State Univ, Ctr Surg Educ, 221 Michigan St NE,Suite 200, Grand Rapids, MI 49503 USA.						BROCK WB, 1995, AM SURGEON, V61, P30; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; Eddy V, 1997, SURG CLIN N AM, V77, P801, DOI 10.1016/S0039-6109(05)70585-5; FIETSAM R, 1989, AM SURGEON, V55, P396; HIRSHBERG A, 1995, ANN SURG, V222, P3, DOI 10.1097/00000658-199507000-00002; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Mayberry JC, 1997, ARCH SURG-CHICAGO, V132, P957; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; MORRIS JA, 1993, ANN SURG, V217, P576, DOI 10.1097/00000658-199305010-00019; Nagy KK, 1996, AM SURGEON, V62, P331; Oelschlager BK, 1997, AM J SURG, V173, P411, DOI 10.1016/S0002-9610(97)00081-0; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; Smith LA, 1997, AM SURGEON, V63, P1102; Williams M, 1997, AM SURGEON, V63, P555	14	62	67	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	AUG	1999	65	8					720	724					5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	220MR	WOS:000081670200009	10432080				2022-02-06	
J	Wada, K; Chatzipanteli, K; Busto, R; Dietrich, WD				Wada, K; Chatzipanteli, K; Busto, R; Dietrich, WD			Effects of L-NAME and 7-NI on NOS catalytic activity and behavioral outcome after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; 3-bromo-' 7-nitro indazole; fluid percussion brain injury; nitric oxide synthase; nitro-L-arginine-methyl ester; rat	NITRIC-OXIDE SYNTHASE; CEREBRAL BLOOD-FLOW; L-ARGININE; MODERATE HYPOTHERMIA; RELAXING FACTOR; HEAD-INJURY; GLUTAMATE NEUROTOXICITY; NMDA RECEPTORS; INFARCT VOLUME; ISCHEMIA	Traumatic brain injury (TBI) produces transient increases in constitutive nitric oxide synthase (cNOS) activity and prolonged behavioral abnormalities. This study investigated the effects of nitro-L-arginine-methyl ester (L-NAME) and 3-bromo-7-nitroindazole (7-NI) treatment on cNOS catalytic activity and sensorimotor behavioral outcome after TBI, Rats underwent moderate (1.8-2.2 atm) parasagittal fluid percussion brain injury (FPI). At 5 min after FPI, cNOS activity was significantly increased within the damaged cerebral cortex of vehicle-treated rats compared to the noninjured contralateral cortex (206.7 +/- 150.5% of contralateral,p < 0.01). Pretreatment with L-NAME and 7-NI significantly reduced injury-induced cNOS activation (47.7 +/- 42.6%,p < 0.05, and 96.16 +/- 12.76, p < 0.05, respectively). Pretreatment with L-NAME and 7-NI also inhibited cNOS activity within the contralateral noninjured cerebral cortex compared to vehicle-treated rats (L-NAME 43.7 +/- 12.47%,p < 0.05; 7-NI 36.8 +/- 7.47%,p < 0.05), Furthermore, pretreatment with 7-NI, but not L-NAME, significantly reduced forelimb placing sensorimotor deficits (3.14 +/- 1.07, p < 0.05) at 1 day after TBI compared to vehicle-treated rats (5.38 +/- 0.42), These data indicate that inhibition of injury-induced elevations in neuronal NOS activity has a beneficial effect on neurological outcome after parasagittal FPI brain injury.	Univ Miami, Sch Med, Dept Neurol D45, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33101 USA; Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 359, Japan; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, POB 016960, Miami, FL 33101 USA.	dalton@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Adams JH, 1982, RECENT ADV NEUROPATH, P165; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DERYCK M, 1992, BRAIN RES, V573, P44; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1991, AM J PHYSIOL, V261, pH1038, DOI 10.1152/ajpheart.1991.261.4.H1038; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; GREENBERG RS, 1995, AM J PHYSIOL-HEART C, V269, pH341, DOI 10.1152/ajpheart.1995.269.1.H341; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HE Z, 1995, BRAIN RES, V699, P208, DOI 10.1016/0006-8993(95)00907-8; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUMURA E, 1994, J CEREBR BLOOD F MET, V14, P487, DOI 10.1038/jcbfm.1994.60; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1989, NEUROSCI LETT, V126, P83; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PAAKKARI I, 1995, ANN MED, V27, P369, DOI 10.3109/07853899509002590; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRADO R, 1992, STROKE, V23, P1118, DOI 10.1161/01.STR.23.8.1118; PRADO R, 1993, J CEREBR BLOOD F MET, V13, P720, DOI 10.1038/jcbfm.1993.91; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Sadoshima S, 1997, BRAIN RES, V744, P246, DOI 10.1016/S0006-8993(96)01063-3; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stagliano NE, 1997, BRAIN RES, V759, P32, DOI 10.1016/S0006-8993(97)00200-X; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; ZILLES L, 1985, CORTEX RAT STEREOTAX; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F	78	62	63	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					203	212		10.1089/neu.1999.16.203			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800002	10195468				2022-02-06	
J	Mazda, K; Khairouni, A; Pennecot, GF; Bensahel, H				Mazda, K; Khairouni, A; Pennecot, GF; Bensahel, H			Closed flexible intramedullary nailing of the femoral shaft fractures in children	JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B			English	Article						femoral fracture; intramedullary nailing; children's fracture	AVASCULAR NECROSIS; FEMUR FRACTURES; ADOLESCENT; HEAD	We treated 34 femoral shaft fractures in 32 children with elastic intramedullary nailing using titanium rods. The 24 boys and 8 girls ranged from 6-17 years. All fractures united. The weight bearing was authorized at an average of 67 days and was complete at average of 89 days. All children returned to school before the end of the second postoperative month. At an average 2.5 years, not rotational malalignment was present. Neither anteroposterior nor frontal malalignment of more than 2 degrees was noticed. A leg length discrepancy of more than 10 mm was present in 3 patients (8%). No injury of femoral head vascularization or of the proximal or distal growth plate was noticed. In our experience, this technique seems to be safe for the surgical treatment of the immature femoral shaft fractures. The elastic properties of titanium provide a very good stability of the montage, when the technique is correctly performed.			Mazda, K (corresponding author), UNIV PARIS 07,HOP ROBERT DEBRE,SERV CHIRURG ORTHOPED,FAC MED XAVIER BICHAT,DEPT ORTHOPAED SURG,F-75019 PARIS,FRANCE.						ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; GALPIN RD, 1994, J PEDIATR ORTHOPED, V14, P184, DOI 10.1097/01241398-199403000-00010; HERZOG B, 1976, Z KINDERCHIR, V19, P74; KIRBY RM, 1981, J PEDIATR ORTHOPED, V1, P193, DOI 10.1097/01241398-198110000-00010; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74, DOI 10.1302/0301-620X.70B1.3339064; METAIZEAU JP, 1984, J CHIR-PARIS, V121, P527; MILESKI RA, 1995, J PEDIATR ORTHOPED, V15, P24, DOI 10.1097/01241398-199501000-00006; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; RANEY EM, 1993, J PEDIATR ORTHOPED, V13, P16; REEVES RB, 1991, J PEDIATR ORTHOPED, V10, P591; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626; ZIV I, 1984, J TRAUMA, V24, P432, DOI 10.1097/00005373-198405000-00011	12	62	65	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1060-152X			J PEDIATR ORTHOP B	J. Pediatr. Orthop.-Part B	JUL	1997	6	3	B				198	202		10.1097/01202412-199707000-00008			5	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	XP645	WOS:A1997XP64500008	9260649				2022-02-06	
J	Ford, JC; Hackney, DB				Ford, JC; Hackney, DB			Numerical model for calculation of apparent diffusion coefficients (ADC) in permeable cylinders - Comparison with measured ADC in spinal cord white matter	MAGNETIC RESONANCE IN MEDICINE			English	Article						diffusion, MR; white matter; spinal cord	WATER DIFFUSION; RESTRICTED DIFFUSION; SYSTEM; INJURY; MRI; RAT; ISCHEMIA; STROKE; BRAIN; CAT	We have implemented a numerical method for calculation of the apparent diffusion coefficient (ADC) in spinal cord injury, which takes into account the distribution of axon diameters and permeability found in spinal cord white matter, as well as relative axonal volume. We propose a procedure for determining the status of axonal integrity from measured ADC values. These methods have been applied to a well characterized rat spinal cord injury model, affording a prediction of the increase in axonal permeability which is presumed to be closely related to functional deficit. ADC values are compared to those calculated from analytical formulas in the literature, and possible factors underlying the ADC behavior are explored. Calculated results indicate both axonal swelling and cell membrane permeability to be important factors contributing to ADC in traumatic spinal cord injury.			Ford, JC (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,1 SILVERSTEIN BLDG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Hackney, David/A-5337-2010		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS25291-06A1.] Funding Source: Medline		Anderson AW, 1996, MAGN RESON MED, V35, P162, DOI 10.1002/mrm.1910350206; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; BIHAN DL, 1991, J MAGN RESON IMAGING, V1, P7; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; FAIRHOLM DJ, 1971, J NEUROSURG, V35, P277, DOI 10.3171/jns.1971.35.3.0277; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; FORD JC, 1994, P 80 M RAD SOC N AM, P306; HAJNAL JV, 1991, J COMPUT ASSIST TOMO, V15, P1, DOI 10.1097/00004728-199101000-00001; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; MOSELEY ME, 1991, MAGNET RESON MED, V19, P321, DOI 10.1002/mrm.1910190222; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neil JJ, 1996, MAGNET RESON MED, V35, P329, DOI 10.1002/mrm.1910350310; NIENDORF T, 1994, MAGNET RESON MED, V32, P672, DOI 10.1002/mrm.1910320520; SEGAWA F, 1993, P SMRM 12 ANN M, V2, P595; STANISZ G, MAGN RESON MED, V37; SYKOVA E, 1994, J CEREBR BLOOD F MET, V14, P301, DOI 10.1038/jcbfm.1994.37; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; TANNER JE, 1978, J CHEM PHYS, V69, P1748, DOI 10.1063/1.436751; VANGELDEREN P, 1994, MAGNET RESON MED, V31, P154, DOI 10.1002/mrm.1910310209; VONZIJL PCM, 1991, P NATL ACAD SCI USA, V88, P3228; WAGNER FC, 1971, J NEUROSURG, V35, P272, DOI 10.3171/jns.1971.35.3.0272	26	62	62	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0740-3194			MAGNET RESON MED	Magn.Reson.Med.	MAR	1997	37	3					387	394		10.1002/mrm.1910370315			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	WJ664	WOS:A1997WJ66400012	9055229				2022-02-06	
J	Soblosky, JS; Matthews, MA; Davidson, JF; Tabor, SL; Carey, ME				Soblosky, JS; Matthews, MA; Davidson, JF; Tabor, SL; Carey, ME			Traumatic brain injury of the forelimb and hindlimb sensorimotor areas in the rat: Physiological, histological and behavioral correlates	BEHAVIOURAL BRAIN RESEARCH			English	Article						behavioral compensation; axonal degeneration; forelimb deficit; hindlimb deficit; cerebellum; sensorimotor cortex; traumatic brain injury; rat	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; MOTOR CORTEX; HEAD-INJURY; FUNCTIONAL RECOVERY; NEOCORTICAL DAMAGE; ORGANIZATION; NOREPINEPHRINE; AMPHETAMINE; CONTUSION	This study characterizes physiological, histological and behavioral effects of traumatic brain injury (TBI) produced by a controlled pneumatic impactor striking the entire right sensorimotor cortex of the anesthetized rat. Damage to both the fore- and hindlimb sensorimotor areas resulted in a hemiparetic animal which allowed us to use four sensitive behavioral/neurological tests to track the recovery sequelae after injury. Initial experiments measured cardiovascular and respiratory effects after cortical impact which depressed the dura to varying depths. Both 0.5 mm and 1 mm cortical depressions produced a momentary decrease (P<0.05) in mean arterial blood pressure (MABP) while cortical impacts to depths of 2 mm or 3 mm produced a momentary increase (P<0.05) in MABP. Normotension was re-established within 30 s after the initial response at all injury levels. Respiratory rate was affected only following 3 mm cortical depressions. A 1 mm cortical depression appeared ideal in terms of minimal cardiorespiratory effects, low mortality and lasting behavioral effects. For behavioral and histologic studies, therefore, additional rats were injured by a 1 mm cortical impact and tested for 8 weeks after TBI using four behavioral tests. Injured rats displayed both fore- and hindlimb deficits up to 56 days while traversing a narrow beam (P<0.001) and up to 28 days when crossing a pegged beam (P<0.05). Forelimb deficits evaluated on a wire grid platform were evident for 28 days (P<0.05). Forepaw preference measured in a non-test setting indicated a bias to use the unaffected::forepaw for 35 days (P<0.05). A biphasic pattern of functional recovery was seen on all tests. A period of rapid functional recovery lasting 7 to 10 days was followed by a slower period of functional recovery lasting many weeks. Possible meanings of this biphasic recovery are discussed as issues of behavioral compensation/adaptation versus true neural recovery. Eight weeks after TBI histological analyses indicated that axonal degeneration was present in the areas adjacent to the ipsilateral cortical injury site. Degenerating fibers also extended across the corpus callosum into the homologous area in the contralateral cortex and were seen in the ipsilateral striatum, somatosensory and motor thalamic nuclei and substantia nigra. Significant axonal degeneration occurred bilaterally around the deep cerebellar nuclei. Degenerating fibers extended into the folia and terminated in the cerebellar granule cell layer. Thus the entire sensorimotor control system appeared to have been affected by a cortical injury.	LOUISIANA STATE UNIV,MED CTR,DEPT ANAT,NEW ORLEANS,LA 70112		Soblosky, JS (corresponding author), LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,NEUROTRAUMA RES LAB,NEW ORLEANS,LA 70112, USA.						BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P901; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; EBRAHIMI A, 1992, NEUROSCI RES, V14, P39, DOI 10.1016/S0168-0102(05)80005-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1993, NEUROSCI PROTOCOLS, P1; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ito M., 1984, CEREBELLUM NEURAL CO; IZUMI Y, 1992, NEUROSCI LETT, V144, P121, DOI 10.1016/0304-3940(92)90730-U; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LEVERE TE, 1980, PHYSIOL PSYCHOL, V8, P297, DOI 10.3758/BF03337462; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARSHALL JF, 1985, INT REV NEUROBIOL, V26, P201, DOI 10.1016/S0074-7742(08)60075-6; MARSHALL JF, 1984, ANNU REV PSYCHOL, V35, P277, DOI 10.1146/annurev.ps.35.020184.001425; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLEGRINO I, 1979, STEREOTAXIC ATLAS RA; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; ROSE FD, 1993, BEHAV BRAIN RES, V5, P93; ROUILLER EM, 1991, NEUROSCI LETT, V125, P93, DOI 10.1016/0304-3940(91)90139-K; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWITZER RC, 1991, NEUROSCI BIOBEHAV R, V15, P89, DOI 10.1016/S0149-7634(05)80097-1; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; [No title captured]	56	62	63	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	SEP	1996	79	1-2					79	92		10.1016/0166-4328(95)00264-2			14	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	VH444	WOS:A1996VH44400009	8883819				2022-02-06	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder, flashbacks, and pseudomemories in closed head injury	JOURNAL OF TRAUMATIC STRESS			English	Article						posttraumatic stress; motor vehicle accidents; traumatic brain injury; flashbacks; pseudomemories	IMPLICIT MEMORY; FOLLOW-UP; ACCIDENTS; ANXIETY; IMPACT; ADULTS	Posttraumatic stress disorder (PTSD) is rarely diagnosed in patients with significant head injury. This paper reviews two patients who were amnesic for events surrounding their motor vehicle accidents (MVAs) but developed delayed-onset PTSD. Symptoms included vivid images of the MVAs that were based on information learnt following the trauma. These cases indicate that amnesic head injured patients can suffer pseudomemories that are phenomenologically similar to flashback observed in PTSD. Implications for understanding the nature of flashbacks are discussed.			Bryant, RA (corresponding author), UNIV NEW S WALES, SCH PSYCHOL, SYDNEY, NSW 2052, AUSTRALIA.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BULL JP, 1979, EPIDEMIOLOGICAL FEAT; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; FRANKEL FH, 1994, INT J CLIN EXP HYP, V42, P321, DOI 10.1080/00207149408409362; HICKLING EJ, 1992, J ANXIETY DISORD, V6, P285, DOI 10.1016/0887-6185(92)90040-E; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Horowitz M.J., 1983, IMAGE FORMATION PSYC; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Johnson M.K., 1988, DELUSIONAL BELIEFS I, P34; JOHNSON MK, 1988, J EXP PSYCHOL GEN, V117, P371, DOI 10.1037/0096-3445.117.4.371; Jurado M A, 1993, Neurologia, V8, P91; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LITZ BT, 1989, CLIN PSYCHOL REV, V9, P243, DOI 10.1016/0272-7358(89)90030-5; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P117; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHWARZ ED, 1993, J TRAUMA STRESS, V6, P545, DOI 10.1007/BF00974322; STRAUMAN TJ, 1992, J ABNORM PSYCHOL, V101, P87, DOI 10.1037/0021-843X.101.1.87; WATSON IPB, 1988, BRIT J PSYCHIAT, V152, P164, DOI 10.1192/bjp.152.2.164	26	62	62	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	JUL	1996	9	3					621	629					9	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	UW921	WOS:A1996UW92100017	8827662				2022-02-06	
J	Korteling, JE; Kaptein, NA				Korteling, JE; Kaptein, NA			Neuropsychological driving fitness tests for brain-damaged subjects	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CEREBRAL-DAMAGE	Objective: The study was carried out to evaluate and develop simple tools to assess the driving fitness of brain-damaged patients. Design: Four neuropsychological tests (predictors) were validated against an open-road driving test (criterion standard), which is used by the Department of Adaptations of the Dutch Driving Licensing Agency for assessing disabled drivers. Setting: The predictor tests were conducted in the involved scientific institute; the criterion standard involved participation in normal traffic. Patients: The subject group consisted of 33 men and 5 women who had recovered to a stabilized level from traumatic brain injuries. All had valid driving licenses when they were injured and they were considered to be potentially able to recommence driving. The subjects had a mean reported driving experience of 109.200km (SD = 86.300km). All subjects were recovered from a brain trauma with an average coma duration of 33 days (SD = 51 days). They were tested at least 1 year after the accident. All subjects had normal or corrected-to-normal vision and none used medications that, according to existing medical criteria, interfere with normal psychomotor or cognitive functioning. Ages at the time of the injury were between 17 and 55 years (mean, 29.8; SD, 10.9). Main Outcome Measures: Pearson product moment correlations (and explained variances) were calculated between the four predictor tests (a Perceptual Speed test, the WAIS Symbol-Digit Substitution subtest, a Tracking-Reaction dual task, and a Time Estimation task) and the open-road criterion standard. Results: The results indicated that performance on both the Perceptual Speed task and the Time Estimation task were significantly correlated with driving performance (p < .05). When combined with coma duration and driving experience, the Perceptual Speed and Tracking-Reaction tests together explained 35.3% (r = .59) of the variance in on-road driving performance. Conclusion: The amount of variance in open-road driving performance that could be accounted for by these tests was insufficient to completely replace an open-road driving fitness assessment. Also, based on other experimental documentation, it is concluded that more integral, domain-specific tests leg, based on driving simulation) need to be developed. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.			Korteling, JE (corresponding author), TNO,HUMAN FACTORS RES INST,POB 23,3769 ZG SOESTERBERG,NETHERLANDS.						BROUWER W, 1992, 2ND INT C OBJ EV REH; Caroll J.B., 1993, HUMAN COGNITIVE ABIL; Deelman B. G., 1980, NEUROPSYCHOLOGIE NED, P253; DUNCAN J, 1990, ERGONOMICS, V33, P1265, DOI 10.1080/00140139008925331; FOX G, 1993, SEP ASTB C, P1; Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1993, ARCH PHYS MED REHAB, V70, P745; Gronwall D, 1974, PSYCHOL EFFECTS CONC; KEMA GN, 1972, PRIMARY MENTAL ABILI; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; KORTELING JE, 1994, THESIS GRONINGEN STA; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; RAVESTEIN R, 1982, DRIVING SKILL REHABI; SAAN RJ, 1981, PSYCHOLOOG, V16, P739; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STINISSEN J, 1970, HANDLEIDING NEDERLAN; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Wechsler, 1997, WECHSLER ADULT INTEL	25	62	63	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					138	146		10.1016/S0003-9993(96)90158-6			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100005	8607737				2022-02-06	
J	ANDERSON, CV; BIGLER, ED				ANDERSON, CV; BIGLER, ED			VENTRICULAR DILATION, CORTICAL ATROPHY, AND NEUROPSYCHOLOGICAL OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED HEAD-INJURY; DEGENERATIVE CHANGES; SEQUELAE; INDEX	Day-of-injury computed tomographic scans were compared with postinjury magnetic resonance imaging of 38 patients with traumatic brain injury. Ventricles and several white and gray matter structures were measured. Results demonstrated signficant changes in ventricular sizes and all measures of white matter. Changes in gray matter were nonsignficant, except in the putamen/globus pallidus. Patients were grouped according to ventricular change, and neuropsychological outcome was examined. The group with the highest ventricular change had significantly lower memory scores but did not show significant differences on tests of intellectual functioning. A three-dimensional image analysis was performed to enhance visualization of the injured brain.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,1086 SWKT,PROVO,UT 84602								ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Barr ML, 1988, HUMAN NERVOUS SYSTEM; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bigler E D, 1987, Arch Clin Neuropsychol, V2, P293, DOI 10.1016/0887-6177(87)90017-5; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Carpenter MB., 1985, CORE TEXT NEUROANATO, V3rd ed.; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVINHS, 1989, J CLIN EXP NEUROPSYC, V12, P129; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MARTINEZ PFA, 1985, NEUROANATOMY; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SATZ P, 1992, NEUROLOGY, V7, P273; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; [No title captured]	26	62	63	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1995	7	1					42	48					7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	QD727	WOS:A1995QD72700007	7711490				2022-02-06	
J	BECA, J; COX, PN; TAYLOR, MJ; BOHN, D; BUTT, W; LOGAN, WJ; RUTKA, JT; BARKER, G				BECA, J; COX, PN; TAYLOR, MJ; BOHN, D; BUTT, W; LOGAN, WJ; RUTKA, JT; BARKER, G			SOMATOSENSORY-EVOKED POTENTIALS FOR PREDICTION OF OUTCOME IN ACUTE SEVERE BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article							SEVERE HEAD-INJURY; COMATOSE CHILDREN; PROGNOSTIC UTILITY; NORMATIVE DATA; INFANTS; SEPS; RELIABILITY; RESPONSES; STATE	The purpose of this study was to evaluate prospectively short-latency somatosensory evoked potentials (SEPs) as a predictor of outcome in acute, severe brain injury, and to compare this with the predictive power of the motor component of the Glasgow Coma Scale score and computed tomographic scan. Outcome was measured with the Glasgow Outcome Scale at a minimum of 6 months after injury. We studied 109 patients (aged 0.1 to 16.8 years) with SEPs within 4 days of the onset of coma. Four patients had absent SEPs and a favorable outcome by the Glasgow Outcome Scale (full recovery or moderate disability); two of these patients had meningitis with bilateral subdural effusions, one had a mid-brain hemorrhage, and one had a decompressive craniectomy for uncontrolled intracranial hypertension. Normal SEPs had a positive predictive value for favorable outcome of 93% (95% confidence interval (Cl), 77% to 99%), and absent SEPs had a positive predictive value for unfavorable outcome by the Glasgow Outcome Scale (severe disability, survival in a persistent vegetative state, or death) of 92% (95% Cl, 80% to 98%). If the above identifiable clinical situations in which a physical barrier existed to impede cutaneous reception of the electrical impulse were excluded, the positive predictive value of absent SEPs for poor outcome reached 100% (95% Cl, 92% to 100%). An absent motor response to painful stimulus also had 100% positive predictive value (95% Cl, 84% to 100%) for unfavorable outcome; however, 23% of patients could not be evaluated because of the effects of muscle relaxants or sedatives. In patients with traumatic brain injury, results of computed tomography did not reliably predict outcome. Of the 59 patients with unfavorable outcome, 76% could be identified with SEPs compared with 36% with examination of motor function. We suggest that SEPs be performed in children with acute severe brain injury because they add an important tool to the physician's prognostic armamentarium. We conclude that in the absence of the above mentioned identifiable clinical situations, absent SEPs predict 100% unfavorable outcome, and this finding may warrant consideration of withdrawal of treatment in children with brain injuries.	HOSP SICK CHILDREN, DEPT CRIT CARE, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT NEUROL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT NEUROSURG, TORONTO, ON M5G 1X8, CANADA; ROYAL CHILDRENS HOSP, DEPT CRIT CARE, MELBOURNE, VIC, AUSTRALIA								ALTMAN DG, 1990, PRACTICAL STATISTICS, P409; BATES D, 1991, J NEUROL NEUROSUR PS, V54, P569, DOI 10.1136/jnnp.54.7.569; BONGERSSCHOKKING CJ, 1989, BRAIN DEV-JPN, V11, P33, DOI 10.1016/S0387-7604(89)80006-3; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; De Meirleir L J, 1986, Pediatr Neurol, V2, P31, DOI 10.1016/0887-8994(86)90036-6; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; GANES T, 1983, J NEUROL NEUROSUR PS, V46, P509, DOI 10.1136/jnnp.46.6.509; GEORGE SR, 1991, ELECTROEN CLIN NEURO, V80, P94, DOI 10.1016/0168-5597(91)90146-O; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GREENBERG RP, 1982, ANN NY ACAD SCI, V388, P683, DOI 10.1111/j.1749-6632.1982.tb50835.x; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; LAUREAU E, 1988, ELECTROEN CLIN NEURO, V71, P100, DOI 10.1016/0168-5597(88)90011-1; LENTER C, 1982, GEIGY SCI TABLES, P89; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; SUTTON LN, 1982, J NEUROSURG, V57, P178, DOI 10.3171/jns.1982.57.2.0178; TAYLOR MJ, 1988, ELECTROEN CLIN NEURO, V71, P323, DOI 10.1016/0168-5597(88)90034-2; TAYLOR MJ, 1992, DEV MED CHILD NEUROL, V34, P507; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; WILLIS J, 1984, ELECTROEN CLIN NEURO, V59, P366, DOI 10.1016/0168-5597(84)90038-8	28	62	65	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	1995	126	1					44	49		10.1016/S0022-3476(95)70498-1			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	QB184	WOS:A1995QB18400008	7815222				2022-02-06	
J	EVANS, RW; EVANS, RI; SHARP, MJ				EVANS, RW; EVANS, RI; SHARP, MJ			THE PHYSICIAN SURVEY ON THE POST-CONCUSSION AND WHIPLASH SYNDROMES	HEADACHE			English	Article						MILD HEAD INJURY; POST-CONCUSSION SYNDROME; WHIPLASH INJURIES	MINOR HEAD-INJURY; CAR ACCIDENTS; MILD; MANAGEMENT; SYMPTOMS	Background: The post-concussion syndrome (PCS) and whiplash syndrome (WS) have been controversial topics among physicians for many decades. There is little information available on the opinions and practices of physicians. Methods: In June of 1992, we performed a national survey by mail of the four physician groups most commonly treating these problems. The number of respondents and response rates were as follows: family physicians, 118, 16%; neurologists, 100, 21%; neurosurgeons, 97, 23%; orthopedists, 82, 13%. The survey instrument contained items on demographics, definitions, causation, prognosis, medico-legal aspects, testing, and treatment. Results: Only a minority of respondents believe that PCS and WS are clearly defined syndromes. A substantial minority report that psychogenic and litigation factors are most responsible for the conditions. Most of the physicians believe that PCS and WS have a 3-6 month recovery time. A significant minority concur that symptoms of the two syndromes resolve when litigation is settled. Most of the physicians order tests to rule out pathology although a minority order tests to reassure patients or because of litigation concerns. Only a minority of respondents believe that effective treatments are available. Not surprisingly, a multitude of conventional and unconventional treatments are sometimes recommended. Conclusions: Many aspects of PCS and WS are controversial among treating physicians. This controversy can have a profound impact on the quality and cost of patient care. Ongoing research is required to discover more effective treatments for mild brain injury and chronic pain.	UNIV TEXAS,SCH MED,DEPT NEUROL,HOUSTON,TX 77025; BAYLOR COLL MED,HOUSTON,TX 77030								[Anonymous], 1989, Neurology, V39, P1100; AUERBACH AH, 1967, DIS NERV SYST, V28, P110; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CROWE H, 1964, Calif Med, V100, P12; DACEY RG, 1989, MILD HEAD INJURY, P83; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; DEANS GT, 1986, BRIT MED J, V292, P94, DOI 10.1136/bmj.292.6513.94-a; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EVANS RW, 1992, NEUROL CLIN, V10, P975, DOI 10.1016/S0733-8619(18)30191-9; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; EVANS RW, 1994, IN PRESS SEMIN NEURO, V14; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; EVANS RW, 1992, PROGNOSIS NEUROLOGIC, P621; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; JENNETT B, 1992, PROGNOSIS NEUROLOGIC, P85; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus JF, 1993, HEAD INJURY, P1; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; MCKINNEY LA, 1989, ARCH EMERG MED, V6, P27; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; ONEIL B, 1972, AM J PUBLIC HEALTH, V62, P403; PENNIE BH, 1990, J BONE JOINT SURG BR, V72, P277, DOI 10.1302/0301-620X.72B2.2312568; PRIGATANO GP, 1993, NEUROL CLIN, V11, P219, DOI 10.1016/S0733-8619(18)30179-8; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; 1992, ACCIDENT FACTS ITASA, P63	37	62	62	1	6	AMER ASSOC STUDY HEADACHE	WOODBURY	875 KINGS HIGHWAY, STE 200, WOODBURY, NJ 08096	0017-8748			HEADACHE	Headache	MAY	1994	34	5					268	274		10.1111/j.1526-4610.1994.hed3405268.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NM276	WOS:A1994NM27600006	8026944				2022-02-06	
J	LINN, RT; ALLEN, K; WILLER, BS				LINN, RT; ALLEN, K; WILLER, BS			AFFECTIVE SYMPTOMS IN THE CHRONIC STAGE OF TRAUMATIC BRAIN INJURY - A STUDY OF MARRIED-COUPLES	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; RELATIVES; SEQUELAE; MOOD	A convenient sample of 60 brain-injured subjects and their spouses was evaluated cross-sectionally in the chronic stage of recovery on self-rated measures of sensory, motor, cognitive and behavioural disability and on the SCL-90 - R depression and anxiety subscales. A majority of the brain-injured subjects, who were on average almost 6 years post-injury, demonstrated elevations on the affective symptom scales, with almost 70% showing depression and 50% showing anxiety. The spouses of the brain-injured individuals also demonstrated significantly elevated affective symptom scales, with 73% acknowledging symptoms of depression and 55% demonstrating symptoms of anxiety. For the individuals with brain injury, those with higher self-ratings of cognitive disability and social aggression had higher self-ratings of depression and anxiety. In contrast, spouse gender appeared to have the greatest association with the presence of elevation affective responses, with female spouses having higher levels of depression and anxiety than male spouses. These findings are discussed in terms of the reactionary nature of affective disturbances in the chronic stage of recovery.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT PSYCHIAT,BUFFALO,NY 14260; SUNY BUFFALO,HLTH SCI LIB,DEPT MED REFERENCE,BUFFALO,NY 14260		LINN, RT (corresponding author), SUNY BUFFALO,BUFFALO,NY 14214, USA.						BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Caplan B., 1992, J CLIN EXPT NEUROPSY, V14, P78; Derogatis LR., 1983, SCL 90 R ADM SCORING; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; HAYS WL, 1988, STATISTICS; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LIVINGSTON MG, 1985, BMJ-BRIT MED J, V291, P919, DOI 10.1136/bmj.291.6500.919; LIVINGSTON MG, 1987, BRAIN INJURY, V1, P333; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PRIGATANO GP, 1981, S REHABILITATION POS; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; ROBINSON RG, 1986, AM J PSYCHIAT, V143, P1238; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTHERFORD WH, 1989, MILD HEAD INJURY, P21; SBORDONE RJ, 1984, INT J CLIN NEUROPSYC, V6, P183; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WOOD RL, 1987, BRAIN INJURY REHABIL, P179; 1990, SPSS PC PLUS 4 0; 1989, USERS MANUAL NONCATA	25	62	63	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1994	8	2					135	147		10.3109/02699059409150965			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	NA029	WOS:A1994NA02900003	8193633				2022-02-06	
J	DUHAYLONGSOD, FG; GLOWER, DD; WOLFE, WG				DUHAYLONGSOD, FG; GLOWER, DD; WOLFE, WG			ACUTE TRAUMATIC AORTIC-ANEURYSM - THE DUKE EXPERIENCE FORM 1970 TO 1990	JOURNAL OF VASCULAR SURGERY			English	Article; Proceedings Paper	45TH ANNUAL MEETING OF THE SOC FOR VASCULAR SURGERY	JUN 04-05, 1991	BOSTON, MA	SOC VASC SURG			THORACIC AORTA; 15-YEAR EXPERIENCE; BLUNT TRAUMA; RISK-FACTORS; RUPTURE; TRANSECTION	Improvements in the operative management of acute traumatic thoracic aortic aneurysm have resulted in safe and expeditious repair. Nonetheless, multisystem injuries continue to inflict significant numbers of deaths. From 1970 to 1990, 108 patients with acute traumatic thoracic aortic aneurysm were evaluated. Mean injury severity score, excluding aortic injury, was 17.5. Ninety-three patients (86%) survived beyond initial resuscitation and came to operation. Median interval from injury to aortic repair was 8 hours (range, 2 hours to 19 days); there were five operative deaths. Lethal nonaortic injuries included 18 closed head injuries, four myocardial contusions, two intraabdominal vascular injuries, and one pulmonary contusion. The overall mortality rate was 39% of total admissions (42 of 108), and 29% of survivors of resuscitation (27 of 93). It is significant that only 11 of the 42 deaths (26%) were directly attributable to thoracic aortic aneurysm. Adjuncts to prevent spinal cord ischemia (shunt/bypass) were used in 76 patients, whereas 12 underwent clamp/repair. Postoperative paraplegia developed in 5 of 79 patients (6.8%, including 4 of 68 (5.9%) repaired with shunt/bypass and 1 of 11 (9.1%) repaired with clamp/repair (p = NS). Among those who developed paraplegia, the injury severity score was 27.0, and the median interval from injury to repair was 4.9 hours (range, 2 to 6.5). Intraoperative hypotension occurred in three of five patients with paraplegia. Death in patients with thoracic aortic aneurysm is due primarily to associated injuries and has remained relatively constant over the 20-year period of review. Overall injury severity, intraoperative hypotension, and extensive aortic tissue destruction may correlate with the development of postoperative paraplegia; however, a larger population sample is required to confirm this conclusion. A plea is made for standardized reporting of all patients with thoracic aortic aneurysm.	DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710								AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; CHAMPION HR, 1991, TRAUMA, P47; COWLEY RA, 1990, J THORAC CARDIOV SUR, V100, P652; EDDY AC, 1990, ARCH SURG-CHICAGO, V125, P1351; KATZ NM, 1981, J THORAC CARDIOV SUR, V81, P669; MURRAY GF, 1976, ANN THORAC SURG, V21, P26, DOI 10.1016/S0003-4975(10)64883-7; PASSARO E, 1959, SURGERY, V46, P787; PICKARD LR, 1977, J TRAUMA, V17, P749, DOI 10.1097/00005373-197710000-00001; STILES QR, 1985, AM J SURG, V150, P132, DOI 10.1016/0002-9610(85)90022-4; STURM JT, 1985, ANN THORAC SURG, V39, P418, DOI 10.1016/S0003-4975(10)61947-9	10	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0741-5214			J VASC SURG	J. Vasc. Surg.	FEB	1992	15	2					331	343		10.1016/0741-5214(92)90255-7			13	Surgery; Peripheral Vascular Disease	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery; Cardiovascular System & Cardiology	HD471	WOS:A1992HD47100009	1735894	Bronze			2022-02-06	
J	JANKOWSKI, LW; SULLIVAN, SJ				JANKOWSKI, LW; SULLIVAN, SJ			AEROBIC AND NEUROMUSCULAR TRAINING - EFFECT ON THE CAPACITY, EFFICIENCY, AND FATIGABILITY OF PATIENTS WITH TRAUMATIC BRAIN INJURIES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									INST READAPTAT MONTREAL,CTR RECH,MONTREAL,QUEBEC,CANADA		JANKOWSKI, LW (corresponding author), CONCORDIA UNIV,DEPT EXERCISE SCI,7141 SHERBROOKE ST W,MONTREAL H4B 1R6,QUEBEC,CANADA.						ALLEN TH, 1956, METABOLISM, V5, P346; ASTRAND PO, 1987, ARCH PHYS MED REHAB, V68, P305; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Berger M, 1976, Fortschr Med, V94, P1553; BLACKBURN H, 1988, NEW ENGL J MED, V319, P1217, DOI 10.1056/NEJM198811033191808; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FINDLEY TW, 1988, ARCH PHYS MED REHAB, V69, P855; FISHER SV, 1978, ARCH PHYS MED REHAB, V59, P124; GASS GC, 1984, MED SCI SPORT EXER, V16, P355; HARKCOM TM, 1985, ARTHRITIS RHEUM, V28, P32, DOI 10.1002/art.1780280106; HJELTNES N, 1986, SCAND J REHABIL MED, V18, P65; HOOK O, 1988, SCAND J REHABIL MED, V17, P65; JANKOWSKI LW, 1976, SCAND J REHABIL MED, V8, P135; MAGNUS BC, 1988, ADAPTED PHYSICAL ACT, V5, P90; NORDEMAR R, 1981, SCAND J RHEUMATOL, V10, P17; OLGIATI R, 1988, ARCH PHYS MED REHAB, V69, P846; PITETTI KH, 1987, J BONE JOINT SURG AM, V69A, P914, DOI 10.2106/00004623-198769060-00018; 1986, GUIDELINES EXERCISE	18	62	62	2	11	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1990	71	7					500	504					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	DH157	WOS:A1990DH15700011	2350220				2022-02-06	
J	YARNELL, PR; LYNCH, S				YARNELL, PR; LYNCH, S			RETROGRADE MEMORY IMMEDIATELY AFTER CONCUSSION	LANCET			English	Article																	BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; MAZZIA VDB, 1966, ARCH NEUROL-CHICAGO, V14, P522, DOI 10.1001/archneur.1966.00470110066008; MCGAUGH TL, 1966, SCIENCE, V153, P1351; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; THOMPSON RF, 1967, FOUNDATIONS PHYSIOLO; WILLIAMS M, 1952, J NEUROL NEUROSUR PS, V15, P54, DOI 10.1136/jnnp.15.1.54; WILLIAMS M, 1969, PATHOLOGY MEMORY	8	62	62	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet		1970	1	7652					863	&					0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	G0871	WOS:A1970G087100005	4191508				2022-02-06	
J	Hoye, A				Hoye, Alena			Bicycle helmets - To wear or not to wear? A meta-analyses of the effects of bicycle helmets on injuries	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Bicycle helmet; Meta-analysis; Head injury	HEAD-INJURIES; SAFETY HELMETS; MOTOR-VEHICLES; TRAUMA CENTER; BRAIN-INJURY; ROAD TRAUMA; RISK; CYCLISTS; CRASHES; ACCIDENTS	A meta-analysis has been conducted of the effects of bicycle helmets on serious head injury and other injuries among crash involved cyclists. 179 effect estimates from 55 studies from 1989-2017 are included in the metaanalysis. The use of bicycle helmets was found to reduce head injury by 48%, serious head injury by 60%, traumatic brain injury by 53%, face injury by 23%, and the total number of killed or seriously injured cyclists by 34%. Bicycle helmets were not found to have any statistically significant effect on cervical spine injury. There is no indication that the results from bicycle helmet studies are affected by a lack of control for confounding variables, time trend bias or publication bias. The results do not indicate that bicycle helmet effects are different between adult cyclists and children. Bicycle helmet effects may be somewhat larger when bicycle helmet wearing is mandatory than otherwise; however, helmet wearing rates were not found to be related to bicycle helmet effectiveness. It is also likely that bicycle helmets have larger effects among drunk cyclists than among sober cyclists, and larger effects in single bicycle crashes than in collisions with motor vehicles. In summary, the results suggest that wearing a helmet while cycling is highly recommendable, especially in situations with an increased risk of single bicycle crashes, such as on slippery or icy roads.	[Hoye, Alena] Inst Transport Econ, Gaustadalleen 21, N-0349 Oslo, Norway		Hoye, A (corresponding author), Inst Transport Econ, Gaustadalleen 21, N-0349 Oslo, Norway.	Alena.Hoye@toi.no	Hoye, Alena Katharina/AAD-4454-2022		Norwegian Public Roads Administration; Department of Transport and Communications	The study has partly been financed by the Norwegian Public Roads Administration and the Department of Transport and Communications. It is a part of the regular updating of the Handbook of Road Safety Measures (Elvik et al., 2009).	Airaksinen N., 2010, ANN ADV AUTOMOTIVE M, V54, P267; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bahrololoom S., 2016, 38 AUSTR TRANSP RES; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bergenstal John, 2012, W V Med J, V108, P78; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Boufous S, 2012, ACCIDENT ANAL PREV, V49, P404, DOI 10.1016/j.aap.2012.03.011; Christensen P., 2003, 6922003 TOI I TRANSP; COOKE CT, 1993, MED J AUSTRALIA, V159, P783, DOI 10.5694/j.1326-5377.1993.tb141349.x; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; Dinh MM, 2015, EMERG MED AUSTRALAS, V27, P323, DOI 10.1111/1742-6723.12407; Dinh MM, 2013, MED J AUSTRALIA, V198, P415, DOI 10.5694/mja12.11580; Dinh MM, 2010, MED J AUSTRALIA, V193, P619, DOI 10.5694/j.1326-5377.2010.tb04078.x; Doom R, 2005, CP02392 BRSI CDO; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Ekstrom C., 2017, FATALLY INJURED CYCL; Elvik R, 2005, TRANSPORT RES REC, P230; Elvik R, 2009, HANDBOOK OF ROAD SAFETY MEASURES, 2ND EDITION, P1; Elvik R., 2013, ACCIDENT ANAL PREV, V43, P1245; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Erke A, 2008, ACCIDENT ANAL PREV, V40, P167, DOI 10.1016/j.aap.2007.05.002; Erke A, 2009, ACCIDENT ANAL PREV, V41, P914, DOI 10.1016/j.aap.2009.05.005; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; Forbes AE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185367; Fyhri A, 2012, TRANSPORT RES F-TRAF, V15, P612, DOI 10.1016/j.trf.2012.06.003; Gulack BC, 2015, SURGERY, V158, P556, DOI 10.1016/j.surg.2015.02.025; Hagel BE, 2006, ACCIDENT ANAL PREV, V38, P277, DOI 10.1016/j.aap.2005.09.004; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Harada MY, 2015, INT J SURG, V24, P14, DOI 10.1016/j.ijsu.2015.10.013; Hausotter W, 2000, Versicherungsmedizin, V52, P28; Helak K, 2017, SOUTH MED J, V110, P441, DOI 10.14423/SMJ.0000000000000665; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hooten KG, 2014, J NEUROTRAUM, V31, P1329, DOI 10.1089/neu.2013.3253; Hoye A, 2017, 15972017 TOI I TRANS; Hoye A, 2016, 14782016 TOI I TRANS; Hoye A, 2016, 15172016 TOI I TRANS; Hoye A, 2014, ACCIDENT ANAL PREV, V73, P200, DOI 10.1016/j.aap.2014.09.001; Hynd D, 2011, PPR446 TRL, P1; Jacobson GA, 1998, AUST NZ J PUBL HEAL, V22, P451, DOI 10.1111/j.1467-842X.1998.tb01413.x; Ji M, 2006, ACCIDENT ANAL PREV, V38, P128, DOI 10.1016/j.aap.2005.08.002; Joseph B, 2017, AM J SURG, V213, P413, DOI 10.1016/j.amjsurg.2016.05.021; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Kaushik R, 2015, INJURY EPIDEMIOL, V2, P1; Kuo CY, 2017, TRAFFIC INJ PREV, V18, P193, DOI 10.1080/15389588.2016.1235270; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; Lindsay H, 2014, CHRONIC DIS INJURIES, V34; Linn S, 1998, Inj Prev, V4, P122; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Malczyk A, 2014, IRCOBI C P; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, J AUSTRALAS COLL ROA, V24, P11; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; McNally DS, 2013, ACCIDENT ANAL PREV, V59, P469, DOI 10.1016/j.aap.2013.07.022; Moore DN, 2011, ACCIDENT ANAL PREV, V43, P621, DOI 10.1016/j.aap.2010.09.015; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G; Olivier J., 2016, 2016 IRCOBI C P INT; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI [10.1093/ije/dyw153, 10.1093/ije/dyw360]; Olofsson E, 2017, SAFETY SCI, V92, P311, DOI 10.1016/j.ssci.2015.11.024; Orsi C, 2014, ACCIDENT ANAL PREV, V65, P97, DOI 10.1016/j.aap.2013.12.019; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Park Jun Chul, 2017, Korean J Neurotrauma, V13, P90, DOI 10.13004/kjnt.2017.13.2.90; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Peters, 2017, TRENDS GLOBAL CO2 TO; Phillips J. L, 2016, J EPIDEMIOL PUBLIC H, V1; Povey L. J., 2003, INVESTIGATION RELATI; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; Rizzi M, 2013, INT RES COUNC BIOM I; Robinson DL, 2007, ACCIDENT ANAL PREV, V39, P86, DOI 10.1016/j.aap.2006.06.007; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Schepers P, 2014, INJURY PREV, V21, P138; Sethi M, 2015, INJURY, V46, P2483, DOI 10.1016/j.injury.2015.07.030; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; Statens vegvesen, 2014, 294 STAT VEGV; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stier R, 2016, ARCH TRAUMA RES, V5, DOI 10.5812/atr.30011; Sze NN, 2011, HONG KONG J EMERG ME, V18, P136, DOI 10.1177/102490791101800302; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson D. C, 1999, COCHRANE DB SYST REV, V4; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Thornley SJ, 2008, INJURY PREV, V14, P11, DOI 10.1136/ip.2007.016675; Vavatsoulas K, 2013, 13 WCTR; Wagner J, 2012, AM SURGEON, V78, P1066; Wall SP, 2016, SAFETY, V2, DOI 10.3390/safety2040026; Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Whyte T, 2015, 24 INT TECHN C ENH S; Zibung E, 2015, EUR J TRAUMA EMERG S, V41, P517, DOI 10.1007/s00068-014-0471-y	96	61	61	3	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	AUG	2018	117						85	97		10.1016/j.aap.2018.03.026			13	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	GL1SI	WOS:000436888400009	29677686				2022-02-06	
J	Evered, L; Silbert, B; Scott, DA; Zetterberg, H; Blennow, K				Evered, Lisbeth; Silbert, Brendan; Scott, David A.; Zetterberg, Henrik; Blennow, Kaj			Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery Results From the CAPACITY and ARCADIAN Studies	JAMA NEUROLOGY			English	Article							POSTOPERATIVE COGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; GENERAL-ANESTHESIA; ALZHEIMERS-DISEASE; FLUID BIOMARKER; MECHANISMS; PROTEIN; NEURODEGENERATION	IMPORTANCE Anesthesia and surgery are believed to act on the central nervous system by a fully reversible mechanism innocuous to nerve cells. Evidence that neurological sequelae may follow would challenge this belief and would thereby suggest a need to reassess theories of the mechanism of anesthetic action or the response of the central nervous system to surgery. OBJECTIVE To measure 2 biomarkers of neurological injury (neurofilament light and tau) in plasma in a series of timed collections before and after anesthesia and surgery. DESIGN, SETTING, AND PARTICIPANTS These 2 related observational studies (CAPACITY and ARCADIAN) recruited patients 60 years and older who were undergoing general anesthesia for surgeries performed within a tertiary hospital. Blood samples were taken immediately before surgical anesthesia was administered and then sequentially after surgery at 30-minute, 6-hour, 24-hour, and 48-hour intervals. Sampling took place from January 2014 to August 2015. Data analysis took place from October 2016 to February 2017. MAIN OUTCOMES AND MEASURES Plasma neurofilament light and tau. RESULTS A total of 30 patients were enrolled (13 from the CAPACITY study and 17 from the ARCADIAN study). The mean (SD) age was 69.1(7.0) years, and 18 members (59%) of the participant group were female; 22 (73%) were undergoing joint arthroplasty. Mean neurofilament light increased at each measurement from a combined baseline mean (SD) of 22.3 (20.4) pg/mL to a maximal combined mean (SD) level of 35.1(28.7) pg/mL, a maximum increase of 67% (95% CI, 45%-89%; P < .001), at 48 hours postoperatively. The level of tau increased significantly from baseline at every measurement, from a combined baseline mean (SD) of 3.1(1.3) pg/mL to a maximal combined mean (SD) of 10.8 (9.5) pg/mL, a peak increase of 257% (95% CI, 154%-361%; P < .001), at 6 hours postoperatively. After 6 hours, the mean level began to return to baseline but remained elevated after 48 hours. CONCLUSIONS AND RELEVANCE Neurofilament light is a specific marker of axonal injury and has been shown to indicate neuronal damage in a number of diseases. Tau proteins are an integral component of axonal integrity, and increased tau indicates neuronal damage. The increases in both neurofilament light and tau over 48 hours after surgery suggest that general anesthesia and surgery may be associated with neuronal damage in the short term. Further investigations will be required to study any association with clinical outcomes. These preliminary findings demand that we question the prevailing assumption that anesthesia and surgery are innocuous, transient, and without injurious changes to the central nervous system.	[Evered, Lisbeth; Silbert, Brendan; Scott, David A.] St Vincents Hosp, Dept Anaesthesia & Acute Pain Med, Ctr Anaesthesia & Cognit Funct, Melbourne, Vic, Australia; [Evered, Lisbeth; Silbert, Brendan; Scott, David A.] Univ Melbourne, Melbourne Med Sch, Anaesthesia Perioperat & Pain Med Unit, Melbourne, Vic, Australia; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Physiol, Molndal, Sweden; [Zetterberg, Henrik] UCL, Dept Mol Neurosci, Inst Neurol, London, England		Silbert, B (corresponding author), St Vincents Hlth, Dept Anaesthesia & Acute Pain Med, POB 2900, Fitzroy, Vic 3065, Australia.	brendan.silbert@svha.org.au			Department of Health National Health and Medical Research Council [1027178]; Australian and New Zealand College of Anaesthetists grant [15/026]; Department of Health/National Health and Medical Research Council Dementia Research Fellowship [1102462]; Svenska Forskningsradet Formas (Swedish Research Council Formas)Swedish Research Council Formas [2013-2546]; European Research CouncilEuropean Research Council (ERC)European Commission [681712]; Swedish State Support for Clinical Research grant [ALFGBG-441051]; Swedish Alzheimer's Foundation [AF-553101, AF-646211]; Research Council Sweden grant [14002]; Swedish Brain Foundation [FO2015-0021]; LUA/ALF-medel Vastra Gotalandsregionen grant [ALFGBG-139671]	Drs Evered, Silbert, and Scott are supported by Department of Health National Health and Medical Research Council grant 1027178 and Australian and New Zealand College of Anaesthetists grant 15/026. Dr Evered is supported by Department of Health/National Health and Medical Research Council Dementia Research Fellowship grant 1102462. Dr Zetterberg is supported by Svenska Forskningsradet Formas (Swedish Research Council Formas) grant 2013-2546, European Research Council grant 681712, and Swedish State Support for Clinical Research grant ALFGBG-441051. Dr Blennow is supported by Swedish Alzheimer's Foundation grants AF-553101 and AF-646211, Research Council Sweden grant 14002, Swedish Brain Foundation grant FO2015-0021, and LUA/ALF-medel Vastra Gotalandsregionen grant ALFGBG-139671.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005; Andropoulos DB, 2017, NEW ENGL J MED, V376, P905, DOI 10.1056/NEJMp1700196; Berger M, 2016, J ALZHEIMERS DIS, V52, P1299, DOI 10.3233/JAD-151190; Evered L, 2016, ANESTHESIOLOGY, V124, P353, DOI 10.1097/ALN.0000000000000953; Fodale V, 2006, BRIT J ANAESTH, V97, P445, DOI 10.1093/bja/ael233; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Hogue CW, 2006, ANESTH ANALG, V103, P21, DOI 10.1213/01.ANE.0000220035.82989.79; Lambert DG, 2017, ANAEST INTENS CARE M, V18, P344, DOI 10.1016/j.mpaic.2017.04.008; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Paredes S, 2016, ACTA ANAESTH SCAND, V60, P1043, DOI 10.1111/aas.12724; POCOCK G, 1991, BRIT J ANAESTH, V66, P116, DOI 10.1093/bja/66.1.116; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Strom C, 2014, ANAESTHESIA, V69, P35, DOI 10.1111/anae.12493; Tang JXX, 2011, ANESTHESIOLOGY, V115, P727, DOI 10.1097/ALN.0b013e31822e9306; van Harten AE, 2012, ANAESTHESIA, V67, P280, DOI 10.1111/j.1365-2044.2011.07008.x; Vutskits L, 2016, NAT REV NEUROSCI, V17, P705, DOI 10.1038/nrn.2016.128; Westermann D, 2017, NAT REV CARDIOL, V14, P472, DOI 10.1038/nrcardio.2017.48; Xie ZC, 2006, ANESTHESIOLOGY, V104, P988, DOI 10.1097/00000542-200605000-00015; Zetterberg H, 2016, NEURON, V91, P1, DOI 10.1016/j.neuron.2016.06.030	28	61	65	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2018	75	5					542	547		10.1001/jamaneurol.2017.4913			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GF9RL	WOS:000432316000007	29459944	Green Published, Bronze			2022-02-06	
J	Azouvi, P; Arnould, A; Dromer, E; Vallat-Azouvi, C				Azouvi, P.; Arnould, A.; Dromer, E.; Vallat-Azouvi, C.			Neuropsychology of traumatic brain injury: An expert overview	REVUE NEUROLOGIQUE			English	Article						Traumatic brain injury: Cognition; Executive function; Memory	CLOSED-HEAD INJURY; WORKING-MEMORY IMPAIRMENTS; IMPAIRED SELF-AWARENESS; DUAL-TASK PERFORMANCE; SUSTAINED ATTENTION; DIVIDED ATTENTION; EXECUTIVE DYSFUNCTION; WHITE-MATTER; SELECTIVE ATTENTION; MISERABLE MINORITY	Traumatic brain injury (TBI) is a serious healthcare problem, and this report is a selective review of recent findings on the epidemiology, pathophysiology and neuropsychological impairments following TBI. Patients who survive moderate-to-severe TBI frequently suffer from a wide range of cognitive deficits and behavioral changes due to diffuse axonal injury. These deficits include slowed information-processing and impaired long-term memory, attention, working memory, executive function, social cognition and self-awareness. Mental fatigue is frequently also associated and can exacerbate the consequences of neuropsychological deficits. Personality and behavioral changes can include combinations of impulsivity and apathy. Even mild TBI raises specific problems: while most patients recover within a few weeks or months, a minority of patients may suffer from long-lasting symptoms (post-concussion syndrome). The pathophysiology of such persistent problems remains a subject of debate, but seems to be due to both injury-related and non-injury-related factors. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Azouvi, P.; Arnould, A.; Dromer, E.] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Azouvi, P.; Arnould, A.; Dromer, E.; Vallat-Azouvi, C.] Univ Versailles St Quentin, HANDIReSP EA 4047, F-78423 Montigny Le Bretonneux, France; [Vallat-Azouvi, C.] Univ Paris 8 St Denis, EA 2027, Lab Psychopathol & Neuropsychol, 2 Rue Liberte, F-93526 St Denis, France; [Vallat-Azouvi, C.] Hop Raymond Poincare, Antenne UEROS UGECAMIDF, 104 Blvd Raymond Poincare, F-92380 Garches, France		Azouvi, P (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.; Azouvi, P (corresponding author), Univ Versailles St Quentin, HANDIReSP EA 4047, F-78423 Montigny Le Bretonneux, France.	Philippe.azouvi@aphp.fr			French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; Institut de Recherche en Sante Publique (IRESP); Assistance publique-Hopitaux de Paris (AP-HP)	Research presented in this paper has been supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004) grant number AOM04084, and the Institut de Recherche en Sante Publique (IRESP). It was also supported by Assistance publique-Hopitaux de Paris (AP-HP).	Arnould A, 2016, ANN PHYS REHABIL MED, V59, P18, DOI 10.1016/j.rehab.2015.09.002; Arnould A, 2015, BRAIN INJURY, V29, P1597, DOI 10.3109/02699052.2015.1075156; Arnould A, 2013, NEUROPSYCHOL REV, V23, P210, DOI 10.1007/s11065-013-9236-3; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Azouvi P, 2016, J HEAD TRAUMA REHAB, V31, pE10, DOI 10.1097/HTR.0000000000000169; Bayen E, 2014, J HEAD TRAUMA REHABI; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chiou KS, 2015, J CLIN EXP NEUROPSYC, V37, P1074, DOI 10.1080/13803395.2015.1078293; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Coste C, 2015, NEUROPSYCHOLOGIA, V71, P133, DOI 10.1016/j.neuropsychologia.2015.03.014; Coste C, 2011, CORTEX, V47, P771, DOI 10.1016/j.cortex.2010.07.004; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen S, 2016, J NEUROTRAUMA; Dobryakova E, 2015, BRAIN CONNECT, V5, P433, DOI 10.1089/brain.2014.0283; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dunning DL, 2016, NEUROPSYCHOLOGY, V30, P811, DOI 10.1037/neu0000285; Dymowski AR, 2015, J CLIN EXP NEUROPSYC, V37, P1024, DOI 10.1080/13803395.2015.1074663; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hartvigsen Jan, 2014, Arch Phys Med Rehabil, V95, pS286, DOI 10.1016/j.apmr.2013.07.029; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jennett B, 1981, MANAGEMENT HEAD INJU; Jourdan C, 2016, ANN PHYS REHABIL MED, V59, P100, DOI 10.1016/j.rehab.2015.10.009; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2017, J HEAD TRAUMA REHABI; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Lange RT, 2005, J CLIN EXP NEUROPSYC, P27; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mioni G, 2012, J INT NEUROPSYCH SOC, V18, P697, DOI 10.1017/S1355617712000306; Morton N, 2010, J INT NEUROPSYCH SOC, V16, P1089, DOI 10.1017/S1355617710000925; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Piolino P, 2007, CORTEX, V43, P176, DOI 10.1016/S0010-9452(08)70474-X; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford JL, 2016, J NEUROTRAUM, V33, P997, DOI 10.1089/neu.2015.4025; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rasmussen KW, 2014, J NEUROPSYCHOL, V8, P34, DOI 10.1111/jnp.12003; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Robertson K, 2015, BRAIN INJURY, V29, P848, DOI 10.3109/02699052.2015.1005135; Rochat L, 2013, J INT NEUROPSYCH SOC, V19, P890, DOI 10.1017/S1355617713000672; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vanderploeg RD, 2014, J CLIN EXP NEUROPSYC, V36, P58, DOI 10.1080/13803395.2013.864600; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	167	61	63	1	45	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0035-3787	2213-0004		REV NEUROL-FRANCE	Rev. Neurol.	JUL-AUG	2017	173	7-8			SI		461	472		10.1016/j.neurol.2017.07.006			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FG7WU	WOS:000410636700005	28847474				2022-02-06	
J	Schwartz, ES; Erdodi, L; Rodriguez, N; Ghosh, JJ; Curtain, JR; Flashman, LA; Roth, RM				Schwartz, Eben S.; Erdodi, Laszlo; Rodriguez, Nicholas; Ghosh, Jyotsna J.; Curtain, Joshua R.; Flashman, Laura A.; Roth, Robert M.			CVLT-II Forced Choice Recognition Trial as an Embedded Validity Indicator: A Systematic Review of the Evidence	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Symptom evaluation; Validity of results; Review; Systematic; Memory deficits; Malingering; Neuropsychology	TRAUMATIC BRAIN-INJURY; LEARNING TEST-II; SYMPTOM VALIDITY; NEUROPSYCHOLOGICAL PERFORMANCE; INVALID PERFORMANCE; CLINICAL NEUROPSYCHOLOGY; AMERICAN ACADEMY; MEMORY; VETERANS; TESTS	Objectives: The Forced Choice Recognition (FCR) trial of the California Verbal Learning Test, 2(nd) edition, was designed as an embedded performance validity test (PVT). To our knowledge, this is the first systematic review of classification accuracy against reference PVTs. Methods: Results from peer-reviewed studies with FCR data published since 2002 encompassing a variety of clinical, research, and forensic samples were summarized, including 37 studies with FCR failure rates (N=7575) and 17 with concordance rates with established PVTs (N=4432). Results: All healthy controls scored >14 on FCR. On average, 16.9% of the entire sample scored 14, while 25.9% failed reference PVTs. Presence or absence of external incentives to appear impaired (as identified by researchers) resulted in different failure rates (13.6% vs. 3.5%), as did failing or passing reference PVTs (49.0% vs. 6.4%). FCR 14 produced an overall classification accuracy of 72%, demonstrating higher specificity (.93) than sensitivity (.50) to invalid performance. Failure rates increased with the severity of cognitive impairment. Conclusions: In the absence of serious neurocognitive disorder, FCR 14 is highly specific, but only moderately sensitive to invalid responding. Passing FCR does not rule out a non-credible presentation, but failing FCR rules it in with high accuracy. The heterogeneity in sample characteristics and reference PVTs, as well as the quality of the criterion measure across studies, is a major limitation of this review and the basic methodology of PVT research in general.	[Schwartz, Eben S.] Waukesha Mem Hosp, Neurosci Ctr, Waukesha, WI USA; [Erdodi, Laszlo; Rodriguez, Nicholas] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Ghosh, Jyotsna J.; Flashman, Laura A.; Roth, Robert M.] Geisel Sch Med Dartmouth, Neuropsychol Program, Lebanon, NH USA; [Curtain, Joshua R.] Stanford Hlth Care, Dept Neurol & Neurol Sci, Stanford, CA USA		Schwartz, ES (corresponding author), ProHlth Waukesha Mem Hosp, Dept Neurosci, 721 Amer Ave,Suite 406, Waukesha, WI 53188 USA.	eben.schwartz@phci.org					Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Binder LM, 2012, ARCH CLIN NEUROPSYCH, V27, P557, DOI 10.1093/arclin/acs051; Boone K.B., 2013, CLIN PRACTICE FORENS; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Clark LR, 2012, CLIN NEUROPSYCHOL, V26, P1201, DOI 10.1080/13854046.2012.728626; Connor D. J., 1997, AM AC NEUR BOST; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis D.C., 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Egeland J, 2015, APPL NEUROPSYCH-ADUL, V22, P215, DOI 10.1080/23279095.2014.910212; Eikeland R, 2012, EUR J NEUROL, V19, P480, DOI 10.1111/j.1468-1331.2011.03563.x; Erdodi L. A., 2016, PSYCHOL ASSESSMENT; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 2003, WORD MEMORY TEST WIN; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hanczar B, 2010, BIOINFORMATICS, V26, P822, DOI 10.1093/bioinformatics/btq037; Hand DJ, 2009, MACH LEARN, V77, P103, DOI 10.1007/s10994-009-5119-5; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; King PR, 2014, ARCH CLIN NEUROPSYCH, V29, P391, DOI 10.1093/arclin/acu011; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lobo JM, 2008, GLOBAL ECOL BIOGEOGR, V17, P145, DOI 10.1111/j.1466-8238.2007.00358.x; Macher RB, 2012, J CLIN EXP NEUROPSYC, V34, P405, DOI 10.1080/13803395.2011.646957; Maksimovskiy Arkadiy L, 2014, J Alcohol Drug Depend, V2, P144; Marshall P, 2007, CLIN NEUROPSYCHOL, V21, P826, DOI 10.1080/13854040600801001; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morse CL, 2013, CLIN NEUROPSYCHOL, V27, P1395, DOI 10.1080/13854046.2013.832385; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Orff H. J., 2015, J SLEEP DISORDERS TR, V4, P1; Peleikis DE, 2013, ACTA PSYCHIAT SCAND, V127, P455, DOI 10.1111/acps.12041; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2016, APPL NEUROPSYCH-ADUL, V23, P105, DOI 10.1080/23279095.2015.1014557; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Sweet JJ, 2015, CLIN NEUROPSYCHOL, V29, P1069, DOI 10.1080/13854046.2016.1140228; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Yochim BP, 2010, NEUROCASE, V16, P451, DOI 10.1080/13554791003623334	54	61	61	1	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2016	22	8					851	858		10.1017/S1355617716000746			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	DX4BU	WOS:000384324800006	27619108				2022-02-06	
J	Artigas, A; Wernerman, J; Arroyo, V; Vincent, JL; Levy, M				Artigas, Antonio; Wernerman, Jan; Arroyo, Vicente; Vincent, Jean-Louis; Levy, Mitchell			Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis	JOURNAL OF CRITICAL CARE			English	Article						Albumin; Cirrhosis; Hepatorenal syndrome; Inflammation; Sepsis	HUMAN-SERUM-ALBUMIN; SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC LIVER-FAILURE; TYPE-1 HEPATORENAL-SYNDROME; TUMOR-NECROSIS-FACTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN; TERLIPRESSIN PLUS ALBUMIN; TRAUMATIC BRAIN-INJURY; INTRAVENOUS ALBUMIN; SYNTHESIS RATES	The metabolism of albumin in inflammatory states such as sepsis or major surgery is complex and still not well characterized. Nevertheless, in inflammatory states, albumin synthesis has been observed to increase. By contrast, in decompensated cirrhosis, a disease characterized by systemic inflammation, albumin synthesis by the liver may decrease to 30% to 50% of normal values. Furthermore, in these conditions, there are high capillary leakage and altered albumin kinetics. The discussion regarding the effect of exogenous albumin administration on intravascular volume in inflammatory states should therefore address albumin turnover. To add complexity to our understanding of the effects of albumin, there are many data indicating that the therapeutic action of albumin is mediated not only through the impact on plasma volume expansion but also through a modulatory effect on inflammation and oxidative stress. All these characteristics are relevant to diseases associated with systemic inflammation including sepsis and decompensated cirrhosis. (C) 2016 Elsevier Inc. All rights reserved.	[Artigas, Antonio] Autonomous Univ Barcelona, Sabadell Hosp, CIBER Enfermedades Resp, Crit Care Ctr,Corp Sanitaria Univ Parc Tauli, Barcelona, Spain; [Wernerman, Jan] Karolinska Univ, Huddinge Hosp, Dept Anesthesiol & Intens Care Med, Stockholm, Sweden; [Arroyo, Vicente] Univ Barcelona, Liver Unit, Hosp Clin, Barcelona, Spain; [Arroyo, Vicente] Ctr Esther Koplowitz, Chron Liver Failure Consortium, Barcelona, Spain; [Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Levy, Mitchell] Rhode Isl Hosp, Pulm & Crit Care Med, Providence, RI USA		Artigas, A (corresponding author), Hosp Sabadell, Serv Med Intens, Parc Tauli 1, Barcelona 08208, Spain.	aartigas@tauli.cat; jan.wernerman@karolinska.se; varroyo@clinic.ub.es; jlvincen@ulb.ac.be; mitchell_levy@brown.edu	; Arroyo, Vicente/F-9189-2015	Vincent, Jean-Louis/0000-0001-6011-6951; antonio, artigas/0000-0002-8029-1017; Arroyo, Vicente/0000-0002-2728-1848	Grifols; Braum; Astute; Phillips; HillRom	This review is based on the contents of a satellite symposium organized by Grifols, manufacturer of albumin, held in the context of the 27th Annual Congress of the European Society of Intensive Care Medicine, Barcelona (Spain), September 27-October 1, 2014. A.A. declares having received a research grant from Grifols, speaker's fees from Grifols, Braum, Astute, Phillips and HillRom, and scientific advisor honorariums from Rubio, Astute, and Ferrer Farma. V.A. declares having received grants and research support from Grifols. J.W. declares being a member of the Medical Advisory Boards and also invited speaker for Baxter, Danone, Fresenius-Kabi, Grifols, and Nestle. J.L.V. declares no conflict of interest regarding this manuscript. M.L. declares being a member of advisory board for Merck and ImmuneExpress.	Albillos A, 2003, HEPATOLOGY, V37, P208, DOI 10.1053/jhep.2003.50038; Alessandria C, 2007, J HEPATOL, V47, P499, DOI 10.1016/j.jhep.2007.04.010; Alphonsus CS, 2014, ANAESTHESIA, V69, P777, DOI 10.1111/anae.12661; Angeli P, 2009, J HEPATOL, V50, pS73, DOI 10.1016/S0168-8278(09)60177-X; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; BALLMER PE, 1990, AM J PHYSIOL, V259, pE797, DOI 10.1152/ajpendo.1990.259.6.E797; Ballmer PE, 1996, HEPATOLOGY, V24, P53, DOI 10.1002/hep.510240111; Barle H, 2006, CLIN SCI, V110, P93, DOI 10.1042/CS20050222; Barle H, 1997, HEPATOLOGY, V25, P154, DOI 10.1053/jhep.1997.v25.pm0008985282; Barle H, 2002, CLIN SCI, V103, P525; Barle H, 2001, INTENS CARE MED, V27, P836, DOI 10.1007/s001340100914; Barle H, 1999, AM J PHYSIOL-ENDOC M, V277, pE591; BEEKEN WL, 1962, J CLIN INVEST, V41, P1312, DOI 10.1172/JCI104594; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bernardi M, 2012, HEPATOLOGY, V55, P1172, DOI 10.1002/hep.24786; Blunt MC, 1998, ANAESTHESIA, V53, P755, DOI 10.1046/j.1365-2044.1998.00488.x; Bortoluzzi A, 2013, HEPATOLOGY, V57, P266, DOI 10.1002/hep.26021; Bourdon E, 2005, FREE RADICAL RES, V39, P15, DOI 10.1080/10715760400024935; Boyer TD, 2011, J HEPATOL, V55, P315, DOI 10.1016/j.jhep.2010.11.020; Bruschi M, 2013, BBA-GEN SUBJECTS, V1830, P5473, DOI 10.1016/j.bbagen.2013.04.017; BYL B, 1993, GASTROENTEROLOGY, V104, P1492, DOI 10.1016/0016-5085(93)90361-F; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; Charpentier J, 2011, INTENS CARE MED, V37, pS115; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DAVID SA, 1995, J ENDOTOXIN RES, V2, P325; de Carvalho GC, 2012, ANN HEPATOL, V11, P90; de Sain-van der Velden MGM, 1998, KIDNEY INT, V53, P181, DOI 10.1046/j.1523-1755.1998.00729.x; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; Esparza GA, 2012, INNATE IMMUN-LONDON, V18, P478, DOI 10.1177/1753425911422723; Essen P, 1998, CRIT CARE MED, V26, P92, DOI 10.1097/00003246-199801000-00022; Fasolato S, 2007, HEPATOLOGY, V45, P223, DOI 10.1002/hep.21443; Fernandez J, 2005, HEPATOLOGY, V42, P627, DOI 10.1002/hep.20829; Fernandez J, 2004, J HEPATOL, V41, P384, DOI 10.1016/j.jhep.2004.05.009; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2006, BRIT MED J, V333, P1044, DOI 10.1136/bmj.38985.398704.7C; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finkenstedt A, 2013, LIVER TRANSPLANT, V19, P879, DOI 10.1002/lt.23678; FITZPATRICK FA, 1984, J BIOL CHEM, V259, P2722; FLECK A, 1985, LANCET, V1, P781; FOLCO G, 1977, FEBS LETT, V82, P321, DOI 10.1016/0014-5793(77)80611-X; FOLLO A, 1994, HEPATOLOGY, V20, P1495, DOI 10.1002/hep.1840200619; Fujiwara S, 2013, BBA-GEN SUBJECTS, V1830, P5427, DOI 10.1016/j.bbagen.2013.03.032; Galley HF, 2011, BRIT J ANAESTH, V107, P57, DOI 10.1093/bja/aer093; Galley HF, 2010, CRIT CARE, V14, DOI 10.1186/cc9098; Garcia-Tsao G, 2010, HEPATOLOGY, V51, P1445, DOI 10.1002/hep.23478; Gines A, 1996, GASTROENTEROLOGY, V111, P1002, DOI 10.1016/S0016-5085(96)70068-9; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; Gines P, 2004, NEW ENGL J MED, V350, P1646, DOI 10.1056/NEJMra035021; Gines P, 2010, J HEPATOL, V53, P397, DOI 10.1016/j.jhep.2010.05.004; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Guevara M, 1998, HEPATOLOGY, V27, P35, DOI 10.1002/hep.510270107; Ha CE, 2013, BBA-GEN SUBJECTS, V1830, P5486, DOI 10.1016/j.bbagen.2013.04.012; Hoque R, 2013, J GASTROEN HEPATOL, V28, P61, DOI 10.1111/jgh.12018; Jalan R, 2002, BLOOD PURIFICAT, V20, P252, DOI 10.1159/000047017; Jalan R, 2014, J HEPATOL, V61, P1038, DOI 10.1016/j.jhep.2014.06.012; Jalan R, 2013, J HEPATOL, V59, P918, DOI 10.1016/j.jhep.2013.08.001; Jiang LB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114666; Jurgens G, 2002, J ENDOTOXIN RES, V8, P115, DOI 10.1179/096805102125000263; Khuroo MS, 2004, LIVER TRANSPLANT, V10, P1099, DOI 10.1002/lt.20139; Kjaergard LL, 2003, JAMA-J AM MED ASSOC, V289, P217, DOI 10.1001/jama.289.2.217; Kragh-Hansen U, 2013, BBA-GEN SUBJECTS, V1830, P5535, DOI 10.1016/j.bbagen.2013.03.015; LEMOINE O, 1995, J HEPATOL, V23, P391, DOI 10.1016/0168-8278(95)80196-0; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Li CP, 1996, J GASTROEN HEPATOL, V11, P635, DOI 10.1111/j.1440-1746.1996.tb00306.x; Martin-Llahi M, 2008, GASTROENTEROLOGY, V134, P1352, DOI 10.1053/j.gastro.2008.02.024; Montoliu C, 2009, J CLIN GASTROENTEROL, V43, P272, DOI 10.1097/MCG.0b013e31815e7f58; Moreau R, 2002, GASTROENTEROLOGY, V122, P923, DOI 10.1053/gast.2002.32364; Moreau R, 2013, GASTROENTEROLOGY, V144, P1426, DOI 10.1053/j.gastro.2013.02.042; MOSHAGE HJ, 1987, J CLIN INVEST, V79, P1635, DOI 10.1172/JCI113000; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Navasa M, 1998, HEPATOLOGY, V27, P1227, DOI 10.1002/hep.510270507; Nazar A, 2010, HEPATOLOGY, V51, P219, DOI 10.1002/hep.23283; Norberg A, 2012, INTENS CARE MED, V38, pS19; Norberg A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136371; O'Brien AJ, 2014, NAT MED, V20, P522, DOI 10.1038/nm.3516; Oettl K, 2013, J HEPATOL, V59, P978, DOI 10.1016/j.jhep.2013.06.013; Oettl K, 2010, METHOD ENZYMOL, V474, P181, DOI 10.1016/S0076-6879(10)74011-8; Ortega R, 2002, HEPATOLOGY, V36, P941, DOI 10.1053/jhep.2002.35819; Patel A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4561; Pereira G, 2012, J HEPATOL, V56, P1040, DOI 10.1016/j.jhep.2011.11.023; Peters T., 1996, ALL ALBUMIN BIOCH GE; Petersen CE, 2000, J BIOL CHEM, V275, P20985, DOI 10.1074/jbc.M001038200; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; REINHARDT GF, 1980, JPEN-PARENTER ENTER, V4, P357, DOI 10.1177/0148607180004004357; Rittler P, 2007, SURGERY, V141, P660, DOI 10.1016/j.surg.2006.09.018; Rittler P, 2011, JPEN-PARENTER ENTER, V35, P405, DOI 10.1177/0148607110382782; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178; Ruiz-del-Arbol W, 2003, HEPATOLOGY, V38, P1210, DOI 10.1053/jhep.2003.50447; RuizdelArbol L, 1997, GASTROENTEROLOGY, V113, P579, DOI 10.1053/gast.1997.v113.pm9247479; Salerno F, 2013, CLIN GASTROENTEROL H, V11, P123, DOI 10.1016/j.cgh.2012.11.007; Salo J, 1997, J HEPATOL, V27, P645, DOI 10.1016/S0168-8278(97)80081-5; Sanyal AJ, 2008, GASTROENTEROLOGY, V134, P1360, DOI 10.1053/j.gastro.2008.02.014; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SHAPIRO MD, 1985, KIDNEY INT, V28, P206, DOI 10.1038/ki.1985.142; Sharma P, 2008, AM J GASTROENTEROL, V103, P1689, DOI 10.1111/j.1572-0241.2008.01828.x; Singer M, 2014, VIRULENCE, V5, P66, DOI 10.4161/viru.26907; Singh V, 2012, J HEPATOL, V56, P1293, DOI 10.1016/j.jhep.2012.01.012; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Taverna M, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-4; Terra C, 2005, GASTROENTEROLOGY, V129, P1944, DOI 10.1053/j.gastro.2005.09.024; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; TOLEDO C, 1993, HEPATOLOGY, V17, P251, DOI 10.1002/hep.1840170215; Uriz J, 2000, J HEPATOL, V33, P43, DOI 10.1016/S0168-8278(00)80158-0; van der Vusse GJ, 2009, DRUG METAB PHARMACOK, V24, P300, DOI 10.2133/dmpk.24.300; Viasus D, 2013, J INFECTION, V66, P415, DOI 10.1016/j.jinf.2012.12.007; Vila MC, 1998, J HEPATOL, V28, P639, DOI 10.1016/S0168-8278(98)80288-2; Vincent JL, 2009, BEST PRACT RES-CLIN, V23, P183, DOI 10.1016/j.bpa.2008.11.004; Vincent JL, 2014, CRIT CARE, V18, DOI 10.1186/cc13991; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; Wang ZM, 2013, BBA-GEN SUBJECTS, V1830, P5356, DOI 10.1016/j.bbagen.2013.06.032; Wiest R, 2014, J HEPATOL, V60, P197, DOI 10.1016/j.jhep.2013.07.044; WYNALDA MA, 1980, PROSTAGLANDINS, V20, P853, DOI 10.1016/0090-6980(80)90138-0; Yang JS, 2002, PROTEIN SCI, V11, P538, DOI 10.1110/ps.28702	122	61	67	2	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	JUN	2016	33						62	70		10.1016/j.jcrc.2015.12.019			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DK8EP	WOS:000375160300015	26831575				2022-02-06	
J	Leddy, JJ; Baker, JG; Willer, B				Leddy, John J.; Baker, John G.; Willer, Barry			Active Rehabilitation of Concussion and Post-concussion Syndrome	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Rehabilitation; Concussion; Post-concussion syndrome; Active; Physiology; Treatment	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; SYMPTOMATIC CONVERGENCE INSUFFICIENCY; COGNITIVE-BEHAVIORAL PREVENTION; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; EARLY INTERVENTION; VOLUNTARY EXERCISE; BALANCE DISORDERS; VESTIBULAR SYSTEM	Concussion is a physiological brain injury with physical, cognitive, and emotional sequelae. The macrophysiological insult to the brain affects the autonomic nervous system and its control of cerebral blood flow. Most patients recover within 2-4 weeks, but some do not. Persistence of symptoms beyond the generally accepted time frame for recovery is called post-concussion syndrome (PCS). PCS is not a single entity; it is a group of disorders that requires specific forms of therapy. Rest has been the mainstay of the treatment for concussion and PCS. This article discusses the rationale for the active treatment of concussion and PCS.	[Leddy, John J.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA; [Baker, John G.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Dept Orthopaed & Sports Med & Nucl Med, Sch Social Work, Buffalo, NY USA; [Willer, Barry] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA		Leddy, JJ (corresponding author), SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu					Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Alla S, 2010, J SCI MED SPORT, V13, P24, DOI 10.1016/j.jsams.2008.12.629; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bazarian JJ, 2010, J HEAD TRAUMA REHAB, V25, P225, DOI 10.1097/HTR.0b013e3181e7f784; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley TA, 2015, J HEAD TRAUMA REHAB; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Clausen M, 2015, J HEAD TRAUMA REHABI; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Cullen KE, 2012, TRENDS NEUROSCI, V35, P185, DOI 10.1016/j.tins.2011.12.001; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Dimberg EL, 2005, CLIN SPORT MED, V24, P637, DOI 10.1016/j.csm.2005.04.002; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Endo K, 2006, EUR SPINE J, V15, P886, DOI 10.1007/s00586-005-0970-y; Friedman Jules M, 2004, Med Health R I, V87, P296; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; Kjeldgaard D, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-81; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leslie O, 2013, CLIN J SPORT MED, V23, P331, DOI 10.1097/JSM.0b013e318295bbb1; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2015, CLIN PEDIATR, P1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Naguib MB, 2012, J LARYNGOL OTOL, V126, P26, DOI 10.1017/S002221511100291X; Palmese CA, 2000, BRAIN INJURY, V14, P535; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Satterthwaite TD, 2014, P NATL ACAD SCI USA, V111, P8643, DOI 10.1073/pnas.1400178111; Scheiman M, 2005, BRIT J OPHTHALMOL, V89, P1318, DOI 10.1136/bjo.2005.068197; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Scheiman M, 2011, J AAPOS, V15, P123, DOI 10.1016/j.jaapos.2011.03.001; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Silver JM, 2014, PSYCHIAT CLIN N AM, V37, P91, DOI 10.1016/j.psc.2013.11.001; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zhang R, 1997, J APPL PHYSIOL, V83, P2139, DOI 10.1152/jappl.1997.83.6.2139	102	61	63	16	99	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					437	+		10.1016/j.pmr.2015.12.003			19	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	DN4RU	WOS:000377055700007	27154855				2022-02-06	
J	Pruitt, DT; Schmid, AN; Kim, LJ; Abe, CM; Trieu, JL; Choua, C; Hays, SA; Kilgard, MP; Rennaker, RL				Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Trieu, Jenny L.; Choua, Connie; Hays, Seth A.; Kilgard, Michael P.; Rennaker, Robert L.			Vagus Nerve Stimulation Delivered with Motor Training Enhances Recovery of Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						motor recovery; neuromodulation; traumatic brain injury; vagal nerve stimulation; vagus nerve stimulation	FOREBRAIN CHOLINERGIC SYSTEM; TREATMENT-RESISTANT DEPRESSION; CORTICAL PLASTICITY; LONG-TERM; REHABILITATION IMPROVE; FORELIMB STRENGTH; REORGANIZATION; NOREPINEPHRINE; IMPAIRMENT; ADMISSION	Traumatic Brain Injury (TBI) is one of the largest health problems in the United States, and affects nearly 2 million people every year. The effects of TBI, including weakness and loss of coordination, can be debilitating and last years after the initial injury. Recovery of motor function is often incomplete. We have developed a method using electrical stimulation of the vagus nerve paired with forelimb use by which we have demonstrated enhanced recovery from ischemic and hemorrhagic stroke. Here we have tested the hypothesis that vagus nerve stimulation (VNS) paired with physical rehabilitation could enhance functional recovery after TBI. We trained rats to pull on a handle to receive a food reward. Following training, they received a controlled-cortical impact (CCI) in the forelimb area of motor cortex opposite the trained forelimb, and were then randomized into two treatment groups. One group of animals received VNS paired with rehabilitative therapy, whereas another group received rehabilitative therapy without VNS. Following CCI, volitional forelimb strength and task success rate in all animals were significantly reduced. VNS paired with rehabilitative therapy over a period of 5 weeks significantly increased recovery of both forelimb strength and success rate on the isometric pull task compared with rehabilitative training without VNS. No significant improvement was observed in the Rehab group. Our findings indicate that VNS paired with rehabilitative therapy enhances functional motor recovery after TBI.	[Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Choua, Connie; Kilgard, Michael P.; Rennaker, Robert L.] Univ Texas Dallas, Sch Behav Brain Sci, 800 West Campbell Rd,GR41, Richardson, TX 75080 USA; [Trieu, Jenny L.; Hays, Seth A.; Rennaker, Robert L.] Univ Texas Dallas, Erik Jonsson Sch Engn & Comp Sci, Richardson, TX 75083 USA; [Pruitt, David T.; Schmid, Ariel N.; Kim, Lily J.; Abe, Caroline M.; Trieu, Jenny L.; Choua, Connie; Hays, Seth A.; Kilgard, Michael P.; Rennaker, Robert L.] Univ Texas Dallas, Texas Biomed Device Ctr, Richardson, TX 75083 USA		Pruitt, DT (corresponding author), Univ Texas Dallas, Sch Behav Brain Sci, 800 West Campbell Rd,GR41, Richardson, TX 75080 USA.	dtp110020@utdallas.edu	, David/ABG-7327-2020; Hays, Seth/U-4701-2019; Rennaker II, Robert/K-9049-2013	, David/0000-0001-8356-0887; Hays, Seth/0000-0003-4225-241X; Kilgard, Michael/0000-0002-6699-1818; Rennaker II, Robert/0000-0003-1260-1973	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS062065, R01 NS085167] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062065, R01NS085167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC008982] Funding Source: NIH RePORTER		Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; Ben-Menachem E, 1999, NEUROLOGY, V52, P1265, DOI 10.1212/WNL.52.6.1265; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Canning CG, 1999, ARCH PHYS MED REHAB, V80, P66, DOI 10.1016/S0003-9993(99)90309-X; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; De Ridder D, 2015, OTOL NEUROTOL, V36, P575, DOI 10.1097/MAO.0000000000000704; De Ridder D, 2014, NEUROMODULATION, V17, P170, DOI 10.1111/ner.12127; DeGiorgio CM, 2000, EPILEPSIA, V41, P1195, DOI 10.1111/j.1528-1157.2000.tb00325.x; Engineer ND, 2011, NATURE, V470, P101, DOI 10.1038/nature09656; Faul M, 2010, TRAUMATIC BRAIN INJU; Follesa P, 2007, BRAIN RES, V1179, P28, DOI 10.1016/j.brainres.2007.08.045; Hays SA, 2014, STROKE, V45, P3097, DOI 10.1161/STROKEAHA.114.006654; Hays SA, 2014, NEUROREPORT, V25, P676, DOI 10.1097/WNR.0000000000000154; Hays SA, 2013, J NEUROSCI METH, V212, P329, DOI 10.1016/j.jneumeth.2012.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Khodaparast N, 2013, NEUROBIOL DIS, V60, P80, DOI 10.1016/j.nbd.2013.08.002; Khodaparast N, 2014, NEUROREHAB NEURAL RE, V28, P698, DOI 10.1177/1545968314521006; Kilgard MP, 2012, TRENDS NEUROSCI, V35, P715, DOI 10.1016/j.tins.2012.09.002; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Microtransponder, 2014, VNS REH IMPR UPP LIM; Microtransponder, 2014, PAIR VAG NERV STIM V; Molina-Luna K, 2008, NEUROIMAGE, V40, P1748, DOI 10.1016/j.neuroimage.2007.11.018; Morris GL, 1999, NEUROLOGY, V53, P1731, DOI 10.1212/WNL.53.8.1731; Nemeroff CB, 2006, NEUROPSYCHOPHARMACOL, V31, P1345, DOI 10.1038/sj.npp.1301082; Nichols JA, 2011, NEUROSCIENCE, V189, P207, DOI 10.1016/j.neuroscience.2011.05.024; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Porter BA, 2012, CEREB CORTEX, V22, P2365, DOI 10.1093/cercor/bhr316; Pruitt D, 2014, BRAIN RES, V1582, P91, DOI 10.1016/j.brainres.2014.07.039; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Ramanathan D, 2009, J NEUROSCI, V29, P5992, DOI 10.1523/JNEUROSCI.0230-09.2009; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Sackeim HA, 2001, NEUROPSYCHOPHARMACOL, V25, P713, DOI 10.1016/S0893-133X(01)00271-8; Shetake JA, 2012, EXP NEUROL, V233, P342, DOI 10.1016/j.expneurol.2011.10.026; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Terry Jr R. S., 2014, VAGUS NERVE STIMULAT; Thompson JN, 2013, BRIT J NEUROSURG, V27, P24, DOI 10.3109/02688697.2012.714818; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	50	61	66	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					871	879		10.1089/neu.2015.3972			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800009	26058501	Green Published			2022-02-06	
J	Smith, DH; Hicks, RR; Johnson, VE; Bergstrom, DA; Cummings, DM; Noble, LJ; Hovda, D; Whalen, M; Ahlers, ST; LaPlaca, M; Tortella, FC; Duhaime, AC; Dixon, CE				Smith, Douglas H.; Hicks, Ramona R.; Johnson, Victoria E.; Bergstrom, Debra A.; Cummings, Diana M.; Noble, Linda J.; Hovda, David; Whalen, Michael; Ahlers, Stephen T.; LaPlaca, Michelle; Tortella, Frank C.; Duhaime, Ann-Christine; Dixon, C. Edward			Pre-Clinical Traumatic Brain Injury Common Data Elements: Toward a Common Language Across Laboratories	JOURNAL OF NEUROTRAUMA			English	Article						common data elements; data dictionary; pre-clinical TBI models; traumatic brain injury	DIFFUSE AXONAL INJURY; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; ACUTE SUBDURAL-HEMATOMA; ADULT-RAT BRAIN; FLUID-PERCUSSION MODEL; LASTING IMPULSE NOISE; ALZHEIMERS-DISEASE; INTRACRANIAL-PRESSURE	Traumatic brain injury (TBI) is a major public health issue exacting a substantial personal and economic burden globally. With the advent of big data approaches to understanding complex systems, there is the potential to greatly accelerate knowledge about mechanisms of injury and how to detect and modify them to improve patient outcomes. High quality, well-defined data are critical to the success of bioinformatics platforms, and a data dictionary of common data elements (CDEs), as well as unique data elements has been created for clinical TBI research. There is no data dictionary, however, for preclinical TBI research despite similar opportunities to accelerate knowledge. To address this gap, a committee of experts was tasked with creating a defined set of data elements to further collaboration across laboratories and enable the merging of data for meta-analysis. The CDEs were subdivided into a Core module for data elements relevant to most, if not all, studies, and Injury-Model-Specific modules for non-generalizable data elements. The purpose of this article is to provide both an overview of TBI models and the CDEs pertinent to these models to facilitate a common language for preclinical TBI research.	[Smith, Douglas H.; Johnson, Victoria E.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Hicks, Ramona R.] One Mind, Seattle, WA USA; [Hicks, Ramona R.; Bergstrom, Debra A.; Cummings, Diana M.] NINDS, NIH, Bethesda, MD 20892 USA; [Noble, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hovda, David] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA; [Whalen, Michael] Massachusetts Gen Hosp, Dept Pediat, Ctr Neurosci, Charlestown, MA USA; [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA; [LaPlaca, Michelle] Georgia Tech, Dept Biomed Engn, Atlanta, GA USA; [LaPlaca, Michelle] Emory Univ, Atlanta, GA 30322 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Duhaime, Ann-Christine] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu			U.S. Department of DefenseUnited States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767] Funding Source: NIH RePORTER	We would like to acknowledge the U.S. Department of Defense and the National Institutes of Health who contributed funding for The Federal Interagency Traumatic Brain Injury Research (FIT-BIR) Informatics System.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Balikci M, 2008, NEUROL RES, V30, P450, DOI 10.1179/016164107X251637; Barbiro-Micahely E, 2001, J NEUROTRAUM, V18, P711, DOI 10.1089/089771501750357654; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BOTEL C, 1994, J EXP ANIM SCI, V36, P78; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dirnagl U, 2010, J CEREBR BLOOD F MET, V30, P1263, DOI 10.1038/jcbfm.2010.51; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Ebmeyer U, 1998, J NEUROTRAUM, V15, P323, DOI 10.1089/neu.1998.15.323; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FITCH W, 1977, J NEUROL NEUROSUR PS, V40, P843, DOI 10.1136/jnnp.40.9.843; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GANZ JC, 1988, ACTA NEUROCHIR, V95, P72, DOI 10.1007/BF01793086; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham D.I., 2002, GREENFIELDS NEUROPAT; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grimmelt AC, 2011, CENT EUR NEUROSURG, V72, P120, DOI 10.1055/s-0031-1271732; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAUERBERG J, 1994, J CEREBR BLOOD F MET, V14, P519, DOI 10.1038/jcbfm.1994.64; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Janda M, 2012, LAB ANIM-UK, V46, P258, DOI 10.1258/la.2011.011149; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; JOHNSTON IH, 1973, J NEUROL NEUROSUR PS, V36, P161, DOI 10.1136/jnnp.36.2.161; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Knight J, 2003, NATURE, V422, P554, DOI 10.1038/422554a; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400; Leung LY, 2014, ANN BIOMED ENG, V42, P1618, DOI 10.1007/s10439-014-1014-8; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; MALKINSON TJ, 1985, BRAIN RES BULL, V15, P321, DOI 10.1016/0361-9230(85)90158-3; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mueller CA, 2007, EXP NEUROL, V208, P228, DOI 10.1016/j.expneurol.2007.07.020; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Institute of Neurological Disorders and Stroke, NINDS COMM DAT EL TR; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; NITTA M, 1990, ACTA NEUROCHIR, V104, P30, DOI 10.1007/BF01842890; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Phillips Y. I., 1991, CONVENTIONAL WARFARE; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryan JB, 2003, J HEART LUNG TRANSPL, V22, P922, DOI 10.1016/S1053-2498(02)00558-2; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Sapsford W, 2003, J R Army Med Corps, V149, P5; Sasaki M, 2001, J NEUROTRAUM, V18, P1241, DOI 10.1089/089771501317095278; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHALIT MN, 1974, J NEUROSURG, V40, P594, DOI 10.3171/jns.1974.40.5.0594; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Tsai M L, 1988, Chin J Physiol, V31, P113; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Wang D, 2010, J NEUROTRAUM, V27, P1489, DOI 10.1089/neu.2009.1057; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang J, 2008, EXP NEUROL, V210, P645, DOI 10.1016/j.expneurol.2007.12.019; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	131	61	61	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1725	1735		10.1089/neu.2014.3861			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500003	26058402	Green Published			2022-02-06	
J	Siman, R; Shahim, P; Tegner, Y; Blennow, K; Zetterberg, H; Smith, DH				Siman, Robert; Shahim, Pashtun; Tegner, Yelverton; Blennow, Kaj; Zetterberg, Henrik; Smith, Douglas H.			Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms	JOURNAL OF NEUROTRAUMA			English	Article						tau; sports concussion; diffuse axonal injury; mild traumatic brain injury; calpain	TRAUMATIC BRAIN-INJURY; CALPAIN-I; CEREBROSPINAL-FLUID; MILD; BIOMARKERS; TETRODOTOXIN; PROTEOLYSIS; ACTIVATION; MANAGEMENT; STATEMENT	Biomarkers for diffuse axonal injury could have utilities for the acute diagnosis and clinical care of concussion, including those related to sports. The calpain-derived alpha II-spectrin N-terminal fragment (SNTF) accumulates in axons after traumatic injury and increases in human blood after mild traumatic brain injury (mTBI) in relation to white matter abnormalities and persistent cognitive dysfunction. However, SNTF has never been evaluated as a biomarker for sports-related concussion. Here, we conducted longitudinal analysis of serum SNTF in professional ice hockey players, 28 of whom had a concussion, along with 45 players evaluated during the preseason, 17 of whom were also tested after a concussion-free training game. Compared with preseason levels, serum SNTF increased at 1 h after concussion and remained significantly elevated from 12 h to 6 days, before declining to preseason baseline. In contrast, serum SNTF levels were unchanged after training. In 8 players, postconcussion symptoms resolved within a few days, and in these cases serum SNTF levels were at baseline. On the other hand, for the 20 players withheld from play for 6 days or longer, serum SNTF levels rose from 1 h to 6 days postconcussion, and at 12-36 h differed significantly from the less-severe concussions (p=0.004). Serum SNTF exhibited diagnostic accuracy for concussion, especially so with delayed return to play (area under the curve=0.87). Multi-variate analyses of serum SNTF and tau improved the diagnostic accuracy, the relationship with the delay in return to play, and the temporal window beyond tau alone. These results provide evidence that blood SNTF, a biomarker for axonal injury after mTBI, may be useful for diagnosis and prognosis of sports-related concussion, as well as for guiding neurobiologically informed decisions on return to play.	[Siman, Robert; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Sahgrenska Acad,Sahlgrenska Univ Hosp, Molndal, Sweden; [Tegner, Yelverton] Lulea Univ Technol, Div Med Sci, Dept Hlth Sci, S-95187 Lulea, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, London, England		Siman, R (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 502 Stemmler Hall 36th & Hamilton Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Tegner, Yelverton/0000-0003-3628-0705	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Centrum for Idrottsforskning; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS P01 NS056202]; Department of Neurosurgery, University of Pennsylvania School of Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This work was supported by grants from the Swedish Medical Research Council, the Centrum for Idrottsforskning, and the National Institutes of Health (NINDS P01 NS056202), along with support from the Department of Neurosurgery, University of Pennsylvania School of Medicine. The authors thank the medical staff of the hockey teams: Bengt Gustafsson, MD, Torsten Johansson, MD, Orjan Frojd, MD, Henrik Wretling, MD, Karin Runblad, MD, Goran Thoren, MD, Christer Andersson, MD, Ulf Nordstrom, MD, Stefan Serenius, MD, Mattias Hell, Jonas Kalman, Sina Hedin, Patrik Johansson, and Billy Nilsson for their valuable contributions to the participant enrollment and assessments of PCS. The authors thank Dr. Sean Ren and Samir Sayed of Children's Hospital of Philadelphia for assistance with the electrochemiluminescence-based SNTF immunoassay and Ryan Cocca for outstanding technical assistance.	Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Gatson JW, 2013, J NEUROTRAUM, V30, pA162; Goedert M, 1991, BRAIN PATHOL, V1, P279, DOI 10.1111/j.1750-3639.1991.tb00671.x; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Johnson VE, 2014, J NEUROTRAUM, V31, pA95; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrea M, 2014, PROG NEUROL SURG, V28, P112, DOI 10.1159/000358769; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryb G. E., 2014, BRAIN INJURY, V9, P1; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xu JL, 2001, BRAIN RES, V898, P171, DOI 10.1016/S0006-8993(01)02156-4; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	44	61	63	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1294	1300		10.1089/neu.2014.3698			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500002	25419578	Green Published			2022-02-06	
J	Dias, C; Silva, MJ; Pereira, E; Monteiro, E; Maia, I; Barbosa, S; Silva, S; Honrado, T; Cerejo, A; Aries, MJH; Smielewski, P; Paiva, JA; Czosnyka, M				Dias, Celeste; Silva, Maria Joao; Pereira, Eduarda; Monteiro, Elisabete; Maia, Isabel; Barbosa, Silvina; Silva, Sofia; Honrado, Teresa; Cerejo, Antonio; Aries, Marcel J. H.; Smielewski, Peter; Paiva, Jose-Artur; Czosnyka, Marek			Optimal Cerebral Perfusion Pressure Management at Bedside: A Single-Center Pilot Study	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Multimodal brain monitoring; Cerebral perfusion pressure; Cerebrovascular pressure reactivity; Optimal cerebral perfusion pressure	NEAR-INFRARED SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW AUTOREGULATION; CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; VASOMOTOR REACTIVITY; CLASSIFICATION; HYPOXIA; TRIAL	Guidelines recommend cerebral perfusion pressure (CPP) values of 50-70 mmHg and intracranial pressure lower than 20 mmHg for the management of acute traumatic brain injury (TBI). However, adequate individual targets are still poorly addressed, since patients have different perfusion thresholds. Bedside assessment of cerebral autoregulation may help to optimize individual CPP-guided treatment. To assess staff compliance and outcome impact of a new method of autoregulation-guided treatment (CPPopt) based on continuous evaluation of cerebrovascular reactivity (PRx). Prospective pilot study of severe TBI adult patients managed with continuous multimodal brain monitoring in a single Neurocritical Care Unit (NCCU). Every minute CPPopt was automatically estimated, based on the previous 4-h window, as the CPP with the lowest PRx indicating the best cerebrovascular pressure reactivity. Patients were managed with CPPopt targets whenever possible and otherwise CPP was managed following general/international guidelines. In addition, other offline CPPopt estimates were calculated using cerebral oximetry (COx-CPPopt), brain tissue oxygenation (ORxs-CPPopt), and cerebral blood flow (CBFx-CPPopt). Eighteen patients with a total multimodal brain monitoring time of 5,520 h were enrolled. During the total monitoring period, 11 patients (61 %) had a CPPopt U-shaped curve, 5 patients (28 %) had either ascending or descending curves, and only 2 patients (11 %) had no fitted curve. Real CPP correlated significantly with calculated CPPopt (r = 0.83, p < 0.0001). Preserved autoregulation was associated with greater Glasgow coma score on admission (p = 0.01) and better outcome (p = 0.01). We demonstrated that patients with the larger discrepancy (> 10 mm Hg) between real CPP and CPPopt more likely have had adverse outcome (p = 0.04). Comparison between CPPopt and the other estimates revealed similar limits of precision. The lowest bias (-0.1 mmHg) was obtained with COx-CPPopt (NIRS). Targeted individual CPP management at the bedside using cerebrovascular pressure reactivity seems feasible. Large deviation from CPPopt seems to be associated with adverse outcome. The COx-CPPopt methodology using non-invasive CO (NIRS) warrants further evaluation.	[Dias, Celeste; Pereira, Eduarda; Monteiro, Elisabete; Maia, Isabel; Barbosa, Silvina; Silva, Sofia; Honrado, Teresa; Paiva, Jose-Artur] Hosp Sao Joao, Dept Intens Care, Neurocrit Care Unit, Oporto, Portugal; [Silva, Maria Joao] Kings Coll London, Diabet & Nutr Sci Div, London WC2R 2LS, England; [Cerejo, Antonio] Hosp Sao Joao, Neurosurg Dept, Oporto, Portugal; [Aries, Marcel J. H.] Univ Groningen, Univ Med Ctr Groningen, Intens Care Crit Care Unit, Groningen, Netherlands; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England		Dias, C (corresponding author), Hosp Sao Joao, Dept Intens Care, Neurocrit Care Unit, Oporto, Portugal.	mceleste.dias@gmail.com	Dias, Celeste/AAD-8711-2019; Paiva, Jose-Artur/AAO-9730-2021; Dias, Celeste/L-9901-2014; Dias, Celeste/AAV-3820-2020	Dias, Celeste/0000-0003-0340-9808; Dias, Celeste/0000-0003-0340-9808; Honrado Santos, Maria Teresa/0000-0001-9416-9971; Paiva, Jose-Artur/0000-0003-4323-0220; Smielewski, Peter/0000-0001-5096-3938; czosnyka, marek/0000-0003-2446-8006	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390] Funding Source: UKRI		Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Cecconi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7129; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Smielewski P, 2005, ACT NEUR S, V95, P43; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Team R. D. C., 2012, R LANG ENV STAT COMP; Tzeng YC, 2014, EUR J APPL PHYSIOL, V114, P545, DOI 10.1007/s00421-013-2667-y; Weerakkody RA, 2010, ACTA NEUROCHIR, V152, P1763, DOI 10.1007/s00701-010-0748-9; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	42	61	64	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2015	23	1					92	102		10.1007/s12028-014-0103-8			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CN8FJ	WOS:000358674600014	25566826				2022-02-06	
J	Gilbert, KS; Kark, SM; Gehrman, P; Bogdanova, Y				Gilbert, Karma Stavitsky; Kark, Sarah M.; Gehrman, Philip; Bogdanova, Yelena			Sleep disturbances, TBI and PTSD: Implications for treatment and recovery	CLINICAL PSYCHOLOGY REVIEW			English	Article						Sleep; PTSD; TBI; Veterans; Cognition; Interventions; Sleep physiology; Neuromodulation; Paradoxical insomnia; Actigraphy	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; VENTROLATERAL PREOPTIC NUCLEUS; RANDOMIZED CONTROLLED-TRIAL; IMAGERY REHEARSAL THERAPY; WAKING DISCHARGE PATTERNS; RETURNING COMBAT VETERANS; CHRONIC PRIMARY INSOMNIA; PITUITARY-ADRENAL AXIS	Post-Traumatic Stress Disorder (PTSD), traumatic brain injury (TBI), and sleep problems significantly affect recovery and functional status in military personnel and Veterans returning from combat. Despite recent attention, sleep is understudied in the Veteran population. Few treatments and rehabilitation protocols target sleep, although poor sleep remains at clinical levels and continues to adversely impact functioning even after the resolution of PTSD or mild TBI symptoms. Recent developments in non-pharmacologic sleep treatments have proven efficacious as stand-alone interventions and have potential to improve treatment outcomes by augmenting traditional behavioral and cognitive therapies. This review discusses the extensive scope of work in the area of sleep as it relates to TBI and PTSD, including pathophysiology and neurobiology of sleep; existing and emerging treatment options; as well as methodological issues in sleep measurements for TBI and PTSD. Understanding sleep problems and their role in the development and maintenance of PTSD and TBI symptoms may lead to improvement in overall treatment outcomes while offering a non-stigmatizing entry in mental health services and make current treatments more comprehensive by helping to address a broader spectrum of difficulties. Published by Elsevier Ltd.	[Gilbert, Karma Stavitsky; Kark, Sarah M.; Bogdanova, Yelena] VA Boston Healthcare Syst, Psychol Res, Boston, MA 02130 USA; [Gilbert, Karma Stavitsky; Bogdanova, Yelena] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Gehrman, Philip] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gehrman, Philip] Philadelphia VA Med Ctr, Philadelphia, PA USA		Bogdanova, Y (corresponding author), VA Boston Healthcare Syst, Psychol Res 151A, 150 South Huntington Ave, Boston, MA 02130 USA.	bogdanov@bu.edu	Kark, Sarah/O-3285-2019	Kark, Sarah/0000-0003-2930-9645; Bogdanova, Yelena/0000-0003-0439-8098	Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) [D6996W, I21RX001773-01]; Boston University Clinical and Translational Science Institute [UL1-RR025771]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; VA Translation Research Center for TBI and Stress Disorders (TRACTS); VA Psychology Research Service; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025771] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I21RX001773] Funding Source: NIH RePORTER	This work was supported by the Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) grants D6996W and I21RX001773-01 to YB, the National Institutes of Health and Boston University Clinical and Translational Science Institute grant UL1-RR025771 to YB, the VA Translation Research Center for TBI and Stress Disorders (TRACTS) [YB], and the VA Psychology Research Service [YB and KSG].	American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; [Anonymous], 2010, VA CONS C; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Arnedt JT, 2013, SLEEP, V36, P353, DOI 10.5665/sleep.2448; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Babson K, 2011, J ANXIETY DISORD, V25, P706, DOI 10.1016/j.janxdis.2011.03.007; Babson KA, 2010, J ANXIETY DISORD, V24, P1, DOI 10.1016/j.janxdis.2009.08.002; Backhaus J, 2004, PSYCHONEUROENDOCRINO, V29, P1184, DOI 10.1016/j.psyneuen.2004.01.010; Baddeley Jenna L, 2013, Am J Psychother, V67, P203; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Bailey SL, 2001, CHRONOBIOL INT, V18, P249, DOI 10.1081/CBI-100103189; Bajor LA, 2011, HARVARD REV PSYCHIAT, V19, P240, DOI 10.3109/10673229.2011.614483; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Belanger L, 2004, J ANXIETY DISORD, V18, P561, DOI 10.1016/S0887-6185(03)00031-8; Belleville G, 2011, J PSYCHOSOM RES, V70, P318, DOI 10.1016/j.jpsychores.2010.09.022; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bennion K.A., 2013, CEREBRAL CORTEX; Bertini M, 2004, SLEEP, V27, P875, DOI 10.1093/sleep/27.5.875; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bogdanova Y., 2014, ARCH PHYS MED REHAB, V95, pe77; Bogdanova Y, 2015, J HEAD TRAUMA REHAB, V30, pE101; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Boynton L, 2009, J PSYCHIATR PRACT, V15, P454, DOI 10.1097/01.pra.0000364287.63210.92; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Breslau N, 2004, ARCH GEN PSYCHIAT, V61, P508, DOI 10.1001/archpsyc.61.5.508; Brownlow JA, 2014, J TRAUMA STRESS, V27, P217, DOI 10.1002/jts.21906; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buchmann A, 2011, J SLEEP RES, V20, P506, DOI 10.1111/j.1365-2869.2011.00916.x; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Calhoun PS, 2007, J TRAUMA STRESS, V20, P1009, DOI 10.1002/jts.20255; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Casement MD, 2012, CLIN PSYCHOL REV, V32, P566, DOI 10.1016/j.cpr.2012.06.002; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chao LL, 2014, SLEEP, V37, P445, DOI 10.5665/sleep.3472; Chen MJ, 2006, BRAIN RES BULL, V68, P257, DOI 10.1016/j.brainresbull.2005.08.013; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Chou TC, 2003, J NEUROSCI, V23, P10691; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Clow A, 2004, STRESS, V7, P29, DOI 10.1080/10253890410001667205; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Cohen DJ, 2013, J SLEEP RES, V22, P76, DOI 10.1111/j.1365-2869.2012.01040.x; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Cook JM, 2010, J TRAUMA STRESS, V23, P553, DOI 10.1002/jts.20569; Dagan Y, 1999, CHRONOBIOL INT, V16, P213, DOI 10.3109/07420529909019087; Dagan Y, 1997, J PSYCHOSOM RES, V42, P577, DOI 10.1016/S0022-3999(97)00013-5; Davis Joanne L, 2006, J Trauma Dissociation, V7, P5, DOI 10.1300/J229v07n01_02; de Kloet CS, 2006, J PSYCHIATR RES, V40, P550, DOI 10.1016/j.jpsychires.2005.08.002; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Deppermann S, 2014, NEUROSCIENCE, V283, P166, DOI 10.1016/j.neuroscience.2014.08.037; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DOD (Department of Defense), 2009, DOD VA COD PROP FIN; Dombovy Mary L, 2011, Continuum (Minneap Minn), V17, P688, DOI 10.1212/01.CON.0000399095.90652.e7; Drake CL, 2003, DEPRESS ANXIETY, V18, P163, DOI 10.1002/da.10151; Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI 10.1016/J.CPR.2005.04.003; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Epstein DR, 2013, REHABIL NURS, V38, P120, DOI 10.1002/rnj.67; Epstein DR, 2012, J REHABIL RES DEV, V49, P867, DOI 10.1682/JRRD.2011.06.0114; Espie CA, 2012, SLEEP, V35, P769, DOI 10.5665/sleep.1872; Faestel PM, 2013, J CLIN SLEEP MED, V9, P577, DOI 10.5664/jcsm.2754; Faraguna U, 2008, J NEUROSCI, V28, P4088, DOI 10.1523/JNEUROSCI.5510-07.2008; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fries E, 2009, INT J PSYCHOPHYSIOL, V72, P67, DOI 10.1016/j.ijpsycho.2008.03.014; Galovski TE, 2009, J TRAUMA STRESS, V22, P197, DOI 10.1002/jts.20418; Galuszko-Wegielnik M, 2012, PSYCHIAT DANUB, V24, pS51; Gamaldo CE, 2012, NEUROL CLIN, V30, P1313, DOI 10.1016/j.ncl.2012.08.007; Gaus SE, 2002, NEUROSCIENCE, V115, P285, DOI 10.1016/S0306-4522(02)00308-1; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Gerhart JI, 2014, HEALTH PSYCHOL, V33, P365, DOI 10.1037/a0032572; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Germain A, 2006, ANN NY ACAD SCI, V1071, P438, DOI 10.1196/annals.1364.038; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Ghadami M.R., 2014, J INJURY VIOLENCE RE; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; Gong H, 2004, J PHYSIOL-LONDON, V556, P935, DOI 10.1113/jphysiol.2003.056622; Gourley SL, 2009, NEUROPSYCHOPHARMACOL, V34, P707, DOI 10.1038/npp.2008.123; Gujar N, 2011, J NEUROSCI, V31, P4466, DOI 10.1523/JNEUROSCI.3220-10.2011; Habukawa M, 2007, BIOL PSYCHIAT, V62, P1179, DOI 10.1016/j.biopsych.2007.01.007; Harb GC, 2013, J TRAUMA STRESS, V26, P570, DOI 10.1002/jts.21854; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hu P, 2006, PSYCHOL SCI, V17, P891, DOI 10.1111/j.1467-9280.2006.01799.x; Huber R, 2007, SLEEP, V30, P129, DOI 10.1093/sleep/30.2.129; Hucklebridge F, 2005, PSYCHONEUROENDOCRINO, V30, P51, DOI 10.1016/j.psyneuen.2004.04.007; Hughes KC, 2011, EXPERT REV NEUROTHER, V11, P275, DOI [10.1586/ern.10.198, 10.1586/ERN.10.198]; Institute of Medicine, 2011, COGN REH THER TRAUM; Jackson ML, 2014, ARCH WOMEN MENT HLTH, V17, P189, DOI 10.1007/s00737-014-0417-8; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kark S., 2013, J INT NEUROPSYCH SOC, V19; Karlin BE, 2013, J CONSULT CLIN PSYCH, V81, P912, DOI 10.1037/a0032554; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KELLNER R, 1992, AM J PSYCHIAT, V149, P659; Kellner R., 1991, ANN CLIN PSYCHIATRY, V3, P67, DOI [10.3109/10401239109147970, DOI 10.3109/10401239109147970]; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kerkhof GA, 2010, PROG BRAIN RES, V185, P49, DOI 10.1016/B978-0-444-53702-7.00004-X; Khawaja IS, 2014, PAK J MED SCI, V30, P438; Klein E, 2003, J SLEEP RES, V12, P35, DOI 10.1046/j.1365-2869.2003.00334.x; Kobayashi I, 2012, SLEEP, V35, P957, DOI 10.5665/sleep.1960; Kobayashi I, 2012, BEHAV SLEEP MED, V10, P180, DOI 10.1080/15402002.2011.654296; Koffel E, 2013, J ANXIETY DISORD, V27, P512, DOI 10.1016/j.janxdis.2013.07.003; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Krakow Barry, 2006, Behav Sleep Med, V4, P45, DOI 10.1207/s15402010bsm0401_4; Kramer TL, 2003, J TRAUMA STRESS, V16, P211, DOI 10.1023/A:1023783705062; Krystal AD, 2008, SLEEP, V31, P79, DOI 10.1093/sleep/31.1.79; Kudielka BM, 2006, BIOL PSYCHOL, V72, P141, DOI 10.1016/j.biopsycho.2005.08.003; Kudielka BM, 2007, BIOL PSYCHOL, V74, P92, DOI 10.1016/j.biopsycho.2006.08.008; Kumari M, 2009, J CLIN ENDOCR METAB, V94, P4801, DOI 10.1210/jc.2009-0555; Lancee J, 2012, BEHAV RES THER, V50, P22, DOI 10.1016/j.brat.2011.09.012; Lang KP, 2014, J HEAD TRAUMA REHAB, V29, P44, DOI 10.1097/HTR.0b013e31829c85d0; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Li Y, 2013, SLEEP MED, V14, P98, DOI 10.1016/j.sleep.2012.08.020; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lofaso F, 1996, CHEST, V109, P896, DOI 10.1378/chest.109.4.896; Long ME, 2011, J ANXIETY DISORD, V25, P531, DOI 10.1016/j.janxdis.2010.12.007; Lu J, 2000, J NEUROSCI, V20, P3830, DOI 10.1523/JNEUROSCI.20-10-03830.2000; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; Marshall KR, 2012, MIL MED, V177, P67, DOI 10.7205/MILMED-D-12-00110; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Matthews EE, 2013, SLEEP MED REV, V17, P453, DOI 10.1016/j.smrv.2013.01.001; McGinty D, 2004, ARCH ITAL BIOL, V142, P501; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Mellman TA, 2014, SLEEP, V37, P1321, DOI 10.5665/sleep.3922; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Milad MR, 2008, J PSYCHIATR RES, V42, P515, DOI 10.1016/j.jpsychires.2008.01.017; Mitchell MD, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-40; Sanchez-Ortuno MM, 2012, CURR PSYCHIAT REP, V14, P519, DOI 10.1007/s11920-012-0312-9; Moore BA, 2007, AM J PSYCHIAT, V164, P683, DOI 10.1176/appi.ajp.164.4.683; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morgenthaler TI, 2007, SLEEP, V30, P1705, DOI 10.1093/sleep/30.12.1705; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Nakamura Y, 2011, J PSYCHOSOM RES, V70, P335, DOI 10.1016/j.jpsychores.2010.09.007; Nappi CM, 2012, NEUROPHARMACOLOGY, V62, P576, DOI 10.1016/j.neuropharm.2011.02.029; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; NIELSEN T, 1992, J SLEEP RES, V1, P197, DOI 10.1111/j.1365-2869.1992.tb00038.x; Nishida M, 2009, CEREB CORTEX, V19, P1158, DOI 10.1093/cercor/bhn155; Ohayon Maurice M, 2007, Rev Prat, V57, P1521; Olff M, 2006, PSYCHONEUROENDOCRINO, V31, P1220, DOI 10.1016/j.psyneuen.2006.09.003; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Orr N., 2010, CHEST HON HAW; Orr SP, 2000, J ABNORM PSYCHOL, V109, P290, DOI 10.1037//0021-843X.109.2.290; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace-Schott EF, 2012, J PSYCHIATR RES, V46, P1036, DOI 10.1016/j.jpsychires.2012.04.015; Pace-Schott EF, 2009, SLEEP, V32, P19; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Payne JD, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00108; Payne JD, 2011, J COGNITIVE NEUROSCI, V23, P1285, DOI 10.1162/jocn.2010.21526; Peppard PE, 2006, ARCH INTERN MED, V166, P1709, DOI 10.1001/archinte.166.16.1709; Pervanidou P, 2010, PROG BRAIN RES, V182, P149, DOI 10.1016/S0079-6123(10)82005-9; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Pillar G, 2000, SLEEP MED REV, V4, P183, DOI 10.1053/smrv.1999.0095; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Pruessner JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Randler C, 2010, BIOL PSYCHOL, V85, P14, DOI 10.1016/j.biopsycho.2010.04.006; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2002, J CLIN PSYCHIAT, V63, P565, DOI 10.4088/JCP.v63n0705; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Raskind MA, 2013, AM J PSYCHIAT, V170, P1003, DOI 10.1176/appi.ajp.2013.12081133; Rasmusson AM, 2002, NEUROPSYCHOPHARMACOL, V27, P133, DOI 10.1016/S0893-133X(02)00286-5; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Richey SM, 2011, CURR PHARM DESIGN, V17, P1471; Rodenbeck A, 2002, NEUROSCI LETT, V324, P159, DOI 10.1016/S0304-3940(02)00192-1; Rosenberg Russell P, 2006, Ann Clin Psychiatry, V18, P49, DOI 10.1080/10401230500464711; ROSS RJ, 1995, BRAIN RES, V701, P129, DOI 10.1016/0006-8993(95)00984-X; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Saper CB, 2005, J COMP NEUROL, V493, P92, DOI 10.1002/cne.20770; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Schoenfeld FB, 2012, J REHABIL RES DEV, V49, P729, DOI 10.1682/JRRD.2011.09.0164; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; Sinclair KL, 2014, NEUROREHAB NEURAL RE, V28, P303, DOI 10.1177/1545968313508472; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stickgold R, 2005, SLEEP, V28, P1225, DOI 10.1093/sleep/28.10.1225; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Stickgold R, 2007, SLEEP MED, V8, P331, DOI 10.1016/j.sleep.2007.03.011; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Straus LD, 2015, J TRAUMA STRESS, V28, P8, DOI 10.1002/jts.21982; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suntsova N, 2002, J PHYSIOL-LONDON, V543, P665, DOI 10.1113/jphysiol.2002.023085; Swinkels CM, 2013, SLEEP, V36, P1019, DOI 10.5665/sleep.2800; Szklo-Coxe M, 2010, AM J EPIDEMIOL, V171, P709, DOI 10.1093/aje/kwp454; Szymusiak R, 1998, BRAIN RES, V803, P178, DOI 10.1016/S0006-8993(98)00631-3; Takahashi K, 2009, NEUROSCIENCE, V161, P269, DOI 10.1016/j.neuroscience.2009.02.075; Talbot LS, 2014, SLEEP, V37, P327, DOI 10.5665/sleep.3408; Taylor F, 2002, J CLIN PSYCHOPHARM, V22, P82, DOI 10.1097/00004714-200202000-00013; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; van Liempt S, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.19142; van Liempt S, 2013, PSYCHONEUROENDOCRINO, V38, P155, DOI 10.1016/j.psyneuen.2012.05.015; van Liempt S, 2011, PSYCHONEUROENDOCRINO, V36, P1361, DOI 10.1016/j.psyneuen.2011.03.009; Vandekerckhove M, 2010, SLEEP MED REV, V14, P219, DOI 10.1016/j.smrv.2010.01.002; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2013, SLEEP MED CLIN, V8, P309, DOI 10.1016/j.jsmc.2013.04.009; Vgontzas AN, 2001, J CLIN ENDOCR METAB, V86, P3787, DOI 10.1210/jc.86.8.3787; Vincent N, 2013, BEHAV RES THER, V51, P161, DOI 10.1016/j.brat.2012.12.003; Wagner U, 2001, LEARN MEMORY, V8, P112, DOI 10.1101/lm.36801; Wagner U, 2006, BIOL PSYCHIAT, V60, P788, DOI 10.1016/j.biopsych.2006.03.061; Wahbeh H, 2013, J TRAUMA STRESS, V26, P241, DOI 10.1002/jts.21798; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Westermeyer J, 2007, J ANXIETY DISORD, V21, P966, DOI 10.1016/j.janxdis.2006.11.009; Wilhelm I, 2007, PSYCHONEUROENDOCRINO, V32, P358, DOI 10.1016/j.psyneuen.2007.01.008; Williams JM, 2013, J GERONTOL B-PSYCHOL, V68, P712, DOI 10.1093/geronb/gbt030; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Wittmann L, 2007, PSYCHOTHER PSYCHOSOM, V76, P25, DOI 10.1159/000096362; Woodward SH, 1996, J TRAUMA STRESS, V9, P137, DOI 10.1007/BF02116839; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Woznica AA, 2014, SLEEP MED REV; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; Wust S, 2000, PSYCHONEUROENDOCRINO, V25, P707, DOI 10.1016/S0306-4530(00)00021-4; Xu C., 2002, PRACTICE J MED PHARM, V19, P407; Xu C., 2001, QIAN WEI J MED PHARM, V18, P337; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; Yoo SS, 2007, CURR BIOL, V17, pR877, DOI 10.1016/j.cub.2007.08.007; Zayfert C, 2004, J TRAUMA STRESS, V17, P69, DOI 10.1023/B:JOTS.0000014679.31799.e7; Zhang JH, 2011, SLEEP, V34, P225, DOI 10.1093/sleep/34.2.225; Zhao JX, 2012, J ATHL TRAINING, V47, P673, DOI 10.4085/1062-6050-47.6.08	282	61	63	1	47	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2015	40						195	212		10.1016/j.cpr.2015.05.008			18	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	CP9ZJ	WOS:000360254100015	26164549	Green Accepted			2022-02-06	
J	McMahon, PJ; Panczykowski, DM; Yue, JK; Puccio, AM; Inoue, T; Sorani, MD; Lingsma, HF; Maas, AIR; Valadka, AB; Yuh, EL; Mukherjee, P; Manley, GT; Okonkwo, DO; Casey, SS; Cheong, M; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Hricik, AJ; Lawless, K; Menon, D; Schnyer, DM; Vassar, MJ				McMahon, Paul J.; Panczykowski, David M.; Yue, John K.; Puccio, Ava M.; Inoue, Tomoo; Sorani, Marco D.; Lingsma, Hester F.; Maas, Andrew I. R.; Valadka, Alex B.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.; Okonkwo, David O.; Casey, Scott S.; Cheong, Maxwell; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Hricik, Allison J.; Lawless, Kerri; Menon, David; Schnyer, David M.; Vassar, Mary J.		TRACK-TBI Investigators Including	Measurement of the Glial Fibrillary Acidic Protein and Its Breakdown Products GFAP-BDP Biomarker for the Detection of Traumatic Brain Injury Compared to Computed Tomography and Magnetic Resonance Imaging	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; imaging; traumatic brain injury	COMMON DATA ELEMENTS; NEW-ORLEANS CRITERIA; MINOR HEAD-INJURY; NEUROSURGICAL INTERVENTION; TRANSFORMING RESEARCH; INTRACRANIAL LESIONS; CLINICAL KNOWLEDGE; DECISION-MAKING; SERUM; MILD	Glial fibrillary acidic protein and its breakdown products (GFAP-BDP) are brain-specific proteins released into serum as part of the pathophysiological response after traumatic brain injury (TBI). We performed a multi-center trial to validate and characterize the use of GFAP-BDP levels in the diagnosis of intracranial injury in a broad population of patients with a positive clinical screen for head injury. This multi-center, prospective, cohort study included patients 16-93 years of age presenting to three level 1 trauma centers with suspected TBI (loss of consciousness, post-trauma amnesia, and so on). Serum GFAP-BDP levels were drawn within 24 h and analyzed, in a blinded fashion, using sandwich enzyme-linked immunosorbent assay. The ability of GFAP-BDP to predict intracranial injury on admission computed tomography (CT) as well as delayed magnetic resonance imaging was analyzed by multiple regression and assessed by the area under the receiver operating characteristic curve (AUC). Utility of GFAP-BDP to predict injury and reduce unnecessary CT scans was assessed utilizing decision curve analysis. A total of 215 patients were included, of which 83% suffered mild TBI, 4% moderate, and 12% severe; mean age was 42.1 +/- 18 years. Evidence of intracranial injury was present in 51% of the sample (median Rotterdam Score, 2; interquartile range, 2). GFAP-BDP demonstrated very good predictive ability (AUC=0.87) and demonstrated significant discrimination of injury severity (odds ratio, 1.45; 95% confidence interval, 1.29-1.64). Use of GFAP-BDP yielded a net benefit above clinical screening alone and a net reduction in unnecessary scans by 12-30%. Used in conjunction with other clinical information, rapid measurement of GFAP-BDP is useful in establishing or excluding the diagnosis of radiographically apparent intracranial injury throughout the spectrum of TBI. As an adjunct to current screening practices, GFAP-BDP may help avoid unnecessary CT scans without sacrificing sensitivity (Registry: ClinicalTrials.gov Identifier: NCT01565551).	[McMahon, Paul J.; Panczykowski, David M.; Puccio, Ava M.; Okonkwo, David O.; Hricik, Allison J.; Lawless, Kerri] Univ Pittsburgh Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Yue, John K.; Inoue, Tomoo; Sorani, Marco D.; Manley, Geoffrey T.; Casey, Scott S.; Cooper, Shelly R.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yuh, Esther L.; Mukherjee, Pratik; Cheong, Maxwell] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Menon, David] Univ Cambridge, Devis Anesthesia, Cambridge, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA		Okonkwo, DO (corresponding author), Univ Pittsburgh Med Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Cooper, Shelly/0000-0003-0026-6688; Mukherjee, Pratik/0000-0001-7473-7409	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RC2 NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was funded by the National Institutes of Health (grant no.: 1RC2 NS069409).	Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hunink MGM, 2005, RADIOLOGY, V235, P375, DOI 10.1148/radiol.2352040727; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Lee YB, 2000, BRAIN RES, V864, P220, DOI 10.1016/S0006-8993(00)02180-6; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	23	61	63	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					527	533		10.1089/neu.2014.3635			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900002	25264814	Green Published			2022-02-06	
J	Yuruker, V; Naziroglu, M; Senol, N				Yuruker, Vehbi; Naziroglu, Mustafa; Senol, Nilgun			Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: Possible involvement of TRPM2 channels	METABOLIC BRAIN DISEASE			English	Article						Apoptosis; Calcium ion entry; TRPM2 channels; Melatonin; Traumatic brain injury; Oxidative stress	DORSAL-ROOT GANGLION; SPINAL-CORD-INJURY; MOLECULAR-MECHANISMS; EXOGENOUS MELATONIN; FUNCTIONAL RECOVERY; N-ACETYLCYSTEINE; CATION CHANNELS; ADP-RIBOSE; ACTIVATION; RECEPTOR	Melatonin, which is a very effective reactive oxygen species (ROS) scavenger, acts through a direct reaction with free radicals. Ca2+ entry induced by traumatic brain injury (TBI) has deleterious effects on human hippocampal function. TRPM2 is a Ca2+ permeable non-selective channel in hippocampal neurons, and its activation of during oxidative stress has been linked to cell death. Despite the importance of oxidative stress in TBI, its role in apoptosis and Ca2+ entry in TBI is poorly understood. Therefore, we tested the effects of melatonin on apoptosis, oxidative stress, and Ca2+ entry through the TRPM2 channel in the hippocampal neurons of TBI-induced rats. Thirty-two rats were divided into the following four groups: control, melatonin, TBI, and TBI + melatonin groups. Melatonin (5 mg/kg body weight) was intraperitoneally given to animals in the melatonin group and the TBI + melatonin group after 1 h of brain trauma. Hippocampal neurons were freshly isolated from the four groups, incubated with a nonspecific TRPM2 blocker (2-aminoethyl diphenylborinate, 2-APB), and then stimulated with cumene hydroperoxide. Apoptosis, caspase-3, caspase-9, intracellular ROS production, mitochondrial membrane depolarization and intracellular free Ca2+ ([Ca2+](i)) values were high in the TBI group, and low in the TBI + melatonin group. The [Ca2+](i) concentration was decreased in the four groups by 2-APB. In our TBI experimental model, TRPM2 channels were involved in Ca2+ entry-induced neuronal death, and the negative modulation of the activity of this channel by melatonin pretreatment may account for the neuroprotective activity of TRPM2 channels against oxidative stress, apoptosis, and Ca2+ entry.	[Yuruker, Vehbi; Senol, Nilgun] Suleyman Demirel Univ, Fac Med, Dept Neurosurg, TR-32260 Isparta, Turkey; [Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey		Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr			Scientific Research Project Unit of Suleyman Demirel UniversitySuleyman Demirel University [BAP-3265-TU-2-12]	The study was partially supported by Scientific Research Project Unit of Suleyman Demirel University (BAP-3265-TU-2-12). The authors wish thanks to Technician Fatih Sahin (Neuroscience Research Center, Suleyman Demirel University) for excellent performance on the analyses of current study. Abstract of the study will be submitted in 5th International Congress on Cell Membranes and Oxidative Stress: Focus on Calcium Signaling and TRP Channels, 9-12 September 2014, Isparta Turkey. (http://www.cmos.org.tr/2014/).	Akpinar A, 2014, J MEMBRANE BIOL, V247, P451, DOI 10.1007/s00232-014-9652-1; Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50; Belrose JC, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-11; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Carrasco C, 2013, CELL BIOCHEM FUNCT, V31, P585, DOI 10.1002/cbf.2942; Celik O, 2012, PHYSIOL BEHAV, V107, P458, DOI 10.1016/j.physbeh.2012.09.013; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Dilek M, 2010, J MEMBRANE BIOL, V233, P135, DOI 10.1007/s00232-010-9233-x; Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002; Ersahin M, 2012, J PINEAL RES, V52, P340, DOI 10.1111/j.1600-079X.2011.00948.x; Espino J, 2013, J PINEAL RES, V54, P442, DOI 10.1111/jpi.12042; Espino J, 2011, J PINEAL RES, V51, P195, DOI 10.1111/j.1600-079X.2011.00876.x; Espino J, 2011, AGE, V33, P497, DOI 10.1007/s11357-010-9194-0; Espino J, 2010, J MEMBRANE BIOL, V233, P105, DOI 10.1007/s00232-010-9230-0; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Ghazizadeh V, 2014, METAB BRAIN DIS; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Iuvone PM, 2014, ADV EXP MED BIOL, V801, P765, DOI 10.1007/978-1-4614-3209-8_96; Maharaj DS, 2006, J NEUROCHEM, V96, P78, DOI 10.1111/j.1471-4159.2005.03532.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Naziroglu M, 2014, NEUROSCIENCE, V263, P27, DOI 10.1016/j.neuroscience.2014.01.006; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2008, NEUROCHEM RES, V33, P1256, DOI 10.1007/s11064-007-9577-5; Naziroglu M, 2008, J NEUROL SCI, V270, P152, DOI 10.1016/j.jns.2008.03.003; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2007, CELL BIOCHEM FUNCT, V25, P383, DOI 10.1002/cbf.1310; Naziroglu M, 2013, MUSCLE NERVE, V48, P945, DOI 10.1002/mus.23844; Naziroglu M, 2012, J RECEPT SIG TRANSD, V32, P290, DOI 10.3109/10799893.2012.737002; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Paredes DS, 2010, CELL MEMBR FREE RADI, V2, P99; Paredes SD, 2007, MOL CELL BIOCHEM, V304, P305, DOI 10.1007/s11010-007-9513-7; Park K, 2010, J PINEAL RES, V48, P270, DOI 10.1111/j.1600-079X.2010.00751.x; Park S, 2012, J PINEAL RES, V52, P107, DOI 10.1111/j.1600-079X.2011.00925.x; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Schafer M.K.E., 2014, CELL TISSUE RES; Senol N, 2014, NEURAL REGEN RES, V9, P1112, DOI 10.4103/1673-5374.135312; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x; Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5; VITTE PA, 1988, J PINEAL RES, V5, P437, DOI 10.1111/j.1600-079X.1988.tb00787.x	49	61	64	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	FEB	2015	30	1					223	231		10.1007/s11011-014-9623-3			9	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	AZ2GS	WOS:000348053100027	25339252				2022-02-06	
J	Dams-O'Connor, K; Cantor, JB; Brown, M; Dijkers, MP; Spielman, LA; Gordon, WA				Dams-O'Connor, Kristen; Cantor, Joshua B.; Brown, Margaret; Dijkers, Marcel P.; Spielman, Lisa A.; Gordon, Wayne A.			Screening for Traumatic Brain Injury: Findings and Public Health Implications	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						prevention; public health; screening; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; UNITED-STATES; ALZHEIMERS-DISEASE; LONG-TERM; RECURRENT CONCUSSION; SUBSTANCE-ABUSE; CO-MORBIDITY; OLDER-ADULTS; MILD; INDIVIDUALS	Objective: To provide an overview of a series of projects that used a structured self-report screening tool in diverse settings and samples to screen for lifetime history of traumatic brain injury (TBI). Setting: Diverse community settings. Participants: Homeless persons (n = 111), individuals with HIV seeking vocational rehabilitation (n = 173), youth in the juvenile justice system (n = 271), public schoolchildren (n = 174), substance users (n = 845), intercollegiate athletes (n = 90), and other community-based samples (n = 396). Design: Cross-sectional. Main Measure: Brain Injury Screening Questionnaire. Results: Screening using the Brain Injury Screening Questionnaire finds that 27% to 54% of those in high-risk populations report a history of TBI with chronic symptoms. Associations between TBI and social, academic, or other problems are evident in several studies. In non-high-risk community samples, 9% to 12% of individuals report TBI with chronic symptoms. Conclusion: Systematic TBI screening can be implemented efficiently and inexpensively in a variety of settings. Lifetime TBI history data gathered using a structured self-report instrument can augment existing estimates of the prevalence of TBI, both as an acute event and as a chronic condition. Identification of individuals with TBI can facilitate primary prevention efforts, such as reducing risk for reinjury in high-risk groups, and provide access to appropriate interventions that can reduce the personal and societal costs of TBI (tertiary prevention).	[Dams-O'Connor, Kristen; Cantor, Joshua B.; Dijkers, Marcel P.; Spielman, Lisa A.; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Brown, Margaret] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA		Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 5 East 98th St,Box 1163, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	Meijer, Anna/K-5118-2016		Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grant No. 1R49CE001171 from the Centers for Disease Control and Prevention to Icahn School of Medicine at Mount Sinai, New York City. The Brain Injury Screening Questionnaire discussed in this article as a tool for screening for traumatic brain injury is sometimes sold to agencies/organizations that want to screen people for brain injury. The proceeds of such sales benefit the Brain Injury Research Center of Mount Sinai, with which all authors are associated.	Agrigoroaei S, 2011, J GERONTOL B-PSYCHOL, V66, P130, DOI 10.1093/geronb/gbr017; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Ashman TA, 2006, MT SINAI J MED, V73, P999; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Betz ME, 2008, J AM GERIATR SOC, V56, P2267, DOI 10.1111/j.1532-5415.2008.02001.x; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Brasfield K, 2010, NCAA MEMORANDUM LEGI; Breed S, 2008, J HEAD TRAUMA REHAB, V23, P149, DOI 10.1097/01.HTR.0000319931.76966.ff; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cantor JB, 2006, J HEAD TRAUMA REHAB, V21, P424, DOI 10.1097/00001199-200609000-00039; Cantu RC, 2013, JAMA NEUROL, V70, P1481, DOI 10.1001/jamaneurol.2013.3231; Centers for Disease Control and Prevention, 2010, WHAT AR SIGNS SYMPT; Centers for Disease Control and Prevention, 2013, TRAUMATIC BRAIN INJU; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Garrison A, 2003, JAMA-J AM MED ASSOC, V290, P1217, DOI 10.1001/jama.290.9.1217; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goldin-Lauretta Y, 2011, ARCH PHYS MED REHAB, V92, P1692; Gordon W. A., 2013, STATE OF THE STATES; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Hibbard M. R., 2005, COGNITIVE BEHAV THER, P189; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoff Clarissa J B, 2010, J La State Med Soc, V162, P352; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Institute of Medicine of the National Academies, 2009, GULF WAR HLTH, V7, P1; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Jaffe MP, 2000, BRAIN INJURY, V14, P35, DOI 10.1080/026990500120916; Jha A, 2001, INT J GERIATR PSYCH, V16, P879, DOI 10.1002/gps.412; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kaba F, J ADOLESC HLTH, V54, P615; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mitchell TN, 2012, ARCH PHYS MED REHAB, V93, pe27; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; Picard M, 1991, INT CTR DISABLED; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Rehabilitation and Neuropsychological Service Department of Physical Medicine and Rehabilitation Medical College of Virginia, TBI SYMPT CHECKL; Resnik DB, 2001, HEALTH POLICY, V55, P129, DOI 10.1016/S0168-8510(00)00121-4; Russell LM, 2013, AM J PUBLIC HEALTH, V103, pS211, DOI 10.2105/AJPH.2013.301485; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shumway-Cook A, 2009, PHYS THER, V89, P324, DOI 10.2522/ptj.20070107; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Sosin DM, 1996, BRAIN INJURY, V10, P47; Surbone A, 2000, ANN NY ACAD SCI, V913, P52; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Vanderploeg RD, 2013, J HEAD TRAUMA REHAB, V28, P211, DOI 10.1097/HTR.0b013e31828b50db; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Wellington R, 2011, 3 FED INT C TRAUM BR; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yi A, 2013, NEUROREHABILITATION, V32, P267, DOI 10.3233/NRE-130843; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P655; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	105	61	61	1	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					479	489		10.1097/HTR.0000000000000099			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800008	25370440	Green Accepted			2022-02-06	
J	Moen, KG; Brezova, V; Skandsen, T; Haberg, AK; Folvik, M; Vik, A				Moen, Kent G.; Brezova, Veronika; Skandsen, Toril; Haberg, Asta K.; Folvik, Mari; Vik, Anne			Traumatic Axonal Injury: The Prognostic Value of Lesion Load in Corpus Callosum, Brain Stem, and Thalamus in Different Magnetic Resonance Imaging Sequences	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; brain stem; corpus callosum; diffuse axonal injury; Glasgow Outcome Scale; prospective studies	SEVERE HEAD-INJURY; OUTCOME PREDICTION; MRI FINDINGS; DIAGNOSIS; MODERATE; SEVERITY; SCALE	The aim of this study was to explore the prognostic value of visible traumatic axonal injury (TAI) loads in different MRI sequences from the early phase after adjusting for established prognostic factors. Likewise, we sought to explore the prognostic role of early apparent diffusion coefficient (ADC) values in normal-appearing corpus callosum. In this prospective study, 128 patients (mean age, 33.9 years; range, 11-69) with moderate (n = 64) and severe traumatic brain injury (TBI) were examined with MRI at a median of 8 days (range, 0-28) postinjury. TAI lesions in fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), and T2*-weighted gradient echo (T2*GRE) sequences were counted and FLAIR lesion volumes estimated. In patients and 47 healthy controls, mean ADC values were computed in 10 regions of interests in the normal-appearing corpus callosum. Outcome measure was the Glasgow Outcome Scale-Extended (GOS-E) at 12 months. In patients with severe TBI, number of DWI lesions and volume of FLAIR lesions in the corpus callosum, brain stem, and thalamus predicted outcome in analyses with adjustment for age, Glasgow Coma Scale score, and pupillary dilation (odds ratio, 1.3-6.9; p = <0.001-0.017). The addition of Rotterdam CT score and DWI lesions in the corpus callosum yielded the highest R-2 (0.24), compared to all other MRI variables, including brain stem lesions. For patients with moderate TBI only the number of cortical contusions (p = 0.089) and Rotterdam CT score (p = 0.065) tended to predict outcome. Numbers of T2*GRE lesions did not affect outcome. Mean ADC values in the normal-appearing corpus callosum did not differ from controls. In conclusion, the loads of visible TAI lesions in the corpus callosum, brain stem, and thalamus in DWI and FLAIR were independent prognostic factors in patients with severe TBI. DWI lesions in the corpus callosum were the most important predictive MRI variable. Interestingly, number of cortical contusions in MRI and CT findings seemed more important for patients with moderate TBI.	[Moen, Kent G.; Brezova, Veronika; Skandsen, Toril; Haberg, Asta K.; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, N-7491 Trondheim, Norway; [Moen, Kent G.; Vik, Anne] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; [Brezova, Veronika; Haberg, Asta K.; Folvik, Mari] St Olavs Univ Hosp, Dept Med Imaging, Trondheim, Norway; [Skandsen, Toril] St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway		Moen, KG (corresponding author), Norwegian Univ Sci & Technol, Dept Neurosci, Postboks 8905, N-7491 Trondheim, Norway.	kent.g.moen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Liaison Committee; National Resource Center for fMRI, Department of Medical Imaging, St. Olav University Hospital	Kent Goran Moen (K. G. M.) and Toril Skandsen (T. S.) have, during the study period, received a research grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. Veronika Brezova (V. B.) has, during the study period, received a research grant from the National Resource Center for fMRI, Department of Medical Imaging, St. Olav University Hospital. The authors thank Kjell Arne Kvistad (K. A. K.) and Jana Rydland (J.R.) for their help in MRI analyses, Ingrid Haavde Strand (I. H. S.) for her help in computing the Rotterdam CT score, and Stine Borgen Lund, Otto Aarhaug, and Beate Holmqvist Karlsen for their management of the patient database and performing the GOS-E interviews.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Fleiss JL, 1986, RELIABILITY MEASUREM, DOI DOI 10.1002/9781118032923; Gasparetto EL, 2011, NEUROIMAG CLIN N AM, V21, P115, DOI 10.1016/j.nic.2011.02.003; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lovstad M., 2014, J HEAD TRAUMA R 0109; Matsusue Eiji, 2006, Magn Reson Med Sci, V5, P99, DOI 10.2463/mrms.5.99; Moen KG, 2014, J NEUROTRAUM, V31, P56, DOI 10.1089/neu.2013.3000; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	39	61	65	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1486	1496		10.1089/neu.2013.3258			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700003	24773587				2022-02-06	
J	Zhou, NN; Tang, Y; Keep, RF; Ma, XX; Xiang, JM				Zhou, Ningna; Tang, Yang; Keep, Richard F.; Ma, Xiaoxia; Xiang, Jianming			Antioxidative effects of Panax notoginseng saponins in brain cells	PHYTOMEDICINE			English	Article						Oxidative stress; Total saponins of Panax notoginseng leaves; Astrocytes; SH-SY5Y cells	OXIDATIVE STRESS; GLUCOSE DEPRIVATION; INDUCED APOPTOSIS; IN-VITRO; INJURY; OXYGEN; ASTROCYTES; MEMBRANE; MODULATION; ISCHEMIA	Oxidative stress resulting from accumulation of reactive oxygen species (ROS) is involved in cell death associated with neurological disorders such as stroke, Alzheimer's disease and traumatic brain injury. Antioxidant compounds that improve endogenous antioxidant defenses have been proposed for neural protection. The purpose of this study was to investigate the potential protective effects of total saponin in leaves of Panax notoginseng (LPNS) on oxidative stress and cell death in brain cells in vitro. Lactate dehydrogenase (LDH) assay indicated that LPNS (5 mu g/ml) reduced H2O2-induced cell death in primary rat cortical astrocytes (23 +/- 8% reduction in LDH release vs. control). Similar protection was found in oxygen and glucose deprivation/reoxygenation induced SH-SY5Y (a human neuroblastoma cell line) cell damage (78 +/- 7% reduction vs. control). The protective effects of LPNS in astrocytes were associated with attenuation of reactive oxygen species (ROS) accumulation. These effects involved activation of Nrf2 (nuclear translocation) and upregulation of downstream antioxidant systems including heme oxygenase-1 (HO-1) and glutathione S-transferase pi 1 (GSTP1). These results demonstrate for the first time that LPNS has antioxidative effects which may be neuroprotective in neurological disorders. (C) 2014 Elsevier GmbH. All rights reserved.	[Zhou, Ningna; Tang, Yang; Keep, Richard F.; Xiang, Jianming] Univ Michigan, Dept Neurosurg, Sch Med, Ann Arbor, MI 48109 USA; [Zhou, Ningna] Yunnan Univ Tradit Chinese Med, Dept Pharmacol, Kunming, Peoples R China; [Keep, Richard F.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Ma, Xiaoxia] Yunnan Univ Tradit Chinese Med, Dept Chinese Med, Kunming, Peoples R China		Xiang, JM (corresponding author), Univ Michigan, Dept Neurosurg, 5014 BSRB, Ann Arbor, MI 48109 USA.	jmxxdrnx@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-034709]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81260649]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034709] Funding Source: NIH RePORTER	This study was supported by a grant, NS-034709 (RFK), from the National Institutes of Health (NIH) and 81260649, from the National Natural Science Foundation of China. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and National Natural Science Foundation of China.	Bienert GP, 2006, BBA-BIOMEMBRANES, V1758, P994, DOI 10.1016/j.bbamem.2006.02.015; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chan P, 2002, ACTA PHARMACOL SIN, V23, P1157; Chen SX, 2011, J ETHNOPHARMACOL, V137, P263, DOI 10.1016/j.jep.2011.05.011; Chen X, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006305.pub2; Choi Roy Chi-Yan, 2010, Chin Med, V5, P38, DOI 10.1186/1749-8546-5-38; COCHRANE CG, 1991, AM J MED, V91, pS23, DOI 10.1016/0002-9343(91)90280-B; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Fu Jian-hua, 2006, Zhongguo Zhong Yao Za Zhi, V31, P62; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x; Gyulkhandanyan AV, 2003, J NEUROCHEM, V87, P448, DOI 10.1046/j.1471-4159.2003.02029.x; Hamdi Y, 2011, J NEUROCHEM, V118, P416, DOI 10.1111/j.1471-4159.2011.07315.x; He L, 2011, PHYTOMEDICINE, V18, P437, DOI 10.1016/j.phymed.2010.10.004; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022; Kedar N P, 2003, J Postgrad Med, V49, P236; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; LEI XL, 1986, AM J CHINESE MED, V14, P145, DOI 10.1142/S0192415X86000235; Lotharius J, 2005, J NEUROSCI, V25, P6329, DOI 10.1523/JNEUROSCI.1746-05.2005; Mathers J, 2004, BIOCHEM SOC SYMP, V71, P157, DOI 10.1042/bss0710157; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Ng TB, 2006, J PHARM PHARMACOL, V58, P1007, DOI 10.1211/jpp.58.8.0001; Papadopoulos MC, 1998, NEUROSCIENCE, V82, P915; Park JS, 2011, J NEUROCHEM, V119, P909, DOI 10.1111/j.1471-4159.2011.07395.x; Pedroso N, 2009, FREE RADICAL BIO MED, V46, P289, DOI 10.1016/j.freeradbiomed.2008.10.039; Peuchen S, 1997, PROG NEUROBIOL, V52, P261, DOI 10.1016/S0301-0082(97)00010-5; Resende R, 2008, FREE RADICAL BIO MED, V44, P2051, DOI 10.1016/j.freeradbiomed.2008.03.012; Sabirzhanova IB, 2009, BIOCHEM BIOPH RES CO, V389, P338, DOI 10.1016/j.bbrc.2009.08.146; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Shen LH, 2008, GLIA, V56, P1747, DOI 10.1002/glia.20722; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Thimmulappa RK, 2002, CANCER RES, V62, P5196; de Almeida LMV, 2008, ARCH BIOCHEM BIOPHYS, V480, P27, DOI 10.1016/j.abb.2008.09.006; Wagner H., 2011, CHROMATOGRAPHIC FING, P843; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; WINTERBOURN CC, 1981, BIOCHEM J, V198, P125, DOI 10.1042/bj1980125; Xiang H, 2011, PHYTOMEDICINE, V18, P731, DOI 10.1016/j.phymed.2010.11.014; Yao Xiao-hao, 2002, Zhongguo Zhongyao Zazhi, V27, P371; Yoo MS, 2003, MOL BRAIN RES, V110, P76, DOI 10.1016/S0169-328X(02)00586-7; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507; Zhu JR, 2010, ACTA PHARMACOL SIN, V31, P273, DOI 10.1038/aps.2010.9	48	61	71	2	59	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0944-7113	1618-095X		PHYTOMEDICINE	Phytomedicine	SEP	2014	21	10					1189	1195		10.1016/j.phymed.2014.05.004			7	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	AN1IT	WOS:000340336700008	24916704	Green Accepted			2022-02-06	
J	Jayakumar, AR; Tong, XY; Ruiz-Cordero, R; Bregy, A; Bethea, JR; Bramlett, HM; Norenberg, MD				Jayakumar, Arumugam R.; Tong, Xiao Y.; Ruiz-Cordero, Roberto; Bregy, Amade; Bethea, John R.; Bramlett, Helen M.; Norenberg, Michael D.			Activation of NF-kappa B Mediates Astrocyte Swelling and Brain Edema in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte swelling; NF-kappa B; traumatic brain injury; transgenic mice	K-CL COTRANSPORTER-1; CULTURED ASTROCYTES; NADPH OXIDASE; OXIDATIVE STRESS; HEPATIC-ENCEPHALOPATHY; IN-VITRO; MECHANISM; CELLS; INFLAMMATION; DISCOVERIES	Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury (TBI). While astrocyte swelling (cytotoxic edema) represents a major component of the brain edema in the early phase of TBI, its mechanisms are unclear. One factor known to be activated by trauma is nuclear factor-kappa B (NF-kappa B). Because this factor has been implicated in the mechanism of cell swelling/brain edema in other neurological conditions, we examined whether NF-kappa B might also be involved in the mediation of post-traumatic astrocyte swelling/brain edema. Here we show an increase in NF-kappa B activation in cultured astrocytes at 1 and 3 h after trauma (fluid percussion injury, FPI), and that BAY 11-7082, an inhibitor of NF-kappa B, significantly blocked the trauma-induced astrocyte swelling. Increased activities of nicotinamide adenine dinucleotide phosphate-oxidase and the Na+, K+, 2Cl(-) cotransporter were also observed in cultured astrocytes after trauma, and BAY 11-7082 reduced these effects. We also examined the role of NF-kappa B in the mechanism of cell swelling by using astrocyte cultures derived from transgenic (Tg) mice with a functional inactivation of astrocytic NF-kappa B. Exposure of cultured astrocytes from wild-type mice to in vitro trauma (3 h) caused a significant increase in cell swelling. By contrast, traumatized astrocyte cultures derived from NF-kappa B Tg mice showed no swelling. We also found increased astrocytic NF-kappa B activation and brain water content in rats after FPI, while BAY 11-7082 significantly reduced such effects. Our findings strongly suggest that activation of astrocytic NF-kappa B represents a key element in the process by which cytotoxic brain edema occurs after TBI.	[Jayakumar, Arumugam R.; Tong, Xiao Y.; Ruiz-Cordero, Roberto; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Bramlett, Helen M.] Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA; [Bregy, Amade; Bethea, John R.; Bramlett, Helen M.] Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu	Ruiz-Cordero, Roberto/AAT-4051-2020	Ruiz-Cordero, Roberto/0000-0002-9747-6069	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. The authors thank Alina Fernandez-Revuelta for the preparation of cell cultures, and Gabriel Gaidosh for assistance with fluorescence imaging.	Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Camandola S, 2007, EXPERT OPIN THER TAR, V11, P123, DOI 10.1517/14728222.11.2.123; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58; Jayakumar AR, 2012, NEUROSCIENCE, V218, P305, DOI 10.1016/j.neuroscience.2012.05.006; Jayakumar AR, 2012, CURR SIGNAL TRANSD T, V7, P35, DOI 10.2174/157436212799278197; Jayakumar AR, 2011, NEUROBIOL DIS, V41, P498, DOI 10.1016/j.nbd.2010.10.021; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2014, J NEUROCHEM, V128, P890, DOI 10.1111/jnc.12516; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jayakumar AR, 2009, J NEUROCHEM, V109, P252, DOI 10.1111/j.1471-4159.2009.05842.x; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Luengo-Blanco M, 2008, BLOOD, V112, P1453, DOI 10.1182/blood-2007-07-099267; Manea A., 2007, Archives of Physiology and Biochemistry, V113, P163, DOI 10.1080/13813450701531235; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; Rick FG, 2013, P NATL ACAD SCI USA, V110, P2617, DOI 10.1073/pnas.1222355110; Sathish V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023662; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; Sirabella R, 2009, STROKE, V40, P922, DOI 10.1161/STROKEAHA.108.531962; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939, DOI 10.1152/jn.1999.81.4.1939; Valsecchi V, 2013, ADV EXP MED BIOL, V961, P137, DOI 10.1007/978-1-4614-4756-6_12; Yu Y, 2009, CIRCULATION, V119, P2313, DOI 10.1161/CIRCULATIONAHA.108.782458	44	61	64	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1249	1257		10.1089/neu.2013.3169			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000002	24471369	Green Published			2022-02-06	
J	Zatzick, D; Russo, J; Lord, SP; Varley, C; Wang, J; Berliner, L; Jurkovich, G; Whiteside, LK; O'Connor, S; Rivara, FP				Zatzick, Douglas; Russo, Joan; Lord, Sarah Peregrine; Varley, Christopher; Wang, Jin; Berliner, Lucy; Jurkovich, Gregory; Whiteside, Lauren K.; O'Connor, Stephen; Rivara, Frederick P.			Collaborative Care Intervention Targeting Violence Risk Behaviors, Substance Use, and Posttraumatic Stress and Depressive Symptoms in Injured Adolescents A Randomized Clinical Trial	JAMA PEDIATRICS			English	Article							TRAUMA-CENTER; EMERGENCY-DEPARTMENTS; ANXIETY DISORDERS; ALCOHOL MISUSE; ASSOCIATION; CHILDREN; HEALTH; IMPACT; PREVALENCE; OUTCOMES	IMPORTANCE Violence and injury risk behaviors, alcohol and drug use problems, and posttraumatic stress disorder (PTSD) and depressive symptoms occur frequently among adolescents presenting to acute care medical settings after traumatic physical injury. OBJECTIVE To test the effectiveness of a stepped collaborative care intervention targeting this constellation of risk behaviors and symptoms in randomly sampled hospitalized adolescents with and without traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS A pragmatic randomized clinical trial was conducted at a single US level I trauma center. Participants included 120 adolescents aged 12 to 18 years randomized to intervention (n = 59) and control (n = 61) conditions. INTERVENTIONS Stepped collaborative care intervention included motivational interviewing elements targeting risk behaviors and substance use as well as medication and cognitive behavioral therapy elements targeting PTSD and depressive symptoms. MAIN OUTCOMES AND MEASURES Adolescents were assessed at baseline before randomization and 2, 5, and 12 months after injury hospitalization. Standardized instruments were used to assess violence risk behaviors, alcohol and drug use, and PTSD and depressive symptoms. RESULTS The investigation attained more than 95% adolescent follow-up at each assessment point. At baseline, approximately one-third of the participants endorsed the violence risk behavior of carrying a weapon. Regression analyses demonstrated that intervention patients experienced significant reductions in weapon carrying compared with controls during the year after injury (group x time effect, F-3,F-344 = 3.0; P =.03). At 12 months after the injury, 4 (7.3%) intervention patients vs 13 (21.3%) control patients reported currently carrying a weapon (relative risk, 0.31; 95% CI, 0.11-0.90). The intervention was equally effective in reducing the risk of weapon carrying among injured adolescents with and without traumatic brain injury. Other treatment targets, including alcohol and drug use problems and high levels of PTSD and depressive symptoms, occurred less frequently in the cohort relative to weapon carrying and were not significantly affected by the intervention. CONCLUSIONS AND RELEVANCE Collaborative care intervention reduced the risk of adolescent weapon carrying during the year after the injury hospitalization. Future investigation should replicate this preliminary observation. If the finding is replicated, orchestrated investigative and policy efforts could systematically implement and evaluate screening and intervention procedures targeting youth violence prevention at US trauma centers.	[Zatzick, Douglas; Wang, Jin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Russo, Joan; Lord, Sarah Peregrine; Varley, Christopher; O'Connor, Stephen] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Berliner, Lucy] Univ Washington, Sch Med, Harborview Ctr Sexual Assault & Traumat Stress, Seattle, WA USA; [Jurkovich, Gregory] Denver Hlth Med Ctr, Trauma & Surg Serv, Denver, CO USA; [Whiteside, Lauren K.] Univ Washington, Sch Med, Div Emergency Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		Zatzick, D (corresponding author), Harborview Injury Prevent & Res Ctr, Dept Psychiat & Behav Sci, 325 Ninth Ave,POB 359960, Seattle, WA 98104 USA.	dzatzick@u.washington.edu		Whiteside, Lauren/0000-0002-0284-5336	Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [H34/MC08508-01-00]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24/MH086814]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH086814] Funding Source: NIH RePORTER	This work was supported by the Health Resources and Services Administration grant H34/MC08508-01-00 and the National Institute of Mental Health grant K24/MH086814 (Dr Zatzick).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; *AM COLL SURG COMM, 2006, RES OPT CAR INJ PAT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bogenschutz MP, 2011, AM J DRUG ALCOHOL AB, V37, P417, DOI 10.3109/00952990.2011.596971; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Cook PJ, 1999, JAMA-J AM MED ASSOC, V282, P447, DOI 10.1001/jama.282.5.447; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; Curran GM, 2012, MED CARE, V50, P217, DOI 10.1097/MLR.0b013e3182408812; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Dunn Chris, 2003, Semin Clin Neuropsychiatry, V8, P188, DOI 10.1016/S1084-3612(03)00025-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Glasgow RE, 2012, AM J PUBLIC HEALTH, V102, P1274, DOI 10.2105/AJPH.2012.300755; Holbrook TL, 2005, J TRAUMA, V59, P1126, DOI 10.1097/01.ta.0000196433.61423.f2; Huemer J, 2010, CHILD PSYCHIAT HUM D, V41, P624, DOI 10.1007/s10578-010-0192-3; Institute of Medicine Board on Health Care Services; Committee on the Future of Emergency Care in the United States Health System, 2006, EM CAR CHILDR GROW P; Johns Hopkins Health Services Research and Development Center, 1989, DET INJ SEV HOS DISC; Kassam-Adams N, 2011, J TRAUMA STRESS, V24, P252, DOI 10.1002/jts.20640; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Kearns MC, 2012, DEPRESS ANXIETY, V29, P833, DOI 10.1002/da.21997; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koepsell TD, 2011, AM J PREV MED, V40, P191, DOI 10.1016/j.amepre.2010.10.022; Kolko DJ, 2012, ARCH PEDIAT ADOL MED, V166, P224, DOI 10.1001/archpediatrics.2011.201; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mahajan P, 2009, PEDIATR EMERG CARE, V25, P715, DOI 10.1097/PEC.0b013e3181bec82f; McCaig Linda F, 2006, Adv Data, P1; Miller TR, 1994, MMWR-MORBID MORTAL W, V43, P581; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; MURRAY CJ, 1996, GLOB BURD DIS COMPR; National Center for Injury Prevention and Control, 2006, CDC INJ FACT BOOK; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; Pickett W, 2005, PEDIATRICS, V116, pE855, DOI 10.1542/peds.2005-0607; Ranney ML, 2012, ANN EMERG MED, V60, P218, DOI 10.1016/j.annemergmed.2012.02.026; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Richardson L, 2009, GEN HOSP PSYCHIAT, V31, P36, DOI 10.1016/j.genhosppsych.2008.09.019; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Roy-Byrne P, 2010, JAMA-J AM MED ASSOC, V303, P1921, DOI 10.1001/jama.2010.608; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shafii T, 2007, AM J PUBLIC HEALTH, V97, P1090, DOI 10.2105/AJPH.2005.068437; Steinberg AM, 2013, J TRAUMA STRESS, V26, P1, DOI 10.1002/jts.21780; Strawn JR, 2010, J CLIN PSYCHIAT, V71, P932, DOI 10.4088/JCP.09r05446blu; TEASDALE G, 1974, LANCET, V2, P81; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1016/j.jclinepi.2008.12.011, 10.1503/cmaj.090523]; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trusz SG, 2011, PSYCHIATRY, V74, P207, DOI 10.1521/psyc.2011.74.3.207; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Villaveces A, 2000, JAMA-J AM MED ASSOC, V283, P1205, DOI 10.1001/jama.283.9.1205; Wagner Amy W, 2003, Semin Clin Neuropsychiatry, V8, P175, DOI 10.1016/S1084-3612(03)00018-2; Walton MA, 2010, JAMA-J AM MED ASSOC, V304, P527, DOI 10.1001/jama.2010.1066; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Winston FK, 2003, JAMA-J AM MED ASSOC, V290, P643, DOI 10.1001/jama.290.5.643; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2001, MED CARE, V39, P327, DOI 10.1097/00005650-200104000-00004; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P168, DOI 10.1016/S1084-3612(03)00015-7; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zatzick D, 2012, J SUBST ABUSE TREAT, V43, P410, DOI 10.1016/j.jsat.2012.08.009; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	68	61	61	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUN	2014	168	6					532	539		10.1001/jamapediatrics.2013.4784			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	AI4MZ	WOS:000336840800011	24733515	Bronze			2022-02-06	
J	Minassian, A; Geyer, MA; Baker, DG; Nievergelt, CM; O'Connor, DT; Risbrough, VB				Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; O'Connor, Daniel T.; Risbrough, Victoria B.		Marine Resiliency Study Team	Heart Rate Variability Characteristics in a Large Group of Active-Duty Marines and Relationship to Posttraumatic Stress	PSYCHOSOMATIC MEDICINE			English	Article						sympathetic nervous system; PTSD; vagal tone; combat; depression; parasympathetic	TRAUMATIC BRAIN-INJURY; CARDIAC VAGAL TONE; PREPULSE INHIBITION; AFGHANISTAN; DISORDER; IRAQ; REST; PHOTOPLETHYSMOGRAPHY; SCHIZOPHRENIA; METAANALYSIS	Objective Heart rate variability (HRV), thought to reflect autonomic nervous system function, is lowered under conditions such as posttraumatic stress disorder (PTSD). The potential confounding effects of traumatic brain injury (TBI) and depression in the relationship between HRV and PTSD have not been elucidated in a large cohort of military service members. Here we describe HRV associations with stress disorder symptoms in a large study of Marines while accounting for well-known covariates of HRV and PTSD including TBI and depression. Methods Four battalions of male active-duty Marines (n = 2430) were assessed 1 to 2 months before a combat deployment. HRV was measured during a 5-minute rest. Depression and PTSD were assessed using the Beck Depression Inventory and Clinician-Administered PTSD Scale, respectively. Results When adjusting for covariates, including TBI, regression analyses showed that lower levels of high-frequency HRV were associated with a diagnosis of PTSD ( = -0.20, p = .035). Depression and PTSD severity were correlated (r = 0.49, p < .001); however, participants with PTSD but relatively low depression scores exhibited reduced high frequency compared with controls (p = .012). Marines with deployment experience (n = 1254) had lower HRV than did those with no experience (p = .033). Conclusions This cross-sectional analysis of a large cohort supports associations between PTSD and reduced HRV when accounting for TBI and depression symptoms. Future postdeployment assessments will be used to determine whether predeployment HRV can predict vulnerability and resilience to the serious psychological and physiological consequences of combat exposure.	[Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] Vet Adm, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92136 USA; [Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [O'Connor, Daniel T.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] VA San Diego Healthcare Syst, San Diego, CA USA		Minassian, A (corresponding author), Vet Adm, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92136 USA.	aminassian@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; Nievergelt, Caroline/0000-0001-5766-8923	VA Health Service Research and Development [SDR 09-0128]; Marine Corps; Navy Bureau of Medicine and Surgery; Center of Excellence for Stress and Mental Health; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH093500]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	This study was funded by VA Health Service Research and Development (Project No. SDR 09-0128; D. G. B., M. A. G., V. B. R.), the Marine Corps (D. G. B., M. A. G., V. B. R.), Navy Bureau of Medicine and Surgery (D. G. B., M. A. G., V. B. R., A. M.), the Center of Excellence for Stress and Mental Health (D. G. B., M. A. G., V. B. R., A. M.), and the National Institutes of Health (MH093500; D. G. B., M. A. G., V. B. R., C.M.N.). The authors have no conflict of interest to declare.	Agorastos A, 2013, STRESS, V16, P300, DOI 10.3109/10253890.2012.751369; AKSELROD S, 1985, AM J PHYSIOL, V249, pH867, DOI 10.1152/ajpheart.1985.249.4.H867; Allen J, 2007, PHYSIOL MEAS, V28, pR1, DOI 10.1088/0967-3334/28/3/R01; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; Berntson GG, 2007, BIOL PSYCHOL, V74, P295, DOI 10.1016/j.biopsycho.2006.08.006; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Bilchick KC, 2006, J CARDIOVASC ELECTR, V17, P691, DOI 10.1111/j.1540-8167.2006.00501.x; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Camm, 1995, HEART RATE VARIABILI; Camm AJ, 1996, EUR HEART J, V17, P354; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carney RM, 2005, PSYCHOSOM MED, V67, pS29, DOI 10.1097/01.psy.0000162254.61556.d5; Chang C, 2013, NEUROIMAGE, V68, P93, DOI 10.1016/j.neuroimage.2012.11.038; Cohen H, 2000, PSYCHIAT RES, V96, P1, DOI 10.1016/S0165-1781(00)00195-5; Cyranowski JM, 2011, PSYCHOSOM MED, V73, P336, DOI 10.1097/PSY.0b013e318213925d; Dinas PC, 2013, INT J CARDIOL, V163, P109, DOI 10.1016/j.ijcard.2011.10.140; Eckberg DL, 1997, CIRCULATION, V96, P3224, DOI 10.1161/01.CIR.96.9.3224; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Falush D, 2003, GENETICS, V164, P1567; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811; Henry BL, 2010, J PSYCHIATR RES, V44, P168, DOI 10.1016/j.jpsychires.2009.07.011; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jennings JR, 1998, BIOL PSYCHOL, V47, P227, DOI 10.1016/S0301-0511(97)00028-8; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King ML, 1997, BRAIN INJURY, V11, P445; KOLLAI M, 1992, BRIT J PSYCHIAT, V161, P831, DOI 10.1192/bjp.161.6.831; Koskinen T, 2009, AUTON NEUROSCI-BASIC, V145, P81, DOI 10.1016/j.autneu.2008.10.011; Lee EAD, 2012, BIOL RES NURS, V14, P412, DOI 10.1177/1099800412454453; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Malaspina D, 1997, BIOL PSYCHIAT, V41, P612, DOI 10.1016/S0006-3223(96)00161-8; Mazic S, 2009, GEN PHYSIOL BIOPHYS, V28, P200; Nievergelt Caroline M, 2013, Investig Genet, V4, P13, DOI 10.1186/2041-2223-4-13; Nunan D, 2010, PACE, V33, P1407, DOI 10.1111/j.1540-8159.2010.02841.x; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schapkin SA, 2012, INT J BEHAV MED, V19, P359, DOI 10.1007/s12529-011-9181-6; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Selvaraj N., 2008, Journal of Medical Engineering & Technology, V32, P479, DOI 10.1080/03091900701781317; Selvaraj N, 2007, IFMBE PROC, V15, P391; Shah AJ, 2013, BIOL PSYCHIAT, V73, P1103, DOI 10.1016/j.biopsych.2013.01.019; Singh JP, 2001, AUTON NEUROSCI-BASIC, V90, P122, DOI 10.1016/S1566-0702(01)00277-6; Sondermeijer HP, 2002, AM J CARDIOL, V90, P906, DOI 10.1016/S0002-9149(02)02725-X; Tabachnick B. G., 1989, USING MULTIVARIATE S; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Teng XF, 2003, IEEE EMBS APBME 2003, P140, DOI 10.1109/APBME.2003.1302623; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Tsuji H, 1996, J AM COLL CARDIOL, V28, P1539, DOI 10.1016/S0735-1097(96)00342-7; Tucker P, 2012, PSYCHOSOM MED, V74, P160, DOI 10.1097/PSY.0b013e318240a801; van Zyl LT, 2008, BIOPSYCHOSOC MED, V2, DOI 10.1186/1751-0759-2-12; Wang XL, 2009, PSYCHOPHYSIOLOGY, V46, P458, DOI 10.1111/j.1469-8986.2009.00793.x; Yeragani VK, 2005, DEPRESS ANXIETY, V21, P130, DOI 10.1002/da.20061; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zhang J, 2007, J MANIP PHYSIOL THER, V30, P374, DOI 10.1016/j.jmpt.2007.04.001	59	61	65	0	33	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0033-3174	1534-7796		PSYCHOSOM MED	Psychosom. Med.	MAY	2014	76	4					292	301		10.1097/PSY.0000000000000056			10	Psychiatry; Psychology; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry; Psychology	AI0AG	WOS:000336507600007	24804881	Green Accepted, Green Published			2022-02-06	
J	Tavender, EJ; Bosch, M; Gruen, RL; Green, SE; Knott, J; Francis, JJ; Michie, S; O'Connor, DA				Tavender, Emma J.; Bosch, Marije; Gruen, Russell L.; Green, Sally E.; Knott, Jonathan; Francis, Jill J.; Michie, Susan; O'Connor, Denise A.			Understanding practice: the factors that influence management of mild traumatic brain injury in the emergency department-a qualitative study using the Theoretical Domains Framework	IMPLEMENTATION SCIENCE			English	Article						Emergency department management; Mild traumatic brain injury; Theoretical Domains Framework; Semi-structured interviews	BEHAVIOR-CHANGE INTERVENTIONS; HEAD-INJURY; IMPLEMENTATION; INFORMATION; PERCEPTIONS; GUIDELINES; PHYSICIANS; DISCHARGE	Background: Mild traumatic brain injury is a frequent cause of presentation to emergency departments. Despite the availability of clinical practice guidelines in this area, there is variation in practice. One of the aims of the Neurotrauma Evidence Translation program is to develop and evaluate a targeted, theory-and evidence-informed intervention to improve the management of mild traumatic brain injury in Australian emergency departments. This study is the first step in the intervention development process and uses the Theoretical Domains Framework to explore the factors perceived to influence the uptake of four key evidence-based recommended practices for managing mild traumatic brain injury. Methods: Semi-structured interviews were conducted with emergency staff in the Australian state of Victoria. The interview guide was developed using the Theoretical Domains Framework to explore current practice and to identify the factors perceived to influence practice. Two researchers coded the interview transcripts using thematic content analysis. Results: A total of 42 participants (9 Directors, 20 doctors and 13 nurses) were interviewed over a seven-month period. The results suggested that (i) the prospective assessment of post-traumatic amnesia was influenced by: knowledge; beliefs about consequences; environmental context and resources; skills; social/professional role and identity; and beliefs about capabilities; (ii) the use of guideline-developed criteria or decision rules to inform the appropriate use of a CT scan was influenced by: knowledge; beliefs about consequences; environmental context and resources; memory, attention and decision processes; beliefs about capabilities; social influences; skills and behavioral regulation; (iii) providing verbal and written patient information on discharge was influenced by: beliefs about consequences; environmental context and resources; memory, attention and decision processes; social/professional role and identity; and knowledge; (iv) the practice of providing brief, routine follow-up on discharge was influenced by: environmental context and resources; social/professional role and identity; knowledge; beliefs about consequences; and motivation and goals. Conclusions: Using the Theoretical Domains Framework, factors thought to influence the management of mild traumatic brain injury in the emergency department were identified. These factors present theoretically based targets for a future intervention.	[Tavender, Emma J.; Bosch, Marije] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Gruen, Russell L.] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst,Dept Trauma, Melbourne, Vic 3181, Australia; [Green, Sally E.; O'Connor, Denise A.] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic 3181, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Melbourne Med Sch, Melbourne, Vic, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Dept Emergency Med, Melbourne, Vic, Australia; [Francis, Jill J.] City Univ London, Sch Hlth Sci, London EC1V 0HB, England; [Michie, Susan] UCL, Dept Clin Educ & Hlth Psychol, London, England		Tavender, EJ (corresponding author), Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia.	emma.tavender@monash.edu	O'Connor, Denise/ABC-6655-2020; Michie, Susan/A-1745-2010	O'Connor, Denise/0000-0002-6836-122X; Tavender, Emma/0000-0002-7230-712X; Francis, Jill/0000-0001-5784-8895; Michie, Susan/0000-0003-0063-6378; Green, Sally Elizabeth/0000-0002-9564-9050	Transport Accident Commission, Australia; Australian Postgraduate AwardAustralian Government; Australian National Health and Medical Research Council Public Health FellowshipNational Health and Medical Research Council of Australia [606726]	The NET Program is funded by the Transport Accident Commission, Australia. EJT is supported by an Australian Postgraduate Award. DOC is supported by an Australian National Health and Medical Research Council Public Health Fellowship (606726).	Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Angus D, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-4; Australian Bureau of Statistics, 2011, 1216 0 AUSTR STAND G; Baker R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005470.pub2; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Bessen T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3056; Bosch M, 2013, J EVAL CLIN PRACT, V19, P763, DOI 10.1111/j.1365-2753.2012.01835.x; Buetow S, 2010, J HEALTH SERV RES PO, V15, P123, DOI 10.1258/jhsrp.2009.009081; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Davies P, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-14; Dayawansa MK, 2010, THESIS MONASH U; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Francis JJ, 2009, BRIT J HEALTH PSYCH, V14, P625, DOI 10.1348/135910708X397025; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Green SE, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-74; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R., 2005, IMPROVING PATIENT CA, V2; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Kerr J, 2005, EMERG MED J, V22, P850, DOI 10.1136/emj.2004.022673; Kerr J, 2007, EMERG MED J, V24, P330, DOI 10.1136/emj.2006.044230; Kuper A, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1035; Meurer WJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-5; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Patey AM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-52; Peachey T, 2011, EMERG MED J, V28, P707, DOI 10.1136/emj.2010.093872; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P42, DOI 10.1017/S0317167100006296; Sandelowski M, 2000, RES NURS HEALTH, V23, P246, DOI 10.1002/1098-240X(200006)23:3<246::AID-NUR9>3.0.CO;2-H; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	39	61	61	1	32	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-5908			IMPLEMENT SCI	Implement. Sci.	JAN 13	2014	9								8	10.1186/1748-5908-9-8			10	Health Care Sciences & Services; Health Policy & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	290YB	WOS:000329793400001	24418161	Green Published, gold, Green Accepted			2022-02-06	
J	Hundza, SR; Hook, WR; Harris, CR; Mahajan, SV; Leslie, PA; Spani, CA; Spalteholz, LG; Birch, BJ; Commandeur, DT; Livingston, NJ				Hundza, Sandra R.; Hook, William R.; Harris, Christopher R.; Mahajan, Sunny V.; Leslie, Paul A.; Spani, Carl A.; Spalteholz, Leonhard G.; Birch, Benjamin J.; Commandeur, Drew T.; Livingston, Nigel J.			Accurate and Reliable Gait Cycle Detection in Parkinson's Disease	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Angular rate reversal; continuous walking gait analysis; gyroscope; medical instrumentation; Parkinsons; stride event detection; stride time validation; stride time variability	TRAUMATIC BRAIN-INJURY; AMBULATORY SYSTEM; WALKING SPEED; OLDER-ADULTS; RELIABILITY; PARAMETERS; FALLS; VARIABILITY; GYROSCOPES; VALIDITY	There is a growing interest in the use of Inertial Measurement Unit (IMU)-based systems that employ gyroscopes for gait analysis. We describe an improved IMU-based gait analysis processing method that uses gyroscope angular rate reversal to identify the start of each gait cycle during walking. In validation tests with six subjects with Parkinson disease (PD), including those with severe shuffling gait patterns, and seven controls, the probability of True-Positive event detection and False-Positive event detection was 100% and 0%, respectively. Stride time validation tests using high-speed cameras yielded a standard deviation of 6.6 ms for controls and 11.8 ms for those with PD. These data demonstrate that the use of our angular rate reversal algorithm leads to improvements over previous gyroscope-based gait analysis systems. Highly accurate and reliable stride time measurements enabled us to detect subtle changes in stride time variability following a Parkinson's exercise class. We found unacceptable measurement accuracy for stride length when using the Aminian et al. gyro-based biomechanical algorithm, with errors as high as 30% in PD subjects. An alternative method, using synchronized infrared timing gates to measure velocity, combined with accurate mean stride time from our angular rate reversal algorithm, more accurately calculates mean stride length.	[Hundza, Sandra R.; Commandeur, Drew T.] Univ Victoria, Sch Exercise Sci Phys & Hlth Educ, Victoria, BC V8W 2Y2, Canada; [Hook, William R.; Leslie, Paul A.; Spani, Carl A.; Spalteholz, Leonhard G.; Livingston, Nigel J.] Univ Victoria, CanAssist, Victoria, BC V8W 2Y2, Canada; [Harris, Christopher R.] Tantalus Syst Corp, Burnaby, BC V5G 4Y1, Canada; [Mahajan, Sunny V.] OMsignal, Montreal, PQ H2Y2M4, Canada; [Birch, Benjamin J.] Camosun Coll, Victoria, BC V9E 2C1, Canada		Hundza, SR (corresponding author), Univ Victoria, Sch Exercise Sci Phys & Hlth Educ, Victoria, BC V8W 2Y2, Canada.	shundza@uvic.ca; wrogershook@gmail.com; crh.iphone@gmail.com; sunnyvm@gmail.com; pleslie@uvic.ca; cspani@uvic.ca; leos@uvic.ca; benj.birch@gmail.com; dcommand@uvic.ca; njl@uvic.ca			Assistive Technology organization CanAssist, University of Victoria, Canada [BC V8W2Y2]	This work was carried out by the Assistive Technology organization CanAssist, University of Victoria, BC V8W2Y2 Canada.	Aminian K, 2002, J BIOMECH, V35, P689, DOI 10.1016/S0021-9290(02)00008-8; Begg R. K., 2009, INSTRUMENTATION USED; Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Bloem BR, 2004, MOVEMENT DISORD, V19, P871, DOI 10.1002/mds.20115; Brach J., 2006, J GERIATR PHYS THER, V29, P118; Furuse N, 2007, IFMBE PROC, V16, P689; Hausdorff JM, 2007, HUM MOVEMENT SCI, V26, P555, DOI 10.1016/j.humov.2007.05.003; Hausdorff JM, 2009, CHAOS, V19, DOI 10.1063/1.3147408; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Herman T, 2010, J GERONTOL A-BIOL, V65, P1086, DOI 10.1093/gerona/glq077; Hetzler RK, 2008, J STRENGTH COND RES, V22, P1969, DOI 10.1519/JSC.0b013e318185f36c; Hollman JH, 2010, GAIT POSTURE, V32, P23, DOI 10.1016/j.gaitpost.2010.02.017; I. CIR Systems, 2010, GAITRITE EL WALKW TE, P1; Mansfield A, 2003, MED ENG PHYS, V25, P879, DOI 10.1016/S1350-4533(03)00116-4; Moore ST, 2007, GAIT POSTURE, V26, P200, DOI 10.1016/j.gaitpost.2006.09.011; MORRIS ME, 1994, BRAIN, V117, P1169, DOI 10.1093/brain/117.5.1169; Qutubuddin AA, 2005, ARCH PHYS MED REHAB, V86, P789, DOI 10.1016/j.apmr.2004.11.005; Rikli R. E., 2012, GERONTOLOGIST, P1; Rueterbories J, 2010, MED ENG PHYS, V32, P545, DOI 10.1016/j.medengphy.2010.03.007; Salarian A, 2004, IEEE T BIO-MED ENG, V51, P1434, DOI 10.1109/TBME.2004.827933; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Verghese J, 2007, J NEUROL NEUROSUR PS, V78, P929, DOI 10.1136/jnnp.2006.106914; VONSCHROEDER HP, 1995, J REHABIL RES DEV, V32, P25; Wong WY, 2007, PROSTHET ORTHOT INT, V31, P62, DOI 10.1080/03093640600983949	26	61	62	7	40	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	JAN	2014	22	1					127	137		10.1109/TNSRE.2013.2282080			11	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	292BK	WOS:000329876500014	24158491				2022-02-06	
J	Su, W; Hopkins, S; Nesser, NK; Sopher, B; Silvestroni, A; Ammanuel, S; Jayadev, S; Moller, T; Weinstein, J; Garden, GA				Su, Wei; Hopkins, Stephanie; Nesser, Nicole K.; Sopher, Bryce; Silvestroni, Aurelio; Ammanuel, Simon; Jayadev, Suman; Moeller, Thomas; Weinstein, Jonathan; Garden, Gwenn A.			The p53 Transcription Factor Modulates Microglia Behavior through MicroRNA-Dependent Regulation of c-Maf	JOURNAL OF IMMUNOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; IL-10 GENE-EXPRESSION; TUMOR-SUPPRESSOR P53; DIFFERENTIAL REGULATION; CELL-DIFFERENTIATION; SCAVENGER RECEPTOR; C/EBP-BETA; MACROPHAGES; ACTIVATION; DISEASE	Neuroinflammation occurs in acute and chronic CNS injury, including stroke, traumatic brain injury, and neurodegenerative diseases. Microglia are specialized resident myeloid cells that mediate CNS innate immune responses. Disease-relevant stimuli, such as reactive oxygen species (ROS), can influence microglia activation. Previously, we observed that p53, a ROS-responsive transcription factor, modulates microglia behaviors in vitro and in vivo, promoting proinflammatory functions and suppressing downregulation of the inflammatory response and tissue repair. In this article we describe a novel mechanism by which p53 modulates the functional differentiation of microglia both in vitro and in vivo. Adult microglia from p53-deficient mice have increased expression of the anti-inflammatory transcription factor c-Maf. To determine how p53 negatively regulates c-Maf, we examined the impact of p53 on known c-Maf regulators. MiR-155 is a microRNA that targets c-Maf. We observed that cytokine-induced expression of miR-155 was suppressed in p53-deficient microglia. Furthermore, Twist2, a transcriptional activator of c-Maf, is increased in p53-deficient microglia. We identified recognition sites in the 39 untranslated region of Twist2 mRNA that are predicted to interact with two p53-dependent microRNAs: miR-34a and miR-145. In this article, we demonstrate that miR-34a and -145 are regulated by p53 and negatively regulate Twist2 and c-Maf expression in microglia and the RAW macrophage cell line. Taken together, these findings support the hypothesis that p53 activation induced by local ROS or accumulated DNA damage influences microglia functions and that one specific molecular target of p53 in microglia is c-Maf.	[Su, Wei; Hopkins, Stephanie; Nesser, Nicole K.; Sopher, Bryce; Silvestroni, Aurelio; Ammanuel, Simon; Jayadev, Suman; Moeller, Thomas; Weinstein, Jonathan; Garden, Gwenn A.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Jayadev, Suman; Weinstein, Jonathan; Garden, Gwenn A.] Univ Washington, Ctr Human Dev & Disabil, Seattle, WA 98195 USA		Garden, GA (corresponding author), Univ Washington, 1959 North East Pacific St, Seattle, WA 98195 USA.	gagarden@uw.edu	Jayadev, Suman/B-6362-2019; Moller, Thomas/W-8974-2019	Weinstein, Jonathan/0000-0001-6080-9758; Garden, Gwenn/0000-0002-8753-6515	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS073848, R03NS70141, R21NS062269];  [P30-HD02274]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002274, U54HD083091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073848, R01NS076620, R03NS070141, R21NS062269] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R01NS073848, R03NS70141, and R21NS062269 (to G.A.G.), with facilities support from Grant P30-HD02274 to the University of Washington Center on Human Development and Disability.	Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bird L, 2011, NAT REV IMMUNOL, V11, P76, DOI 10.1038/nri2924; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Cao SJ, 2005, J IMMUNOL, V174, P3484, DOI 10.4049/jimmunol.174.6.3484; Cao SJ, 2002, J IMMUNOL, V169, P5715, DOI 10.4049/jimmunol.169.10.5715; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; De Haas AH, 2007, GLIA, V55, P1374, DOI 10.1002/glia.20554; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Feng ZH, 2011, J MOL CELL BIOL, V3, P44, DOI 10.1093/jmcb/mjq040; Garden GA, 2004, FASEB J, V18, P1141, DOI 10.1096/fj.04-1676fje; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Homma Y, 2007, J INTERF CYTOK RES, V27, P799, DOI 10.1089/jir.2007.0006; Jayadev S, 2007, J NEUROIMMUNE PHARM, V2, P359, DOI 10.1007/s11481-007-9095-x; Jayadev S, 2011, GLIA, V59, P1402, DOI 10.1002/glia.21178; Jebelli JD, 2012, GLIA, V60, P515, DOI 10.1002/glia.22268; Kataoka K, 2007, J BIOCHEM, V141, P775, DOI 10.1093/jb/mvm105; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu FY, 2012, CURR MOL MED, V12, P917; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Louafi F, 2010, J BIOL CHEM, V285, P41328, DOI 10.1074/jbc.M110.146852; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Mendrysa Susan M, 2011, Genes Cancer, V2, P431, DOI 10.1177/1947601911409736; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muir KW, 2007, CURR OPIN NEUROL, V20, P334, DOI 10.1097/WCO.0b013e32813ba151; Mukhopadhyay S, 2006, EUR J IMMUNOL, V36, P940, DOI 10.1002/eji.200535389; Nakamura M, 2009, GENE, V445, P66, DOI 10.1016/j.gene.2009.06.003; Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528; Perruisseau-Carrier C, 2011, MOL NEUROBIOL, V43, P215, DOI 10.1007/s12035-011-8179-z; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Rani A, 2011, J IMMUNOL, V187, P3721, DOI 10.4049/jimmunol.1002354; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rickard AJ, 2009, J MOL ENDOCRINOL, V42, P449, DOI 10.1677/JME-08-0144; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Salmina AB, 2009, J ALZHEIMERS DIS, V16, P485, DOI 10.3233/JAD-2009-0988; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464	78	61	66	1	11	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	JAN 1	2014	192	1					358	366		10.4049/jimmunol.1301397			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	279HJ	WOS:000328950700037	24319262	Green Accepted, Bronze			2022-02-06	
J	Dams-O'Connor, K; Cuthbert, JP; Whyte, J; Corrigan, JD; Faul, M; Harrison-Felix, C				Dams-O'Connor, Kristen; Cuthbert, Jeffrey P.; Whyte, John; Corrigan, John D.; Faul, Mark; Harrison-Felix, Cynthia			Traumatic Brain Injury among Older Adults at Level I and II Trauma Centers	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; epidemiology; geriatric brain injury; traumatic brain injury	EMERGENCY-DEPARTMENT VISITS; UNITED-STATES; MORTALITY; AGE; HOSPITALIZATIONS; ASSOCIATION; DISCHARGE; RECOVERY; OUTCOMES; DEATHS	Individuals 65 years of age and over have the highest rates of traumatic brain injury (TBI)-related hospitalizations and deaths, and older adults (defined variably across studies) have particularly poor outcomes after TBI. The factors predicting these outcomes remain poorly understood, and age-specific care guidelines for TBI do not exist. This study provides an overview of TBI in older adults using data from the National Trauma Data Bank (NTDB) gathered between 2007 and 2010, evaluates age group-specific trends in rates of TBI over time using U.S. Census data, and examines whether routinely collected information is able to predict hospital discharge status among older adults with TBI in the NTDB. Results showed a 20-25% increase in trauma center admissions for TBI among the oldest age groups (those >=75 years), relative to the general population, between 2007 and 2010. Older adults (>=65 years) with TBI tended to be white females who have incurred an injury from a fall resulting in a severe Abbreviated Injury Scale (AIS) score of the head. Older adults had more in-hospital procedures, such as neuroimaging and neurosurgery, tended to experience longer hospital stays, and were more likely to require continued medical care than younger adults. Older age, injury severity, and hypotension increased the odds of in-hospital death. The public health burden of TBI among older adults will likely increase as the Baby Boom generation ages. Improved primary and secondary prevention of TBI in this cohort is needed.	[Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Elkins Pk, PA USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kdams13@gmail.com		Whyte, John/0000-0002-4381-1474; Faul, Mark/0000-0002-7683-0348	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD074651] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER		AANS, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9999; Agency for Healthcare Quality and Research, 2013, H CUPNET HEALTHC COS; AHA, 2011, UND BLOOD PRESS READ; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; CDC, 2010, US CENS BRIDG RAC PO; Cefalu CA, 2011, CLIN GERIATR MED, V27, P491, DOI 10.1016/j.cger.2011.07.001; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Chisholm KM, 2010, AM J FOREN MED PATH, V31, P350, DOI 10.1097/PAF.0b013e3181f69c87; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P14; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; Farrer SR, 2007, GROWING OLDER AM HLT; Faul M, 2010, TRAUMATIC BRAIN INJU; Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; Goble S, 2009, J TRAUMA, V67, P637, DOI 10.1097/TA.0b013e3181b84294; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; IBM, 2010, IBM SPSS STAT WIND V; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1197/aemj.10.3.244; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Marr A, 2002, CENTRAL NERVOUS SYST; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Neal M., 2005, NATL TRAUMA DATA BAN; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Reistetter TA, 2010, ARCH PHYS MED REHAB, V91, P345, DOI 10.1016/j.apmr.2009.11.010; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryb GE, 2011, J TRAUMA, V71, P742, DOI 10.1097/TA.0b013e31822ba010; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sasser SM, 2009, GUIDELINES FIELD TRI; Scheetz LJ, 2011, PREHOSP EMERG CARE, V15, P83, DOI 10.3109/10903127.2010.514088; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Tri-Analytics, 1997, ICDMAP 90 INJ SEV CO; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269	51	61	61	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2001	2013		10.1089/neu.2013.3047			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500001	23962046	Green Published			2022-02-06	
J	Winston, CN; Chellappa, D; Wilkins, T; Barton, DJ; Washington, PM; Loane, DJ; Zapple, DN; Burns, MP				Winston, Charisse N.; Chellappa, Deepa; Wilkins, Tiffany; Barton, David J.; Washington, Patricia M.; Loane, David J.; Zapple, David N.; Burns, Mark P.			Controlled Cortical Impact Results in an Extensive Loss of Dendritic Spines that Is Not Mediated by Injury-Induced Amyloid-Beta Accumulation	JOURNAL OF NEUROTRAUMA			English	Article						amyloid beta; brain trauma; controlled cortical impact; dendritic spine; gamma-secretase inhibitor	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; IN-VIVO; PYRAMIDAL NEURONS; GAMMA-SECRETASE; MODEL; MILD; MICE; ACTIVATION; DEPOSITION	The clinical manifestations that occur after traumatic brain injury (TBI) include a wide range of cognitive, emotional, and behavioral deficits. The loss of excitatory synapses could potentially explain why such diverse symptoms occur after TBI, and a recent preclinical study has demonstrated a loss of dendritic spines, the postsynaptic site of the excitatory synapse, after fluid percussion injury. The objective of this study was to determine if controlled cortical impact (CCI) also resulted in dendritic spine retraction and to probe the underlying mechanisms of this spine loss. We used a unilateral CCI and visualized neurons and dendtritic spines at 24 h post-injury using Golgi stain. We found that TBI caused a 32% reduction of dendritic spines in layer II/III of the ipsilateral cortex and a 20% reduction in the dendritic spines of the ipsilateral dentate gyrus. Spine loss was not restricted to the ipsilateral hemisphere, however, with similar reductions in spine numbers recorded in the contralateral cortex (25% reduction) and hippocampus (23% reduction). Amyloid-beta (A beta), a neurotoxic peptide commonly associated with Alzheimer disease, accumulates rapidly after TBI and is also known to cause synaptic loss. To determine if A beta contributes to spine loss after brain injury, we administered a gamma-secretase inhibitor LY450139 after TBI. We found that while LY450139 administration could attenuate the TBI-induced increase in A beta, it had no effect on dendritic spine loss after TBI. We conclude that the acute, global loss of dendritic spines after TBI is independent of gamma-secretase activity or TBI-induced A beta accumulation.	[Winston, Charisse N.; Chellappa, Deepa; Wilkins, Tiffany; Barton, David J.; Washington, Patricia M.; Zapple, David N.; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.] Univ Maryland, Sch Med, Ctr Shock,Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD 21201 USA		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20057 USA.	mpb37@georgetown.edu	Loane, David/ABD-5177-2021; Barton, David J/C-9282-2011	Loane, David/0000-0003-0393-3503; Barton, David J/0000-0003-0976-0383; Burns, Mark P/0000-0003-4750-2000	Georgetown University Neural Injury and Plasticity Training Program [T32NS041218]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute for Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS067417, R01NS081068]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R03NS067417, R01NS081068] Funding Source: NIH RePORTER	This work was supported by grant number T32NS041218 from the Georgetown University Neural Injury and Plasticity Training Program supported by the National Institutes of Health (CNW and PMW, PI: Dr. Jean Wrathall and Dr. Kathleen Maguire-Zeiss) and grants number R03NS067417 & R01NS081068 from the National Institute for Neurological Disorders and Stroke (MPB). We would like to thank Dr. Hyang-Sook Hoe and Dr. Daniel Pak for assistance with the Golgi staining technique.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bittner T, 2009, J NEUROSCI, V29, P10405, DOI 10.1523/JNEUROSCI.2288-09.2009; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; CATALA I, 1988, HUM NEUROBIOL, V6, P255; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Garey LJ, 1998, J NEUROL NEUROSUR PS, V65, P446, DOI 10.1136/jnnp.65.4.446; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kochanski R, 2013, J NEUROCHEM, V126, P113, DOI 10.1111/jnc.12169; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Ng AN, 2008, FASEB J, V22, P2832, DOI 10.1096/fj.07-103903; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rozkalne A, 2011, NEUROBIOL DIS, V41, P650, DOI 10.1016/j.nbd.2010.11.014; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schulz-Schaeffer WJ, 2010, ACTA NEUROPATHOL, V120, P131, DOI 10.1007/s00401-010-0711-0; Schwartz N, 2009, NEURON, V62, P655, DOI 10.1016/j.neuron.2009.05.007; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010	33	61	61	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2013	30	23					1966	1972		10.1089/neu.2013.2960			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AI0FA	WOS:000336520400005	23879560	Green Published			2022-02-06	
J	Jourdan, C; Bosserelle, V; Azerad, S; Ghout, I; Bayen, E; Aegerter, P; Weiss, JJ; Mateo, J; Lescot, T; Vigue, B; Tazarourte, K; Pradat-Diehl, P; Azouvi, P				Jourdan, C.; Bosserelle, V.; Azerad, S.; Ghout, I.; Bayen, E.; Aegerter, P.; Weiss, J. J.; Mateo, J.; Lescot, T.; Vigue, B.; Tazarourte, K.; Pradat-Diehl, P.; Azouvi, P.		PariS-TBI Study	Predictive factors for 1-year outcome of a cohort of patients with severe traumatic brain injury (TBI): Results from the PariS-TBI study	BRAIN INJURY			English	Article						Brain injury; craniocerebral trauma; disability; dysexecutive questionnaire; outcome	ECOLOGICAL VALIDITY; EXECUTIVE DYSFUNCTION; EMPLOYMENT; RETURN; WORK; REHABILITATION; MODERATE; PEOPLE; MODELS; TESTS	Objectives: To assess outcome and predicting factors 1 year after a severe traumatic brain injury (TBI). Methods: Multi-centre prospective inception cohort study of patients aged 15 or older with a severe TBI in the Parisian area, France. Data were collected prospectively starting the day of injury. One-year evaluation included the relatives-rating of the Dysexecutive Questionnaire (DEX-R), the Glasgow Outcome Scale-Extended (GOSE) and employment. Univariate and multivariate tests were computed. Results: Among 257 survivors, 134 were included (mean age 36 years, 84% men). Good recovery concerned 19%, moderate disability 43% and severe disability 38%. Among patients employed pre-injury, 42% were working, 28% with no job change. DEX-R score was significantly associated with length of education only. Among initial severity measures, only the IMPACT prognostic score was significantly related to GOSE in univariate analyses, while measures relating to early evolution were more significant predictors. In multivariate analyses, independent predictors of GOSE were length of stay in intensive care (LOS), age and education. Independent predictors of employment were LOS and age. Conclusions: Age, education and injury severity are independent predictors of global disability and return to work 1 year after a severe TBI.	[Jourdan, C.; Azouvi, P.] Hop Raymond Poincare, APHP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Jourdan, C.; Aegerter, P.; Azouvi, P.] Univ Versailles St Quentin Yvelines, Versailles, France; [Jourdan, C.; Bayen, E.; Pradat-Diehl, P.; Azouvi, P.] UPMC, Unite ER 6, Paris, France; [Bosserelle, V.; Azerad, S.; Weiss, J. J.] Hop Broussais, APHP, CRFTC, F-75674 Paris, France; [Bosserelle, V.; Azerad, S.; Ghout, I.; Aegerter, P.] Hop Ambroise Pare, APHP, URC, Boulogne, France; [Bayen, E.; Pradat-Diehl, P.] Univ Paris 06, Paris, France; [Bayen, E.; Pradat-Diehl, P.] Grp Hosp Pitie Salpetriere, APHP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Mateo, J.] Hop Lariboisiere, APHP, Dept Anesthesiol, F-75475 Paris, France; [Mateo, J.] Hop Lariboisiere, APHP, SAMU, F-75475 Paris, France; [Lescot, T.] Grp Hosp Pitie Salpetriere, APHP, Dept Anesthesiol, F-75634 Paris, France; [Vigue, B.] Hop Bicetre, APHP, Dept Anesthesiol & Soins Intensifs, Le Kremlin Bicetre, France; [Tazarourte, K.] Hop Marc Jacquet, SAMU 77, Mobile Care Unit, Melun, France		Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr	AEGERTER, Philippe/AAY-6003-2021	AEGERTER, Philippe/0000-0002-9156-5028; tazarourte, karim/0000-0002-3376-1258	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Unite de Recherche Clinique Paris-Ouest	This study was funded by a grant of the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM04084), sponsored by AP-HP (Departement de la Recherche Clinique et du Developpement) and carried out with the support of Unite de Recherche Clinique Paris-Ouest. The authors report no conflicts of interest.	Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bayen E, 2012, J HEAD TRAUMA REHABI; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Boelen DHE, 2009, NEUROPSYCHOL REHABIL, V19, P625, DOI 10.1080/09602010802613853; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2011, PSYCHIAT RES, V185, P340, DOI 10.1016/j.psychres.2010.06.009; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gerstorf D, 2008, AGING NEUROPSYCHOL C, V15, P424, DOI 10.1080/13825580701640374; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Harrell FE Jr, 2017, REGRESSION MODELING; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sherer M, 1999, BRAIN INJURY, V13, P973; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	44	61	62	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1000	1007		10.3109/02699052.2013.794971			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100003	23730948				2022-02-06	
J	McCrory, P; Meeuwisse, WH; Aubry, M; Cantu, B; Dvorak, J; Echemendia, RJ; Engebretsen, L; Johnston, K; Kutcher, JS; Raftery, M; Sills, A; Benson, BW; Davis, GA; Ellenbogan, R; Guskiewicz, K; Herring, SA; Iverson, GL; Jordan, BD; Kissick, J; McCrea, M; McIntosh, AS; Maddocks, D; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, CH; Turner, M				McCrory, Paul; Meeuwisse, Willem H.; Aubry, Mark; Cantu, Bob; Dvorak, Jiri; Echemendia, Ruben J.; Engebretsen, Lars; Johnston, Karen; Kutcher, Jeffrey S.; Raftery, Martin; Sills, Allen; Benson, Brian W.; Davis, Gavin A.; Ellenbogan, Richard; Guskiewicz, Kevin; Herring, Stanley A.; Iverson, Grant L.; Jordan, Barry D.; Kissick, James; McCrea, Michael; McIntosh, Andrew S.; Maddocks, David; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles H.; Turner, Michael			Consensus Statement on Concussion in Sport: The 4th International Conference on Concussion in Sport Held in Zurich, November 2012	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURIES; POSTURAL CONTROL; LONG-TERM; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem H.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Aubry, Mark] IOC Med Commiss Games Grp, Ottawa, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Bob] Boston Univ, Dept Neurosurg, Med Ctr, Boston, MA USA; [Cantu, Bob] Boston Univ, Study Traumat Encephalopathy, Med Ctr, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, Dept Neurol, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zurich, F MARC FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Engebretsen, Lars] Univ Oslo, Oslo Univ Hosp, Dept Orthopaed Surg, N-0316 Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] IOC, Lausanne, Switzerland; [Johnston, Karen] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Johnston, Karen] Concuss Management Program Athlet Edge Sports Med, Toronto, ON, Canada; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Dept Neurosurg Orthopaed Surg & Rehabil, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian W.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Dept Family Med, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin A.] Austin & Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, Gavin A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogan, Richard] Univ Washington Seattle, Dept Neurol Surg, Seattle, WA USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Sports Concuss Program, Team Phys Seattle Seahawks & Seattle Mariner, Seattle, WA USA; [Iverson, Grant L.] Univ British Columbia, Neuropsychol Outcome Assessment Lab, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; [Jordan, Barry D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry D.] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Univ Ottawa, Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Monash Univ, Australian Ctr Res Injury Sports & its Prevent,Mo, Sydney, NSW 2052, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne Physiotherapy Dept, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Schneider, Kathryn] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Tator, Charles H.] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles H.] Krembil Neurosci Ctr, Toronto, ON, Canada; [Turner, Michael] British Horseracing Author, London, England		McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.	paulmccr@bigpond.net.au		Guskiewicz, Kevin/0000-0002-8682-2130; makdissi, michael/0000-0003-0334-7133; McCrory, Paul/0000-0003-4850-0568; Iverson, Grant/0000-0001-7348-9570; Schneider, Kathryn/0000-0002-5951-5899			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10, DOI 10.1071/HE08010; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JH, 2005, J SOL ENERG-T ASME, V127, P1, DOI 10.1115/1.1854691; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Sandberg Nordqvist AC, 1996, BRAIN RES MOL BRAIN, V38, P285; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	156	61	62	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2013	216	5					E55	E71		10.1016/j.jamcollsurg.2013.02.020			17	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	140UF	WOS:000318680500004	23582174	Green Submitted, Green Accepted			2022-02-06	
J	Thelin, EP; Johannesson, L; Nelson, D; Bellander, BM				Thelin, Eric Peter; Johannesson, Louise; Nelson, David; Bellander, Bo-Michael			S100B Is an Important Outcome Predictor in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; humans; outcome; S100B; TBI	SEVERE HEAD-INJURY; SERUM S-100B PROTEIN; COMPUTED-TOMOGRAPHY FINDINGS; NEURON-SPECIFIC ENOLASE; GLASGOW COMA SCALE; PROGNOSTIC VALUE; SUBARACHNOID HEMORRHAGE; NEUROBIOCHEMICAL MARKERS; EXTRACRANIAL INJURIES; CT FINDINGS	The objective of the study was to examine how S100B, a biomarker of traumatic brain injury (TBI), contributes to outcome prediction after adjusting for known parameters, including age, Glasgow Coma Scale (GCS), pupil reaction, and computed tomography (CT) variables; to examine which parameters have the best correlation to elevated serum levels of S100B; and to investigate when to sample S100B to achieve the strongest association to outcome. This retrospective study included 265 patients with TBI admitted to the neurointensive care unit, Karolinska University Hospital Solna, Stockholm, Sweden. Univariate and multivariate proportional odds regressions were performed to determine parameters most closely related to outcome, and how S100B adds to prediction accuracy. Age (p < 0.0001), pupil reaction (p < 0.0001), and levels of S100B (p < 0.0001) had the strongest statistical correlation to outcome. The area under curve of S100B, the first 48 h after trauma, yielded an additional explained variance of 6.6% in excess of known outcome parameters, including age, GCS, pupil reaction, and CT variables, themselves exhibiting an explained variance of 29.3%. S100B adds substantial information regarding patient outcome, in excess of that provided by known parameters. Only CT variables were found to be significant predictors of increased levels of S100B in uni- and multivariate analysis. Early samples of S100B, within 12 h after trauma, appear to have little prognostic value, and S100B should likely be sampled 12-36 h following trauma to best enhance TBI outcome prediction.	[Thelin, Eric Peter; Bellander, Bo-Michael] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, SE-17176 Stockholm, Sweden; [Nelson, David] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, SE-17176 Stockholm, Sweden; [Johannesson, Louise] Stockholm Univ, Dept Econ, S-10691 Stockholm, Sweden		Thelin, EP (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, R3 02, SE-17176 Stockholm, Sweden.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012	Thelin, Eric Peter/0000-0002-2338-4364; Nelson, David/0000-0003-2530-8207; Johannesson, Liza/0000-0001-8572-3811	Stockholm County CouncilStockholm County Council; Karolinska Institutet (ALF)Karolinska Institutet	We thank the staff at our NICU, especially Vivian Hamback-Hellkvist and Birgitta Ohlgren; the Karolinska Univeristy Hospital, Department of Clinical Chemistry for analyzing the S100B samples; and Gunilla Malmborg-Bornhall for keeping track of the trauma database at the Karolinska NICU. The study was funded by grants from the regional agreement between Stockholm County Council and Karolinska Institutet (ALF).	Acker JE, 2004, ADV TRAUMA LIFE SUPP; Aminmansour B, 2009, J RES MED SCI, V14, P343; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gonzalez-Mao MC, 2011, CLIN LAB, V57, P587; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	75	61	68	1	13	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					519	528		10.1089/neu.2012.2553			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300003	23297751				2022-02-06	
J	Woods, AS; Colsch, B; Jackson, SN; Post, J; Baldwin, K; Roux, A; Hoffer, B; Cox, BM; Hoffer, M; Rubovitch, V; Pick, CG; Schultz, JA; Balaban, C				Woods, Amina S.; Colsch, Benoit; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Roux, Aurelie; Hoffer, Barry; Cox, Brian M.; Hoffer, Michael; Rubovitch, Vardit; Pick, Chaim G.; Schultz, J. Albert; Balaban, Carey			Gangliosides and Ceramides Change in a Mouse Model of Blast Induced Traumatic Brain Injury	ACS CHEMICAL NEUROSCIENCE			English	Article							TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; PRESSURE; SYSTEM	Explosive detonations generate atmospheric pressure changes that produce nonpenetrating blast induced "mild" traumatic brain injury (bTBI). The structural basis for mild bTBI has been extremely controversial. The present study applies matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging to track the distribution of gangliosides in mouse brain tissue that were exposed to very low level of explosive detonations (2.5-5.5 psi peak overpressure). We observed major increases of the ganglioside GM2 in the hippocampus, thalamus, and hypothalamus after a single blast exposure. Moreover, these changes were accompanied by depletion of ceramides. No neurological or brain structural signs of injury could be inferred using standard light microscopic techniques. The first source of variability is generated by the Latency between blast and tissue sampling (peak intensity of the blast wave). These findings suggest that subtle molecular changes in intracellular membranes and plasmalemma compartments may be biomarkers for biological responses to mild bTBI. This is also the first report of a GM2 increase in the brains of mature mice from a nongenetic etiology.	[Woods, Amina S.; Colsch, Benoit; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Roux, Aurelie] NIDA, IRP, Struct Biol Unit, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Cox, Brian M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Hoffer, Michael] US Naval Hosp, San Diego, CA USA; [Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Balaban, Carey] Univ Pittsburgh, Pittsburgh, PA USA; [Woods, Amina S.; Post, Jeremy; Cox, Brian M.] Ctr Neurosci & Regenerat Med, Rockville, MD USA; [Schultz, J. Albert] Ionwerks Inc, Houston, TX USA		Woods, AS (corresponding author), NIDA, IRP, NIH, 333 Cassell Dr,Room 1120, Baltimore, MD 21224 USA.	awoods@mail.nih.gov	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Intramural Research Program of the National Institute on Drug Abuse, NIH; Center for Neuroscience and Regenerative Medicine, Bethesda, MD (Department of Defense) through the Henry M. Jackson Foundation for the Advancement of Military Medicine; Office of National Drug Control Policy (ONDCP); SBIR Phase II NIH-NIDA [1RC3DA031431]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000589, RC3DA031431, ZIADA000593] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, NIH, and by the Center for Neuroscience and Regenerative Medicine, Bethesda, MD (Department of Defense) through the Henry M. Jackson Foundation for the Advancement of Military Medicine. The authors thank the Office of National Drug Control Policy (ONDCP) for instrumentation funding, without which this and other projects could not have been accomplished. J.A.S. and C.B. acknowledge funding from SBIR Phase II NIH-NIDA grant 1RC3DA031431.	ARGOV Z, 1984, ANN NEUROL, V16, P14, DOI 10.1002/ana.410160105; Bodennec J, 2000, J LIPID RES, V41, P1524; Colsch B, 2011, ACS CHEM NEUROSCI, V2, P213, DOI 10.1021/cn100096h; Colsch B, 2010, GLYCOBIOLOGY, V20, P661, DOI 10.1093/glycob/cwq031; FOLCH J, 1957, J BIOL CHEM, V226, P497; Franklin K., 2007, MOUSE BRAIN STEREOTA, VThird; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Hsu FF, 2002, J AM SOC MASS SPECTR, V13, P558, DOI 10.1016/S1044-0305(02)00358-6; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; O'Connor PB, 2002, J AM SOC MASS SPECTR, V13, P402, DOI 10.1016/S1044-0305(02)00351-3; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; ROSEBUSH PI, 1995, J CLIN PSYCHIAT, V56, P347; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sugiura Y, 2009, J LIPID RES, V50, P1776, DOI 10.1194/jlr.M900047-JLR200; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Xu YH, 2010, J LIPID RES, V51, P1643, DOI 10.1194/jlr.R003996; Yu RK, 2004, J LIPID RES, V45, P783, DOI 10.1194/jlr.R3000020-JLR200	24	61	61	0	55	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	APR	2013	4	4					594	600		10.1021/cn300216h			7	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	129VV	WOS:000317873000009	23590251	Green Published			2022-02-06	
J	Logan, TT; Villapol, S; Symes, AJ				Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.			TGF-beta Superfamily Gene Expression and Induction of the Runx1 Transcription Factor in Adult Neurogenic Regions after Brain Injury	PLOS ONE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEURAL STEM-CELLS; ENHANCED HIPPOCAMPAL NEUROGENESIS; TRANSFORMING GROWTH-FACTOR-BETA-1; NEURONAL DIFFERENTIATION; INCREASES NEUROGENESIS; SUBVENTRICULAR ZONE; COGNITIVE RECOVERY; PROGENITOR CELLS; ANALYSIS REVEALS	Traumatic brain injury (TBI) increases neurogenesis in the forebrain subventricular zone (SVZ) and the hippocampal dentate gyrus (DG). Transforming growth factor-beta (TGF-beta) superfamily cytokines are important regulators of adult neurogenesis, but their involvement in the regulation of this process after brain injury is unclear. We subjected adult mice to controlled cortical impact (CCI) injury, and isolated RNA from the SVZ and DG at different post-injury time points. qPCR array analysis showed that cortical injury caused significant alterations in the mRNA expression of components and targets of the TGF-beta, BMP, and activin signaling pathways in the SVZ and DG after injury, suggesting that these pathways could regulate post-injury neurogenesis. In both neurogenic regions, the injury also induced expression of Runt-related transcription factor-1 (Runx1), which can interact with intracellular TGF-beta Smad signaling pathways. CCI injury strongly induced Runx1 expression in activated and proliferating microglial cells throughout the neurogenic regions. Runx1 protein was also expressed in a subset of Nestin-and GFAP-expressing putative neural stem or progenitor cells in the DG and SVZ after injury. In the DG only, these Runx1+ progenitors proliferated. Our data suggest potential roles for Runx1 in the processes of microglial cell activation and proliferation and in neural stem cell proliferation after TBI.	[Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Villapol, Sonia/D-1949-2014; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300604 11.0 60855]	This project was funded by the Center for Neuroscience and Regenerative Medicine (grant no: 300604 11.0 60855), http://www.usuhs.mil/cnrm/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdipranoto-Cowley A, 2009, STEM CELLS, V27, P1330, DOI 10.1002/stem.80; Ageta H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001869; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; Beck K, 2012, CELL TISSUE RES, V347, P187, DOI 10.1007/s00441-011-1228-0; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonaguidi MA, 2008, J NEUROSCI, V28, P9194, DOI 10.1523/JNEUROSCI.3314-07.2008; Bonnert TP, 2006, EUR J NEUROSCI, V24, P661, DOI 10.1111/j.1460-9568.2006.04912.x; Buckwalter MS, 2006, AM J PATHOL, V169, P154, DOI 10.2353/ajpath.2006.051272; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Challen GA, 2010, EXP HEMATOL, V38, P403, DOI 10.1016/j.exphem.2010.02.011; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Cheng XX, 2007, STEM CELLS, V25, P3204, DOI 10.1634/stemcells.2007-0284; Curry Parichat, 2011, Int J Crit Illn Inj Sci, V1, P27, DOI 10.4103/2229-5151.79279; Dhaliwal J, 2011, EUR J NEUROSCI, V33, P1025, DOI 10.1111/j.1460-9568.2011.07600.x; Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Florio P, 2007, ADV CLIN CHEM, V43, P117, DOI 10.1016/S0065-2423(06)43004-3; Franklin K., 2007, MOUSE BRAIN STEREOTA, VThird; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Fujita Y, 2001, BIOCHEM BIOPH RES CO, V281, P1248, DOI 10.1006/bbrc.2001.4513; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Ginhoux F, 2011, M S-MED SCI, V27, P719, DOI 10.1051/medsci/2011278013; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gobeske KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007506; Goings GE, 2006, GLIA, V54, P329, DOI 10.1002/glia.20381; Graciarena M, 2010, BRAIN BEHAV IMMUN, V24, P1301, DOI 10.1016/j.bbi.2010.06.005; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hultman K, 2010, J NEUROSCI RES, V88, P2441, DOI 10.1002/jnr.22412; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; Kandasamy M, 2010, J NEUROPATH EXP NEUR, V69, P717, DOI 10.1097/NEN.0b013e3181e4f733; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kobayashi A, 2012, MOL CELL NEUROSCI, V49, P23, DOI 10.1016/j.mcn.2011.08.009; Kovesdi E, 2007, PROG BRAIN RES, V161, P81, DOI 10.1016/S0079-6123(06)61006-6; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Li LY, 2012, J MOL NEUROSCI; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117; Mahmood A, 2012, EXP NEUROL; Mathieu P, 2010, NEUROIMMUNOMODULAT, V17, P200, DOI 10.1159/000258723; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131; Nagai N, 2005, J THROMB HAEMOST, V3, P1379, DOI 10.1111/j.1538-7836.2005.01466.x; Nakagawa M, 2011, BLOOD, V118, P6626, DOI 10.1182/blood-2010-12-326710; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Stifani N, 2008, P NATL ACAD SCI USA, V105, P6451, DOI 10.1073/pnas.0711299105; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Swiers G, 2010, INT J DEV BIOL, V54, P1151, DOI 10.1387/ijdb.103106gs; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004; Theriault FM, 2005, J NEUROSCI, V25, P2050, DOI 10.1523/JNEUROSCI.5108-04.2005; Tjarnlund-Wolf A, 2012, STROKE, V43, P2833, DOI 10.1161/STROKEAHA.111.622217; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Wang YZ, 2011, STEM CELLS, V29, P907, DOI 10.1002/stem.644; Wang Y, 2010, J MOL NEUROSCI, V41, P383, DOI 10.1007/s12031-010-9329-x; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; Xiong Y, 2010, DISCOV MED, V10, P434; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yun SJ, 2002, MOL BRAIN RES, V107, P57, DOI 10.1016/S0169-328X(02)00447-3; Zagami CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013944; Zusso M, 2012, J NEUROSCI, V32, P11285, DOI 10.1523/JNEUROSCI.6182-11.2012	78	61	62	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59250	10.1371/journal.pone.0059250			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	111UM	WOS:000316546400027	23555640	Green Published, gold, Green Submitted			2022-02-06	
J	Chio, CC; Chang, CH; Wang, CC; Cheong, CU; Chao, CM; Cheng, BC; Yang, CZ; Chang, CP				Chio, Chung-Ching; Chang, Chin-Hong; Wang, Che-Chuan; Cheong, Chong-Un; Chao, Chien-Ming; Cheng, Bor-Chih; Yang, Chung-Zhing; Chang, Ching-Ping			Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha	BMC NEUROSCIENCE			English	Article						Traumatic brain injury; Microglia; Tumor necrosis factor-alpha; Astrocyte; Neuron	CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; TNF-ALPHA; CYTOKINE EXPRESSION; NEUROTROPHIC FACTOR; INTERLEUKIN-6; PLASMA; DEFICIENT; ELEVATION; ISCHEMIA	Background: Tumor necrosis factor-alpha (TNF-alpha) is elevated early in injured brain after traumatic brain injury (TBI), in humans and in animals. Etanercept (a TNF-alpha antagonist with anti-inflammatory effects) attenuates TBI in rats by reducing both microglial and astrocytic activation and increased serum levels of TNF-alpha. However, it is not known whether etanercept improves outcomes of TBI by attenuating microglia-associated, astrocytes-associated, and/or neurons-associated TNF-alpha expression in ischemic brain. A well clinically relevant rat model, where a lateral fluid percussion is combined with systemic administration of etanercept immediately after TBI, was used. The neurological severity score and motor function was measured on all rats preinjury and on day 3 after etanercept administration. At the same time, the neuronal and glial production of TNF-alpha was measured by Immunofluorescence staining. In addition, TNF alpha contents of ischemic cerebral homogenates was measured using commercial enzyme-linked immunosorbent assay kits. Results: In addition to inducing brain ischemia as well as neurological and motor deficits, TBI caused significantly higher numbers of microglia-TNF-alpha double positive cells, but not neurons-TNF-alpha or astrocytes-TNF-alpha double positive cells in the injured brain areas than did the sham operated controls, when evaluated 3 days after TBI. The TBI-induced cerebral ischemia, neurological motor deficits, and increased numbers of microglia-TNF-alpha double positive cells and increased TNF-alpha levels in the injured brain were all significantly attenuated by etanercept therapy. Conclusion: This finding indicates that early microglia overproduction of TNF-alpha in the injured brain region after TBI contributes to cerebral ischemia and neurological motor deficits, which can be attenuated by etanercept therapy. Studies in this model could provide insight into the mechanisms underlying neurological motor disturbance in brain-injured patients.	[Chio, Chung-Ching; Chang, Chin-Hong; Wang, Che-Chuan; Chao, Chien-Ming; Cheng, Bor-Chih] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Cheong, Chong-Un; Chao, Chien-Ming] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Chang, Ching-Ping] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Cheng, Bor-Chih; Yang, Chung-Zhing] Taipei Med Univ, PhD Program Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan		Chang, CP (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.	jessica.cpchang@gmail.com	Bilfinger, Thomas V./J-6392-2019	Chang, Ching-Ping/0000-0003-0890-9414	Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC98-2314-B-218-MY2, NSC99-2314-B-384-004-MY3, NSC100-2314-B-218-001, NSC101-2314-B-218-001-MY3]; Taiwan Department of Health Center of Excellence for Clinical Trials and Research in Neuroscience [DOH99-TD-B-111-003]	This study was funded in part by the Taiwan National Science Council (NSC98-2314-B-218-MY2, NSC99-2314-B-384-004-MY3, NSC100-2314-B-218-001, NSC101-2314-B-218-001-MY3), and the Taiwan Department of Health Center of Excellence for Clinical Trials and Research in Neuroscience (DOH99-TD-B-111-003).	Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Perry SW, 2002, J NEUROVIROL, V8, P611, DOI 10.1080/13550280290101021; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Taupin V, 1993, J NEUROIMMUNOL, V42, P177; Wang Y, 1997, J NEUROSCI, V17, P4341; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	39	61	63	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	MAR 15	2013	14								33	10.1186/1471-2202-14-33			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	139WM	WOS:000318615700001	23496862	gold, Green Published			2022-02-06	
J	Zhang, MR; Red, SD; Lin, AH; Patel, SS; Sereno, AB				Zhang, Marsha R.; Red, Stuart D.; Lin, Angela H.; Patel, Saumil S.; Sereno, Anne B.			Evidence of Cognitive Dysfunction after Soccer Playing with Ball Heading Using a Novel Tablet-Based Approach	PLOS ONE			English	Article							NEUROPSYCHOLOGICAL CONSEQUENCE; TASK-PERFORMANCE; PLAYERS; SCHIZOPHRENIA; ASSOCIATIONS; EXERCISE; FEMALE	Does frequent head-to-ball contact cause cognitive dysfunctions and brain injury to soccer players? An iPad-based experiment was designed to examine the impact of ball-heading among high school female soccer players. We examined both direct, stimulus-driven, or reflexive point responses (Pro-Point) as well as indirect, goal-driven, or voluntary point responses (Anti-Point), thought to require cognitive functions in the frontal lobe. The results show that soccer players were significantly slower than controls in the Anti-Point task but displayed no difference in Pro-Point latencies, indicating a disruption specific to voluntary responses. These findings suggest that even subconcussive blows in soccer can result in cognitive function changes that are consistent with mild traumatic brain injury of the frontal lobes. There is great clinical and practical potential of a tablet-based application for quick detection and monitoring of cognitive dysfunction.	[Zhang, Marsha R.; Red, Stuart D.; Lin, Angela H.; Patel, Saumil S.; Sereno, Anne B.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA; [Patel, Saumil S.] Baylor Coll Med, Houston, TX 77030 USA		Sereno, AB (corresponding author), Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.	Anne.B.Sereno@uth.tmc.edu		Patel, Saumil/0000-0002-2386-8940	NSFNational Science Foundation (NSF) [BS 0924636]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30EY010608]; Division Of Behavioral and Cognitive SciNational Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE) [0924636] Funding Source: National Science Foundation; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY010608] Funding Source: NIH RePORTER	This work was supported in part by NSF BS 0924636 and NIH P30EY010608 grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Audiffren M, 2008, ACTA PSYCHOL, V129, P410, DOI 10.1016/j.actpsy.2008.09.006; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Broerse A, 2001, PSYCHIAT RES, V103, P167, DOI 10.1016/S0165-1781(01)00275-X; Everling S, 1998, NEUROPSYCHOLOGIA, V36, P885, DOI 10.1016/S0028-3932(98)00020-7; Gooding DC, 2004, PSYCHOL MED, V34, P921, DOI 10.1017/S003329170300165X; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hill SK, 2008, SCHIZOPHRENIA BULL, V34, P494, DOI 10.1093/schbul/sbm112; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V22, P1; Kelly JC, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/371970; Khatoon S, 2002, VISION RES, V42, P2693, DOI 10.1016/S0042-6989(02)00327-9; Kim N, 2011, MAKING SOCCER SAFER; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lambourne K, 2010, BRAIN RES, V1341, P12, DOI 10.1016/j.brainres.2010.03.091; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rutherford A, 2003, NEUROPSYCHOL REV, V13; SERENO AB, 1995, BIOL PSYCHIAT, V37, P394, DOI 10.1016/0006-3223(94)00127-O; Shrestha Y, 2011, TABLET BASED STIMULU, P64; Squire LR, 2009, ENCY NEUROSCIENCE, P117; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Toni I, 2001, EXP BRAIN RES, V141, P359, DOI 10.1007/s002210100877; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wise SP, 2000, TRENDS NEUROSCI, V23, P271, DOI 10.1016/S0166-2236(00)01570-8; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	29	61	62	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e57364	10.1371/journal.pone.0057364			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	098BN	WOS:000315519000097	23460843	gold, Green Published			2022-02-06	
J	Liu, X; An, CY; Jin, P; Liu, XS; Wang, LH				Liu, Xin; An, Chiying; Jin, Peng; Liu, Xuesong; Wang, Longhu			Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia	BIOMATERIALS			English	Article						Tanshinone IIA; Cationic bovine serum albumin; PEGylated nanoparticles; Cerebral ischemia; Neuroprotection	TRAUMATIC BRAIN-INJURY; THERAPEUTIC TARGET; COPOLYMER NANOPARTICLES; MOLECULAR-MECHANISMS; REPERFUSION INJURY; PLA NANOPARTICLES; ARTERY OCCLUSION; PPAR-GAMMA; STROKE; INFLAMMATION	Tanshinone IIA is a good candidate for treating cerebral ischemia, but its short half-life and poor permeability across the blood brain-barrier (BBB) limit its curative efficacy. In this study, we successfully developed cationic bovine serum albumin-conjugated tanshinone IIA PEGylated nanoparticles (CBSA-PEG-TIIA-NPs). A cerebral ischemia rat model was established to evaluate the treatment efficacy and protective mechanism of CBSA-PEG-TIIA-NPs. CBSA-PEG-TIIA-NPs showed the mean particle size 118 +/- 14 nm with drug loaded ratio and encapsulation efficiency 5.69 +/- 0.6% and 83.2 +/- 2.6%, respectively. The pharmacokinetics demonstrated that CBSA-PEG-TIIA-NPs could significantly prolong circulation time and increase plasma concentration compared with intravenously administrated TIIA solution. The biodistribution and brain uptake study confirmed that CBSA-PEG-TIIA-NPs possessed better brain delivery efficacy with a high accumulation in brain. CBSA-PEG-TIIA-NPs obviously ameliorated infarct volume, neurological deficit and histopathological severity. Treatment with CBSA-PEG-TIIA-NPs markedly inhibited the levels of the MPO, TNF-alpha, IL-1 beta p and IL-6. Furthermore, CBSA-PEG-TIIA-NPs significantly decreased the mRNA expressions of iNOS and p38MAPK, upregulated PPAR gamma expression, and inhibited the protein levels of iNOS, GFAP and p38MAPK phosphorylation. These results demonstrated that CBSA-PEG-TIIA-NPs possessed remarkable neuroprotective effects on ischemic stroke through modulation of inflammatory cascades and neuronal signal pathways involved in cerebral ischemia. Crown Copyright (c) 2012 Published by Elsevier Ltd. All rights reserved.	[Liu, Xin; Liu, Xuesong; Wang, Longhu] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; [An, Chiying] Harbin Med Univ, Affiliated Hosp 1, Harbin 150001, Peoples R China; [Jin, Peng] Harbin Med Univ, Affiliated Hosp 4, Harbin 150001, Peoples R China		Liu, X (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.	xinliu98@126.com		Liu, Xin/0000-0001-5934-2118	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30902008]; Youth Scientific Innovation Special Program of Basic research Foundation of Zhejiang University, China [2010QNA7026]	This study was supported by grants from the National Natural Science Foundation of China (NO. 30902008) and the Youth Scientific Innovation Special Program of Basic research Foundation of Zhejiang University, China (NO. 2010QNA7026).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barone FC, 1992, STROKE, V23, P1347; BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420; BERGMANN P, 1984, CLIN SCI, V67, P35, DOI 10.1042/cs0670035; Bernardi A, 2010, NEUROCHEM INT, V57, P629, DOI 10.1016/j.neuint.2010.07.012; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745; Castellanos M, 2002, STROKE, V33, P982, DOI 10.1161/hs0402.105339; Chen J, 2009, HIPPOCAMPUS, V19, P79, DOI 10.1002/hipo.20479; Chen X, 2007, XENOBIOTICA, V37, P635, DOI 10.1080/00498250701411258; Cheyuo C, 2012, NEUROPHARMACOLOGY, V62, P890, DOI 10.1016/j.neuropharm.2011.09.018; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Cimini A, 2012, ACTA BIOMATER, V8, P2056, DOI 10.1016/j.actbio.2012.01.035; Collino Massimo, 2008, Ther Adv Cardiovasc Dis, V2, P179, DOI 10.1177/1753944708090924; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; Dong YC, 2004, BIOMATERIALS, V25, P2843, DOI 10.1016/j.biomaterials.2003.09.055; [杜玮 DU Wei], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P786; Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Gao F, 2002, CARDIOVASC RES, V53, P414, DOI 10.1016/S0008-6363(01)00488-6; Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164; Jain AK, 2010, INT J PHARMACEUT, V387, P253, DOI 10.1016/j.ijpharm.2009.12.013; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Jeong S, 2012, J NEUROSURG ANESTH, V24, P51, DOI 10.1097/ANA.0b013e3182368d70; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Karakoti AS, 2011, ANGEW CHEM INT EDIT, V50, P1980, DOI 10.1002/anie.201002969; Kovalska M, 2012, NEUROCHEM RES, V37, P1568, DOI 10.1007/s11064-012-0752-y; Lerouet D, 2002, BRAIN RES, V958, P166, DOI 10.1016/S0006-8993(02)03685-5; Liu JP, 2005, DRUG DEV IND PHARM, V31, P551, DOI 10.1080/03639040500214761; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lou HY, 2004, CHINESE J PHYSIOL, V47, P197; Lu W, 2007, J CONTROL RELEASE, V118, P38, DOI 10.1016/j.jconrel.2006.11.015; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Parikh T, 2010, EUR J PHARM BIOPHARM, V74, P442, DOI 10.1016/j.ejpb.2009.11.001; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Soo PL, 2008, EUR J PHARM BIOPHARM, V69, P149, DOI 10.1016/j.ejpb.2007.11.003; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tang C, 2010, PHYTOMEDICINE, V17, P1145, DOI 10.1016/j.phymed.2010.03.017; Vila N, 2001, STROKE, V32, P1234, DOI 10.1161/01.STR.32.5.1234-a; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wang XL, 2007, APOPTOSIS, V12, P1209, DOI 10.1007/s10495-007-0055-y; Wei Q, 2008, J COLLOID INTERF SCI, V323, P267, DOI 10.1016/j.jcis.2008.04.058; Xiao RZ, 2010, INT J NANOMED, V5, P1057, DOI [10.2147/ijn.S14912, 10.2147/IJN.S14912]; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Yu JH, 2008, INT J BIOCHEM CELL B, V40, P677, DOI 10.1016/j.biocel.2007.10.007; Zhang Y, 2004, COLLOID POLYM SCI, V282, P1323, DOI 10.1007/s00396-004-1068-5	59	61	62	2	82	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JAN	2013	34	3					817	830		10.1016/j.biomaterials.2012.10.017			14	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	060ER	WOS:000312759800022	23111336				2022-02-06	
J	Macher, H; Egea-Guerrero, JJ; Revuelto-Rey, J; Gordillo-Escobar, E; Enamorado-Enamorado, J; Boza, A; Rodriguez, A; Molinero, P; Guerrero, JM; Dominguez-Roldan, JM; Murillo-Cabezas, F; Rubio, A				Macher, Hada; Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Boza, Antonio; Rodriguez, Ana; Molinero, Patrocinio; Guerrero, Juan M.; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco; Rubio, Amalia			Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						Cell free-DNA; Prognostic marker; Real-time PCR; Traumatic brain injury	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PLASMA DNA; S100-BETA PROTEIN; DAMAGE; SERUM; EXCHANGE; ORIGIN; S100B	Introduction: Circulating cell-free DNA levels are increased after trauma injury. This increase is higher since the first hours after trauma and may be related with primary outcome. A sensitive and reliable biomarker for patients at higher risk is needed to identify these patients to initiate early intervention. In this way, circulating DNA may be a possible biological marker after severe TBI. Materials and methods: We investigated DNA plasma concentrations after severe traumatic brain injury and during the next 96 h in the Intensive Care Unit (ICU) by real time PCR. 65 patients suffering severe TBI were included in the study. Results: Cell-free DNA levels were considerably higher in patients samples compared with voluntary control ones. After the following four days we observed a 51% decrease during the first 24 h and a 71% fall from 48 h. TBI population was stratified for the primary outcome (survivors/non-survivor) and DNA levels decrease ratio was calculated for the first 48 h. A higher decrease in the survivors from 0 h to 24 h compared with the non-survivors was found. A cut-off point of 1.95 ratio was established for the detection of the highest proportions of patients after the TBI that will not survive after the injury with a sensitivity of 70% and specificity of 66%. Conclusions: In summary we showed that severe TBI is associated with elevated cf-DNA levels and we propose that cf-DNA decrease during the first 24 h may predict patient outcome. (C) 2012 Elsevier B.V. All rights reserved.	[Macher, Hada; Boza, Antonio; Rodriguez, Ana; Molinero, Patrocinio; Guerrero, Juan M.; Rubio, Amalia] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS, Seville, Spain; [Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio Sevilla, Serv Cuidados Criticos, Seville, Spain; [Egea-Guerrero, Juan J.; Revuelto-Rey, Jaume; Gordillo-Escobar, Elena; Enamorado-Enamorado, Judy; Dominguez-Roldan, Jose M.; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio Sevilla, Urgencias Hosp Traumatol, Seville, Spain		Rubio, A (corresponding author), Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS, Seville, Spain.	hadamacher@hotmail.com; jjegeaguerrero@gmail.com; drjau@hotmail.com; lenylane@hotmail.com; drajudyenamorado@gmail.com; darkenns@gmail.com; swroder_an@hotmail.com; molinero@us.es; guerrero@us.es; jmdominguez@telefonica.net; murillomunoz@telefonica.net; amaliarubio@us.es	Dominguez-Roldan, Jose-Maria/M-1728-2016; IBIS, NEUROCRITICOS/C-1805-2016; Rodriguez-Rodriguez, Ana/F-4718-2016; Egea-Guerrero, Juan Jose JJ/P-5080-2014; Guerrero, Josep M./Y-2929-2019; Rubio, Amalia/L-1992-2017; Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROINMUNO/O-9306-2015	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Rodriguez-Rodriguez, Ana/0000-0002-6854-9695; Egea-Guerrero, Juan Jose JJ/0000-0002-4166-313X; Guerrero, Josep M./0000-0001-5236-4592; Rubio, Amalia/0000-0002-5905-0534; Revuelto-Rey, Jaume/0000-0001-8350-9555; Guerrero, Juan Miguel/0000-0001-7553-0119; Macher, Hada/0000-0002-8622-1175; Molinero Hueso, Patrocinio/0000-0002-2988-0422	MAPFRE Foundation	This work was supported by a research grant from the MAPFRE Foundation.	Arnalich F, 2010, CRIT CARE, V14, DOI 10.1186/cc8934; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Burns S, 2004, ANN NY ACAD SCI, V1022, P323; Butt AN, 2008, ANN NY ACAD SCI, V1137, P236, DOI 10.1196/annals.1448.002; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; DUFF D, 2003, AXONE, V23, P18; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Gahan PB, 2008, ANN NY ACAD SCI, V1137, P7, DOI 10.1196/annals.1448.046; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Holdenrieder S, 2009, CRIT REV CL LAB SCI, V46, P1, DOI [10.1080/10408360802485875, 10.1080/10408360802485875 ]; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Lam NYL, 2003, CLIN CHEM, V49, P1286, DOI 10.1373/49.8.1286; LEON SA, 1977, CANCER RES, V37, P646; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Lo YMD, 2000, CLIN CHEM, V46, P319; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Macher HC, 2012, CLIN CHIM ACTA, V413, P490, DOI 10.1016/j.cca.2011.11.004; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Navratil O, 2006, Bratisl Lek Listy, V107, P110; Ohayon S, 2012, J NEUROTRAUM, V29, P261, DOI 10.1089/neu.2011.1938; Palomaki GE, 2011, GENET MED, V13, P913, DOI 10.1097/GIM.0b013e3182368a0e; Papasavva T, 2008, ANN NY ACAD SCI, V1137, P302, DOI 10.1196/annals.1448.029; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Rainer TH, 2001, CLIN CHIM ACTA, V313, P81, DOI 10.1016/S0009-8981(01)00653-2; Saukkonen K, 2008, CLIN CHEM, V54, P1000, DOI 10.1373/clinchem.2007.101030; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Tong YK, 2006, CLIN CHIM ACTA, V363, P187, DOI 10.1016/j.cccn.2005.05.048; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	38	61	67	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC 24	2012	414						12	17		10.1016/j.cca.2012.08.001			6	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	059DU	WOS:000312685400003	22902808				2022-02-06	
J	Ahmed, F; Gyorgy, A; Kamnaksh, A; Ling, G; Tong, L; Parks, S; Agoston, D				Ahmed, Farid; Gyorgy, Andrea; Kamnaksh, Alaa; Ling, Geoffrey; Tong, Lawrence; Parks, Steve; Agoston, Denes			Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury	ELECTROPHORESIS			English	Article						Biomarkers; Blast traumatic brain injury; CSF; Large animal model; Proteins	NEURON-SPECIFIC ENOLASE; ENDOTHELIAL GROWTH-FACTOR; VON-WILLEBRAND-FACTOR; CREATINE-KINASE BB; CSF BIOMARKERS; FACTOR VEGF; S100B; SERUM; PATHOPHYSIOLOGY; DAMAGE	Time-dependent changes of protein biomarkers in the cerebrospinal fluid (CSF) can be used to identify the pathological processes in traumatic brain injury (TBI) as well as to follow the progression of the disease. We obtained CSF from a large animal model (swine) of blast-induced traumatic brain injury prior to and at 6, 24, 72 h, and 2 wk after a single exposure to blast overpressure, and determined changes in the CSF levels of neurofilament-heavy chain, neuron-specific enolase, brain-specific creatine kinase, glial fibrillary acidic protein, calcium-binding protein beta (S100 beta), Claudin-5, vascular endothelial growth factor, and von Willebrand factor using reverse phase protein microarray. We detected biphasic temporal patterns in the CSF concentrations of all tested protein markers except S100 beta. The CSF levels of all markers were significantly increased 6 h after the injury compared to preinjury levels. Values were then decreased at 24 h, prior to a second increase in all markers but S100 beta at 72 h. At 2 wk postinjury, the CSF concentrations of all biomarkers were decreased once again; brain-specific creatine kinase, Claudin-5, von Willebrand factor, and S100 beta levels were no longer significantly higher than their preinjury values while neurofilament-heavy chain, neuron-specific enolase, vascular endothelial growth factor, and glial fibrillary acidic protein levels remained significantly elevated compared to baseline. Our findings implicate neuronal and glial cell damage, compromised vascular permeability, and inflammation in blast-induced traumatic brain injury, as well as demonstrate the value of determining the temporal pattern of biomarker changes that may be of diagnostic value.	[Ahmed, Farid; Gyorgy, Andrea; Kamnaksh, Alaa; Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Tong, Lawrence] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Parks, Steve] ORA Inc, Fredericksburg, VA USA		Agoston, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Defense Advanced Research Projects Agency's (DARPA) Preventing Violent Explosive Neurologic Trauma (PREVENT)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	The work was funded by the Defense Advanced Research Projects Agency's (DARPA) Preventing Violent Explosive Neurologic Trauma (PREVENT). We thank Dr. Mattias Skold for his input regarding the clinical implications of our findings. The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency (DARPA) or the Department of Defense (DoD). Approved for public release; distribution unlimited.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Andersson M, 2011, INT J GERIATR PSYCH, V26, P100, DOI 10.1002/gps.2496; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cooper I, 2011, METHODS MOL BIOL, V762, P347, DOI 10.1007/978-1-61779-185-7_25; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Engelhardt B, 2009, SEMIN IMMUNOPATHOL, V31, P497, DOI 10.1007/s00281-009-0177-0; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Guy R J, 2000, J R Nav Med Serv, V86, P27; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HAYAKAWA T, 1984, Neurologia Medico-Chirurgica, V24, P13, DOI 10.2176/nmc.24.13; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Ling G, 2006, NEUROLOGY, V67, P14, DOI 10.1212/01.wnl.0000227781.79800.93; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marmarou A, 2003, ACT NEUR S, V86, P7; Matter K, 2003, J CELL BIOL, V161, P459, DOI 10.1083/jcb.200304039; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Merrill MJ, 2005, J NEUROSURG, V103, P853, DOI 10.3171/jns.2005.103.5.0853; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NORDBY HK, 1982, ACTA NEUROCHIR, V65, P93, DOI 10.1007/BF01405445; Noubade R, 2008, AM J PATHOL, V173, P892, DOI 10.2353/ajpath.2008.080001; PASAOGLU A, 1989, ACTA NEUROCHIR, V97, P71; Paulinska P, 2009, HAMOSTASEOLOGIE, V29, P32, DOI 10.1055/s-0037-1616936; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Plurad DS, 2011, MIL MED, V176, P276, DOI 10.7205/MILMED-D-10-00147; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Ramasamy A, 2009, J R Army Med Corps, V155, P258; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; SANCHEZRODRIGUEZ VF, 1995, AM J FOREN MED PATH, V16, P210, DOI 10.1097/00000433-199509000-00004; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schmitt B, 1998, BRAIN DEV-JPN, V20, P536, DOI 10.1016/S0387-7604(98)00046-1; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sook-Kyung CK, 2011, FRONT NEUROL, V2, P1; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yates D, 2011, NAT REV NEUROL, V7, P63, DOI 10.1038/nrneurol.2010.190; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	88	61	62	4	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3705	3711		10.1002/elps.201200299			7	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900013	23161535				2022-02-06	
J	Moen, KG; Skandsen, T; Folvik, M; Brezova, V; Kvistad, KA; Rydland, J; Manley, GT; Vik, A				Moen, Kent Goran; Skandsen, Toril; Folvik, Mari; Brezova, Veronika; Kvistad, Kjell Arne; Rydland, Jana; Manley, Geoffrey T.; Vik, Anne			A longitudinal MRI study of traumatic axonal injury in patients with moderate and severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							WHITE-MATTER LESIONS; SEVERE HEAD-INJURY; PROGNOSTIC VALUE; CLASSIFICATION; HEMOSIDERIN; DIAGNOSIS; ATROPHY; SCALE; MILD	Objective To study the evolution of traumatic axonal injury (TAI) detected by structural MRI in patients with moderate and severe traumatic brain injury (TBI) during the first year and relate findings to outcome. Methods 58 patients with TBI (Glasgow Coma Scale score 3-13) were examined with MRI at a median of 7 days, 3 months and 12 months post injury. TAI lesions were evaluated blinded and categorised into three stages based on location: hemispheres, corpus callosum and brainstem. Lesions in T2* weighted gradient echo (GRE), fluid attenuated inversion recovery (FLAIR) and diffusion weighted imaging (DWI) were counted and FLAIR lesion volumes were estimated. Inter-rater reliability score was calculated. Outcome was assessed 12 months post injury using the Glasgow Outcome Scale Extended. Results In the initial MRI, 31% had brainstem lesions compared with 17% at 3 months (p=0.008). In the FLAIR sequences, number and volumes of lesions were reduced from early to 3 months (p<0.001). In T2* GRE sequences, the number of lesions persisted at 3 months but was reduced at 12 months (p=0.007). The number of lesions in DWI and volume of FLAIR lesions on early MRI predicted worse clinical outcome in adjusted analyses (p<0.05). Conclusion This is the first study to demonstrate and quantify attenuation of non-haemorrhagic TAI lesions on structural MRI during the first 3 months after TBI; most importantly, the disappearance of brainstem lesions. Haemorrhagic TAI lesions attenuate first after 3 months. Only early MRI findings predicted clinical outcome after adjustment for other prognostic factors. Hence valuable clinical information may be missed if MRI is performed too late after TBI.	[Moen, Kent Goran; Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7489 Trondheim, Norway; [Moen, Kent Goran; Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, Trondheim, Norway; [Folvik, Mari; Kvistad, Kjell Arne; Rydland, Jana] Univ Trondheim Hosp, Dept Diagnost Imaging, St Olavs Hosp, Trondheim, Norway; [Brezova, Veronika; Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Diagnost Imaging, N-7489 Trondheim, Norway; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, Brain & Spinal Injury Ctr, San Francisco, CA USA		Moen, KG (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7489 Trondheim, Norway.	kent.g.moen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Central Norway Regional Health Authority (RHA); Norwegian University of Science and Technology (NTNU); National Resource Center for fMRI, Department of Diagnostic Imaging, St Olav University Hospital	KGM and TS have, during the study period, received a research grant from the liaison committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). VB has, during the study period, received a research grant from the National Resource Center for fMRI, Department of Diagnostic Imaging, St Olav University Hospital.	Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fleiss JL, 1986, RELIABILITY MEASUREM, DOI DOI 10.1002/9781118032923; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goebel R, 2006, HUM BRAIN MAPP, V27, P392, DOI 10.1002/hbm.20249; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Matsusue Eiji, 2006, Magn Reson Med Sci, V5, P99, DOI 10.2463/mrms.5.99; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	37	61	63	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1193	1200		10.1136/jnnp-2012-302644			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700016	22933813				2022-02-06	
J	Ahmad, A; Crupi, R; Impellizzeri, D; Campolo, M; Marino, A; Esposito, E; Cuzzocrea, S				Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Campolo, Michela; Marino, Angela; Esposito, Emanuela; Cuzzocrea, Salvatore			Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Inflammation; PEA; Mast cells; GFAP	SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; MAST-CELLS; BEHAVIORAL RECOVERY; CEREBRAL-ISCHEMIA; HYPERALGESIA; INFLAMMATION; RAT; ENDOCANNABINOIDS	Traumatic brain injury (TBI) is a major Cause of preventable death and morbidity in young adults. This complex condition is characterized by significant blood brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether treatments that enhance plasticity might improve functional recovery, a controlled cortical impact (CCI) in adult mice, as a model of TBI, in which a controlled cortical impactor produced full thickness lesions of the forelimb region of the sensorimotor cortex, was performed. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The endogenous fatty acid palmitoylethanolamide (PEA) is one of the members of N-acyl-ethanolamines family that maintain not only redox balance but also inhibit the mechanisms of secondary injury. Therefore, we tested whether PEA shows efficacy in a mice model of experimental TBI. PEA treatment is able to reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level further support the efficacy of PEA therapy. The PEA treatment blocked infiltration of astrocytes and restored CCI-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, CD11b and GFAP. PEA inhibited the TBI-mediated decrease in the expression of RINK and NF-kappa B. PEA-treated injured animals improved neurobehavioral functions as evaluated by behavioral tests. (C) 2012 Elsevier Inc. All rights reserved.	[Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Campolo, Michela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, I-98100 Messina, Italy; [Marino, Angela] Univ Messina, Sect Gen Physiol & Pharmacol, Dept Life Sci M Malpighi, I-98100 Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Sch Med, Manchester Royal Infirm, Manchester Biomed Res Ctr, Manchester M13 9PL, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, Policlin Univ Via C, I-98100 Messina, Italy.	salvator@unime.it	Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019	Ahmad, Akbar/0000-0003-1841-9670; Cuzzocrea, Salvatore/0000-0001-6131-3690; Impellizzeri, Daniela/0000-0001-9492-3161; Crupi, Rosalia/0000-0002-7629-3132	European CommunityEuropean Commission [PON01-02512]	This study was supported by a grant from European Community (National Operative Programme "Research and Competitiveness 2007-2013", PON01-02512). The authors thank Carmelo La Spada for their excellent technical assistance during this study.	Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Bethea JR, 1998, J NEUROSCI, V18, P3251; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Farquhar-Smith WP, 2001, ANESTHESIOLOGY, V94, P507, DOI 10.1097/00000542-200103000-00023; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; KOWNATZKI E, 1982, MOL IMMUNOL, V19, P1297, DOI 10.1016/0161-5890(82)90296-6; Lambert DM, 2001, EPILEPSIA, V42, P321, DOI 10.1046/j.1528-1157.2001.41499.x; Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Michaloudi HC, 1999, J ANAT, V195, P577, DOI 10.1046/j.1469-7580.1999.19540577.x; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rice ASC, 2002, PROSTAG LEUKOTR ESS, V66, P243, DOI 10.1054/plef.2001.0362; Ross RA, 2000, EUR J PHARMACOL, V401, P121, DOI 10.1016/S0014-2999(00)00437-4; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Theodosiou M, 1999, PAIN, V81, P245, DOI 10.1016/S0304-3959(99)00018-4; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zuo YX, 2003, PAIN, V105, P467, DOI 10.1016/S0304-3959(03)00261-6	48	61	65	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2012	26	8					1310	1321		10.1016/j.bbi.2012.07.021			12	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	025JV	WOS:000310186000016	22884901				2022-02-06	
J	Viola-Saltzman, M; Watson, NF				Viola-Saltzman, Mari; Watson, Nathaniel F.			Traumatic Brain Injury and Sleep Disorders	NEUROLOGIC CLINICS			English	Article						Traumatic brain injury; Concussion; Insomnia; Fatigue; Hypersomnia; Sleep apnea; Restless legs syndrome	EXCESSIVE DAYTIME SLEEPINESS; KLEINE-LEVIN-SYNDROME; MINOR HEAD-INJURY; CIRCADIAN-RHYTHM; UNITED-STATES; DISTURBANCES; INSOMNIA; PREVALENCE; VETERANS; COMPLAINTS	Sleep disturbance is common after traumatic brain injury (TBI). Insomnia, fatigue, and sleepiness are the most frequent post-TBI sleep complaints with narcolepsy (with or without cataplexy), sleep apnea (obstructive or central), periodic limb movement disorder, and parasomnias occurring less commonly. In addition, depression, anxiety, and pain are common TBI comorbidities with substantial influence on sleep quality. Diagnosis of sleep disorders after TBI may involve polysomnography, multiple sleep latency testing, or actigraphy. Treatment is disorder-specific and includes the use of medications, continuous positive airway pressure, or behavioral modifications. Unfortunately, treatment of sleep disorders associated with TBI often does not improve sleepiness or neuropsychologic function.	[Watson, Nathaniel F.] Univ Washington, Med Sleep Ctr, Seattle, WA 98104 USA; [Viola-Saltzman, Mari] N Shore Univ HealthSyst, Pritzker Sch Med, Dept Neurol, Evanston, IL 60201 USA		Watson, NF (corresponding author), Univ Washington, Med Sleep Ctr, 325 9th Ave,Box 359803, Seattle, WA 98104 USA.	nwatson@uw.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23 HL083350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL083350] Funding Source: NIH RePORTER		[Anonymous], 2005, INT CLASS SLEEP DIS, p[xviii, 297]; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Arnulf I, 2005, BRAIN, V128, P2763, DOI 10.1093/brain/awh620; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; BRICOLO A, 1968, ACTA NEUROL SCAND, V44, P512, DOI 10.1111/j.1600-0404.1968.tb05589.x; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Carter KA, 2010, J CLIN SLEEP MED, V6, P205; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Dauvilliers Y, 2003, J NEUROL NEUROSUR PS, V74, P1667, DOI 10.1136/jnnp.74.12.1667; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kelly JP, 1997, NEUROLOGY, V48, P581; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leduc BE, 2007, ARCH PHYS MED REHAB, V88, P333, DOI 10.1016/j.apmr.2006.12.025; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schenck CH, 1997, SLEEP, V20, P972, DOI 10.1093/sleep/20.11.972; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Theodorou AA, 2007, J CLIN SLEEP MED, V3, P347; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; WINSTON SR, 1979, J IOWA MED SOC, V69, P393; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	55	61	65	1	33	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2012	30	4					1299	+		10.1016/j.ncl.2012.08.008			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047XI	WOS:000311874400016	23099139	Green Accepted			2022-02-06	
J	Timaru-Kast, R; Luh, C; Gotthardt, P; Huang, CS; Schafer, MK; Engelhard, K; Thal, SC				Timaru-Kast, Ralph; Luh, Clara; Gotthardt, Philipp; Huang, Changsheng; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.			Influence of Age on Brain Edema Formation, Secondary Brain Damage and Inflammatory Response after Brain Trauma in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; PROSPECTIVE MULTICENTER TRIAL; NF-KAPPA-B; OXIDATIVE STRESS; GENE-EXPRESSION; OLDER-ADULTS; HEAD-INJURY; ENVIRONMENTAL ENRICHMENT; NEURONAL DEATH	After traumatic brain injury (TBI) elderly patients suffer from higher mortality rate and worse functional outcome compared to young patients. However, experimental TBI research is primarily performed in young animals. Aim of the present study was to clarify whether age affects functional outcome, neuroinflammation and secondary brain damage after brain trauma in mice. Young (2 months) and old (21 months) male C57Bl6N mice were anesthetized and subjected to a controlled cortical impact injury (CCI) on the right parietal cortex. Animals of both ages were randomly assigned to 15 min, 24 h, and 72 h survival. At the end of the observation periods, contusion volume, brain water content, neurologic function, cerebral and systemic inflammation (CD3+ T cell migration, inflammatory cytokine expression in brain and lung, blood differential cell count) were determined. Old animals showed worse neurological function 72 h after CCI and a high mortality rate (19.2%) compared to young (0%). This did not correlate with histopathological damage, as contusion volumes were equal in both age groups. Although a more pronounced brain edema formation was detected in old mice 24 hours after TBI, lack of correlation between brain water content and neurological deficit indicated that brain edema formation is not solely responsible for age-dependent differences in neurological outcome. Brains of old naive mice were about 8% smaller compared to young naive brains, suggesting age-related brain atrophy with possible decline in plasticity. Onset of cerebral inflammation started earlier and primarily ipsilateral to damage in old mice, whereas in young mice inflammation was delayed and present in both hemispheres with a characteristic T cell migration pattern. Pulmonary interleukin 1 beta expression was up-regulated after cerebral injury only in young, not aged mice. The results therefore indicate that old animals are prone to functional deficits and strong ipsilateral cerebral inflammation without major differences in morphological brain damage compared to young.	[Timaru-Kast, Ralph; Luh, Clara; Gotthardt, Philipp; Huang, Changsheng; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anaesthesiol, Mainz, Germany; [Huang, Changsheng; Schaefer, Michael K.; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci, Mainz, Germany		Timaru-Kast, R (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anaesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Huang, Changsheng/0000-0003-0535-1865	Focus Program Translational Neurosciences of the Johannes Gutenberg-University	This work was supported by grants from the Focus Program Translational Neurosciences of the Johannes Gutenberg-University to SCT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PLOS ONE; Arnett HA, 2003, J NEUROSCI, V23, P9824; Ashcroft GS, 2002, BIOGERONTOLOGY, V3, P337, DOI 10.1023/A:1021399228395; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Barnes CJ, 1998, AGING-CLIN EXP RES, V10, P455, DOI 10.1007/BF03340159; Barreto G, 2010, J NEUROSURG ANESTH, V22, P214, DOI 10.1097/ANA.0b013e3181d56c98; Bieber AJ, 2003, ANN NEUROL, V53, P680, DOI 10.1002/ana.10578; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Castillo-Ruiz MM, 2007, EXP GERONTOL, V42, P343, DOI 10.1016/j.exger.2006.10.008; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Popa-Wagner A, 2007, ACTA NEUROPATHOL, V113, P277, DOI 10.1007/s00401-006-0164-7; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Popa-Wagner A, 2010, CURR NEUROVASC RES, V7, P251, DOI 10.2174/156720210792231813; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Sandhu SK, 2002, BIOGERONTOLOGY, V3, P161, DOI 10.1023/A:1015643107449; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharman KG, 2002, NEUROBIOL AGING, V23, P633, DOI 10.1016/S0197-4580(01)00329-3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Williams B, 2007, NEUROSCI LETT, V413, P110, DOI 10.1016/j.neulet.2006.11.040; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	79	61	65	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2012	7	8							e43829	10.1371/journal.pone.0043829			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	997ZH	WOS:000308206500024	22952778	gold, Green Published, Green Submitted			2022-02-06	
J	Chen, A; Bushmeneva, K; Zagorski, B; Colantonio, A; Parsons, D; Wodchis, WP				Chen, Amy; Bushmeneva, Ksenia; Zagorski, Brandon; Colantonio, Angela; Parsons, Daria; Wodchis, Walter P.			Direct cost associated with acquired brain injury in Ontario	BMC NEUROLOGY			English	Article							MEDICAL-CARE; EPIDEMIOLOGY; COHORT; HEALTH; OUTCOMES; MILD	Background: Acquired Brain Injury (ABI) from traumatic and non traumatic causes is a leading cause of disability worldwide yet there is limited research summarizing the health system economic burden associated with ABI. The objective of this study was to determine the direct cost of publicly funded health care services from the initial hospitalization to three years post-injury for individuals with traumatic (TBI) and non-traumatic brain injury (nTBI) in Ontario Canada. Methods: A population-based cohort of patients discharged from acute hospital with an ABI code in any diagnosis position in 2004 through 2007 in Ontario was identified from administrative data. Publicly funded health care utilization was obtained from several Ontario administrative healthcare databases. Patients were stratified according to traumatic and non-traumatic causes of brain injury and whether or not they were discharged to an inpatient rehabilitation center. Health system costs were calculated across a continuum of institutional and community settings for up to three years after initial discharge. The continuum of settings included acute care emergency departments inpatient rehabilitation (IR) complex continuing care home care services and physician visits. All costs were calculated retrospectively assuming the government payer's perspective. Results: Direct medical costs in an ABI population are substantial with mean cost in the first year post-injury per TBI and nTBI patient being $32132 and $38018 respectively. Among both TBI and nTBI patients those discharged to IR had significantly higher treatment costs than those not discharged to IR across all institutional and community settings. This tendency remained during the entire three-year follow-up period. Annual medical costs of patients hospitalized with a brain injury in Ontario in the first follow-up year were approximately $120.7 million for TBI and $368.7 million for nTBI. Acute care cost accounted for 46-65% of the total treatment cost in the first year overwhelming all other cost components. Conclusions: The main finding of this study is that direct medical costs in ABI population are substantial and vary considerably by the injury cause. Although most expenses occur in the first follow-up year ABI patients continue to use variety of medical services in the second and third year with emphasis shifting over time from acute care and inpatient rehabilitation towards homecare physician services and long-term institutional care. More research is needed to capture economic costs for ABI patients not admitted to acute care.	[Chen, Amy; Colantonio, Angela; Parsons, Daria; Wodchis, Walter P.] Toronto Rehabil Inst, Toronto, ON, Canada; [Bushmeneva, Ksenia; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Zagorski, Brandon; Wodchis, Walter P.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada		Wodchis, WP (corresponding author), Toronto Rehabil Inst, Toronto, ON, Canada.	walter.wodchis@utoronto.ca	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Colantonio, Angela/0000-0003-2094-4765; wodchis, walter/0000-0003-2494-7031	Ontario Neurotrauma Foundation; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Health System Performance Research Network	This study was supported by funding from the Ontario Neurotrauma Foundation and a grant from the Ministry of Health and Long Term Care to Toronto Rehabilitation Institute as well as funding from the Health System Performance Research Network which is also supported by a grant from the Ontario Ministry of Health and Long-Term Care. We would like to thank the Ministry of Health and Long Term Care in providing us with data and the Canadian Institute for Health Information for advice on data quality and codes. Finally we would like to extend our thanks to Rika Vander Laan for her input in methodology discussions.	ABI Network, 2012, DEF ACQ BRAIN INJ; Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS84, DOI 10.1007/s10198-005-0293-2; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Canadian Institute of Health Information, NRS LENGTH STAY LENG; Canadian Institute of Health Information, NAT REH REP SYST NRS; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chen AY, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-16; Colantonio A, 2009, TORONTO ABI DATASET; Collier R, 2009, CAN MED ASSOC J, V181, P668, DOI 10.1503/cmaj.109-3068; Croxford R., 2006, CANADIAN I HLTH INFO; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Krahn MD, 2010, BJU INT, V105, P338, DOI 10.1111/j.1464-410X.2009.08758.x; Krajden M, 2010, CAN J GASTROENTEROL, V24, P717, DOI 10.1155/2010/569692; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Mar J, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-46; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; National health expenditure trends, 1975, NAT HLTH EXP TRENDS; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ontario Joint Policy and Planning Committee, DEV REH PAT GROUPS R; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; SNOW WG, 1988, CAN J SURG, V31, P191; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Wodchis WP, 2008, MED CARE, V46, P882, DOI 10.1097/MLR.0b013e3181789471; Wodchis WP, 2011, TARGETING HLTH SYSTE; Wooder SD., 2011, PRIMARY CARE COMPENS; World Health Organization (WHO), 2006, NEUR DIS	40	61	61	1	20	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 17	2012	12								76	10.1186/1471-2377-12-76			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	052MJ	WOS:000312201700001	22901094	Green Published, gold			2022-02-06	
J	Kalkonde, YV; Jawaid, A; Qureshi, SU; Shirani, P; Wheaton, M; Pinto-Patarroyo, GP; Schulz, PE				Kalkonde, Yogeshwar V.; Jawaid, Ali; Qureshi, Salah U.; Shirani, Peyman; Wheaton, Michael; Pinto-Patarroyo, Gineth P.; Schulz, Paul E.			Medical and environmental risk factors associated with frontotemporal dementia: A case-control study in a veteran population	ALZHEIMERS & DEMENTIA			English	Article						Frontotemporal dementia; Veterans; Risk factors; Traumatic brain injury; Heart disease; Cerebrovascular disease	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; LOBAR DEGENERATION; INTERNATIONAL WORKSHOP; PROPENSITY SCORE; PROGRANULIN; HEALTH; ENCEPHALOPATHY; PREVALENCE	Background: Compared with other major dementias, very little is known about the medical and environmental risk factors associated with frontotemporal dementia (FTD). In this study, we evaluated medical and environmental disorders associated with FTD in a veteran population. Methods: The medical records of 845 consecutive veterans who were evaluated for cognitive and/or behavioral complaints at a cognitive disorders clinic in an academic medical center between March 1, 2003, and June 30, 2008, were reviewed and 554 patients received a diagnosis of dementia. Medical disorders and environmental risk factors in 63 patients with behavioral variant of FTD were compared with 491 patients with non-FTD dementias. Results: The prevalence of traumatic brain injury (TBI) was significantly greater in patients with FTD versus those with non-FTD dementias (12.7% vs 3.5%; P < .05). The FTD group also had a lower prevalence of heart disease (19.0% vs 36.7%; P < .05) and cerebrovascular diseases (12.7% vs 26.1%; P < .05), although the prevalence of vascular risk factors was comparable between FTD and non-FTD dementia groups: hypertension (65.1% vs 68.2%), diabetes (31.7% vs 26.9%), hyperlipidemia (42.9% vs 48.9%), and tobacco use (7.9% vs 8.8%; P > .05 for all). In multivariate analysis, the risk for FTD was increased in patients with TBI (OR, 4.4; 95% CI, 1.6-11.8). The risk for FTD was marginally decreased in patients with heart disease (OR, 0.4; 95% CI, 0.3-0.96). Conclusions: In a clinical sample of veterans, risk of FTD was increased in patients with TBI and marginally decreased in patients with heart disease. Prospective studies are needed to confirm these associations temporally and to identify their underlying mechanisms. (C) 2012 The Alzheimer's Association. All rights reserved.	[Jawaid, Ali; Schulz, Paul E.] Univ Texas Hlth Sci Ctr, Dept Neurol, Houston, TX 77225 USA; [Kalkonde, Yogeshwar V.; Qureshi, Salah U.; Shirani, Peyman; Wheaton, Michael; Pinto-Patarroyo, Gineth P.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Kalkonde, Yogeshwar V.; Qureshi, Salah U.; Shirani, Peyman] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Qureshi, Salah U.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA		Schulz, PE (corresponding author), Univ Texas Hlth Sci Ctr, Dept Neurol, Houston, TX 77225 USA.	Paul.E.Schulz@uth.tmc.edu	Kalkonde, Yogeshwar/O-2926-2019	Kalkonde, Yogeshwar/0000-0003-3543-3618; Jawaid, Ali/0000-0002-5126-6744	Lou DeGeorge Foundation; Department of Veteran AffairsUS Department of Veterans Affairs	The authors thank the Lou DeGeorge family for continued invaluable support. The study was supported in part by the Lou DeGeorge Foundation and the Department of Veteran Affairs. Both of these sources did not have any role in the study design and implementation, data analysis and interpretation, or the preparation of this report.	Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Becker SO, 2002, STATA J, V2, P358, DOI 10.1177/1536867X0200200403; Benussi L, 2010, EUR J NEUROL, V17, P143, DOI 10.1111/j.1468-1331.2009.02767.x; Bernardi L, 2006, NEUROBIOL AGING, V27, P702, DOI 10.1016/j.neurobiolaging.2005.03.008; Bird T, 2003, ANN NEUROL, V54, pS29, DOI 10.1002/ana.10572; Brunnstrom H, 2009, ARCH GERONTOL GERIAT, V49, P146, DOI 10.1016/j.archger.2008.06.005; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Duckworth J, CURR OPIN C IN PRESS; Dupuis L, 2008, NEUROLOGY, V70, P1004, DOI 10.1212/01.wnl.0000285080.70324.27; Finch N, 2009, BRAIN, V132, P583, DOI 10.1093/brain/awn352; Fitzmaurice G, 2006, NUTRITION, V22, P1214, DOI 10.1016/j.nut.2006.08.015; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; Ghidoni R, 2008, NEUROLOGY, V71, P1235, DOI 10.1212/01.wnl.0000325058.10218.fc; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jawaid A, 2010, EUR J NEUROL, V17, P733, DOI 10.1111/j.1468-1331.2009.02923.x; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; KNOPMAN DS, 1990, NEUROLOGY, V40, P251, DOI 10.1212/WNL.40.2.251; Lehmann DJ, 2000, J NEUROL NEUROSUR PS, V69, P404, DOI 10.1136/jnnp.69.3.404; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x; Passant U, 1997, INT J GERIATR PSYCH, V12, P395, DOI 10.1002/(SICI)1099-1166(199703)12:3<395::AID-GPS527>3.3.CO;2-R; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Riedijk SR, 2006, DEMENT GERIATR COGN, V22, P405, DOI 10.1159/000095750; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Rosso SM, 2002, J NEUROL NEUROSUR PS, V72, P820, DOI 10.1136/jnnp.72.6.820; Shelley BP, 2007, DEMENT GERIATR COGN, V24, P280, DOI 10.1159/000107494; Snowden JS, 2001, J NEUROL NEUROSUR PS, V70, P323, DOI 10.1136/jnnp.70.3.323; StataCorp, 2003, STAT STAT SOFTW REL; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; van Swieten JC, 2008, LANCET NEUROL, V7, P965, DOI 10.1016/S1474-4422(08)70194-7; Xydakis MS, 2008, NEW ENGL J MED, V358, P2177, DOI 10.1056/NEJMc086083	43	61	61	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAY	2012	8	3					204	210		10.1016/j.jalz.2011.03.011			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	945NP	WOS:000304283500006	22465176				2022-02-06	
J	Wilde, EA; Merkley, TL; Bigler, ED; Max, JE; Schmidt, AT; Ayoub, KW; McCauley, SR; Hunter, JV; Hanten, G; Li, XQ; Chu, ZLD; Levin, HS				Wilde, Elisabeth A.; Merkley, Tricia L.; Bigler, Erin D.; Max, Jeffrey E.; Schmidt, Adam T.; Ayoub, Kareem W.; McCauley, Stephen R.; Hunter, Jill V.; Hanten, Gerri; Li, Xiaoqi; Chu, Zili D.; Levin, Harvey S.			Longitudinal changes in cortical thickness in children after traumatic brain injury and their relation to behavioral regulation and emotional control	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury; Child; Imaging; Volumetrics; Longitudinal; Behavior; Emotion; Frontal lobes; Cortical thickness	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EXECUTIVE FUNCTION BRIEF; CLOSED-HEAD INJURY; PERSONALITY-CHANGE; CEREBRAL-CORTEX; RATING INVENTORY; NERVOUS-SYSTEM; ADOLESCENTS 6; CELL-DEATH; MODERATE	The purpose of this study was to assess patterns of cortical development over time in children who had sustained traumatic brain injury (TBI) as compared to children with orthopedic injury (OI), and to examine how these patterns related to emotional control and behavioral dysregulation, two common post-TBI symptoms. Cortical thickness was measured at approximately 3 and 18 months post-injury in 20 children aged 8.2-17.5 years who had sustained moderate-to-severe closed head injury and 21 children aged 7.4-16.7 years who had sustained OI. At approximately 3 months post-injury, the TBI group evidenced decreased cortical thickness bilaterally in aspects of the superior frontal, dorsolateral frontal, orbital frontal, and anterior cingulate regions compared to the control cohort, areas of anticipated vulnerability to TBI-induced change. At 18 months post-injury, some of the regions previously evident at 3 months post-injury remained significantly decreased in the TBI group, including bilateral frontal, fusiform, and lingual regions. Additional regions of significant cortical thinning emerged at this time interval (bilateral frontal regions and fusiform gyrus and left parietal regions). However, differences in other regions appeared attenuated (no longer areas of significant cortical thinning) by 18 months post-injury including large bilateral regions of the medial aspects of the frontal lobes and anterior cingulate. Cortical thinning within the OI group was evident over time in dorsolateral frontal and temporal regions bilaterally and aspects of the left medial frontal and precuneus, and right inferior parietal regions. Longitudinal analyses within the TBI group revealed decreases in cortical thickness over time in numerous aspects throughout the right and left cortical surface, but with notable "sparing" of the right and left frontal and temporal poles, the medial aspects of both the frontal lobes, the left fusiform gyrus, and the cingulate bilaterally. An analysis of longitudinal changes in cortical thickness over time (18 months-3 months) in the TBI versus OI group demonstrated regions of relative cortical thinning in the TBI group in bilateral superior parietal and right paracentral regions, but relative cortical thickness increases in aspects of the medial orbital frontal lobes and bilateral cingulate and in the right lateral orbital frontal lobe. Finally, findings from analyses correlating the longitudinal cortical thickness changes in TBI with symptom report on the Emotional Control subscale of the Behavior Rating Inventory of Executive Function (BRIEF) demonstrated a region of significant correlation in the right medial frontal and right anterior cingulate gyrus. A region of significant correlation between the longitudinal cortical thickness changes in the TBI group and symptom report on the Behavioral Regulation Index was also seen in the medial aspect of the left frontal lobe. Longitudinal analyses of cortical thickness highlight an important deviation from the expected pattern of developmental change in children and adolescents with TBI, particularly in the medial frontal lobes, where typical patterns of thinning fail to occur over time. Regions which fail to undergo expected cortical thinning in the medial aspects of the frontal lobes correlate with difficulties in emotional control and behavioral regulation, common problems for youth with TBI. Examination of post-TBI brain development in children may be critical to identification of children that may be at risk for persistent problems with executive functioning deficits and the development of interventions to address these issues. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili D.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Utah Brain Inst, Salt Lake City, UT USA; [Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Max, Jeffrey E.] Rady Childrens Hosp, San Diego, CA USA; [Ayoub, Kareem W.] Rice Univ, Dept Bioengn, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Hunter, Jill V.; Chu, Zili D.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). We also acknowledge the generous contribution of Mission Connect of the TIRR Foundation. We gratefully acknowledge the contribution of Ana C. Vasquez, Deleene Menefee, PhD., Summer Lane, Lori Cook, Sandra B. Chapman, Ph.D., and Gillian Hotz, Ph.D. in data collection, and Joshua Cooper and Ragini Yallampalli in manuscript preparation. We thank the participants and their families for their participation in this research.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Athinoula A., 2005, FREESURFER; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M, 2010, TRAUMATIC BRAIN INJU; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Ferriero DM, 2010, J ANAT, V217, P429, DOI 10.1111/j.1469-7580.2010.01226.x; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Huttenlocher P.R., 1994, SYNAPTOGENESIS HUMAN, P137; Jernigan TL, 2011, PROG BRAIN RES, V189, P77, DOI 10.1016/B978-0-444-53884-0.00019-1; Kim WR, 2011, DEV GROWTH DIFFER, V53, P225, DOI 10.1111/j.1440-169X.2010.01226.x; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Landing BH, 2002, PEDIATR PATHOL MOL M, V21, P321, DOI 10.1080/02770930290056541; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max . I. E., 2010, J NEUROPSYCHIATRY CL, V22, P30, DOI [10.1176/appi.neuropsych.22.1.30, DOI 10.1176/APPI.NEUROPSYCH.22.1.30]; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Porto L, 2011, EUR J PAEDIATR NEURO, V15, P493, DOI [10. 1016/j.ejpn.2011.06.004, DOI 10.1016/J.EJPN.2011.06.004]; Potter JL, 2011, REHABIL PSYCHOL, V56, P351, DOI 10.1037/a0025445; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Raznahan A, 2011, J NEUROSCI, V31, P7174, DOI 10.1523/JNEUROSCI.0054-11.2011; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rosso IM, 2004, ANN NY ACAD SCI, V1021, P355, DOI 10.1196/annals.1308.045; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stiles J, 2010, NEUROPSYCHOL REV, V20, P327, DOI 10.1007/s11065-010-9148-4; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; Thurman D.J., 2007, BRAIN INJURY MED PRI; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Westlye LT, 2010, NEUROIMAGE, V52, P172, DOI 10.1016/j.neuroimage.2010.03.056; Whitford TJ, 2007, HUM BRAIN MAPP, V28, P228, DOI 10.1002/hbm.20273; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	82	61	62	1	43	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		267	276		10.1016/j.ijdevneu.2012.01.003			10	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800013	22266409	Green Accepted			2022-02-06	
J	Bramley, H; Patrick, K; Lehman, E; Silvis, M				Bramley, Harry; Patrick, Katherine; Lehman, Erik; Silvis, Matthew			High School Soccer Players With Concussion Education Are More Likely to Notify Their Coach of a Suspected Concussion	CLINICAL PEDIATRICS			English	Article						concussion; traumatic brain injury; head injuries; pediatrics; soccer	TRAUMATIC BRAIN-INJURY; UNITED-STATES; SPORT; MANAGEMENT; LEAGUE	Previously published studies have found that concussion symptoms are underreported in youth athletics. This study evaluated the likelihood high school soccer players would identify themselves as having concussion related symptoms during game situations. A questionnaire inquiring about past concussion education and the likelihood of notifying their coach of concussion symptoms was administered to 183 high school soccer players. Of the 60 (33%) who completed the survey, 18 (72%) athletes who had acknowledged receiving concussion training responded that they would always notify their coach of concussion symptoms, as compared with 12 (36%) of the players who reported having no such training (P = .01). The results of this study suggest that athletes with past concussion training are more likely to notify their coach of concussion symptoms, potentially reducing their risk for further injury. Concussion education should be considered for all high school soccer players.	[Bramley, Harry; Lehman, Erik; Silvis, Matthew] Penn State Milton S Hershey Med Ctr, Dept Pediat, Hershey, PA 17033 USA; [Patrick, Katherine] Penn State Coll Med, Hershey, PA USA		Bramley, H (corresponding author), Penn State Milton S Hershey Med Ctr, Dept Pediat, Mail Code H085,500 Univ Dr, Hershey, PA 17033 USA.	hbramley@hmc.psu.edu		Patrick, Katherine/0000-0002-4293-5619			Bovard RS, 2008, CURR SPORT MED REP, V7, P359, DOI 10.1249/JSR.0b013e31818f0bed; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; *CDCP, HEADS CONC YOUTH SPO; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Melnick MJ, 2010, HEALTH EDUC BEHAV, V37, P23, DOI 10.1177/1090198107308377; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sulloway FJ, 2010, PERS SOC PSYCHOL REV, V14, P402, DOI 10.1177/1088868310361241; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Washington State Department of Health, CONC MAN SCH SPORTS; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	20	61	61	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	APR	2012	51	4					332	336		10.1177/0009922811425233			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	915FF	WOS:000302008800004	22007039				2022-02-06	
J	Chuang, JY; Lee, CW; Shih, YH; Yang, TT; Yu, L; Kuo, YM				Chuang, Jia-Ying; Lee, Chu-Wan; Shih, Yao-Hsiang; Yang, Tingting; Yu, Lung; Kuo, Yu-Min			Interactions between Amyloid-beta and Hemoglobin: Implications for Amyloid Plaque Formation in Alzheimer's Disease	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SENILE PLAQUES; A-BETA; DIFFERENTIAL EXPRESSION; MICROVASCULAR PATHOLOGY; CEREBROSPINAL-FLUID; PROTEIN-PRECURSOR; APOLIPOPROTEIN-E; MOUSE MODEL; RAT-BRAIN	Accumulation of amyloid-beta (A beta) peptides in the brain is one of the central pathogenic events in Alzheimer's disease (AD). However, why and how A beta aggregates within the brain of AD patients remains elusive. Previously, we demonstrated hemoglobin (Hb) binds to A beta and co-localizes with the plaque and vascular amyloid deposits in post-mortem AD brains. In this study, we further characterize the interactions between Hb and A beta in vitro and in vivo and report the following observations: 1) the binding of Hb to A beta required iron-containing heme; 2) other heme-containing proteins, such as myoglobin and cytochrome C, also bound to A beta; 3) hemin-induced cytotoxicity was reduced in neuroblastoma cells by low levels of A beta; 4) Hb was detected in neurons and glial cells of post-mortem AD brains and was up-regulated in aging and APP/PS1 transgenic mice; 5) microinjection of human Hb into the dorsal hippocampi of the APP/PS1 transgenic mice induced the formation of an envelope-like structure composed of A beta surrounding the Hb droplets. Our results reveal an enhanced endogenous expression of Hb in aging brain cells, probably serving as a compensatory mechanism against hypoxia. In addition, A beta binds to Hb and other hemoproteins via the iron-containing heme moiety, thereby reducing Hb/heme/iron-induced cytotoxicity. As some of the brain Hb could be derived from the peripheral circulation due to a compromised blood-brain barrier frequently observed in aged and AD brains, our work also suggests the genesis of some plaques may be a consequence of sustained amyloid accretion at sites of vascular injury.	[Chuang, Jia-Ying; Lee, Chu-Wan; Shih, Yao-Hsiang; Yu, Lung; Kuo, Yu-Min] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan; [Yang, Tingting] I Shou Univ, Sch Chinese Med Postbaccalaureate, Div Neurosci & Neuropathol, Kaohsiung, Taiwan; [Yu, Lung] Natl Cheng Kung Univ, Inst Behav Med, Tainan 70101, Taiwan; [Kuo, Yu-Min] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 70101, Taiwan		Chuang, JY (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.	lungyu@mail.ncku.edu.tw; kuoym@mail.ncku.edu.tw	Ting-Ting, YANG/E-6009-2010; Kuo, Yu-Min/A-9050-2013	Ting-Ting, YANG/0000-0001-5975-8359; Kuo, Yu-Min/0000-0003-4867-2482; Shih, Yao-Hsiang/0000-0001-9145-7492	National Science council (NSC) of TaiwanMinistry of Science and Technology, Taiwan [99-2320-B-006-017-MY3, NSC99-2321-B-006-003, NSC97-2410-H-006-074-MY3]	This work was supported by National Science council (NSC 99-2320-B-006-017-MY3, NSC99-2321-B-006-003, NSC97-2410-H-006-074-MY3) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ascoli F, 1981, Methods Enzymol, V76, P72; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Atamna H, 2004, P NATL ACAD SCI USA, V101, P11153, DOI 10.1073/pnas.0404349101; Atwood CS, 2003, BRAIN RES REV, V43, P164, DOI 10.1016/S0165-0173(03)00206-6; Biagioli M, 2009, P NATL ACAD SCI USA, V106, P15454, DOI 10.1073/pnas.0813216106; Bishop GM, 2004, BRAIN PATHOL, V14, P448; Bishop GM, 2003, J NEUROSCI RES, V73, P316, DOI 10.1002/jnr.10661; Blalock EM, 2003, J NEUROSCI, V23, P3807; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Cortes-Canteli M, 2010, NEURON, V66, P695, DOI 10.1016/j.neuron.2010.05.014; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Grammas P, 2002, J ALZHEIMERS DIS, V4, P217, DOI 10.3233/JAD-2002-4311; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HAMAZAKI H, 1995, BIOCHEM BIOPH RES CO, V211, P349, DOI 10.1006/bbrc.1995.1819; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HARDY JA, 1986, NEUROBIOL AGING, V7, P489, DOI 10.1016/0197-4580(86)90086-2; Hardy J, 2006, J ALZHEIMERS DIS, V9, P151; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; He YD, 2009, J CEREBR BLOOD F MET, V29, P596, DOI 10.1038/jcbfm.2008.145; Holcomb LA, 2000, MECH AGEING DEV, V112, P135, DOI 10.1016/S0047-6374(99)00086-X; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; KARELIN AA, 1994, BIOCHEM BIOPH RES CO, V202, P410, DOI 10.1006/bbrc.1994.1943; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khan S, 2008, CAN MED ASSOC J, V178, P1687, DOI 10.1503/cmaj.1080038; Kokjohn TA, 2011, IS ALZHEIMERS DIS AM; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; KOO EH, 1990, NEURON, V4, P97, DOI 10.1016/0896-6273(90)90446-M; Kumar-Singh S, 2005, AM J PATHOL, V167, P527, DOI 10.1016/S0002-9440(10)62995-1; Kuo YM, 1999, BIOCHEM BIOPH RES CO, V257, P787, DOI 10.1006/bbrc.1999.0552; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MASLIAH E, 1994, ACTA NEUROPATHOL, V87, P135; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; Meyer EP, 2008, P NATL ACAD SCI USA, V105, P3587, DOI 10.1073/pnas.0709788105; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; MIYAKAWA T, 1979, ACTA NEUROPATHOL, V48, P153, DOI 10.1007/BF00691158; MIYAKAWA T, 1982, VIRCHOWS ARCH B, V40, P121, DOI 10.1007/BF02932857; ONO T, 1978, P NATL ACAD SCI USA, V75, P4431, DOI 10.1073/pnas.75.9.4431; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Raby CA, 1998, J NEUROCHEM, V71, P2505; Raymackers J, 2000, ELECTROPHORESIS, V21, P2266, DOI 10.1002/1522-2683(20000601)21:11<2266::AID-ELPS2266>3.0.CO;2-Z; Richter F, 2009, J COMP NEUROL, V515, P538, DOI 10.1002/cne.22062; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; Schelshorn DW, 2009, J CEREBR BLOOD F MET, V29, P585, DOI 10.1038/jcbfm.2008.152; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SLEMMON JR, 1994, J NEUROSCI, V14, P2225; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Wu CW, 2004, NEUROBIOL DIS, V17, P367, DOI 10.1016/j.nbd.2004.08.014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009; Zlokovic BV, 2005, TRENDS NEUROSCI, V28, P202, DOI 10.1016/j.tins.2005.02.001; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	78	61	61	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2012	7	3							e33120	10.1371/journal.pone.0033120			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928XD	WOS:000303021100049	22412990	gold, Green Submitted, Green Published			2022-02-06	
S	Sarkamo, T; Soto, D			Annals NY Acad Sci	Sarkamo, Teppo; Soto, David			Music listening after stroke: beneficial effects and potential neural mechanisms	NEUROSCIENCES AND MUSIC IV: LEARNING AND MEMORY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Neurosciences and Music-IV - Learning and Memory	JUN 09-12, 2011	Univ Edinburgh, Edinburgh, SCOTLAND	Mariani Fdn, Inst Mus Human & Social Dev	Univ Edinburgh	music listening; stroke; emotion; cognition; rehabilitation; neuroplasticity	TRAUMATIC BRAIN-INJURY; RAT AUDITORY-CORTEX; MELODIC INTONATION THERAPY; NMDA-RECEPTOR ANTAGONIST; WORKING-MEMORY PERFORMANCE; EARLY-ONSET STIMULATION; HEALTHY OLDER-ADULTS; SHORT-TERM-MEMORY; MISMATCH NEGATIVITY; EMOTIONAL RESPONSES	Music is an enjoyable leisure activity that also engages many emotional, cognitive, and motor processes in the brain. Here, we will first review previous literature on the emotional and cognitive effects of music listening in healthy persons and various clinical groups. Then we will present findings about the short-and long-term effects of music listening on the recovery of cognitive function in stroke patients and the underlying neural mechanisms of these music effects. First, our results indicate that listening to pleasant music can have a short-term facilitating effect on visual awareness in patients with visual neglect, which is associated with functional coupling between emotional and attentional brain regions. Second, daily music listening can improve auditory and verbal memory, focused attention, and mood as well as induce structural gray matter changes in the early poststroke stage. The psychological and neural mechanisms potentially underlying the rehabilitating effect of music after stroke are discussed.	[Sarkamo, Teppo] Univ Helsinki, Inst Behav Sci, Cognit Brain Res Unit, FI-00014 Helsinki, Finland; [Sarkamo, Teppo] Univ Jyvaskyla, Finnish Ctr Excellence Interdisciplinary Mus Res, Jyvaskyla, Finland; [Soto, David] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Neurosci, London, England		Sarkamo, T (corresponding author), Univ Helsinki, Inst Behav Sci, Cognit Brain Res Unit, Siltavuorenpenger 1 B,POB 9, FI-00014 Helsinki, Finland.	teppo.sarkamo@helsinki.fi	Soto, David/R-3711-2019	Soto, David/0000-0003-0205-7513; Sarkamo, Teppo/0000-0002-1470-4530	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802212] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802212] Funding Source: UKRI		Abikoff H, 1996, J LEARN DISABIL, V29, P238, DOI 10.1177/002221949602900302; Ahveninen J, 1999, ALCOHOL CLIN EXP RES, V23, P1507, DOI 10.1111/j.1530-0277.1999.tb04674.x; ALBERT ML, 1973, ARCH NEUROL-CHICAGO, V29, P130, DOI 10.1001/archneur.1973.00490260074018; Altenmuller E, 2009, ANN NY ACAD SCI, V1169, P395, DOI 10.1111/j.1749-6632.2009.04580.x; Amunts K, 1997, HUM BRAIN MAPP, V5, P206, DOI 10.1002/(SICI)1097-0193(1997)5:3<206::AID-HBM5>3.0.CO;2-7; Angelucci F, 2007, NEUROSCI LETT, V429, P152, DOI 10.1016/j.neulet.2007.10.005; Angelucci F, 2007, BEHAV PHARMACOL, V18, P491, DOI 10.1097/FBP.0b013e3282d28f50; Antic S, 2008, COLLEGIUM ANTROPOL, V32, P19; Ashburner J, 2009, MAGN RESON IMAGING, V27, P1163, DOI 10.1016/j.mri.2009.01.006; Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; ASTROM M, 1993, STROKE, V24, P52, DOI 10.1161/01.STR.24.1.52; Ayotte J, 2000, BRAIN, V123, P1926, DOI 10.1093/brain/123.9.1926; Baldeweg T, 2004, SCHIZOPHR RES, V69, P203, DOI 10.1016/j.schres.2003.09.009; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baumgartner T, 2006, INT J PSYCHOPHYSIOL, V60, P34, DOI 10.1016/j.ijpsycho.2005.04.007; Beh HC, 1999, ERGONOMICS, V42, P1087, DOI 10.1080/001401399185153; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Bi CX, 2006, BRAIN RES, V1110, P30, DOI 10.1016/j.brainres.2006.06.056; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Bose M, 2010, SYNAPSE, V64, P97, DOI 10.1002/syn.20710; Boyle R, 1996, Q J EXP PSYCHOL-A, V49, P398, DOI 10.1080/027249896392702; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Brown S, 2007, BRAIN COGNITION, V63, P59, DOI 10.1016/j.bandc.2006.08.006; Chabris CF, 1999, NATURE, V400, P826, DOI 10.1038/23608; Chaudhury S, 2009, INT J DEV NEUROSCI, V27, P583, DOI 10.1016/j.ijdevneu.2009.06.004; Chikahisa S, 2006, BEHAV BRAIN RES, V169, P312, DOI 10.1016/j.bbr.2006.01.021; CLARK DM, 1985, J PERS SOC PSYCHOL, V48, P1595, DOI 10.1037/0022-3514.48.6.1595; Cohen A., 2002, PSYCHOMUSICOLOGY J R, V18, P89, DOI [10.1037/h0094049, DOI 10.1037/H0094049]; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Engineer ND, 2004, J NEUROPHYSIOL, V92, P73, DOI 10.1152/jn.00059.2004; Escoffier N, 2010, ACTA PSYCHOL, V135, P12, DOI 10.1016/j.actpsy.2010.04.005; Feduccia AA, 2008, BRAIN RES BULL, V77, P189, DOI 10.1016/j.brainresbull.2008.07.007; Forsblom A, 2012, MUSIC MED, V2, P229, DOI [DOI 10.1177/1943862110378110, 10.1177/1943862110378110]; Forsblom A, 2009, ANN NY ACAD SCI, V1169, P426, DOI 10.1111/j.1749-6632.2009.04776.x; Foster NA, 2001, EXP AGING RES, V27, P215, DOI 10.1080/036107301300208664; Franceschini R, 2001, BIOMED PHARMACOTHER, V55, P458, DOI 10.1016/S0753-3322(01)00086-5; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Fukui H, 2003, NEUROENDOCRINOL LETT, V24, P173; Gaab N, 2003, NEUROIMAGE, V19, P1417, DOI 10.1016/S1053-8119(03)00224-6; Gaser C, 2003, J NEUROSCI, V23, P9240; Gosselin N, 2006, BRAIN, V129, P2585, DOI 10.1093/brain/awl240; Grahn JA, 2007, J COGNITIVE NEUROSCI, V19, P893, DOI 10.1162/jocn.2007.19.5.893; Greene CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011739; Griffiths TD, 1999, NEUROREPORT, V10, P3825, DOI 10.1097/00001756-199912160-00019; Griffiths TD, 2004, J NEUROL NEUROSUR PS, V75, P344; Groussard M, 2010, NEUROIMAGE, V49, P2764, DOI 10.1016/j.neuroimage.2009.10.039; Hallam S, 2002, EDUC STUD, V28, P111, DOI 10.1080/03055690220124551; Hays T., 2005, PSYCHOL MUSIC, V33, P437, DOI [10.1177/0305735605056160, DOI 10.1177/0305735605056160]; HOMMEL M, 1990, ARCH NEUROL-CHICAGO, V47, P573, DOI 10.1001/archneur.1990.00530050097018; Hyde KL, 2008, NEUROPSYCHOLOGIA, V46, P632, DOI 10.1016/j.neuropsychologia.2007.09.004; Hyde KL, 2007, J NEUROSCI, V27, P13028, DOI 10.1523/JNEUROSCI.3039-07.2007; Hyde KL, 2006, BRAIN, V129, P2562, DOI 10.1093/brain/awl204; Hyde KL, 2009, J NEUROSCI, V29, P3019, DOI 10.1523/JNEUROSCI.5118-08.2009; Ilvonen TM, 2003, STROKE, V34, P1746, DOI 10.1161/01.STR.0000078836.26328.3B; Irish M, 2006, DEMENT GERIATR COGN, V22, P108, DOI 10.1159/000093487; ISEN AM, 1987, J PERS SOC PSYCHOL, V52, P1122, DOI 10.1037/0022-3514.52.6.1122; ISEN AM, 1985, J EXP PSYCHOL GEN, V114, P388, DOI 10.1037/0096-3445.114.3.388; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; James CE, 2008, NEUROIMAGE, V42, P1597, DOI 10.1016/j.neuroimage.2008.06.025; Janata P, 2002, SCIENCE, V298, P2167, DOI 10.1126/science.1076262; Janata P, 2002, COGN AFFECT BEHAV NE, V2, P121, DOI 10.3758/CABN.2.2.121; Janata P, 2009, CEREB CORTEX, V19, P2579, DOI 10.1093/cercor/bhp008; Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962; Jeong SH, 2007, APPL NURS RES, V20, P125, DOI 10.1016/j.apnr.2007.04.005; Johnsrude IS, 2000, BRAIN, V123, P155, DOI 10.1093/brain/123.1.155; Juslin PN, 2004, J NEW MUSIC RES, V33, P217, DOI 10.1080/0929821042000317813; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Knab AM, 2010, INT J BIOL SCI, V6, P133; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Koelsch S, 2005, TRENDS COGN SCI, V9, P578, DOI 10.1016/j.tics.2005.10.001; Koelsch S, 2005, NEUROIMAGE, V25, P1068, DOI 10.1016/j.neuroimage.2004.12.050; Koelsch S, 2010, TRENDS COGN SCI, V14, P131, DOI 10.1016/j.tics.2010.01.002; Korostenskaja M, 2007, BRAIN RES BULL, V72, P275, DOI 10.1016/j.brainresbull.2007.01.007; Kreisel SH, 2006, CEREBROVASC DIS, V21, P6, DOI 10.1159/000089588; Kreutz G, 2004, J BEHAV MED, V27, P623, DOI 10.1007/s10865-004-0006-9; Krumhansl CL, 1997, CAN J EXP PSYCHOL, V51, P336, DOI 10.1037/1196-1961.51.4.336; Kujala T, 2001, P NATL ACAD SCI USA, V98, P10509, DOI 10.1073/pnas.181589198; Lee BK, 2007, ARCH GEN PSYCHIAT, V64, P810, DOI 10.1001/archpsyc.64.7.810; Levitin DJ, 2003, NEUROIMAGE, V20, P2142, DOI 10.1016/j.neuroimage.2003.08.016; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; Lundqvist LO, 2009, PSYCHOL MUSIC, V37, P61, DOI 10.1177/0305735607086048; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Maess B, 2001, NAT NEUROSCI, V4, P540, DOI 10.1038/87502; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; Malhotra PA, 2006, ANN NEUROL, V59, P186, DOI 10.1002/ana.20701; Mammarella N, 2007, AGING CLIN EXP RES, V19, P394; Matteis M, 1997, J NEUROL SCI, V149, P57, DOI 10.1016/S0022-510X(97)05375-6; McDermott J, 2005, MUSIC PERCEPT, V23, P29, DOI 10.1525/mp.2005.23.1.29; Mehta MA, 2006, CURR PHARM DESIGN, V12, P2487, DOI 10.2174/138161206777698891; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; Merriam Alan, 1964, ANTHR MUSIC; Mikkola K, 2007, CLIN NEUROPHYSIOL, V118, P1494, DOI 10.1016/j.clinph.2007.04.012; Milner B., 1962, INTERHEMISPHERIC REL, P177; Mitterschiffthaler MT, 2007, HUM BRAIN MAPP, V28, P1150, DOI 10.1002/hbm.20337; Mutschler I, 2009, NEUROSCI LETT, V457, P66, DOI 10.1016/j.neulet.2009.03.101; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Nettl B, 2000, ORIGINS OF MUSIC, P463; Nichols JA, 2007, NEUROSCIENCE, V145, P832, DOI 10.1016/j.neuroscience.2006.12.061; Nieoullon A, 2002, PROG NEUROBIOL, V67, P53, DOI 10.1016/S0301-0082(02)00011-4; Nilsson U, 2009, HEART LUNG, V38, P201, DOI 10.1016/j.hrtlng.2008.07.008; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Norton A, 2009, ANN NY ACAD SCI, V1169, P431, DOI 10.1111/j.1749-6632.2009.04859.x; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Omar R, 2011, NEUROIMAGE, V56, P1814, DOI 10.1016/j.neuroimage.2011.03.002; Panksepp J, 2002, BEHAV PROCESS, V60, P133, DOI 10.1016/S0376-6357(02)00080-3; Patterson RD, 2002, NEURON, V36, P767, DOI 10.1016/S0896-6273(02)01060-7; Percaccio CR, 2005, J NEUROPHYSIOL, V94, P3590, DOI 10.1152/jn.00433.2005; PERETZ I, 1990, BRAIN, V113, P1185, DOI 10.1093/brain/113.4.1185; Peretz I, 2009, ANN NY ACAD SCI, V1169, P256, DOI 10.1111/j.1749-6632.2009.04557.x; Plailly J, 2007, CEREB CORTEX, V17, P2650, DOI 10.1093/cercor/bhl173; Platel H, 2003, NEUROIMAGE, V20, P244, DOI 10.1016/S1053-8119(03)00287-8; Popescu M, 2004, NEUROIMAGE, V21, P1622, DOI 10.1016/j.neuroimage.2003.11.002; Racette A, 2007, MEM COGNITION, V35, P242, DOI 10.3758/BF03193445; Racette A, 2006, BRAIN, V129, P2571, DOI 10.1093/brain/awl250; Radley JJ, 2005, AGEING RES REV, V4, P271, DOI 10.1016/j.arr.2005.03.004; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; Rasquin S, 2005, CEREBROVASC DIS, V19, P309, DOI 10.1159/000084499; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; Rickard Nikki S, 2005, Behav Cogn Neurosci Rev, V4, P235, DOI 10.1177/1534582305285869; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; ROBIN DA, 1990, BRAIN LANG, V39, P539, DOI 10.1016/0093-934X(90)90161-9; Rowe G, 2007, P NATL ACAD SCI USA, V104, P383, DOI 10.1073/pnas.0605198104; Saarikallio S., 2007, PSYCHOL, V35, P88, DOI [DOI 10.1177/0305735607068889, 10.1177/0305735607068889]; Saarikallio S, 2011, PSYCHOL MUSIC, V39, P307, DOI 10.1177/0305735610374894; Sacks O, 2006, BRAIN, V129, P2528, DOI 10.1093/brain/awl234; SALAME P, 1989, Q J EXP PSYCHOL-A, V41, P107, DOI 10.1080/14640748908402355; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; SAMSON S, 1988, BRAIN COGNITION, V7, P348, DOI 10.1016/0278-2626(88)90008-5; Sandmann P., 2009, BEHAV BRAIN FUNC, V6, P1; Sarkamo T., 2011, THESIS U HELSINKI FI; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Sarkamo T, 2010, J COGNITIVE NEUROSCI, V22, P2716, DOI 10.1162/jocn.2009.21376; Satoh M, 2006, AM J NEURORADIOL, V27, P1101; Schauer M, 2003, CLIN REHABIL, V17, P713, DOI 10.1191/0269215503cr668oa; Schellenberg E.G., 2007, PSYCHOL MUSIC, V35, P5, DOI [DOI 10.1177/0305735607068885, 10.1177/0305735607068885]; SCHLAUG G, 1995, NEUROPSYCHOLOGIA, V33, P1047, DOI 10.1016/0028-3932(95)00045-5; Schlaug G, 2008, MUSIC PERCEPT, V25, P315, DOI 10.1525/MP.2008.25.4.315; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Schneider N, 2001, NEURORADIOLOGY, V43, P472, DOI 10.1007/s002340000522; Schneider S, 2007, J NEUROL, V254, P1339, DOI 10.1007/s00415-006-0523-2; Schneider S, 2010, MUSIC PERCEPT, V27, P271, DOI 10.1525/MP.2010.27.4.271; Schon D, 2008, COGNITION, V106, P975, DOI 10.1016/j.cognition.2007.03.005; Schonwiesner M, 2005, EUR J NEUROSCI, V22, P1521, DOI 10.1111/j.1460-9568.2005.04315.x; Schuppert M, 2000, BRAIN, V123, P546, DOI 10.1093/brain/123.3.546; SHAPIRO BE, 1981, NEUROPSYCHOLOGIA, V19, P161, DOI 10.1016/0028-3932(81)90101-9; Simmons-Stern NR, 2010, NEUROPSYCHOLOGIA, V48, P3164, DOI 10.1016/j.neuropsychologia.2010.04.033; Singh-Curry V, 2010, CLIN REHABIL, V24, P675, DOI 10.1177/0269215509357851; Sloboda J.A., 2001, MUSIC EMOTION THEORY, P413; Sluming V, 2002, NEUROIMAGE, V17, P1613, DOI 10.1006/nimg.2002.1288; Smith A, 1996, NATURE, V380, P291, DOI 10.1038/380291a0; Soto D, 2009, P NATL ACAD SCI USA, V106, P6011, DOI 10.1073/pnas.0811681106; SPARKS R, 1974, Cortex, V10, P303; Stewart L, 2006, BRAIN, V129, P2533, DOI 10.1093/brain/awl171; Straube T, 2008, NEUROPSYCHOLOGIA, V46, P1505, DOI 10.1016/j.neuropsychologia.2008.01.008; Suda M, 2008, NEUROREPORT, V19, P75, DOI 10.1097/WNR.0b013e3282f3476f; Sutoo D, 2004, BRAIN RES, V1016, P255, DOI 10.1016/j.brainres.2004.05.018; Tervaniemi M, 2001, ANN NY ACAD SCI, V930, P259, DOI 10.1111/j.1749-6632.2001.tb05737.x; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 2005, ANN NY ACAD SCI, V1060, P243, DOI 10.1196/annals.1360.017; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Thompson RG, 2005, EXP AGING RES, V31, P91, DOI 10.1080/03610730590882819; Thompson WF, 2001, PSYCHOL SCI, V12, P248, DOI 10.1111/1467-9280.00345; Tikhonravov D, 2008, BRAIN RES, V1203, P97, DOI 10.1016/j.brainres.2008.02.006; Tillmann B, 2003, COGNITIVE BRAIN RES, V16, P145, DOI 10.1016/S0926-6410(02)00245-8; Toyomaki A, 2008, PROG NEURO-PSYCHOPH, V32, P95, DOI 10.1016/j.pnpbp.2007.07.020; Trainor L, 2008, NATURE, V453, P598, DOI 10.1038/453598a; Trehub SE, 2003, NAT NEUROSCI, V6, P669, DOI 10.1038/nn1084; Umbricht D, 2002, BIOL PSYCHIAT, V51, P400, DOI 10.1016/S0006-3223(01)01242-2; Vollmer-Haase J, 1998, NEUROPSYCHOLOGIA, V36, P857, DOI 10.1016/S0028-3932(98)00024-4; WALLACE WT, 1994, J EXP PSYCHOL LEARN, V20, P1471, DOI 10.1037/0278-7393.20.6.1471; Warren JD, 2005, NEUROIMAGE, V24, P1052, DOI 10.1016/j.neuroimage.2004.10.031; Wilson SJ, 2006, MUSIC PERCEPT, V24, P23, DOI 10.1525/mp.2006.24.1.23; WOOD JV, 1990, J PERS SOC PSYCHOL, V58, P899, DOI 10.1037/0022-3514.58.5.899; Xu F, 2007, NEUROSCI LETT, V420, P179, DOI 10.1016/j.neulet.2007.05.005; Xu JH, 2009, BEHAV BRAIN RES, V196, P49, DOI 10.1016/j.bbr.2008.07.018; Zatorre R, 2005, NATURE, V434, P312, DOI 10.1038/434312a; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/jneurosci.14-04-01908.1994; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946; Zentner M, 2008, EMOTION, V8, P494, DOI 10.1037/1528-3542.8.4.494	189	61	63	6	127	BLACKWELL SCIENCE PUBL	OXFORD	OSNEY MEAD, OXFORD OX2 0EL, ENGLAND	0077-8923		978-1-57331-841-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2012	1252						266	281		10.1111/j.1749-6632.2011.06405.x			16	Multidisciplinary Sciences; Neurosciences; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology; Psychology	BAU07	WOS:000305518900036	22524369				2022-02-06	
J	Amen, DG; Newberg, A; Thatcher, R; Jin, Y; Wu, J; Keator, D; Willeumier, K				Amen, Daniel G.; Newberg, Andrew; Thatcher, Robert; Jin, Yi; Wu, Joseph; Keator, David; Willeumier, Kristen			Impact of Playing American Professional Football on Long-Term Brain Function	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; CLOSED-HEAD INJURY; EEG PHASE RESET; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; PERFORMANCE; DEPRESSION; PLAYERS; SPECT; MILD	The authors recruited 100 active and former National Football League players, representing 27 teams and all positions. Players underwent a clinical history, brain SPECT imaging, qEEG, and multiple neuropsychological measures, including MicroCog. Relative to a healthy-comparison group, players showed global decreased perfusion, especially in the prefrontal, temporal, parietal, and occipital lobes, and cerebellar regions. Quantitative EEG findings were consistent, showing elevated slow waves in the frontal and temporal regions. Significant decreases from normal values were found in most neuropsychological tests. This is the first large-scale brain-imaging study to demonstrate significant differences consistent with a chronic brain trauma pattern in professional football players. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:98-106)	[Amen, Daniel G.; Willeumier, Kristen] Amen Clin Inc, Newport Beach, CA 92660 USA; [Newberg, Andrew] Thomas Jefferson Univ & Hosp, Myrna Brind Ctr Integrat Med, Philadelphia, PA USA; [Wu, Joseph; Keator, David] Univ Calif Irvine, Irvine, CA 92717 USA		Amen, DG (corresponding author), Amen Clin Inc, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com		Newberg, Andrew/0000-0001-8230-1752; Keator, David/0000-0001-5281-5576; Willeumier, Kristen/0000-0002-1229-8516			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ALEXANDER GE, 1995, J NEUROPSYCH CLIN N, V7, P188; Amen DG, 2009, J NEUROPSYCH CLIN N, V21, P430, DOI 10.1176/appi.neuropsych.21.4.430; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BOUTROS N, 2008, AM PSYCHIAT TXB NEUR; *CDCP, 1997, SPORTS REL REC BRAIN; Centers for Disease Control and Prevention (CDCP), 2010, OB HALT EP MAK HLTH; *CNN, HOUS PAN CONS BRAIN; Conners CK, 2003, J ABNORM CHILD PSYCH, V31, P555, DOI 10.1023/A:1025457300409; Conners K, CONNERS CPT 2 V 5; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Ferguson GA., 1976, STAT ANAL PSYCHOL ED; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; JOHN ER, 1977, FUNCTIONAL NEUROSCIE, V2; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medical Care Corporation, 2007, MILD COGN IMP SCREEN; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; Nunez P, 1981, ELECT FIELDS BRAIN; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Powell D, 2004, MICROCOG ASSESSMENT; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Shankle WR, 2009, ALZHEIMERS DEMENT, V5, P295, DOI 10.1016/j.jalz.2008.11.001; Tana M G, 2010, Comput Intell Neurosci, P329213, DOI 10.1155/2010/329213; Thatcher RW, 2008, NEUROIMAGE, V42, P1639, DOI 10.1016/j.neuroimage.2008.06.009; Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211; Thatcher R. W., 2003, Journal of Neurotherapy, V7, P87, DOI 10.1300/J184v07n03_05; Thatcher RW, 2009, HUM BRAIN MAPP, V30, P553, DOI 10.1002/hbm.20524; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trenkle DL, 2007, J ALZHEIMERS DIS, V11, P323; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Weir D. R., 2009, STUDY RETIRED NFL PL	42	61	61	0	36	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2011	23	1					98	106		10.1176/appi.neuropsych.23.1.98			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	717VY	WOS:000287076700038	21304145				2022-02-06	
J	Wade, SL; Walz, NC; Carey, J; McMullen, KM; Cass, J; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.; Cass, Jennifer; Mark, Erin; Yeates, Keith Owen			Effect on Behavior Problems of Teen Online Problem-Solving for Adolescent Traumatic Brain Injury	PEDIATRICS			English	Article						adolescents; traumatic brain injury; telehealth; behavioral interventions	FAMILY; CHILDREN; PREDICTORS; CHILDHOOD; EFFICACY	PURPOSE: To report the results of a randomized clinical trial of teen online problem-solving (TOPS) meant to improve behavioral outcomes of adolescents with traumatic brain injury (TBI). METHODS: A randomized clinical trial was conducted to compare the efficacy of TOPS with access to Internet resources in teenagers with TBI in improving parent and self-reported behavior problems and parentteen conflicts. Participants included 41 adolescents aged 11 to 18 years (range: 11.47-17.90 years) who had sustained a moderate-to-severe TBI between 3 and 19 months earlier. Teens in the TOPS group received 10 to 14 online sessions that provided training in problem-solving, communication skills, and self-regulation. Outcomes were assessed before treatment and at a follow-up assessment an average of 8 months later. Groups were compared on follow-up scores after we controlled for pretreatment levels. Injury severity and socioeconomic status were examined as potential moderators of treatment efficacy. RESULTS: Forty-one participants provided consent and completed baseline assessments, and follow-up assessments were completed for 35 participants (16 TOPS, 19 Internet resource comparison). The TOPS group reported significantly less parent-teen conflict at follow-up than did the Internet-resource-comparison group. Improvements in teen behavior after TOPS were moderated by injury severity; there were greater improvements in the teens' internalizing symptoms after TOPS among adolescents with severe TBI. Family socioeconomic status also moderated the efficacy of TOPS in improving behavior problems reported by both parents and teens, although the nature of the moderation effects varied. CONCLUSION: Our findings suggest that TOPS contributes to improvements in parent-teen conflict generally and parent and self-reported teen behavior problems for certain subsets of participants. Pediatrics 2011; 128: e947-e953	[Wade, Shari L.] Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Med Ctr,Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA		Wade, SL (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Med Ctr,Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research [H133G050239]; US Department of Education and Emergency Medical Services from the Ohio Department of Safety [10503]	This work was supported by National Institute of Disability and Rehabilitation Research grant H133G050239 (to Dr Wade) and US Department of Education and Emergency Medical Services grant 10503 from the Ohio Department of Safety.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2010, PEDIAT TRAUMATIC BRA, P179; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Robin AL, 1989, NEGOTIATING PARENT A; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007	15	61	61	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2011	128	4					E947	E953		10.1542/peds.2010-3721			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	827DH	WOS:000295406800021	21890828	Green Published			2022-02-06	
J	Bye, N; Carron, S; Han, XD; Agyapomaa, D; Ng, SY; Yan, E; Rosenfeld, JV; Morganti-Kossmann, MC				Bye, Nicole; Carron, Sarah; Han, Xiaodi; Agyapomaa, Doreen; Ng, Si Yun; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina			Neurogenesis and Glial Proliferation Are Stimulated Following Diffuse Traumatic Brain Injury in Adult Rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurogenesis; traumatic axonal injury rat model; astrocytes; microglia; polydendrocytes	INTERLEUKIN-6 MESSENGER-RNA; SUBVENTRICULAR ZONE CELLS; FOCAL CEREBRAL-ISCHEMIA; AXONAL INJURY; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; CORTICAL NEUROGENESIS; COGNITIVE RECOVERY; MAMMALIAN BRAIN; STEM-CELLS	Although increased neurogenesis has been described in rodent models of focal traumatic brain injury (TBI), the neurogenic response occurring after diffuse TBI uncomplicated by focal injury has not been examined to date, despite the pervasiveness of this distinct type of brain injury in the TBI patient population. Here we characterize multiple stages of neurogenesis following a traumatic axonal injury (TAI) model of diffuse TBI as well as the proliferative response of glial cells. TAI was induced in adult rats using an impact-acceleration model, and 5-bromo-20-deoxyuridine (BrdU) was administered on days 1-4 posttrauma or sham operation to label mitotic cells. Using immunohistochemistry for BrdU combined with phenotype-specific markers, we found that proliferation was increased following TAI in the subventricular zone of the lateral ventricles and in the hippocampal subgranular zone, although the ultimate production of new dentate granule neurons at 8 weeks was not significantly enhanced. Also, abundant proliferating and reactive astrocytes, microglia, and polydendrocytes were detected throughout the brain following TAI, indicating that a robust glial response occurs in this model, although very few new cells in the nonneurogenic brain regions became mature neurons. We conclude that diffuse brain injury stimulates early stages of a neurogenic response similar to that described for models of focal TBI. (C) 2011 Wiley-Liss, Inc.	[Bye, Nicole; Carron, Sarah; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Bye, Nicole; Yan, Edwin; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Han, Xiaodi] Univ Rochester, Dept Neurosurg, Rochester, NY USA; [Agyapomaa, Doreen] La Trobe Univ, Ctr AgriBiosci, Bundoora, Vic, Australia; [Ng, Si Yun] Natl Univ Singapore, Dept Physiol, Ctr Life Sci, Singapore 117548, Singapore; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3004, Australia		Bye, N (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	nicole.bye@monash.edu	Rosenfeld, Jeffrey V/B-7249-2011	Morganti-Kossmann, Cristina/0000-0002-0807-2063	Transport Accident Commission; Victorian Neurotrauma Initiative	Contract grant sponsor: Transport Accident Commission; Contract grant sponsor: Victorian Neurotrauma Initiative.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Reimers D, 2008, CURR STEM CELL RES T, V3, P247, DOI 10.2174/157488808786733980; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x	59	61	63	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL	2011	89	7					986	1000		10.1002/jnr.22635			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	764IY	WOS:000290624300004	21488090				2022-02-06	
J	Matsushita, M; Hosoda, K; Naitoh, Y; Yamashita, H; Kohmura, E				Matsushita, Makoto; Hosoda, Kohkichi; Naitoh, Yasuo; Yamashita, Haruo; Kohmura, Eiji			Utility of diffusion tensor imaging in the acute stage of mild to moderate traumatic brain injury for detecting white matter lesions and predicting long-term cognitive function in adults Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cognitive dysfunction; diffuse brain injury; diffusion tensor imaging; magnetic resonance imaging; traumatic brain injury	AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; CLASSIFICATION; PERFORMANCE; P300	Object. Traumatic brain injury (TBI) often impairs cognitive function. Diffusion tensor (DT) imaging, a novel modality, permits evaluation of the effects of head trauma on white matter nerve fibers. The objectives of the current study were to investigate where the white matter injury following mild to moderate TBI is specifically located on DT imaging in the acute disease stage and to examine the relationship between the severity of the white matter lesion on DT imaging in the acute stage of TBI and future cognitive function in the chronic disease stage. Methods. Twenty adult patients with mild to moderate TBI (Glasgow Coma Scale score between 9 and 15) underwent conventional MR and DT imaging a median of 3.5 days after injury, and 27 matched healthy controls also underwent both imaging modalities. The patients with TBI were further subdivided into 2 groups, that is, mild and more severe TBI groups, based on clinical (mild or moderate TBI), CT (diffuse brain injury [DBI] I or II), or MR imaging (normal or pathological appearance) classification. Fractional anisotropies (FAs) were compared between patients and controls using the region of interest method. Regions of interest were located in 8 different areas including the genu, stem, and splenium of the corpus callosum and the corona radiata (CR), anterior limb of the internal capsule (ALIC), posterior limb of the internal capsule (PLIC), frontal white matter (FWM), and occipital white matter (OWM) of the periventricular white matter. Eleven patients with TBI also underwent neuropsychological testing, which included the Trail Making Test, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale-Revised, and P300 testing in the chronic disease stage (median 364 days). Results. Region of interest analysis demonstrated significantly lower FA values in the genu, stem, and splenium of the corpus callosum in more severe TBI groups (moderate TBI on clinical classification; DBI 11 on CT classification, and pathological appearance on MR imaging classification) than in controls. A significant difference was also observed in the FA of the splenium between controls and the mild TBI group of the clinical classification. No significant difference was observed in the FA of the CR, ALIC, PLIC, FWM, and OWM between controls and any of the TBI groups of clinical or imaging classifications. No significant difference was observed in the FA of any regions between mild and more severe TBI groups of the clinical or imaging classifications. Multiple regression analysis showed a statistically significant positive linear relationship between FA in the splenium and total IQ (r = 0.79, p = 0.004). A significant negative linear relationship between FA in the FWM and P300 latency was also observed (r = 0.62, p = 0.04). Conclusions. Fractional anisotropy reductions in the splenium and FWM in the acute stage of mild to moderate TBI may be a useful prognostic factor for long-term cognitive dysfunction. (DOI: 10.3171/2011.2.JNS101547)	[Hosoda, Kohkichi] Kobe Univ, Grad Sch Med, Dept Neurosurg, Chou Ku, Kobe, Hyogo 6500017, Japan; [Matsushita, Makoto; Yamashita, Haruo] Kobe Red Cross Hosp, Hyogo Emergency Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan; [Naitoh, Yasuo] Osaka Prefecture Univ, Sch Comprehens Rehabil, Osaka, Japan		Hosoda, K (corresponding author), Kobe Univ, Grad Sch Med, Dept Neurosurg, Chou Ku, 7-5-1 Kusunoki Chou, Kobe, Hyogo 6500017, Japan.	khosoda@med.kobe-u.ac.jp	Hosoda, Kohkichi/AAF-1949-2020		General Insurance Association of Japan [19591674]	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) (19591674) and a medical research grant on traffic accidents from the General Insurance Association of Japan.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BROWN EC, 1958, J CONSULT PSYCHOL, V22, P469, DOI 10.1037/h0039980; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fujita K., 2006, JAPANESE VERSION WAI; GIL R, 1993, ELECTROEN CLIN NEURO, V88, P182, DOI 10.1016/0168-5597(93)90003-8; Hawkins KA, 2002, ARCH CLIN NEUROPSYCH, V17, P49, DOI 10.1016/S0887-6177(00)00099-8; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kato M., 1988, KEIO IGAKU, V65, P861; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee CEC, 2009, NEURORADIOLOGY, V51, P3, DOI 10.1007/s00234-008-0441-3; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu F, 2010, BRAIN RES, V1343, P37, DOI 10.1016/j.brainres.2010.04.064; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Naito Yasuo, 2005, Kobe Journal of Medical Sciences, V51, P95; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	31	61	63	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2011	115	1					130	139		10.3171/2011.2.JNS101547			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	782JO	WOS:000292004700027	21417709				2022-02-06	
J	Chen, JL; Yeh, DP; Lee, JP; Chen, CY; Huang, CY; Lee, SD; Chen, CC; Kuo, TBJ; Kao, CL; Kuo, CH				Chen, Jui-Lien; Yeh, Ding-Peng; Lee, Jo-Ping; Chen, Chung-Yu; Huang, Chih-Yang; Lee, Shin-Da; Chen, Chiu-Chou; Kuo, Terry B. J.; Kao, Chung-Lan; Kuo, Chia-Hua			PARASYMPATHETIC NERVOUS ACTIVITY MIRRORS RECOVERY STATUS IN WEIGHTLIFTING PERFORMANCE AFTER TRAINING	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						fatigue; weightlifter; strength performance; frequency-domain analysis; muscle power; vagal	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN-INJURY; VAGAL-CARDIAC CONTROL; RESISTANCE EXERCISE; FUNCTIONAL RECOVERY; BLOOD-PRESSURE; DEHYDROEPIANDROSTERONE; HEALTH; MOOD; DHEA	Chen, J-L, Yeh, D-P, Lee, J-P, Chen, C-Y, Huang, C-Y, Lee, S-D, Chen, C-C, Kuo, TBJ, Kao, C-L, and Kuo, C-H. Parasympathetic nervous activity mirrors recovery status in weightlifting performance after training. J Strength Cond Res 25(6): 1546-1552, 2011-Heart rate variability (HRV) and parasympathetic power are closely related to the well-being and health status in humans. The main goal of the study was to determine whether these measures can reflect recovery status after weight training. After a 10-day detraining period, 7 weightlifters were challenged with a 2-hour weight training which elicited approximately fourfold increases in circulating muscle creatine kinase level and protracted pain feeling (p < 0.05). Weightlifting performance was then evaluated 3, 24, 48, and 72 hours after training to determine the degree of recovery from fatigue. Heart rate variability, circulating dehydroepiandrostendione sulfate (DHEA-S), and muscle damage markers were measured before each performance test. An electrocardiogram was recorded for 5 minutes continuously at rest in seated positions. After training, weightlifting performance of the subjects decreased below baseline in paralleled with suppressed parasympathetic power (high-frequency [HF] HRV), whereas sympathetic power (normalized low-frequency HRV) was slightly elevated at 3 hours of recovery (p < 0.05). Both weightlifting performances and parasympathetic power returned to baseline values in 24 hours and further increased above baseline during 48-72 hours of recovery in a similar fashion (p < 0.05). Circulating DHEA-S level dropped at 24 hours (p < 0.05) and returned to normal values by 48 hours. Muscle pain increased at 3 hours after training and remained higher than baseline values for the 72-hour recovery period (p < 0.05). Our data suggest that parasympathetic power, indicated by HF HRV, is able to reflect the recovery status of weightlifters after training.	[Chen, Jui-Lien; Yeh, Ding-Peng; Lee, Jo-Ping; Chen, Chung-Yu; Chen, Chiu-Chou; Kuo, Chia-Hua] Taipei Phys Educ Coll, Lab Exercise Biochem, Taipei, Taiwan; [Huang, Chih-Yang] China Med Univ, Grad Inst Chinese Med Sci, Grad Inst Basic Med Sci, Taichung, Taiwan; [Huang, Chih-Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Lee, Shin-Da; Kuo, Chia-Hua] China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan; [Lee, Shin-Da] Asia Univ, Dept Healthcare Adm, Taichung, Taiwan; [Kuo, Terry B. J.; Kao, Chung-Lan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Kao, Chung-Lan] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan		Kuo, CH (corresponding author), Taipei Phys Educ Coll, Lab Exercise Biochem, Taipei, Taiwan.	clkao@vghtpe.gov.tw; kuochiahua@gmail.com	Lee, Shin-Da/Q-2798-2015; Yuang, Chih-Yang/O-5111-2015	Lee, Shin-Da/0000-0002-8393-8349; Kuo, Chia-Hua/0000-0002-1731-4984	National Science Council, Taipei, TaiwanMinistry of Science and Technology, Taiwan [NSC 96-2413-H-154-003-MY3]	This work was partly sponsored by a grant from the National Science Council (grant number: NSC 96-2413-H-154-003-MY3), Taipei, Taiwan. Conflict of interest: N/A.	AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Buchheit M, 2007, AM J PHYSIOL-HEART C, V293, pH133, DOI 10.1152/ajpheart.00062.2007; Burton AR, 2009, J PHYSIOL-LONDON, V587, P183, DOI 10.1113/jphysiol.2008.162230; Camm AJ, 1996, EUR HEART J, V17, P354; Carter JR, 2003, J APPL PHYSIOL, V94, P2212, DOI 10.1152/japplphysiol.01109.2002; Collier SR, 2009, ACTA PHYSIOL, V195, P339, DOI 10.1111/j.1748-1716.2008.01897.x; Cooke WH, 2005, EUR J APPL PHYSIOL, V93, P719, DOI 10.1007/s00421-004-1243-x; Figueroa A, 2008, CLIN PHYSIOL FUNCT I, V28, P49, DOI 10.1111/j.1475-097X.2007.00776.x; Garet M, 2004, MED SCI SPORT EXER, V36, P2112, DOI 10.1249/01.MSS.0000147588.28955.48; Gudemez E, 2002, MICROSURG, V22, P234, DOI 10.1002/micr.10039; Hanson EKS, 2001, BIOL PSYCHOL, V56, P23, DOI 10.1016/S0301-0511(01)00066-7; Hedelin R, 2001, MED SCI SPORT EXER, V33, P1394, DOI 10.1097/00005768-200108000-00023; Herbert J, 1998, EXP GERONTOL, V33, P713, DOI 10.1016/S0531-5565(98)00039-4; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Iellamo F, 2004, MED SCI SPORT EXER, V36, P1342, DOI 10.1249/01.MSS.0000135796.75091.8A; Karemaker JM, 2000, EUR HEART J, V21, P435, DOI 10.1053/euhj.1999.1969; KRISTALBONEH E, 1995, SCAND J WORK ENV HEA, V21, P85, DOI 10.5271/sjweh.15; Lee WC, 2006, HIGH ALT MED BIOL, V7, P228, DOI 10.1089/ham.2006.7.228; LIU TC, 2009, ADAPT MED, V1, P24; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McCraty R, 1998, INTEGR PHYS BEH SCI, V33, P151, DOI 10.1007/BF02688660; Melo RC, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.035246; Montano N, 2000, HYPERTENSION, V36, P1029, DOI 10.1161/01.HYP.36.6.1029; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; SAYERS BM, 1973, ERGONOMICS, V16, P17; Straub RH, 2002, EUR J ENDOCRINOL, V146, P365, DOI 10.1530/eje.0.1460365; Taylor AC, 2003, MED SCI SPORT EXER, V35, P251, DOI 10.1249/01.MSS.0000048725.15026.B5; Tsai YM, 2006, LIFE SCI, V79, P1281, DOI 10.1016/j.lfs.2006.04.001; Wang HT, 2009, J SPORT SCI, V27, P291, DOI 10.1080/02640410802520810; Wang JS, 2009, STEROIDS, V74, P945, DOI 10.1016/j.steroids.2009.06.011	31	61	66	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1064-8011	1533-4287		J STRENGTH COND RES	J. Strength Cond. Res.	JUN	2011	25	6					1546	1552		10.1519/JSC.0b013e3181da7858			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	766OD	WOS:000290792600007	21273908				2022-02-06	
J	Gyorgy, A; Ling, G; Wingo, D; Walker, J; Tong, L; Parks, S; Januszkiewicz, A; Baumann, R; Agoston, DV				Gyorgy, Andrea; Ling, Geoffrey; Wingo, Daniel; Walker, John; Tong, Lawrence; Parks, Steve; Januszkiewicz, Adolph; Baumann, Richard; Agoston, Denes V.			Time-Dependent Changes in Serum Biomarker Levels after Blast Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blast traumatic brain injury; reverse phase protein microarray	NEURON-SPECIFIC ENOLASE; HEAD-INJURY; CARDIAC-ARREST; SPONTANEOUS CIRCULATION; BIOCHEMICAL MARKERS; NEUROFILAMENT; PROTEIN; S-100B; DAMAGE; PREDICTORS	Neuronal and glial proteins detected in the peripheral circulating blood after injury can reflect the extent of the damage caused by blast traumatic brain injury (bTBI). The temporal pattern of their serum levels can further predict the severity and outcome of the injury. As part of characterizing a large-animal model of bTBI, we determined the changes in the serum levels of S100B, neuron-specific enolase (NSE), myelin basic protein (MBP), and neurofilament heavy chain (NF-H). Blood samples were obtained prior to injury and at 6, 24, 72 h, and 2 weeks post-injury from animals with different severities of bTBI; protein levels were determined using reverse phase protein microarray (RPPM) technology. Serum levels of S100B, MBP, and NF-H, but not NSE, showed a time-dependent increase following injury. The detected changes in S100B and MBP levels showed no correlation with the severity of the injury. However, serum NF-H levels increased in a unique, rapid manner, peaking at 6 h post-injury only in animals exposed to severe blast with poor clinical and pathological outcomes. We conclude that the sudden increase in serum NF-H levels following bTBI may be a useful indicator of injury severity. If additional studies verify our findings, the observed early peak of serum NF-H levels can be developed into a useful diagnostic tool for predicting the extent of damage following bTBI.	[Agoston, Denes V.] Uniformed Serv Univ USU, Dept Anat Physiol & Genet, Program Neurosci, Natl Capital Consortium,Neurosurg Program,Sch Med, Bethesda, MD 20814 USA; [Ling, Geoffrey] Uniformed Serv Univ USU, Dept Neurol, Bethesda, MD USA; [Tong, Lawrence; Januszkiewicz, Adolph; Baumann, Richard] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD USA; [Parks, Steve] ORA Inc, Fredericksburg, VA USA		Agoston, DV (corresponding author), Uniformed Serv Univ USU, Dept Anat Physiol & Genet, Program Neurosci, Natl Capital Consortium,Neurosurg Program,Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.mil			DARPA PREVENT	The work was funded by DARPA PREVENT. We thank Mrs. Carla Olsen for her help with the statistical analysis, and Ms. Nicole Draghic and Ms. Alaa Kamnaksh for editorial support.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ekmektzoglou KA, 2007, RESUSCITATION, V75, P219, DOI 10.1016/j.resuscitation.2007.03.016; Ergun R, 1998, NEUROL RES, V20, P418; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gyorgy A.B., 2010, J NEUROSCI METHODS; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Korfias S, 2009, MINI-REV MED CHEM, V9, P227, DOI 10.2174/138955709787315994; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Shinozaki K, 2009, CRIT CARE, V13, DOI 10.1186/cc7973; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; THOMAS D G T, 1978, Lancet, V1, P113; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; YAMAZAKI Y, 1995, SURG NEUROL, V43, P270	36	61	68	11	22	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					1121	1126		10.1089/neu.2010.1561			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600022	21428721				2022-02-06	
J	Tremblay, S; de Beaumont, L; Lassonde, M; Theoret, H				Tremblay, Sara; de Beaumont, Louis; Lassonde, Maryse; Theoret, Hugo			Evidence for the Specificity of Intracortical Inhibitory Dysfunction in Asymptomatic Concussed Athletes	JOURNAL OF NEUROTRAUMA			English	Article						afferent inhibition; intracortical inhibition; somatosensory evoked potentials; sport concussions; TMS	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; LATENCY AFFERENT INHIBITION; SOMATOSENSORY-EVOKED POTENTIALS; MOTOR CORTEX EXCITABILITY; EXCITATORY AMINO-ACIDS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SPORTS CONCUSSION; LONG-TERM	Sports concussions affect thousands of individuals every year and are a major public health concern. Still, little is known about the long-term and cumulative effects of concussions on brain neurophysiology. The principal objective of this study was to investigate the long-lasting effects of multiple sports concussions on sensorimotor integration and somatosensory processing in a sample of 12 concussed athletes and 14 non-concussed athletes of similar age (mean, 23 years) and education (mean, 16 years). Right median nerve stimulation was paired with transcranial magnetic stimulation (TMS) of the left primary motor cortex to investigate sensorimotor integration with short latency afferent inhibition (SAI) and long latency afferent inhibition (LAI) at five interstimulus intervals (18, 20, 22, 100, 200 msec). Somatosensory evoked potentials (SEP) were recorded from the left centro-parietal region. We also investigated primary motor cortex inhibitory mechanisms with three TMS protocols: cortical silent period, long interval intracortical inhibition, and short interval intracortical inhibition. Motor evoked potentials were recorded from the right abductor pollicis brevis muscle. No differences were observed between groups for SAI, LAI, and SEP. However, cortical silent period duration was prolonged and long interval intracortical inhibition was enhanced in the concussed group. These findings suggest that multiple sports concussions lead to specific, long-term neurophysiological dysfunctions of intracortical inhibitory mechanisms in primary motor cortex while somatosensory processing and sensorimotor integration are spared. This study provides additional evidence for the presence of specific and stable alterations of GABA(B) receptor activity in primary motor cortex that may be of clinical value for prognosis and diagnosis.	[Tremblay, Sara; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Tremblay, Sara; Lassonde, Maryse; Theoret, Hugo] Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; [de Beaumont, Louis] McGill Univ, Montreal, PQ, Canada		Theoret, H (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca	Tremblay, Sara/X-5471-2019	Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec	This work was supported by grants from the Canadian Institutes of Health Research and the Fonds de la Recherche en Sante du Quebec.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; Alle H, 2009, J PHYSIOL-LONDON, V587, P5163, DOI 10.1113/jphysiol.2009.179820; Baumer T, 2007, NEUROLOGY, V69, P1976, DOI 10.1212/01.wnl.0000278109.76607.0a; Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen R, 1999, EXP BRAIN RES, V129, P77, DOI 10.1007/s002210050938; Chen R, 2004, EXP BRAIN RES, V154, P1, DOI 10.1007/s00221-003-1684-1; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; COOPER R, 1980, EEG TECHNOLOGY; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2007, CLIN NEUROPHYSIOL, V118, P2207, DOI 10.1016/j.clinph.2007.07.005; Di Lazzaro V, 2005, J NEUROL NEUROSUR PS, V76, P1064, DOI 10.1136/jnnp.2004.051334; Di Lazzaro V, 2004, J NEUROL NEUROSUR PS, V75, P555, DOI 10.1136/jnnp.2003.018127; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P581; Kessler KR, 2005, MOVEMENT DISORD, V20, P238, DOI 10.1002/mds.20295; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maeda F, 2000, BRIT J PSYCHIAT, V177, P169, DOI 10.1192/bjp.177.2.169; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Orth M, 2005, BRAIN, V128, P1292, DOI 10.1093/brain/awh473; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Richardson SP, 2009, EXP BRAIN RES, V193, P173, DOI 10.1007/s00221-008-1605-4; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rossi S, 2009, BIOL PSYCHIAT, V66, P54, DOI 10.1016/j.biopsych.2009.03.008; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Sailer A, 2003, BRAIN, V126, P1883, DOI 10.1093/brain/awg183; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Wu L, 2002, CLIN NEUROPHYSIOL, V113, P1286, DOI 10.1016/S1388-2457(02)00160-8; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Zumsteg D, 2006, CAN J NEUROL SCI, V33, P379, DOI 10.1017/S0317167100005333	73	61	62	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					493	502		10.1089/neu.2010.1615			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200001	21219259				2022-02-06	
J	Palacios, EM; Fernandez-Espejo, D; Junque, C; Sanchez-Carrion, R; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Sanchez-Carrion, Rocio; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Diffusion tensor imaging differences relate to memory deficits in diffuse traumatic brain injury	BMC NEUROLOGY			English	Article							WHITE-MATTER INJURY; PREFRONTAL CORTEX; WORKING-MEMORY; AXONAL INJURY; HEAD-INJURY; COGNITIVE DYSFUNCTION; DORSAL HIPPOCAMPUS; CORPUS-CALLOSUM; CEREBRAL-CORTEX; MILD	Background: Memory is one of the most impaired functions after traumatic brain injury (TBI). We used diffusion tensor imaging (DTI) to determine the structural basis of memory deficit. We correlated fractional anisotropy (FA) of the fasciculi connecting the main cerebral regions that are involved in declarative and working memory functions. Methods: Fifteen patients with severe and diffuse TBI and sixteen healthy controls matched by age and years of education were scanned. The neuropsychological assessment included: Letter-number sequencing test (LNS), 2-back task, digit span (forwards and backwards) and the Rivermead profilet. DTI was analyzed by a tract-based spatial statics (TBSS) approach. Results: Whole brain DTI analysis showed a global decrease in FA values that correlated with the 2-back d-prime index, but not with the Rivermead profile. ROI analysis revealed positive correlations between working memory performance assessed by 2-back d-prime and superior longitudinal fasciculi, corpus callosum, arcuate fasciculi and fornix. Declarative memory assessed by the Rivermead profile scores correlated with the fornix and the corpus callosum. Conclusions: Diffuse TBI is associated with a general decrease of white matter integrity. Nevertheless deficits in specific memory domains are related to different patterns of white matter damage.	[Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Palacios, Eva M.; Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Inst Biomed Res August Pi I Sunyer IDIBAPS, Barcelona, Spain; [Sanchez-Carrion, Rocio; Roig, Teresa; Tormos, Jose M.] Inst Univ Neurorehabil Guttmann, Dept Neurophysiol, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge, Hosp Clin Barcelona CDIC, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Bargallo, Nuria/G-6854-2016; Vendrell, Pere/B-4392-2011; Junque, Carme/B-4400-2011; Fernandez-Espejo, Davinia/AAT-5481-2021	Bargallo, Nuria/0000-0001-6284-5402; Vendrell, Pere/0000-0001-8918-5440; Junque, Carme/0000-0002-6381-3063; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Tormos Munoz, Jose Maria/0000-0002-8764-2289	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [2009SGR941]; Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) [890003I3]; Spanish Ministry for EducationSpanish Government [AP2006-00862]	This work was supported by a grant from the Spanish Ministry of Science and Innovation (SAF2007-66077) and a grant from the Generalitat de Catalunya (2009SGR941) to the Neuropsychology Research Group. Eva M. Palacios was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) (890003I3). Davinia Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-00862).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barbas H, 1995, HIPPOCAMPUS, V5, P511, DOI 10.1002/hipo.450050604; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonzano L, 2009, NEUROIMAGE, V44, P9, DOI 10.1016/j.neuroimage.2008.08.015; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 2002, NEUROIMAGE, V16, P317, DOI 10.1006/nimg.2002.1063; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; Chumbley JR, 2009, NEUROIMAGE, V44, P62, DOI 10.1016/j.neuroimage.2008.05.021; Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Davachi L, 2002, J NEUROPHYSIOL, V88, P982, DOI 10.1152/jn.2002.88.2.982; Dineen RA, 2009, BRAIN, V132, P239, DOI 10.1093/brain/awn275; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; Eickhoff SB, 2007, NEUROIMAGE, V36, P511, DOI 10.1016/j.neuroimage.2007.03.060; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FERINO F, 1987, EXP BRAIN RES, V65, P421; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Izaki Y, 2008, EUR J NEUROSCI, V27, P3029, DOI 10.1111/j.1460-9568.2008.06284.x; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Jonides J, 1998, J NEUROSCI, V18, P5026; Klingberg T, 1997, CEREB CORTEX, V7, P465, DOI 10.1093/cercor/7.5.465; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laroche S, 2000, HIPPOCAMPUS, V10, P438; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Lee I, 2003, J NEUROSCI, V23, P1517, DOI 10.1523/JNEUROSCI.23-04-01517.2003; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2005, MRI ATLAS HUMAN WHIT; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ranganath C, 2001, NEURON, V31, P865, DOI 10.1016/S0896-6273(01)00411-1; Rissman J, 2008, CEREB CORTEX, V18, P1618, DOI 10.1093/cercor/bhm195; ROSENE DL, 1977, SCIENCE, V198, P315, DOI 10.1126/science.410102; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 2004, NEUROBIOL LEARN MEM, V82, P171, DOI 10.1016/j.nlm.2004.06.005; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Thierry AM, 2000, HIPPOCAMPUS, V10, P411, DOI 10.1002/1098-1063(2000)10:4<411::AID-HIPO7>3.0.CO;2-A; Toga AW, 2006, NAT REV NEUROSCI, V7, P952, DOI 10.1038/nrn2012; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; WECHSLER D, 1999, ESCALA INTENTELIGENC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wills P, 2000, BRAIN INJURY, V14, P693; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yoon T, 2008, LEARN MEMORY, V15, P97, DOI 10.1101/lm.850808; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247	84	61	64	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	FEB 23	2011	11								24	10.1186/1471-2377-11-24			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	730VN	WOS:000288063400001	21345223	Green Published, gold			2022-02-06	
J	Koehler, DM; Shipman, J; Davidson, MA; Guillamondegui, O				Koehler, Daniel M.; Shipman, Jason; Davidson, Mario A.; Guillamondegui, Oscar			Is Early Venous Thromboembolism Prophylaxis Safe in Trauma Patients With Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	40th Annual Meeting of the Western-Trauma-Association	FEB 28-MAR 07, 2010	Telluride, CO	Western Trauma Assoc		Traumatic brain injury; Venous thromboembolism prophylaxis; Exacerbation of intracranial hemorrhagic injury	MOLECULAR-WEIGHT HEPARIN; MAJOR TRAUMA; BRAIN-INJURY; COMPRESSION STOCKINGS; PULMONARY-EMBOLISM; ENOXAPARIN; NEUROSURGERY; PREVENTION; MANAGEMENT	Background: Patients with traumatic brain injuries (TBIs) are at high risk for venous thromboembolic sequelae; however, prophylaxis is often delayed because of the perceived risk of intracranial hemorrhagic exacerbation. The goal of this study was to determine whether enoxaparin for early venous thromboembolism (VTE) prophylaxis is safe for hemodynamically stable patients with TBIs. Methods: This is a retrospective cohort study from a Level I Trauma Center of patients with TBIs receiving early (0-72 hours) or late (>72 hours) VTE prophylaxis. Inclusion criteria included evidence of acute intracranial hemorrhagic injury (IHI) on admission computed tomography, head/neck abbreviated injury score >= 3, age >= 16 years, and hospital length of stay >= 72 hours. Exclusion criteria included intracranial pressure monitor/ventriculostomy, current systemic anticoagulation, pregnancy, coagulopathy, history of DVT, ongoing intra-abdominal hemorrhage 24 hours postadmission, and preexisting inferior vena cava filter. Progression of IHI defined as lesion expansion/new IHI on repeat computed tomography. Results: Totally, 669 patients were identified: 268 early (40.1%) and 401 late (59.9%), with a mean injury severity score of 27.8 +/- 10.2 and 29.4 +/- 11, respectively. Head neck abbreviated injury score of 3 (47% vs. 34%), 4 (42% vs. 46%), 5 (11% vs. 19%), and 6 (0% vs. 1%) were reported for the early and late treatment groups, respectively. Mean time to prophylaxis was 2.77 days +/- 0.49 days and 5.31 days +/- 1.97 days. IHI progression before prophylaxis was 9.38% versus 17.41% (p < 0.001) and after prophylaxis was 1.46% versus 1.54% (p > 0.9). Proportions of proximal DVT were 1.5% versus 3.5% (p = 0.117) and pulmonary embolism were 1.5% versus 2.2% (p = 0.49). There were no differences in injury severity score, age, and pelvic and/or long bone fractures. Conclusions: We found no evidence that early VTE prophylaxis increases the rate of IHI progression in hemodynamically stable patients with TBIs. The natural rate of IHI progression observed is comparable with previous studies. Although not powered to detect differences in the incidence of DVT and pulmonary embolism, the data trend toward increased proportions of both VTE outcomes in the late group.	[Koehler, Daniel M.; Shipman, Jason; Davidson, Mario A.; Guillamondegui, Oscar] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA		Guillamondegui, O (corresponding author), 1211 21 Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	oscar.guillamondegui@vanderbilt.edu	Davidson, Mario/AAX-1102-2021				Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Kiphuth IC, 2009, CEREBROVASC DIS, V27, P146, DOI 10.1159/000177923; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87	19	61	65	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2011	70	2					324	329		10.1097/TA.0b013e31820b5d22			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	719FV	WOS:000287187700014	21307729				2022-02-06	
J	Colantonio, A; Harris, JE; Ratcliff, G; Chase, S; Ellis, K				Colantonio, Angela; Harris, Jocelyn E.; Ratcliff, Graham; Chase, Susan; Ellis, Kristina			Gender differences in self reported long term outcomes following moderate to severe traumatic brain injury	BMC NEUROLOGY			English	Article							SEX-DIFFERENCES; SLEEP DISTURBANCE; HEAD-INJURY; HEALTH; POPULATION; HOSPITALIZATION; REHABILITATION; EPIDEMIOLOGY; ADJUSTMENT; ANXIETY	Background: The majority of research on health outcomes after a traumatic brain injury is focused on male participants. Information examining gender differences in health outcomes post traumatic brain injury is limited. The purpose of this study was to investigate gender differences in symptoms reported after a traumatic brain injury and to examine the degree to which these symptoms are problematic in daily functioning. Methods: This is a secondary data analysis of a retrospective cohort study of 306 individuals who sustained a moderate to severe traumatic brain injury 8 to 24 years ago. Data were collected using the Problem Checklist (PCL) from the Head Injury Family Interview (HIFI). Using Bonferroni correction, group differences between women and men were explored using Chi-square and Wilcoxon analysis. Results: Chi-square analysis by gender revealed that significantly more men reported difficulty setting realistic goals and restlessness whereas significantly more women reported headaches, dizziness and loss of confidence. Wilcoxon analysis by gender revealed that men reported sensitivity to noise and sleep disturbances as significantly more problematic than women, whereas for women, lack of initiative and needing supervision were significantly more problematic in daily functioning. Conclusion: This study provides insight into gender differences on outcomes after traumatic brain injury. There are significant differences between problems reported by men compared to women. This insight may facilitate health service planners and clinicians when developing programs for individuals with brain injury.	[Colantonio, Angela; Harris, Jocelyn E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Colantonio, Angela; Ellis, Kristina] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Chase, Susan] Working Order, Sharpsburg, PA USA		Colantonio, A (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON, Canada.	angela.colantonio@utoronto.ca	Harris, Jocelyn Ellen/ABE-7420-2021	Harris, Jocelyn Ellen/0000-0002-3293-1833; Colantonio, Angela/0000-0003-2094-4765	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A1]; Washington County Brain Injury Association; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Toronto Rehabilitation InstituteUniversity of Toronto; CIHR Fellowship AwardCanadian Institutes of Health Research (CIHR); Strategic Training Fellowship in Health Care, Technology and Place [FRN: STP 53911]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER	Funding for this study was obtained from NINDS (NS34740-2), NIA (F33 AGO5856-01A1), Washington County Brain Injury Association, the Canadian Institutes for Health Research and the Toronto Rehabilitation Institute. Support for this study was given to JEH in a CIHR Fellowship Award and a Strategic Training Fellowship in Health Care, Technology and Place (FRN: STP 53911).	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; LANGELY RL, 2003, SEX GENDER DIFFERENC; MacIntyre S, 1996, SOC SCI MED, V42, P617, DOI 10.1016/0277-9536(95)00335-5; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PAVUR R, 1988, AM STAT, V42, P171, DOI 10.2307/2684994; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Tate D G, 2001, Phys Med Rehabil Clin N Am, V12, P23; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	51	61	62	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	OCT 28	2010	10								102	10.1186/1471-2377-10-102			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	697ZB	WOS:000285557200001	21029463	Green Published, gold			2022-02-06	
J	Shear, DA; Lu, XCM; Bombard, MC; Pedersen, R; Chen, ZY; Davis, A; Tortella, FC				Shear, Deborah A.; Lu, Xi-Chun May; Bombard, Matthew C.; Pedersen, Rebecca; Chen, Zhiyong; Davis, Angela; Tortella, Frank C.			Longitudinal Characterization of Motor and Cognitive Deficits in a Model of Penetrating Ballistic-Like Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; cognitive function; models of injury; penetrating ballistic-like brain injury; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN; POSTTRAUMATIC HYDROCEPHALUS; FUNCTIONAL RECOVERY; PROSPECTIVE MEMORY; PREFRONTAL CORTEX; GUNSHOT WOUNDS; ROTAROD TEST; RAT MODEL; MICE	Traumatic brain injury (TBI) produces a wide range of motor and cognitive changes. While some neurological symptoms may respond to therapeutic intervention during the initial recovery period, others may persist for many years after the initial insult, and often have a devastating impact on quality of life for the TBI victim. The aim of the current study was to develop neurobehavioral testing parameters designed to provide a longitudinal assessment of neurofunctional deficits in a rodent model of penetrating ballistic-like brain injury (PBBI). We report here a series of experiments in which unilateral frontal PBBI was induced in rats, and motor/cognitive abilities were assessed using a battery of tests ranging from 30 min to 10 weeks post-injury. The results showed that PBBI produced consistent and significant (1) neurological deficits (neuroscore examination: 30 min to 10 weeks post-PBBI), (2) sensorimotor dysfunction in the contralateral forelimb (forelimb asymmetry task: 7 and 21 days), (3) motor dysfunction (balance beam task: 3-7 days; and fixed-speed rotarod task: 3-28 days), and (4) spatial learning deficits in the Morris water maze (MWM) task out to 10 weeks post-injury. Overall, the results of this study demonstrate that PBBI produces enduring motor and cognitive deficits, and identifies the optimal task and testing parameters for facilitating longitudinal screening of promising therapeutic interventions in this brain injury model.	[Shear, Deborah A.; Lu, Xi-Chun May; Bombard, Matthew C.; Pedersen, Rebecca; Chen, Zhiyong; Davis, Angela; Tortella, Frank C.] MRMC UWI C, Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; [Bombard, Matthew C.; Pedersen, Rebecca; Davis, Angela] Geneva Fdn, Lakewood, WA USA		Shear, DA (corresponding author), MRMC UWI C, Walter Reed Army Inst Res, Dept Appl Neurobiol, Bldg 503-2W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Shear, Deborah/B-3607-2011	Bombard, Matthew/0000-0002-3039-5192	Department of the Army [W81XWH-08-2-0127]; U.S. Army Medical Research Acquisition Activity, Fort Detrick, MD	This work was supported by the Department of the Army, award W81XWH-08-2-0127, with the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, as the awarding and administering acquisition office.	BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bohlen M, 2009, J NEUROSCI METH, V178, P10, DOI 10.1016/j.jneumeth.2008.11.001; Carlson JN, 1996, BRAIN RES, V707, P122, DOI 10.1016/0006-8993(95)01341-5; Carter RJ, 1999, J NEUROSCI, V19, P3248; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; COWEY A, 1974, BRAIN RES, V72, P53, DOI 10.1016/0006-8993(74)90649-0; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; GLICK SD, 1976, LIFE SCI, V18, P889, DOI 10.1016/0024-3205(76)90405-7; Guyot LL, 2000, NEUROL RES, V22, P25; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; HOCHMAN MS, 1983, EPILEPSIA, V24, P11, DOI 10.1111/j.1528-1157.1983.tb04860.x; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; KATZ RT, 1989, AM J PHYS MED REHAB, V68, P91, DOI 10.1097/00002060-198904000-00009; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Nestor SM, 2008, BRAIN, V131, P2443, DOI 10.1093/brain/awn146; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peeling J, 2001, J Stroke Cerebrovasc Dis, V10, P166, DOI 10.1053/jscd.2001.26865; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roof RL, 2001, STROKE, V32, P2648, DOI 10.1161/hs1101.097397; Rustay NR, 2003, BEHAV BRAIN RES, V141, P237, DOI 10.1016/S0166-4328(02)00376-5; Sapsford W, 2003, J R Army Med Corps, V149, P5; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 2002, PHARM CEREBRAL ISCHE, P210; Schrimsher GW, 2002, J CHILD NEUROL, V17, P877, DOI 10.1177/08830738020170122001; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2009, PHARMACOL BIOCHEM BE, V94, P56, DOI 10.1016/j.pbb.2009.07.006; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; WATZMAN N, 1968, PSYCHOPHARMACOLOGIA, V12, P414, DOI 10.1007/BF00401346; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828	52	61	61	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1911	1923		10.1089/neu.2010.1399			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600015	20684676				2022-02-06	
J	Coldren, RL; Kelly, MP; Parish, RV; Dretsch, M; Russell, ML				Coldren, Rodney L.; Kelly, Mark P.; Parish, Robert V.; Dretsch, Michael; Russell, Michael L.			Evaluation of the Military Acute Concussion Evaluation for Use in Combat Operations More Than 12 Hours After Injury	MILITARY MEDICINE			English	Article							RECOVERY	The diagnosis and management of concussion can be difficult in a combat environment, especially in the absence of loss of consciousness or post-traumatic amnesia. As no validated test exists to diagnose or grade neurocognitive impairment from a concussion, the military currently employs the Military Acute Concussion Evaluation (MACE) in Iraq. This is a two-part test, which incorporates the standardized assessment of concussion (SAC) as its objective score, although it has not been shown to be valid unless administered shortly after injury. A research team deployed to Iraq between January and April 2009 to examine the validity of several tests of neurocognitive function following a concussion, including the MACE. When administered more than 12 hours after the concussive injury, the MACE lacked sufficient sensitivity and specificity to be clinically useful.	[Coldren, Rodney L.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Kelly, Mark P.; Parish, Robert V.] Walter Reed Army Med Ctr, Dept Psychol, Washington, DC 20003 USA; [Dretsch, Michael] USA, Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Russell, Michael L.] Lincoln Ctr, San Antonio, TX 78230 USA		Coldren, RL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.						Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *DEP DEF, 2007, 07030 DEP DEF HLTH A; Giza CC, 2001, J ATHL TRAINING, V36, P228; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Nassiri JD, 2002, MIL MED, V167, P873, DOI 10.1093/milmed/167.10.873; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; *OFF US ARM SURG G, 2009, 09068 OTSGMEDCOM OFF; Tanielian T., 2008, INVISIBLE WOUNDS WAR	15	61	61	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JUL	2010	175	7					477	481		10.7205/MILMED-D-09-00258			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	624EN	WOS:000279799200005	20684450	Bronze			2022-02-06	
J	Kharatishvili, I; Pitkanen, A				Kharatishvili, Irina; Pitkanen, Asla			Association of the severity of cortical damage with the occurrence of spontaneous seizures and hyperexcitability in an animal model of posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						Cortical damage; Epilepsy; Fluid percussion brain injury; Histopathology; Hyperexcitability	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; LITHIUM-PILOCARPINE MODEL; GUINEA-PIG BRAIN; HIPPOCAMPAL-ENTORHINAL LOOP; PREFERENTIAL NEURONAL LOSS; SYSTEM IN-VITRO; HEAD-INJURY; PARAHIPPOCAMPAL REGION; EPILEPTIFORM ACTIVITY	Posttraumatic epilepsy is a common consequence of traumatic brain injury in humans. Major predictors for the development of posttraumatic epilepsy include the severity of injury and occurrence of cortical contusions. The effect of the size or location of the cortical lesion on the risk of epileptogenesis, however, is poorly understood. Here, we investigated the extent and location of cortical damage and its association with a lowered seizure threshold and the occurrence of spontaneous seizures in rats (n=77) that had experienced moderate or severe lateral fluid-percussion brain injury (FPBI) 12 months earlier. Spontaneous seizures were detected with video-electroencephalography monitoring and a lowered seizure threshold was determined based on a pentylenetetrazol (PTZ) test. Cortical atrophy was evaluated from thionin-stained sections using the Cavalieri estimation in four different experiments in which rats developed either spontaneous recurrent seizures (i.e., epilepsy) or a lowered seizure threshold. Our data show that damage to the cortex ipsilateral to the injury was more severe and extended more caudally in epileptic animals than in those without epilepsy (p<0.05 and p<0.001 for 2 independent experiments). Further, the extent of the cortical damage correlated positively with chronically increased hyperexcitability (number of spikes in PTZ test) in animals with traumatic brain injury (r=-0.54, p<0.05; r=-0.72, p<0.01 for 2 independent experiments). Specifically, cortical lesions located at the level of the perirhinal, entorhinal, and postrhinal cortices were associated with a lowered seizure threshold and seizures. The severity of the cortical injury did not correlate with the severity of hippocampal damage. These findings indicate that, like in humans, the severity of cortical injury correlates with epileptogenesis and epilepsy in an experimental model of posttraumatic epilepsy. (C) 2010 Elsevier B.V. All rights reserved.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uef.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Epilepsy Foundation; Finnish Cultural FoundationFinnish Cultural FoundationFinnish IT center for science	This study was supported by the Academy of Finland (A.P.), the Sigrid Juselius Foundation (A.P.), the Finnish Epilepsy Foundation (I.K.), and the Northern Savo Regional Fund of the Finnish Cultural Foundation (I.K.)	Aarabi B, 2000, Neurosurg Focus, V8, pe1; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Andre V, 2007, EPILEPSIA, V48, P41, DOI 10.1111/j.1528-1167.2007.01288.x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Avoli M, 2002, PROG NEUROBIOL, V68, P167, DOI 10.1016/S0301-0082(02)00077-1; Avoli M, 1996, J NEUROSCI, V16, P3912; Barbarosie M, 2000, J NEUROPHYSIOL, V83, P1115, DOI 10.1152/jn.2000.83.3.1115; Barbarosie M, 1997, J NEUROSCI, V17, P9308; Bartolomei F, 2005, EPILEPSIA, V46, P677, DOI 10.1111/j.1528-1167.2005.43804.x; BEAR J, 1993, EPILEPSY RES, V14, P183, DOI 10.1016/0920-1211(93)90043-7; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bernasconi N, 1999, NEUROLOGY, V52, P1870, DOI 10.1212/WNL.52.9.1870; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bernasconi N, 2001, NEUROLOGY, V56, P1335, DOI 10.1212/WNL.56.10.1335; Bernasconi N, 2000, ANN NY ACAD SCI, V911, P495; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bonilha L, 2003, J NEUROL NEUROSUR PS, V74, P1627, DOI 10.1136/jnnp.74.12.1627; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BULLOCK MR, 2005, HEAD INJURY PATHOPHY, P113; Burwell RD, 1995, HIPPOCAMPUS, V5, P390, DOI 10.1002/hipo.450050503; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DASILVA AM, 1990, ACT NEUR S, V50, P48; de Curtis M, 1998, BRAIN RES PROTOC, V3, P221, DOI 10.1016/S1385-299X(98)00044-0; De Guzman P, 2004, NEUROSCIENCE, V123, P875, DOI 10.1016/j.neuroscience.2003.11.013; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; DU F, 1995, J NEUROSCI, V15, P6301; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gean AD, 1994, IMAGING HEAD TRAUMA; Gnatkovsky V, 2008, ANN NEUROL, V64, P674, DOI 10.1002/ana.21519; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Guyot LL, 2000, NEUROL RES, V22, P25; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Insausti R, 1997, HIPPOCAMPUS, V7, P146, DOI 10.1002/(SICI)1098-1063(1997)7:2<146::AID-HIPO4>3.0.CO;2-L; Jutila L, 2001, AM J NEURORADIOL, V22, P1490; Kazemi M, 2004, MAGN RESON IMAGING, V22, P653, DOI 10.1016/j.mri.2004.01.043; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2009, EXP NEUROL, V217, P154, DOI 10.1016/j.expneurol.2009.01.026; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikkonen M, 1998, ANN NEUROL, V44, P923, DOI 10.1002/ana.410440611; Nagao T, 1996, NEUROSCIENCE, V72, P399, DOI 10.1016/0306-4522(95)00534-X; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Noulhiane A, 2006, J NEUROSCI METH, V156, P293, DOI 10.1016/j.jneumeth.2006.02.021; PARE D, 1992, J NEUROSCI, V12, P1867; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P465, DOI 10.1016/B978-012088554-1/50039-6; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Roch C, 2002, EPILEPSIA, V43, P1129, DOI 10.1046/j.1528-1157.2002.17802.x; Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salmenpera T, 2000, SEIZURE-EUR J EPILEP, V9, P208, DOI 10.1053/seiz.1999.0373; Salmenpera T, 2000, EPILEPSY RES, V40, P155, DOI 10.1016/S0920-1211(00)00121-2; SCHIERHOUT G, 2000, COCHRANE DB SYST REV, V2; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPENCER SS, 1994, EPILEPSIA, V35, P721, DOI 10.1111/j.1528-1157.1994.tb02502.x; Sudbury JR, 2007, EUR J NEUROSCI, V26, P3571, DOI 10.1111/j.1460-9568.2007.05962.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Uva L, 2005, EPILEPSIA, V46, P1914, DOI 10.1111/j.1528-1167.2005.00342.x; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Watson, 1998, RAT BRAIN STEREOTACT; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wozny C, 2005, NEUROBIOL DIS, V19, P451, DOI 10.1016/j.nbd.2005.01.016; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	92	61	62	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUN	2010	90	1-2					47	59		10.1016/j.eplepsyres.2010.03.007			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	621FK	WOS:000279560700008	20435440				2022-02-06	
J	Kharatishvili, I; Pitkanen, A				Kharatishvili, Irina; Pitkanen, Asla			Posttraumatic epilepsy	CURRENT OPINION IN NEUROLOGY			English	Article						animal models; early seizures; epilepsy; prevention; risk factors; traumatic brain injury; unprovoked seizures	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; TUBEROUS SCLEROSIS COMPLEX; TEMPORAL-LOBE EPILEPSY; MAMMALIAN TARGET; APOE-EPSILON-4 ALLELE; RISK-FACTORS; HEAD-INJURY; SEIZURES; RAPAMYCIN	Purpose of review The purpose of this study is to focus on recent advances in understanding of the genetic and epidemiologic risk factors, development, modeling, and prevention of epilepsy after traumatic brain injury (TBI). Recent findings Epidemiologic data suggest that the epileptogenic period after TBI in humans may last longer than previously thought. Depression was found to be an important risk factor for posttraumatic epilepsy (PTE). Once PTE has developed, it remits less often than previously reported. Moreover, patients with PTE appear to have a higher mortality rate than patients with TBI without epilepsy. In animal models it was reported that in addition to rats, also mice develop PTE. Furthermore, the immature rat brain is sensitive to TBI-induced epileptogenesis. The development of a lowered seizure threshold after TBI can be alleviated by pharmacotherapy in rats. Summary These observations provide small but encouraging steps towards a better understanding of the mechanisms of posttraumatic epileptogenesis, which is a key to developing a cure for this condition.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uku.fi			Medical Council of the Academy of FinlandAcademy of Finland; Sigrid Juselius FoundationSigrid Juselius Foundation; Citizens United for Research in Epilepsy	This study was supported by the Medical Council of the Academy of Finland, the Sigrid Juselius Foundation, and Citizens United for Research in Epilepsy.	AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; FERGUSON PL, 2009, EPILEPSIA; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Gurkoff GG, 2009, NEUROSCIENCE, V164, P862, DOI 10.1016/j.neuroscience.2009.08.021; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2009, ENCYCLOPEDIA OF BASIC EPILEPSY RESEARCH, VOLS 1-3, P1229; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Saccucci P, 2004, NEUROGENETICS, V5, P245, DOI 10.1007/s10048-004-0192-1; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Shavelle R, 2000, J Insur Med, V32, P163; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wong M, 2010, EPILEPSIA, V51, P27, DOI 10.1111/j.1528-1167.2009.02341.x; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	45	61	68	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	APR	2010	23	2					183	188		10.1097/WCO.0b013e32833749e4			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	577BU	WOS:000276196700015	20125011				2022-02-06	
J	Meierhans, R; Bechir, M; Ludwig, S; Sommerfeld, J; Brandi, G; Haberthur, C; Stocker, R; Stover, JF				Meierhans, Roman; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Brandi, Giovanna; Haberthuer, Christoph; Stocker, Reto; Stover, John F.			Brain metabolism is significantly impaired at blood glucose below 6 mM and brain glucose below 1 mM in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							INTENSIVE INSULIN THERAPY; CEREBRAL ENERGY-METABOLISM; GLYCEMIC CONTROL; MICRODIALYSIS; HYPERGLYCEMIA; GLUTAMATE; LACTATE; IMPACT; ACCUMULATION; HOMEOSTASIS	Introduction: The optimal blood glucose target following severe traumatic brain injury (TBI) must be defined. Cerebral microdialysis was used to investigate the influence of arterial blood and brain glucose on cerebral glucose, lactate, pyruvate, glutamate, and calculated indices of downstream metabolism. Methods: In twenty TBI patients, microdialysis catheters inserted in the edematous frontal lobe were dialyzed at 1 mu l/min, collecting samples at 60 minute intervals. Occult metabolic alterations were determined by calculating the lactate-pyruvate (L/P), lactate-glucose (L/Glc), and lactate-glutamate (L/Glu) ratios. Results: Brain glucose was influenced by arterial blood glucose. Elevated L/P and L/Glc were significantly reduced at brain glucose above 1 mM, reaching lowest values at blood and brain glucose levels between 6-9 mM (P < 0.001). Lowest cerebral glutamate was measured at brain glucose 3-5 mM with a significant increase at brain glucose below 3 mM and above 6 mM. While L/Glu was significantly increased at low brain glucose levels, it was significantly decreased at brain glucose above 5 mM (P < 0.001). Insulin administration increased brain glutamate at low brain glucose, but prevented increase in L/Glu. Conclusions: Arterial blood glucose levels appear to be optimal at 6-9 mM. While low brain glucose levels below 1 mM are detrimental, elevated brain glucose are to be targeted despite increased brain glutamate at brain glucose > 5 mM. Pathogenity of elevated glutamate appears to be relativized by L/Glu and suggests to exclude insulin-induced brain injury.	[Meierhans, Roman; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Brandi, Giovanna; Stocker, Reto; Stover, John F.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Brandi, Giovanna] Osped Maggiore Policlin Milano, I-20122 Milan, Italy; [Haberthuer, Christoph] Luzerner Kantonsspital, CH-6000 Luzern 16, Switzerland		Stover, JF (corresponding author), Univ Zurich Hosp, Ramistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch			Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF); SUVA Fonds	The help of the nursing staff in collecting and analyzing subcutaneous and cerebral microdialysis samples is gratefully acknowledged. The study was supported by grants from the Swiss National Science Foundation (SNF) and the SUVA Fonds to JFS and RS.	Alessandri B, 1999, ACT NEUR S, V75, P25; Alm-Kruse K, 2008, BMC NURS, V7, DOI 10.1186/1472-6955-7-1; Aronson D, 2008, ADV CARDIOL, V45, P1, DOI 10.1159/000115118; Bak LK, 2007, NEUROCHEM RES, V32, P671, DOI 10.1007/s11064-006-9161-4; Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bingham EM, 2002, DIABETES, V51, P3384, DOI 10.2337/diabetes.51.12.3384; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Duarte AI, 2003, BRAIN RES, V977, P23, DOI 10.1016/S0006-8993(03)02679-9; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Guyot LL, 2000, NEUROSCI LETT, V288, P61, DOI 10.1016/S0304-3940(00)01168-X; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hattori N, 2004, J NUCL MED, V45, P775; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Li PA, 1999, FREE RADICAL BIO MED, V27, P1033, DOI 10.1016/S0891-5849(99)00152-5; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Occhipinti R, 2009, J NEUROPHYSIOL, V101, P2528, DOI 10.1152/jn.90377.2008; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pellerin L, 2008, CURR OPIN CLIN NUTR, V11, P701, DOI 10.1097/MCO.0b013e328312c368; Poblete-Naredo I, 2009, NEUROSCI LETT, V451, P134, DOI 10.1016/j.neulet.2008.12.049; Ringel F, 2006, NEUROSCI LETT, V398, P306, DOI 10.1016/j.neulet.2006.01.012; Ronald Zielke H, 2009, J NEUROCHEM, V109, P24, DOI 10.1111/j.1471-4159.2009.05941.x; Samuelsson C, 2009, J NEUROSURG, V111, P910, DOI 10.3171/2008.8.JNS0889; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Strong AJ, 2007, CURR OPIN CRIT CARE, V13, P126, DOI 10.1097/MCC.0b013e32807faffb; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	56	61	66	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	1							R13	10.1186/cc8869			13	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	587KD	WOS:000276989800047	20141631	Green Accepted, Green Published, gold			2022-02-06	
S	Sharma, HS; Zimmermann-Meinzingen, S; Johanson, CE		Andrews, RJ; Slikker, W; Trembly, B; Patterson, TA		Sharma, Hari Shanker; Zimmermann-Meinzingen, Sibilla; Johanson, Conrad E.			Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Conference on Neuroprotective Agents	SEP 07-11, 2008	Marine Biol Lab, Woods Hole, MA		Marine Biol Lab	traumatic brain injury; brain edema; blood-brain barrier; blood-CSF barrier; choroid plexus; neuronal injury; cell death; Cerebrolysin; intracerebroventricular administration; sensory-motor function	SPINAL-CORD-INJURY; ANTIOXIDANT COMPOUND H-290/51; WHOLE-BODY HYPERTHERMIA; EDEMA FORMATION; HEAT-STRESS; NEUROTROPHIC FACTORS; CELL INJURY; 5-HT LEVEL; PATHOPHYSIOLOGY; DISRUPTION	Traumatic brain injuries (TBIs) induce profound breakdown of the blood-brain and blood-cerebrospinal fluid barriers (BCSFB), brain pathology/edema, and sensory-motor disturbances. Because neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and glial cell-derived neurotrophic factor (GDNF), are neuroprotective in models of brain and spinal cord injuries, we hypothesized that a combination of neurotrophic factors would enhance neuroprotective efficacy. In the present investigation, we examined the effects of Cerebrolysin, a mixture of different neurotrophic factors (Ebewe Neuro Pharma, Austria) on the brain pathology and functional outcome in a rat model of TBI. TBI was produced under Equithesin (3 mL/kg, i.p.) anesthesia by making a longitudinal incision into the right parietal cerebral cortex. Untreated injured rats developed profound disruption of the blood-brain barrier (BBB) to proteins, edema/cell injury, and marked sensory-motor dysfunctions on rota-rod and grid-walking tests at 5 h TBI. Intracerebroventricular administration of Cerebrolysin (10 or 30 mu L) either 5 min or 1 h after TBI significantly reduced leakage of Evans blue and radioiodine tracers across the BBB and BCSFB, and attenuated brain edema formation/neuronal damage in the cortex as well as underlying subcortical regions. Cerebrolysin-treated animals also had improved sensory-motor functions. However, administration of Cerebrolysin 2 h after TBI did not affect these parameters significantly. These observations in TBI demonstrate that early intervention with Cerebrolysin reduces BBB and BCSFB permeability changes, attenuates brain pathology and brain edema, and mitigates functional deficits. Taken together, our observations suggest that Cerebrolysin has potential therapeutic value in TBI.	[Sharma, Hari Shanker] Uppsala Univ, Univ Hosp, Dept Anaesthesiol & Intens Care, Lab Cerebrovasc Res,Inst Surg Sci, Uppsala, Sweden; [Zimmermann-Meinzingen, Sibilla] EVER Neuro Pharma, Unterach, Austria; [Johanson, Conrad E.] Rhode Isl Hosp, Brown Med Sch, Dept Clin Neurosci, Providence, RI USA		Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se		Johanson, Conrad/0000-0002-1297-5484	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [2710]; Astra-Zeneca, Molndal, SwedenAstraZeneca; National Institute of Health, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS27601]; Alexander von Humboldt Foundation, GermanyAlexander von Humboldt Foundation; Ebewe Neuro-Pharma, Austria Sweden; The University Grants Commission, New Delhi, IndiaUniversity Grants Commission, India; Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027601] Funding Source: NIH RePORTER	The authors' research is supported by grants from Swedish Medical Research Council (2710, HSS); Astra-Zeneca, Molndal (HSS), Sweden; National Institute of Health (NS27601, CEJ), USA; Alexander von Humboldt Foundation (HSS), Germany; Ebewe Neuro-Pharma, Austria Sweden (HSS); The University Grants Commission (HSS), New Delhi, India; and The Indian Council of Medical Research (HSS), New Delhi, India. The expert technical assistance of Karstin Flink, Kerstin Rystedt, Franziska Drum, and Katherin Kern, the secretarial assistance of Aruna Sharma, and the graphical and editing contributions of Nancy and Julie Johanson are all greatly appreciated.	Abdolvahabi RM, 2001, NEUROL RES, V23, P210, DOI 10.1179/016164101101198361; ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Guzman DC, 2009, BIOMED PHARMACOTHER, V63, P517, DOI 10.1016/j.biopha.2008.09.013; Chan W W, 2008, Ir Med J, V101, P255; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DEY PK, 1983, INDIAN J MED RES, V77, P554; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Johanson CE, 2000, CELL MOL NEUROBIOL, V20, P197, DOI 10.1023/A:1007097622590; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Muresanu DF, 2007, ANN NY ACAD SCI, V1122, P1, DOI 10.1196/annals.1403.001; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P295, DOI 10.1196/annals.1403.022; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P159; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI 10.1517/14656566.9.16.2773 ; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P112, DOI 10.1196/annals.1403.008; Sharma HS, 2007, PROG BRAIN RES, V162, P459, DOI 10.1016/S0079-6123(06)62023-2; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2008, ANN NY ACAD SCI, V1139, P242, DOI 10.1196/annals.1432.052; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 2000, ACT NEUR S, V76, P91; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; SHARMA HS, 2009, ANN NEW YOR IN PRESS; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Windisch M, 1998, J NEURAL TRANSM-SUPP, P289; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59	41	61	64	0	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-777-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1199						125	137		10.1111/j.1749-6632.2009.05329.x			13	Multidisciplinary Sciences; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BRJ59	WOS:000282838900015	20633118				2022-02-06	
J	Trabold, R; Eros, C; Zweckberger, K; Relton, J; Beck, H; Nussberger, J; Muller-Esterl, W; Bader, M; Whalley, E; Plesnila, N				Trabold, Raimund; Eroes, Christian; Zweckberger, Klaus; Relton, Jane; Beck, Heike; Nussberger, Juerg; Mueller-Esterl, Werner; Bader, Michael; Whalley, Eric; Plesnila, Nikolaus			The role of bradykinin B-1 and B-2 receptors for secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury; brain edema; inflammation; bradykinin; Kallikerin-kinin system; neuroptotection	CONTROLLED CORTICAL IMPACT; KALLIKREIN-KININ SYSTEM; MIDDLE CEREBRAL-ARTERY; BINDING-SITES; LF 16-0687MS; RAT MODEL; EDEMA; ANTAGONIST; PERMEABILITY; MEDIATOR	Inflammatory mechanisms are known to contribute to the pathophysiology of traumatic brain injury (TBI). Since bradykinin is one of the first mediators activated during inflammation, we investigated the role of bradykinin and its receptors in posttraumatic secondary brain damage. We subjected wild-type (WT), B-1-, and B-2-receptor-knockout mice to controlled cortical impact (CCI) and analyzed tissue bradykinin as well as kinin receptor mRNA and protein expression up to 48 h thereafter. Brain edema, contusion volume, and functional outcome were assessed 24 h and 7 days after CCI. Tissue bradykinin was maximally increased 2 h after trauma (P < 0.01 versus sham). Kinin B-1 receptor mRNA was upregulated up to four-fold 24 h after CCI. Immunohistochemistry showed that B-1 and B-2 receptors were expressed in the brain and were significantly upregulated in the traumatic penumbra 1 to 24 h after CCI. B2R-/- mice had significantly less brain edema (-51% versus WT, 24 h; P < 0.001), smaller contusion volumes (similar to 50% versus WT 24 h and 7 d after CCI; P < 0.05), and better functional outcome 7 days after TBI as compared with WT mice (P < 0.05). The present results show that bradykinin and its B-2 receptors play a causal role for brain edema formation and cell death after TBI. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 130-139; doi: 10.1038/jcbfm.2009.196; published online 23 September 2009	[Trabold, Raimund; Eroes, Christian; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany; [Trabold, Raimund; Eroes, Christian; Zweckberger, Klaus; Beck, Heike; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Walter Brendel Ctr Expt Med, Inst Surg Res, Munich, Germany; [Relton, Jane; Whalley, Eric] Biogen Idec Inc, Dept Pharmacol, Cambridge Ctr, Cambridge, MA USA; [Nussberger, Juerg] Univ Lausanne Hosp, Div Hypertens & Vasc Med, Lausanne, Switzerland; [Mueller-Esterl, Werner] Goethe Univ Frankfurt, Inst Biochem, Frankfurt, Germany; [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany		Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stephens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019	Bader, Michael/0000-0003-4780-4164			Austinat M, 2009, STROKE, V40, P285, DOI 10.1161/STROKEAHA.108.526673; Bartus RT, 1996, IMMUNOPHARMACOLOGY, V33, P270, DOI 10.1016/0162-3109(96)00070-7; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHOLEWINSKI AJ, 1991, J NEUROCHEM, V57, P1456, DOI 10.1111/j.1471-4159.1991.tb08314.x; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FUJIWARA Y, 1989, LIFE SCI, V44, P1645, DOI 10.1016/0024-3205(89)90481-5; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; KARIYA K, 1985, J NEUROCHEM, V44, P1892, DOI 10.1111/j.1471-4159.1985.tb07185.x; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Noda M, 2003, LIFE SCI, V72, P1573, DOI 10.1016/S0024-3205(02)02449-9; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; Plesnila N, 2001, PROG INFLAM RES, P333; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; PRIVITERA PJ, 1992, BRAIN RES, V577, P73, DOI 10.1016/0006-8993(92)90539-L; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Raidoo DM, 1997, IMMUNOPHARMACOLOGY, V36, P153, DOI 10.1016/S0162-3109(97)00015-5; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; Sarker MH, 2000, J PHYSIOL-LONDON, V528, P177, DOI 10.1111/j.1469-7793.2000.00177.x; Shughrue PJ, 2003, J COMP NEUROL, V465, P372, DOI 10.1002/cne.10846; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; TODA N, 1977, AM J PHYSIOL, V232, pH267, DOI 10.1152/ajpheart.1977.232.3.H267; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	41	61	63	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2010	30	1					130	139		10.1038/jcbfm.2009.196			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	539IL	WOS:000273247500014	19773800	Green Published, Bronze			2022-02-06	
J	von Reyn, CR; Spaethling, JM; Mesfin, MN; Ma, M; Neumar, RW; Smith, DH; Siman, R; Meaney, DF				von Reyn, Catherine R.; Spaethling, Jennifer M.; Mesfin, Mahlet N.; Ma, Marek; Neumar, Robert W.; Smith, Douglas H.; Siman, Robert; Meaney, David F.			Calpain Mediates Proteolysis of the Voltage-Gated Sodium Channel alpha-Subunit	JOURNAL OF NEUROSCIENCE			English	Article							NA+ CHANNELS; INJURY; MECHANISMS; NEURONS; CLEAVAGE	Alterations in the expression, molecular composition, and localization of voltage-gated sodium channels play major roles in a broad range of neurological disorders. Recent evidence identifies sodium channel proteolysis as a key early event after ischemia and traumatic brain injury, further expanding the role of the sodium channel in neurological diseases. In this study, we investigate the protease responsible for proteolytic cleavage of voltage-gated sodium channels (NaChs). NaCh proteolysis occurs after protease activation in rat brain homogenates, pharmacological disruption of ionic homeostasis in cortical cultures, and mechanical injury using an in vitro model of traumatic brain injury. Proteolysis requires Ca2+ and calpain activation but is not influenced by caspase-3 or cathepsin inhibition. Proteolysis results in loss of the full-length alpha-subunits, and the creation of fragments comprising all domains of the channel that retain interaction even after proteolysis. Cell surface biotinylation after mechanical injury indicates that proteolyzed NaChs remain in the membrane before noticeable evidence of neuronal death, providing a mechanism for altered action potential initiation, propagation, and downstream signaling events after Ca2+ elevation.	[von Reyn, Catherine R.; Mesfin, Mahlet N.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Spaethling, Jennifer M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Smith, Douglas H.; Siman, Robert; Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Ma, Marek; Neumar, Robert W.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Ma, Marek] Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122; von Reyn, Catherine/0000-0002-5753-2134	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 35712, NS PPG P01 NS 056202, U24NS050606]; NHBLI Gene Therapy Resource Program; University of Pennsylvania Preclinical Vector Core facility; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24NS050606, P01NS056202, R01NS035712, R01NS048234] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) Grants NS 35712 and NS PPG P01 NS 056202. The monoclonal antibodies Na<INF>v</INF>1.1 and Na<INF>v</INF>1.2 were developed by and/or obtained from the University of California, Davis/NIH NeuroMab Facility, supported by NIH Grant U24NS050606, and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis. Support for vector production was provided by the NHBLI Gene Therapy Resource Program and the University of Pennsylvania Preclinical Vector Core facility.	Agrawal SK, 1996, J NEUROSCI, V16, P545; Beacham D, 2007, J NEUROSCI, V27, P11543, DOI 10.1523/JNEUROSCI.1743-07.2007; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cantrell AR, 2001, NAT REV NEUROSCI, V2, P397, DOI 10.1038/35077553; Fache MP, 2004, J CELL BIOL, V166, P571, DOI 10.1083/jcb.200312155; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Jette N, 2006, J CEREBR BLOOD F MET, V26, P777, DOI 10.1038/sj.jcbfm.9600226; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Paillart C, 1996, J CELL BIOL, V134, P499, DOI 10.1083/jcb.134.2.499; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R, 1996, ADV NEUROL, V71, P167; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; STYS PK, 1992, J NEUROSCI, V12, P430; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Waxman SG, 2007, NAT NEUROSCI, V10, P405, DOI 10.1038/nn1857; Wu HY, 2007, J BIOL CHEM, V282, P20075, DOI 10.1074/jbc.M700624200	26	61	62	1	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 19	2009	29	33					10350	10356		10.1523/JNEUROSCI.2339-09.2009			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	484YQ	WOS:000269087300018	19692609	Green Published, Green Accepted, Bronze			2022-02-06	
J	Martins, ET; Linhares, MN; Sousa, DS; Schroeder, HK; Meinerz, J; Rigo, LA; Bertotti, MM; Gullo, J; Hohl, A; Dal-Pizzol, F; Walz, R				Martins, Evandro Tostes; Linhares, Marcelo Neves; Sousa, Daniel Santos; Schroeder, Humberto Kruger; Meinerz, Jardel; Rigo, Luis Antonio; Bertotti, Melina More; Gullo, Jackson; Hohl, Alexandre; Dal-Pizzol, Felipe; Walz, Roger			Mortality in Severe Traumatic Brain Injury: A Multivariated Analysis of 748 Brazilian Patients From Florianopolis City	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Severe traumatic brain injury; Prognostic models; Mortality; Logistic regression	COMA DATA-BANK; PROGNOSTIC VALUE; HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; IMPACT; CLASSIFICATION; DESIGN	Background: Traumatic brain injury (TBI) is a major cause of incapacity and mortality worldwide, with most of the burden occurring in low-income and middle-income countries. A number of clinical, demographic, and neurosurgical variables of patients with TBI were associated with their outcome. Methods: We investigated the mortality of Brazilian patients with severe TBI at the time of discharge, using a multiple logistic regression analysis. Clinical, demographic, radiologic, and neurosurgical variables, and mortality at time of discharge of all consecutive patients (n = 748) with severe TBI (admission Glasgow scale <= 8) treated in our intensive care unit were analyzed. The variables were collected in a prospective manner between January 1994 and December 2003. Results: Eighty-four percent (n = 631) of the patients were men. The mean age was 34.8 (+/- 16.3) years mid the mortality was 33.3%. After the multiple logistic regression, the adjusted odds ratio (OR) for death was higher in older (>60 years) than younger (up to 30 years) patients (OR = 2.51, 95% confidence interval [CI] 1.31-4.79, p = 0.006). The mortality was also associated with subarachnoid hemorrhage (OR = 1.86, 95% CI = 1.23-2.81, p = 0.003) on computed tomography (CT) scan; admission Glasgow Scale of 3 or 4 in comparison to 7 or 8 (OR = 3.97, 95% CI = 2.49- 6.31, p < 0.001); bilateral midryasis (OR = 11.52, 95% CI = 5.56-23.87, p < 0.0001), or anisocoria (OR = 2.65, 95% CI = 1.69-4.17, p < 0.0001) in comparison to isocoric pupils. There was a trend for higher mortality in patients with type III injury on the Marshall classification of CT (OR = 3.63, 95% CI = 0.84-15.76, p = 0.08) than in patients with normal CT. Patients without thoracic trauma disclose higher mortality than patients with associated thoracic trauma do (OR = 2.02, 95% CI = 1.19-3.41, p = 0.009). The final model presented disclosed 76.9% of overall correct prediction with the survival and death predicted at 87.6% and 55.6%, respectively. Conclusion: Age, CT findings, Glasgow coma scale, pupil examination, and the presence of thoracic trauma at admission were independently associated with mortality at the time of discharge in Brazilian patients with severe TBI.	[Martins, Evandro Tostes; Meinerz, Jardel; Rigo, Luis Antonio] Hosp Governador Celso Ramos, Unidade Terapia Intens, Florianopolis, SC, Brazil; [Martins, Evandro Tostes; Linhares, Marcelo Neves; Schroeder, Humberto Kruger; Bertotti, Melina More; Gullo, Jackson; Hohl, Alexandre; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, NUPNEC, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Sousa, Daniel Santos] Univ Fed Santa Catarina, Dept Cirurgia, Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil; [Dal-Pizzol, Felipe] Univ Extremo Sul Catarinense, Lab Lab Fisiopatol Expt, Criciuma, SC, Brazil		Walz, R (corresponding author), Univ Fed Santa Catarina, Dept Clin Med, Univ Hosp, NUPNEC, 3 Andar,Campus Univ, BR-88040970 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Dal-Pizzol, Felipe/F-2756-2015; Hohl, Alexandre/R-9269-2019; Walz, Roger/K-9096-2013	Dal-Pizzol, Felipe/0000-0003-3003-8977; Hohl, Alexandre/0000-0002-8073-5837; Walz, Roger/0000-0002-9875-6687	CNPq (Brazilian Council for Scientific and Technologic Development, Brazil)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); FAPESC (Foundation for Scientific Research and Technology of Santa Catarina State); FEESC (Foundation for Education and Engineering of Santa Catarina)	Supported by CNPq (Brazilian Council for Scientific and Technologic Development, Brazil), FAPESC (Foundation for Scientific Research and Technology of Santa Catarina State). The FEESC (Foundation for Education and Engineering of Santa Catarina) supported the technician work of Shumaia Deguer from The Cyclops Project, UFSC.	Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARION DW, 2004, NEUROLOGY CLIN PRACT, P1127; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92	22	61	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2009	67	1					85	90		10.1097/TA.0b013e318187acee			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	470CZ	WOS:000267953100015	19590314				2022-02-06	
J	McCrory, P; Meeuwisse, W; Johnston, K; Dvorak, J; Aubry, M; Molloy, M; Cantu, R				McCrory, Paul; Meeuwisse, Willem; Johnston, Karen; Dvorak, Jiri; Aubry, Mark; Molloy, Mick; Cantu, Robert			Consensus Statement on Concussion in Sport - The 3rd International Conference on Concussion in Sport Held in Zurich, November 2008	PM&R			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURIES; PROFESSIONAL FOOTBALL; POSTURAL CONTROL; LONG-TERM; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Meeuwisse, Willem] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem] Univ Calgary, Dept Community Hlth Sci, Fac Med, Calgary, AB, Canada; [Johnston, Karen] Toronto Rehabil Inst, Sport Concuss Clin, Toronto, ON, Canada; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin, Zurich, Switzerland; [Aubry, Mark] Int Ice Hockey Federat & Hockey Canada, Ottawa, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Molloy, Mick] Int Rugby Board, Dublin 2, Ireland; [Cantu, Robert] Emerson Hosp, Concord, MA USA		McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10, DOI 10.1071/HE08010; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	147	61	61	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	MAY	2009	1	5					406	420		10.1016/j.pmrj.2009.03.010			15	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LI	WOS:000208411500003	19627927	Green Submitted, Green Published			2022-02-06	
J	Immonen, RJ; Kharatishvili, I; Grohn, H; Pitkanen, A; Grohn, OHJ				Immonen, Riikka J.; Kharatishvili, Irina; Grohn, Heidi; Pitkanen, Asla; Grohn, Olli H. J.			Quantitative MRI predicts long-term structural and functional outcome after experimental traumatic brain injury	NEUROIMAGE			English	Article						Diffusion; Fluid percussion model; Head trauma; Long-term; Outcome; Quantitative MRI; T-1 rho; T-2; Traumatic brain injury	FLUID PERCUSSION INJURY; MAGNETIC-RESONANCE; HEAD-INJURY; CEREBRAL-ISCHEMIA; STATUS EPILEPTICUS; REGIONAL PATTERNS; ROTATING-FRAME; MOUSE MODEL; FOLLOW-UP; RATS	In traumatic brain injury (TBI) the initial impact causes both immediate damage and also launches a cascade of slowly progressive secondary damage. The chronic outcome disabilities vary greatly and can occur several years later. The aim of this study was to find predictive factors for the long-term outcome using multiparametric, non-invasive magnetic resonance imaging (MRI) methodology and a clinically relevant rat model of fluid percussion induced TBI. Our results demonstrated that the multiparametric quantitative MRI (T-2, T-1 rho, trace of the diffusion tensor D-av, the extent of hyperintense lesion and intracerebral hemorrhage) acquired during acute and sub acute phases 3 h, 3 days, 9 days and 23 days post-injury has potential to predict the functional and histopathological outcome 6 to 12 months later. The acute D-av changes in the ipsilateral hippocampus correlated with the chronic spatial learning and memory impairment evaluated using the Morris water maze (p<0.05). Similarly, T-1 rho, T-2 and D-av correlated with hippocampal atrophy and with histologically quantified neurodegeneration (p<0.01). The early lesion volume and quantitative MRI changes in the perilesional region prefigured the final lesion extent (p<0.01). Furthermore, the severity of acute intracerebral hemorrhage correlated with the final cortical atrophy (p<0.05), hippocampal atrophy (p<0.01), and also with the water maze performance (p<0.01). We conclude that, assessment of early quantitative MRI changes in the hippocampus and in the perifocal area may help to predict the long-term outcome after experimental TBI. (C) 2008 Elsevier Inc. All rights reserved.	[Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, FIN-70211 Kuopio, Finland; [Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Grohn, Heidi] N Karelia Cent Hosp, Dept Clin Physiol Nucl Med & Neurophysiol, Joensuu, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Grohn, OHJ (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural FoundationFinnish IT center for science	This work was supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, CURE (Citizens United for Research for Epilepsy), the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Maarit Pulkkinen, Mr. Jarmo Hartikainen, Mrs. Merja Lukkari and Jari Nissinen, Ph. D., for technical assistance, and Nick Hayward, M. Sc., for revising the language of the manuscript.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; FREUND TF, 1992, BRAIN RES BULL, V28, P27, DOI 10.1016/0361-9230(92)90227-O; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Grohn OHJ, 1999, MAGNET RESON MED, V42, P268; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; ITO U, 1979, STROKE, V10, P542, DOI 10.1161/01.STR.10.5.542; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Makela HI, 2001, BIOCHEM BIOPH RES CO, V289, P813, DOI 10.1006/bbrc.2001.6058; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Morais DF, 2008, ARQ NEURO-PSIQUIAT, V66, P53, DOI 10.1590/S0004-282X2008000100013; Nairismagi J, 2004, EPILEPSIA, V45, P1024, DOI 10.1111/j.0013-9580.2004.08904.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Oh Hyun Soo, 2006, Taehan Kanho Hakhoe Chi, V36, P621; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEPPONEN RE, 1985, J COMPUT ASSIST TOMO, V9, P1007, DOI 10.1097/00004728-198511000-00002; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smits AJ, 1997, EXP THERM FLUID SCI, V14, P1, DOI 10.1016/S0894-1777(96)00189-6; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	62	61	63	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR	2009	45	1					1	9		10.1016/j.neuroimage.2008.11.022			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	414KR	WOS:000263862900001	19101638				2022-02-06	
J	Eriksson, G; Kottorp, A; Borg, J; Tham, K				Eriksson, Gunilla; Kottorp, Anders; Borg, Jorgen; Tham, Kerstin			RELATIONSHIP BETWEEN OCCUPATIONAL GAPS IN EVERYDAY LIFE, DEPRESSIVE MOOD AND LIFE SATISFACTION AFTER ACQUIRED BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	COTEC Conference 2008	MAY 20-21, 2008	Hamburg, GERMANY			brain injuries; activities of daily living; adaptation psychological; quality of life	18-TO 64-YEAR-OLD SWEDES; SCALE; ANXIETY; STROKE	Objective: To explore the relationship between occupational gaps, depressive mood and life satisfaction in persons who have acquired a brain injury during the past 1-4 years and to test the Occupational Gaps Questionnaire. Design: A cross-sectional study. Subjects: A total of 116 persons with traumatic brain injury or subarachnoid haemorrhage acquired 1-4 years previously. Methods: A postal survey with questions on occupational gaps, focusing on the domains instrumental activities of daily living, social life, leisure and work (Occupational Gaps Questionnaire), life satisfaction (LiSat-11 checklist) and depressive mood (Hospital Anxiety and Depression Scale). Rasch analyses and principal component analyses were performed to ensure that data from the LiSat-11 and Occupational Gaps Questionnaire could be used subsequently as valid unidimensional measures in regression and correlational analyses. Results: Calibration of the Occupational Gaps Questionnaire and the LiSat-11 revealed that the items and persons demonstrated acceptable goodness-of-fit to the Rasch models respectively, supporting internal scale validity and person-response validity. In addition, principal component analyses revealed that the measures could be used as valid uni-dimensional estimations of occupational gaps and life satisfaction. There was a strong relationship between the extent of occupational gaps and perceived life satisfaction, a weaker relationship with depressive mood and a non-significant relationship with the aetiological diagnoses and life satisfaction. The factors explained 32% (occupational gaps), 6% (depressive mood), and 2% (diagnosis), respectively, of the total explained variance (40%). Conclusion: There was a strong correlation between participation in desired everyday occupations and life satisfaction 1-4 years after an acquired brain injury. This indicates that individually perceived occupational gaps, as recorded by the for tailored interventions in order to improve life satisfaction among clients with acquired brain injuries.	[Eriksson, Gunilla; Kottorp, Anders; Tham, Kerstin] Karolinska Inst, Caring Sci & Soc, Dept Neurobiol, Div Occupat Therapy, Stockholm, Sweden; [Eriksson, Gunilla; Borg, Jorgen] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Eriksson, Gunilla] Univ Uppsala Hosp, Dept Occupat Therapy, Uppsala, Sweden		Eriksson, G (corresponding author), Karolinska Inst, Caring Sci & Soc, Dept Neurobiol, Div Occupat Therapy, Alfred Nobels Alle 23,4th Floor, SE-14183 Huddinge, Sweden.	gunilla.eriksson@ki.se	; Tham, Kerstin/T-3964-2018	Borg, Jorgen/0000-0002-2372-7478; Kottorp, Anders/0000-0002-8976-2612; Tham, Kerstin/0000-0001-7025-5226			Atchley R.C., 1999, CONTINUITY ADAPTATIO; BAUM CM, 1993, EFFECTS OCCUPATION B; BECKER G, 1993, GERONTOLOGIST, V33, P148, DOI 10.1093/geront/33.2.148; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bodlund O, 1999, SCAND J PRIM HEALTH, V17, P153; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Fisher W., 1992, RASCH MEAS T, V6, P238; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Gaete Jorge Moncayo, 2008, Expert Rev Neurother, V8, P75, DOI 10.1586/14737175.8.1.75; Gordon WA, 1997, ARCH PHYS MED REHAB, V78, P658, DOI 10.1016/S0003-9993(97)90433-0; Hoofien D, 2001, BRAIN INJURY, V15, P189; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Linacre J, 2006, WINSTEPS RASCH MEASU; LINACRE JM, 1991, USERS GUIDE WINSTEPS; Linacre John M, 2002, J Appl Meas, V3, P85; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PAKARINEN S, 1967, ACTA NEUROL SCAND, VS 43, P9; Prigatano GP, 1991, AWARENESS DEFICIT BR, P11; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Tham K, 2000, AM J OCCUP THER, V54, P398, DOI 10.5014/ajot.54.4.398; Townsend E.A., 2002, ENABLING OCCUPATION; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILCOCK A. A, 1998, OCCUPATIONAL PERSPEC; Wilson M., 2005, CONSTRUCTING MEASURE; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright B, 1979, BEST TEST DESIGN; Wright B, 1994, MEASUREMENT T, V8, P370; Wright BD., 1982, RATING SCALE ANAL	41	61	63	0	18	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2009	41	3					187	194		10.2340/16501977-0307			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	416PD	WOS:000264017100013	19229453	Green Submitted, gold, Green Published			2022-02-06	
J	Hutchison, M; Mainwaring, LM; Comper, P; Richards, DW; Bisschop, SM				Hutchison, Michael; Mainwaring, Lynda M.; Comper, Paul; Richards, Doug W.; Bisschop, Sean M.			Differential Emotional Responses of Varsity Athletes to Concussion and Musculoskeletal Injuries	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						athletic injury; emotions; mild traumatic brain injury; sport-related concussion	SPORTS; PERFORMANCE; RECOVERY; VALIDITY	Objective: To determine if athletes with concussion and those with minor musculoskeletal injuries experienced differential emotional response to injury. Design: A prospective longitudinal cohort study. Setting: University of Toronto, Ontario, Canada. Participants: Thirty-four injured athletes from Canadian Interuniversity Sport (CIS) and 19 healthy, physically active undergraduate students participated in the Study. Intervention: All participants completed the Profile of Mood States (POMS; short version) oil 3 nonconsecutive days during a 2-week period after a baseline test. Main Outcome Measures: Emotional responses were assessed using the POMS. The 7 main Outcome Measures assessed by POMS were tension, depression, anger, vigor, fatigue, confusion, and total mood disturbance, Results: After injury, concussion produced all emotional profile characterized by significantly elevated fatigue and decreased vigor. In contrast, athletes with musculoskeletal injuries displayed a significant increase in anger that resolved to a pre-injury level within 2 weeks. Conclusions: The results revealed that both injured groups experienced emotional disturbance after injury. More importantly, the findings strongly suggest that the emotional reaction after concussion is different from that of musculoskeletal injury. Therefore, we concluded that assessing emotional reactions to Concussion is particularly important and recommend that sports medicine professionals assess and monitor emotional functioning as well as somatic complaints and neurocognitive changes during recovery.	[Hutchison, Michael; Mainwaring, Lynda M.; Richards, Doug W.] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5S 2W6, Canada; [Comper, Paul; Bisschop, Sean M.] Toronto Rehabil Inst, Toronto, ON, Canada		Hutchison, M (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca		Bisschop, Sean/0000-0002-3307-292X			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BREWER BW, 2001, COPING SPORT INJURIE, P1; BREWER BW, 1995, ACAD ATHLETIC J, V10, P11; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; CHUTE NW, 1997, PSYCHOL RESPONSES AD; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston LH, 1998, J SPORT REHABIL, V7, P267, DOI 10.1123/jsr.7.4.267; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; MCNAIR DM, 1992, MANUAL PROFILE MOODS; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; NUNNELY J, 1978, PSYCHOMETRIC THEORY; Pearson L, 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Quackenbush N., 1994, Journal of Sport Behavior, V17, P178; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Uemukai K, 1993, P 8 WORLD C SPORT PS, P500; Whitson, 1993, HOCKEY NIGHT CANADA	37	61	61	3	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2009	19	1					13	19		10.1097/JSM.0b013e318190ba06			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	393PE	WOS:000262384400004	19124978				2022-02-06	
J	Pinzon, A; Marcillo, A; Quintana, A; Stamler, S; Bunge, MB; Bramlett, HM; Dietrich, WD				Pinzon, Alberto; Marcillo, Alexander; Quintana, Ada; Stamler, Sarah; Bunge, Mary Bartlett; Bramlett, Helen M.; Dietrich, W. Dalton			A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model	BRAIN RESEARCH			English	Article						Spinal cord injury; Neuroprotection; Minocycline; Behavioral outcome	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C RELEASE; BRAIN-INJURY; ACTIVATION; RECOVERY; DEATH; EXPRESSION; PROTECTION; CASPASE-1	This study was initiated due to an NIH "Facilities of Research-Spinal Cord Injury" contract to support independent replication of published studies that could be considered for a clinical trial in time. Minocycline has been shown to have neuroprotective effects in models of central nervous system injury, including in a contusive spinal cord injury (SCI) model at the thoracic level. Beneficial effects of minocycline treatment included a significant improvement in locomotor behavior and reduced histopathological changes [Lee, S.M., Yune, T.Y., Kim, S.J., Park, D.O.W., Lee, Y.K., Kim, Y.C., Oh, Y.J., Markelonis, G.J., Oh, T.H., 2003. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 20, 1017-1027.] To verify these important observations, we repeated this study in our laboratory. The NYU (MASCIS) Impactor was used to produce a moderate cord lesion at the vertebral level T9-T10 (height 12.5 mm, weight 10 g), (n = 45), followed by administration of minocycline, 90 mg/kg (group 1: minocycline IP, n = 15; group 2: minocycline IV, n = 15; group 3: vehicle IP, n = 8; group 4: vehicle IV, n = 7) immediately after surgery and followed by two more doses of 45 mg/kg/IP at 12 h and 24 h. Open field locomotion (BBB) and subscores were examined up to 6 weeks after SCI and cords were processed for quantitative histopathological analysis. Administration of minocycline after SCI did not lead to significant behavioral or histopathological improvement. Although positive effects with minocycline have been reported in several animal models of injury with different drug administration schemes, the use of minocycline following contusive SCI requires further investigation before clinical trials are implemented. (C) 2008 Elsevier B.V. All rights reserved.	[Pinzon, Alberto; Marcillo, Alexander; Quintana, Ada; Stamler, Sarah; Bunge, Mary Bartlett; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bunge, Mary Bartlett; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Facilities of Research Excellence in Spinal Cord Injury (FORE-SCI) [N01-NS-3-2352]; The Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032352] Funding Source: NIH RePORTER	We would like to thank Diana Ospina, Ileana Oropesa, Denise Koivisto, Andres Maldonado, Rosa Abril, and Monica Stagg for animal care and behavioral analysis; Paulo Diaz and Michael Shumm for performing the contusion injuries; Gladys L. Ruenes and Lyudmila Rusakova for tissue processing; Robert Camarena for photography; and Charlaine Rowlette and Jeremy Lytle for expert editorial assistance and word processing. This work was supported by funds from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Facilities of Research Excellence in Spinal Cord Injury (FORE-SCI) under contract No. N01-NS-3-2352, and The Miami Project to Cure Paralysis.	Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hoang TX, 2008, EXP BRAIN RES, V189, P71, DOI 10.1007/s00221-008-1398-5; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Saganova K, 2008, NEUROSCI LETT, V433, P246, DOI 10.1016/j.neulet.2008.01.041; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	26	61	66	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 3	2008	1243						146	151		10.1016/j.brainres.2008.09.047			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	384YL	WOS:000261780000016	18838063	Green Accepted			2022-02-06	
J	Waters, EM; Torres-Reveron, A; McEwen, BS; Milner, TA				Waters, Elizabeth M.; Torres-Reveron, Annelyn; McEwen, Bruce S.; Milner, Teresa A.			Ultrastructural localization of extranuclear progestin receptors in the rat hippocampal formation	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						estrogen-inducible progestin receptors; progesterone; extranuclear	DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; ESTROUS-CYCLE; SUBCELLULAR-DISTRIBUTION; DIFFERENTIAL REGULATION; BETA IMMUNOREACTIVITY; ISOFORMS EXPRESSION; SEX-DIFFERENCES; PURKINJE-CELLS	Progesterone's effects on hippocampus-dependent behavior and synaptic connectivity maybe mediated through the progestin receptor (PR). Although estrogen induces PR mRNA and cytosolic PR in the hippocampus, nuclear PR immunoreactivity is undetectable by light microscopy, suggesting that PR is present at extranuclear sites. To determine whether this is the case, we used immunoelectron microscopy to examine PR distribution in the hippocampal formation of proestrus rats. Ultrastructural analysis revealed that PR labeling is present in extranuclear profiles throughout the CA1 and CA3 regions and dentate gyrus, and, in contrast to light microscopic findings, in nuclei of a few pyramidal and subgranular zone cells. Most neuronal PR labeling is extranuclear and is divided between pre- and postsynaptic compartments; approximately 30% of labeled profiles were axon terminals and 30% were dendrites and dendritic spines. In most laminae, except in CA3 stratum lucidum, about 15% of PR-immunoreactive profiles were unmyelinated axons. In stratum lucidum, where the mossy fiber axons course, more than 50% of PR-labeled profiles were axonal. The remaining 25% of PR-labeled profiles were glia, some resembling astrocytes. PR labeling is strongly dependent on estrogen priming, insofar as few PR-labeled profiles were detected in ovariectomized, oil-replaced females. Synapses formed by PR-labeled terminals were predominantly asymmetric, consistent with a role for progesterone in directly regulating excitatory transmission. These findings suggest that some of progesterone's actions in the hippocampal formation may be mediated by direct and rapid actions on extranuclear PRs and that PRs are well positioned to regulate progesterone-induced changes at synapses.	[Waters, Elizabeth M.; McEwen, Bruce S.; Milner, Teresa A.] Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, New York, NY 10065 USA; [Torres-Reveron, Annelyn; Milner, Teresa A.] Weill Cornell Med Coll, Div Neurobiol, Dept Neurol & Neurosci, New York, NY 10021 USA		Waters, EM (corresponding author), Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendocri, 1230 York Ave, New York, NY 10065 USA.	ewaters@rockefeller.edu	Torres, Annelyn/AAS-1981-2021; McEwen, Bruce/Z-1630-2019		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS007080, T32 DK07313, DA08259, HL18974]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL018974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK007313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011853, R01NS007080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA008259] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health: Grant number: NS007080 (to B.S.M.): Grant number T32 DK07313 (to B.S.M., E.M.W.); Grant number: DA08259 (to T.A.M, A.T.-R.); Grant number: HL18974 (T.A.M.).	Adams MM, 2004, J COMP NEUROL, V474, P419, DOI 10.1002/cne.20148; Aoki C, 2001, SYNAPSE, V40, P239, DOI 10.1002/syn.1047; Ballare C, 2006, J STEROID BIOCHEM, V102, P2, DOI 10.1016/j.jsbmb.2006.09.030; Camacho-Arroyo I, 1998, NEUROREPORT, V9, P3993, DOI 10.1097/00001756-199812210-00001; Cammarata PR, 2004, EXP EYE RES, V78, P861, DOI 10.1016/j.exer.2003.09.027; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Drake CT, 2007, PROG BRAIN RES, V163, P245, DOI 10.1016/S0079-6123(07)63015-5; Edwards HE, 2000, NEUROSCIENCE, V101, P895, DOI 10.1016/S0306-4522(00)00439-5; Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P3928, DOI 10.1210/en.140.9.3928; Foy MR, 1999, J NEUROPHYSIOL, V81, P925, DOI 10.1152/jn.1999.81.2.925; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Gazzaley AH, 1996, J NEUROSCI, V16, P6830; Ghoumari AM, 2005, PROG BRAIN RES, V148, P37, DOI 10.1016/S0079-6123(04)48004-2; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P313; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; Guerra-Araiza C, 2000, LIFE SCI, V66, P1743, DOI 10.1016/S0024-3205(00)00497-5; Guerra-Araiza C, 2002, BRAIN RES BULL, V59, P105, DOI 10.1016/S0361-9230(02)00845-6; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hanekamp EE, 2004, ENDOCR-RELAT CANCER, V11, P831, DOI 10.1677/erc.1.00844; Haywood SA, 1999, ENDOCRINOLOGY, V140, P3255, DOI 10.1210/en.140.7.3255; Herrick SP, 2006, BRAIN RES, V1121, P46, DOI 10.1016/j.brainres.2006.08.084; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kurita T, 1998, ENDOCRINOLOGY, V139, P4708, DOI 10.1210/en.139.11.4708; Lacroix-Fralish ML, 2006, NEURON GLIA BIOL, V2, P227, DOI 10.1017/S1740925X07000385; Lange CA, 2007, ANNU REV PHYSIOL, V69, P171, DOI 10.1146/annurev.physiol.69.031905.160319; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; MACLUSKY NJ, 1980, ENDOCRINOLOGY, V106, P192, DOI 10.1210/endo-106-1-192; MACLUSKY NJ, 1978, NATURE, V274, P276, DOI 10.1038/274276a0; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Milner TA, 2001, J COMP NEUROL, V429, P355; MILNER TA, 2007, NEUROSCI LE IN PRESS; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nishida H, 2007, J NEUROSCI, V27, P331, DOI 10.1523/JNEUROSCI.4466-06.2007; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; PARSONS B, 1982, J NEUROSCI, V2, P1446; Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Quadros PS, 2007, J COMP NEUROL, V504, P42, DOI 10.1002/cne.21427; Quadros PS, 2002, ENDOCRINOLOGY, V143, P3727, DOI 10.1210/en.2002-211438; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Sandstrom NJ, 2001, BEHAV NEUROSCI, V115, P384, DOI 10.1037//0735-7044.115.2.384; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Scharfman HE, 2003, J NEUROSCI, V23, P11641; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; SIERRA A, 2008, GLIA IN PRESS; Sinchak K, 2001, J NEUROSCI, V21, P5723, DOI 10.1523/JNEUROSCI.21-15-05723.2001; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Smith CC, 2005, J NEUROSCI, V25, P7780, DOI 10.1523/JNEUROSCI.0762-05.2005; STEIN DG, 2007, BRAIN RES R IN PRESS; STERNBERGER LA, 1979, IMMUNOHISTCHEMISTRY; Sul JY, 2004, NEURON GLIA BIOL, V1, P3, DOI 10.1017/S1740925X04000031; SWANSON LW, 2000, BRAIN MAPS STRUCTURE; Tabori NE, 2005, NEUROSCIENCE, V130, P151, DOI 10.1016/j.neuroscience.2004.08.048; Tibbetts TA, 1999, P NATL ACAD SCI USA, V96, P12021, DOI 10.1073/pnas.96.21.12021; Tournell CE, 2006, NEUROSCIENCE, V141, P1327, DOI 10.1016/j.neuroscience.2006.05.004; TRAISH AM, 1990, ENDOCRINOLOGY, V127, P1167, DOI 10.1210/endo-127-3-1167; Turner C. D., 1971, GEN ENDOCRINOLOGY; Venkatesan C, 1996, J COMP NEUROL, V365, P79; Villamar-Cruz O, 2006, BRAIN RES BULL, V69, P276, DOI 10.1016/j.brainresbull.2005.12.006; Villoslada P, 2004, PROG BRAIN RES, V146, P403; Wang G, 2006, BRAIN RES, V1094, P163, DOI 10.1016/j.brainres.2006.03.089; WILLIAMS TJ, 2007, ANN M SOC NEUR, V625, P3; Woolley CS, 2007, ANNU REV PHARMACOL, V47, P657, DOI 10.1146/annurev.pharmtox.47.120505.105219; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zaborszky L, 2006, NEUROANATOMICAL TRAC	81	61	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	NOV 1	2008	511	1					34	46		10.1002/cne.21826			13	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	356PI	WOS:000259789700003	18720413	Green Accepted			2022-02-06	
J	Enzinger, C; Ropele, S; Fazekas, F; Loitfelder, M; Gorani, F; Seifert, T; Reiter, G; Neuper, C; Pfurtscheller, G; Muller-Putz, G				Enzinger, Christian; Ropele, Stefan; Fazekas, Franz; Loitfelder, Marisa; Gorani, Faton; Seifert, Thomas; Reiter, Gudrun; Neuper, Christa; Pfurtscheller, Gert; Mueller-Putz, Gernot			Brain motor system function in a patient with complete spinal cord injury following extensive brain-computer interface training	EXPERIMENTAL BRAIN RESEARCH			English	Article						functional MRI; motor recovery; brain-computer interface; spinal cord injury; motor imagery	EEG-BASED CONTROL; PARAPLEGIC PATIENTS; HAND MOVEMENTS; FOOT MOVEMENTS; IMAGERY; ACTIVATION; STROKE; REHABILITATION; COMMUNICATION; STIMULATION	Although several features of brain motor function appear to be preserved even in chronic complete SCI, previous functional MRI (fMRI) studies have also identified significant derangements such as a strongly reduced volume of activation, a poor modulation of function and abnormal activation patterns. It might be speculated that extensive motor imagery training may serve to prevent such abnormalities. We here report on a unique patient with a complete traumatic SCI below C5 who learned to elicit electroencephalographic signals beta-bursts in the midline region upon imagination of foot movements. This enabled him to use a neuroprosthesis and to "walk from thought" in a virtual environment via a brain-computer interface (BCI). We here used fMRI at 3T during imagined hand and foot movements to investigate the effects of motor imagery via persistent BCI training over 8 years on brain motor function and compared these findings to a group of five untrained healthy age-matched volunteers during executed and imagined movements. We observed robust primary sensorimotor cortex (SMC) activity in expected somatotopy in the tetraplegic patient upon movement imagination while such activation was absent in healthy untrained controls. Sensorimotor network activation with motor imagery in the patient (including SMC contralateral to and the cerebellum ipsilateral to the imagined side of movement as well as supplementary motor areas) was very similar to the pattern observed with actual movement in the controls. We interpret our findings as evidence that BCI training as a conduit of motor imagery training may assist in maintaining access to SMC in largely preserved somatopy despite complete deafferentation.	[Enzinger, Christian; Ropele, Stefan; Fazekas, Franz; Loitfelder, Marisa; Seifert, Thomas; Reiter, Gudrun] Med Univ, Dept Neurol, A-8036 Graz, Austria; [Enzinger, Christian] Med Univ, Div Neuroradiol, Dept Radiol, A-8036 Graz, Austria; [Loitfelder, Marisa; Neuper, Christa] Karl Franzens Univ Graz, Inst Psychol, Graz, Austria; [Gorani, Faton] Univ Erlangen Nurnberg, Dept Neurosurg, Erlangen, Germany; [Neuper, Christa; Pfurtscheller, Gert; Mueller-Putz, Gernot] Graz Univ Technol, Lab Brain Comp Interfaces, Inst Knowledge Discovery, A-8010 Graz, Austria		Enzinger, C (corresponding author), Med Univ, Dept Neurol, Auenbruggerpl 22, A-8036 Graz, Austria.	chris.enzinger@meduni-graz.at		Muller-Putz, Gernot/0000-0002-0087-3720	FWF Austrian Science FundAustrian Science Fund (FWF) [P15158]	This work has been supported by the FWF Austrian Science Fund (SR, grant number P15158), "Lorenz Bohler Gesellschaft" and "Allgemeine Unfallversicherung AUVA" (GP, G-M P). We thank the patient for his enthusiasm with the BCI training and this project and Karin Brodtrager for technical assistance.	Alkadhi H, 2005, CEREB CORTEX, V15, P131, DOI 10.1093/cercor/bhh116; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Binkofski F, 2004, NEUROLOGY, V63, P1223, DOI 10.1212/01.WNL.0000140468.92212.BE; Birbaumer N, 2007, J PHYSIOL-LONDON, V579, P621, DOI 10.1113/jphysiol.2006.125633; Cramer SC, 2005, BRAIN, V128, P2941, DOI 10.1093/brain/awh648; Cramer SC, 2007, EXP BRAIN RES, V177, P233, DOI 10.1007/s00221-006-0662-9; de Vries S, 2007, J REHABIL MED, V39, P5, DOI 10.2340/16501977-0020; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; Floyer-Lea A, 2005, J NEUROPHYSIOL, V94, P512, DOI 10.1152/jn.00717.2004; Friehs GM, 2004, STROKE, V35, P2702, DOI 10.1161/01.STR.0000143235.93497.03; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; Hotz-Boenden-Naker S, 2008, NEUROIMAGE, V39, P383, DOI 10.1016/j.neuroimage.2007.07.065; Jackson PL, 2003, NEUROIMAGE, V20, P1171, DOI 10.1016/S1053-8119(03)00369-0; Johnson-Frey SH, 2004, BRAIN COGNITION, V55, P328, DOI 10.1016/j.bandc.2004.02.032; Kalb RG, 2003, ARCH NEUROL-CHICAGO, V60, P805, DOI 10.1001/archneur.60.6.805; Kasess CH, 2008, NEUROIMAGE, V40, P828, DOI 10.1016/j.neuroimage.2007.11.040; Kirshblum SC, 2007, ARCH PHYS MED REHAB, V88, pS62, DOI 10.1016/j.apmr.2006.12.003; Lacourse MG, 2005, NEUROIMAGE, V27, P505, DOI 10.1016/j.neuroimage.2005.04.025; Lauer RT, 1999, NEUROREPORT, V10, P1767, DOI 10.1097/00001756-199906030-00026; Leeb Robert, 2007, Comput Intell Neurosci, P79642, DOI 10.1155/2007/79642; Muller-Putz GR, 2007, BRAIN RES, V1137, P84, DOI 10.1016/j.brainres.2006.12.052; Neuper C, 2006, PROG BRAIN RES, V159, P393, DOI 10.1016/S0079-6123(06)59025-9; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Pfurtscheller G, 2006, BRAIN RES, V1071, P145, DOI 10.1016/j.brainres.2005.11.083; Pfurtscheller G, 2005, EURASIP J APPL SIG P, V2005, P3152, DOI 10.1155/ASP.2005.3152; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; Sabbah P, 2002, J NEUROTRAUM, V19, P53, DOI 10.1089/089771502753460231; Schmahmann JD, 2000, MRI ATLAS HUMAN CERE; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; Suga R, 1999, J NEUROL SCI, V167, P102, DOI 10.1016/S0022-510X(99)00148-3; Tobimatsu S, 1998, J NEUROL, V245, P256, DOI 10.1007/s004150050215; Weiller C, 1996, NEUROIMAGE, V4, P105, DOI 10.1006/nimg.1996.0034; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127	37	61	64	2	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	SEP	2008	190	2					215	223		10.1007/s00221-008-1465-y			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	337RP	WOS:000258453500010	18592230				2022-02-06	
J	Dikranian, K; Cohen, R; Mac Donald, C; Pan, Y; Brakefield, D; Bayly, P; Parsadanian, A				Dikranian, K.; Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Bayly, P.; Parsadanian, A.			Mild traumatic brain injury to the infant mouse causes robust white matter axonal degeneration which precedes apoptotic death of cortical and thalamic neurons	EXPERIMENTAL NEUROLOGY			English	Article						mild traumatic brain injury; neuronal apoptosis; caspase-3; axonal degeneration; amyloid precursor protein; electron microscopy	QUANTITATIVE-ANALYSIS; IMMATURE RAT; NEURODEGENERATION; CHILDREN; CORTEX; MODEL; VULNERABILITY; ACTIVATION; TRANSPORT; PATHWAYS	The immature brain in the first several years of childhood is very vulnerable to trauma. Traumatic brain injury (TBI) during this critical period often leads to neuropathological and cognitive impairment. Previous experimental studies in rodent models of infant TBI were mostly concentrated on neuronal degeneration, while axonal injury and its relationship to cell death have attracted much less attention. To address this, we developed a closed controlled head injury model in infant (P7) mice and characterized the temporospatiall pattern of axonal degeneration and neuronal cell death in the brain following mild injury. Using amyloid precursor protein (APP) as marker of axonal injury we found that mild head trauma causes robust axonal degeneration in the cingulum/external capsule as early as 30 min post-impact. These levels of axonal injury persisted throughout a 24 h period, but significantly declined by 48 h. During the first 24 h injured axons underwent significant and rapid pathomorphological changes. Initial small axonal swellings evolved into larger spheroids and club-like swellings indicating the early disconnection of axons. Ultrastructural analysis revealed compaction of organelles, axolemmal and cytoskeletal defects. Axonal degeneration was followed by profound apoptotic cell death in the posterior cingulate and retrosplenial cortex and anterior thalamus which peaked between 16 and 24 h post-injury. At early stages post-injury no evidence of excitotoxic neuronal death at the impact site was found. At 48 h apoptotic cell death was reduced and paralleled with the reduction in the number of APP-labeled axonal profiles. Our data suggest that early degenerative response to injury in axons of the cingulum and external capsule may cause disconnection between cortical and thalamic neurons, and lead to their delayed apoptotic death. (C) 2008 Elsevier Inc. All rights reserved.	[Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Parsadanian, A.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Cohen, R.; Mac Donald, C.; Pan, Y.; Brakefield, D.; Parsadanian, A.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Dikranian, K.] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Bayly, P.] Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; [Bayly, P.] Washington Univ, Dept Mech & Aerosp Engn, St Louis, MO 63110 USA		Parsadanian, A (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	parsadaniana@neuro.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042794] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042794, R01 NS042794-05, NS042794] Funding Source: Medline		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bailey CDC, 2004, J NEUROCHEM, V91, P1369, DOI 10.1111/j.1471-4159.2004.02825.x; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burek MJ, 1999, CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM, P145; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Conti AC, 1998, J NEUROSCI, V18, P5663; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magill CK, 2007, EXP NEUROL, V207, P64, DOI 10.1016/j.expneurol.2007.05.028; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mechawar N, 2001, NEUROSCIENCE, V108, P555, DOI 10.1016/S0306-4522(01)00389-X; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; Paxinos G., 2007, ATLAS DEV MOUSE BRAI, V1st; PRICE JL, 1995, RAT NERVOUS SYSTEM; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Repici M, 2003, NEUROSCIENCE, V117, P859, DOI 10.1016/S0306-4522(02)00968-5; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SHIBATA H, 1993, J COMP NEUROL, V330, P533, DOI 10.1002/cne.903300409; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	52	61	63	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2008	211	2					551	560		10.1016/j.expneurol.2008.03.012			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	306UH	WOS:000256272800029	18440507	Green Accepted			2022-02-06	
J	Lu, KT; Cheng, NC; Wu, CY; Yang, YL				Lu, Kwok-Tung; Cheng, Nai-Chi; Wu, Chang-Yen; Yang, Yi-Ling			NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade	CRITICAL CARE MEDICINE			English	Article						rats; traumatic brain injury; Na+-K+-2CI(-) co-transporter isoform 1; mitogen-activated protein kinase	K-CL COTRANSPORTER; CEREBRAL-ARTERY OCCLUSION; ACTIVATED PROTEIN-KINASES; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; DAMAGE; TRANSPORTERS; STIMULATION; INHIBITION; EXPRESSION	Objective. Brain edema is one of the characteristic features of patients with severe traumatic brain injury. The aim of this study was to examine the effects. of Na+-K+-2CI(-) co-transporter on traumatic brain injury-induced brain edema and neuron damage and to elucidate the relationship between Na+-K+-2CI(-) co-transporter and mitogen-activated protein kinase (MAPK) cascade. Design: Laboratory investigation. Setting: University research laboratory. Subjects: Male Wistar rats weighing 350-400 g. Interventions: Anesthetized animals were subjected to a weight-drop device (450-g weight, 1.8-m height) to induce traumatic brain injury. Measurements and Main Results: The expression of Na+-K(+)2CI(-) co-transporter and phosphorylation of MAPK cascade were determined by Western blot test. We also analyzed the degree of brain edema and neuronal damage in this study. We found that the messenger RNA and protein of Na+-K+-2CI(-) co-transporter were up-regulated mainly in hippocampus neurons from 2 to 24 hrs after traumatic brain injury. After traumatic brain injury, animals displayed severe brain edema and neuron damage. The phosphorylation of extracellular signal-regulated kinase, MAPK kinase, and Raf also was significantly elevated after traumatic brain injury. Bumetanide (15.2 mg/kg), a specific Na+-K+-2CI(-) co-transporter inhibitor, significantly attenuated the neuronal damage and brain edema after traumatic brain injury by decreasing the phosphorylation of Raf/MEK/ERK cascade proteins. Conclusions. The present study suggests that Na+-K+-2CI(-) co-transporter plays an important role in TBI-induced brain edema and neuronal damage via activation of MAPK cascade.	[Lu, Kwok-Tung] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Cheng, Nai-Chi; Wu, Chang-Yen; Yang, Yi-Ling] Natl Chia Yi Normal Univ, Inst Biotechnol, Chiayi, Taiwan		Lu, KT (corresponding author), Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan.	ylyang@mail.ncyu.edu.tw					Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beck J, 2003, J NEUROSCI, V23, P5061; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; Ikebe M, 2001, J AM SOC NEPHROL, V12, P423, DOI 10.1681/ASN.V123423; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; Lu J, 2005, ACT NEUR S, V95, P281; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, NEUROTRAUMA, V17, P143; O'Donnell ME, 2006, J CEREBR BLOOD F MET, V26, P1234, DOI 10.1038/sj.jcbfm.9600278; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC747, DOI 10.1152/ajpcell.1995.268.3.C747; Panet R, 2006, J CELL PHYSIOL, V206, P578, DOI 10.1002/jcp.20506; Panet R, 2002, J CELL PHYSIOL, V190, P227, DOI 10.1002/JCP.10055; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Schomberg SL, 2001, J NEUROPHYSIOL, V85, P2563, DOI 10.1152/jn.2001.85.6.2563; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772, DOI 10.1152/ajpcell.1998.275.3.C772; TROPPER JN, 1997, J CLIN INVEST, V99, P2941; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Yang YL, 2005, NEUROSCIENCE, V134, P247, DOI 10.1016/j.neuroscience.2005.04.003	38	61	66	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2008	36	3					917	922		10.1097/CCM.0B013E31816590C4			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266QD	WOS:000253450500035	18431281				2022-02-06	
J	Chevignard, MP; Taillefer, C; Picq, C; Poncet, F; Noulhiane, M; Pradat-Diehl, P				Chevignard, M. P.; Taillefer, C.; Picq, C.; Poncet, F.; Noulhiane, M.; Pradat-Diehl, P.			Ecological assessment of the dysexecutive syndrome using execution of a cooking task	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						ecological assessment; executive functions; multi-tasking; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROSPECTIVE MEMORY; PERFORMING ACTIVITIES; COGNITIVE STRUCTURE; HEAD-INJURY; DEFICITS; DYSFUNCTION; TESTS; EVENT; REHABILITATION	Patients with a dysexecutive syndrome often have severe disabilities in daily life activities. The aims of this study were to use a naturalistic experimental task to assess patients' disabilities, and to study the nature of the cognitive disorders underlying them. Execution of a cooking task involving multi-tasking (Chevignard et al., 2000) was studied in 45 patients with a dysexecutive syndrome following acquired brain injury. Patients made significantly more errors and were slower than controls; more than half of the patients did not achieve the goal and demonstrated dangerous behaviours. Those results were significantly correlated to the results of the Six Elements Task and to a behavioural questionnaire. They were also correlated to brain injury severity and to patients' cooking habits. This naturalistic assessment is clinically relevant to better assess patients' dysexecutive impairments in complex activities of daily living. Correlations of the results in the cooking task with the neuropsychological assessment highlighted the role of the dysexecutive syndrome in patients' disabilities, indicating control alterations rather than planning disorders, difficulty in dealing with the environment, and inhibiting inappropriate actions. The role of attention and prospective memory was also underlined, whereas other cognitive functions did not influence task performance.	[Chevignard, M. P.] Hop Natl St Maurice, INR A, Dept Rehabil Children Acquired Brain Injury, F-94410 St Maurice, France; [Taillefer, C.; Picq, C.; Poncet, F.; Pradat-Diehl, P.] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Chevignard, M. P.; Taillefer, C.; Picq, C.; Pradat-Diehl, P.] INSERM, U731, Paris, France; [Chevignard, M. P.; Taillefer, C.; Picq, C.; Pradat-Diehl, P.] Univ Paris 06, UMR S731, Paris, France; [Noulhiane, M.] Univ Paris 05, CNRS, F-75270 Paris, France; [Noulhiane, M.] Lab Psychol & Neurosci Cognit, FRE 2987, Paris, France		Chevignard, MP (corresponding author), Hop Natl St Maurice, INR A, Dept Rehabil Children Acquired Brain Injury, 14 Rue Val Osne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr		Noulhiane, Marion/0000-0003-2832-0332			Allain P, 2004, REV NEUROPSYCHOL, V14, P285; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BRICKENKAMP R, 1966, ADAPTATION FRANCAISE; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BURGESS PW, 1994, REV NEUROPSYCHOL, V4, P345; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Cripe L. I., 1998, ECOLOGICAL VALIDITY, P171; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; DUTIL E, 2003, PROFIL AVQ VERSION 3; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; Garnier C, 1998, REV NEUROPSYCHOL, V8, P385; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Le Thiec F., 1999, Annales de Readaptation et de Medecine Physique, V42, P1, DOI 10.1016/S0168-6054(99)80030-0; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404; Luria A.R., 1966, HIGHER CORTICAL FUNC; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Mazaux JM, 2002, ACT NEUR S, V79, P49; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; Miotto EC, 1998, CORTEX, V34, P639, DOI 10.1016/S0010-9452(08)70770-6; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pandya DN, 1996, RES PER NEUROSCI, P13; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Quintard B., 2002, Annales de Readaptation et de Medecine Physique, V45, P456, DOI 10.1016/S0168-6054(02)00296-9; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rey A., 1959, TEST COPIE REPROD ME; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, ALLOCATION PROCESSIN, P328; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Sohlberg M., 2001, COGNITIVE REHABILITA; TEASDALE G, 1974, LANCET, V2, P81; Teuber H. L., 1964, FRONTAL GRANULAR COR; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D., 2000, ECHELLE INTELLIGENCE; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Zalla T, 2001, NEUROPSYCHOLOGIA, V39, P759, DOI 10.1016/S0028-3932(01)00019-7; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; ZIMMERMANN P, 1992, BATTERIE TESTS NEURO; [No title captured]	81	61	61	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	4					461	485		10.1080/09602010701643472			25	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	318SO	WOS:000257113000004	18576272				2022-02-06	
J	Hlatky, R; Valadka, AB; Gopinath, SP; Robertson, CS				Hlatky, Roman; Valadka, Alex B.; Gopinath, Shankar P.; Robertson, Claudia S.			Brain tissue oxygen tension response to induced hyperoxia reduced in hypoperfused brain	JOURNAL OF NEUROSURGERY			English	Article						brain tissue oxygenation; brain trauma; cerebral blood flow; hyperoxia	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; TOMOGRAPHY; METABOLISM; THERAPY; HYPOXIA; PO2	Object. Increasing PaO2 can increase brain tissue PO2 (PbtO(2)). Nevertheless, the small increase in arterial O-2 content induced by hyperoxia does not increase O-2 delivery much, especially when cerebral blood flow (CBF) is low, and the effectiveness of hyperoxia as a therapeutic intervention remains controversial. The purpose of this study was to examine the role of regional (r)CBF at the site of the PO2 probe in determining the response of PbtO(2) to induced hyperoxia. Methods. The authors measured PaO2 and PbtO(2) at baseline normoxic conditions and after increasing inspired O-2 concentration to 100% on I I I occasion. in 83 patients with severe traumatic brain injury in whom a stable xenon-enhanced computed tomography measurement of CBF was available. The 0, reactivity was calculated as the change in PbtO(2) X 100/change in PaO2. Results. The O-2 reactivity was significantly different (p < 0.001) at the 5 levels of rCBF (< 10, 11-15, 16-20, 21-40, and > 40 ml/100 g/min). When rCBF was < 20 ml/100 g/min, the increase in PNO2 induced by hyperoxia was very small compared with the increase that occurred when rCBF was > 20 ml/100 g/min. Conclusions. Although the level of CBF is probably only one of the factors that determines the PbtO(2) response to hyperoxia, it is apparent from these results that the areas of the brain that would most likely benefit from improved oxygenation are the areas that are the least likely to have increased PbtO(2).	[Hlatky, Roman; Gopinath, Shankar P.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Hlatky, Roman] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Valadka, Alex B.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Ahn Edward S, 2005, Clin Neurosurg, V52, P348; Bardt TF, 1998, ACT NEUR S, V71, P153; Dings J, 1998, NEUROL RES, V20, pS71; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Kiening KL, 1998, ACT NEUR S, V71, P172; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; ROSTRUP E, 1995, NMR BIOMED, V8, P41, DOI 10.1002/nbm.1940080109; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Watson NA, 2000, EUR J ANAESTH, V17, P152, DOI 10.1046/j.1365-2346.2000.00640.x	25	61	63	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					53	58		10.3171/JNS/2008/108/01/0053			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300007	18173310				2022-02-06	
J	McAllister, TW; Flashman, LA; Rhodes, CH; Tyler, AL; Moore, JH; Saykin, AJ; McDonald, BC; Tosteson, TD; Tsongalis, GJ				McAllister, Thomas W.; Flashman, Laura A.; Rhodes, C. Harker; Tyler, Anna L.; Moore, Jason H.; Saykin, Andrew J.; McDonald, Brenna C.; Tosteson, Tor D.; Tsongalis, Gregory J.			Single nucleotide polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after traumatic brain injury: A replication and extension study	BRAIN INJURY			English	Article						traumatic brain injury; polymorphisms; dopamine receptor; cognition	HEALTHY-VOLUNTEERS; A1 ALLELE; ASSOCIATION; BINDING; DRD2; POPULATION; HAPLOTYPES	Objective: The two objectives of this study were (1) to replicate the previous finding that a single nucleotide polymorphism (SNP) in the ANKK1 gene (SNP rs1800497 formerly known as the DRD2 TAQ1 A allele) is associated with measures of learning and response latency after traumatic brain injury (TBI) and (2) to further characterize the genetic basis of the effect by testing the strength of association and degree of linkage disequilibrium between the cognitive outcome measures and a selected ensemble of 31 polymorphisms from three adjacent genes in the region of rs1800497. Method: A cohort of 54 patients with TBI and 21 comparison subjects were genotyped for the DRD2 TAQ1 A polymorphism (rs1800497). Ninety-three patients with TBI and 48 comparison subjects (the current cohort and an earlier independent cohort) were also genotyped for 31 additional neighbouring polymorphisms in NCAM, ANKK1 and DRD2. TBI patients were studied 1 month after injury. All subjects completed memory and attention tests, including the California Verbal Learning Test (CVLT) recognition task and the Gordon Continuous Performance Test (CPT). Results: As in a previous study the T allele of TAQ1 A (rs1800497) was associated with poorer performance on the CVLT recognition trial in both TBI and control subjects. There was also a significant diagnosis-by-allele interaction on CPT measures of response latency, largely driven by slower performance in the TBI participants with the T allele. Analysis of 31 additional neighbouring polymorphisms from NCAM, ANKK1 and DRD2 in the TBI patients showed four haploblocks. A haploblock of three SNPs in ANKK1 (rs11604671, rs4938016 and rs1800497 (TAQ1A)) showed the greatest association with cognitive outcome measures. Conclusions: The results confirm a previously published association between the TAQ1 A (rs1800497) T allele and cognitive outcome measures 1 month after TBI and suggest that a haploblock of polymorphisms in ANKK1, rather than the adjacent DRD2 gene, has the highest association with these measures after TBI.	[McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Dartmouth Hitchcock Med Ctr, Dept Psychiat, Lebanon, NH 03756 USA; [Rhodes, C. Harker; Tsongalis, Gregory J.] Dartmouth Med Sch, Sect Mol Pathol, Lebanon, NH 03756 USA; [Tyler, Anna L.; Moore, Jason H.] Dartmouth Med Sch, Computat Genet Lab, Lebanon, NH 03756 USA; [Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA; [Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Tosteson, Tor D.] Dartmouth Med Sch, Epidemiol & Biostat Sect, Dept Community & Family Med, Lebanon, NH 03756 USA		McAllister, TW (corresponding author), Dartmouth Med Sch, Sect Neuropsychiat, Dartmouth Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Moore, Jason H./AAV-9645-2021; Saykin, Andrew/A-1318-2007	Moore, Jason H./0000-0002-5015-1099; Saykin, Andrew/0000-0002-1376-8532; Tyler, Anna/0000-0001-8371-2377	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472, R01NS055020] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA023108] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176-05, R01 HD048176-03, R01 HD048176-04, R01 HD048176-02, R01 HD048176, R01 HD048176-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040472-03, R01 NS040472-01, R01 NS055020, R01 NS040472-02, R01 NS040472-04, R01 NS040472] Funding Source: Medline		Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; First M., 1997, STRUCTURED CLIN INTE; Gemignani F, 2005, CANCER EPIDEM BIOMAR, V14, P1633, DOI 10.1158/1055-9965.EPI-05-0057; Gordon N, 1996, EUR J DISORDER COMM, V31, P359; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hryniewicz-Jankowska A, 2002, FOLIA HISTOCHEM CYTO, V40, P239; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Laruelle M, 1998, MOL PSYCHIATR, V3, P261, DOI 10.1038/sj.mp.4000343; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; LONG JC, 1995, AM J HUM GENET, V56, P799; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Pritchard JK, 2000, GENETICS, V155, P945; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; SAVILLE DJ, 1990, AM STAT, V44, P174, DOI 10.2307/2684163; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wong AHC, 2000, EUR J PHARMACOL, V410, P183; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986	29	61	63	1	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	9					705	714		10.1080/02699050802263019			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600008	18698520	Green Accepted			2022-02-06	
J	Rabinstein, AA; Sandhu, K				Rabinstein, Alejandro A.; Sandhu, Kirsten			Non-infectious fever in the neurological intensive care unit: incidence, causes and predictors	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SUBARACHNOID HEMORRHAGE; BODY-TEMPERATURE; BRAIN-INJURY; HYPERTHERMIA; DAMAGE; FEASIBILITY; VASOSPASM; TRIAL; RISK	Background and objective: Non-infectious causes of fever are often considered in critical neurological patients but their true significance has not been formally studied. The aim of this study was to evaluate the incidence, causes and predictors of fever in patients with acute neurological/neurosurgical disease and no documented infection. Methods: Prospective data collection of consecutive patients admitted to the neurological intensive care unit (NICU) of an academic medical centre for more than 48 h was carried out. Fever was defined as body temperature >= 101 degrees F (38.3 degrees C) documented on at least one measurement for 2 consecutive days. Patients were enrolled only if a diagnostic workup, including cultures of >= 2 body samples, was performed before antibiotic use. Febrile patients with no proven evidence of infection were considered to have non-infectious fever. Results: 93 patients were included in the final analysis. Fever was non-infectious in 31 patients (33%). There were no differences between the infectious and non-infectious fever groups in terms of age, use and duration of invasive catheters, daily duration of fever and number of days with fever. Documented infections tended to be more common among febrile patients with traumatic brain injury (52% vs 36%; p = 0.06). Non-infectious fever was more frequent among patients with subarachnoid haemorrhage (48% vs 18%; p = 0.01) in whom it was associated with vasospasm ( p = 0.03) and symptomatic vasospasm ( p = 0.05). Non-infectious fever started earlier ( mean 2.6 vs 4 days; p = 0.007) and onset of fever within the first 72 h of admission predicted negative evaluation for infection ( p = 0.01). Subarachnoid haemorrhage and fever onset within the first 72 h were independent predictors of non-infectious fever on multivariable analysis. Conclusions: Fever in the absence of documented infections occurs commonly in the NICU, especially among patients with subarachnoid haemorrhage and vasospasm. Early onset of fever predicts a non-infectious cause.	Univ Miami, Jackson Mem Hosp, Sch Med, Neurosci Intens Care Unit, Miami, FL 33136 USA		Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, W8b,200 1st St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu					Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Badjatia N, 2004, NEUROCRIT CARE, V1, P145, DOI 10.1385/NCC:1:2:145; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Frosini M, 1999, EXP BRAIN RES, V126, P252, DOI 10.1007/s002210050734; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Marik PE, 2000, CHEST, V117, P855, DOI 10.1378/chest.117.3.855; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; O'Grady NP, 1998, CRIT CARE MED, V26, P392, DOI 10.1097/00003246-199802000-00046; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Shibata M, 1998, MED HYPOTHESES, V50, P185, DOI 10.1016/S0306-9877(98)90016-0; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X	20	61	65	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2007	78	11					1278	1280		10.1136/jnnp.2006.112730			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	225LE	WOS:000250518600030	17940175	Green Published			2022-02-06	
J	Nakase-Richardson, R; Yablon, SA; Sherer, M				Nakase-Richardson, Risa; Yablon, Stuart A.; Sherer, Mark			Prospective comparison of acute confusion severity with duration of post-traumatic amnesia in predicting employment outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; GALVESTON ORIENTATION; RECOVERY; SCALE	Background: Measurement of the duration of post-traumatic amnesia ( PTA) is common practice, serving as an important index of the severity of traumatic brain injury (TBI) and a predictor of functional outcome. However, controversy exists regarding the nature of PTA; some studies indicate that it is a confusional state with symptoms that extend beyond disorientation and amnesia. Objective: To evaluate the contribution of the severity of acute confusion 1 month after TBI to prediction of employment at 1 year after injury, comparing it with PTA duration. Methods: Prospective study involving 171 participants with complete data, who met the study criteria, from 228 consecutive TBI Model System admissions. Outcome measures included weekly administration of the Delirium Rating Scale-Revised-98 (DeIRS-R98) to measure the severity of acute confusion. Evaluations closest to 1 month after injury were used for study purposes. Duration of PTA was defined as the interval from injury until two consecutive Galveston Orientation and Amnesia Test scores of >= 76 were obtained within a period of 24-72 h. Univariable and multivariable logistic regression were used to predict employment status at 1 year after injury. Results: Age, education and DeIRS-R98 were significant predictors accounting for 34% of outcome variance. Individuals with greater confusion severity at 1 month after injury, older age and lower levels of education were less likely to be employed at 1 year after injury. Severity of confusion was more strongly associated with employment outcome (r(s) = 0.39) than was PTA duration (r(s) = 0.34). Conclusions: In addition to demographic indices, severity of acute confusion makes a unique contribution to predicting late outcome after TBI.	Methodist Rehabil Ctr, Dept Neuropsychol, Brain Injury Program, Jackson, MS 39216 USA		Nakase-Richardson, R (corresponding author), Methodist Rehabil Ctr, Dept Neuropsychol, Brain Injury Program, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	nakase@aol.com					Ahmed S, 2000, BRAIN INJURY, V14, P765; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P124; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	27	61	62	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2007	78	8					872	876		10.1136/jnnp.2006.104190			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	190IW	WOS:000248053500021	17178822	Green Published			2022-02-06	
J	Morgan, R; Kreipke, CW; Roberts, G; Bagchi, M; Rafols, JA				Morgan, Randy; Kreipke, Christian W.; Roberts, George; Bagchi, Mihir; Rafols, Jose A.			Neovascularization following traumatic brain injury: possible evidence for both angiogenesis and vasculogenesis	NEUROLOGICAL RESEARCH			English	Article						brain trauma; VEGF; capillary density	ENDOTHELIAL GROWTH-FACTOR; CEREBRAL-ISCHEMIA; UP-REGULATION; RAT-BRAIN; EXPRESSION; MODEL; VEGF; BARRIER	Objective: Our goal was to characterize the angiogenic response following traumatic brain injury (TBI). Methods: Western analysis for vascular endothelial growth factor (VEGF) expression, double immunofluorescence labeling of endothelium and vascular endothelial growth factor receptor 2 (VEGFR2), bromodioxyuridine (BrdU) incorporation and measurement of capillary density, were all used to determine the temporal angiogenic response following TBI. Results: The angiogenic factors, VEGF and VEGFR2, increase following trauma. Capillary density increases and BrdU incorporation confirm the presence of newly formed vessels up to 48 hours post-injury. Discussion: Our results indicated that following TBI, there is a substantial increase in angiogenesis and based on morphologic characterization of BrdU-positive nuclei within the endothelium, we provide evidence for vasculogenesis following injury.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Gu WG, 2001, ACTA NEUROPATHOL, V102, P216; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hayashi T, 2006, CURR NEUROVASC RES, V3, P119, DOI 10.2174/156720206776875902; Hurtado Olivia, 2006, Cerebrovasc Dis, V21 Suppl 2, P54, DOI 10.1159/000091704; *I LAB AN RES COMM, 1996, NIH PUBL; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Lambrechts D, 2006, TRENDS MOL MED, V12, P345, DOI 10.1016/j.molmed.2006.06.008; Li B, 2006, FASEB J, V20, P1495, DOI 10.1096/fj.05-5137fje; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinez A, 2006, CANCER LETT, V236, P157, DOI 10.1016/j.canlet.2005.04.008; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; PING FC, 1978, CAN ANAESTH SOC J, V25, P468, DOI 10.1007/BF03007408; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Tomanek Robert J., 2005, Angiogenesis, V8, P273, DOI 10.1007/s10456-005-9014-9; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	28	61	63	0	8	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2007	29	4					375	381		10.1179/016164107X204693			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	192PM	WOS:000248214200007	17626733				2022-02-06	
J	Watson, NF; Dikmen, S; Machamer, J; Doherty, M; Temkin, N				Watson, Nathaniel F.; Dikmen, Sureyya; Machamer, Joan; Doherty, Michael; Temkin, Nancy			Hypersomnia Following Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						Brain; injury; trauma; sleepiness; hypersomnia		Study Objectives: To evaluate the prevalence and natural history of sleepiness following traumatic brain injury. Methods: This prospective cohort study used the Sickness Impact Profile to evaluate sleepiness in 514 consecutive subjects with traumatic brain injury (TBI), 132 non-cranial trauma controls, and 102 trauma-free controls 1 month and 1 year after injury. Results: Fifty-five percent of TBI subjects, 41% of non-cranial trauma controls, and 3% of trauma-free controls endorsed 1 or more sleepiness items 1 month following injury (p < .001). One year following injury, 27% of TBI subjects, 23% of non-cranial trauma controls, and 1% of trauma-free controls endorsed 1 or more sleepiness items (p < .001). Patients with TBI were sleepier than non-cranial trauma controls at 1 month (p < .02) but not 1 year after injury. Brain-injured subjects were divided into injury-severity groups based on time to follow commands (TFC). At 1 month, the non-cranial trauma controls were less sleepy than the 1- to 6-day (p < .05), 7- to 13-day (p < .01), and 14-day or longer (p < .01) TFC groups. In addition, the <= 24-hour group was less sleepy then the 7- to 13-day and 14-day or longer groups (each p < .05). At 1 year, the non-cranial trauma control group (p < .05) and the <= 24-hour TFC group (p < .01) were less sleepy than the 14-day or longer TFC group. Sleepiness improved in 84% to 100% of subjects in the TBI TFC groups, as compared with 78% of the non-cranial trauma control group (p < .01). Conclusions: Sleepiness is common following traumatic injury, particularly TBI, with more severe injuries resulting in greater sleepiness. Sleepiness improves in many patients, particularly those with TBI. However, about a quarter of TBI subjects and non-cranial trauma control subjects remained sleepy 1 year after injury.	[Watson, Nathaniel F.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Doherty, Michael] Swedish Neurosci Inst, Seattle, WA USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Watson, NF (corresponding author), Univ Washington, Sleep Disorders Ctr, Box 359803,325 Ninth Ave, Seattle, WA 98104 USA.	nwatson@u.washington.edu			NIN-NINDS [R01 NS19463]; AHCPR [HS04146, HS05304]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019463] Funding Source: NIH RePORTER	Grant support: Supported by grants R01 NS19463 from NIN-NINDS, and HS04146 and HS05304 from AHCPR.	American Academy of Sleep Medicine, 2005, INT CLASSLEEP DIS; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FAHY TJ, 1967, LANCET, V2, P475; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Jameison K., 1971, P INT S HEAD INJ, P12; Jennett B., 1971, CLIN NEUROSURG, P200; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Olson LG, 1998, J SLEEP RES, V7, P248, DOI 10.1046/j.1365-2869.1998.00123.x; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	32	61	62	0	2	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2007	3	4					363	368					6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V44VK	WOS:000209776300005	17694724				2022-02-06	
J	Prigatano, GP; Gupta, S				Prigatano, George P.; Gupta, Saurabh			Friends after traumatic brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						academic performance; affect; children; cognition; friends; TBI	HEAD-INJURY; ACADEMIC-PERFORMANCE; REHABILITATION; ADOLESCENTS; COMPETENCE; BEHAVIOR; DAMAGE	Objective: To determine whether a dose-response relation exists between the number of reported close friends and traumatic brain injury (TBI) severity in the postacute phase in school-age children. Design: A retrospective relational study. Setting and Participants: Primary care hospital/medical center-based study on parental perspectives of recovery following TBI in school-age children (14 with severe TBI; 10 with moderate TBI; 36 with mild TBI; and 16 trauma controls). Main Outcome Measures: Parental ratings on the Child Behavior Checklist and selected neuropsychological test findings and ratings of academic performance. Results: Seventy-five percent of trauma controls but only 38.9% of children with mild and 20% of children with moderate TBI reportedly had 4 or more friends. Only 14.3% of children with severe TBI reportedly had 4 or more friends. Glasgow Coma Scale score at admission correlated with the number of friends postacutely (by parental reports) (r = +0.307, N = 76, P = .007). Conclusion: More severe brain injury is associated with fewer friends in the postacute phase following TBI. The relation, however, was not purely linear and the hypothesis was supported only partially. Broadening the social network of children with moderate and severe TBI should be a major goal of neuropsychological rehabilitation.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA		Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	gprigat@cbw.edu					Achenbach T. M., 2001, CHILD BEHAV CHECKLIS; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANZEN EA, 1973, NEUROPSYCHOLOGIA, V11, P141, DOI 10.1016/0028-3932(73)90002-X; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2006, Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology, P225, DOI 10.1007/4-431-28576-8_36; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Prigatano GP, 2004, BARROW Q, V20, P27; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCARR S, 1986, UNDERSTANDING DEV; TEASDALE G, 1974, LANCET, V2, P81; Webster-Stratton C, 2004, INFANT YOUNG CHILD, V17, P96, DOI 10.1097/00001163-200404000-00002; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	31	61	61	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					505	513		10.1097/00001199-200611000-00005			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400005	17122681				2022-02-06	
J	Winstanley, J; Simpson, G; Tate, R; Myles, B				Winstanley, Julie; Simpson, Grahame; Tate, Robyn; Myles, Bridget			Early indicators and contributors to psychological distress in relatives during rehabilitation following severe traumatic brain injury - Findings from the brain injury outcomes study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						family; psychological distress; traumatic brain injury	BLUNT HEAD-INJURY; PRIMARY CAREGIVERS; SOCIAL SUPPORT; FAMILY; PREDICTORS; BURDEN; HEALTH	Objectives: To develop a multivariate model of the dynamic interactions among key variables associated with relative distress and disrupted family functioning after traumatic brain injury (TBI). Participants: A relative sample (parents, spouses, close others; n = 134) derived from a statewide cohort of people with TBI recruited to the multicenter Brain Injury Outcomes Study. Setting: A consecutive series of referrals over a 2-year period to the 11 adult units of the Brain Injury Rehabilitation Program in New South Wales, Australia. Main Outcome Measures: Relative measures included General Health Questionnaire-28 (psychological distress), Family Assessment Device (family functioning), and BIOS Family Needs Questionnaire (perceived adequacy of support). The degree of impairment and level of participation of the person with TBI were assessed by the Mayo-Portland Adaptability Inventory and Sydney Psychosocial Reintegration Scale, respectively. Analysis: Path analysis examined the varying contribution of impairment, participation, and support variables to both relative distress and disturbances in family functioning. Results: The overall model accounted for substantial proportions of the variance in psychological distress and family functioning. Importantly, the distress experienced by relatives was not due to the direct impact of the neurobehavioral impairments, but the effect of these impairments was mediated by the degree of community participation achieved by the person with TBI. Conclusions: The model highlights the impact on families when the person with TBI experiences restrictions in participation. Clinically, a greater focus on the provision of respite or case management services may assist in reducing relative distress.	Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore, Qld 4558, Australia; Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Winstanley, J (corresponding author), Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore, Qld 4558, Australia.	JWinstan@usc.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Winstanley, Julie/0000-0002-9353-6757			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arbuckle J. L., 1999, AMOS 4 0 USERS GUIDE; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GREY JM, 1994, CLIN REHABIL, V8, P188; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holmes-Smith P, 2002, STRUCTURAL EQUATION; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McDonald RP, 1996, MULTIVAR BEHAV RES, V31, P239, DOI 10.1207/s15327906mbr3102_5; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Norusis M., 1986, STAT PACKAGE SOCIAL; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Panting A, 1972, REHABILITATION, V38, P33; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Siegel S., 1956, NONPARAMETRIC STAT B, pXVII, 312; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, BRAIN INJURY OUTCOME; Tate R.L., 2006, BRAIN IMPAIR, V7, P1, DOI DOI 10.1375/brim.7.1.1; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	38	61	62	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					453	466		10.1097/00001199-200611000-00001			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400001	17122677				2022-02-06	
